,approvalStatus,efficacyEvidence,evidenceType,id,indication.id,indication.name,indication.source,molecularProfile.id,molecularProfile.profileName,references,responseType,therapy.id,therapy.therapyName,Gene_id
0,Preclinical,"In a preclinical study, treatment with Sprycel (dasatinib) in decreased CRKL phosphorylation and reduced viability of lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) in culture (PMID: 26758680).",Actionable,7337,3910,lung adenocarcinoma,DOID,25102,ABL1 R332W,"[{'id': 6310, 'pubMedId': 26758680, 'title': 'Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26758680'}]",sensitive,717,Dasatinib,25
1,Preclinical - Cell line xenograft,"In a preclinical study, Gleevec (imatinib) inhibited growth of a lung adenocarcinoma cell line harboring ABL1 R332W (also reported as R351W) in culture, and inhibited tumor growth in xenograft models (PMID: 26758680).",Actionable,7334,3910,lung adenocarcinoma,DOID,25102,ABL1 R332W,"[{'id': 6310, 'pubMedId': 26758680, 'title': 'Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26758680'}]",sensitive,770,Imatinib,25
2,Preclinical,"In a preclinical study, lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) and expressing ABL1 T315I demonstrated resistance to Sprycel (dasatinib) in culture (PMID: 26758680).",Actionable,7339,3910,lung adenocarcinoma,DOID,25103,ABL1 R332W ABL1 T315I,"[{'id': 6310, 'pubMedId': 26758680, 'title': 'Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26758680'}]",resistant,717,Dasatinib,25
3,Preclinical - Cell line xenograft,"In a preclinical study, lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) and expressing ABL1 T315I demonstrated resistance to Gleevec (imatinib) in culture and in xenograft models (PMID: 26758680).",Actionable,7336,3910,lung adenocarcinoma,DOID,25103,ABL1 R332W ABL1 T315I,"[{'id': 6310, 'pubMedId': 26758680, 'title': 'Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26758680'}]",resistant,770,Imatinib,25
4,Preclinical,"In a preclinical study, Gleevec (imatinib) inhibited growth of a lung adenocarcinoma cell line harboring ABL1 G321L (also reported as G340L) in culture (PMID: 26758680).",Actionable,7335,3910,lung adenocarcinoma,DOID,25109,ABL1 G321L,"[{'id': 6310, 'pubMedId': 26758680, 'title': 'Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26758680'}]",sensitive,770,Imatinib,25
5,Preclinical,"In a preclinical study, treatment with Sprycel (dasatinib) in decreased CRKL phosphorylation and reduced viability of lung adenocarcinoma cells harboring ABL1 G321L (also reported as G340L) in culture (PMID: 26758680).",Actionable,7338,3910,lung adenocarcinoma,DOID,25109,ABL1 G321L,"[{'id': 6310, 'pubMedId': 26758680, 'title': 'Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26758680'}]",sensitive,717,Dasatinib,25
6,Clinical Study,"In a clinical study, Tasigna (nilotinib) treatment resulted in no benefit in a patient with oral cavity cancer harboring ABL1 G250R and G251D (PMID: 28514312). ",Actionable,11048,8618,oral cavity cancer,DOID,27899,ABL1 G250R ABL1 G251D,"[{'id': 9046, 'pubMedId': 28514312, 'title': 'Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28514312'}]",no benefit,829,Nilotinib,25
0,Phase II,"In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients harboring mutations in PIK3CA, AKT1, or PTEN (J Clin Oncol 35, 2017 (suppl; abstr 1009)).",Actionable,11169,60081,triple-receptor negative breast cancer,DOID,1209,AKT1 mutant,"[{'id': 9130, 'pubMedId': None, 'title': 'LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).', 'url': 'http://abstracts.asco.org/199/AbstView_199_183382.html'}]",predicted – sensitive,1588,Ipatasertib + Paclitaxel,207
1,Phase II,"In a Phase II trial, Apitolisib (GDC-0980) was poorly tolerated, but demonstrated efficacy in endometrial cancer patients harboring mutations in PIK3CA, PTEN, or AKT1 (J Clin Oncol 32:5s, 2014 (suppl; abstr 5513)).",Actionable,5205,1380,endometrial cancer,DOID,1209,AKT1 mutant,"[{'id': 4913, 'pubMedId': None, 'title': 'Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results.', 'url': 'http://meetinglibrary.asco.org/content/132500-144'}]",sensitive,750,GDC-0980,207
2,Phase II,"In a retrospective study of a Phase II trial, Torisel (temsirolimus) treatment resulted in an increased progression-free survival (HR 0.16) and response rate (response difference 0.83) in advanced endometrial cancer patients harboring AKT1 mutations (PMID: 27016228).",Actionable,6401,1380,endometrial cancer,DOID,1209,AKT1 mutant,"[{'id': 5557, 'pubMedId': 27016228, 'title': 'Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27016228'}]",predicted – sensitive,936,Temsirolimus,207
3,Phase II,"In a Phase II trial, AKT1 mutations were more frequent in  muscle-invasive urothelial bladder cancer patients that did not respond to Nexavar (sorafenib), Platinol (cisplatin) and Gemzar (gemcitabine) combination therapy than those who did respond (J Clin Oncol 35, 2017 (suppl 6S; abstract 345)).",Actionable,10325,6477,invasive bladder transitional cell carcinoma,DOID,1209,AKT1 mutant,"[{'id': 8305, 'pubMedId': None, 'title': 'Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): Final results and translational findings of an open-label, single-arm, phase II study.', 'url': 'http://meetinglibrary.asco.org/content/179076-197'}]",predicted – resistant,5462,Cisplatin + Gemcitabine + Sorafenib,207
4,Preclinical - Cell line xenograft,"In a preclinical study, Rapamune (sirolimus) and Adriamycin (doxorubicin) combination treatment resulted in improved survival and prolonged remission in cell line xenograft animal models of lymphoma overexpressing constitutively active Akt (PMID: 18708578).",Actionable,4856,60058,lymphoma,DOID,1281,AKT1 act mut,"[{'id': 4758, 'pubMedId': 18708578, 'title': 'Tumorigenic activity and therapeutic inhibition of Rheb GTPase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18708578'}]",predicted – sensitive,3663,Doxorubicin + Sirolimus,207
5,Preclinical - Cell line xenograft,"In a preclinical study, lymphoma cells overexpressing constitutively active Akt demonstrated reduced sensitivity to Adriamycin (doxorubicin) treatment in cell line xenograft models (PMID: 18708578).",Actionable,4851,60058,lymphoma,DOID,1281,AKT1 act mut,"[{'id': 4758, 'pubMedId': 18708578, 'title': 'Tumorigenic activity and therapeutic inhibition of Rheb GTPase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18708578'}]",decreased response,1009,Doxorubicin,207
6,Preclinical - Cell line xenograft,"In a preclinical study, Rapamune (sirolimus) treatment did not improve survival in cell line xenograft animal models of lymphoma overexpressing constitutively active Akt (PMID: 18708578).",Actionable,4853,60058,lymphoma,DOID,1281,AKT1 act mut,"[{'id': 4758, 'pubMedId': 18708578, 'title': 'Tumorigenic activity and therapeutic inhibition of Rheb GTPase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18708578'}]",no benefit,917,Sirolimus,207
7,Phase I,"In a Phase I trial, Triciribine (API-2) demonstrated safety, but lacked efficacy as a monotherapy in advanced solid tumor patients with activated Akt (PMID: 20644979).",Actionable,2891,10000003,Advanced Solid Tumor,JAX,1281,AKT1 act mut,"[{'id': 3516, 'pubMedId': 20644979, 'title': 'Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20644979'}]",no benefit,948,Triciribine,207
8,Preclinical - Cell line xenograft,"In a preclinical study, Perifosine (KRX-0401) inhibited Akt1 signaling, inhibited proliferation, and induced apoptosis in human ovarian clear cell cancer cells with activated Akt1 in culture and inhibited tumor growth in cell line xenografts (PMID: 25519148).",Actionable,4720,50934,ovarian clear cell carcinoma,DOID,26309,AKT1 positive,"[{'id': 4674, 'pubMedId': 25519148, 'title': 'Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25519148'}]",predicted – sensitive,855,Perifosine,207
9,Preclinical - Cell culture,"In a preclinical study, Perifosine (KRX-0401) enhanced the sensitivity of human ovarian clear cell cancer cells with activated Akt1 to Platinol (cisplatin) treatment in culture (PMID: 25519148).",Actionable,4721,50934,ovarian clear cell carcinoma,DOID,26309,AKT1 positive,"[{'id': 4674, 'pubMedId': 25519148, 'title': 'Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25519148'}]",predicted – sensitive,3600,Cisplatin + Perifosine,207
10,Preclinical - Cell line xenograft,"In a preclinical study, ONC201 (TIC-10) inhibited Akt activation and induced apoptosis and tumor regression in a variety of cell line xenograft models (PMID: 23390247). ",Actionable,3624,10000003,Advanced Solid Tumor,JAX,3110,AKT1 amp,"[{'id': 989, 'pubMedId': 23390247, 'title': 'Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23390247'}]",predicted – sensitive,1687,ONC201,207
11,Clinical Study,"In a clinical study, a patient with lung adenocarcinoma harboring AKT1 E17K demonstrated a partial response when treated with AZD5363 (PMID: 28489509). ",Actionable,11436,3910,lung adenocarcinoma,DOID,643,AKT1 E17K,"[{'id': 9361, 'pubMedId': 28489509, 'title': 'AKT Inhibition in Solid Tumors With AKT1 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28489509'}]",sensitive,655,AZD5363,207
12,Phase I,"In a Phase I clinical trial in patients with advanced solid tumors, AZD5363 demonstrated safety and preliminary antitumor activity, with stable disease in 27% (10/37) of patients and partial response in two patients, both of whom harbored an AKT1 E17K mutation (PMID: 26931343).",Actionable,1336,10000003,Advanced Solid Tumor,JAX,643,AKT1 E17K,"[{'id': 1049, 'pubMedId': None, 'title': '459P A Phase I study to assess the safety and tolerability of the selective Akt inhibitor AZD5363 in Japanese patients with advanced solid tumours', 'url': 'http://annonc.oxfordjournals.org/content/25/suppl_4/iv153.1.full.pdf'}, {'id': 5230, 'pubMedId': 26931343, 'title': 'Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26931343'}]",sensitive,655,AZD5363,207
13,Phase I,"In a Phase I clinical study, a patient with endometrioid ovarian carcinoma harboring AKT1 E17K had a sustained partial response to AZD5363 for more than two years (PMID: 26351323).",Actionable,3621,6212,ovarian endometrial cancer,DOID,643,AKT1 E17K,"[{'id': 3912, 'pubMedId': 26351323, 'title': 'Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26351323'}]",sensitive,655,AZD5363,207
14,Preclinical,"In a preclinical study, AZD5363 inhibited growth and colony formation of breast cancer cells expressing AKT E17K in cell culture and in xenografts as well as breast cancer explant models harboring AKT E17K (PMID: 26351323).",Actionable,3633,1612,breast cancer,DOID,643,AKT1 E17K,"[{'id': 3912, 'pubMedId': 26351323, 'title': 'Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26351323'}]",sensitive,655,AZD5363,207
15,Clinical Study,"In a clinical study, four patients with ESR1-positive breast cancer harboring AKT1 E17K demonstrated a partial response when treated with AZD5363 (PMID: 28489509).",Actionable,11432,1612,breast cancer,DOID,643,AKT1 E17K,"[{'id': 9361, 'pubMedId': 28489509, 'title': 'AKT Inhibition in Solid Tumors With AKT1 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28489509'}]",sensitive,655,AZD5363,207
16,Clinical Study,"In a clinical study, a patient with cervical cancer harboring AKT1 E17K demonstrated a partial response when treated with AZD5363 (PMID: 28489509). ",Actionable,11434,4362,cervical cancer,DOID,643,AKT1 E17K,"[{'id': 9361, 'pubMedId': 28489509, 'title': 'AKT Inhibition in Solid Tumors With AKT1 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28489509'}]",sensitive,655,AZD5363,207
17,Preclinical,"In a preclinical study, the pan AKT inhibitor GSK2141795 displayed similar levels of inhibition against ATK1 E17K (activating mutation) as ATK1 wild-type (PMID: 24978597).
",Actionable,1227,162,cancer,DOID,643,AKT1 E17K,"[{'id': 962, 'pubMedId': 24978597, 'title': 'Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24978597'}]",sensitive,764,GSK2141795,207
18,Phase I,"In a Phase I clinical trial, a patient with ER-positive, ERBB2 (HER2)-negative papillary breast carcinoma harboring AKT1 E17K had a sustained partial response to AZD5363 (PMID: 26351323).",Actionable,3622,5592,breast papillary carcinoma,DOID,643,AKT1 E17K,"[{'id': 3912, 'pubMedId': 26351323, 'title': 'Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26351323'}]",sensitive,655,AZD5363,207
19,Phase I,"In a Phase I trial, a patient with ERBB2 (HER2)-receptor negative breast cancer harboring AKT1 E17K demonstrated a complete metabolic response when treated with Ipatasertib (GDC-0068) (PMID: 27872130). ",Actionable,9713,60080,Her2-receptor negative breast cancer,DOID,643,AKT1 E17K,"[{'id': 7487, 'pubMedId': 27872130, 'title': 'A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27872130'}]",sensitive,747,Ipatasertib,207
20,Preclinical - Cell culture,"In a preclinical study, Uprosertib (GSK2141795) inhibited the growth of melanoma cells harboring AKT1 E17K in culture (PMID: 24735930).",Actionable,10809,1909,melanoma,DOID,643,AKT1 E17K,"[{'id': 8844, 'pubMedId': 24735930, 'title': 'Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24735930'}]",sensitive,764,GSK2141795,207
21,Preclinical - Pdx,"In a preclinical study, treatment with BAY1125976 reduced tumor growth and resulted in partial tumor regression or stable disease in anal cancer patient-derived xenograft (PDX) models harboring AKT1 E17K (PMID: 27699769).",Actionable,3828,50688,anal canal cancer,DOID,643,AKT1 E17K,"[{'id': 2275, 'pubMedId': None, 'title': 'Abstract 3685: BAY 1125976, is a selective allosteric AKT1/2 inhibitor with high efficacy in AKT1-mutated cancers', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/3685'}, {'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",sensitive,994,BAY1125976,207
22,Preclinical - Cell line xenograft,"In a preclinical study, an endometrial cell line xenograft model harboring AKT E17K was sensitive to ARQ 751, demonstrating inhibition of tumor growth (PMID: 26469692). ",Actionable,10279,1380,endometrial cancer,DOID,643,AKT1 E17K,"[{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",sensitive,4331,ARQ 751,207
23,Clinical Study,"In a clinical case study, a patient with meningothelial meningioma harboring AKT1 E17K demonstrated stable disease and some tumor regression when treated with AZD5363 (PMID: 28376212). ",Actionable,10807,7212,meningothelial meningioma,DOID,643,AKT1 E17K,"[{'id': 8837, 'pubMedId': 28376212, 'title': 'Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28376212'}]",sensitive,655,AZD5363,207
24,Clinical Study,"In a clinical study, a patient with triple-receptor negative breast cancer harboring AKT1 E17K demonstrated a partial response when treated with AZD5363 (PMID: 28489509). ",Actionable,11435,60081,triple-receptor negative breast cancer,DOID,643,AKT1 E17K,"[{'id': 9361, 'pubMedId': 28489509, 'title': 'AKT Inhibition in Solid Tumors With AKT1 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28489509'}]",sensitive,655,AZD5363,207
25,Phase I,"In a Phase I trial, a patient with ovarian granulosa cell tumor cancer harboring subclonal AKT E17K demonstrated an overall tumor regression of 24% when treated with AZD5363, which lasted 253 days (PMID: 28489509). ",Actionable,11452,2999,granulosa cell tumor,DOID,643,AKT1 E17K,"[{'id': 9361, 'pubMedId': 28489509, 'title': 'AKT Inhibition in Solid Tumors With AKT1 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28489509'}]",sensitive,655,AZD5363,207
26,Preclinical - Cell line xenograft,"In a preclinical study, an endometrial cell line xenograft model harboring AKT E17K was sensitive to ARQ092, demonstrating inhibition of tumor growth (PMID: 26469692). ",Actionable,10278,1380,endometrial cancer,DOID,643,AKT1 E17K,"[{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",sensitive,635,ARQ092,207
27,Clinical Study,"In a clinical study, two patients with endometrial cancer harboring AKT1 E17K demonstrated a partial response when treated with AZD5363 (PMID: 28489509). ",Actionable,11433,1380,endometrial cancer,DOID,643,AKT1 E17K,"[{'id': 9361, 'pubMedId': 28489509, 'title': 'AKT Inhibition in Solid Tumors With AKT1 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28489509'}]",sensitive,655,AZD5363,207
28,Preclinical - Pdx,"In a preclinical study, BAY1125976 induced complete tumor regression in a patient-derived xenograft (PDX) model of breast cancer harboring AKT E17K (PMID: 27699769).",Actionable,8807,1612,breast cancer,DOID,643,AKT1 E17K,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",sensitive,994,BAY1125976,207
29,Clinical Study,"In a retrospective study, 100% (2/2) colorectal carcinoma patients harboring an AKT1 E17K mutation and wild-type KRAS/BRAF demonstrated resistance to Erbitux (cetuximab) in combination with Camptosar (irinotecan) (PMID: 25714871).
",Actionable,3614,9256,colorectal cancer,DOID,13841,AKT1 E17K KRAS wild-type BRAF wild-type,"[{'id': 3888, 'pubMedId': 25714871, 'title': 'AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25714871'}]",resistant,1874,Cetuximab + Irinotecan,207
30,Preclinical,"In a preclinical study, the combined therapy of AZD5363 and AZD4547 resulted in tumor regression in urinary bladder cancer xenograft models simultaneously harboring the mutations, AKT1 E17K and FGFR3 Y373C (PMID: 26351323). ",Actionable,3811,11054,urinary bladder cancer,DOID,14066,AKT1 E17K FGFR3 Y373C,"[{'id': 3912, 'pubMedId': 26351323, 'title': 'Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26351323'}]",sensitive,3346,AZD5363 + AZD4547,207
31,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited Akt activation and downstream signaling in bladder cancer cell lines carrying both Akt1 E17K and Nras Q61R mutations (AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3685).",Actionable,3830,4007,bladder carcinoma,DOID,16525,AKT1 E17K NRAS Q61R,"[{'id': 2275, 'pubMedId': None, 'title': 'Abstract 3685: BAY 1125976, is a selective allosteric AKT1/2 inhibitor with high efficacy in AKT1-mutated cancers', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/3685'}]",sensitive,994,BAY1125976,207
32,Preclinical - Cell line xenograft,"In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring AKT E17K and NRAS G12D in culture, and demonstrated antitumor activity in xenograft models (PMID: 27699769).",Actionable,8810,10283,prostate cancer,DOID,26446,AKT1 E17K NRAS G12D,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",sensitive,994,BAY1125976,207
33,Preclinical - Cell culture,"In a preclinical study, expression of AKT1 E17K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).",Actionable,8103,1909,melanoma,DOID,26172,AKT1 E17K BRAF V600X PTEN pos,"[{'id': 6551, 'pubMedId': 24265152, 'title': 'A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265152'}]",resistant,342,Vemurafenib,207
34,Clinical Study,"In a clinical study, an ovarian cancer patient harboring AKT1 Q79K demonstrated tumor regression that lasted 14 months when treated with AZD5363 (PMID: 28489509). ",Actionable,11437,2394,ovarian cancer,DOID,2989,AKT1 Q79K,"[{'id': 9361, 'pubMedId': 28489509, 'title': 'AKT Inhibition in Solid Tumors With AKT1 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28489509'}]",sensitive,655,AZD5363,207
35,Preclinical - Cell culture,"In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited AKT activation and growth of PTEN-expressing BRAF V600-mutant melanoma cells expressing AKT1 Q79K in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8125,1909,melanoma,DOID,26173,AKT1 Q79K BRAF V600X PTEN pos,"[{'id': 6551, 'pubMedId': 24265152, 'title': 'A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265152'}]",sensitive,4635,MK2206 + Vemurafenib,207
36,Preclinical - Cell culture,"In a preclinical study, expression of AKT1 Q79K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).",Actionable,8106,1909,melanoma,DOID,26173,AKT1 Q79K BRAF V600X PTEN pos,"[{'id': 6551, 'pubMedId': 24265152, 'title': 'A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265152'}]",resistant,342,Vemurafenib,207
37,Preclinical - Cell culture,"In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",Actionable,8881,1612,breast cancer,DOID,26496,AKT1 over exp PIK3CA H1047R,"[{'id': 6782, 'pubMedId': 27604488, 'title': 'Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27604488'}]",resistant,691,BYL719,207
38,Preclinical - Cell culture,"In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA E545K resulted in resistance to Pictilisib (GDC-0941) in culture (PMID: 27604488).",Actionable,8896,1612,breast cancer,DOID,26498,AKT1 over exp PIK3CA E545K,"[{'id': 6782, 'pubMedId': 27604488, 'title': 'Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27604488'}]",resistant,749,GDC-0941,207
39,Phase Ib/II,"In a Phase I/II trial, RX-0201 and Afinitor (everolimus) combination therapy resulted in stable disease in 40% (2/5) of patients with metastatic clear cell renal carcinoma (J Clin Oncol 34, 2016 (suppl 2S; abstr 550)).",Actionable,5997,4467,renal clear cell carcinoma,DOID,372,AKT1 wild-type,"[{'id': 5219, 'pubMedId': None, 'title': 'Archexin, a novel AKT-1–specific inhibitor for the treatment of metastatic renal cancer: Preliminary phase I data.', 'url': 'http://meetinglibrary.asco.org/content/158080-172'}]",sensitive,2262,Everolimus + RX-0201,207
40,Phase I,"In a Phase I trial, GSK2141795 treatment resulted in Akt inhibition and clinical benefit in 27% (3/11) of ovarian cancer patients (PMID: 26429956).",Actionable,6032,2394,ovarian cancer,DOID,372,AKT1 wild-type,"[{'id': 5245, 'pubMedId': 26429956, 'title': 'Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26429956'}]",predicted – sensitive,764,GSK2141795,207
41,Preclinical,"In a preclinical study, GSK2141795 inhibited all isoforms of AKT in human cancer cell lines (PMID: 23795919).",Actionable,835,162,cancer,DOID,372,AKT1 wild-type,"[{'id': 184, 'pubMedId': 23795919, 'title': 'Characterization of a chemical affinity probe targeting Akt kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23795919'}]",sensitive,764,GSK2141795,207
42,Preclinical,"In a preclinical study, breast cancer cells expressing AKT1 W80A were resistant to MK2206 in culture, resulting in repression of induced cell death when compared to wild-type AKT1 (PMID: 25551293). ",Actionable,4033,1612,breast cancer,DOID,3021,AKT1 W80A,"[{'id': 2571, 'pubMedId': 25551293, 'title': 'A kinase-independent function of AKT promotes cancer cell survival.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25551293'}]",resistant,816,MK2206,207
0,Preclinical,"In a preclinical study, transformed cells expressing an ALK fusion with ALK S1206Y were resistant to Xalkori (crizotinib) (PMID: 25806224, PMID: 22277784).",Actionable,2956,10000003,Advanced Solid Tumor,JAX,10724,ALK fusion ALK S1206Y,"[{'id': 683, 'pubMedId': 22277784, 'title': 'Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22277784'}, {'id': 3386, 'pubMedId': 25806224, 'title': 'Targeting EML4-ALK driven non-small cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806224'}]",resistant,706,Crizotinib,238
1,Clinical Study,"In a clinical study, an ALK S1206Y secondary mutation in the context of EML4-ALK was associated with resistance to Xalkori (crizotinib) in a patient with non-small cell lung cancer, and resistance was replicated in cell culture studies (PMID: 22277784).",Actionable,1001,3908,non-small cell lung carcinoma,DOID,5338,EML4-ALK ALK S1206Y,"[{'id': 683, 'pubMedId': 22277784, 'title': 'Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22277784'}]",resistant,706,Crizotinib,238
2,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing S1206Y in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9263,10000003,Advanced Solid Tumor,JAX,5338,EML4-ALK ALK S1206Y,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,238
3,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK S1206Y demonstrated growth inhibition with Zykadia (ceritinib) treatment in culture (PMID: 24675041). ",Actionable,2099,10000003,Advanced Solid Tumor,JAX,5338,EML4-ALK ALK S1206Y,"[{'id': 2525, 'pubMedId': 24675041, 'title': 'The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24675041'}]",sensitive,789,Ceritinib,238
4,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK S1206Y in the context of EML4-ALK in culture  (PMID: 26144315). ",Actionable,8296,10000003,Advanced Solid Tumor,JAX,5338,EML4-ALK ALK S1206Y,"[{'id': 3367, 'pubMedId': 26144315, 'title': 'PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144315'}]",sensitive,869,PF-06463922,238
5,Preclinical,"In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3466,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,698,Alectinib,238
6,Preclinical,"In a preclinical trial, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750).",Actionable,3485,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,789,Ceritinib,238
7,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with  ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3554,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,643,ASP3026,238
8,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750).",Actionable,3437,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,634,AP26113,238
9,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3454,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,706,Crizotinib,238
10,Preclinical,"In a preclinical study, TPX-0005 inhibited cell proliferation in transformed cell lines over expressing ALK L1196M in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",Actionable,5834,10000003,Advanced Solid Tumor,JAX,537,ALK L1196M,"[{'id': 5176, 'pubMedId': None, 'title': 'The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=055d4461-9793-4f83-b663-f356d9ae0fdb&cKey=ff6f8d25-f06a-4ae4-9dbf-7e390ef45123&mKey={1D10D749-4B6A-4AB3-BCD4-F80FB1922267}'}]",sensitive,3950,TPX-0005,238
11,Preclinical - Cell line xenograft,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK L196M in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853).",Actionable,5702,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,238
12,Preclinical - Cell line xenograft,"In a preclinical study, Zykadia (ceritinib) inhibited cell survival and PI3K/AKT, MEK/ERK, and mTOR signaling in two human non-small cell lung carcinoma cell lines harboring the Xalkori (crizotinib) resistance mutation EML4-ALK ALK L1196M in culture and inhibited tumor growth in xenograft models of one of those cell lines (PMID: 24675041).",Actionable,2056,3908,non-small cell lung carcinoma,DOID,5335,EML4-ALK ALK L1196M,"[{'id': 2525, 'pubMedId': 24675041, 'title': 'The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24675041'}]",sensitive,789,Ceritinib,238
13,Preclinical,"In preclinical studies, transformed cells expressing EML4-ALK ALK L1196M were insensitive to Xalkori (crizotinib) as demonstrated by lack of growth inhibition and Alk phosphorylation in culture (PMID: 21613408, PMID: 26698910). ",Actionable,2094,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 2442, 'pubMedId': 21613408, 'title': 'Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21613408'}, {'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,706,Crizotinib,238
14,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227). ",Actionable,5708,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}, {'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",conflicting,869,PF-06463922,238
15,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were sensitive to Entrectinib (RXDX-101), resulting in anti-proliferative activity (PMID: 26939704).",Actionable,5638,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 5130, 'pubMedId': 26939704, 'title': 'Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26939704'}]",sensitive,1455,Entrectinib,238
16,Preclinical,"In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK ALK L1196M (PMID: 21613408).",Actionable,2095,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 2442, 'pubMedId': 21613408, 'title': 'Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21613408'}]",sensitive,961,X-396,238
17,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M demonstrated decreased sensitivity to Alecensa (alectinib) compared to cells expressing EML4-ALK with wild-type ALK, in culture (PMID: 26698910).",Actionable,5701,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",conflicting,698,Alectinib,238
18,Preclinical - Cell line xenograft,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing an EML4-ALK fusion and ALK L1196M in culture and in xenograft models (PMID: 21575866).",Actionable,10341,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 1817, 'pubMedId': 21575866, 'title': 'CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21575866'}]",conflicting,698,Alectinib,238
19,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK L1196M demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8634,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,789,Ceritinib,238
20,Preclinical - Cell culture,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 26698910)",Actionable,10342,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,789,Ceritinib,238
21,Preclinical - Cell culture,"In a preclinical study, TPX-0005 inhibited Alk activity and proliferation of transformed cells over expressing ALK L1196M in the context of EML4-ALK in culture (European Journal of Cancer , Volume 69, S32).",Actionable,10345,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 8338, 'pubMedId': None, 'title': 'TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants', 'url': 'http://www.ejcancer.com/article/S0959-8049%2816%2932675-2/abstract'}]",sensitive,3950,TPX-0005,238
22,Preclinical - Cell line xenograft,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and proliferation of non-small cell lung carcinoma cells over expressing ALK L1196M in the context of EML4-ALK in culture, and resulted in tumor regression in cell line xenograft models (PMID: 26144315). ",Actionable,2650,3908,non-small cell lung carcinoma,DOID,5335,EML4-ALK ALK L1196M,"[{'id': 3367, 'pubMedId': 26144315, 'title': 'PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144315'}]",sensitive,869,PF-06463922,238
23,Preclinical,"In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N in culture (PMID: 25421750).",Actionable,3550,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,643,ASP3026,238
24,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3442,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,238
25,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3483,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,789,Ceritinib,238
26,Preclinical,"In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3467,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,698,Alectinib,238
27,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).",Actionable,3452,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,706,Crizotinib,238
28,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3460,10000003,Advanced Solid Tumor,JAX,13328,NPM1-ALK ALK L1122V ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,698,Alectinib,238
29,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Brigatinib (AP26113) in culture (PMID: 25421750).",Actionable,3435,50744,anaplastic large cell lymphoma,DOID,13328,NPM1-ALK ALK L1122V ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,238
30,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).",Actionable,3451,10000003,Advanced Solid Tumor,JAX,13328,NPM1-ALK ALK L1122V ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,706,Crizotinib,238
31,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3552,10000003,Advanced Solid Tumor,JAX,13328,NPM1-ALK ALK L1122V ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,643,ASP3026,238
32,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3440,10000003,Advanced Solid Tumor,JAX,13328,NPM1-ALK ALK L1122V ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,238
33,Clinical Study,"In multiple clinical trials, ALK L1196M conferred resistance to Xalkori (crizotinib) in the context of ALK positive aberrations in non-small cell lung carcinoma patients (PMID: 22277784, PMID: 25806224).",Actionable,187,3908,non-small cell lung carcinoma,DOID,10720,ALK fusion ALK L1196M,"[{'id': 683, 'pubMedId': 22277784, 'title': 'Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22277784'}, {'id': 3386, 'pubMedId': 25806224, 'title': 'Targeting EML4-ALK driven non-small cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806224'}]",resistant,706,Crizotinib,238
34,Preclinical,"In a preclinical study, brigatinib (AP26113) inhibited growth of cell lines expressing ALK L1196M in the context of EML4-ALK in culture (PMID: 21502504).",Actionable,2965,3908,non-small cell lung carcinoma,DOID,10720,ALK fusion ALK L1196M,"[{'id': 3553, 'pubMedId': 21502504, 'title': 'Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21502504'}]",sensitive,634,AP26113,238
35,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F were resistant to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910).",Actionable,5707,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,634,AP26113,238
36,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5704,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,789,Ceritinib,238
37,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5706,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,869,PF-06463922,238
38,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5705,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,698,Alectinib,238
39,Preclinical,"In a preclinical study, Xalkori (crizotinib) resistance was reduced in transformed cells expressing EML4-ALK with ALK L1196M with the addition of ALK L1198F in culture (PMID: 26698910).",Actionable,5703,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,706,Crizotinib,238
40,Preclinical,"In a preclinical study, a transformed cell line expressing ALK R1275Q was sensitive to Brigatinib (AP26113) in culture and in vivo, resulting in cell growth inhibition (PMID: 27049722). ",Actionable,5876,10000003,Advanced Solid Tumor,JAX,1416,ALK R1275Q,"[{'id': 5182, 'pubMedId': 27049722, 'title': 'Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27049722'}]",sensitive,634,AP26113,238
41,Preclinical - Cell line xenograft,"In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK R1275Q in culture, and only delayed tumor growth in cell line xenograft models (PMID: 26554404).",Actionable,8371,769,neuroblastoma,DOID,1416,ALK R1275Q,"[{'id': 6636, 'pubMedId': 26554404, 'title': 'The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26554404'}]",resistant,706,Crizotinib,238
42,Preclinical - Cell line xenograft,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, resulted in growth inhibition of neuroblastoma cells over expressing ALK R1275Q in culture and irapid and sustained complete tumor regression in cell line xenograft models (PMID: 26554404).",Actionable,8376,769,neuroblastoma,DOID,1416,ALK R1275Q,"[{'id': 6636, 'pubMedId': 26554404, 'title': 'The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26554404'}]",sensitive,869,PF-06463922,238
43,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to sustain tumor regression in human neuroblastoma cell line xenograft models harboring ALK R1275Q and wild-type TP53 (PMID: 26438783).",Actionable,4730,769,neuroblastoma,DOID,1416,ALK R1275Q,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,238
44,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited foci formation more efficiently than Xalkori (crizotinib) in transformed cells over expressing ALK R1275Q in culture (PMID: 26554404).",Actionable,8382,10000003,Advanced Solid Tumor,JAX,1416,ALK R1275Q,"[{'id': 6636, 'pubMedId': 26554404, 'title': 'The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26554404'}]",sensitive,869,PF-06463922,238
45,Phase I,"In a Phase I trial, ALK C1156Y mediates resistance to Xalkori (crizotinib) in ALK positive non-small cell lung cancer tumors (PMID: 25806224, PMID: 20979473).",Actionable,2895,3908,non-small cell lung carcinoma,DOID,10721,ALK fusion ALK C1156Y,"[{'id': 912, 'pubMedId': 20979473, 'title': 'EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20979473'}, {'id': 3386, 'pubMedId': 25806224, 'title': 'Targeting EML4-ALK driven non-small cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806224'}]",resistant,706,Crizotinib,238
46,Preclinical,"In a preclinical study, Alecensa (alectinib) was able to inhibit ALK C1156Y in the context of transformed cells expressing an ALK fusion (PMID: 25806224, PMID: 21575866). ",Actionable,2961,10000003,Advanced Solid Tumor,JAX,10721,ALK fusion ALK C1156Y,"[{'id': 1817, 'pubMedId': 21575866, 'title': 'CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21575866'}, {'id': 3386, 'pubMedId': 25806224, 'title': 'Targeting EML4-ALK driven non-small cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806224'}]",sensitive,698,Alectinib,238
47,Preclinical,"In a preclinical study, transformed human cells expressing the ALK fusion resistance mutation, ALK C1156Y, demonstrated minimal sensitivity to Zykadia (ceritinib) (PMID: 24675041).",Actionable,2960,10000003,Advanced Solid Tumor,JAX,10721,ALK fusion ALK C1156Y,"[{'id': 2525, 'pubMedId': 24675041, 'title': 'The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24675041'}, {'id': 3386, 'pubMedId': 25806224, 'title': 'Targeting EML4-ALK driven non-small cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806224'}]",sensitive,789,Ceritinib,238
48,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5684,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,698,Alectinib,238
49,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5679,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,869,PF-06463922,238
50,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910).",Actionable,5688,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,634,AP26113,238
51,Phase I,"In a Phase I clinical trial, a patient with EML4-ALK positive non-small lung cancer initially responded to Xalkori (crizotinib) but developed resistance with the emergence of a secondary ALK mutation C1156Y, and subsequently redeveloped sensitivity to Xalkori (crizotinib) upon the emergence of a second ALK mutation, L1198F arising from resistance to Lorlatinib (PF-06463922) (PMID: 26698910).",Actionable,5673,3908,non-small cell lung carcinoma,DOID,21372,EML4-ALK ALK C1156Y ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,706,Crizotinib,238
52,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F in culture (PMID: 26698910).",Actionable,5676,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,706,Crizotinib,238
53,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5687,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,789,Ceritinib,238
54,Phase I,"In a Phase I clinical trial, a patient with EML4-ALK positive non-small lung cancer with a secondary Xalkori (critzotinib) resistance mutation C1156Y, responded to Lorlatinib (PF-06463922) but subsequently developed resistance upon the emergence of a second ALK mutation, L1198F (PMID: 26698910).",Actionable,5672,3908,non-small cell lung carcinoma,DOID,21372,EML4-ALK ALK C1156Y ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,869,PF-06463922,238
55,Preclinical,"In a preclinical study, ALK C1156Y was sensitive to Alecensa (alectinib) in an in vitro assay (PMID: 21575866).",Actionable,3061,10000003,Advanced Solid Tumor,JAX,1982,ALK C1156Y,"[{'id': 1817, 'pubMedId': 21575866, 'title': 'CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21575866'}]",sensitive,698,Alectinib,238
56,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156Y were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5410,50744,anaplastic large cell lymphoma,DOID,20770,NPM1-ALK ALK C1156Y,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,238
57,Phase I,"In a Phase I clinical study, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation ALK C1156Y, was treated with Lorlatinib (PF-06463922) and displayed a 41% reduction in tumor growth after 5 weeks of treatment (PMID: 26698910).",Actionable,5669,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,869,PF-06463922,238
58,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth and ALK phosphorylation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).",Actionable,5677,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,869,PF-06463922,238
59,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were sensitive to Entrectinib (RXDX-101), resulting in anti-proliferative activity (PMID: 26939704). ",Actionable,5637,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,"[{'id': 5130, 'pubMedId': 26939704, 'title': 'Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26939704'}]",sensitive,1455,Entrectinib,238
60,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).",Actionable,5685,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,789,Ceritinib,238
61,Preclinical,"In a preclinical study, transformed human cells expressing EML4-ALK with ALK C1156Y were sensitive to Alecensa (alectinib) in culture (PMID: 21575866).",Actionable,2981,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,"[{'id': 1817, 'pubMedId': 21575866, 'title': 'CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21575866'}]",sensitive,698,Alectinib,238
62,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).",Actionable,5682,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,698,Alectinib,238
63,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).",Actionable,5674,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,706,Crizotinib,238
64,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK ALK C1156Y were insensitive to Xalkori (crizotinib) as demonstrated by lack of growth inhibition and lack of kinase inhibition in culture (PMID: 21613408). ",Actionable,2092,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,"[{'id': 2442, 'pubMedId': 21613408, 'title': 'Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21613408'}]",resistant,706,Crizotinib,238
65,Preclinical,"In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK C1156Y (PMID: 21613408). ",Actionable,2093,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,"[{'id': 2442, 'pubMedId': 21613408, 'title': 'Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21613408'}]",sensitive,961,X-396,238
66,Clinical Study,"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer with an ALK C1156Y secondary Xalkori (crizotinib) resistance mutation did not respond to Luminespib (AUY922) therapy (PMID: 26698910).",Actionable,5671,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,647,AUY922,238
67,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).",Actionable,5689,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,634,AP26113,238
68,Clinical Study,"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer developed resistance to Xalkori (crizotinib) with the emergence of ALK C1156Y, a secondary resistance mutation (PMID: 26698910).",Actionable,5668,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,706,Crizotinib,238
69,Preclinical - Cell line xenograft,"In a preclinical study, Zykadia (ceritinib) demonstrated tumor growth inhibition in xenograft models of a human non-small cell lung cancer cell line harboring EML4-ALK with ALK C1156Y when compared to Xalkori (crizotinib) (PMID: 24675041).",Actionable,2982,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,"[{'id': 2525, 'pubMedId': 24675041, 'title': 'The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24675041'}]",conflicting,789,Ceritinib,238
70,Clinical Study,"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation C1156Y, did not respond to Zykadia (ceritinib) therapy (PMID: 26698910).",Actionable,5720,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",conflicting,789,Ceritinib,238
71,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5430,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,634,AP26113,238
72,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK N1178H were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5417,50744,anaplastic large cell lymphoma,DOID,20899,NPM1-ALK ALK N1178H,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,238
73,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034).",Actionable,5482,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,706,Crizotinib,238
74,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5425,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",decreased response,643,ASP3026,238
75,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5499,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,869,PF-06463922,238
76,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5489,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,789,Ceritinib,238
77,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034).",Actionable,5434,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,698,Alectinib,238
78,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Xalkori (Crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5354,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,706,Crizotinib,238
79,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P had a reduced response to AZD3463 mediated growth inhibition in culture relative to NPM1-ALK (PMID: 27009859).",Actionable,5359,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",decreased response,1586,AZD3463,238
80,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5357,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,634,AP26113,238
81,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5358,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,643,ASP3026,238
82,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5356,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,698,Alectinib,238
83,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK R1192P were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).",Actionable,5350,50744,anaplastic large cell lymphoma,DOID,20661,NPM1-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,706,Crizotinib,238
84,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5355,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,238
85,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5364,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,643,ASP3026,238
86,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5361,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,238
87,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5365,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,1586,AZD3463,238
88,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5363,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,634,AP26113,238
89,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5362,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,698,Alectinib,238
90,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5360,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,706,Crizotinib,238
91,Preclinical,"In a preclinical study, a transformed cell line expressing ALK R1192P was sensitive to Brigatinib (AP26113) in culture, resulting in cell growth inhibition (PMID: 27049722). ",Actionable,5874,10000003,Advanced Solid Tumor,JAX,1415,ALK R1192P,"[{'id': 5182, 'pubMedId': 27049722, 'title': 'Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27049722'}]",sensitive,634,AP26113,238
92,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK T1151dup in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9258,10000003,Advanced Solid Tumor,JAX,26807,EML4-ALK ALK T1151dup,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,238
93,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK T1151dup in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).",Actionable,9264,10000003,Advanced Solid Tumor,JAX,26807,EML4-ALK ALK T1151dup,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",decreased response,706,Crizotinib,238
94,Preclinical,"In a preclinical study, transformed cells expressing an ALK fusion with ALK T1151dup were resistant to Xalkori (crizotinib) (PMID: 25806224, PMID: 22277784).",Actionable,2958,10000003,Advanced Solid Tumor,JAX,10719,ALK fusion ALK T1151dup,"[{'id': 683, 'pubMedId': 22277784, 'title': 'Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22277784'}, {'id': 3386, 'pubMedId': 25806224, 'title': 'Targeting EML4-ALK driven non-small cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806224'}]",resistant,706,Crizotinib,238
95,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK F1174I were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5392,50744,anaplastic large cell lymphoma,DOID,20772,NPM1-ALK ALK F1174I,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,238
96,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5433,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,698,Alectinib,238
97,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5435,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,634,AP26113,238
98,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5481,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,706,Crizotinib,238
99,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174I were resistant to ASP3026 relative to wild type NPM1-ALK in culture (PMID: 25749034).",Actionable,5424,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,238
100,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5484,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,789,Ceritinib,238
101,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5493,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,869,PF-06463922,238
102,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5341,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,698,Alectinib,238
103,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).",Actionable,5352,50744,anaplastic large cell lymphoma,DOID,20659,NPM1-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,238
104,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5346,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,643,ASP3026,238
105,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5337,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,706,Crizotinib,238
106,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK F1174L in culture (PMID: 27009859).",Actionable,5344,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,634,AP26113,238
107,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5339,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,238
108,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5347,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,1586,AZD3463,238
109,Preclinical - Cell culture,"In a preclinical study, a transformed cell line expressing ALK F1174L was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722). ",Actionable,5873,10000003,Advanced Solid Tumor,JAX,698,ALK F1174L,"[{'id': 5182, 'pubMedId': 27049722, 'title': 'Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27049722'}]",sensitive,634,AP26113,238
110,Preclinical - Pdx & cell culture,"In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK F1174L in culture, and only delayed tumor growth in patient-derived and cell line xenograft models harboring ALK F1174L (PMID: 26554404).",Actionable,8369,769,neuroblastoma,DOID,698,ALK F1174L,"[{'id': 6636, 'pubMedId': 26554404, 'title': 'The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26554404'}]",resistant,706,Crizotinib,238
111,Preclinical - Pdx & cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of neuroblastoma cells over expressing ALK F1174L in culture, and induced rapid and sustained complete tumor regression in both patient-derived and cell line xenograft models harboring ALK F1174L (PMID: 26554404).",Actionable,8374,769,neuroblastoma,DOID,698,ALK F1174L,"[{'id': 6636, 'pubMedId': 26554404, 'title': 'The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26554404'}]",sensitive,869,PF-06463922,238
112,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited foci formation more efficiently than Xalkori (crizotinib) in transformed cells over expressing ALK F1174L in culture (PMID: 26554404).",Actionable,8383,10000003,Advanced Solid Tumor,JAX,698,ALK F1174L,"[{'id': 6636, 'pubMedId': 26554404, 'title': 'The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26554404'}]",sensitive,869,PF-06463922,238
113,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5345,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,643,ASP3026,238
114,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Brigatinib (AP26113) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5343,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,634,AP26113,238
115,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).",Actionable,5342,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,698,Alectinib,238
116,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK F1174L in the context of EML4-ALK in culture  (PMID: 26144315). ",Actionable,8297,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,"[{'id': 3367, 'pubMedId': 26144315, 'title': 'PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144315'}]",sensitive,869,PF-06463922,238
117,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).",Actionable,5348,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,1586,AZD3463,238
118,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5340,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,238
119,Preclinical - Cell culture,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).",Actionable,5338,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",conflicting,706,Crizotinib,238
120,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK F1174L in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).",Actionable,9266,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",conflicting,706,Crizotinib,238
121,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to sustain tumor regression in xenograft models of a crizotinib-resistant human neuroblastoma cell line harboring ALK F1174L and wild-type TP53 (PMID: 26438783).",Actionable,4731,769,neuroblastoma,DOID,18879,ALK	F1174L TP53	wild-type,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,238
122,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227). ",Actionable,8654,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,869,PF-06463922,238
123,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Alecensa (alectinib) in culture (PMID: 27432227). ",Actionable,8652,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,698,Alectinib,238
124,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Xalkori (crizotinib) in culture (PMID: 27432227). ",Actionable,8651,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",resistant,706,Crizotinib,238
125,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Zykadia (ceritinib) in culture (PMID: 27432227). ",Actionable,8666,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",resistant,789,Ceritinib,238
126,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Brigatinib (AP26113) in culture (PMID: 27432227). ",Actionable,8653,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,634,AP26113,238
127,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5698,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,789,Ceritinib,238
128,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910).",Actionable,5696,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,634,AP26113,238
129,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5700,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,698,Alectinib,238
130,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5694,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,869,PF-06463922,238
131,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).",Actionable,5692,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,706,Crizotinib,238
132,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).",Actionable,5697,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}, {'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",conflicting,789,Ceritinib,238
133,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910).",Actionable,5693,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,869,PF-06463922,238
134,Preclinical,"In a preclinical study, Brigatinib (AP26113) modestly inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910).",Actionable,5695,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",decreased response,634,AP26113,238
135,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).",Actionable,5691,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,706,Crizotinib,238
136,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C demonstrated decreased sensitivity to Alecensa (alectinib) in culture compared to cells expressing EML4-ALK with wild-type ALK (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227). ",Actionable,5699,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}, {'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",conflicting,698,Alectinib,238
137,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156F were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5416,50744,anaplastic large cell lymphoma,DOID,20881,NPM1-ALK ALK C1156F,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,238
138,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5427,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,634,AP26113,238
139,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5486,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,789,Ceritinib,238
140,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5495,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,869,PF-06463922,238
141,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5421,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,238
142,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5436,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,698,Alectinib,238
143,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK C1156F in culture (PMID: 25749034).",Actionable,5480,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,706,Crizotinib,238
144,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5432,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,634,AP26113,238
145,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5502,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,869,PF-06463922,238
146,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5440,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,698,Alectinib,238
147,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).",Actionable,5479,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,706,Crizotinib,238
148,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK C1156F and D1203N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5414,50744,anaplastic large cell lymphoma,DOID,20896,NPM1-ALK ALK C1156F ALK D1203N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,238
149,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5423,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,238
150,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with C1156F and D1203N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5491,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,789,Ceritinib,238
151,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK G1128S in culture (PMID: 25749034).",Actionable,5426,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,634,AP26113,238
152,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5420,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,238
153,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5441,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,698,Alectinib,238
154,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1128S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5413,50744,anaplastic large cell lymphoma,DOID,20894,NPM1-ALK ALK G1128S,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,238
155,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5494,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,869,PF-06463922,238
156,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5485,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,789,Ceritinib,238
157,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).",Actionable,5476,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,706,Crizotinib,238
158,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227). ",Actionable,8655,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,706,Crizotinib,238
159,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Brigatinib (AP26113) in culture (PMID: 27432227). ",Actionable,8658,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,634,AP26113,238
160,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227). ",Actionable,8659,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,869,PF-06463922,238
161,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Zykadia (ceritinib) in culture (PMID: 27432227). ",Actionable,8656,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,789,Ceritinib,238
162,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Alecensa (alectinib) in culture (PMID: 27432227). ",Actionable,8657,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,698,Alectinib,238
163,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).  ",Actionable,8643,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,698,Alectinib,238
164,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8641,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,706,Crizotinib,238
165,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Brigatinib (AP26113) in culture (PMID: 27432227).  ",Actionable,8644,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,634,AP26113,238
166,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8642,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,789,Ceritinib,238
167,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8645,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,869,PF-06463922,238
168,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8647,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,789,Ceritinib,238
169,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Brigatinib (AP26113) in culture (PMID: 27432227).  ",Actionable,8649,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,634,AP26113,238
170,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).  ",Actionable,8648,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,698,Alectinib,238
171,Clinical Study,"In a clinical study, a lung cancer patient harboring EML4-ALK demonstrated progression when treated with Xalkori (crizotinib) due to the secondary acquired resistance mutation, ALK E1210K, however, in vitro transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8646,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",conflicting,706,Crizotinib,238
172,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8650,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,869,PF-06463922,238
173,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5422,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,238
174,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5501,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,869,PF-06463922,238
175,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK E1210K were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5415,50744,anaplastic large cell lymphoma,DOID,20888,NPM1-ALK ALK E1210K,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,238
176,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK E1210K in culture (PMID: 25749034).",Actionable,5483,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,706,Crizotinib,238
177,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with E1210K were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5490,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,789,Ceritinib,238
178,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5431,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,634,AP26113,238
179,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5439,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,698,Alectinib,238
180,Preclinical,"In a preclinical study, transformed cells expressing an ALK fusion and ALK G1269A were resistant to Xalkori (crizotinib) (PMID: 25806224, PMID: 22235099).",Actionable,2897,10000003,Advanced Solid Tumor,JAX,10723,ALK fusion ALK G1269A,"[{'id': 2524, 'pubMedId': 22235099, 'title': 'Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22235099'}, {'id': 3386, 'pubMedId': 25806224, 'title': 'Targeting EML4-ALK driven non-small cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806224'}]",resistant,706,Crizotinib,238
181,Phase Ib/II,"In a phase I/II clinical trial, AP26113 was determined to be safe and efficacious in patients with advanced, ALK-fusion positive NSCLC (PMID: 24091716).",Actionable,2964,3908,non-small cell lung carcinoma,DOID,2446,ALK fusion,"[{'id': 11, 'pubMedId': 24091716, 'title': 'Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24091716'}]",sensitive,634,AP26113,238
182,FDA approved,"In clinical trials that supported FDA approval, treatment with Xalkori (crizotinib) resulted in an objective response rate of 61.2% (71/116) in the Phase I expansion trial, and 50% (68/135) in the Phase II trial in patients with ALK-positive non-small cell lung cancer (PMID: 24573551).",Actionable,1959,3908,non-small cell lung carcinoma,DOID,2446,ALK fusion,"[{'id': 2408, 'pubMedId': 24573551, 'title': 'U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24573551'}]",sensitive,706,Crizotinib,238
183,Phase Ib/II,"In a Phase Ib/II trial, treatment with Xalkori (crizotinib) resulted in an objective response rate of 83% (5/6, all complete responses), at the 165 mg/m^2 dose, and 90% (18/20), with complete response in 80% (16/20), at the recommended phase 2 dose of 280 mg/m^2, in patients with anaplastic large cell lymphoma harboring an ALK fusion (PMID: 28787259; NCT00939770).",Actionable,11798,50744,anaplastic large cell lymphoma,DOID,2446,ALK fusion,"[{'id': 9791, 'pubMedId': 28787259, 'title': ""Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28787259'}]",sensitive,706,Crizotinib,238
184,Phase I,"In a Phase I clinical trial, Entrectinib (RXDX-101) treatment resulted in partial response for more than 3 months in a colorectal cancer patient harboring a CAD-ALK gene fusion (PMID: 26633560).",Actionable,3948,9256,colorectal cancer,DOID,2446,ALK fusion,"[{'id': 4305, 'pubMedId': 26633560, 'title': 'Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26633560'}]",sensitive,1455,Entrectinib,238
185,Phase Ib/II,"In a Phase Ib/II trial, treatment with Xalkori (crizotinib) resulted in an objective response rate of 86% (12/14), with complete response in 36% (5/14), in patients with inflammatory myofibroblastic tumor harboring an ALK fusion (PMID: 28787259; NCT00939770).",Actionable,11797,50905,inflammatory myofibroblastic tumor,DOID,2446,ALK fusion,"[{'id': 9791, 'pubMedId': 28787259, 'title': ""Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28787259'}]",sensitive,706,Crizotinib,238
186,Phase II,"In a Phase II clincial trial, treatment with Alecensa (alectinib) resulted in a 49% (60/122) overall response rate in non-small cell lung cancer patients positive for an ALK fusion who had previously progressed on Xalkori (crizotinib) therapy (J Clin Oncol 33, 2015 (suppl; abstr 8008))",Actionable,2963,3908,non-small cell lung carcinoma,DOID,2446,ALK fusion,"[{'id': 3554, 'pubMedId': None, 'title': 'Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: an open-label, single-arm, global phase 2 study (NP28673).', 'url': 'http://meetinglibrary.asco.org/content/149578-156'}]",sensitive,698,Alectinib,238
187,Phase III,"In a Phase III clinical trial, treatment with Alecensa (alectinib) resulted in improved progression-free survival compared to treatment with Xalkori (crizotinib) (Hazard ratio: 0.34)  in ALK-positive non-small cell lung cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 9008)).",Actionable,6816,3908,non-small cell lung carcinoma,DOID,2446,ALK fusion,"[{'id': 5832, 'pubMedId': None, 'title': 'Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study.', 'url': 'http://meetinglibrary.asco.org/content/167434-176'}]",sensitive,698,Alectinib,238
188,Phase I,"In a Phase I clinical trial, Lorlatinib (PF-06463922) demonstrated safety and resulted in a 50% (26/52) overall response rate in patients with ALK-positive or ROS1-positive non-small cell lung cancer, including intracranial responses in patients with CNS metastasis (J Clin Oncol 34, 2016 (suppl; abstr 9009)).",Actionable,6817,3908,non-small cell lung carcinoma,DOID,2446,ALK fusion,"[{'id': 5834, 'pubMedId': None, 'title': 'Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).', 'url': 'http://abstracts.asco.org/176/AbstView_176_161846.html'}]",sensitive,869,PF-06463922,238
189,FDA approved,Zykadia (ceritinib) is FDA approved for the treatment of ALK fusion positive metastatic non-small cell lung cancer (NSCLC) in patients previously treated with crizotinib (FDA.gov).,Actionable,2959,3908,non-small cell lung carcinoma,DOID,2446,ALK fusion,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",sensitive,789,Ceritinib,238
190,FDA approved,"In a Phase I trial that supported FDA approval, Zykadia (ceritinib) resulted in a 58% (66/114) overall response rate in non-small cell lung cancer patients positive for an ALK fusion and a 56% (45/80) overall response rate in non-small cell lung cancer patients positive for an ALK fusion who had previously received Xalkori (crizotinib) (PMID: 24670165). ",Actionable,2983,3908,non-small cell lung carcinoma,DOID,2446,ALK fusion,"[{'id': 3549, 'pubMedId': 24670165, 'title': 'Ceritinib in ALK-rearranged non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24670165'}]",sensitive,789,Ceritinib,238
191,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring an ALK fusion and ALK L1152R were resistant to Xalkori (crizotinib) (PMID: 25806224, PMID: 21791641).",Actionable,2896,3908,non-small cell lung carcinoma,DOID,10722,ALK fusion ALK L1152R,"[{'id': 918, 'pubMedId': 21791641, 'title': 'A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21791641'}, {'id': 3386, 'pubMedId': 25806224, 'title': 'Targeting EML4-ALK driven non-small cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806224'}]",resistant,706,Crizotinib,238
192,Preclinical,"In a preclinical study, transformed cells expressing an ALK fusion and ALK G1202R were resistant to Xalkori (crizotinib) (PMID: 25806224, PMID: 22277784).",Actionable,2957,10000003,Advanced Solid Tumor,JAX,10725,ALK fusion ALK G1202R,"[{'id': 683, 'pubMedId': 22277784, 'title': 'Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22277784'}, {'id': 3386, 'pubMedId': 25806224, 'title': 'Targeting EML4-ALK driven non-small cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806224'}]",resistant,706,Crizotinib,238
193,Phase I,"In a Phase I clinical trial, treatment with Lorlatinib (PF-06463922) demonstrated safety and resulted in durable responses in patients with ALK-positive non-small cell lung cancer, including patients harboring ALK G1202R (J Clin Oncol 34, 2016 (suppl; abstr 9009)).",Actionable,6820,3908,non-small cell lung carcinoma,DOID,10725,ALK fusion ALK G1202R,"[{'id': 5834, 'pubMedId': None, 'title': 'Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).', 'url': 'http://abstracts.asco.org/176/AbstView_176_161846.html'}]",sensitive,869,PF-06463922,238
194,FDA approved,"In a Phase II trial that supported FDA approval, Alunbrig (brigatinib) treatment resulted an overall response rate of 46% (51/112) in the 90mg arm and 54% (59/110) in the 180mg arm, and median progression-free survival of 8.8 mo and 11.0 mo respectively, in ALK-positive non-small cell lung carcinoma patients who progressed on Xalkori (crizotinib) (J Clin Oncol 34, 2016 (suppl; abstr 9007)).",Actionable,6704,3908,non-small cell lung carcinoma,DOID,1772,ALK positive,"[{'id': 5753, 'pubMedId': None, 'title': 'Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).', 'url': 'http://abstracts.asco.org/176/AbstView_176_165056.html'}]",sensitive,634,AP26113,238
195,FDA approved,Zykadia (ceritinib) is FDA approved for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients previously treated with crizotinib (FDA.gov).,Actionable,1481,3908,non-small cell lung carcinoma,DOID,1772,ALK positive,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",sensitive,789,Ceritinib,238
196,Phase III,"In a Phase III trial, Alecensa (alectinib) treatment resulted in improved median progression-free survival (not reached vs. 11.1 months), and 12 month event-free survival rate (68.4% vs. 48.7%), when compared to Xalkori (crizotinib) treatment in ALK-positive non-small cell lung carcinoma patients (PMID: 28586279; NCT02075840).",Actionable,11293,3908,non-small cell lung carcinoma,DOID,1772,ALK positive,"[{'id': 9216, 'pubMedId': None, 'title': 'Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.', 'url': 'http://abstracts.asco.org/199/AbstView_199_185951.html'}, {'id': 9690, 'pubMedId': 28586279, 'title': 'Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28586279'}]",sensitive,698,Alectinib,238
197,Phase I,"In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in stable disease in a patient with ALK-positive non-small cell lung carcinoma (J Clin Oncol 32:5s, 2014 (suppl; abstr 2502)).",Actionable,10350,3908,non-small cell lung carcinoma,DOID,1772,ALK positive,"[{'id': 8339, 'pubMedId': None, 'title': 'Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.', 'url': 'http://meetinglibrary.asco.org/content/131059-144'}]",predicted – sensitive,1455,Entrectinib,238
198,Phase I,"In a Phase I clinical trial, Belizatinib (TSR-011) treatment resulted in a partial response in 60% (3/5) of non-small cell lung cancer patients positive for Alk (J Clin Oncol 32, 2014 (suppl; abstr e19005)).",Actionable,3954,3908,non-small cell lung carcinoma,DOID,1772,ALK positive,"[{'id': 4310, 'pubMedId': None, 'title': 'Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations', 'url': 'http://meetinglibrary.asco.org/content/134653-144'}]",sensitive,949,TSR-011,238
199,Phase Ib/II,"In a Phase I trial, Belizatinib (TSR-011) treatment resulted in a response in 100% (3/3) of patients with ALK positive advanced solid tumors when administered at higher doses, and stable disease for 7 months or longer in 56% (5/9) of patients at lower dose (J Clin Oncol 33, 2015 (suppl; abstr 8063)).",Actionable,10344,10000003,Advanced Solid Tumor,JAX,1772,ALK positive,"[{'id': 8337, 'pubMedId': None, 'title': 'Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer.', 'url': 'http://meetinglibrary.asco.org/content/148387-156'}]",sensitive,949,TSR-011,238
200,Phase III,"In a Phase III trial, Xalkori (crizotinib) treatment resulted in improved objective response (87.5%, 90/103 vs 45.6%, 47/103) and median progression free survival (11.1 vs 6.8 mo) compared to pemetrexed, cisplatin and carboplatinin combination treatment in treatment-naive ALK positive advanced non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9058)).",Actionable,7060,3908,non-small cell lung carcinoma,DOID,1772,ALK positive,"[{'id': 6060, 'pubMedId': None, 'title': 'Phase 3 study of first-line crizotinib vs pemetrexed?cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).', 'url': 'http://meetinglibrary.asco.org/content/165546-176'}]",sensitive,706,Crizotinib,238
201,Phase Ib/II,"In a Phase Ib/II trial, Ensartinib (X-396) treatment resulted in partial response (PR) in 60% (19/30) and stable disease in 7% (2/30) of ALK positive non-small cell lung carcinoma patients, PR was 88% (7/8) in crizotinib-naïve patients and 83% (10/12) in patients with prior crizotinib treatment (J Clin Oncol 34, 2016 (suppl; abstr 9056)).",Actionable,1785,3908,non-small cell lung carcinoma,DOID,1772,ALK positive,"[{'id': 6058, 'pubMedId': None, 'title': 'Plasma genotyping of patients enrolled on the expansion phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC).', 'url': 'http://meetinglibrary.asco.org/content/169016-176'}]",sensitive,961,X-396,238
202,Phase II,"In a Phase II trial, Onalespib (AT13387) and Xalkori (crizotinib) combination treatment did not significantly improve median progression free survival (269 vs 266 days) or objective response rate (55.4%, 38/68 vs 45.3%, 31/68) compared to Xalkori (crizotinib) single treatment in ALK positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9059)).",Actionable,7062,3908,non-small cell lung carcinoma,DOID,1772,ALK positive,"[{'id': 6063, 'pubMedId': None, 'title': 'Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC: Results of a randomized phase 2 study.', 'url': 'http://meetinglibrary.asco.org/content/171030-176'}]",no benefit,4355,Crizotinib + Onalespib,238
203,Phase I,"In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in partial response in a patient with ALK-positive neuroblastoma (J Clin Oncol 32:5s, 2014 (suppl; abstr 2502)).",Actionable,10349,769,neuroblastoma,DOID,1772,ALK positive,"[{'id': 8339, 'pubMedId': None, 'title': 'Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.', 'url': 'http://meetinglibrary.asco.org/content/131059-144'}]",predicted – sensitive,1455,Entrectinib,238
204,Preclinical,"In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).",Actionable,3464,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,698,Alectinib,238
205,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).",Actionable,3455,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,706,Crizotinib,238
206,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3486,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,789,Ceritinib,238
207,Preclinical,"In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).",Actionable,3549,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,643,ASP3026,238
208,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK P1139S in culture (PMID: 25421750).",Actionable,3446,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,634,AP26113,238
209,Preclinical,"In a preclinical study, a transformed cell line expressing ALK G1269A was sensitive to Brigatinib (AP26113) in culture, resulting in cell growth inhibition (PMID: 27049722). ",Actionable,5878,10000003,Advanced Solid Tumor,JAX,4863,ALK G1269A,"[{'id': 5182, 'pubMedId': 27049722, 'title': 'Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27049722'}]",sensitive,634,AP26113,238
210,Preclinical - Patient cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and growth of non-small cell lung cancer (NSCLC) cells over expressing ALK G1269A in the context of EML4-ALK in culture and in cell line xenograft models, as well as inhibited  growth of patient derived NSCLC cells harboring EML4-ALK ALK G1269A in culture (PMID: 26144315). ",Actionable,3159,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,"[{'id': 3367, 'pubMedId': 26144315, 'title': 'PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144315'}]",sensitive,869,PF-06463922,238
211,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859).",Actionable,5389,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,1586,AZD3463,238
212,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910).",Actionable,5721,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,869,PF-06463922,238
213,Preclinical,"In preclinical studies, Brigatinib (AP26113) inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859, PMID: 26698910).",Actionable,5388,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}, {'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,634,AP26113,238
214,Clinical Study,"In a clinical case study, a patient with EML4-ALK fusion positive non-small cell lung cancer with ALK G1269A had a partial response to Alecensa (alectinib) treatment (PMID: 26849637).",Actionable,4621,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,"[{'id': 4562, 'pubMedId': 26849637, 'title': 'Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26849637'}]",sensitive,698,Alectinib,238
215,Preclinical - Cell line xenograft,"In a preclinical study, Alecensa (alectinib) inhibited proliferation of a Xalkori (crizotinib)-resistant human non-small cell lung cancer (NSCLC) cell line harboring an EML-ALK fusion with ALK G1269A in culture and induced tumor regression in xenograft models (PMID: 26849637, PMID: 23344087).",Actionable,4462,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,"[{'id': 2523, 'pubMedId': 23344087, 'title': 'Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23344087'}, {'id': 4562, 'pubMedId': 26849637, 'title': 'Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26849637'}]",sensitive,698,Alectinib,238
216,Preclinical,"In preclinical studies, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910, PMID: 27009859).",Actionable,5385,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}, {'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,789,Ceritinib,238
217,Preclinical,"In preclinical studies, human lung cancer cell lines expressing EML4-ALK G1269A demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 22235099, PMID: 23344087, PMID: 24675041).",Actionable,2054,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,"[{'id': 2523, 'pubMedId': 23344087, 'title': 'Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23344087'}, {'id': 2524, 'pubMedId': 22235099, 'title': 'Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22235099'}, {'id': 2525, 'pubMedId': 24675041, 'title': 'The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24675041'}]",resistant,706,Crizotinib,238
218,Preclinical,"In a preclinical study, human lung cancer cell lines harboring EML4-ALK with ALK G1269A demonstrated sensitivity to Zykadia (ceritinib) in culture (PMID: 24675041).",Actionable,2055,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,"[{'id': 2525, 'pubMedId': 24675041, 'title': 'The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24675041'}]",sensitive,789,Ceritinib,238
219,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated a decreased response when treated with Entrectinib (RXDX-101) (PMID: 26939704). ",Actionable,5640,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,"[{'id': 5130, 'pubMedId': 26939704, 'title': 'Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26939704'}]",decreased response,1455,Entrectinib,238
220,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5387,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,643,ASP3026,238
221,Preclinical,"In a preclinical study, Alecensa (alectinib) modestly inhibited growth of transformed cells expression EML4-ALK with ALK G1269A in culture (PMID: 26698910).",Actionable,5722,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",conflicting,698,Alectinib,238
222,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).
",Actionable,5386,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",conflicting,698,Alectinib,238
223,Preclinical,"In preclinical studies, transformed cells expressing EML4-ALK with ALK G1269A were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859, PMID: 26698910).",Actionable,5384,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}, {'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,706,Crizotinib,238
224,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).",Actionable,5383,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,1586,AZD3463,238
225,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).",Actionable,5381,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,634,AP26113,238
226,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5380,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,698,Alectinib,238
227,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).",Actionable,5351,50744,anaplastic large cell lymphoma,DOID,20662,NPM1-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,706,Crizotinib,238
228,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5379,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,238
229,Preclinical,"In a preclinical study, ASP3026 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).",Actionable,5382,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,643,ASP3026,238
230,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5378,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,706,Crizotinib,238
231,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5725,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,869,PF-06463922,238
232,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with G1269A were re-sensitized and modestly sensitive to Xalkori (crizotinib) with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).",Actionable,5723,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,706,Crizotinib,238
233,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5726,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,789,Ceritinib,238
234,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5727,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,698,Alectinib,238
235,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A and L1198F in culture (PMID: 26698910).",Actionable,5724,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,634,AP26113,238
236,Phase I,"In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in partial response that lasted 8.3 months in a patient with neuroblastoma harboring ALK F1245V, who remained on treatment for over 3.5 years due to clinical benefit (PMID: 28183697).",Actionable,10489,769,neuroblastoma,DOID,27527,ALK F1245V,"[{'id': 8566, 'pubMedId': 28183697, 'title': 'Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28183697'}]",predicted – sensitive,1455,Entrectinib,238
237,Preclinical - Patient cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell growth in patient derived non-small cell lung cancer cells harboring ALK I1171T in the context of EML4-ALK in culture (PMID: 26144315).",Actionable,3160,3908,non-small cell lung carcinoma,DOID,5340,EML4-ALK ALK I1171T,"[{'id': 3367, 'pubMedId': 26144315, 'title': 'PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144315'}]",sensitive,869,PF-06463922,238
238,Preclinical,"In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing EML4-ALK ALK I1171T in culture (PMID: 25228534).",Actionable,3399,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",sensitive,2386,TAE684,238
239,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8632,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,706,Crizotinib,238
240,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK I1171T in culture (PMID: 25228534).",Actionable,2058,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",sensitive,789,Ceritinib,238
241,Preclinical,"In a preclinical study, a transformed cell line expressing EML4-ALK with ALK I1171T was resistant to ASP3026 treatment in culture (PMID: 25228534).",Actionable,3407,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",resistant,643,ASP3026,238
242,Preclinical,"In a preclinical study, a transformed cell line expressing EML4-ALK with ALK I1171T was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534), however, another study with comparable cells demonstrated sensitivity in culture (PMID: 27432227). ",Actionable,3397,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}, {'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",conflicting,698,Alectinib,238
243,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8633,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,869,PF-06463922,238
244,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of a transformed cell line expressing EML4-ALK I1171T but to a lesser degree than EML4-ALK in culture (PMID: 25228534).",Actionable,3404,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",decreased response,634,AP26113,238
245,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5419,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,238
246,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5497,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,869,PF-06463922,238
247,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171T were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5411,50744,anaplastic large cell lymphoma,DOID,5337,NPM1-ALK ALK I1171T,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,238
248,Preclinical,"In a preclinical study, an anaplastic large-cell lymphoma cell line expressing NPM-ALK I1171T demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 24509625).",Actionable,2057,50744,anaplastic large cell lymphoma,DOID,5337,NPM1-ALK ALK I1171T,"[{'id': 1898, 'pubMedId': 24509625, 'title': 'Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24509625'}]",resistant,706,Crizotinib,238
249,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).",Actionable,5478,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,706,Crizotinib,238
250,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5438,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,698,Alectinib,238
251,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5488,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,789,Ceritinib,238
252,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5429,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,634,AP26113,238
253,Clinical Study,"In a clinical case study, a patient with a lung adenocarcinoma tumor harboring an ALK rearrangement with ALK I1171T progressed on Alecensa (alectinib) therapy after 4 months and resistance was confirmed using cell culture with cells derived from the patient’s tumor (PMID: 25228534). ",Actionable,3394,3910,lung adenocarcinoma,DOID,13309,ALK rearrange ALK I1171T,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",resistant,698,Alectinib,238
254,Clinical Study,"In a clinical case study, a de novo ALK I1171N mutation was identified in the liver metastasis site and circulating DNA of a non-small cell lung cancer patient harboring ALK rearrangement after the disease progressed while on Alecensa (alectinib) treatment (PMID: 27565911).",Actionable,10417,3908,non-small cell lung carcinoma,DOID,13309,ALK rearrange ALK I1171T,"[{'id': 8431, 'pubMedId': 27565911, 'title': 'Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27565911'}]",predicted – resistant,698,Alectinib,238
255,Clinical Study,"In a clinical case study, a patient with a lung adenocarcinoma tumor harboring ALK rearrange and ALK I1171T progressed on Xalkori (crizotinib) therapy after 8 months and resistance was confirmed using cell culture with cells derived from the patient’s tumor (PMID: 25228534). 
",Actionable,3395,3910,lung adenocarcinoma,DOID,13309,ALK rearrange ALK I1171T,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",resistant,706,Crizotinib,238
256,Phase II,"In a Phase I trial, Xalkori (crizotinib) treatment resulted in an objective response rate of 69% (89/129), and a median duration of treatment of 7.8 months in ALK negative, ROS1 positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9022)).",Actionable,6993,3908,non-small cell lung carcinoma,DOID,24174,ALK neg ROS1 pos,"[{'id': 6003, 'pubMedId': None, 'title': 'Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).', 'url': 'http://meetinglibrary.asco.org/content/168126-176'}]",sensitive,706,Crizotinib,238
257,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing ALK L1196Q were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).",Actionable,5504,50744,anaplastic large cell lymphoma,DOID,20952,NPM1-ALK ALK L1196Q,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,706,Crizotinib,238
258,Preclinical,"In a preclinical study, ASP3026 inhibited growth of human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing the crizotinib-resistant mutation ALK L1196Q in culture (PMID: 25749034).",Actionable,5503,50744,anaplastic large cell lymphoma,DOID,20952,NPM1-ALK ALK L1196Q,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,643,ASP3026,238
259,Preclinical,"In a preclinical study, a transformed cell line expressing ALK Y1278S was sensitive to Brigatinib (AP26113) in culture, resulting in cell growth inhibition (PMID: 27049722). ",Actionable,5877,10000003,Advanced Solid Tumor,JAX,13480,ALK Y1278S,"[{'id': 5182, 'pubMedId': 27049722, 'title': 'Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27049722'}]",sensitive,634,AP26113,238
260,Preclinical - Cell culture,"In a preclinical study, AZD3463 treatment enhanced the cytotoxic effects of Adriamycin (doxorubicin) in a neuroblastoma cell line harboring ALK D1091N, demonstrating increased apoptotic activity and decreased cell viability in culture (PMID: 28455243). ",Actionable,11451,769,neuroblastoma,DOID,23761,ALK D1091N,"[{'id': 9400, 'pubMedId': 28455243, 'title': 'The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28455243'}]",sensitive,5990,AZD3463 + Doxorubicin,238
261,Preclinical - Cell culture,"In a preclinical study, AZD3463 treatment in a neuroblastoma cell line harboring ALK D1091N resulted in inhibition of colony formation, repression of Pi3k signaling, and induction of apoptosis in culture (PMID: 26786851). ",Actionable,11450,769,neuroblastoma,DOID,23761,ALK D1091N,"[{'id': 7594, 'pubMedId': 26786851, 'title': 'Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26786851'}]",predicted – sensitive,1586,AZD3463,238
262,Preclinical - Cell culture,"In a preclinical study, Alecensa (alectinib) treatment in a neuroblastoma cell line harboring ALK D1091N resulted in decreased cell viability, inhibition of colony formation, and inhibition of Pi3k pathway signaling in culture (PMID: 28455243). ",Actionable,11448,769,neuroblastoma,DOID,23761,ALK D1091N,"[{'id': 9400, 'pubMedId': 28455243, 'title': 'The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28455243'}]",predicted – sensitive,698,Alectinib,238
263,Preclinical - Cell culture,"In a preclinical study, Alecensa (alectinib) treatment enhanced the cytotoxic effects of Adriamycin (doxorubicin) in a neuroblastoma cell line harboring ALK D1091N, demonstrating increased apoptotic activity and decreased cell viability in culture (PMID: 28455243). ",Actionable,11449,769,neuroblastoma,DOID,23761,ALK D1091N,"[{'id': 9400, 'pubMedId': 28455243, 'title': 'The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28455243'}]",predicted – sensitive,5989,Alectinib + Doxorubicin,238
264,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) in culture (PMID: 27780853).",Actionable,9269,10000003,Advanced Solid Tumor,JAX,26806,EML4-ALK ALK L1152P,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",decreased response,789,Ceritinib,238
265,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).",Actionable,9265,10000003,Advanced Solid Tumor,JAX,26806,EML4-ALK ALK L1152P,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",decreased response,706,Crizotinib,238
266,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK L1152P in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9260,10000003,Advanced Solid Tumor,JAX,26806,EML4-ALK ALK L1152P,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,238
267,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8626,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,706,Crizotinib,238
268,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8630,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,869,PF-06463922,238
269,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Brigatinib (AP26113) in culture (PMID: 27432227).  ",Actionable,8629,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,634,AP26113,238
270,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8627,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,789,Ceritinib,238
271,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated resistance to treatment with Alecensa (alectinib) in culture (PMID: 27432227).  ",Actionable,8628,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",resistant,698,Alectinib,238
272,Preclinical,"In a preclinical study, a transformed cell line expressing ALK I1171N was sensitive to Brigatinib (AP26113) in culture, resulting in cell growth inhibition (PMID: 27049722). ",Actionable,5872,10000003,Advanced Solid Tumor,JAX,1407,ALK I1171N,"[{'id': 5182, 'pubMedId': 27049722, 'title': 'Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27049722'}]",sensitive,634,AP26113,238
273,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5412,50744,anaplastic large cell lymphoma,DOID,20769,NPM1-ALK ALK I1171N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,238
274,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5437,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,698,Alectinib,238
275,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5418,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,238
276,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5496,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,869,PF-06463922,238
277,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5428,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,634,AP26113,238
278,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).",Actionable,5477,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,706,Crizotinib,238
279,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5487,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,789,Ceritinib,238
280,Preclinical,"In a preclinical study, ASP3026 inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).",Actionable,3406,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",sensitive,643,ASP3026,238
281,Preclinical,"In a preclinical study, a human non-small cell lung cancer cell line harboring EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534).",Actionable,3392,3908,non-small cell lung carcinoma,DOID,12072,EML4-ALK ALK V1180L,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",resistant,698,Alectinib,238
282,Preclinical,"In a preclinical study, a human non-small cell lung cancer cell line harboring EML4-ALK ALK V1180L was resistant to Xalkori (crizotinib) treatment in culture (PMID: 25228534).",Actionable,3393,3908,non-small cell lung carcinoma,DOID,12072,EML4-ALK ALK V1180L,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",resistant,706,Crizotinib,238
283,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).",Actionable,3400,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",sensitive,789,Ceritinib,238
284,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis of non-small cell lung carcinoma cells harboring ALK V1180L in the context of EML4-ALK in culture (PMID: 26144315). ",Actionable,2648,3908,non-small cell lung carcinoma,DOID,12072,EML4-ALK ALK V1180L,"[{'id': 3367, 'pubMedId': 26144315, 'title': 'PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144315'}]",sensitive,869,PF-06463922,238
285,Preclinical,"In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing EML4-ALK ALK V1180L in culture (PMID: 25228534).",Actionable,3398,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",sensitive,2386,TAE684,238
286,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of a transformed cell line expressing EML4-ALK ALK V1180L in culture (PMID: 25228534).",Actionable,3403,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",sensitive,634,AP26113,238
287,Preclinical,"In a preclinical study, a transformed cell line expressing EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534).",Actionable,3396,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",resistant,698,Alectinib,238
288,Clinical Study,"In a retrospective analysis, patients with ALK-rearrangement positive non-small cell lung cancer that acquired ALK drug resistance mutations following Xalkori (crizotinib) treatment had a median progression-free survival (mPFS) of 5.4 months on Zykadia (ceritinib), which was not significantly different than the mPFS of 6.5 months for patients without ALK mutations (PMID: 25724526).",Actionable,3297,3908,non-small cell lung carcinoma,DOID,13109,ALK rearrange ALK mut,"[{'id': 3718, 'pubMedId': 25724526, 'title': 'Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25724526'}]",sensitive,789,Ceritinib,238
289,Preclinical,"In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in patient-derived neuroblastoma cell lines harboring Alk mutations and functional TP53, resulting in growth inhibition in culture and tumor regression in animal models (PMID: 26438783).",Actionable,4736,769,neuroblastoma,DOID,18888,ALK mutant TP53 wild-type,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,238
290,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8640,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,869,PF-06463922,238
291,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8637,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,789,Ceritinib,238
292,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Brigatinib (AP26113) in culture (PMID: 27432227).  ",Actionable,8639,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,634,AP26113,238
293,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Alecensa (alectinib) in culture (PMID: 27432227).  ",Actionable,8638,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,698,Alectinib,238
294,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8636,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,706,Crizotinib,238
295,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3551,10000003,Advanced Solid Tumor,JAX,13326,NPM1-ALK ALK L1122V,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,643,ASP3026,238
296,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3459,10000003,Advanced Solid Tumor,JAX,13326,NPM1-ALK ALK L1122V,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,698,Alectinib,238
297,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).",Actionable,3480,10000003,Advanced Solid Tumor,JAX,13326,NPM1-ALK ALK L1122V,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,789,Ceritinib,238
298,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3441,10000003,Advanced Solid Tumor,JAX,13326,NPM1-ALK ALK L1122V,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,238
299,Preclinical,"In a preclinical study, a transformed cell line expressing ALK G1128A was sensitive to Brigatinib (AP26113) in culture, resulting in cell growth inhibition (PMID: 27049722). ",Actionable,5871,10000003,Advanced Solid Tumor,JAX,1404,ALK G1128A,"[{'id': 5182, 'pubMedId': 27049722, 'title': 'Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27049722'}]",sensitive,634,AP26113,238
300,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK S1206F in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9262,10000003,Advanced Solid Tumor,JAX,26804,EML4-ALK ALK S1206F,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,238
301,Preclinical - Patient cell culture,"In a preclinical study, NSCLC patient derived cells harboring an ALK rearrangement demonstrated resistance to Zykadia (ceritinib) due to the acquired mutation MAP2K1 K57N, however, sensitivity was restored to Zykadia (ceritinib) with the addition of AZD6244, resulting in decreased cell survival in culture and reduced tumor volume in xenograft models (PMID: 25394791).",Actionable,8661,3908,non-small cell lung carcinoma,DOID,26393,ALK rearrange MAP2K1 K57N,"[{'id': 1693, 'pubMedId': 25394791, 'title': 'Patient-derived models of acquired resistance can identify effective drug combinations for cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25394791'}]",sensitive,4786,Ceritinib + Selumetinib,238
302,Clinical Study,"In a clinical study, three patients with non-small cell lung carcinoma co-harboring an ALK rearrangement and ALK amplification demonstrated resistance to Xalkori (crizotinib) treatment (PMID: 27432227).",Actionable,8660,3908,non-small cell lung carcinoma,DOID,26389,ALK rearrange ALK amp,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",resistant,706,Crizotinib,238
303,Clinical Study,"In a clinical case study, RB1 C706F and loss of exons 1-11 in TP53 were identified in the pericardium infiltrating small cell lung cancer that developed while on Lorlatinib (PF-06463922) treatment in a patient with ALK-rearranged non-small cell lung carcinoma (PMID: 28285684).",Actionable,10437,5409,lung small cell carcinoma,DOID,27462,ALK rearrange RB1 C706F TP53 loss,"[{'id': 8449, 'pubMedId': 28285684, 'title': 'Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28285684'}]",predicted – resistant,869,PF-06463922,238
304,Clinical Study,"In a clinical case study, ALK G1202R was identified in a patient with ALK-rearranged non-small cell lung carcinoma after the disease progressed while on Zykadia (ceritinib) followed by Alecensa (alectinib) therapy (PMID: 28285684).",Actionable,10436,3908,non-small cell lung carcinoma,DOID,27461,ALK rearrange ALK G1202R,"[{'id': 8449, 'pubMedId': 28285684, 'title': 'Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28285684'}]",predicted – resistant,698,Alectinib,238
305,Clinical Study,"In a retrospective study, non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement demonstrated prolonged survival following treatment with the combination of an ALK-targeted tyrosine kinase inhibitor, including Ensartinib (X-396), and radiotherapy (PMID: 26438117).",Actionable,3665,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,"[{'id': 3941, 'pubMedId': 26438117, 'title': 'Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438117'}]",sensitive,961,X-396,238
306,Clinical Study,"In a retrospective study, non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement demonstrated prolonged survival following treatment with the combination of an ALK-targeted tyrosine kinase inhibitor, including Brigatinib (AP26113), and radiotherapy (PMID: 26438117).",Actionable,3663,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,"[{'id': 3941, 'pubMedId': 26438117, 'title': 'Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438117'}]",sensitive,634,AP26113,238
307,Phase Ib/II,"In a Phase I/II trial, Brigatinib (AP26113) treatment resulted in an objective response rate of 100% (8/8) in ALK inhibitor-naive ALK-rearranged non-small cell lung cancer (NSCLC) patients, 72% (51/71) in crizotinib-treated ALK-rearranged NSCLC patients, and 83% (5/6) in ALK-rearranged NSCLC patients with CNS metastases (PMID: 27836716).",Actionable,9228,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,"[{'id': 7043, 'pubMedId': 27836716, 'title': 'Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27836716'}]",sensitive,634,AP26113,238
308,Phase II,"In a Phase II trial, non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement and previously treated with Xalkori (crizotinib) and chemotherapy demonstrated strong responses for overall response, time to response, and progression free survival when treated with Zykadia (ceritinib) (PMID: 27432917). ",Actionable,8210,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,"[{'id': 6568, 'pubMedId': 27432917, 'title': 'Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432917'}]",sensitive,789,Ceritinib,238
309,Phase III,"In a Phase III trial, first-line treatment with Zykadia (ceritinib) resulted in an improved median progression-free survival of 16.1 months, compared to 8.1 months with chemotherapy, in patients with ALK-rearranged non-squamous non-small cell lung cancer (PMID: 28126333).",Actionable,9560,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,"[{'id': 7279, 'pubMedId': None, 'title': 'First-line Ceritinib Versus Chemotherapy in Patients With ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)', 'url': 'http://library.iaslc.org/virtual-library-search?product_id=6&author=&category=&date=&session_type=&session=&presentation=PL03.07&keyword='}, {'id': 7718, 'pubMedId': 28126333, 'title': 'First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28126333'}]",sensitive,789,Ceritinib,238
310,Clinical Study,"In a retrospective study, non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement demonstrated prolonged survival following treatment with the combination of an ALK-targeted tyrosine kinase inhibitor, including Zykadia (ceritinib), and radiotherapy (PMID: 26438117).",Actionable,3662,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,"[{'id': 3941, 'pubMedId': 26438117, 'title': 'Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438117'}]",sensitive,789,Ceritinib,238
311,Clinical Study,"In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",Actionable,8429,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,"[{'id': 6652, 'pubMedId': 27225694, 'title': 'EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27225694'}]",decreased response,1312,Nivolumab,238
312,Clinical Study,"In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Imfinzi (durvalumab), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",Actionable,8431,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,"[{'id': 6652, 'pubMedId': 27225694, 'title': 'EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27225694'}]",decreased response,1356,Durvalumab,238
313,Phase III,"In a Phase III trial, Xalkori (crizotinib) treatment resulted in improved progression-free survival (PFS) (PFS=10.9 months, n=172) relative to chemotherapy (PFS=7.0 months, n=171) in NSCLC patients with ALK rearrangements, including patients with and without brain metastases at baseline, and improved intracranial disease rate in patients with brain metastases at baseline (PMID: 27022118).",Actionable,5667,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,"[{'id': 5142, 'pubMedId': 27022118, 'title': 'Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27022118'}]",sensitive,706,Crizotinib,238
314,FDA approved,Xalkori (crizotinib) is FDA approved for the use in NSCLC patients harboring ALK rearrangements independently of any prior treatment the patients have received (PMID: 25806224). ,Actionable,2866,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,"[{'id': 3386, 'pubMedId': 25806224, 'title': 'Targeting EML4-ALK driven non-small cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806224'}]",sensitive,706,Crizotinib,238
315,FDA approved,"In a Phase II clinical trial that supported FDA approval, Alecensa (alectinib) treatment was effective in treating non-small cell lung cancer patients with ALK rearrangement, resulting in a 50% (61/122) objective response rate (ORR) in all patients, a 45% (43/96) ORR in Crizotinib-refractory patients, and an 83% (70/84) CNS disease control rate (PMID: 26598747).",Actionable,3730,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,"[{'id': 4000, 'pubMedId': 26598747, 'title': 'Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26598747'}]",sensitive,698,Alectinib,238
316,Clinical Study,"In a retrospective study, non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement demonstrated prolonged survival following treatment with the combination of an ALK-targeted tyrosine kinase inhibitor, including Alecensa (alectinib), and radiotherapy (PMID: 26438117).",Actionable,3664,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,"[{'id': 3941, 'pubMedId': 26438117, 'title': 'Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438117'}]",sensitive,698,Alectinib,238
317,Clinical Study,"In a retrospective analysis of patients with ALK-rearrangement positive non-small cell lung cancer, the combined median progression-free survival for sequential treatment with Xalkori (crizotinib) and Zykadia (ceritinib) without intervening treatments was 17.0 months, and overall survival was 49.4 months (PMID: 25724526).",Actionable,3296,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,"[{'id': 3718, 'pubMedId': 25724526, 'title': 'Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25724526'}]",sensitive,3108,Ceritinib + Crizotinib,238
318,Clinical Study,"In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",Actionable,8432,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,"[{'id': 6652, 'pubMedId': 27225694, 'title': 'EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27225694'}]",decreased response,1201,Atezolizumab,238
319,Phase I,"In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in objection response in 67% (4/6) of patients with advanced solid tumors harboring rearrangement in ALK gene (AACR Apr 2016, Abstract # CT007).",Actionable,6729,10000003,Advanced Solid Tumor,JAX,1248,ALK rearrange,"[{'id': 5790, 'pubMedId': None, 'title': 'Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=4abd89d1-63f0-4e65-b91c-486888d54e7a&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]",sensitive,1455,Entrectinib,238
320,Phase I,"In a clinical study analyzing combined results of 2 Phase I trials, Entrectinib (RXDX-101) treatment resulted in an objective response rate of 57% (4/7) in patients with ALK rearranged advanced solid tumors that were treatment-naive, but no response (0/19) in patients received prior Alk inhibitor treatments (PMID: 28183697).",Actionable,10496,10000003,Advanced Solid Tumor,JAX,1248,ALK rearrange,"[{'id': 8566, 'pubMedId': 28183697, 'title': 'Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28183697'}]",sensitive,1455,Entrectinib,238
321,Clinical Study,"In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",Actionable,8430,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,"[{'id': 6652, 'pubMedId': 27225694, 'title': 'EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27225694'}]",decreased response,1447,Pembrolizumab,238
322,Preclinical - Patient cell culture,"In a preclinical study, the combination of Saracatinib (AZD0530) and (Zykadia) ceritinib demonstrated efficacy in non-small cell lung cancer patient derived cells harboring an ALK fusion and upregulation of SRC in culture (PMID: 25394791).",Actionable,1618,3908,non-small cell lung carcinoma,DOID,26396,ALK rearrange SRC pos,"[{'id': 1693, 'pubMedId': 25394791, 'title': 'Patient-derived models of acquired resistance can identify effective drug combinations for cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25394791'}]",sensitive,1939,Saracatinib + Ceritinib,238
323,Preclinical - Cell line xenograft,"In a preclinical study, TPX-0005 inhibited ALK G1202R and suppressed tumor growth in cell line xenograft models with ALK G1202R (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",Actionable,5833,10000003,Advanced Solid Tumor,JAX,1681,ALK G1202R,"[{'id': 5176, 'pubMedId': None, 'title': 'The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=055d4461-9793-4f83-b663-f356d9ae0fdb&cKey=ff6f8d25-f06a-4ae4-9dbf-7e390ef45123&mKey={1D10D749-4B6A-4AB3-BCD4-F80FB1922267}'}]",sensitive,3950,TPX-0005,238
324,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5716,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,698,Alectinib,238
325,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5718,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,789,Ceritinib,238
326,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910).",Actionable,5717,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,634,AP26113,238
327,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).",Actionable,5714,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,706,Crizotinib,238
328,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5715,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,869,PF-06463922,238
329,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5710,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,698,Alectinib,238
330,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202R demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8635,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,869,PF-06463922,238
331,Preclinical - Cell line xenograft,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK G1202R in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853).",Actionable,5713,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,238
332,Preclinical - Cell line xenograft,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis in transformed cells over expressing ALK G1202R in the context of EML4-ALK in culture and in cell line xenograft models (PMID: 26144315). ",Actionable,2649,1324,lung cancer,DOID,5339,EML4-ALK ALK G1202R,"[{'id': 3367, 'pubMedId': 26144315, 'title': 'PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144315'}]",conflicting,869,PF-06463922,238
333,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,8294,1324,lung cancer,DOID,5339,EML4-ALK ALK G1202R,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",conflicting,869,PF-06463922,238
334,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5711,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,789,Ceritinib,238
335,Preclinical - Cell line xenograft,"In a preclinical study, TPX-0005 inhibited Alk activity and proliferation of transformed cells over expressing ALK G1201R in the context of EML4-ALK in culture, resulted in tumor regression in cell line xenograft models (European Journal of Cancer , Volume 69, S32).",Actionable,10346,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,"[{'id': 8338, 'pubMedId': None, 'title': 'TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants', 'url': 'http://www.ejcancer.com/article/S0959-8049%2816%2932675-2/abstract'}]",sensitive,3950,TPX-0005,238
336,Clinical Study,"In a clinical study, an ALK G1202R secondary mutation in the context of EML4-ALK was associated with resistance to Xalkori (crizotinib) in a patient with non-small cell lung cancer, and resistance was replicated in cell culture studies (PMID: 22277784).",Actionable,1000,3908,non-small cell lung carcinoma,DOID,5339,EML4-ALK ALK G1202R,"[{'id': 683, 'pubMedId': 22277784, 'title': 'Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22277784'}]",resistant,706,Crizotinib,238
337,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).",Actionable,5709,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,706,Crizotinib,238
338,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were insensitive to Zykadia (ceritinib) in culture (PMID: 24675041). ",Actionable,2097,3908,non-small cell lung carcinoma,DOID,5339,EML4-ALK ALK G1202R,"[{'id': 2525, 'pubMedId': 24675041, 'title': 'The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24675041'}]",resistant,789,Ceritinib,238
339,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to RXDX-101 (PMID: 26939704). ",Actionable,5639,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,"[{'id': 5130, 'pubMedId': 26939704, 'title': 'Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26939704'}]",resistant,1455,Entrectinib,238
340,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3553,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,643,ASP3026,238
341,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3461,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,698,Alectinib,238
342,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F in culture (PMID: 25421750).",Actionable,3458,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,706,Crizotinib,238
343,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).",Actionable,3482,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,789,Ceritinib,238
344,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Brigatinib (AP26113) in culture (PMID: 25421750).",Actionable,3434,50744,anaplastic large cell lymphoma,DOID,13333,NPM1-ALK ALK F1174V ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,238
345,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK1198F were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3438,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,238
346,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3462,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,698,Alectinib,238
347,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3444,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,238
348,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3555,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,643,ASP3026,238
349,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1198F in culture (PMID: 25421750).",Actionable,3457,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,706,Crizotinib,238
350,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).",Actionable,3481,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,789,Ceritinib,238
351,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5686,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,789,Ceritinib,238
352,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EML4-ALK with L1198F in culture (PMID: 26698910).",Actionable,5690,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,634,AP26113,238
353,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).",Actionable,5683,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}, {'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",conflicting,698,Alectinib,238
354,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with L1198F had reduced sensitivity to growth inhibition mediated by Lorlatinib (PF-06463922) in comparison to EML4-ALK wild type in culture (PMID: 26698910).",Actionable,5680,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",decreased response,869,PF-06463922,238
355,Preclinical,"In a preclinical study, Xalkori (crizotinib) enhanced growth inhibition of transformed cells expressing EML4-ALK with L1198F in culture (PMID: 26698910).",Actionable,5675,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,706,Crizotinib,238
356,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3439,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,238
357,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3487,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,789,Ceritinib,238
358,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3453,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,706,Crizotinib,238
359,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK ALK S1206C were resistant to brigatinib (AP26113) in culture (PMID: 25421750).",Actionable,3436,50744,anaplastic large cell lymphoma,DOID,13332,NPM1-ALK ALK S1206C,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,238
360,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK and ALK S1206C were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3556,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,643,ASP3026,238
361,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3463,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,698,Alectinib,238
362,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to delay tumor growth in xenograft models of a human neuroblastoma cell line harboring constitutively phosphorylated wild-type Alk and wild-type TP53 (PMID: 26438783).",Actionable,4733,769,neuroblastoma,DOID,18886,ALK act mut TP53 wild-type,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",predicted – sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,238
363,Preclinical,"In a preclinical study, neuroblastoma cells harboring ALK F1174V were sensitive to Brigatinib (AP26113) in culture and in vivo, resulting in inhibition of both Alk activity and cell proliferation (PMID: 27049722). ",Actionable,5880,769,neuroblastoma,DOID,3081,ALK F1174V,"[{'id': 5182, 'pubMedId': 27049722, 'title': 'Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27049722'}]",sensitive,634,AP26113,238
364,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).",Actionable,3456,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,706,Crizotinib,238
365,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).",Actionable,3443,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,634,AP26113,238
366,Preclinical,"In a preclinical trial, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).",Actionable,3484,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,789,Ceritinib,238
367,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3465,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,698,Alectinib,238
368,Preclinical,"In a preclinical trial, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3557,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,643,ASP3026,238
369,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK F1174V in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).",Actionable,9267,10000003,Advanced Solid Tumor,JAX,26808,EML4-ALK ALK F1174V,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",decreased response,706,Crizotinib,238
370,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK F1174V in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9261,10000003,Advanced Solid Tumor,JAX,26808,EML4-ALK ALK F1174V,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,238
371,Preclinical - Pdx,"In a preclinical study, Xalkori (crizotinib) worked synergistically with Topotecan and Cytoxan (cyclophosphamide), resulting in sustained tumor regression in crizotinib-resistant neuroblastoma PDX models harboring ALK F1245C and wild-type Tp53 (PMID: 26438783).",Actionable,4732,769,neuroblastoma,DOID,18883,ALK	F1245C TP53	wild-type,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,238
372,Clinical Study,"In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 that demonstrated resistance to treatment with Xalkori (crizotinib) after acquisition of ALK F1245C, achieved a complete radiographic response with no evidence of progression at 6 months following treatment with Zykadia (ceritinib) (PMID: 26775591).",Actionable,10734,3908,non-small cell lung carcinoma,DOID,27740,EML4-ALK ALK F1245C,"[{'id': 8753, 'pubMedId': 26775591, 'title': 'A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26775591'}]",sensitive,789,Ceritinib,238
373,Clinical Study,"In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 demonstrated an initial response to treatment with Xalkori (crizotinib), but progressed after 27 months and was found to have acquired ALK F1245C (PMID: 26775591).",Actionable,10733,3908,non-small cell lung carcinoma,DOID,27740,EML4-ALK ALK F1245C,"[{'id': 8753, 'pubMedId': 26775591, 'title': 'A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26775591'}]",resistant,706,Crizotinib,238
374,Preclinical,"In a preclinical study, a transformed cell line expressing ALK F1245C was sensitive to Brigatinib (AP26113) in culture, resulting in cell growth inhibition (PMID: 27049722). ",Actionable,5875,10000003,Advanced Solid Tumor,JAX,1414,ALK F1245C,"[{'id': 5182, 'pubMedId': 27049722, 'title': 'Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27049722'}]",sensitive,634,AP26113,238
375,Preclinical - Pdx & cell culture,"In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK F1245C in culture, and only delayed tumor growth in patient-derived xenograft models harboring ALK F1245C (PMID: 26554404).",Actionable,8370,769,neuroblastoma,DOID,1414,ALK F1245C,"[{'id': 6636, 'pubMedId': 26554404, 'title': 'The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26554404'}]",resistant,706,Crizotinib,238
376,Preclinical - Pdx & cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of neuroblastoma cells over expressing ALK F1245C in culture, and induced rapid and sustained complete tumor regression in patient-derived xenograft models harboring ALK F1245C (PMID: 26554404).",Actionable,8375,769,neuroblastoma,DOID,1414,ALK F1245C,"[{'id': 6636, 'pubMedId': 26554404, 'title': 'The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26554404'}]",sensitive,869,PF-06463922,238
377,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited foci formation more efficiently than Xalkori (crizotinib) in transformed cells over expressing ALK F1245C in culture (PMID: 26554404).",Actionable,8384,10000003,Advanced Solid Tumor,JAX,1414,ALK F1245C,"[{'id': 6636, 'pubMedId': 26554404, 'title': 'The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26554404'}]",sensitive,869,PF-06463922,238
378,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5367,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,238
379,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5368,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,698,Alectinib,238
380,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5370,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,643,ASP3026,238
381,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5371,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,1586,AZD3463,238
382,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Brigatinib (AP26113) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5369,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,634,AP26113,238
383,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).",Actionable,5353,50744,anaplastic large cell lymphoma,DOID,20657,NPM1-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,238
384,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5366,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,706,Crizotinib,238
385,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).",Actionable,5372,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,706,Crizotinib,238
386,Preclinical,"In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to ASP3026 in culture (PMID: 27009859).",Actionable,5377,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,643,ASP3026,238
387,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).",Actionable,5373,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,698,Alectinib,238
388,Preclinical,"In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).",Actionable,5376,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,238
389,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).",Actionable,5374,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,634,AP26113,238
390,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).",Actionable,5375,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,1586,AZD3463,238
391,Preclinical,"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 P177T in culture (PMID: 26438783).",Actionable,4738,769,neuroblastoma,DOID,18889,ALK	wild-type TP53 P177T,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,238
392,Preclinical,"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 C176F in culture (PMID: 26438783).",Actionable,4737,769,neuroblastoma,DOID,18880,ALK	wild-type TP53 C176F,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,238
393,Preclinical - Cell line xenograft,"In a preclinical study, TPX-0005 inhibited cell proliferation in transformed cell lines over expressing wild-type ALK in culture and suppressed tumor growth in xenograft models (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",Actionable,5832,10000003,Advanced Solid Tumor,JAX,391,ALK wild-type,"[{'id': 5176, 'pubMedId': None, 'title': 'The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=055d4461-9793-4f83-b663-f356d9ae0fdb&cKey=ff6f8d25-f06a-4ae4-9dbf-7e390ef45123&mKey={1D10D749-4B6A-4AB3-BCD4-F80FB1922267}'}]",sensitive,3950,TPX-0005,238
394,Preclinical - Cell line xenograft,"In a preclinical study, Dalantercept (ACE-041) in combination with Platinol (cisplatin) resulted in decreased tumor growth in cell line xenograft models of breast cancer (PMID: 26373572).",Actionable,5322,1612,breast cancer,DOID,391,ALK wild-type,"[{'id': 5020, 'pubMedId': 26373572, 'title': 'Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26373572'}]",predicted – sensitive,3834,Dalantercept + Cisplatin,238
395,Preclinical - Cell line xenograft,"In a preclinical study, Dalantercept (ACE-041) in combination with Adria (doxorubicin) resulted in decreased tumor growth in cell line xenograft models of melanoma, with increased efficacy over either agent alone (PMID: 26373572).",Actionable,5323,1909,melanoma,DOID,391,ALK wild-type,"[{'id': 5020, 'pubMedId': 26373572, 'title': 'Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26373572'}]",sensitive,3837,Dalantercept + Doxorubicin,238
396,Phase II,"In a Phase II clinical trial, treatment with Dalantercept (ACE-041) did not demonstrate activity as single agent in recurrent or persistent endometrial cancer, with a median progression-free survival (PFS) of 2.1 months, overall survival of 14.5 months, no objective responses, and stable disease in 57% (16/28) of patients (PMID: 25888978).",Actionable,5320,1380,endometrial cancer,DOID,391,ALK wild-type,"[{'id': 5023, 'pubMedId': 25888978, 'title': 'Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25888978'}]",no benefit,1244,dalantercept  ,238
397,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) did not inhibit growth of ALK wild-type neuroblastoma cells in culture (PMID: 26554404).",Actionable,8380,769,neuroblastoma,DOID,391,ALK wild-type,"[{'id': 6636, 'pubMedId': 26554404, 'title': 'The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26554404'}]",resistant,869,PF-06463922,238
398,Preclinical - Cell line xenograft,"In a preclinical study, the addition of Dalantercept (ACE-041) to Platinol (cisplatin) treatment resulted in increased cytoxicity and decreased tumor growth in cell line xenograft models of head and neck cancer (PMID: 26373572).",Actionable,5321,11934,head and neck cancer,DOID,391,ALK wild-type,"[{'id': 5020, 'pubMedId': 26373572, 'title': 'Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26373572'}]",predicted – sensitive,3834,Dalantercept + Cisplatin,238
399,Preclinical - Cell line xenograft,"In a preclinical study, Xalkori (crizotinib) did not improve the effect of Topotecan and Cytoxan (cyclophosphamide) on tumor growth suppression in xenograft models of a human neuroblastoma cell line harboring wild-type ALK and TP53 H168R (PMID: 26438783).",Actionable,4734,769,neuroblastoma,DOID,18884,ALK	wild-type TP53 H168R,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,238
400,Preclinical,"In a preclinical study, Topotecan and Cytoxan (cyclophosphamide) combination treatment resulted in mild  tumor growth suppression in neuroblastoma xenograft models harboring wild-type Alk and TP53 H168R (PMID: 26438783).",Actionable,4742,769,neuroblastoma,DOID,18884,ALK	wild-type TP53 H168R,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",not applicable,2590,Cyclophosphamide + Topotecan,238
401,Preclinical,"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and wild-type TP53 in culture (PMID: 26438783).",Actionable,4741,769,neuroblastoma,DOID,18892,ALK wild-type TP53 wild-type,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,238
402,Preclinical,"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 mutations in culture (PMID: 26438783).",Actionable,4739,769,neuroblastoma,DOID,18890,ALK	wild-type TP53 mutant,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,238
403,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859), however, in another study comparable cells demonstrated sensitivity (PMID: (PMID: (PMID: 27432227).",Actionable,5328,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}, {'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",conflicting,789,Ceritinib,238
404,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5330,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,698,Alectinib,238
405,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171S demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8631,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,869,PF-06463922,238
406,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Brigatinib (AP26113) mediated growth inhibition in culture (PMID: 27009859), however, another study with comparable cells demonstrated sensitivity (PMID: 27432227). ",Actionable,5331,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}, {'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",resistant,634,AP26113,238
407,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5333,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,643,ASP3026,238
408,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5336,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,1586,AZD3463,238
409,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5325,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,706,Crizotinib,238
410,Clinical Study,"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer initially responded to Alecensa (alectinib) but progressed with the emergence of a secondary ALK I1171S mutation (PMID: 25393796).",Actionable,5391,3908,non-small cell lung carcinoma,DOID,20653,EML4-ALK ALK I1171S,"[{'id': 5028, 'pubMedId': 25393796, 'title': 'Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25393796'}]",resistant,698,Alectinib,238
411,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859).",Actionable,5335,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,1586,AZD3463,238
412,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5334,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,643,ASP3026,238
413,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859).",Actionable,5332,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,634,AP26113,238
414,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5329,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,698,Alectinib,238
415,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1161S were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).",Actionable,5349,50744,anaplastic large cell lymphoma,DOID,20654,NPM1-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,706,Crizotinib,238
416,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5326,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,706,Crizotinib,238
417,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5327,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,238
418,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Brigatinib (AP26113) in culture (PMID: 25421750).",Actionable,3432,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,238
419,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK demonstrated a decreased response compared to parental cell lines harboring NPM1-ALK when treated with Alecensa (alectinib) in culture (PMID: 25421750).",Actionable,3427,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,698,Alectinib,238
420,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3431,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,643,ASP3026,238
421,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).",Actionable,3425,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,706,Crizotinib,238
422,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).",Actionable,3426,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,789,Ceritinib,238
423,Preclinical,"In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in neuroblastoma cell lines harboring Alk amplification and functional TP53, resulting in growth inhibition in culture (PMID: 26438783).",Actionable,4740,769,neuroblastoma,DOID,18891,ALK amp Tp53 wild-type,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,238
424,Preclinical - Cell culture,"In a preclinical study, ALK amplified neuroblastoma cells demonstrated decreased response to Xalkori (crizotinib) induced growth of inhibition in culture (PMID: 26554404).",Actionable,8373,769,neuroblastoma,DOID,1760,ALK amp,"[{'id': 6636, 'pubMedId': 26554404, 'title': 'The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26554404'}]",decreased response,706,Crizotinib,238
425,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of ALK amplified neuroblastoma cells in culture (PMID: 26554404).",Actionable,8379,769,neuroblastoma,DOID,1760,ALK amp,"[{'id': 6636, 'pubMedId': 26554404, 'title': 'The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26554404'}]",sensitive,869,PF-06463922,238
426,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK L1152R in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) in culture (PMID: 27780853).",Actionable,9268,10000003,Advanced Solid Tumor,JAX,5425,EML4-ALK ALK L1152R,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",decreased response,789,Ceritinib,238
427,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK L1152R in the context of EML4-ALK in culture  (PMID: 26144315). ",Actionable,8295,10000003,Advanced Solid Tumor,JAX,5425,EML4-ALK ALK L1152R,"[{'id': 3367, 'pubMedId': 26144315, 'title': 'PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144315'}]",sensitive,869,PF-06463922,238
428,Preclinical,"In preclinical studies, transformed cell lines expressing EML4-ALK L1152R demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 21791641).",Actionable,2144,10000003,Advanced Solid Tumor,JAX,5425,EML4-ALK ALK L1152R,"[{'id': 918, 'pubMedId': 21791641, 'title': 'A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21791641'}]",resistant,706,Crizotinib,238
429,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK L1152R in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9259,10000003,Advanced Solid Tumor,JAX,5425,EML4-ALK ALK L1152R,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,238
0,Preclinical - Cell culture,"In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cells harboring APC L1488* in culture (PMID: 27798265).",Actionable,9090,9256,colorectal cancer,DOID,4327,APC L1488*,"[{'id': 6906, 'pubMedId': 27798265, 'title': 'Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27798265'}]",sensitive,4896,TASIN-1,324
1,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line harboring APC  N1819fs*7 and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481).",Actionable,10559,9256,colorectal cancer,DOID,27591,APC N1819fs,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",resistant,2455,IWR-1,324
2,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line harboring APC  N1819fs (reported as N1819fs*7) and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481).",Actionable,10552,9256,colorectal cancer,DOID,27619,APC N1819fs APC wild-type,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",resistant,2991,G007-LK,324
3,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line harboring APC  N1819fs (reported as N1819fs*7) and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481).",Actionable,10565,9256,colorectal cancer,DOID,27619,APC N1819fs APC wild-type,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",resistant,1732,XAV939,324
4,Preclinical - Cell culture,"In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cell lines harboring APC G11416* in culture (PMID: 27798265).",Actionable,9091,9256,colorectal cancer,DOID,26725,APC G1416*,"[{'id': 6906, 'pubMedId': 27798265, 'title': 'Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27798265'}]",sensitive,4896,TASIN-1,324
5,Preclinical - Cell culture,"In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cells harboring APC Q1131* and Q1303* in culture (PMID: 27798265).",Actionable,9088,9256,colorectal cancer,DOID,26729,APC Q1131* APC Q1303*,"[{'id': 6906, 'pubMedId': 27798265, 'title': 'Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27798265'}]",sensitive,4896,TASIN-1,324
6,Preclinical,"In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) resulted in reduced tumor growth and additive effect on survival compared to single agent in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",Actionable,9200,9256,colorectal cancer,DOID,26771,APC inact mut KRAS G12D,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",sensitive,4932,BEZ235 + Binimetinib,324
7,Preclinical,"In a preclinical study, Binimetinib (MEK162) increased apoptosis in tumors and improved survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",Actionable,9193,9256,colorectal cancer,DOID,26771,APC inact mut KRAS G12D,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",sensitive,807,Binimetinib,324
8,Preclinical,"In a preclinical study, BEZ235 inhibited  PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",Actionable,9190,9256,colorectal cancer,DOID,26771,APC inact mut KRAS G12D,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",sensitive,672,BEZ235,324
9,Preclinical,"In a preclinical study, Binimetinib (MEK162) reduced proliferation in tumors acutely but did not improve survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",Actionable,9192,9256,colorectal cancer,DOID,26770,APC inact mut PTEN inact mut,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",no benefit,807,Binimetinib,324
10,Preclinical,"In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) did not improve survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",Actionable,9199,9256,colorectal cancer,DOID,26770,APC inact mut PTEN inact mut,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",no benefit,4932,BEZ235 + Binimetinib,324
11,Preclinical,"In a preclinical study, BEZ235 inhibited  PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",Actionable,9189,9256,colorectal cancer,DOID,26770,APC inact mut PTEN inact mut,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",sensitive,672,BEZ235,324
12,Preclinical,"In a preclinical study, Binimetinib (MEK162) increased both apoptosis and proliferation in tumors, resulted in no improvement in survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",Actionable,9194,9256,colorectal cancer,DOID,26772,APC inact mut KRAS G12D PTEN inact mut,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",no benefit,807,Binimetinib,324
13,Preclinical,"In a preclinical study, BEZ235 inhibited mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation, and KRAS G12D (PMID: 26206338).",Actionable,9191,9256,colorectal cancer,DOID,26772,APC inact mut KRAS G12D PTEN inact mut,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",sensitive,672,BEZ235,324
14,Preclinical,"In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) increased survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",Actionable,9201,9256,colorectal cancer,DOID,26772,APC inact mut KRAS G12D PTEN inact mut,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",sensitive,4932,BEZ235 + Binimetinib,324
15,Preclinical,"In a preclinical study, iCRT-5 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture (PMID: 21393571).",Actionable,3151,219,colon cancer,DOID,1734,APC inact mut,"[{'id': 3647, 'pubMedId': 21393571, 'title': 'An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21393571'}]",sensitive,2452,iCRT-5,324
16,Preclinical,"In a preclinical study, colorectal cancer mouse models carrying APC inactivating mutations had reduced intestinal tumor burden after treatment with Clinoril (sulindac) (PMID: 19755659).",Actionable,1714,9256,colorectal cancer,DOID,1734,APC inact mut,"[{'id': 1927, 'pubMedId': 19755659, 'title': 'Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19755659'}]",sensitive,2126,Sulindac,324
17,Preclinical,"In a preclinical study, the combination of Sprycel (dasatinib) and curcumin inhibited tumor growth in a mouse model of colorectal cancer harboring an Apc mutation (PMID: 20473900).",Actionable,1716,9256,colorectal cancer,DOID,1734,APC inact mut,"[{'id': 1949, 'pubMedId': 20473900, 'title': 'Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20473900'}]",sensitive,717,Dasatinib,324
18,Preclinical,"In a preclinical study, Caprelsa (vandetanib) reduced the number of dextran sodium sulfate-induced tumors in an APC-deficient mouse model for colon cancer (PMID: 20811697).",Actionable,1029,219,colon cancer,DOID,1734,APC inact mut,"[{'id': 745, 'pubMedId': 20811697, 'title': 'Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20811697'}]",sensitive,953,Vandetanib,324
19,Preclinical,"In a preclinical study, XAV939 inhibited growth of colorectal cancer cells harboring APC inactivating mutations in culture (PMID: 19759537).",Actionable,3122,9256,colorectal cancer,DOID,1734,APC inact mut,"[{'id': 1147, 'pubMedId': 19759537, 'title': 'Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19759537'}]",sensitive,1732,XAV939,324
20,Preclinical,"In a preclinical study, iCRT-3 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture (PMID: 21393571).",Actionable,3146,219,colon cancer,DOID,1734,APC inact mut,"[{'id': 3647, 'pubMedId': 21393571, 'title': 'An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21393571'}]",sensitive,2404,iCRT-3,324
21,Preclinical,"In a preclinical study, CCT036477 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).",Actionable,3143,9256,colorectal cancer,DOID,1734,APC inact mut,"[{'id': 2213, 'pubMedId': 20610623, 'title': 'A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20610623'}]",sensitive,2398,CCT036477,324
22,Preclinical,"In a preclinical study, PKF115-584 inhibited proliferation of colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).",Actionable,1726,219,colon cancer,DOID,1734,APC inact mut,"[{'id': 1950, 'pubMedId': 14749129, 'title': 'Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/14749129'}]",sensitive,2081,PKF115-584,324
23,Preclinical - Cell line xenograft,"In a preclinical study, ibuprofen, in combination with Tarceva (erlotinib), demonstrated efficacy in reducing tumor number and volume in APC inactivating mutant mice and in cell line xenograft models of colorectal cancer (PMID: 17909047).",Actionable,1715,9256,colorectal cancer,DOID,1734,APC inact mut,"[{'id': 1924, 'pubMedId': 17909047, 'title': 'Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17909047'}]",sensitive,2127,Erlotinib + Ibuprofen,324
24,Preclinical,"In a preclinical study, ICG-001 decreased cell proliferation in colon cancer cell lines and in mouse models carrying APC inactivating mutations (PMID: 15314234). ",Actionable,1722,219,colon cancer,DOID,1734,APC inact mut,"[{'id': 1915, 'pubMedId': 15314234, 'title': 'A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected].', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15314234'}]",sensitive,2084,ICG-001,324
25,Preclinical,"In a preclinical study, mouse models of colon cancer carrying an APC 716del mutation had reduced polyp formation after treatment with MF tricyclic (PMID: 23843721).",Actionable,1723,219,colon cancer,DOID,1734,APC inact mut,"[{'id': 1954, 'pubMedId': 23843721, 'title': 'Recent progress in mouse models for tumor suppressor genes and its implications in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23843721'}]",sensitive,2089,MF tricyclic,324
26,Preclinical - Cell line xenograft,"In a preclinical study, iCRT-14 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture and decreased initial tumor growth in APC-mutant colon cancer cell line xenograft models (PMID: 21393571).",Actionable,3152,219,colon cancer,DOID,1734,APC inact mut,"[{'id': 3647, 'pubMedId': 21393571, 'title': 'An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21393571'}]",sensitive,2453,iCRT-14,324
27,Preclinical - Cell line xenograft,"In a preclinical study, NC043 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC truncation mutations in culture and in cell line xenograft models (PMID: 21321609).",Actionable,3147,9256,colorectal cancer,DOID,1734,APC inact mut,"[{'id': 2218, 'pubMedId': 21321609, 'title': 'A diterpenoid derivative 15-oxospiramilactone inhibits Wnt/β-catenin signaling and colon cancer cell tumorigenesis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21321609'}]",sensitive,2405,NC043,324
28,Preclinical - Cell line xenograft,"In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cell lines harboring APC truncation mutations in culture and in cell line xenograft models (PMID: 27798265).",Actionable,9085,9256,colorectal cancer,DOID,1734,APC inact mut,"[{'id': 6906, 'pubMedId': 27798265, 'title': 'Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27798265'}]",sensitive,4896,TASIN-1,324
29,Preclinical,"In a preclinical study, Pyrvinium inhibited Wnt signaling and decreased viability of colon cancer cells harboring APC mutations in culture (PMID: 20890287).",Actionable,3150,9256,colorectal cancer,DOID,1734,APC inact mut,"[{'id': 2226, 'pubMedId': 20890287, 'title': 'Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20890287'}]",sensitive,2412,Pyrvinium,324
30,Preclinical,"In a preclinical study, StAx-35 inhibited proliferation of colon cancer cell lines carrying APC deletions in culture (PMID: 23071338).",Actionable,1729,219,colon cancer,DOID,1734,APC inact mut,"[{'id': 1916, 'pubMedId': 23071338, 'title': 'Inhibition of oncogenic Wnt signaling through direct targeting of β-catenin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23071338'}]",sensitive,2085,StAx-35,324
31,Preclinical,"In a preclinical study, CCT070535 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).",Actionable,3144,9256,colorectal cancer,DOID,1734,APC inact mut,"[{'id': 2213, 'pubMedId': 20610623, 'title': 'A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20610623'}]",sensitive,2399,CCT070535,324
32,Preclinical,"In a preclinical study, Niclosamide inhibited proliferation of colorectal cancer cells harboring APC mutations in culture (PMID: 21531761).",Actionable,3161,9256,colorectal cancer,DOID,1734,APC inact mut,"[{'id': 3654, 'pubMedId': 21531761, 'title': 'Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21531761'}]",sensitive,3072,Niclosamide,324
33,Preclinical,"In a preclinical study, JW55 inhibited proliferation of colorectal cancer cells with an APC truncation mutation in culture and decreased tumor development in a mouse model expressing a conditional APC truncation mutation (PMID: 22440753).",Actionable,3149,219,colon cancer,DOID,1734,APC inact mut,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}]",sensitive,2411,JW55,324
34,Preclinical,"In a preclinical study, PKF118-310 inhibited proliferation of colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).",Actionable,3142,9256,colorectal cancer,DOID,1734,APC inact mut,"[{'id': 1950, 'pubMedId': 14749129, 'title': 'Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/14749129'}]",sensitive,2397,PKF118-310,324
35,Preclinical,"In a preclinical study, FH535 inhibited beta-catenin/TCF-dependent transactivation and demonstrated toxicity in colon carcinoma cells harboring an APC mutation in culture (PMID: 18347139).",Actionable,3140,1520,colon carcinoma,DOID,1734,APC inact mut,"[{'id': 1914, 'pubMedId': 18347139, 'title': 'A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18347139'}]",sensitive,2083,FH535,324
36,Preclinical - Cell line xenograft,"In a preclinical study, G007-LK inhibited growth of APC-mutant colorectal cancer cell lines in culture and in xenograft models (PMID: 23539443).",Actionable,3153,219,colon cancer,DOID,1734,APC inact mut,"[{'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",sensitive,2991,G007-LK,324
37,Preclinical,"In preclinical trials, Sirolimus (rapamycin) was shown effective in reducing tumors in mouse models of familial adenomatous polyposis and colon cancer with APC deficient tumors (PMID: 18768809, PMID: 20080688).",Actionable,1020,219,colon cancer,DOID,1734,APC inact mut,"[{'id': 737, 'pubMedId': 18768809, 'title': 'Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18768809'}, {'id': 738, 'pubMedId': 20080688, 'title': 'Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20080688'}]",sensitive,917,Sirolimus,324
38,Preclinical,"In a preclinical study, CGP049090 inhibited proliferation of a colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).",Actionable,1717,219,colon cancer,DOID,1734,APC inact mut,"[{'id': 1950, 'pubMedId': 14749129, 'title': 'Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/14749129'}]",sensitive,2082,CGP049090,324
39,Preclinical,"In a preclinical study, APC inactivating mutant mouse models of colon cancer had reduced polyp formation after treatment with Celebra (celecoxib) (PMID: 17909047).",Actionable,1713,9256,colorectal cancer,DOID,1734,APC inact mut,"[{'id': 1924, 'pubMedId': 17909047, 'title': 'Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17909047'}]",sensitive,2124,Celecoxib,324
40,Preclinical,"In preclinical studies, cells deficient in Apc protein had increased sensitivity to Navelbine (vinorelbine) compared to wild-type cells, and Navelbine (vinorelbine) treament decreased adenoma size in an Apc-deficient mouse model (PMID: 22399804).",Actionable,1024,219,colon cancer,DOID,1734,APC inact mut,"[{'id': 740, 'pubMedId': 22399804, 'title': 'The microtubule poison vinorelbine kills cells independently of mitotic arrest and targets cells lacking the APC tumour suppressor more effectively.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22399804'}]",sensitive,1685,Vinorelbine,324
41,Preclinical,"In a preclinical study, CCT031374 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).",Actionable,3145,9256,colorectal cancer,DOID,1734,APC inact mut,"[{'id': 2213, 'pubMedId': 20610623, 'title': 'A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20610623'}]",sensitive,2400,CCT031374,324
42,Preclinical - Cell line xenograft,"In a preclinical study, Celebra (celecoxib), in combination with Tarceva (erlotinib), demonstrated efficacy in reducing tumor number and volume in APC inactivating mutant mice and in human colorectal cancer cell line xenograft models (PMID: 17909047).",Actionable,1712,9256,colorectal cancer,DOID,1734,APC inact mut,"[{'id': 1924, 'pubMedId': 17909047, 'title': 'Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17909047'}]",sensitive,2125,Celecoxib + Erlotinib,324
43,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs*3 demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481).",Actionable,10567,9256,colorectal cancer,DOID,27597,APC E853* APC T1556fs,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",resistant,1732,XAV939,324
44,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs*3 demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481).",Actionable,10557,9256,colorectal cancer,DOID,27597,APC E853* APC T1556fs,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",resistant,2455,IWR-1,324
45,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs*3 demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481).",Actionable,10551,9256,colorectal cancer,DOID,27597,APC E853* APC T1556fs,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",resistant,2991,G007-LK,324
46,Preclinical - Cell line xenograft,"In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cells harboring APC E853* and K1555* in culture and in cell line xenograft models (PMID: 27798265).",Actionable,9087,9256,colorectal cancer,DOID,26728,APC E853* APC K1555*,"[{'id': 6906, 'pubMedId': 27798265, 'title': 'Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27798265'}]",sensitive,4896,TASIN-1,324
47,Preclinical - Patient cell culture,"In a preclinical study, G007-LK inhibited growth of a patient-derived colorectal cancer cell line harboring APC I1164fs in culture (PMID: 28179481).",Actionable,10572,9256,colorectal cancer,DOID,27625,APC I1164fs,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",sensitive,2991,G007-LK,324
48,Preclinical - Cell culture,"In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC I1164fs in culture (PMID: 28179481).",Actionable,10573,9256,colorectal cancer,DOID,27625,APC I1164fs,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",sensitive,2455,IWR-1,324
49,Preclinical - Cell line xenograft,"In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cells harboring APC E1309* in culture and in cell line xenograft models (PMID: 27798265).",Actionable,9086,9256,colorectal cancer,DOID,4281,APC E1309*,"[{'id': 6906, 'pubMedId': 27798265, 'title': 'Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27798265'}]",sensitive,4896,TASIN-1,324
50,Clinical Study,"In a clinical case study, a rectal adenocarcinoma patient harboring APC Q1429fs, BRAF N581S, and ERBB2 L755S did not respond to Herceptin (trastuzumab) treatment in combination with Fluorouracil and Wellcovorin (leucovorin) (PMID: 27626067).",Actionable,9333,1996,rectum adenocarcinoma,DOID,26822,APC Q1429fs BRAF N581S ERBB2 L755S,"[{'id': 7088, 'pubMedId': 27626067, 'title': 'Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27626067'}]",no benefit,4970,Fluorouracil + Leucovorin + Trastuzumab,324
51,Preclinical - Pdx,"In a preclinical study, Vantictumab (OMP-18R5) inhibited tumor growth in patient-derived xenograft models of colon cancer with wild-type CTNNB1 (beta-catenin) and APC (PMID: 22753465).",Actionable,7164,219,colon cancer,DOID,24535,APC wild-type CTNNB1 wild-type,"[{'id': 6127, 'pubMedId': 22753465, 'title': 'Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22753465'}]",predicted – sensitive,4397,Vantictumab,324
52,Preclinical - Cell line xenograft,"In a preclinical study, TASIN-1 did not inhibit survival of APC wild-type colorectal cancer cells in culture or in cell line xenograft models (PMID: 27798265).",Actionable,9084,9256,colorectal cancer,DOID,508,APC wild-type,"[{'id': 6906, 'pubMedId': 27798265, 'title': 'Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27798265'}]",resistant,4896,TASIN-1,324
53,Preclinical - Cell culture,"In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC R216* in culture (PMID: 28179481).",Actionable,10571,9256,colorectal cancer,DOID,4408,APC R216*,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",sensitive,2455,IWR-1,324
54,Preclinical - Cell culture,"In a preclinical study, a patient-derived colorectal cancer cell line harboring APC R216* demonstrated sensitivity to G007-LK in culture (PMID: 28179481).",Actionable,10570,9256,colorectal cancer,DOID,4408,APC R216*,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",sensitive,2991,G007-LK,324
55,Preclinical - Cell culture,"In a preclinical study, G007-LK inhibited growth of a patient-derived colorectal cancer cell line harboring APC W553* in culture (PMID: 28179481).",Actionable,10575,9256,colorectal cancer,DOID,27627,APC W553*,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",sensitive,2991,G007-LK,324
56,Preclinical - Cell culture,"In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC W553* in culture (PMID: 28179481).",Actionable,10574,9256,colorectal cancer,DOID,27627,APC W553*,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",sensitive,2455,IWR-1,324
57,Preclinical - Cell culture,"In a preclinical study, treatment with IWR-1 decreased active beta-catenin levels and reduced growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481).",Actionable,10553,9256,colorectal cancer,DOID,27569,APC S811*,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",sensitive,2455,IWR-1,324
58,Preclinical - Cell culture,"In a preclinical study, XAV939 inhibited growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481).",Actionable,10562,9256,colorectal cancer,DOID,27569,APC S811*,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",sensitive,1732,XAV939,324
59,Preclinical - Cell culture,"In a preclinical study, treatment with G007-LK decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481).",Actionable,10543,9256,colorectal cancer,DOID,27569,APC S811*,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",sensitive,2991,G007-LK,324
60,Preclinical,"In a preclinical study, JW67 inhibited Wnt signaling and decreased proliferation of colorectal cancer cells harboring APC Q1338* in culture (PMID: 21199802).",Actionable,3289,9256,colorectal cancer,DOID,4364,APC Q1338*,"[{'id': 755, 'pubMedId': 21199802, 'title': 'Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21199802'}]",sensitive,3103,JW67,324
61,Preclinical - Cell culture,"In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cell lines harboring APC Q1338* in culture (PMID: 27798265).",Actionable,9089,9256,colorectal cancer,DOID,4364,APC Q1338*,"[{'id': 6906, 'pubMedId': 27798265, 'title': 'Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27798265'}]",sensitive,4896,TASIN-1,324
62,Preclinical,"In a preclinical study, JW74 inhibited Wnt signaling and decreased growth of colorectal cancer cells harboring APC Q1338* in culture and in xenograft models (PMID: 21199802).",Actionable,3290,9256,colorectal cancer,DOID,4364,APC Q1338*,"[{'id': 755, 'pubMedId': 21199802, 'title': 'Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21199802'}]",sensitive,3104,JW74,324
63,Preclinical - Cell culture,"In a preclinical study, treatment with IWR-1 decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481).",Actionable,10554,9256,colorectal cancer,DOID,27595,APC S1197* APC S1278*,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",sensitive,2455,IWR-1,324
64,Preclinical - Cell culture,"In a preclinical study, treatment with G007-LK decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481).",Actionable,10546,9256,colorectal cancer,DOID,27595,APC S1197* APC S1278*,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",sensitive,2991,G007-LK,324
65,Preclinical - Cell culture,"In a preclinical study, XAV939 inhibited growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481).",Actionable,10564,9256,colorectal cancer,DOID,27595,APC S1197* APC S1278*,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",sensitive,1732,XAV939,324
66,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481).",Actionable,10566,9256,colorectal cancer,DOID,27596,APC L665* APC R1450*,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",sensitive,1732,XAV939,324
67,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481).",Actionable,10558,9256,colorectal cancer,DOID,27596,APC L665* APC R1450*,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",sensitive,2455,IWR-1,324
68,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481).",Actionable,10550,9256,colorectal cancer,DOID,27596,APC L665* APC R1450*,"[{'id': 8618, 'pubMedId': 28179481, 'title': 'APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179481'}]",resistant,2991,G007-LK,324
69,Preclinical,"In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369). ",Actionable,2135,9256,colorectal cancer,DOID,5415,APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut,"[{'id': 2380, 'pubMedId': 25261369, 'title': 'Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25261369'}]",sensitive,1282,Sapanisertib,324
70,Clinical Study,"In a clinical case study, Stivarga (regorafenib) treatment resulted in durable partial response in a colorectal cancer patient harboring KDR R961W and mutations in APC and KRAS (PMID: 27004155).",Actionable,5559,9256,colorectal cancer,DOID,21268,APC mutant KRAS mutant KDR R961W,"[{'id': 5105, 'pubMedId': 27004155, 'title': 'KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27004155'}]",sensitive,890,Regorafenib,324
71,Preclinical - Cell line xenograft,"In a preclinical study, G-631 inhibited Wnt pathway signaling in colorectal cancer cell line xenograft models harboring an APC mutation, but demonstrated little anti-tumor activity and led to intestinal toxicity (PMID: 26692561).",Actionable,4287,9256,colorectal cancer,DOID,5414,APC mutant,"[{'id': 4481, 'pubMedId': 26692561, 'title': 'Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index < 1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26692561'}]",no benefit,3471,G-631,324
72,Preclinical,"In a preclinical study, JW74 reduced tumor formation and growth in a mouse model of colorectal cancer harboring an APC mutation (PMID: 21199802).",Actionable,3291,9256,colorectal cancer,DOID,5414,APC mutant,"[{'id': 755, 'pubMedId': 21199802, 'title': 'Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21199802'}]",sensitive,3104,JW74,324
73,Preclinical,"In a preclinical study, K-756 inhibited Wnt signaling and reduced growth of 2/3 tested APC-mutant colorectal cancer cell lines in culture (PMID: 27196752).",Actionable,7260,9256,colorectal cancer,DOID,5414,APC mutant,"[{'id': 6261, 'pubMedId': 27196752, 'title': 'The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196752'}]",predicted – sensitive,4427,K-756,324
0,Clinical Study,"In clinical analyses, mutations in ASXL1 were associated with poor prognosis in patients in patients with myelodysplastic syndrome (PMID: 24220272, PMID: 21714648).",Prognostic,6036,50908,myelodysplastic syndrome,DOID,3486,ASXL1 mutant,"[{'id': 5253, 'pubMedId': 24220272, 'title': 'Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24220272'}, {'id': 5254, 'pubMedId': 21714648, 'title': 'Clinical effect of point mutations in myelodysplastic syndromes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21714648'}]",not applicable,1776,N/A,171023
1,Clinical Study,"In a clinical study, myelodysplastic syndrome patients carrying wild-type ASXL1 and TET2 mutations demonstrated increased response to the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) (PMID: 25224413).",Actionable,6169,4972,myelodysplastic/myeloproliferative neoplasm,DOID,22786,ASXL1 wild-type TET2 mutant,"[{'id': 3740, 'pubMedId': 25224413, 'title': 'TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25224413'}]",sensitive,651,Azacitidine,171023
2,Clinical Study,"In a clinical study, myelodysplastic syndrome patients carrying wild-type ASXL1 and TET2 mutations demonstrated increased response to the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) (PMID: 25224413).",Actionable,6170,4972,myelodysplastic/myeloproliferative neoplasm,DOID,22786,ASXL1 wild-type TET2 mutant,"[{'id': 3740, 'pubMedId': 25224413, 'title': 'TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25224413'}]",sensitive,650,Decitabine,171023
3,Clinical Study,"In multiple clinical studies, nonsense and frameshift mutations in ASXL1 were associated with decreased overall survival in patients with chronic myelomonocytic leukemia (PMID: 26849014, PMID: 23690417, PMID: 20880116).",Prognostic,3320,4972,myelodysplastic/myeloproliferative neoplasm,DOID,22424,ASXL1 inact mut,"[{'id': 3731, 'pubMedId': 20880116, 'title': 'ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20880116'}, {'id': 5278, 'pubMedId': 26849014, 'title': 'Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26849014'}, {'id': 5343, 'pubMedId': 23690417, 'title': 'Prognostic score including gene mutations in chronic myelomonocytic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23690417'}]",not applicable,1776,N/A,171023
0,Preclinical,"In a preclinical study, a KRAS G12D driven lung adenocarcinoma mouse model with homozygous deletion of ATM was sensitive to Lynparza (olaparib), demonstrating reduced tumor volume and greater overall survival when compared to models treated with control (PMID: 28363999).",Actionable,11387,3910,lung adenocarcinoma,DOID,27978,ATM del KRAS G12D,"[{'id': 9282, 'pubMedId': 28363999, 'title': 'ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363999'}]",sensitive,837,Olaparib,472
1,Preclinical,"In a preclinical study, a KRAS G12D driven lung adenocarcinoma mouse model with homozygous deletion of ATM was sensitive to VX-970, demonstrating decreased tumor volume and greater overall survival compared to control treated models (PMID: 28363999). ",Actionable,11388,3910,lung adenocarcinoma,DOID,27978,ATM del KRAS G12D,"[{'id': 9282, 'pubMedId': 28363999, 'title': 'ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363999'}]",sensitive,2879,VX-970,472
2,Clinical Study,"In a clinical case study, addition of Afinitor (everolimus)  to Caprelsa (vandetanib) treatment resulted in significant tumor reduction in a medullary thyroid carcinoma patient harboring ATM L804fs*4, ATM S978fs*12, and RET M918T, that achieved prolonged stable disease on Caprelsa (vandetanib) treatment alone (PMID: 27683183).",Actionable,10637,3973,thyroid medullary carcinoma,DOID,27653,ATM L804fs*4 ATM S978fs*12 RET M918T ,"[{'id': 8676, 'pubMedId': 27683183, 'title': 'RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27683183'}]",predicted – sensitive,1163,Vandetanib + Everolimus,472
3,Preclinical,"In a preclinical study, E7449 inhibited proliferation of a ATM-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair pathway mutations (PMID: 26513298).",Actionable,6507,10000003,Advanced Solid Tumor,JAX,522,ATM inact mut,"[{'id': 4121, 'pubMedId': 26513298, 'title': 'E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26513298'}]",sensitive,724,E7449,472
4,Preclinical - Cell culture,"In a preclinical study, an ATM-deficient cell line demonstrated increased sensitivity to Veliparib (ABT-888) compared to an ATM-reconstituted cell line, in culture (PMID: 21300883).",Actionable,8423,10000003,Advanced Solid Tumor,JAX,522,ATM inact mut,"[{'id': 6648, 'pubMedId': 21300883, 'title': 'Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21300883'}]",sensitive,954,Veliparib,472
5,Phase II,"In a Phase II clinical trial, 80% (4/5) of metastatic, castration-resistant prostate cancer patients harboring an ATM inactivating mutation responded to Lynparza (olaparib) (PMID: 26510020).",Actionable,3635,10283,prostate cancer,DOID,522,ATM inact mut,"[{'id': 3921, 'pubMedId': 26510020, 'title': 'DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26510020'}]",sensitive,837,Olaparib,472
6,Preclinical - Cell line xenograft,"In a preclinical study, a mantle cell lymphoma cell line with ATM inactivation demonstrated sensitivity to Lynparza (olaparib) in culture and in xenograft models (PMID: 20739657).",Actionable,7681,50746,mantle cell lymphoma,DOID,522,ATM inact mut,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",sensitive,837,Olaparib,472
7,Preclinical - Patient cell culture,"In a preclinical study, patient-derived chronic lymphocytic leukemia cells with inactivating mutations in ATM, that had been induced to proliferate in culture, demonstrated increased sensitivity to growth inhibition by Lynparza (olaparib) compared to ATM wild-type cells (PMID: 20739657).",Actionable,7688,1040,chronic lymphocytic leukemia,DOID,522,ATM inact mut,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",sensitive,837,Olaparib,472
8,Preclinical - Patient cell culture,"In a preclinical study, lymphoblastoid cell lines with ATM inactivation derived from ataxia-telangiectasia patients demonstrated increased sensitivity to Lynparza (olaparib) in culture, compared to ATM wild-type cell lines (PMID: 20739657).",Actionable,185,1037,lymphoblastic leukemia,DOID,522,ATM inact mut,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",sensitive,837,Olaparib,472
9,Preclinical - Cell culture,"In a preclinical study, Lynparza (olaparib) sensitized a mantle cell lymphoma cell line harboring an ATM inactivating mutation to Fludara (fludarabine) in cell culture, resulting in decreased cell survival (PMID: 20739657).",Actionable,7701,50746,mantle cell lymphoma,DOID,522,ATM inact mut,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",sensitive,4550,Fludarabine + Olaparib,472
10,Preclinical - Cell culture,"In a preclinical study, Lynparza (olaparib) sensitized a mantle cell lymphoma cell line harboring an ATM inactivating mutation to Treanda (bendamustine) in cell culture, resulting in growth inhibition (PMID: 20739657).",Actionable,7693,50746,mantle cell lymphoma,DOID,522,ATM inact mut,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",sensitive,4548,Bendamustine + Olaparib,472
11,Preclinical - Cell culture,"In a preclinical study, the combination of Lynparza (olaparib) an valproic acid worked synergistically to inhibit growth of a mantle cell lymphoma cell line harboring an ATM inactivating mutation in culture (PMID: 20739657).",Actionable,7696,50746,mantle cell lymphoma,DOID,522,ATM inact mut,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",sensitive,4549,Olaparib + Valproic Acid,472
12,Preclinical - Cell line xenograft,"In a preclinical study, knockdown of ATM in a gastric cancer cell line resulted in increased sensitivity to Veliparib (ABT-888) in culture and in xenograft models (PMID:  27638859).",Actionable,8422,10534,stomach cancer,DOID,1391,ATM dec exp,"[{'id': 6647, 'pubMedId': 27638859, 'title': 'ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27638859'}]",sensitive,954,Veliparib,472
13,Phase II,"In a Phase II trial, addition of Lynparza (olaparib) to Taxol (paclitaxel) did not significantly improve progression free survival (5.29 vs 3.68 months) compared to Taxol alone, but did significantly prolong overall survival (HR = 0.35) in metastatic gastric cancer patients with decreased Atm expression (PMID: 26282658).",Actionable,8766,10534,stomach cancer,DOID,1391,ATM dec exp,"[{'id': 6735, 'pubMedId': 26282658, 'title': 'Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26282658'}]",predicted – sensitive,4807,Olaparib + Paclitaxel,472
14,Preclinical,"In a preclinical study, knockdown of ATM expression sensitized breast cancer cells to treatment with Talazoparib (BMN-673) in culture (PMID: 23881923).",Actionable,864,1612,breast cancer,DOID,1391,ATM dec exp,"[{'id': 520, 'pubMedId': 23881923, 'title': 'BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23881923'}]",sensitive,682,Talazoparib,472
15,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Camptosar (irinotecan) and Veliparib (ABT-888) demonstrated synergy in gastric cancer cell lines with high ATM expression, resulting in increased apoptosis in culture, and enhanced tumor growth inhibition in cell line xenograft models (PMID: 27638859).",Actionable,9554,10534,stomach cancer,DOID,26891,ATM over exp,"[{'id': 6647, 'pubMedId': 27638859, 'title': 'ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27638859'}]",sensitive,3314,Irinotecan + Veliparib,472
16,Preclinical - Cell culture,"In a preclinical study, high ATM expression was associated with decreased response to Camptosaur (irinotecan) in gastric cancer cell lines in culture (PMID: 27638859).",Actionable,9555,10534,stomach cancer,DOID,26891,ATM over exp,"[{'id': 6647, 'pubMedId': 27638859, 'title': 'ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27638859'}]",decreased response,1074,Irinotecan,472
17,Preclinical - Cell culture,"In a preclinical study, high ATM expression was associated with decreased response to Veliparib (ABT-888) in gastric cancer cell lines in culture (PMID: 27638859).",Actionable,9553,10534,stomach cancer,DOID,26891,ATM over exp,"[{'id': 6647, 'pubMedId': 27638859, 'title': 'ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27638859'}]",decreased response,954,Veliparib,472
18,Phase II,"In a Phase II clinical trial, 80% (4/5) of metastatic castration-resistant prostate cancer patients with ATM truncation mutations demonstrated response to Lynparza (olaparib) treatment (Cancer Res August 1, 2015 75:CT322).",Actionable,3285,10283,prostate cancer,DOID,3274,ATM mutant,"[{'id': 3712, 'pubMedId': None, 'title': 'DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322.short'}]",sensitive,837,Olaparib,472
19,Clinical Study,"In a clinical study, a melanoma patient harboring an ATM mutation and NRAS Q61R demonstrated a partial response and 16 month progression free survival when treated with Binimetinib (MEK162) (PMID: 28514312). ",Actionable,11054,1909,melanoma,DOID,27905,ATM mut NRAS Q61R,"[{'id': 9046, 'pubMedId': 28514312, 'title': 'Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28514312'}]",sensitive,807,Binimetinib,472
20,Preclinical,"In a preclinical study, YU238259 demonstrated increased cytotoxicity in ATM-deficient transformed human cell lines in culture (PMID: 26116172).",Actionable,5531,10000003,Advanced Solid Tumor,JAX,11378,ATM loss,"[{'id': 5087, 'pubMedId': 26116172, 'title': 'YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26116172'}]",sensitive,3880,YU238259,472
21,Preclinical,"In a preclinical study, AZD6482 induced cell death in ATM-deficient chronic lymphocytic leukemia cells in culture and inhibited tumor growth in xenograft models (PMID: 26563132).",Actionable,5522,1040,chronic lymphocytic leukemia,DOID,11378,ATM loss,"[{'id': 5085, 'pubMedId': 26563132, 'title': 'ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26563132'}]",sensitive,659,AZD6482,472
22,Preclinical,"In a preclinical study, AZD6738 and Platinol (cisplatin) synergistically induced cell death in ATM-deficient non-small cell lung carcinoma cell lines in culture, and caused rapid tumor regression in xenograft models (PMID: 26517239).",Actionable,5520,3908,non-small cell lung carcinoma,DOID,11378,ATM loss,"[{'id': 5084, 'pubMedId': 26517239, 'title': 'The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26517239'}]",sensitive,3876,AZD6738 + Cisplatin,472
23,Preclinical,"In a preclinical study, AZD6738 sensitized ATM-deficient chronic lymphocytic leukemia cells to Imbruvica (Ibrutinib) treatment in culture (PMID: 26563132).",Actionable,5524,1040,chronic lymphocytic leukemia,DOID,11378,ATM loss,"[{'id': 5085, 'pubMedId': 26563132, 'title': 'ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26563132'}]",sensitive,3877,AZD6738 + Ibrutinib,472
24,Preclinical - Cell culture,"In a preclinical study, the combination of AZD6738 and Lynparza (olaparib) resulted in a synergistic effect, demonstrating cell death in head and neck cancer cells harboring ATM loss in culture (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C60).",Actionable,11900,11934,head and neck cancer,DOID,11378,ATM loss,"[{'id': 9892, 'pubMedId': None, 'title': 'Abstract C60: Pre-clinical efficacy of the ATR inhibitor AZD6738 in combination with the PARP inhibitor olaparib', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/C60'}]",predicted – sensitive,4739,AZD6738 + Olaparib,472
25,Phase I,"In a Phase I trial, VX-970 treatment resulted in complete response for more than 19 months in a colorectal cancer patient harboring ATM loss (J Clin Oncol 34, 2016 (suppl; abstr 2504)).",Actionable,6709,9256,colorectal cancer,DOID,11378,ATM loss,"[{'id': 5761, 'pubMedId': None, 'title': 'Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies.', 'url': 'http://abstracts.asco.org/176/AbstView_176_165738.html'}]",sensitive,2879,VX-970,472
0,Preclinical,"In a preclinical study, E7449 inhibited proliferation of a ATRX-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair pathway mutations (PMID: 26513298).",Actionable,6510,10000003,Advanced Solid Tumor,JAX,23602,ATRX inact mut,"[{'id': 4121, 'pubMedId': 26513298, 'title': 'E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26513298'}]",sensitive,724,E7449,546
1,Preclinical,"In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505).",Actionable,6204,3068,glioblastoma multiforme,DOID,22832,ATRX loss,"[{'id': 5444, 'pubMedId': 26936505, 'title': 'ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26936505'}]",sensitive,942,Topotecan,546
2,Preclinical,"In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505).",Actionable,6203,3068,glioblastoma multiforme,DOID,22832,ATRX loss,"[{'id': 5444, 'pubMedId': 26936505, 'title': 'ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26936505'}]",sensitive,1074,Irinotecan,546
3,Preclinical,"In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505).",Actionable,6202,3068,glioblastoma multiforme,DOID,22832,ATRX loss,"[{'id': 5444, 'pubMedId': 26936505, 'title': 'ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26936505'}]",sensitive,1009,Doxorubicin,546
4,Phase I,"In a Phase I trial, Gemzar (gemcitabine) plus radiation therapy resulted in median overall survival of 73.5 months in 7 high-grade glioma patients with IDH mutated, non-codeleted tumors with ATRX loss (PMID: 26853339).",Actionable,6205,3070,malignant glioma,DOID,22833,ATRX loss IDH1 mutant,"[{'id': 5446, 'pubMedId': 26853339, 'title': 'Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26853339'}]",predicted – sensitive,4093,Gemcitabine + Radiotherapy,546
0,Clinical Study,"In multiple clinical analyses, internal tandem duplications of the BCOR gene were consistently found in clear cell sarcoma of the kidney (PMID: 26098867, PMID: 26516930, PMID: 26573325, PMID: 26150234), suggesting that this may serve as a future diagnostic biomarker.",Emerging,6206,4880,kidney clear cell sarcoma,DOID,22834,BCOR mutant,"[{'id': 5449, 'pubMedId': 26098867, 'title': 'Consistent in-frame internal tandem duplications of BCOR characterize clear cell sarcoma of the kidney.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26098867'}, {'id': 5450, 'pubMedId': 26516930, 'title': 'Whole transcriptome sequencing identifies BCOR internal tandem duplication as a common feature of clear cell sarcoma of the kidney.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26516930'}, {'id': 5451, 'pubMedId': 26573325, 'title': 'Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26573325'}, {'id': 5452, 'pubMedId': 26150234, 'title': 'Kidney cancer: BCOR mutations that might help in diagnosis of CCSK.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26150234'}]",not applicable,1776,N/A,54880
1,Clinical Study,"In a clinical case study, a patient with acute promyelocytic leukemia harboring BCOR-RARA demonstrated sensitivity to treatment with Vesanoid (tretinoin) and achieved a complete response (PMID: 25790901). ",Actionable,7912,60318,acute promyelocytic leukemia,DOID,24667,BCOR-RARA,"[{'id': 6523, 'pubMedId': 25790901, 'title': 'Successful treatment of acute promyelocytic leukemia with a t(X;17)(p11.4;q21) and BCOR-RARA fusion gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25790901'}]",sensitive,1877,Tretinoin  ,54880
0,Clinical Study,"In a clinical study, BCORL1 over expression was associated with decreased overall survival and recurrence-free survival in patients with hepatocellular carcinoma (PMID: 26879601), suggesting that this may serve as a future prognostic biomarker.",Emerging,6207,684,hepatocellular carcinoma,DOID,22835,BCORL1 over exp,"[{'id': 5456, 'pubMedId': 26879601, 'title': 'BCORL1 is an independent prognostic marker and contributes to cell migration and invasion in human hepatocellular carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26879601'}]",not applicable,1776,N/A,63035
0,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601T (PMID: 26343582).",Actionable,9417,10000003,Advanced Solid Tumor,JAX,3573,BRAF K601T,"[{'id': 7141, 'pubMedId': 26343582, 'title': 'BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343582'}]",resistant,342,Vemurafenib,673
1,Preclinical,"In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation in transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I in culture (PMID: 20538618).",Actionable,6843,10000003,Advanced Solid Tumor,JAX,23818,BRAF V600E BRAF T529I,"[{'id': 5859, 'pubMedId': 20538618, 'title': 'Gatekeeper mutations mediate resistance to BRAF-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538618'}]",sensitive,699,CI-1040,673
2,Preclinical,"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529I were insensitive to PLX4720-mediated inhibition of ERK signaling in culture (PMID: 20538618).",Actionable,6835,10000003,Advanced Solid Tumor,JAX,23818,BRAF V600E BRAF T529I,"[{'id': 5859, 'pubMedId': 20538618, 'title': 'Gatekeeper mutations mediate resistance to BRAF-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538618'}]",predicted – resistant,1060,PLX4720,673
3,Preclinical,"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529I were insensitive to SB590885-mediated inhibition of ERK signaling in culture (PMID: 20538618).",Actionable,6826,10000003,Advanced Solid Tumor,JAX,23818,BRAF V600E BRAF T529I,"[{'id': 5859, 'pubMedId': 20538618, 'title': 'Gatekeeper mutations mediate resistance to BRAF-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538618'}]",predicted – resistant,4281,SB590885,673
4,Preclinical,"In a preclinical study, RAF265 inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",Actionable,6830,10000003,Advanced Solid Tumor,JAX,23818,BRAF V600E BRAF T529I,"[{'id': 5859, 'pubMedId': 20538618, 'title': 'Gatekeeper mutations mediate resistance to BRAF-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538618'}]",predicted – sensitive,884,RAF265,673
5,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",Actionable,6840,10000003,Advanced Solid Tumor,JAX,23818,BRAF V600E BRAF T529I,"[{'id': 5859, 'pubMedId': 20538618, 'title': 'Gatekeeper mutations mediate resistance to BRAF-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538618'}]",predicted – sensitive,920,Sorafenib,673
6,Preclinical,"In a preclinical study, LY3009120 modestly inhibited soft agar growth of human melanoma cancer cells harboring NRAS R167L, BRAF K601E, and BRAF A665V in culture (PMID: 26343583).",Actionable,6597,1909,melanoma,DOID,23641,NRAS R167L BRAF K601E BRAF A665V,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",decreased response,3268,LY3009120,673
7,Preclinical,"In a preclinical study, human melanoma cells harboring BRAF K601E, BRAF A665V, and NRAS R167L were insensitive to Selumetinib (AZD6244) in culture (PMID: 26343583).",Actionable,6605,1909,melanoma,DOID,23641,NRAS R167L BRAF K601E BRAF A665V,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,913,Selumetinib,673
8,Phase II,"In a Phase II trial, a melanoma patient harboring BRAF K601E demonstrated a partial response and a progression free survival of 32 weeks when treated with Mekinist (trametinib) (PMID: 23248257; NCT01037127).",Actionable,12070,1909,melanoma,DOID,655,BRAF K601E,"[{'id': 10005, 'pubMedId': 23248257, 'title': 'Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248257'}]",sensitive,2,Trametinib,673
9,Clinical Study,"In a clinical case study, a melanoma patient with BRAF K601E demonstrated a 48% reduction in lymphadenopathy when treated with Mekinist (trametinib) and after more than 36 months of treatment showed a complete response (PMID: 28344857). ",Actionable,12068,1909,melanoma,DOID,655,BRAF K601E,"[{'id': 8660, 'pubMedId': 28344857, 'title': 'Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36\xa0months.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28344857'}]",sensitive,2,Trametinib,673
10,Preclinical - Cell culture,"In a preclinical study, the MEK inhibitor, Mekinist (trametinib) decreased activation of MEK and ERK in cells expressing BRAF K601E in culture (PMID: 22798288).",Actionable,697,10000003,Advanced Solid Tumor,JAX,655,BRAF K601E,"[{'id': 3, 'pubMedId': 22798288, 'title': 'BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22798288'}]",sensitive,2,Trametinib,673
11,Preclinical,"In a preclinical study, treatment of cells expressing BRAF K601E with the BRAF inhibitor, Zelboraf (vemurafenib), decreased activation of MEK and ERK (PMID: 22798288).",Actionable,698,10000003,Advanced Solid Tumor,JAX,655,BRAF K601E,"[{'id': 3, 'pubMedId': 22798288, 'title': 'BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22798288'}]",conflicting,342,Vemurafenib,673
12,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601E (PMID: 26343582).",Actionable,9408,10000003,Advanced Solid Tumor,JAX,655,BRAF K601E,"[{'id': 7141, 'pubMedId': 26343582, 'title': 'BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343582'}]",conflicting,342,Vemurafenib,673
13,Phase I,"In a Phase I trial, no responses were demonstrated among three melanoma patients with non-V600 BRAF mutations, including two patients harboring BRAF K601E, following treatment with Tafinlar (dabrafenib), compared to a confirmed response rate of 50% in patients harboring BRAF V600 mutations (PMID: 22608338).",Actionable,12069,1909,melanoma,DOID,655,BRAF K601E,"[{'id': 467, 'pubMedId': 22608338, 'title': 'Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22608338'}]",no benefit,3,Dabrafenib,673
14,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601N (PMID: 26343582).",Actionable,9418,10000003,Advanced Solid Tumor,JAX,2437,BRAF K601N,"[{'id': 7141, 'pubMedId': 26343582, 'title': 'BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343582'}]",resistant,342,Vemurafenib,673
15,Preclinical - Cell culture,"In a preclinical study, a hematological tumor cell line harboring BRAF K601N demonstrated sensitivity to LY3009120 in culture (PMID: 26732095).",Actionable,12071,2531,hematologic cancer,DOID,2437,BRAF K601N,"[{'id': 3, 'pubMedId': 22798288, 'title': 'BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22798288'}]",sensitive,3268,LY3009120,673
16,Preclinical,"Preclinical studies demonstrated the MEK inhibitor, Mekinist (trametinib) caused decreased activation of MEK and ERK in cells expressing BRAF L597S (PMID: 22798288).",Actionable,696,10000003,Advanced Solid Tumor,JAX,994,BRAF L597S,"[{'id': 3, 'pubMedId': 22798288, 'title': 'BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22798288'}]",sensitive,2,Trametinib,673
17,Phase I,"In a Phase I trial, one metastatic melanoma patient carrying a BRAF L597S mutation, had a partial response to the MEK inhibitor, TAK-33 (PMID: 22798288).",Actionable,699,1909,melanoma,DOID,994,BRAF L597S,"[{'id': 3, 'pubMedId': 22798288, 'title': 'BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22798288'}]",sensitive,932,TAK-733,673
18,Preclinical,"In a preclinical study, treatment of cells expressing BRAF L597S with the BRAF inhibitor, Zelboraf (vemurafenib), decreased activation of MEK and ERK (PMID: 22798288).",Actionable,695,10000003,Advanced Solid Tumor,JAX,994,BRAF L597S,"[{'id': 3, 'pubMedId': 22798288, 'title': 'BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22798288'}]",sensitive,342,Vemurafenib,673
19,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G464R (PMID: 26343582).",Actionable,9412,10000003,Advanced Solid Tumor,JAX,2961,BRAF G464R,"[{'id': 7141, 'pubMedId': 26343582, 'title': 'BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343582'}]",resistant,342,Vemurafenib,673
20,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).",Actionable,12155,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",sensitive,342,Vemurafenib,673
21,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12152,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",resistant,2,Trametinib,673
22,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",Actionable,7700,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1916,Cetuximab + Encorafenib,673
23,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment in culture, likely due to the acquired secondary resistant mutation of MAP2K1 V211D (PMID: 27312529).",Actionable,7629,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4536,Cetuximab + Selumetinib,673
24,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by Selumetinib (AZD6244) in cell culture (PMID: 19915144).",Actionable,5821,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 134, 'pubMedId': 19915144, 'title': 'MEK1 mutations confer resistance to MEK and B-RAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19915144'}]",resistant,913,Selumetinib,673
25,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7702,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1066,Trametinib + Dabrafenib,673
26,Preclinical - Cell culture,"In a preclinical study, BVD-523 (Ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712). ",Actionable,12158,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",sensitive,997,BVD-523,673
27,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",Actionable,7704,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,2618,SCH772984,673
28,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by CI-1040 in cell culture (PMID: 19915144).",Actionable,5820,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 134, 'pubMedId': 19915144, 'title': 'MEK1 mutations confer resistance to MEK and B-RAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19915144'}]",resistant,699,CI-1040,673
29,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7703,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4541,Cetuximab + Dabrafenib + Trametinib,673
30,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12149,1909,melanoma,DOID,28495,BRAF V600E MAP2K1 I111N,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",resistant,2,Trametinib,673
31,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N  in culture (PMID: 28655712).",Actionable,12153,1909,melanoma,DOID,28495,BRAF V600E MAP2K1 I111N,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",sensitive,342,Vemurafenib,673
32,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5956,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,342,Vemurafenib,673
33,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) did not improve the response to human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture (PMID: 22389471).",Actionable,5989,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",no benefit,4004,Dabrafenib + GSK2126458,673
34,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E and also had reduced sensitivity in comparison to cell lines harboring BRAF V600E and NRAS A146T in culture (PMID: 22389471).",Actionable,5960,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,2,Trametinib,673
35,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5966,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,763,GSK2126458,673
36,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5950,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,3,Dabrafenib,673
37,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",Actionable,5992,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,3027,GSK2126458 + Trametinib,673
38,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and SCH772984 in culture (PMID: 27312529).",Actionable,7679,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4543,Cetuximab + SCH772984,673
39,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7673,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1711,Vemurafenib + Cetuximab,673
40,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Selumetinib (AZD6244) in culture (PMID: 27312529).",Actionable,7675,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4536,Cetuximab + Selumetinib,673
41,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) in culture (PMID: 27312529).",Actionable,7668,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4525,Cetuximab + Dabrafenib,673
42,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7677,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4541,Cetuximab + Dabrafenib + Trametinib,673
43,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7676,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1066,Trametinib + Dabrafenib,673
44,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture, likely due to the acquisition of KRAS G13D (PMID: 27312529).",Actionable,7622,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1916,Cetuximab + Encorafenib,673
45,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",Actionable,7678,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,2618,SCH772984,673
46,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).",Actionable,7674,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1917,LGX818 + Cetuximab + BYL719,673
47,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment in culture, likely due to the acquired BRAF V600E amplification (PMID: 27312529).",Actionable,7630,9256,colorectal cancer,DOID,25928,BRAF amp BRAF V600E,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4536,Cetuximab + Selumetinib,673
48,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired BRAF V600E amplification and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7705,9256,colorectal cancer,DOID,25928,BRAF amp BRAF V600E,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1711,Vemurafenib + Cetuximab,673
49,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired BRAF V600E amplification and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",Actionable,7706,9256,colorectal cancer,DOID,25928,BRAF amp BRAF V600E,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,2618,SCH772984,673
50,Preclinical - Cell line xenograft,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and growth of colorectal cancer cells harboring BRAF V600E, PIK3CA P449T, and TP53 R273H in culture and in cell line xenograft models, but did not have synergistic effect on apoptosis (PMID: 26272063).",Actionable,8565,9256,colorectal cancer,DOID,26358,BRAF V600E PIK3CA P449T TP53 R273H,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,673
51,Preclinical,"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to SB590885 in culture (PMID: 20538618).",Actionable,6833,10000003,Advanced Solid Tumor,JAX,23816,BRAF V600E BRAF T529N,"[{'id': 5859, 'pubMedId': 20538618, 'title': 'Gatekeeper mutations mediate resistance to BRAF-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538618'}]",resistant,4281,SB590885,673
52,Preclinical,"In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation and growth of transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529N in culture (PMID: 20538618).",Actionable,6841,10000003,Advanced Solid Tumor,JAX,23816,BRAF V600E BRAF T529N,"[{'id': 5859, 'pubMedId': 20538618, 'title': 'Gatekeeper mutations mediate resistance to BRAF-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538618'}]",sensitive,699,CI-1040,673
53,Preclinical,"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to PLX4720 in culture (PMID: 20538618).",Actionable,6837,10000003,Advanced Solid Tumor,JAX,23816,BRAF V600E BRAF T529N,"[{'id': 5859, 'pubMedId': 20538618, 'title': 'Gatekeeper mutations mediate resistance to BRAF-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538618'}]",resistant,1060,PLX4720,673
54,Preclinical,"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to Nexavar (sorafenib)-mediated inhibition of Erk phosphorylation but were equally as sensitive to Nexavar (sorafenib)-mediated growth inhibition as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",Actionable,6838,10000003,Advanced Solid Tumor,JAX,23816,BRAF V600E BRAF T529N,"[{'id': 5859, 'pubMedId': 20538618, 'title': 'Gatekeeper mutations mediate resistance to BRAF-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538618'}]",conflicting,920,Sorafenib,673
55,Preclinical,"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to RAF265 in culture (PMID: 20538618).",Actionable,6829,10000003,Advanced Solid Tumor,JAX,23816,BRAF V600E BRAF T529N,"[{'id': 5859, 'pubMedId': 20538618, 'title': 'Gatekeeper mutations mediate resistance to BRAF-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538618'}]",resistant,884,RAF265,673
56,Preclinical - Pdx,"In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring BRAF V600E and PIK3CA H1047K was sensitive to the combination treatment of ARQ092 and Mekinist (trametinib), demonstrating a greater inhibition of tumor growth when compared to either agent alone (PMID: 26469692). ",Actionable,10288,1909,melanoma,DOID,27343,BRAF V600E PIK3CA H1047K,"[{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",sensitive,5456,ARQ092 + Trametinib,673
57,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).",Actionable,7639,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,694,Cetuximab,673
58,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) in culture (PMID: 27312529).",Actionable,7640,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,845,Panitumumab,673
59,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7694,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4542,Cetuximab + Dabrafenib + SCH772984,673
60,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Iressa (gefitinib) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7645,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,1709,Vemurafenib + Gefitinib,673
61,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Iressa (gefitinib) in culture (PMID: 27312529).",Actionable,7642,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,751,Gefitinib,673
62,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired secondary resistance mutation of EGFR G465R (PMID: 27312529).",Actionable,7627,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1711,Vemurafenib + Cetuximab,673
63,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7643,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1717,Vemurafenib + Panitumumab,673
64,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7692,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4544,Dabrafenib + SCH772984,673
65,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7641,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,342,Vemurafenib,673
66,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5951,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,3,Dabrafenib,673
67,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",Actionable,5991,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,3027,GSK2126458 + Trametinib,673
68,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",Actionable,5988,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,4004,Dabrafenib + GSK2126458,673
69,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5955,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,342,Vemurafenib,673
70,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5965,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,763,GSK2126458,673
71,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were >10-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5959,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,2,Trametinib,673
72,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",Actionable,5977,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,1066,Trametinib + Dabrafenib,673
73,Preclinical - Cell line xenograft,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PTEN loss in culture and in cell line xenograft models (PMID: 26272063).",Actionable,8569,9256,colorectal cancer,DOID,26362,BRAF V600E PTEN loss TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,673
74,Preclinical - Cell culture,"In a preclinical study, over expression of wild type EGFR in colorectal cancer cells harboring BRAF V600E resulted in sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7631,9256,colorectal cancer,DOID,25929,BRAF V600E EGFR over exp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,3773,Selumetinib + Vemurafenib,673
75,Preclinical - Cell line xenograft,"In a preclinical study, a colorectal cancer cell line xenograft model co-harboring BRAF V600E and a PIK3CA mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).",Actionable,11042,9256,colorectal cancer,DOID,27895,BRAF V600E PIK3CA mut,"[{'id': 9035, 'pubMedId': None, 'title': 'Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/B100.short'}]",sensitive,5827,ASN003,673
76,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",Actionable,6839,10000003,Advanced Solid Tumor,JAX,23817,BRAF V600E BRAF T529M,"[{'id': 5859, 'pubMedId': 20538618, 'title': 'Gatekeeper mutations mediate resistance to BRAF-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538618'}]",predicted – sensitive,920,Sorafenib,673
77,Preclinical,"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529M were insensitive to PLX4720-mediated inhibition of ERK signaling in culture (PMID: 20538618).",Actionable,6834,10000003,Advanced Solid Tumor,JAX,23817,BRAF V600E BRAF T529M,"[{'id': 5859, 'pubMedId': 20538618, 'title': 'Gatekeeper mutations mediate resistance to BRAF-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538618'}]",predicted – resistant,1060,PLX4720,673
78,Preclinical,"In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation in transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M in culture (PMID: 20538618).",Actionable,6842,10000003,Advanced Solid Tumor,JAX,23817,BRAF V600E BRAF T529M,"[{'id': 5859, 'pubMedId': 20538618, 'title': 'Gatekeeper mutations mediate resistance to BRAF-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538618'}]",predicted – sensitive,699,CI-1040,673
79,Preclinical,"In a preclinical study, RAF265 inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",Actionable,6831,10000003,Advanced Solid Tumor,JAX,23817,BRAF V600E BRAF T529M,"[{'id': 5859, 'pubMedId': 20538618, 'title': 'Gatekeeper mutations mediate resistance to BRAF-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538618'}]",predicted – sensitive,884,RAF265,673
80,Preclinical,"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529M were insensitive to SB590885-mediated inhibition of ERK signaling in culture (PMID: 20538618).",Actionable,6828,10000003,Advanced Solid Tumor,JAX,23817,BRAF V600E BRAF T529M,"[{'id': 5859, 'pubMedId': 20538618, 'title': 'Gatekeeper mutations mediate resistance to BRAF-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538618'}]",predicted – resistant,4281,SB590885,673
81,Preclinical - Cell culture,"In a preclinical study, expression of MAP2K1 K57E in a melanoma cell line harboring BRAF V600E conferred resistance to Tafinlar (dabrafenib) in culture (PMID: 25370473).",Actionable,7592,1909,melanoma,DOID,25914,BRAF V600E MAP2K1 K57E,"[{'id': 6439, 'pubMedId': 25370473, 'title': 'Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25370473'}]",resistant,3,Dabrafenib,673
82,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).",Actionable,12163,1909,melanoma,DOID,28498,BRAF V600E MAP2K1 P124L,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",decreased response,342,Vemurafenib,673
83,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Mekinist (trametinib) in culture (PMID: 28655712). ",Actionable,12162,1909,melanoma,DOID,28498,BRAF V600E MAP2K1 P124L,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",decreased response,2,Trametinib,673
84,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment did not result in enhanced antitumor activity compared to Ibrance (palbociclib) alone in PDX models of KRAS wild-type colorectal cancer harboring BRAF V600E (PMID: 26369631).",Actionable,5623,9256,colorectal cancer,DOID,21304,BRAF V600E KRAS wild-type,"[{'id': 5128, 'pubMedId': 26369631, 'title': 'Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26369631'}]",no benefit,1368,Palbociclib + Trametinib,673
85,Preclinical,"In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Erbitux (cetuximab) in culture (PMID: 25838391).",Actionable,4936,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",resistant,694,Cetuximab,673
86,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",Actionable,8204,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4657,Pimasertib + Regorafenib,673
87,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",Actionable,8194,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4656,Everolimus + Pimasertib,673
88,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",Actionable,8189,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,871,Pimasertib,673
89,Preclinical,"In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring BRAF V600E and PIK3CA P449T in culture (PMID: 25838391).",Actionable,4950,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",sensitive,1305,Regorafenib + Cetuximab,673
90,Preclinical,"In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4940,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",resistant,890,Regorafenib,673
91,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",Actionable,8199,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,1659,Pimasertib + Sorafenib,673
92,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquisition of KRAS G12D (PMID: 27312529).",Actionable,7626,9256,colorectal cancer,DOID,25922,BRAF V600E KRAS G12D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1711,Vemurafenib + Cetuximab,673
93,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7691,9256,colorectal cancer,DOID,25922,BRAF V600E KRAS G12D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4543,Cetuximab + SCH772984,673
94,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7690,9256,colorectal cancer,DOID,25922,BRAF V600E KRAS G12D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4541,Cetuximab + Dabrafenib + Trametinib,673
95,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).",Actionable,7689,9256,colorectal cancer,DOID,25922,BRAF V600E KRAS G12D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1917,LGX818 + Cetuximab + BYL719,673
96,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",Actionable,7005,1909,melanoma,DOID,24283,BRAF V600E MAP2K1 G128V,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",sensitive,4351,VRT11E,673
97,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",Actionable,7058,1909,melanoma,DOID,24283,BRAF V600E MAP2K1 G128V,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,3,Dabrafenib,673
98,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Mekinist (trametinib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",Actionable,7059,1909,melanoma,DOID,24283,BRAF V600E MAP2K1 G128V,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,2,Trametinib,673
99,Preclinical,"In a preclinical study, MAP2K1 G128V conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).",Actionable,7033,1909,melanoma,DOID,24283,BRAF V600E MAP2K1 G128V,"[{'id': 6036, 'pubMedId': 24265154, 'title': 'MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265154'}]",resistant,1066,Trametinib + Dabrafenib,673
100,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7698,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1711,Vemurafenib + Cetuximab,673
101,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Selumetinib (AZD6244) in culture (PMID: 27312529).",Actionable,7699,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4536,Cetuximab + Selumetinib,673
102,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",Actionable,7695,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1916,Cetuximab + Encorafenib,673
103,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to combination treatment consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture, likely due to the acquisition of KRAS A146V and A146T secondary resistance mutations (PMID: 27312529).",Actionable,7628,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1917,LGX818 + Cetuximab + BYL719,673
104,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) in culture (PMID: 27312529).",Actionable,7697,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4525,Cetuximab + Dabrafenib,673
105,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in cell culture (PMID: 25370473).",Actionable,7593,1909,melanoma,DOID,25915,BRAF V600E MAP2K1 P124Q,"[{'id': 6439, 'pubMedId': 25370473, 'title': 'Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25370473'}]",decreased response,3,Dabrafenib,673
106,Preclinical,"In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell line harboring BRAF V600E mutation and overexpressing MAP2K1 C121S in culture (PMID: 24448821).",Actionable,4029,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,"[{'id': 4380, 'pubMedId': 24448821, 'title': 'Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24448821'}]",sensitive,1011,E6201,673
107,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12159,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",resistant,2,Trametinib,673
108,Preclinical,"In a preclinical study, MAP2K1 C121S conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).",Actionable,7032,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,"[{'id': 6036, 'pubMedId': 24265154, 'title': 'MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265154'}]",resistant,1066,Trametinib + Dabrafenib,673
109,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",Actionable,7003,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",sensitive,4351,VRT11E,673
110,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E mutation and overexpressing MAP2K1 C121S were less sensitive than those overexpressing wild-type MAP2K1 to Selumetinib (AZD6244)-induced inhibition of Mapk pathway activation and cell proliferation in culture (PMID: 24448821).",Actionable,4031,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,"[{'id': 4380, 'pubMedId': 24448821, 'title': 'Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24448821'}]",decreased response,913,Selumetinib,673
111,Clinical Study,"In a clinical case study, a patient harboring BRAF V600E demonstrated an initial response to treatment with Zelboraf (vemurafenib), but progressed following emergence of a MAP2K1 C121S mutation (PMID: 21383288).",Actionable,7037,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,"[{'id': 4378, 'pubMedId': 21383288, 'title': 'Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21383288'}]",decreased response,342,Vemurafenib,673
112,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E mutation and overexpressing MAP2K1 C121S were less sensitive than those overexpressing wild-type MAP2K1 to Zelboraf (vemurafenib)-induced inhibition of Mapk pathway activation and cell proliferation in culture (PMID: 24448821).",Actionable,4030,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,"[{'id': 4380, 'pubMedId': 24448821, 'title': 'Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24448821'}]",decreased response,342,Vemurafenib,673
113,Preclinical,"In a preclinical study, expression of MAP2K1 C121S conferred resistance to PLX4720 in melanoma cells harboring BRAF V600E in culture (PMID: 21383288).",Actionable,7038,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,"[{'id': 4378, 'pubMedId': 21383288, 'title': 'Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21383288'}]",resistant,1060,PLX4720,673
114,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5968,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,763,GSK2126458,673
115,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5954,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,3,Dabrafenib,673
116,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).",Actionable,5963,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,2,Trametinib,673
117,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5958,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,342,Vemurafenib,673
118,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",Actionable,5994,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,3027,GSK2126458 + Trametinib,673
119,Clinical Study,"In a clinical case study, a melanoma patient harboring BRAF V600E  treated with Zelboraf (vemurafenib) subsequently demonstrated resistance likely due to the secondary resistance mutation, BRAF L505H (PMID: 25515853).",Actionable,3564,1909,melanoma,DOID,13538,BRAF V600E BRAF L505H,"[{'id': 3825, 'pubMedId': 25515853, 'title': 'Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25515853'}]",resistant,342,Vemurafenib,673
120,Preclinical - Cell culture,"In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K in culture (PMID: 28655712). ",Actionable,12166,1909,melanoma,DOID,28497,BRAF V600E MAP2K1 E203K,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",sensitive,997,BVD-523,673
121,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12160,1909,melanoma,DOID,28497,BRAF V600E MAP2K1 E203K,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",resistant,2,Trametinib,673
122,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).",Actionable,12161,1909,melanoma,DOID,28497,BRAF V600E MAP2K1 E203K,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",resistant,342,Vemurafenib,673
123,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E treated with Selumetinib (AZD6244) in culture demonstrated resistance, which was a result of the resistance mutation, MAP2K1 H119P (PMID: 19915144).",Actionable,6895,1909,melanoma,DOID,23996,BRAF V600E MAP2K1 H119P,"[{'id': 134, 'pubMedId': 19915144, 'title': 'MEK1 mutations confer resistance to MEK and B-RAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19915144'}]",resistant,913,Selumetinib,673
124,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment in culture, likely due to the acquired KRAS amplification (PMID: 27312529).",Actionable,7625,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4525,Cetuximab + Dabrafenib,673
125,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",Actionable,7683,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1916,Cetuximab + Encorafenib,673
126,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 in culture (PMID: 27312529).",Actionable,7686,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4544,Dabrafenib + SCH772984,673
127,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",Actionable,7685,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,2618,SCH772984,673
128,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7684,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1711,Vemurafenib + Cetuximab,673
129,Preclinical,"In a preclinical study, over expression of BRAF V600E in KRAS-mutant colorectal cancer cells resulted in resistance to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",Actionable,5813,9256,colorectal cancer,DOID,21629,BRAF V600E KRAS mutant,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",resistant,849,PD-0325901,673
130,Preclinical - Cell culture,"In a preclinical study, DEL-22379 inhibited growth of KRAS-mutant melanoma cells over expressing BRAF V600E in culture (PMID: 26267534).",Actionable,5815,9256,colorectal cancer,DOID,21629,BRAF V600E KRAS mutant,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",sensitive,3769,DEL-22379,673
131,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5962,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,2,Trametinib,673
132,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5967,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,763,GSK2126458,673
133,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",Actionable,5993,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,3027,GSK2126458 + Trametinib,673
134,Preclinical,"In a preclinical study, the response of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S to Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) was conflicting as one cell line with this mutation profile responded to the combination and another cell line with the mutation profile did not (PMID: 22389471).",Actionable,5990,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",conflicting,4004,Dabrafenib + GSK2126458,673
135,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5952,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,3,Dabrafenib,673
136,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 22389471).",Actionable,5961,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,342,Vemurafenib,673
137,Preclinical,"In a preclinical study, over expression of MAPK21 I103N in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",Actionable,5811,1909,melanoma,DOID,21628,BRAF V600E MAP2K1 I103N,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",resistant,849,PD-0325901,673
138,Preclinical - Cell culture,"In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N in culture (PMID: 26267534).",Actionable,5816,1909,melanoma,DOID,21628,BRAF V600E MAP2K1 I103N,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",sensitive,3769,DEL-22379,673
139,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing NRAS Q61K were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).",Actionable,5949,1909,melanoma,DOID,6906,BRAF V600E NRAS Q61K,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,3,Dabrafenib,673
140,Preclinical,"In a preclinical study, treatment with XL888 resulted in increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant melanoma cells harboring BRAF V600E along with NRAS Q61K in cell culture (PMID: 22351686).",Actionable,2275,1909,melanoma,DOID,6906,BRAF V600E NRAS Q61K,"[{'id': 2956, 'pubMedId': 22351686, 'title': 'The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22351686'}]",sensitive,970,XL888,673
141,Preclinical,"In a preclinical study, a NRAS Q61K mutation conferred resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323).",Actionable,2279,1909,melanoma,DOID,6906,BRAF V600E NRAS Q61K,"[{'id': 2959, 'pubMedId': 21107323, 'title': 'Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21107323'}]",resistant,342,Vemurafenib,673
142,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).",Actionable,5978,1909,melanoma,DOID,6906,BRAF V600E NRAS Q61K,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,1066,Trametinib + Dabrafenib,673
143,Preclinical,"In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the MEK inhibitor selumetinib (AZD6244) cell culture.",Actionable,183,1909,melanoma,DOID,520,MAP2K1 Q56P BRAF V600E,"[{'id': 134, 'pubMedId': 19915144, 'title': 'MEK1 mutations confer resistance to MEK and B-RAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19915144'}]",resistant,913,Selumetinib,673
144,Preclinical,"In a preclinical study, combined treatment with selumetinib and PLX4720 strongly suppressed the emergence of resistant MAP2K1 mutations in BRAF V600E cells in culture (PMID: 19915144).",Actionable,506,1909,melanoma,DOID,520,MAP2K1 Q56P BRAF V600E,"[{'id': 134, 'pubMedId': 19915144, 'title': 'MEK1 mutations confer resistance to MEK and B-RAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19915144'}]",sensitive,1061,Selumetinib + PLX4720,673
145,Preclinical,"In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the B-RAF inhibitor PLX4720 in culture (PMID: 19915144).",Actionable,505,1909,melanoma,DOID,520,MAP2K1 Q56P BRAF V600E,"[{'id': 134, 'pubMedId': 19915144, 'title': 'MEK1 mutations confer resistance to MEK and B-RAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19915144'}]",resistant,1060,PLX4720,673
146,Preclinical,"In a preclinical study, expression of NRAS G12V in melanoma cells harboring BRAF V600E conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 26267534).",Actionable,5785,1909,melanoma,DOID,21619,BRAF V600E NRAS G12V,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",resistant,342,Vemurafenib,673
147,Preclinical - Cell culture,"In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and over expressing NRAS G12V in culture (PMID: 26267534).",Actionable,5786,1909,melanoma,DOID,21619,BRAF V600E NRAS G12V,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",sensitive,3769,DEL-22379,673
148,Preclinical - Cell line xenograft,"In a preclinical study, a melanoma cell line xenograft model co-harboring BRAF V600E and a PTEN mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).",Actionable,11043,1909,melanoma,DOID,27896,BRAF V600E PTEN mut,"[{'id': 9035, 'pubMedId': None, 'title': 'Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/B100.short'}]",sensitive,5827,ASN003,673
149,Phase II,"In a Phase II study, Nexavar (sorafenib) displayed negligible efficacy in melanoma patients with BRAF V600E mutations (PMID: 16880785, PMID: 22394203).",Actionable,509,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 294, 'pubMedId': 22394203, 'title': 'Sorafenib in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22394203'}, {'id': 3156, 'pubMedId': 16880785, 'title': 'Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16880785'}]",no benefit,920,Sorafenib,673
150,Phase I,"In a Phase I trial, BGB-283 resulted in partial response in 1 thyroid cancer patient harboring BRAF V600E, who remained on treatment for over 481 days (AACR Annual Meeting, Apr 2016, abstract # CT005).",Actionable,7231,1781,thyroid cancer,DOID,1,BRAF V600E,"[{'id': 6230, 'pubMedId': None, 'title': 'Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=46a0776a-1444-49d6-b533-4f68e298c39d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]",sensitive,4025,BGB-283,673
151,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",Actionable,8188,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,871,Pimasertib,673
152,Preclinical,"In a preclinical study, saracatinib inhibited proliferation of human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture (PMID: 23242808).",Actionable,3336,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 3755, 'pubMedId': 23242808, 'title': 'Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23242808'}]",sensitive,912,Saracatinib,673
153,Preclinical - Pdx,"In a preclinical study, DEL-22379 inhibited tumor growth in a colorectal adenocarcinoma patient-derived xenograft model harboring BRAF V600E (PMID: 26267534).",Actionable,5780,50861,colorectal adenocarcinoma,DOID,1,BRAF V600E,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",sensitive,3769,DEL-22379,673
154,Preclinical,"In a preclinical study, PD-0325901 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 26267534).",Actionable,5777,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",sensitive,849,PD-0325901,673
155,Preclinical - Cell line xenograft,"In a preclinical study, PLX4720 and TAK-632 combination treatment resulted in durable inhibition of Erk signaling and tumor growth in xenograft models of colorectal cancer cells harboring BRAF V600E (PMID: 27523909). ",Actionable,7966,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,4607,PLX4720 + TAK-632,673
156,Preclinical,"In a preclinical study, SBI-755199 induced cell death in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897).",Actionable,3789,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4137, 'pubMedId': 26603897, 'title': 'SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26603897'}]",sensitive,3309,SBI-755199,673
157,Preclinical,"In a preclinical study, colorectal cancer cells harboring a BRAF V600E mutation had increased sensitivity to Mekinist (trametinib) compared to other colorectal cancer lines in culture (PMID: 25309914).",Actionable,1319,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 1025, 'pubMedId': 25309914, 'title': 'Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25309914'}]",sensitive,2,Trametinib,673
158,Preclinical - Cell line xenograft,"In a preclinical study, treatment with Ibrance (palbociclib) in a melanoma cell line xenograft model harboring BRAF V600E resulted in no benefit, demonstrating low but continuous growth (PMID: 27488531). ",Actionable,8548,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",no benefit,850,Palbociclib,673
159,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) inhibited growth of both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",Actionable,7838,1781,thyroid cancer,DOID,1,BRAF V600E,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",predicted – sensitive,2,Trametinib,673
160,Preclinical - Cell line xenograft,"In a preclinical study, the combination treatment of PD-0325901 and Ibrance (palbociclib) resulted in significant tumor regression in melanoma cell line xenograft models harboring BRAF V600E and demonstrated a 56% (5/9) complete response rate (PMID: 27488531). ",Actionable,8549,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",sensitive,1823,PD-0325901 + Palbociclib,673
161,Phase II,"In a Phase II trial, a favorable response rate to selumetinib (AZD6244) was observed in mutant BRAF but not BRAF wild-type melanoma patients (PMID: 22048237).
",Actionable,1131,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 228, 'pubMedId': 22048237, 'title': 'Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22048237'}]",sensitive,913,Selumetinib,673
162,Preclinical - Cell line xenograft,"In preclinical studies, Encorafenib (LGX818) treatment of human melanoma xenograft models with BRAF V600E significantly decreased Mek activation and resulted in tumor regression (Cancer Res: 72(8) Suppl 1, Abstract #3790). ",Actionable,686,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 417, 'pubMedId': None, 'title': 'Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor', 'url': 'http://cancerres.aacrjournals.org/cgi/content/short/72/8_MeetingAbstracts/3790'}]",sensitive,796,Encorafenib,673
163,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",Actionable,8193,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4656,Everolimus + Pimasertib,673
164,Preclinical,"In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation and growth of transformed cells expressing BRAF V600E in culture (PMID: 20538618).",Actionable,6844,10000003,Advanced Solid Tumor,JAX,1,BRAF V600E,"[{'id': 5859, 'pubMedId': 20538618, 'title': 'Gatekeeper mutations mediate resistance to BRAF-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538618'}]",sensitive,699,CI-1040,673
165,Preclinical - Cell line xenograft,"In a preclinical study, PLX4720 inhibited growth of melanoma cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 18287029).",Actionable,503,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 291, 'pubMedId': 18287029, 'title': 'Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18287029'}]",sensitive,1060,PLX4720,673
166,Preclinical - Cell line xenograft,"In a preclinical study, BGB-283 in combination with Erbitux (cetuximab) demonstrated enhanced tumor suppression in colorectal cancer cell line xenograft models harboring BRAF V600E (PMID: 26208524).",Actionable,8069,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 5280, 'pubMedId': 26208524, 'title': 'BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26208524'}]",sensitive,4628,BGB-283 + Cetuximab,673
167,Preclinical,"In a preclinical study, SCH772984 inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 26267534).",Actionable,5776,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",sensitive,2618,SCH772984,673
168,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5986,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,4004,Dabrafenib + GSK2126458,673
169,Preclinical,"In a preclinical study, SCH772984 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 26267534).",Actionable,5779,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",sensitive,2618,SCH772984,673
170,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7651,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4543,Cetuximab + SCH772984,673
171,Preclinical - Cell line xenograft,"In a preclinical study, PLX7904 inhibited survival of colorectal cancer cells harboring BRAF V600E in culture and demonstrated anti-tumor activity in cell line xenograft models (PMID: 26466569).",Actionable,7901,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 6521, 'pubMedId': 26466569, 'title': 'RAF inhibitors that evade paradoxical MAPK pathway activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26466569'}]",sensitive,4606,PLX7904,673
172,Preclinical,"In a preclinical study, TW-37 enhanced the inhibitory effect of Zelboraf (vemurafenib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4534,3908,non-small cell lung carcinoma,DOID,1,BRAF V600E,"[{'id': 4582, 'pubMedId': 25665005, 'title': 'The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25665005'}]",sensitive,3531,Vemurafenib + TW-37,673
173,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Alpelisib (BYL719) and PLX4720 enhanced antitumor activity in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and decreased Akt signaling in culture (PMID: 27924459).",Actionable,9662,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 7369, 'pubMedId': 27924459, 'title': 'Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27924459'}]",sensitive,5119,Alpelisib + PLX4720,673
174,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 27523909).",Actionable,7943,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,3300,TAK-632,673
175,Preclinical - Cell line xenograft,"In a preclinical study, GDC0879 inhibited survival of colon cancer cell lines harboring BRAF V600E in cell culture and cell line xenograft models (PMID: 19276360).",Actionable,7874,219,colon cancer,DOID,1,BRAF V600E,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",sensitive,1095,GDC0879,673
176,Phase Ib/II,"In a Phase Ib/II trial, Encorafenib (LGX818) and Kisqali (ribociclib) combination treatment resulted in confirmed partial response in 7.1% (2/28), unconfirmed partial response in 10.7% (3/28), and stable disease in 35.7% (10/28) of patients with melanoma harboring BRAF V600E (PMID: 28351928). ",Actionable,11415,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 9298, 'pubMedId': 28351928, 'title': 'Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28351928'}]",sensitive,1260,Encorafenib + Ribociclib,673
177,Preclinical - Cell line xenograft,"In a preclinical study, PLX4720 inhibited growth of colon cancer cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 18287029).",Actionable,8002,219,colon cancer,DOID,1,BRAF V600E,"[{'id': 291, 'pubMedId': 18287029, 'title': 'Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18287029'}]",sensitive,1060,PLX4720,673
178,Preclinical,"In a preclinical study, Refametinib (BAY86-9766) inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture and suppressed tumor growth in cell line xenograft models (PMID: 19706763).",Actionable,1343,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 877, 'pubMedId': 19706763, 'title': 'RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19706763'}]",sensitive,888,Refametinib,673
179,Preclinical - Cell line xenograft,"In preclinical studies, CEP-32496 (RXDX-105) reduced tumor volume and promoted tumor regression in xenograft models of a BRAF V600E mutant human melanoma cell line (PMID: 22319199).",Actionable,306,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 203, 'pubMedId': 22319199, 'title': 'CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22319199'}]",sensitive,1002,CEP-32496,673
180,Preclinical - Pdx & cell culture,"In a preclinical study, BGB-283 inhibited Braf phosphorylation and cell proliferation in colorectal cancer cell lines harboring BRAF V600E in culture, and resulted in partial tumor regression in both cell line and patient-derived xenograft models (PMID: 26208524).",Actionable,8057,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 5280, 'pubMedId': 26208524, 'title': 'BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26208524'}]",sensitive,4025,BGB-283,673
181,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7650,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4541,Cetuximab + Dabrafenib + Trametinib,673
182,Preclinical,"In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Erbitux (cetuximab) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115). ",Actionable,4984,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 4823, 'pubMedId': 26916115, 'title': 'A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26916115'}]",sensitive,3711,BI 882370 + Cetuximab,673
183,Preclinical - Cell line xenograft,"In a preclinical study, DT01 increased sensitivity of human colorectal cancer (CRC) cells harboring BRAF V600E to Eloxatin (oxaliplatin) and Adrucil (5-fluorouracil), and the combination resulted in decreased liver tumor growth in CRC cell line xenograft metastasis models (PMID: 26637369).",Actionable,6180,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 5384, 'pubMedId': 26637369, 'title': 'The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26637369'}]",sensitive,4083,DT01 + Fluorouracil + Oxaliplatin,673
184,Preclinical - Cell line xenograft,"In a preclinical study, CI-1040 inhibited growth of a human ovarian cancer cell line harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models (PMID: 19018267).
",Actionable,2742,2394,ovarian cancer,DOID,1,BRAF V600E,"[{'id': 3448, 'pubMedId': 19018267, 'title': 'KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19018267'}]",sensitive,699,CI-1040,673
185,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Cotellic (cobimetinib) and Zelboraf (vemurafenib) inhibited tumor growth in a cell line xenograft model of colorectal cancer harboring BRAF V600E (PMID: 28649441).",Actionable,11939,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 9924, 'pubMedId': 28649441, 'title': 'Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28649441'}]",sensitive,1657,Vemurafenib + Cobimetinib,673
186,Guideline,Colorectal cancer patients harboring BRAF V600E may not be responsive to Erbitux (cetuximab) as a single therapy or in combination with a chemotherapeutic (Guidelines).,Actionable,9947,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",predicted – resistant,694,Cetuximab,673
187,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cell lines harboring BRAF V600E were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).",Actionable,7614,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",predicted – resistant,694,Cetuximab,673
188,Preclinical - Cell line xenograft,"In a preclinical study, treatment with BI-847325 resulted in decreased expression of Mcl-1 and Mek, and inhibited growth of melanoma cell lines harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models of BRAF V600E-positive melanoma, including models with BRAF-inhibitor resistance (PMID: 25873592).",Actionable,7823,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 6506, 'pubMedId': 25873592, 'title': 'The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25873592'}]",sensitive,1059,BI-847325,673
189,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) decreased tumor growth in a cell line xenograft model of colorectal cancer harboring BRAF V600E (PMID: 23942066).",Actionable,2528,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 3253, 'pubMedId': 23942066, 'title': 'Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23942066'}]",sensitive,913,Selumetinib,673
190,Preclinical - Cell culture,"In a preclinical study, thyroid cancer cells harboring BRAF V600E demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",Actionable,7959,1781,thyroid cancer,DOID,1,BRAF V600E,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",decreased response,342,Vemurafenib,673
191,Preclinical,"In a preclinical study, colorectal cancer cell lines harboring a BRAF V600E mutation were sensitive to Nexavar (sorafenib) in culture (PMID: 24885690).",Actionable,1320,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 1028, 'pubMedId': 24885690, 'title': 'Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24885690'}]",sensitive,920,Sorafenib,673
192,Preclinical,"In a preclinical study, Sprycel (dasatinib) inhibited cell invasion, cell signaling, and proliferation in human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture and in animal models (PMID: 23242808).",Actionable,3335,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 3755, 'pubMedId': 23242808, 'title': 'Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23242808'}]",sensitive,717,Dasatinib,673
193,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7652,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4544,Dabrafenib + SCH772984,673
194,Phase II,"In two Phase II clinical studies, patients with refractory hairy cell leukemia harboring BRAF V600E responded to Zelboraf (vemurafenib) with overall response rates of 96% (25/26) and 100% (24/24) as well as complete response rates of 35% (9/26) and 42% (10/24) with median follow up times of 8 and 12 weeks, respectively (PMID: 26352686).",Actionable,3620,285,hairy cell leukemia,DOID,1,BRAF V600E,"[{'id': 3911, 'pubMedId': 26352686, 'title': 'Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26352686'}]",sensitive,342,Vemurafenib,673
195,Preclinical - Cell culture,"In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated sensitivity to BI2536 in culture (PMID: 26573800).",Actionable,10194,3068,glioblastoma multiforme,DOID,1,BRAF V600E,"[{'id': 8161, 'pubMedId': 26573800, 'title': 'Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26573800'}]",sensitive,676,BI2536,673
196,FDA approved,"In a Phase III trial that supported FDA approval, Zelboraf (vemurafenib), as compared to Deticene (dacarbazine), resulted in an improved overall survival rate of 84% at 6 months in patients with BRAF V600E positive metastatic melanoma (PMID: 21639808).",Actionable,586,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 222, 'pubMedId': 21639808, 'title': 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21639808'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",sensitive,342,Vemurafenib,673
197,Guideline,Zelboraf (vemurafenib) is an active regimen for melanoma patients with BRAF V600E (Guidelines).,Actionable,1510,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 1442, 'pubMedId': None, 'title': 'NCCN Guidelines Melanoma version 3.2015', 'url': 'http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf'}, {'id': 1444, 'pubMedId': None, 'title': '', 'url': 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202429s006lbl.pdf'}]",sensitive,342,Vemurafenib,673
198,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) and PLX4720 synergistically inhibited growth and induced apoptosis in glioma cell lines in culture, resulted in prolonged survival in cell line xenograft models (PMID: 27217440).",Actionable,9107,3070,malignant glioma,DOID,1,BRAF V600E,"[{'id': 6921, 'pubMedId': 27217440, 'title': 'BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27217440'}]",predicted – sensitive,1061,Selumetinib + PLX4720,673
199,Clinical Study,"In a clinical case report, Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment resulted in a clinical and radiologic response that lasted for 9 months in an anaplastic thyroid cancer patient harboring BRAF V600E (PMID: 27697975).",Actionable,8711,1781,thyroid cancer,DOID,1,BRAF V600E,"[{'id': 6714, 'pubMedId': 27697975, 'title': 'Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27697975'}]",sensitive,1066,Trametinib + Dabrafenib,673
200,Preclinical,"In a preclinical study, PLX8394 had been shown to block survival and growth of vemurafenib/PLX4720-resistant cells harboring distinct BRAF V600E splice variants (PMID: 24422853).",Actionable,442,10000003,Advanced Solid Tumor,JAX,1,BRAF V600E,"[{'id': 195, 'pubMedId': 24422853, 'title': 'Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24422853'}]",sensitive,1041,PLX8394,673
201,Preclinical - Cell culture,"In a preclincial study, colorectal cancer cell lines harboring BRAF V600E demonstrated resistance to SHP099 in culture (PMID: 27362227).",Actionable,7521,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 6394, 'pubMedId': 27362227, 'title': 'Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27362227'}]",resistant,4504,SHP099,673
202,Preclinical - Cell culture,"In a preclinical study, BGB-283 inhibited viability of a variety of cancer cell lines harboring BRAF V600E in culture (PMID: 26208524).",Actionable,8066,10000003,Advanced Solid Tumor,JAX,1,BRAF V600E,"[{'id': 5280, 'pubMedId': 26208524, 'title': 'BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26208524'}]",sensitive,4025,BGB-283,673
203,Preclinical,"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4529,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4582, 'pubMedId': 25665005, 'title': 'The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25665005'}]",sensitive,1386,Trametinib + Navitoclax,673
204,Preclinical - Cell line xenograft,"In a preclinical study, DETD-35 inhibited proliferation and colony formation of melanoma cells harboring BRAF V600E in culture and reduced tumor size in xenograft models (PMID: 27048951).",Actionable,6673,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 5730, 'pubMedId': 27048951, 'title': 'A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27048951'}]",sensitive,4230,DETD-35,673
205,Preclinical,"In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4531,3908,non-small cell lung carcinoma,DOID,1,BRAF V600E,"[{'id': 4582, 'pubMedId': 25665005, 'title': 'The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25665005'}]",sensitive,3532,Trametinib + TW-37,673
206,Guideline,Mekinist (trametinib) is an active regimen for melanoma patients with BRAF V600E (Guidelines).,Actionable,1512,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 1442, 'pubMedId': None, 'title': 'NCCN Guidelines Melanoma version 3.2015', 'url': 'http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf'}, {'id': 1445, 'pubMedId': None, 'title': '', 'url': 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204114s001lbl.pdf'}]",sensitive,2,Trametinib,673
207,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7653,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4542,Cetuximab + Dabrafenib + SCH772984,673
208,Preclinical,"In a preclinical study, SBI-0640756 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).",Actionable,3784,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4137, 'pubMedId': 26603897, 'title': 'SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26603897'}, {'id': 4139, 'pubMedId': 20531415, 'title': 'Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20531415'}]",sensitive,3306,SBI-0640756,673
209,Preclinical,"In a preclinical study, SBI-0640726 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).",Actionable,3785,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4137, 'pubMedId': 26603897, 'title': 'SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26603897'}, {'id': 4139, 'pubMedId': 20531415, 'title': 'Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20531415'}]",sensitive,3307,SBI-0640726,673
210,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7647,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4525,Cetuximab + Dabrafenib,673
211,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5985,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,3027,GSK2126458 + Trametinib,673
212,Preclinical - Cell culture,"In a preclinical study, RO4987655 inhibited proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 26438159).",Actionable,8461,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",sensitive,903,RO4987655,673
213,Clinical Study,"In a clinical case study, Mekinist (trametinib) and Zelboraf (vemurafenib) combination treatment resulted in a rapid and sustained clinical response in a patient with a rectal neuroendocrine tumor harboring a BRAF V600E mutation (PMID: 27048246).",Actionable,6681,169,neuroendocrine tumor,DOID,1,BRAF V600E,"[{'id': 5733, 'pubMedId': 27048246, 'title': 'BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27048246'}]",sensitive,4234,Trametinib + Vemurafenib,673
214,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",Actionable,7862,1781,thyroid cancer,DOID,1,BRAF V600E,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,4600,Dasatinib + Selumetinib,673
215,Preclinical - Cell line xenograft,"In a preclinical study, a melanoma xenograft model harboring BRAF V600E demonstrated tumor regression when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).",Actionable,11041,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 9035, 'pubMedId': None, 'title': 'Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/B100.short'}]",sensitive,5827,ASN003,673
216,FDA approved,"In a Phase III clinical trial that supported FDA approval, Tafinlar (dabrafenib) improved progression free survival compared to Deticene (dacarbazine) in patients with BRAF V600E positive melanoma (PMID: 22735384).",Actionable,554,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 232, 'pubMedId': 22735384, 'title': 'Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22735384'}]",sensitive,3,Dabrafenib,673
217,Guideline,Tafinlar (dabrafenib) is an active regimen for melanoma patients with BRAF V600E (Guidelines).,Actionable,1507,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 1437, 'pubMedId': None, 'title': '', 'url': 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202806s002lbl.pdf'}]",sensitive,3,Dabrafenib,673
218,Preclinical,"In a preclinical study, Iressa (gefitinib) in combination with PLX4720 inhibited proliferation and tumorigenicity in human melanoma cell line harboring BRAF V600E and resistant to Braf inhibition in culture and in animal models (PMID: 23242808).",Actionable,3334,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 3755, 'pubMedId': 23242808, 'title': 'Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23242808'}]",sensitive,3131,Gefitinib + PLX4720,673
219,Phase II,"In a Phase II trial, 20% (8/41) of melanoma patients with BRAF V600 mutations had a partial response to Binimetinib (MEK162) (PMID: 23414587).",Actionable,1121,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 180, 'pubMedId': 23414587, 'title': 'MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23414587'}]",sensitive,807,Binimetinib,673
220,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) and Afinitor (everolimus) synergistically inhibited growth and induced apoptosis in glioma cell lines in culture, resulted in prolonged survival in cell line xenograft models (PMID: 27217440).",Actionable,9106,3070,malignant glioma,DOID,1,BRAF V600E,"[{'id': 6921, 'pubMedId': 27217440, 'title': 'BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27217440'}]",predicted – sensitive,4901,Everolimus + Selumetinib,673
221,Preclinical - Cell line xenograft,"In a preclinical study, PD-0325901 demonstrated antitumor activity against BRAF V600E colon cancer cell line xenografts (PMID: 16273091).",Actionable,1782,219,colon cancer,DOID,1,BRAF V600E,"[{'id': 2074, 'pubMedId': 16273091, 'title': 'BRAF mutation predicts sensitivity to MEK inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16273091'}]",sensitive,849,PD-0325901,673
222,Preclinical,"In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Gilotrif (afatinib) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115). ",Actionable,4985,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 4823, 'pubMedId': 26916115, 'title': 'A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26916115'}]",sensitive,3712,BI 882370 + Afatinib,673
223,Preclinical,"In a preclinical study, PLX4720, Cediranib (AZD-2171) and Selumetinib (AZD6244) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).",Actionable,4955,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4807, 'pubMedId': 26461489, 'title': 'Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26461489'}]",sensitive,3699,Cediranib + Selumetinib + PLX4720,673
224,Preclinical,"In a preclinical study, PLX4720 and Selumetinib (AZD6244) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).",Actionable,4954,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4807, 'pubMedId': 26461489, 'title': 'Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26461489'}]",sensitive,1061,Selumetinib + PLX4720,673
225,Preclinical - Pdx & cell culture,"In a preclinical study, GDC0879 inhibited survival of melanoma cell lines harboring BRAF V600E in cell culture, cell line xenograft and patient-derived xenograft (PDX) models (PMID: 19276360).",Actionable,7873,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",sensitive,1095,GDC0879,673
226,Preclinical - Pdx,"In a preclinical study, LSN3074753 demonstrated modest efficacy in patient-derived xenograft models of colorectal cancer harboring BRAF V600E, resulted in tumor growth inhibition or regression, but relapse upon discontinuation of treatment (PMID: 28611205).",Actionable,12192,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 10143, 'pubMedId': 28611205, 'title': 'Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28611205'}]",predicted – sensitive,6337,LSN3074753,673
227,Preclinical,"In a preclinical study, Sprycel (dasatinib) failed to induce apoptosis in lung carcinoma cells expressing BRAF V600E (PMID: 22649091).",Actionable,692,3905,lung carcinoma,DOID,1,BRAF V600E,"[{'id': 423, 'pubMedId': 22649091, 'title': 'Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649091'}]",resistant,717,Dasatinib,673
228,Preclinical,"In a preclinical study, BI-69A11 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).",Actionable,3783,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4137, 'pubMedId': 26603897, 'title': 'SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26603897'}, {'id': 4139, 'pubMedId': 20531415, 'title': 'Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20531415'}]",sensitive,3308,BI-69A11,673
229,Phase Ib/II,"In a Phase Ib/II trial, treatment with the combination of Vectibix (panitumumab) and Tafinlar (dabrafenib) resulted in stable disease in 7/8 colorectal cancer patients harboring a BRAF V600E mutation (J Clin Oncol 32:5s, 2014 (suppl; abstr 3515)).",Actionable,1345,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 1051, 'pubMedId': None, 'title': 'Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).', 'url': 'http://meetinglibrary.asco.org/content/131642-144'}]",sensitive,1718,Panitumumab + Dabrafenib,673
230,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).",Actionable,7936,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,3300,TAK-632,673
231,Preclinical - Cell culture,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of transformed cells over expressing BRAF V600E in culture, while single agent inhibition had no effect (PMID: 26140595).",Actionable,10250,10000003,Advanced Solid Tumor,JAX,1,BRAF V600E,"[{'id': 8232, 'pubMedId': 26140595, 'title': 'A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26140595'}]",predicted – sensitive,5443,PF3644022 + PF-477736,673
232,Clinical Study,"In a clinical case study, Tafinlar (dabrafenib) treatment resulted in a near complete response and resolution of leptomeningeal dissemination in a patient with pilocytic astrocytoma harboring BRAF V600E (PMID: 28784858).",Actionable,11710,4851,pilocytic astrocytoma,DOID,1,BRAF V600E,"[{'id': 9723, 'pubMedId': 28784858, 'title': 'Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28784858'}]",sensitive,3,Dabrafenib,673
233,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",Actionable,8198,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,1659,Pimasertib + Sorafenib,673
234,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7618,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4536,Cetuximab + Selumetinib,673
235,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) inhibited growth of both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",Actionable,7856,1781,thyroid cancer,DOID,1,BRAF V600E,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,913,Selumetinib,673
236,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",Actionable,7863,1781,thyroid cancer,DOID,1,BRAF V600E,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,4601,Dasatinib + SCH772984,673
237,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7649,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,1066,Trametinib + Dabrafenib,673
238,Preclinical - Cell culture,"In a preclinical study, the addition of PAC-1 to Mekinist (trametinib) and Zelboraf (vemurafenib) led to greater levels of caspase-3 activity and apoptosis in melanoma cells harboring BRAF V600E when compared to Zelboraf (vemurafenib) and Mekinist (trametinib) treatment without PAC-1 (PMID: 27297867). ",Actionable,7872,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 6518, 'pubMedId': 27297867, 'title': 'The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27297867'}]",sensitive,4603,PAC-1 + Trametinib + Vemurafenib,673
239,Preclinical - Cell line xenograft,"In a preclinical study, the Hsp90 inhibitor Ganetespib destabilized BRAF, especially BRAF V600E, resulted in loss of cell viability in culture and antitumor effects in cell line xenograft models of melanoma (PMID: 24398428).",Actionable,3,8923,skin melanoma,DOID,1,BRAF V600E,"[{'id': 249, 'pubMedId': 24398428, 'title': 'Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24398428'}]",sensitive,745,Ganetespib,673
240,Preclinical,"In a preclinical study, PLX4720 inhibited Erk phosphorylation and cell proliferation of transformed cells expression BRAF V600E in culture (PMID: 20538618).",Actionable,6836,10000003,Advanced Solid Tumor,JAX,1,BRAF V600E,"[{'id': 5859, 'pubMedId': 20538618, 'title': 'Gatekeeper mutations mediate resistance to BRAF-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538618'}]",sensitive,1060,PLX4720,673
241,Phase III,"In a post-hoc analysis of a Phase III trial, BRAF V600E mutations in colon adenocarcinoma patients with microsatellite stable tumors were associated with a shorter disease-free survival and overall survival compared to those patients with microsatellite instability tumors, suggesting that BRAF V600E may serve as a future prognostic biomarker in this patient population (PMID: 26768652). ",Emerging,6437,234,colon adenocarcinoma,DOID,1,BRAF V600E,"[{'id': 5600, 'pubMedId': 26768652, 'title': 'Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26768652'}]",not applicable,1776,N/A,673
242,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).",Actionable,7906,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,1093,AZ628,673
243,Preclinical,"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4524,3908,non-small cell lung carcinoma,DOID,1,BRAF V600E,"[{'id': 4582, 'pubMedId': 25665005, 'title': 'The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25665005'}]",sensitive,3530,Navitoclax + Vemurafenib,673
244,Preclinical - Pdx,"In a preclinical study, CCT196969 inhibited growth of a human melanoma cell line harboring BRAF V600E in culture, and induced tumor regression in several BRAF V600E-mutant melanoma patient-derived xenograft models (PMID: 25500121).",Actionable,3306,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 3714, 'pubMedId': 25500121, 'title': 'Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25500121'}]",sensitive,3105,CCT196969,673
245,Preclinical,"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4527,3908,non-small cell lung carcinoma,DOID,1,BRAF V600E,"[{'id': 4582, 'pubMedId': 25665005, 'title': 'The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25665005'}]",sensitive,1386,Trametinib + Navitoclax,673
246,Preclinical,"In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4530,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4582, 'pubMedId': 25665005, 'title': 'The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25665005'}]",sensitive,3532,Trametinib + TW-37,673
247,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Zelboraf (vemurafenib) and Tarceva (erlotinib) resulted in improved inhibition of tumor growth in BRAF V600E mutant human colon cancer cell line xenograft models compared to either drug as monotherapy (PMID: 22448344).",Actionable,1325,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 1032, 'pubMedId': 22448344, 'title': 'EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22448344'}]",sensitive,1710,Vemurafenib + Erlotinib,673
248,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Gleevec (imatinib) and PLX4720 enhanced antitumor efficacy of melanoma cells harboring BRAF V600E, demonstrating decreased cell survival in xenograft models, and decreased phosphorylation of Mapk1 in culture (PMID: 27924459). ",Actionable,9660,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 7369, 'pubMedId': 27924459, 'title': 'Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27924459'}]",sensitive,5118,Imatinib + PLX4720,673
249,Preclinical,"In a preclinical study, CLM3 inhibited growth, Egfr signaling, and CCND1 expression in thyroid cancer cells harboring BRAF V600E in culture (PMID: 24423321).",Actionable,4417,1781,thyroid cancer,DOID,1,BRAF V600E,"[{'id': 4527, 'pubMedId': 24423321, 'title': 'CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24423321'}]",sensitive,3502,CLM3,673
250,Preclinical,"In a preclinical study, RAF265 inhibited Erk phosphorylation and cell proliferation in BRAF V600E expressing cells in culture (PMID: 20538618).",Actionable,6832,10000003,Advanced Solid Tumor,JAX,1,BRAF V600E,"[{'id': 5859, 'pubMedId': 20538618, 'title': 'Gatekeeper mutations mediate resistance to BRAF-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538618'}]",sensitive,884,RAF265,673
251,Preclinical - Cell culture,"In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated a decreased response to treatment with PD-0325901, demonstrating increased viability of CD133 positive cells in culture (PMID: 26573800). ",Actionable,10191,3068,glioblastoma multiforme,DOID,1,BRAF V600E,"[{'id': 8161, 'pubMedId': 26573800, 'title': 'Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26573800'}]",decreased response,849,PD-0325901,673
252,Preclinical,"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human colon cancer cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4528,219,colon cancer,DOID,1,BRAF V600E,"[{'id': 4582, 'pubMedId': 25665005, 'title': 'The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25665005'}]",sensitive,1386,Trametinib + Navitoclax,673
253,Clinical Study,"In a clinical case report, a patient with metastatic colon cancer harboring BRAF V600E demonstrated a mixed radiographic response, with slight progression in some locations, however, response or stable disease for 7 months in other locations following treatment with the combination of Nexavar (sorafenib) and Erbitux (cetuximab) (PMID: 23792568).",Actionable,11930,219,colon cancer,DOID,1,BRAF V600E,"[{'id': 9915, 'pubMedId': 23792568, 'title': 'Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23792568'}]",predicted – sensitive,6209,Cetuxmab + Sorafenib,673
254,FDA approved,"In a Phase II trial that supported FDA approval, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in an overall response rate of 66.7% (38/57) in patients with non-small cell lung cancer harboring BRAF V600E, versus 32.1% (25/78) with Tafinlar (dabrafenib) alone (J Clin Onc. 35, no. 15_suppl (May 2017) 9075).",Actionable,11287,3908,non-small cell lung carcinoma,DOID,1,BRAF V600E,"[{'id': 9207, 'pubMedId': None, 'title': 'Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.', 'url': 'http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9075'}]",sensitive,1066,Trametinib + Dabrafenib,673
255,Preclinical - Cell line xenograft,"In a preclinical study, the Hsp90 inhibitor, Ganetespib, in combination with the MEK1/2 inhibitor TAK-733, caused the regression of tumors in vemurafenib-resistant cell line xenograft models of melanoma (PMID: 24398428). ",Actionable,1267,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 249, 'pubMedId': 24398428, 'title': 'Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24398428'}]",sensitive,1684,Ganetespib + TAK-733,673
256,Preclinical,"In a preclinical study, RO5126766 inhibited Mek signaling and increased radioiodide uptake and response in transgenic animal models of papillary thyroid carcinoma driven by BRAF V600E (PMID: 27669459).",Actionable,9182,3969,papillary thyroid carcinoma,DOID,1,BRAF V600E,"[{'id': 6994, 'pubMedId': 27669459, 'title': 'Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27669459'}]",sensitive,2011,RO5126766,673
257,Preclinical - Cell line xenograft,"In a preclinical study, Zelboraf (vemurafenib) in combination with SBI-0640756 inhibited the association of eIF4G1 and eIF4E in Zelboraf (vemurafenib) resistant human melanoma cell lines harboring BRAF V600E in culture and reduced tumor growth in xenograft models (PMID: 26603897).",Actionable,3790,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4137, 'pubMedId': 26603897, 'title': 'SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26603897'}]",sensitive,3310,Vemurafenib + SBI-060756,673
258,Preclinical,"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human colon cancer cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4525,219,colon cancer,DOID,1,BRAF V600E,"[{'id': 4582, 'pubMedId': 25665005, 'title': 'The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25665005'}]",sensitive,3530,Navitoclax + Vemurafenib,673
259,Clinical Study,"In a clinical case study, a non-small cell lung cancer patient harboring a BRAF V600E mutation had a complete response after treatment with Zelboraf (vemurafenib) (PMID: 23733758).",Actionable,705,3908,non-small cell lung carcinoma,DOID,1,BRAF V600E,"[{'id': 1011, 'pubMedId': 23733758, 'title': 'Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23733758'}]",sensitive,342,Vemurafenib,673
260,Guideline,Colorectal cancer patients harboring BRAF V600E may not be responsive to Vectibix (panitumumab) as a single therapy or in combination with a chemotherapeutic (Guidelines).,Actionable,9944,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",predicted – resistant,845,Panitumumab,673
261,Preclinical,"In a preclinical study, CCT241161 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 25500121, PMID: 15294323).
",Actionable,3311,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 3714, 'pubMedId': 25500121, 'title': 'Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25500121'}, {'id': 3729, 'pubMedId': 15294323, 'title': 'Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15294323'}]",sensitive,3106,CCT241161,673
262,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7646,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,1916,Cetuximab + Encorafenib,673
263,Preclinical,"In a preclinical study, S3I-201 inhibited cell invasion and Stat3 signaling in human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture (PMID: 23242808).",Actionable,3341,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 3755, 'pubMedId': 23242808, 'title': 'Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23242808'}]",sensitive,3124,S3I-201,673
264,Preclinical,"In a preclinical study, CCT196969 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 25500121, PMID: 15294323).
",Actionable,3310,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 3714, 'pubMedId': 25500121, 'title': 'Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25500121'}, {'id': 3729, 'pubMedId': 15294323, 'title': 'Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15294323'}]",sensitive,3105,CCT196969,673
265,Preclinical - Cell culture,"In a preclinical study, RO5126766 inhibited proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 26438159).",Actionable,8478,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",sensitive,2011,RO5126766,673
266,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of thyroid cancer cells harboring BRAF V600E in culture (PMID: 27523909).",Actionable,7944,1781,thyroid cancer,DOID,1,BRAF V600E,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,3300,TAK-632,673
267,Guideline,"BRAF V600E is used in the diagnosis of hairy cell leukemia (Guidelines, PMID: 25110197, PMID: 23848818). ",Actionable,12170,285,hairy cell leukemia,DOID,1,BRAF V600E,"[{'id': 10123, 'pubMedId': 25110197, 'title': 'Hairy cell leukemia: Update on molecular profiling and therapeutic advances.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25110197'}, {'id': 10124, 'pubMedId': 23848818, 'title': 'BRAF V600E mutation-specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23848818'}, {'id': 10125, 'pubMedId': None, 'title': 'NCCN Guidelines Version 2.2018 Hairy Cell Leukemia', 'url': ''}]",not applicable,1776,N/A,673
268,Preclinical - Cell line xenograft,"In a preclinical study, the combination of PLX4720 and Adriamycin (doxorubicin) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and inhibition of cell growth in culture (PMID: 27924459).",Actionable,9664,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 7369, 'pubMedId': 27924459, 'title': 'Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27924459'}]",sensitive,5122,PLX4720 + Doxorubicin,673
269,Preclinical - Cell line xenograft,"In a preclinical study, the combination of BI 2536 and PLX4720 resulted in suppression of downstream signaling, increased apoptotic activity, inhibition of cell proliferation, and tumor growth suppression in glioblastoma cell line xenograft models harboring BRAF V600E (PMID: 26573800). ",Actionable,10196,3068,glioblastoma multiforme,DOID,1,BRAF V600E,"[{'id': 8161, 'pubMedId': 26573800, 'title': 'Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26573800'}]",sensitive,5422,BI2536 + PLX4720,673
270,Preclinical - Cell line xenograft,"In a preclinical study, DETD-35 and Zelboraf (vemurafenib) synergistically inhibited proliferation and colony formation of melanoma cells harboring BRAF V600E in culture and reduced tumor size in xenograft models (PMID: 27048951).",Actionable,6674,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 5730, 'pubMedId': 27048951, 'title': 'A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27048951'}]",sensitive,4232,DETD-35 + Vemurafenib,673
271,Preclinical - Cell line xenograft,"In a preclinical study, the combination of PLX4720 and Erbitux (cetuximab) inhibited tumor growth in colorectal cancer cell line xenograft models harboring BRAF V600E (PMID: 22281684).",Actionable,11929,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 9911, 'pubMedId': 22281684, 'title': 'Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22281684'}]",sensitive,6208,Cetuximab + PLX4720,673
272,Preclinical - Cell line xenograft,"In a preclinical study, colorectal cancer cell lines were not sensitive to growth inhibition by Zelboraf (vemurafenib) in culture or xenograft models, due to feedback activation of EGFR signaling (PMID: 22281684).",Actionable,11927,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 9911, 'pubMedId': 22281684, 'title': 'Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22281684'}]",no benefit,342,Vemurafenib,673
273,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cell lines harboring BRAF V600E demonstrated decreased response to Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7615,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",no benefit,342,Vemurafenib,673
274,Phase II,"In a Phase II trial, Zelboraf (vemurafenib) did not demonstrate clinical activity as a single agent in patients with metastatic colorectal cancer harboring BRAF V600E (PMID: 26460303).",Actionable,9421,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 7183, 'pubMedId': 26460303, 'title': 'Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26460303'}]",no benefit,342,Vemurafenib,673
275,Preclinical - Cell line xenograft,"In a preclinical study, DEL-22379 inhibited growth of melanoma cells harboring BRAF V600E with high levels of ERK dimerization in culture and inhibited tumor progression in melanoma xenograft models harboring BRAF V600E (PMID: 26267534).",Actionable,5564,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",sensitive,3769,DEL-22379,673
276,Preclinical - Cell line xenograft,"In a preclinical study, a melanoma cell line xenograft model harboring BRAF V600E treated with PD-0325901 demonstrated stable tumor growth, but by day 44, growth ensued and thus, demonstrated no benefit (PMID: 27488531). ",Actionable,8547,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",conflicting,849,PD-0325901,673
277,Preclinical - Cell culture,"In a preclinical study, PD-0325901 inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 26267534).",Actionable,5778,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",conflicting,849,PD-0325901,673
278,Clinical Study,"In a clinical case study, the combination of Zelboraf (vemurafenib) and Erbitux (cetuximab) was tolerated and showed clinical benefit in a patient with BRAF V600E mutant colorectal cancer (PMID: 24523613).",Actionable,1326,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 1033, 'pubMedId': 24523613, 'title': 'Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24523613'}]",sensitive,1711,Vemurafenib + Cetuximab,673
279,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) and Erbitux (cetuximab) combination treatment inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7616,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,1711,Vemurafenib + Cetuximab,673
280,Preclinical,"In a preclinical study, Tykerb (lapatinib) and Faridak (panobinostat) worked synergistically to inhibit growth of BRAF V600E mutant colorectal cancer cells in culture (PMID: 21464044).",Actionable,1323,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 1031, 'pubMedId': 21464044, 'title': 'The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21464044'}]",sensitive,1708,Lapatinib + Panobinostat,673
281,Preclinical,"In a preclinical study, LY3009120 inhibited growth, downstream MAPK signaling and soft agar growth in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26343583).",Actionable,6589,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,3268,LY3009120,673
282,Preclinical - Cell culture,"In a preclinical study, SB590885 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).",Actionable,7946,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,4281,SB590885,673
283,Preclinical,"In a preclinical study, the combination of Tykerb (lapatinib) and Zelboraf (vemurafenib) inhibited growth of thyroid cancer cells harboring a BRAF V600E mutation in culture and in BRAF-mutant mouse models of thyroid cancer (PMID: 23365119).",Actionable,1322,1781,thyroid cancer,DOID,1,BRAF V600E,"[{'id': 1029, 'pubMedId': 23365119, 'title': 'Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23365119'}]",sensitive,1707,Lapatinib + Vemurafenib,673
284,Preclinical,"In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5970,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,763,GSK2126458,673
285,Preclinical,"In a preclinical study, PLX4720 and Tivozanib (AV-951) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).",Actionable,4956,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4807, 'pubMedId': 26461489, 'title': 'Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26461489'}]",sensitive,3700,PLX4720 + Tivozanib,673
286,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",Actionable,7861,1781,thyroid cancer,DOID,1,BRAF V600E,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,4599,Dasatinib + Trametinib,673
287,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7648,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,1917,LGX818 + Cetuximab + BYL719,673
288,Clinical Study,"In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in a rapid and sustained clinical response in a patient with a rectal neuroendocrine tumor harboring a BRAF V600E mutation (PMID: 27048246).",Actionable,6680,169,neuroendocrine tumor,DOID,1,BRAF V600E,"[{'id': 5733, 'pubMedId': 27048246, 'title': 'BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27048246'}]",sensitive,1066,Trametinib + Dabrafenib,673
289,Phase II,"In a Phase II trial, BRAF V600E positive melanoma patients who progressed on treatment with BRAF inhibitors or the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) were treated again with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) after 12 weeks off treatment, demonstrating a partial response in 35% (8/25) and stable disease in 40% (10/25) (PMID: 28268064). ",Actionable,10549,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 8631, 'pubMedId': 28268064, 'title': 'Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28268064'}]",sensitive,1066,Trametinib + Dabrafenib,673
290,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cells harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5987,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,1066,Trametinib + Dabrafenib,673
291,Preclinical - Cell line xenograft,"In a preclinical study, the combination of PLX4720 and Tarceva (erlotinib) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models and culture (PMID: 27924459).",Actionable,9665,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 7369, 'pubMedId': 27924459, 'title': 'Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27924459'}]",sensitive,5120,Erlotinib + PLX4720,673
292,Preclinical,"In a preclinical study, SHP099 did not inhibit proliferation or ERK activation in a melanoma cell line harboring BRAF V600E in culture (PMID: 27362227).",Actionable,7515,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 6394, 'pubMedId': 27362227, 'title': 'Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27362227'}]",no benefit,4504,SHP099,673
293,Preclinical - Cell line xenograft,"In a preclinical study, the combination of PAC-1 and Zelboraf (vemurafenib) resulted in a synergistic effect when treating melanoma cells harboring BRAF V600E in culture and xenograft models, demonstrating increased apoptosis and decreased tumor volume (PMID: 27297867). ",Actionable,7871,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 6518, 'pubMedId': 27297867, 'title': 'The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27297867'}]",sensitive,4604,PAC-1 + Vemurafenib,673
294,Preclinical - Cell line xenograft,"In preclinical studies, CEP-32496 (RXDX-105) reduced tumor volume and promoted tumor regression in xenograft models of a BRAF V600E mutant human colon carcinoma cell line (PMID: 22319199).",Actionable,307,1520,colon carcinoma,DOID,1,BRAF V600E,"[{'id': 203, 'pubMedId': 22319199, 'title': 'CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22319199'}]",sensitive,1002,CEP-32496,673
295,Phase I,"In a Phase I trial, 83% (10/12) of patients with colorectal cancer carrying a BRAF V600E mutation demonstrated tumor regression when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 25589621).",Actionable,1849,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 2277, 'pubMedId': 25589621, 'title': 'Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25589621'}]",sensitive,1717,Vemurafenib + Panitumumab,673
296,Preclinical - Cell line xenograft,"In a preclinical study, Stivarga (regorafenib) inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture and suppressed angiogenesis and tumor growth in cell line xenograft models (PMID: 21170960).",Actionable,1312,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 318, 'pubMedId': 21170960, 'title': 'Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21170960'}]",sensitive,890,Regorafenib,673
297,Preclinical - Cell culture,"In a preclinical study, Afinitor (everolimus) and PLX4720 synergistically inhibited growth and induced apoptosis in glioma cell lines in culture (PMID: 27217440).",Actionable,9108,3070,malignant glioma,DOID,1,BRAF V600E,"[{'id': 6921, 'pubMedId': 27217440, 'title': 'BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27217440'}]",predicted – sensitive,4902,Everolimus + PLX4720,673
298,Preclinical - Cell line xenograft,"In a preclinical study, INU-152 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture, and reduced tumor growth in BRAF V600E-mutant colorectal cancer cell line xenograft models (PMID: 28645859).",Actionable,12058,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 9993, 'pubMedId': 28645859, 'title': 'Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF(V600E) mutant cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28645859'}]",sensitive,6241,INU-152,673
299,Preclinical,"In a preclinical study, TW-37 enhanced the inhibitory effect of Zelboraf (vemurafenib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4533,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4582, 'pubMedId': 25665005, 'title': 'The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25665005'}]",sensitive,3531,Vemurafenib + TW-37,673
300,Preclinical,"In a preclinical study, xenograft models of melanoma harboring BRAF V600E treated with the combination of BI 882370 and Mekinist (trametinib) demonstrated tumor regression with no regrowth during the 5 weeks of treatment (PMID: 26916115). ",Actionable,4981,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4823, 'pubMedId': 26916115, 'title': 'A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26916115'}]",sensitive,3709,BI 882370 + Trametinib,673
301,Preclinical - Cell line xenograft,"In a preclinical study, PLX4720 and navitoclax (ABT-263) worked synergistically to inhibit growth and increase apoptosis of BRAF V600E mutant melanoma cells in culture and in xenografts (PMID: 24983357).",Actionable,2614,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 3334, 'pubMedId': 24983357, 'title': 'Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24983357'}]",sensitive,2960,PLX4720 + Navitoclax,673
302,Preclinical,"In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Mekinist (trametinib) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115). ",Actionable,4986,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 4823, 'pubMedId': 26916115, 'title': 'A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26916115'}]",sensitive,3709,BI 882370 + Trametinib,673
303,Preclinical - Cell line xenograft,"In a preclinical study, INU-152 reduced MEK and ERK phosphorylation and growth of a melanona cell line harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models (PMID: 28645859).",Actionable,12057,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 9993, 'pubMedId': 28645859, 'title': 'Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF(V600E) mutant cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28645859'}]",sensitive,6241,INU-152,673
304,Preclinical - Cell culture,"In a preclinical study, PLX7904 inhibited survival of melanoma cell lines harboring monomeric BRAF V600E as well as cells harboring the Zelboraf (vemurafenib)-resistant dimeric BRAF V600E in culture (PMID: 26466569).",Actionable,7900,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 6521, 'pubMedId': 26466569, 'title': 'RAF inhibitors that evade paradoxical MAPK pathway activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26466569'}]",sensitive,4606,PLX7904,673
305,Preclinical - Pdx,"In a preclinical study, CCT241161 inhibited growth of a human melanoma cell line harboring BRAF V600E in culture, and induced tumor regression in several BRAF V600E-mutant melanoma patient-derived xenograft models (PMID: 25500121).",Actionable,3307,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 3714, 'pubMedId': 25500121, 'title': 'Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25500121'}]",sensitive,3106,CCT241161,673
306,Preclinical - Cell line xenograft,"In a preclinical study, PLX4720 and Cediranib (AZD-2171) worked synergistically to inhibit cell growth and induce apoptosis in PLX4720-resistant human melanoma cell lines harboring BRAF V600E in culture and to suppress tumor growth in xenograft models (PMID: 26461489).",Actionable,4953,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4807, 'pubMedId': 26461489, 'title': 'Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26461489'}]",sensitive,3698,Cediranib + PLX4720,673
307,Clinical Study,"In a clinical case study, a patient with metastatic renal cell carcinoma harboring BRAF V600E demonstrated a partial response following treatment with Zelboraf (vemurafenib) (PMID: 26918217).",Actionable,5648,4450,renal cell carcinoma,DOID,1,BRAF V600E,"[{'id': 5134, 'pubMedId': 26918217, 'title': 'A Rare Finding of a BRAF Mutation in Renal Cell Carcinoma with Response to BRAF-Directed Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26918217'}]",sensitive,342,Vemurafenib,673
308,Preclinical,"In a preclinical study, SB590885 inhibited inhibited Erk phosphorylation and cell proliferation of transformed cells expression BRAF V600E in culture (PMID: 20538618).",Actionable,6827,10000003,Advanced Solid Tumor,JAX,1,BRAF V600E,"[{'id': 5859, 'pubMedId': 20538618, 'title': 'Gatekeeper mutations mediate resistance to BRAF-targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20538618'}]",sensitive,4281,SB590885,673
309,Preclinical - Cell line xenograft,"In a preclinical study, Refametinib (BAY86-9766) inhibited growth of melanoma cell lines harboring BRAF V600E in culture and suppressed tumor growth in cell line xenograft models (PMID: 19706763).",Actionable,1130,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 877, 'pubMedId': 19706763, 'title': 'RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19706763'}]",sensitive,888,Refametinib,673
310,Preclinical,"In a preclinical study, the combination of Zelboraf (vemurafenib) and Iressa (gefitinib) decreased the number of viable colorectal cancer cells harboring a BRAF V600E mutation in cell culture (PMID: 22448344).",Actionable,1324,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 1032, 'pubMedId': 22448344, 'title': 'EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22448344'}]",sensitive,1709,Vemurafenib + Gefitinib,673
311,Preclinical - Cell culture,"In a preclinical study, BGB-283 inhibited Braf phosphorylation and cell proliferation in melanoma cell lines harboring BRAF V600E in culture (PMID: 26208524).",Actionable,8056,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 5280, 'pubMedId': 26208524, 'title': 'BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26208524'}]",sensitive,4025,BGB-283,673
312,Phase I,"In a Phase I trial, BGB-283 resulted in partial response in 1 of 2 melanoma patients harboring BRAF V600E, who remained on treatment for over 249 days (AACR Annual Meeting, Apr 2016, abstract # CT005).",Actionable,7229,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 6230, 'pubMedId': None, 'title': 'Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=46a0776a-1444-49d6-b533-4f68e298c39d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]",sensitive,4025,BGB-283,673
313,Phase I,"In a Phase I trial, Encorafenib (LGX818) showed activity in patients with advanced metastatic colorectal cancer harboring a BRAF V600E mutation, with a response of stable disease in 66.7% (12/18) (Ann Oncol (2014) 25 (suppl 4): iv182-iv183).",Actionable,1341,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 1050, 'pubMedId': None, 'title': '53P Encorafenib (LGX818), an oral BRAF inhibitor, in patients (PTS) WITH BRAF V600E metastatic colorectal cancer (MCRC): results of dose expansion in an open-label, phase I study.', 'url': ''}]",sensitive,796,Encorafenib,673
314,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",Actionable,8203,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4657,Pimasertib + Regorafenib,673
315,Preclinical - Cell line xenograft,"In a preclinical study, the combination of PLX4720 and Zolinza (vorinostat) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and decreased Rb phosphorylation in culture (PMID: 27924459).",Actionable,9663,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 7369, 'pubMedId': 27924459, 'title': 'Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27924459'}]",sensitive,5121,PLX4720 + Vorinostat,673
316,Phase II,"In a Phase II trial, 33% (26/78) of previously treated non-small cell lung carcinoma patients harboring BRAF V600E demonstrated an overall response, which included all partial responses, when treated with Tafinlar (dabrafenib) while 67% (4/6) receiving Tafinlar (dabrafenib) as a first-line treatment achieved partial responses (PMID: 27080216).",Actionable,706,3908,non-small cell lung carcinoma,DOID,1,BRAF V600E,"[{'id': 6410, 'pubMedId': 27080216, 'title': 'Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27080216'}]",sensitive,3,Dabrafenib,673
317,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited Braf V600E in vitro and inhibited growth of human colon cancer cells harboring BRAF V600E in culture (PMID: 21325073, PMID: 24042735).",Actionable,3130,219,colon cancer,DOID,1,BRAF V600E,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3639, 'pubMedId': 24042735, 'title': 'Epigenetic and genetic features of 24 colon cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24042735'}]",sensitive,1040,PF-05212384,673
318,Preclinical,"In a preclinical study, colorectal cancer cell lines harboring a BRAF V600E mutation had increased sensitivity to Tafinlar (dabrafenib) in culture compared to cell lines with wild-type BRAF (PMID: 24885690).",Actionable,1321,9256,colorectal cancer,DOID,1,BRAF V600E,"[{'id': 1028, 'pubMedId': 24885690, 'title': 'Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24885690'}]",sensitive,3,Dabrafenib,673
319,Preclinical - Cell line xenograft,"In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated a decreased response to treatment with PLX4720, demonstrating increased viability of CD133 positive cells in culture and in xenograft models (PMID: 26573800). ",Actionable,10192,3068,glioblastoma multiforme,DOID,1,BRAF V600E,"[{'id': 8161, 'pubMedId': 26573800, 'title': 'Targeting a Plk1-Controlled Polarity Checkpoint in Therapy-Resistant Glioblastoma-Propagating Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26573800'}]",decreased response,1060,PLX4720,673
320,Phase I,"In a Phase I trial, Cotellic (cobimetinib) treatment resulted in a confirmed partial response in six melanoma patients harboring BRAF V600E (PMID: 27424159).",Actionable,12087,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 10025, 'pubMedId': 27424159, 'title': 'A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27424159'}]",sensitive,1004,Cobimetinib,673
321,Preclinical,"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4526,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4582, 'pubMedId': 25665005, 'title': 'The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25665005'}]",sensitive,3530,Navitoclax + Vemurafenib,673
322,Preclinical,"In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell lines harboring BRAF V600E mutation in culture (PMID: 24448821).",Actionable,4028,1909,melanoma,DOID,1,BRAF V600E,"[{'id': 4380, 'pubMedId': 24448821, 'title': 'Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24448821'}]",sensitive,1011,E6201,673
323,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P displayed reduced sensitivity to Mekinist (trametinib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).",Actionable,5976,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,2,Trametinib,673
324,Preclinical - Cell culture,"In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 28655712). ",Actionable,12165,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",sensitive,997,BVD-523,673
325,Preclinical,"In a preclinical study, the combination of Talfinlar (dabrafenib)    and Mekinist (trametinib) resulted in improved growth inhibition in melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 22389471).",Actionable,5982,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,1066,Trametinib + Dabrafenib,673
326,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling in culture (PMID: 22389471).",Actionable,5975,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,3,Dabrafenib,673
327,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712). ",Actionable,12164,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",resistant,342,Vemurafenib,673
328,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",Actionable,7665,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,2618,SCH772984,673
329,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment in culture (PMID: 27312529).",Actionable,7633,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4536,Cetuximab + Selumetinib,673
330,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Selumetinib (AZD6244), and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7634,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4540,Cetuximab + Selumetinib + Vemurafenib,673
331,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).",Actionable,7635,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,694,Cetuximab,673
332,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Selumetinib (AZD6244) in culture (PMID: 27312529).",Actionable,7637,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,913,Selumetinib,673
333,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired EGFR amplification (PMID: 27312529).",Actionable,7621,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,3773,Selumetinib + Vemurafenib,673
334,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7632,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1711,Vemurafenib + Cetuximab,673
335,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7666,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4542,Cetuximab + Dabrafenib + SCH772984,673
336,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",Actionable,7663,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1916,Cetuximab + Encorafenib,673
337,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7636,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,342,Vemurafenib,673
338,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7664,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1066,Trametinib + Dabrafenib,673
339,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7660,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4543,Cetuximab + SCH772984,673
340,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12151,1909,melanoma,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",resistant,2,Trametinib,673
341,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7654,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,1916,Cetuximab + Encorafenib,673
342,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7655,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4525,Cetuximab + Dabrafenib,673
343,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7657,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,1917,LGX818 + Cetuximab + BYL719,673
344,Preclinical - Cell culture,"In a preclinical study, SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7659,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,2618,SCH772984,673
345,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 28655712).",Actionable,12154,1909,melanoma,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",sensitive,342,Vemurafenib,673
346,Preclinical,"In a preclinical study, over expression of MAPK21 L115P in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",Actionable,5812,1909,melanoma,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",resistant,849,PD-0325901,673
347,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture, likely due to the acquired secondary resistance mutation MAP2K1 L115P (PMID: 27312529).",Actionable,7620,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1066,Trametinib + Dabrafenib,673
348,Preclinical - Cell culture,"In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 26267534).",Actionable,5817,1909,melanoma,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",sensitive,3769,DEL-22379,673
349,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7662,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4542,Cetuximab + Dabrafenib + SCH772984,673
350,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7656,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,1711,Vemurafenib + Cetuximab,673
351,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7658,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4541,Cetuximab + Dabrafenib + Trametinib,673
352,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7661,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4544,Dabrafenib + SCH772984,673
353,Preclinical,"In a preclinical study, a melanoma mouse model harboring BRAF V600E treated with Zelboraf (vemurafenib) demonstrated a greater drug induced sensitivity when treatment was combined with PLX3397, resulting in increased infiltration of lymphocytes via Csf1r inhibition and elevated antitumor activity (PMID: 25939769).",Actionable,6075,1909,melanoma,DOID,22385,BRAF V600E CSF1R positive,"[{'id': 5274, 'pubMedId': 25939769, 'title': 'Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25939769'}]",sensitive,1339,PLX3397 + Vemurafenib,673
354,Clinical Study,"In a clinical study, a colon cancer patient harboring BRAF V600E and TP53 Q192K demonstrated a partial response when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 28514312). ",Actionable,11052,219,colon cancer,DOID,27902,BRAF V600E TP53 Q192K,"[{'id': 9046, 'pubMedId': 28514312, 'title': 'Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28514312'}]",sensitive,1717,Vemurafenib + Panitumumab,673
355,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5969,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,763,GSK2126458,673
356,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).",Actionable,5964,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,2,Trametinib,673
357,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).",Actionable,5983,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,4004,Dabrafenib + GSK2126458,673
358,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E harboring MAP2K1 K59del in culture (PMID: 22389471).",Actionable,5980,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,1066,Trametinib + Dabrafenib,673
359,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5953,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,3,Dabrafenib,673
360,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).",Actionable,5984,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,3027,GSK2126458 + Trametinib,673
361,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5957,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,342,Vemurafenib,673
362,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cells harboring BRAF V600E and NRAS A146T and NRAS Q61K in culture (PMID: 22389471).",Actionable,5979,1909,melanoma,DOID,22097,BRAF V600E NRAS Q61K NRAS A146T,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,1066,Trametinib + Dabrafenib,673
363,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",Actionable,7056,1909,melanoma,DOID,24281,BRAF V600E MAP2K1 V60E,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,3,Dabrafenib,673
364,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",Actionable,7002,1909,melanoma,DOID,24281,BRAF V600E MAP2K1 V60E,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",sensitive,4351,VRT11E,673
365,Clinical Study,"In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to treatment with Afinitor (everolimus) (PMID: 27797976). ",Actionable,10814,3963,thyroid carcinoma,DOID,26356,BRAF V600E PIK3CA H1047R,"[{'id': 8849, 'pubMedId': 27797976, 'title': 'Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27797976'}]",resistant,735,Everolimus,673
366,Clinical Study,"In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to the combination therapy, Mekinist (trametinib) and Tafinlar (dabrafenib) (PMID: 27797976).",Actionable,10815,3963,thyroid carcinoma,DOID,26356,BRAF V600E PIK3CA H1047R,"[{'id': 8849, 'pubMedId': 27797976, 'title': 'Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27797976'}]",resistant,1066,Trametinib + Dabrafenib,673
367,Clinical Study,"In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated tumor regression when treated with the triple combination, Tafinlar (dabrafenib), Mekinist (trametinib), and Afinitor (everolimus) (PMID: 27797976).",Actionable,10812,3963,thyroid carcinoma,DOID,26356,BRAF V600E PIK3CA H1047R,"[{'id': 8849, 'pubMedId': 27797976, 'title': 'Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27797976'}]",sensitive,5650,Dabrafenib + Everolimus + Trametinib,673
368,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).",Actionable,7687,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1917,LGX818 + Cetuximab + BYL719,673
369,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture, likely due to the acquired secondary resistance mutation KRAS A146T (PMID: 27312529).",Actionable,7623,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1916,Cetuximab + Encorafenib,673
370,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7680,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1711,Vemurafenib + Cetuximab,673
371,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment in culture, likely due to the acquired secondary resistance mutation KRAS A146T (PMID: 27312529).",Actionable,7624,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4525,Cetuximab + Dabrafenib,673
372,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture (PMID: 27312529).",Actionable,7682,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4541,Cetuximab + Dabrafenib + Trametinib,673
373,Clinical Study,"In a clinical study, a colorectal cancer patient harboring EGFR amplification, BRAF V600E, and EGFR S492R demonstrated resistance to Erbitux (cetuximab) (PMID: 22270724). ",Actionable,3221,9256,colorectal cancer,DOID,12768,EGFR amp EGFR S492R BRAF V600E,"[{'id': 3682, 'pubMedId': 22270724, 'title': 'Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22270724'}]",resistant,694,Cetuximab,673
374,Preclinical,"In a preclinical study, treatment with the combination of GSK2636771 and a PD-1 antibody resulted in greater tumor infiltration of T-cells and tumor growth inhibition in mouse melanoma models expressing BRAF V600E with PTEN loss compared to either agent alone (PMID: 26645196).",Actionable,10891,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,"[{'id': 4556, 'pubMedId': 26645196, 'title': 'Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26645196'}]",sensitive,5673,GSK2636771 + unspecified PD-1 antibody,673
375,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600E (PMID: 25637314).",Actionable,6318,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,"[{'id': 5522, 'pubMedId': 25637314, 'title': 'The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25637314'}]",sensitive,1050,XL147,673
376,Clinical Study,"In a clinical study, a melanoma patient harboring PTEN loss and BRAF V600E demonstrated resistance to Afinitor (everolimus) treatment, resulting in progressive disease (PMID: 20664172).",Actionable,1233,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,"[{'id': 219, 'pubMedId': 20664174, 'title': ""PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20664174'}, {'id': 1067, 'pubMedId': 20664172, 'title': 'Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20664172'}]",resistant,735,Everolimus,673
377,Preclinical - Cell culture,"In a preclinical study, GDC0879 and Pictilisib (GDC-0941) synergistically inhibited survival of melanoma cell lines harboring BFAF V600E and PTEN loss in cell culture (PMID: 19276360).",Actionable,7899,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",sensitive,4605,GDC0879 + GDC-0941,673
378,Preclinical,"In a preclinical study, a melanoma cell line harboring BRAF V600E and PTEN loss demonstrated sensitivity when treated with a combination of Pictilisib (GDC-0941) and PLX4720, resulting in decreased cell proliferation in culture (PMID: 24265153).",Actionable,7081,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",sensitive,4358,GDC-0941 + PLX4720,673
379,Preclinical - Cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063).",Actionable,8568,9256,colorectal cancer,DOID,26361,BRAF V600E PIK3CA H1047R TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,673
380,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture (PMID: 24265153).",Actionable,7057,1909,melanoma,DOID,24282,BRAF V600E MAP2K1 P124S,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,3,Dabrafenib,673
381,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 24265153).",Actionable,7061,1909,melanoma,DOID,24282,BRAF V600E MAP2K1 P124S,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,2,Trametinib,673
382,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and MAP2K1 P124S demonstrated decreased sensitivity to Selumetinib (AZD6244) compared to cells harboring BRAF V600E alone in culture (PMID: 22197931).",Actionable,7035,1909,melanoma,DOID,24282,BRAF V600E MAP2K1 P124S,"[{'id': 429, 'pubMedId': 22197931, 'title': 'Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22197931'}]",decreased response,913,Selumetinib,673
383,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",Actionable,7004,1909,melanoma,DOID,24282,BRAF V600E MAP2K1 P124S,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",sensitive,4351,VRT11E,673
384,Clinical Study,"In a clinical case study, a patient with synchronous BRAF wild-type hepatocellular carcinoma and non-small cell lung cancer harboring BRAF G469V demonstrated a partial response in primary lung lesions and complete response in the lung metastasis following treatment with Nexavar (sorafenib) (PMID: 27388325). ",Actionable,9613,3908,non-small cell lung carcinoma,DOID,1777,BRAF G469V,"[{'id': 7323, 'pubMedId': 27388325, 'title': 'Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27388325'}]",sensitive,920,Sorafenib,673
385,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G469V (PMID: 26343582).",Actionable,9414,10000003,Advanced Solid Tumor,JAX,1777,BRAF G469V,"[{'id': 7141, 'pubMedId': 26343582, 'title': 'BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343582'}]",resistant,342,Vemurafenib,673
386,Clinical Study,"In a clinical case study, a rectal adenocarcinoma patient harboring APC Q1429fs, BRAF N581S, and ERBB2 L755S did not respond to Herceptin (trastuzumab) treatment in combination with Fluorouracil and Wellcovorin (leucovorin) (PMID: 27626067).",Actionable,9333,1996,rectum adenocarcinoma,DOID,26822,APC Q1429fs BRAF N581S ERBB2 L755S,"[{'id': 7088, 'pubMedId': 27626067, 'title': 'Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27626067'}]",no benefit,4970,Fluorouracil + Leucovorin + Trastuzumab,673
387,Preclinical - Patient cell culture,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 combination treatment resulted in significant apoptosis in primary tumor cells isolated from a lung adenocarcinoma patient harboring BRAF N581S in culture (PMID: 26140595).",Actionable,10261,3910,lung adenocarcinoma,DOID,3326,BRAF N581S,"[{'id': 8232, 'pubMedId': 26140595, 'title': 'A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26140595'}]",predicted – sensitive,5443,PF3644022 + PF-477736,673
388,Preclinical - Pdx,"In a preclinical study, treatment with Mekinist (trametinib) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",Actionable,11661,4464,collecting duct carcinoma,DOID,28180,BRAF D594N BRAF G466A EGFR over exp MET over exp,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",sensitive,2,Trametinib,673
389,Preclinical - Pdx,"In a preclinical study, the combination of Mekinist (trametinib) and Capmatinib (INC280) induced tumor regression in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",Actionable,11662,4464,collecting duct carcinoma,DOID,28180,BRAF D594N BRAF G466A EGFR over exp MET over exp,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",sensitive,6103,INC280 + Trametinib,673
390,Preclinical - Pdx,"In a preclinical study, treatment with Capmatinib (INC280) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",Actionable,11660,4464,collecting duct carcinoma,DOID,28180,BRAF D594N BRAF G466A EGFR over exp MET over exp,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",sensitive,1065,Capmatinib,673
391,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring BRAF L485Y were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).",Actionable,7876,3908,non-small cell lung carcinoma,DOID,26081,BRAF L485Y,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",resistant,1095,GDC0879,673
392,Clinical Study,"In a clinical case study, a lung adenocarcinoma patient harboring BRAF G469L did not respond to Zelboraf (vemurafenib) therapy (PMID: 24035431).",Actionable,9610,3910,lung adenocarcinoma,DOID,4782,BRAF G469L,"[{'id': 7321, 'pubMedId': 24035431, 'title': 'Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24035431'}]",no benefit,342,Vemurafenib,673
393,Clinical Study,"In a clinical study, mutant BRAF correlated with prolonged duration on Opdivo (nivolumab) therapy compared to wild-type BRAF in non-small cell lung carcinoma patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #1138PD).",Actionable,12099,3908,non-small cell lung carcinoma,DOID,465,BRAF mutant,"[{'id': 10039, 'pubMedId': None, 'title': 'Immune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC)', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]",predicted – sensitive,1312,Nivolumab,673
394,Preclinical - Cell culture,"In a preclinical study, MLN2480 inhibited downstream signaling and proliferation of several BRAF mutant solid tumor cell lines in culture (EJC Supp, Nov 2010, Vol 8(7), p40-41).
",Actionable,9609,10000003,Advanced Solid Tumor,JAX,465,BRAF mutant,"[{'id': 7320, 'pubMedId': None, 'title': '105 BIIB024, a potent pan-Raf kinase inhibitor for melanoma and solid tumors', 'url': 'http://www.ejcancersupplements.com/article/S1359-6349%2810%2971810-3/abstract'}]",predicted – sensitive,1034,MLN2480,673
395,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) resulted in some reduced cell growth in colon cancer cells harboring a BRAF mutation in culture (PMID: 27655129). ",Actionable,10057,219,colon cancer,DOID,465,BRAF mutant,"[{'id': 7992, 'pubMedId': 27655129, 'title': 'MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27655129'}]",predicted – sensitive,913,Selumetinib,673
396,Phase I,"In a Phase I study, selumetinib demonstrated an increase in iodine uptake and retention in a subgroup of patients with thyroid cancer that was refractory to radioiodine; including patients with BRAF and NRAS mutations disease (PMID: 23406027).",Actionable,1028,1781,thyroid cancer,DOID,465,BRAF mutant,"[{'id': 744, 'pubMedId': 23406027, 'title': 'Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23406027'}]",sensitive,913,Selumetinib,673
397,Phase I,"In a Phase I clinical trial, Tafinlar (dabrafenib) demonstrated safety and efficacy in patients with BRAF V600E positive solid tumors (PMID: 22608338).",Actionable,701,10000003,Advanced Solid Tumor,JAX,465,BRAF mutant,"[{'id': 467, 'pubMedId': 22608338, 'title': 'Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22608338'}]",sensitive,3,Dabrafenib,673
398,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant gastric carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11701,5517,stomach carcinoma,DOID,465,BRAF mutant,"[{'id': 9707, 'pubMedId': None, 'title': 'KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short'}]",predicted – sensitive,5747,KO-947,673
399,Phase I,"In a Phase I trial, Encorafenib (LGX818) treatment resulted in an overall response rate (ORR) of 60% (15/25) and a median progression-free survival (mPFS) of 12.4 months in BRAF inhibitor-naïve melanoma patients harboring BRAF mutations, and an ORR of 22% (6/29) and mPFS of 1.9 months in BRAF inhibitor-pretreated patients (PMID: 28611198; NCT01436656).",Actionable,12133,1909,melanoma,DOID,465,BRAF mutant,"[{'id': 10108, 'pubMedId': 28611198, 'title': 'Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28611198'}]",sensitive,796,Encorafenib,673
400,Preclinical - Cell culture,"In a preclinical study, combination of S63845 and Mekinist (trametinib) resulted in potent cytotoxic effects in BRAF-mutated melanoma cells in culture compared to the cytostatic effect of Mekinist (trametinib) alone (PMID: 27760111).",Actionable,9039,1909,melanoma,DOID,465,BRAF mutant,"[{'id': 6851, 'pubMedId': 27760111, 'title': 'The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27760111'}]",sensitive,4864,S63845 + Trametinib,673
401,Preclinical - Pdx,"In a preclinical study, LSN3074753 resulted in a disease control rate of 8.3% (1/12) in BRAF mutant patient-derived xenograft models of colorectal cancer (PMID: 28611205).",Actionable,12191,9256,colorectal cancer,DOID,465,BRAF mutant,"[{'id': 10143, 'pubMedId': 28611205, 'title': 'Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28611205'}]",predicted – sensitive,6337,LSN3074753,673
402,Phase I,"In a Phase I trial, MLN2480 resulted in a median progression free survival of 4.6 months and a partial response in 50% (8/16) of melanoma patients harboring a BRAF mutation (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 410P; NCT01425008).",Actionable,11978,1909,melanoma,DOID,465,BRAF mutant,"[{'id': 9943, 'pubMedId': None, 'title': 'Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK- 580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis', 'url': 'http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts'}]",sensitive,1034,MLN2480,673
403,Preclinical,"In a preclinical study, MLN2480 demonstrated efficacy in BRAF mutant xenograft models of melanoma and colorectal cancer (J Clin Oncol 31, 2013 (suppl; abstr e13529)).",Actionable,1128,1909,melanoma,DOID,465,BRAF mutant,"[{'id': 876, 'pubMedId': None, 'title': 'Use of combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 on the growth of BRAF-mutant and RAS-mutant preclinical models of melanoma and CRC.', 'url': 'http://meetinglibrary.asco.org/content/114757-132'}]",sensitive,1034,MLN2480,673
404,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of human multiple myeloma cells harboring mutant BRAF in culture (PMID: 26343583).",Actionable,6687,9538,multiple myeloma,DOID,465,BRAF mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,2,Trametinib,673
405,Preclinical - Cell culture,"In a preclinical study, BRAF mutant colorectal cancer cell lines demonstrated reduced sensitivity to PLX4720 in culture (PMID: 26351322).",Actionable,8667,9256,colorectal cancer,DOID,465,BRAF mutant,"[{'id': 6708, 'pubMedId': 26351322, 'title': 'Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26351322'}]",decreased response,1060,PLX4720,673
406,Preclinical - Cell line xenograft,"In a preclinical study, Buparlisib (BKM120) treatment in human melanoma cell line xenograft models with brain metastases and harboring a BRAF mutation resulted in inhibition of brain tumor growth (PMID: 27307593). ",Actionable,10124,1909,melanoma,DOID,465,BRAF mutant,"[{'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",sensitive,680,BKM120,673
407,Preclinical,"In a preclinical study, MLN2480 demonstrated efficacy in BRAF mutant xenograft models of melanoma and colorectal cancer (J Clin Oncol 31, 2013 (suppl; abstr e13529)).",Actionable,1127,9256,colorectal cancer,DOID,465,BRAF mutant,"[{'id': 876, 'pubMedId': None, 'title': 'Use of combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 on the growth of BRAF-mutant and RAS-mutant preclinical models of melanoma and CRC.', 'url': 'http://meetinglibrary.asco.org/content/114757-132'}]",sensitive,1034,MLN2480,673
408,Phase I,"In a Phase I trial, BGB-283 demonstrated safety and preliminary efficacy, resulted in partial response in 14% (4/29), and prolonged stable disease in 48% (14/29) of advanced solid tumor patients harboring mutations in KRAS, NRAS, and/or BRAF (AACR Annual Meeting, Apr 2016, abstract # CT005).",Actionable,7228,10000003,Advanced Solid Tumor,JAX,465,BRAF mutant,"[{'id': 6230, 'pubMedId': None, 'title': 'Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=46a0776a-1444-49d6-b533-4f68e298c39d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]",sensitive,4025,BGB-283,673
409,Preclinical,"In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with BRAF mutations (PMID: 23039341).",Actionable,5624,1909,melanoma,DOID,465,BRAF mutant,"[{'id': 1840, 'pubMedId': 23039341, 'title': 'Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23039341'}]",sensitive,1011,E6201,673
410,Preclinical - Cell line xenograft,"In a preclinical study, PET-16 and Zelboraf (vemurafenib) synergistically inhibited growth of melanoma cell lines in culture, resulted in enhanced tumor growth inhibition in cell ine xenograft models (PMID: 26984758).",Actionable,11223,1909,melanoma,DOID,465,BRAF mutant,"[{'id': 8968, 'pubMedId': 26984758, 'title': 'HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26984758'}]",sensitive,5911,PET-16 + Vemurafenib,673
411,Phase Ib/II,"In a Phase I/II trial, treatment with the triple combination of Tafinlar (dabrafenib), Mekinist (trametinib), and Vectibix (panitumumab) resulted in an objective response rate (ORR) of 21% and median progression-free survival (mPFS) of 4.2 mo, compared with 0% ORR and mPFS of 2.6 mo with Mekinist (trametinib) plus Vectibix (panitumumab), and 10% ORR and mPFS of 3.5 mo with Tafinlar (dabrafenib) plus Vectibix (panitumumab) in patients with BRAF-mutant colorectal cancer (PMID: 27770002; NCT01750918).",Actionable,11932,9256,colorectal cancer,DOID,465,BRAF mutant,"[{'id': 9918, 'pubMedId': 27770002, 'title': 'Triple Therapy Improves Colorectal Cancer Response.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27770002'}]",predicted – sensitive,1992,Panitumumab + Trametinib + Dabrafenib,673
412,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant pancreatic cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11697,1793,pancreatic cancer,DOID,465,BRAF mutant,"[{'id': 9707, 'pubMedId': None, 'title': 'KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short'}]",predicted – sensitive,5747,KO-947,673
413,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant colorectal cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11699,9256,colorectal cancer,DOID,465,BRAF mutant,"[{'id': 9707, 'pubMedId': None, 'title': 'KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short'}]",predicted – sensitive,5747,KO-947,673
414,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of lung adenocarcinoma cells harboring mutant BRAF in culture (PMID: 26343583).",Actionable,6697,3910,lung adenocarcinoma,DOID,465,BRAF mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,2,Trametinib,673
415,Preclinical,"In a preclinical study, E6201 and LY294002 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations in culture, regardless of PTEN mutation status (PMID: 23039341).",Actionable,5627,1909,melanoma,DOID,465,BRAF mutant,"[{'id': 1840, 'pubMedId': 23039341, 'title': 'Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23039341'}]",sensitive,3911,E6201 + LY294002,673
416,Preclinical,"In a preclinical study, Tubastatin A inhibited proliferation of BRAF mutant melanoma cell lines in culture (PMID: 25957812).",Actionable,4764,1909,melanoma,DOID,465,BRAF mutant,"[{'id': 4713, 'pubMedId': 25957812, 'title': 'Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25957812'}]",sensitive,3635,Tubastatin A,673
417,Phase I,"In a Phase Ia trial, CC-90003 treatment did not result in any objective responses and demonstrated toxicity in advanced solid tumor patients harboring KRAS, NRAS, or BRAF mutations (AJ Clin Oncol 35, 2017 (suppl; abstr 2577)).",Actionable,11066,10000003,Advanced Solid Tumor,JAX,465,BRAF mutant,"[{'id': 9060, 'pubMedId': None, 'title': 'A phase Ia study of CC-90003, a selective extracellular signal-regulated kinase (ERK) inhibitor, in patients with relapsed or refractory BRAF or RAS-mutant tumors.', 'url': 'http://abstracts.asco.org/199/AbstView_199_186986.html'}]",no benefit,2874,CC-90003,673
418,Preclinical - Pdx,"In a preclinical study, LSN3074753 and Erbitux (cetuximab) synergistically inhibited tumor growth in patient-derived xenograft models of colorectal cancer harboring BRAF mutations, resulted in a disease control rate of 41.7% (5/12) (PMID: 28611205).",Actionable,12194,9256,colorectal cancer,DOID,465,BRAF mutant,"[{'id': 10143, 'pubMedId': 28611205, 'title': 'Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28611205'}]",sensitive,6338,Cetuximab + LSN3074753,673
419,Preclinical,"In a preclinical study, a majority of human colorectal cancer cell lines (4/7) harboring mutant BRAF were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6738,9256,colorectal cancer,DOID,465,BRAF mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,2,Trametinib,673
420,Phase I,"In a Phase I trial, Voruciclib (P1446A-05) and Zelboraf (vemurafenib) combination therapy demonstrated safety and preliminary efficacy, resulted in complete response in 33% (1/3) and partial response in 67% (2/3) of BRAFi-naïve melanoma patients harboring BRAF mutations (J Clin Oncol 33, 2015 (suppl; abstr 9076)).",Actionable,5891,1909,melanoma,DOID,465,BRAF mutant,"[{'id': 5185, 'pubMedId': None, 'title': 'Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma.', 'url': 'http://meetinglibrary.asco.org/content/153239-156'}]",sensitive,1238,Vemurafenib + Voruciclib,673
421,Preclinical - Cell line xenograft,"In a preclinical study, treatment with BI-847325 resulted in decreased expression of Mcl-1 and Mek, and inhibited growth of BRAF-mutant melanoma cell lines in culture, and inhibited tumor growth melanoma cell line xenograft models harboring BRAF mutations, including models with BRAF inhibitor resistance (PMID: 25873592).",Actionable,7827,1909,melanoma,DOID,465,BRAF mutant,"[{'id': 6506, 'pubMedId': 25873592, 'title': 'The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25873592'}]",predicted – sensitive,1059,BI-847325,673
422,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant cervical carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11703,2893,cervix carcinoma,DOID,465,BRAF mutant,"[{'id': 9707, 'pubMedId': None, 'title': 'KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short'}]",predicted – sensitive,5747,KO-947,673
423,Phase I,"In a Phase I trial, Binimetinib (MEK162) treatment resulted in an estimated progression free survival of 1.4 months and overall survival of 7.1 months in colorectal cancer patients harboring BRAF mutations (PMID: 28152546).",Actionable,10459,9256,colorectal cancer,DOID,465,BRAF mutant,"[{'id': 8465, 'pubMedId': 28152546, 'title': 'A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28152546'}]",predicted – sensitive,807,Binimetinib,673
424,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant non-small cell lung cancer harboring (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11695,3908,non-small cell lung carcinoma,DOID,465,BRAF mutant,"[{'id': 9707, 'pubMedId': None, 'title': 'KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short'}]",predicted – sensitive,5747,KO-947,673
425,Preclinical,"In a preclinical study, obatoclax decreased proliferation in human tumor cell lines with BRAF mutation in culture (PMID: 22460902).",Actionable,1823,10000003,Advanced Solid Tumor,JAX,465,BRAF mutant,"[{'id': 2158, 'pubMedId': 22460902, 'title': 'Systematic identification of genomic markers of drug sensitivity in cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22460902'}]",sensitive,834,Obatoclax,673
426,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of human pancreatic adenocarcinoma cells harboring mutant BRAF in culture (PMID: 26343583).",Actionable,6731,4074,pancreatic adenocarcinoma,DOID,465,BRAF mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,2,Trametinib,673
427,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) and AZ628 synergistically inhibited Mapk signaling and cell proliferation in BRAF mutant colorectal cancer cell lines in culture (PMID: 26351322).",Actionable,8676,9256,colorectal cancer,DOID,465,BRAF mutant,"[{'id': 6708, 'pubMedId': 26351322, 'title': 'Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26351322'}]",sensitive,4791,AZ628 + Selumetinib,673
428,Preclinical - Cell culture,"In a preclinical study, combination of S63845 and Zelboraf (vemurafenib) resulted in potent cytotoxic effects in BRAF-mutated melanoma cells in culture compared to the cytostatic effect of Zelboraf (vemurafenib) alone (PMID: 27760111).",Actionable,9041,1909,melanoma,DOID,465,BRAF mutant,"[{'id': 6851, 'pubMedId': 27760111, 'title': 'The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27760111'}]",sensitive,4865,S63845 + Vemurafenib,673
429,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased proliferation and increased apoptosis and enhanced ERK inhibition compared to either agent alone in non-small cell lung cancer cell lines harboring non-BRAF V600 mutations in culture (PMID: 27577079).",Actionable,9612,3908,non-small cell lung carcinoma,DOID,465,BRAF mutant,"[{'id': 7322, 'pubMedId': 27577079, 'title': 'Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27577079'}]",predicted – sensitive,1066,Trametinib + Dabrafenib,673
430,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring a BRAF mutation demonstrated greater sensitivity to the combination treatment of Mekinist (trametinib) and Ibrance (palbociclib) in culture when compared to either agent alone (PMID: 27488531). ",Actionable,8542,1909,melanoma,DOID,465,BRAF mutant,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",sensitive,1368,Palbociclib + Trametinib,673
431,Preclinical - Cell line xenograft,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of BRAF mutant colon cancer (PMID: 26140595).",Actionable,10259,219,colon cancer,DOID,465,BRAF mutant,"[{'id': 8232, 'pubMedId': 26140595, 'title': 'A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26140595'}]",predicted – sensitive,5443,PF3644022 + PF-477736,673
432,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant melanoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11693,1909,melanoma,DOID,465,BRAF mutant,"[{'id': 9707, 'pubMedId': None, 'title': 'KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short'}]",predicted – sensitive,5747,KO-947,673
433,Phase II,"In a Phase II trial in patients with advanced melanoma, 5/6 patients exhibiting a response to selumetinib had BRAF-mutant tumors (PMID: 22048237).
",Actionable,713,1909,melanoma,DOID,465,BRAF mutant,"[{'id': 228, 'pubMedId': 22048237, 'title': 'Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22048237'}]",sensitive,913,Selumetinib,673
434,Preclinical - Pdx,"In a preclinical study, KO-947 resulted in tumor regression in patient derived xenograft (PDX) models harboring either a BRAF mutation, NRAS mutation, or KRAS mutation (EJC Dec 2016, 69:1; S126).",Actionable,10965,10000003,Advanced Solid Tumor,JAX,465,BRAF mutant,"[{'id': 8965, 'pubMedId': None, 'title': 'KO-947, a potent and selective ERK inhibitor with slow dissociation kinetics', 'url': 'http://www.ejcancer.com/article/S0959-8049(16)32974-4/abstract'}]",predicted – sensitive,5747,KO-947,673
435,Preclinical,"In a preclinical study, tumor cell lines harboring BRAF mutations demonstrated limited sensitivity to XL147 treatment in culture (PMID: 25637314).",Actionable,6302,10000003,Advanced Solid Tumor,JAX,465,BRAF mutant,"[{'id': 5522, 'pubMedId': 25637314, 'title': 'The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25637314'}]",decreased response,1050,XL147,673
436,Phase Ib/II,"In a Phase Ib/II trial, the combination therapy of Erbitux (cetuximab) and Encorafenib (LGX818) in colorectal cancer patients harboring a BRAF mutation resulted in an overall response rate of 19% (5/26), including 1 patient with a complete response and 4 patients with a partial response, and led to a median progression free survival of 3.7 months and response duration of 46 weeks (PMID: 28363909).",Actionable,11203,9256,colorectal cancer,DOID,465,BRAF mutant,"[{'id': 9149, 'pubMedId': 28363909, 'title': 'A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363909'}]",sensitive,1916,Cetuximab + Encorafenib,673
437,Preclinical,"In a preclinical study, PLX8394 blocked survival and growth of vemurafenib/PLX4720-resistant melanoma cells harboring BRAF V600E splice variants in culture (PMID: 24422853).",Actionable,2529,1909,melanoma,DOID,465,BRAF mutant,"[{'id': 195, 'pubMedId': 24422853, 'title': 'Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24422853'}]",sensitive,1041,PLX8394,673
438,Preclinical - Cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring a BRAF mutation in culture (PMID: 27307593). ",Actionable,10120,1909,melanoma,DOID,465,BRAF mutant,"[{'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",sensitive,5400,Binimetinib + BKM120,673
439,Phase Ib/II,"In a Phase Ib/II trial, the triple combination therapy of Encorafenib (LGX818), Erbitux (cetuximab), and Alpelisib (BYL719) resulted in an overall response rate of 18% (5/28), including 5 patients with a partial response, and led to a median progression free survival of 4.2 months and response duration of 12 weeks (PMID: 28363909).",Actionable,6961,9256,colorectal cancer,DOID,465,BRAF mutant,"[{'id': 5987, 'pubMedId': None, 'title': 'Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).', 'url': 'http://meetinglibrary.asco.org/content/166237-176'}, {'id': 9149, 'pubMedId': 28363909, 'title': 'A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363909'}]",sensitive,1917,LGX818 + Cetuximab + BYL719,673
440,Preclinical - Cell culture,"In a preclinical study, the combination of Buparlisib (BKM120) and Encorafenib (LGX818) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring a BRAF mutation in culture (PMID: 27307593). ",Actionable,10123,1909,melanoma,DOID,465,BRAF mutant,"[{'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",sensitive,1337,Encorafenib + BKM120,673
441,Preclinical - Cell line xenograft,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of various cancer cell lines harboring BRAF mutations in culture and in cell line xenograft models (PMID: 26140595).",Actionable,10254,10000003,Advanced Solid Tumor,JAX,465,BRAF mutant,"[{'id': 8232, 'pubMedId': 26140595, 'title': 'A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26140595'}]",predicted – sensitive,5443,PF3644022 + PF-477736,673
442,Preclinical - Cell culture,"In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to a KRAS mutation in culture (PMID: 25873592).",Actionable,7831,1909,melanoma,DOID,26062,BRAF mut KRAS mut,"[{'id': 6506, 'pubMedId': 25873592, 'title': 'The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25873592'}]",predicted – sensitive,1059,BI-847325,673
443,Preclinical - Cell culture,"In a preclinical study, BRAF mutant melanoma cells over-expressing KRAS G12V were resistant to Selumetinib (AZD6244) and AZ628 combination treatment in culture (PMID: 26351322).",Actionable,8682,1909,melanoma,DOID,26406,BRAF mut KRAS G12V,"[{'id': 6708, 'pubMedId': 26351322, 'title': 'Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26351322'}]",resistant,4791,AZ628 + Selumetinib,673
444,Preclinical - Cell line xenograft,"In a preclinical study, E6201 resulted in a cytostatic response in melanoma cell lines harboring both BRAF and PTEN mutations in culture and only inhibited tumor growth at very high doses in cell line xenograft models (PMID: 23039341).",Actionable,5628,1909,melanoma,DOID,21306,BRAF mut PTEN mut,"[{'id': 1840, 'pubMedId': 23039341, 'title': 'Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23039341'}]",decreased response,1011,E6201,673
445,Preclinical - Cell culture,"In a preclinical study, knocking down of Ptpn11 expression via shRNA sensitized BRAF mutant colorectal cancer cell lines to PLX4720 in culture (PMID: 26351322).",Actionable,8668,9256,colorectal cancer,DOID,26402,BRAF mut PTPN11 dec exp,"[{'id': 6708, 'pubMedId': 26351322, 'title': 'Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26351322'}]",sensitive,1060,PLX4720,673
446,Preclinical,"In a preclinical study, AZD6482 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6103,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4044,AZD6482 + NVP-AEW541,673
447,Preclinical - Cell line xenograft,"In a preclinical study, the combination of GSK2636771 and Alpelisib (BYL719) synergized to inhibit proliferation of human melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture, and inhibited tumor growth in xenograft models of one cell line harboring these mutations (PMID: 26577700).",Actionable,6102,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4042,BYL719 + GSK2636771,673
448,Preclinical,"In a preclinical study, GSK2636771 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6111,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4055,GSK2636771 + LGX818,673
449,Preclinical - Cell line xenograft,"In a preclinical study, combination treatment consisting of GSK2636771 and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",Actionable,6136,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4067,GSK2636771 + unspecified IGF-1R antibody,673
450,Preclinical,"In a preclinical study, Pictilisib (GDC-0941) and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6109,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4056,GDC-0941 + LGX818,673
451,Preclinical - Cell line xenograft,"In a preclinical study, the combination of GSK2636771, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently inhibited tumor growth in xenograft models of a human melanoma cell line harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",Actionable,6133,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4065,BYL719 + GSK2636771 + LGX818,673
452,Preclinical - Cell line xenograft,"In a preclinical study, combination treatment consisting of GSK2636771, Encorafenib (LGX818), and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",Actionable,6138,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4069,GSK2636771 + LGX818 + unspecified IGF-1R antibody,673
453,Preclinical,"In a preclinical study, Alpelisib (BYL719) and Encorafenib (LGX818) combination treatment did not enhance growth inhibition in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6113,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",no benefit,4049,BYL719 + LGX818,673
454,Preclinical,"In a preclinical study, Pictilisib (GDC-0941) and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6115,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4053,GDC-0941 + Binimetinib,673
455,Preclinical,"In a preclinical study, combination treatment consisting of AZD6482, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6125,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4062,AZD6482 + LGX818 + BYL719,673
456,Preclinical,"In a preclinical study, AZD6482 and Alpelisib (BYL719) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6101,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,3714,AZD6482 + BYL719,673
457,Preclinical,"In a preclinical study, AZD6482 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6117,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4054,AZD6482 + Binimetinib,673
458,Preclinical,"In a preclincal study, Pictilisib (GDC-0941) inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6099,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,749,GDC-0941,673
459,Preclinical,"In a preclinical study, combination treatment consists of Encorafenib (LGX818) and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",Actionable,6137,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4068,LGX818 + unspecified IGF-1R antibody,673
460,Preclinical,"In a preclinical study, combination treatment consists of AZD6482, Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6126,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4061,AZD6482 + LGX818 + NVP-AEW541,673
461,Preclinical,"In a preclinical study, GSK2636771 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6118,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4052,GSK2636771 + Binimetinib,673
462,Preclinical,"In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6131,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4063,AZD6482 + Binimetinib + LGX818 + BYL719,673
463,Preclinical,"In a preclinical study, Alpelisib (BYL719) and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6119,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",no benefit,1311,BYL719 + MEK162,673
464,Preclinical,"In a preclinical study, GSK2636771 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6104,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4045,GSK2636771 + NVP-AEW541,673
465,Preclinical,"In a preclincal study, TGX-221 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6098,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,2514,TGX-221,673
466,Preclinical,"In a preclinical study, Pictilisib (GDC-0941) and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6105,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4046,GDC-0941 + NVP-AEW541,673
467,Preclinical,"In a preclinical study, AZD6482 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6110,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4048,AZD6482 + LGX818,673
468,Preclinical,"In a preclincal study, AZD6482 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6097,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,659,AZD6482,673
469,Preclinical,"In a preclinical study, Alpelisib (BYL719) and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6106,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",no benefit,4047,BYL719 + NVP-AEW541,673
470,Preclinical,"In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6128,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4060,AZD6482 + Binimetinib + NVP-AEW541,673
471,Preclinical,"In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6130,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4064,AZD6482 + Binimetinib + LGX818 + NVP-AEW541,673
472,Preclinical,"In a preclincal study, melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations were less sensitive to Alpelisib (BYL719)-induced growth inhibition in culture (PMID: 26577700).",Actionable,6100,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",decreased response,691,BYL719,673
473,Preclinical - Cell culture,"In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6127,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4059,AZD6482 + Binimetinib + BYL719,673
474,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line with a BRAF mutation and loss of RB1 demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531). ",Actionable,8546,1909,melanoma,DOID,26352,BRAF mut RB1 loss,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",decreased response,1368,Palbociclib + Trametinib,673
475,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring a BRAF mutation and loss of RB1 demonstrated a decreased response to Ibrance (palbociclib) treatment in culture when compared to treatment of melanoma cell lines wild-type for BRAF (PMID: 27488531). ",Actionable,8536,1909,melanoma,DOID,26352,BRAF mut RB1 loss,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",decreased response,850,Palbociclib,673
476,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring a BRAF mutation and RB1 loss demonstrated reduced sensitivity when treated with Mekinist (trametinib) in culture (PMID: 27488531). ",Actionable,8539,1909,melanoma,DOID,26352,BRAF mut RB1 loss,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",decreased response,2,Trametinib,673
477,Preclinical - Cell culture,"In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Tafinlar (dabrafenib), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and TP53 mutation in culture compared to the double or triple combinations of the therapies (PMID: 27659046). ",Actionable,9934,9256,colorectal cancer,DOID,27213,BRAF mut TP53 mut,"[{'id': 7782, 'pubMedId': 27659046, 'title': 'High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27659046'}]",sensitive,5318,ABT-263 + Alpelisib + Dabrafenib + Erlotinib,673
478,Preclinical - Cell line xenograft,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Zelboraf (vemurafenib) both in culture and in cell line xenograft models (PMID: 27500726).",Actionable,7791,1909,melanoma,DOID,26042,BRAF mut STAG2 dec exp,"[{'id': 6497, 'pubMedId': 27500726, 'title': 'Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27500726'}]",decreased response,342,Vemurafenib,673
479,Preclinical - Cell culture,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment in culture (PMID: 27500726).",Actionable,7793,1909,melanoma,DOID,26042,BRAF mut STAG2 dec exp,"[{'id': 6497, 'pubMedId': 27500726, 'title': 'Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27500726'}]",decreased response,1066,Trametinib + Dabrafenib,673
480,Preclinical - Cell culture,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Tafinlar (dabrafenib) in culture (PMID: 27500726).",Actionable,7790,1909,melanoma,DOID,26042,BRAF mut STAG2 dec exp,"[{'id': 6497, 'pubMedId': 27500726, 'title': 'Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27500726'}]",decreased response,3,Dabrafenib,673
481,Preclinical - Cell culture,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).",Actionable,7792,1909,melanoma,DOID,26042,BRAF mut STAG2 dec exp,"[{'id': 6497, 'pubMedId': 27500726, 'title': 'Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27500726'}]",decreased response,2,Trametinib,673
482,Preclinical,"In a preclinical study, the combination of CGM097 and Encorafenib (LGX818) synergized to inhibit cell growth of a human melanoma cell line harboring mutant BRAF and wild-type TP53 in culture, and promoted tumor regression in xenograft models (Cancer Res October 1, 2014 74; 5466).",Actionable,1787,1909,melanoma,DOID,3307,BRAF mut + TP53 wild-type,"[{'id': 7241, 'pubMedId': None, 'title': '', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/5466'}]",sensitive,2285,CGM097 + LGX818,673
483,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 inhibited growth of a melanoma cell line with wild-type TP53, that also harbored a BRAF mutation, in culture and inhibited tumor growth in a TP53 wild-type BRAF-mutant melanoma cell line xenograft model (PMID: 25567130).",Actionable,8097,1909,melanoma,DOID,3307,BRAF mut + TP53 wild-type,"[{'id': 2082, 'pubMedId': 25567130, 'title': 'The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25567130'}]",sensitive,1452,AMG 232,673
484,Preclinical - Cell culture,"In a preclinical study, the combination of Navitoclax (ABT-263), CGM097, Tafinlar (dabrafenib), and PF04217903 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046). ",Actionable,9933,9256,colorectal cancer,DOID,3307,BRAF mut + TP53 wild-type,"[{'id': 7782, 'pubMedId': 27659046, 'title': 'High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27659046'}]",sensitive,5317,ABT-263 + CGM097 + Dabrafenib + PF-04217903,673
485,Preclinical,"In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369). ",Actionable,2135,9256,colorectal cancer,DOID,5415,APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut,"[{'id': 2380, 'pubMedId': 25261369, 'title': 'Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25261369'}]",sensitive,1282,Sapanisertib,673
486,Preclinical - Pdx & cell culture,"In a preclinical study, mutations in BRAF, KRAS, or NRAS were associated with sensitivity to TAK-733 in colorectal cancer cell lines in culture, and patient-derived xenograft models harboring KRAS or BRAF mutations with wild-type PIK3CA demonstrated a trend toward higher tumor growth inhibition following TAK-733 treatment (PMID: 26439693).",Actionable,10776,9256,colorectal cancer,DOID,27794,BRAF mut PIK3CA wild-type,"[{'id': 8454, 'pubMedId': 26439693, 'title': 'Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26439693'}]",predicted – sensitive,932,TAK-733,673
487,Phase I,"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 100% (5/5) of melanoma patients harboring BRAF mutations and wild-type NRAS (PMID: 26169970).",Actionable,3796,1909,melanoma,DOID,15931,BRAF mut NRAS wild-type,"[{'id': 3994, 'pubMedId': 26169970, 'title': 'Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26169970'}]",sensitive,792,Lenvatinib,673
488,Preclinical,"In a preclinical study, human triple negative breast cancer cells harboring mutant BRAF, KRAS, and CDKN2A were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6690,60081,triple-receptor negative breast cancer,DOID,23670,BRAF mut KRAS mut CDKN2A mut,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,2,Trametinib,673
489,Phase I,"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 50% (1/2) of melanoma patients harboring both BRAF and NRAS mutations (PMID: 26169970).",Actionable,3688,1909,melanoma,DOID,14782,BRAF mut NRAS mut,"[{'id': 3994, 'pubMedId': 26169970, 'title': 'Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26169970'}]",sensitive,792,Lenvatinib,673
490,Preclinical - Cell culture,"In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to an NRAS mutation in culture (PMID: 25873592).",Actionable,7829,1909,melanoma,DOID,14782,BRAF mut NRAS mut,"[{'id': 6506, 'pubMedId': 25873592, 'title': 'The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25873592'}]",predicted – sensitive,1059,BI-847325,673
491,Preclinical,"In a preclinical study, GSK2636771 resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196). ",Actionable,4456,1909,melanoma,DOID,18163,BRAF mut PTEN loss,"[{'id': 4556, 'pubMedId': 26645196, 'title': 'Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26645196'}]",no benefit,765,GSK2636771,673
492,Preclinical,"In a preclinical study, a melanoma mouse model harboring a BRAF mutation and PTEN loss was sensitive to the combination of GSK2636771 and Keytruda (pembrolizumab), demonstrating greater tumor growth inhibition and improved survival when compared to either therapy alone (PMID: 26645196). ",Actionable,4455,1909,melanoma,DOID,18163,BRAF mut PTEN loss,"[{'id': 4556, 'pubMedId': 26645196, 'title': 'Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26645196'}]",sensitive,3518,GSK2636771 + Pembrolizumab,673
493,Preclinical - Cell line xenograft,"In a preclinical study, SAR260301 and Zelboraf (vemurafenib) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",Actionable,7773,1909,melanoma,DOID,18163,BRAF mut PTEN loss,"[{'id': 6491, 'pubMedId': 27196754, 'title': 'Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196754'}]",sensitive,1225,SAR260301 + Vemurafenib,673
494,Preclinical,"In a preclinical study, Keytruda (pembrolizumab) resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196). ",Actionable,4457,1909,melanoma,DOID,18163,BRAF mut PTEN loss,"[{'id': 4556, 'pubMedId': 26645196, 'title': 'Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26645196'}]",no benefit,1447,Pembrolizumab,673
495,Preclinical - Cell line xenograft,"In a preclinical study, SAR260301 and Selumetinib (AZD6244) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",Actionable,7774,1909,melanoma,DOID,18163,BRAF mut PTEN loss,"[{'id': 6491, 'pubMedId': 27196754, 'title': 'Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196754'}]",sensitive,4573,SAR260301 + Selumetinib,673
496,Preclinical - Cell line xenograft,"In a preclinical study, SAR260301 inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",Actionable,7771,1909,melanoma,DOID,18163,BRAF mut PTEN loss,"[{'id': 6491, 'pubMedId': 27196754, 'title': 'Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196754'}]",sensitive,1052,SAR260301,673
497,Preclinical,"In a preclinical study, AZD6482 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6121,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",no benefit,4054,AZD6482 + Binimetinib,673
498,Preclinical,"In a preclinical study, AZD6482 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6107,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",no benefit,4044,AZD6482 + NVP-AEW541,673
499,Preclinical - Cell line xenograft,"In a preclinical study, E6201 resulted in a cytocidal response in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture and inhibited tumor growth in cell line xenograft models (PMID: 23039341).",Actionable,5629,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,"[{'id': 1840, 'pubMedId': 23039341, 'title': 'Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23039341'}]",sensitive,1011,E6201,673
500,Preclinical,"In a preclinical study, GSK2636771 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6122,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",no benefit,4052,GSK2636771 + Binimetinib,673
501,Preclinical,"In a preclinical study, GSK2636771 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6124,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",no benefit,4055,GSK2636771 + LGX818,673
502,Preclinical,"In a preclinical study, GSK2636771 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6108,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",no benefit,4045,GSK2636771 + NVP-AEW541,673
503,Preclinical,"In a preclinical study, AZD6482 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6123,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",no benefit,4048,AZD6482 + LGX818,673
504,Preclinical,"In a preclinical study, PLX8394 had been shown to block survival and growth of vemurafenib/PLX4720-resistant cells harboring distinct BRAF activating mutations (PMID: 24422853).",Actionable,1027,10000003,Advanced Solid Tumor,JAX,696,BRAF act mut,"[{'id': 195, 'pubMedId': 24422853, 'title': 'Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24422853'}]",sensitive,1041,PLX8394,673
505,Preclinical - Cell culture,"In a preclinical study, inhibition of Erk signaling by VX-11e did not sensitize colorectal cancer cell lines harboring KRAS or BRAF activating mutations to Venclexta (venetoclax) in culture (PMID: 27974663).",Actionable,10077,9256,colorectal cancer,DOID,696,BRAF act mut,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",no benefit,5375,Venetoclax + VX-11e,673
506,Preclinical - Cell culture,"In a preclinical study, inhibition of Erk signaling by VX-11e sensitized colorectal cancer cell lines harboring KRAS or BRAF activating mutations to WEHI-539 in culture (PMID: 27974663).",Actionable,10075,9256,colorectal cancer,DOID,696,BRAF act mut,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",predicted – sensitive,5374,VX-11e + WEHI-539,673
507,Phase II,"In a Phase II study, Nexavar (sorafenib) displayed negligible efficacy in melanoma patients with BRAF mutations (PMID: 16880785, PMID: 22394203).",Actionable,510,1909,melanoma,DOID,696,BRAF act mut,"[{'id': 294, 'pubMedId': 22394203, 'title': 'Sorafenib in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22394203'}, {'id': 3156, 'pubMedId': 16880785, 'title': 'Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16880785'}]",no benefit,920,Sorafenib,673
508,Preclinical - Cell line xenograft,"In a preclinical study, Cobimetinib (GDC-0973) induced cell death in human melanoma cell lines harboring BRAF activating mutations in culture and inhibited tumor growth in xenograft models (PMID: 22084396).",Actionable,552,1909,melanoma,DOID,696,BRAF act mut,"[{'id': 353, 'pubMedId': 22084396, 'title': 'Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22084396'}]",sensitive,1004,Cobimetinib,673
509,Phase I,"In a Phase I trial, Zelboraf (vemurafenib) demonstrated safety and efficacy in metastatic papillary thyroid cancer patients carrying BRAF activating mutations (PMID: 23489023).
",Actionable,891,1781,thyroid cancer,DOID,696,BRAF act mut,"[{'id': 579, 'pubMedId': 23489023, 'title': 'Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23489023'}]",sensitive,342,Vemurafenib,673
510,Phase Ib/II,"In a Phase Ib/II trial, Binimetinib (MEK162), in combination with Encorafenib (LGX818), demonstrated safety and efficacy in patients with BRAF mutant advanced solid tumors (J Clin Oncol 31, 2013 (suppl; abstr 9029)).",Actionable,1025,10000003,Advanced Solid Tumor,JAX,696,BRAF act mut,"[{'id': 743, 'pubMedId': None, 'title': 'Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors.', 'url': ''}]",sensitive,1100,Binimetinib + Encorafenib,673
511,Preclinical - Pdx,"In a preclinical study, LSN3074753 and Erbitux (cetuximab) worked synergistically, resulting in tumor regression in a patient-derived xenograft model of colorectal cancer harboring BRAF G596V and NRAS G13R (PMID: 28611205).",Actionable,12197,9256,colorectal cancer,DOID,28547,BRAF G596V NRAS G13R,"[{'id': 10143, 'pubMedId': 28611205, 'title': 'Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28611205'}]",sensitive,6338,Cetuximab + LSN3074753,673
512,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF V600R in culture (PMID: 27523909).",Actionable,7910,1909,melanoma,DOID,654,BRAF V600R,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,1093,AZ628,673
513,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF V600R in culture (PMID: 27523909).",Actionable,7940,1909,melanoma,DOID,654,BRAF V600R,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,3300,TAK-632,673
514,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909).",Actionable,7954,1909,melanoma,DOID,654,BRAF V600R,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,342,Vemurafenib,673
515,Preclinical - Cell culture,"In a preclinical study, PLX7904 inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909).",Actionable,7950,1909,melanoma,DOID,654,BRAF V600R,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,4606,PLX7904,673
516,Preclinical - Cell culture,"In a preclinical study, Tafinlar (dabrafenib) inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909).",Actionable,7962,1909,melanoma,DOID,654,BRAF V600R,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,3,Dabrafenib,673
517,Clinical Study,"In a clinical case study, a melanoma patient harboring BRAF V600R treated with Tafinlar (dabrafenib) demonstrated a reduction in lesion size after 2.5 months and at 5 months, stable disease, however, after 7 months progression ensued (PMID: 27255157). ",Actionable,9030,1909,melanoma,DOID,654,BRAF V600R,"[{'id': 6880, 'pubMedId': 27255157, 'title': 'Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27255157'}]",sensitive,3,Dabrafenib,673
518,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring BRAF G466V demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",Actionable,7958,3908,non-small cell lung carcinoma,DOID,669,BRAF G466V,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",decreased response,342,Vemurafenib,673
519,Preclinical - Pdx,"In a preclinical study, treatment with Mekinist (trametinib) delayed tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).",Actionable,11658,9256,colorectal cancer,DOID,669,BRAF G466V,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",sensitive,2,Trametinib,673
520,Preclinical - Pdx,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit ERK signaling or tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).",Actionable,11659,9256,colorectal cancer,DOID,669,BRAF G466V,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",no benefit,342,Vemurafenib,673
521,Clinical Study,"In a clinical case study, a patient with metastatic colorectal cancer harboring BRAF G466V, and with wild-type RAS and NF1, demonstrated tumor regression following treatment with Vectibix (panitumumab) plus Camptosar (irinotecan) (PMID: 28783719).",Actionable,11663,9256,colorectal cancer,DOID,669,BRAF G466V,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",predicted – sensitive,4138,Irinotecan + Panitumumab,673
522,Preclinical - Pdx,"In a preclinical study, treatment with Erbitux (cetuximab) reduced ERK signaling and resulted in tumor regression in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).",Actionable,11657,9256,colorectal cancer,DOID,669,BRAF G466V,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",sensitive,694,Cetuximab,673
523,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of non-small cell lung cancer cell lines harboring BRAF G466V in culture (PMID: 28783719).",Actionable,11653,3908,non-small cell lung carcinoma,DOID,669,BRAF G466V,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",sensitive,2,Trametinib,673
524,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of non-small cell lung cancer cells harboring BRAF G466V in culture (PMID: 27523909).",Actionable,7942,3908,non-small cell lung carcinoma,DOID,669,BRAF G466V,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,3300,TAK-632,673
525,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) induced apoptosis in non-small cell lung cancer cells expressing BRAF G466V in culture (PMID: 22649091).",Actionable,691,3908,non-small cell lung carcinoma,DOID,669,BRAF G466V,"[{'id': 423, 'pubMedId': 22649091, 'title': 'Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649091'}]",sensitive,717,Dasatinib,673
526,Preclinical - Cell culture,"In a preclinical study, PLX8394 decreased growth of lung adenocarcinoma cell lines harboring BRAF G466V in culture (PMID: 27834212).",Actionable,12073,3910,lung adenocarcinoma,DOID,669,BRAF G466V,"[{'id': 10006, 'pubMedId': 27834212, 'title': 'Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27834212'}]",sensitive,1041,PLX8394,673
527,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased proliferation and increased apoptosis, and enhanced ERK inhibition compared to either agent alone in a non-small cell lung cancer cell line harboring BRAF G466V in culture (PMID: 27577079).",Actionable,11736,3908,non-small cell lung carcinoma,DOID,669,BRAF G466V,"[{'id': 7322, 'pubMedId': 27577079, 'title': 'Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27577079'}]",sensitive,1066,Trametinib + Dabrafenib,673
528,Preclinical,"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring BRAF G466V mutation in culture (PMID: 26090892).",Actionable,3934,3908,non-small cell lung carcinoma,DOID,669,BRAF G466V,"[{'id': 4301, 'pubMedId': 26090892, 'title': 'TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26090892'}]",sensitive,2086,TAE226,673
529,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) growth of a non-small cell lung cancer cell line harboring BRAF G466V and expressing NRAS Q61K in culture (PMID: 28783719).",Actionable,11667,3908,non-small cell lung carcinoma,DOID,28181,BRAF G466V NRAS Q61K,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",sensitive,2,Trametinib,673
530,Preclinical - Cell line xenograft,"In a preclinical study, Ganetespib treatment resulted in decreased activation of MEK, AKT, and ERK and inhibited growth of a non-small cell lung cancer cell line with wild-type EGFR and BRAF G466V in culture, and inhibited tumor growth in xenograft models (PMID: 25077897).",Actionable,8231,3908,non-small cell lung carcinoma,DOID,26202,BRAF G466V EGFR wild-type,"[{'id': 2971, 'pubMedId': 25077897, 'title': 'The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25077897'}]",sensitive,745,Ganetespib,673
531,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not reduce activation of Mek in transformed cells expressing BRAF D594N in culture (PMID: 28783719).",Actionable,11666,10000003,Advanced Solid Tumor,JAX,987,BRAF D594N,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",predicted – resistant,342,Vemurafenib,673
532,Preclinical,"In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).",Actionable,6603,1909,melanoma,DOID,23638,BRAF G469R NRAS Q61K,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",decreased response,913,Selumetinib,673
533,Preclinical,"In a preclinical study, human melanoma cells harboring BRAF G469R and NRAS G61K were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).",Actionable,6612,1909,melanoma,DOID,23638,BRAF G469R NRAS Q61K,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,342,Vemurafenib,673
534,Preclinical,"In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).",Actionable,6592,1909,melanoma,DOID,23638,BRAF G469R NRAS Q61K,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,3268,LY3009120,673
535,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF L597Q (PMID: 26343582).",Actionable,9416,10000003,Advanced Solid Tumor,JAX,993,BRAF L597Q,"[{'id': 7141, 'pubMedId': 26343582, 'title': 'BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343582'}]",resistant,342,Vemurafenib,673
536,Phase I,"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 83% (5/6) of melanoma patients harboring NRAS mutations and wild-type BRAF (PMID: 26169970).",Actionable,3797,1909,melanoma,DOID,1299,BRAF wild-type NRAS mutant,"[{'id': 3994, 'pubMedId': 26169970, 'title': 'Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26169970'}]",sensitive,792,Lenvatinib,673
537,Preclinical - Cell line xenograft,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type colon cancer cells harboring KRAS G13D in culture ann in cell line xenograft models (PMID: 19276360).",Actionable,7883,219,colon cancer,DOID,26083,BRAF wild-type KRAS G13D,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",resistant,1095,GDC0879,673
538,Preclinical - Pdx,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS G12C in patient-derived xenograft models (PMID: 19276360).",Actionable,7893,3908,non-small cell lung carcinoma,DOID,26088,BRAF wild-type KRAS G12C,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",resistant,1095,GDC0879,673
539,Preclinical - Cell line xenograft,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS Q61K in culture and in cell line xenograft models (PMID: 19276360).",Actionable,7884,3908,non-small cell lung carcinoma,DOID,26085,BRAF wild-type KRAS Q61K,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",resistant,1095,GDC0879,673
540,Preclinical - Pdx,"In a preclinical study, LSN3074753 demonstrated limited efficacy in BRAF and KRAS wild-type patient-derived xenograft models of colorectal cancer, resulted in a disease control rate of 3.8% (1/26) (PMID: 28611205).",Actionable,12189,9256,colorectal cancer,DOID,28546,BRAF wild-type KRAS wild-type,"[{'id': 10143, 'pubMedId': 28611205, 'title': 'Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28611205'}]",decreased response,6337,LSN3074753,673
541,Preclinical - Cell line xenograft,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type pancreatic cancer cells harboring KRAS G12D in cell line xenograft models (PMID: 19276360).",Actionable,7887,1793,pancreatic cancer,DOID,26084,BRAF wild-type KRAS G12D,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",resistant,1095,GDC0879,673
542,Guideline,Gleevec (imatinib) is an active regimen for melanoma patients with wild-type BRAF and a c-KIT positive mutation (Guidelines). ,Actionable,1938,1909,melanoma,DOID,4361,BRAF wild-type KIT positive,"[{'id': 1442, 'pubMedId': None, 'title': 'NCCN Guidelines Melanoma version 3.2015', 'url': 'http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf'}]",sensitive,770,Imatinib,673
543,Preclinical - Pdx,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS G12V in patient-derived xenograft models (PMID: 19276360).",Actionable,7895,3908,non-small cell lung carcinoma,DOID,26087,BRAF wild-type KRAS G12V,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",resistant,1095,GDC0879,673
544,Clinical Study,"In a retrospective study, Erbitux (cetuximab) treatment, alone or in combination, resulted in disease regression or stable disease in 88% (7/8) KRAS/BRAF-wild type colorectal carcinoma patients harboring a PIK3CA mutation (PMID: 25714871).",Actionable,3671,9256,colorectal cancer,DOID,14283,BRAF wild-type KRAS wild-type PIK3CA mutant,"[{'id': 3888, 'pubMedId': 25714871, 'title': 'AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25714871'}]",sensitive,694,Cetuximab,673
545,Preclinical,"In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells wild-type for BRAF, KRAS, NRAS and PIK3CA in culture (PMID: 25838391).",Actionable,4934,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",sensitive,694,Cetuximab,673
546,Preclinical,"In a preclinical study, colorectal cancer cell lines with wild-type BRAF, KRAS, NRAS and PIK3CA were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4944,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",resistant,890,Regorafenib,673
547,Phase II,"In a Phase II trial, Erbitux (cetuximab) in combination with FOLFOX resulted in improved median progression-free survival (6.9 months) comparing to FOLFOX alone (5.3 months) in BRAF, KRAS, NRAS, and PIK3CA wild-type colorectal cancer patients (hazard ratio =0.56) (PMID: 27002107).",Actionable,5563,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,"[{'id': 5108, 'pubMedId': 27002107, 'title': 'Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27002107'}]",predicted – sensitive,2182,Cetuximab + FOLFOX,673
548,Phase I,"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 44% (4/9) and partial response in 22% (2/9) of melanoma patients carrying wild-type BRAF and NRAS (PMID: 26169970).",Actionable,3798,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,"[{'id': 3994, 'pubMedId': 26169970, 'title': 'Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26169970'}]",sensitive,792,Lenvatinib,673
549,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).",Actionable,7945,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,3300,TAK-632,673
550,Preclinical - Cell culture,"In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to PLX7904 in culture (PMID: 27523909).",Actionable,7952,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",resistant,4606,PLX7904,673
551,Preclinical - Cell culture,"In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to Zelboraf (vemurafenib) in culture (PMID: 27523909).",Actionable,7960,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",resistant,342,Vemurafenib,673
552,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).",Actionable,7935,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,1093,AZ628,673
553,Preclinical - Cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line with wild-type BRAF and wild-type NRAS in culture (PMID: 27307593). ",Actionable,10122,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,"[{'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",sensitive,5400,Binimetinib + BKM120,673
554,Preclinical - Pdx & cell culture,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells in culture and in patient-derived xenograft models (PMID: 19276360).",Actionable,7891,3908,non-small cell lung carcinoma,DOID,4,BRAF wild-type,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",resistant,1095,GDC0879,673
555,Phase I,"In a Phase I study, 10% (4/39) of wild-type BRAF melanoma patients had a partial response to Mekinist (trametinib) (PMID: 22805292).
",Actionable,1256,1909,melanoma,DOID,4,BRAF wild-type,"[{'id': 233, 'pubMedId': 22805292, 'title': 'Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805292'}]",sensitive,2,Trametinib,673
556,Preclinical - Cell culture,"In a preclinical study, Afinitor (everolimus) and Selumetinib (AZD6244) synergistically inhibited growth and induced apoptosis in glioma cell lines in culture (PMID: 27217440).",Actionable,9109,3070,malignant glioma,DOID,4,BRAF wild-type,"[{'id': 6921, 'pubMedId': 27217440, 'title': 'BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27217440'}]",predicted – sensitive,4901,Everolimus + Selumetinib,673
557,Preclinical - Pdx & cell culture,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type melanoma cells in cell culture, cell line xenograft models, and patient-derived xenograft models (PMID: 19276360).",Actionable,7890,1909,melanoma,DOID,4,BRAF wild-type,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",resistant,1095,GDC0879,673
558,Preclinical - Cell culture,"In a preclinical study, BRAF wild-type melanoma cells demonstrated decreased cell viability when treated with Ibrance (palbociclib) in culture (PMID: 27488531). ",Actionable,8534,1909,melanoma,DOID,4,BRAF wild-type,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",sensitive,850,Palbociclib,673
559,Phase II,"In a Phase II trial, a favorable response rate to Selumetinib (AZD6244) was observed in mutant BRAF, but not BRAF wild-type, melanoma patients (PMID: 22048237).",Actionable,714,1909,melanoma,DOID,4,BRAF wild-type,"[{'id': 228, 'pubMedId': 22048237, 'title': 'Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22048237'}]",no benefit,913,Selumetinib,673
560,Preclinical,"In a preclinical study, RAF265 inhibited the growth of melanoma tumors orthotopically implanted in mice, including tumors wild-type for BRAF (PMID: 22351689).",Actionable,452,1909,melanoma,DOID,4,BRAF wild-type,"[{'id': 61, 'pubMedId': 22351689, 'title': 'RAF265 inhibits the growth of advanced human melanoma tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22351689'}]",sensitive,884,RAF265,673
561,Preclinical - Cell culture,"In a preclinical study, a BRAF wild-type melanoma cell line demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531). ",Actionable,8544,1909,melanoma,DOID,4,BRAF wild-type,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",decreased response,1368,Palbociclib + Trametinib,673
562,Preclinical,"In a preclinical study, CLM3 inhibited growth, Egfr signaling, and CCND1 expression, in BRAF wild-type thyroid cancer cells in culture (PMID: 24423321). ",Actionable,4418,1781,thyroid cancer,DOID,4,BRAF wild-type,"[{'id': 4527, 'pubMedId': 24423321, 'title': 'CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24423321'}]",sensitive,3502,CLM3,673
563,Preclinical - Cell line xenograft,"In a preclinical study, PLX4720 did not inhibit growth of BRAF wild-type melanoma cells in culture or in cell line xenograft models (PMID: 18287029).",Actionable,504,1909,melanoma,DOID,4,BRAF wild-type,"[{'id': 291, 'pubMedId': 18287029, 'title': 'Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18287029'}]",resistant,1060,PLX4720,673
564,Preclinical - Cell culture,"In a preclinical study, a variety of BRAF wild-type tumor cell lines were insensitive to BGB-283 in culture (PMID: 26208524).",Actionable,8068,10000003,Advanced Solid Tumor,JAX,4,BRAF wild-type,"[{'id': 5280, 'pubMedId': 26208524, 'title': 'BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26208524'}]",resistant,4025,BGB-283,673
565,Preclinical - Pdx,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type melanoma cells harboring NRAS Q61K in patient-derived xenograft models (PMID: 19276360).",Actionable,7889,1909,melanoma,DOID,26086,BRAF wild-type NRAS Q61K,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",resistant,1095,GDC0879,673
566,Clinical Study,"In a retrospective study, 100% (2/2) colorectal carcinoma patients harboring an AKT1 E17K mutation and wild-type KRAS/BRAF demonstrated resistance to Erbitux (cetuximab) in combination with Camptosar (irinotecan) (PMID: 25714871).
",Actionable,3614,9256,colorectal cancer,DOID,13841,AKT1 E17K KRAS wild-type BRAF wild-type,"[{'id': 3888, 'pubMedId': 25714871, 'title': 'AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25714871'}]",resistant,1874,Cetuximab + Irinotecan,673
567,Preclinical,"In a preclinical study, a non-small cell lung carcinoma cell line harboring BRAF L485_P490delinsY was sensitive to Mekinist (trametinib), resulting in cell growth inhibition (PMID: 26732095). ",Actionable,4925,3908,non-small cell lung carcinoma,DOID,19835,BRAF L485_P490delinsY,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",sensitive,2,Trametinib,673
568,Preclinical,"In a preclinical study, a non-small cell lung carcinoma cell line harboring BRAF L485_P490delinsY was resistant to Tafinlar (dabrafenib) (PMID: 26732095). ",Actionable,4926,3908,non-small cell lung carcinoma,DOID,19835,BRAF L485_P490delinsY,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",resistant,342,Vemurafenib,673
569,Preclinical,"In a preclinical study, a non-small cell lung carcinoma cell line harboring BRAF L485_P490delinsY was sensitive to LY3009120 in both culture and xenograft models, resulting in significant tumor regression and inhibition of MEK and ERK phosphorylation (PMID: 26732095). ",Actionable,4924,3908,non-small cell lung carcinoma,DOID,19835,BRAF L485_P490delinsY,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",sensitive,3268,LY3009120,673
570,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of a melanoma cell line harboring BRAF D594G in culture (PMID: 28783719).",Actionable,11654,1909,melanoma,DOID,989,BRAF D594G,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",sensitive,2,Trametinib,673
571,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).",Actionable,7951,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",decreased response,4606,PLX7904,673
572,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).",Actionable,7965,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",decreased response,3,Dabrafenib,673
573,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).",Actionable,7911,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,1093,AZ628,673
574,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",Actionable,7957,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",decreased response,342,Vemurafenib,673
575,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).",Actionable,7941,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,3300,TAK-632,673
576,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF L597V (PMID: 26343582).",Actionable,9415,10000003,Advanced Solid Tumor,JAX,663,BRAF L597V,"[{'id': 7141, 'pubMedId': 26343582, 'title': 'BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343582'}]",resistant,342,Vemurafenib,673
577,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).",Actionable,7964,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",decreased response,3,Dabrafenib,673
578,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909).",Actionable,7909,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,1093,AZ628,673
579,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61L demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).",Actionable,7949,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",decreased response,4606,PLX7904,673
580,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909).",Actionable,7939,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,3300,TAK-632,673
581,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",Actionable,7956,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",decreased response,342,Vemurafenib,673
582,Clinical Study,"In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, BRAF amplification and NRAS Q61K, during treatment with Zelboraf (vemurafenib) (PMID: 24265153).",Actionable,7070,1909,melanoma,DOID,24387,BRAF amp BRAF V600X NRAS Q61K,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,342,Vemurafenib,673
583,Preclinical - Cell culture,"In a preclinical study, expression of AKT1 E17K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).",Actionable,8103,1909,melanoma,DOID,26172,AKT1 E17K BRAF V600X PTEN pos,"[{'id': 6551, 'pubMedId': 24265152, 'title': 'A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265152'}]",resistant,342,Vemurafenib,673
584,Clinical Study,"In a clinical study, a melanoma patient harboring a BRAF V600 mutation and PTEN H93D treated with Zelboraf (vemurafenib) for 66 weeks demonstrated a partial response (PMID: 24265153).",Actionable,7083,1909,melanoma,DOID,24401,BRAF V600X PTEN H93D,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",sensitive,342,Vemurafenib,673
585,Preclinical - Cell culture,"In a preclinical study, lack of PTEN expression was associated with increased sensitivity to GSK2141795 in BRAF V600-mutant melanoma cell lines in culture (PMID: 24265152).",Actionable,8168,1909,melanoma,DOID,26183,BRAF V600X PTEN neg,"[{'id': 6551, 'pubMedId': 24265152, 'title': 'A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265152'}]",sensitive,764,GSK2141795,673
586,Phase II,"In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) in colorectal cancer patients with BRAF V600 mutations did not result in clinical benefit, with no patients achieving response, and 50% (5/10) demonstrating progressive disease (PMID: 26287849).",Actionable,3300,9256,colorectal cancer,DOID,1186,BRAF V600X,"[{'id': 3720, 'pubMedId': 26287849, 'title': 'Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26287849'}]",no benefit,342,Vemurafenib,673
587,Guideline,"Tafinlar (dabrafenib), in combination with Mekinist (trametinib), is an active regimen for melanoma patients with BRAF V600 mutations (Guidelines).",Actionable,1519,1909,melanoma,DOID,1186,BRAF V600X,"[{'id': 1442, 'pubMedId': None, 'title': 'NCCN Guidelines Melanoma version 3.2015', 'url': 'http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf'}]",sensitive,1066,Trametinib + Dabrafenib,673
588,Phase Ib/II,"In a Phase I/II clinical trial, patients with BRAF V600 mutant melanoma (n=78) treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) had a median overall survival of greater than 2 years (PMID: 26811525).",Actionable,4933,1909,melanoma,DOID,1186,BRAF V600X,"[{'id': 4804, 'pubMedId': 26811525, 'title': 'Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26811525'}]",sensitive,1066,Trametinib + Dabrafenib,673
589,Preclinical - Pdx,"In a preclinical study, melanoma patient derived xenograft (PDX) model harboring a BRAF V600 mutation demonstrated antitumor activity when treated with ASN003 (J Clin Oncol 35, 2017 (suppl; abstr e14102)). ",Actionable,11044,1909,melanoma,DOID,1186,BRAF V600X,"[{'id': 9034, 'pubMedId': None, 'title': 'ASN003, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors', 'url': 'http://abstracts.asco.org/199/AbstView_199_186123.html'}]",sensitive,5827,ASN003,673
590,Phase II,"In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) resulted in an overall response rate of 29% (2/7), with 1 complete response and 1 partial response, in patients with anaplastic thyroid cancer patients with BRAF V600 mutations (PMID:     26287849).",Actionable,3302,1781,thyroid cancer,DOID,1186,BRAF V600X,"[{'id': 3720, 'pubMedId': 26287849, 'title': 'Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26287849'}]",predicted – sensitive,342,Vemurafenib,673
591,Phase II,"In a Phase II trial, 20% (8/41) of melanoma patients with BRAF V600 mutations had a partial response to Binimetinib (MEK162) (PMID: 23414587).",Actionable,1120,1909,melanoma,DOID,1186,BRAF V600X,"[{'id': 180, 'pubMedId': 23414587, 'title': 'MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23414587'}]",sensitive,807,Binimetinib,673
592,FDA approved,"In a Phase III clinical trial that supported FDA approval, the combined treatment of Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months compared to 7.2 months with Zelboraf (vemurafenib) alone among patients with BRAF V600-mutated metastatic melanoma (PMID: 25265494, J Clin Oncol 33, 2015 (suppl; abstr 9006)).",Actionable,1211,1909,melanoma,DOID,1186,BRAF V600X,"[{'id': 942, 'pubMedId': 25265494, 'title': 'Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25265494'}, {'id': 3903, 'pubMedId': None, 'title': 'Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma', 'url': 'http://meetinglibrary.asco.org/content/144759-156'}]",sensitive,1657,Vemurafenib + Cobimetinib,673
593,Preclinical - Cell culture,"In a preclinical study, the combination of Buparlisib (BKM120) and Mekinist (trametinib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8164,1909,melanoma,DOID,1186,BRAF V600X,"[{'id': 6551, 'pubMedId': 24265152, 'title': 'A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265152'}]",sensitive,1974,BKM120 + Trametinib,673
594,Preclinical - Cell culture,"In a preclinical study, the combination of Selumetinib (AZD6244) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8161,1909,melanoma,DOID,1186,BRAF V600X,"[{'id': 6551, 'pubMedId': 24265152, 'title': 'A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265152'}]",sensitive,3773,Selumetinib + Vemurafenib,673
595,Preclinical - Cell culture,"In a preclinical study, the combination of Buparlisib (BKM120) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8163,1909,melanoma,DOID,1186,BRAF V600X,"[{'id': 6551, 'pubMedId': 24265152, 'title': 'A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265152'}]",sensitive,1322,BKM120 + Vemurafenib,673
596,Phase Ib/II,"In a Phase Ib/II trial, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in partial response or better in 12% (5/43), including 1 complete response, and stable disease in 51% (22/43) of patients with BRAF V600-mutant colorectal cancer (PMID: 26392102).",Actionable,2525,9256,colorectal cancer,DOID,1186,BRAF V600X,"[{'id': 3250, 'pubMedId': None, 'title': 'Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.', 'url': 'http://meetinglibrary.asco.org/content/131743-144'}, {'id': 3713, 'pubMedId': 26392102, 'title': 'Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26392102'}]",sensitive,1066,Trametinib + Dabrafenib,673
597,Phase Ib/II,"In a Phase Ib trial, the addition of Zelboraf (vemurafenib) to Camptosar (irinotecan) plus Erbitux (cetuximab) improved progression-free survival (4.4 mo vs. 2.0 mo), and disease control rate (67% vs. 22%), compared to Camptosar (irinotecan) plus Erbitux (cetuximab) without Zelboraf (vemurafenib), in patients with BRAF V600-mutant colorectal cancer (J Clin Oncol 35, 2017 (suppl 4S; abstract 520)).",Actionable,9868,9256,colorectal cancer,DOID,1186,BRAF V600X,"[{'id': 7724, 'pubMedId': None, 'title': 'Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).', 'url': 'http://abstracts.asco.org/195/AbstView_195_176737.html'}]",sensitive,1331,Vemurafenib + Cetuximab + Irinotecan ,673
598,Guideline,Tafinlar (dabrafenib) is an active regimen for melanoma patients with BRAF V600 mutations (Guidelines).,Actionable,1509,1909,melanoma,DOID,1186,BRAF V600X,"[{'id': 1442, 'pubMedId': None, 'title': 'NCCN Guidelines Melanoma version 3.2015', 'url': 'http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf'}]",sensitive,3,Dabrafenib,673
599,Preclinical - Cell culture,"In a preclinical study, the combination of Buparlisib (BKM120) and Selumetinib (AZD6244) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8165,1909,melanoma,DOID,1186,BRAF V600X,"[{'id': 6551, 'pubMedId': 24265152, 'title': 'A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265152'}]",sensitive,4652,BKM120 + Selumetinib,673
600,Phase I,"In a Phase I trial, the combination therapy of AMG 232, Mekinist (trametinib), and Tafinlar (dabrafenib) in 6 patients with metastatic cutaneous melanoma harboring a BRAF V600 mutation resulted in 4 patients with a partial response and 2 patients with stable disease, and of the 6 patients, all experienced tumor reduction (J Clin Oncol 35, 2017 (suppl; abstr 2575)).",Actionable,11096,1909,melanoma,DOID,1186,BRAF V600X,"[{'id': 9073, 'pubMedId': None, 'title': 'Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM)', 'url': 'http://abstracts.asco.org/199/AbstView_199_181299.html'}]",sensitive,1453,AMG 232 + Trametinib + Dabrafenib,673
601,Preclinical - Cell culture,"In a preclinical study, the combination of MK2206 and Mekinist (trametinib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8167,1909,melanoma,DOID,1186,BRAF V600X,"[{'id': 6551, 'pubMedId': 24265152, 'title': 'A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265152'}]",sensitive,4653,MK2206 + Trametinib,673
602,Guideline,Zelboraf (vemurafenib) is an active regimen for melanoma patients with BRAF V600 mutations (Guidelines).,Actionable,1511,1909,melanoma,DOID,1186,BRAF V600X,"[{'id': 1442, 'pubMedId': None, 'title': 'NCCN Guidelines Melanoma version 3.2015', 'url': 'http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf'}]",sensitive,342,Vemurafenib,673
603,Phase II,"In a Phase II clinical trial, treatment with the combination of Zelboraf (vemurafenib) and Erbitux (cetuximab) resulted in an overall response rate of 4% (1/26), stable disease in 69% (18/26), and a median progression-free survival of 3.7 months in patients with BRAF V600-mutant colorectal cancer (PMID: 26287849).",Actionable,3301,9256,colorectal cancer,DOID,1186,BRAF V600X,"[{'id': 3720, 'pubMedId': 26287849, 'title': 'Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26287849'}]",sensitive,1711,Vemurafenib + Cetuximab,673
604,Preclinical - Cell culture,"In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8166,1909,melanoma,DOID,1186,BRAF V600X,"[{'id': 6551, 'pubMedId': 24265152, 'title': 'A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265152'}]",sensitive,4635,MK2206 + Vemurafenib,673
605,Phase II,"In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) resulted in partial response in 12% (1/8) and stable disease in 50% (4/8) of cholangiocarcinoma patients with BRAF V600 mutations (PMID: 26287849).",Actionable,3303,4947,cholangiocarcinoma,DOID,1186,BRAF V600X,"[{'id': 3720, 'pubMedId': 26287849, 'title': 'Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26287849'}]",sensitive,342,Vemurafenib,673
606,Preclinical - Cell culture,"In a preclinical study, the combination of Mekinist (trametinib) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8160,1909,melanoma,DOID,1186,BRAF V600X,"[{'id': 6551, 'pubMedId': 24265152, 'title': 'A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265152'}]",sensitive,4234,Trametinib + Vemurafenib,673
607,Phase Ib/II,"In a Phase Ib trial, the combination of Tecentriq (atezolizumab), Cotellic (cobimetinib), and Zelboraf (vemurafenib) resulted in antitumor efficacy in BRAF V600 positive melanoma patients, demonstrating an unconfirmed RECIST response in 85.3% (29/34) of patients, including 6 CRs and 23 PRs, and confirmed PRs in three patients (J Clin Oncol 35, 2017 (suppl; abstr 3063)).",Actionable,11112,1909,melanoma,DOID,1186,BRAF V600X,"[{'id': 9081, 'pubMedId': None, 'title': 'Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.', 'url': 'http://abstracts.asco.org/199/AbstView_199_186773.html'}]",sensitive,4825,Atezolizumab + Vemurafenib + Cobimetinib,673
608,Guideline,Mekinist (trametinib) is an active regimen for melanoma patients with BRAF V600 mutations (Guidelines).,Actionable,1514,1909,melanoma,DOID,1186,BRAF V600X,"[{'id': 1442, 'pubMedId': None, 'title': 'NCCN Guidelines Melanoma version 3.2015', 'url': 'http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf'}]",sensitive,2,Trametinib,673
609,Clinical Study,"In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153).",Actionable,7068,1909,melanoma,DOID,24385,BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,342,Vemurafenib,673
610,Clinical Study,"In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in a patient with ovarian clear cell carcinoma harboring PIK3CA H1047 and BRAF V600 mutations (PMID: 21216929).",Actionable,3381,4001,ovarian carcinoma,DOID,13306,PIK3CA H1047X BRAF V600X,"[{'id': 3726, 'pubMedId': 21216929, 'title': 'PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21216929'}]",sensitive,1121,Bevacizumab + Temsirolimus + Doxil,673
611,Preclinical - Cell culture,"In a preclinical study, expression of AKT1 Q79K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).",Actionable,8106,1909,melanoma,DOID,26173,AKT1 Q79K BRAF V600X PTEN pos,"[{'id': 6551, 'pubMedId': 24265152, 'title': 'A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265152'}]",resistant,342,Vemurafenib,673
612,Preclinical - Cell culture,"In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited AKT activation and growth of PTEN-expressing BRAF V600-mutant melanoma cells expressing AKT1 Q79K in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8125,1909,melanoma,DOID,26173,AKT1 Q79K BRAF V600X PTEN pos,"[{'id': 6551, 'pubMedId': 24265152, 'title': 'A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265152'}]",sensitive,4635,MK2206 + Vemurafenib,673
613,Clinical Study,"In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153). ",Actionable,7082,1909,melanoma,DOID,24398,BRAF V600X PIK3CA H1047R PTEN Y86fs,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,342,Vemurafenib,673
614,Preclinical,"In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471).",Actionable,5974,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,763,GSK2126458,673
615,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).",Actionable,5995,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,3027,GSK2126458 + Trametinib,673
616,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).",Actionable,5981,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,1066,Trametinib + Dabrafenib,673
617,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).",Actionable,5996,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,4004,Dabrafenib + GSK2126458,673
618,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5971,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,3,Dabrafenib,673
619,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were 3-7 fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600K in culture (PMID: 22389471).",Actionable,5972,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,2,Trametinib,673
620,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).",Actionable,7603,1909,melanoma,DOID,25916,BRAF V600K MAP2K1 P124L,"[{'id': 6439, 'pubMedId': 25370473, 'title': 'Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25370473'}]",sensitive,2,Trametinib,673
621,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124L demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).",Actionable,7599,1909,melanoma,DOID,25916,BRAF V600K MAP2K1 P124L,"[{'id': 6439, 'pubMedId': 25370473, 'title': 'Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25370473'}]",decreased response,3,Dabrafenib,673
622,Preclinical,"In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).",Actionable,7600,1909,melanoma,DOID,25916,BRAF V600K MAP2K1 P124L,"[{'id': 6439, 'pubMedId': 25370473, 'title': 'Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25370473'}]",sensitive,2804,VX-11e,673
623,Preclinical - Cell culture,"In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).",Actionable,7601,1909,melanoma,DOID,25913,BRAF V600K MAP2K1 P124Q,"[{'id': 6439, 'pubMedId': 25370473, 'title': 'Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25370473'}]",sensitive,2804,VX-11e,673
624,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).",Actionable,7602,1909,melanoma,DOID,25913,BRAF V600K MAP2K1 P124Q,"[{'id': 6439, 'pubMedId': 25370473, 'title': 'Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25370473'}]",sensitive,2,Trametinib,673
625,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).",Actionable,7598,1909,melanoma,DOID,25913,BRAF V600K MAP2K1 P124Q,"[{'id': 6439, 'pubMedId': 25370473, 'title': 'Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25370473'}]",decreased response,3,Dabrafenib,673
626,Guideline,Mekinist (trametinib) is an active regimen for melanoma patients with BRAF V600K (Guidelines).,Actionable,1513,1909,melanoma,DOID,2,BRAF V600K,"[{'id': 1442, 'pubMedId': None, 'title': 'NCCN Guidelines Melanoma version 3.2015', 'url': 'http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf'}, {'id': 1445, 'pubMedId': None, 'title': '', 'url': 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204114s001lbl.pdf'}]",sensitive,2,Trametinib,673
627,Preclinical,"In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471).",Actionable,5973,1909,melanoma,DOID,2,BRAF V600K,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,763,GSK2126458,673
628,Guideline,Tafinlar (dabrafenib) is an active regimen for melanoma patients with BRAF V600K (Guidelines).,Actionable,1508,1909,melanoma,DOID,2,BRAF V600K,"[{'id': 1437, 'pubMedId': None, 'title': '', 'url': 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202806s002lbl.pdf'}, {'id': 1442, 'pubMedId': None, 'title': 'NCCN Guidelines Melanoma version 3.2015', 'url': 'http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf'}]",sensitive,3,Dabrafenib,673
629,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) induced apoptosis in non-small cell lung carcinoma cells harboring BRAF Y472C in culture (PMID: 22649091).",Actionable,690,3908,non-small cell lung carcinoma,DOID,986,BRAF Y472C,"[{'id': 423, 'pubMedId': 22649091, 'title': 'Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649091'}]",sensitive,717,Dasatinib,673
630,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600D (PMID: 25637314).",Actionable,6320,1909,melanoma,DOID,23100,BRAF V600D PTEN loss,"[{'id': 5522, 'pubMedId': 25637314, 'title': 'The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25637314'}]",sensitive,1050,XL147,673
631,Preclinical,"In a preclinical study, CCT241161 inhibited MEK and ERK phosphorylation and growth of melanoma cells harboring BRAF V600D in culture (PMID: 25500121, PMID: 17210691).",Actionable,3309,1909,melanoma,DOID,653,BRAF V600D,"[{'id': 3714, 'pubMedId': 25500121, 'title': 'Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25500121'}, {'id': 3730, 'pubMedId': 17210691, 'title': 'Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17210691'}]",sensitive,3106,CCT241161,673
632,Preclinical,"In a preclinical study, CCT196969 inhibited MEK and ERK phosphorylation and growth of melanoma cells harboring BRAF V600D in culture (PMID: 25500121, PMID: 17210691).",Actionable,3308,1909,melanoma,DOID,653,BRAF V600D,"[{'id': 3714, 'pubMedId': 25500121, 'title': 'Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25500121'}, {'id': 3730, 'pubMedId': 17210691, 'title': 'Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17210691'}]",sensitive,3105,CCT196969,673
633,Preclinical - Cell culture,"In a preclinical study, PLX7904 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).",Actionable,7947,1909,melanoma,DOID,653,BRAF V600D,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,4606,PLX7904,673
634,Preclinical - Cell culture,"In a preclinical study, Tafinlar (dabrafenib) inhibited proliferation of melanoma cells harboring BRAF V600D in culture (PMID: 27523909).",Actionable,7961,1909,melanoma,DOID,653,BRAF V600D,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,3,Dabrafenib,673
635,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).",Actionable,7937,1909,melanoma,DOID,653,BRAF V600D,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,3300,TAK-632,673
636,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).",Actionable,7907,1909,melanoma,DOID,653,BRAF V600D,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,1093,AZ628,673
637,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600D in culture (PMID: 27523909).",Actionable,7953,1909,melanoma,DOID,653,BRAF V600D,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,342,Vemurafenib,673
638,Clinical Study,"In a clinical case study, single Tafinlar (dabrafenib) and subsequent Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment resulted in disease stablization in a patient with pilocytic astrocytoma harboring BRAF V600D (PMID: 28784858).",Actionable,11711,4851,pilocytic astrocytoma,DOID,653,BRAF V600D,"[{'id': 9723, 'pubMedId': 28784858, 'title': 'Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28784858'}]",sensitive,1066,Trametinib + Dabrafenib,673
639,Preclinical - Cell culture,"In a preclinical study, colon cancer cells harboring BRAF N581Y were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).",Actionable,7875,219,colon cancer,DOID,23804,BRAF N581Y,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",resistant,1095,GDC0879,673
640,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing BRAF F247L demonstrated sensitivity to Tafinlar (dabrafenib) in culture (PMID: 28512244).",Actionable,11371,10000003,Advanced Solid Tumor,JAX,27972,BRAF F247L,"[{'id': 9257, 'pubMedId': 28512244, 'title': 'Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28512244'}]",sensitive,3,Dabrafenib,673
641,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing BRAF F247L demonstrated sensitivity to Mekinist (trametinib) in culture (PMID: 28512244).",Actionable,11370,10000003,Advanced Solid Tumor,JAX,27972,BRAF F247L,"[{'id': 9257, 'pubMedId': 28512244, 'title': 'Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28512244'}]",sensitive,2,Trametinib,673
642,Preclinical,"In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition and sustained inhibition of Erk signaling in lung cancer cells harboring KRAS G12C with decreased Braf expression through shRNA knockdown in culture (PMID: 27338794).",Actionable,7359,1324,lung cancer,DOID,25302,BRAF dec exp KRAS G12C,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",sensitive,2,Trametinib,673
643,Preclinical,"In a preclinical study, Selumetinib (AZD6244) and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5184,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,"[{'id': 4903, 'pubMedId': 26137449, 'title': 'Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26137449'}]",sensitive,3773,Selumetinib + Vemurafenib,673
644,Preclinical,"In a preclinical study, A66 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5190,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,"[{'id': 4903, 'pubMedId': 26137449, 'title': 'Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26137449'}]",no benefit,617,A66,673
645,Preclinical,"In a preclinical study, Zydelig (idelalisib) did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5192,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,"[{'id': 4903, 'pubMedId': 26137449, 'title': 'Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26137449'}]",no benefit,1023,Idelalisib,673
646,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergitically inhibited tumor growth in cell line xenograft models (PMID: 26137449).",Actionable,5188,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,"[{'id': 4903, 'pubMedId': 26137449, 'title': 'Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26137449'}]",sensitive,1420,Selumetinib + BEZ235,673
647,Preclinical,"In a preclinical study, ZSTK474 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5186,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,"[{'id': 4903, 'pubMedId': 26137449, 'title': 'Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26137449'}]",sensitive,3772,Vemurafenib + ZSTK474,673
648,Preclinical,"In a preclinical study, BEZ235 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5185,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,"[{'id': 4903, 'pubMedId': 26137449, 'title': 'Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26137449'}]",sensitive,3774,BEZ235 + Vemurafenib,673
649,Preclinical,"In a preclinical study, TGX-221 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5191,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,"[{'id': 4903, 'pubMedId': 26137449, 'title': 'Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26137449'}]",no benefit,2514,TGX-221,673
650,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) and ZSTK474 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergistically inhibited tumor growth in cell line xenograft models (PMID: 26137449).",Actionable,5187,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,"[{'id': 4903, 'pubMedId': 26137449, 'title': 'Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26137449'}]",sensitive,3771,Selumetinib + ZSTK474,673
651,Phase I,"In a Phase I trial, Mekinist (trametinib) resulted in complete response in 7% (2/30), partial response in 33% (10/30), and stable disease in 37% (11/30) of BRAF-mutant melanoma patients (PMID: 22805292).",Actionable,178,1909,melanoma,DOID,499,BRAF V600E/K,"[{'id': 233, 'pubMedId': 22805292, 'title': 'Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805292'}]",sensitive,2,Trametinib,673
652,FDA approved,"In a Phase III trial that supported FDA approval, Mekinist (trametinib) resulted in improved progression free survival and an overall six month survival rate of 81% in patients with BRAF V600E/K positive metastatic melanoma (PMID: 22663011). ",Actionable,1912,1909,melanoma,DOID,499,BRAF V600E/K,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 468, 'pubMedId': 22663011, 'title': 'Improved survival with MEK inhibition in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22663011'}]",sensitive,2,Trametinib,673
653,Guideline,Mekinist (trametinib) is an active regimen for melanoma patients with BRAF V600E or V600K (Guidelines).,Actionable,1515,1909,melanoma,DOID,499,BRAF V600E/K,"[{'id': 1442, 'pubMedId': None, 'title': 'NCCN Guidelines Melanoma version 3.2015', 'url': 'http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf'}, {'id': 1445, 'pubMedId': None, 'title': '', 'url': 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204114s001lbl.pdf'}]",sensitive,2,Trametinib,673
654,FDA approved,"In a Phase III trial that supported FDA approval, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) significantly improved progression-free survival in patients with BRAF V600E/K-positive metastatic melanoma (PMID: 25265492, J Clin Oncol 32:5s, 2014 (Suppl; abstr 9011)). ",Actionable,1909,1909,melanoma,DOID,499,BRAF V600E/K,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 2390, 'pubMedId': None, 'title': 'COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutan', 'url': 'http://meetinglibrary.asco.org/content/128598-144'}, {'id': 2396, 'pubMedId': 25265492, 'title': 'Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25265492'}]",sensitive,1066,Trametinib + Dabrafenib,673
655,Phase III,"In a Phase III trial, treatment with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved estimated 3-year relapse-free survival rate (58% vs 39%, HR=0.47, P<0.001) and 3-year overall survival rate (86% vs 77%, HR=0.57; 95% CI, 0.42 to 0.79, P=0.0006) compared to placebo in stage III melanoma patients harboring BRAF V600E or V600K mutations (PMID: 28891408; NCT01682083).",Actionable,12034,1909,melanoma,DOID,499,BRAF V600E/K,"[{'id': 9986, 'pubMedId': 28891408, 'title': 'Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28891408'}]",sensitive,1066,Trametinib + Dabrafenib,673
656,Guideline,"Tafinlar (dabrafenib), in combination with Mekinist (trametinib), is an active regimen for melanoma patients with BRAF V600E or V600K (Guidelines).",Actionable,1518,1909,melanoma,DOID,499,BRAF V600E/K,"[{'id': 1437, 'pubMedId': None, 'title': '', 'url': 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202806s002lbl.pdf'}, {'id': 1442, 'pubMedId': None, 'title': 'NCCN Guidelines Melanoma version 3.2015', 'url': 'http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf'}]",sensitive,1066,Trametinib + Dabrafenib,673
657,Preclinical,"In a preclinical study, melanoma cells expressing BRAF L505H were resistant to Zelboraf (vemurafenib) (PMID: 24283590). ",Actionable,1475,1909,melanoma,DOID,2594,BRAF L505H,"[{'id': 1371, 'pubMedId': 24283590, 'title': 'Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24283590'}]",resistant,342,Vemurafenib,673
658,Preclinical - Cell culture,"In a preclinical study, treatment with Zelboraf (vemurafenib) did not reduce activation of Mek and Erk by BRAF F595L in transformed cells in culture (PMID: 26582644).",Actionable,11664,10000003,Advanced Solid Tumor,JAX,2417,BRAF F595L,"[{'id': 9695, 'pubMedId': 26582644, 'title': 'Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26582644'}]",resistant,342,Vemurafenib,673
659,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G464V (PMID: 26343582).",Actionable,9411,10000003,Advanced Solid Tumor,JAX,664,BRAF G464V,"[{'id': 7141, 'pubMedId': 26343582, 'title': 'BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343582'}]",resistant,342,Vemurafenib,673
660,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 demonstrated decreased response to tumor growth inhibition in xenograft models of human breast cancer cell lines harboring KRAS G13D and BRAF G464V (PMID: 21558396).",Actionable,2973,1612,breast cancer,DOID,10754,BRAF G464V KRAS G13D,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",decreased response,2152,CH5132799,673
661,Preclinical - Cell line xenograft,"In a preclinical study, Stivarga (regorafenib) inhibited proliferation of breast cancer cells harboring BRAF G464V and KRAS G13D in culture and inhibited angiogenesis and tumor growth in cell line xenograft models (PMID: 21170960).",Actionable,1075,1612,breast cancer,DOID,10754,BRAF G464V KRAS G13D,"[{'id': 318, 'pubMedId': 21170960, 'title': 'Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21170960'}]",sensitive,890,Regorafenib,673
662,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring BRAF G464V and KRAS G13D in culture (PMID: 21325073, PMID: 17314276).",Actionable,3129,1612,breast cancer,DOID,10754,BRAF G464V KRAS G13D,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3636, 'pubMedId': 17314276, 'title': 'Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17314276'}]",sensitive,1040,PF-05212384,673
663,Preclinical - Cell line xenograft,"In a preclinical study, DHM25 increased cell death and decreased migration of a triple-negative breast cancer cell line harboring KRAS G13D and BRAF G464V in culture, and reduced tumor growth and lung metastasis in xenograft models (PMID: 26237138).",Actionable,10363,60081,triple-receptor negative breast cancer,DOID,10754,BRAF G464V KRAS G13D,"[{'id': 8367, 'pubMedId': 26237138, 'title': 'A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26237138'}]",sensitive,5494,DHM25,673
664,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) resulted in minimal growth inhibitory activity of an ovarian cancer cell line harboring BRAF N486_P490del (PMID: 26732095). ",Actionable,4919,2394,ovarian cancer,DOID,19833,BRAF N486_P490del,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",predicted – resistant,3,Dabrafenib,673
665,Preclinical,"In a preclinical study, an ovarian cancer cell line harboring BRAF  N486_P490del was sensitive to LY3009120, resulting in inhibition of cell growth and decreased phosphorylation of MEK and ERK in culture (PMID: 26732095). ",Actionable,4916,2394,ovarian cancer,DOID,19833,BRAF N486_P490del,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",sensitive,3268,LY3009120,673
666,Preclinical,"In a preclinical study, an ovarian cancer cell line harboring BRAF N486_P490del was resistant to Zelboraf (vemurafenib), resulting in minimal inhibition of both cell growth and phosphorylation of MEK and ERK in culture (PMID: 26732095). ",Actionable,4918,2394,ovarian cancer,DOID,19833,BRAF N486_P490del,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",resistant,342,Vemurafenib,673
667,Preclinical,"In a preclinical study, an ovarian cancer cell line harboring BRAF  N486_P490del was sensitive to Mekinist (trametinib), resulting in inhibition of cell growth in culture (PMID: 26732095). ",Actionable,4917,2394,ovarian cancer,DOID,19833,BRAF N486_P490del,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",sensitive,2,Trametinib,673
668,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G464E (PMID: 26343582).",Actionable,9410,10000003,Advanced Solid Tumor,JAX,1779,BRAF G464E,"[{'id': 7141, 'pubMedId': 26343582, 'title': 'BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343582'}]",resistant,342,Vemurafenib,673
669,Preclinical,"In a preclinical study, treatment of cells expressing BRAF L597R with the BRAF inhibitor, Zelboraf (vemurafenib), decreased activation of MEK and ERK (PMID: 22798288).",Actionable,694,10000003,Advanced Solid Tumor,JAX,992,BRAF L597R,"[{'id': 3, 'pubMedId': 22798288, 'title': 'BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22798288'}]",sensitive,342,Vemurafenib,673
670,Preclinical,"Preclinical studies demonstrated the MEK inhibitor, Mekinist (trametinib) caused decreased activation of MEK and ERK in cells expressing BRAF L597R (PMID: 22798288).",Actionable,693,10000003,Advanced Solid Tumor,JAX,992,BRAF L597R,"[{'id': 3, 'pubMedId': 22798288, 'title': 'BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22798288'}]",sensitive,2,Trametinib,673
671,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF G466E in culture (PMID: 27523909).",Actionable,7938,1909,melanoma,DOID,3324,BRAF G466E,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,3300,TAK-632,673
672,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).",Actionable,7963,1909,melanoma,DOID,3324,BRAF G466E,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",decreased response,3,Dabrafenib,673
673,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF G466E in culture (PMID: 27523909).",Actionable,7908,1909,melanoma,DOID,3324,BRAF G466E,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,1093,AZ628,673
674,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",Actionable,7955,1909,melanoma,DOID,3324,BRAF G466E,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",decreased response,342,Vemurafenib,673
675,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).",Actionable,7948,1909,melanoma,DOID,3324,BRAF G466E,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",decreased response,4606,PLX7904,673
676,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of a melanoma cell line harboring BRAF G466E and HRAS Q61K in culture (PMID: 28783719).",Actionable,11656,1909,melanoma,DOID,28179,BRAF G466E HRAS Q61K,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",sensitive,2,Trametinib,673
677,Preclinical - Cell line xenograft,"In a preclinical study, a human pancreatic cancer cell line harboring BRAF V487_P492delinsA was resistant to treatment with Zelboraf (vemurafenib) in both culture and xenograft models (PMID: 26732095).",Actionable,4922,1793,pancreatic cancer,DOID,19834,BRAF V487_P492delinsA,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",resistant,342,Vemurafenib,673
678,Preclinical,"In a preclinical study, a pancreatic cancer cell line harboring BRAF V487_P492delinsA was resistant to Tafinlar (dabrafenib) (PMID: 26732095). ",Actionable,4923,1793,pancreatic cancer,DOID,19834,BRAF V487_P492delinsA,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",resistant,3,Dabrafenib,673
679,Preclinical,"In a preclinical study, a pancreatic cancer cell line harboring BRAF V487_P492delinsA was sensitive to Mekinist (trametinib) in culture, resulting in cell growth inhibition (PMID: 26732095). ",Actionable,4921,1793,pancreatic cancer,DOID,19834,BRAF V487_P492delinsA,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",sensitive,2,Trametinib,673
680,Preclinical,"In a preclinical study, a pancreatic cancer cell line harboring BRAF V487_P492delinsA were sensitive to LY3009120 in culture and in xenograft models, resulting in inhibition of tumor growth and partial tumor regression (PMID: 26732095).",Actionable,4920,1793,pancreatic cancer,DOID,19834,BRAF V487_P492delinsA,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",sensitive,3268,LY3009120,673
681,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G469A (PMID: 26343582).",Actionable,9413,10000003,Advanced Solid Tumor,JAX,651,BRAF G469A,"[{'id': 7141, 'pubMedId': 26343582, 'title': 'BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343582'}]",resistant,342,Vemurafenib,673
682,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) induced apoptosis and inhibited growth of a non-small cell lung cancer cell line harboring BRAF G469A in culture (PMID: 25706985).",Actionable,9615,3908,non-small cell lung carcinoma,DOID,651,BRAF G469A,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}]",sensitive,2,Trametinib,673
683,Preclinical - Cell culture,"In a preclinical study, a non-small cell lung cancer cell line harboring BRAF G469A demonstrated resistance to induction of apoptosis by Zelboraf (vemurafenib,) and treatment with Zelboraf (vemurafenib) was not effective in inhibiting growth in culture (PMID: 25706985).",Actionable,9614,3908,non-small cell lung carcinoma,DOID,651,BRAF G469A,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}]",resistant,342,Vemurafenib,673
684,Preclinical - Cell culture,"In a preclinical study, the combination of Mekinist (trametinib) and Zelboraf (vemurafenib) inhibited growth of  a non-small cell lung cancer cell line harboring BRAF G469A in culture, and prevented Mekinist (trametinib)-related activation of AKT and resulted in increased induction of apoptosis compared to either agent alone (PMID: 25706985).",Actionable,9616,3908,non-small cell lung carcinoma,DOID,651,BRAF G469A,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}]",sensitive,4234,Trametinib + Vemurafenib,673
685,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased viability and enhanced ERK inhibition compared to either agent alone, in a non-small cell lung cancer cell line harboring BRAF G469A in culture (PMID: 27577079).",Actionable,9611,3908,non-small cell lung carcinoma,DOID,651,BRAF G469A,"[{'id': 7322, 'pubMedId': 27577079, 'title': 'Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27577079'}]",sensitive,1066,Trametinib + Dabrafenib,673
686,Preclinical - Cell line xenograft,"In a preclinical study, PLX8394 decreased growth of lung adenocarcinoma cell lines harboring BRAF G469A in culture, and reduced tumor growth in xenograft models (PMID: 27834212).",Actionable,12072,3910,lung adenocarcinoma,DOID,651,BRAF G469A,"[{'id': 10006, 'pubMedId': 27834212, 'title': 'Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27834212'}]",sensitive,1041,PLX8394,673
687,Preclinical,"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring BRAF G469A mutation in culture (PMID: 26090892).",Actionable,3933,3908,non-small cell lung carcinoma,DOID,651,BRAF G469A,"[{'id': 4301, 'pubMedId': 26090892, 'title': 'TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26090892'}]",sensitive,2086,TAE226,673
688,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased proliferation and increased apoptosis, and enhanced ERK inhibition compared to either agent alone in a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 27577079).",Actionable,11737,9256,colorectal cancer,DOID,2416,BRAF G596R,"[{'id': 7322, 'pubMedId': 27577079, 'title': 'Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27577079'}]",sensitive,1066,Trametinib + Dabrafenib,673
689,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not reduce activation of Erk and Mek in a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 28783719).",Actionable,11665,9256,colorectal cancer,DOID,2416,BRAF G596R,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",resistant,342,Vemurafenib,673
690,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) reduced Erk signaling and inhibited proliferation of a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 28783719).",Actionable,11655,9256,colorectal cancer,DOID,2416,BRAF G596R,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",sensitive,2,Trametinib,673
691,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells harboring both BRAF G596R and PIK3CA E545K in culture (PMID: 26243863).",Actionable,7117,9256,colorectal cancer,DOID,24419,BRAF G596R PIK3CA E545K,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,828,Neratinib,673
0,Clinical Study,"In a clinical study, an ovarian carcinoma patient harboring a BRCA1 L392Qfs*5 germline mutation demonstrated a partial response when treated with Rubraca (rucaparib) (PMID: 28588062). ",Actionable,12052,4001,ovarian carcinoma,DOID,28324,BRCA1 L392Qfs*5,"[{'id': 9883, 'pubMedId': 28588062, 'title': 'Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28588062'}]",sensitive,906,Rucaparib,672
1,Preclinical,"In a preclinical study, Lynparza (olaparib) inhibited growth of human breast cancer cells harboring BRCA1 L1795Pfs*3 (referred to as BRCA1 5382insC) in culture, and resulted in prolonged overall survival in transgenic mouse models of breast cancer (PMID: 27454287).",Actionable,8664,1612,breast cancer,DOID,26391,BRCA1 L1795Pfs*3,"[{'id': 6707, 'pubMedId': 27454287, 'title': 'BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27454287'}]",sensitive,837,Olaparib,672
2,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Lynparza (olaparib) when treatment was combined with KU-0063794, resulting in greater decreased cell proliferation and apoptosis in culture (PMID: 26546619). ",Actionable,6059,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,"[{'id': 5259, 'pubMedId': 26546619, 'title': 'mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26546619'}]",sensitive,4015,Olaparib + KU-0063794,672
3,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Talazoparib (BMN673) when treatment was combined with KU-0063794, resulting in greater decreased cell proliferation and apoptosis in culture (PMID: 26546619). ",Actionable,6057,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,"[{'id': 5259, 'pubMedId': 26546619, 'title': 'mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26546619'}]",sensitive,4013,KU-0063794 + Talazoparib,672
4,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Lynparza (olaparib) when treatment was combined with Afinitor (everolimus), resulting in greater decreased cell proliferation and apoptosis in culture (PMID: 26546619). ",Actionable,6058,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,"[{'id': 5259, 'pubMedId': 26546619, 'title': 'mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26546619'}]",sensitive,4014,Olaparib + Everolimus,672
5,Phase III,"In a Phase III trial that supported FDA approval, Zejula (niraparib) maintenance therapy improved median progression-free survival compared to placebo (9.3 vs. 3.9 months, HR=0.45) in platinum-sensitive, recurrent ovarian cancer patients without germline BRCA mutations, with and without homologous recombination deficiency (12.9 vs. 3.8 months, HR=0.38) (PMID: 27717299).",Actionable,9006,2394,ovarian cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,"[{'id': 6850, 'pubMedId': 27717299, 'title': 'Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27717299'}]",predicted – sensitive,832,Niraparib,672
6,Phase I,"In a Phase I trial, VX-970 in combination with Platinol (cisplatin) resulted in an objective response rate of 38.9% (7/18, all partial responses) and a disease control rate of 72.2% (13/18) in patients with BRCA1/2 wild-type triple-receptor negative breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 242PD; NCT02157792).",Actionable,12060,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,"[{'id': 9994, 'pubMedId': None, 'title': 'Initial results of a phase 1 dose expansion cohort of M6620 (formerly VX-970), an ATR inhibitor, in combination with cisplatin in patients with advanced triple-negative breast cancer (NCT02157792)', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]",predicted – sensitive,3109,Cisplatin + VX-970,672
7,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Talazoparib (BMN673) when treatment was combined with Afinitor (everolimus), resulting in greater decreased cell proliferation and apoptosis in culture and reduced tumor volume in xenograft models (PMID: 26546619). ",Actionable,6056,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,"[{'id': 5259, 'pubMedId': 26546619, 'title': 'mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26546619'}]",sensitive,4012,Everolimus + Talazoparib,672
8,Preclinical,"In a preclinical study, BRCA1 proficient transgenic mouse models of breast cancer did not respond to Lynparza (olaparib) treatment (PMID: 27454287).",Actionable,8662,1612,breast cancer,DOID,518,BRCA1 wild-type,"[{'id': 6707, 'pubMedId': 27454287, 'title': 'BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27454287'}]",resistant,837,Olaparib,672
9,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Veliparib (ABT-888) and Paraplatin (carboplatin) provided no survival benefit in an intracranial human BRCA wild-type triple-negative breast cancer cell line xenograft model (PMID: 25824335).",Actionable,2194,60081,triple-receptor negative breast cancer,DOID,518,BRCA1 wild-type,"[{'id': 2753, 'pubMedId': 25824335, 'title': 'Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25824335'}]",no benefit,2704,Veliparib + Carboplatin,672
10,Preclinical,"In a preclinical study,  Lynparza (olaparib) inhibited the growth of triple-receptor negative breast cancer cell lines expressing wild-type BRCA1 under hypoxic conditions (PMID: 25193512).",Actionable,2868,60081,triple-receptor negative breast cancer,DOID,518,BRCA1 wild-type,"[{'id': 3461, 'pubMedId': 25193512, 'title': 'Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25193512'}]",sensitive,837,Olaparib,672
11,Phase I,"In a Phase I trial, the combination of Talazoparib (BMN673) and Temodar (temozolomide) resulted in a partial response in 50% (2/4) of ovarian cancer patients harboring wild-type BRCA1 (European Journal of Cancer, Sep 2015, 51:3, S60). ",Actionable,9961,2394,ovarian cancer,DOID,518,BRCA1 wild-type,"[{'id': 7822, 'pubMedId': None, 'title': 'Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies', 'url': 'http://www.ejcancer.com/article/S0959-8049(16)30182-4/abstract'}]",sensitive,1377,Talazoparib + Temozolomide,672
12,Preclinical,"In a preclinical study, knockdown of BRCA1 increased sensitivity of triple-negative breast cancer cells to Platinol (cisplatin) under hypoxic conditions (PMID: 25193512).",Actionable,2870,60081,triple-receptor negative breast cancer,DOID,2485,BRCA1 dec exp,"[{'id': 3461, 'pubMedId': 25193512, 'title': 'Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25193512'}]",sensitive,700,Cisplatin,672
13,Preclinical,"In a preclinical study, BRCA1 knockdown enhanced growth inhibition by Ambochlorin (chlorambucil) in triple-receptor negative breast cancer cell lines in culture (PMID: 25193512).",Actionable,2878,60081,triple-receptor negative breast cancer,DOID,2485,BRCA1 dec exp,"[{'id': 3461, 'pubMedId': 25193512, 'title': 'Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25193512'}]",sensitive,3035,Chlorambucil,672
14,Preclinical,"In a preclinical study, decreasing Brca1 expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells with Met over expression to Rubraca (rucaparib) in culture (PMID: 26779812).",Actionable,6150,60081,triple-receptor negative breast cancer,DOID,22729,BRCA1 dec exp MET over exp,"[{'id': 5319, 'pubMedId': 26779812, 'title': 'Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26779812'}]",no benefit,906,Rucaparib,672
15,Preclinical,"In a preclinical study, decreasing Brca1 expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells with low expression of Met to Rubraca (rucaparib) in culture (PMID: 26779812).",Actionable,6148,60081,triple-receptor negative breast cancer,DOID,22726,BRCA1 dec exp MET dec exp,"[{'id': 5319, 'pubMedId': 26779812, 'title': 'Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26779812'}]",sensitive,906,Rucaparib,672
16,Preclinical - Cell line xenograft,"In a preclinical study, breast invasive ductal carcinoma cells harboring BRCA1 E23Vfs*17 (also referred to as BRCA1 185delAG) acquired resistance to Rubraca (rucaparib) both in culture and in cell line xenograft models through the expression of a RING-less Brca1 protein utilizing an in-frame translation start site downstream of the mutation (PMID: 27454289).",Actionable,8822,3008,invasive ductal carcinoma,DOID,26390,BRCA1 E23Vfs*17,"[{'id': 6763, 'pubMedId': 27454289, 'title': 'RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27454289'}]",resistant,906,Rucaparib,672
17,Preclinical - Pdx & cell culture,"In a preclinical study, breast cancer cells harboring BRCA1 E23Vfs*17 (referred to as BRCA1 185delAG) demonstrated reduced sensitivity, developed resistance to Lynparza (olaparib) in culture and in patient-derived xenograft models due to the expression of a RING-less form of Brca1 (PMID: 27454287).",Actionable,8665,1612,breast cancer,DOID,26390,BRCA1 E23Vfs*17,"[{'id': 6707, 'pubMedId': 27454287, 'title': 'BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27454287'}]",decreased response,837,Olaparib,672
18,Preclinical - Cell line xenograft,"In a preclinical study, breast invasive ductal carcinoma cells harboring BRCA1 E23Vfs*17 (also referred to as BRCA1 185delAG) acquired resistance to Platinol (cisplatin) both in culture and in cell line xenograft models through the expression of a RING-less Brca1 protein utilizing an in-frame translation start site downstream of the mutation (PMID: 27454289).",Actionable,8823,3008,invasive ductal carcinoma,DOID,26390,BRCA1 E23Vfs*17,"[{'id': 6763, 'pubMedId': 27454289, 'title': 'RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27454289'}]",resistant,700,Cisplatin,672
19,Preclinical - Cell line xenograft,"In a preclinical study, E7449 inhibited tumor growth in a triple-negative breast cancer cell line xenograft model harboring a BRCA1 splice donor site mutation (PMID: 26513298).",Actionable,6539,60081,triple-receptor negative breast cancer,DOID,1282,BRCA1 inact mut,"[{'id': 4121, 'pubMedId': 26513298, 'title': 'E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26513298'}]",predicted – sensitive,724,E7449,672
20,Phase I,"In a Phase I clinical trial, Zejula (niraparib) demonstrated safety and efficacy in ovarian cancer patients with BRCA1 inactivating mutations (PMID: 23810788).
",Actionable,1738,2394,ovarian cancer,DOID,1282,BRCA1 inact mut,"[{'id': 1986, 'pubMedId': 23810788, 'title': 'The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23810788'}]",sensitive,832,Niraparib,672
21,Phase II,"In a Phase II clinical trial, the combination of Veliparib (ABT-888) and Cytoxan (cyclophosphamide) did not demonstrate improved response rate or progression-free survival over Cytoxan (cyclophosphamide) alone in ovarian cancer patients harboring deleterious mutations in BRCA1 or BRCA2 (PMID: 25589624).",Actionable,6848,2394,ovarian cancer,DOID,1282,BRCA1 inact mut,"[{'id': 5876, 'pubMedId': 25589624, 'title': 'Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25589624'}]",no benefit,4283,Veliparib + Cyclophosphamide,672
22,Preclinical,"In a preclinical study, E7449 inhibited proliferation of a BRCA1-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair pathway mutations (PMID: 26513298).",Actionable,6505,10000003,Advanced Solid Tumor,JAX,1282,BRCA1 inact mut,"[{'id': 4121, 'pubMedId': 26513298, 'title': 'E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26513298'}]",sensitive,724,E7449,672
23,Phase I,"In a Phase I trial, Talazoparib (BMN673) treatment demonstrated safety and preliminary efficacy in patients with advanced solid tumors harboring deleterious BRCA1/2 mutations (J Clin Oncol 31, 2013 (suppl; abstr 2580)).",Actionable,6846,10000003,Advanced Solid Tumor,JAX,1282,BRCA1 inact mut,"[{'id': 5875, 'pubMedId': None, 'title': 'First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors', 'url': 'http://meetinglibrary.asco.org/content/111725-132'}]",predicted – sensitive,682,Talazoparib,672
24,Phase II,"In a Phase II trial, the combination of Veliparib (ABT-888), Paraplatin (carboplatin), and Taxol (paclitaxel) resulted in a higher objective response rate (77.8% vs 61.3%) compared to placebo plus Paraplatin (carboplatin) and Taxol (paclitaxel) in breast cancer patients harboring either BRCA1 or BRCA2 deleterious mutations (SABCS, 2016, Abstract # S2-05).",Actionable,9866,1612,breast cancer,DOID,1282,BRCA1 inact mut,"[{'id': 7723, 'pubMedId': None, 'title': 'Efficacy and tolerability of veliparib (V, ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer- A randomized, phase 2 study', 'url': 'https://www.sabcs.org/Past-Meetings'}]",predicted – sensitive,5274,Carboplatin + Paclitaxel + Veliparib,672
25,Clinical Study,"In a clinical study, an ovarian carcinoma patient harboring a BRCA1 W1782* germline mutation demonstrated stable disease when treated with Rubraca (rucaparib) (PMID: 28588062). ",Actionable,12056,4001,ovarian carcinoma,DOID,28325,BRCA1 W1782*,"[{'id': 9883, 'pubMedId': 28588062, 'title': 'Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28588062'}]",sensitive,906,Rucaparib,672
26,Preclinical,"In a preclinical study, BRCA1 deficient cancer cell lines with DNA repair deficiency demonstrated high sensitivity to the PARP inhibitor, BMN673 (PMID: 23881923). ",Actionable,1178,10000003,Advanced Solid Tumor,JAX,2075,BRCA1 negative,"[{'id': 520, 'pubMedId': 23881923, 'title': 'BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23881923'}]",sensitive,682,Talazoparib,672
27,Preclinical,"In a preclinical study, Lynparza (olaparib) treatment resulted in prolonged overall survival in BRCA1 deficient transgenic mouse models of breast cancer (PMID: 27454287).",Actionable,8663,1612,breast cancer,DOID,1787,BRCA1 loss,"[{'id': 6707, 'pubMedId': 27454287, 'title': 'BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27454287'}]",sensitive,837,Olaparib,672
28,Phase II,"In a Phase II trial, high dose Paraplatin (carboplatin) chemotherapy was more beneficial for breast cancer patients with BRCA1 loss than was conventional anthracycline-based chemotherapy (PMID: 21135055).",Actionable,1057,1612,breast cancer,DOID,1787,BRCA1 loss,"[{'id': 768, 'pubMedId': 21135055, 'title': 'An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21135055'}]",sensitive,1092,Carboplatin,672
29,Preclinical,"In a preclinical study, a breast cancer model lacking BRCA1 and TP53 demonstrated sensitivity to treatment with AZD2461, which resulted in decreased tumor volume (PMID: 27550455). ",Actionable,8945,1612,breast cancer,DOID,26544,BRCA1 loss TP53 loss,"[{'id': 6793, 'pubMedId': 27550455, 'title': 'The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550455'}]",sensitive,2542,AZD2461,672
30,Clinical Study,"In a clinical study, an ovarian carcinoma patient harboring a BRCA1 L631Qfs*4 germline mutation demonstrated a partial response when treated with Rubraca (rucaparib) (PMID: 28588062). ",Actionable,12061,4001,ovarian carcinoma,DOID,28326,BRCA1 L631Qfs*4,"[{'id': 9883, 'pubMedId': 28588062, 'title': 'Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28588062'}]",sensitive,906,Rucaparib,672
31,Phase II,"In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 E298* and mutations in BRCA1 (PMID: 27998224). ",Actionable,11779,2394,ovarian cancer,DOID,28241,BRCA1 mut TP53 E298*,"[{'id': 9762, 'pubMedId': 27998224, 'title': 'Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27998224'}]",predicted – sensitive,1194,MK-1775 + Carboplatin ,672
32,Phase II,"In a Phase II clinical trial, treatment with Rubraca (rucaparib) was tolerated and demonstrated activity in ovarian cancer patients with germline BRCA1/2 mutations (PMID: 27002934).",Actionable,8863,2394,ovarian cancer,DOID,1205,BRCA1 mutant,"[{'id': 6778, 'pubMedId': 27002934, 'title': 'Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27002934'}]",predicted – sensitive,906,Rucaparib,672
33,FDA approved,"In a retrospective analysis of 2 Phase II trials that supported FDA approval, Rubraca (rucaparib) treatment resulted in an overall response (complete response + partial response) rate of 53.7% (36/67) in high-grade ovarian cancer patients harboring BRCA1 or BRCA2 mutations (2016 ESMO Congress; October 7-11, 2016; Copenhagen, Denmark. Abstract 8560).",Actionable,9161,2394,ovarian cancer,DOID,1205,BRCA1 mutant,"[{'id': 6965, 'pubMedId': None, 'title': 'Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)', 'url': 'http://clovisoncology.com/files/Rucaparib_RKristeleit_ESMO2016.pdf'}]",predicted – sensitive,906,Rucaparib,672
34,FDA approved,"In a Phase III trial that supported FDA approval, maintenance Zejula (niraparib) therapy significantly improved median progression-free survival compared to placebo (21.0 vs. 5.5 months, HR=0.27) in patients with platinum-sensitive, recurrent ovarian cancer harboring germline BRCA mutations (PMID: 27717299).",Actionable,9004,2394,ovarian cancer,DOID,1205,BRCA1 mutant,"[{'id': 6850, 'pubMedId': 27717299, 'title': 'Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27717299'}]",sensitive,832,Niraparib,672
35,Phase I,"In a Phase I trial, Veliparib (ABT-888), in combination with Platinol (cisplatin) and Navelbine (vinorelbine), resulted in a greater complete response (7%, 1/14), partial response (50%, 7/14), and 6-month progression free survival rate (71%, 10/14) in Erbb2 (Her2) negative breast cancer patients harboring germline BRCA1 or BRCA2 mutations compared to BRCA wild-type patients (PMID: 26801247).",Actionable,6874,60080,Her2-receptor negative breast cancer,DOID,1205,BRCA1 mutant,"[{'id': 5936, 'pubMedId': 26801247, 'title': 'Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26801247'}]",sensitive,4286,Cisplatin + Veliparib + Vinorelbine,672
36,Phase I,"In a Phase I trial, Talazoparib (BMN-673) treatment in patients with triple-receptor negative breast cancer carrying a BRCA1 and/or BRCA2 mutation resulted in a lower clinical benefit rate (56% vs 89%) compared to treatment in non-triple-receptor negative breast cancer patients carrying a BRCA1/2 mutation (PMID: 28242752).",Actionable,11194,60081,triple-receptor negative breast cancer,DOID,1205,BRCA1 mutant,"[{'id': 9147, 'pubMedId': 28242752, 'title': 'Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28242752'}]",decreased response,682,Talazoparib,672
37,Phase I,"In a Phase I trial, BGB-290 treatment resulted in improved objective response rate in ovarian cancer patients harboring germline BRCA1/2 mutations (58%, 7/12) compared to BRCA1/2 wild-type (25%, 2/8) patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 368PD; NCT02361723).",Actionable,11980,2394,ovarian cancer,DOID,1205,BRCA1 mutant,"[{'id': 9945, 'pubMedId': None, 'title': 'Dose escalation/expansion study to investigate the safety, pharmacokinetics, food effect, and antitumor activity of BGB-290 in patients with advanced solid tumors', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]",predicted – sensitive,2947,BGB-290,672
38,Preclinical,"In a preclinical study, Lynparza (olaparib) inhibited the growth of triple-receptor negative BRCA1-mutant breast cancer cell lines under hypoxic conditions (PMID: 25193512).",Actionable,2869,60081,triple-receptor negative breast cancer,DOID,1205,BRCA1 mutant,"[{'id': 3461, 'pubMedId': 25193512, 'title': 'Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25193512'}]",sensitive,837,Olaparib,672
39,Phase II,"In a Phase II trial, Lynparza (olaparib) demonstrated safety and efficacy in breast cancer patients with BRCA1 mutations, with an objective response rate of 50% (9/18) in the maximum tolerated dose cohort and 19% (3/16) in the lower dose cohort (PMID: 20609467).",Actionable,1051,1612,breast cancer,DOID,1205,BRCA1 mutant,"[{'id': 770, 'pubMedId': 20609467, 'title': 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20609467'}]",sensitive,837,Olaparib,672
40,Phase I,"In a Phase I clinical trial, the combination of Veliparib (ABT-888) and Paraplatin (carboplatin) demonstrated preliminary efficacy in  metastatic breast cancer patients, with partial response in 25% (4/16) and stable disease in 62.5% (10/16) of patients with BRCA1/2 mutations or Fanconi Anemia pathway defects (J Clin Oncol 32:5s, 2014 (suppl; abstr 1074)).",Actionable,6852,1612,breast cancer,DOID,1205,BRCA1 mutant,"[{'id': 5878, 'pubMedId': None, 'title': 'Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC).', 'url': 'http://meetinglibrary.asco.org/content/132155-144'}]",predicted – sensitive,2704,Veliparib + Carboplatin,672
41,Phase I,"In a Phase I trial, Talazoparib (BMN673) treatment in breast cancer patients harboring germline deleterious BRCA1/2 mutations resulted in an objective response rate of 50% (7/14) including one patient with a complete response and six patients with a partial response and a median progression free survival of 34.6 weeks (PMID: 28242752). ",Actionable,11193,1612,breast cancer,DOID,1205,BRCA1 mutant,"[{'id': 9147, 'pubMedId': 28242752, 'title': 'Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28242752'}]",predicted – sensitive,682,Talazoparib,672
42,Phase I,"In a Phase I clinical trial, Talazoparib (BMN-673) was well-tolerated and demonstrated preliminary efficacy in patients with advanced solid tumors harboring deleterious BRCA1/2 mutations, including objective responses in 33% (2/6) of breast cancer patients carrying BRCA mutations (J Clin Oncol 31, 2013 (suppl; abstr 2580)).",Actionable,6858,1612,breast cancer,DOID,1205,BRCA1 mutant,"[{'id': 5875, 'pubMedId': None, 'title': 'First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors', 'url': 'http://meetinglibrary.asco.org/content/111725-132'}]",predicted – sensitive,682,Talazoparib,672
43,Clinical Study,"In a clinical study, Xgeva (denosumab) inhibited cell proliferation in normal breast tissues of BRCA1 mutation carriers, provided a potential strategy to prevent breast cancer in this population (PMID: 27322743). ",Emerging,7478,1612,breast cancer,DOID,1205,BRCA1 mutant,"[{'id': 6366, 'pubMedId': 27322743, 'title': 'RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27322743'}]",not applicable,1198,Denosumab,672
44,Preclinical - Cell culture,"In a preclinical study, AZD2461 inhibited cell growth of BRCA1 mutant breast cancer cells in culture (PMID: 27550455). ",Actionable,8943,1612,breast cancer,DOID,1205,BRCA1 mutant,"[{'id': 6793, 'pubMedId': 27550455, 'title': 'The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550455'}]",sensitive,2542,AZD2461,672
45,Phase II,"In a Phase II trial, Rubraca (rucaparib) treatment resulted in an objective response rate of 11% (2/19), disease control rate of 32% (6/19) in advanced pancreatic cancer patients with a known deleterious BRCA mutation, of whom 79% harbored a BRCA2 mutation (J Clin Oncol 34, 2016 (suppl; abstr 4110)).",Actionable,6745,1793,pancreatic cancer,DOID,1205,BRCA1 mutant,"[{'id': 5806, 'pubMedId': None, 'title': 'RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation.', 'url': 'http://meetinglibrary.asco.org/content/166810-176'}]",predicted – sensitive,906,Rucaparib,672
46,Phase I,"In a Phase I trial, ABT-767 treatment resulted in a response rate of 18% (n=79) in patients with high grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer or with solid tumors harboring germline BRCA1 or BRCA2 mutations, with an overall 6 month time to progression rate of 22% (Ann Oncol (2014) 25 (suppl 4): iv150). ",Actionable,6519,10000003,Advanced Solid Tumor,JAX,1205,BRCA1 mutant,"[{'id': 5681, 'pubMedId': None, 'title': 'A STUDY OF ABT-767 IN ADVANCED SOLID TUMORS WITH BRCA 1 AND BRCA 2 MUTATIONS AND HIGH GRADE SEROUS OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER', 'url': 'http://annonc.oxfordjournals.org/content/25/suppl_4/iv150.2.short'}]",predicted – sensitive,4133,ABT-767,672
47,Phase I,"In a Phase I clinical trial, Zejula (niraparib) was well-tolerated and demonstrated preliminary efficacy in advanced solid tumor patients, including partial responses in 50% (2/4) of breast cancer patients carrying BRCA1 or BRCA2 mutations (PMID: 23810788).",Actionable,6857,1612,breast cancer,DOID,1205,BRCA1 mutant,"[{'id': 1986, 'pubMedId': 23810788, 'title': 'The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23810788'}]",predicted – sensitive,832,Niraparib,672
48,FDA approved,"In a Phase II study that supported FDA approval, 40% (78/193) of patients with ovarian cancer harboring germline BRCA 1/2 mutations treated with Lynparza (olaparib) demonstrated stable disease at 8 weeks while a tumor response rate was observed in 31% (60/193) (PMID: 25366685).",Actionable,2145,2394,ovarian cancer,DOID,1205,BRCA1 mutant,"[{'id': 2644, 'pubMedId': 25366685, 'title': 'Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25366685'}]",sensitive,837,Olaparib,672
49,Phase I,"In a Phase I trial, Talazoparib (BMN-673) treatment in ovarian cancer patients harboring germline deleterious BRCA1/2 mutations resulted in an objective response rate of 48%, including one complete response, and a clinical benefit rate of 76% at 24 weeks (PMID: 28242752). ",Actionable,11195,2394,ovarian cancer,DOID,1205,BRCA1 mutant,"[{'id': 9147, 'pubMedId': 28242752, 'title': 'Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28242752'}]",predicted – sensitive,682,Talazoparib,672
50,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Veliparib (ABT-888) and Paraplatin (carboplatin) induced DNA damage and decreased tumor growth in an intracranial human BRCA-mutant triple-negative breast cancer cell line xenograft model, but did not provide a significant survival benefit over Paraplatin (carboplatin) alone (PMID: 25824335).",Actionable,2193,60081,triple-receptor negative breast cancer,DOID,1205,BRCA1 mutant,"[{'id': 2753, 'pubMedId': 25824335, 'title': 'Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25824335'}]",sensitive,2704,Veliparib + Carboplatin,672
51,Preclinical - Cell line xenograft,"In a preclinical study, BGB-290 inhibited PARylation and demonstrated anti-tumor activity in cell line xenograft models of breast cance harboring BRCA1 mutations (Cancer Res 2015; 75(15 Suppl): Abstract nr 1653).",Actionable,10817,1612,breast cancer,DOID,1205,BRCA1 mutant,"[{'id': 8853, 'pubMedId': None, 'title': 'BGB-290: A highly potent and specific PARP1/2 inhibitor potentiates anti-tumor activity of chemotherapeutics in patient biopsy derived SCLC models', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/1653.short'}]",sensitive,2947,BGB-290,672
52,Phase I,"In a Phase I trial, Veliparib (ABT-888) and Camptosar (irinotecan) combination therapy resulted in partial response in 11% (1/9) and stable disease in 67% (6/9) of ovarian cancer patients harboring germline mutations in BRCA1 or BRCA2 (PMID: 26842236).",Actionable,7525,2394,ovarian cancer,DOID,1205,BRCA1 mutant,"[{'id': 6398, 'pubMedId': 26842236, 'title': 'Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26842236'}]",predicted – sensitive,3314,Irinotecan + Veliparib,672
53,Phase III,"In a Phase III trial, Lynparza (olaparib) treatment resulted in improved progression free survival (7.0 vs 4.2 months) and objective response rate (59.9%, 123/205 vs 28.8%, 26/288) compared to single agent chemotherapy in patients with Erbb2 (Her2)-negative breast cancer that also harbored germline BRCA mutations (J Clin Oncol 35, 2017 (suppl; abstr LBA4)).",Actionable,11131,60080,Her2-receptor negative breast cancer,DOID,27913,BRCA1 mut ERBB2 neg,"[{'id': 9101, 'pubMedId': None, 'title': 'OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).', 'url': 'http://abstracts.asco.org/199/AbstView_199_186720.html'}]",predicted – sensitive,837,Olaparib,672
54,Phase I,"In a Phase I trial, VX-970 and Paraplatin (carboplatin) combination treatment resulted in partial response for 6 months in a PARP inhibitor-resistant ovarian cancer patient harboring a germline BRCA1 mutation and TP53 Y220C (J Clin Oncol 34, 2016 (suppl; abstr 2504)).",Actionable,6711,2394,ovarian cancer,DOID,23675,BRCA1 mut TP53 Y220C,"[{'id': 5761, 'pubMedId': None, 'title': 'Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies.', 'url': 'http://abstracts.asco.org/176/AbstView_176_165738.html'}]",sensitive,4253,Carboplatin + VX-970,672
55,Preclinical,"In a preclinical study, mouse breast cancer models harboring BRCA1 C61G with conditional loss of Tp53 had a decreased response to Lynparza (olaparib) compared to models with conditional loss of Brca1 and Tp53 (PMID: 22172724).",Actionable,2016,1612,breast cancer,DOID,4728,BRCA1 C61G TP53 loss,"[{'id': 2497, 'pubMedId': 22172724, 'title': 'BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22172724'}]",decreased response,837,Olaparib,672
56,Clinical Study,"In a clinical study, an ovarian carcinoma patient harboring a BRCA1 N682* germline mutation demonstrated a partial response when treated with Rubraca (rucaparib) (PMID: 28588062). ",Actionable,12062,4001,ovarian carcinoma,DOID,28327,BRCA1 N682*,"[{'id': 9883, 'pubMedId': 28588062, 'title': 'Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28588062'}]",sensitive,906,Rucaparib,672
0,Preclinical,"In a preclinical study, BRCA2 deficient cancer cell lines with DNA repair deficiency demonstrated high sensitivity to the PARP inhibitor, BMN673 (PMID: 23881923). ",Actionable,1179,10000003,Advanced Solid Tumor,JAX,2076,BRCA2 negative,"[{'id': 520, 'pubMedId': 23881923, 'title': 'BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23881923'}]",sensitive,682,Talazoparib,675
1,Preclinical - Cell culture,"In a preclinical study, AZD6738 increased sensitivity to radiotherapy in a colorectal adenocarcinoma cell line harboring wild-type BRCA2 in culture, resulting in a greater decrease in cell survival compared to radiotherapy alone (PMID: 28062704). ",Actionable,10019,50861,colorectal adenocarcinoma,DOID,442,BRCA2 wild-type,"[{'id': 7909, 'pubMedId': 28062704, 'title': 'Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28062704'}]",sensitive,5346,AZD6738 + Radiotherapy,675
2,Phase III,"In a Phase III trial that supported FDA approval, Zejula (niraparib) maintenance therapy improved median progression-free survival compared to placebo (9.3 vs. 3.9 months, HR=0.45) in platinum-sensitive, recurrent ovarian cancer patients without germline BRCA mutations, with and without homologous recombination deficiency (12.9 vs. 3.8 months, HR=0.38) (PMID: 27717299).",Actionable,9006,2394,ovarian cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,"[{'id': 6850, 'pubMedId': 27717299, 'title': 'Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27717299'}]",predicted – sensitive,832,Niraparib,675
3,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Talazoparib (BMN673) when treatment was combined with KU-0063794, resulting in greater decreased cell proliferation and apoptosis in culture (PMID: 26546619). ",Actionable,6057,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,"[{'id': 5259, 'pubMedId': 26546619, 'title': 'mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26546619'}]",sensitive,4013,KU-0063794 + Talazoparib,675
4,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Lynparza (olaparib) when treatment was combined with Afinitor (everolimus), resulting in greater decreased cell proliferation and apoptosis in culture (PMID: 26546619). ",Actionable,6058,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,"[{'id': 5259, 'pubMedId': 26546619, 'title': 'mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26546619'}]",sensitive,4014,Olaparib + Everolimus,675
5,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Lynparza (olaparib) when treatment was combined with KU-0063794, resulting in greater decreased cell proliferation and apoptosis in culture (PMID: 26546619). ",Actionable,6059,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,"[{'id': 5259, 'pubMedId': 26546619, 'title': 'mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26546619'}]",sensitive,4015,Olaparib + KU-0063794,675
6,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Talazoparib (BMN673) when treatment was combined with Afinitor (everolimus), resulting in greater decreased cell proliferation and apoptosis in culture and reduced tumor volume in xenograft models (PMID: 26546619). ",Actionable,6056,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,"[{'id': 5259, 'pubMedId': 26546619, 'title': 'mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26546619'}]",sensitive,4012,Everolimus + Talazoparib,675
7,Phase I,"In a Phase I trial, VX-970 in combination with Platinol (cisplatin) resulted in an objective response rate of 38.9% (7/18, all partial responses) and a disease control rate of 72.2% (13/18) in patients with BRCA1/2 wild-type triple-receptor negative breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 242PD; NCT02157792).",Actionable,12060,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,"[{'id': 9994, 'pubMedId': None, 'title': 'Initial results of a phase 1 dose expansion cohort of M6620 (formerly VX-970), an ATR inhibitor, in combination with cisplatin in patients with advanced triple-negative breast cancer (NCT02157792)', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]",predicted – sensitive,3109,Cisplatin + VX-970,675
8,Preclinical,"In a preclinical study, YU238259 and Lynparza (olaparib) synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172).",Actionable,5537,9256,colorectal cancer,DOID,1788,BRCA2 loss,"[{'id': 5087, 'pubMedId': 26116172, 'title': 'YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26116172'}]",sensitive,3883,Olaparib + YU238259,675
9,Phase II,"In a Phase II clinical trial, 100% (7/7) of metastatic castration-resistant prostate cancer patients with BRCA2 loss demonstrated response to Lynparza (olaparib) treatment (PMID: 26510020).",Actionable,3284,10283,prostate cancer,DOID,1788,BRCA2 loss,"[{'id': 3921, 'pubMedId': 26510020, 'title': 'DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26510020'}]",sensitive,837,Olaparib,675
10,Preclinical - Cell line xenograft,"In a preclinical study, YU238259 induced cytotoxicity in a human BRCA2-deficient colorectal cancer cell line in culture and slowed tumor growth in xenograft models (PMID: 26116172).",Actionable,5530,9256,colorectal cancer,DOID,1788,BRCA2 loss,"[{'id': 5087, 'pubMedId': 26116172, 'title': 'YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26116172'}]",sensitive,3880,YU238259,675
11,Preclinical,"In a preclinical study, YU238259 and Eposin (etoposide) synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172).",Actionable,5535,9256,colorectal cancer,DOID,1788,BRCA2 loss,"[{'id': 5087, 'pubMedId': 26116172, 'title': 'YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26116172'}]",sensitive,3881,Etoposide + YU238259,675
12,Preclinical,"In a preclinical study, YU238259 and radiotherapy synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172).",Actionable,5536,9256,colorectal cancer,DOID,1788,BRCA2 loss,"[{'id': 5087, 'pubMedId': 26116172, 'title': 'YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26116172'}]",sensitive,3882,Radiotherapy + YU238259,675
13,Preclinical,"In a preclinical study, YU238259 demonstrated increased cytotoxicity in BRCA2-deficient ovarian adenocarcinoma cell lines in culture (PMID: 26116172).",Actionable,5529,3713,ovary adenocarcinoma,DOID,1788,BRCA2 loss,"[{'id': 5087, 'pubMedId': 26116172, 'title': 'YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26116172'}]",sensitive,3880,YU238259,675
14,Preclinical - Cell culture,"In a preclinical study, AZD6738 increased sensitivity to radiotherapy in a colorectal adenocarcinoma cell line deficient for BRCA2 in culture, resulting in a greater decrease in cell survival compared to radiotherapy alone (PMID: 28062704). ",Actionable,10020,50861,colorectal adenocarcinoma,DOID,1788,BRCA2 loss,"[{'id': 7909, 'pubMedId': 28062704, 'title': 'Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28062704'}]",sensitive,5346,AZD6738 + Radiotherapy,675
15,Phase I,"In a Phase I trial, BGB-290 treatment resulted in improved objective response rate in ovarian cancer patients harboring germline BRCA1/2 mutations (58%, 7/12) compared to BRCA1/2 wild-type (25%, 2/8) patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 368PD; NCT02361723).",Actionable,11981,2394,ovarian cancer,DOID,1206,BRCA2 mutant,"[{'id': 9945, 'pubMedId': None, 'title': 'Dose escalation/expansion study to investigate the safety, pharmacokinetics, food effect, and antitumor activity of BGB-290 in patients with advanced solid tumors', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]",predicted – sensitive,2947,BGB-290,675
16,Phase I,"In a Phase I trial, Veliparib (ABT-888) in combination with Platinol (cisplatin) and Navelbine (vinorelbine) resulted in a greater complete response (7%, 1/14), partial response (50%, 7/14), and 6-month progression free survival rate (71%, 10/14) in Erbb2 (Her2) negative breast cancer patients harboring germline BRCA1 or BRCA2 mutations compared to BRCA wild-type patients (PMID: 26801247).",Actionable,6875,60080,Her2-receptor negative breast cancer,DOID,1206,BRCA2 mutant,"[{'id': 5936, 'pubMedId': 26801247, 'title': 'Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26801247'}]",predicted – sensitive,4286,Cisplatin + Veliparib + Vinorelbine,675
17,Preclinical - Pdx,"In a preclinical study, Lynparza (olaparib) decreased tumor growth in patient-derived xenografts carrying BRCA2 mutation (PMID: 21097693).",Actionable,1825,2394,ovarian cancer,DOID,1206,BRCA2 mutant,"[{'id': 2236, 'pubMedId': 21097693, 'title': 'Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21097693'}]",sensitive,837,Olaparib,675
18,FDA approved,"In a Phase II study that supported FDA approval, 40% (78/193) of patients with ovarian cancer harboring germline BRCA 1/2 mutations treated with Lynparza (olaparib) demonstrated stable disease at 8 weeks while a tumor response rate was observed in 31% (60/193) (PMID: 25366685).",Actionable,2146,2394,ovarian cancer,DOID,1206,BRCA2 mutant,"[{'id': 2644, 'pubMedId': 25366685, 'title': 'Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25366685'}]",sensitive,837,Olaparib,675
19,Phase III,"In a Phase III trial that supported FDA approval, maintenance Zejula (niraparib) therapy significantly improved median progression-free survival compared to placebo (21.0 vs. 5.5 months, HR=0.27) in patients with platinum-sensitive, recurrent ovarian cancer harboring germline BRCA mutations (PMID: 27717299).",Actionable,9005,2394,ovarian cancer,DOID,1206,BRCA2 mutant,"[{'id': 6850, 'pubMedId': 27717299, 'title': 'Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27717299'}]",sensitive,832,Niraparib,675
20,Phase II,"In a Phase II clinical trial, treatment with Rubraca (rucaparib) was tolerated and demonstrated activity in ovarian cancer patients with germline BRCA1/2 mutations (PMID: 27002934).",Actionable,8867,2394,ovarian cancer,DOID,1206,BRCA2 mutant,"[{'id': 6778, 'pubMedId': 27002934, 'title': 'Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27002934'}]",predicted – sensitive,906,Rucaparib,675
21,FDA approved,"In a retrospective analysis of 2 Phase II trials that supported FDA approval, Rubraca (rucaparib) treatment resulted in an overall response (complete response + partial response) rate of 53.7% (36/67) in high-grade ovarian cancer patients harboring BRCA1 or BRCA2 mutations (2016 ESMO Congress; October 7-11, 2016; Copenhagen, Denmark. Abstract 8560).",Actionable,9160,2394,ovarian cancer,DOID,1206,BRCA2 mutant,"[{'id': 6965, 'pubMedId': None, 'title': 'Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)', 'url': 'http://clovisoncology.com/files/Rucaparib_RKristeleit_ESMO2016.pdf'}]",predicted – sensitive,906,Rucaparib,675
22,Phase I,"In a Phase I trial, Talazoparib (BMN-673) treatment in patients with triple-receptor negative breast cancer carrying a BRCA1 and/or BRCA2 mutation resulted in a lower clinical benefit rate (56% vs 89%) compared to treatment in non-triple-receptor negative breast cancer patients carrying a BRCA1/2 mutation (PMID: 28242752).",Actionable,11201,60081,triple-receptor negative breast cancer,DOID,1206,BRCA2 mutant,"[{'id': 9147, 'pubMedId': 28242752, 'title': 'Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28242752'}]",decreased response,682,Talazoparib,675
23,Phase I,"In a Phase I trial, Veliparib (ABT-888) and Camptosar (irinotecan) combination therapy resulted in partial response in 11% (1/9) and stable disease in 67% (6/9) of ovarian cancer patients harboring germline mutations in BRCA1 or BRCA2 (PMID: 26842236).",Actionable,7531,2394,ovarian cancer,DOID,1206,BRCA2 mutant,"[{'id': 6398, 'pubMedId': 26842236, 'title': 'Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26842236'}]",predicted – sensitive,3314,Irinotecan + Veliparib,675
24,Phase I,"In a Phase I trial, ABT-767 treatment resulted in a response rate of 18% (n=79) in patients with high grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer or with solid tumors harboring germline BRCA1 or BRCA2 mutations, with an overall 6 month time to progression rate of 22% (Ann Oncol (2014) 25 (suppl 4): iv150). ",Actionable,6520,10000003,Advanced Solid Tumor,JAX,1206,BRCA2 mutant,"[{'id': 5681, 'pubMedId': None, 'title': 'A STUDY OF ABT-767 IN ADVANCED SOLID TUMORS WITH BRCA 1 AND BRCA 2 MUTATIONS AND HIGH GRADE SEROUS OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER', 'url': 'http://annonc.oxfordjournals.org/content/25/suppl_4/iv150.2.short'}]",predicted – sensitive,4133,ABT-767,675
25,Phase I,"In a Phase I trial, Talazoparib (BMN-673) treatment in pancreatic cancer patients resulted in four patients with a clinical benefit including a partial response in one patient harboring a BRCA2 mutation (PMID: 28242752). ",Actionable,11197,1793,pancreatic cancer,DOID,1206,BRCA2 mutant,"[{'id': 9147, 'pubMedId': 28242752, 'title': 'Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28242752'}]",sensitive,682,Talazoparib,675
26,Phase I,"In a Phase I clinical trial, the combination of Veliparib (ABT-888) and Paraplatin (carboplatin) demonstrated preliminary efficacy in  metastatic breast cancer patients, with partial response in 25% (4/16) and stable disease in 62.5% (10/16) of patients with BRCA1/2 mutations or Fanconi Anemia pathway defects (J Clin Oncol 32:5s, 2014 (suppl; abstr 1074)).",Actionable,6854,1612,breast cancer,DOID,1206,BRCA2 mutant,"[{'id': 5878, 'pubMedId': None, 'title': 'Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC).', 'url': 'http://meetinglibrary.asco.org/content/132155-144'}]",predicted – sensitive,2704,Veliparib + Carboplatin,675
27,Phase II,"In a Phase II trial, Rubraca (rucaparib) treatment resulted in an objective response rate of 11% (2/19), disease control rate of 32% (6/19) in advanced pancreatic cancer patients with a known deleterious BRCA mutation, of whom 79% harbored a BRCA2 mutation (J Clin Oncol 34, 2016 (suppl; abstr 4110)).",Actionable,6744,1793,pancreatic cancer,DOID,1206,BRCA2 mutant,"[{'id': 5806, 'pubMedId': None, 'title': 'RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation.', 'url': 'http://meetinglibrary.asco.org/content/166810-176'}]",predicted – sensitive,906,Rucaparib,675
28,Phase II,"In a Phase II clinical trial, Veliparib (ABT-888) demonstrated preliminary clinical activity in patients with BRCA2-mutant metastatic castration resistant prostate cancer, with an overall response rate of 66% (2/3) and clinical benefit rate of 100% (3/3) (J Clin Oncol 33, 2015 (suppl 7; abstr 170)).",Actionable,6855,10283,prostate cancer,DOID,1206,BRCA2 mutant,"[{'id': 5880, 'pubMedId': None, 'title': 'Preliminary activity of veliparib (V) in BRCA2-mutated metastatic castration-resistant prostate cancer (mCRPC).', 'url': 'http://meetinglibrary.asco.org/content/141499-159'}]",sensitive,954,Veliparib,675
29,Phase I,"In a Phase I trial, Talazoparib (BMN-673) treatment in ovarian cancer patients harboring germline deleterious BRCA1/2 mutations resulted in an objective response rate of 48%, including one complete response, and a clinical benefit rate of 76% at 24 weeks (PMID: 28242752). ",Actionable,11202,2394,ovarian cancer,DOID,1206,BRCA2 mutant,"[{'id': 9147, 'pubMedId': 28242752, 'title': 'Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28242752'}]",predicted – sensitive,682,Talazoparib,675
30,Phase I,"In a Phase I trial, Talazoparib (BMN673) treatment in breast cancer patients harboring germline deleterious BRCA1/2 mutations resulted in an objective response rate of 50% (7/14) including one patient with a complete response and six patients with a partial response and a median progression free survival of 34.6 weeks (PMID: 28242752). ",Actionable,11200,1612,breast cancer,DOID,1206,BRCA2 mutant,"[{'id': 9147, 'pubMedId': 28242752, 'title': 'Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28242752'}]",predicted – sensitive,682,Talazoparib,675
31,Phase II,"In a Phase II clinical trial, Lynparza (olaparib) demonstrated safety and efficacy in breast cancer patients with BRCA2 mutations (PMID: 20609467).",Actionable,1055,1612,breast cancer,DOID,1206,BRCA2 mutant,"[{'id': 770, 'pubMedId': 20609467, 'title': 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20609467'}]",sensitive,837,Olaparib,675
32,Phase III,"In a Phase III trial, Lynparza (olaparib) treatment resulted in improved progression free survival (7.0 vs 4.2 months) and objective response rate (59.9%, 123/205 vs 28.8%, 26/288) compared to single agent chemotherapy in patients with Erbb2 (Her2)-negative breast cancer that also harbored germline BRCA mutations (J Clin Oncol 35, 2017 (suppl; abstr LBA4)).",Actionable,11132,60080,Her2-receptor negative breast cancer,DOID,27914,BRCA2 mut ERBB2 neg,"[{'id': 9101, 'pubMedId': None, 'title': 'OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).', 'url': 'http://abstracts.asco.org/199/AbstView_199_186720.html'}]",predicted – sensitive,837,Olaparib,675
33,Preclinical,"In a preclinical study, colorectal adenocarcinoma cells with BRCA2 deletion demonstrated increased sensitivity to Ambochlorin (chlorambucil) compared to cells with intact BRCA2 in culture  (PMID: 25193512).",Actionable,3066,50861,colorectal adenocarcinoma,DOID,11671,BRCA2 del,"[{'id': 3461, 'pubMedId': 25193512, 'title': 'Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25193512'}]",sensitive,3035,Chlorambucil,675
34,Preclinical - Cell line xenograft,"In a preclinical study, colorectal adenocarcinoma cells with BRCA2 deletion demonstrated increased sensitivity to Evofosfamide (TH-302) compared to cells with intact BRCA2 in culture and human cell line xenograft models (PMID: 25193512).
",Actionable,3065,50861,colorectal adenocarcinoma,DOID,11671,BRCA2 del,"[{'id': 3461, 'pubMedId': 25193512, 'title': 'Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25193512'}]",sensitive,1317,Evofosfamide,675
35,Preclinical - Cell line xenograft,"In a preclinical study, colorectal adenocarcinoma cells with BRCA2 deletion demonstrated increased sensitivity to PR-104 compared to cells with intact BRCA2 in culture and in cell line xenograft models (PMID: 25193512)",Actionable,3064,50861,colorectal adenocarcinoma,DOID,11671,BRCA2 del,"[{'id': 3461, 'pubMedId': 25193512, 'title': 'Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25193512'}]",sensitive,3029,PR-104,675
36,Preclinical - Cell line xenograft,"In a preclinical study, Platinol (cisplatin) inhibited growth of a human colorectal adenocarcinoma cell line harboring BRCA2 deletion in culture, and inhibited tumor growth in xenograft models (PMID: 25193512).",Actionable,3063,50861,colorectal adenocarcinoma,DOID,11671,BRCA2 del,"[{'id': 3461, 'pubMedId': 25193512, 'title': 'Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25193512'}]",sensitive,700,Cisplatin,675
37,Phase II,"In a Phase II clinical trial, the combination of Veliparib (ABT-888) and Cytoxan (cyclophosphamide) did not demonstrate improved response rate or progression-free survival over Cytoxan (cyclophosphamide) alone in ovarian cancer patients harboring deleterious mutations in BRCA1 or BRCA2 (PMID: 25589624).",Actionable,6849,2394,ovarian cancer,DOID,1283,BRCA2 inact mut,"[{'id': 5876, 'pubMedId': 25589624, 'title': 'Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25589624'}]",no benefit,4283,Veliparib + Cyclophosphamide,675
38,Preclinical - Cell culture,"In a preclinical study, a BRCA2 deficient breast cancer cell line resistant to Lynparza (olaparib) demonstrated sensitivity to treatment with AZD2461 in culture, resulting in reduced cell viability (PMID: 27550455). ",Actionable,8944,1612,breast cancer,DOID,1283,BRCA2 inact mut,"[{'id': 6793, 'pubMedId': 27550455, 'title': 'The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550455'}]",sensitive,2542,AZD2461,675
39,Phase II,"In a Phase II trial, the combination of Veliparib (ABT-888), Paraplatin (carboplatin), and Taxol (paclitaxel) resulted in a higher objective response rate (77.8% vs 61.3%) compared to placebo plus Paraplatin (carboplatin) and Taxol (paclitaxel) in breast cancer patients harboring either BRCA1 or BRCA2 deleterious mutations (SABCS, 2016, Abstract # S2-05).",Actionable,9867,1612,breast cancer,DOID,1283,BRCA2 inact mut,"[{'id': 7723, 'pubMedId': None, 'title': 'Efficacy and tolerability of veliparib (V, ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer- A randomized, phase 2 study', 'url': 'https://www.sabcs.org/Past-Meetings'}]",predicted – sensitive,5274,Carboplatin + Paclitaxel + Veliparib,675
40,Preclinical,"In a preclinical study, E7449 inhibited proliferation of a BRCA2-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair mutations (PMID: 26513298).",Actionable,6506,10000003,Advanced Solid Tumor,JAX,1283,BRCA2 inact mut,"[{'id': 4121, 'pubMedId': 26513298, 'title': 'E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26513298'}]",sensitive,724,E7449,675
41,Phase I,"In a Phase I trial, Talazoparib (BMN673) treatment demonstrated safety and preliminary efficacy in patients with advanced solid tumors harboring deleterious BRCA1/2 mutations, including one patient with prostate cancer (J Clin Oncol 31, 2013 (suppl; abstr 2580)).",Actionable,6860,10283,prostate cancer,DOID,1283,BRCA2 inact mut,"[{'id': 5875, 'pubMedId': None, 'title': 'First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors', 'url': 'http://meetinglibrary.asco.org/content/111725-132'}]",predicted – sensitive,682,Talazoparib,675
42,Phase II,"In a Phase II clinical trial, Lynparza (olaparib) demonstrated safety and efficacy in breast cancer patients with BRCA2 inactivating mutations (PMID: 20609467).
",Actionable,1054,1612,breast cancer,DOID,1283,BRCA2 inact mut,"[{'id': 770, 'pubMedId': 20609467, 'title': 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20609467'}]",sensitive,837,Olaparib,675
43,Phase I,"In a Phase I trial, Talazoparib (BMN673) treatment demonstrated safety and preliminary efficacy in patients with advanced solid tumors harboring deleterious BRCA1/2 mutations (J Clin Oncol 31, 2013 (suppl; abstr 2580)).",Actionable,6847,10000003,Advanced Solid Tumor,JAX,1283,BRCA2 inact mut,"[{'id': 5875, 'pubMedId': None, 'title': 'First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors', 'url': 'http://meetinglibrary.asco.org/content/111725-132'}]",predicted – sensitive,682,Talazoparib,675
44,Preclinical,"In a preclinical study, decreasing Brca2 expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells with low expression of Met to Rubraca (rucaparib) in culture (PMID: 26779812).",Actionable,6149,60081,triple-receptor negative breast cancer,DOID,22728,BRCA2 dec exp MET dec exp,"[{'id': 5319, 'pubMedId': 26779812, 'title': 'Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26779812'}]",sensitive,906,Rucaparib,675
45,Preclinical,"In a preclinical study, decreasing Brca2 expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells with Met over expression to Rubraca (rucaparib) in culture (PMID: 26779812).",Actionable,6151,60081,triple-receptor negative breast cancer,DOID,22730,BRCA2 dec exp MET over exp,"[{'id': 5319, 'pubMedId': 26779812, 'title': 'Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26779812'}]",no benefit,906,Rucaparib,675
46,Preclinical - Cell culture,"In a preclinical study, knockdown of Brca2 with siRNA sensitized breast cancer cell lines to NU1025 in culture (PMID: 15829966).",Actionable,10847,1612,breast cancer,DOID,22727,BRCA2 dec exp,"[{'id': 4603, 'pubMedId': 15829966, 'title': 'Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15829966'}]",sensitive,2946,NU1025,675
0,Clinical Study,"In a clinical study, Roferon-A (Alpha 2 Interferon) treatment resulted in hematologic response in 100% (31/31) and complete molecular response in 6% (2/31) of essential thrombocythemia (ET) patients harboring CALR mutations (PMID: 26486786).",Actionable,6433,4960,bone marrow cancer,DOID,23414,CALR mutant,"[{'id': 5594, 'pubMedId': 26486786, 'title': 'Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26486786'}]",predicted – sensitive,1187,Alpha 2 Interferon,811
1,Clinical Study,"CALR mutations are used in the diagnosis of myeloproliferative neoplasms, especially of essential thrombocythemia and primary myelofibrosis (PMID: 26697989, PMID: 26449662, PMID: 26071474, PMID: 25873496).",Diagnostic,6434,4960,bone marrow cancer,DOID,23414,CALR mutant,"[{'id': 5595, 'pubMedId': 26697989, 'title': 'Myeloproliferative neoplasms: Current molecular biology and genetics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26697989'}, {'id': 5596, 'pubMedId': 26449662, 'title': 'Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26449662'}, {'id': 5597, 'pubMedId': 26071474, 'title': 'The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26071474'}, {'id': 5598, 'pubMedId': 25873496, 'title': 'CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25873496'}]",not applicable,1776,N/A,811
0,Preclinical - Cell line xenograft,"In a preclinical study, addition of Tarceva (erlotinib) overcame Gemzar (gemcitabine)-resistance in pancreatic ductal carcinoma cell lines with reduced Cbl expression via shRNA, resulted in decreased viability in cell culture and reduced tumor growth in cell line xenograft models (PMID: 25348515).",Emerging,6423,3587,pancreatic ductal carcinoma,DOID,23382,CBL dec exp,"[{'id': 5579, 'pubMedId': 25348515, 'title': 'Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25348515'}]",predicted – sensitive,2381,Erlotinib + Gemcitabine,867
1,Clinical Study,"In clinical analyses, mutations in CBL were associated with adverse prognosis in patients with chronic myelomonocytic leukemia (PMID: 26230957, PMID: 23690417, PMID: 19901108). ",Prognostic,3323,4972,myelodysplastic/myeloproliferative neoplasm,DOID,13184,CBL mutant,"[{'id': 3735, 'pubMedId': 26230957, 'title': 'An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26230957'}, {'id': 5343, 'pubMedId': 23690417, 'title': 'Prognostic score including gene mutations in chronic myelomonocytic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23690417'}, {'id': 5344, 'pubMedId': 19901108, 'title': 'Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19901108'}]",not applicable,1776,N/A,867
2,Preclinical,"In a preclinical study, Quizartinib (AC220) reduced white blood cell counts and decreased myeloid cell invasion in a CBL mutant mouse model with myeloproliferative disorder (PMID: 22990016). ",Actionable,3331,4960,bone marrow cancer,DOID,13184,CBL mutant,"[{'id': 3302, 'pubMedId': 22990016, 'title': 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22990016'}]",sensitive,882,Quizartinib,867
3,Preclinical,"In a preclinical study, Fasudil (HA-1077) selectively inhibited proliferation of CBL and CBLB double knockout hematopoietic stem/progenitor cells in mouse model of myeloproliferative disorder (PMID: 26177294).",Actionable,6425,4960,bone marrow cancer,DOID,23386,CBL del CBLB del,"[{'id': 5583, 'pubMedId': 26177294, 'title': 'Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disorders.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26177294'}]",predicted – sensitive,1777,Fasudil,867
0,Preclinical,"In a preclinical study, Fasudil (HA-1077) selectively inhibited proliferation of CBL and CBLB double knockout hematopoietic stem/progenitor cells in mouse model of myeloproliferative disorder (PMID: 26177294).",Actionable,6425,4960,bone marrow cancer,DOID,23386,CBL del CBLB del,"[{'id': 5583, 'pubMedId': 26177294, 'title': 'Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disorders.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26177294'}]",predicted – sensitive,1777,Fasudil,868
1,Preclinical,"In a preclinical study, gastric cancer cell lines with decreased Cblb expression level via shRNA knockdown demonstrated reduced sensitivity to Adrucil (fluorouracil) in cell culture (PMID: 24351824).",Actionable,6427,10534,stomach cancer,DOID,23411,CBLB dec exp,"[{'id': 5588, 'pubMedId': 24351824, 'title': 'Cbl-b enhances sensitivity to 5-fluorouracil via EGFR- and mitochondria-mediated pathways in gastric cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24351824'}]",decreased response,1715,Fluorouracil,868
0,Preclinical,"In a preclinical study, decreased Cblc expression through siRNA knockdown enhanced sensitivity to Lynparza (olaparib) in cultured osterosarcoma cell lines (PMID: 25883215).",Actionable,6429,3347,osteosarcoma,DOID,23413,CBLC dec exp,"[{'id': 5591, 'pubMedId': 25883215, 'title': 'Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25883215'}]",predicted – sensitive,837,Olaparib,23624
1,Preclinical,"In a preclinical study, decreased Cblc expression through siRNA knockdown enhanced sensitivity to Lynparza (olaparib) in cultured breast cancer cell lines (PMID: 25883215).",Actionable,6430,1612,breast cancer,DOID,23413,CBLC dec exp,"[{'id': 5591, 'pubMedId': 25883215, 'title': 'Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25883215'}]",predicted – sensitive,837,Olaparib,23624
2,Clinical Study,"In a clinical study, over expression of Cblc was identified as a promising diagnostic biomarker for non-small cell lung cancer (PMID: 17671213).",Emerging,6428,3908,non-small cell lung carcinoma,DOID,23412,CBLC over exp,"[{'id': 5590, 'pubMedId': 17671213, 'title': 'Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17671213'}]",not applicable,1776,N/A,23624
0,Clinical Study,"Pathogenic germline CDH1 mutations are used in the diagnosis of hereditary diffuse gastric cancer (PMID: 26380059, PMID: 26182300).",Diagnostic,3819,10534,stomach cancer,DOID,16466,CDH1 mutant,"[{'id': 4197, 'pubMedId': 26182300, 'title': 'Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26182300'}, {'id': 5723, 'pubMedId': 26380059, 'title': 'Hereditary diffuse gastric cancer: What the clinician should know.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26380059'}]",not applicable,1776,N/A,999
1,Clinical Study,"In a clinical case study, treatment with the combination of  Tykerb (lapatinib) and Xeloda (capecitabine) resulted in prolonged response and reduction in liver metastasis in a metastatic breast cancer patient harboring ERBB2 L869Q and CDH1 R63* mutations (PMID: 26487584).",Actionable,5027,1612,breast cancer,DOID,20031,CDH1 R63* ERBB2 L869Q,"[{'id': 4844, 'pubMedId': 26487584, 'title': 'A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26487584'}]",sensitive,1399,Lapatinib + Capecitabine,999
2,Phase II,"In a Phase II clinical trial, patients with pancreatic ductal adenocarcinoma tumors expressing high levels of Cdh1 were more likely to respond to a combination therapy of Tarceva (erlotinib) and Selumetinib (AZD6244) (PMID: 26251290).",Actionable,3820,3498,pancreatic ductal adenocarcinoma,DOID,16477,CDH1 over exp,"[{'id': 4200, 'pubMedId': 26251290, 'title': 'A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26251290'}]",sensitive,3361,Erlotinib + Selumetinib,999
3,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells over expressing CDH1 were resistant to BI2536 in culture (PMID: 26597303). ",Actionable,6134,3908,non-small cell lung carcinoma,DOID,16477,CDH1 over exp,"[{'id': 5317, 'pubMedId': 26597303, 'title': 'Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26597303'}]",resistant,676,BI2536,999
4,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells over expressing CDH1 were resistant to volasertib in culture (PMID: 26597303). ",Actionable,6135,3908,non-small cell lung carcinoma,DOID,16477,CDH1 over exp,"[{'id': 5317, 'pubMedId': 26597303, 'title': 'Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26597303'}]",resistant,957,Volasertib,999
0,Phase II,"In a Phase II trial, treatment with Ibrance (palbociclib) resulted in and stable disease in 50% (8/16) of non-small cell lung cancer patients with CDKN2A loss (J Clin Oncol 32:5s, 2014 (suppl; abstr 8077)).",Actionable,2935,3908,non-small cell lung carcinoma,DOID,1806,CDKN2A loss,"[{'id': 3540, 'pubMedId': None, 'title': 'A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A.', 'url': 'http://meetinglibrary.asco.org/content/135087-144'}]",sensitive,850,Palbociclib,1029
1,Preclinical,"In a preclinical study, melanoma cell lines with CDKN2A loss demonstrated a greater sensitivity to Alvocidib (flavopiridol) as compared to melanoma cell lines positive for CDKN2A (PMID: 12777976).",Actionable,2268,1909,melanoma,DOID,1806,CDKN2A loss,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",sensitive,628,Alvocidib,1029
2,Preclinical - Cell culture,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of multiple cancer cell lines harboring CDKN2A loss and in Cdkn2a-depleted transformed cells in culture (PMID: 26140595).",Actionable,10252,10000003,Advanced Solid Tumor,JAX,1806,CDKN2A loss,"[{'id': 8232, 'pubMedId': 26140595, 'title': 'A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26140595'}]",predicted – sensitive,5443,PF3644022 + PF-477736,1029
3,Preclinical,"In a preclinical study, an orthotopic mouse model treated with ZK 304709 demonstrated an 80% tumor growth reduction in neuroendocrine tumor cells with CDKN2A loss (PMID: 18829975). ",Actionable,2270,169,neuroendocrine tumor,DOID,1806,CDKN2A loss,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",sensitive,2735,ZK304709,1029
4,Preclinical - Cell culture,"In a preclinical study, Abemaciclib (LY2835219) inhibited growth of chordoma cell lines with CDKN2A loss and loss of p16 protein expression in culture (PMID: 26183925).",Actionable,7585,3302,chordoma,DOID,1806,CDKN2A loss,"[{'id': 4578, 'pubMedId': 26183925, 'title': 'Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26183925'}]",sensitive,802,Abemaciclib,1029
5,Preclinical,"In a preclinical study, Ibrance (palbociclib) antagonized the efficacy of GSK461364 in pancreatic cancer cells with CDKN2A loss in culture (PMID: 25156567).",Actionable,1062,1793,pancreatic cancer,DOID,1806,CDKN2A loss,"[{'id': 780, 'pubMedId': 25156567, 'title': 'CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25156567'}]",decreased response,1511,GSK461364 + PD0332991,1029
6,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line with CDKN2A loss demonstrated sensitivity to Mekinist (trametinib) in culture, resulting in inhibition of cell growth (PMID: 27488531). ",Actionable,8540,1909,melanoma,DOID,1806,CDKN2A loss,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",sensitive,2,Trametinib,1029
7,Preclinical - Cell line xenograft,"In a preclinical study, Milciclib (PHA-848125AC) resulted in tumor regression in glioma cell line xenograft models with CDKN2A loss (PMID: 23347136).",Actionable,2269,3073,brain glioblastoma multiforme,DOID,1806,CDKN2A loss,"[{'id': 2840, 'pubMedId': 23347136, 'title': 'Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23347136'}]",sensitive,2654,PHA-848125AC,1029
8,Preclinical,"In a preclinical study, Ibrance (palbociclib) antagonized the efficacy of ON-01910 in pancreatic cancer cell lines with CDKN2A loss in culture (PMID: 25156567).",Actionable,1063,1793,pancreatic cancer,DOID,1806,CDKN2A loss,"[{'id': 780, 'pubMedId': 25156567, 'title': 'CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25156567'}]",decreased response,1512,ON-01910 + PD0332991,1029
9,Preclinical,"In a preclinical study, renal cell carcinoma cell lines with CDKN2A loss were sensitive to Palbociclib (PD-0332991) (PMID: 23898052). ",Actionable,2267,4450,renal cell carcinoma,DOID,1806,CDKN2A loss,"[{'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",sensitive,850,Palbociclib,1029
10,Preclinical - Cell culture,"In a preclinical study, Ibrance (palbociclib) inhibited expression of phosphorylated Rb and growth of chordoma cell lines with CDKN2A loss and loss of p16 protein expression in culture (PMID: 26183925).",Actionable,7583,3302,chordoma,DOID,1806,CDKN2A loss,"[{'id': 4578, 'pubMedId': 26183925, 'title': 'Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26183925'}]",sensitive,850,Palbociclib,1029
11,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line deficient for CDKN2A demonstrated resistance to treatment with Ibrance (palbociclib) in culture (PMID: 27488531). ",Actionable,8537,1909,melanoma,DOID,1806,CDKN2A loss,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",resistant,850,Palbociclib,1029
12,Preclinical,"In a preclinical study, Ibrance (palbociclib) antagonized the efficacy of Gemzar (gemcitabine) in pancreatic cancer cells with CDKN2A loss in culture (PMID: 25156567).",Actionable,1061,1793,pancreatic cancer,DOID,1806,CDKN2A loss,"[{'id': 780, 'pubMedId': 25156567, 'title': 'CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25156567'}]",decreased response,1510,PD0332991 + Gemcitabine,1029
13,Preclinical,"In a preclinical study, Ibrance (palbociclib) antagonized the activity of HMN-214 in pancreatic cancer cell lines with CDKN2A loss in culture (PMID: 25156567).",Actionable,1064,1793,pancreatic cancer,DOID,1806,CDKN2A loss,"[{'id': 780, 'pubMedId': 25156567, 'title': 'CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25156567'}]",decreased response,1514,HMN-214 + PD0332991,1029
14,Phase I,"In a Phase I trial, a squamous non-small cell lung carcinoma patient with KRAS wild-type and loss of CDKN2A demonstrated a partial response when treated with Abemaciclib (LY2835219) (PMID: 27217383). ",Actionable,7431,3908,non-small cell lung carcinoma,DOID,25455,CDKN2A loss KRAS wild-type,"[{'id': 6356, 'pubMedId': 27217383, 'title': 'Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27217383'}]",sensitive,802,Abemaciclib,1029
15,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Ibrance (palbociclib) and Mekinist (trametinib) induced tumor regression in a mouse melanoma model expressing NRAS Q61K and harboring CDKN2A loss (PMID: 22983396).",Actionable,2923,1909,melanoma,DOID,10733,NRAS Q61K CDKN2A loss,"[{'id': 3528, 'pubMedId': 22983396, 'title': 'Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22983396'}]",sensitive,1368,Palbociclib + Trametinib,1029
16,Preclinical,"In a preclinical study, SBI-0640726 delayed tumor growth of melanomas in mice with a genetic background of NRAS Q61K and CDKN2A loss (PMID: 26603897).",Actionable,3791,1909,melanoma,DOID,10733,NRAS Q61K CDKN2A loss,"[{'id': 4137, 'pubMedId': 26603897, 'title': 'SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26603897'}]",sensitive,3306,SBI-0640756,1029
17,Phase I,"In a Phase I trial, Abemaciclib (LY2835219) resulted in a partial response in a melanoma patient with CDKN2A loss and NRAS mutation (PMID: 27217383).",Actionable,2266,1909,melanoma,DOID,6894,CDKN2A loss NRAS mutant,"[{'id': 2947, 'pubMedId': None, 'title': 'A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer', 'url': 'http://meetinglibrary.asco.org/content/111069-132'}, {'id': 6356, 'pubMedId': 27217383, 'title': 'Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27217383'}]",sensitive,802,Abemaciclib,1029
18,Preclinical,"In a preclinical study, CDKN2A (p16) over expression was associated with decreased sensitivity to Ibrance (palbociclib) in a SMARCB1-negative malignant rhabdoid tumor cell line in culture (PMID: 21871868).",Actionable,5767,3672,rhabdoid cancer,DOID,21572,CDKN2A over exp SMARCB1 negative,"[{'id': 5148, 'pubMedId': 21871868, 'title': 'Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21871868'}]",decreased response,850,Palbociclib,1029
19,Preclinical - Pdx & cell culture,"In a preclinical study, Ibrance (palbociclib) inhibited proliferation of patient-derived glioblastoma cells harboring homozygous deletion of CDKN2A in culture and prolonged survival in patient-derived xenograft models (PMID: 22711607).",Actionable,9368,3068,glioblastoma multiforme,DOID,6542,CDKN2A del,"[{'id': 3561, 'pubMedId': 22711607, 'title': 'p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22711607'}]",sensitive,850,Palbociclib,1029
20,Preclinical - Cell line xenograft,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of CDKN2A-deleted lung cancer (PMID: 26140595).",Actionable,10260,1324,lung cancer,DOID,6542,CDKN2A del,"[{'id': 8232, 'pubMedId': 26140595, 'title': 'A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26140595'}]",predicted – sensitive,5443,PF3644022 + PF-477736,1029
21,Clinical Study,"In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",Actionable,11544,3498,pancreatic ductal adenocarcinoma,DOID,28131,EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*,"[{'id': 9613, 'pubMedId': 28476735, 'title': 'Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28476735'}]",predicted – sensitive,698,Alectinib,1029
22,Clinical Study,"In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",Actionable,11543,3498,pancreatic ductal adenocarcinoma,DOID,28131,EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*,"[{'id': 9613, 'pubMedId': 28476735, 'title': 'Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28476735'}]",resistant,706,Crizotinib,1029
23,Preclinical - Patient cell culture,"In a preclinical study, patient-derived glioblastoma cells harboring RB1 truncation mutation and expressing Cdkn2a were resistant to Ibrance (palbociclib) in culture (PMID: 22711607).",Actionable,9364,3068,glioblastoma multiforme,DOID,26833,CDKN2A pos RB1 inact mut,"[{'id': 3561, 'pubMedId': 22711607, 'title': 'p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22711607'}]",resistant,850,Palbociclib,1029
24,Preclinical - Cell line xenograft,"In a preclinical study, a gastric carcinoma cell line harboring CDKN2A R80* was sensitive to Ibrance (palbociclib) both in culture and in cell line xenograft models (PMID: 26380006, PMID: 20952405).",Actionable,3558,5517,stomach carcinoma,DOID,7936,CDKN2A R80*,"[{'id': 3810, 'pubMedId': 26380006, 'title': 'CDK4/6 inhibitor suppresses gastric cancer with CDKN2A mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26380006'}, {'id': 3811, 'pubMedId': 20952405, 'title': 'COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20952405'}]",sensitive,850,Palbociclib,1029
25,Clinical Study,"In a clinical study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312).",Actionable,11053,1909,melanoma,DOID,27904,CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H,"[{'id': 9046, 'pubMedId': 28514312, 'title': 'Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28514312'}]",sensitive,5833,Imatinib + Carboplatin + Paclitaxel,1029
26,Preclinical,"In a preclinical study, a breast cancer cell line harboring mutations in PIK3CA and CDKN2A demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369). ",Actionable,2105,1612,breast cancer,DOID,5388,PIK3CA mutant CDKN2A mutant,"[{'id': 2380, 'pubMedId': 25261369, 'title': 'Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25261369'}]",sensitive,1282,Sapanisertib,1029
27,Preclinical,"In a preclinical study, human triple negative breast cancer cells harboring mutant BRAF, KRAS, and CDKN2A were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6690,60081,triple-receptor negative breast cancer,DOID,23670,BRAF mut KRAS mut CDKN2A mut,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,2,Trametinib,1029
28,Preclinical,"In a preclinical study, human acute lymphoblastic leukemia cells harboring NRAS and CDKN2A mutations were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6683,9952,acute lymphocytic leukemia,DOID,23669,NRAS mut CDKN2A mut,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,2,Trametinib,1029
0,Clinical Study,"In clinical analyses, mutations in GATA2 were associated with better overall survival in patients with cytogenetically normal acute myeloid leukemia (CN-AML) harboring biallelic CEBPA gene mutations (PMID: 22814295, PMID: 23521373, PMID: 25241285).",Prognostic,3612,9119,acute myeloid leukemia,DOID,22783,CEBPA mutant GATA2 mutant,"[{'id': 3883, 'pubMedId': 22814295, 'title': 'GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22814295'}, {'id': 5352, 'pubMedId': 23521373, 'title': 'CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23521373'}, {'id': 5353, 'pubMedId': 25241285, 'title': 'GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25241285'}]",not applicable,1776,N/A,1050
1,Clinical Study,"In clinical analyses, biallelic CEBPA mutations were associated with favorable clinical outcome in patients with cytogenetically normal acute myeloid leukemia (PMID: 26601784, PMID: 19171880, PMID: 20038735, PMID: 22915647).",Prognostic,6167,9119,acute myeloid leukemia,DOID,13812,CEBPA mutant,"[{'id': 5328, 'pubMedId': 26601784, 'title': 'The multifaceted functions of C/EBPα in normal and malignant haematopoiesis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26601784'}, {'id': 5336, 'pubMedId': 19171880, 'title': 'Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19171880'}, {'id': 5337, 'pubMedId': 20038735, 'title': 'Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20038735'}]",not applicable,1776,N/A,1050
0,Preclinical,"In a preclinical study, CSFR1 Y571D conferred sensitivity to Gleevec (imatinib) in myeloid cell lines in culture (PMID: 18971950).",Actionable,683,8692,myeloid leukemia,DOID,952,CSF1R Y571D,"[{'id': 397, 'pubMedId': 18971950, 'title': 'Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18971950'}]",sensitive,770,Imatinib,1436
1,Phase I,"In a Phase I trial, PLX3397 reduced tenosynovial giant cell tumor volume in patients with overexpression of Csf1r (PMID: 26222558).",Actionable,2791,314,tenosynovial giant cell tumor,DOID,10685,CSF1R over exp,"[{'id': 3480, 'pubMedId': 26222558, 'title': 'Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26222558'}]",sensitive,874,PLX3397,1436
2,Preclinical,"In a preclinical study, a melanoma mouse model harboring BRAF V600E treated with Zelboraf (vemurafenib) demonstrated a greater drug induced sensitivity when treatment was combined with PLX3397, resulting in increased infiltration of lymphocytes via Csf1r inhibition and elevated antitumor activity (PMID: 25939769).",Actionable,6075,1909,melanoma,DOID,22385,BRAF V600E CSF1R positive,"[{'id': 5274, 'pubMedId': 25939769, 'title': 'Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25939769'}]",sensitive,1339,PLX3397 + Vemurafenib,1436
3,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited CSF1R phosphorylation and induced apoptosis in Hodgkin's lymphoma cells in culture (PMID: 21517818)",Actionable,2453,8567,Hodgkin's lymphoma,DOID,7709,CSF1R positive,"[{'id': 3071, 'pubMedId': 21517818, 'title': 'BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21517818'}]",sensitive,920,Sorafenib,1436
4,Clinical Study,"In multiple clinical studies, elevated levels of CSF1R expression were associated with a worse survival in patients with Hodgkin's lymphoma (PMID: 24619759, PMID: 26066800, PMID: 22955918). ",Prognostic,6066,8567,Hodgkin's lymphoma,DOID,7709,CSF1R positive,"[{'id': 5269, 'pubMedId': 24619759, 'title': 'CSF-1R expression in tumor-associated macrophages is associated with worse prognosis in classical Hodgkin lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24619759'}, {'id': 5270, 'pubMedId': 26066800, 'title': 'CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26066800'}, {'id': 5271, 'pubMedId': 22955918, 'title': 'Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22955918'}]",not applicable,1776,N/A,1436
0,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) reduces colony formation of cells expressing CSF3R T640N in culture (PMID: 26475333).",Actionable,4653,10000003,Advanced Solid Tumor,JAX,18726,CSF3R T640N,"[{'id': 4663, 'pubMedId': 26475333, 'title': 'The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26475333'}]",sensitive,907,Ruxolitinib,1441
1,Clinical Study,"In clinical studies, high frequency of CSF3R mutations was identified in patients with chronic neutrophilic leukemia (PMID: 23656643, PMID: 24081659), suggesting that this may serve as a future diagnostic biomarker (PMID: 24441292).",Emerging,6483,4960,bone marrow cancer,DOID,23595,CSF3R mutant,"[{'id': 3951, 'pubMedId': 23656643, 'title': 'Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23656643'}, {'id': 5647, 'pubMedId': 24081659, 'title': 'The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24081659'}, {'id': 5648, 'pubMedId': 24441292, 'title': 'An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24441292'}]",not applicable,1776,N/A,1441
2,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) reduces colony formation of cells expressing CSF3R T618I in culture (PMID: 26475333).",Actionable,4654,10000003,Advanced Solid Tumor,JAX,14885,CSF3R T618I,"[{'id': 4663, 'pubMedId': 26475333, 'title': 'The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26475333'}]",sensitive,907,Ruxolitinib,1441
0,Clinical Study,"In a retrospective analysis, patients with desmoid fibromatosis harboring CTNNB1 T41A demonstrated a greater progression arrest rate at 6 months (70%) compared to patients with CTNNB1 wild-type (45%) when treated with Gleevec (imatinib) (PMID: 26861905). ",Actionable,4869,1115,sarcoma,DOID,3980,CTNNB1 T41A,"[{'id': 4761, 'pubMedId': 26861905, 'title': 'Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26861905'}]",sensitive,770,Imatinib,1499
1,Clinical Study,"In a retrospective analysis, patients with desmoid fibromatosis harboring CTNNB1 activating mutations demonstrated a greater progression arrest rate at 6 months compared to patients with CTNNB1 wild-type when treated with Gleevec (imatinib) (PMID: 26861905).",Actionable,4868,1115,sarcoma,DOID,3638,CTNNB1 act mut,"[{'id': 4761, 'pubMedId': 26861905, 'title': 'Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26861905'}]",sensitive,770,Imatinib,1499
2,Preclinical - Pdx,"In a preclinical study, the combination of NVP-TNKS656 and Triciribine (API-2) inhibited tumor growth in Triciribine (API-2)-resistant patient-derived xenograft (PDX) models of colon cancer with high nuclear CTNNB1 (Beta-catenin) levels (PMID: 26224873).",Actionable,10333,219,colon cancer,DOID,26160,CTNNB1 over exp,"[{'id': 8313, 'pubMedId': 26224873, 'title': 'Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26224873'}]",predicted – sensitive,5469,NVP-TNKS656 + Triciribine,1499
3,Preclinical,"In a preclinical study, human liver cancer cells harboring mutant NRAS and mutant CTNNB1 were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6696,3571,liver cancer,DOID,23671,CTNNB1 mut NRAS mut,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,2,Trametinib,1499
4,Preclinical,"In a preclinical study, BC21 inhibited growth and viability of a colorectal cancer cell line with a CTNNB1 mutation and increased beta-catenin expression in culture (PMID: 22224445).",Actionable,3148,9256,colorectal cancer,DOID,11801,CTNNB1 mutant,"[{'id': 2222, 'pubMedId': 22224445, 'title': 'Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22224445'}]",sensitive,2410,BC21,1499
5,Phase II,"In a retrospective study of a Phase II trial, Torisel (temsirolimus) treatment resulted in an increased progression-free survival (HR 0.46) but not response rate (response difference 0.00) in advanced endometrial cancer patients harboring CTNNB1 mutations (PMID: 27016228).",Actionable,6402,1380,endometrial cancer,DOID,11801,CTNNB1 mutant,"[{'id': 5557, 'pubMedId': 27016228, 'title': 'Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27016228'}]",predicted – sensitive,936,Temsirolimus,1499
6,Preclinical,"In a preclinical study, PMED-1 decreased Wnt expression and decreased proliferation of hepatocellular carcinoma cells with Ctnnb1 mutations (PMID: 2481996).",Actionable,3826,684,hepatocellular carcinoma,DOID,11801,CTNNB1 mutant,"[{'id': 4232, 'pubMedId': 24819961, 'title': 'Identification and characterization of a novel small-molecule inhibitor of β-catenin signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24819961'}]",sensitive,3370,PMED-1,1499
7,Phase I,"In a Phase I trial, CWP232291 reduced beta-catenin expression and demonstrated safety and preliminary efficacy in acute myeloid leukemia (J Clin Oncol (Meeting Abstracts) 2015 33: 7044)).",Actionable,3168,9119,acute myeloid leukemia,DOID,4007,CTNNB1 amp,"[{'id': 3657, 'pubMedId': None, 'title': 'Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).', 'url': 'http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7044'}]",predicted – sensitive,3081,CWP232291,1499
8,Preclinical - Pdx,"In a preclinical study, Vantictumab (OMP-18R5) inhibited tumor growth in patient-derived xenograft models of colon cancer with wild-type CTNNB1 (beta-catenin) and APC (PMID: 22753465).",Actionable,7164,219,colon cancer,DOID,24535,APC wild-type CTNNB1 wild-type,"[{'id': 6127, 'pubMedId': 22753465, 'title': 'Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22753465'}]",predicted – sensitive,4397,Vantictumab,1499
9,Clinical Study,"In a retrospective analysis, patients with desmoid fibromatosis harboring CTNNB1 S45F demonstrated a greater progression arrest rate at 6 months (85%) compared to patients with CTNNB1 wild-type (45%) when treated with Gleevec (imatinib) (PMID: 26861905). ",Actionable,4867,1115,sarcoma,DOID,4008,CTNNB1 S45F,"[{'id': 4761, 'pubMedId': 26861905, 'title': 'Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26861905'}]",sensitive,770,Imatinib,1499
0,Clinical Study,"In a clinical study, acute myeloid leukemia patients harboring DNMT3A mutations demonstrated a greater complete response rate (60% vs 33%) compared to acute myeloid leukemia patients with wild-type DNMT3A when treated with hypomethylating agents such as Dacogen (decitabine) (PMID: 27418649).
",Actionable,7518,9119,acute myeloid leukemia,DOID,3485,DNMT3A mut,"[{'id': 6396, 'pubMedId': 27418649, 'title': 'Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27418649'}]",predicted – sensitive,650,Decitabine,1788
1,Clinical Study,"In clinical analyses, mutations in DNMT3A were associated with poor prognosis and shorter overall survival in patients with acute myeloid leukemia (PMID: 22490330, PMID: 21881046, PMID: 21670448).",Prognostic,3571,9119,acute myeloid leukemia,DOID,3485,DNMT3A mut,"[{'id': 5345, 'pubMedId': 22490330, 'title': 'Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22490330'}, {'id': 5346, 'pubMedId': 21881046, 'title': 'Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21881046'}, {'id': 5347, 'pubMedId': 21670448, 'title': 'Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21670448'}]",not applicable,1776,N/A,1788
2,Clinical Study,"In a retrospective analysis, of patients with acute myeloid leukemia, the combination of DNMT3A, FLT3, and NPM1 mutations was highly associated with decreased event free survival and overall survival, suggesting that this combination profile may serve as a future prognostic biomarker (PMID: 25281355).  ",Emerging,3573,9119,acute myeloid leukemia,DOID,13674,DNMT3A R882H FLT3 Y599_D600insSTDNEYFYVDFREYEY NPM1 W288fs,"[{'id': 3849, 'pubMedId': 25281355, 'title': 'Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25281355'}]",not applicable,1776,N/A,1788
0,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing an EGFR D770delinsGY/EGFR C797S double mutation demonstrated resistance to dacomitinib in culture (PMID: 28363995).",Actionable,10510,10000003,Advanced Solid Tumor,JAX,27534,EGFR D770delinsGY EGFR C797S,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",resistant,714,Dacomitinib,1956
1,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing an EGFR D770delinsGY/EGFR C797S double mutation demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995).",Actionable,10511,10000003,Advanced Solid Tumor,JAX,27534,EGFR D770delinsGY EGFR C797S,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",sensitive,623,Afatinib,1956
2,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR D770delinsGY demonstrated resistance to Nerlynx (neratinib) in culture (PMID: 28363995).",Actionable,12175,10000003,Advanced Solid Tumor,JAX,27528,EGFR D770delinsGY,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",resistant,828,Neratinib,1956
3,Preclinical - Cell culture,"In a preclinical study, dacomitinib inhibited EGFR phosphorylation and growth of transformed cells expressing EGFR D770delinsGY in culture (PMID: 28363995).",Actionable,10498,10000003,Advanced Solid Tumor,JAX,27528,EGFR D770delinsGY,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",sensitive,714,Dacomitinib,1956
4,Preclinical - Cell culture,"In a preclinical study, acquisition of EGFR T790M was associated with resistance to dacomitinib in transformed cells expressing EGFR D770delinsGY (PMID: 28363995).",Actionable,10509,10000003,Advanced Solid Tumor,JAX,27533,EGFR D770delinsGY EGFR T790M,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",resistant,714,Dacomitinib,1956
5,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing an EGFR D770delinsGY/EGFR T790M double mutation demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995).",Actionable,10512,10000003,Advanced Solid Tumor,JAX,27533,EGFR D770delinsGY EGFR T790M,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",sensitive,623,Afatinib,1956
6,Preclinical - Cell culture,"In a preclinical study, the addition of Mekinist (trametinib) to WZ4002 treatment did not significantly impact cell viability compared to WZ4002 alone, but delayed onset of drug resistance in a non-small cell lung cancer cell line harboring EGFR A750P and EGFR L747_E749del in culture (PMID: 26036643).",Actionable,9056,3908,non-small cell lung carcinoma,DOID,26702,EGFR A750P EGFR L747_E749del,"[{'id': 6890, 'pubMedId': 26036643, 'title': 'Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26036643'}]",sensitive,3351,WZ4002 + Trametinib,1956
7,Clinical Study,"In an analysis of published clinical data, 14/18 (78%) non-small cell lung cancer patients harboring an EGFR G719X (X=A, C, or S) mutation were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, Iressa (gefitinib) (PMID: 23344264).",Actionable,768,3908,non-small cell lung carcinoma,DOID,649,EGFR G719S,"[{'id': 1, 'pubMedId': 23344264, 'title': 'DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23344264'}]",sensitive,751,Gefitinib,1956
8,Preclinical,"In preclinical in vitro assays, EGFR G719S was demonstrated to stabilize the active conformation of Egfr and sensitize the protein to Iressa (gefitinib) (PMID: 17349580). ",Actionable,767,3908,non-small cell lung carcinoma,DOID,649,EGFR G719S,"[{'id': 438, 'pubMedId': 17349580, 'title': 'Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17349580'}]",sensitive,751,Gefitinib,1956
9,Preclinical,"In preclinical in vitro assays, EGFR G719S was demonstrated to stabilize the active conformation of Egfr and sensitize the protein to Gilotrif (afatinib) (PMID: 17349580). ",Actionable,765,3908,non-small cell lung carcinoma,DOID,649,EGFR G719S,"[{'id': 438, 'pubMedId': 17349580, 'title': 'Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17349580'}]",sensitive,4,Erlotinib,1956
10,Clinical Study,"In an analysis of published clinical data, 14/18 (78%) non-small cell lung cancer patients harboring an EGFR G719X (X=A, C, D, or S) mutation were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Tarceva (erlotinib) (PMID: 23344264).",Actionable,766,3908,non-small cell lung carcinoma,DOID,649,EGFR G719S,"[{'id': 1, 'pubMedId': 23344264, 'title': 'DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23344264'}]",sensitive,4,Erlotinib,1956
11,Phase III,"In Phase III clinical trials, patients with NSCLC tumors harboring an EGFR G719X (X=A, C, or S) mutation responded to EGFR tyrosine kinase inhibitors including dacomitinib (PMID: 24857124).
",Actionable,764,3908,non-small cell lung carcinoma,DOID,649,EGFR G719S,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",sensitive,714,Dacomitinib,1956
12,Phase III,"In Phase III trials, non-small cell lung carcinoma patients harboring EGFR G719X mutations (G719A, C, or S) demonstrated a response rate of 78% (14/18) following treatment with Gilotrif (afatinib) (PMID: 24790411).",Actionable,762,3908,non-small cell lung carcinoma,DOID,649,EGFR G719S,"[{'id': 1, 'pubMedId': 23344264, 'title': 'DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23344264'}, {'id': 2366, 'pubMedId': 24790411, 'title': 'Clinical and comparative utility of afatinib in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24790411'}]",sensitive,623,Afatinib,1956
13,Preclinical,"In preclinical in vitro assays, EGFR G719S was demonstrated to stabilize the active conformation of Egfr and sensitize the protein to Gilotrif (afatinib) (PMID: 17349580). ",Actionable,1862,3908,non-small cell lung carcinoma,DOID,649,EGFR G719S,"[{'id': 438, 'pubMedId': 17349580, 'title': 'Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17349580'}]",sensitive,623,Afatinib,1956
14,Preclinical,"In a preclinical study, a colorectal cancer cell line harboring MAP2K1 mutations Q56P, H119Y, and D351G and an EGFR G719S mutation demonstrated some sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713). ",Actionable,6493,9256,colorectal cancer,DOID,23597,MAP2K1 Q56P MAP2K1 H119Y MAP2K1 D351G EGFR G719S,"[{'id': 5602, 'pubMedId': 26582713, 'title': 'Identification of an ""Exceptional Responder"" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26582713'}]",sensitive,2,Trametinib,1956
15,Clinical Study,"In a clinical study, a patient with non-small cell lung carcinoma harboring EGFR K745_E746insIPVAIK demonstrated a partial response when treated with Gilotrif (afatinib) (PMID: 22190593). ",Actionable,10913,3908,non-small cell lung carcinoma,DOID,27853,EGFR K745_E746insIPVAIK,"[{'id': 439, 'pubMedId': 22190593, 'title': 'EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22190593'}]",sensitive,623,Afatinib,1956
16,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in progressive disease in a non-small cell lung carcinoma patient carrying an EGFR R776H mutation (PMID: 26354527).",Actionable,3327,3908,non-small cell lung carcinoma,DOID,3302,EGFR R776H,"[{'id': 3736, 'pubMedId': 26354527, 'title': 'Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26354527'}]",no benefit,623,Afatinib,1956
17,Phase II,"In a Phase II clinical trial, 74% (34/46) of patients with EGFR exon 19 or 21 mutant lung cancers had partial response (PFS average= 17 months) to first line treatment with dacomitinib (J Clin Oncol 30, 2012 (suppl; abstr 7530)).",Actionable,773,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,"[{'id': 448, 'pubMedId': None, 'title': 'First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers', 'url': 'http://meetinglibrary.asco.org/content/99805-114'}]",sensitive,714,Dacomitinib,1956
18,FDA approved,"In a Phase III trial that supported FDA approval, Tarceva (erlotinib) improved progression-free survival in non-small cell lung cancer patients harboring EGFR exon 19 deletions (HR= 0.27), such as EGFR E746_A750del (PMID: 24868098).",Actionable,344,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 2334, 'pubMedId': 24868098, 'title': 'U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24868098'}]",sensitive,4,Erlotinib,1956
19,FDA approved,"In a comparison of clinical outcomes, NSCLC patients with either EGFR exon 19 deletion or the L858R mutation responded to treatment with Iressa (gefitinib) or Tarceva (erlotinib) with similar effectiveness, with overall response rates > 75% (PMID: 24736073).",Actionable,774,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,"[{'id': 449, 'pubMedId': 24736073, 'title': 'Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24736073'}]",sensitive,751,Gefitinib,1956
20,FDA approved,"In a Phase III trial, Gilotrif (afatinib) increased progression-free survival in non-small cell lung cancer (NSCLC) patients harboring EGFR exon 19 deletions, such as EGFR E746_A750del, which supported FDA approval for use in these patients (PMID: 23816960, FDA.gov). ",Actionable,772,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 2368, 'pubMedId': 23816960, 'title': 'Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23816960'}]",sensitive,623,Afatinib,1956
21,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Ganetespib and Tarceva (erlotinib) demonstrated improved antitumor activity compared to either agent alone in cell line xenograft models of non-small cell lung cancer harboring EGFR E746_A750del (PMID: 25077897).",Actionable,2292,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,"[{'id': 2971, 'pubMedId': 25077897, 'title': 'The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25077897'}]",sensitive,2802,Erlotinib + Ganetespib,1956
22,Clinical Study,"In a retrospective analysis, 5 patients with lung adenocarcinoma harboring EGFR E746_A750del were found to respond to Iressa (gefitinib) therapy, with 4 achieving partial response and 1 stable disease (PMID: 18981003).",Actionable,3046,3910,lung adenocarcinoma,DOID,624,EGFR E746_A750del,"[{'id': 3591, 'pubMedId': 18981003, 'title': 'Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18981003'}]",sensitive,751,Gefitinib,1956
23,Preclinical - Cell line xenograft,"In a preclinical study, BGB-283 inhibited Egfr phosphorylation and cell proliferation in lung carcinoma cells harboring EGFR E746_A750del in culture, and resulted in tumor regression in cell line xenograft models (PMID: 26208524).",Actionable,8059,3905,lung carcinoma,DOID,624,EGFR E746_A750del,"[{'id': 5280, 'pubMedId': 26208524, 'title': 'BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26208524'}]",sensitive,4025,BGB-283,1956
24,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells harboring EGFR E746_A750del demonstrated resistance to growth inhibition by Tykerb (lapatinib) in cell culture (PMID: 18199554).
",Actionable,3059,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,"[{'id': 3592, 'pubMedId': 18199554, 'title': 'Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18199554'}]",resistant,787,Lapatinib,1956
25,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring  EGFR E746_A750del in culture (PMID: 21325073, PMID: 16731747).",Actionable,3135,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3642, 'pubMedId': 16731747, 'title': 'Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16731747'}]",sensitive,1040,PF-05212384,1956
26,Preclinical - Cell line xenograft,"In a preclinical study, the combination of WZ4002 and Mekinist (trametinib) inhibited tumor growth, and resulted in reduced tumor rebound compared to WZ4002 alone in non-small cell lung cancer cell line xenograft models harboring EGFR E746_A750del (PMID: 26036643).",Actionable,9055,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,"[{'id': 6890, 'pubMedId': 26036643, 'title': 'Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26036643'}]",sensitive,3351,WZ4002 + Trametinib,1956
27,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EGFR E746_A750del in culture (PMID: 27780853).",Actionable,9253,10000003,Advanced Solid Tumor,JAX,624,EGFR E746_A750del,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,1956
28,Preclinical - Cell line xenograft,"In a preclinical study, the combination of ER2 and Platinol (cisplatin) demonstrated synergy in inhibiting tumor growth in a non-small cell lung cancer cell line xenograft model harboring EGFR E746_A750del (PMID: 27040853).",Actionable,8041,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,"[{'id': 5133, 'pubMedId': 27040853, 'title': 'ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27040853'}]",sensitive,4625,ER2 + Cisplatin,1956
29,Preclinical - Cell line xenograft,"In a preclinical study, lung adenocarcinoma cells harboring EGFR E746_A750del demonstrated sensitivity to treatment with AC0010MA, which resulted in inhibition of both cell growth and Egfr phosphorylation in culture, and tumor regression in xenograft models (PMID: 27573423). ",Actionable,9114,3910,lung adenocarcinoma,DOID,624,EGFR E746_A750del,"[{'id': 6924, 'pubMedId': 27573423, 'title': 'AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27573423'}]",sensitive,2909,AC0010MA,1956
30,Preclinical - Cell line xenograft,"In a preclinical study, treatment with ER2 resulted in decreased proliferation and increased apoptosis of non-small cell lung cancer (NSCLC) cells harboring EGFR E746_A750del in culture, and delayed tumor growth in NSCLC cell line xenograft models with EGFR E746_A750del (PMID: 27040853).",Actionable,5647,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,"[{'id': 5133, 'pubMedId': 27040853, 'title': 'ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27040853'}]",sensitive,3916,ER2,1956
31,Clinical Study,"In a retrospective analysis, 4 patients with lung adenocarcinoma harboring EGFR E746_A750del that had developed Iressa (gefitinib) resistance were found to have acquired EGFR T790M mutations (PMID: 18981003). ",Actionable,3048,3910,lung adenocarcinoma,DOID,11380,EGFR E746_A750del EGFR T790M,"[{'id': 3591, 'pubMedId': 18981003, 'title': 'Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18981003'}]",resistant,751,Gefitinib,1956
32,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EGFR E746_A750del and T790M in culture (PMID: 27780853).",Actionable,9254,10000003,Advanced Solid Tumor,JAX,11380,EGFR E746_A750del EGFR T790M,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,1956
33,Preclinical - Cell line xenograft,"In a preclinical study, treatment with the combination of WZ4002 and Mekinist (trametinib)  inhibited tumor growth, and resulted in increased ERK inhibition and reduced tumor rebound compared to WZ4002 alone in non-small cell lung cancer cell line xenograft models harboring both EGFR E746_A750del and EGFR T790M (PMID: 26036643).",Actionable,9054,3908,non-small cell lung carcinoma,DOID,11380,EGFR E746_A750del EGFR T790M,"[{'id': 6890, 'pubMedId': 26036643, 'title': 'Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26036643'}]",sensitive,3351,WZ4002 + Trametinib,1956
34,Clinical Study,"In a retrospective analysis, 3 of 4 patients with lung adenocarcinoma harboring EGFR E746_A750del and EGFR T790M were found to rapidly progress on Tarceva (erlotinib) therapy (PMID: 18981003). ",Actionable,3047,3910,lung adenocarcinoma,DOID,11380,EGFR E746_A750del EGFR T790M,"[{'id': 3591, 'pubMedId': 18981003, 'title': 'Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18981003'}]",resistant,4,Erlotinib,1956
35,Preclinical,"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR L718Q double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).
",Actionable,3076,10000003,Advanced Solid Tumor,JAX,11692,EGFR E746_A750del EGFR L718Q,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,1003,CO1686,1956
36,Preclinical,"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L718Q double mutation in culture (PMID: 25948633).",Actionable,3086,10000003,Advanced Solid Tumor,JAX,11692,EGFR E746_A750del EGFR L718Q,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,660,Osimertinib,1956
37,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L718Q double mutation in culture (PMID: 25948633).",Actionable,3099,10000003,Advanced Solid Tumor,JAX,11692,EGFR E746_A750del EGFR L718Q,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,623,Afatinib,1956
38,Preclinical - Cell line xenograft,"In a preclinical study, the addition of NPS-1034 to treatment with Iressa (gefitinib) overcame Iressa (gefitinib) resistance in a cell line xenograft model of non-small cell lung cancer reported to harbor EGFR E746_A750del (PMID: 23542356), which has acquired resistance to Iressa (gefitinib) due to MET amplification and over expression, resulting in tumor growth inhibition (PMID: 24165158).",Actionable,9655,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,"[{'id': 7367, 'pubMedId': 24165158, 'title': 'MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24165158'}, {'id': 7368, 'pubMedId': 23542356, 'title': 'Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23542356'}]",sensitive,5116,Gefitinib + NPS-1034,1956
39,Preclinical - Cell line xenograft,"In a preclinical study, the combination of PHA-665752 and Iressa (gefitinib) overcame Iressa (gefitinib) resistance in a cell line xenograft model of non-small cell lung cancer reported to harbor EGFR E746_A750del (PMID: 23542356), which has acquired resistance to Iressa (gefitinib) due to MET amplification and over expression, resulting in tumor growth inhibition (PMID: 24165158).",Actionable,9656,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,"[{'id': 7367, 'pubMedId': 24165158, 'title': 'MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24165158'}, {'id': 7368, 'pubMedId': 23542356, 'title': 'Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23542356'}]",sensitive,5094,Gefitinib + PHA-665752,1956
40,Preclinical - Pdx,"In a preclinical study, treatment with Capmatinib (INC280) plus Gilotrif (afatinib) resulted in improved survival with no evidence of tumor 300 days post-transplantation in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification (PMID: 28961841).",Actionable,12150,3910,lung adenocarcinoma,DOID,26798,EGFR E746_A750del MET amp,"[{'id': 10116, 'pubMedId': 28961841, 'title': 'Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28961841'}]",sensitive,6313,Afatinib + Capmatinib,1956
41,Preclinical - Pdx,"In a preclinical study, treatment with Capmatinib (INC280) resulted in improved survival in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification (PMID: 28961841).",Actionable,12148,3910,lung adenocarcinoma,DOID,26798,EGFR E746_A750del MET amp,"[{'id': 10116, 'pubMedId': 28961841, 'title': 'Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28961841'}]",sensitive,1065,Capmatinib,1956
42,Preclinical - Pdx,"In a preclinical study, treatment with Gilotrif (afatinib) did not demonstrate benefit in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification, with all treated mice demonstrating progression (PMID: 28961841).",Actionable,12157,3910,lung adenocarcinoma,DOID,26798,EGFR E746_A750del MET amp,"[{'id': 10116, 'pubMedId': 28961841, 'title': 'Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28961841'}]",no benefit,623,Afatinib,1956
43,Preclinical - Cell culture,"In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in non-small cell lung cancer cell line harboring EGFR E746_A750del and MET amplification in culture (PMID: 27283993).",Actionable,9248,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,"[{'id': 7047, 'pubMedId': 27283993, 'title': 'Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27283993'}]",sensitive,4962,CO1686 + Crizotinib,1956
44,Preclinical - Cell line xenograft,"In a preclinical study, emergence of MET amplification was associated with resistance to Rociletinib (CO1686) in non-small cell lung cancer cell line xenograft models harboring EGFR E746_A750del (PMID: 27283993).",Actionable,9247,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,"[{'id': 7047, 'pubMedId': 27283993, 'title': 'Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27283993'}]",resistant,1003,CO1686,1956
45,Clinical Study,"In a clinical case study, a patient with metastatic lung adenocarcinoma harboring EGFR E746_A750del (referred to as K745_A750delinsK) and T790M demonstrated an initial response, but subsequent progression, of the brain metastasis following Tagrisso (osimertinib) treatment, and analysis of the brain metastasis showed loss of EGFR T790M as well as acquisition of high-level MET amplification, and resistance to Tagrisso (osimertinib) was recapitulated in a patient-derived xenograft (PDX) model (PMID: 28961841)",Actionable,12147,3910,lung adenocarcinoma,DOID,26798,EGFR E746_A750del MET amp,"[{'id': 10116, 'pubMedId': 28961841, 'title': 'Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28961841'}]",resistant,660,Osimertinib,1956
46,Preclinical - Cell culture,"In a preclinical study, acquired amplification of MET conferred resistance to Iressa (gefitinib) in a non-small cell lung cancer cell line harboring EGFR E746_A750del in culture (PMID: 27612490).",Actionable,9557,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,"[{'id': 7271, 'pubMedId': 27612490, 'title': 'Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27612490'}]",resistant,751,Gefitinib,1956
47,Preclinical,"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR C797S double mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).",Actionable,3090,10000003,Advanced Solid Tumor,JAX,11691,EGFR E746_A750del EGFR C797S,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,660,Osimertinib,1956
48,Preclinical - Cell culture,"In a preclinical study, a non-small cell lung cancer cell line harboring EGFR DelE746_A750 and expressing EGFR DelE746_A750/C797S demonstrated resistance to growth inhibition by Rociletinib (CO1686) in culture (PMID: 25948633).",Actionable,10299,3908,non-small cell lung carcinoma,DOID,11691,EGFR E746_A750del EGFR C797S,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,1003,CO1686,1956
49,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR C797S double mutation in culture (PMID: 25948633).",Actionable,3102,10000003,Advanced Solid Tumor,JAX,11691,EGFR E746_A750del EGFR C797S,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,623,Afatinib,1956
50,Preclinical - Cell culture,"In a preclinical study, Iressa (gefitinib) inhibited growth of a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S in culture (PMID: 25948633).",Actionable,10302,3908,non-small cell lung carcinoma,DOID,11691,EGFR E746_A750del EGFR C797S,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,751,Gefitinib,1956
51,Preclinical,"In a preclinical study, cells expressing an EGFR E746_A750del/EGFR C797S double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3078,10000003,Advanced Solid Tumor,JAX,11691,EGFR E746_A750del EGFR C797S,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,1003,CO1686,1956
52,Preclinical - Cell culture,"In a preclinical study, Gilotrif (afatinib) inhibited growth of a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S in culture (PMID: 25948633).",Actionable,10303,3908,non-small cell lung carcinoma,DOID,11691,EGFR E746_A750del EGFR C797S,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,623,Afatinib,1956
53,Preclinical - Cell culture,"In a preclinical study, a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S demonstrated resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25948633).",Actionable,10301,3908,non-small cell lung carcinoma,DOID,11691,EGFR E746_A750del EGFR C797S,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,660,Osimertinib,1956
54,Preclinical - Cell culture,"In a preclinical study, a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S demonstrated resistance to growth inhibition by WZ4002 in culture (PMID: 25948633).",Actionable,10300,3908,non-small cell lung carcinoma,DOID,11691,EGFR E746_A750del EGFR C797S,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,3075,WZ4002,1956
55,Preclinical,"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR Q791R triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3094,10000003,Advanced Solid Tumor,JAX,11733,EGFR E746_A750del EGFR T790M EGFR Q791R,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,1003,CO1686,1956
56,Preclinical,"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR Q791R triple mutation in culture (PMID: 25948633).
",Actionable,3096,10000003,Advanced Solid Tumor,JAX,11733,EGFR E746_A750del EGFR T790M EGFR Q791R,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,660,Osimertinib,1956
57,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR E746_A750del and EGFR L792F demonstrated decreased sensitivity to Gilotrif (afatinib) in culture compared to cells expressing E746_A750del alone (PMID: 27913578).",Actionable,9990,10000003,Advanced Solid Tumor,JAX,27220,EGFR E746_A750del EGFR L792F,"[{'id': 7760, 'pubMedId': 27913578, 'title': 'Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27913578'}]",decreased response,623,Afatinib,1956
58,Preclinical,"In a preclinical study, the combination of Odomzo (sonidegib) and Iressa (gefitinib) decreased viability and migration of non-small cell lung cancer (NSCLC) cells harboring an EGFR E746_A750del mutation and SMO amplification in culture and inhibited tumor growth in NSCLC xenograft models with EGFR E746_A750del and SMO amplification (PMID: 26124204).",Actionable,2657,3908,non-small cell lung carcinoma,DOID,9076,EGFR E746_A750del SMO amp,"[{'id': 3267, 'pubMedId': 26124204, 'title': 'SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26124204'}]",sensitive,2986,Gefitinib + Sonidegib,1956
59,Preclinical,"In a preclinical study, the combination of Odomzo (sonidegib) and PHA-665752 decreased viability and migration of non-small cell lung cancer (NSCLC) cells harboring EGFR E746_A750del and SMO amplification in culture, and resulted in complete response in 100% (8/8) of NSCLC xenograft models with EGFR E746_A750del and SMO amplification (PMID: 26124204).",Actionable,2658,3908,non-small cell lung carcinoma,DOID,9076,EGFR E746_A750del SMO amp,"[{'id': 3267, 'pubMedId': 26124204, 'title': 'SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26124204'}]",sensitive,2987,PHA-665752 + Sonidegib,1956
60,Preclinical,"In a preclinical study, Odomzo (sonidegib) did not decrease viability or migration of non-small cell lung cancer cells harboring EGFR E746_A750del and amplification of SMO in culture (PMID: 26124204).",Actionable,2656,3908,non-small cell lung carcinoma,DOID,9076,EGFR E746_A750del SMO amp,"[{'id': 3267, 'pubMedId': 26124204, 'title': 'SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26124204'}]",no benefit,1428,Sonidegib,1956
61,Preclinical,"In a preclinical study, amplification of SMO conferred acquired resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring EGFR E746_A750del in culture (PMID: 26124204).",Actionable,2547,3908,non-small cell lung carcinoma,DOID,9076,EGFR E746_A750del SMO amp,"[{'id': 3267, 'pubMedId': 26124204, 'title': 'SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26124204'}]",resistant,751,Gefitinib,1956
62,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L844V double mutation in culture (PMID: 25948633).",Actionable,3101,10000003,Advanced Solid Tumor,JAX,11693,EGFR E746_A750del EGFR L844V,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,623,Afatinib,1956
63,Preclinical,"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR L844V double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3077,10000003,Advanced Solid Tumor,JAX,11693,EGFR E746_A750del EGFR L844V,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,1003,CO1686,1956
64,Preclinical,"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L844V double mutation in culture (PMID: 25948633).",Actionable,3085,10000003,Advanced Solid Tumor,JAX,11693,EGFR E746_A750del EGFR L844V,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,660,Osimertinib,1956
65,Preclinical - Cell culture,"In a preclinical study, Erbitux (cetuximab) did not inhibit growth of transformed cells expressing a EGFR E746_A750del/T790M/C797S triple mutation in culture (PMID: 25948633).",Actionable,10305,10000003,Advanced Solid Tumor,JAX,11688,EGFR E746_A750del EGFR T790M EGFR C797S,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",no benefit,694,Cetuximab,1956
66,Preclinical,"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).",Actionable,3093,10000003,Advanced Solid Tumor,JAX,11689,EGFR E746_A750del EGFR T790M EGFR L718Q,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,660,Osimertinib,1956
67,Preclinical,"In a preclinical study, AZD9291 inhibited growth of non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M and ectopically expressing an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation in culture (PMID: 25948633).",Actionable,3108,3908,non-small cell lung carcinoma,DOID,11689,EGFR E746_A750del EGFR T790M EGFR L718Q,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,660,Osimertinib,1956
68,Preclinical,"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3074,10000003,Advanced Solid Tumor,JAX,11689,EGFR E746_A750del EGFR T790M EGFR L718Q,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,1003,CO1686,1956
69,Preclinical,"In a preclinical study, expression of an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation conferred resistance to Rociletinib (CO-1686) in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture (PMID: 25948633).",Actionable,3107,3908,non-small cell lung carcinoma,DOID,11689,EGFR E746_A750del EGFR T790M EGFR L718Q,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,1003,CO1686,1956
70,Preclinical - Cell line xenograft,"In a preclinical study, ABT-414 demonstrated cytotoxicity against a lung adenocarcinoma cell line that harbored EGFR amplification and EGFR E746_A750del in culture and induced tumor regression in cell line xenograft models (PMID: 26846818).",Actionable,6932,3910,lung adenocarcinoma,DOID,24031,EGFR amp EGFR E746_A750del,"[{'id': 5960, 'pubMedId': 26846818, 'title': 'ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26846818'}]",sensitive,976,ABT-414,1956
71,Preclinical,"In a preclinical study, expression of an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation conferred resistance to Rociletinib (CO-1686) in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture (PMID: 25948633).",Actionable,3106,3908,non-small cell lung carcinoma,DOID,11690,EGFR E746_A750del EGFR T790M EGFR L844V,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,1003,CO1686,1956
72,Preclinical,"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation in culture (PMID: 25948633).",Actionable,3088,10000003,Advanced Solid Tumor,JAX,11690,EGFR E746_A750del EGFR T790M EGFR L844V,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,660,Osimertinib,1956
73,Preclinical,"In a preclinical study, AZD9291 inhibited growth of non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M and ectopically expressing an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation in culture (PMID: 25948633).",Actionable,3104,3908,non-small cell lung carcinoma,DOID,11690,EGFR E746_A750del EGFR T790M EGFR L844V,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,660,Osimertinib,1956
74,Preclinical,"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3083,10000003,Advanced Solid Tumor,JAX,11690,EGFR E746_A750del EGFR T790M EGFR L844V,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,1003,CO1686,1956
75,Clinical Study,"In a retrospective clinical study, non-small lung cancer patients harboring EGFR S768I demonstrated a median progression-free survival of 2.7 months following treatment with EGFR tyrosine kinase inhibitors such as Tarceva (erlotinib), Iressa (gefitinib), or Icotinib, compared to 10.8 months in patients with EGFR L858R and EGFR exon 19 deletions  (PMID: 27468240).",Actionable,7802,3908,non-small cell lung carcinoma,DOID,3321,EGFR S768I,"[{'id': 6499, 'pubMedId': 27468240, 'title': 'Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27468240'}]",decreased response,751,Gefitinib,1956
76,Preclinical - Cell culture,"In a preclinical study, non-small cell lung carcinoma cells expressing EGFR S768I had decreased sensitivity to Tarceva (erltonib) in cell culture (PMID: 19147750).",Actionable,1819,3908,non-small cell lung carcinoma,DOID,3321,EGFR S768I,"[{'id': 1890, 'pubMedId': 19147750, 'title': 'Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19147750'}]",decreased response,4,Erlotinib,1956
77,Clinical Study,"In a retrospective clinical study, non-small lung cancer patients harboring EGFR S768I demonstrated a median progression-free survival of 2.7 months following treatment with EGFR tyrosine kinase inhibitors such as Tarceva (erlotinib), Iressa (gefitinib), or Icotinib, compared to 10.8 months in patients with EGFR L858R and EGFR exon 19 deletions (PMID: 27468240).",Actionable,7801,3908,non-small cell lung carcinoma,DOID,3321,EGFR S768I,"[{'id': 6499, 'pubMedId': 27468240, 'title': 'Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27468240'}]",decreased response,4,Erlotinib,1956
78,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR S768I demonstrated a response rate of 25% and disease control rate of 80%, and a median progression-free survival of 3.2 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).",Actionable,11154,3908,non-small cell lung carcinoma,DOID,3321,EGFR S768I,"[{'id': 9121, 'pubMedId': None, 'title': 'Clinical efficacy of icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 18, 20 and 21 uncommon mutations.', 'url': 'http://abstracts.asco.org/199/AbstView_199_186649.html'}]",decreased response,769,Icotinib,1956
79,Clinical Study,"In a retrospective clinical study, non-small cell lung cancer patients harboring EGFR S768I demonstrated a median progression-free survival of 2.7 months following treatment with EGFR tyrosine kinase inhibitors such as Tarceva (erlotinib), Iressa (gefitinib), or icotinib, compared to 10.8 months in patients with EGFR L858R  and EGFR exon 19 deletions (PMID: 27468240).",Actionable,7803,3908,non-small cell lung carcinoma,DOID,3321,EGFR S768I,"[{'id': 6499, 'pubMedId': 27468240, 'title': 'Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27468240'}]",decreased response,769,Icotinib,1956
80,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in stable disease in a non-small cell lung carcinoma patient harboring EGFR S768I (PMID: 26354527).
",Actionable,3367,3908,non-small cell lung carcinoma,DOID,3321,EGFR S768I,"[{'id': 3736, 'pubMedId': 26354527, 'title': 'Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26354527'}]",sensitive,623,Afatinib,1956
81,Phase II,"In a post-hoc analysis of Gilotrif (afatinib) activity in Phase II and Phase III clinical trials, 100% (8/8) of non-small cell lung cancer patients harboring EGFR S768I mutations were found to have demonstrated an objective response, with a mean progression-free survival of 14.7 months (PMID: 26051236).",Actionable,3250,3908,non-small cell lung carcinoma,DOID,3321,EGFR S768I,"[{'id': 3328, 'pubMedId': 26051236, 'title': 'Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26051236'}]",sensitive,623,Afatinib,1956
82,Preclinical,"In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring mutations in EGFR (EGFRvIII, A289T) and PTEN (I253N, N69D) in culture (PMID: 26561558).",Actionable,6038,3068,glioblastoma multiforme,DOID,22288,EGFR act mut EGFR A289T PTEN I253N PTEN N69D,"[{'id': 5255, 'pubMedId': 26561558, 'title': 'InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26561558'}]",sensitive,4008,Gefitinib + Linsitinib,1956
83,Preclinical,"In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR (A289T, EGFRvIII) and PTEN (N69D, I253N) mutations in culture (PMID: 26561558).",Actionable,6046,3068,glioblastoma multiforme,DOID,22288,EGFR act mut EGFR A289T PTEN I253N PTEN N69D,"[{'id': 5255, 'pubMedId': 26561558, 'title': 'InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26561558'}]",sensitive,4009,BMS-754807 + Dacomitinib,1956
84,Clinical Study,"In a clinical case study, a lung adenocarcinoma patient harboring a compound EGFR L833V/H835L mutation responded to treatment with Iressa (gefitinib), with disease progression after 34 weeks of treatment (PMID: 21422421).",Actionable,6890,3910,lung adenocarcinoma,DOID,23970,EGFR L833V EGFR H835L,"[{'id': 5952, 'pubMedId': 21422421, 'title': 'Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21422421'}]",sensitive,751,Gefitinib,1956
85,Preclinical,"In a preclinical study, Tarceva (erlotinib) inhibited EGFR phosphorylation and cell proliferation in transformed cells expressing the kinase domain duplication mutant EGFR L698_S1037dup in culture (PMID: 26286086).",Actionable,4638,10000003,Advanced Solid Tumor,JAX,18657,EGFR L698_S1037dup,"[{'id': 4643, 'pubMedId': 26286086, 'title': 'EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26286086'}]",sensitive,4,Erlotinib,1956
86,Preclinical,"In a preclinical study, Tagrisso (osimertinib) inhibited EGFR phosphorylation and cell proliferation in transformed cells expressing kinase domain duplication mutant EGFR L698_S1037dup in culture (PMID: 26286086).",Actionable,4639,10000003,Advanced Solid Tumor,JAX,18657,EGFR L698_S1037dup,"[{'id': 4643, 'pubMedId': 26286086, 'title': 'EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26286086'}]",sensitive,660,Osimertinib,1956
87,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and cell proliferation in transformed cells expressing kinase domain duplication mutant EGFR L698_S1037dup in culture (PMID: 26286086).",Actionable,4640,10000003,Advanced Solid Tumor,JAX,18657,EGFR L698_S1037dup,"[{'id': 4643, 'pubMedId': 26286086, 'title': 'EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26286086'}]",sensitive,623,Afatinib,1956
88,Clinical Study,"In a clinical study, a patient with EGFR L698_S1037dup expressing lung adenocarcinoma had a partial response after two cycles of Gilotrif (afatinib) after failing first line chemotherapy (PMID: 26286086).",Actionable,4641,3910,lung adenocarcinoma,DOID,18657,EGFR L698_S1037dup,"[{'id': 4643, 'pubMedId': 26286086, 'title': 'EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26286086'}]",sensitive,623,Afatinib,1956
89,Clinical Study,"In a clinical case study, a patient with EGFR L698_S1037dup expressing lung adenocarcinoma had a partial response after two cycles of Gilotrif (afatinib), but subsequently developed resistance to the therapy after amplification of EGFR (PMID: 26286086).",Actionable,4642,3910,lung adenocarcinoma,DOID,18658,EGFR amp EGFR L698_S1037dup,"[{'id': 4643, 'pubMedId': 26286086, 'title': 'EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26286086'}]",resistant,623,Afatinib,1956
90,Preclinical,"In a preclinical study, Tarceva (erlotinib) decreased viability of transformed cells expressing EGFR T263P in culture (PMID: 17177598).",Actionable,6918,10000003,Advanced Solid Tumor,JAX,24028,EGFR T263P,"[{'id': 1877, 'pubMedId': 17177598, 'title': 'Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17177598'}]",sensitive,4,Erlotinib,1956
91,Clinical Study,"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_S752del had a partial response to Iressa (gefitinib) therapy (PMID: 18981003).",Actionable,3052,3910,lung adenocarcinoma,DOID,4963,EGFR L747_S752del,"[{'id': 3591, 'pubMedId': 18981003, 'title': 'Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18981003'}]",sensitive,751,Gefitinib,1956
92,Clinical Study,"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_S752del that developed Iressa (gefitinib) resistance was demonstrated to have acquired an EGFR T790M mutation (PMID: 18981003).",Actionable,3055,3910,lung adenocarcinoma,DOID,11381,EGFR L747_S752del EGFR T790M,"[{'id': 3591, 'pubMedId': 18981003, 'title': 'Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18981003'}]",resistant,751,Gefitinib,1956
93,Clinical Study,"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_S752del and EGFR T790M was found to rapidly progress on Tarceva (erlotinib) therapy (PMID: 18981003).",Actionable,3056,3910,lung adenocarcinoma,DOID,11381,EGFR L747_S752del EGFR T790M,"[{'id': 3591, 'pubMedId': 18981003, 'title': 'Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18981003'}]",resistant,4,Erlotinib,1956
94,Preclinical,"In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).",Actionable,6037,3068,glioblastoma multiforme,DOID,22287,EGFR amp EGFR act mut PTEN R308C,"[{'id': 5255, 'pubMedId': 26561558, 'title': 'InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26561558'}]",sensitive,4008,Gefitinib + Linsitinib,1956
95,Preclinical,"In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).",Actionable,6045,3068,glioblastoma multiforme,DOID,22287,EGFR amp EGFR act mut PTEN R308C,"[{'id': 5255, 'pubMedId': 26561558, 'title': 'InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26561558'}]",sensitive,4009,BMS-754807 + Dacomitinib,1956
96,Preclinical - Cell line xenograft,"In a preclinical study, ABT-414 induced cytoxicity in a glioblastoma cell line harboring amplified EGFR vIII (exon 2-7 deletion) in culture, and induced complete tumor regression in cell line xenograft models of glioblastoma harboring amplified EGFR vIII (PMID: 26846818).",Actionable,6981,3068,glioblastoma multiforme,DOID,24170,EGFR act mut EGFR amp,"[{'id': 5960, 'pubMedId': 26846818, 'title': 'ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26846818'}]",predicted – sensitive,976,ABT-414,1956
97,Preclinical - Cell line xenograft,"In a preclinical study, ABT-414 in combination with Temodar (temozolomide) and radiotherapy inhibited tumor growth and resulted in tumor growth delay in a glioblastoma multiforme cell line xenograft model harboring amplified EGFR vIII (exon 2-7 deletion), with increased efficacy compared to the combination of Temodar (temozolomide) and radiotherapy (PMID: 26846818).",Actionable,6994,3068,glioblastoma multiforme,DOID,24170,EGFR act mut EGFR amp,"[{'id': 5960, 'pubMedId': 26846818, 'title': 'ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26846818'}]",predicted – sensitive,4346,ABT-414 + Temozolomide + Radiotherapy,1956
98,Phase Ib/II,"In a Phase Ib/II clinical trial, the combination of AUY922 and Tarceva (erlotinib) demonstrated limited clinical benefit in patients with EGFR-mutant non-small cell carcinoma with acquired resistance to EGFR tyrosine kinase inhibitors, including patients with EGFR T790M, with 16% (4/25) patients achieving partial response (PMID: 25870087).",Actionable,3263,3908,non-small cell lung carcinoma,DOID,13014,EGFR act mut EGFR T790M,"[{'id': 3702, 'pubMedId': 25870087, 'title': 'Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870087'}]",no benefit,2799,AUY922 + Erlotinib,1956
99,Phase II,"In a Phase II trial, Avastin (bevacizumab) and Tarceva (erlotinib) combination treatment resulted in a median progression-free survival of 16.0 months and a 12 month progression-free survival of 68% (25/37) in treatment-naive lung adenocarcinoma patients harboring activating EGFR mutations (exon 19 deletion or L858R) and EGFR T790M (PMID: 28408243).",Actionable,10689,3910,lung adenocarcinoma,DOID,13014,EGFR act mut EGFR T790M,"[{'id': 8747, 'pubMedId': 28408243, 'title': 'Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28408243'}]",sensitive,1146,Bevacizumab + Erlotinib,1956
100,Phase II,"In a Phase II trial, Avastin (bevacizumab) and Tarceva (erlotinib) combination treatment resulted in a median progression-free survival of 13.2 months and a 12 month progression-free survival of 55% (60/109) in treatment-naive lung adenocarcinoma patients harboring activating EGFR mutations (exon 19 deletion or L858R) (PMID: 28408243).",Actionable,10688,3910,lung adenocarcinoma,DOID,423,EGFR act mut,"[{'id': 8747, 'pubMedId': 28408243, 'title': 'Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28408243'}]",sensitive,1146,Bevacizumab + Erlotinib,1956
101,Phase I,"In a Phase I trial, Glesatinib (MGCD265) and Tarceva (erlotinib) combination treatment resulted in partial response in a non-small cell lung carcinoma patient harboring an EGFR activating mutation (J Clin Oncol 30, 2012 (suppl; abstr e13602)).",Actionable,5291,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,"[{'id': 4988, 'pubMedId': None, 'title': 'MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with erlotinib in patients with advanced solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/96526-114'}]",predicted – sensitive,1126,MGCD265 + Erlotinib,1956
102,Phase II,"In a Phase II trial, Gilotrif (afatinib) treatment, when compared to Iressa (gefitinib), resulted in statistically significant improvement of progression free survival (11.0 vs 10.9 months, HR 0.74, p=0.0178), time-to-treatment failure (13.7 vs 11.5 months, HR 0.75, p=0.0136), and objective response rate (72.5% vs 56%, odd ratio 2.121, p=0.0018) (PMID: 28169392).",Actionable,10235,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,"[{'id': 8174, 'pubMedId': 28169392, 'title': 'Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28169392'}]",sensitive,623,Afatinib,1956
103,Preclinical - Cell line xenograft,"In a preclinical study, Rociletinib (CO-1686) inhibited tumor growth in xenograft models of human non-small cell lung cancer cell lines harboring EGFR activating mutations (PMID: 24065731). ",Actionable,86,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,"[{'id': 157, 'pubMedId': 24065731, 'title': 'Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24065731'}]",sensitive,1003,CO1686,1956
104,Phase II,"In a Phase II study, XL647 demonstrated antitumor activity and increased progression-free survival in non-small cell lung cancer patients harboring EGFR activating mutations (PMID: 22722787).",Actionable,1310,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,"[{'id': 1015, 'pubMedId': 22722787, 'title': 'Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22722787'}]",sensitive,967,XL647,1956
105,Preclinical,"In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFRvIII in culture (PMID: 26561558).",Actionable,6042,3068,glioblastoma multiforme,DOID,423,EGFR act mut,"[{'id': 5255, 'pubMedId': 26561558, 'title': 'InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26561558'}]",sensitive,4008,Gefitinib + Linsitinib,1956
106,Preclinical - Cell culture,"In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing EGFR activating mutations in culture, regardless of the presence or absence of EGFR T790M (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).",Actionable,5912,10000003,Advanced Solid Tumor,JAX,423,EGFR act mut,"[{'id': 5195, 'pubMedId': None, 'title': 'AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=407e597a-33c8-4936-87f4-08ee4b23e8b9&cKey=34ee7ebf-07c6-40ea-825f-28fb5018ec92&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]",sensitive,3981,AP32788,1956
107,Preclinical,"In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFRvIII in culture (PMID: 26561558).",Actionable,6043,3068,glioblastoma multiforme,DOID,423,EGFR act mut,"[{'id': 5255, 'pubMedId': 26561558, 'title': 'InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26561558'}]",sensitive,4009,BMS-754807 + Dacomitinib,1956
108,Phase I,"In a Phase I trial, ABT-806 treatment in patients with advanced solid tumors that often express EGFR amplification or EGFR vIII was well-tolerated, demonstrated safety, and resulted in stable disease in two patients (PMID: 25895099). ",Actionable,6719,10000003,Advanced Solid Tumor,JAX,423,EGFR act mut,"[{'id': 5781, 'pubMedId': 25895099, 'title': 'A phase 1 study of ABT-806 in subjects with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25895099'}]",predicted – sensitive,4256,ABT-806,1956
109,Phase II,"In a Phase II trial, non-small cell lung cancer patients harboring EGFR activating mutations treated with Tarceva (erlotinib), in combination with MK-2206, demonstrated a 9% (4/45) response rate, which did not reach the primary endpoint rate of 20% or more, therefore, indicating no benefit (PMID: 26106072). ",Actionable,3298,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,"[{'id': 3719, 'pubMedId': 26106072, 'title': 'Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26106072'}]",no benefit,1097,Erlotinib + MK2206,1956
110,Phase II,"In a Phase II clinical trial, progression-free survival at 4 months was 95.5% in patients with EGFR-mutant non-small cell lung cancer following treatment with dacomitinib, compared to 76.8% in the overall treatment population (PMID: 25456362).",Actionable,2423,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,"[{'id': 3046, 'pubMedId': 25456362, 'title': 'Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25456362'}]",sensitive,714,Dacomitinib,1956
111,Phase III,"In a Phase III trial, dacomitinib demonstrated superior efficacy compared to Iressa (gefitinib) as first-line therapy in non-small cell lung cancer patients harboring activating mutations in EGFR, resulting in a median progression-free survival of 14.7 months, compared to 9.2 months with Iressa (gefitinib) (J Clin Oncol 35, 2017 (suppl; abstr LBA9007); NCT01774721).",Actionable,11670,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,"[{'id': 9697, 'pubMedId': None, 'title': 'Dacomitinib Versus Gefitinib For The First-Line Treatment of Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (ARCHER 1050): A Randomized, Open-Label Phase III Trial', 'url': 'http://meetinglibrary.asco.org/record/145472/abstract'}]",sensitive,714,Dacomitinib,1956
112,Phase I,"In a Phase I trial, ASP8273 demonstrated preliminary antitumor activity in non-small cell lung patients harboring EGFR activating mutations (J Clin Oncol 33, 2015 (suppl; abstr 8014).",Actionable,2425,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,"[{'id': 3048, 'pubMedId': None, 'title': 'ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: Preliminary results of first-in-human phase I study in Japan.', 'url': 'http://meetinglibrary.asco.org/content/147772-156'}]",sensitive,1082,ASP8273,1956
113,Phase I,"In a Phase I trial, Nerlynx (neratinib) demonstrated limited clinical activity in EGFR-mutant non-small cell lung cancer patients with prior EGFR TKI therapy, with a response rate of 3.4% (3/88), stable disease as best response in 50% (44/88), and prolonged stable disease in 10%, (9/88) (PMID: 20479403).",Actionable,2563,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,"[{'id': 3315, 'pubMedId': 20479403, 'title': 'Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20479403'}]",decreased response,828,Neratinib,1956
114,Preclinical - Cell line xenograft,"In a preclinical study, non-small cell lung cancer cell lines harboring activating EGFR mutations demonstrated sensitivity to the combination of amlexanox and Selumetinib (AZD6244), resulting in synergistic growth inhibition in culture and reduced tumor growth in xenograft models (PMID: 27287717).",Actionable,9781,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,"[{'id': 7601, 'pubMedId': 27287717, 'title': 'IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non-Small Cell Lung Cancer with Activating Mutations of EGFR.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27287717'}]",sensitive,5229,Amlexanox + Selumetinib,1956
115,Phase II,"In a Phase II trial, non-small cell lung cancer patients with EGFR mutations demonstrated a median progression-free survival of 10.8 months, overall survival of 31.0 months, an overall response rate of 66.2% (137/207), and a disease control rate of 82.6% (2 complete responses; 135 partial responses, and 34 stable disease) following treatment with Tarceva (erlotinib) (PMID: 26720423).",Actionable,5303,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,"[{'id': 4999, 'pubMedId': 26720423, 'title': 'First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26720423'}]",predicted – sensitive,4,Erlotinib,1956
116,Phase III,"In a Phase III trial, a trend toward disease free survival was observed in non-small cell lung cancer patients harboring EGFR activating mutations when treated with Tarceva (erlotinib) vs placebo in the adjuvant setting, but significance was not demonstrated due to study design (PMID: 26324372).",Actionable,4438,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,"[{'id': 4546, 'pubMedId': 26324372, 'title': 'Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26324372'}]",predicted – sensitive,4,Erlotinib,1956
117,Phase III,"In a Phase III trial, adjuvant Iressa (gefitinib) treatment resulted in prolonged disease-free survival (28.7 vs 18.0 months) compared to Navelbine (vinorelbine) and Platinol (cisplatin) combination in completely resected non-small cell lung cancer patients harboring EGFR-activating mutations (J Clin Oncol 35, 2017 (suppl; abstr 8500)).",Actionable,11141,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,"[{'id': 9112, 'pubMedId': None, 'title': 'Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104).', 'url': 'http://meetinglibrary.asco.org/record/145337/abstract'}]",sensitive,751,Gefitinib,1956
118,Clinical Study,Iressa (gefitinib) has been recommended as a first-line treatment in patients with EGFR activating mutations (PMID: 22997455).,Actionable,356,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,"[{'id': 72, 'pubMedId': 22997455, 'title': 'Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22997455'}]",sensitive,751,Gefitinib,1956
119,Phase III,"In a Phase III clinical trial, Iressa (gefitinib) treatment resulted in an objective response rate of 71.2% (94/132) and increased progression-free survival in non-small cell lung cancer patients harboring EGFR activating mutations (PMID: 19692680).",Actionable,1873,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,"[{'id': 2375, 'pubMedId': 19692680, 'title': 'Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19692680'}]",sensitive,751,Gefitinib,1956
120,Phase Ib/II,"In a Phase Ib/II clinical trial, the combination of AUY922 and Tarceva (erlotinib) demonstrated limited clinical benefit in patients with EGFR-mutant non-small cell carcinoma with acquired resistance to EGFR tyrosine kinase inhibitors, with 16% (4/25) patients achieving partial response (PMID: 25870087).",Actionable,3262,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,"[{'id': 3702, 'pubMedId': 25870087, 'title': 'Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870087'}]",no benefit,2799,AUY922 + Erlotinib,1956
121,Preclinical - Cell line xenograft,"In a preclinical study, Sapitinib (AZD8931) inhibited EGFR, ERBB2, and ERBB3 kinase activity, and inhibited growth in several non-small cell lung cancer cell lines and xenograft models, including those with EGFR activating mutations (PMID: 20145185).",Actionable,1702,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,"[{'id': 42, 'pubMedId': 20145185, 'title': 'AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20145185'}]",sensitive,910,Sapitinib,1956
122,Preclinical - Pdx,"In a preclinical study, ABT-414 induced tumor regression in a patient-derived xenograft model of glioblastoma multiforme harboring amplified wild-type EGFR and EGFR vIII (exon 2-7 deletion) (PMID: 26846818).",Actionable,6991,3068,glioblastoma multiforme,DOID,24172,EGFR amp EGFR wild-type EGFR act mut,"[{'id': 5960, 'pubMedId': 26846818, 'title': 'ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26846818'}]",predicted – sensitive,976,ABT-414,1956
123,Phase I,"In a Phase I trial, MM-151 treatment resulted in marked reduction of EGFR G465E in circulating cell-free tumor DNA and reduced tumor size in a colorectal cancer patient harboring both EGFR G465E and EGFR G465R (PMID: 26843189).",Actionable,6647,9256,colorectal cancer,DOID,23660,EGFR G465E EGFR G465R,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",sensitive,821,MM-151,1956
124,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7641,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,342,Vemurafenib,1956
125,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).",Actionable,7639,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,694,Cetuximab,1956
126,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7643,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1717,Vemurafenib + Panitumumab,1956
127,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Iressa (gefitinib) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7645,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,1709,Vemurafenib + Gefitinib,1956
128,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7694,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4542,Cetuximab + Dabrafenib + SCH772984,1956
129,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) in culture (PMID: 27312529).",Actionable,7640,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,845,Panitumumab,1956
130,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired secondary resistance mutation of EGFR G465R (PMID: 27312529).",Actionable,7627,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1711,Vemurafenib + Cetuximab,1956
131,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Iressa (gefitinib) in culture (PMID: 27312529).",Actionable,7642,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,751,Gefitinib,1956
132,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7692,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4544,Dabrafenib + SCH772984,1956
133,Phase I,"In a Phase I trial, MM-151 treatment resulted in reduction of EGFR S464L and stabilization of EGFR G465R in circulating cell-free tumor DNA and prolonged stable disease in a colorectal cancer patient harboring both EGFR G465R and EGFR S464L (PMID: 26843189).",Actionable,6648,9256,colorectal cancer,DOID,23659,EGFR G465R EGFR S464L,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",sensitive,821,MM-151,1956
134,Preclinical,"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR G465R in culture (PMID: 26843189).",Actionable,6635,9256,colorectal cancer,DOID,23654,EGFR G465R,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",sensitive,821,MM-151,1956
135,Preclinical - Cell line xenograft,"In a preclinical study, SYM004 inhibited EGFR downstream signaling and proliferation of a colorectal cancer cell line harboring EGFR G465R in culture, and induced tumor regression in xenograft models (PMID: 26888827).",Actionable,9308,9256,colorectal cancer,DOID,23654,EGFR G465R,"[{'id': 7071, 'pubMedId': 26888827, 'title': 'The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26888827'}]",sensitive,931,SYM004,1956
136,Clinical Study,"In a clinical study, a patient with Erbitux (cetuximab)-resistant metastatic colorectal cancer harboring EGFR G465R demonstrated stable disease for 15 weeks following treatment with SYM004 (PMID: 26888827). ",Actionable,9309,9256,colorectal cancer,DOID,23654,EGFR G465R,"[{'id': 7071, 'pubMedId': 26888827, 'title': 'The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26888827'}]",sensitive,931,SYM004,1956
137,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR G465R were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6636,9256,colorectal cancer,DOID,23654,EGFR G465R,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",resistant,845,Panitumumab,1956
138,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR G465R were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6637,9256,colorectal cancer,DOID,23654,EGFR G465R,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",resistant,694,Cetuximab,1956
139,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR G719 mutations demonstrated a response rate of 58% and disease control rate of 73.68%, and a median progression-free survival of 2.8 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).",Actionable,11155,3908,non-small cell lung carcinoma,DOID,1207,EGFR G719X,"[{'id': 9121, 'pubMedId': None, 'title': 'Clinical efficacy of icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 18, 20 and 21 uncommon mutations.', 'url': 'http://abstracts.asco.org/199/AbstView_199_186649.html'}]",decreased response,769,Icotinib,1956
140,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 14% (1/7), stable disease in 43% (3/7), and progressive disease in 43% (3/7) of non-small cell lung carcinoma patients carrying an EGFR G719 mutation (PMID: 26354527).",Actionable,3361,3908,non-small cell lung carcinoma,DOID,1207,EGFR G719X,"[{'id': 3736, 'pubMedId': 26354527, 'title': 'Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26354527'}]",sensitive,623,Afatinib,1956
141,Phase III,"In Phase III trials, non-small cell lung carcinoma patients harboring EGFR G719X mutations (G719A, C, or S) demonstrated a response rate of 78% (14/18) following treatment with Gilotrif (afatinib) (PMID: 24790411).
",Actionable,1861,3908,non-small cell lung carcinoma,DOID,1207,EGFR G719X,"[{'id': 2366, 'pubMedId': 24790411, 'title': 'Clinical and comparative utility of afatinib in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24790411'}]",sensitive,623,Afatinib,1956
142,Phase II,"In a Phase II clinical trial, treatment with Nerlynx (neratinib) resulted in partial response in 75% (3/4) and stable disease in 25% (1/4) of non-small cell lung cancer patients harboring EGFR G719 mutations (PMID: 20479403).",Actionable,3729,3908,non-small cell lung carcinoma,DOID,1207,EGFR G719X,"[{'id': 3315, 'pubMedId': 20479403, 'title': 'Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20479403'}]",sensitive,828,Neratinib,1956
143,Clinical Study,"In an analysis of published clinical data, 14/18 (78%) non-small cell lung cancer patients harboring an EGFR G719X (X=A, C, D, or S) mutation were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Iressa (gefitinib) (PMID: 23344264).",Actionable,751,3908,non-small cell lung carcinoma,DOID,1207,EGFR G719X,"[{'id': 1, 'pubMedId': 23344264, 'title': 'DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23344264'}]",sensitive,751,Gefitinib,1956
144,Clinical Study,"In an analysis of published clinical data, 14/18 (78%) non-small cell lung cancer patients harboring an EGFR G719X (X=A, C, D, or S) mutation were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Tarceva (erlotinib) (PMID: 23344264).",Actionable,750,3908,non-small cell lung carcinoma,DOID,1207,EGFR G719X,"[{'id': 1, 'pubMedId': 23344264, 'title': 'DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23344264'}]",sensitive,4,Erlotinib,1956
145,Preclinical,"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR Q791R triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3095,10000003,Advanced Solid Tumor,JAX,11732,EGFR L858R EGFR Q791R EGFR T790M,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,1003,CO1686,1956
146,Preclinical,"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR L858R/EGFR T790M/EGFR Q791R triple mutation in culture (PMID: 25948633).",Actionable,3097,10000003,Advanced Solid Tumor,JAX,11732,EGFR L858R EGFR Q791R EGFR T790M,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,660,Osimertinib,1956
147,Preclinical - Pdx,"In a preclinical study, treatment with Mekinist (trametinib) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",Actionable,11661,4464,collecting duct carcinoma,DOID,28180,BRAF D594N BRAF G466A EGFR over exp MET over exp,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",sensitive,2,Trametinib,1956
148,Preclinical - Pdx,"In a preclinical study, treatment with Capmatinib (INC280) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",Actionable,11660,4464,collecting duct carcinoma,DOID,28180,BRAF D594N BRAF G466A EGFR over exp MET over exp,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",sensitive,1065,Capmatinib,1956
149,Preclinical - Pdx,"In a preclinical study, the combination of Mekinist (trametinib) and Capmatinib (INC280) induced tumor regression in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",Actionable,11662,4464,collecting duct carcinoma,DOID,28180,BRAF D594N BRAF G466A EGFR over exp MET over exp,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",sensitive,6103,INC280 + Trametinib,1956
150,Preclinical - Cell line xenograft,"In a preclinical study, ABT-414 demonstrated cytoxicity against a lung squamous cell carcinoma cell line with EGFR over expression in culture and induced tumor regression in EGFR over expressing lung squamous cell carcinoma cell line xenograft models (PMID: 26846818).",Actionable,6934,3907,lung squamous cell carcinoma,DOID,2419,EGFR over exp,"[{'id': 5960, 'pubMedId': 26846818, 'title': 'ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26846818'}]",sensitive,976,ABT-414,1956
151,Preclinical - Cell line xenograft,"In a preclinical study, BGB-283 inhibited Egfr phosphorylation in Egfr over expressing squamous cell carcinoma cells in culture, and inhibited tumor growth in cell line xenograft models (PMID: 26208524).",Actionable,8058,1749,squamous cell carcinoma,DOID,2419,EGFR over exp,"[{'id': 5280, 'pubMedId': 26208524, 'title': 'BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26208524'}]",sensitive,4025,BGB-283,1956
152,Preclinical - Cell line xenograft,"In a preclinical study, TAK-285 inhibited growth of squamous cell carcinoma cells harboring EGFR over expression in culture and in cell line xenograft models (PMID: 23983820).",Actionable,7849,1749,squamous cell carcinoma,DOID,2419,EGFR over exp,"[{'id': 1960, 'pubMedId': 23983820, 'title': 'Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23983820'}]",sensitive,2135,TAK-285,1956
153,Preclinical - Cell culture,"In a preclinical study, BGB-283 inhibited proliferation of Egfr over expressing lung cancer cells in culture (PMID: 26208524).",Actionable,8065,1324,lung cancer,DOID,2419,EGFR over exp,"[{'id': 5280, 'pubMedId': 26208524, 'title': 'BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26208524'}]",sensitive,4025,BGB-283,1956
154,Preclinical,"In a preclinical study, treatment with GA201 resulted in inhibition of EGFR signaling and induced antibody-dependent cell-mediated cytotoxicity towards EGFR-over expressing squamous cell carcinoma cells in culture (PMID: 23209031).",Actionable,3780,1749,squamous cell carcinoma,DOID,2419,EGFR over exp,"[{'id': 3814, 'pubMedId': 23209031, 'title': 'GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209031'}]",sensitive,3154,GA201,1956
155,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR1 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a synergistic effect (PMID: 26936917). ",Actionable,7833,5520,head and neck squamous cell carcinoma,DOID,26058,EGFR over exp FGFR1 amp,"[{'id': 6507, 'pubMedId': 26936917, 'title': 'FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26936917'}]",sensitive,4585,AZD4547 + Gefitinib,1956
156,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells with EGFR over expression and FGFR1 amplification demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917). ",Actionable,7830,5520,head and neck squamous cell carcinoma,DOID,26058,EGFR over exp FGFR1 amp,"[{'id': 6507, 'pubMedId': 26936917, 'title': 'FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26936917'}]",resistant,654,AZD4547,1956
157,Preclinical - Cell culture,"In a preclinical study, the combination of Triciribine (API-2) and Mekinist (trametinib) worked synergistically to inhibit growth of a pancreatic adenocarcinoma cell line with wild-type KRAS that demonstrated high EGFR expression and activation in culture (PMID: 28957417).",Actionable,12146,4074,pancreatic adenocarcinoma,DOID,28493,EGFR over exp KRAS wild-type,"[{'id': 10109, 'pubMedId': 28957417, 'title': 'Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28957417'}]",sensitive,6312,Trametinib + Triciribine,1956
158,Preclinical - Cell culture,"In a preclinical study, the combination of Gilotrif (afatinib) and Mekinist (trametinib) worked synergistically to inhibit growth of a pancreatic adenocarcinoma cell line with wild-type KRAS that demonstrated high EGFR expression and activation in culture (PMID: 28957417).",Actionable,12145,4074,pancreatic adenocarcinoma,DOID,28493,EGFR over exp KRAS wild-type,"[{'id': 10109, 'pubMedId': 28957417, 'title': 'Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28957417'}]",sensitive,4482,Afatinib + Trametinib,1956
159,Preclinical - Cell culture,"In a preclinical study, over expression of wild type EGFR in colorectal cancer cells harboring BRAF V600E resulted in sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7631,9256,colorectal cancer,DOID,25929,BRAF V600E EGFR over exp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,3773,Selumetinib + Vemurafenib,1956
160,Preclinical - Pdx & cell culture,"In a preclinical study, Sapitinib (AZD8931) demonstrated antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).",Actionable,964,6263,inflammatory breast carcinoma,DOID,23650,EGFR over exp ERBB2 dec exp,"[{'id': 625, 'pubMedId': 24886365, 'title': 'AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24886365'}]",sensitive,910,Sapitinib,1956
161,Preclinical - Pdx & cell culture,"In a preclinical study, combination of Sapatinib (AZD8931) and Taxol (paclitaxel) demonstrated enhanced antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erbb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).",Actionable,965,6263,inflammatory breast carcinoma,DOID,23650,EGFR over exp ERBB2 dec exp,"[{'id': 625, 'pubMedId': 24886365, 'title': 'AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24886365'}]",sensitive,1416,Sapitinib + Paclitaxel,1956
162,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917). ",Actionable,7832,5520,head and neck squamous cell carcinoma,DOID,26059,EGFR over exp FGFR2 amp,"[{'id': 6507, 'pubMedId': 26936917, 'title': 'FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26936917'}]",resistant,654,AZD4547,1956
163,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a moderate synergistic effect (PMID: 26936917). ",Actionable,7835,5520,head and neck squamous cell carcinoma,DOID,26059,EGFR over exp FGFR2 amp,"[{'id': 6507, 'pubMedId': 26936917, 'title': 'FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26936917'}]",sensitive,4585,AZD4547 + Gefitinib,1956
164,Phase III,"In Phase III clinical trials, patients with NSCLC tumors harboring an EGFR G719X (X=A, C, or S) mutation responded to EGFR tyrosine kinase inhibitors including dacomitinib (PMID: 24857124).
",Actionable,756,3908,non-small cell lung carcinoma,DOID,1046,EGFR G719C,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",sensitive,714,Dacomitinib,1956
165,Clinical Study,"In an analysis of published clinical data, 14/18 (78%) non-small cell lung cancer patients harboring an EGFR G719X (X=A, C, D, or S) mutation were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Tarceva (erlotinib) (PMID: 23344264).",Actionable,758,3908,non-small cell lung carcinoma,DOID,1046,EGFR G719C,"[{'id': 1, 'pubMedId': 23344264, 'title': 'DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23344264'}]",predicted – sensitive,4,Erlotinib,1956
166,Phase III,"In Phase III trials, non-small cell lung carcinoma patients harboring EGFR G719X mutations (G719A, C, or S) demonstrated a response rate of 78% (14/18) following treatment with Gilotrif (afatinib) (PMID: 24790411).",Actionable,753,3908,non-small cell lung carcinoma,DOID,1046,EGFR G719C,"[{'id': 2366, 'pubMedId': 24790411, 'title': 'Clinical and comparative utility of afatinib in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24790411'}]",sensitive,623,Afatinib,1956
167,Clinical Study,"In an analysis of published clinical data, 14/18 (78%) non-small cell lung cancer patients harboring an EGFR G719X (X=A, C, D, or S) mutation were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Iressa (gefitinib) (PMID: 23344264).",Actionable,760,3908,non-small cell lung carcinoma,DOID,1046,EGFR G719C,"[{'id': 1, 'pubMedId': 23344264, 'title': 'DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23344264'}]",predicted – sensitive,751,Gefitinib,1956
168,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and Tagrisso (osimertinib) resulted in increased inhibition of ERK phosphorylation and proliferation compared to either agent alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",Actionable,11307,1324,lung cancer,DOID,27945,EGFR exon 19 del EGFR T790M,"[{'id': 8735, 'pubMedId': 28416483, 'title': 'SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28416483'}]",sensitive,2225,Osimertinib + Selumetinib,1956
169,Preclinical - Cell line xenograft,"In a preclinical study, Tagrisso (osimertinib) and Sprycel (dasatinib) in combination resulted in increased PARP cleavage and inhibition of proliferation in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M compared to Tagrisso (osimertinib) alone, and inhibited tumor growth in xenograft models, with 3 out of 7 models demonstrating no tumor rebound after cessation of therapy (PMID: 28416483).",Actionable,11303,1324,lung cancer,DOID,27945,EGFR exon 19 del EGFR T790M,"[{'id': 8735, 'pubMedId': 28416483, 'title': 'SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28416483'}]",sensitive,4946,Dasatinib + Osimertinib,1956
170,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of TAK-632 and Tagrisso (osimertinib) resulted in increased inhibition of ERK phosphorylation and proliferation compared to either agent alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",Actionable,11306,1324,lung cancer,DOID,27945,EGFR exon 19 del EGFR T790M,"[{'id': 8735, 'pubMedId': 28416483, 'title': 'SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28416483'}]",sensitive,5937,Osimertinib + TAK-632,1956
171,Preclinical,"In a preclinical study, EGFR C797S conferred resistance to growth inhibition by Rociletinib (CO-1686) when expressed on the same allele as EGFR L858R and T790M in transformed cells in culture (PMID: 25939061).",Actionable,3697,10000003,Advanced Solid Tumor,JAX,14859,EGFR C797S EGFR L858R EGFR T790M,"[{'id': 3996, 'pubMedId': 25939061, 'title': 'Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25939061'}]",resistant,1003,CO1686,1956
172,Preclinical,"In a preclinical study, expression of EGFR C797S on the same allele as both EGFR L858R and T790M in transformed cell lines resulted in resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25939061).",Actionable,3696,10000003,Advanced Solid Tumor,JAX,14859,EGFR C797S EGFR L858R EGFR T790M,"[{'id': 3996, 'pubMedId': 25939061, 'title': 'Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25939061'}]",resistant,660,Osimertinib,1956
173,Preclinical - Cell culture,"In a preclinical study, Erbitux (cetuximab) inhibited growth of transformed cells expressing a EGFR L858R/T790M/C797S triple mutation in culture (PMID: 25948633).",Actionable,10304,10000003,Advanced Solid Tumor,JAX,14859,EGFR C797S EGFR L858R EGFR T790M,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,694,Cetuximab,1956
174,Preclinical,"In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment induced tumor regression in an EGFR L858R/T790M/C797S-mutant-driven lung cancer mouse model (PMID: 27251290).",Actionable,7596,1324,lung cancer,DOID,14859,EGFR C797S EGFR L858R EGFR T790M,"[{'id': 6436, 'pubMedId': 27251290, 'title': 'Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27251290'}]",sensitive,4521,Cetuximab + EAI045,1956
175,Preclinical - Cell culture,"In a preclinical study, EAI045 and Erbitux (cetuximab) synergistically inhibited proliferation of transformed cells over expressing EGFR that harbors concomitant C797S, L858R and T790M mutations in culture (PMID: 27251290).",Actionable,7597,10000003,Advanced Solid Tumor,JAX,14859,EGFR C797S EGFR L858R EGFR T790M,"[{'id': 6436, 'pubMedId': 27251290, 'title': 'Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27251290'}]",sensitive,4521,Cetuximab + EAI045,1956
176,Preclinical,"In a preclinical study, the combination of Tagrisso (osimertinib) and Selumetinib increased Parp cleavage, and highly suppressed phosphorylated Erk in human non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and a gain in KRAS in culture (PMID: 25870145).",Actionable,4500,3908,non-small cell lung carcinoma,DOID,18232,EGFR exon 19 del EGFR T790M KRAS amp,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",sensitive,2225,Osimertinib + Selumetinib,1956
177,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M and amplified KRAS were resistant to Tagrisso (osimertinib) treatment in culture (PMID: 25870145).",Actionable,4475,3908,non-small cell lung carcinoma,DOID,18232,EGFR exon 19 del EGFR T790M KRAS amp,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,660,Osimertinib,1956
178,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of EGFR T790M and amplified KRAS in culture (PMID: 25870145).",Actionable,4474,3908,non-small cell lung carcinoma,DOID,18232,EGFR exon 19 del EGFR T790M KRAS amp,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,751,Gefitinib,1956
179,Preclinical,"In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Tagrisso (osimertinib) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416).",Actionable,8802,3910,lung adenocarcinoma,DOID,26437,EGFR T790M MET amp,"[{'id': 6756, 'pubMedId': 27252416, 'title': 'Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27252416'}]",resistant,660,Osimertinib,1956
180,Clinical Study,"In an analysis of EGFR T790M-positive non-small cell lung cancer patients, emergence of MET amplification was identified in 26% (28/43) of patients with acquired resistance to Rociletinib (CO1686), and patients with MET amplification prior to Rociletinib (CO1686) treatment demonstrated a decreased response compared to patients without MET amplification (PMID: 27283993).",Actionable,9246,3908,non-small cell lung carcinoma,DOID,26437,EGFR T790M MET amp,"[{'id': 7047, 'pubMedId': 27283993, 'title': 'Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27283993'}]",resistant,1003,CO1686,1956
181,Preclinical,"In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Rociletinib (CO-1686) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416).",Actionable,8801,3910,lung adenocarcinoma,DOID,26437,EGFR T790M MET amp,"[{'id': 6756, 'pubMedId': 27252416, 'title': 'Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27252416'}]",resistant,1003,CO1686,1956
182,Preclinical - Cell culture,"In a preclinical study, acquisition of EGFR T790M was associated with resistance to Gilotrif (afatinib) in transformed cells expressing EGFR G719A in culture (PMID: 27913578).",Actionable,9923,10000003,Advanced Solid Tumor,JAX,27160,EGFR G719A EGFR T790M,"[{'id': 7760, 'pubMedId': 27913578, 'title': 'Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27913578'}]",resistant,623,Afatinib,1956
183,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).",Actionable,8186,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4657,Pimasertib + Regorafenib,1956
184,Preclinical - Cell line xenograft,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited Mapk and Akt signaling, resulted in growth inhibition of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture and in cell line xenograft models (PMID: 23629727).",Actionable,8181,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,1659,Pimasertib + Sorafenib,1956
185,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).",Actionable,8177,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4656,Everolimus + Pimasertib,1956
186,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, T790M, and PIK3CA G118D demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).",Actionable,8172,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",decreased response,871,Pimasertib,1956
187,Preclinical - Cell line xenograft,"In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).",Actionable,8187,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,1660,Pimasertib + BEZ235,1956
188,Preclinical,"In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",Actionable,5758,3910,lung adenocarcinoma,DOID,14858,EGFR C797S EGFR del exon 19 EGFR T790M,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",resistant,751,Gefitinib,1956
189,Preclinical,"In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",Actionable,5759,3910,lung adenocarcinoma,DOID,14858,EGFR C797S EGFR del exon 19 EGFR T790M,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",resistant,3075,WZ4002,1956
190,Phase I,"In a Phase I clinical trial, 40% (6/15) of non-small cell lung cancer patients harboring an EGFR exon 19 deletion and EGFR T790M  developed resistance to Tagrisso (osimertinib) due to acquired EGFR C797S mutations (PMID: 25939061).",Actionable,3692,3908,non-small cell lung carcinoma,DOID,14858,EGFR C797S EGFR del exon 19 EGFR T790M,"[{'id': 3996, 'pubMedId': 25939061, 'title': 'Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25939061'}]",resistant,660,Osimertinib,1956
191,Preclinical,"In a preclinical study, Iressa (gefitinib) treatment resulted in partial inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).",Actionable,5754,10000003,Advanced Solid Tumor,JAX,14858,EGFR C797S EGFR del exon 19 EGFR T790M,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",conflicting,751,Gefitinib,1956
192,Preclinical,"In a preclinical study, EGFR C797S conferred resistance to growth inhibition by Rociletinib (CO-1686) when expressed on the same allele as an EGFR exon 19 deletion mutation and T790M in transformed cells in culture (PMID: 25939061).",Actionable,3695,10000003,Advanced Solid Tumor,JAX,14858,EGFR C797S EGFR del exon 19 EGFR T790M,"[{'id': 3996, 'pubMedId': 25939061, 'title': 'Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25939061'}]",resistant,1003,CO1686,1956
193,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture, regardless of the allelic context of EGFR T790M and EGFR C797S (PMID: 25964297).",Actionable,5745,3908,non-small cell lung carcinoma,DOID,14858,EGFR C797S EGFR del exon 19 EGFR T790M,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",resistant,3075,WZ4002,1956
194,Preclinical,"In a preclinical study, WZ4002 treatment resulted in partial inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).",Actionable,5755,10000003,Advanced Solid Tumor,JAX,14858,EGFR C797S EGFR del exon 19 EGFR T790M,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",conflicting,3075,WZ4002,1956
195,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture, regardless of the allelic context of EGFR T790M and EGFR C797S (PMID: 25964297).",Actionable,5744,3908,non-small cell lung carcinoma,DOID,14858,EGFR C797S EGFR del exon 19 EGFR T790M,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",resistant,751,Gefitinib,1956
196,Preclinical,"In a preclinical study, transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling in culture (PMID: 25964297).",Actionable,5757,10000003,Advanced Solid Tumor,JAX,14858,EGFR C797S EGFR del exon 19 EGFR T790M,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",resistant,623,Afatinib,1956
197,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",Actionable,5746,3908,non-small cell lung carcinoma,DOID,14858,EGFR C797S EGFR del exon 19 EGFR T790M,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",resistant,623,Afatinib,1956
198,Preclinical,"In a preclinical study, expression of EGFR C797S on the same allele as an EGFR exon 19 deletion and EGFR T790M in transformed cell lines resulted in resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25939061).",Actionable,3694,10000003,Advanced Solid Tumor,JAX,14858,EGFR C797S EGFR del exon 19 EGFR T790M,"[{'id': 3996, 'pubMedId': 25939061, 'title': 'Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25939061'}]",resistant,660,Osimertinib,1956
199,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to the combination of Iressa (gefitinib) and WZ4002 when T790M and C797S were in cis, but were sensitive when EGFR T790M and EGFR C797S were in trans (PMID: 25964297).",Actionable,5747,3908,non-small cell lung carcinoma,DOID,14858,EGFR C797S EGFR del exon 19 EGFR T790M,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",conflicting,3921,Gefitinib + WZ4002,1956
200,Preclinical,"In a preclinical study, Iressa (gefitinib) and WZ4002 combination treatment resulted in complete inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).",Actionable,5756,10000003,Advanced Solid Tumor,JAX,14858,EGFR C797S EGFR del exon 19 EGFR T790M,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",conflicting,3921,Gefitinib + WZ4002,1956
201,Preclinical,"In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",Actionable,5760,3910,lung adenocarcinoma,DOID,14858,EGFR C797S EGFR del exon 19 EGFR T790M,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",resistant,623,Afatinib,1956
202,Clinical Study,"In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M developed resistance to Tagrisso (osimertinib), and was found to have acquired high level amplification of MET (PMID: 27393507).",Actionable,9236,3910,lung adenocarcinoma,DOID,18241,EGFR exon 19 del EGFR T790M MET amp,"[{'id': 7045, 'pubMedId': 27393507, 'title': 'High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27393507'}]",resistant,660,Osimertinib,1956
203,Clinical Study,"In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M and resistance to Tagrisso (osimertinib) following acquired MET amplification, demonstrated some improvement in symptoms with treatment with Xalkori (crizotinib) (PMID: 27393507).",Actionable,9238,3910,lung adenocarcinoma,DOID,18241,EGFR exon 19 del EGFR T790M MET amp,"[{'id': 7045, 'pubMedId': 27393507, 'title': 'High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27393507'}]",predicted – sensitive,706,Crizotinib,1956
204,Preclinical,"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3075,10000003,Advanced Solid Tumor,JAX,11729,EGFR L858R EGFR L718Q EGFR T790M,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,1003,CO1686,1956
205,Preclinical,"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).",Actionable,3092,10000003,Advanced Solid Tumor,JAX,11729,EGFR L858R EGFR L718Q EGFR T790M,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,660,Osimertinib,1956
206,Preclinical - Cell line xenograft,"In a preclinical study, non-small cell lung cancer cells harboring the double mutation, EGFR L858R and EGFR T790M, demonstrated sensitivity to treatment with AC0010MA, resulting in inhibition of both cell growth and Egfr phosphorylation in culture, and tumor regression in xenograft models (PMID: 27573423). ",Actionable,9113,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 6924, 'pubMedId': 27573423, 'title': 'AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27573423'}]",sensitive,2909,AC0010MA,1956
207,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EGFR L858R and T790M in culture (PMID: 27780853).",Actionable,9234,10000003,Advanced Solid Tumor,JAX,2422,EGFR L858R EGFR T790M,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,1956
208,Preclinical - Cell culture,"In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).",Actionable,11314,1324,lung cancer,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 8735, 'pubMedId': 28416483, 'title': 'SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28416483'}]",sensitive,2225,Osimertinib + Selumetinib,1956
209,Clinical Study,"In a clinical case study, Tagrisso (osimertinib) resulted in a partial response and stable disease of brain metastases in a NSCLC patient harboring EGFR L858R and a secondary resistance mutation, EGFR T790M, which occurred post Tarceva (erlotinib) therapy (PMID: 27435396).",Actionable,8972,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 6826, 'pubMedId': 27435396, 'title': 'Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27435396'}]",sensitive,660,Osimertinib,1956
210,Phase I,"In a Phase I trial, AZD9291 treatment resulted in a response rate of 57% (24/24) in patients harboring both EGFR L858R and T790M mutations (PMID: 25923549).",Actionable,2158,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 2666, 'pubMedId': 25923549, 'title': 'AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25923549'}]",sensitive,660,Osimertinib,1956
211,Preclinical,"In a preclinical study, non-small cell carcinoma cancer cell lines harboring EGFR L858R and T790M mutations demonstrated resistance to growth inhibition by Tykerb (lapatinib) in culture (PMID: 18199554).

",Actionable,3054,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 3592, 'pubMedId': 18199554, 'title': 'Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18199554'}]",resistant,787,Lapatinib,1956
212,Clinical Study,"In a clinical study, acquired EGFR T790M mutations were detected in 47.6% (20/42) of lung adenocarcinoma patients with acquired resistance to Gilotrif (afatinib), with 10/20 of those patients harboring EGFR L858R as their primary EGFR mutation (PMID: 26862733).",Actionable,4911,3910,lung adenocarcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 4789, 'pubMedId': 26862733, 'title': 'The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26862733'}]",resistant,623,Afatinib,1956
213,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring EGFR L858R EGFR T790M in culture (PMID: 21325073, PMID: 19238632).",Actionable,3134,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3641, 'pubMedId': 19238632, 'title': 'Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19238632'}]",sensitive,1040,PF-05212384,1956
214,Phase Ib/II,"In a Phase Ib/II trial, treatment with Rociletinib (CO-1686) resulted in an objective response rate of 53.3% (8/15) in non-small cell lung cancer patients harboring both EGFR L858R and EGFR T790M (PMID: 25923550).",Actionable,3119,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 3633, 'pubMedId': 25923550, 'title': 'Rociletinib in EGFR-mutated non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25923550'}]",sensitive,1003,CO1686,1956
215,Preclinical - Pdx,"In a preclinical study, Rociletinib (CO-1686) inhibited tumor growth in human non-small cell lung cancer cell line and patient-derived xenograft models of non-small cell lung cancer harboring both EGFR L858R and EGFR T790M (PMID: 24065731).",Actionable,9486,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 157, 'pubMedId': 24065731, 'title': 'Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24065731'}]",sensitive,1003,CO1686,1956
216,Clinical Study,"In a clinical case report, a non-small cell lung cancer patient that progressed on Iressa (gefitinib) was demonstrated to harbor EGFR L858R and a secondary EGFR T790M mutation (PMID: 15737014).",Actionable,1705,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 1879, 'pubMedId': 15737014, 'title': 'Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15737014'}]",resistant,751,Gefitinib,1956
217,Clinical Study,"In a clinical study, EGFR T790M mutations were associated with acquired resistance to Iressa (gefitinib) in non-small cell lung cancer patients harboring EGFR L858R (PMID: 22263058).",Actionable,6668,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 5727, 'pubMedId': 22263058, 'title': 'T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22263058'}]",resistant,751,Gefitinib,1956
218,Preclinical - Cell line xenograft,"In a preclinical study, the addition of Ganetespib overcame resistance to Tarceva (erlotinib) in cell line xenograft models of non-small cell lung cancer harboring EGFR L858R and EGFR T790M (PMID: 25077897).",Actionable,2293,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 2971, 'pubMedId': 25077897, 'title': 'The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25077897'}]",sensitive,2802,Erlotinib + Ganetespib,1956
219,Preclinical,"In a preclinical study, EGFR T790M was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed  after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).",Actionable,6653,3910,lung adenocarcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 5721, 'pubMedId': 26341921, 'title': 'Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26341921'}]",resistant,4190,Afatinib + Cetuximab,1956
220,Preclinical,"In a preclinical study, addition of Rapamune (sirolimus) to Gilotrif (afatinib) and Erbitux (cetuximab) combination treatment restored sensitivity in transgenic animal models of lung adenocarcinoma driven by EGFR L858R and T790M that acquired resistance to the combination treatment, resulted in tumor shrinkage (PMID: 24813888).",Actionable,8526,3910,lung adenocarcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 4088, 'pubMedId': 24813888, 'title': 'Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24813888'}]",sensitive,4764,Afatinib + Cetuximab + Sirolimus,1956
221,Preclinical - Cell culture,"In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).",Actionable,11313,1324,lung cancer,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 8735, 'pubMedId': 28416483, 'title': 'SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28416483'}]",sensitive,4946,Dasatinib + Osimertinib,1956
222,Preclinical - Cell culture,"In a preclinical study, a lung cancer cell line harboring EGFR L858R and T790M did not demonstrate sensitivity to AZD3759 in culture (PMID: 27928026).",Actionable,9569,1324,lung cancer,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 7282, 'pubMedId': 27928026, 'title': 'AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27928026'}]",resistant,2912,AZD3759,1956
223,Preclinical,"In a preclinical study, EGFR T790M was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which occurred after repeated treatments with Tarceva (erlotinib) and resulted in drug resistance (PMID: 26341921).",Actionable,6652,3910,lung adenocarcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 5721, 'pubMedId': 26341921, 'title': 'Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26341921'}]",resistant,4,Erlotinib,1956
224,Preclinical,"In a preclinical study, the combination of Tagrisso (osimertinib) and Selumetinib inhibited growth of lung adenocarcinoma tumors driven by EGFR L858R and EGFR T790M that had developed resistance through continued exposure to Tagrisso (osimertinib) (PMID: 25870145).",Actionable,4501,3910,lung adenocarcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",sensitive,2225,Osimertinib + Selumetinib,1956
225,Preclinical - Pdx & cell culture,"In a preclinical study, EGF816 inhibited proliferation of non-small cell lung cancer (NSCLC) cells harboring both EGFR L858R and EGFR T790M in culture, and induced tumor regression in NSCLC patient derived xenograft (PDX) models harboring both EGFR L858R and EGFR T790M (PMID: 26825170).",Actionable,5650,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 5135, 'pubMedId': 26825170, 'title': 'EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26825170'}]",sensitive,1309,EGF816,1956
226,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Ganetespib and Gilotrif (afatinib) demonstrated improved antitumor activity compared to either agent alone in  cell line xenograft models of non-small cell lung cancer harboring EGFR L858R and EGFR T790M (PMID: 25077897).",Actionable,2294,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 2971, 'pubMedId': 25077897, 'title': 'The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25077897'}]",sensitive,2801,Afatinib + Ganetespib,1956
227,Preclinical,"In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment induced tumor regression in an EGFR L858R/T790M-mutant-driven lung cancer mouse model (PMID: 27251290).",Actionable,7594,1324,lung cancer,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 6436, 'pubMedId': 27251290, 'title': 'Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27251290'}]",sensitive,4521,Cetuximab + EAI045,1956
228,Preclinical,"In a preclinical study, AV-412 inhibited EGFR signaling in a NSCLC cell line carrying the double EGFR mutant, L858R and T790M (PMID: 17888033).",Actionable,1380,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 1110, 'pubMedId': 17888033, 'title': 'Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17888033'}]",sensitive,990,AV-412,1956
229,Preclinical,"In a preclinical study, transformed cells expressing EGFR L858R and T790M demonstrated decreased sensitivity to EKI-285 (CL-387,785) in culture (PMID: 17085664).",Actionable,3001,10000003,Advanced Solid Tumor,JAX,2422,EGFR L858R EGFR T790M,"[{'id': 2798, 'pubMedId': 17085664, 'title': 'Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17085664'}]",decreased response,2911,EKI-285,1956
230,Preclinical,"In a preclinical study, treatment with the combination of WZ4002 and Mekinist (trametinib) resulted in tumor regression, and decreased tumor rebound and increased survival compared to WZ4002 alone in non-small cell lung cancer mouse models expressing EGFR L858R and EGFR T790M (PMID: 26036643).",Actionable,9052,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 6890, 'pubMedId': 26036643, 'title': 'Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26036643'}]",sensitive,3351,WZ4002 + Trametinib,1956
231,Preclinical - Cell culture,"In a preclinical study, EAI045 inhibited proliferation of transformed cells over expressing EGFR that harbors both L858R and T790M in culture, although at a concentration much higher than the biochemical IC50 of the compound (PMID: 27251290).",Actionable,7580,10000003,Advanced Solid Tumor,JAX,2422,EGFR L858R EGFR T790M,"[{'id': 6436, 'pubMedId': 27251290, 'title': 'Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27251290'}]",sensitive,4520,EAI045,1956
232,Preclinical - Cell culture,"In a preclinical study, EAI045 and Erbitux (cetuximab) synergistically inhibited proliferation of transformed cells over expressing EGFR that harbors both L858R and T790M in culture (PMID: 27251290).",Actionable,7590,10000003,Advanced Solid Tumor,JAX,2422,EGFR L858R EGFR T790M,"[{'id': 6436, 'pubMedId': 27251290, 'title': 'Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27251290'}]",sensitive,4521,Cetuximab + EAI045,1956
233,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) and Nerlynx (neratinib) in combination worked syngerstically to inhibit Akt phosphorylation in a human non-small cell lung cancer cell line harboring EGFR L858R and T790M in culture (PMID: 21325073).",Actionable,3898,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}]",sensitive,3379,Gedatolisib + Neratinib,1956
234,Preclinical - Pdx,"In a preclinical study, JNJ-61186372 induced tumor regression in lung adenocaricnoma patient-derived xenograft (PDX) models harboring EGFR L858R and EGFR T790M, with response continuing up to 2 months post-treatment cessation (PMID: 27216193).",Actionable,7504,3910,lung adenocarcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 6352, 'pubMedId': 27216193, 'title': 'A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27216193'}]",sensitive,4491,JNJ-61186372,1956
235,Preclinical - Cell culture,"In a preclinical study, the addition of Buparlisib (BKM-120) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).",Actionable,11315,1324,lung cancer,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 8735, 'pubMedId': 28416483, 'title': 'SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28416483'}]",sensitive,5935,BKM120 + Osimertinib,1956
236,Preclinical,"In a preclinical study, transformed cells expressing EGFR L858R and T790M demonstrated decreased sensitivity to Nerlynx (neratinib) in culture (PMID: 17085664).",Actionable,2997,10000003,Advanced Solid Tumor,JAX,2422,EGFR L858R EGFR T790M,"[{'id': 2798, 'pubMedId': 17085664, 'title': 'Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17085664'}]",decreased response,828,Neratinib,1956
237,Preclinical,"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring both EGFR L858R and EGFR T790M mutations in culture (PMID: 26090892).",Actionable,3931,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 4301, 'pubMedId': 26090892, 'title': 'TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26090892'}]",sensitive,2086,TAE226,1956
238,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Tagrisso (osimertinib) and JNJ-61186372 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring EGFR L858R and EGFR T790M, and resulted in durable response following treatment cessation (PMID: 27216193).",Actionable,7506,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 6352, 'pubMedId': 27216193, 'title': 'A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27216193'}]",sensitive,4502,AZD9291 + JNJ-61186372,1956
239,Preclinical - Cell culture,"In a preclinical study, EAI045 inhibited Egfr activation but not proliferation of non-small cell lung cancer cells harboring EGFR with both L858R and T790M mutations in culture (PMID: 27251290).",Actionable,7586,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 6436, 'pubMedId': 27251290, 'title': 'Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27251290'}]",no benefit,4520,EAI045,1956
240,Preclinical - Cell culture,"In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Gilotrif (afatinib) in a lung cancer cell line harboring EGFR L858R and T790M in culture (PMID: 28145866).",Actionable,11912,1324,lung cancer,DOID,2422,EGFR L858R EGFR T790M,"[{'id': 9896, 'pubMedId': 28145866, 'title': 'KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28145866'}]",decreased response,623,Afatinib,1956
241,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4494,3908,non-small cell lung carcinoma,DOID,18240,EGFR exon 19 del EGFR T790M NRAS Q61K,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,660,Osimertinib,1956
242,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4495,3908,non-small cell lung carcinoma,DOID,18261,EGFR L858R EGFR T790M NRAS Q61K,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,660,Osimertinib,1956
243,Preclinical,"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L844V triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3082,10000003,Advanced Solid Tumor,JAX,11730,EGFR L858R EGFR L844V EGFR T790M,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,1003,CO1686,1956
244,Preclinical,"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L844V triple-mutation in culture (PMID: 25948633).",Actionable,3087,10000003,Advanced Solid Tumor,JAX,11730,EGFR L858R EGFR L844V EGFR T790M,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,660,Osimertinib,1956
245,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of EGFR T790M in culture (PMID: 25870145).",Actionable,4479,3908,non-small cell lung carcinoma,DOID,5705,EGFR del exon 19 EGFR T790M,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,623,Afatinib,1956
246,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297).",Actionable,5750,10000003,Advanced Solid Tumor,JAX,5705,EGFR del exon 19 EGFR T790M,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",sensitive,623,Afatinib,1956
247,Preclinical,"In a preclinical study, WZ4002 inhibited EGFR signaling and cell growth in 1st generation TKI-resistant non-small cell lung carcinoma cells harboring EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297).",Actionable,5732,3908,non-small cell lung carcinoma,DOID,5705,EGFR del exon 19 EGFR T790M,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",sensitive,3075,WZ4002,1956
248,Preclinical,"In a preclinical study, WZ4002 inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297).",Actionable,5749,10000003,Advanced Solid Tumor,JAX,5705,EGFR del exon 19 EGFR T790M,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",sensitive,3075,WZ4002,1956
249,Preclinical - Cell culture,"In a preclinical study, the combination of Tagrisso (osimertinib) with PF-573328 and Saracatinib (AZD0530) resulted in increased inhibition of AKT, FAK, and SFK phosphorylation and growth compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",Actionable,11308,1324,lung cancer,DOID,5705,EGFR del exon 19 EGFR T790M,"[{'id': 8735, 'pubMedId': 28416483, 'title': 'SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28416483'}]",sensitive,5938,Osimertinib + PF-573328 + Saracatinib,1956
250,Preclinical - Cell line xenograft,"In a preclinical study, TAE226 treatment inhibited cell proliferation and decreased xenograft tumor size of non-small cell lung carcinoma cell lines harboring both EGFR T790M and EGFR Exon 19 deletion mutations (PMID: 26090892).",Actionable,3929,3908,non-small cell lung carcinoma,DOID,5705,EGFR del exon 19 EGFR T790M,"[{'id': 4301, 'pubMedId': 26090892, 'title': 'TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26090892'}]",sensitive,2086,TAE226,1956
251,Clinical Study,"In an analysis of lung adenocarcinoma patients treated with Gilotrif (afatinib), second-site EGFR T790M mutations were detected in 47.6% (20/42) of patients with acquired resistance, with 9/20 patients harboring primary EGFR exon 19 deletion mutations (PMID: 26862733).",Actionable,4912,3910,lung adenocarcinoma,DOID,5705,EGFR del exon 19 EGFR T790M,"[{'id': 4789, 'pubMedId': 26862733, 'title': 'The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26862733'}]",resistant,623,Afatinib,1956
252,Clinical Study,"In a clinical case study, Tagrisso (osimertinib) resulted in a partial response and stable disease of brain metastases in a NSCLC patient harboring EGFR exon 19 deletion and a secondary resistance mutation, EGFR T790M, which occurred post Iressa (gefitinib) therapy (PMID: 27435396).",Actionable,8969,3908,non-small cell lung carcinoma,DOID,5705,EGFR del exon 19 EGFR T790M,"[{'id': 6826, 'pubMedId': 27435396, 'title': 'Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27435396'}]",sensitive,660,Osimertinib,1956
253,Phase I,"In a Phase I trial, AZD9291 treatment resulted in a response rate of 64% (49/77) in NSCLC patients that harbored both EGFR exon 19 deletions and T790M mutations (PMID: 25923549).",Actionable,2157,3908,non-small cell lung carcinoma,DOID,5705,EGFR del exon 19 EGFR T790M,"[{'id': 2666, 'pubMedId': 25923549, 'title': 'AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25923549'}]",sensitive,660,Osimertinib,1956
254,Preclinical,"In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment did not induced response in an EGFR exon 19 deletion/T790M-driven lung cancer mouse model (PMID: 27251290).",Actionable,7595,1324,lung cancer,DOID,5705,EGFR del exon 19 EGFR T790M,"[{'id': 6436, 'pubMedId': 27251290, 'title': 'Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27251290'}]",resistant,4521,Cetuximab + EAI045,1956
255,Preclinical,"In a preclinical study, non-small cell lung cancercarcinoma cells harboring EGFR exon 19 deletion and EGFR T790M were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",Actionable,5731,3908,non-small cell lung carcinoma,DOID,5705,EGFR del exon 19 EGFR T790M,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",resistant,751,Gefitinib,1956
256,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of GSK2334470 and Tagrisso (osimertinib) resulted in increased inhibition of AKT phosphorylation and proliferation compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",Actionable,11305,1324,lung cancer,DOID,5705,EGFR del exon 19 EGFR T790M,"[{'id': 8735, 'pubMedId': 28416483, 'title': 'SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28416483'}]",sensitive,5936,GSK2334470 + Osimertinib,1956
257,Phase Ib/II,"In a Phase Ib/II trial, treatment with Rociletinib (CO-1686) resulted in an objective response rate of 64.3% (18/28) in non-small cell lung cancer patients harboring both EGFR exon 19 deletions and EGFR T790M (PMID: 25923550).",Actionable,3120,3908,non-small cell lung carcinoma,DOID,5705,EGFR del exon 19 EGFR T790M,"[{'id': 3633, 'pubMedId': 25923550, 'title': 'Rociletinib in EGFR-mutated non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25923550'}]",sensitive,1003,CO1686,1956
258,Preclinical - Cell culture,"In a preclinical study, EAI045 did not inhibit proliferation of transformed cells over expressing EGFR that harbors both exon 19 deletion and T790M in culture (PMID: 27251290).",Actionable,7582,10000003,Advanced Solid Tumor,JAX,5705,EGFR del exon 19 EGFR T790M,"[{'id': 6436, 'pubMedId': 27251290, 'title': 'Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27251290'}]",resistant,4520,EAI045,1956
259,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of Buparlisib (BKM120) and Tagrisso (osimertinib) resulted in increased inhibition of AKT phosphorylation and proliferation compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",Actionable,11304,1324,lung cancer,DOID,5705,EGFR del exon 19 EGFR T790M,"[{'id': 8735, 'pubMedId': 28416483, 'title': 'SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28416483'}]",sensitive,5935,BKM120 + Osimertinib,1956
260,Preclinical - Cell culture,"In a preclinical study, the combination of Tagrisso (osimertinib) with PF-573328 and Bosulif (bosutinib) resulted in increased inhibition of AKT, FAK, and SFK phosphorylation and growth compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",Actionable,11309,1324,lung cancer,DOID,5705,EGFR del exon 19 EGFR T790M,"[{'id': 8735, 'pubMedId': 28416483, 'title': 'SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28416483'}]",sensitive,5939,Osimertinib + Bosutinib + PF-573328,1956
261,Preclinical - Cell culture,"In a preclinical study, combination of EAI045 and Erbitux (cetuximab) did not inhibit proliferation of transformed cells over expressing EGFR that harbors both exon 19 deletion and T790M in culture (PMID: 27251290).",Actionable,7591,10000003,Advanced Solid Tumor,JAX,5705,EGFR del exon 19 EGFR T790M,"[{'id': 6436, 'pubMedId': 27251290, 'title': 'Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27251290'}]",resistant,4521,Cetuximab + EAI045,1956
262,Preclinical,"In a preclinical study, transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M were resistant to Iressa (gefitinib) induced suppression of EGFR signaling in culture (PMID: 25964297).",Actionable,5748,10000003,Advanced Solid Tumor,JAX,5705,EGFR del exon 19 EGFR T790M,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",resistant,751,Gefitinib,1956
263,Preclinical - Cell culture,"In a preclinical study, BGB-283 inhibited proliferation of transformed cells over expressing both EGFR exon 19 deletion mutation and T790M in culture (PMID: 26208524).",Actionable,8062,10000003,Advanced Solid Tumor,JAX,5705,EGFR del exon 19 EGFR T790M,"[{'id': 5280, 'pubMedId': 26208524, 'title': 'BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26208524'}]",sensitive,4025,BGB-283,1956
264,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing EGFR that harbors concomitant L858R, T790M and I941R mutations demonstrated increased sensitivity to EAI045 induced growth inhibition in culture (PMID: 27251290).",Actionable,7589,10000003,Advanced Solid Tumor,JAX,25912,EGFR I941R EGFR L858R EGFR T790M,"[{'id': 6436, 'pubMedId': 27251290, 'title': 'Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27251290'}]",sensitive,4520,EAI045,1956
265,Clinical Study,"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_T751delinsP and EGFR T790M was found to rapidly progress on Tarceva (erlotinib) therapy (PMID: 18981003).",Actionable,3053,3910,lung adenocarcinoma,DOID,11384,EGFR L747_T751delinsP EGFR T790M,"[{'id': 3591, 'pubMedId': 18981003, 'title': 'Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18981003'}]",resistant,4,Erlotinib,1956
266,Clinical Study,"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_T751delinsP that had developed Iressa (gefitinib) resistance was demonstrated to have acquired an EGFR T790M mutation (PMID: 18981003).",Actionable,3051,3910,lung adenocarcinoma,DOID,11384,EGFR L747_T751delinsP EGFR T790M,"[{'id': 3591, 'pubMedId': 18981003, 'title': 'Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18981003'}]",resistant,751,Gefitinib,1956
267,Clinical Study,"In a retrospective study, Opdivo (nivolumab) treatment after disease progression during EGFR tyrosine kinase inhibitors resulted in longer median progression-free survival (2.1 vs 1.3 months, HR=0.48, p=0.099) in T790M-negative, EGFR mutant non-small cell lung cancer patients compared to T790M-positive patients (PMID: 28407039).",Actionable,11341,3908,non-small cell lung carcinoma,DOID,27962,EGFR T790M EGFR mut,"[{'id': 9243, 'pubMedId': 28407039, 'title': 'Tumor Immune Microenvironment and Nivolumab Efficacy in EGFR Mutation-Positive Non-Small Cell Lung Cancer Based on T790M Status after Disease Progression During EGFR-TKI Treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28407039'}]",decreased response,1312,Nivolumab,1956
268,Preclinical,"In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Tagrisso (osimertinib) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416).",Actionable,8799,3910,lung adenocarcinoma,DOID,26436,EGFR T790M ERBB2 over exp,"[{'id': 6756, 'pubMedId': 27252416, 'title': 'Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27252416'}]",resistant,660,Osimertinib,1956
269,Preclinical,"In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Rociletinib (CO-1686) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416).",Actionable,8800,3910,lung adenocarcinoma,DOID,26436,EGFR T790M ERBB2 over exp,"[{'id': 6756, 'pubMedId': 27252416, 'title': 'Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27252416'}]",resistant,1003,CO1686,1956
270,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 15% (4/27), stable disease in 56% (15/27), and progressive disease in 30% (8/27) of non-small cell lung carcinoma patients carrying an EGFR T790M mutation (PMID: 26354527).",Actionable,3365,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,"[{'id': 3736, 'pubMedId': 26354527, 'title': 'Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26354527'}]",predicted – resistant,623,Afatinib,1956
271,Clinical Study,"In a clinical study, EGFR T790M mutations were associated with resistance to Iressa (gefitinib) in lung adenocarcinoma patients (PMID: 15737014).",Actionable,49,3910,lung adenocarcinoma,DOID,370,EGFR T790M,"[{'id': 194, 'pubMedId': 24410791, 'title': 'Novel agents and strategies for overcoming EGFR TKIs resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24410791'}, {'id': 1879, 'pubMedId': 15737014, 'title': 'Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15737014'}]",resistant,751,Gefitinib,1956
272,Phase I,"In a Phase I trial, ASP8273 treatment resulted in partial response in 38% (15/40) and stable disease in 28% (11/40) of non-small cell lung carcinoma patients harboring EGFR T790M, with a median progression free survival of 6.7 months (J Clin Oncol 34, 2016 (suppl; abstr 9050)).",Actionable,4350,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,"[{'id': 6005, 'pubMedId': None, 'title': 'Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study.', 'url': 'http://meetinglibrary.asco.org/content/162561-176'}]",sensitive,1082,ASP8273,1956
273,Preclinical,"In a preclinical study, Selumetinib (AZD6244) mildly inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with an EGFR T790M mutation (PMID: 24939055). ",Actionable,982,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,"[{'id': 642, 'pubMedId': 24939055, 'title': 'Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24939055'}]",decreased response,913,Selumetinib,1956
274,Phase I,"In a Phase I study, EGF816 treatment resulted in an objective response rate of 44% (56/127), disease control rate of 91% (115/127), and an estimated progression free survival of 9.2 months in non-small cell lung carcinoma patients harboring EGFR T790M (J Clin Oncol 34, 2016 (suppl; abstr 9044)).",Actionable,6995,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,"[{'id': 6004, 'pubMedId': None, 'title': 'Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.', 'url': 'http://meetinglibrary.asco.org/content/162578-176'}]",sensitive,1309,EGF816,1956
275,Phase II,"In a Phase II trial, BI 1482694 (HM61713) treatment resulted in a disease control rate of 90% (64/71), and objective response with a median duration of 8.3 months in 56% (40/71) of patients with EGFR tyrosine kinase inhibitor-resistant non-small cell lung carcinoma harboring EGFR T790M (J Clin Oncol 34, 2016 (suppl; abstr 9055)).",Actionable,7049,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,"[{'id': 6057, 'pubMedId': None, 'title': 'BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.', 'url': 'http://meetinglibrary.asco.org/content/164852-176'}]",sensitive,2137,HM61713,1956
276,Clinical Study,"In a clinical study, 83% (5/6) of non-small cell lung cancer patients that had progressed on prior treatment with Iressa (gefinitib) with secondary EGFR T790M mutations had progressive disease as best response to treatment with Tarceva (erlotinib) (PMID: 18981003).",Actionable,43,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,"[{'id': 194, 'pubMedId': 24410791, 'title': 'Novel agents and strategies for overcoming EGFR TKIs resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24410791'}, {'id': 3591, 'pubMedId': 18981003, 'title': 'Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18981003'}]",resistant,4,Erlotinib,1956
277,Phase Ib/II,"In a Phase I/II trial, Brigatinib (AP26113) treatment did not result in objective response in EGFRT790M-positive non-small cell lung cancer patients resistant to one previous EGFR tyrosine kinase inhibitor (PMID: 27836716).",Actionable,9230,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,"[{'id': 7043, 'pubMedId': 27836716, 'title': 'Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27836716'}]",no benefit,634,AP26113,1956
278,Preclinical,"In a preclinical study, AV-412 inhibited the kinase activity of EGFR T790M (PMID: 17888033).",Actionable,1379,10000003,Advanced Solid Tumor,JAX,370,EGFR T790M,"[{'id': 1110, 'pubMedId': 17888033, 'title': 'Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17888033'}]",sensitive,990,AV-412,1956
279,Preclinical,"In a preclinical study, CUDC-101 inhibited the growth of lung cancer cells expressing EGFR T790M (PMID: 20388807).",Actionable,314,1324,lung cancer,DOID,370,EGFR T790M,"[{'id': 43, 'pubMedId': 20388807, 'title': 'CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20388807'}]",sensitive,1005,CUDC-101,1956
280,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically inhibited proliferation of Iressa (gefitinib)-resistant NSCLC cells harboring EGFR T790M in culture and in cell line xenograft models (PMID: 24939055).",Actionable,987,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,"[{'id': 642, 'pubMedId': 24939055, 'title': 'Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24939055'}]",sensitive,1420,Selumetinib + BEZ235,1956
281,Preclinical,"In a preclinical study, BEZ235 suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with an EGFR T790M mutation (PMID: 24939055).",Actionable,986,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,"[{'id': 642, 'pubMedId': 24939055, 'title': 'Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24939055'}]",sensitive,672,BEZ235,1956
282,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR T790M demonstrated a response rate of 4.76% and disease control rate of 47.62%, and a median progression-free survival of 1.6 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).",Actionable,11157,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,"[{'id': 9121, 'pubMedId': None, 'title': 'Clinical efficacy of icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 18, 20 and 21 uncommon mutations.', 'url': 'http://abstracts.asco.org/199/AbstView_199_186649.html'}]",decreased response,769,Icotinib,1956
283,Clinical Study,"In a clinical study, two patients with non-small cell lung cancer harboring EGFR T790M demonstrated tumor reductions of 31% and 36% when treated with AC0010MA (PMID: 27573423). ",Actionable,9118,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,"[{'id': 6924, 'pubMedId': 27573423, 'title': 'AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27573423'}]",sensitive,2909,AC0010MA,1956
284,Phase Ib/II,"In a Phase Ib/II trial, treatment with Rociletinib (CO-1686) resulted in a response rate of 59% (27/46) and a disease control rate of 93% (43/46) in non-small cell lung cancer patients harboring EGFR T790M (PMID: 25923550).",Actionable,3118,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,"[{'id': 3633, 'pubMedId': 25923550, 'title': 'Rociletinib in EGFR-mutated non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25923550'}]",sensitive,1003,CO1686,1956
285,Phase I,"In a Phase I trial, CO-1686 has demonstrated safety and efficacy in NSCLC patients carrying EGFR T790M mutations (J Clin Oncol 31, 2013 (suppl; abstr 2524)).",Actionable,46,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,"[{'id': 976, 'pubMedId': None, 'title': 'First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M.', 'url': 'http://meetinglibrary.asco.org/content/117319-132'}]",sensitive,1003,CO1686,1956
286,Phase I,"In a Phase I clinical trial, HMPL-813 (Epitinib) demonstrated safety and preliminary efficacy in patients with NSCLC, including a patient with EGFR T790M (J Clin Oncol 31, 2013 (suppl; abstr e19042).",Actionable,4877,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,"[{'id': 4765, 'pubMedId': None, 'title': 'Phase I study of the safety and pharmacokinetics of epitinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/114269-132'}]",predicted – sensitive,3667,Epitinib,1956
287,Preclinical - Cell line xenograft,"In a preclinical study, non-small cell lung cancer cell lines harboring activating EGFR mutations, including EGFR T790M, demonstrated sensitivity to the combination of amlexanox and Selumetinib (AZD6244), resulting in synergistic growth inhibition in culture and reduced tumor growth in xenograft models (PMID: 27287717).",Actionable,9782,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,"[{'id': 7601, 'pubMedId': 27287717, 'title': 'IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non-Small Cell Lung Cancer with Activating Mutations of EGFR.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27287717'}]",sensitive,5229,Amlexanox + Selumetinib,1956
288,Clinical Study,"In a clinical study, second-site EGFR T790M mutations were detected in 47.6% (20/42) of lung adenocarcinoma patients with acquired resistance to Gilotrif (afatinib) (PMID: 26862733).",Actionable,6669,3910,lung adenocarcinoma,DOID,370,EGFR T790M,"[{'id': 4789, 'pubMedId': 26862733, 'title': 'The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26862733'}]",resistant,623,Afatinib,1956
289,Phase I,"In a Phase I trial, AZD9291 demonstrated efficacy in 50% (9/18) of NSCLC patients carrying EGFR T790M mutations (PMID: 24410791).
",Actionable,45,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,"[{'id': 194, 'pubMedId': 24410791, 'title': 'Novel agents and strategies for overcoming EGFR TKIs resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24410791'}]",sensitive,660,Osimertinib,1956
290,FDA approved,"In a Phase I extension trial that supported FDA approval, treatment with Tagrisso (osimertinib) resulted in in an objective response rate of 58% (115/119) and disease control rate of 92%  in patients with EGFR-TKI resistant non-small cell lung cancer harboring EGFR T790M mutations (World Conf on Lung Cancer 2015. Abst MINI16.06).",Actionable,3623,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,"[{'id': 3913, 'pubMedId': None, 'title': 'AZD9291 in Pre-Treated T790M Positive Advanced NSCLC: AURA Study Phase II Extension Cohort.', 'url': 'http://library.iaslc.org/virtual-library-search?product_id=1&author=Yang&category=&date=&session_type=&session=&presentation=&keyword=AURA'}]",sensitive,660,Osimertinib,1956
291,Phase I,"In a Phase I trial, AZD9291 treatment resulted in an objective response rate of 61% (78/127) and a disease control rate of 95% (121/127) in NSCLC patients harboring EGFR T790M mutations (PMID: 25923549).",Actionable,2156,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,"[{'id': 2666, 'pubMedId': 25923549, 'title': 'AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25923549'}]",sensitive,660,Osimertinib,1956
292,Phase III,"In a Phase III trial, treatment with Tagrisso (osimertinib) resulted in an improved median progression-free survival of 10.1 months vs. 4.4 months with platinum plus pemetrexed, and an objective response rate of 71% (95% CI, 65 to 76) compared to 31% (95% CI, 24 to 40) with platinum plus pemetrexed therapy in patients with EGFR T790M-positive non-small cell lung cancer (PMID: 27959700).",Actionable,9600,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,"[{'id': 7315, 'pubMedId': 27959700, 'title': 'Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27959700'}]",sensitive,660,Osimertinib,1956
293,Clinical Study,"In a clinical case study, Tagrisso (osimertinib) treatment resulted in partial response for over 8 months in a patient with lung adenocarcinoma harboring EGFR G719A, L861Q, and T790M that has progressed while on Tarceva (erlotinib) treatment (PMID: 28343545).",Actionable,10488,3910,lung adenocarcinoma,DOID,27526,EGFR G719A EGFR L861Q EGFR T790M,"[{'id': 8565, 'pubMedId': 28343545, 'title': 'Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28343545'}]",predicted – sensitive,660,Osimertinib,1956
294,Clinical Study,"In a clinical case study, EGFR T790M was detected at the time of progression in a patient with lung adenocarcinoma harboring EGFR G719A and L861Q that was treated with Tarceva (erlotinib) (PMID: 28343545).",Actionable,10487,3910,lung adenocarcinoma,DOID,27526,EGFR G719A EGFR L861Q EGFR T790M,"[{'id': 8565, 'pubMedId': 28343545, 'title': 'Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28343545'}]",predicted – resistant,4,Erlotinib,1956
295,Clinical Study,"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR L747S had an initial partial response to Tarceva (erlotinib), but was found to progress after 6 months (PMID: 18981003).",Actionable,3058,3910,lung adenocarcinoma,DOID,11382,EGFR L858R EGFR L747S,"[{'id': 3591, 'pubMedId': 18981003, 'title': 'Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18981003'}]",decreased response,4,Erlotinib,1956
296,Clinical Study,"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L858R that had developed Iressa (gefitinib) resistance was demonstrated to have acquired an EGFR L747S mutation (PMID: 18981003).
",Actionable,3057,3910,lung adenocarcinoma,DOID,11382,EGFR L858R EGFR L747S,"[{'id': 3591, 'pubMedId': 18981003, 'title': 'Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18981003'}]",resistant,751,Gefitinib,1956
297,Preclinical - Patient cell culture,"In a preclinical study, dacomitinib inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR N771_H773dup (also referred to as H773_V774insNPH) in culture (PMID: 28363995).",Actionable,10519,3910,lung adenocarcinoma,DOID,13013,EGFR N771_H773dup,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",sensitive,714,Dacomitinib,1956
298,Preclinical - Patient cell culture,"In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR N771_H773dup (also referred to as H773_V774insNPH) in culture (PMID: 28363995).",Actionable,10522,3910,lung adenocarcinoma,DOID,13013,EGFR N771_H773dup,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",sensitive,623,Afatinib,1956
299,Preclinical,"In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR N771_H773dup demonstrated resistance to Tarceva (erlotinib) in culture (PMID: 25931286).",Actionable,3256,5520,head and neck squamous cell carcinoma,DOID,13013,EGFR N771_H773dup,"[{'id': 3698, 'pubMedId': 25931286, 'title': 'High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25931286'}]",resistant,4,Erlotinib,1956
300,Preclinical,"In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR N771_H773dup demonstrated resistance to Iressa (gefinitib) in culture (PMID: 25931286).",Actionable,3255,5520,head and neck squamous cell carcinoma,DOID,13013,EGFR N771_H773dup,"[{'id': 3698, 'pubMedId': 25931286, 'title': 'High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25931286'}]",resistant,751,Gefitinib,1956
301,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited growth of sinonasal squamous cell carcinoma cells harboring EGFR N771_H773dup in culture (PMID: 25931286).",Actionable,3259,5520,head and neck squamous cell carcinoma,DOID,13013,EGFR N771_H773dup,"[{'id': 3698, 'pubMedId': 25931286, 'title': 'High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25931286'}]",sensitive,828,Neratinib,1956
302,Preclinical,"In a preclinical study, cells expressing the double EGFR L858R/E844K mutation demonstrated decreased sensitivity to Tarceva (erlotinib) in culture compared to cells expressing EGFR L858R alone (PMID: 19015641).",Actionable,6888,10000003,Advanced Solid Tumor,JAX,23963,EGFR L858R EGFR E884K,"[{'id': 5950, 'pubMedId': 19015641, 'title': 'Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19015641'}]",decreased response,4,Erlotinib,1956
303,Preclinical,"In a preclinical study, cells expressing the double EGFR L858R/E884K mutation demonstrated increased sensitivity to inhibition of Egfr phosphorylation by EKI-285 compared to cells expressing EGFR L858R alone (PMID: 20942962).",Actionable,6921,10000003,Advanced Solid Tumor,JAX,23963,EGFR L858R EGFR E884K,"[{'id': 1956, 'pubMedId': 20942962, 'title': 'Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20942962'}]",sensitive,2911,EKI-285,1956
304,Preclinical,"In a preclinical study, cells expressing the double EGFR L858R/E884K mutation demonstrated increased sensitivity to inhibition by Iressa (gefitinib) compared to cells expressing EGFR L858R alone (PMID: 20942962).",Actionable,6920,10000003,Advanced Solid Tumor,JAX,23963,EGFR L858R EGFR E884K,"[{'id': 1956, 'pubMedId': 20942962, 'title': 'Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20942962'}]",sensitive,751,Gefitinib,1956
305,Phase I,"In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 29% (5/17) of EGFR wild-type, MET over-expressing non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).",Actionable,7065,3908,non-small cell lung carcinoma,DOID,24382,EGFR wild-type MET over exp,"[{'id': 6064, 'pubMedId': None, 'title': 'Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).', 'url': 'http://meetinglibrary.asco.org/content/165406-176'}]",sensitive,1065,Capmatinib,1956
306,Preclinical - Cell line xenograft,"In a preclinical study, Ganetespib treatment resulted in decreased activation of MEK, AKT, and ERK and inhibited growth of a non-small cell lung cancer cell line with wild-type EGFR and BRAF G466V in culture, and inhibited tumor growth in xenograft models (PMID: 25077897).",Actionable,8231,3908,non-small cell lung carcinoma,DOID,26202,BRAF G466V EGFR wild-type,"[{'id': 2971, 'pubMedId': 25077897, 'title': 'The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25077897'}]",sensitive,745,Ganetespib,1956
307,Preclinical,"In a preclinical study, the combination of K-756 and Iressa (gefitinib) worked synergistically to inhibit growth of non-small cell lung cancer cells with wild-type EGFR or EGFR exon 19 deletion in culture (PMID: 27196752).",Actionable,7255,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,"[{'id': 6261, 'pubMedId': 27196752, 'title': 'The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196752'}]",sensitive,4428,K-756 + Gefitinib,1956
308,Preclinical - Pdx & cell culture,"In a preclinical study, Dacomitinib did not inhibit Egfr signaling or survival of patient-derived EGFR wild-type glioblastoma cells in culture and in intracranial xenograft models (PMID: 25939761).",Actionable,8044,3068,glioblastoma multiforme,DOID,343,EGFR wild-type,"[{'id': 6540, 'pubMedId': 25939761, 'title': 'Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25939761'}]",no benefit,714,Dacomitinib,1956
309,Preclinical - Cell culture,"In a preclinical study, Tarceva (erlotinib) demonstrated decreased potency in inhibition of Egfr phosphorylation and resulted in decreased inhibition of downstream targets, including Stat5, in transformed cells expressing wild-type EGFR, compared to EGFR L858R expressing cells in culture (PMID: 25573954).",Actionable,4778,10000003,Advanced Solid Tumor,JAX,343,EGFR wild-type,"[{'id': 4727, 'pubMedId': 25573954, 'title': 'Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25573954'}]",decreased response,4,Erlotinib,1956
310,Phase II,"In a Phase II trial, EGFR wild-type non-small cell lung cancer patients treated with Tarceva (erlotinib), in combination with MK-2206, demonstrated a clinical benefit as indicated by a disease control rate of 43% (15/43), thus, exceeding the primary endpoint rate of 20% (PMID: 26106072). ",Actionable,3299,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,"[{'id': 3719, 'pubMedId': 26106072, 'title': 'Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26106072'}]",sensitive,1097,Erlotinib + MK2206,1956
311,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) did not inhibit growth of lung carcinoma cells with activated wild-type EGFR signaling via EGF stimulation in culture (PMID: 27780853).",Actionable,9239,3905,lung carcinoma,DOID,343,EGFR wild-type,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",resistant,634,AP26113,1956
312,Preclinical - Cell culture,"In a preclinical study, EAI045 did not inhibit proliferation of transformed cells harboring wild type EGFR in culture (PMID: 27251290).",Actionable,7584,10000003,Advanced Solid Tumor,JAX,343,EGFR wild-type,"[{'id': 6436, 'pubMedId': 27251290, 'title': 'Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27251290'}]",resistant,4520,EAI045,1956
313,Phase II,"In a Phase II trial, treatment with Cometriq (cabozantinib) resulted in an improved median progression-free survival of 4.3 months, compared to 1.8 months with Tarceva (erlotinib), and an improved median overall survival of 9.2 months, versus 5.1 with Tarceva (erlotinib), in patients with EGFR wild-type non-small cell lung cancer (PMID: 27825638).",Actionable,9742,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,"[{'id': 7519, 'pubMedId': 27825638, 'title': 'Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27825638'}]",unknown,998,cabozantinib,1956
314,Preclinical - Cell line xenograft,"In a preclinical study, ER2 inhibited EGFR signaling and proliferation and induced apoptosis of EGFR wild-type non-small cell lung cancer cells in culture and delayed tumor growth in non-small cell lung cancer cell line xenograft models with wild-type EGFR (PMID: 27040853).",Actionable,5646,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,"[{'id': 5133, 'pubMedId': 27040853, 'title': 'ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27040853'}]",sensitive,3916,ER2,1956
315,Phase III,"In a Phase III trial, postoperative adjuvant Iressa (gefitinib) did not provide prolonged disease-free survival nor increased overall survival in NSCLC patients with wild-type EGFR (PMID: 23980091).",Actionable,9,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,"[{'id': 241, 'pubMedId': 23980091, 'title': 'Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23980091'}]",no benefit,751,Gefitinib,1956
316,Phase III,"In Phase II and III clinical trials, Chinese patients with advanced NSCLC have shown Conmana (icotinib) to be safe and effective, with indication that patients with EGFR wild-type may receive some benefit  (PMID:23372346, PMID:2394835, PMID:24438614, PMID: 25261231).",Actionable,1217,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,"[{'id': 75, 'pubMedId': 23372346, 'title': 'Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23372346'}, {'id': 98, 'pubMedId': 24438614, 'title': 'Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24438614'}, {'id': 956, 'pubMedId': 25261231, 'title': 'A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25261231'}, {'id': 957, 'pubMedId': 2394835, 'title': 'Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/2394835'}]",sensitive,769,Icotinib,1956
317,Preclinical - Cell culture,"In a preclinical study, Iressa (gefitinib) demonstrated decreased potency in inhibition of Egfr phosphorylation and inhibition of downstream targets, including Cbl, in EGFR wild-type expressing compared to EGFR L858R expressing transformed cells in culture (PMID: 25573954).",Actionable,4776,10000003,Advanced Solid Tumor,JAX,343,EGFR wild-type,"[{'id': 4727, 'pubMedId': 25573954, 'title': 'Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25573954'}]",decreased response,751,Gefitinib,1956
318,Preclinical,"In a preclinical study, TAE226 treatment demonstrated reduced potency inhibiting proliferation of non-small cell lung carcinoma cell lines harboring wild-type EGFR in culture (PMID: 26090892).",Actionable,3938,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,"[{'id': 4301, 'pubMedId': 26090892, 'title': 'TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26090892'}]",decreased response,2086,TAE226,1956
319,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Tarceva (erlotinib) and Ganetespib led to tumor regression in cell line xenograft models of EGFR wild-type non-small cell lung cancer, and demonstrated improved efficacy over either agent alone (PMID: 25077897).",Actionable,8232,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,"[{'id': 2971, 'pubMedId': 25077897, 'title': 'The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25077897'}]",sensitive,2802,Erlotinib + Ganetespib,1956
320,Preclinical,"In a preclinical study, the combined treatment of DNA methyltransferase inhibitor decitabine and EGFR inhibitor gefitinib on EGFR wild-type colon cancer cell lines resulted in synergistic effects in inhibiting cell growth and migration (PMID: 24874286).",Actionable,1088,219,colon cancer,DOID,343,EGFR wild-type,"[{'id': 822, 'pubMedId': 24874286, 'title': 'Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24874286'}]",sensitive,1531,Decitabine + Gefitinib,1956
321,Preclinical - Cell line xenograft,"In a preclinical study, the combination of ER2 and Platinol (cisplatin) demonstrated synergy in inhibiting tumor growth in non-small cell lung cancer cell line xenograft models with wild-type EGFR (PMID: 27040853).",Actionable,8040,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,"[{'id': 5133, 'pubMedId': 27040853, 'title': 'ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27040853'}]",sensitive,4625,ER2 + Cisplatin,1956
322,Phase II,"In a Phase II clinical trial, Nexavar (sorafenib) demonstrated efficacy in NSCLC patients with wild-type EGFR (PMID: 24166906).",Actionable,1229,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,"[{'id': 244, 'pubMedId': 24166906, 'title': 'Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24166906'}]",sensitive,920,Sorafenib,1956
323,Phase II,"In a Phase II trial, the combination of Cometriq (cabozantinib) and Tarceva (erlotinib) resulted in an improved median progression-free survival of 4.7 mo vs. 1.8 mo with Tarceva (erlotinib) alone, and an improved median overall survival of 13.3 months vs 5.1 mo with Tarceva (erlotinib) in patients with EGFR wild-type non-small cell lung cancer (PMID: 27825638).",Actionable,9741,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,"[{'id': 7519, 'pubMedId': 27825638, 'title': 'Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27825638'}]",unknown,1255,Cabozantinib + Erlotinib,1956
324,Preclinical - Cell line xenograft,"In a preclinical study, AC0010MA resulted in no antitumor activity when treating a squamous cell carcinoma cell line xenograft model harboring wild-type EGFR (PMID: 27573423).",Actionable,9117,1749,squamous cell carcinoma,DOID,343,EGFR wild-type,"[{'id': 6924, 'pubMedId': 27573423, 'title': 'AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27573423'}]",no benefit,2909,AC0010MA,1956
325,Preclinical,"In a preclinical study, expression of EGFR T854A decreased sensitivity of transformed cells expressing EGFR L858R to Tarceva (erlotinib) in culture (PMID: 19010870).",Actionable,2226,10000003,Advanced Solid Tumor,JAX,6333,EGFR L858R EGFR T854A,"[{'id': 965, 'pubMedId': 19010870, 'title': 'Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19010870'}]",decreased response,4,Erlotinib,1956
326,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR L858R/EGFR L718Q double mutation in culture (PMID: 25948633).",Actionable,3100,10000003,Advanced Solid Tumor,JAX,11694,EGFR L858R EGFR L718Q,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,623,Afatinib,1956
327,Preclinical,"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR L718Q double mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).",Actionable,3089,10000003,Advanced Solid Tumor,JAX,11694,EGFR L858R EGFR L718Q,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,660,Osimertinib,1956
328,Preclinical,"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR L718Q double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3079,10000003,Advanced Solid Tumor,JAX,11694,EGFR L858R EGFR L718Q,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,1003,CO1686,1956
329,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited EGFR phosphorylation and growth of cells expressing EGFR L718Q in culture (PMID: 25948633).",Actionable,3068,10000003,Advanced Solid Tumor,JAX,11685,EGFR L718Q,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,828,Neratinib,1956
330,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of cells expressing EGFR L718Q in culture (PMID: 25948633).",Actionable,3067,10000003,Advanced Solid Tumor,JAX,11685,EGFR L718Q,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,623,Afatinib,1956
331,Preclinical,"In a preclinical study, EKI-285 inhibited EGFR phosphorylation and growth of cells expressing EGFR L718Q in culture (PMID: 25948633).
",Actionable,3069,10000003,Advanced Solid Tumor,JAX,11685,EGFR L718Q,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,2911,EKI-285,1956
332,Preclinical,"In a preclinical study, transformed human cells harboring EGFR exon 19 deletion and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling in culture (PMID: 25964297).",Actionable,5753,10000003,Advanced Solid Tumor,JAX,21570,EGFR C797S EGFR exon 19 del,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",resistant,3075,WZ4002,1956
333,Preclinical,"In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",Actionable,5763,3910,lung adenocarcinoma,DOID,21570,EGFR C797S EGFR exon 19 del,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",resistant,3075,WZ4002,1956
334,Preclinical,"In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling and cell growth in lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).",Actionable,5762,3910,lung adenocarcinoma,DOID,21570,EGFR C797S EGFR exon 19 del,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",sensitive,623,Afatinib,1956
335,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).",Actionable,5752,10000003,Advanced Solid Tumor,JAX,21570,EGFR C797S EGFR exon 19 del,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",sensitive,623,Afatinib,1956
336,Preclinical,"In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling and cell growth in lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).",Actionable,5761,3910,lung adenocarcinoma,DOID,21570,EGFR C797S EGFR exon 19 del,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",sensitive,751,Gefitinib,1956
337,Preclinical,"In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).",Actionable,5751,10000003,Advanced Solid Tumor,JAX,21570,EGFR C797S EGFR exon 19 del,"[{'id': 3620, 'pubMedId': 25964297, 'title': 'The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964297'}]",sensitive,751,Gefitinib,1956
338,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified KRAS in culture (PMID: 25870145).",Actionable,4480,3908,non-small cell lung carcinoma,DOID,18233,EGFR exon 19 del KRAS amp,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,623,Afatinib,1956
339,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified KRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4481,3908,non-small cell lung carcinoma,DOID,18233,EGFR exon 19 del KRAS amp,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,660,Osimertinib,1956
340,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K were resistant to Tagrisso (osimertinib) AZD9291 treatment in culture (PMID: 25870145).",Actionable,4478,3908,non-small cell lung carcinoma,DOID,18231,EGFR exon 19 del NRAS E63K,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,660,Osimertinib,1956
341,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of NRAS E63K in culture (PMID: 25870145).",Actionable,4477,3908,non-small cell lung carcinoma,DOID,18231,EGFR exon 19 del NRAS E63K,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,751,Gefitinib,1956
342,Preclinical,"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K in culture (PMID: 25870145).",Actionable,4476,3908,non-small cell lung carcinoma,DOID,18231,EGFR exon 19 del NRAS E63K,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",sensitive,913,Selumetinib,1956
343,Clinical Study,"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion, MET amplification, and MET D1228V demonstrated a strong response to the combination of Tarceva (erlotinib) and Cometriq (Cabometyx, cabozantinib), resulting in reduced tumor size (PMID: 27694386).",Actionable,9534,3910,lung adenocarcinoma,DOID,26887,EGFR exon 19 del MET amp MET D1228V,"[{'id': 7247, 'pubMedId': 27694386, 'title': 'Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27694386'}]",sensitive,1255,Cabozantinib + Erlotinib,1956
344,Preclinical - Pdx & cell culture,"In a preclinical study, EGF816 inhibited proliferation of non-small cell lung cancer (NSCLC) cells harboring an exon 19 deletion in culture, and induced tumor regression in NSCLC patient derived xenograft (PDX) models harboring an exon 19 deletion (PMID: 26825170).",Actionable,5649,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,"[{'id': 5135, 'pubMedId': 26825170, 'title': 'EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26825170'}]",sensitive,1309,EGF816,1956
345,Preclinical,"In a preclinical study, the combination of K-756 and Iressa (gefitinib) worked synergistically to inhibit growth of non-small cell lung cancer cells with wild-type EGFR or EGFR exon 19 deletion in culture (PMID: 27196752).",Actionable,7253,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,"[{'id': 6261, 'pubMedId': 27196752, 'title': 'The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196752'}]",sensitive,4428,K-756 + Gefitinib,1956
346,Preclinical - Pdx,"In a preclinical study, JNJ-61186372 induced tumor regression in lung adenocaricnoma patient-derived xenograft (PDX) models harboring an EGFR exon 19 deletion, with continued response following treatment cessation (PMID: 27216193).",Actionable,7505,3910,lung adenocarcinoma,DOID,367,EGFR exon 19 del,"[{'id': 6352, 'pubMedId': 27216193, 'title': 'A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27216193'}]",sensitive,4491,JNJ-61186372,1956
347,Phase III,"In a meta-analysis of 12 Phase III trials investigating EGFR tyrosine kinase inhibitors in NSCLC patients with EFGR mutations (primarily exon 19 deletions or L858R) indicated TKIs, including icotinib, were superior to standard chemotherapy (PMID: 24533047).",Actionable,771,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,"[{'id': 450, 'pubMedId': 24533047, 'title': 'Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24533047'}]",sensitive,769,Icotinib,1956
348,Preclinical - Cell line xenograft,"In a preclinical study, Rociletinib (CO-1686) did not result in tumor regression or a survival benefit when treating a NSCLC cell line xenograft model harboring an EGFR exon 19 deletion (PMID: 27435396). ",Actionable,8970,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,"[{'id': 6826, 'pubMedId': 27435396, 'title': 'Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27435396'}]",no benefit,1003,CO1686,1956
349,Guideline,Gilotrif (afatinib) is an active regimen in patients with metastatic NSCLC harboring sensitizing EGFR mutations (Guidelines).,Actionable,2014,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,"[{'id': 2454, 'pubMedId': None, 'title': 'NCCN Guidelines Version 5.2015 Non-Small Cell Lung Cancer', 'url': ''}]",sensitive,623,Afatinib,1956
350,FDA approved,"In a Phase III study that supported FDA approval, Gilotrif (afatinib) treatment resulted in increased progression-free survival in NSCLC patients with EGFR exon 19 deletions (PMID: 23816960, PMID: 23991291).
",Actionable,33,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 2367, 'pubMedId': 23991291, 'title': 'Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23991291'}, {'id': 2368, 'pubMedId': 23816960, 'title': 'Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23816960'}]",sensitive,623,Afatinib,1956
351,Phase II,"In a Phase II trial, Gilotrif (afatinib) treatment resulted in improved progression-free survival (11.0 vs 10.9 months) and time-to-treatment failure (13.7 vs 11.5 months) compared to Iressa (gefitinib) in treatment-naive non-small cell lung carcinoma patients harboring EGFR exon 19 deletion or L858R (PMID: 27083334).",Actionable,6161,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,"[{'id': 5321, 'pubMedId': 27083334, 'title': 'Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27083334'}]",sensitive,623,Afatinib,1956
352,Preclinical - Cell line xenograft,"In a preclinical study, JNJ-61186372 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring an EGFR exon 19 deletion, with increased efficacy following treatment cessation compared to Tarceva (erlotinib) (PMID: 27216193).",Actionable,7502,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,"[{'id': 6352, 'pubMedId': 27216193, 'title': 'A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27216193'}]",sensitive,4491,JNJ-61186372,1956
353,Preclinical - Cell line xenograft,"In a preclinical study, addition of Golvatinib (E7050) overcame Hgf-induced Iressa (gefitinib)-resistance in lung adenocarcinoma cell lines harboring EGFR exon 19 deletions in culture and in cell line xenograft models (PMID: 22789825).",Actionable,10759,3910,lung adenocarcinoma,DOID,367,EGFR exon 19 del,"[{'id': 8809, 'pubMedId': 22789825, 'title': 'Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22789825'}]",sensitive,5610,Gefitinib + Golvatinib,1956
354,Preclinical - Cell culture,"In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell line harboring an EGFR exon 19 deletion in culture (PMID: 28416483).",Actionable,11318,1324,lung cancer,DOID,367,EGFR exon 19 del,"[{'id': 8735, 'pubMedId': 28416483, 'title': 'SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28416483'}]",sensitive,4946,Dasatinib + Osimertinib,1956
355,Preclinical - Cell line xenograft,"In a preclinical study, AZD3759 inhibited EGFR activation and growth of a lung cancer cell line harboring an EGFR exon 19 deletion in culture and induced tumor regression in subcutaneous xenograft models, and inhibited tumor growth in brain and leptomeningeal xenograft models (PMID: 27928026).",Actionable,9568,1324,lung cancer,DOID,367,EGFR exon 19 del,"[{'id': 7282, 'pubMedId': 27928026, 'title': 'AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27928026'}]",sensitive,2912,AZD3759,1956
356,FDA approved,"In a comparison of clinical outcomes, NSCLC patients with either EGFR exon 19 deletion or the L858R mutation responded to treatment with Iressa (gefitinib) or Tarceva (erlotinib) with similar effectiveness, with overall response rates > 75% (PMID: 24736073).",Actionable,770,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,"[{'id': 449, 'pubMedId': 24736073, 'title': 'Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24736073'}]",sensitive,751,Gefitinib,1956
357,Phase III,"In a Phase III trial, treatment with dacomitinib as first-line therapy in patients with non-small cell lung cancer harboring an EGFR exon 19 deletion or EGFR L858R resulted in an improved median progression-free survival (mPFS) of 14.7 months compared to 9.2 months with Iressa (gefitinib), with a mPFS of 12.3 months with dacomitnib vs. 9.8 months with Iressa (gefitinib) among patients with EGFR exon 19 deletions (PMID: 28958502; NCT01777421).",Actionable,12177,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,"[{'id': 10136, 'pubMedId': 28958502, 'title': 'Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28958502'}]",sensitive,714,Dacomitinib,1956
358,Phase II,"In a Phase II clinical trial, 74% (34/46) of patients with EGFR exon 19 or 21 mutant lung cancers had partial response (PFS average= 17 months) to first line treatment with dacomitinib (J Clin Oncol 30, 2012 (suppl; abstr 7530); NCT00818441).",Actionable,769,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,"[{'id': 448, 'pubMedId': None, 'title': 'First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers', 'url': 'http://meetinglibrary.asco.org/content/99805-114'}]",sensitive,714,Dacomitinib,1956
359,Preclinical - Cell line xenograft,"In a preclinical study, a human NSCLC cell line xenograft model with brain metastases harboring an EGFR exon 19 deletion demonstrated tumor regression and improved survival benefit when treated with Tagrisso (osimertinib) (PMID: 27435396). ",Actionable,8968,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,"[{'id': 6826, 'pubMedId': 27435396, 'title': 'Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27435396'}]",sensitive,660,Osimertinib,1956
360,Phase I,"In a Phase I trial, non-small cell lung cancer patients harboring EGFR exon 19 deletions demonstrated a response rate of 30% (8/27) following treatment with Tagrisso (osimertinib) (PMID: 25923549).",Actionable,2159,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,"[{'id': 2666, 'pubMedId': 25923549, 'title': 'AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25923549'}]",sensitive,660,Osimertinib,1956
361,Preclinical - Cell culture,"In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in a lung cancer cell line harboring an EGFR exon 19 deletion in culture (PMID: 28416483).",Actionable,11317,1324,lung cancer,DOID,367,EGFR exon 19 del,"[{'id': 8735, 'pubMedId': 28416483, 'title': 'SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28416483'}]",sensitive,2225,Osimertinib + Selumetinib,1956
362,Preclinical - Cell line xenograft,"In a preclinical study, TH-4000 induced tumor regression in erlotinib-resistant human cell line xenograft models of non-small cell lung cancer harboring EGFR exon 19 deletion mutations (J Clin Oncol 33, 2015 (suppl; abstr e13548)).",Actionable,2551,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,"[{'id': 3281, 'pubMedId': None, 'title': 'TH-4000, a hypoxia-activated EGFR/Her2 inhibitor to treat EGFR-TKI resistant T790M-negative NSCLC.', 'url': 'http://meetinglibrary.asco.org/content/153293-156'}]",sensitive,2910,TH-4000,1956
363,Preclinical - Cell culture,"In a preclinical study, BGB-283 inhibited proliferation of transformed cells over expressing EGFR exon 19 deletion mutation in culture (PMID: 26208524).",Actionable,8060,10000003,Advanced Solid Tumor,JAX,367,EGFR exon 19 del,"[{'id': 5280, 'pubMedId': 26208524, 'title': 'BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26208524'}]",sensitive,4025,BGB-283,1956
364,Guideline,"Tarceva (erlotinib) is an active regimen in patients with advanced, recurrent, or metastatic non-small cell lung cancer with sensitizing EGFR mutations (Guidelines).",Actionable,2010,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,"[{'id': 2454, 'pubMedId': None, 'title': 'NCCN Guidelines Version 5.2015 Non-Small Cell Lung Cancer', 'url': ''}]",sensitive,4,Erlotinib,1956
365,Phase II,"In a Phase II clinical trial, treatment with Tarceva (erlotinib) resulted in a median progression-free survival (PFS) of 10.8 months for the intent-to-treat population of non-small cell lung cancer patients with EGFR mutations, with a PFS of 11.0 months for patients harboring EGFR exon 19 deletions (PMID: 26720423).",Actionable,5304,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,"[{'id': 4999, 'pubMedId': 26720423, 'title': 'First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26720423'}]",sensitive,4,Erlotinib,1956
366,FDA approved,"In a Phase III trial that supported FDA approval, Tarceva (erlotinib) improved progression-free survival in non-small cell lung cancer patients harboring EGFR exon 19 deletions (HR= 0.27) (PMID: 24868098).",Actionable,724,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 2334, 'pubMedId': 24868098, 'title': 'U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24868098'}]",sensitive,4,Erlotinib,1956
367,Preclinical - Cell line xenograft,"In a preclinical study, TAE226 treatment inhibited cell proliferation and decreased xenograft tumor size of non-small cell lung carcinoma cell lines harboring EGFR Exon 19 deletion mutation (PMID: 26090892).",Actionable,3928,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,"[{'id': 4301, 'pubMedId': 26090892, 'title': 'TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26090892'}]",sensitive,2086,TAE226,1956
368,Clinical Study,"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Gilotrif (afatinib) (PMID: 27694386). ",Actionable,9531,3910,lung adenocarcinoma,DOID,25627,EGFR exon 19 del MET amp,"[{'id': 7247, 'pubMedId': 27694386, 'title': 'Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27694386'}]",sensitive,623,Afatinib,1956
369,Preclinical - Cell line xenograft,"In a preclinical study, JNJ-61186372 inhibited tumor growth in Tarceva (erlotinib)-resistant non-small cell lung cancer cell line xenograft models harboring an EGFR exon 19 deletion and MET amplification (PMID: 27216193).",Actionable,7503,3908,non-small cell lung carcinoma,DOID,25627,EGFR exon 19 del MET amp,"[{'id': 6352, 'pubMedId': 27216193, 'title': 'A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27216193'}]",sensitive,4491,JNJ-61186372,1956
370,Clinical Study,"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Tarceva (erlotinib) (PMID: 27694386). ",Actionable,9532,3910,lung adenocarcinoma,DOID,25627,EGFR exon 19 del MET amp,"[{'id': 7247, 'pubMedId': 27694386, 'title': 'Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27694386'}]",resistant,4,Erlotinib,1956
371,Clinical Study,"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification demonstrated a near complete response when treated with the combination of Savolitinib (AZD6094) and Tagrisso (osimertinib), however, after 36 weeks presented with progression (PMID: 27694386).",Actionable,9533,3910,lung adenocarcinoma,DOID,25627,EGFR exon 19 del MET amp,"[{'id': 7247, 'pubMedId': 27694386, 'title': 'Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27694386'}]",sensitive,2224,Osimertinib + Savolitinib,1956
372,Preclinical,"In a preclinical study, amplification of MET conferred resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring an EGFR exon 19 deletion mutation in culture (PMID: 17463250).",Actionable,2471,3908,non-small cell lung carcinoma,DOID,8120,EGFR del exon19 MET amp,"[{'id': 3145, 'pubMedId': 17463250, 'title': 'MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17463250'}]",resistant,751,Gefitinib,1956
373,Clinical Study,"In a clinical study, treatment with first-line tyrosine kinase inhibitors resulted in a median progression free survival of 4.2 months in non-small cell lung carcinoma patients harboring both TP53 exon 8 and EGFR mutations, compared to 16.8 months in patients harboring TP53 exon 8 wild-type and EGFR exon 19 deletion (J Clin Oncol 34, 2016 (suppl; abstr 9052)).",Actionable,7001,3908,non-small cell lung carcinoma,DOID,24186,EGFR exon 19 del TP53 wild-type,"[{'id': 6006, 'pubMedId': None, 'title': 'Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.', 'url': 'http://meetinglibrary.asco.org/content/165599-176'}]",sensitive,1776,N/A,1956
374,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to WZ4002 after the emergence of NRAS Q61K in culture (PMID: 25870145).",Actionable,4487,3908,non-small cell lung carcinoma,DOID,18236,EGFR exon 19 del NRAS Q61K,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,3075,WZ4002,1956
375,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4485,3908,non-small cell lung carcinoma,DOID,18236,EGFR exon 19 del NRAS Q61K,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,660,Osimertinib,1956
376,Preclinical,"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K in culture (PMID: 25870145).",Actionable,4486,3908,non-small cell lung carcinoma,DOID,18236,EGFR exon 19 del NRAS Q61K,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",sensitive,913,Selumetinib,1956
377,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4491,3908,non-small cell lung carcinoma,DOID,18239,EGFR exon 19 del NRAS G12R,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,660,Osimertinib,1956
378,Preclinical,"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R in culture (PMID: 25870145).",Actionable,4492,3908,non-small cell lung carcinoma,DOID,18239,EGFR exon 19 del NRAS G12R,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",sensitive,913,Selumetinib,1956
379,Preclinical,"In a preclinical study, expression of KRAS G12S in lung adenocarcinoma cells harboring EGFR exon 19 deletion resulted in resistance to Tagrisso (osimertinib) in culture, consistent with KRAS G12S identified in tumor samples of a lung adenocarcinoma patient harboring EGFR exon 19 deletion who developed resistance to Tagrisso (osimertinib) (PMID: 27252416).",Actionable,8803,3910,lung adenocarcinoma,DOID,26445,EGFR exon 19 del KRAS G12S,"[{'id': 6756, 'pubMedId': 27252416, 'title': 'Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27252416'}]",resistant,660,Osimertinib,1956
380,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12V were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4490,3908,non-small cell lung carcinoma,DOID,18238,EGFR exon 19 del NRAS G12V,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,660,Osimertinib,1956
381,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4483,3908,non-small cell lung carcinoma,DOID,18234,EGFR exon 19 del NRAS amp,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,660,Osimertinib,1956
382,Preclinical,"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS in culture (PMID: 25870145).  ",Actionable,4482,3908,non-small cell lung carcinoma,DOID,18234,EGFR exon 19 del NRAS amp,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",sensitive,913,Selumetinib,1956
383,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified NRAS in culture (PMID: 25870145).",Actionable,4484,3908,non-small cell lung carcinoma,DOID,18234,EGFR exon 19 del NRAS amp,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,623,Afatinib,1956
384,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 50% (1/2) and stable disease in 50% (1/2) of non-small cell lung carcinoma patients carrying an EGFR exon 19 deletion and insertion (PMID: 26354527).",Actionable,3363,3908,non-small cell lung carcinoma,DOID,13300,EGFR del exon 19 EGFR exon 19 ins,"[{'id': 3736, 'pubMedId': 26354527, 'title': 'Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26354527'}]",sensitive,623,Afatinib,1956
385,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR S768_D770dup (also referred to as D770_N771insSVD) demonstrated resistance to dacomitinib in culture (PMID: 28363995).",Actionable,10506,10000003,Advanced Solid Tumor,JAX,13009,EGFR S768_D770dup,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",resistant,714,Dacomitinib,1956
386,Preclinical,"In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR S768_D770dup demonstrated resistance to Iressa (gefinitib) in culture (PMID: 25931286).",Actionable,3254,5520,head and neck squamous cell carcinoma,DOID,13009,EGFR S768_D770dup,"[{'id': 3698, 'pubMedId': 25931286, 'title': 'High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25931286'}]",resistant,751,Gefitinib,1956
387,Preclinical,"In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR S768_D770dup demonstrated resistance to Tarceva (erlotinib) in culture (PMID: 25931286).",Actionable,3257,5520,head and neck squamous cell carcinoma,DOID,13009,EGFR S768_D770dup,"[{'id': 3698, 'pubMedId': 25931286, 'title': 'High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25931286'}]",resistant,4,Erlotinib,1956
388,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited EGFR signaling and reduced growth of sinonasal squamous cell carcinoma cells harboring EGFR S768_D770dup in culture (PMID: 25931286).",Actionable,3258,5520,head and neck squamous cell carcinoma,DOID,13009,EGFR S768_D770dup,"[{'id': 3698, 'pubMedId': 25931286, 'title': 'High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted Sinonasal Papilloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25931286'}]",sensitive,828,Neratinib,1956
389,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in progressive disease in 50% (1/2) of non-small cell lung carcinoma patients carrying an EGFR A750V mutation (PMID: 26354527).",Actionable,3362,3908,non-small cell lung carcinoma,DOID,13299,EGFR A750V,"[{'id': 3736, 'pubMedId': 26354527, 'title': 'Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26354527'}]",no benefit,623,Afatinib,1956
390,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3871,9256,colorectal cancer,DOID,16552,EGFR dec exp KRAS wild-type,"[{'id': 3814, 'pubMedId': 23209031, 'title': 'GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209031'}]",sensitive,3154,GA201,1956
391,Preclinical - Cell line xenograft,"In a preclinical study, treatment with the combination of GA201 and Camptosar (irinotecan) resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to either as a single agent (PMID: 23209031).",Actionable,3873,9256,colorectal cancer,DOID,16552,EGFR dec exp KRAS wild-type,"[{'id': 3814, 'pubMedId': 23209031, 'title': 'GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209031'}]",sensitive,3373,GA201 + Irinotecan,1956
392,Preclinical - Cell line xenograft,"In a preclinical study, the combination of ER2 and Platinol (cisplatin) demonstrated synergy in inhibiting tumor growth in a non-small cell lung cancer cell line xenograft model with low expression of wild-type EGFR, that also harbors a KRAS mutation (PMID: 27040853).",Actionable,8042,3908,non-small cell lung carcinoma,DOID,16550,EGFR dec exp KRAS mut,"[{'id': 5133, 'pubMedId': 27040853, 'title': 'ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27040853'}]",sensitive,4625,ER2 + Cisplatin,1956
393,Preclinical,"In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3867,9256,colorectal cancer,DOID,16550,EGFR dec exp KRAS mut,"[{'id': 3814, 'pubMedId': 23209031, 'title': 'GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209031'}]",sensitive,3154,GA201,1956
394,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 induced antibody-dependent cell-mediated cytotoxicity against KRAS-mutant lung adenocarcinoma with low EGFR expression in culture and improved overall survival in low EGFR expressing, KRAS-mutant lung adenocarcinoma cell line xenograft models, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3866,3910,lung adenocarcinoma,DOID,16550,EGFR dec exp KRAS mut,"[{'id': 3814, 'pubMedId': 23209031, 'title': 'GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209031'}]",sensitive,3154,GA201,1956
395,Preclinical,"In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant non-small cell lung cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3865,3908,non-small cell lung carcinoma,DOID,16550,EGFR dec exp KRAS mut,"[{'id': 3814, 'pubMedId': 23209031, 'title': 'GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209031'}]",sensitive,3154,GA201,1956
396,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR V769M demonstrated a response rate of 0% and disease control rate of 100%, and a median progression-free survival of 3.2 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).",Actionable,11159,3908,non-small cell lung carcinoma,DOID,4978,EGFR V769M,"[{'id': 9121, 'pubMedId': None, 'title': 'Clinical efficacy of icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 18, 20 and 21 uncommon mutations.', 'url': 'http://abstracts.asco.org/199/AbstView_199_186649.html'}]",decreased response,769,Icotinib,1956
397,Preclinical - Cell line xenograft,"In a preclinical study, Tarceva (erlotinib) inhibited cell survival of a human glioblastoma multiforme cell line harboring an EGFR-SEPT14 fusion, and inhibited tumor growth in xenograft models (PMID: 23917401).",Actionable,8573,3068,glioblastoma multiforme,DOID,26359,EGFR-SEPT14,"[{'id': 3963, 'pubMedId': 23917401, 'title': 'The integrated landscape of driver genomic alterations in glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23917401'}]",sensitive,4,Erlotinib,1956
398,Preclinical - Cell line xenograft,"In a preclinical study, Tykerb (lapatinib) inhibited cell survival of a human glioblastoma multiforme cell line harboring an EGFR-SEPT14 fusion, and inhibited tumor growth in xenograft models (PMID: 23917401).",Actionable,8572,3068,glioblastoma multiforme,DOID,26359,EGFR-SEPT14,"[{'id': 3963, 'pubMedId': 23917401, 'title': 'The integrated landscape of driver genomic alterations in glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23917401'}]",sensitive,787,Lapatinib,1956
399,Clinical Study,"In a clinical case study, Tarceva (erlotinib) treatment resulted in partial response lasting for 18 months in a patient with lung adenocarcinoma harboring EGFR G719A and L861Q (PMID: 28343545).",Actionable,10486,3910,lung adenocarcinoma,DOID,27525,EGFR G719A EGFR L861Q,"[{'id': 8565, 'pubMedId': 28343545, 'title': 'Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28343545'}]",predicted – sensitive,4,Erlotinib,1956
400,Preclinical - Cell line xenograft,"In a preclinical study, Gilotrif (afatinib) treatment resulted in apoptotic induction in esophagus squamous carcinoma cells harboring EGFR L861Q in culture and inhibited tumor growth in cell line xenograft models (PMID: 27207775). ",Actionable,7882,3748,esophagus squamous cell carcinoma,DOID,1051,EGFR L861Q,"[{'id': 6519, 'pubMedId': 27207775, 'title': 'Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27207775'}]",sensitive,623,Afatinib,1956
401,FDA approved,"A study cataloging tyrosine kinase inhibitor responses of NSCLC patients harboring EGFR mutations determined that EGFR L861Q responded to Iressa (gefitinib), but possibly not as favorably as EGFR L858R, exon 19 deletion, and G719X mutations (PMID: 23344264).",Actionable,784,3908,non-small cell lung carcinoma,DOID,1051,EGFR L861Q,"[{'id': 1, 'pubMedId': 23344264, 'title': 'DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23344264'}]",sensitive,751,Gefitinib,1956
402,Preclinical,"In a preclinical study, esophageal squamous cell carcinoma cells harboring EGFR L861Q demonstrated resistance to treatment with Erbitux (cetuximab) in a cell viability assay (PMID: 27207775). ",Actionable,7881,3748,esophagus squamous cell carcinoma,DOID,1051,EGFR L861Q,"[{'id': 6519, 'pubMedId': 27207775, 'title': 'Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27207775'}]",resistant,694,Cetuximab,1956
403,Clinical Study,"In an analysis of published clinical data, non-small cell cancer patients harboring EGFR L861Q were demonstrated to respond to treatment with Tarceva (erlotinib), but possibly not as favorably as EGFR L858R, exon 19 deletion, and G719X mutations (PMID: 23344264).",Actionable,783,3908,non-small cell lung carcinoma,DOID,1051,EGFR L861Q,"[{'id': 1, 'pubMedId': 23344264, 'title': 'DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23344264'}]",sensitive,4,Erlotinib,1956
404,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR L861Q demonstrated a response rate of 23.53% and disease control rate of 64.71%, and a median progression-free survival of 2.2 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).",Actionable,11160,3908,non-small cell lung carcinoma,DOID,1051,EGFR L861Q,"[{'id': 9121, 'pubMedId': None, 'title': 'Clinical efficacy of icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 18, 20 and 21 uncommon mutations.', 'url': 'http://abstracts.asco.org/199/AbstView_199_186649.html'}]",decreased response,769,Icotinib,1956
405,Phase II,"In a post-hoc analysis of Gilotrif (afatinib) activity in Phase II and Phase III clinical trials, 56.3% (9/16) of non-small cell lung cancer patients harboring EGFR L861Q mutations were found to have demonstrated an objective response, with a mean progression-free survival of 8.2 months, and overall survival of 17.1 months (PMID: 26051236).",Actionable,3251,3908,non-small cell lung carcinoma,DOID,1051,EGFR L861Q,"[{'id': 3328, 'pubMedId': 26051236, 'title': 'Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26051236'}]",sensitive,623,Afatinib,1956
406,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 33% (2/6), stable disease in 50% (3/6), and progressive disease in 17% (1/6) of non-small cell lung carcinoma patients harboring EGFR L861Q (PMID: 26354527).",Actionable,3329,3908,non-small cell lung carcinoma,DOID,1051,EGFR L861Q,"[{'id': 3736, 'pubMedId': 26354527, 'title': 'Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26354527'}]",sensitive,623,Afatinib,1956
407,Preclinical - Cell culture,"In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR L861Q demonstrated resistance to treatment with Tarceva (erlotinib) in a cell viability assay (PMID: 27207775). ",Actionable,7879,3748,esophagus squamous cell carcinoma,DOID,1051,EGFR L861Q,"[{'id': 6519, 'pubMedId': 27207775, 'title': 'Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27207775'}]",resistant,4,Erlotinib,1956
408,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR Y764_V765insHH demonstrated resistance to dacomitinib in culture (PMID: 28363995).",Actionable,10508,10000003,Advanced Solid Tumor,JAX,27529,EGFR Y764_V765insHH,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",resistant,714,Dacomitinib,1956
409,Preclinical - Cell culture,"In a preclinical study, the addition of Mekinist (trametinib) to WZ4002 treatment did not significantly impact cell viability compared to WZ4002 alone, but delayed onset of drug resistance in a non-small cell lung cancer cell line harboring EGFR L747_T751del and EGFR S752I in culture (PMID: 26036643).",Actionable,9057,3908,non-small cell lung carcinoma,DOID,26703,EGFR L747_T751del EGFR S752I,"[{'id': 6890, 'pubMedId': 26036643, 'title': 'Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26036643'}]",sensitive,3351,WZ4002 + Trametinib,1956
410,Preclinical - Cell line xenograft,"In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human breast cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). ",Actionable,7722,1612,breast cancer,DOID,2242,EGFR pos ERBB2 pos,"[{'id': 1835, 'pubMedId': 24837299, 'title': 'Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24837299'}]",sensitive,1048,S-222611,1956
411,Preclinical,"In a preclinical study, colorectal cancer cells positive for EGFR and ERBB2 (HER2) had decreased growth upon Gilotrif (afatinib) treatment (PMID: 21617858).",Actionable,1214,9256,colorectal cancer,DOID,2242,EGFR pos ERBB2 pos,"[{'id': 601, 'pubMedId': 21617858, 'title': 'Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21617858'}]",sensitive,623,Afatinib,1956
412,Preclinical - Cell line xenograft,"In a preclinical study, S-222611 inhibited cell growth, decreased phosphorylation of Egfr and Erbb2, and resulted in anti-tumor activity of human gastric cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). ",Actionable,2842,10534,stomach cancer,DOID,2242,EGFR pos ERBB2 pos,"[{'id': 1835, 'pubMedId': 24837299, 'title': 'Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24837299'}]",sensitive,1048,S-222611,1956
413,Preclinical - Cell line xenograft,"In a preclinical study, Gilotrif (afatinib) pre-treatment inhibited radiotherapy-induced activation of EGFR and ERBB2 (HER2) and downstream AKT and radiosensitized bladder cancer cell lines in culture, and Gilotrif (afatinib) in combination with radiotherapy led to improved tumor growth inhibition in bladder cancer cell line xenograft models compared to radiotherapy alone (PMID: 25589492).",Actionable,8342,11054,urinary bladder cancer,DOID,2242,EGFR pos ERBB2 pos,"[{'id': 6623, 'pubMedId': 25589492, 'title': 'Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25589492'}]",predicted – sensitive,4711,Afatinib + Radiotherapy,1956
414,Preclinical - Cell line xenograft,"In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human lung cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). ",Actionable,7723,1324,lung cancer,DOID,2242,EGFR pos ERBB2 pos,"[{'id': 1835, 'pubMedId': 24837299, 'title': 'Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24837299'}]",sensitive,1048,S-222611,1956
415,Preclinical - Cell line xenograft,"In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human colon cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). ",Actionable,7724,219,colon cancer,DOID,2242,EGFR pos ERBB2 pos,"[{'id': 1835, 'pubMedId': 24837299, 'title': 'Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24837299'}]",sensitive,1048,S-222611,1956
416,Preclinical - Cell line xenograft,"In a preclinical study, SYM004 demonstrated efficacy in cell line xenograft models of Erbitux (cetuximab)-resistant non-small cell lung cancer (PMID: 24204198).",Actionable,1231,3908,non-small cell lung carcinoma,DOID,1102,EGFR positive,"[{'id': 243, 'pubMedId': 24130052, 'title': 'Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24130052'}, {'id': 246, 'pubMedId': 24204198, 'title': 'Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24204198'}]",predicted – sensitive,931,SYM004,1956
417,Phase I,"In a Phase I clinical trial, AC480 (BMS-599626) treatment demonstrated preliminary clinical activity, resulting in stable disease as best response in 25% (11/44) of patients with advanced solid tumors, including patients expressing EGFR and/or ERBB2, with 2 patients achieving stable disease for greater than 6 months (PMID: 21576284).",Actionable,4371,10000003,Advanced Solid Tumor,JAX,1102,EGFR positive,"[{'id': 53, 'pubMedId': 21576284, 'title': 'Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21576284'}]",predicted – sensitive,977,AC480,1956
418,Phase I,"In a Phase I study, 13% (5/39) of patients with metastatic colorectal cancer resistant to EGFR therapy had a partial response to SYM004 while 44% (17/39) demonstrated tumor regression (PMID: 25962717).",Actionable,2229,9256,colorectal cancer,DOID,1102,EGFR positive,"[{'id': 2801, 'pubMedId': 25962717, 'title': 'Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25962717'}]",sensitive,931,SYM004,1956
419,Preclinical - Cell culture,"In a preclinical study, tumor cell lines expressing EGFR  demonstrated efficacy in culture when treated with the bispecific antibody, AFM24 (J Clin Oncol 35, 2017 (suppl; abstr e14001)).",Actionable,11075,10000003,Advanced Solid Tumor,JAX,1102,EGFR positive,"[{'id': 9065, 'pubMedId': None, 'title': 'EGFR/CD16A tetravalent bispecific antibody AFM24 to engage NK-cells to kill EGFR expressing tumor cells and safety results in cynomolgus monkey studies', 'url': 'http://abstracts.asco.org/199/AbstView_199_191813.html'}]",sensitive,5856,AFM24,1956
420,Phase II,"In a Phase II trial, addition of Nimotuzumab to Camptosar (irinotecan) improved median progression-free survival (118.5 vs 59.0 days), median overall survival (358.5 vs 229.5 days) and response rate (33.3% vs 0.0 %) compared to Camptosar alone in EGFR positive gastric cancer patients (PMID: 25185971).",Actionable,8760,10534,stomach cancer,DOID,1102,EGFR positive,"[{'id': 6733, 'pubMedId': 25185971, 'title': 'Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25185971'}]",predicted – sensitive,4806,Irinotecan + Nimotuzumab,1956
421,Phase I,"In a Phase I clinical trial, S-222611 demonstrated safety and some efficacy in patients with advanced solid tumors expressing EGFR or ERBB2 (HER2), with an overall clinical benefit rate of 27% (7/33) (PMID: 25434923).",Actionable,1148,10000003,Advanced Solid Tumor,JAX,1102,EGFR positive,"[{'id': 4497, 'pubMedId': 25434923, 'title': 'Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25434923'}]",predicted – sensitive,1048,S-222611,1956
422,Preclinical - Cell line xenograft,"In a preclinical study, GC1118 inhibited EGFR ligand binding and reduced ligand-induced downstream signaling and proliferation of colorectal cancer cell lines exposed to a variety of EGFR ligands in culture, and inhibited tumor growth in colorectal cancer cell line xenograft models expressing high-affinity EGFR ligands (PMID: 26586721).",Actionable,9299,9256,colorectal cancer,DOID,1102,EGFR positive,"[{'id': 7066, 'pubMedId': 26586721, 'title': 'GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26586721'}]",predicted – sensitive,2913,GC1118,1956
423,Phase I,"In a Phase I trial, ABBV-221 demonstrated safety and preliminary efficacy, resulting in stable disease in 38% (16/42) of patients with EGFR-dependent solid tumors (Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 2510-2510; NCT02365662). ",Actionable,11803,10000003,Advanced Solid Tumor,JAX,1102,EGFR positive,"[{'id': 9794, 'pubMedId': None, 'title': 'Preliminary results from a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to express EGFR.', 'url': 'http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2510'}]",predicted – sensitive,2914,ABBV-221,1956
424,Preclinical - Cell line xenograft,"In a preclinical study, S-222611 inhibited tumor growth of human kidney cancer cells expressing EGFR in cell line xenograft models (PMID: 24837299). ",Actionable,7725,263,kidney cancer,DOID,1102,EGFR positive,"[{'id': 1835, 'pubMedId': 24837299, 'title': 'Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24837299'}]",sensitive,1048,S-222611,1956
425,Phase I,"In a Phase I clinical trial in patients with advanced solid tumors, MM-151 demonstrated safety and preliminary antitumor activity in patients with colorectal cancer (CRC), with 2 partial responses and 30% (8/26) of CRC patients demonstrating stable disease for greater than 4 months (J Clin Oncol 32:5s, 2014 (suppl; abstr 2518)).",Actionable,7048,9256,colorectal cancer,DOID,1102,EGFR positive,"[{'id': 6054, 'pubMedId': None, 'title': 'Phase 1 trial of MM-151, a novel oligoclonal anti-EGFR antibody combination in patients with refractory solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/132144-144'}]",predicted – sensitive,821,MM-151,1956
426,Preclinical - Cell line xenograft,"In a preclinical study, SYM004 enhanced sensitivity to radiation therapy in non-small cell lung cancer cells in culture and in cell line xenografts (PMID: 24130052).",Actionable,6671,3908,non-small cell lung carcinoma,DOID,1102,EGFR positive,"[{'id': 243, 'pubMedId': 24130052, 'title': 'Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24130052'}]",predicted – sensitive,4231,SYM004 + Radiotherapy,1956
427,Phase I,"In a Phase I trial, ABBV-221 demonstrated safety and preliminary efficacy, resulting in unconfirmed partial response in a patient with head and neck cancer that expressed high level of Egfr and its ligand (Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 2510-2510; NCT02365662). ",Actionable,11804,11934,head and neck cancer,DOID,1102,EGFR positive,"[{'id': 9794, 'pubMedId': None, 'title': 'Preliminary results from a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to express EGFR.', 'url': 'http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2510'}]",predicted – sensitive,2914,ABBV-221,1956
428,Phase III,"In a Phase III trial, no difference in disease free survival was observed in non-small cell lung cancer patients positive for Egfr treated with Tarceva (erlotinib) vs placebo in the adjuvant setting (PMID: 26324372).",Actionable,4437,3908,non-small cell lung carcinoma,DOID,1102,EGFR positive,"[{'id': 4546, 'pubMedId': 26324372, 'title': 'Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26324372'}]",no benefit,4,Erlotinib,1956
429,Preclinical - Cell line xenograft,"In a preclinical study, EGFRBi-armed autologous activated T cells demonstrated efficacy in cultured cells and cell line mouse xenograft models of a variety of EGFR positive tumor types including pancreatic adenocarcinoma (PMID: 16397041).",Actionable,335,4074,pancreatic adenocarcinoma,DOID,1102,EGFR positive,"[{'id': 1030, 'pubMedId': 16397041, 'title': 'Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16397041'}]",sensitive,1012,EGFRBi-armed autologous activated T cells,1956
430,Preclinical - Cell culture,"In a preclinical study, AVID100 demonstrated activity against several EGFR-positive tumor cell lines in culture (Eur J Cancer, Dec 2016, Vol 69, S147).",Actionable,10973,10000003,Advanced Solid Tumor,JAX,1102,EGFR positive,"[{'id': 8969, 'pubMedId': None, 'title': 'Development of AVID100, a novel antibody–drug conjugate for the treatment of EGFR expressing solid tumors', 'url': 'http://www.ejcancer.com/article/S0959-8049%2816%2933037-4/abstract'}]",predicted – sensitive,5755,AVID100,1956
431,Preclinical - Cell culture,"In a preclinical study, EGFRBi-armed autologous activated T cells demonstrated efficacy in cultured cells of a variety of EGFR positive tumor types (PMID: 16397041).",Actionable,336,10000003,Advanced Solid Tumor,JAX,1102,EGFR positive,"[{'id': 1030, 'pubMedId': 16397041, 'title': 'Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16397041'}]",sensitive,1012,EGFRBi-armed autologous activated T cells,1956
432,Phase I,"In a Phase I study, patients with advanced solid tumors that were positive for EGFR expression demonstrated no complete or partial responses when treated with Pelitinib (EKB-569) (PMID: 16710023). ",Actionable,23,10000003,Advanced Solid Tumor,JAX,1102,EGFR positive,"[{'id': 1089, 'pubMedId': 16710023, 'title': 'Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16710023'}]",no benefit,852,Pelitinib,1956
433,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 resulted in improved overall survival in EGFR-positive pancreatic cancer cell line xenograft models harboring KRAS mutations, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).
",Actionable,3869,1793,pancreatic cancer,DOID,16548,EGFR pos KRAS mut,"[{'id': 3814, 'pubMedId': 23209031, 'title': 'GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209031'}]",sensitive,3154,GA201,1956
434,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 resulted in increased tumor growth inhibition in EGFR-positive triple-negative breast cancer cell line xenograft models harboring KRAS mutations when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).
",Actionable,3870,60081,triple-receptor negative breast cancer,DOID,16548,EGFR pos KRAS mut,"[{'id': 3814, 'pubMedId': 23209031, 'title': 'GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209031'}]",sensitive,3154,GA201,1956
435,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 resulted in improved overall survival in EGFR-positive renal cell carcinoma cell line xenograft models harboring KRAS mutations, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3868,4450,renal cell carcinoma,DOID,16548,EGFR pos KRAS mut,"[{'id': 3814, 'pubMedId': 23209031, 'title': 'GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209031'}]",sensitive,3154,GA201,1956
436,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR L833F demonstrated a response rate of 0% and disease control rate of 100%, and a median progression-free survival of 4.2 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).",Actionable,11162,3908,non-small cell lung carcinoma,DOID,27921,EGFR L833F,"[{'id': 9121, 'pubMedId': None, 'title': 'Clinical efficacy of icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 18, 20 and 21 uncommon mutations.', 'url': 'http://abstracts.asco.org/199/AbstView_199_186649.html'}]",decreased response,769,Icotinib,1956
437,Clinical Study,"In a retrospective clinical study, non-small cell lung cancer patients with EGFR exon 20 insertions demonstrated inferior progression-free survival following treatment with first-generation EGFR tyrosine kinase inhibitors such as Iressa (gefitinib), Tarceva (erlotinib), or Icotinib compared to patients with EGFR L858R and exon 19 deletion mutations (1.9 months vs. 10.8 months) (PMID: 27468240).",Actionable,7799,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,"[{'id': 6499, 'pubMedId': 27468240, 'title': 'Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27468240'}]",predicted – resistant,4,Erlotinib,1956
438,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions displayed progressive disease following treatment with Tarceva (erlotinib), and resistance to Tarceva (erlotinib) was replicated in cell culture studies (PMID: 24353160).",Actionable,2568,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,"[{'id': 440, 'pubMedId': 24353160, 'title': 'Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24353160'}]",predicted – resistant,4,Erlotinib,1956
439,Preclinical - Pdx & cell culture,"In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing EGFR exon 20 insertions in culture, and induced tumor regression in PDX models (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).",Actionable,5915,10000003,Advanced Solid Tumor,JAX,4039,EGFR exon 20 ins,"[{'id': 5195, 'pubMedId': None, 'title': 'AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=407e597a-33c8-4936-87f4-08ee4b23e8b9&cKey=34ee7ebf-07c6-40ea-825f-28fb5018ec92&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]",sensitive,3981,AP32788,1956
440,Preclinical - Cell culture,"In a preclinical study, EGF816 inhibited growth of transformed cell lines expressing three different EGFR exon 20 insertions in culture (PMID: 26825170).",Actionable,5655,10000003,Advanced Solid Tumor,JAX,4039,EGFR exon 20 ins,"[{'id': 5135, 'pubMedId': 26825170, 'title': 'EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26825170'}]",predicted – sensitive,1309,EGF816,1956
441,Preclinical,"In a preclinical study, cells expressing an EGFR exon 20 insertion demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 24065731).",Actionable,2561,10000003,Advanced Solid Tumor,JAX,4039,EGFR exon 20 ins,"[{'id': 157, 'pubMedId': 24065731, 'title': 'Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24065731'}]",resistant,1003,CO1686,1956
442,Clinical Study,"In a retrospective study, non-small cell lung cancer patients with EGFR exon 20 insertions demonstrated inferior progression-free survival following treatment with first-generation EGFR tyrosine kinase inhibitors such as Iressa (gefitinib), Tarceva (erlotinib), or icotinib compared to patients with EGFR L858R or exon 19 deletion mutations (1.9 months vs. 10.8 months) (PMID: 27468240).",Actionable,7800,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,"[{'id': 6499, 'pubMedId': 27468240, 'title': 'Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27468240'}]",decreased response,769,Icotinib,1956
443,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions demonstrated a response rate of 11.11%  and disease control rate of 44.44%, and a median progression-free survival of 1.9 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)). ",Actionable,11153,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,"[{'id': 9121, 'pubMedId': None, 'title': 'Clinical efficacy of icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 18, 20 and 21 uncommon mutations.', 'url': 'http://abstracts.asco.org/199/AbstView_199_186649.html'}]",decreased response,769,Icotinib,1956
444,Phase II,"In a post-hoc analysis of Gilotrif (afatinib) activity in non-small cell lung cancer patients with uncommon EGFR mutations, Gilotrif (afatinib) was found to have limited clinical activity in patients harboring EGFR exon 20 insertions, with 8.7% (2/23) patients achieving partial response and a median progression-free survival of 2.7 months (PMID: 26051236).",Actionable,2612,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,"[{'id': 3328, 'pubMedId': 26051236, 'title': 'Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26051236'}]",resistant,623,Afatinib,1956
445,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 33% (1/3), stable disease in 33% (1/3), and progressive disease in 337% (1/3) in non-small cell lung carcinoma patients carrying an EGFR exon 20 insertion mutation (PMID: 26354527).
",Actionable,3364,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,"[{'id': 3736, 'pubMedId': 26354527, 'title': 'Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26354527'}]",resistant,623,Afatinib,1956
446,Preclinical,"In a preclinical study, non-small cell carcinoma cell lines harboring EGFR exon 20 insertions demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160).",Actionable,2567,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,"[{'id': 440, 'pubMedId': 24353160, 'title': 'Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24353160'}]",resistant,623,Afatinib,1956
447,Phase II,"In a Phase II trial, AUY922 demonstrated safety and preliminary efficacy in EGFR TKI-resistant non-small cell lung cancer patients harboring EGFR exon 20 insertions, with 10% (1/10) of patients achieving partial response and 30% of (3/10) patients achieving stable disease, and a median progression-free survival of 6.1 months (J Clin Oncol 33, 2015 (suppl; abstr 8015)).",Actionable,2559,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,"[{'id': 3291, 'pubMedId': None, 'title': 'Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.', 'url': 'http://meetinglibrary.asco.org/content/148352-156'}]",sensitive,647,AUY922,1956
448,Preclinical,"In a preclinical study, transformed cells expressing an EGFR exon 20 insertion mutation had decreased response to Dacomitinib compared to other EGFR activating mutations, with inhibitory doses exceeding clinically attainable levels (PMID: 18089823, PMID: 21764376).",Actionable,2562,10000003,Advanced Solid Tumor,JAX,4039,EGFR exon 20 ins,"[{'id': 3313, 'pubMedId': 18089823, 'title': 'PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18089823'}, {'id': 3314, 'pubMedId': 21764376, 'title': 'EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21764376'}]",resistant,714,Dacomitinib,1956
449,Preclinical,"In a preclinical study, cells expressing an EGFR exon 20 insertion mutation were resistant to AZD9291 in culture (PMID: 24893891).",Actionable,2564,10000003,Advanced Solid Tumor,JAX,4039,EGFR exon 20 ins,"[{'id': 537, 'pubMedId': 24893891, 'title': 'AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24893891'}]",resistant,660,Osimertinib,1956
450,Clinical Study,"In a retrospective clinical study, non-small cell lung cancer patients with EGFR exon 20 insertions demonstrated inferior progression-free survival following treatment with first-generation EGFR tyrosine kinase inhibitors such as Iressa (gefitinib), Tarceva (erlotinib), or Icotinib compared to patients with EGFR L858R and exon 19 deletion mutations (1.9 months vs. 10.8 months) (PMID: 27468240).",Actionable,7798,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,"[{'id': 6499, 'pubMedId': 27468240, 'title': 'Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27468240'}]",resistant,751,Gefitinib,1956
451,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions displayed progressive disease following treatment with Iressa (gefitinib), and resistance to Iressa (gefitinib) was replicated in cell culture studies (PMID: 24353160).",Actionable,2569,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,"[{'id': 440, 'pubMedId': 24353160, 'title': 'Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24353160'}]",resistant,751,Gefitinib,1956
452,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR H773_V774insH, displayed progressive disease following treatment with Iressa (gefitinib) (PMID: 24353160).",Actionable,793,3908,non-small cell lung carcinoma,DOID,1047,EGFR H773_V774insH,"[{'id': 440, 'pubMedId': 24353160, 'title': 'Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24353160'}]",resistant,751,Gefitinib,1956
453,Preclinical,"In a preclinical study, non-small cell carcinoma cell lines harboring EGFR exon 20 insertions, including EGFR H773_V774insH, demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160).",Actionable,795,3908,non-small cell lung carcinoma,DOID,1047,EGFR H773_V774insH,"[{'id': 440, 'pubMedId': 24353160, 'title': 'Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24353160'}]",resistant,623,Afatinib,1956
454,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR H773_V774insH, displayed progressive disease following treatment with Tarceva (erlotinib), and resistance to Tarceva (erlotinib) was replicated in cell culture studies (PMID: 24353160).",Actionable,794,3908,non-small cell lung carcinoma,DOID,1047,EGFR H773_V774insH,"[{'id': 440, 'pubMedId': 24353160, 'title': 'Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24353160'}]",resistant,4,Erlotinib,1956
455,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR E709 mutations demonstrated a response rate of 66.66% and a median progression-free survival of 3.1 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).",Actionable,11156,3908,non-small cell lung carcinoma,DOID,13298,EGFR E709X,"[{'id': 9121, 'pubMedId': None, 'title': 'Clinical efficacy of icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 18, 20 and 21 uncommon mutations.', 'url': 'http://abstracts.asco.org/199/AbstView_199_186649.html'}]",decreased response,769,Icotinib,1956
456,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 50% (2/4) and stable disease in 50% (2/4) of non-small cell lung carcinoma patients carrying an EGFR E709 mutation (PMID: 26354527).",Actionable,3360,3908,non-small cell lung carcinoma,DOID,13298,EGFR E709X,"[{'id': 3736, 'pubMedId': 26354527, 'title': 'Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26354527'}]",sensitive,623,Afatinib,1956
457,Preclinical,"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR G465E in culture (PMID: 26843189).",Actionable,6632,9256,colorectal cancer,DOID,23653,EGFR G465E,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",sensitive,821,MM-151,1956
458,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR G465E were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6634,9256,colorectal cancer,DOID,23653,EGFR G465E,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",resistant,694,Cetuximab,1956
459,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR G465E were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6633,9256,colorectal cancer,DOID,23653,EGFR G465E,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",resistant,845,Panitumumab,1956
460,Preclinical - Cell culture,"In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with EGFR and MET copy number gain in culture (PMID: 27595477).",Actionable,11557,4914,esophagus adenocarcinoma,DOID,17304,EGFR amp MET amp,"[{'id': 9641, 'pubMedId': 27595477, 'title': 'Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27595477'}]",sensitive,3440,Crizotinib + Lapatinib,1956
461,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",Actionable,7665,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,2618,SCH772984,1956
462,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7664,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1066,Trametinib + Dabrafenib,1956
463,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Selumetinib (AZD6244) in culture (PMID: 27312529).",Actionable,7637,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,913,Selumetinib,1956
464,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7666,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4542,Cetuximab + Dabrafenib + SCH772984,1956
465,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).",Actionable,7635,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,694,Cetuximab,1956
466,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment in culture (PMID: 27312529).",Actionable,7633,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4536,Cetuximab + Selumetinib,1956
467,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7636,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,342,Vemurafenib,1956
468,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",Actionable,7663,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1916,Cetuximab + Encorafenib,1956
469,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Selumetinib (AZD6244), and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7634,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4540,Cetuximab + Selumetinib + Vemurafenib,1956
470,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7632,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1711,Vemurafenib + Cetuximab,1956
471,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired EGFR amplification (PMID: 27312529).",Actionable,7621,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,3773,Selumetinib + Vemurafenib,1956
472,Phase III,"In a Phase III study, response to Vectibix (pantitumumab) was associated with EGFR amplification in colorectal cancer patients (PMID: 17664472).",Actionable,2554,9256,colorectal cancer,DOID,447,EGFR amp,"[{'id': 3284, 'pubMedId': 17664472, 'title': 'Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17664472'}]",sensitive,845,Panitumumab,1956
473,Phase Ib/II,"In a Phase I/II clinical trial, Torisel (temsirolimus) in combination with Tarceva (erlotinib) demostrated minimal efficacy at the maximum tolerated dosage in high-grade glioma patients, with no correlation between EGFR amplification and survival (PMID: 24470557).",Actionable,847,3070,malignant glioma,DOID,447,EGFR amp,"[{'id': 491, 'pubMedId': 24470557, 'title': 'Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24470557'}]",no benefit,1340,Temsirolimus + Erlotinib,1956
474,Preclinical - Cell line xenograft,"In a preclinical study, Gilotrif (afatinib) inhibited growth of head and neck squamous cell carcinoma (HNSCC) cell lines in culture, and inhibited tumor growth in HNSCC cell line xenograft models, with highest efficacy against EGFR-amplified cell lines (PMID: 25559287).",Actionable,6072,5520,head and neck squamous cell carcinoma,DOID,447,EGFR amp,"[{'id': 2348, 'pubMedId': 25559287, 'title': 'Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25559287'}]",sensitive,623,Afatinib,1956
475,Preclinical,"In a preclinical study, ABT-414 demonstrated cytotoxicity against a EGFR-amplified triple-negative breast cancer cell line in culture (PMID: 26846818).",Actionable,6996,60081,triple-receptor negative breast cancer,DOID,447,EGFR amp,"[{'id': 5960, 'pubMedId': 26846818, 'title': 'ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26846818'}]",sensitive,976,ABT-414,1956
476,Preclinical - Cell culture,"In a preclinical study, the combination of Tarceva (erlotinib) and PF-431396 resulted in a synergistic effect in a triple-receptor negative breast cancer cell line harboring EGFR amplification, demonstrating inhibition of cell growth in culture (PMID: 27793840). ",Actionable,10109,60081,triple-receptor negative breast cancer,DOID,447,EGFR amp,"[{'id': 8020, 'pubMedId': 27793840, 'title': 'Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27793840'}]",sensitive,5393,Erlotinib + PF-431396,1956
477,Preclinical - Cell culture,"In a preclinical study, combination of an unspecified EGFR antibody, an unspecified Erbb3 (Her3) antibody, and an unspecified Igf-1r antibody resulted in potent inhibition of survival in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",Actionable,7781,11934,head and neck cancer,DOID,447,EGFR amp,"[{'id': 6493, 'pubMedId': 27196767, 'title': 'Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196767'}]",sensitive,4580,EGFR antibody + ERBB3 antibody + IGF-1R antibody,1956
478,Preclinical - Cell culture,"In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Tarceva (erlotinib) in a cell viability assay (PMID: 27207775). ",Actionable,7894,3748,esophagus squamous cell carcinoma,DOID,447,EGFR amp,"[{'id': 6519, 'pubMedId': 27207775, 'title': 'Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27207775'}]",resistant,4,Erlotinib,1956
479,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Erbitux (cetuximab) in a cell viability assay (PMID: 27207775).",Actionable,7897,5520,head and neck squamous cell carcinoma,DOID,447,EGFR amp,"[{'id': 6519, 'pubMedId': 27207775, 'title': 'Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27207775'}]",resistant,694,Cetuximab,1956
480,Preclinical - Cell culture,"In a preclinical study, the combination of Iressa (gefitinib) and PF-573228 resulted in a synergistic effect in a triple-receptor negative breast cancer cell line harboring EGFR amplification, demonstrating decreased colony formation in culture (PMID: 27793840). ",Actionable,10100,60081,triple-receptor negative breast cancer,DOID,447,EGFR amp,"[{'id': 8020, 'pubMedId': 27793840, 'title': 'Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27793840'}]",sensitive,5389,Gefitinib + PF-573228,1956
481,Preclinical - Pdx,"In preclinical studies, Erbitux (cetuximab) promoted tumor growth inhibition in several patient-derived xenograft models of gastric cancers with EGFR amplification (PMID: 24141978).
",Actionable,140,3119,gastrointestinal system cancer,DOID,447,EGFR amp,"[{'id': 973, 'pubMedId': 24141978, 'title': 'A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141978'}]",sensitive,694,Cetuximab,1956
482,Preclinical - Cell line xenograft,"In a preclinical study, SHP099 inhibited ERK activation and reduced proliferation of EGFR-amplified esophageal squamous cell carcinoma cells in culture, and inhibited tumor growth in EGFR-amplified esophageal squamous cell carcinoma cell line xenograft models (PMID: 27362227).",Actionable,7513,3748,esophagus squamous cell carcinoma,DOID,447,EGFR amp,"[{'id': 6394, 'pubMedId': 27362227, 'title': 'Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27362227'}]",sensitive,4504,SHP099,1956
483,Preclinical - Cell culture,"In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Erbitux (cetuximab) in a cell viability assay (PMID: 27207775). ",Actionable,7896,3748,esophagus squamous cell carcinoma,DOID,447,EGFR amp,"[{'id': 6519, 'pubMedId': 27207775, 'title': 'Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27207775'}]",resistant,694,Cetuximab,1956
484,Phase I,"In a Phase I trial, ABT-414 displayed safety and preliminary efficacy in advanced solid tumor patients with EGFR amplification (J Clin Oncol 33, 2015 (suppl; abstr 2510)).",Actionable,3741,10000003,Advanced Solid Tumor,JAX,447,EGFR amp,"[{'id': 4090, 'pubMedId': None, 'title': 'ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR)', 'url': 'http://meetinglibrary.asco.org/content/146940-156'}]",sensitive,976,ABT-414,1956
485,Preclinical - Cell culture,"In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Gilotrif (afatinib) in a cell viability assay (PMID: 27207775). ",Actionable,7892,3748,esophagus squamous cell carcinoma,DOID,447,EGFR amp,"[{'id': 6519, 'pubMedId': 27207775, 'title': 'Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27207775'}]",resistant,623,Afatinib,1956
486,Preclinical - Cell culture,"In a preclinical study, the combination of Iressa (gefitinib) and PF-431396 resulted in a synergistic effect in a triple-receptor negative breast cancer cell line harboring EGFR amplification, demonstrating a decrease in colony formation in culture (PMID: 27793840). ",Actionable,10104,60081,triple-receptor negative breast cancer,DOID,447,EGFR amp,"[{'id': 8020, 'pubMedId': 27793840, 'title': 'Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27793840'}]",sensitive,5391,Gefitinib + PF-431396,1956
487,Preclinical - Pdx & cell culture,"In a preclinical study, Dacomitinib inhibited Egfr signaling and survival of patient-derived EGFR amplified glioblastoma cells in culture and in intracranial xenograft models (PMID: 25939761).",Actionable,8043,3068,glioblastoma multiforme,DOID,447,EGFR amp,"[{'id': 6540, 'pubMedId': 25939761, 'title': 'Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25939761'}]",sensitive,714,Dacomitinib,1956
488,Preclinical - Cell line xenograft,"In a preclinical study, ABT-414 demonstrated cytoxicity against an EGFR-amplified head and neck squamous cell carcinoma (HNSCC) cell line in culture and induced tumor regression in EGFR-amplified HNSCC cell line xenograft models (PMID: 26846818).",Actionable,6933,5520,head and neck squamous cell carcinoma,DOID,447,EGFR amp,"[{'id': 5960, 'pubMedId': 26846818, 'title': 'ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26846818'}]",sensitive,976,ABT-414,1956
489,Clinical Study,"In a clinical case study, a patient with esophageal adenocarcinoma progressed on AMG 337 therapy upon outgrowth of EGFR amplified tumor cells (PMID: 26432108).",Actionable,4101,4914,esophagus adenocarcinoma,DOID,447,EGFR amp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",resistant,1064,AMG 337,1956
490,Preclinical,"In a preclinical study, MM-151 antagonized EGFR activity and inhibited proliferation in several tumor cell lines in culture (PMID: 25911688).",Actionable,2553,10000003,Advanced Solid Tumor,JAX,447,EGFR amp,"[{'id': 3282, 'pubMedId': 25911688, 'title': 'Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25911688'}]",predicted – sensitive,821,MM-151,1956
491,Preclinical - Cell culture,"In a preclinical study, combination of two unspecified EGFR antibodies targeting nonoverlapping epitopes of Egfr resulted in Egfr degradation and inhibition of proliferation in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",Actionable,7776,11934,head and neck cancer,DOID,447,EGFR amp,"[{'id': 6493, 'pubMedId': 27196767, 'title': 'Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196767'}]",sensitive,4575,unspecified EGFR antibody,1956
492,Preclinical - Cell culture,"In a preclinical study, Ganetespib inhibited growth of a non-small cell lung cancer cell line with EGFR amplification and overexpression in culture (PMID: 25077897).",Actionable,8230,3908,non-small cell lung carcinoma,DOID,447,EGFR amp,"[{'id': 2971, 'pubMedId': 25077897, 'title': 'The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25077897'}]",sensitive,745,Ganetespib,1956
493,Phase II,"In a Phase II trial, Caprelsa (vandetinib), in combination with radiation therapy and Temodar (temozolomide), demonstrated no difference in PFS and OS in glioblastoma patients harboring EGFR amplification versus glioblastoma patients without EGFR amplification (PMID: 25910950). ",Actionable,3239,3068,glioblastoma multiforme,DOID,447,EGFR amp,"[{'id': 3688, 'pubMedId': 25910950, 'title': 'A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25910950'}]",no benefit,3094,Vandetanib + Temozolomide,1956
494,Preclinical - Cell culture,"In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Erbb3 (Her3) antibody resulted in inhibition of survival in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",Actionable,7779,11934,head and neck cancer,DOID,447,EGFR amp,"[{'id': 6493, 'pubMedId': 27196767, 'title': 'Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196767'}]",sensitive,4579,unspecified EGFR antibody + unspecified ERBB3 antibody,1956
495,Phase II,"In a Phase II clinical trial, three urothelial carcinoma  patients with EGFR amplification in the absence of other ERBB family member alterations, received no benefit from Gilotrif (afatinib) therapy (PMID: 27044931).",Actionable,5941,11054,urinary bladder cancer,DOID,447,EGFR amp,"[{'id': 5203, 'pubMedId': 27044931, 'title': 'Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27044931'}]",no benefit,623,Afatinib,1956
496,Phase I,"In a Phase I trial, ABT-414 displayed safety and preliminary efficacy in glioblastoma patients with EGFR amplification (J Clin Oncol 33, 2015 (suppl; abstr 2016)).",Actionable,3740,3068,glioblastoma multiforme,DOID,447,EGFR amp,"[{'id': 4089, 'pubMedId': None, 'title': 'Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM).', 'url': 'http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2016'}]",sensitive,976,ABT-414,1956
497,Phase I,"In a Phase I trial, ABT-414 treatment resulted in partial response in 5% (3/56), stable disease in 43% (24/56), and an estimated 6-month progression-free survival rate of 25.3% in patients with bevacizumab-naïve, recurrent glioblastoma harboring EGFR amplification (Neuro Oncol (2016) 18 (suppl 6): vi2.).",Actionable,9358,3068,glioblastoma multiforme,DOID,447,EGFR amp,"[{'id': 7123, 'pubMedId': None, 'title': 'EFFICACY OF A NOVEL ANTIBODY-DRUG CONJUGATE (ADC), ABT-414, AS MONOTHERAPY IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (EGFRamp), RECURRENT GLIOBLASTOMA (rGBM)', 'url': 'http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi2.3.abstract?sid=ef6007c0-0537-40d1-920d-fceb55d555f5'}]",sensitive,976,ABT-414,1956
498,Preclinical - Cell culture,"In a preclinical study, SHP099 inhibited ERK activation and reduced proliferation of an EGFR-amplified triple-negative breast cancer cell line in culture (PMID: 27362227).",Actionable,7514,60081,triple-receptor negative breast cancer,DOID,447,EGFR amp,"[{'id': 6394, 'pubMedId': 27362227, 'title': 'Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27362227'}]",sensitive,4504,SHP099,1956
499,Phase I,"In a Phase I trial, ABT-806 treatment resulted in stable disease for more than 2.5 years in a penile cancer patient harboring EGFR amplification (PMID: 25895099).",Actionable,6891,11615,penile cancer,DOID,447,EGFR amp,"[{'id': 5781, 'pubMedId': 25895099, 'title': 'A phase 1 study of ABT-806 in subjects with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25895099'}]",sensitive,4256,ABT-806,1956
500,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to  Tarceva (erlotinib) in a cell viability assay (PMID: 27207775). ",Actionable,7898,5520,head and neck squamous cell carcinoma,DOID,447,EGFR amp,"[{'id': 6519, 'pubMedId': 27207775, 'title': 'Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27207775'}]",resistant,4,Erlotinib,1956
501,Preclinical - Cell culture,"In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Igf-1r antibody resulted in growth inhibition in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",Actionable,7780,11934,head and neck cancer,DOID,447,EGFR amp,"[{'id': 6493, 'pubMedId': 27196767, 'title': 'Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196767'}]",sensitive,4578,unspecified EGFR antibody + unspecified IGF-1R antibody,1956
502,Clinical Study,"In a clinical study, a colorectal cancer patient harboring EGFR amplification, BRAF V600E, and EGFR S492R demonstrated resistance to Erbitux (cetuximab) (PMID: 22270724). ",Actionable,3221,9256,colorectal cancer,DOID,12768,EGFR amp EGFR S492R BRAF V600E,"[{'id': 3682, 'pubMedId': 22270724, 'title': 'Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22270724'}]",resistant,694,Cetuximab,1956
503,Preclinical - Cell culture,"In a preclinical study, a lung cancer cell line with co-amplification of FGFR1 and EGFR and harboring KRAS G13C demonstrated insensitivity to JNJ-42756493 (erdafitinib) in culture (PMID: 28341788).",Actionable,11185,1324,lung cancer,DOID,27923,EGFR amp FGFR1 amp KRAS G13C,"[{'id': 9140, 'pubMedId': 28341788, 'title': 'Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28341788'}]",resistant,1028,JNJ-42756493,1956
504,Preclinical,"In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification and EGFR G719A in culture (PMID: 26561558).",Actionable,6040,3068,glioblastoma multiforme,DOID,22289,EGFR amp EGFR G719A,"[{'id': 5255, 'pubMedId': 26561558, 'title': 'InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26561558'}]",sensitive,4008,Gefitinib + Linsitinib,1956
505,Preclinical,"In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification and EGFR G719A in culture (PMID: 26561558).",Actionable,6044,3068,glioblastoma multiforme,DOID,22289,EGFR amp EGFR G719A,"[{'id': 5255, 'pubMedId': 26561558, 'title': 'InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26561558'}]",sensitive,4009,BMS-754807 + Dacomitinib,1956
506,Preclinical,"In a preclinical study, Gleevec (imatinib) and Iressa (gefitinib) acted synergistically to decrease downstream signaling activity and inhibit cell growth of glioblastoma cell lines with EGFR and PDGFRA coamplification (PMID: 22323597). ",Actionable,1860,3068,glioblastoma multiforme,DOID,4004,PDGFRA amp EGFR amp,"[{'id': 2352, 'pubMedId': 22323597, 'title': 'Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22323597'}]",sensitive,2483,Gefitinib + Imatinib,1956
507,Phase II,"In a Phase II clinical trial, two urothelial carcinoma patients with ERBB2 (HER2) and EGFR co-amplification had improved progression free survival when treated with Gilotrif (afatinib), and median PFS was 6.6 months for patients with ERBB2 or ERBB3 alterations relative to 1.4 months for patients lacking alterations (PMID: 27044931).",Actionable,5942,11054,urinary bladder cancer,DOID,22032,EGFR amp ERBB2 amp,"[{'id': 5203, 'pubMedId': 27044931, 'title': 'Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27044931'}]",sensitive,623,Afatinib,1956
508,Clinical Study,"In a clinical study, a colorectal cancer patient harboring EGFR amplification and EGFR S492R demonstrated resistance to Erbitux (cetuximab) (PMID: 22270724).",Actionable,3220,9256,colorectal cancer,DOID,12767,EGFR amp EGFR S492R,"[{'id': 3682, 'pubMedId': 22270724, 'title': 'Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22270724'}]",resistant,694,Cetuximab,1956
509,Clinical Study,"In a clinical study, a colorectal cancer patient harboring both EGFR amplification and EGFR S492R demonstrated a 50% tumor reduction when treated with Vectibix (panitumumab) (PMID: 22270724). ",Actionable,3219,9256,colorectal cancer,DOID,12767,EGFR amp EGFR S492R,"[{'id': 3682, 'pubMedId': 22270724, 'title': 'Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22270724'}]",sensitive,845,Panitumumab,1956
510,Preclinical - Pdx & cell culture,"In a preclinical study, patient-derived EGFR amplified glioblastoma cells harboring PTEN loss demonstrated reduced sensitivity to Dacomitinib induced growth inhibition in culture and in xenograft models (PMID: 25939761).",Actionable,8045,3068,glioblastoma multiforme,DOID,26141,EGFR amp PTEN loss,"[{'id': 6540, 'pubMedId': 25939761, 'title': 'Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25939761'}]",decreased response,714,Dacomitinib,1956
511,Preclinical - Cell culture,"In a preclinical study, lung cancer cell lines with co-amplification of FGFR1 and EGFR demonstrated insensitivity to JNJ-42756493 (erdafitinib) in culture (PMID: 28341788).",Actionable,11184,1324,lung cancer,DOID,27922,EGFR amp FGFR1 amp,"[{'id': 9140, 'pubMedId': 28341788, 'title': 'Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28341788'}]",resistant,1028,JNJ-42756493,1956
512,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated increased sensitivity to second-generation EGFR inhibitors including Gilotrif (afatinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).",Actionable,3723,10000003,Advanced Solid Tumor,JAX,14932,EGFR E709_T710delinsD,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",sensitive,623,Afatinib,1956
513,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated decreased sensitivity to the first-generation EGFR inhibitor Iressa (gefitinib) in culture, when compared to second-generation inhibitors, with an IC90 concentration approximately two-times the estimated trough concentration at the recommended dose (PMID: 26206867).",Actionable,3727,10000003,Advanced Solid Tumor,JAX,14932,EGFR E709_T710delinsD,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",decreased response,751,Gefitinib,1956
514,Phase I,"In a clinical case study, treatment with Gilotrif (afatinib) in a lung adenocarcinoma patient harboring EGFR E709_T710delinsD resulted in tumor shrinkage, while prior treatment with Tarceva (erlotinib) had achieved stable disease (PMID: 26206867).",Actionable,3728,3910,lung adenocarcinoma,DOID,14932,EGFR E709_T710delinsD,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",sensitive,623,Afatinib,1956
515,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated decreased sensitivity to third-generation EGFR inhibitors including Rociletinib (CO-1686) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3725,10000003,Advanced Solid Tumor,JAX,14932,EGFR E709_T710delinsD,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",decreased response,1003,CO1686,1956
516,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated increased sensitivity to second-generation EGFR inhibitors including Dacomitinib in culture, when compared to first and third-generation inhibitors (PMID: 26206867).",Actionable,3722,10000003,Advanced Solid Tumor,JAX,14932,EGFR E709_T710delinsD,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",sensitive,714,Dacomitinib,1956
517,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated decreased sensitivity to first-generation EGFR inhibitors including Tarceva (erlotinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3724,10000003,Advanced Solid Tumor,JAX,14932,EGFR E709_T710delinsD,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",decreased response,4,Erlotinib,1956
518,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated decreased sensitivity to third-generation EGFR inhibitors including Tagrisso (AZD9291) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3726,10000003,Advanced Solid Tumor,JAX,14932,EGFR E709_T710delinsD,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",decreased response,660,Osimertinib,1956
519,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated increased sensitivity to second-generation EGFR inhibitors including Nerlynx (neratinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).
",Actionable,3721,10000003,Advanced Solid Tumor,JAX,14932,EGFR E709_T710delinsD,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",sensitive,828,Neratinib,1956
520,Preclinical - Cell culture,"In a preclinical study, dacomitinib inhibited growth of transformed cells expressing EGFR E709_T710delinsD and EGFR L792F in culture (PMID: 27913578).",Actionable,9926,10000003,Advanced Solid Tumor,JAX,27167,EGFR E709_T710delinsD EGFR L792F,"[{'id': 7760, 'pubMedId': 27913578, 'title': 'Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27913578'}]",sensitive,714,Dacomitinib,1956
521,Preclinical - Cell culture,"In a preclinical study, acquisition of EGFR L792F was associated with resistance to Gilotrif in transformed cells expressing EGFR E709_T710delinsD in culture (PMID: 27913578).",Actionable,9925,10000003,Advanced Solid Tumor,JAX,27167,EGFR E709_T710delinsD EGFR L792F,"[{'id': 7760, 'pubMedId': 27913578, 'title': 'Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27913578'}]",resistant,623,Afatinib,1956
522,Preclinical,"In a preclinical study, EKI-285 (CL-387,785) inhibited growth of transformed cells expressing EGFR L858R and EGFR D716Y in culture (PMID: 17085664).",Actionable,3000,10000003,Advanced Solid Tumor,JAX,6332,EGFR D761Y EGFR L858R,"[{'id': 2798, 'pubMedId': 17085664, 'title': 'Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17085664'}]",sensitive,2911,EKI-285,1956
523,Preclinical,"In a preclinical study, transformed cells expressing EGFR L858R and D761Y demonstrated decreased sensitivity to Nerlynx (neratinib) in culture (PMID: 17085664).",Actionable,2996,10000003,Advanced Solid Tumor,JAX,6332,EGFR D761Y EGFR L858R,"[{'id': 2798, 'pubMedId': 17085664, 'title': 'Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17085664'}]",decreased response,828,Neratinib,1956
524,Preclinical,"In a preclinical study, transformed cells expressing EGFR L858R and EGFR D761Y demonstrated decreased sensitivity to Iressa (gefitinib) in culture (PMID: 17085664).",Actionable,2225,10000003,Advanced Solid Tumor,JAX,6332,EGFR D761Y EGFR L858R,"[{'id': 2798, 'pubMedId': 17085664, 'title': 'Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17085664'}]",decreased response,751,Gefitinib,1956
525,Clinical Study,"In a retrospective analysis, a patient with EGFR L858R-mutant non-small lung cancer that developed resistance to Iressa (gefitinib) was demonstrated to have acquired a secondary EGFR D761Y mutation (PMID: 17085664).",Actionable,3248,3908,non-small cell lung carcinoma,DOID,6332,EGFR D761Y EGFR L858R,"[{'id': 2798, 'pubMedId': 17085664, 'title': 'Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17085664'}]",resistant,751,Gefitinib,1956
526,Preclinical,"In a preclinical study, Tarceva (erlotinib) decreased viability of transformed cells expressing EGFR A289V in culture (PMID: 17177598).",Actionable,6917,10000003,Advanced Solid Tumor,JAX,2929,EGFR A289V,"[{'id': 1877, 'pubMedId': 17177598, 'title': 'Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17177598'}]",sensitive,4,Erlotinib,1956
527,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in stable disease in a non-small cell lung carcinoma patient harboring EGFR V769L (PMID: 26354527).
",Actionable,3366,3908,non-small cell lung carcinoma,DOID,3070,EGFR V769L,"[{'id': 3736, 'pubMedId': 26354527, 'title': 'Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26354527'}]",predicted – sensitive,623,Afatinib,1956
528,Preclinical,"In a preclinical study, KRAS G12V was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).",Actionable,6656,3910,lung adenocarcinoma,DOID,23663,EGFR L858R KRAS G12V,"[{'id': 5721, 'pubMedId': 26341921, 'title': 'Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26341921'}]",resistant,4190,Afatinib + Cetuximab,1956
529,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR L858R and EGFR L792F demonstrated decreased sensitivity to Gilotrif (afatinib) in culture compared to cells expressing EGFR L858R alone (PMID: 27913578).",Actionable,9991,10000003,Advanced Solid Tumor,JAX,27221,EGFR L792F EGFR L858R,"[{'id': 7760, 'pubMedId': 27913578, 'title': 'Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27913578'}]",decreased response,623,Afatinib,1956
530,Preclinical - Cell culture,"In a preclinical study, EAI045 inhibited proliferation of transformed cells over expressing EGFR L858R in culture, although at a concentration much higher than the biochemical IC50 of the compound (PMID: 27251290).",Actionable,7581,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,"[{'id': 6436, 'pubMedId': 27251290, 'title': 'Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27251290'}]",sensitive,4520,EAI045,1956
531,Preclinical,"In a preclinical study, CO-1686 demonstrated efficacy in treating transgenic mouse models of lung adenocarcinoma expressing EGFR L858R (PMID: 24065731). ",Actionable,40,3910,lung adenocarcinoma,DOID,369,EGFR L858R,"[{'id': 157, 'pubMedId': 24065731, 'title': 'Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24065731'}]",sensitive,1003,CO1686,1956
532,Preclinical - Cell culture,"In a preclinical study, neither single agent or combination of Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 inhibited growth of transformed cells over expressing EGFR L858R in culture (PMID: 26140595).",Actionable,10251,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,"[{'id': 8232, 'pubMedId': 26140595, 'title': 'A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26140595'}]",no benefit,5443,PF3644022 + PF-477736,1956
533,Preclinical - Cell culture,"In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation and inhibited phosphorylation of downstream signaling molecules Cbl, Erk, Akt, phospholipase C gamma, Stat3, and Stat5 in EGFR L858R expressing transformed cells to a greater degree than EGFR wild-type expressing transformed cells in culture (PMID: 25573954).",Actionable,4779,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,"[{'id': 4727, 'pubMedId': 25573954, 'title': 'Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25573954'}]",sensitive,4,Erlotinib,1956
534,Phase II,"In a Phase II clinical trial, 74% (34/46) of patients with EGFR exon 19 or 21 mutant lung cancers had partial response (PFS average= 17 months) to first line treatment with dacomitinib (J Clin Oncol 30, 2012 (suppl; abstr 7530); NCT00818441).",Actionable,780,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,"[{'id': 448, 'pubMedId': None, 'title': 'First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers', 'url': 'http://meetinglibrary.asco.org/content/99805-114'}]",sensitive,714,Dacomitinib,1956
535,Phase III,"In a Phase III trial, treatment with dacomitinib as first-line therapy in patients with non-small cell lung cancer harboring an EGFR exon 19 deletion or EGFR L858R resulted in an improved median progression-free survival (mPFS) of 14.7 months compared to 9.2 months with Iressa (gefitinib), with a mPFS of 16.5 months with dacomitnib vs. 9.2 months with Iressa (gefitinib) among patients with EGFR L858R (PMID: 28958502; NCT01777421).",Actionable,12178,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,"[{'id': 10136, 'pubMedId': 28958502, 'title': 'Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28958502'}]",sensitive,714,Dacomitinib,1956
536,Preclinical,"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring EGFR L858R mutation in culture (PMID: 26090892).",Actionable,3930,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,"[{'id': 4301, 'pubMedId': 26090892, 'title': 'TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26090892'}]",sensitive,2086,TAE226,1956
537,Phase III,"In a meta-analysis of 12 phase III trials investigating EGFR tyrosine kinase inhibitors in NSCLC patients with EFGR mutations (primarily exon 19 deletions or L858R) indicated TKIs, including icotinib, were superior to standard chemotherapy (PMID: 24533047).",Actionable,782,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,"[{'id': 450, 'pubMedId': 24533047, 'title': 'Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24533047'}]",sensitive,769,Icotinib,1956
538,Preclinical,"In a preclinical study, the combination of Tagrisso (osimertinib) and Selumetinib inhibited growth of lung adenocarcinoma tumors driven by EGFR L858R that had developed resistance through continued exposure to Tagrisso (osimertinib) (PMID: 25870145).",Actionable,4502,3910,lung adenocarcinoma,DOID,369,EGFR L858R,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",sensitive,2225,Osimertinib + Selumetinib,1956
539,FDA approved,"In a Phase III trial that supported FDA approval, Iressa (gefitinib) treatment resulted in an objective response rate of 71.2% (94/132) and increased progression-free survival in non-small cell lung cancer patients harboring EGFR activating mutations including EGFR L858R (PMID: 19692680, NCT00322452).",Actionable,2420,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,"[{'id': 2375, 'pubMedId': 19692680, 'title': 'Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19692680'}]",sensitive,751,Gefitinib,1956
540,Clinical Study,"A network meta-analysis of 12 Phase III trials investigating EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations (primarily exon 19 deletions or L858R) indicated TKIs, including Iressa (gefitinib), were superior to standard chemotherapy (PMID: 24533047).",Actionable,781,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,"[{'id': 450, 'pubMedId': 24533047, 'title': 'Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24533047'}]",sensitive,751,Gefitinib,1956
541,FDA approved,"In a Phase III trial that supported FDA approval, Tarceva (erlotinib) improved progression-free survival in non-small cell lung cancer patients harboring EGFR exon 21 (L858R) substitution mutations (HR= 0.52) (PMID: 24868098).",Actionable,211,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 2334, 'pubMedId': 24868098, 'title': 'U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24868098'}]",sensitive,4,Erlotinib,1956
542,Phase II,"In a Phase II clinical trial, treatment with Tarceva (erlotinib) resulted in a median progression-free survival (PFS) of 10.8 months for the intent-to-treat population of non-small cell lung cancer patients with EGFR mutations, with a PFS of 9.2 months for patients harboring EGFR L858R (PMID: 26720423).",Actionable,5301,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,"[{'id': 4999, 'pubMedId': 26720423, 'title': 'First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26720423'}]",sensitive,4,Erlotinib,1956
543,Preclinical - Cell culture,"In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R in culture (PMID: 28416483).",Actionable,11311,1324,lung cancer,DOID,369,EGFR L858R,"[{'id': 8735, 'pubMedId': 28416483, 'title': 'SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28416483'}]",sensitive,2225,Osimertinib + Selumetinib,1956
544,Preclinical - Cell culture,"In a preclinical study, Iressa (gefitinib) inhibited Egfr phosphorylation and inhibited phosphorylation of downstream signaling molecules Cbl, Erk, Akt, phospholipase C gamma, and Stat5 in EGFR L858R expressing transformed cells to a greater degree than EGFR wild-type expressing transformed cells in culture (PMID: 25573954).",Actionable,4777,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,"[{'id': 4727, 'pubMedId': 25573954, 'title': 'Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25573954'}]",sensitive,751,Gefitinib,1956
545,Clinical Study,"In two clinical case studies, treatment with AZD3759 inhibited EGFR activity and demonstrated antitumor activity in patients harboring EGFR L858R, resulting in decreased CSF tumor cell number in the patient with leptomeningeal metastasis, and decreased brain tumor growth in the patient with brain metastasis (PMID: 27928026). ",Actionable,9567,1324,lung cancer,DOID,369,EGFR L858R,"[{'id': 7282, 'pubMedId': 27928026, 'title': 'AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27928026'}]",sensitive,2912,AZD3759,1956
546,Preclinical - Cell line xenograft,"In a preclinical study, AZD3759 inhibited EGFR activation and growth of a lung cancer cell line harboring EGFR L858R in culture, and inhibited tumor growth in xenograft models (PMID: 27928026).",Actionable,9566,1324,lung cancer,DOID,369,EGFR L858R,"[{'id': 7282, 'pubMedId': 27928026, 'title': 'AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27928026'}]",sensitive,2912,AZD3759,1956
547,Preclinical,"In a preclinical study, Gilotrif (afatinib) and Erbitux (cetuximab) combination treatment resulted in the least tumor recurrence after treatment cessation, and delayed development of treatment resistance compared to single drug treatment in animal models of EGFR L858R-induced lung adenocarcinoma (PMID: 26341921).",Actionable,6651,3910,lung adenocarcinoma,DOID,369,EGFR L858R,"[{'id': 5721, 'pubMedId': 26341921, 'title': 'Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26341921'}]",sensitive,4190,Afatinib + Cetuximab,1956
548,Preclinical - Cell line xenograft,"In a preclinical study, EGF816 inhibited tumor growth and induced tumor regression in cell line xenograft models of non-small cell lung cancer harboring EGFR L858R (Cancer Res 2014;74(19 Suppl):Abstract nr 1733). ",Actionable,2424,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,"[{'id': 3047, 'pubMedId': None, 'title': 'Abstract 1733: EGF816, a novel covalent inhibitor of mutant-selective epidermal growth factor receptor, overcomes T790M-mediated resistance in NSCLC', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/1733.short'}]",sensitive,1309,EGF816,1956
549,Preclinical,"In a preclinical study, Erbitux (cetuximab) inhibited tumor growth in mouse lung adenocarcinoma models expressing EGFR L858R (PMID: 24063894).",Actionable,3109,3910,lung adenocarcinoma,DOID,369,EGFR L858R,"[{'id': 1846, 'pubMedId': 24063894, 'title': 'Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24063894'}]",sensitive,694,Cetuximab,1956
550,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EGFR L858R in culture (PMID: 27780853).",Actionable,9233,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,1956
551,Phase I,"In a Phase I trial, treatment with AZD9291 resulted in a response rate of 11% (2/19) in NSCLC patients harboring EGFR L858R without EGFR T790M (PMID: 25923549).",Actionable,2422,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,"[{'id': 2666, 'pubMedId': 25923549, 'title': 'AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25923549'}]",sensitive,660,Osimertinib,1956
552,Preclinical,"In a preclinical study, EKI-285 (CL-387,785) inhibited growth of transformed cells expressing EGFR L858R in culture (PMID: 17085664).",Actionable,2999,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,"[{'id': 2798, 'pubMedId': 17085664, 'title': 'Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17085664'}]",sensitive,2911,EKI-285,1956
553,Preclinical - Cell culture,"In a preclinical study, EAI045 inhibited Egfr activation but not proliferation of non-small cell lung cancer cells harboring EGFR L858R in culture (PMID: 27251290).",Actionable,7587,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,"[{'id': 6436, 'pubMedId': 27251290, 'title': 'Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27251290'}]",no benefit,4520,EAI045,1956
554,Preclinical,"In a preclinical study, TAE226 treatment inhibited proliferation of transformed human cell lines harboring EGFR L858R mutation in culture (PMID: 26090892).",Actionable,3939,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,"[{'id': 4301, 'pubMedId': 26090892, 'title': 'TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26090892'}]",sensitive,2086,TAE226,1956
555,Preclinical,"In a preclinical study, AV-412 inhibited the kinase activity of EGFR L858R (PMID: 17888033).",Actionable,1378,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,"[{'id': 1110, 'pubMedId': 17888033, 'title': 'Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17888033'}]",sensitive,990,AV-412,1956
556,Preclinical - Cell culture,"In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell lines harboring EGFR L858R in culture (PMID: 28416483).",Actionable,11312,1324,lung cancer,DOID,369,EGFR L858R,"[{'id': 8735, 'pubMedId': 28416483, 'title': 'SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28416483'}]",sensitive,4600,Dasatinib + Selumetinib,1956
557,Phase II,"In a Phase II trial, Gilotrif (afatinib) treatment resulted in improved progression-free survival (11.0 vs 10.9 months) and time-to-treatment failure (13.7 vs 11.5 months) compared to Iressa (gefitinib) in treatment-naive non-small cell lung carcinoma patients harboring EGFR exon 19 deletion or L858R (PMID: 27083334).",Actionable,6162,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,"[{'id': 5321, 'pubMedId': 27083334, 'title': 'Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27083334'}]",sensitive,623,Afatinib,1956
558,FDA approved,"In a Phase III study that supported FDA approval, Gilotrif (afatinib) treatment resulted in increased progression-free survival in NSCLC patients with EGFR L858R mutations (PMID: 23816960, PMID: 23991291).
",Actionable,39,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 2367, 'pubMedId': 23991291, 'title': 'Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23991291'}, {'id': 2368, 'pubMedId': 23816960, 'title': 'Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23816960'}]",sensitive,623,Afatinib,1956
559,Guideline,Gilotrif (afatinib) is an active regimen in patients with metastatic NSCLC harboring sensitizing EGFR mutations (Guidelines).,Actionable,2015,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,"[{'id': 2454, 'pubMedId': None, 'title': 'NCCN Guidelines Version 5.2015 Non-Small Cell Lung Cancer', 'url': ''}]",sensitive,623,Afatinib,1956
560,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited growth of transformed cells expressing EGFR L858R in culture (PMID: 17085664).",Actionable,2998,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,"[{'id': 2798, 'pubMedId': 17085664, 'title': 'Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17085664'}]",sensitive,828,Neratinib,1956
561,Preclinical - Cell culture,"In a preclinical study, BGB-283 inhibited proliferation of transformed cells over expressing EGFR L858R in culture (PMID: 26208524).",Actionable,8061,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,"[{'id': 5280, 'pubMedId': 26208524, 'title': 'BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26208524'}]",sensitive,4025,BGB-283,1956
562,Preclinical - Cell culture,"In a preclinical study, the addition of Buparlisib (BKM-120) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R in culture (PMID: 28416483).",Actionable,11310,1324,lung cancer,DOID,369,EGFR L858R,"[{'id': 8735, 'pubMedId': 28416483, 'title': 'SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28416483'}]",sensitive,5935,BKM120 + Osimertinib,1956
563,Preclinical - Pdx,"In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in a patient-derived xenograft model of non-small cell lung cancer harboring EGFR L858R and MET amplification, resulting in tumor growth inhibition (PMID: 27283993).",Actionable,9249,3908,non-small cell lung carcinoma,DOID,26799,EGFR L858R MET amp,"[{'id': 7047, 'pubMedId': 27283993, 'title': 'Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27283993'}]",sensitive,4962,CO1686 + Crizotinib,1956
564,Preclinical,"In a preclinical study, KRAS G12D was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).",Actionable,6654,3910,lung adenocarcinoma,DOID,23661,EGFR L858R KRAS G12D,"[{'id': 5721, 'pubMedId': 26341921, 'title': 'Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26341921'}]",resistant,4190,Afatinib + Cetuximab,1956
565,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR L858R/EGFR L844V double mutation in culture (PMID: 25948633).",Actionable,3098,10000003,Advanced Solid Tumor,JAX,11695,EGFR L858R EGFR L844V,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,623,Afatinib,1956
566,Preclinical,"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR L858R/EGFR L844V double mutation in culture (PMID: 25948633).",Actionable,3084,10000003,Advanced Solid Tumor,JAX,11695,EGFR L858R EGFR L844V,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,660,Osimertinib,1956
567,Preclinical,"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR L844V double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3081,10000003,Advanced Solid Tumor,JAX,11695,EGFR L858R EGFR L844V,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,1003,CO1686,1956
568,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR L858R/EGFR C797S double mutation in culture (PMID: 25948633).",Actionable,3103,10000003,Advanced Solid Tumor,JAX,11696,EGFR L858R EGFR C797S,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,623,Afatinib,1956
569,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR L858R and EGFR C797S demonstrated sensitivity to Tarceva (erlotinib) in culture (PMID: 27913578).",Actionable,9989,10000003,Advanced Solid Tumor,JAX,11696,EGFR L858R EGFR C797S,"[{'id': 7760, 'pubMedId': 27913578, 'title': 'Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27913578'}]",sensitive,4,Erlotinib,1956
570,Preclinical,"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR C797S double mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).",Actionable,3091,10000003,Advanced Solid Tumor,JAX,11696,EGFR L858R EGFR C797S,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,660,Osimertinib,1956
571,Preclinical,"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR C797S double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3080,10000003,Advanced Solid Tumor,JAX,11696,EGFR L858R EGFR C797S,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",resistant,1003,CO1686,1956
572,Preclinical,"In a preclinical study, KRAS G12R was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).",Actionable,6655,3910,lung adenocarcinoma,DOID,23662,EGFR L858R KRAS G12R,"[{'id': 5721, 'pubMedId': 26341921, 'title': 'Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26341921'}]",resistant,4190,Afatinib + Cetuximab,1956
573,Preclinical,"In a preclinical study, cells expressing EGFR E734Q demonstrated sensitivity to Tarceva (erlotinib) in culture (PMID: 20942962).",Actionable,2100,10000003,Advanced Solid Tumor,JAX,4960,EGFR E734Q,"[{'id': 1956, 'pubMedId': 20942962, 'title': 'Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20942962'}]",sensitive,4,Erlotinib,1956
574,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR A767_V769dup (also referred to as V769_D770insASV) demonstrated resistance to dacomitinib in culture (PMID: 28363995).",Actionable,10507,10000003,Advanced Solid Tumor,JAX,27532,EGFR A767_V769dup,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",resistant,714,Dacomitinib,1956
575,Preclinical,"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR I491M in culture (PMID: 26843189).",Actionable,6641,9256,colorectal cancer,DOID,23655,EGFR I491M,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",sensitive,821,MM-151,1956
576,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR I491M were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6642,9256,colorectal cancer,DOID,23655,EGFR I491M,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",resistant,845,Panitumumab,1956
577,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR I491M were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6643,9256,colorectal cancer,DOID,23655,EGFR I491M,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",resistant,694,Cetuximab,1956
578,Preclinical - Cell culture,"In a preclinical study, SYM004 inhibited phosphorylation of EGFR in cells expressing EGFR R451C in culture (PMID: 26888827).",Actionable,9310,10000003,Advanced Solid Tumor,JAX,23657,EGFR R451C,"[{'id': 7071, 'pubMedId': 26888827, 'title': 'The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26888827'}]",predicted – sensitive,931,SYM004,1956
579,Preclinical,"In a preclinical study, Erbitux (cetuximab) inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189).",Actionable,6627,9256,colorectal cancer,DOID,23657,EGFR R451C,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",sensitive,694,Cetuximab,1956
580,Preclinical,"In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189).",Actionable,6628,9256,colorectal cancer,DOID,23657,EGFR R451C,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",sensitive,845,Panitumumab,1956
581,Preclinical,"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189).",Actionable,6626,9256,colorectal cancer,DOID,23657,EGFR R451C,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",sensitive,821,MM-151,1956
582,Preclinical,"In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR S492R in culture (PMID: 26843189).",Actionable,6645,9256,colorectal cancer,DOID,12766,EGFR S492R,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",sensitive,845,Panitumumab,1956
583,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR S492R were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6646,9256,colorectal cancer,DOID,12766,EGFR S492R,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",resistant,694,Cetuximab,1956
584,Phase I,"In a Phase I study, a colorectal cancer patient harboring EGFR S492R demonstrated a partial response when treated with SYM004 (PMID: 25962717).",Actionable,3218,9256,colorectal cancer,DOID,12766,EGFR S492R,"[{'id': 2801, 'pubMedId': 25962717, 'title': 'Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25962717'}]",sensitive,931,SYM004,1956
585,Preclinical,"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR S492R in culture (PMID: 26843189).",Actionable,6644,9256,colorectal cancer,DOID,12766,EGFR S492R,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",sensitive,821,MM-151,1956
586,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR-RAD51 demonstrated sensitivity to treatment with Gilotrif (afatinib) in culture, resulting in decreased cell viability and inhibition of downstream MAPK and PI3K signaling (PMID: 27102076). ",Actionable,7540,10000003,Advanced Solid Tumor,JAX,25735,EGFR-RAD51,"[{'id': 6404, 'pubMedId': 27102076, 'title': 'EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27102076'}]",sensitive,623,Afatinib,1956
587,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR-RAD51 demonstrated sensitivity to treatment with Erbitux (cetuximab) in culture, resulting in decreased cell viability (PMID: 27102076). ",Actionable,7542,10000003,Advanced Solid Tumor,JAX,25735,EGFR-RAD51,"[{'id': 6404, 'pubMedId': 27102076, 'title': 'EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27102076'}]",sensitive,694,Cetuximab,1956
588,Clinical Study,"In a clinical study, three patients with lung adenocarcinoma harboring EGFR-RAD51 demonstrated partial responses as indicated by tumor regression, when treated with Tarceva (erlotinib) (PMID: 27102076). ",Actionable,7538,3910,lung adenocarcinoma,DOID,25735,EGFR-RAD51,"[{'id': 6404, 'pubMedId': 27102076, 'title': 'EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27102076'}]",sensitive,4,Erlotinib,1956
589,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR-RAD51 demonstrated some sensitivity to treatment with Tagrisso (osimertinib) in culture, resulting in decreased cell viability (PMID: 27102076). ",Actionable,7541,10000003,Advanced Solid Tumor,JAX,25735,EGFR-RAD51,"[{'id': 6404, 'pubMedId': 27102076, 'title': 'EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27102076'}]",predicted – sensitive,660,Osimertinib,1956
590,Clinical Study,"In a clinical study, a patient with non-small cell lung carcinoma harboring EGFR I744_K745insKIPVAI demonstrated a partial response when treated with Tarceva (erlotinib) (PMID: 22190593). ",Actionable,10914,3908,non-small cell lung carcinoma,DOID,27852,EGFR I744_K745insKIPVAI,"[{'id': 439, 'pubMedId': 22190593, 'title': 'EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22190593'}]",sensitive,4,Erlotinib,1956
591,Clinical Study,"In a clinical study, two patients with non-small cell lung carcinoma each harboring EGFR I744_K745insKIPVAI demonstrated some efficacy when treated with Iressa (gefitinib), including a partial response and stable disease (PMID: 28089594). ",Actionable,10908,3908,non-small cell lung carcinoma,DOID,27852,EGFR I744_K745insKIPVAI,"[{'id': 8924, 'pubMedId': 28089594, 'title': 'Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28089594'}]",sensitive,751,Gefitinib,1956
592,Clinical Study,"In a clinical study, a patient with non-small cell lung carcinoma harboring EGFR K745_E746insTPVAIK demonstrated a partial response when treated with Tarceva (erlotinib) (PMID: 22190593).",Actionable,10915,3908,non-small cell lung carcinoma,DOID,27854,EGFR K745_E746insTPVAIK,"[{'id': 439, 'pubMedId': 22190593, 'title': 'EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22190593'}]",sensitive,4,Erlotinib,1956
593,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring mutant EGFR and wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).",Actionable,3542,3908,non-small cell lung carcinoma,DOID,13351,EGFR mutant FGFR1 wild-type,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",resistant,877,Ponatinib,1956
594,Clinical Study,"In a clinical study, treatment with first-line tyrosine kinase inhibitors resulted in a disease control rate (DCR) of 70% (26/37) in non-small cell lung carcinoma patients harboring both EGFR and TP53 mutations, compared to a DCR of 88% (76/86) in TP53 wild-type, EGFR mutated patients (J Clin Oncol 34, 2016 (suppl; abstr 9052)).",Actionable,6998,3908,non-small cell lung carcinoma,DOID,24178,EGFR mut TP53 mut,"[{'id': 6006, 'pubMedId': None, 'title': 'Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.', 'url': 'http://meetinglibrary.asco.org/content/165599-176'}]",decreased response,1776,N/A,1956
595,Clinical Study,"In a clinical study, treatment with first-line tyrosine kinase inhibitors resulted in a disease control rate (DCR) of 67% (8/13) in EGFR mutated, non-small cell lung carcinoma patients harboring nondisruptive TP53 mutations, compared to a DCR of 87% (21/24) in patients harboring disruptive TP53 mutations (J Clin Oncol 34, 2016 (suppl; abstr 9052)).",Actionable,7000,3908,non-small cell lung carcinoma,DOID,24180,EGFR mut TP53 inact mut,"[{'id': 6006, 'pubMedId': None, 'title': 'Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.', 'url': 'http://meetinglibrary.asco.org/content/165599-176'}]",sensitive,1776,N/A,1956
596,Clinical Study,"In a clinical study, treatment with first-line tyrosine kinase inhibitors resulted in a disease control rate (DCR) of 42% (5/12), median PFS and OS of 4.2 and 16.2 months in non-small cell lung carcinoma patients harboring both TP53 exon 8 and EGFR mutations, compared to 87% (97/111),  12.5 and 32.3 months in TP53 exon 8 wild-type patients (J Clin Oncol 34, 2016 (suppl; abstr 9052)).",Actionable,6999,3908,non-small cell lung carcinoma,DOID,24179,EGFR mut TP53 exon 8,"[{'id': 6006, 'pubMedId': None, 'title': 'Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.', 'url': 'http://meetinglibrary.asco.org/content/165599-176'}]",decreased response,1776,N/A,1956
597,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 22% (22/58), stable disease in 47% (27/58), and progressive disease in 31% (18/58) of non-small cell lung carcinoma patients carrying an EGFR mutation (PMID: 26354527).",Actionable,3358,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,"[{'id': 3736, 'pubMedId': 26354527, 'title': 'Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26354527'}]",predicted – sensitive,623,Afatinib,1956
598,Phase II,"In a Phase II trial, Tykerb (lapatinib) demonstrated safety in patients with non-small cell lung cancer, but demonstrated minimal antitumor activity with no responses in patients harboring EGFR mutations (PMID: 20215545).",Actionable,2421,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,"[{'id': 3045, 'pubMedId': 20215545, 'title': 'Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20215545'}]",no benefit,787,Lapatinib,1956
599,Phase I,"In a Phase I study, Pelitinib (EKB-569) demonstrated efficacy in 2 patients with non-small cell lung cancer with EGFR mutations and acquired resistance to gefitinib (PMID: 16364494).",Actionable,22,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,"[{'id': 1088, 'pubMedId': 16364494, 'title': 'EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16364494'}]",sensitive,852,Pelitinib,1956
600,Clinical Study,"In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",Actionable,8428,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,"[{'id': 6652, 'pubMedId': 27225694, 'title': 'EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27225694'}]",decreased response,1201,Atezolizumab,1956
601,Preclinical - Cell culture,"In a preclinical study, NGI-1 inhibited EGFR phosphorylation and proliferation and induced cell cycle arrest in non-small cell lung cancer cell lines harboring kinase domain mutations in EGFR in culture (PMID: 27694802).",Actionable,9227,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,"[{'id': 7042, 'pubMedId': 27694802, 'title': 'Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27694802'}]",predicted – sensitive,4957,NGI-1,1956
602,Phase I,"In a Phase I trial, ASP8273 treatment resulted in partial response in 36% (16/45) and stable disease in 27% (12/45) of non-small cell lung carcinoma patients harboring EGFR mutations, with a median progression free survival of 6.7 months (J Clin Oncol 34, 2016 (suppl; abstr 9050)).",Actionable,6997,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,"[{'id': 6005, 'pubMedId': None, 'title': 'Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study.', 'url': 'http://meetinglibrary.asco.org/content/162561-176'}]",sensitive,1082,ASP8273,1956
603,Preclinical - Cell line xenograft,"In a preclinical study, treatment with the combination of DS-1205b and Tagrisso (osimertinib) delayed the onset of therapeutic resistance compared to Tagrisso (osimertinib) alone in an EGFR-mutant non-small cell lung cancer cell line xenograft model (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #395P).",Actionable,12019,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,"[{'id': 9970, 'pubMedId': None, 'title': 'DS-1205b, a novel, selective, small-molecule inhibitor of AXL, delays the onset of resistance and overcomes acquired resistance to EGFR- TKIs in a human EGFR-mutant NSCLC (T790M-negative) xenograft model', 'url': 'http://www.poster-submission.com/esmo2017/visitors/eposter/34996'}]",predicted – sensitive,6231,DS-1205b + Osimertinib,1956
604,Preclinical - Cell culture,"In a preclinical study, combination of S63845 and Tarceva (erlotinib) resulted in potent cytotoxic effects in EGFR mutated non-small cell lung cancer cells in culture compared to the cytostatic effect of Tarceva (erlotinib) alone (PMID: 27760111).",Actionable,9038,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,"[{'id': 6851, 'pubMedId': 27760111, 'title': 'The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27760111'}]",sensitive,4860,Erlotinib + S63845,1956
605,Clinical Study,"In a clinical study, 87.5% (7/8) of solid tumor patients harboring EGFR alterations experienced disease progression within 2 months of anti-PD1/PD-L1 monotherapy, indicating a risk for hyperprogression on immunotherapy (PMID: 28351930).",Emerging,11638,10000003,Advanced Solid Tumor,JAX,1202,EGFR mutant,"[{'id': 9671, 'pubMedId': 28351930, 'title': 'Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28351930'}]",no benefit,1776,N/A,1956
606,Phase II,"In a Phase IIa clinical trial, BMS-690514 demonstrated safety and preliminary anti-tumor activity in patients with non-small cell lung cancer, with patients harboring EGFR mutations achieving a disease control rate (DCR) of 70% (7/10), compared to a DCR of 29% (6/21) in EGFR-wild type patients (PMID: 23490650).",Actionable,4408,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,"[{'id': 78, 'pubMedId': 23490650, 'title': 'Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23490650'}]",predicted – sensitive,685,BMS-690514,1956
607,Preclinical - Cell line xenograft,"In a preclinical study, Rociletinib (CO-1686) induced tumor regression in EGFR-mutant human non-small cell lung cancer cell line xenograft models, while slightly inhibiting tumor growth in xenograft models of a wild-type EGFR human squamous carcinoma cell line (PMID: 24065731).",Actionable,308,1324,lung cancer,DOID,1202,EGFR mutant,"[{'id': 157, 'pubMedId': 24065731, 'title': 'Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24065731'}]",sensitive,1003,CO1686,1956
608,Clinical Study,"In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate  (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",Actionable,8425,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,"[{'id': 6652, 'pubMedId': 27225694, 'title': 'EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27225694'}]",decreased response,1312,Nivolumab,1956
609,Phase I,"In a Phase I trial, AP26113 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including NSCLC patients harboring EGFR mutations (J Clin Oncol 31, 2013 (suppl; abstr 8031)).",Actionable,2556,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,"[{'id': 3286, 'pubMedId': None, 'title': 'First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.', 'url': 'http://meetinglibrary.asco.org/content/114967-132'}]",sensitive,634,AP26113,1956
610,Phase III,"In a Phase III trial, treatment with Nexavar (sorafenib) in non-small cell lung cancer patients harboring an EGFR mutation resulted in a greater overall survival and progression free survival when compared to placebo (PMID: 26743856). ",Actionable,7709,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,"[{'id': 6454, 'pubMedId': 26743856, 'title': 'Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26743856'}]",sensitive,920,Sorafenib,1956
611,Phase II,"In a Phase II trial, Poziotinib (HM781-36B) displayed modest efficacy in lung adenocarcinoma patients with mutant EGFR (J Clin Oncol 33, 2015 (suppl; abstr 8085).",Actionable,3260,3910,lung adenocarcinoma,DOID,1202,EGFR mutant,"[{'id': 3700, 'pubMedId': None, 'title': 'A phase II, single-arm, efficacy and safety study of poziotinib (NOV120101) in Korean patients with advanced or metastatic lung adenocarcinoma who have acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.', 'url': 'http://meetinglibrary.asco.org/content/153342-156'}]",sensitive,1042,poziotinib,1956
612,Clinical Study,"In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Imfinzi (durvalumab), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",Actionable,8427,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,"[{'id': 6652, 'pubMedId': 27225694, 'title': 'EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27225694'}]",decreased response,1356,Durvalumab,1956
613,Clinical Study,"In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",Actionable,8426,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,"[{'id': 6652, 'pubMedId': 27225694, 'title': 'EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27225694'}]",decreased response,1447,Pembrolizumab,1956
614,Preclinical - Cell line xenograft,"In a preclinical study, treatment with the combination of DS-1205b and Tarceva (erlotinib) delayed the onset of therapeutic resistance compared to Tarceva (erlotinib) alone in an EGFR-mutant non-small cell lung cancer cell line xenograft model, and overcame resistance to Tarceva (erlotinib) in a Tarceva (erlotinib)-resistant xenograft model (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #395P).",Actionable,12020,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,"[{'id': 9970, 'pubMedId': None, 'title': 'DS-1205b, a novel, selective, small-molecule inhibitor of AXL, delays the onset of resistance and overcomes acquired resistance to EGFR- TKIs in a human EGFR-mutant NSCLC (T790M-negative) xenograft model', 'url': 'http://www.poster-submission.com/esmo2017/visitors/eposter/34996'}]",predicted – sensitive,6232,DS-1205b + Erlotinib,1956
615,Clinical Study,"In a clinical study, lung adenocarcinoma patients with compound EGFR mutations had inferior overall survival when compared to patients with single EGFR mutations (PMID: 26785607), suggesting that the presence of compound EGFR mutations may be have prognostic significance in lung adenocarcinoma.",Emerging,6345,3910,lung adenocarcinoma,DOID,1202,EGFR mutant,"[{'id': 5534, 'pubMedId': 26785607, 'title': 'Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26785607'}]",not applicable,1776,N/A,1956
616,Preclinical,"In a preclinical study, AEE788 inhibited the growth of cultured cells expressing the EGFR exon 19 variant, L747_P753delinsS (PMID: 19147750).
",Actionable,1840,10000003,Advanced Solid Tumor,JAX,3680,EGFR L747_P753delinsS,"[{'id': 1890, 'pubMedId': 19147750, 'title': 'Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19147750'}]",sensitive,622,AEE788,1956
617,Preclinical,"In a preclinical study, Iressa (gefitinib) inhibited the growth of cultured cells expressing the EGFR exon 19 variant, L747_P753delinsS (PMID: 19147750).",Actionable,1838,10000003,Advanced Solid Tumor,JAX,3680,EGFR L747_P753delinsS,"[{'id': 1890, 'pubMedId': 19147750, 'title': 'Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19147750'}]",sensitive,751,Gefitinib,1956
618,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in progressive disease in a non-small cell lung carcinoma patient carrying an EGFR A702S mutation (PMID: 26354527).",Actionable,3326,3908,non-small cell lung carcinoma,DOID,2932,EGFR A702S,"[{'id': 3736, 'pubMedId': 26354527, 'title': 'Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26354527'}]",no benefit,623,Afatinib,1956
619,Preclinical - Pdx,"In a preclinical study, EGF816 inhibited tumor growth in patient-derived xenograft models of non-small cell lung cancer harboring EGFR H773_V774insNPH (PMID: 26825170).",Actionable,5654,3908,non-small cell lung carcinoma,DOID,3086,EGFR H773_V774insNPH,"[{'id': 5135, 'pubMedId': 26825170, 'title': 'EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26825170'}]",sensitive,1309,EGF816,1956
620,Preclinical - Cell culture,"In a preclinical study, EGF816 inhibited growth of transformed cells expressing EGFR H773_V774insNPH in culture (PMID: 26825170).",Actionable,5653,10000003,Advanced Solid Tumor,JAX,3086,EGFR H773_V774insNPH,"[{'id': 5135, 'pubMedId': 26825170, 'title': 'EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26825170'}]",sensitive,1309,EGF816,1956
621,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of cells expressing EGFR L844V in culture (PMID: 25948633).",Actionable,3071,10000003,Advanced Solid Tumor,JAX,11697,EGFR L844V,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,623,Afatinib,1956
622,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited EGFR phosphorylation and growth of cells expressing EGFR L844V in culture (PMID: 25948633).",Actionable,3070,10000003,Advanced Solid Tumor,JAX,11697,EGFR L844V,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,828,Neratinib,1956
623,Preclinical,"In a preclinical study, EKI-285 inhibited EGFR phosphorylation and growth of cells expressing EGFR L844V in culture (PMID: 25948633).",Actionable,3072,10000003,Advanced Solid Tumor,JAX,11697,EGFR L844V,"[{'id': 3618, 'pubMedId': 25948633, 'title': 'EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25948633'}]",sensitive,2911,EKI-285,1956
624,Preclinical,"In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation in cells expressing EGFR R831H in culture (PMID: 20942962).",Actionable,6923,10000003,Advanced Solid Tumor,JAX,24022,EGFR R831H,"[{'id': 1956, 'pubMedId': 20942962, 'title': 'Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20942962'}]",sensitive,4,Erlotinib,1956
625,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR A763_Y764insFQEA mutations demonstrated sensitivity to Gilotrif (afatinib) in cell culture, in contrast to other EGFR exon 20 insertion mutations (PMID: 24353160).",Actionable,776,3908,non-small cell lung carcinoma,DOID,1052,EGFR A763_Y764insFQEA,"[{'id': 440, 'pubMedId': 24353160, 'title': 'Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24353160'}]",sensitive,623,Afatinib,1956
626,Clinical Study,"In a clinical study, a patient with non-small cell lung carcinoma harboring EGFR A763_Y764insFQEA demonstrated a partial response when treated with Iressa (gefitinib) (PMID: 28089594).",Actionable,10916,3908,non-small cell lung carcinoma,DOID,1052,EGFR A763_Y764insFQEA,"[{'id': 8924, 'pubMedId': 28089594, 'title': 'Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28089594'}]",sensitive,751,Gefitinib,1956
627,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR A763_Y764insFQEA mutations demonstrated sensitivity to Iressa (gefitinib) in culture, in contrast to other Egfr exon 20 insertions, and consistent with clinical observations (PMID: 24353160).",Actionable,779,3908,non-small cell lung carcinoma,DOID,1052,EGFR A763_Y764insFQEA,"[{'id': 440, 'pubMedId': 24353160, 'title': 'Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24353160'}]",sensitive,751,Gefitinib,1956
628,Clinical Study,"In contrast to other known exon 20 insertions, EGFR A763_Y764insFQEA is sensitive to tyrosine kinase inhibitors, such as Tarceva (erlotinib), in cells, in animal models and in NSCLC patients (PMID: 24353160).",Actionable,778,3908,non-small cell lung carcinoma,DOID,1052,EGFR A763_Y764insFQEA,"[{'id': 440, 'pubMedId': 24353160, 'title': 'Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24353160'}]",sensitive,4,Erlotinib,1956
629,Clinical Study,"In a clinical study, a patient with non-small cell lung carcinoma harboring EGFR A763_Y764insFQEA demonstrated a partial response after treatment with Tarceva (erlotinib), however, another patient with the same mutation and tumor type demonstrated progressive disease when treated with Tarceva (erlotinib) (PMID: 28089594). ",Actionable,10909,3908,non-small cell lung carcinoma,DOID,1052,EGFR A763_Y764insFQEA,"[{'id': 8924, 'pubMedId': 28089594, 'title': 'Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28089594'}]",sensitive,4,Erlotinib,1956
630,Preclinical - Cell culture,"In a preclinical study, AZD4547 treatment of head and neck squamous cell carcinoma cells over expressing FGFR1 and negative for EGFR resulted in decreased cell growth and reduced downstream signaling of Erk1/2 (PMID: 26936917).",Actionable,7828,5520,head and neck squamous cell carcinoma,DOID,26061,EGFR neg FGFR1 over exp,"[{'id': 6507, 'pubMedId': 26936917, 'title': 'FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26936917'}]",sensitive,654,AZD4547,1956
631,Preclinical,"In a preclinical study, transformed cells expressing EGFR G719A demonstrated increased sensitivity to second-generation EGFR inhibitors including Nerlynx (neratinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).",Actionable,3719,10000003,Advanced Solid Tumor,JAX,1044,EGFR G719A,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",sensitive,828,Neratinib,1956
632,Preclinical,"In a preclinical study, transformed cells expressing EGFR G719A demonstrated increased sensitivity to second-generation EGFR inhibitors including Dacomitinib in culture, when compared to first and third-generation inhibitors (PMID: 26206867).",Actionable,3713,10000003,Advanced Solid Tumor,JAX,1044,EGFR G719A,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",sensitive,714,Dacomitinib,1956
633,Clinical Study,"In an analysis of published clinical data, 7/11 non-small cell lung cancer patients harboring EGFR G719A were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Iressa (gefitinib) (PMID: 23344264).",Actionable,6667,3908,non-small cell lung carcinoma,DOID,1044,EGFR G719A,"[{'id': 1, 'pubMedId': 23344264, 'title': 'DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23344264'}]",predicted – sensitive,751,Gefitinib,1956
634,Preclinical - Cell culture,"In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing EGFR G719A in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).",Actionable,5918,10000003,Advanced Solid Tumor,JAX,1044,EGFR G719A,"[{'id': 5195, 'pubMedId': None, 'title': 'AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=407e597a-33c8-4936-87f4-08ee4b23e8b9&cKey=34ee7ebf-07c6-40ea-825f-28fb5018ec92&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]",sensitive,3981,AP32788,1956
635,Phase III,"In Phase III trials, non-small cell lung carcinoma patients harboring EGFR G719X mutations (G719A, C, or S) demonstrated a response rate of 78% (14/18) following treatment with Gilotrif (afatinib) (PMID: 24790411).",Actionable,746,3908,non-small cell lung carcinoma,DOID,1044,EGFR G719A,"[{'id': 2366, 'pubMedId': 24790411, 'title': 'Clinical and comparative utility of afatinib in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24790411'}]",sensitive,623,Afatinib,1956
636,Preclinical,"In a preclinical study, transformed cells expressing EGFR G719A demonstrated increased sensitivity to second-generation EGFR inhibitors including Gilotrif (afatinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).",Actionable,3715,10000003,Advanced Solid Tumor,JAX,1044,EGFR G719A,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",sensitive,623,Afatinib,1956
637,Preclinical,"In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to first-generation EGFR inhibitors including Tarceva (erlotinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3716,10000003,Advanced Solid Tumor,JAX,1044,EGFR G719A,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",decreased response,4,Erlotinib,1956
638,Preclinical,"In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to third-generation EGFR inhibitors including Tagrisso (AZD9291) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3717,10000003,Advanced Solid Tumor,JAX,1044,EGFR G719A,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",decreased response,660,Osimertinib,1956
639,Preclinical,"In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to third-generation EGFR inhibitors including Rociletinib (CO-1686) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3718,10000003,Advanced Solid Tumor,JAX,1044,EGFR G719A,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",decreased response,1003,CO1686,1956
640,Clinical Study,"In an analysis of published clinical data, 7/11 non-small cell lung cancer patients harboring EGFR G719A were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Tarceva (erlotinib) (PMID: 23344264).",Actionable,6666,3908,non-small cell lung carcinoma,DOID,1044,EGFR G719A,"[{'id': 1, 'pubMedId': 23344264, 'title': 'DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23344264'}]",predicted – sensitive,4,Erlotinib,1956
641,Phase III,"In Phase III clinical trials, patients with NSCLC tumors harboring an EGFR G719X (X=A, C, or S) mutation responded to EGFR tyrosine kinase inhibitors including dacomitinib (PMID: 24857124).
",Actionable,748,3908,non-small cell lung carcinoma,DOID,1044,EGFR G719A,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",sensitive,714,Dacomitinib,1956
642,Preclinical,"In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to first-generation EGFR inhibitors including Iressa (gefitinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3714,10000003,Advanced Solid Tumor,JAX,1044,EGFR G719A,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",decreased response,751,Gefitinib,1956
643,Preclinical - Cell culture,"In a preclinical study, EGF816 inhibited growth of transformed cells expressing EGFR D770_N771insSVD in culture (PMID: 26825170).",Actionable,5651,10000003,Advanced Solid Tumor,JAX,1049,EGFR D770_N771insSVD,"[{'id': 5135, 'pubMedId': 26825170, 'title': 'EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26825170'}]",sensitive,1309,EGF816,1956
644,Preclinical,"In a preclinical study, transformed cells expressing EGFR D770_N771insSVD, demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160).",Actionable,787,10000003,Advanced Solid Tumor,JAX,1049,EGFR D770_N771insSVD,"[{'id': 440, 'pubMedId': 24353160, 'title': 'Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24353160'}]",resistant,623,Afatinib,1956
645,Phase I,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR D770_N771insSVD, displayed progressive disease following treatment with Tarceva (erlotinib), and resistance to Tarceva (erlotinib) was replicated in cell culture studies (PMID: 24353160).",Actionable,786,3908,non-small cell lung carcinoma,DOID,1049,EGFR D770_N771insSVD,"[{'id': 440, 'pubMedId': 24353160, 'title': 'Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24353160'}]",resistant,4,Erlotinib,1956
646,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to first-generation EGFR inhibitors including Iressa (gefitinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3709,10000003,Advanced Solid Tumor,JAX,3079,EGFR E709K,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",decreased response,751,Gefitinib,1956
647,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709K demonstrated increased sensitivity to second-generation EGFR inhibitors including Gilotrif (afatinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).",Actionable,3706,10000003,Advanced Solid Tumor,JAX,3079,EGFR E709K,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",sensitive,623,Afatinib,1956
648,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709K demonstrated increased sensitivity to second-generation EGFR inhibitors including Dacomitinib in culture, when compared to first and third-generation inhibitors (PMID: 26206867).",Actionable,3707,10000003,Advanced Solid Tumor,JAX,3079,EGFR E709K,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",sensitive,714,Dacomitinib,1956
649,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709K demonstrated increased sensitivity to second-generation EGFR inhibitors including Nerlynx (neratinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).",Actionable,3708,10000003,Advanced Solid Tumor,JAX,3079,EGFR E709K,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",sensitive,828,Neratinib,1956
650,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to first-generation EGFR inhibitors including Tarceva (erlotinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3710,10000003,Advanced Solid Tumor,JAX,3079,EGFR E709K,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",decreased response,4,Erlotinib,1956
651,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to third-generation EGFR inhibitors including Rociletinib (CO-1686) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3712,10000003,Advanced Solid Tumor,JAX,3079,EGFR E709K,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",decreased response,1003,CO1686,1956
652,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to third-generation EGFR inhibitors including Tagrisso (AZD9291) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3711,10000003,Advanced Solid Tumor,JAX,3079,EGFR E709K,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",decreased response,660,Osimertinib,1956
653,Preclinical,"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR S464L in culture (PMID: 26843189).",Actionable,6629,9256,colorectal cancer,DOID,23658,EGFR S464L,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",sensitive,821,MM-151,1956
654,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR S464L were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6631,9256,colorectal cancer,DOID,23658,EGFR S464L,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",resistant,694,Cetuximab,1956
655,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR S464L were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6630,9256,colorectal cancer,DOID,23658,EGFR S464L,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",resistant,845,Panitumumab,1956
656,Preclinical,"In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation in cells expressing EGFR E868G in culture (PMID: 20942962).",Actionable,6922,10000003,Advanced Solid Tumor,JAX,3115,EGFR E868G,"[{'id': 1956, 'pubMedId': 20942962, 'title': 'Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20942962'}]",sensitive,4,Erlotinib,1956
657,Clinical Study,"In clinical case study, a patient with olfactory neuroblastoma harboring EGFR R521K, FGFR2 M186T, KDR Q472H, KDR V297I, and RET M1009T demonstrated sensitivity to the combination of Sutent (sunitinib) and Erbitux (cetuximab), resulting in a complete response (PMID: 27149458).",Actionable,7758,369,olfactory neuroblastoma,DOID,26023,EGFR R521K FGFR2 M186T KDR Q472H KDR V297I RET M1009T,"[{'id': 6481, 'pubMedId': 27149458, 'title': 'Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27149458'}]",sensitive,4568,Cetuximab + Sunitinib,1956
658,Preclinical - Patient cell culture,"In a preclinical study, dacomitinib inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR P772_H773insPNP in culture (PMID: 28363995).",Actionable,10520,3910,lung adenocarcinoma,DOID,27539,EGFR P772_H773insPNP,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",sensitive,714,Dacomitinib,1956
659,Preclinical - Patient cell culture,"In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR P772_H773insPNP in culture (PMID: 28363995).",Actionable,10521,3910,lung adenocarcinoma,DOID,27539,EGFR P772_H773insPNP,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",sensitive,623,Afatinib,1956
660,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR K467T were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6639,9256,colorectal cancer,DOID,23656,EGFR K467T,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",resistant,694,Cetuximab,1956
661,Preclinical,"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR K467T in culture (PMID: 26843189).",Actionable,6638,9256,colorectal cancer,DOID,23656,EGFR K467T,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",sensitive,821,MM-151,1956
662,Preclinical,"In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR K467T in culture (PMID: 26843189).",Actionable,6640,9256,colorectal cancer,DOID,23656,EGFR K467T,"[{'id': 5719, 'pubMedId': 26843189, 'title': 'MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26843189'}]",sensitive,845,Panitumumab,1956
663,Preclinical - Cell culture,"In a preclinical study, SYM004 inhibited phosphorylation of EGFR in cells expressing EGFR K467T in culture (PMID: 26888827).",Actionable,9311,10000003,Advanced Solid Tumor,JAX,23656,EGFR K467T,"[{'id': 7071, 'pubMedId': 26888827, 'title': 'The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26888827'}]",predicted – sensitive,931,SYM004,1956
664,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 100% (2 of 2) of non-small cell lung carcinoma patients carrying EGFR L858M mutation (PMID: 26354527).",Actionable,3328,3908,non-small cell lung carcinoma,DOID,3104,EGFR L858M,"[{'id': 3736, 'pubMedId': 26354527, 'title': 'Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26354527'}]",sensitive,623,Afatinib,1956
665,Clinical Study,"In a clinical study, a patient with lung adenocarcinoma harboring EGFR-PURB demonstrated a partial response when treated with Tarceva (erlotinib), resulting in a 48% decrease in lesion size and ongoing therapy for 20 months without indication of progression (PMID: 27102076). ",Actionable,7539,3910,lung adenocarcinoma,DOID,25738,EGFR-PURB,"[{'id': 6404, 'pubMedId': 27102076, 'title': 'EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27102076'}]",sensitive,4,Erlotinib,1956
666,Preclinical,"In a preclinical study, Tarceva (erlotinib) decreased viability of transformed cells expressing EGFR R108K in culture (PMID: 17177598).",Actionable,6919,10000003,Advanced Solid Tumor,JAX,2925,EGFR R108K,"[{'id': 1877, 'pubMedId': 17177598, 'title': 'Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17177598'}]",sensitive,4,Erlotinib,1956
667,Preclinical,"In a preclinical study, transformed cells expressing EGFR N826S demonstrated resistance to AEE788 in cell culture (PMID: 19147750).",Actionable,6894,10000003,Advanced Solid Tumor,JAX,23983,EGFR N826S,"[{'id': 1890, 'pubMedId': 19147750, 'title': 'Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19147750'}]",resistant,622,AEE788,1956
668,Preclinical,"In a preclinical study, transformed cells expressing EGFR N826S demonstrated resistance to Tarceva (erlotinib) in cell culture (PMID: 19147750).",Actionable,6892,10000003,Advanced Solid Tumor,JAX,23983,EGFR N826S,"[{'id': 1890, 'pubMedId': 19147750, 'title': 'Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19147750'}]",resistant,4,Erlotinib,1956
669,Preclinical,"In a preclinical study, transformed cells expressing EGFR N826S demonstrated resistance to Iressa (gefitinib) in cell culture (PMID: 19147750).",Actionable,6893,10000003,Advanced Solid Tumor,JAX,23983,EGFR N826S,"[{'id': 1890, 'pubMedId': 19147750, 'title': 'Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19147750'}]",resistant,751,Gefitinib,1956
670,Preclinical - Cell culture,"In a preclinical study, Erbitux (cetuximab) did not efficiently inhibit Egfr phosphorylation in transformed cells over expressing T34_A289del in culture (PMID: 27216155). ",Actionable,7813,10000003,Advanced Solid Tumor,JAX,26048,EGFR T34_A289del,"[{'id': 6503, 'pubMedId': 27216155, 'title': 'A Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27216155'}]",decreased response,694,Cetuximab,1956
671,Preclinical - Cell culture,"In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation and cell proliferation in neuroblastoma cells over expressing EGFR T34_A289del in culture (PMID: 27216155).",Actionable,7810,769,neuroblastoma,DOID,26048,EGFR T34_A289del,"[{'id': 6503, 'pubMedId': 27216155, 'title': 'A Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27216155'}]",sensitive,4,Erlotinib,1956
672,Preclinical - Cell culture,"In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation and cell proliferation in transformed cells over expressing EGFR T34_A289del in culture (PMID: 27216155).",Actionable,7811,10000003,Advanced Solid Tumor,JAX,26048,EGFR T34_A289del,"[{'id': 6503, 'pubMedId': 27216155, 'title': 'A Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27216155'}]",sensitive,4,Erlotinib,1956
673,Preclinical - Cell culture,"In a preclinical study, neuroblastoma cells over expressing EGFR T34_A289del were resistant to Eposin (etoposide) in culture (PMID: 27216155).",Actionable,7812,769,neuroblastoma,DOID,26048,EGFR T34_A289del,"[{'id': 6503, 'pubMedId': 27216155, 'title': 'A Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27216155'}]",resistant,1136,Etoposide,1956
674,Phase I,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR V769_D770insASV (also referred to as A767_V769dup), displayed progressive disease following treatment with Tarceva (erlotinib), and resistance to Tarceva (erlotinib) was replicated in cell culture studies (PMID: 24353160).",Actionable,791,3908,non-small cell lung carcinoma,DOID,1048,EGFR V769_D770insASV,"[{'id': 440, 'pubMedId': 24353160, 'title': 'Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24353160'}]",resistant,4,Erlotinib,1956
675,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR V769_D770insASV (also referred to as A767_V769dup), displayed progressive disease following treatment with Iressa (gefitinib), and resistance to Iressa (gefitinib) was replicated in cell culture studies (PMID: 24353160).",Actionable,792,3908,non-small cell lung carcinoma,DOID,1048,EGFR V769_D770insASV,"[{'id': 440, 'pubMedId': 24353160, 'title': 'Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24353160'}]",resistant,751,Gefitinib,1956
676,Preclinical,"In a preclinical study, transformed cells expressing EGFR exon 20 insertions, including EGFR V769_D770insASV (also known as A767_V769dupASV), demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160).",Actionable,790,10000003,Advanced Solid Tumor,JAX,1048,EGFR V769_D770insASV,"[{'id': 440, 'pubMedId': 24353160, 'title': 'Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24353160'}]",resistant,623,Afatinib,1956
677,Preclinical - Cell culture,"In a preclinical study, EGF816 inhibited growth of transformed cells expressing EGFR V769_D770insASV in culture (PMID: 26825170).",Actionable,5652,10000003,Advanced Solid Tumor,JAX,1048,EGFR V769_D770insASV,"[{'id': 5135, 'pubMedId': 26825170, 'title': 'EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26825170'}]",sensitive,1309,EGF816,1956
678,Clinical Study,"In a retrospective analysis, 3 patients with lung adenocarcinoma harboring EGFR L747_T751delinsP were found to respond to Iressa (gefitinib) therapy (PMID: 18981003).",Actionable,3049,3910,lung adenocarcinoma,DOID,11383,EGFR L747_T751delinsP,"[{'id': 3591, 'pubMedId': 18981003, 'title': 'Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18981003'}]",sensitive,751,Gefitinib,1956
0,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Brigatinib (AP26113) in culture (PMID: 27432227).  ",Actionable,8639,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,634,AP26113,27436
1,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8636,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,706,Crizotinib,27436
2,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8640,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,869,PF-06463922,27436
3,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Alecensa (alectinib) in culture (PMID: 27432227).  ",Actionable,8638,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,698,Alectinib,27436
4,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8637,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,789,Ceritinib,27436
5,Phase I,"In a Phase I clinical trial, a patient with EML4-ALK positive non-small lung cancer initially responded to Xalkori (crizotinib) but developed resistance with the emergence of a secondary ALK mutation C1156Y, and subsequently redeveloped sensitivity to Xalkori (crizotinib) upon the emergence of a second ALK mutation, L1198F arising from resistance to Lorlatinib (PF-06463922) (PMID: 26698910).",Actionable,5673,3908,non-small cell lung carcinoma,DOID,21372,EML4-ALK ALK C1156Y ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,706,Crizotinib,27436
6,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5684,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,698,Alectinib,27436
7,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910).",Actionable,5688,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,634,AP26113,27436
8,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5687,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,789,Ceritinib,27436
9,Phase I,"In a Phase I clinical trial, a patient with EML4-ALK positive non-small lung cancer with a secondary Xalkori (critzotinib) resistance mutation C1156Y, responded to Lorlatinib (PF-06463922) but subsequently developed resistance upon the emergence of a second ALK mutation, L1198F (PMID: 26698910).",Actionable,5672,3908,non-small cell lung carcinoma,DOID,21372,EML4-ALK ALK C1156Y ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,869,PF-06463922,27436
10,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5679,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,869,PF-06463922,27436
11,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F in culture (PMID: 26698910).",Actionable,5676,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,706,Crizotinib,27436
12,Preclinical,"In preclinical studies, Brigatinib (AP26113) inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859, PMID: 26698910).",Actionable,5388,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}, {'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,634,AP26113,27436
13,Preclinical,"In preclinical studies, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910, PMID: 27009859).",Actionable,5385,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}, {'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,789,Ceritinib,27436
14,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5387,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,643,ASP3026,27436
15,Preclinical - Patient cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and growth of non-small cell lung cancer (NSCLC) cells over expressing ALK G1269A in the context of EML4-ALK in culture and in cell line xenograft models, as well as inhibited  growth of patient derived NSCLC cells harboring EML4-ALK ALK G1269A in culture (PMID: 26144315). ",Actionable,3159,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,"[{'id': 3367, 'pubMedId': 26144315, 'title': 'PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144315'}]",sensitive,869,PF-06463922,27436
16,Preclinical,"In preclinical studies, human lung cancer cell lines expressing EML4-ALK G1269A demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 22235099, PMID: 23344087, PMID: 24675041).",Actionable,2054,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,"[{'id': 2523, 'pubMedId': 23344087, 'title': 'Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23344087'}, {'id': 2524, 'pubMedId': 22235099, 'title': 'Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22235099'}, {'id': 2525, 'pubMedId': 24675041, 'title': 'The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24675041'}]",resistant,706,Crizotinib,27436
17,Preclinical,"In a preclinical study, human lung cancer cell lines harboring EML4-ALK with ALK G1269A demonstrated sensitivity to Zykadia (ceritinib) in culture (PMID: 24675041).",Actionable,2055,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,"[{'id': 2525, 'pubMedId': 24675041, 'title': 'The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24675041'}]",sensitive,789,Ceritinib,27436
18,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910).",Actionable,5721,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,869,PF-06463922,27436
19,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated a decreased response when treated with Entrectinib (RXDX-101) (PMID: 26939704). ",Actionable,5640,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,"[{'id': 5130, 'pubMedId': 26939704, 'title': 'Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26939704'}]",decreased response,1455,Entrectinib,27436
20,Preclinical,"In a preclinical study, Alecensa (alectinib) modestly inhibited growth of transformed cells expression EML4-ALK with ALK G1269A in culture (PMID: 26698910).",Actionable,5722,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",conflicting,698,Alectinib,27436
21,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).
",Actionable,5386,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",conflicting,698,Alectinib,27436
22,Preclinical,"In preclinical studies, transformed cells expressing EML4-ALK with ALK G1269A were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859, PMID: 26698910).",Actionable,5384,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}, {'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,706,Crizotinib,27436
23,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859).",Actionable,5389,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,1586,AZD3463,27436
24,Clinical Study,"In a clinical case study, a patient with EML4-ALK fusion positive non-small cell lung cancer with ALK G1269A had a partial response to Alecensa (alectinib) treatment (PMID: 26849637).",Actionable,4621,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,"[{'id': 4562, 'pubMedId': 26849637, 'title': 'Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26849637'}]",sensitive,698,Alectinib,27436
25,Preclinical - Cell line xenograft,"In a preclinical study, Alecensa (alectinib) inhibited proliferation of a Xalkori (crizotinib)-resistant human non-small cell lung cancer (NSCLC) cell line harboring an EML-ALK fusion with ALK G1269A in culture and induced tumor regression in xenograft models (PMID: 26849637, PMID: 23344087).",Actionable,4462,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,"[{'id': 2523, 'pubMedId': 23344087, 'title': 'Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23344087'}, {'id': 4562, 'pubMedId': 26849637, 'title': 'Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26849637'}]",sensitive,698,Alectinib,27436
26,Preclinical,"In a preclinical study, Xalkori (crizotinib) resistance was reduced in transformed cells expressing EML4-ALK with ALK L1196M with the addition of ALK L1198F in culture (PMID: 26698910).",Actionable,5703,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,706,Crizotinib,27436
27,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5706,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,869,PF-06463922,27436
28,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5704,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,789,Ceritinib,27436
29,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F were resistant to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910).",Actionable,5707,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,634,AP26113,27436
30,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5705,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,698,Alectinib,27436
31,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK F1174V in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9261,10000003,Advanced Solid Tumor,JAX,26808,EML4-ALK ALK F1174V,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,27436
32,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK F1174V in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).",Actionable,9267,10000003,Advanced Solid Tumor,JAX,26808,EML4-ALK ALK F1174V,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",decreased response,706,Crizotinib,27436
33,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227). ",Actionable,8655,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,706,Crizotinib,27436
34,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Alecensa (alectinib) in culture (PMID: 27432227). ",Actionable,8657,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,698,Alectinib,27436
35,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Zykadia (ceritinib) in culture (PMID: 27432227). ",Actionable,8656,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,789,Ceritinib,27436
36,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227). ",Actionable,8659,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,869,PF-06463922,27436
37,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Brigatinib (AP26113) in culture (PMID: 27432227). ",Actionable,8658,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,634,AP26113,27436
38,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).",Actionable,5689,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,634,AP26113,27436
39,Clinical Study,"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer with an ALK C1156Y secondary Xalkori (crizotinib) resistance mutation did not respond to Luminespib (AUY922) therapy (PMID: 26698910).",Actionable,5671,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,647,AUY922,27436
40,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).",Actionable,5682,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,698,Alectinib,27436
41,Preclinical,"In a preclinical study, transformed human cells expressing EML4-ALK with ALK C1156Y were sensitive to Alecensa (alectinib) in culture (PMID: 21575866).",Actionable,2981,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,"[{'id': 1817, 'pubMedId': 21575866, 'title': 'CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21575866'}]",sensitive,698,Alectinib,27436
42,Preclinical - Cell line xenograft,"In a preclinical study, Zykadia (ceritinib) demonstrated tumor growth inhibition in xenograft models of a human non-small cell lung cancer cell line harboring EML4-ALK with ALK C1156Y when compared to Xalkori (crizotinib) (PMID: 24675041).",Actionable,2982,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,"[{'id': 2525, 'pubMedId': 24675041, 'title': 'The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24675041'}]",conflicting,789,Ceritinib,27436
43,Clinical Study,"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation C1156Y, did not respond to Zykadia (ceritinib) therapy (PMID: 26698910).",Actionable,5720,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",conflicting,789,Ceritinib,27436
44,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).",Actionable,5685,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,789,Ceritinib,27436
45,Phase I,"In a Phase I clinical study, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation ALK C1156Y, was treated with Lorlatinib (PF-06463922) and displayed a 41% reduction in tumor growth after 5 weeks of treatment (PMID: 26698910).",Actionable,5669,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,869,PF-06463922,27436
46,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth and ALK phosphorylation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).",Actionable,5677,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,869,PF-06463922,27436
47,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were sensitive to Entrectinib (RXDX-101), resulting in anti-proliferative activity (PMID: 26939704). ",Actionable,5637,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,"[{'id': 5130, 'pubMedId': 26939704, 'title': 'Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26939704'}]",sensitive,1455,Entrectinib,27436
48,Preclinical,"In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK C1156Y (PMID: 21613408). ",Actionable,2093,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,"[{'id': 2442, 'pubMedId': 21613408, 'title': 'Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21613408'}]",sensitive,961,X-396,27436
49,Clinical Study,"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer developed resistance to Xalkori (crizotinib) with the emergence of ALK C1156Y, a secondary resistance mutation (PMID: 26698910).",Actionable,5668,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,706,Crizotinib,27436
50,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK ALK C1156Y were insensitive to Xalkori (crizotinib) as demonstrated by lack of growth inhibition and lack of kinase inhibition in culture (PMID: 21613408). ",Actionable,2092,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,"[{'id': 2442, 'pubMedId': 21613408, 'title': 'Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21613408'}]",resistant,706,Crizotinib,27436
51,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).",Actionable,5674,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,706,Crizotinib,27436
52,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated resistance to treatment with Alecensa (alectinib) in culture (PMID: 27432227).  ",Actionable,8628,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",resistant,698,Alectinib,27436
53,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8626,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,706,Crizotinib,27436
54,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8630,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,869,PF-06463922,27436
55,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Brigatinib (AP26113) in culture (PMID: 27432227).  ",Actionable,8629,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,634,AP26113,27436
56,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8627,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,789,Ceritinib,27436
57,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) in culture (PMID: 27780853).",Actionable,9269,10000003,Advanced Solid Tumor,JAX,26806,EML4-ALK ALK L1152P,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",decreased response,789,Ceritinib,27436
58,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).",Actionable,9265,10000003,Advanced Solid Tumor,JAX,26806,EML4-ALK ALK L1152P,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",decreased response,706,Crizotinib,27436
59,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK L1152P in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9260,10000003,Advanced Solid Tumor,JAX,26806,EML4-ALK ALK L1152P,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,27436
60,Preclinical,"In a preclinical study, TPX-0005 inhibited Alk and Src signaling, and cell proliferation in lung cancer cell lines harboring EML4-ALK and elevated Src activity in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",Actionable,5831,1324,lung cancer,DOID,21947,EML4 - ALK SRC act mut,"[{'id': 5176, 'pubMedId': None, 'title': 'The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=055d4461-9793-4f83-b663-f356d9ae0fdb&cKey=ff6f8d25-f06a-4ae4-9dbf-7e390ef45123&mKey={1D10D749-4B6A-4AB3-BCD4-F80FB1922267}'}]",sensitive,3950,TPX-0005,27436
61,Preclinical,"In a preclinical study, lung cancer cell lines harboring EML4-ALK and elevated Src activity were resistant to Zykadia (ceritinib) induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",Actionable,5836,10000003,Advanced Solid Tumor,JAX,21947,EML4 - ALK SRC act mut,"[{'id': 5176, 'pubMedId': None, 'title': 'The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=055d4461-9793-4f83-b663-f356d9ae0fdb&cKey=ff6f8d25-f06a-4ae4-9dbf-7e390ef45123&mKey={1D10D749-4B6A-4AB3-BCD4-F80FB1922267}'}]",resistant,789,Ceritinib,27436
62,Preclinical,"In a preclinical study, lung cancer cell lines harboring EML4-ALK and elevated Src activity were resistant to Xalkori (crizotinib) induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",Actionable,5835,1324,lung cancer,DOID,21947,EML4 - ALK SRC act mut,"[{'id': 5176, 'pubMedId': None, 'title': 'The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=055d4461-9793-4f83-b663-f356d9ae0fdb&cKey=ff6f8d25-f06a-4ae4-9dbf-7e390ef45123&mKey={1D10D749-4B6A-4AB3-BCD4-F80FB1922267}'}]",resistant,706,Crizotinib,27436
63,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Brigatinib (AP26113) in culture (PMID: 27432227). ",Actionable,8653,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,634,AP26113,27436
64,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Alecensa (alectinib) in culture (PMID: 27432227). ",Actionable,8652,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,698,Alectinib,27436
65,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227). ",Actionable,8654,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,869,PF-06463922,27436
66,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Xalkori (crizotinib) in culture (PMID: 27432227). ",Actionable,8651,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",resistant,706,Crizotinib,27436
67,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Zykadia (ceritinib) in culture (PMID: 27432227). ",Actionable,8666,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",resistant,789,Ceritinib,27436
68,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5715,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,869,PF-06463922,27436
69,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5718,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,789,Ceritinib,27436
70,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5716,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,698,Alectinib,27436
71,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910).",Actionable,5717,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,634,AP26113,27436
72,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).",Actionable,5714,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,706,Crizotinib,27436
73,Preclinical,"In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to ASP3026 in culture (PMID: 27009859).",Actionable,5377,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,643,ASP3026,27436
74,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).",Actionable,5375,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,1586,AZD3463,27436
75,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).",Actionable,5374,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,634,AP26113,27436
76,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).",Actionable,5372,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,706,Crizotinib,27436
77,Preclinical,"In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).",Actionable,5376,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,27436
78,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).",Actionable,5373,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,698,Alectinib,27436
79,Preclinical,"In preclinical studies, transformed cell lines expressing EML4-ALK L1152R demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 21791641).",Actionable,2144,10000003,Advanced Solid Tumor,JAX,5425,EML4-ALK ALK L1152R,"[{'id': 918, 'pubMedId': 21791641, 'title': 'A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21791641'}]",resistant,706,Crizotinib,27436
80,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK L1152R in the context of EML4-ALK in culture  (PMID: 26144315). ",Actionable,8295,10000003,Advanced Solid Tumor,JAX,5425,EML4-ALK ALK L1152R,"[{'id': 3367, 'pubMedId': 26144315, 'title': 'PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144315'}]",sensitive,869,PF-06463922,27436
81,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK L1152R in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9259,10000003,Advanced Solid Tumor,JAX,5425,EML4-ALK ALK L1152R,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,27436
82,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK L1152R in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) in culture (PMID: 27780853).",Actionable,9268,10000003,Advanced Solid Tumor,JAX,5425,EML4-ALK ALK L1152R,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",decreased response,789,Ceritinib,27436
83,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).",Actionable,5683,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}, {'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",conflicting,698,Alectinib,27436
84,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5686,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,789,Ceritinib,27436
85,Preclinical,"In a preclinical study, Xalkori (crizotinib) enhanced growth inhibition of transformed cells expressing EML4-ALK with L1198F in culture (PMID: 26698910).",Actionable,5675,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,706,Crizotinib,27436
86,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EML4-ALK with L1198F in culture (PMID: 26698910).",Actionable,5690,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,634,AP26113,27436
87,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with L1198F had reduced sensitivity to growth inhibition mediated by Lorlatinib (PF-06463922) in comparison to EML4-ALK wild type in culture (PMID: 26698910).",Actionable,5680,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",decreased response,869,PF-06463922,27436
88,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Brigatinib (AP26113) in culture (PMID: 27432227).  ",Actionable,8644,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,634,AP26113,27436
89,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).  ",Actionable,8643,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,698,Alectinib,27436
90,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8642,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,789,Ceritinib,27436
91,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8641,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,706,Crizotinib,27436
92,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8645,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,869,PF-06463922,27436
93,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing S1206Y in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9263,10000003,Advanced Solid Tumor,JAX,5338,EML4-ALK ALK S1206Y,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,27436
94,Clinical Study,"In a clinical study, an ALK S1206Y secondary mutation in the context of EML4-ALK was associated with resistance to Xalkori (crizotinib) in a patient with non-small cell lung cancer, and resistance was replicated in cell culture studies (PMID: 22277784).",Actionable,1001,3908,non-small cell lung carcinoma,DOID,5338,EML4-ALK ALK S1206Y,"[{'id': 683, 'pubMedId': 22277784, 'title': 'Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22277784'}]",resistant,706,Crizotinib,27436
95,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK S1206Y demonstrated growth inhibition with Zykadia (ceritinib) treatment in culture (PMID: 24675041). ",Actionable,2099,10000003,Advanced Solid Tumor,JAX,5338,EML4-ALK ALK S1206Y,"[{'id': 2525, 'pubMedId': 24675041, 'title': 'The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24675041'}]",sensitive,789,Ceritinib,27436
96,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK S1206Y in the context of EML4-ALK in culture  (PMID: 26144315). ",Actionable,8296,10000003,Advanced Solid Tumor,JAX,5338,EML4-ALK ALK S1206Y,"[{'id': 3367, 'pubMedId': 26144315, 'title': 'PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144315'}]",sensitive,869,PF-06463922,27436
97,Clinical Study,"In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 that demonstrated resistance to treatment with Xalkori (crizotinib) after acquisition of ALK F1245C, achieved a complete radiographic response with no evidence of progression at 6 months following treatment with Zykadia (ceritinib) (PMID: 26775591).",Actionable,10734,3908,non-small cell lung carcinoma,DOID,27740,EML4-ALK ALK F1245C,"[{'id': 8753, 'pubMedId': 26775591, 'title': 'A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26775591'}]",sensitive,789,Ceritinib,27436
98,Clinical Study,"In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 demonstrated an initial response to treatment with Xalkori (crizotinib), but progressed after 27 months and was found to have acquired ALK F1245C (PMID: 26775591).",Actionable,10733,3908,non-small cell lung carcinoma,DOID,27740,EML4-ALK ALK F1245C,"[{'id': 8753, 'pubMedId': 26775591, 'title': 'A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26775591'}]",resistant,706,Crizotinib,27436
99,Preclinical,"In a preclinical study, ASP3026 inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).",Actionable,3406,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",sensitive,643,ASP3026,27436
100,Preclinical,"In a preclinical study, a transformed cell line expressing EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534).",Actionable,3396,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",resistant,698,Alectinib,27436
101,Preclinical,"In a preclinical study, a human non-small cell lung cancer cell line harboring EML4-ALK ALK V1180L was resistant to Xalkori (crizotinib) treatment in culture (PMID: 25228534).",Actionable,3393,3908,non-small cell lung carcinoma,DOID,12072,EML4-ALK ALK V1180L,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",resistant,706,Crizotinib,27436
102,Preclinical,"In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing EML4-ALK ALK V1180L in culture (PMID: 25228534).",Actionable,3398,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",sensitive,2386,TAE684,27436
103,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis of non-small cell lung carcinoma cells harboring ALK V1180L in the context of EML4-ALK in culture (PMID: 26144315). ",Actionable,2648,3908,non-small cell lung carcinoma,DOID,12072,EML4-ALK ALK V1180L,"[{'id': 3367, 'pubMedId': 26144315, 'title': 'PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144315'}]",sensitive,869,PF-06463922,27436
104,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).",Actionable,3400,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",sensitive,789,Ceritinib,27436
105,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of a transformed cell line expressing EML4-ALK ALK V1180L in culture (PMID: 25228534).",Actionable,3403,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",sensitive,634,AP26113,27436
106,Preclinical,"In a preclinical study, a human non-small cell lung cancer cell line harboring EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534).",Actionable,3392,3908,non-small cell lung carcinoma,DOID,12072,EML4-ALK ALK V1180L,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",resistant,698,Alectinib,27436
107,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK S1206F in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9262,10000003,Advanced Solid Tumor,JAX,26804,EML4-ALK ALK S1206F,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,27436
108,Preclinical - Patient cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell growth in patient derived non-small cell lung cancer cells harboring ALK I1171T in the context of EML4-ALK in culture (PMID: 26144315).",Actionable,3160,3908,non-small cell lung carcinoma,DOID,5340,EML4-ALK ALK I1171T,"[{'id': 3367, 'pubMedId': 26144315, 'title': 'PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144315'}]",sensitive,869,PF-06463922,27436
109,Preclinical,"In a preclinical study, a transformed cell line expressing EML4-ALK with ALK I1171T was resistant to ASP3026 treatment in culture (PMID: 25228534).",Actionable,3407,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",resistant,643,ASP3026,27436
110,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8633,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,869,PF-06463922,27436
111,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK I1171T in culture (PMID: 25228534).",Actionable,2058,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",sensitive,789,Ceritinib,27436
112,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of a transformed cell line expressing EML4-ALK I1171T but to a lesser degree than EML4-ALK in culture (PMID: 25228534).",Actionable,3404,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",decreased response,634,AP26113,27436
113,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8632,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",decreased response,706,Crizotinib,27436
114,Preclinical,"In a preclinical study, a transformed cell line expressing EML4-ALK with ALK I1171T was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534), however, another study with comparable cells demonstrated sensitivity in culture (PMID: 27432227). ",Actionable,3397,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}, {'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",conflicting,698,Alectinib,27436
115,Preclinical,"In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing EML4-ALK ALK I1171T in culture (PMID: 25228534).",Actionable,3399,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",sensitive,2386,TAE684,27436
116,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK T1151dup in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9258,10000003,Advanced Solid Tumor,JAX,26807,EML4-ALK ALK T1151dup,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,27436
117,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK T1151dup in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).",Actionable,9264,10000003,Advanced Solid Tumor,JAX,26807,EML4-ALK ALK T1151dup,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",decreased response,706,Crizotinib,27436
118,Preclinical - Cell line xenograft,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and proliferation of non-small cell lung carcinoma cells over expressing ALK L1196M in the context of EML4-ALK in culture, and resulted in tumor regression in cell line xenograft models (PMID: 26144315). ",Actionable,2650,3908,non-small cell lung carcinoma,DOID,5335,EML4-ALK ALK L1196M,"[{'id': 3367, 'pubMedId': 26144315, 'title': 'PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144315'}]",sensitive,869,PF-06463922,27436
119,Preclinical - Cell line xenograft,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK L196M in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853).",Actionable,5702,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,27436
120,Preclinical,"In preclinical studies, transformed cells expressing EML4-ALK ALK L1196M were insensitive to Xalkori (crizotinib) as demonstrated by lack of growth inhibition and Alk phosphorylation in culture (PMID: 21613408, PMID: 26698910). ",Actionable,2094,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 2442, 'pubMedId': 21613408, 'title': 'Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21613408'}, {'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,706,Crizotinib,27436
121,Preclinical,"In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK ALK L1196M (PMID: 21613408).",Actionable,2095,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 2442, 'pubMedId': 21613408, 'title': 'Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21613408'}]",sensitive,961,X-396,27436
122,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M demonstrated decreased sensitivity to Alecensa (alectinib) compared to cells expressing EML4-ALK with wild-type ALK, in culture (PMID: 26698910).",Actionable,5701,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",conflicting,698,Alectinib,27436
123,Preclinical - Cell line xenograft,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing an EML4-ALK fusion and ALK L1196M in culture and in xenograft models (PMID: 21575866).",Actionable,10341,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 1817, 'pubMedId': 21575866, 'title': 'CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21575866'}]",conflicting,698,Alectinib,27436
124,Preclinical - Cell line xenograft,"In a preclinical study, Zykadia (ceritinib) inhibited cell survival and PI3K/AKT, MEK/ERK, and mTOR signaling in two human non-small cell lung carcinoma cell lines harboring the Xalkori (crizotinib) resistance mutation EML4-ALK ALK L1196M in culture and inhibited tumor growth in xenograft models of one of those cell lines (PMID: 24675041).",Actionable,2056,3908,non-small cell lung carcinoma,DOID,5335,EML4-ALK ALK L1196M,"[{'id': 2525, 'pubMedId': 24675041, 'title': 'The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24675041'}]",sensitive,789,Ceritinib,27436
125,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227). ",Actionable,5708,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}, {'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",conflicting,869,PF-06463922,27436
126,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK L1196M demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8634,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,789,Ceritinib,27436
127,Preclinical - Cell culture,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 26698910)",Actionable,10342,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,789,Ceritinib,27436
128,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were sensitive to Entrectinib (RXDX-101), resulting in anti-proliferative activity (PMID: 26939704).",Actionable,5638,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 5130, 'pubMedId': 26939704, 'title': 'Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26939704'}]",sensitive,1455,Entrectinib,27436
129,Preclinical - Cell culture,"In a preclinical study, TPX-0005 inhibited Alk activity and proliferation of transformed cells over expressing ALK L1196M in the context of EML4-ALK in culture (European Journal of Cancer , Volume 69, S32).",Actionable,10345,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,"[{'id': 8338, 'pubMedId': None, 'title': 'TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants', 'url': 'http://www.ejcancer.com/article/S0959-8049%2816%2932675-2/abstract'}]",sensitive,3950,TPX-0005,27436
130,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK in culture (PMID: 26698910).",Actionable,5681,10000003,Advanced Solid Tumor,JAX,4138,EML4-ALK,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,698,Alectinib,27436
131,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK in culture (PMID: 26698910).",Actionable,5678,10000003,Advanced Solid Tumor,JAX,4138,EML4-ALK,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,869,PF-06463922,27436
132,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of a transformed cell line expressing EML4-ALK in culture (PMID: 25228534).",Actionable,3402,10000003,Advanced Solid Tumor,JAX,4138,EML4-ALK,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",sensitive,634,AP26113,27436
133,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of neuroblastoma cells harboring EML4-ALK in culture (PMID: 26554404).",Actionable,8378,769,neuroblastoma,DOID,4138,EML4-ALK,"[{'id': 6636, 'pubMedId': 26554404, 'title': 'The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26554404'}]",sensitive,869,PF-06463922,27436
134,Preclinical - Cell culture,"In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing EML4-ALK in culture (PMID: 26554404).",Actionable,8372,769,neuroblastoma,DOID,4138,EML4-ALK,"[{'id': 6636, 'pubMedId': 26554404, 'title': 'The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26554404'}]",resistant,706,Crizotinib,27436
135,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells harboring EML4-ALK were sensitive to Entrectinib (RXDX-101), resulting in inhibition of cell proliferation and complete tumor regression (PMID: 26939704).",Actionable,5636,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,"[{'id': 5130, 'pubMedId': 26939704, 'title': 'Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26939704'}]",sensitive,1455,Entrectinib,27436
136,Preclinical - Cell line xenograft,"In a preclinical study, combination of Gilotrif (afatinib) and Alecensa (alectinib) restored sensitivity to Alecensa (alectinib) in non-small cell lung cancer cells harboring EML4-ALK fusion that acquired resistance to Alecensa (alectinib) through up-regulating Egfr signaling in culture, inhibited tumor progression in cell line xenograft models (PMID: 26682573).",Actionable,9072,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,"[{'id': 6894, 'pubMedId': 26682573, 'title': 'Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26682573'}]",sensitive,4873,Afatinib + Alectinib,27436
137,Preclinical,"In a preclinical study, ASP3026 inhibited growth of a transformed cell line expressing EML4-ALK in culture (PMID: 25228534).",Actionable,3405,10000003,Advanced Solid Tumor,JAX,4138,EML4-ALK,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",sensitive,643,ASP3026,27436
138,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK in culture (PMID: 25228534).",Actionable,3401,10000003,Advanced Solid Tumor,JAX,4138,EML4-ALK,"[{'id': 3371, 'pubMedId': 25228534, 'title': 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25228534'}]",sensitive,789,Ceritinib,27436
139,Preclinical - Cell line xenograft,"In a preclinical study, X-376 inhibited Alk signaling, resulted in growth inhibition in lung cancer cells harboring EML4-ALK fusion in culture and in cell line xenograft models (PMID: 21613408).",Actionable,10343,1324,lung cancer,DOID,4138,EML4-ALK,"[{'id': 2442, 'pubMedId': 21613408, 'title': 'Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21613408'}]",sensitive,2520,X-376,27436
140,Preclinical - Cell line xenograft,"In a preclinical study, Alecensa (alectinib) inhibited Alk phosphorylation and growth of a human non-small cell lung cancer cell line harboring EML4-ALK in culture and in cell line xenografts (PMID: 21575866).",Actionable,6396,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,"[{'id': 1817, 'pubMedId': 21575866, 'title': 'CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21575866'}]",sensitive,698,Alectinib,27436
141,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited phosphorylation of Alk and inhibited growth of human non-small cell lung cancer cell lines harboring EML4-ALK in culture (PMID: 25173427).",Actionable,6395,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,"[{'id': 5545, 'pubMedId': 25173427, 'title': 'Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25173427'}]",sensitive,789,Ceritinib,27436
142,Preclinical - Cell line xenograft,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and proliferation of non-small cell lung carcinoma cells harboring EML4-ALK fusion, and reduced tumor size in intracranial cell line xenograft models (PMID: 26144315). ",Actionable,2651,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,"[{'id': 3367, 'pubMedId': 26144315, 'title': 'PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144315'}]",sensitive,869,PF-06463922,27436
143,Preclinical,"In a preclinical study, transformed non-small cell lung cancer cells harboring EML4-ALK demonstrated enhanced growth inhibition to a combination treatment with Afinitor (sirolimus) and Ensartinib (X-396) (PMID: 21613408).",Actionable,2096,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,"[{'id': 2442, 'pubMedId': 21613408, 'title': 'Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21613408'}]",sensitive,2592,Sirolimus + X-396,27436
144,Preclinical - Cell line xenograft,"In a preclinical study, Brigatinib (AP26113) inhibited Alk phosphorylation and growth in non-small cell lung cancer cell lines harboring EML4-ALK in culture, and induced near complete tumor regression in cell line xenograft models (PMID: 27780853).",Actionable,9255,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,27436
145,Clinical Study,"In a clinical study, non-small cell lung carcinoma patients harboring an EML4-ALK fusion, in which exon 13 of EML4 is fused to exon 20 of ALK, demonstrated a significantly longer PFS compared to patients with an EML4-ALK fusion that includes either exon 20 or exon 6a/6b fused to ALK, when treated with Xalkori (crizotinib) (PMID: 27354483). ",Actionable,7510,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,"[{'id': 6384, 'pubMedId': 27354483, 'title': 'Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27354483'}]",sensitive,706,Crizotinib,27436
146,Phase I,"In a Phase I clinical trial, Xalkori (crizotinib) inhibited tumor growth by at least 30% from baseline in 90% (18/20) of patients with EML4-ALK positive non-small cell lung carcinoma (PMID: 20979469).",Actionable,6394,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,"[{'id': 512, 'pubMedId': 20979469, 'title': 'Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20979469'}]",sensitive,706,Crizotinib,27436
147,Preclinical,"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring EML4-ALK fusion in culture (PMID: 26090892).",Actionable,3932,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,"[{'id': 4301, 'pubMedId': 26090892, 'title': 'TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26090892'}]",sensitive,2086,TAE226,27436
148,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).",Actionable,5342,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,698,Alectinib,27436
149,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5340,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,27436
150,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).",Actionable,5348,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,1586,AZD3463,27436
151,Preclinical - Cell culture,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).",Actionable,5338,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",conflicting,706,Crizotinib,27436
152,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK F1174L in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).",Actionable,9266,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",conflicting,706,Crizotinib,27436
153,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5345,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,643,ASP3026,27436
154,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Brigatinib (AP26113) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5343,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,634,AP26113,27436
155,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK F1174L in the context of EML4-ALK in culture  (PMID: 26144315). ",Actionable,8297,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,"[{'id': 3367, 'pubMedId': 26144315, 'title': 'PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144315'}]",sensitive,869,PF-06463922,27436
156,Preclinical - Cell line xenograft,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis in transformed cells over expressing ALK G1202R in the context of EML4-ALK in culture and in cell line xenograft models (PMID: 26144315). ",Actionable,2649,1324,lung cancer,DOID,5339,EML4-ALK ALK G1202R,"[{'id': 3367, 'pubMedId': 26144315, 'title': 'PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144315'}]",conflicting,869,PF-06463922,27436
157,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,8294,1324,lung cancer,DOID,5339,EML4-ALK ALK G1202R,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",conflicting,869,PF-06463922,27436
158,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to RXDX-101 (PMID: 26939704). ",Actionable,5639,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,"[{'id': 5130, 'pubMedId': 26939704, 'title': 'Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26939704'}]",resistant,1455,Entrectinib,27436
159,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).",Actionable,5709,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,706,Crizotinib,27436
160,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5711,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,789,Ceritinib,27436
161,Preclinical - Cell line xenograft,"In a preclinical study, TPX-0005 inhibited Alk activity and proliferation of transformed cells over expressing ALK G1201R in the context of EML4-ALK in culture, resulted in tumor regression in cell line xenograft models (European Journal of Cancer , Volume 69, S32).",Actionable,10346,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,"[{'id': 8338, 'pubMedId': None, 'title': 'TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants', 'url': 'http://www.ejcancer.com/article/S0959-8049%2816%2932675-2/abstract'}]",sensitive,3950,TPX-0005,27436
162,Preclinical - Cell line xenograft,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK G1202R in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853).",Actionable,5713,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,27436
163,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202R demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8635,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,869,PF-06463922,27436
164,Clinical Study,"In a clinical study, an ALK G1202R secondary mutation in the context of EML4-ALK was associated with resistance to Xalkori (crizotinib) in a patient with non-small cell lung cancer, and resistance was replicated in cell culture studies (PMID: 22277784).",Actionable,1000,3908,non-small cell lung carcinoma,DOID,5339,EML4-ALK ALK G1202R,"[{'id': 683, 'pubMedId': 22277784, 'title': 'Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22277784'}]",resistant,706,Crizotinib,27436
165,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were insensitive to Zykadia (ceritinib) in culture (PMID: 24675041). ",Actionable,2097,3908,non-small cell lung carcinoma,DOID,5339,EML4-ALK ALK G1202R,"[{'id': 2525, 'pubMedId': 24675041, 'title': 'The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24675041'}]",resistant,789,Ceritinib,27436
166,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5710,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,698,Alectinib,27436
167,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8650,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,869,PF-06463922,27436
168,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Brigatinib (AP26113) in culture (PMID: 27432227).  ",Actionable,8649,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,634,AP26113,27436
169,Clinical Study,"In a clinical study, a lung cancer patient harboring EML4-ALK demonstrated progression when treated with Xalkori (crizotinib) due to the secondary acquired resistance mutation, ALK E1210K, however, in vitro transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8646,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",conflicting,706,Crizotinib,27436
170,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8647,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,789,Ceritinib,27436
171,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).  ",Actionable,8648,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,698,Alectinib,27436
172,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C demonstrated decreased sensitivity to Alecensa (alectinib) in culture compared to cells expressing EML4-ALK with wild-type ALK (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227). ",Actionable,5699,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}, {'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",conflicting,698,Alectinib,27436
173,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910).",Actionable,5693,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,869,PF-06463922,27436
174,Preclinical,"In a preclinical study, Brigatinib (AP26113) modestly inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910).",Actionable,5695,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",decreased response,634,AP26113,27436
175,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).",Actionable,5691,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,706,Crizotinib,27436
176,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).",Actionable,5697,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}, {'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",conflicting,789,Ceritinib,27436
177,Clinical Study,"In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",Actionable,11543,3498,pancreatic ductal adenocarcinoma,DOID,28131,EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*,"[{'id': 9613, 'pubMedId': 28476735, 'title': 'Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28476735'}]",resistant,706,Crizotinib,27436
178,Clinical Study,"In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",Actionable,11544,3498,pancreatic ductal adenocarcinoma,DOID,28131,EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*,"[{'id': 9613, 'pubMedId': 28476735, 'title': 'Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28476735'}]",predicted – sensitive,698,Alectinib,27436
179,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171S demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8631,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,"[{'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",sensitive,869,PF-06463922,27436
180,Clinical Study,"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer initially responded to Alecensa (alectinib) but progressed with the emergence of a secondary ALK I1171S mutation (PMID: 25393796).",Actionable,5391,3908,non-small cell lung carcinoma,DOID,20653,EML4-ALK ALK I1171S,"[{'id': 5028, 'pubMedId': 25393796, 'title': 'Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25393796'}]",resistant,698,Alectinib,27436
181,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5325,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,706,Crizotinib,27436
182,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Brigatinib (AP26113) mediated growth inhibition in culture (PMID: 27009859), however, another study with comparable cells demonstrated sensitivity (PMID: 27432227). ",Actionable,5331,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}, {'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",resistant,634,AP26113,27436
183,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5330,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,698,Alectinib,27436
184,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859), however, in another study comparable cells demonstrated sensitivity (PMID: (PMID: (PMID: 27432227).",Actionable,5328,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}, {'id': 6706, 'pubMedId': 27432227, 'title': 'Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27432227'}]",conflicting,789,Ceritinib,27436
185,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5336,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,1586,AZD3463,27436
186,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5333,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,643,ASP3026,27436
187,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5694,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,869,PF-06463922,27436
188,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5698,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,789,Ceritinib,27436
189,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).",Actionable,5692,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,706,Crizotinib,27436
190,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910).",Actionable,5696,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,634,AP26113,27436
191,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5700,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,698,Alectinib,27436
192,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5363,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,634,AP26113,27436
193,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5360,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,706,Crizotinib,27436
194,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5365,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,1586,AZD3463,27436
195,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5364,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,643,ASP3026,27436
196,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5362,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,698,Alectinib,27436
197,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5361,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,27436
198,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5727,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,698,Alectinib,27436
199,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5726,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,789,Ceritinib,27436
200,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with G1269A were re-sensitized and modestly sensitive to Xalkori (crizotinib) with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).",Actionable,5723,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,706,Crizotinib,27436
201,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A and L1198F in culture (PMID: 26698910).",Actionable,5724,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",sensitive,634,AP26113,27436
202,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5725,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,"[{'id': 5143, 'pubMedId': 26698910, 'title': 'Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26698910'}]",resistant,869,PF-06463922,27436
0,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 D769Y reverted to normal morphology in culture upon Tykerb (lapatinib) treatment (PMID: 23220880).
",Actionable,2025,1612,breast cancer,DOID,3129,ERBB2 D769Y,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,787,Lapatinib,2064
1,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) D769Y reverted to normal morphology in culture upon Nerlynx (neratinib) treatment (PMID: 23220880).
",Actionable,2026,1612,breast cancer,DOID,3129,ERBB2 D769Y,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,828,Neratinib,2064
2,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 D769Y reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).
",Actionable,2027,1612,breast cancer,DOID,3129,ERBB2 D769Y,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,947,Trastuzumab,2064
3,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) T733I in culture (PMID: 18413839).",Actionable,7319,10000003,Advanced Solid Tumor,JAX,24166,ERBB2 T733I,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",sensitive,967,XL647,2064
4,Preclinical,"In a preclinical study, transformed cells expressing ERBB2 (HER2) T733I demonstrated resistance to treatment with Tykerb (lapatinib) (PMID: 18413839).",Actionable,6973,10000003,Advanced Solid Tumor,JAX,24166,ERBB2 T733I,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",resistant,787,Lapatinib,2064
5,Preclinical,"In a preclinical study, xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y were resistant to Erbitux (cetuximab) (PMID: 26243863).",Actionable,7118,9256,colorectal cancer,DOID,3285,ERBB2 S310Y,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",resistant,694,Cetuximab,2064
6,Preclinical,"In a preclinical study, Tykerb (lapatinib) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).",Actionable,7122,9256,colorectal cancer,DOID,3285,ERBB2 S310Y,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,787,Lapatinib,2064
7,Preclinical,"In a preclinical study, Herceptin (trastuzumab) and Tykerb (lapatinib) combination treatment resulted in tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).",Actionable,7124,9256,colorectal cancer,DOID,3285,ERBB2 S310Y,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,1414,Trastuzumab + Lapatinib,2064
8,Preclinical,"In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment resulted in tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).",Actionable,7123,9256,colorectal cancer,DOID,3285,ERBB2 S310Y,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,4359,Neratinib + Trastuzumab,2064
9,Preclinical,"In a preclinical study, Herceptin (trastuzumab) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).",Actionable,7120,9256,colorectal cancer,DOID,3285,ERBB2 S310Y,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,947,Trastuzumab,2064
10,Preclinical,"In a preclinical study, Nerlynx (neratinib) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).",Actionable,7121,9256,colorectal cancer,DOID,3285,ERBB2 S310Y,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,828,Neratinib,2064
11,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) and ERBB2 (HER2) C805S demonstrated resistance to Nerlynx (neratinib) in culture (PMID: 28363995).",Actionable,10513,10000003,Advanced Solid Tumor,JAX,27537,ERBB2 Y772_A775dup ERBB2 C805S,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",resistant,828,Neratinib,2064
12,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing ERBB2 (HER2) C805S and ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) demonstrated resistance to dacomitinib in culture (PMID: 28363995).",Actionable,10514,10000003,Advanced Solid Tumor,JAX,27537,ERBB2 Y772_A775dup ERBB2 C805S,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",resistant,714,Dacomitinib,2064
13,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) and ERBB2 (HER2) C805S demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995).",Actionable,10515,10000003,Advanced Solid Tumor,JAX,27537,ERBB2 Y772_A775dup ERBB2 C805S,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",resistant,623,Afatinib,2064
14,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) in culture (PMID: 26545934).",Actionable,6956,1324,lung cancer,DOID,3148,ERBB2 Y772_A775dup,"[{'id': 5974, 'pubMedId': 26545934, 'title': 'Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26545934'}]",sensitive,623,Afatinib,2064
15,Preclinical,"In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",Actionable,6963,1324,lung cancer,DOID,3148,ERBB2 Y772_A775dup,"[{'id': 5974, 'pubMedId': 26545934, 'title': 'Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26545934'}]",no benefit,751,Gefitinib,2064
16,Clinical Study,"In a clinical study, a lung adenocarcinoma patient harboring ERBB2 Y772_A775dup (also referred to as A775_G776insYVMA and E740_A741insAYVM) achieved a partial response for 5 months following treatment with pulse Gilotrif (afatinib), however, a second patient harboring ERBB2 Y772_A775dup treated with pulse Gilotrif (afatinib) demonstrated progressive disease (PMID: 26964772).",Actionable,7400,3910,lung adenocarcinoma,DOID,3148,ERBB2 Y772_A775dup,"[{'id': 6345, 'pubMedId': 26964772, 'title': 'Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26964772'}]",conflicting,623,Afatinib,2064
17,Preclinical - Cell culture,"In a preclinical study, Nerlynx (neratinib) inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as ERBB2 A775_G776insYVMA) in culture (PMID: 28363995).",Actionable,10528,10000003,Advanced Solid Tumor,JAX,3148,ERBB2 Y772_A775dup,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",sensitive,828,Neratinib,2064
18,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E719G in culture (PMID: 18413839).",Actionable,7317,10000003,Advanced Solid Tumor,JAX,24159,ERBB2 E719G,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",sensitive,967,XL647,2064
19,Preclinical,"In a preclinical study, transformed cells over expressing ERBB2 (HER2) E719G demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).",Actionable,7311,10000003,Advanced Solid Tumor,JAX,24159,ERBB2 E719G,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",decreased response,787,Lapatinib,2064
20,Preclinical,"In a preclinical study, Canertinib inhibited Erbb2 (Her2) phosphorylation and cell growth in transformed human cell lines expressing ERBB2 (HER2) G776_V777insYVMA (PMID: 16843263). ",Actionable,2906,10000003,Advanced Solid Tumor,JAX,3959,ERBB2 G776_V777insYVMA,"[{'id': 2004, 'pubMedId': 16843263, 'title': 'HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16843263'}]",sensitive,2136,Canertinib,2064
21,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).",Actionable,7090,219,colon cancer,DOID,3284,ERBB2 S310F,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,828,Neratinib,2064
22,Preclinical,"In a preclinical study, bladder cancer cells over expressing ERBB2 (HER2) S310F demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture (PMID: 24971884).",Actionable,7173,11054,urinary bladder cancer,DOID,3284,ERBB2 S310F,"[{'id': 6134, 'pubMedId': 24971884, 'title': 'Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24971884'}]",decreased response,913,Selumetinib,2064
23,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 24971884).",Actionable,7171,11054,urinary bladder cancer,DOID,3284,ERBB2 S310F,"[{'id': 6134, 'pubMedId': 24971884, 'title': 'Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24971884'}]",sensitive,623,Afatinib,2064
24,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 24971884).",Actionable,7172,11054,urinary bladder cancer,DOID,3284,ERBB2 S310F,"[{'id': 6134, 'pubMedId': 24971884, 'title': 'Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24971884'}]",sensitive,787,Lapatinib,2064
25,Preclinical,"In a preclinical study, Nerlynx (neratinib) decreased cell survival of transformed human cells expressing ERBB2 (HER2) S310F (PMID: 22908275). ",Actionable,2914,10000003,Advanced Solid Tumor,JAX,3284,ERBB2 S310F,"[{'id': 1979, 'pubMedId': 22908275, 'title': 'Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22908275'}]",sensitive,828,Neratinib,2064
26,Preclinical,"In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).",Actionable,7086,219,colon cancer,DOID,3284,ERBB2 S310F,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,947,Trastuzumab,2064
27,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).",Actionable,7112,9256,colorectal cancer,DOID,3284,ERBB2 S310F,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,623,Afatinib,2064
28,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cells expressing ERBB2 S310F in culture (PMID: 22908275).",Actionable,2877,10000003,Advanced Solid Tumor,JAX,3284,ERBB2 S310F,"[{'id': 1979, 'pubMedId': 22908275, 'title': 'Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22908275'}]",sensitive,787,Lapatinib,2064
29,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).",Actionable,7107,9256,colorectal cancer,DOID,3284,ERBB2 S310F,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,828,Neratinib,2064
30,Preclinical,"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) S310F were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).",Actionable,7103,9256,colorectal cancer,DOID,3284,ERBB2 S310F,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",resistant,845,Panitumumab,2064
31,Preclinical,"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) S310F were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).",Actionable,7102,9256,colorectal cancer,DOID,3284,ERBB2 S310F,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",resistant,694,Cetuximab,2064
32,Preclinical,"In a preclinical study, bladder cancer cells over expressing both ERBB2 (HER2) D277H and S310F demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture (PMID: 24971884).",Actionable,7180,11054,urinary bladder cancer,DOID,24585,ERBB2 D277H ERBB2 S310F,"[{'id': 6134, 'pubMedId': 24971884, 'title': 'Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24971884'}]",decreased response,913,Selumetinib,2064
33,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing both ERBB2 (HER2) D277H and S310F in culture (PMID: 24971884).",Actionable,7179,11054,urinary bladder cancer,DOID,24585,ERBB2 D277H ERBB2 S310F,"[{'id': 6134, 'pubMedId': 24971884, 'title': 'Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24971884'}]",sensitive,787,Lapatinib,2064
34,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited foci formation of bladder cancer cells over expressing both ERBB2 (HER2) D277H and S310F in culture (PMID: 24971884).",Actionable,7178,11054,urinary bladder cancer,DOID,24585,ERBB2 D277H ERBB2 S310F,"[{'id': 6134, 'pubMedId': 24971884, 'title': 'Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24971884'}]",sensitive,623,Afatinib,2064
35,Phase II,"In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), with 1 complete response, 1 partial response, and 3 patients achieving stable disease for 24 weeks or more, which included a patient harboring ERBB2 (HER2) S310F and V842I (PMID: 28679771).",Actionable,11643,1612,breast cancer,DOID,28175,ERBB2 S310F ERBB2 V842I,"[{'id': 9679, 'pubMedId': 28679771, 'title': 'Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28679771'}]",predicted – sensitive,828,Neratinib,2064
36,Preclinical,"In a preclinical study, transformed cell lines expressing ERBB2 (HER2) H878Y demonstrated growth inhibition when treated with AEE788 in culture (PMID: 22046346).
",Actionable,2031,10000003,Advanced Solid Tumor,JAX,3144,ERBB2 H878Y,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",sensitive,622,AEE788,2064
37,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited proliferation of  transformed cell lines expressing ERBB2 (HER2) H878Y in culture (PMID: 22046346).
",Actionable,2032,10000003,Advanced Solid Tumor,JAX,3144,ERBB2 H878Y,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",sensitive,787,Lapatinib,2064
38,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 V842I reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).
",Actionable,2053,1612,breast cancer,DOID,3235,ERBB2 V842I,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,947,Trastuzumab,2064
39,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) V842I demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).
",Actionable,2052,1612,breast cancer,DOID,3235,ERBB2 V842I,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,828,Neratinib,2064
40,Preclinical,"In a preclinical study, transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V842I were resistant to Herceptin (trastuzumab) in culture (PMID: 26243863).",Actionable,7093,219,colon cancer,DOID,3235,ERBB2 V842I,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",resistant,947,Trastuzumab,2064
41,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing ERBB2 (HER2) V842I were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).",Actionable,7094,9256,colorectal cancer,DOID,3235,ERBB2 V842I,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",resistant,694,Cetuximab,2064
42,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 V842I demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).
",Actionable,2051,1612,breast cancer,DOID,3235,ERBB2 V842I,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,787,Lapatinib,2064
43,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cell lines over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863).",Actionable,7108,9256,colorectal cancer,DOID,3235,ERBB2 V842I,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,828,Neratinib,2064
44,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cell lines over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863).",Actionable,7113,9256,colorectal cancer,DOID,3235,ERBB2 V842I,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,623,Afatinib,2064
45,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing ERBB2 (HER2) V842I were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).",Actionable,7095,9256,colorectal cancer,DOID,3235,ERBB2 V842I,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",resistant,845,Panitumumab,2064
46,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863).",Actionable,7091,219,colon cancer,DOID,3235,ERBB2 V842I,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,828,Neratinib,2064
47,Preclinical,"In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755P demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346).
",Actionable,2034,10000003,Advanced Solid Tumor,JAX,3150,ERBB2 L755P,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",resistant,787,Lapatinib,2064
48,Preclinical,"In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755P demonstrated resistance when treated with AEE788 in culture (PMID: 22046346).
",Actionable,2033,10000003,Advanced Solid Tumor,JAX,3150,ERBB2 L755P,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",resistant,622,AEE788,2064
49,Preclinical,"In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755P in culture (PMID: 22046346).",Actionable,3034,10000003,Advanced Solid Tumor,JAX,3150,ERBB2 L755P,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",sensitive,3075,WZ4002,2064
50,Preclinical,"In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755P in culture (PMID: 22046346).",Actionable,3033,10000003,Advanced Solid Tumor,JAX,3150,ERBB2 L755P,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",sensitive,2911,EKI-285,2064
51,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) V839G in culture (PMID: 18413839).",Actionable,7328,10000003,Advanced Solid Tumor,JAX,24614,ERBB2 V839G,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",sensitive,967,XL647,2064
52,Preclinical - Cell culture,"In a preclinical study, Gilotrif (afatinib) inhibited ERBB2 (HER2) phosphorylation and growth of transformed breast epithelial cells expressing ERBB2 (HER2) L869R in culture (PMID: 28274957).",Actionable,11221,1612,breast cancer,DOID,18584,ERBB2 L869R,"[{'id': 9156, 'pubMedId': 28274957, 'title': 'An Acquired HER2(T798I) Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28274957'}]",sensitive,623,Afatinib,2064
53,Clinical Study,"In a clinical study, ERBB2 (HER2) L869R conferred resistant to ERBB2 (HER2)-directed therapy including Tarceva (erlotinib) and Tykerb (lapatinib) in a patient with lung adenocarcinoma (PMID: 27900369).",Actionable,10404,3910,lung adenocarcinoma,DOID,18584,ERBB2 L869R,"[{'id': 8396, 'pubMedId': 27900369, 'title': 'Genomic profiling of multiple sequentially acquired tumor metastatic sites from an ""exceptional responder"" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27900369'}]",resistant,4,Erlotinib,2064
54,Preclinical - Cell line xenograft,"In a preclinical study, transformed breast cancer cells over expressing ERBB2 (HER2) L869R were resistant to Tykerb (lapatinib) in culture, formed tumors and metastasized readily in xenograft animal models (PMID: 27900369).",Actionable,10402,1612,breast cancer,DOID,18584,ERBB2 L869R,"[{'id': 8396, 'pubMedId': 27900369, 'title': 'Genomic profiling of multiple sequentially acquired tumor metastatic sites from an ""exceptional responder"" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27900369'}]",resistant,787,Lapatinib,2064
55,Clinical Study,"In a clinical study, ERBB2 (HER2) L869R conferred resistant to ERBB2 (HER2)-directed therapy including Tarceva (erlotinib) and Tykerb (lapatinib) in a patient with lung adenocarcinoma (PMID: 27900369).",Actionable,10405,3910,lung adenocarcinoma,DOID,18584,ERBB2 L869R,"[{'id': 8396, 'pubMedId': 27900369, 'title': 'Genomic profiling of multiple sequentially acquired tumor metastatic sites from an ""exceptional responder"" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27900369'}]",resistant,787,Lapatinib,2064
56,Preclinical - Cell culture,"In a preclinical study, transformed breast cancer cells over expressing ERBB2 (HER2) L869R were resistant to Tarceva (erlotinib) in culture (PMID: 27900369).",Actionable,10403,1612,breast cancer,DOID,18584,ERBB2 L869R,"[{'id': 8396, 'pubMedId': 27900369, 'title': 'Genomic profiling of multiple sequentially acquired tumor metastatic sites from an ""exceptional responder"" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27900369'}]",resistant,4,Erlotinib,2064
57,Phase II,"In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), with 1 complete response, 1 partial response, and 3 patients achieving stable disease for 24 weeks or more, which included a patient harboring ERBB2 (HER2) L869R (PMID: 28679771).",Actionable,11641,1612,breast cancer,DOID,18584,ERBB2 L869R,"[{'id': 9679, 'pubMedId': 28679771, 'title': 'Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28679771'}]",sensitive,828,Neratinib,2064
58,Preclinical - Cell culture,"In a preclinical study, Nerlynx (neratinib) inhibited ERBB2 (HER2) phosphorylation and growth of transformed breast epithelial cells expressing ERBB2 (HER2) L869R in culture (PMID: 28274957).",Actionable,11220,1612,breast cancer,DOID,18584,ERBB2 L869R,"[{'id': 9156, 'pubMedId': 28274957, 'title': 'An Acquired HER2(T798I) Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28274957'}]",sensitive,828,Neratinib,2064
59,Preclinical,"In a preclinical study, breast cancer cells expressing ERBB2 T798M demonstrated resistance to CI-1040 (PMID: 23948973).",Actionable,963,1612,breast cancer,DOID,1572,ERBB2 T798M,"[{'id': 624, 'pubMedId': 23948973, 'title': 'Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23948973'}]",resistant,699,CI-1040,2064
60,Preclinical,"In a preclinical study, breast cancer cells expressing ERBB2 T798M were sensitive to the combination of Herceptin (trastuzumab) and XL147 (PMID: 23948973). ",Actionable,962,1612,breast cancer,DOID,1572,ERBB2 T798M,"[{'id': 624, 'pubMedId': 23948973, 'title': 'Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23948973'}]",sensitive,1415,Trastuzumab + XL147,2064
61,Preclinical,"In a preclinical study, transformed cell lines expressing ERBB2  (HER2) T798M demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346).
",Actionable,3030,10000003,Advanced Solid Tumor,JAX,1572,ERBB2 T798M,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",resistant,787,Lapatinib,2064
62,Preclinical,"In a preclinical study, transformed cell lines expressing ERBB2 (HER2) T798M demonstrated resistance when treated with AEE788 in culture (PMID: 22046346).
",Actionable,2046,10000003,Advanced Solid Tumor,JAX,1572,ERBB2 T798M,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",resistant,622,AEE788,2064
63,Preclinical,"In a preclinical study, breast cancer cells expressing the ERBB2 (HER2) T798M mutant were resistant to Erbitux (cetuximab)(PMID: 23948973).",Actionable,959,1612,breast cancer,DOID,1572,ERBB2 T798M,"[{'id': 624, 'pubMedId': 23948973, 'title': 'Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23948973'}]",resistant,694,Cetuximab,2064
64,Preclinical,"In a preclinical study, breast cancer cell lines expressing ERBB2 (HER2) T798M demonstrated sensitivity to XL147 (SAR245408) in cell culture (PMID: 23948973).",Actionable,956,1612,breast cancer,DOID,1572,ERBB2 T798M,"[{'id': 624, 'pubMedId': 23948973, 'title': 'Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23948973'}]",sensitive,1050,XL147,2064
65,Preclinical - Cell line xenograft,"In a preclinical study, human breast cancer cell lines and cell line xenografts expressing ERBB2 T798M demonstrated sensitivity to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23948973).",Actionable,961,1612,breast cancer,DOID,1572,ERBB2 T798M,"[{'id': 624, 'pubMedId': 23948973, 'title': 'Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23948973'}]",sensitive,1414,Trastuzumab + Lapatinib,2064
66,Preclinical - Cell line xenograft,"In preclinical studies, the combination of Erbitux (cetuximab) and Tykerb (lapatinib) inhibited cell growth of a human breast cancer cell line harboring ERBB2 T798M and synergized to inhibit tumor growth in xenograft models (PMID: 23948973).",Actionable,960,1612,breast cancer,DOID,1572,ERBB2 T798M,"[{'id': 624, 'pubMedId': 23948973, 'title': 'Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23948973'}]",sensitive,1672,Cetuximab + Lapatinib,2064
67,Preclinical,"In a preclinical study, breast cancer cells expressing ERBB2(HER2) T798M were sensitive to Gilotrif (afatinib) (PMID: 23948973).",Actionable,957,1612,breast cancer,DOID,1572,ERBB2 T798M,"[{'id': 624, 'pubMedId': 23948973, 'title': 'Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23948973'}]",sensitive,623,Afatinib,2064
68,Preclinical,"In a preclinical study, ERBB2 (HER2)-receptor positive breast cancer cells expressing ERBB2 (HER2) T798M were resistant to Tykerb (lapatinib) in both culture and xenograft models (PMID: 23948973).",Actionable,953,60079,Her2-receptor positive breast cancer,DOID,1572,ERBB2 T798M,"[{'id': 624, 'pubMedId': 23948973, 'title': 'Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23948973'}]",resistant,787,Lapatinib,2064
69,Preclinical,"In a preclinical study, human breast cancer cells expressing the ERBB2 (HER2) T798M mutation demonstrated sensitivity to BKM120 (PMID: 23948973).",Actionable,955,1612,breast cancer,DOID,1572,ERBB2 T798M,"[{'id': 624, 'pubMedId': 23948973, 'title': 'Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23948973'}]",sensitive,680,BKM120,2064
70,Preclinical,"In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T798M in culture (PMID: 22046346).",Actionable,3031,10000003,Advanced Solid Tumor,JAX,1572,ERBB2 T798M,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",sensitive,2911,EKI-285,2064
71,Preclinical,"In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T798M in culture (PMID: 22046346).",Actionable,3032,10000003,Advanced Solid Tumor,JAX,1572,ERBB2 T798M,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",sensitive,3075,WZ4002,2064
72,Preclinical - Cell line xenograft,"In a preclinical study, a human ERBB2-amplified breast cancer cell line expressing ERBB2 (HER2) T798M was resistant to Herceptin (trastuzumab) in culture and in xenograft models (PMID: 23948973).",Actionable,954,1612,breast cancer,DOID,23649,ERBB2 amp ERBB2 T798M,"[{'id': 624, 'pubMedId': 23948973, 'title': 'Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23948973'}]",resistant,947,Trastuzumab,2064
73,Clinical Study,"In a clinical case study, treatment with the combination of  Tykerb (lapatinib) and Xeloda (capecitabine) resulted in prolonged response and reduction in liver metastasis in a metastatic breast cancer patient harboring ERBB2 L869Q and CDH1 R63* mutations (PMID: 26487584).",Actionable,5027,1612,breast cancer,DOID,20031,CDH1 R63* ERBB2 L869Q,"[{'id': 4844, 'pubMedId': 26487584, 'title': 'A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26487584'}]",sensitive,1399,Lapatinib + Capecitabine,2064
74,Preclinical,"In a preclinical study, an ERBB2 (HER2) L726I mutation was detected in a murine breast cancer cell line that acquired resistance to Iressa (gefitinib) in culture (PMID: 17638894).",Actionable,7181,1612,breast cancer,DOID,24594,ERBB2 L726I,"[{'id': 6138, 'pubMedId': 17638894, 'title': 'Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17638894'}]",resistant,751,Gefitinib,2064
75,Preclinical,"In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G776delinsLC did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",Actionable,6966,1324,lung cancer,DOID,24128,ERBB2 G776delinsLC,"[{'id': 5974, 'pubMedId': 26545934, 'title': 'Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26545934'}]",no benefit,751,Gefitinib,2064
76,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G776delinsLC in culture (PMID: 26545934).",Actionable,6958,1324,lung cancer,DOID,24128,ERBB2 G776delinsLC,"[{'id': 5974, 'pubMedId': 26545934, 'title': 'Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26545934'}]",sensitive,623,Afatinib,2064
77,Preclinical,"In a preclinical study, transformed cell lines expressing ERBB2 (HER2) V777L demonstrated growth inhibition when treated with AEE788 in culture (PMID: 22046346).
",Actionable,2047,10000003,Advanced Solid Tumor,JAX,3234,ERBB2 V777L,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",sensitive,622,AEE788,2064
78,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V777L in culture (PMID: 22046346).",Actionable,3043,10000003,Advanced Solid Tumor,JAX,3234,ERBB2 V777L,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",sensitive,787,Lapatinib,2064
79,Preclinical,"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) V777L were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).",Actionable,7099,9256,colorectal cancer,DOID,3234,ERBB2 V777L,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",resistant,845,Panitumumab,2064
80,Preclinical - Cell line xenograft,"In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture and suppressed tumor growth in cell line xenograft models (PMID: 26243863).",Actionable,7114,9256,colorectal cancer,DOID,3234,ERBB2 V777L,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,4359,Neratinib + Trastuzumab,2064
81,Preclinical,"In a preclinical study, transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V777L were resistant to Herceptin (trastuzumab) in culture (PMID: 26243863).",Actionable,7092,219,colon cancer,DOID,3234,ERBB2 V777L,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",resistant,947,Trastuzumab,2064
82,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture (PMID: 26243863).",Actionable,7110,9256,colorectal cancer,DOID,3234,ERBB2 V777L,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,623,Afatinib,2064
83,Preclinical - Cell line xenograft,"In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture and suppressed tumor growth in cell line xenograft models (PMID: 26243863).",Actionable,7105,9256,colorectal cancer,DOID,3234,ERBB2 V777L,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,828,Neratinib,2064
84,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 V777L demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).
",Actionable,2048,1612,breast cancer,DOID,3234,ERBB2 V777L,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,787,Lapatinib,2064
85,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V777L in culture (PMID: 26243863).",Actionable,7088,219,colon cancer,DOID,3234,ERBB2 V777L,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,828,Neratinib,2064
86,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 V777L reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).
",Actionable,2050,1612,breast cancer,DOID,3234,ERBB2 V777L,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,947,Trastuzumab,2064
87,Preclinical - Pdx,"In a preclinical study, human colorectal cancer cells over expressing ERBB2 (HER2) V777L were resistant to Erbitux (cetuximab) in culture and in patient-derived xenograft models (PMID: 26243863).",Actionable,7098,9256,colorectal cancer,DOID,3234,ERBB2 V777L,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",resistant,694,Cetuximab,2064
88,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) V777L demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).
",Actionable,2049,1612,breast cancer,DOID,3234,ERBB2 V777L,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,828,Neratinib,2064
89,Preclinical - Cell culture,"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Nerlynx (neratinib) in culture, resulting in decreased colony formation (PMID: 27697991). ",Actionable,8751,1612,breast cancer,DOID,26427,ERBB2 L768S,"[{'id': 6720, 'pubMedId': 27697991, 'title': 'Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27697991'}]",sensitive,828,Neratinib,2064
90,Preclinical - Cell culture,"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Herceptin (trastuzumab) in culture, resulting in decreased colony formation (PMID: 27697991). ",Actionable,8748,1612,breast cancer,DOID,26427,ERBB2 L768S,"[{'id': 6720, 'pubMedId': 27697991, 'title': 'Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27697991'}]",sensitive,947,Trastuzumab,2064
91,Preclinical - Cell culture,"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Tykerb (lapatinib) in culture, resulting in decreased colony formation (PMID: 27697991). ",Actionable,8750,1612,breast cancer,DOID,26427,ERBB2 L768S,"[{'id': 6720, 'pubMedId': 27697991, 'title': 'Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27697991'}]",sensitive,787,Lapatinib,2064
92,Preclinical - Cell culture,"In a preclinical study, dacomitinib inhibited growth of transformed cells expressing ERBB2 (HER2) G778_S779insCPG in culture (PMID: 28363995).",Actionable,10526,10000003,Advanced Solid Tumor,JAX,27531,ERBB2 G778_S779insCPG,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",sensitive,714,Dacomitinib,2064
93,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) P780L in culture (PMID: 18413839).",Actionable,7321,10000003,Advanced Solid Tumor,JAX,24176,ERBB2 P780L,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",sensitive,967,XL647,2064
94,Preclinical,"In a preclinical study, transformed cells expressing ERBB2 (HER2) P780L demonstrated resistance to treatment with Tykerb (lapatinib) (PMID: 18413839).",Actionable,6992,10000003,Advanced Solid Tumor,JAX,24176,ERBB2 P780L,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",resistant,787,Lapatinib,2064
95,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L915M in culture (PMID: 19718025).",Actionable,7329,10000003,Advanced Solid Tumor,JAX,24608,ERBB2 L915M,"[{'id': 566, 'pubMedId': 19718025, 'title': 'Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19718025'}]",sensitive,967,XL647,2064
96,Clinical Study,"In a clinical study, treatment with Herceptin (trastuzumab) in combination with chemotherapy resulted in an objective response rate of 67% (4/6) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies (PMID: 28167203). ",Actionable,10131,3908,non-small cell lung carcinoma,DOID,1216,ERBB2 mutant,"[{'id': 8141, 'pubMedId': 28167203, 'title': 'ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28167203'}]",predicted – sensitive,947,Trastuzumab,2064
97,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring an ERBB2 (HER2) mutation demonstrated sensitivity to AV-412, resulting in decreased phosphorylation of Erbb2, Akt, and Erk (PMID: 19459856). ",Actionable,2907,3908,non-small cell lung carcinoma,DOID,1216,ERBB2 mutant,"[{'id': 3519, 'pubMedId': 19459856, 'title': 'Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19459856'}]",sensitive,990,AV-412,2064
98,Clinical Study,"In a clinical study, treatment with Gilotrif (afatinib) resulted in an objective response rate of 33% (2/6) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies (PMID: 28167203). ",Actionable,10130,3908,non-small cell lung carcinoma,DOID,1216,ERBB2 mutant,"[{'id': 8141, 'pubMedId': 28167203, 'title': 'ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28167203'}]",predicted – sensitive,623,Afatinib,2064
99,Phase I,"In a Phase I clinical trial, Nerlynx (neratinib) administered with Torisel (temsirolimus) was tolerable and demonstrated antitumor activity in ERBB2 (HER2)-mutant non-small-cell lung cancer (PMID: 24323026).",Actionable,427,1324,lung cancer,DOID,1216,ERBB2 mutant,"[{'id': 94, 'pubMedId': 24323026, 'title': 'Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24323026'}]",sensitive,828,Neratinib,2064
100,Phase II,"In a Phase II trial, Nerlynx (neratinib) treatment resulted in complete response in 12.5% (3/24) and partial response in 20.8% (5/24) of ERBB2 (HER2) mutant but not amplified breast cancer patients (Cancer Res 2017;77(4 Suppl):Abstract nr PD2-08).",Actionable,10950,60079,Her2-receptor positive breast cancer,DOID,1216,ERBB2 mutant,"[{'id': 8951, 'pubMedId': None, 'title': 'Neratinib + fulvestrant in ERBB2-mutant, HER2–non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial', 'url': 'http://cancerres.aacrjournals.org/content/77/4_Supplement/PD2-08.short'}]",sensitive,828,Neratinib,2064
101,Phase II,"In a Phase II trial, ERBB2 (HER2) mutations were only detected in  patients with muscle-invasive urothelial bladder cancer that responded to Nexavar (sorafenib), Platinol (cisplatin) and Gemzar (gemcitabine) combination therapy (J Clin Oncol 35, 2017 (suppl 6S; abstract 345)).",Actionable,10322,6477,invasive bladder transitional cell carcinoma,DOID,1216,ERBB2 mutant,"[{'id': 8305, 'pubMedId': None, 'title': 'Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): Final results and translational findings of an open-label, single-arm, phase II study.', 'url': 'http://meetinglibrary.asco.org/content/179076-197'}]",predicted – sensitive,5462,Cisplatin + Gemcitabine + Sorafenib,2064
102,Phase II,"In a Phase II trial, treatment with Gilotrif (afatinib) resulted in objective response in 3 lung adenocarcinoma patients harboring ERBB2 (HER2) mutations (PMID: 22325357).",Actionable,2888,3910,lung adenocarcinoma,DOID,1216,ERBB2 mutant,"[{'id': 3514, 'pubMedId': 22325357, 'title': 'Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22325357'}]",sensitive,623,Afatinib,2064
103,Phase I,"In a Phase I study, Nerlynx (neratinib) administered with temsirolimus was tolerable and demonstrated antitumor activity in ERBB2-mutant non-small-cell lung cancer (PMID:24323026).",Actionable,428,3908,non-small cell lung carcinoma,DOID,1216,ERBB2 mutant,"[{'id': 94, 'pubMedId': 24323026, 'title': 'Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24323026'}]",sensitive,828,Neratinib,2064
104,Phase II,"In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, with treatment resulting in a clinical benefit rate of 31% (5/16; 1 complete response, 1 partial response, and 3 patients achieving stable disease for 24 weeks or more) and a median progression-free survival of 16 weeks (PMID: 28679771).",Actionable,11634,1612,breast cancer,DOID,1216,ERBB2 mutant,"[{'id': 9679, 'pubMedId': 28679771, 'title': 'Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28679771'}]",predicted – sensitive,828,Neratinib,2064
105,Phase II,"In a Phase II trial, Pyrotinib treatment in non-small cell lung cancer patients harboring an ERBB2 (HER2) mutation resulted in a partial response in 54.5% (6/11) of patients and stable disease in 27.3% (3/11) of patients, and a PFS of 6.2 months (Journal of Thoracic Oncology, Vol. 12, Issue 1, S359).",Actionable,9850,3908,non-small cell lung carcinoma,DOID,1216,ERBB2 mutant,"[{'id': 7688, 'pubMedId': None, 'title': 'Preliminary Results of a Phase II Study about the Efficacy and Safety of Pyrotinib in Patients with HER2 Mutant Advanced NSCLC', 'url': 'http://www.jto.org/action/doSearch?seriesISSNFltraddfilter=1556-0864&issueType=normal&issue=1&volume=12&searchType=singleIssue&journalCode=jtho&searchText=Pyrotinib&occurrences=all'}]",sensitive,3082,Pyrotinib,2064
106,Preclinical,"In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) N862A in culture (PMID: 22046346).",Actionable,3038,10000003,Advanced Solid Tumor,JAX,11336,ERBB2 T862A,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",decreased response,787,Lapatinib,2064
107,Preclinical,"In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T862A in culture (PMID: 22046346).",Actionable,3041,10000003,Advanced Solid Tumor,JAX,11336,ERBB2 T862A,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",sensitive,622,AEE788,2064
108,Preclinical - Cell culture,"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Nerlynx (nerlatinib) in culture, resulting in decreased colony formation (PMID: 27697991). ",Actionable,8754,1612,breast cancer,DOID,26428,ERBB2 V773L,"[{'id': 6720, 'pubMedId': 27697991, 'title': 'Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27697991'}]",sensitive,828,Neratinib,2064
109,Preclinical - Cell culture,"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Herceptin (trastuzumab) in culture, resulting in decreased colony formation (PMID: 27697991). ",Actionable,8752,1612,breast cancer,DOID,26428,ERBB2 V773L,"[{'id': 6720, 'pubMedId': 27697991, 'title': 'Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27697991'}]",sensitive,947,Trastuzumab,2064
110,Preclinical - Cell culture,"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Tykerb (lapatinib) in culture, resulting in decreased colony formation (PMID: 27697991). ",Actionable,8753,1612,breast cancer,DOID,26428,ERBB2 V773L,"[{'id': 6720, 'pubMedId': 27697991, 'title': 'Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27697991'}]",sensitive,787,Lapatinib,2064
111,Preclinical - Pdx & cell culture,"In a preclinical study, Sapitinib (AZD8931) demonstrated antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).",Actionable,964,6263,inflammatory breast carcinoma,DOID,23650,EGFR over exp ERBB2 dec exp,"[{'id': 625, 'pubMedId': 24886365, 'title': 'AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24886365'}]",sensitive,910,Sapitinib,2064
112,Preclinical - Pdx & cell culture,"In a preclinical study, combination of Sapatinib (AZD8931) and Taxol (paclitaxel) demonstrated enhanced antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erbb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).",Actionable,965,6263,inflammatory breast carcinoma,DOID,23650,EGFR over exp ERBB2 dec exp,"[{'id': 625, 'pubMedId': 24886365, 'title': 'AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24886365'}]",sensitive,1416,Sapitinib + Paclitaxel,2064
113,Preclinical,"In a preclinical study, bladder cancer cells over expressing ERBB2 (HER2) S653C demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture (PMID: 24971884).",Actionable,7176,11054,urinary bladder cancer,DOID,24587,ERBB2 S653C,"[{'id': 6134, 'pubMedId': 24971884, 'title': 'Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24971884'}]",decreased response,913,Selumetinib,2064
114,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S653C in culture (PMID: 24971884).",Actionable,7174,11054,urinary bladder cancer,DOID,24587,ERBB2 S653C,"[{'id': 6134, 'pubMedId': 24971884, 'title': 'Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24971884'}]",sensitive,623,Afatinib,2064
115,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S653C in culture (PMID: 24971884).",Actionable,7175,11054,urinary bladder cancer,DOID,24587,ERBB2 S653C,"[{'id': 6134, 'pubMedId': 24971884, 'title': 'Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24971884'}]",sensitive,787,Lapatinib,2064
116,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) G309A demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).
",Actionable,2029,1612,breast cancer,DOID,3131,ERBB2 G309A,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,828,Neratinib,2064
117,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 G309A demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).
",Actionable,2028,1612,breast cancer,DOID,3131,ERBB2 G309A,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,787,Lapatinib,2064
118,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 G309A reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).
",Actionable,2030,1612,breast cancer,DOID,3131,ERBB2 G309A,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,947,Trastuzumab,2064
119,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) R678Q demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).
",Actionable,2042,1612,breast cancer,DOID,3281,ERBB2 R678Q,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,828,Neratinib,2064
120,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 R678Q demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).
",Actionable,2041,1612,breast cancer,DOID,3281,ERBB2 R678Q,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,787,Lapatinib,2064
121,Phase II,"In a Phase II trial, a lung adenocarcinoma patient harboring ERBB2 (HER2) M774delinsWLV demonstrated a partial response to treatment with dacomitinib (PMID: 25899785).",Actionable,10500,3910,lung adenocarcinoma,DOID,27530,ERBB2 M774delinsWLV,"[{'id': 8574, 'pubMedId': 25899785, 'title': 'Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25899785'}]",sensitive,714,Dacomitinib,2064
122,Preclinical - Cell culture,"In a preclinical study, dacomitinib inhibited growth of transformed cells expressing ERBB2 (HER2) M774delinsWLV in culture (PMID: 28363995).",Actionable,10524,10000003,Advanced Solid Tumor,JAX,27530,ERBB2 M774delinsWLV,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",sensitive,714,Dacomitinib,2064
123,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing ERBB2 (HER2) M774delinsWLV and ERBB2 (HER2) C805S demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995).",Actionable,10516,10000003,Advanced Solid Tumor,JAX,27538,ERBB2 M774delinsWLV ERBB2 C805S,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",resistant,623,Afatinib,2064
124,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing ERBB2 (HER2) M774delinsWLV and ERBB2 (HER2) C805S demonstrated resistance to Nerlynx (neratinib) in culture (PMID: 28363995).",Actionable,10517,10000003,Advanced Solid Tumor,JAX,27538,ERBB2 M774delinsWLV ERBB2 C805S,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",resistant,828,Neratinib,2064
125,Preclinical - Cell culture,"In a preclinical study, acquisition of ERBB2 (HER2) C805S in transformed cells expressing ERBB2 (HER2) M774delinsWLV conferred resistance to dacomitinib in culture (PMID: 28363995).",Actionable,10518,10000003,Advanced Solid Tumor,JAX,27538,ERBB2 M774delinsWLV ERBB2 C805S,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",resistant,714,Dacomitinib,2064
126,Preclinical,"In a preclinical study, the combination of 23814 and Tivozanib (AV-951) inhibited tumor growth in several transgenic mouse models of breast cancer expressing ERBB2 (HER2) V659E, including those with resistance to VEGFR inhibitors (PMID: 25995436).",Actionable,8843,1612,breast cancer,DOID,11379,ERBB2 V659E,"[{'id': 6764, 'pubMedId': 25995436, 'title': '23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25995436'}]",sensitive,4824,23814 + Tivozanib,2064
127,Preclinical,"In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) V659E did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",Actionable,6969,1324,lung cancer,DOID,11379,ERBB2 V659E,"[{'id': 5974, 'pubMedId': 26545934, 'title': 'Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26545934'}]",no benefit,751,Gefitinib,2064
128,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) V659E in culture (PMID: 26545934).",Actionable,6971,1324,lung cancer,DOID,11379,ERBB2 V659E,"[{'id': 5974, 'pubMedId': 26545934, 'title': 'Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26545934'}]",sensitive,623,Afatinib,2064
129,Preclinical,"In a preclinical study, colorectal cancer cells positive for EGFR and ERBB2 (HER2) had decreased growth upon Gilotrif (afatinib) treatment (PMID: 21617858).",Actionable,1214,9256,colorectal cancer,DOID,2242,EGFR pos ERBB2 pos,"[{'id': 601, 'pubMedId': 21617858, 'title': 'Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21617858'}]",sensitive,623,Afatinib,2064
130,Preclinical - Cell line xenograft,"In a preclinical study, Gilotrif (afatinib) pre-treatment inhibited radiotherapy-induced activation of EGFR and ERBB2 (HER2) and downstream AKT and radiosensitized bladder cancer cell lines in culture, and Gilotrif (afatinib) in combination with radiotherapy led to improved tumor growth inhibition in bladder cancer cell line xenograft models compared to radiotherapy alone (PMID: 25589492).",Actionable,8342,11054,urinary bladder cancer,DOID,2242,EGFR pos ERBB2 pos,"[{'id': 6623, 'pubMedId': 25589492, 'title': 'Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25589492'}]",predicted – sensitive,4711,Afatinib + Radiotherapy,2064
131,Preclinical - Cell line xenograft,"In a preclinical study, S-222611 inhibited cell growth, decreased phosphorylation of Egfr and Erbb2, and resulted in anti-tumor activity of human gastric cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). ",Actionable,2842,10534,stomach cancer,DOID,2242,EGFR pos ERBB2 pos,"[{'id': 1835, 'pubMedId': 24837299, 'title': 'Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24837299'}]",sensitive,1048,S-222611,2064
132,Preclinical - Cell line xenograft,"In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human breast cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). ",Actionable,7722,1612,breast cancer,DOID,2242,EGFR pos ERBB2 pos,"[{'id': 1835, 'pubMedId': 24837299, 'title': 'Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24837299'}]",sensitive,1048,S-222611,2064
133,Preclinical - Cell line xenograft,"In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human lung cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). ",Actionable,7723,1324,lung cancer,DOID,2242,EGFR pos ERBB2 pos,"[{'id': 1835, 'pubMedId': 24837299, 'title': 'Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24837299'}]",sensitive,1048,S-222611,2064
134,Preclinical - Cell line xenograft,"In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human colon cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). ",Actionable,7724,219,colon cancer,DOID,2242,EGFR pos ERBB2 pos,"[{'id': 1835, 'pubMedId': 24837299, 'title': 'Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24837299'}]",sensitive,1048,S-222611,2064
135,Preclinical - Cell line xenograft,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).",Actionable,7745,60079,Her2-receptor positive breast cancer,DOID,25948,ERBB2 pos PIK3CA K111N,"[{'id': 6466, 'pubMedId': 26920887, 'title': 'Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26920887'}]",sensitive,1402,trastuzumab emtansine,2064
136,Clinical Study,"In a clinical study, a retrospective analysis of Herceptin (trastuzumab) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302). ",Actionable,9164,60079,Her2-receptor positive breast cancer,DOID,25947,ERBB2 pos PIK3CA mut,"[{'id': 6968, 'pubMedId': 27687302, 'title': 'Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27687302'}]",decreased response,947,Trastuzumab,2064
137,Phase III,"In a Phase III trial, Tykerb (lapatinib) and Xeloda (capecitabine) combination treatment resulted in decreased median progression free survival (4.3 vs. 6.4 months), median overall survival (17.3 vs. 27.8 months), and overall response rate(17.1% vs. 39.7%) in ERBB2 (HER2) positive breast cancer patients harboring PIK3CA mutations compared to PIK3CA wild type patients (PMID: 26920887). ",Actionable,7744,60079,Her2-receptor positive breast cancer,DOID,25947,ERBB2 pos PIK3CA mut,"[{'id': 6466, 'pubMedId': 26920887, 'title': 'Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26920887'}]",decreased response,1399,Lapatinib + Capecitabine,2064
138,Clinical Study,"In a clinical study, a retrospective analysis of Tykerb (lapatinib) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302). ",Actionable,9163,60079,Her2-receptor positive breast cancer,DOID,25947,ERBB2 pos PIK3CA mut,"[{'id': 6968, 'pubMedId': 27687302, 'title': 'Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27687302'}]",decreased response,787,Lapatinib,2064
139,Preclinical - Cell line xenograft,"In a preclinical study, AT13148 inhibited tumor growth in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model harboring mutant PIK3CA (PMID: 22781553).",Actionable,4784,60079,Her2-receptor positive breast cancer,DOID,25947,ERBB2 pos PIK3CA mut,"[{'id': 204, 'pubMedId': 22781553, 'title': 'AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22781553'}]",sensitive,3653,AT13148,2064
140,Preclinical,"In a preclinical study, circulating tumor cells (CTC) from patients with ERBB2 (HER2)-negative breast cancer were demonstrated to contain both ERBB2 (HER2)-positive and ERBB2 (HER2)-negative subpopulations, and the combination of RO4929097 and Taxol (paclitaxel) resulted in increased tumor growth inhibition in CTC-derived xenograft models compared to either agent alone  (PMID: 27556950).",Actionable,8862,60080,Her2-receptor negative breast cancer,DOID,26477,ERBB2 neg ERBB2 pos,"[{'id': 6775, 'pubMedId': 27556950, 'title': 'HER2 expression identifies dynamic functional states within circulating breast cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27556950'}]",sensitive,4840,RO4929097 + Paclitaxel,2064
141,Preclinical,"In a preclinical study, circulating tumor cells (CTC) from patients with ERBB2 (HER2)-negative breast cancer were demonstrated to contain both ERBB2 (HER2)-positive and ERBB2 (HER2)-negative subpopulations, and the combination of LY411575 and Taxol (paclitaxel) resulted in increased tumor growth inhibition in CTC-derived xenograft models compared to either agent alone (PMID: 27556950).",Actionable,8861,60080,Her2-receptor negative breast cancer,DOID,26477,ERBB2 neg ERBB2 pos,"[{'id': 6775, 'pubMedId': 27556950, 'title': 'HER2 expression identifies dynamic functional states within circulating breast cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27556950'}]",sensitive,4841,LY411575 + Paclitaxel,2064
142,Clinical Study,"In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation due to PTEN loss and/or PIK3CA activating mutation demonstrated a decreased median progression-free survival of 4.5 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217).",Actionable,875,60079,Her2-receptor positive breast cancer,DOID,1409,ERBB2 pos PIK3CA act mut,"[{'id': 224, 'pubMedId': 21676217, 'title': 'PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21676217'}]",decreased response,947,Trastuzumab,2064
143,Clinical Study,"In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563).",Actionable,6664,60079,Her2-receptor positive breast cancer,DOID,1409,ERBB2 pos PIK3CA act mut,"[{'id': 213, 'pubMedId': 17936563, 'title': 'A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17936563'}]",decreased response,947,Trastuzumab,2064
144,Preclinical,"In a preclinical study, Taselisib (GDC-0032) inhibited growth of HER2 positive uterine cancer cell lines with PIK3CA mutations (PMID: 25172762).",Actionable,2850,363,uterine cancer,DOID,1409,ERBB2 pos PIK3CA act mut,"[{'id': 3505, 'pubMedId': 25172762, 'title': 'Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25172762'}]",sensitive,1016,GDC-0032,2064
145,Phase I,"In a Phase I trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on trastuzumab-based therapy (PMID: 24470511).",Actionable,286,60079,Her2-receptor positive breast cancer,DOID,1409,ERBB2 pos PIK3CA act mut,"[{'id': 196, 'pubMedId': 24470511, 'title': 'Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24470511'}]",predicted – sensitive,1417,BKM120 + Trastuzumab,2064
146,Preclinical,"In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit survival of ERBB2 (HER2)-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",Actionable,5857,60079,Her2-receptor positive breast cancer,DOID,1409,ERBB2 pos PIK3CA act mut,"[{'id': 5181, 'pubMedId': 27020857, 'title': 'Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27020857'}]",sensitive,3956,Palbociclib + GDC-0941,2064
147,Preclinical - Cell culture,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture (PMID: 26920887).",Actionable,7746,60079,Her2-receptor positive breast cancer,DOID,25949,ERBB2 pos PIK3CA I391M,"[{'id': 6466, 'pubMedId': 26920887, 'title': 'Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26920887'}]",sensitive,1402,trastuzumab emtansine,2064
148,Preclinical - Cell line xenograft,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA H1047R in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).",Actionable,7748,60079,Her2-receptor positive breast cancer,DOID,25951,ERBB2 pos PIK3CA H1047R,"[{'id': 6466, 'pubMedId': 26920887, 'title': 'Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26920887'}]",sensitive,1402,trastuzumab emtansine,2064
149,Preclinical - Cell line xenograft,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA E545K in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).",Actionable,7749,60079,Her2-receptor positive breast cancer,DOID,20859,ERBB2 pos PIK3CA E545K,"[{'id': 6466, 'pubMedId': 26920887, 'title': 'Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26920887'}]",sensitive,1402,trastuzumab emtansine,2064
150,Phase II,"In a Phase II trial, ERBB2-positive breast cancer patients harboring PIK3CA mutations demonstrated lower pathologic complete remission rate (12.5%) compared to those with wild-type PIK3CA (48.4%) after Herceptin (trastuzumab) and Tykerb (lapatinib) combination therapy (PMID: 26245675).",Actionable,5246,60079,Her2-receptor positive breast cancer,DOID,1669,PIK3CA mutant ERBB2 pos,"[{'id': 3761, 'pubMedId': 26245675, 'title': 'Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26245675'}]",decreased response,1414,Trastuzumab + Lapatinib,2064
151,Clinical Study,"In a clinical study, a retrospective analysis of the combined treatment, Herceptin (trastuzumab) and Tykerb (lapatinib), in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302). ",Actionable,9165,60079,Her2-receptor positive breast cancer,DOID,1669,PIK3CA mutant ERBB2 pos,"[{'id': 6968, 'pubMedId': 27687302, 'title': 'Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27687302'}]",decreased response,1414,Trastuzumab + Lapatinib,2064
152,Phase I,"In a Phase I clinical trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on Herceptin (trastuzumab)-based therapy (PMID: 24470511).",Actionable,4370,60079,Her2-receptor positive breast cancer,DOID,23651,ERBB2 pos PTEN mut,"[{'id': 196, 'pubMedId': 24470511, 'title': 'Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24470511'}]",predicted – sensitive,1417,BKM120 + Trastuzumab,2064
153,Preclinical - Cell culture,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA C420R in culture (PMID: 26920887).",Actionable,7747,60079,Her2-receptor positive breast cancer,DOID,25950,ERBB2 pos PIK3CA C420R,"[{'id': 6466, 'pubMedId': 26920887, 'title': 'Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26920887'}]",sensitive,1402,trastuzumab emtansine,2064
154,Clinical Study,"In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563).",Actionable,6663,60079,Her2-receptor positive breast cancer,DOID,23664,ERBB2 pos PTEN dec exp,"[{'id': 213, 'pubMedId': 17936563, 'title': 'A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17936563'}]",decreased response,947,Trastuzumab,2064
155,Preclinical,"In a preclinical study, the combination of Herceptin (trastuzumab) and Eloxatin (oxaliplatin) resulted in growth inhibition of ERBB2 (HER2)-positive gastric cancer cells in culture (PMID: 24300914).",Actionable,947,10534,stomach cancer,DOID,1187,ERBB2 positive,"[{'id': 620, 'pubMedId': 24300914, 'title': 'Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24300914'}]",sensitive,1412,Trastuzumab + Oxaliplatin,2064
156,Preclinical - Cell culture,"In a preclinical study, SYD985 decreased survival of a ERBB2 (HER2)-positive ovarian carcinoma cell line in culture (PMID: 25589493).",Actionable,8248,4001,ovarian carcinoma,DOID,1187,ERBB2 positive,"[{'id': 6587, 'pubMedId': 25589493, 'title': 'The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25589493'}]",sensitive,4539,SYD985,2064
157,Phase I,"In a Phase I trial, ZW25 treatment resulted in partial response in 28.6% (2/7) and stable disease in 28.6% (2/7) of patients with ERBB2 (HER2)-positive breast cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123).",Actionable,12051,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 9992, 'pubMedId': None, 'title': 'Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]",predicted – sensitive,6240,ZW25,2064
158,Phase III,"In a Phase III trial, adjuvant Herceptin (trastuzumab), Perjeta (pertuzumab), plus chemotherapy resulted in improved invasive disease-free survival compared to Herceptin (trastuzumab) plus chemotherapy in patients with Erbb2 (Her2)-positive breast cancer (J Clin Oncol 35, 2017 (suppl; abstr LBA500)).",Actionable,11142,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 9114, 'pubMedId': None, 'title': 'APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).', 'url': 'http://meetinglibrary.asco.org/record/145538/abstract'}]",sensitive,1389,Trastuzumab + Pertuzumab,2064
159,Phase I,"In a Phase I clinical trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated in patients with ERBB2 (HER2)-positive advanced or metastatic breast cancer that had progressed on Herceptin (trastuzumab) (PMID: 24470511).",Actionable,288,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 196, 'pubMedId': 24470511, 'title': 'Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24470511'}]",sensitive,1417,BKM120 + Trastuzumab,2064
160,Phase I,"In a Phase I trial, treatment with Tucatinib (ARRY-380) resulted in a response rate of 14% (3/22; all partial responses (PR)) and a clinical benefit rate (PR plus stable disease for greater than or equal to 24 weeks) of 27% (6/22) in Erbb2 (Her2)-positive breast cancer patients (PMID: 28053022).",Actionable,2915,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 7781, 'pubMedId': 28053022, 'title': 'Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2(+)-Advanced Solid Tumors, with an Expansion Cohort in HER2(+) Metastatic Breast Cancer (MBC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28053022'}]",sensitive,639,Tucatinib,2064
161,Preclinical - Pdx & cell culture,"In a preclinical study, DS-8201 inhibited growth of a ERBB2 (HER2)-positive gastric carcinoma cell line in culture and in xenograft models, and induced tumor regression in a patient-derived xenograft (PDX) model of ERBB2 (HER2)-positive gastric cancer (PMID: 27026201).",Actionable,8870,10534,stomach cancer,DOID,1187,ERBB2 positive,"[{'id': 6780, 'pubMedId': 27026201, 'title': 'DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27026201'}]",sensitive,4844,DS-8201a,2064
162,FDA approved,"In a Phase III trial that supported FDA approval, treatment with Perjeta (pertuzumab), combined with Herceptin (trastuzumab) and docetaxel, improved median progression free survival to 18.5 months in patients with HER2-positive metastatic breast cancer (PMID: 23801166).",Actionable,2018,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",sensitive,1978,Pertuzumab + Trastuzumab + Docetaxel,2064
163,Phase III,"In a Phase III trial, ERBB2 (HER2) positive breast cancer patients with diabetes demonstrated a greater disease free survival and overall survival when treated with Glucophage (metformin) compared to ERBB2 (HER2) positive breast cancer patients with diabetes not treated with Glucophage (metformin) (PMID: 28375706).",Actionable,11061,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 9054, 'pubMedId': 28375706, 'title': 'Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28375706'}]",predicted – sensitive,1031,Metformin,2064
164,Phase I,"In a Phase I trial, ZW25 treatment resulted in stable disease in 20% (1/5) of patients with ERBB2 (HER2)-positive gastric or esophageal cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #255P; NCT02892123).",Actionable,12053,5041,esophageal cancer,DOID,1187,ERBB2 positive,"[{'id': 9992, 'pubMedId': None, 'title': 'Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]",predicted – sensitive,6240,ZW25,2064
165,Phase II,"In a Phase II trial, Sutent (sunitinib), in combination with Herceptin (trastuzumab), demonstrated safety and efficacy in ERBB2 (HER2) positive advanced breast cancer patients (PMID: 24606768).",Actionable,906,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 591, 'pubMedId': 24606768, 'title': 'Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24606768'}]",sensitive,1658,Sunitinib + Trastuzumab,2064
166,Phase Ib/II,"In a Phase Ib trial, the combination of Tucatinib (ARRY-380) with other agents demonstrated clinical activity in central nervous system (CNS) metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 1/1 evaluable patient treated with Tucatinib (ARRY-380) and Capecitabine achieving CNS partial response (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).",Actionable,3808,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 4180, 'pubMedId': None, 'title': '[P4-14-19] ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets)', 'url': 'http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_1267&terms='}]",predicted – sensitive,1577,ARRY-380 + Capecitabine,2064
167,Preclinical - Cell culture,"In a preclinical study, SYD985 decreased survival of a ERBB2 (HER2)-positive gastric carcinoma cell line in culture (PMID: 25589493).",Actionable,8247,5517,stomach carcinoma,DOID,1187,ERBB2 positive,"[{'id': 6587, 'pubMedId': 25589493, 'title': 'The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25589493'}]",sensitive,4539,SYD985,2064
168,Phase II,"In a Phase II trial, Tykerb (lapatinib) and Herceptin (trastuzumab) combination treatment resulted in complete response in the breast in 10.6% (7/66) and minimal residual disease in 16.7% (11/66) of ERBB2-positive breast cancer patients 11 days after receiving the treatment (European Breast Cancer Conference; Mar 2016; Abstract #6LBA).",Actionable,5079,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 4875, 'pubMedId': None, 'title': 'Effects of perioperative lapatinib and trastuzumab, alone and in combination, in early HER2+ breast cancer - the UK EPHOS-B trial (CRUK/08/002)', 'url': 'http://www.ecco-org.eu/Events/EBCC10/Abstract-search?abstractid=25368'}]",sensitive,1414,Trastuzumab + Lapatinib,2064
169,Clinical Study,"In a meta-analysis of six randomized clinical trials, Tykerb (lapatinib) and Herceptin (trastuzumab) combination treatment resulted in 13% absolute improvement in pathologic complete response rate in ERBB2 (HER2)-positive breast cancer patients compared to Herceptin (trastuzumab) single treatment (PMID: 27140927).",Actionable,8433,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 6655, 'pubMedId': 27140927, 'title': 'Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27140927'}]",sensitive,1414,Trastuzumab + Lapatinib,2064
170,Phase I,"In a Phase I trial, treatment with DS-8201a was well-tolerated and resulted in an overall response rate (ORR) of 38% (19/50) and disease control rate (DCR) of 90% (45/50) in patients with ERBB2 (HER2)-expressing solid tumors, and an ORR of 29% (4/14) and DCR of 93% (13/14) in patients with low ERBB2 (HER2) expression (J Clin Oncol 35, 2017 (suppl; abstr 108)).",Actionable,11103,10000003,Advanced Solid Tumor,JAX,1187,ERBB2 positive,"[{'id': 9075, 'pubMedId': None, 'title': 'Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors.', 'url': 'http://abstracts.asco.org/199/AbstView_199_191619.html'}]",predicted – sensitive,4844,DS-8201a,2064
171,Guideline,"Doxorubicin and cyclophosphamide (AC), followed by a one year treatment with Taxol (paclitaxel) and Herceptin (trastuzumab) is an active adjuvant regiment for patients with Her2-receptor positive breast cancer (Guidelines).",Actionable,2021,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 2502, 'pubMedId': None, 'title': 'NCCN Guidelines Version 2.2015 Breast Cancer', 'url': ''}]",sensitive,1503,Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide,2064
172,Phase III,"In a Phase III trial, the combination of Afinitor (everolimus), Herceptin (trastuzumab), and Navelbine (vinorelbine) increased progression-free survival in patients with Herceptin (trastuzumab)-resistant, ERBB2 (HER2)-positive, advanced breast cancer who had prior taxane treatment (PMID: 24742739). ",Actionable,945,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 619, 'pubMedId': 24742739, 'title': 'Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24742739'}]",sensitive,1411,Trastuzumab + Everolimus + Vinorelbine,2064
173,Phase Ib/II,"In a Phase I/Ib clinical trial, vaccination with a HER2-peptide pulsed dendritic cell vaccine was well-tolerated and resulted in immune response in patients with ERBB2 (HER2)-positive ductal carcinoma in situ (DCIS), and resulted in pathologic complete response rate of 28% (12/42), compared to 8.3% (1/12) in patients with invasive breast cancer (PMID: 27965306).",Actionable,10237,60074,ductal carcinoma in situ,DOID,1187,ERBB2 positive,"[{'id': 8179, 'pubMedId': 27965306, 'title': 'Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2(pos) DCIS Independent of Route: Results of Randomized Selection Design Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27965306'}]",predicted – sensitive,5222,HER2-pulsed DC1 vaccine,2064
174,Preclinical - Pdx & cell culture,"In a preclinical study, SYD985 decreased survival of ERBB2 (HER2)-positive breast carcinoma cell lines in culture, and inhibited tumor growth and induced tumor remission in cell line and patient-derived xenograft models of ERBB2 (HER2)-positive breast carcinoma, including models with low ERBB2 (HER2) expression (PMID: 25589493).",Actionable,8251,3459,breast carcinoma,DOID,1187,ERBB2 positive,"[{'id': 6587, 'pubMedId': 25589493, 'title': 'The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25589493'}]",sensitive,4539,SYD985,2064
175,Preclinical - Cell line xenograft,"In a preclinical study, Imbruvica (ibrutinib) inhibited Her family receptor signaling, resulted in apoptosis and growth inhibition in ERBB2 (HER2)-positive breast cancer cell lines in culture and in cell line xenograft models (PMID: 27256378).",Actionable,8229,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 6582, 'pubMedId': 27256378, 'title': ""Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27256378'}]",predicted – sensitive,768,Ibrutinib,2064
176,Phase II,"In a Phase II trial, Neuvenge (lapuleucel-T) treatment did not result in statistically significant improvement of overall survival (37.0 vs 22.2 months, HR = 0.96) or disease recurrence-free survival (11.9 vs 10.1 months, HR = 0.99) compared to standard of care in ERBB2 (HER2) positive urothelial cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 4513)).",Actionable,6974,2671,transitional cell carcinoma,DOID,1187,ERBB2 positive,"[{'id': 5991, 'pubMedId': None, 'title': 'Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts).', 'url': 'http://meetinglibrary.asco.org/content/162594-176'}]",no benefit,4344,lapuleucel-T,2064
177,Preclinical - Cell line xenograft,"In a preclinical study, treatment with Hertuzumab-vc-MMAE decreased viability of ERBB2 (HER2)-positive ovarian cancer cell lines in culture and inhibited tumor growth in ERBB2 (HER2)-positive ovarian cancer cell line xenograft models (PMID: 27509865).",Actionable,7809,2394,ovarian cancer,DOID,1187,ERBB2 positive,"[{'id': 6501, 'pubMedId': 27509865, 'title': 'HER2-targeted antibody drug conjugates for ovarian cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27509865'}]",sensitive,4583,Hertuzumab-vc-MMAE,2064
178,Phase III,"In a Phase III trial, ABP 980 treatment demonstrated safety and efficacy similar to Herceptin (trastuzumab), with pathologic complete response rates of 48% and 40.5%, respectively, in patients with Erbb2 (Her2)-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 151PD; NCT01901146).",Actionable,12067,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 10002, 'pubMedId': None, 'title': 'Efficacy and safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early breast cancer', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]",predicted – sensitive,6243,ABP 980,2064
179,Preclinical,"In a preclinical study, the combination of Herceptin (trastuzumab) and Eloxatin (oxaliplatin) resulted in growth inhibition of ERBB2 (HER2)-positive breast cancer cells in culture (PMID: 24300914).",Actionable,946,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 620, 'pubMedId': 24300914, 'title': 'Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24300914'}]",sensitive,1412,Trastuzumab + Oxaliplatin,2064
180,Preclinical - Cell line xenograft,"In a preclinical study, DS-8201a inhibited tumor growth in a pancreatic cancer cell line xenograft model with low ERBB2 (HER2) expression (PMID: 27026201).",Actionable,8873,1793,pancreatic cancer,DOID,1187,ERBB2 positive,"[{'id': 6780, 'pubMedId': 27026201, 'title': 'DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27026201'}]",sensitive,4844,DS-8201a,2064
181,Phase II,"In a Phase II clinical trial, Nerlynx (neratinib) demonstrated safety and efficacy as a monotherapy in patients with ERBB2 (HER2)-positive breast cancer (PMID: 23953056).
",Actionable,896,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 581, 'pubMedId': 23953056, 'title': 'A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23953056'}]",sensitive,828,Neratinib,2064
182,FDA approved,"In a Phase III trial that supported FDA approval, ERBB2 (HER2)-positive breast cancer patients previously treated with Herceptin (trastuzumab) demonstrated a significantly greater two year invasive disease-free survival rate (93.9%) when treated with Nerlynx (neratinib) compared to the rate (91.6%) in those patients treated with placebo (PMID: 26874901; NCT00878709). ",Actionable,11507,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 9591, 'pubMedId': 26874901, 'title': 'Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26874901'}]",sensitive,828,Neratinib,2064
183,Phase II,"In Phase II clinical trials, the combination of Xeloda (capecitabine) and Herceptin (trastuzumab) demonstrated efficacy with a manageable toxicity profile in heavily pretreated patients with ERBB2 (HER2)-positive advanced breast cancer and earlier Herceptin (trastuzumab) exposure (PMID: 17679724). ",Actionable,938,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 613, 'pubMedId': 17679724, 'title': 'Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17679724'}]",sensitive,1409,Capecitabine + Trastuzumab,2064
184,Phase III,"In a Phase III trial, MYL-1401O demonstrated safety and efficacy comparable to Herceptin (trastuzumab) when given in combination with Taxol (paclitaxel), resulted in an objective response rate of 69.6% in ERBB2 (HER2)-positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr LBA503)).",Actionable,6814,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 5830, 'pubMedId': None, 'title': 'Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin.', 'url': 'http://meetinglibrary.asco.org/content/162159-176'}]",sensitive,4263,MYL-1401O + Paclitaxel,2064
185,Phase I,"In a Phase I trial, Margetuximab (MGAH22) treatment resulted in tumor reduction in 78% (18/23) of patients with ERBB2 (HER2)-positive breast cancer (PMID: 28119295).",Actionable,897,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 8461, 'pubMedId': 28119295, 'title': 'First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28119295'}]",predicted – sensitive,808,MGAH22,2064
186,Phase I,"In a Phase I expansion trial, 36% (5/14) of metastatic breast cancer patients positive for ERBB2 (HER2) demonstrated stable disease for up to 16 weeks when treated with Varlitinib (ARRY-334543) (Cancer Res May 1, 2009 69; 3603).",Actionable,2904,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 3518, 'pubMedId': None, 'title': 'Abstract #3603: ARRY-334543 in ErbB2 positive metastatic breast cancer and other ErbB expressing-cancers: experience from expansion cohorts on a phase I study', 'url': 'http://cancerres.aacrjournals.org/content/69/9_Supplement/3603'}]",sensitive,1057,varlitinib,2064
187,FDA approved,"In a Phase III trial, Kadclya (trastuzumab emtansine) demonstrated improved median progression free survival and overall survival compared to Tykerb (lapatinib) and Xeloda (capecitabine) combination treatment in patients with ERBB2 (HER2) positive breast cancer, regardless of the expression level of Erbb2 (Her2), Egfr, and Her3, or PIK3CA mutation status (PMID: 26920887). ",Actionable,7743,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 6466, 'pubMedId': 26920887, 'title': 'Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26920887'}]",predicted – sensitive,1402,trastuzumab emtansine,2064
188,FDA approved,"In a Phase III trial that supported FDA approval, treatment with Kadclya (trastuzumab emtansine) improved median progression free survival in patients with metastatic ERBB2 (HER2) positive breast cancer (PMID: 24879797). ",Actionable,2017,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 2499, 'pubMedId': 24879797, 'title': 'FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24879797'}]",predicted – sensitive,1402,trastuzumab emtansine,2064
189,Preclinical,"In a preclinical study, withacnistin induced tumor regression in transgenic mouse models of Erbb2 (Her2)-driven breast cancer (PMID: 24983364).",Actionable,4927,1612,breast cancer,DOID,1187,ERBB2 positive,"[{'id': 4802, 'pubMedId': 24983364, 'title': 'Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24983364'}]",sensitive,3697,Withacnistin,2064
190,Phase III,"In a Phase III trial, second-line treatment using Tykerb (lapatinib) with paclitaxel demonstrated some efficacy in patients with HER2-positive advanced gastric cancer (PMID: 24868024). ",Actionable,939,10534,stomach cancer,DOID,1187,ERBB2 positive,"[{'id': 614, 'pubMedId': 24868024, 'title': 'Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24868024'}]",sensitive,1410,Lapatinib + Paclitaxel,2064
191,Preclinical - Cell line xenograft,"In a preclinical study, SYD895 induced cell death in ERBB2 (HER2)-expressing primary uterine serous carcinoma (USC) cell lines in culture, including cell lines with both high and low levels of ERBB2 (HER2) expression, and inhibited tumor growth and improved survival in ERBB2 (HER2)-expressing USC primary cell line xenografts (PMID: 27256376).",Actionable,7638,5750,uterine corpus serous adenocarcinoma,DOID,1187,ERBB2 positive,"[{'id': 6448, 'pubMedId': 27256376, 'title': 'SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27256376'}]",sensitive,4539,SYD985,2064
192,Phase II,"In a Phase II trial, Taxol (paclitaxel) and Herceptin (trastuzumab) treatment in combination with MM-111 did not improve progression free survival (9.6 weeks) and median overall survival (32.1 weeks) compared to without MM-111 (23.3 weeks, 56.1 weeks) in ERBB2 positive gastroesophageal junction cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 4043)).",Actionable,6713,4944,gastroesophageal junction adenocarcinoma,DOID,1187,ERBB2 positive,"[{'id': 5771, 'pubMedId': None, 'title': 'Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC).', 'url': 'http://abstracts.asco.org/176/AbstView_176_166103.html'}]",no benefit,1892,Paclitaxel + Trastuzumab + MM-111,2064
193,Phase Ib/II,"In a Phase Ib/II trial, Kadcyla (trastuzumab emtansine), Taxotere (docetaxel) and Perjeta (pertuzumab) combination treatment resulted in pathologic complete response in 60.3% (44/73) of patients with ERBB2 (HER2)-positive locally advanced breast cancer (PMID: 27052654).",Actionable,5819,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 5158, 'pubMedId': 27052654, 'title': 'Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27052654'}]",sensitive,3931,Docetaxel + T-DM1 + Pertuzumab,2064
194,Phase I,"In a Phase I trial, Margetuximab (MGAH22) treatment resulted in partial responses in 12% (7/60) and stable disease in 50% (30/60) of patients with ERBB2 (HER2)-positive breast or gastric cancer, or other carcinomas that overexpress Erbb2 (Her2) (PMID: 28119295).",Actionable,10448,10534,stomach cancer,DOID,1187,ERBB2 positive,"[{'id': 8461, 'pubMedId': 28119295, 'title': 'First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28119295'}]",predicted – sensitive,808,MGAH22,2064
195,Preclinical,"In a preclinical study, the combination of Tykerb (lapatinib) and Ibrance (palbociclib) worked additively to suppress growth of ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 25221644). ",Actionable,2979,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 3547, 'pubMedId': 25221644, 'title': 'CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25221644'}]",sensitive,3042,Lapatinib + Palbociclib,2064
196,Preclinical,"In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of ERBB2 (HER2)-positive breast cancer (PMID: 26880266).",Actionable,6441,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 5601, 'pubMedId': 26880266, 'title': 'A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26880266'}]",sensitive,2054,CDX-3379,2064
197,Phase Ib/II,"In a Phase I/II trial, treatment with ERBB2 (HER2)-specific CAR-T cells resulted in stable disease for 12 weeks to 14 months in 4/17 evaluable patients with ERBB2 (HER2)-positive sarcomas and a median overall survival of 10.3 months (PMID: 25800760; NCT00902044).",Actionable,11502,1115,sarcoma,DOID,1187,ERBB2 positive,"[{'id': 9563, 'pubMedId': 25800760, 'title': 'Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25800760'}]",predicted – sensitive,6007,HER2 CAR-T cells,2064
198,Phase I,"In a Phase I clinical trial, AC480 (BMS-599626) treatment demonstrated preliminary clinical activity, resulting in stable disease as best response in 25% (11/44) of patients with advanced solid tumors, including patients expressing EGFR and/or ERBB2, with 2 patients achieving stable disease for greater than 6 months (PMID: 21576284).",Actionable,2909,10000003,Advanced Solid Tumor,JAX,1187,ERBB2 positive,"[{'id': 53, 'pubMedId': 21576284, 'title': 'Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21576284'}]",predicted – sensitive,977,AC480,2064
199,Phase II,"In a Phase II trial, Poziotinib (HM781-36B) treatment resulted in a median progression-free survival of 4.04 months, and a disease control rate of 75.49% (77/102; 20 partial responses) in heavily-treated Erbb2 (Her2)-positive breast cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 237O; NCT02418689).",Actionable,12065,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 9996, 'pubMedId': None, 'title': 'A phase II trial of pan-HER inhibitor Poziotinib, in patients with HER2-positive metastatic breast cancer who have received at least two prior HER2-directed regimens: The results of NOV120101-203 trial', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]",predicted – sensitive,1042,poziotinib,2064
200,Phase III,"In a Phase III trial, CT-P6 demonstrated equivalence to reference Herceptin (trastuzumab) in patients with ERBB2 (HER2)-positive breast cancer, with 46.8% (116/248) of patients treated with CT-P6 achieving pathologic complete response compared to 50.4% (129/256) with Herceptin (trastuzumab) treatment (PMID: 28592386).",Actionable,11356,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 9249, 'pubMedId': 28592386, 'title': 'CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28592386'}]",sensitive,5954,CT-P6,2064
201,Preclinical - Cell culture,"In a preclinical study, Hertuzumab-vc-MMAE decreased viability of ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 27509865).",Actionable,7808,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 6501, 'pubMedId': 27509865, 'title': 'HER2-targeted antibody drug conjugates for ovarian cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27509865'}]",sensitive,4583,Hertuzumab-vc-MMAE,2064
202,Phase I,"In a Phase I trial, glioblastoma patients positive for ERBB2 (HER2) demonstrated antitumor activity when treated with ERBB2 (HER2)-CAR-T cell therapy including one patient with a partial response and seven patients with stable disease ranging from 8 weeks to 29 months (PMID: 28426845). ",Actionable,11716,3068,glioblastoma multiforme,DOID,1187,ERBB2 positive,"[{'id': 9733, 'pubMedId': 28426845, 'title': 'HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28426845'}]",sensitive,6007,HER2 CAR-T cells,2064
203,Phase II,"In a Phase II trial, Nerlynx (neratinib) plus Taxol (paclitaxel) demonstrated similar efficacy to Herceptin (trastuzumab) plus Taxol (paclitaxel), with an median progression-free survival of 12.9 months, however, potentially decreased CNS metastasis risk, with an incidence of 8.3% (20/242) compared to 17.3% (41/237) in the Herceptin (trastuzumab) plus Taxol (paclitaxel) group (PMID: 27078022).",Actionable,9585,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 7298, 'pubMedId': 27078022, 'title': 'Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27078022'}]",sensitive,5101,Neratinib + Paclitaxel,2064
204,Phase Ib/II,"In a Phase Ib trial, the combination of Tucatinib (ARRY-380), Herceptin (trastuzumab), and Capecitabine demonstrated clinical activity in CNS metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 50% (1/2) of evaluable patients achieving CNS partial response and 50% (1/2) achieving CNS stable disease (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).
",Actionable,3810,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 4180, 'pubMedId': None, 'title': '[P4-14-19] ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets)', 'url': 'http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_1267&terms='}]",predicted – sensitive,3340,ARRY-380 + Capecitabine + Trastuzumab,2064
205,Phase III,"In a Phase III trial, Kadcyla (trastuzumab emtansine) did not demonstrated efficacy benefit over Taxol (paclitaxel) on median overall survival (7.9 vs 8.6 months) in patients with previously treated ERBB2 (HER2)-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (J Clin Oncol 34, 2016 (suppl 4S; abstr 5)).",Actionable,8740,4944,gastroesophageal junction adenocarcinoma,DOID,1187,ERBB2 positive,"[{'id': 6725, 'pubMedId': None, 'title': 'A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma', 'url': 'http://meetinglibrary.asco.org/content/159174-173'}]",no benefit,1402,trastuzumab emtansine,2064
206,Phase Ib/II,"In a Phase Ib/II trial, Kadcyla (trastuzumab emtansine) and Taxotere (docetaxel) combination treatment resulted in median progression-free survival of 13.8 months and objective response in 80.0% (20/25) of patients with ERBB2 (HER2)-positive metastatic breast cancer (PMID: 27052654).",Actionable,5818,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 5158, 'pubMedId': 27052654, 'title': 'Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27052654'}]",sensitive,3930,Docetaxel + T-DM1,2064
207,Preclinical - Pdx & cell culture,"In a preclinical study, XMT-1522 inhibited growth of Erbb2 (Her2)-positive breast cancer cells in culter, resulted in tumor regression in both cell line and patient-derived xenograft models (Cancer Res 2016;76(4 Suppl): Abstract nr P4-14-28).",Actionable,11055,1612,breast cancer,DOID,1187,ERBB2 positive,"[{'id': 9048, 'pubMedId': None, 'title': 'XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer', 'url': 'http://cancerres.aacrjournals.org/content/76/4_Supplement/P4-14-28'}]",sensitive,5834,XMT-1522,2064
208,Phase II,"In a Phase II clinical trial, the combination of TS-1 (S-1) and Herceptin (trastuzumab) demonstrated safety and efficacy in patients with ERBB2 (HER2)-positive metastatic breast cancer, with an overall response rate of 53.6% (15/28), and a clinical benefit rate of 75.0% (21/28)  (PMID: 24982373).",Actionable,937,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 984, 'pubMedId': 24982373, 'title': 'Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24982373'}]",sensitive,1408,Trastuzumab + TS-1,2064
209,Phase I,"In a Phase I study, MM-302 demonstrated safety in patients with ERBB2 (HER2) positive breast cancer (Cancer Res 2012;72(24 Suppl):Abstract nr P5-18-09)",Actionable,899,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 583, 'pubMedId': None, 'title': 'A Phase I Study of MM-302, a HER2-targeted Liposomal Doxorubicin, in Patients with Advanced, HER2- Positive Breast Cancer', 'url': 'http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/P5-18-09'}]",sensitive,1401,MM-302,2064
210,Phase Ib/II,"In a Phase Ib trial, the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) demonstrated clinical activity in CNS metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 12.5% (1/8) evaluable patients achieving CNS complete response, 25% (2/8) partial CNS response, and 62.5% (5/8) CNS stable disease (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).",Actionable,3809,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 4180, 'pubMedId': None, 'title': '[P4-14-19] ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets)', 'url': 'http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_1267&terms='}]",predicted – sensitive,1573,ARRY-380 + Trastuzumab emtansine,2064
211,Phase Ib/II,"In a Phase Ib clinical trial, treatment with the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) resulted in an overall response rate of 47% (15/52) and median progression-free survival of 6.5 months in patients with ERBB2 (HER2)-positive metastatic breast cancer, including patients with CNS metastasis (J Clin Oncol 34, 2016 (suppl; abstr 513)).",Actionable,7045,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 6051, 'pubMedId': None, 'title': 'Efficacy results of a phase 1b study of ont-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases.', 'url': 'http://meetinglibrary.asco.org/content/170543-176'}]",predicted – sensitive,1573,ARRY-380 + Trastuzumab emtansine,2064
212,Phase Ib/II,"In a Phase Ib clinical trial, treatment with the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) resulted in partial response in 33% (11/33) and stable disease in 48% (16/33) and a clinical benefit rate of 58% (19/33) in patients with ERBB2 (HER2)-positive metastatic breast cancer (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-20).",Actionable,3806,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 4179, 'pubMedId': None, 'title': '[P4-14-20] A phase 1b study of ONT 380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+ metastatic breast cancer (MBC)', 'url': 'http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_1338&terms='}]",predicted – sensitive,1573,ARRY-380 + Trastuzumab emtansine,2064
213,Phase I,"In a Phase I trial, combination treatment consisted of Entinostat, Tykerb (lapatinib) and Herceptin (trastuzumab) resulted in complete response in 9% (2/22), partial response in 14% (3/22), and stable disease in 27% (6/22) of ERBB2 (HER2) positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 609)).",Actionable,6716,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 5776, 'pubMedId': None, 'title': 'Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab.', 'url': 'http://abstracts.asco.org/176/AbstView_176_170293.html'}]",sensitive,1542,Entinostat + Lapatinib + Trastuzumab,2064
214,Phase II,"In a Phase II trial, Nerlynx (neratinib) and Xeloda (capecitabine) combination therapy resulted in an overall 12-month survival rate of 63% (23/37) in patients with Erbb2 (Her2)-positive breast cancer brain metastases (J Clin Oncol 35, 2017 (suppl; abstr 1005)).",Actionable,11165,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 9129, 'pubMedId': None, 'title': 'TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).', 'url': 'http://abstracts.asco.org/199/AbstView_199_186113.html'}]",sensitive,1543,Capecitabine + Neratinib,2064
215,Preclinical - Pdx,"In a preclinical study, ADCT-502 demonstrated anti-tumor activity in ERBB2 (HER2)-expressing breast cancer cell line and patient-derived xenograft (PDX) models, including PDX models expressing low levels of ERBB2 (HER2) (Eur J Cancer, 2016, Vol. 69, Supp1, S28).",Actionable,10927,1612,breast cancer,DOID,1187,ERBB2 positive,"[{'id': 8939, 'pubMedId': None, 'title': '62 - ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody–drug conjugate (ADC) targeting low HER2-expressing solid cancers', 'url': 'http://www.sciencedirect.com/science/article/pii/S0959804916326624'}]",sensitive,5689,ADCT-502,2064
216,Phase I,"In a Phase I trial, ZW25 treatment resulted in stable disease in 20% (1/5) of patients with ERBB2 (HER2)-positive gastric or esophageal cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #255P; NCT02892123).",Actionable,12054,10534,stomach cancer,DOID,1187,ERBB2 positive,"[{'id': 9992, 'pubMedId': None, 'title': 'Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]",predicted – sensitive,6240,ZW25,2064
217,Phase I,"In a Phase I trial, Tykerb (lapatinib) and MK2206 combination treatment resulted in stable disease for more than 6 months in 40% (2/5) of patients with ERBB2 (HER2)-positive breast cancer (PMID: 27026198).",Actionable,6029,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 5238, 'pubMedId': 27026198, 'title': 'Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27026198'}]",sensitive,4007,Lapatinib + MK2206,2064
218,Preclinical - Pdx & cell culture,"In a preclinical study, DS-8201 inhibited growth of ERBB2 (HER2)-positive breast cancer cell lines in culture and xenograft models, and demonstrated antitumor activity in patient-derived xenograft (PDX) models of ERBB2 (HER2)-positive breast cancer, including models with low ERBB2 (HER2) expression (PMID: 27026201).",Actionable,8871,1612,breast cancer,DOID,1187,ERBB2 positive,"[{'id': 6780, 'pubMedId': 27026201, 'title': 'DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27026201'}]",sensitive,4844,DS-8201a,2064
219,Preclinical - Cell culture,"In a preclinical study, Tucatinib (ARRY-380) inhibited tumor growth in a ERBB2 (HER2)-positive gastric carcinoma cell line xenograft model (Cancer Res April 15, 2012 72:852).",Actionable,2916,5517,stomach carcinoma,DOID,1187,ERBB2 positive,"[{'id': 3525, 'pubMedId': None, 'title': 'Abstract 852: ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice', 'url': 'http://cancerres.aacrjournals.org/content/72/8_Supplement/852'}]",sensitive,639,Tucatinib,2064
220,Phase III,"In a Phase III trial, SB3 treatment demonstrated safety, immunogenicity, and survival result similar to Herceptin (trastuzumab), resulted in event-free-survival rates of 92.2% and 91.6%, respectively, in patients with Erbb2 (Her2)-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 153PD; NCT02149524).",Actionable,12066,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 9997, 'pubMedId': None, 'title': 'One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]",predicted – sensitive,6242,SB3,2064
221,Phase Ib/II,"In a Phase Ib clinical trial, the combination of Tucatinib (ARRY-380) and Herceptin (trastuzumab) demonstrated clinical activity in central nervous system (CNS) metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 100% (3/3) patients achieving CNS stable disease as best response (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).",Actionable,3807,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 4180, 'pubMedId': None, 'title': '[P4-14-19] ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets)', 'url': 'http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_1267&terms='}]",predicted – sensitive,1560,ARRY-380 + Trastuzumab,2064
222,Preclinical - Cell line xenograft,"In a preclinical study, Trodusquemine (MSI-1436) inhibited tumor growth and metastasis in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model (PMID: 24845231).",Actionable,4464,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 4563, 'pubMedId': 24845231, 'title': 'Targeting the disordered C terminus of PTP1B with an allosteric inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24845231'}]",sensitive,3521,Trodusquemine,2064
223,Phase I,"In a Phase I trial, Entinostat and Tykerb (lapatinib) combination treatment resulted in complete response in 7% (1/15) and stable disease in 27% (4/15) of ERBB2 (HER2) positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 609)).",Actionable,6715,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 5776, 'pubMedId': None, 'title': 'Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab.', 'url': 'http://abstracts.asco.org/176/AbstView_176_170293.html'}]",sensitive,4255,Entinostat + Lapatinib,2064
224,Preclinical,"In a preclinical study, breast cancer cell lines with a PIK3CA activating mutation and/or ERBB2 (HER2)-over expression demonstrated increased sensitivity to inhibition of proliferation by Aliqopa (copanlisib) in culture, compared to ERBB2 (HER2)-negative and wild-type PIK3CA cell lines (PMID: 24170767).",Actionable,1373,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 245, 'pubMedId': 24170767, 'title': 'BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24170767'}]",sensitive,995,Copanlisib,2064
225,Phase I,"In a Phase I trial, Pyrotinib treatment resulted in an objective response rate of 50% (18/36, all partial responses), and a clinical benefit rate of 61.1% (22/36), and a median progression-free survival of 35.4 weeks in patients with ERBB2 (HER2)-positive breast cancer (PMID: 28498781, NCT01937689).",Actionable,9851,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 7689, 'pubMedId': None, 'title': 'Abstract P4-14-18: Phase I study of single-agent pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with ErbB2+ metastatic breast cancer', 'url': 'http://cancerres.aacrjournals.org/content/76/4_Supplement/P4-14-18'}, {'id': 9800, 'pubMedId': 28498781, 'title': 'Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28498781'}]",sensitive,3082,Pyrotinib,2064
226,Phase I,"In a Phase I trial, treatment with DS-8201a resulted in a partial response in 40% (2/5) of evaluable patients with colorectal cancer and ERBB2 (HER2) expression (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 409P; NCT02564900).",Actionable,11991,9256,colorectal cancer,DOID,1187,ERBB2 positive,"[{'id': 9950, 'pubMedId': None, 'title': 'Updated results of phase 1 study of DS-8201a in patients with HER2 expressing non-breast, non-gastric malignancies', 'url': 'http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts'}]",predicted – sensitive,4844,DS-8201a,2064
227,Phase II,"In Phase II clinical trials, ERBB2 (HER2) vaccines demonstrated safety and some efficacy in the adjuvant setting in ERBB2 (HER2)-positive breast cancer patients (PMID: 23585514).",Actionable,909,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 595, 'pubMedId': 23585514, 'title': 'Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23585514'}]",predicted – sensitive,1404,HER2 Vaccine,2064
228,Phase I,"In a Phase I trial, treatment with DS-8201a resulted in a partial response in 50% (2/4) of evaluable patients with salivary gland cancer and ERBB2 (HER2) expression (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 409P; NCT02564900).",Actionable,11992,8850,salivary gland cancer,DOID,1187,ERBB2 positive,"[{'id': 9950, 'pubMedId': None, 'title': 'Updated results of phase 1 study of DS-8201a in patients with HER2 expressing non-breast, non-gastric malignancies', 'url': 'http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts'}]",predicted – sensitive,4844,DS-8201a,2064
229,FDA approved,"In a Phase III trial that supported FDA approval, treatment with the combination of Tykerb (lapatinib) and Femara (letrozole) resulted in an improved median progression-free survival of 8.2 months in patients with hormone receptor-positive/Erbb2 (Her2)-positive metastatic breast cancer, compared to 3.0 months with Femara (letrozole) and placebo (PMID: 19786658). ",Actionable,2019,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 2500, 'pubMedId': 19786658, 'title': 'Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19786658'}]",sensitive,1497,Lapatinib + Letrozole,2064
230,Phase III,"In a Phase III trial, Kadcyla (trastuzumab emtansine) did not demonstrated efficacy benefit over Taxol (paclitaxel) on median overall survival (7.9 vs 8.6 months) in patients with previously treated ERBB2 (HER2)-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (J Clin Oncol 34, 2016 (suppl 4S; abstr 5)).",Actionable,8739,5635,gastric adenosquamous carcinoma,DOID,1187,ERBB2 positive,"[{'id': 6725, 'pubMedId': None, 'title': 'A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma', 'url': 'http://meetinglibrary.asco.org/content/159174-173'}]",no benefit,1402,trastuzumab emtansine,2064
231,Phase I,"In a Phase I trial, ZW25 treatment resulted in partial response in 14% (2/14) and stable disease in 21% (3/14) of patients with ERBB2 (HER2)-positive tumors, including breast, gastric, esophageal, colorectal, and adnexal cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123).",Actionable,12059,10000003,Advanced Solid Tumor,JAX,1187,ERBB2 positive,"[{'id': 9992, 'pubMedId': None, 'title': 'Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]",predicted – sensitive,6240,ZW25,2064
232,Preclinical - Patient cell culture,"In a preclinical study, ERBB2 (HER2)-specific cytotoxic T-cell lines generated from gastric cancer patients demonstrated activity against autologous ERBB2 (HER2)-expressing gastric cancer cells in culture (PMID: 9754653).",Actionable,928,10534,stomach cancer,DOID,1187,ERBB2 positive,"[{'id': 605, 'pubMedId': 9754653, 'title': 'Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/9754653'}]",sensitive,1404,HER2 Vaccine,2064
233,Phase II,"In a Phase II clinical trial, treatment with Gilotrif (afatinib) resulted in a clinical benefit rate of 35% (9/26) in patients with ERBB2 (HER2)-positive inflammatory breast cancer, with 8 confirmed partial responses and 1 patient achieving stable disease for greater than 6 months (PMID: 27923043).",Actionable,9570,6263,inflammatory breast carcinoma,DOID,1187,ERBB2 positive,"[{'id': 7283, 'pubMedId': 27923043, 'title': 'Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27923043'}]",predicted – sensitive,623,Afatinib,2064
234,Phase I,"In a Phase I clinical trial, ERBB2 (HER2)-positive breast cancer patients treated with Gilotrif (afatinib), in combination with Herceptin (trastuzumab), demonstrated an overall objective response rate of 11% (2/18)  while 28% (5/18) attained a best response of stable disease (PMID: 25370464).",Actionable,2655,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,"[{'id': 3373, 'pubMedId': 25370464, 'title': 'Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25370464'}]",sensitive,1106,Afatinib + Trastuzumab,2064
235,Phase I,"In a Phase I clinical trial, S-222611 demonstrated safety and some efficacy in patients with advanced solid tumors expressing EGFR or ERBB2 (HER2), with an overall clinical benefit rate of 27% (7/33) (PMID: 25434923).",Actionable,1215,10000003,Advanced Solid Tumor,JAX,1187,ERBB2 positive,"[{'id': 891, 'pubMedId': None, 'title': 'A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/93825-114'}, {'id': 4497, 'pubMedId': 25434923, 'title': 'Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25434923'}]",predicted – sensitive,1048,S-222611,2064
236,Phase I,"In a Phase I trial, ZW25 treatment resulted in disease progression in a patient with ERBB2 (HER2)-positive colorectal cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123).",Actionable,12055,9256,colorectal cancer,DOID,1187,ERBB2 positive,"[{'id': 9992, 'pubMedId': None, 'title': 'Phase 1 dose-escalation study of single-agent ZW25, a HER2-targeted bispecific antibody, in patients (pts) with HER2-expressing cancers', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]",no benefit,6240,ZW25,2064
237,Preclinical - Cell culture,"In a preclinical study, DS-8201 inhibited growth of an ERBB2 (HER2)-positive breast adenocarcinoma cell line in culture (PMID: 27026201).",Actionable,8869,3458,breast adenocarcinoma,DOID,1187,ERBB2 positive,"[{'id': 6780, 'pubMedId': 27026201, 'title': 'DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27026201'}]",sensitive,4844,DS-8201a,2064
238,Phase I,"In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PTEN loss demonstrated a decreased median progression-free survival of 6.0 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217).",Actionable,874,60079,Her2-receptor positive breast cancer,DOID,1410,ERBB2 pos PTEN loss ,"[{'id': 224, 'pubMedId': 21676217, 'title': 'PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21676217'}]",decreased response,947,Trastuzumab,2064
239,Preclinical,"In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in ERBB2 (HER2)-positive breast cancer cell lines harboring PTEN loss in culture (PMID: 27020857).",Actionable,5862,60079,Her2-receptor positive breast cancer,DOID,1410,ERBB2 pos PTEN loss ,"[{'id': 5181, 'pubMedId': 27020857, 'title': 'Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27020857'}]",no benefit,3956,Palbociclib + GDC-0941,2064
240,Phase II,"In a Phase II clinical trial, 30% (8/27) of patients with ERBB2 (HER2)-positive KRAS wild-type colorectal cancer achieved an objective response and 44% (12/27) of patients had stable disease when treated with the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 27108243).",Actionable,6482,9256,colorectal cancer,DOID,23355,ERBB2 positive KRAS wild-type,"[{'id': 5566, 'pubMedId': 27108243, 'title': 'Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27108243'}]",sensitive,1414,Trastuzumab + Lapatinib,2064
241,Preclinical - Cell line xenograft,"In a preclinical study, Gilotrif (afatinib) induced tumor regression in a gastric cancer cell line xenograft model with HER2 (ERBB2) amplification and over expression (PMID: 23578997).",Actionable,2913,10534,stomach cancer,DOID,25933,ERBB2 amp ERBB2 over exp,"[{'id': 3522, 'pubMedId': 23578997, 'title': 'Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23578997'}]",sensitive,623,Afatinib,2064
242,Preclinical - Cell line xenograft,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification and over expression (PMID: 21458915).",Actionable,2928,10534,stomach cancer,DOID,25933,ERBB2 amp ERBB2 over exp,"[{'id': 3533, 'pubMedId': 21458915, 'title': 'Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21458915'}]",sensitive,1402,trastuzumab emtansine,2064
243,Preclinical,"In a preclinical study, ADXS31-164 prevented development of spontaneous mammary tumors in Erbb2 (Her2)-over expressing transgenic animal models (PMID: 20725099).",Actionable,8169,60079,Her2-receptor positive breast cancer,DOID,1270,ERBB2 over exp,"[{'id': 6565, 'pubMedId': 20725099, 'title': 'Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20725099'}]",sensitive,4654,ADXS31-164,2064
244,Preclinical - Cell culture,"In a preclinical study, Tucatinib (ARRY-380) inhibited proliferation of an ERBB2 (HER2) over expressing gastric cancer cell line in culture (Cancer Res April 15, 2010 70:3610).",Actionable,2889,10534,stomach cancer,DOID,1270,ERBB2 over exp,"[{'id': 3515, 'pubMedId': None, 'title': 'Abstract 3610: Pan-ErbB inhibition by ARRY-334543 is superior to selective ErbB inhibition in a preclinical model that signals through multiple ErbB receptors', 'url': 'http://cancerres.aacrjournals.org/content/70/8_Supplement/3610.short'}]",sensitive,639,Tucatinib,2064
245,Preclinical - Cell culture,"In a preclinical study, Tykerb (lapatinib) inhibited growth of HER2-over expressing breast carcinoma cell lines in culture (PMID: 27450453).",Actionable,8531,60079,Her2-receptor positive breast cancer,DOID,1270,ERBB2 over exp,"[{'id': 6681, 'pubMedId': 27450453, 'title': 'JNK Pathway Activation Modulates Acquired Resistance to EGFR/HER2-Targeted Therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27450453'}]",sensitive,787,Lapatinib,2064
246,Preclinical - Cell line xenograft,"In a preclinical study, MM-111, in combination with Herceptin (trastuzumab) and Taxol (paclitaxel), resulted in a synergistic effect thereby inhibiting ErbB2 in ERBB2 (HER2) over expressing gastric cancer cell line xenograft models (J Clin Oncol 31, 2013 (suppl 4; abstr 48)).",Actionable,2925,10534,stomach cancer,DOID,1270,ERBB2 over exp,"[{'id': 3530, 'pubMedId': None, 'title': 'Preclinical activity of MM-111, a bispecific ErbB2/ErbB3 antibody in previously treated ErbB2-positive gastric and gastroesophageal junction cancer', 'url': 'http://meetinglibrary.asco.org/content/106018-133'}]",sensitive,1892,Paclitaxel + Trastuzumab + MM-111,2064
247,Preclinical - Cell line xenograft,"In a preclinical study, combination of MM-302 and Herceptin (trastuzumab) synergistically inhibited tumor growth in cell line xenograft models of Erbb2 (Her2)-over expressing breast cancer (PMID: 26759238).",Actionable,10877,1612,breast cancer,DOID,1270,ERBB2 over exp,"[{'id': 8885, 'pubMedId': 26759238, 'title': 'Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26759238'}]",sensitive,1888,MM-302 + Trastuzumab,2064
248,Preclinical,"In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth by 43% in N87 gastric cancer xenograft model, which has been demonstrated to have ERBB2 (HER2) amplification and overexpression (AACR; 2015. Abstract nr 1558, PMID: 18441328).",Actionable,2926,10534,stomach cancer,DOID,1270,ERBB2 over exp,"[{'id': 3531, 'pubMedId': 18441328, 'title': 'HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18441328'}, {'id': 3532, 'pubMedId': None, 'title': 'Association of ErbB/HER biomarkers with antitumor activity of the anti-ErbB3/HER3 monoclonal antibody KTN3379 in SCCHN', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3682&sKey=8ef53702-fa4b-4bcd-959a-adc80c411249&cKey=8eef59f4-1b14-46a5-933b-b20bbb91a185&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424'}]",sensitive,2054,CDX-3379,2064
249,Preclinical,"In a preclinical study, KU004 inhibited growth and induced apoptosis in breast cancer cell lines over expressing ERBB2 in culture (PMID: 26437915).",Actionable,3565,1612,breast cancer,DOID,1270,ERBB2 over exp,"[{'id': 3826, 'pubMedId': 26437915, 'title': 'A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26437915'}]",sensitive,3157,KU004,2064
250,Phase I,"In a Phase I trial, a patient with perihilar cholangiocarcinoma over expressing ERBB2 achieved a partial response and progression-free survival for 4.5 months following treatment with ERBB2 (HER2)-specific CAR-T cells (PMID: 28710747, NCT01935843).",Actionable,11505,4947,cholangiocarcinoma,DOID,1270,ERBB2 over exp,"[{'id': 9587, 'pubMedId': 28710747, 'title': 'Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28710747'}]",predicted – sensitive,6007,HER2 CAR-T cells,2064
251,Preclinical - Cell line xenograft,"In a preclinical study, VS-5584 inhibited tumor growth in human gastric cancer cell line xenograft models overexpressing ERBB2 (HER2) (PMID: 23270925).",Actionable,2893,3717,gastric adenocarcinoma,DOID,1270,ERBB2 over exp,"[{'id': 351, 'pubMedId': 23270925, 'title': 'VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23270925'}]",sensitive,960,VS-5584,2064
252,Phase I,"In a Phase I trial, S-222611 resulted in a complete response in a gastric-esophageal junction cancer patient over expressing ERBB2 (HER2) and a partial response in a gastric cancer patient also over expressing ERBB2 (HER2) (J Clin Oncol 33, 2015 (suppl; abstr 2511)).",Actionable,2847,4944,gastroesophageal junction adenocarcinoma,DOID,1270,ERBB2 over exp,"[{'id': 3502, 'pubMedId': None, 'title': 'Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases', 'url': 'http://meetinglibrary.asco.org/content/148414-156'}]",sensitive,1048,S-222611,2064
253,Phase Ib/II,"In Phase I clinical trial, Margetuximab (MGAH22) displayed safety and had initial efficacy in patients with ERBB2 (HER2) positive breast cancer (J Clin Oncol 31, 2013 (suppl; abstr 3004)).",Actionable,2924,60079,Her2-receptor positive breast cancer,DOID,1270,ERBB2 over exp,"[{'id': 582, 'pubMedId': None, 'title': 'Phase I study of margetuximab (MGAH22), an FC-modified chimeric monoclonal antibody (MAb), in patients (pts) with advanced solid tumors expressing the HER2 oncoprotein.', 'url': 'http://meetinglibrary.asco.org/content/115290-132'}]",predicted – sensitive,808,MGAH22,2064
254,Preclinical,"In a preclinical study, BMS-690514 inhibited tumor growth in a gastric cancer xenograft model with ERBB2 (HER2) amplification and overexpression (PMID: 21531814).",Actionable,2920,10534,stomach cancer,DOID,1270,ERBB2 over exp,"[{'id': 1825, 'pubMedId': 21531814, 'title': 'Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21531814'}]",sensitive,685,BMS-690514,2064
255,Preclinical - Cell line xenograft,"In a preclinical study, Varlitinib (ARRY-334543) resulted in a 74%  tumor growth inhibition and tumor regression in 88% (7/8) of human cell line xenograft models of gastric cancer overexpressing ERBB2 (HER2) (Cancer Res January 15, 2009 69; 2150). ",Actionable,2903,10534,stomach cancer,DOID,1270,ERBB2 over exp,"[{'id': 3506, 'pubMedId': None, 'title': 'In vivo activity of ARRY-543, a potent, small molecule inhibitor of EGFR/ErbB-2 in combination with trastuzumab or docetaxel', 'url': 'http://cancerres.aacrjournals.org/content/69/2_Supplement/2150'}]",sensitive,1057,varlitinib,2064
256,Phase I,"In a Phase I trial, Margetuximab (MGAH22) treatment resulted in partial responses in 12% (7/60) and stable disease in 50% (30/60) of patients with ERBB2 (HER2)-positive breast or gastric cancer, or other carcinomas that overexpress Erbb2 (Her2) (PMID: 28119295).",Actionable,10447,305,carcinoma,DOID,1270,ERBB2 over exp,"[{'id': 8461, 'pubMedId': 28119295, 'title': 'First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28119295'}]",predicted – sensitive,808,MGAH22,2064
257,Preclinical - Cell line xenograft,"In a preclinical study, AV-412 inhibited growth of ERBB2 (HER2)-over expressing breast cancer cell lines in culture, and inhibited tumor growth in a ERBB2 (HER2)-over expressing breast cancer cell line xenograft model (PMID: 17888033).",Actionable,1381,1612,breast cancer,DOID,1270,ERBB2 over exp,"[{'id': 1110, 'pubMedId': 17888033, 'title': 'Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17888033'}]",sensitive,990,AV-412,2064
258,Phase I,"In a Phase I clinical trial, a breast cancer patient with ERBB2 (HER2) over expression that had progressed on Herceptin (trastuzumab) demonstrated stable disease for more than 12 weeks following treatment with CUDC-101 (PMID: 25107918). ",Actionable,2832,60079,Her2-receptor positive breast cancer,DOID,1270,ERBB2 over exp,"[{'id': 3496, 'pubMedId': 25107918, 'title': 'Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25107918'}]",sensitive,1005,CUDC-101,2064
259,Preclinical,"In a preclinical study, ERBB2 (HER2) over expressing gastric cancer xenograft models demonstrated anti-tumor activity when treated with MM-302 (Cancer Res December 15, 2010 70; P3-14-09).",Actionable,2929,10534,stomach cancer,DOID,1270,ERBB2 over exp,"[{'id': 3534, 'pubMedId': None, 'title': 'Abstract P3-14-09: Preclinical Safety and Activity of MM-302, a HER2-Targeted Liposomal Doxorubicin Designed To Have an Improved Safety and Efficacy Profile over Approved Anthracyclines', 'url': 'http://cancerres.aacrjournals.org/content/70/24_Supplement/P3-14-09'}]",predicted – sensitive,1401,MM-302,2064
260,Preclinical,"In a preclinical study, PF-05280014 inhibited growth of ERBB2 (HER2)-over expressing breast cancer cells with activity comparable to Herceptin (trastuzumab) in culture (PMID: 25001079).",Actionable,4620,60079,Her2-receptor positive breast cancer,DOID,1270,ERBB2 over exp,"[{'id': 4629, 'pubMedId': 25001079, 'title': 'Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®)).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25001079'}]",sensitive,3554,PF-05280014,2064
261,Preclinical - Cell line xenograft,"In a preclinical study, TAK-285 inhibited growth of breast cancer cell line harboring ERBB2 (HER2) over expression in culture and in cell line xenograft models (PMID: 23983820).",Actionable,7848,60079,Her2-receptor positive breast cancer,DOID,1270,ERBB2 over exp,"[{'id': 1960, 'pubMedId': 23983820, 'title': 'Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23983820'}]",sensitive,2135,TAK-285,2064
262,Phase I,"In a Phase I trial, treatment with ERBB2 (HER2)-specific CAR-T cells demonstrated safety and preliminary activity in patients with biliary tract or pancreatic carcinoma with ERBB2 (HER2) over expression, resulting in partial response in one of 11 patients and stable disease in 5, and a median progression free survival of 4.8 months (PMID: 28710747; NCT01935843).",Actionable,11504,4905,pancreatic carcinoma,DOID,1270,ERBB2 over exp,"[{'id': 9587, 'pubMedId': 28710747, 'title': 'Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28710747'}]",predicted – sensitive,6007,HER2 CAR-T cells,2064
263,Preclinical - Cell line xenograft,"In a preclinical study, Varlitinib (ARRY-334543), in combination with Herceptin (trastuzumab), resulted in a 91% tumor growth inhibition and tumor regression in human cell line xenograft models of gastric cancer overexpressing ERBB2 (HER2) (Cancer Res January 15, 2009 69; 2150).  ",Actionable,2852,10534,stomach cancer,DOID,1270,ERBB2 over exp,"[{'id': 3506, 'pubMedId': None, 'title': 'In vivo activity of ARRY-543, a potent, small molecule inhibitor of EGFR/ErbB-2 in combination with trastuzumab or docetaxel', 'url': 'http://cancerres.aacrjournals.org/content/69/2_Supplement/2150'}]",sensitive,3034,trastuzumab + varlitinib,2064
264,Preclinical,"In a preclinical study, NAX014 induced cellular senescence, prevented tumor growth, and decreased tumor volume in a Her2 positive breast cancer mouse model (PMID: 26168818). ",Actionable,2647,60079,Her2-receptor positive breast cancer,DOID,1270,ERBB2 over exp,"[{'id': 3369, 'pubMedId': 26168818, 'title': 'Antiangiogenic and antitumor activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26168818'}]",sensitive,2984,NAX014,2064
265,Phase I,"In a Phase I trial, treatment with ERBB2 (HER2)-specific CAR-T cells demonstrated safety and preliminary activity in patients with biliary tract or pancreatic carcinoma with ERBB2 (HER2) over expression, resulting in partial response in one of 11 patients and stable disease in 5, and a median progression free survival of 4.8 months (PMID: 28710747; NCT01935843).",Actionable,11503,4607,biliary tract cancer,DOID,1270,ERBB2 over exp,"[{'id': 9587, 'pubMedId': 28710747, 'title': 'Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28710747'}]",predicted – sensitive,6007,HER2 CAR-T cells,2064
266,Preclinical,"In a preclinical study, KU004 inhibited growth and induced apoptosis in gastric cancer cell lines over expressing ERBB2 in culture and suppressed growth in a dose dependent manner in xenograft models (PMID: 26437915).",Actionable,3566,10534,stomach cancer,DOID,1270,ERBB2 over exp,"[{'id': 3826, 'pubMedId': 26437915, 'title': 'A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26437915'}]",sensitive,3157,KU004,2064
267,Phase II,"In a Phase II trial, Dacomitinib resulted in a 7.4% (2/27) response rate and 40.7% (11/27) disease control rate when treating advanced gastric cancer patients with ERBB2 (HER2) over expression (J Clin Oncol 30, 2012 (suppl 4; abstr 54)).",Actionable,2917,10534,stomach cancer,DOID,1270,ERBB2 over exp,"[{'id': 3526, 'pubMedId': None, 'title': 'A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen', 'url': 'http://meetinglibrary.asco.org/content/88180-115'}]",sensitive,714,Dacomitinib,2064
268,Preclinical,"In a preclinical study, ERBB2 (HER2) over expressing gastric cancer cells were sensitive to Dacomitinib, resulting in inhibition of ERBB2 (HER2)/ERBB3 (HER3) heterodimers (PMID: 22135232).",Actionable,2934,10534,stomach cancer,DOID,1270,ERBB2 over exp,"[{'id': 3539, 'pubMedId': 22135232, 'title': 'Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22135232'}]",sensitive,714,Dacomitinib,2064
269,Preclinical - Cell line xenograft,"In a preclinical study, ERBB2 (HER2) over expression was associated with resistance to Erbitux (cetuximab) treatment in a human cell line xenograft model of colorectal cancer (PMID: 26296355).",Actionable,11355,9256,colorectal cancer,DOID,1270,ERBB2 over exp,"[{'id': 3655, 'pubMedId': 26296355, 'title': 'Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26296355'}]",resistant,694,Cetuximab,2064
270,Preclinical - Cell line xenograft,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification and over expression (PMID: 21458915).",Actionable,2927,10534,stomach cancer,DOID,1270,ERBB2 over exp,"[{'id': 3533, 'pubMedId': 21458915, 'title': 'Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21458915'}]",sensitive,1402,trastuzumab emtansine,2064
271,Preclinical,"In a preclinical study, the N87 gastric cancer cell line, which has been demonstrated to have ERBB2 (HER2) amplification and over expression, was sensitive to TAK-285, inhibiting phosphorylation of ERBB2 (HER2) and ERBB3 (HER3) (PMID: 25594012, PMID: 18441328).",Actionable,2977,10534,stomach cancer,DOID,1270,ERBB2 over exp,"[{'id': 3531, 'pubMedId': 18441328, 'title': 'HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18441328'}, {'id': 3546, 'pubMedId': 25594012, 'title': 'HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25594012'}]",sensitive,2135,TAK-285,2064
272,Preclinical - Cell line xenograft,"In a preclinical study, TAK-285 inhibited tumor growth in gastric cancer cell line xenograft models over expressing ERBB2 (HER2)  (PMID: 23983820).",Actionable,2905,10534,stomach cancer,DOID,1270,ERBB2 over exp,"[{'id': 1960, 'pubMedId': 23983820, 'title': 'Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23983820'}]",sensitive,2135,TAK-285,2064
273,Preclinical - Cell line xenograft,"In a preclinical study, combination of MM-302 and Herceptin (trastuzumab) resulted in improved tumor growth inhibition in cell line xenograft models of Erbb2 (Her2)-over expressing gastric cancer (PMID: 26759238).",Actionable,10878,10534,stomach cancer,DOID,1270,ERBB2 over exp,"[{'id': 8885, 'pubMedId': 26759238, 'title': 'Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26759238'}]",sensitive,1888,MM-302 + Trastuzumab,2064
274,Preclinical - Cell line xenograft,"In a preclinical study, ERBB2 (HER2)-specific CAR-T cells induced cell death in ERBB2 (HER2)-over expressing gastric cancer cell lines in culture, and inhibited tumor growth and improved survival in a ERBB2 (HER2)-over expressing gastric cancer cell line xenograft model (PMID: 28284008).",Actionable,11506,10534,stomach cancer,DOID,1270,ERBB2 over exp,"[{'id': 9588, 'pubMedId': 28284008, 'title': 'Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28284008'}]",sensitive,6007,HER2 CAR-T cells,2064
275,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited growth of HER2-amplified and HER2-over expressing gastric cancer cell lines in culture (PMID: 18774637).",Actionable,2911,10534,stomach cancer,DOID,1270,ERBB2 over exp,"[{'id': 3521, 'pubMedId': 18774637, 'title': 'The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18774637'}]",sensitive,787,Lapatinib,2064
276,Phase I,"In a Phase I trial, S-222611 resulted in a complete response in a gastric-esophageal junction cancer patient overexpressing ERBB2 (HER2) and a partial response in a gastric cancer patient also overexpressing ERBB2 (HER2) (J Clin Oncol 33, 2015 (suppl; abstr 2511)).",Actionable,2846,10534,stomach cancer,DOID,1270,ERBB2 over exp,"[{'id': 3502, 'pubMedId': None, 'title': 'Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases', 'url': 'http://meetinglibrary.asco.org/content/148414-156'}]",sensitive,1048,S-222611,2064
277,Preclinical,"In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Tagrisso (osimertinib) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416).",Actionable,8799,3910,lung adenocarcinoma,DOID,26436,EGFR T790M ERBB2 over exp,"[{'id': 6756, 'pubMedId': 27252416, 'title': 'Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27252416'}]",resistant,660,Osimertinib,2064
278,Preclinical,"In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Rociletinib (CO-1686) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416).",Actionable,8800,3910,lung adenocarcinoma,DOID,26436,EGFR T790M ERBB2 over exp,"[{'id': 6756, 'pubMedId': 27252416, 'title': 'Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27252416'}]",resistant,1003,CO1686,2064
279,Preclinical,"In a preclinical study, the combination of Herceptin (trastuzumab) and Buparlisib (BKM120) inhibited tumor growth in mouse ERBB2 (HER2)-over expressing breast cancer models expressing PIK3CA H1047R, with moderate efficacy over Buparlisib (BKM120) alone (PMID: 23940356).",Actionable,968,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,"[{'id': 240, 'pubMedId': 23940356, 'title': 'Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23940356'}]",sensitive,1417,BKM120 + Trastuzumab,2064
280,Preclinical,"In a preclinical study, mouse breast cancer models over expressing ERBB2 (HER2) and expressing PIK3CA H1047R were resistant to Herceptin (trastuzumab) (PMID: 23940356).",Actionable,966,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,"[{'id': 240, 'pubMedId': 23940356, 'title': 'Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23940356'}]",resistant,947,Trastuzumab,2064
281,Preclinical,"In a preclinical study, treatment with Buparlisib (BKM120) resulted in decreased tumor growth, but not tumor regression, in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R (PMID: 23940356).",Actionable,967,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,"[{'id': 240, 'pubMedId': 23940356, 'title': 'Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23940356'}]",sensitive,1178,BKM120 + Bevacizumab,2064
282,Preclinical,"In a preclinical study, a mouse breast cancer model with mammary ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23940356).",Actionable,969,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,"[{'id': 240, 'pubMedId': 23940356, 'title': 'Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23940356'}]",resistant,1414,Trastuzumab + Lapatinib,2064
283,Preclinical,"In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Tykerb (lapatinib) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, but efficacy was not significantly improved over Buparlisib (BKM120) alone (PMID: 23940356). ",Actionable,972,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,"[{'id': 240, 'pubMedId': 23940356, 'title': 'Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23940356'}]",no benefit,1419,BKM120 + Trastuzumab + Lapatinib,2064
284,Preclinical,"In a preclinical study, a mouse breast cancer model with ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Heceptin (trastuzumab) and Perjeta (pertuzumab) (PMID: 23940356).",Actionable,970,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,"[{'id': 240, 'pubMedId': 23940356, 'title': 'Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23940356'}]",resistant,1389,Trastuzumab + Pertuzumab,2064
285,Preclinical,"In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Perjeta (pertuzumab) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, with improved efficacy over Buparlisib (BKM120) alone (PMID: 23940356).",Actionable,971,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,"[{'id': 240, 'pubMedId': 23940356, 'title': 'Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23940356'}]",sensitive,1418,BKM120 + Trastuzumab + Pertuzumab,2064
286,Preclinical - Pdx,"In a preclinical study, treatment with Tykerb (lapatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft model of bladder cancer with ERBB2 (HER2) over expression, which also over expressed SRC and harbored PIK3CA H1047R (PMID: 26270481).",Actionable,7456,11054,urinary bladder cancer,DOID,25513,ERBB2 over exp PIK3CA H1047R SRC over exp,"[{'id': 6363, 'pubMedId': 26270481, 'title': 'Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26270481'}]",no benefit,787,Lapatinib,2064
287,Preclinical - Pdx,"In a preclinical study, treatment with Iclusig (ponatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft model of bladder cancer with SRC over expression, which also over expressed ERBB2 (HER2) and harbored PIK3CA H1047R (PMID: 26270481).",Actionable,7457,11054,urinary bladder cancer,DOID,25513,ERBB2 over exp PIK3CA H1047R SRC over exp,"[{'id': 6363, 'pubMedId': 26270481, 'title': 'Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26270481'}]",no benefit,877,Ponatinib,2064
288,Preclinical - Cell line xenograft,"In a preclinical study, PKI-179 inhibited growth of breast cancer cells harboring PIK3CA mutations and ERBB2 (HER2) over expression in culture and cell line xenograft models (PMID: 20797855).",Actionable,2737,60079,Her2-receptor positive breast cancer,DOID,26179,ERBB2 over exp PIK3CA mut,"[{'id': 1040, 'pubMedId': 20797855, 'title': 'PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20797855'}]",sensitive,872,PKI-179,2064
289,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of ARQ092 and Herceptin (trastuzumab), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692). ",Actionable,10286,1612,breast cancer,DOID,26179,ERBB2 over exp PIK3CA mut,"[{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",sensitive,5454,ARQ092 + Trastuzumab,2064
290,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of ARQ092 and Taxol (paclitaxel), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692). ",Actionable,10287,1612,breast cancer,DOID,26179,ERBB2 over exp PIK3CA mut,"[{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",sensitive,5455,ARQ092 + Paclitaxel,2064
291,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G660D in culture (PMID: 26545934).",Actionable,6972,1324,lung cancer,DOID,24165,ERBB2 G660D,"[{'id': 5974, 'pubMedId': 26545934, 'title': 'Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26545934'}]",sensitive,623,Afatinib,2064
292,Preclinical,"In a preclinical study, bronchial epithelial cells cells expressing ERBB2 (HER2) G660D did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",Actionable,6970,1324,lung cancer,DOID,24165,ERBB2 G660D,"[{'id': 5974, 'pubMedId': 26545934, 'title': 'Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26545934'}]",no benefit,751,Gefitinib,2064
293,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) S783P in culture (PMID: 18413839).",Actionable,7322,10000003,Advanced Solid Tumor,JAX,24612,ERBB2 S783P,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",sensitive,967,XL647,2064
294,Preclinical,"In a preclinical study, transformed cells over expressing ERBB2 (HER2) S783P were resistant to Tykerb (lapatinib) in culture (PMID: 18413839).",Actionable,7309,10000003,Advanced Solid Tumor,JAX,24612,ERBB2 S783P,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",resistant,787,Lapatinib,2064
295,Clinical Study,"In a clinical study, targeted therapy with Gilotrif (afatinib) or Herceptin (trastuzumab) resulted in an objective response rate of 44% (4/9) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies, all four responders harbored ERBB2 (HER2) exon 20 insertions (PMID: 28167203). ",Actionable,10132,3908,non-small cell lung carcinoma,DOID,22000,ERBB2 exon 20 ins,"[{'id': 8141, 'pubMedId': 28167203, 'title': 'ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28167203'}]",predicted – sensitive,623,Afatinib,2064
296,Clinical Study,"In a clinical study, targeted therapy with Gilotrif (afatinib) or Herceptin (trastuzumab) resulted in an objective response rate of 44% (4/9) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies, all four responders harbored ERBB2 (HER2) exon 20 insertions (PMID: 28167203). ",Actionable,10133,3908,non-small cell lung carcinoma,DOID,22000,ERBB2 exon 20 ins,"[{'id': 8141, 'pubMedId': 28167203, 'title': 'ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28167203'}]",predicted – sensitive,947,Trastuzumab,2064
297,Preclinical - Pdx & cell culture,"In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing ERBB2 (HER2) exon 20 insertions in culture, and induced tumor regression in PDX models (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).",Actionable,5916,10000003,Advanced Solid Tumor,JAX,22000,ERBB2 exon 20 ins,"[{'id': 5195, 'pubMedId': None, 'title': 'AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=407e597a-33c8-4936-87f4-08ee4b23e8b9&cKey=34ee7ebf-07c6-40ea-825f-28fb5018ec92&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]",sensitive,3981,AP32788,2064
298,Clinical Study,"In a clinical study, treatment with pulse Gilotrif (afatinib) resulted in an objective response rate of 33.3% (1/3) in lung adenocarcinoma patients with ERBB2 (HER2) exon 20 insertion mutations (PMID: 26964772).",Actionable,7399,3910,lung adenocarcinoma,DOID,22000,ERBB2 exon 20 ins,"[{'id': 6345, 'pubMedId': 26964772, 'title': 'Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26964772'}]",predicted – sensitive,623,Afatinib,2064
299,Preclinical,"In a preclinical study, transformed cells over expressing ERBB2 (HER2) T798I were resistant to Tykerb (lapatinib) in culture (PMID: 25238247).",Actionable,7330,10000003,Advanced Solid Tumor,JAX,24613,ERBB2 T798I,"[{'id': 6146, 'pubMedId': 25238247, 'title': 'Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25238247'}]",resistant,787,Lapatinib,2064
300,Preclinical,"In a preclinical study, transformed lung cancer cells over expressing ERBB2 (HER2) T798I were resistant to Tykerb (lapatinib) in culture (PMID: 25238247).",Actionable,7333,1324,lung cancer,DOID,24613,ERBB2 T798I,"[{'id': 6146, 'pubMedId': 25238247, 'title': 'Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25238247'}]",resistant,787,Lapatinib,2064
301,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) T798I in culture (PMID: 18413839).",Actionable,7324,10000003,Advanced Solid Tumor,JAX,24613,ERBB2 T798I,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",sensitive,967,XL647,2064
302,Preclinical,"In a preclinical study, AZD8055 inhibited tumor growth in a mouse model of spontaneous breast cancer harboring an ERBB2 (HER2) activating mutation and loss of STK11 (LKB1), which was enhanced by the addition of 2-DG (2-deoxyglucose) (PMID: 25436981).",Actionable,5405,1612,breast cancer,DOID,20860,ERBB2 act mut STK11 loss,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}]",sensitive,1519,AZD8055,2064
303,Preclinical,"In a preclinical study, breast cancer cells with mutations in both ERBB2 (HER2) and PIK3CA were more sensitive to VS-5584 (PMID: 23270925). ",Actionable,2894,1612,breast cancer,DOID,10726,PIK3CA act mut ERBB2 act mut,"[{'id': 351, 'pubMedId': 23270925, 'title': 'VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23270925'}]",sensitive,960,VS-5584,2064
304,Preclinical,"In a preclinical study, transformed cells expressing ERBB2 (HER2) activation loop mutations demonstrated sensitivity to AEE788 in culture (PMID: 22046346).",Actionable,2890,10000003,Advanced Solid Tumor,JAX,1243,ERBB2 act mut,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",sensitive,622,AEE788,2064
305,Phase I,"In a Phase I trial, Vistusertib (AZD2014) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a patient with ER-positive breast cancer harboring an ERBB2 activating mutation (PMID: 25805799). ",Actionable,4390,60075,estrogen-receptor positive breast cancer,DOID,1243,ERBB2 act mut,"[{'id': 3000, 'pubMedId': 25805799, 'title': 'First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25805799'}]",predicted – sensitive,991,Vistusertib,2064
306,Phase II,"In a Phase II clinical trial, Nerlynx (neratinib) treatment resulted in clinical benefit in 36% (5/14) of metastatic breast cancer patients harboring ERBB2 (HER2) activating mutations, with 1 complete response, 1 partial response, and 2 patients achieving stable disease for greater than 6 months, and a median progression-free survival of 5 months (J Clin Oncol 34, 2016 (suppl; abstr 516)).",Actionable,7046,1612,breast cancer,DOID,1243,ERBB2 act mut,"[{'id': 6052, 'pubMedId': None, 'title': 'Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC).', 'url': 'http://meetinglibrary.asco.org/content/164601-176'}]",sensitive,828,Neratinib,2064
307,Preclinical - Cell culture,"In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing ERBB2 (HER2) G776V in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).",Actionable,5919,10000003,Advanced Solid Tumor,JAX,3960,ERBB2 G776V,"[{'id': 5195, 'pubMedId': None, 'title': 'AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=407e597a-33c8-4936-87f4-08ee4b23e8b9&cKey=34ee7ebf-07c6-40ea-825f-28fb5018ec92&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]",sensitive,3981,AP32788,2064
308,Preclinical,"In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing wild-type ERBB2 (HER2) in culture (PMID: 22046346).",Actionable,3045,10000003,Advanced Solid Tumor,JAX,530,ERBB2 wild-type,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",sensitive,622,AEE788,2064
309,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing wild-type ERBB2 (HER2) in culture (PMID: 22046346).",Actionable,3044,10000003,Advanced Solid Tumor,JAX,530,ERBB2 wild-type,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",sensitive,787,Lapatinib,2064
310,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 R896C reverted to normal morphology in culture upon Tykerb (lapatinib) treatment (PMID: 23220880).
",Actionable,2043,1612,breast cancer,DOID,3283,ERBB2 R896C,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,787,Lapatinib,2064
311,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 R896C reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).
",Actionable,2045,1612,breast cancer,DOID,3283,ERBB2 R896C,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,947,Trastuzumab,2064
312,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) R896C reverted to normal morphology in culture upon Nerlynx (neratinib) treatment (PMID: 23220880).
",Actionable,2044,1612,breast cancer,DOID,3283,ERBB2 R896C,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,828,Neratinib,2064
313,Phase III,"In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).",Actionable,8746,3717,gastric adenocarcinoma,DOID,26426,ERBB2 neg MET pos,"[{'id': 6730, 'pubMedId': None, 'title': 'METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).', 'url': 'http://meetinglibrary.asco.org/content/147779-156'}]",no benefit,838,Onartuzumab,2064
314,Phase III,"In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).",Actionable,10905,4914,esophagus adenocarcinoma,DOID,26426,ERBB2 neg MET pos,"[{'id': 8918, 'pubMedId': 27918764, 'title': 'Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27918764'}]",no benefit,5676,Onartuzumab + mFOLFOX6,2064
315,Phase III,"In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).",Actionable,10904,3717,gastric adenocarcinoma,DOID,26426,ERBB2 neg MET pos,"[{'id': 8918, 'pubMedId': 27918764, 'title': 'Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27918764'}]",no benefit,5676,Onartuzumab + mFOLFOX6,2064
316,Phase III,"In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).",Actionable,8747,4944,gastroesophageal junction adenocarcinoma,DOID,26426,ERBB2 neg MET pos,"[{'id': 6730, 'pubMedId': None, 'title': 'METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).', 'url': 'http://meetinglibrary.asco.org/content/147779-156'}]",no benefit,838,Onartuzumab,2064
317,Phase III,"In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).",Actionable,8744,4944,gastroesophageal junction adenocarcinoma,DOID,26426,ERBB2 neg MET pos,"[{'id': 6729, 'pubMedId': None, 'title': 'Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal juncti', 'url': 'http://meetinglibrary.asco.org/content/147255-156'}]",no benefit,629,AMG102,2064
318,Phase III,"In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).",Actionable,8745,3717,gastric adenocarcinoma,DOID,26426,ERBB2 neg MET pos,"[{'id': 6729, 'pubMedId': None, 'title': 'Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal juncti', 'url': 'http://meetinglibrary.asco.org/content/147255-156'}]",no benefit,629,AMG102,2064
319,Phase III,"In a Phase III trial, Cyramze (ramucirumab) in combination with Taxotere (docetaxel) did not improve clinical outcomes in ERBB2 (HER2)-negative breast cancer patients (PMID: 25185099).",Actionable,1065,60080,Her2-receptor negative breast cancer,DOID,1184,ERBB2 neg,"[{'id': 665, 'pubMedId': 25185099, 'title': 'Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25185099'}]",no benefit,1423,Ramucirumab + Docetaxel,2064
320,Phase Ib/II,"In a Phase I/II trial, combination of Navelbine (vinorelbine) and Nexavar (sorafenib) resulted in a response rate of 30% (8/27), median progression free survival of 5.7 months, and a clinical benefit rate (absence of disease progression at 6 months) of 48% (13/27) in patients with ERBB2 (HER2)-negative metastatic breast cancer (PMID: 27992451).",Actionable,10434,60080,Her2-receptor negative breast cancer,DOID,1184,ERBB2 neg,"[{'id': 8447, 'pubMedId': 27992451, 'title': 'Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27992451'}]",predicted – sensitive,2357,Sorafenib + Vinorelbine,2064
321,Phase II,"In a Phase II trial, Seribantumab (MM-12) and Aromasin (exemestane) combination treatment resulted in a 74% decrease in risk of progression (HR 0.26) and a a 59% decrease in risk of death (HR 0.436) compared to exemestane alone in ERBB2-negative, hormone receptor positive breast cancer patients (AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer, May 2016, Abstract # A14).",Actionable,6540,60080,Her2-receptor negative breast cancer,DOID,1184,ERBB2 neg,"[{'id': 5690, 'pubMedId': None, 'title': 'Identification of heregulin expression as a driver of a difficult-to-treat cancer phenotype and development of a prospective companion diagnostic for the heregulin-ErbB3 targeting drug seribantumab', 'url': 'http://files.shareholder.com/downloads/AMDA-IWDM2/2127694404x0x892308/7BACAE03-69E0-423A-A4D5-8A19EFED7AE1/MM-121_AACR_Precision_Medicine_Poster_11May2016_FINAL.pdf'}]",predicted – sensitive,4141,Exemestane + Seribantumab,2064
322,Phase III,"In a Phase III trial, Lynparza (olaparib) treatment resulted in improved progression free survival (7.0 vs 4.2 months) and objective response rate (59.9%, 123/205 vs 28.8%, 26/288) compared to single agent chemotherapy in patients with Erbb2 (Her2)-negative breast cancer that also harbored germline BRCA mutations (J Clin Oncol 35, 2017 (suppl; abstr LBA4)).",Actionable,11131,60080,Her2-receptor negative breast cancer,DOID,27913,BRCA1 mut ERBB2 neg,"[{'id': 9101, 'pubMedId': None, 'title': 'OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).', 'url': 'http://abstracts.asco.org/199/AbstView_199_186720.html'}]",predicted – sensitive,837,Olaparib,2064
323,Phase III,"In a Phase III trial, Lynparza (olaparib) treatment resulted in improved progression free survival (7.0 vs 4.2 months) and objective response rate (59.9%, 123/205 vs 28.8%, 26/288) compared to single agent chemotherapy in patients with Erbb2 (Her2)-negative breast cancer that also harbored germline BRCA mutations (J Clin Oncol 35, 2017 (suppl; abstr LBA4)).",Actionable,11132,60080,Her2-receptor negative breast cancer,DOID,27914,BRCA2 mut ERBB2 neg,"[{'id': 9101, 'pubMedId': None, 'title': 'OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).', 'url': 'http://abstracts.asco.org/199/AbstView_199_186720.html'}]",predicted – sensitive,837,Olaparib,2064
324,Preclinical - Cell culture,"In a preclinical study, the combination of AZD-4547 and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and FGFR2 amplification in culture (PMID: 27595477).",Actionable,11556,4914,esophagus adenocarcinoma,DOID,28144,ERBB2 amp FGFR2 amp,"[{'id': 9641, 'pubMedId': 27595477, 'title': 'Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27595477'}]",sensitive,6062,AZD4547 + Lapatinib,2064
325,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA K111N and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).",Actionable,2969,1612,breast cancer,DOID,10753,ERBB2 amp PIK3CA K111N,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,2064
326,Preclinical,"In a preclinical study, knockdown of PTEN expression resulted in a decreased response to treatment with CDX-3379 (KTN3379) in ERBB2 (HER2)-amplified breast cancer cells in culture (PMID: 26880266).",Actionable,6465,60079,Her2-receptor positive breast cancer,DOID,23519,ERBB2 amp PTEN dec exp,"[{'id': 5601, 'pubMedId': 26880266, 'title': 'A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26880266'}]",decreased response,2054,CDX-3379,2064
327,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA N345K and ERBB2 (HER2) amplification in culture (PMID: 21558396).",Actionable,2952,1612,breast cancer,DOID,10739,ERBB2 amp PIK3CA N345K,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,2064
328,Preclinical,"In a preclinical study, colorectal cancer tumorgrafts with ERBB2 (HER2) amplification demonstrated resistance to Herceptin (trastuzumab) treatment in animal models (PMID: 26296355).",Actionable,3162,9256,colorectal cancer,DOID,531,ERBB2 amp,"[{'id': 3655, 'pubMedId': 26296355, 'title': 'Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26296355'}]",resistant,947,Trastuzumab,2064
329,Preclinical,"In a preclinical study, SYD895 induced cell death in ERBB2 (HER2)-amplified primary uterine serous carcinoma (USC) cell lines in culture and inhibited tumor growth and improved survival in ERBB2 (HER2)-amplified USC primary cell line xenografts (PMID: 27256376).",Actionable,7644,5750,uterine corpus serous adenocarcinoma,DOID,531,ERBB2 amp,"[{'id': 6448, 'pubMedId': 27256376, 'title': 'SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27256376'}]",sensitive,4539,SYD985,2064
330,Phase III,"In a Phase III clinical trial, the addition of Tykerb (lapatinib) to Xeloda (capecitabine) and Eloxatin (oxaliplatin) combination treatment did not significantly prolong overall survival compared to placebo, but did improve progression-free survival and response rate in gastric adenocarcinoma patients harboring ERBB2 amplification (PMID: 26628478).",Actionable,3800,3717,gastric adenocarcinoma,DOID,531,ERBB2 amp,"[{'id': 4167, 'pubMedId': 26628478, 'title': 'Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26628478'}]",no benefit,787,Lapatinib,2064
331,Phase II,"In a Phase II clinical trial, patients with ERBB2 (HER2) amplified urothelial carcinoma had improved progression free survival when treated with Gilotrif (afatinib), and median PFS was 6.6 months for patients with ERBB2 or ERBB3 alterations relative to 1.4 months for patients lacking alterations (PMID: 27044931).",Actionable,5940,11054,urinary bladder cancer,DOID,531,ERBB2 amp,"[{'id': 5203, 'pubMedId': 27044931, 'title': 'Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27044931'}]",sensitive,623,Afatinib,2064
332,Preclinical - Pdx,"In a preclinical study, Perjeta (pertuzumab) did not inhibit tumor growth in patient-derived xenograft (PDX) models of ERBB2 (HER2)-amplified colorectal cancer (PMID: 22586653).",Actionable,11360,9256,colorectal cancer,DOID,531,ERBB2 amp,"[{'id': 9255, 'pubMedId': 22586653, 'title': 'A molecularly annotated platform of patient-derived xenografts (""xenopatients"") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22586653'}]",no benefit,856,Pertuzumab,2064
333,Preclinical,"In a preclinical study, the combination of Herceptin (trastuzumab) and CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of ERBB2 (HER2)-amplified breast cancer, with increased efficacy compared to KTN3379 alone (PMID: 26880266).",Actionable,6443,60079,Her2-receptor positive breast cancer,DOID,531,ERBB2 amp,"[{'id': 5601, 'pubMedId': 26880266, 'title': 'A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26880266'}]",sensitive,2064,CDX-3379 + Trastuzumab,2064
334,Preclinical - Cell culture,"In a preclinical study, MK-2206 and KRIBB11 synergistically inhibited growth of ERBB2 (HER2)-amplified breast cancer cell lines in culture (PMID: 28598816).",Actionable,11548,60079,Her2-receptor positive breast cancer,DOID,531,ERBB2 amp,"[{'id': 9624, 'pubMedId': 28598816, 'title': 'Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28598816'}]",predicted – sensitive,6057,KRIBB11 + MK2206,2064
335,Phase II,"In a Phase II trial, Gilotrif (afatinib), demonstrated safety and efficacy in various advanced solid tumor patients with ERBB2 (HER2) amplification (PMID: 23775486).",Actionable,903,10000003,Advanced Solid Tumor,JAX,531,ERBB2 amp,"[{'id': 588, 'pubMedId': 23775486, 'title': 'Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775486'}]",sensitive,623,Afatinib,2064
336,Preclinical,"In a preclinical study, Poziotinib suppressed cell growth, decreased phosphorylation of downstream signaling molecules, and induced apoptosis of human gastric cancer cells harboring ERBB2 (HER2) amplification (PMID: 21306821). ",Actionable,2918,10534,stomach cancer,DOID,531,ERBB2 amp,"[{'id': 2314, 'pubMedId': 21306821, 'title': 'Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21306821'}]",sensitive,1042,poziotinib,2064
337,Preclinical - Pdx,"In a preclinical study, treatment with Tykerb (lapatinib) resulted in initial disease stabilization with subsequent progression, in patient-derived colorectal cancer tumorgraft models with ERBB2 (HER2) amplification (PMID: 26296355).",Actionable,3164,9256,colorectal cancer,DOID,531,ERBB2 amp,"[{'id': 3655, 'pubMedId': 26296355, 'title': 'Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26296355'}]",decreased response,787,Lapatinib,2064
338,Preclinical - Cell culture,"In a preclinical study, ERBB2 (HER2) amplified breast cancer cells treated with Tykerb (lapatinib) demonstrated decreased phosphorylation of Erbb2 (her2) and Akt, however, after 4-8 hours, Akt-driven Rictor showed upregulation, thereby resulting in a decreased treatment response (PMID: 27197158). ",Actionable,7814,1612,breast cancer,DOID,531,ERBB2 amp,"[{'id': 6505, 'pubMedId': 27197158, 'title': 'Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27197158'}]",decreased response,787,Lapatinib,2064
339,Phase III,"In a Phase III clinical trial, the addition of Tykerb (lapatinib) to Xeloda (capecitabine) and Eloxatin (oxaliplatin) combination treatment did not significantly prolong overall survival compared to placebo, but did improve progression-free survival and response rate in gastroesophageal junction adenocarcinoma patients harboring ERBB2 amplification (PMID: 26628478).",Actionable,3802,4944,gastroesophageal junction adenocarcinoma,DOID,531,ERBB2 amp,"[{'id': 4167, 'pubMedId': 26628478, 'title': 'Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26628478'}]",no benefit,787,Lapatinib,2064
340,Preclinical - Cell line xenograft,"In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of Perjeta (pertuzumab) and Nerlynx (neratinib), resulting in a delay of brain lesion growth and improved survival (PMID: 28539475).",Actionable,11528,1612,breast cancer,DOID,531,ERBB2 amp,"[{'id': 9597, 'pubMedId': 28539475, 'title': 'The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28539475'}]",sensitive,6013,Neratinib + Pertuzumab,2064
341,Preclinical - Cell line xenograft,"In a preclinical study, Herceptin (trastuzumab) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification (PMID: 26296355).",Actionable,3163,10534,stomach cancer,DOID,531,ERBB2 amp,"[{'id': 3655, 'pubMedId': 26296355, 'title': 'Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26296355'}]",sensitive,947,Trastuzumab,2064
342,Preclinical,"In a preclinical study, a lung squamous cell carcinoma cell line with ERBB2 (HER2) amplification demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 26545934).",Actionable,6962,3907,lung squamous cell carcinoma,DOID,531,ERBB2 amp,"[{'id': 5974, 'pubMedId': 26545934, 'title': 'Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26545934'}]",resistant,751,Gefitinib,2064
343,Preclinical - Cell line xenograft,"In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of Herceptin (trastuzumab) and LJM716, resulting in a delay of brain lesion growth and improved survival (PMID: 28539475).  ",Actionable,11525,1612,breast cancer,DOID,531,ERBB2 amp,"[{'id': 9597, 'pubMedId': 28539475, 'title': 'The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28539475'}]",sensitive,2037,LJM716 + Trastuzumab,2064
344,Clinical Study,"In a clinical study, ERBB2 (HER2) amplification was associated with resistance to Erbitux (cetuximab) in colorectal cancer patients (PMID: 21900593).",Actionable,11354,9256,colorectal cancer,DOID,531,ERBB2 amp,"[{'id': 9247, 'pubMedId': 21900593, 'title': 'Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21900593'}]",resistant,694,Cetuximab,2064
345,Preclinical - Cell culture,"In a preclinical study, a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification demonstrated sensitivity to treatment with Taselisib (GDC-0032) in culture, resulting in inhibition of cell growth (PMID: 26333383). ",Actionable,9061,5750,uterine corpus serous adenocarcinoma,DOID,531,ERBB2 amp,"[{'id': 6891, 'pubMedId': 26333383, 'title': 'Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26333383'}]",sensitive,1016,GDC-0032,2064
346,Preclinical,"In preclinical studies, Tykerb (lapatinib) demonstrated antiproliferative activity in HER2-amplified gastric cancer in cell assays and in xenograft models (PMID: 20179222).",Actionable,926,10534,stomach cancer,DOID,531,ERBB2 amp,"[{'id': 604, 'pubMedId': 20179222, 'title': 'Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20179222'}]",sensitive,787,Lapatinib,2064
347,Clinical Study,"In a clinical case study, a patient with metastatic colorectal adenocarcinoma harboring ERBB2 (HER2) amplification demonstrated clinical benefit with stable disease in the primary tumor for 7 months following treatment with Kadcyla (trastuzumab emtansine) (PMID: 28040715).",Actionable,9714,50861,colorectal adenocarcinoma,DOID,531,ERBB2 amp,"[{'id': 7488, 'pubMedId': 28040715, 'title': 'Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28040715'}]",sensitive,1402,trastuzumab emtansine,2064
348,Preclinical - Pdx,"In a preclinical study, the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) treatment induced tumor regression in patient-derived colorectal cancer tumorgraft models harboring ERBB2 (HER2) amplification (PMID: 26296355).",Actionable,3165,9256,colorectal cancer,DOID,531,ERBB2 amp,"[{'id': 3655, 'pubMedId': 26296355, 'title': 'Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26296355'}]",sensitive,1414,Trastuzumab + Lapatinib,2064
349,Preclinical - Cell line xenograft,"In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of Herceptin (trastuzumab) and Perjeta (pertuzumab), resulting in a delay of brain lesion growth and improved survival (PMID: 28539475).  ",Actionable,11526,1612,breast cancer,DOID,531,ERBB2 amp,"[{'id': 9597, 'pubMedId': 28539475, 'title': 'The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28539475'}]",sensitive,1389,Trastuzumab + Pertuzumab,2064
350,Preclinical - Cell culture,"In a preclinical study, the combination of Taselisib (GDC-0032) and Nerlynx (neratinib) resulted in a synergistic effect, demonstrating greater cell growth inhibitory activity in uterine serous carcinoma cells harboring ERBB2 (HER2) amplification compared to either agent alone (PMID: 26333383). ",Actionable,9062,5750,uterine corpus serous adenocarcinoma,DOID,531,ERBB2 amp,"[{'id': 6891, 'pubMedId': 26333383, 'title': 'Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26333383'}]",sensitive,4871,GDC-0032 + Neratinib,2064
351,Preclinical - Cell culture,"In a preclinical study, combination of S63845 and Tykerb (lapatinib) resulted in potent cytotoxic effects in ERBB2 (HER2)-amplified breast cancer cells in culture compared to the cytostatic effect of Tykerb (lapatinib) alone (PMID: 27760111).",Actionable,9037,1612,breast cancer,DOID,531,ERBB2 amp,"[{'id': 6851, 'pubMedId': 27760111, 'title': 'The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27760111'}]",sensitive,4859,Lapatinib + S63845,2064
352,Preclinical - Cell culture,"In a preclinical study, ERBB2 (HER2) amplified breast cancer cells treated with Torkinib (PP242) demonstrated some efficacy in culture including reduced phosphorylation of S6 and Akt, apoptosis, and decreased cell growth (PMID: 27197158). ",Actionable,7821,1612,breast cancer,DOID,531,ERBB2 amp,"[{'id': 6505, 'pubMedId': 27197158, 'title': 'Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27197158'}]",sensitive,2240,Torkinib,2064
353,Clinical Study,"In a clinical case study, a patient with duodenal adenocarcinoma harboring ERBB2 (HER2) amplification demonstrated a complete pathologic response after treatment with a combination of Herceptin (trastuzumab), Adrucil (fluorouracil), Wellcovorin (leucovorin), and Eloxatin (oxaliplatin) (PMID: 28784859).  ",Actionable,11715,10816,duodenum adenocarcinoma,DOID,531,ERBB2 amp,"[{'id': 9726, 'pubMedId': 28784859, 'title': 'Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28784859'}]",sensitive,3439,Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin,2064
354,FDA approved,"In a Phase III clinical trial that supported FDA approval, gastric cancer patients with either ERBB2 (HER2) over expression or ERBB2 (HER2) amplification had increased overall survival when treated with Herceptin (trastuzumab), in combination with chemotherapy (PMID: 20728210).",Actionable,893,3717,gastric adenocarcinoma,DOID,531,ERBB2 amp,"[{'id': 893, 'pubMedId': 20728210, 'title': 'Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20728210'}]",sensitive,947,Trastuzumab,2064
355,Preclinical - Cell culture,"In a preclinical study, a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification demonstrated sensitivity to treatment with Nerlynx (neratinib) in culture, resulting in inhibition of cell growth (PMID: 26333383). ",Actionable,9059,5750,uterine corpus serous adenocarcinoma,DOID,531,ERBB2 amp,"[{'id': 6891, 'pubMedId': 26333383, 'title': 'Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26333383'}]",sensitive,828,Neratinib,2064
356,Preclinical,"In a preclinical study, the combination of Ibrance (palbociclib) and Herceptin (trastuzumab) worked synergistically to inhibit growth of ERBB2 (HER2)-amplified breast cancer cells in culture (PMID: 19874578).",Actionable,2978,60079,Her2-receptor positive breast cancer,DOID,531,ERBB2 amp,"[{'id': 805, 'pubMedId': 19874578, 'title': 'PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19874578'}]",sensitive,3041,Palbociclib + Trastuzumab,2064
357,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited proliferation of breast cancer cell lines with ERBB2 (HER2) amplification in culture (PMID: 26545934).",Actionable,6947,1612,breast cancer,DOID,531,ERBB2 amp,"[{'id': 5974, 'pubMedId': 26545934, 'title': 'Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26545934'}]",sensitive,623,Afatinib,2064
358,Preclinical - Cell line xenograft,"In a preclinical study, Debio 1347 did not inhibit tumor growth in cell line xenograft models of ERBB2 (HER2) amplified gastric carcinoma (PMID: 26438159).",Actionable,8494,5517,stomach carcinoma,DOID,531,ERBB2 amp,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,1014,FF-284,2064
359,Preclinical,"In a preclinical study, BMS-690514 inhibited tumor growth in a gastric cancer xenograft model with ERBB2 (HER2) amplification and overexpression (PMID: 21531814).",Actionable,2919,10534,stomach cancer,DOID,531,ERBB2 amp,"[{'id': 1825, 'pubMedId': 21531814, 'title': 'Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21531814'}]",sensitive,685,BMS-690514,2064
360,Preclinical - Cell line xenograft,"In a preclinical study, Gilotrif (afatinib) inhibited proliferation and induced cell-cycle arrest and apoptosis of non-small cell lung cancer (NSCLC) cell lines with ERBB2 (HER2) amplification in culture, and inhibited tumor growth in ERBB2 (HER2)-amplified NSCLC cell line xenograft models (PMID: 26545934).",Actionable,6946,3908,non-small cell lung carcinoma,DOID,531,ERBB2 amp,"[{'id': 5974, 'pubMedId': 26545934, 'title': 'Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26545934'}]",sensitive,623,Afatinib,2064
361,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) treatment induced tumor regression in ERBB2 (HER2)-amplified cell line xenograft models of gastric cancer (PMID: 26296355).",Actionable,3166,10534,stomach cancer,DOID,531,ERBB2 amp,"[{'id': 3655, 'pubMedId': 26296355, 'title': 'Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26296355'}]",sensitive,1414,Trastuzumab + Lapatinib,2064
362,Preclinical - Cell culture,"In a preclinical study, esophageal cancer cells with ERBB2 (HER2) amplification demonstrated sensitivity to Imbruvica (ibrutinib), resulting in decreased survival in culture (PMID: 28830912).",Actionable,11801,5041,esophageal cancer,DOID,531,ERBB2 amp,"[{'id': 9793, 'pubMedId': 28830912, 'title': 'Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28830912'}]",sensitive,768,Ibrutinib,2064
363,Phase I,"In a Phase I clinical trial, Nerlynx (neratinib) administered with Torisel (temsirolimus) was tolerable and demonstrated antitumor activity in ERBB2 (HER2)-amplified breast cancer resistant to (Herceptin) trastuzumab (PMID:24323026).",Actionable,426,1612,breast cancer,DOID,531,ERBB2 amp,"[{'id': 94, 'pubMedId': 24323026, 'title': 'Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24323026'}]",predicted – sensitive,1527,Temsirolimus + Neratinib,2064
364,Preclinical - Pdx,"In a preclinical study, the combination of Perjeta (pertuzumab) and Tykerb (lapatinib) induced tumor regression in patient-derived xenograft (PDX) models of colorectal cancer with ERBB2 (HER2) amplification (PMID: 22586653).",Actionable,11359,9256,colorectal cancer,DOID,531,ERBB2 amp,"[{'id': 9255, 'pubMedId': 22586653, 'title': 'A molecularly annotated platform of patient-derived xenografts (""xenopatients"") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22586653'}]",sensitive,5958,Lapatinib + Pertuzumab,2064
365,Preclinical,"In a preclinical study, dacomitinib was more effective in preventing proliferation in ERBB2 (HER2) amplified breast cancer cells than in wild-type ERBB2 (HER2) breast cancer cells (PMID: 22761403).",Actionable,907,1612,breast cancer,DOID,531,ERBB2 amp,"[{'id': 593, 'pubMedId': 22761403, 'title': 'Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22761403'}]",sensitive,714,Dacomitinib,2064
366,Clinical Study,"In a meta-analysis, breast cancer patients with >12 copies of ERBB2 (HER2) had a better response to Herceptin (trastuzumab) than patients with 6-12 copies of ERBB2 (HER2) (PMID: 24691421).",Actionable,892,60079,Her2-receptor positive breast cancer,DOID,531,ERBB2 amp,"[{'id': 892, 'pubMedId': 24691421, 'title': 'Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24691421'}]",sensitive,947,Trastuzumab,2064
367,Preclinical - Cell culture,"In a preclinical study, the combination therapy of Tykerb (lapatinib) and Torkinib (PP242) in ERBB2 (HER2) amplified breast cancer cells in culture blocked cell growth, inhibited phosphorylation of Akt and S6, and led to greater caspase activity when compared to each agent alone (PMID: 27197158).  ",Actionable,7822,1612,breast cancer,DOID,531,ERBB2 amp,"[{'id': 6505, 'pubMedId': 27197158, 'title': 'Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27197158'}]",sensitive,4584,Lapatinib + Torkinib,2064
368,Preclinical - Cell line xenograft,"In a preclinical study, ABT-414 demonstrated cytoxicity against a EGFR-amplified vulvar epidermoid carcinoma cell line in culture and induced tumor regression in EGFR-amplified vulvar epidermoid carcinoma cell line xenograft models (PMID: 26846818).",Actionable,6979,2101,vulva squamous cell carcinoma,DOID,531,ERBB2 amp,"[{'id': 5960, 'pubMedId': 26846818, 'title': 'ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26846818'}]",sensitive,976,ABT-414,2064
369,Preclinical,"In a preclinical study, dacomitinib demonstrated significant growth-inhibitory effects in HER2- amplified gastric cancer cells (PMID: 18606718).",Actionable,930,3119,gastrointestinal system cancer,DOID,531,ERBB2 amp,"[{'id': 606, 'pubMedId': 18606718, 'title': 'Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18606718'}]",sensitive,714,Dacomitinib,2064
370,Preclinical - Cell line xenograft,"In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of LJM716 and Nerlynx (neratinib), resulting in a delay of brain lesion growth and improved survival (PMID: 28539475).  ",Actionable,11527,1612,breast cancer,DOID,531,ERBB2 amp,"[{'id': 9597, 'pubMedId': 28539475, 'title': 'The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28539475'}]",sensitive,6012,LJM716 + Neratinib,2064
371,Preclinical - Pdx,"In a preclinical study, the combination of Erbitux (cetuximab) and Tykerb (lapatinib) induced tumor regression in patient-derived xenograft (PDX) models of colorectal cancer with ERBB2 (HER2) amplification (PMID: 22586653).",Actionable,11358,9256,colorectal cancer,DOID,531,ERBB2 amp,"[{'id': 9255, 'pubMedId': 22586653, 'title': 'A molecularly annotated platform of patient-derived xenografts (""xenopatients"") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22586653'}]",sensitive,1672,Cetuximab + Lapatinib,2064
372,Preclinical - Cell culture,"In a preclinical study, BGB-283 inhibited proliferation of ERBB2 (HER2) amplified breast cancer cells in culture (PMID: 26208524).",Actionable,8064,60079,Her2-receptor positive breast cancer,DOID,531,ERBB2 amp,"[{'id': 5280, 'pubMedId': 26208524, 'title': 'BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26208524'}]",predicted – sensitive,4025,BGB-283,2064
373,Preclinical,"In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of ERBB2 (HER2)-amplified breast cancer (PMID: 26880266).",Actionable,6442,60079,Her2-receptor positive breast cancer,DOID,531,ERBB2 amp,"[{'id': 5601, 'pubMedId': 26880266, 'title': 'A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26880266'}]",sensitive,2054,CDX-3379,2064
374,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer cell line xenograft model harboring ERBB2 (HER2) amplification demonstrated tumor regression within the mammary fat pad when treated with Buparlisib (BKM120) (PMID: 28539475). ",Actionable,11513,1612,breast cancer,DOID,531,ERBB2 amp,"[{'id': 9597, 'pubMedId': 28539475, 'title': 'The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28539475'}]",sensitive,680,BKM120,2064
375,FDA approved,"In a Phase III trial that supported FDA approval, gastric cancer patients with ERBB2 (HER2) amplification had increased overall survival when treated with Herceptin (trastuzumab), in combination with chemotherapy (PMID: 20728210).",Actionable,894,4944,gastroesophageal junction adenocarcinoma,DOID,531,ERBB2 amp,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 893, 'pubMedId': 20728210, 'title': 'Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20728210'}]",sensitive,947,Trastuzumab,2064
376,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of breast cancer cells with ERBB2 (HER2) amplification in culture (PMID: 21558396).",Actionable,2943,1612,breast cancer,DOID,531,ERBB2 amp,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,2064
377,Phase III,"In a Phase III clinical trial, the addition of Tykerb (lapatinib) to Xeloda (capecitabine) and Eloxatin (oxaliplatin) combination treatment did not significantly prolong overall survival compared to placebo, but did improve progression-free survival and response rate in esophagus adenocarcinoma patients harboring ERBB2 amplification (PMID: 26628478).",Actionable,3801,4914,esophagus adenocarcinoma,DOID,531,ERBB2 amp,"[{'id': 4167, 'pubMedId': 26628478, 'title': 'Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26628478'}]",no benefit,787,Lapatinib,2064
378,Phase II,"In a Phase II clinical trial, two urothelial carcinoma patients with ERBB2 (HER2) and EGFR co-amplification had improved progression free survival when treated with Gilotrif (afatinib), and median PFS was 6.6 months for patients with ERBB2 or ERBB3 alterations relative to 1.4 months for patients lacking alterations (PMID: 27044931).",Actionable,5942,11054,urinary bladder cancer,DOID,22032,EGFR amp ERBB2 amp,"[{'id': 5203, 'pubMedId': 27044931, 'title': 'Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27044931'}]",sensitive,623,Afatinib,2064
379,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).",Actionable,2968,1612,breast cancer,DOID,10752,ERBB2 amp PIK3CA H1047R,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,2064
380,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring ERBB2 (HER2) amplification and PIK3CA H1047R in culture (PMID: 21325073, PMID: 17314276).",Actionable,3125,1612,breast cancer,DOID,10752,ERBB2 amp PIK3CA H1047R,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3636, 'pubMedId': 17314276, 'title': 'Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17314276'}]",sensitive,1040,PF-05212384,2064
381,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited cell growth in a human ovarian cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).
",Actionable,2970,2394,ovarian cancer,DOID,10752,ERBB2 amp PIK3CA H1047R,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,2064
382,Preclinical - Cell line xenograft,"In a preclinical study, the combination of CH5132799 and Herceptin (trastuzumab) inhibited tumor growth and overcame Herceptin (trastuzumab) insensitivity in xenograft models of a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification (PMID: 21558396).",Actionable,2975,1612,breast cancer,DOID,10752,ERBB2 amp PIK3CA H1047R,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,3039,CH5132799 + Trastuzumab,2064
383,Preclinical,"In a preclinical study, CUDC-907 inhibited downstream signaling and growth of PIK3CA-mutant breast cancer cells with ERBB2 amplification in culture (PMID: 22693356).",Actionable,3016,1612,breast cancer,DOID,19124,ERBB2 amp PIK3CA mut,"[{'id': 1018, 'pubMedId': 22693356, 'title': 'Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693356'}]",sensitive,709,CUDC-907,2064
384,Preclinical - Cell line xenograft,"In a preclinical study, ERBB2 (HER2)-receptor positive breast cancer cell line xenograft models harboring amplification of ERBB2 (HER2) and a PIK3CA mutation demonstrated sensitivity to treatment with Ipatasertib (GDC-0068), resulting in inhibition of tumor growth (PMID: 24141624). ",Actionable,8966,60079,Her2-receptor positive breast cancer,DOID,19124,ERBB2 amp PIK3CA mut,"[{'id': 191, 'pubMedId': 24141624, 'title': 'Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141624'}]",sensitive,747,Ipatasertib,2064
385,Preclinical - Cell line xenograft,"In a preclinical study, Aliqopa (copanlisib) promoted tumor regression in xenograft models of a human ERBB2 (HER2)-amplified breast cancer cell line harboring a PIK3CA activating mutation (PMID: 24170767).",Actionable,1374,60079,Her2-receptor positive breast cancer,DOID,19124,ERBB2 amp PIK3CA mut,"[{'id': 245, 'pubMedId': 24170767, 'title': 'BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24170767'}]",sensitive,995,Copanlisib,2064
386,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Nerlynx (neratinib) and Taselisib (GDC-0032), compared to either agent alone, resulted in greater inhibition of cell cycle activity in a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification and a PIK3CA mutation in culture, and in xenograft models, showed increased tumor growth inhibition and tumor regression (PMID: 26333383). ",Actionable,9067,5750,uterine corpus serous adenocarcinoma,DOID,19124,ERBB2 amp PIK3CA mut,"[{'id': 6891, 'pubMedId': 26333383, 'title': 'Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26333383'}]",sensitive,4871,GDC-0032 + Neratinib,2064
387,Clinical Study,"In a clinical case study, a patient with gastric adenocarcinoma containing amplification of ERBB2 (HER2) and a TP53 R158H mutation progressed and developed metastases while being treated with AMG 337 (PMID: 26432108).",Actionable,4099,3717,gastric adenocarcinoma,DOID,17302,ERBB2 amp TP53 R158H,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",predicted – resistant,1064,AMG 337,2064
388,Preclinical,"In a preclinical study, Nerlynx (neratinib) treatment resulted in stable tumor size in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863).",Actionable,7126,9256,colorectal cancer,DOID,24420,ERBB2 amp ERBB2 L866M,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,828,Neratinib,2064
389,Preclinical,"In a preclinical study, Herceptin (trastuzumab) had no effect on tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863).",Actionable,7125,9256,colorectal cancer,DOID,24420,ERBB2 amp ERBB2 L866M,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",resistant,947,Trastuzumab,2064
390,Preclinical,"In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment resulted in sustained tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863).",Actionable,7127,9256,colorectal cancer,DOID,24420,ERBB2 amp ERBB2 L866M,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,4359,Neratinib + Trastuzumab,2064
391,Preclinical,"In a preclinical study, xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification were resistant to Erbitux (cetuximab) (PMID: 26243863).",Actionable,7119,9256,colorectal cancer,DOID,24420,ERBB2 amp ERBB2 L866M,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",resistant,694,Cetuximab,2064
392,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA C420R and ERBB2 (HER2) amplification (PMID: 21558396).",Actionable,2951,1612,breast cancer,DOID,10738,ERBB2 amp PIK3CA C420R,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,2064
393,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer cell line xenograft model co-harboring ERBB2 (HER2) amplification and PIK3CA E545K demonstrated tumor regression within the mammary fat pad when treated with Buparlisib (BKM120) (PMID: 28539475). ",Actionable,11514,1612,breast cancer,DOID,11011,ERBB2 amp PIK3CA E545K,"[{'id': 9597, 'pubMedId': 28539475, 'title': 'The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28539475'}]",sensitive,680,BKM120,2064
394,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K and ERBB2 (HER2) amplification in culture (PMID: 21558396).",Actionable,3003,1612,breast cancer,DOID,11011,ERBB2 amp PIK3CA E545K,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,2064
395,Preclinical,"In a preclinical study, gastric cancer cells with wild-type FGFR2  and ERBB2 (HER2) amplification were resistant to treatment with AZD4547 in culture (PMID: 22869148).",Actionable,2581,10534,stomach cancer,DOID,9482,FGFR2 wild-type ERBB2 amp,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",resistant,654,AZD4547,2064
396,Preclinical - Cell culture,"In a preclinical study, the combination of Taselisib (GDC-0032) and Nerlynx (neratinib) delayed cell cycle activity in a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture (PMID: 26333383). ",Actionable,9065,5750,uterine corpus serous adenocarcinoma,DOID,26704,ERBB2 amp PIK3CA wild-type,"[{'id': 6891, 'pubMedId': 26333383, 'title': 'Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26333383'}]",sensitive,4871,GDC-0032 + Neratinib,2064
397,Preclinical - Cell line xenograft,"In a preclinical study, Taselisib (GDC-0032) did not result in delay of cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, however, did result in tumor growth inhibition in xenograft models (PMID: 26333383). ",Actionable,9063,5750,uterine corpus serous adenocarcinoma,DOID,26704,ERBB2 amp PIK3CA wild-type,"[{'id': 6891, 'pubMedId': 26333383, 'title': 'Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26333383'}]",sensitive,1016,GDC-0032,2064
398,Preclinical - Cell line xenograft,"In a preclinical study, Nerlynx (neratinib) delayed cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, and inhibited tumor growth in xenograft models (PMID: 26333383). ",Actionable,9064,5750,uterine corpus serous adenocarcinoma,DOID,26704,ERBB2 amp PIK3CA wild-type,"[{'id': 6891, 'pubMedId': 26333383, 'title': 'Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26333383'}]",sensitive,828,Neratinib,2064
399,Preclinical - Cell line xenograft,"In a preclinical study, Gedatolisib (PKI-587) inhibited PI3K signaling, cell growth and induced apoptosis in human breast cancer cells harboring ERBB2 (HER2) amplification, PIK3CA E545K, and PIK3CA K567R in culture and in cell line xenografts (PMID: 21325073, PMID: 17314276).",Actionable,3124,60079,Her2-receptor positive breast cancer,DOID,11788,ERBB2 amp PIK3CA E545K PIK3CA K567R,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3636, 'pubMedId': 17314276, 'title': 'Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17314276'}]",sensitive,1040,PF-05212384,2064
400,Preclinical,"In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 and MET was resistant to Xalkori (crizotinib) in culture (PMID: 26432108).",Actionable,4089,1107,esophageal carcinoma,DOID,17215,ERBB2 amp MET amp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",resistant,706,Crizotinib,2064
401,Clinical Study,"In a clinical case study, a patient with ERBB2 (HER2) amplified gastric adenocarcinoma progressed rapidly when treated with Herceptin (trastuzumab) with Xeloda (capecitabine), Eloxatin (oxaliplatin), and Avastin (bevacizumab), and reprofiling of the tumor revealed co-amplification of MET (PMID: 26432108).",Actionable,4093,3717,gastric adenocarcinoma,DOID,17215,ERBB2 amp MET amp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",resistant,3441,Bevacizumab + Capecitabine + Oxaliplatin + Trastuzumab,2064
402,Preclinical - Cell culture,"In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and MET amplification in culture (PMID: 27595477).",Actionable,11555,4914,esophagus adenocarcinoma,DOID,17215,ERBB2 amp MET amp,"[{'id': 9641, 'pubMedId': 27595477, 'title': 'Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27595477'}]",sensitive,3440,Crizotinib + Lapatinib,2064
403,Clinical Study,"In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma had near complete regression of the disease after 2 months of treatment with Herceptin (trastuzumab), Xalkori (crizotinib) and weekly Taxol (paclitaxel) (PMID: 26432108).",Actionable,4094,3717,gastric adenocarcinoma,DOID,17215,ERBB2 amp MET amp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",sensitive,3442,Crizotinib + Trastuzumab + Paclitaxel,2064
404,Preclinical,"In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was sensitive to inhibition by Tykerb (lapatinib) and Xalkori (crizotinib) in culture (PMID: 26432108).",Actionable,4092,1107,esophageal carcinoma,DOID,17215,ERBB2 amp MET amp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",sensitive,3440,Crizotinib + Lapatinib,2064
405,Preclinical,"In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 and MET was resistant to Tykerb (lapatinib) in culture (PMID: 26432108).",Actionable,4090,1107,esophageal carcinoma,DOID,17215,ERBB2 amp MET amp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",resistant,787,Lapatinib,2064
406,Clinical Study,"In a clinical case study, a patient with ERBB2 (HER2) and MET amplified gastric adenocarcinoma was insensitive to AMG 337 therapy (PMID: 26432108).",Actionable,4084,3717,gastric adenocarcinoma,DOID,17215,ERBB2 amp MET amp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",resistant,1064,AMG 337,2064
407,Clinical Study,"In a clinical case study, a patient with ERBB2 (HER2) and MET amplified gastric adenocarcinoma was insensitive to treatment with Herceptin (trastuzumab) and FOLFOX (PMID: 26432108).",Actionable,4091,3717,gastric adenocarcinoma,DOID,17215,ERBB2 amp MET amp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",resistant,3439,Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin,2064
408,Preclinical,"In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L755_T759del were resistant to treatment with Tykerb (lapatinib), resulting in decreased growth inhibition (PMID: 23220880). ",Actionable,6943,1612,breast cancer,DOID,24091,ERBB2 L755_T759del,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",resistant,787,Lapatinib,2064
409,Preclinical,"In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L755_T759del were sensitive to treatment with Nerlynx (neratinib) (PMID: 23220880). ",Actionable,6945,1612,breast cancer,DOID,24091,ERBB2 L755_T759del,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,828,Neratinib,2064
410,Preclinical,"In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L755_T759del were sensitive to treatment with Iressa (gefitinib) (PMID: 23220880). ",Actionable,6944,1612,breast cancer,DOID,24091,ERBB2 L755_T759del,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,751,Gefitinib,2064
411,Preclinical,"In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V773A in culture (PMID: 22046346).",Actionable,3040,10000003,Advanced Solid Tumor,JAX,11339,ERBB2 V773A,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",sensitive,622,AEE788,2064
412,Preclinical,"In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V773A in culture (PMID: 22046346).",Actionable,3039,10000003,Advanced Solid Tumor,JAX,11339,ERBB2 V773A,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",decreased response,787,Lapatinib,2064
413,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).",Actionable,7111,9256,colorectal cancer,DOID,24403,ERBB2 L866M,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,623,Afatinib,2064
414,Preclinical,"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L866M were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).",Actionable,7100,9256,colorectal cancer,DOID,24403,ERBB2 L866M,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",resistant,694,Cetuximab,2064
415,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).",Actionable,7106,9256,colorectal cancer,DOID,24403,ERBB2 L866M,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,828,Neratinib,2064
416,Preclinical,"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L866M were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).",Actionable,7101,9256,colorectal cancer,DOID,24403,ERBB2 L866M,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",resistant,845,Panitumumab,2064
417,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).",Actionable,7089,219,colon cancer,DOID,24403,ERBB2 L866M,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,828,Neratinib,2064
418,Preclinical,"In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).",Actionable,7085,219,colon cancer,DOID,24403,ERBB2 L866M,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,947,Trastuzumab,2064
419,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) P780_Y781insGSP reverted to normal morphology in culture upon Nerlynx (neratinib) treatment (PMID: 23220880).
",Actionable,2039,1612,breast cancer,DOID,3278,ERBB2 G778_P780dup,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,828,Neratinib,2064
420,Phase II,"In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), which included patients with ERBB2 G778_P780dup (1 complete response (referred to as V777_G778insGSP) and 1 patient with stable disease for more than 24 weeks (referred to as P780_Y781insGSP) (PMID: 28679771).",Actionable,11645,1612,breast cancer,DOID,3278,ERBB2 G778_P780dup,"[{'id': 9679, 'pubMedId': 28679771, 'title': 'Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28679771'}]",sensitive,828,Neratinib,2064
421,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 26545934).",Actionable,6959,1324,lung cancer,DOID,3278,ERBB2 G778_P780dup,"[{'id': 5974, 'pubMedId': 26545934, 'title': 'Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26545934'}]",sensitive,623,Afatinib,2064
422,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 P780_Y781insGSP demonstrated resistance when treated with Tykerb (lapatinib) (PMID: 23220880).
",Actionable,2038,1612,breast cancer,DOID,3278,ERBB2 G778_P780dup,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",resistant,787,Lapatinib,2064
423,Preclinical - Cell culture,"In a preclinical study, Nerlynx (neratinib) inhibited growth of transformed cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 28363995).",Actionable,10527,10000003,Advanced Solid Tumor,JAX,3278,ERBB2 G778_P780dup,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",sensitive,828,Neratinib,2064
424,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 P780_Y781insGSP demonstrated resistance when treated with Herceptin (trastuzumab) (PMID: 23220880).
",Actionable,2040,1612,breast cancer,DOID,3278,ERBB2 G778_P780dup,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",resistant,947,Trastuzumab,2064
425,Preclinical - Cell culture,"In a preclinical study, dacomitinib inhibited growth of transformed cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 28363995).",Actionable,10525,10000003,Advanced Solid Tumor,JAX,3278,ERBB2 G778_P780dup,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",sensitive,714,Dacomitinib,2064
426,Preclinical,"In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",Actionable,6967,1324,lung cancer,DOID,3278,ERBB2 G778_P780dup,"[{'id': 5974, 'pubMedId': 26545934, 'title': 'Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26545934'}]",no benefit,751,Gefitinib,2064
427,Phase II,"In a Phase II trial, two lung adenocarcinoma patients harboring ERBB2 (HER2) P780_Y781insGSP (also referred to as G778_780dup) demonstrated partial response to treatment with dacomitinib (PMID: 25899785).",Actionable,10501,3910,lung adenocarcinoma,DOID,3278,ERBB2 G778_P780dup,"[{'id': 8574, 'pubMedId': 25899785, 'title': 'Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25899785'}]",sensitive,714,Dacomitinib,2064
428,Clinical Study,"In a clinical study, a lung adenocarcinoma patient harboring ERBB2 (HER2) G778_P780dup (also referred to as V747_G748insGSP and G748_P750dup), demonstrated a 13% regression of target lesions and stable disease for 11 months following treatment with pulse Gilotrif (afatinib) (PMID: 26964772).",Actionable,8055,3910,lung adenocarcinoma,DOID,3278,ERBB2 G778_P780dup,"[{'id': 6345, 'pubMedId': 26964772, 'title': 'Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26964772'}]",predicted – sensitive,623,Afatinib,2064
429,Clinical Study,"In a clinical study, a patient with metastatic lung adenocarcinoma harboring ERBB2 (HER2) G778_P780dup (also referred to as V777_G778insGSP) demonstrated tumor shrinkage and clinical response for 7 months following treatment with Gilotrif (afatinib) (PMID: 28363995).",Actionable,10523,3910,lung adenocarcinoma,DOID,3278,ERBB2 G778_P780dup,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",predicted – sensitive,623,Afatinib,2064
430,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) Y803N in culture (PMID: 18413839).",Actionable,7325,10000003,Advanced Solid Tumor,JAX,24616,ERBB2 Y803N,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",sensitive,967,XL647,2064
431,Preclinical,"In a preclinical study, transformed cells over expressing ERBB2 (HER2) Y803N demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).",Actionable,7314,10000003,Advanced Solid Tumor,JAX,24616,ERBB2 Y803N,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",decreased response,787,Lapatinib,2064
432,Clinical Study,"In a clinical case study, a rectal adenocarcinoma patient harboring APC Q1429fs, BRAF N581S, and ERBB2 L755S did not respond to Herceptin (trastuzumab) treatment in combination with Fluorouracil and Wellcovorin (leucovorin) (PMID: 27626067).",Actionable,9333,1996,rectum adenocarcinoma,DOID,26822,APC Q1429fs BRAF N581S ERBB2 L755S,"[{'id': 7088, 'pubMedId': 27626067, 'title': 'Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27626067'}]",no benefit,4970,Fluorouracil + Leucovorin + Trastuzumab,2064
433,Preclinical,"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L755S were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).",Actionable,7096,9256,colorectal cancer,DOID,3151,ERBB2 L755S,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",resistant,694,Cetuximab,2064
434,Preclinical,"In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755S in culture (PMID: 22046346).",Actionable,3035,10000003,Advanced Solid Tumor,JAX,3151,ERBB2 L755S,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",sensitive,2911,EKI-285,2064
435,Phase II,"In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), with 1 complete response, 1 partial response in a patient with ERBB2 (HER2) L755S, and 3 patients achieving stable disease for 24 weeks or more (PMID: 28679771).",Actionable,11640,219,colon cancer,DOID,3151,ERBB2 L755S,"[{'id': 9679, 'pubMedId': 28679771, 'title': 'Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28679771'}]",sensitive,828,Neratinib,2064
436,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).",Actionable,7087,219,colon cancer,DOID,3151,ERBB2 L755S,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,828,Neratinib,2064
437,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ERBB2 L755S demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346).
",Actionable,2036,10000003,Advanced Solid Tumor,JAX,3151,ERBB2 L755S,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}, {'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",resistant,787,Lapatinib,2064
438,Preclinical,"In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755S demonstrated resistance to AEE788 in culture, except at very high doses (PMID: 22046346).
",Actionable,2035,10000003,Advanced Solid Tumor,JAX,3151,ERBB2 L755S,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",resistant,622,AEE788,2064
439,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) L755S demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).
",Actionable,2037,1612,breast cancer,DOID,3151,ERBB2 L755S,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,828,Neratinib,2064
440,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).",Actionable,7109,9256,colorectal cancer,DOID,3151,ERBB2 L755S,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,623,Afatinib,2064
441,Preclinical,"In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755S in culture (PMID: 22046346).",Actionable,3036,10000003,Advanced Solid Tumor,JAX,3151,ERBB2 L755S,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",sensitive,3075,WZ4002,2064
442,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).",Actionable,7104,9256,colorectal cancer,DOID,3151,ERBB2 L755S,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,828,Neratinib,2064
443,Preclinical,"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L755S were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).",Actionable,7097,9256,colorectal cancer,DOID,3151,ERBB2 L755S,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",resistant,845,Panitumumab,2064
444,Preclinical,"In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).",Actionable,7084,219,colon cancer,DOID,3151,ERBB2 L755S,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,947,Trastuzumab,2064
445,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L755S in culture (PMID: 18413839).",Actionable,7320,10000003,Advanced Solid Tumor,JAX,3151,ERBB2 L755S,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",sensitive,967,XL647,2064
446,Preclinical,"In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G776delinsVC did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",Actionable,6965,1324,lung cancer,DOID,24125,ERBB2 G776delinsVC,"[{'id': 5974, 'pubMedId': 26545934, 'title': 'Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26545934'}]",no benefit,751,Gefitinib,2064
447,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 26545934).",Actionable,6957,1324,lung cancer,DOID,24125,ERBB2 G776delinsVC,"[{'id': 5974, 'pubMedId': 26545934, 'title': 'Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26545934'}]",sensitive,623,Afatinib,2064
448,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring ERBB2 (HER2) G776delinsVC demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 26545934).",Actionable,6960,3908,non-small cell lung carcinoma,DOID,24125,ERBB2 G776delinsVC,"[{'id': 5974, 'pubMedId': 26545934, 'title': 'Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26545934'}]",resistant,751,Gefitinib,2064
449,Preclinical - Cell line xenograft,"In a preclinical study, Gilotrif (afatinib) inhibited proliferation and induced cell-cycle arrest and apoptosis of a non-small cell lung cancer (NSCLC) cell line harboring ERBB2 (HER2) G776delinsVC in culture and inhibited tumor growth in NSCLC cell line xenografts carrying ERBB2 (HER2) G776delinsVC (PMID: 26545934).",Actionable,6948,3908,non-small cell lung carcinoma,DOID,24125,ERBB2 G776delinsVC,"[{'id': 5974, 'pubMedId': 26545934, 'title': 'Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26545934'}]",sensitive,623,Afatinib,2064
450,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L726F in culture (PMID: 19718025).",Actionable,7318,10000003,Advanced Solid Tumor,JAX,24164,ERBB2 L726F,"[{'id': 566, 'pubMedId': 19718025, 'title': 'Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19718025'}]",sensitive,967,XL647,2064
451,Preclinical,"In a preclinical study, transformed cells over expressing ERBB2 (HER2) L726F demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).",Actionable,7312,10000003,Advanced Solid Tumor,JAX,24164,ERBB2 L726F,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",decreased response,787,Lapatinib,2064
452,Preclinical,"In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L726F demonstrated resistance to Tykerb (lapatinib) in both culture and xenograft models (PMID: 25435280).",Actionable,6968,1612,breast cancer,DOID,24164,ERBB2 L726F,"[{'id': 5989, 'pubMedId': 25435280, 'title': 'HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25435280'}]",resistant,787,Lapatinib,2064
453,Preclinical - Cell culture,"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753 were sensitive to Nerlynx (neratinib) in culture, resulting in decreased colony formation (PMID: 27697991).",Actionable,8757,1612,breast cancer,DOID,26418,ERBB2 K753E,"[{'id': 6720, 'pubMedId': 27697991, 'title': 'Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27697991'}]",sensitive,828,Neratinib,2064
454,Preclinical - Cell culture,"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753E were resistant to Tykerb (lapatinib) in culture (PMID: 27697991).",Actionable,8756,1612,breast cancer,DOID,26418,ERBB2 K753E,"[{'id': 6720, 'pubMedId': 27697991, 'title': 'Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27697991'}]",resistant,787,Lapatinib,2064
455,Preclinical - Cell culture,"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753E were resistant to Herceptin (trastuzumab) in culture (PMID: 27697991).",Actionable,8755,1612,breast cancer,DOID,26418,ERBB2 K753E,"[{'id': 6720, 'pubMedId': 27697991, 'title': 'Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27697991'}]",resistant,947,Trastuzumab,2064
456,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 D769H demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).",Actionable,2022,1612,breast cancer,DOID,3128,ERBB2 D769H,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,787,Lapatinib,2064
457,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 D769H reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).",Actionable,2024,1612,breast cancer,DOID,3128,ERBB2 D769H,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,947,Trastuzumab,2064
458,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) D769H demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).",Actionable,2023,1612,breast cancer,DOID,3128,ERBB2 D769H,"[{'id': 1980, 'pubMedId': 23220880, 'title': 'Activating HER2 mutations in HER2 gene amplification negative breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23220880'}]",sensitive,828,Neratinib,2064
459,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) D821N in culture (PMID: 18413839).",Actionable,7327,10000003,Advanced Solid Tumor,JAX,24591,ERBB2 D821N,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",sensitive,967,XL647,2064
460,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E812K in culture (PMID: 18413839).",Actionable,7326,10000003,Advanced Solid Tumor,JAX,24592,ERBB2 E812K,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",sensitive,967,XL647,2064
461,Preclinical,"In a preclinical study, transformed cells over expressing ERBB2 (HER2) E812K demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).",Actionable,7315,10000003,Advanced Solid Tumor,JAX,24592,ERBB2 E812K,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",decreased response,787,Lapatinib,2064
462,Preclinical,"In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing ERBB2(HER2) N857S in culture (PMID: 22046346).",Actionable,3042,10000003,Advanced Solid Tumor,JAX,11334,ERBB2 N857S,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",sensitive,622,AEE788,2064
463,Preclinical,"In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) N857S in culture (PMID: 22046346).",Actionable,3037,10000003,Advanced Solid Tumor,JAX,11334,ERBB2 N857S,"[{'id': 621, 'pubMedId': 22046346, 'title': 'Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22046346'}]",decreased response,787,Lapatinib,2064
464,Preclinical,"In a preclinical study, transformed cells over expressing ERBB2 (HER2) E717K demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).",Actionable,7310,10000003,Advanced Solid Tumor,JAX,24119,ERBB2 E717K,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",decreased response,787,Lapatinib,2064
465,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E717K in culture (PMID: 18413839).",Actionable,7316,10000003,Advanced Solid Tumor,JAX,24119,ERBB2 E717K,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",sensitive,967,XL647,2064
466,Clinical Study,"In a clinical study, the PIK3CA R425L mutation was identified as a potential resistance mechanism in a non-small cell lung carcinoma patient harboring ERBB2 (HER2) A775_G776insYVMA, that progressed during Herceptin (trastuzumab) treatment (PMID: 28167203). ",Actionable,10134,3908,non-small cell lung carcinoma,DOID,27298,ERBB2 A775_G776insYVMA PIK3CA R425L,"[{'id': 8141, 'pubMedId': 28167203, 'title': 'ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28167203'}]",predicted – resistant,947,Trastuzumab,2064
467,Preclinical,"In a preclinical study, transformed cells over expressing ERBB2 (HER2) L785F demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).",Actionable,7313,10000003,Advanced Solid Tumor,JAX,24607,ERBB2 L785F,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",decreased response,787,Lapatinib,2064
468,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L785F in culture (PMID: 18413839).",Actionable,7323,10000003,Advanced Solid Tumor,JAX,24607,ERBB2 L785F,"[{'id': 5983, 'pubMedId': 18413839, 'title': 'EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18413839'}]",sensitive,967,XL647,2064
0,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival and induced apoptosis in melanoma cells harboring ERBB4 E563K in culture (PMID: 19718025).",Actionable,7258,1909,melanoma,DOID,24621,ERBB4 E563K,"[{'id': 566, 'pubMedId': 19718025, 'title': 'Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19718025'}]",sensitive,787,Lapatinib,2066
1,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival and induced apoptosis in melanoma cells harboring ERBB4 E317K in culture (PMID: 19718025).",Actionable,7254,1909,melanoma,DOID,24619,ERBB4 E317K,"[{'id': 566, 'pubMedId': 19718025, 'title': 'Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19718025'}]",sensitive,787,Lapatinib,2066
2,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C demonstrated resistance to treatment with Erbitux (cetuximab) in a cell viability assay (PMID: 27207775). ",Actionable,7886,5520,head and neck squamous cell carcinoma,DOID,26082,ERBB4 G1109C,"[{'id': 6519, 'pubMedId': 27207775, 'title': 'Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27207775'}]",resistant,694,Cetuximab,2066
3,Preclinical - Cell line xenograft,"In a preclinical study, Gilotrif (afatinib) treatment resulted in apoptotic induction in head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C in culture and inhibited tumor growth in cell line xenograft models (PMID: 27207775). ",Actionable,7888,5520,head and neck squamous cell carcinoma,DOID,26082,ERBB4 G1109C,"[{'id': 6519, 'pubMedId': 27207775, 'title': 'Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27207775'}]",sensitive,623,Afatinib,2066
4,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C demonstrated resistance to treatment with Tarceva (erlotinib) in a cell viability assay (PMID: 27207775). ",Actionable,7885,5520,head and neck squamous cell carcinoma,DOID,26082,ERBB4 G1109C,"[{'id': 6519, 'pubMedId': 27207775, 'title': 'Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27207775'}]",resistant,4,Erlotinib,2066
5,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival and induced apoptosis in melanoma cells harboring ERBB4 E452K in culture (PMID: 19718025).",Actionable,7256,1909,melanoma,DOID,24620,ERBB4 E452K,"[{'id': 566, 'pubMedId': 19718025, 'title': 'Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19718025'}]",sensitive,787,Lapatinib,2066
6,Preclinical,"In a preclinical study, Tykerb (lapatinib) induced apoptosis in melanoma cells harboring ERBB4 R544W in culture (PMID: 19718025).",Actionable,7257,1909,melanoma,DOID,24624,ERBB4 R544W,"[{'id': 566, 'pubMedId': 19718025, 'title': 'Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19718025'}]",sensitive,787,Lapatinib,2066
7,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival of melanoma cells harboring ERBB4 R393W in culture (PMID: 19718025). ",Actionable,7259,1909,melanoma,DOID,24809,ERBB4 R393W,"[{'id': 566, 'pubMedId': 19718025, 'title': 'Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19718025'}]",sensitive,787,Lapatinib,2066
0,Preclinical - Cell culture,"In a preclinical study, treatment with AZD4547 decreased Myc expression and inhibited growth of transformed cells expressing ETV6-FGFR1 (TEL-FGFR1) in culture (PMID: 27401245).",Actionable,10008,10000003,Advanced Solid Tumor,JAX,27222,ETV6-FGFR1,"[{'id': 7899, 'pubMedId': 27401245, 'title': 'c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27401245'}]",sensitive,654,AZD4547,2120
1,Preclinical - Cell culture,"In a preclinical study, treatment with AZD4547 decreased Myc expression and inhibited growth of transformed cells expressing ETV6-FGFR4 (TEL-FGFR4) in culture (PMID: 27401245).",Actionable,10010,10000003,Advanced Solid Tumor,JAX,27224,ETV6-FGFR4,"[{'id': 7899, 'pubMedId': 27401245, 'title': 'c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27401245'}]",sensitive,654,AZD4547,2120
2,Clinical Study,"In multiple clinical studies, the ETV6-RUNX1 fusion was associated with a favorable prognosis in acute lymphocytic leukemia patients (PMID: 8609706, PMID: 10086740, PMID: 11432885, Guidelines). ",Prognostic,6166,9952,acute lymphocytic leukemia,DOID,11683,ETV6-RUNX1,"[{'id': 5333, 'pubMedId': 8609706, 'title': 'TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/8609706'}, {'id': 5334, 'pubMedId': 10086740, 'title': 'TEL-AML1 fusion transcript designates a favorable outcome with an intensified protocol in childhood acute lymphoblastic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/10086740'}, {'id': 5335, 'pubMedId': 11432885, 'title': 'Relapse of TEL-AML1--positive acute lymphoblastic leukemia in childhood: a matched-pair analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11432885'}, {'id': 5390, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2016 Acute Lymphoblastic Leukemia', 'url': ''}]",not applicable,1776,N/A,2120
3,Clinical Study,"ETV6-RUNX1 is used in the diagnosis of acute lymphocytic leukemia (PMID: 26711002, PMID: 15704129, PMID: 8609706, Guidelines).",Diagnostic,6165,9952,acute lymphocytic leukemia,DOID,11683,ETV6-RUNX1,"[{'id': 5331, 'pubMedId': 26711002, 'title': 'Determination of ETV6-RUNX1 genomic breakpoint by next-generation sequencing.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26711002'}, {'id': 5332, 'pubMedId': 15704129, 'title': 'ETV6/RUNX1 fusion at diagnosis and relapse: some prognostic indications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15704129'}, {'id': 5333, 'pubMedId': 8609706, 'title': 'TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/8609706'}, {'id': 5390, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2016 Acute Lymphoblastic Leukemia', 'url': ''}]",not applicable,1776,N/A,2120
4,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ETV6-ALK demonstrated sensitivity  to Entrectinib (RXDX-101) in culture (PMID: 26939704).",Actionable,5634,10000003,Advanced Solid Tumor,JAX,21319,ETV6-ALK,"[{'id': 5130, 'pubMedId': 26939704, 'title': 'Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26939704'}]",sensitive,1455,Entrectinib,2120
5,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells expressing ETV6-ROS1 were sensitive to Entrectinib (RXDX-101), resulting in inhibition of cell proliferation in culture and decreased tumor growth in xenograft models (PMID: 26939704).",Actionable,5632,10000003,Advanced Solid Tumor,JAX,21307,ETV6-ROS1,"[{'id': 5130, 'pubMedId': 26939704, 'title': 'Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26939704'}]",sensitive,1455,Entrectinib,2120
6,Phase I,"In a Phase I clinical trial, treatment with Entrectinib (RXDX-101) resulted in a durable partial response in a patient with mammary analogue secretory carcinoma harboring ETV6-NTRK3 (PMID: 26884591).",Actionable,7378,8850,salivary gland cancer,DOID,2514,ETV6-NTRK3,"[{'id': 6326, 'pubMedId': 26884591, 'title': 'What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26884591'}]",sensitive,1455,Entrectinib,2120
7,Preclinical,"In a preclinical study, transformed cells expressing ETV6-NTRK3 demonstrated sensitivity to Altiratinib (DCC-2701) in culture, resulting in inhibition of Ntrk3 phosphorylation and decreased cell proliferation (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 790).",Actionable,7380,10000003,Advanced Solid Tumor,JAX,2514,ETV6-NTRK3,"[{'id': 6329, 'pubMedId': None, 'title': 'Abstract 790: Altiratinib is a potent inhibitor of TRK kinases and is efficacious in TRK-fusion driven cancer models', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/790.short'}]",sensitive,1656,Altiratinib,2120
8,Preclinical,"In a preclinical study, transformed cells expressing the fusion, ETV6-NTRK3, were treated with Lestaurtinib (CEP-701), which resulted in inhibition of ETV6-NTRK3 autophosphorylation and restoration of Tgf-b1 signaling (PMID: 16258068).",Actionable,3864,10000003,Advanced Solid Tumor,JAX,2514,ETV6-NTRK3,"[{'id': 4250, 'pubMedId': 16258068, 'title': 'The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-beta signaling by inactivating the TGF-beta type II receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16258068'}]",sensitive,793,Lestaurtinib,2120
9,Preclinical,"In a preclinical study, the broad spectrum kinase inhibitor midostaurin inhibited growth of cells dependent on the fusion protein ETV6–NTRK3, reducing ETV6–NTRK3 kinase activity and downstream signaling and inducing apoptosis (PMID: 23131561).",Actionable,1567,162,cancer,DOID,2514,ETV6-NTRK3,"[{'id': 1543, 'pubMedId': 23131561, 'title': 'ETV6-NTRK3 as a therapeutic target of small molecule inhibitor PKC412.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23131561'}]",sensitive,810,Midostaurin,2120
10,Preclinical,"In a preclinical study, BMS-754807 inhibited growth of a breast cancer xenograft models expressing ETV6-NTRK3 (PMID: 21148487).",Actionable,2500,1612,breast cancer,DOID,2514,ETV6-NTRK3,"[{'id': 3183, 'pubMedId': 21148487, 'title': 'ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21148487'}]",sensitive,686,BMS-754807,2120
11,Guideline,"ETV6-NTRK3 fusions are used in the diagnosis of congenital fibrosarcoma (Guidelines, PMID: 24517889, PMID: 9462753).",Diagnostic,3988,8418,congenital fibrosarcoma,DOID,2514,ETV6-NTRK3,"[{'id': 4355, 'pubMedId': 26606880, 'title': 'Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26606880'}, {'id': 5205, 'pubMedId': None, 'title': 'NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma, Version 2.2016', 'url': 'http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#sarcoma'}, {'id': 5206, 'pubMedId': 9462753, 'title': 'A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/9462753'}, {'id': 5207, 'pubMedId': 24517889, 'title': 'ChildSeq-RNA: A next-generation sequencing-based diagnostic assay to identify known fusion transcripts in childhood sarcomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24517889'}]",not applicable,1776,N/A,2120
12,Clinical Study,"In a clinical case study, a patient with congenital fibrosarcoma harboring ETV6-NTRK3 demonstrated tumor regression by 90% when treated with LOXO-101 (PMID: 28578312). ",Actionable,11265,8418,congenital fibrosarcoma,DOID,2514,ETV6-NTRK3,"[{'id': 9187, 'pubMedId': 28578312, 'title': 'A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28578312'}]",sensitive,2650,LOXO-101,2120
13,Phase I,"In a Phase I clinical trial, treatment with LOXO-101 resulted in a partial response in a pediatric patient with infantile fibrosarcoma harboring ETV6-NTRK3 (PMID: 27093299).",Actionable,7379,8418,congenital fibrosarcoma,DOID,2514,ETV6-NTRK3,"[{'id': 6328, 'pubMedId': 27093299, 'title': 'Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27093299'}]",sensitive,2650,LOXO-101,2120
14,Preclinical,"In a preclinical study, LOXO-101 inhibited cell growth and downstream signaling in acute myeloid leukemia cells harboring ETV6-NTRK3 in culture and xenografts (PMID: 26216294).",Actionable,3246,9119,acute myeloid leukemia,DOID,2514,ETV6-NTRK3,"[{'id': 3689, 'pubMedId': 26216294, 'title': 'An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26216294'}]",sensitive,2650,LOXO-101,2120
15,Preclinical - Cell line xenograft,"In a preclinical study, Xalkori (crizotinib) inhibited ETV6-NTRK3 activity, reduced cell growth in a human acute myeloid leukemia cell line harboring ETV6-NTRK3, and had anti-tumor activity in xenograft models (PMID: 23811600).",Actionable,1421,9119,acute myeloid leukemia,DOID,2514,ETV6-NTRK3,"[{'id': 1250, 'pubMedId': 23811600, 'title': 'Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23811600'}]",sensitive,706,Crizotinib,2120
16,Preclinical,"In a preclinical study, transformed human cells expressing ETV6-NTRK3 were sensitive to BMS-536924, demonstrating a reduction in both cell survival and transformation activity in culture (PMID: 21804605).",Actionable,3975,10000003,Advanced Solid Tumor,JAX,2514,ETV6-NTRK3,"[{'id': 4256, 'pubMedId': 21804605, 'title': 'A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21804605'}]",sensitive,683,BMS-536924,2120
17,Preclinical,"In a preclinical study, transformed cells expressing ETV6-NTRK3 were sensitive to Entrectinib (RXDX-101), resulting in inhibition of cell proliferation (PMID: 26939704).",Actionable,5631,10000003,Advanced Solid Tumor,JAX,2514,ETV6-NTRK3,"[{'id': 5130, 'pubMedId': 26939704, 'title': 'Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26939704'}]",sensitive,1455,Entrectinib,2120
18,Preclinical - Cell culture,"In a preclinical study, HMPL-523 decreased viability of cells expressing ETV6-SYK in culture (Blood Dec 2016, 128 (22) 3970).",Actionable,9879,10000003,Advanced Solid Tumor,JAX,22332,ETV6-SYK,"[{'id': 7733, 'pubMedId': None, 'title': 'HMPL-523, a Novel SYK Inhibitor Showed Anti-Tumor Activities In Vitro and In Vivo', 'url': 'http://www.bloodjournal.org/content/128/22/3970?sso-checked=true'}]",sensitive,5279,HMPL-523,2120
19,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the R1127K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5581,2531,hematologic cancer,DOID,21294,ETV6 - JAK2 JAK2 R1127K,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,2120
20,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the N909K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,2449,2531,hematologic cancer,DOID,7560,ETV6-JAK2 JAK2 N909K,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,2120
21,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the R975G mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,2447,2531,hematologic cancer,DOID,7562,ETV6-JAK2 JAK2 R975G,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,2120
22,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the G935R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5577,2531,hematologic cancer,DOID,21291,ETV6 - JAK2 JAK2 G935R,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,2120
23,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the P1057S mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5580,2531,hematologic cancer,DOID,21293,ETV6 - JAK2 JAK2 P1057S,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,2120
24,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the M929I mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5579,2531,hematologic cancer,DOID,21292,ETV6 - JAK2 JAK2 M929I,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,2120
25,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the G831R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5576,2531,hematologic cancer,DOID,21289,ETV6 - JAK2 JAK2 G831R,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,2120
26,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the Y918H mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5582,2531,hematologic cancer,DOID,21295,ETV6 - JAK2 JAK2 Y918H,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,2120
27,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the V881A mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,2448,2531,hematologic cancer,DOID,7564,ETV6-JAK2 JAK2 V881A,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,2120
28,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the E864K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5575,2531,hematologic cancer,DOID,21290,ETV6 - JAK2 JAK2 E864K,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,2120
29,Clinical Study,"In multiple clinical studies, ETV6 inactivating germline mutations were shown to be a risk factor for the development of acute lymphocytic leukemia (PMID: 26522332, PMID: 26102509, PMID: 25807284). ",Risk Factor,8529,9952,acute lymphocytic leukemia,DOID,22787,ETV6 inact mut,"[{'id': 3579, 'pubMedId': 25807284, 'title': 'Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25807284'}, {'id': 6676, 'pubMedId': 26522332, 'title': 'Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26522332'}, {'id': 6677, 'pubMedId': 26102509, 'title': 'Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26102509'}]",not applicable,1776,N/A,2120
30,Preclinical,"In a preclinical study, transformed cells expressing ETV6-NTRK2 were sensitive to Entrectinib (RXDX-101), resulting in inhibition of cell proliferation (PMID: 26939704).",Actionable,5630,10000003,Advanced Solid Tumor,JAX,21305,ETV6-NTRK2,"[{'id': 5130, 'pubMedId': 26939704, 'title': 'Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26939704'}]",sensitive,1455,Entrectinib,2120
31,Clinical Study,"In multiple clinical studies, ETV6 mutations were associated with a shorter overall survival in patients with myelodysplastic syndrome (Guidelines, PMID: 21714648, PMID: 21877899, PMID: 26769228). ",Actionable,6163,50908,myelodysplastic syndrome,DOID,22742,ETV6 mutant,"[{'id': 5254, 'pubMedId': 21714648, 'title': 'Clinical effect of point mutations in myelodysplastic syndromes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21714648'}, {'id': 5326, 'pubMedId': 21877899, 'title': 'Update on cytogenetic and molecular changes in myelodysplastic syndromes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21877899'}, {'id': 5327, 'pubMedId': 26769228, 'title': 'Myelodysplastic syndromes: Contemporary review and how we treat.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26769228'}, {'id': 5393, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2016 Myelodysplastic Syndromes (MDS)', 'url': ''}]",not applicable,1776,N/A,2120
32,Clinical Study,"In a clinical case report, a patient with ETV6-PDGFRA positive chronic eosinophilic leukemia experienced complete cytogenic remission after treatment with Gleevec (imatinib) (PMID: 17555450).",Actionable,4652,1036,chronic leukemia,DOID,18676,ETV6-PDGFRA,"[{'id': 4649, 'pubMedId': 17555450, 'title': 'Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17555450'}]",sensitive,770,Imatinib,2120
33,Preclinical - Cell culture,"In a preclinical study, treatment with AZD4547 decreased Myc expression and inhibited growth of transformed cells expressing ETV6-FGFR3 (TEL-FGFR3) in culture (PMID: 27401245).",Actionable,10009,10000003,Advanced Solid Tumor,JAX,18674,ETV6-FGFR3,"[{'id': 7899, 'pubMedId': 27401245, 'title': 'c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27401245'}]",sensitive,654,AZD4547,2120
0,Preclinical - Cell culture,"In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y646S demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture (PMID: 28135235).",Actionable,11146,50745,diffuse large B-cell lymphoma,DOID,1176,EZH2 Y646S,"[{'id': 9115, 'pubMedId': 28135235, 'title': 'An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28135235'}]",sensitive,5886,EED226,2146
1,Preclinical,"In a preclinical study, EPZ005687 promoted apoptosis in non-Hodgkin lymphoma cell lines expressing EZH2 Y641C (PMID: 23023262).",Actionable,2178,60060,non-Hodgkin lymphoma,DOID,675,EZH2 Y641C,"[{'id': 2699, 'pubMedId': 23023262, 'title': 'A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23023262'}]",sensitive,2663,EPZ005687,2146
2,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing EZH2 carrying simultaneous A677G and Y111D mutations demonstrated reduced sensitivity to GSK126 in culture (PMID: 26360609).",Actionable,7819,10000003,Advanced Solid Tumor,JAX,26054,EZH2 Y111D EZH2 Y641F,"[{'id': 6504, 'pubMedId': 26360609, 'title': 'Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26360609'}]",decreased response,2925,GSK126,2146
3,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing EZH2 carrying simultaneous Y641F and Y111D mutations demonstrated reduced sensitivity to Tazemetostat (EPZ-6438) in culture (PMID: 26360609).",Actionable,7820,10000003,Advanced Solid Tumor,JAX,26054,EZH2 Y111D EZH2 Y641F,"[{'id': 6504, 'pubMedId': 26360609, 'title': 'Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26360609'}]",decreased response,2683,Tazemetostat,2146
4,Preclinical - Cell culture,"In a preclinical study, over expression of EZH2 Y111D in transformed cells harboring wild-type Ezh2 resulted in resistance to GSK126 treatment in culture (PMID: 26360609).",Actionable,7824,10000003,Advanced Solid Tumor,JAX,26049,EZH2 Y111D,"[{'id': 6504, 'pubMedId': 26360609, 'title': 'Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26360609'}]",resistant,2925,GSK126,2146
5,Preclinical - Cell culture,"In a preclinical study, over expression of EZH2 Y111D in transformed cells harboring wild-type Ezh2 resulted in resistance to Tazemetostat (EPZ-6438) treatment in culture (PMID: 26360609).",Actionable,7825,10000003,Advanced Solid Tumor,JAX,26049,EZH2 Y111D,"[{'id': 6504, 'pubMedId': 26360609, 'title': 'Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26360609'}]",resistant,2683,Tazemetostat,2146
6,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing EZH2 carrying simultaneous A677G and Y111D mutations were resistant to GSK126 in culture (PMID: 26360609).",Actionable,7818,10000003,Advanced Solid Tumor,JAX,26052,EZH2 A677G EZH2 Y111D,"[{'id': 6504, 'pubMedId': 26360609, 'title': 'Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26360609'}]",resistant,2925,GSK126,2146
7,Preclinical - Cell culture,"In a preclinical study, EZH2 Y111D conferred resistance to Tazemetostat (EPZ-6438) when occurred in the same allele as EZH2 A677G in B-cell lymphoma cells in culture (PMID: 26360609).",Actionable,7815,707,B-cell lymphoma,DOID,26052,EZH2 A677G EZH2 Y111D,"[{'id': 6504, 'pubMedId': 26360609, 'title': 'Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26360609'}]",resistant,2683,Tazemetostat,2146
8,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing EZH2 carrying simultaneous A677G and Y111D mutations were resistant to Tazemetostat (EPZ-6438) in culture (PMID: 26360609).",Actionable,7816,10000003,Advanced Solid Tumor,JAX,26052,EZH2 A677G EZH2 Y111D,"[{'id': 6504, 'pubMedId': 26360609, 'title': 'Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26360609'}]",resistant,2683,Tazemetostat,2146
9,Preclinical - Cell culture,"In a preclinical study, EZH2 Y111D conferred resistance to GSK126 when occurred in the same allele as EZH2 A677G in B-cell lymphoma cells in culture (PMID: 26360609).",Actionable,7817,707,B-cell lymphoma,DOID,26052,EZH2 A677G EZH2 Y111D,"[{'id': 6504, 'pubMedId': 26360609, 'title': 'Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26360609'}]",resistant,2925,GSK126,2146
10,Preclinical - Cell culture,"In a preclinical study, over expression of EZH2 Y111D in rhabdoid tumor cells harboring an SMARCB1 inactivating mutation resulted in resistance to Tazemetostat (EPZ-6438) treatment in culture (PMID: 26360609).",Actionable,7826,3672,rhabdoid cancer,DOID,26057,EZH2 Y111D SMARCB1 inact mut,"[{'id': 6504, 'pubMedId': 26360609, 'title': 'Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26360609'}]",resistant,2683,Tazemetostat,2146
11,Preclinical - Cell culture,"In a preclinical study, a murine acute myeloid leukemia cell line expressing EZH2 T678_R679delinsKK were resistant to Tazemetostat (EPZ-6438) in culture (PMID: 28231254).",Actionable,11713,9119,acute myeloid leukemia,DOID,28195,EZH2 T678_R679delinsKK,"[{'id': 9725, 'pubMedId': 28231254, 'title': 'Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28231254'}]",resistant,2683,Tazemetostat,2146
12,Preclinical - Cell culture,"In a preclinical study, diffuse large B-cell lymphoma cells co-expressing EZH2 F120L and EZH2 Y111N were resistant to EI1 in culture, demonstrating no inhibition of cell proliferation (PMID: 28135235). ",Actionable,11147,50745,diffuse large B-cell lymphoma,DOID,27920,EZH2 F120L EZH2 Y111N,"[{'id': 9115, 'pubMedId': 28135235, 'title': 'An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28135235'}]",resistant,2927,EI1,2146
13,Preclinical - Cell culture,"In a preclinical study, diffuse large B-cell lymphoma cells co-expressing EZH2 F120L and EZH2 Y111N were sensitive to EED226, demonstrating inhibition of cell proliferation in culture (PMID: 28135235). ",Actionable,11149,50745,diffuse large B-cell lymphoma,DOID,27920,EZH2 F120L EZH2 Y111N,"[{'id': 9115, 'pubMedId': 28135235, 'title': 'An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28135235'}]",sensitive,5886,EED226,2146
14,Preclinical - Cell culture,"In a preclinical study, a cancer cell line co-expressing EZH2 F120L and EZH2 Y111N was resistant to Tazemetostat (EPZ-6438) in culture, demonstrating no inhibition of cell proliferation (PMID: 28135235). ",Actionable,11148,10000003,Advanced Solid Tumor,JAX,27920,EZH2 F120L EZH2 Y111N,"[{'id': 9115, 'pubMedId': 28135235, 'title': 'An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28135235'}]",resistant,2683,Tazemetostat,2146
15,Preclinical,"In a preclinical study, GSK126 inhibited H3K27 trimethylation in human melanoma cells harboring wild-type EZH2 in culture (PMID: 26936398).",Actionable,5616,1909,melanoma,DOID,535,EZH2 wild-type,"[{'id': 5127, 'pubMedId': 26936398, 'title': 'Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26936398'}]",predicted – sensitive,2925,GSK126,2146
16,Preclinical,"In a preclinical study, GSK126 inhibited H3K27 trimethylation and reversed transcriptional silencing in human melanoma cells harboring EZH2 Y641H in culture (PMID: 26936398).",Actionable,5613,1909,melanoma,DOID,674,EZH2 Y641H,"[{'id': 5127, 'pubMedId': 26936398, 'title': 'Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26936398'}]",predicted – sensitive,2925,GSK126,2146
17,Preclinical,"In a preclinical study, JQEZ5 inhibited proliferation of human EZH2 over expressing non-small cell lung cancer cells in culture and induced tumor regression in mouse models of EZH2-over expressing lung adenocarcinoma (PMID: 27312177).",Actionable,7042,3908,non-small cell lung carcinoma,DOID,24368,EZH2 over exp,"[{'id': 6049, 'pubMedId': 27312177, 'title': 'Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312177'}]",sensitive,4354,JQEZ5,2146
18,Preclinical,"In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated sensitivity to ACY-957 in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023). ",Actionable,6552,50745,diffuse large B-cell lymphoma,DOID,673,EZH2 Y641S,"[{'id': 5689, 'pubMedId': 25605023, 'title': 'HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605023'}]",sensitive,4144,ACY-957,2146
19,Preclinical,"In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated a decreased response to GSK126 in culture (PMID: 25605023). ",Actionable,6562,50745,diffuse large B-cell lymphoma,DOID,673,EZH2 Y641S,"[{'id': 5689, 'pubMedId': 25605023, 'title': 'HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605023'}]",decreased response,2925,GSK126,2146
20,Preclinical,"In a preclinical study, DZNeP enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641S in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023). ",Actionable,6561,50745,diffuse large B-cell lymphoma,DOID,673,EZH2 Y641S,"[{'id': 5689, 'pubMedId': 25605023, 'title': 'HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605023'}]",sensitive,4147,ACY-957 + DZNeP,2146
21,Preclinical,"In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023). ",Actionable,6557,50745,diffuse large B-cell lymphoma,DOID,673,EZH2 Y641S,"[{'id': 5689, 'pubMedId': 25605023, 'title': 'HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605023'}]",sensitive,1077,Vorinostat,2146
22,Preclinical,"In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated a decreased response to DZNeP in culture (PMID: 25605023). ",Actionable,6564,50745,diffuse large B-cell lymphoma,DOID,673,EZH2 Y641S,"[{'id': 5689, 'pubMedId': 25605023, 'title': 'HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605023'}]",decreased response,2702,DZNeP,2146
23,Preclinical,"In a preclinical study, GSK126 enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641S in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023). ",Actionable,6559,50745,diffuse large B-cell lymphoma,DOID,673,EZH2 Y641S,"[{'id': 5689, 'pubMedId': 25605023, 'title': 'HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605023'}]",sensitive,4148,ACY-957 + GSK126,2146
24,Preclinical,"In a preclinical study, GSK126 reversed transcriptional silencing in human melanoma cells harboring wild-type EZH2 Y641S in culture (PMID: 26936398).",Actionable,5617,1909,melanoma,DOID,673,EZH2 Y641S,"[{'id': 5127, 'pubMedId': 26936398, 'title': 'Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26936398'}]",predicted – sensitive,2925,GSK126,2146
25,Preclinical,"In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023). ",Actionable,6554,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,"[{'id': 5689, 'pubMedId': 25605023, 'title': 'HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605023'}]",sensitive,1077,Vorinostat,2146
26,Preclinical - Cell culture,"In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y641N demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture and delayed tumor growth and tumor regression in a cell line xenograft model (PMID: 28135235).",Actionable,11145,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,"[{'id': 9115, 'pubMedId': 28135235, 'title': 'An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28135235'}]",sensitive,5886,EED226,2146
27,Preclinical,"In a preclinical study, GSK126 inhibited H3K27 trimethylation and reversed transcriptional silencing in human melanoma cells harboring EZH2 Y641N in culture (PMID: 26936398).",Actionable,5614,1909,melanoma,DOID,672,EZH2 Y641N,"[{'id': 5127, 'pubMedId': 26936398, 'title': 'Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26936398'}]",predicted – sensitive,2925,GSK126,2146
28,Preclinical,"In a preclinical study, DZNeP enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641N in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023). ",Actionable,6560,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,"[{'id': 5689, 'pubMedId': 25605023, 'title': 'HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605023'}]",sensitive,4147,ACY-957 + DZNeP,2146
29,Preclinical,"In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated a decreased response to GSK126 in culture (PMID: 25605023). ",Actionable,6563,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,"[{'id': 5689, 'pubMedId': 25605023, 'title': 'HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605023'}]",decreased response,2925,GSK126,2146
30,Preclinical,"In a preclinical study, DLBCL cells harboring EZH2 Y641N treated with the combination of ACY-957 and Adriamycin (doxorubicin) resulted in a greater sensitivity to cell death compared to treatment with either agent alone (PMID: 25605023). ",Actionable,6625,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,"[{'id': 5689, 'pubMedId': 25605023, 'title': 'HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605023'}]",sensitive,4187,ACY-957 + Doxorubicin,2146
31,Preclinical,"In a preclinical study, UNC1999 treatment reduced H3K27me3 levels, decreased proliferation, and increased cell death in diffuse large B-cell lymphoma cells harboring an EZH2 Y641N mutation in cell culture (PMID: 23614352).",Actionable,1426,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,"[{'id': 1266, 'pubMedId': 23614352, 'title': 'An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23614352'}]",sensitive,1757,UNC1999,2146
32,Preclinical,"In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated sensitivity to ACY-957 in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023). ",Actionable,6551,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,"[{'id': 5689, 'pubMedId': 25605023, 'title': 'HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605023'}]",sensitive,4144,ACY-957,2146
33,Preclinical,"In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated a decreased response to DZNeP in culture (PMID: 25605023). ",Actionable,6565,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,"[{'id': 5689, 'pubMedId': 25605023, 'title': 'HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605023'}]",decreased response,2702,DZNeP,2146
34,Preclinical,"In a preclinical study, GSK126 enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641N in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023). ",Actionable,6558,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,"[{'id': 5689, 'pubMedId': 25605023, 'title': 'HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605023'}]",sensitive,4148,ACY-957 + GSK126,2146
35,Preclinical - Cell culture,"In a preclinical study, the combination therapy of EED226 and EI1 synergistically inhibited cell proliferation of a diffuse large B-cell lymphoma harboring EZH2 Y641N (PMID: 28135235). ",Actionable,11151,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,"[{'id': 9115, 'pubMedId': 28135235, 'title': 'An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28135235'}]",sensitive,5887,EED226 + EI1,2146
36,Preclinical - Cell line xenograft,"In a preclinical study, a diffuse large B-cell lymphoma cell line harboring an EZH2 mutation demonstrated sensitivity to A-395, showing inhibition of tumor growth, however, due to its chemical properties A-395 will not proceed to clinical development (PMID: 28135237). ",Actionable,11161,50745,diffuse large B-cell lymphoma,DOID,27863,EZH2 mutant,"[{'id': 9122, 'pubMedId': 28135237, 'title': 'The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28135237'}]",sensitive,5889,A-395,2146
37,Preclinical,"In a preclinical study, GSK126 treatment inhibited cell growth via suppression of downstream tumor suppressor gene targets and induced apoptosis in melanoma cells harboring EZH2 Y646N in culture (PMID: 26304929). ",Actionable,4027,1909,melanoma,DOID,1175,EZH2 Y646N,"[{'id': 4379, 'pubMedId': 26304929, 'title': 'Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26304929'}]",sensitive,2925,GSK126,2146
38,Preclinical - Cell culture,"In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y646N demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture (PMID: 28135235).",Actionable,11144,50745,diffuse large B-cell lymphoma,DOID,1175,EZH2 Y646N,"[{'id': 9115, 'pubMedId': 28135235, 'title': 'An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28135235'}]",sensitive,5886,EED226,2146
39,Phase I,"In a Phase I trial, Tazemetostat (EPZ-6438) treatment resulted in partial response for more than 16 weeks in a non-Hodgkin lymphoma patient harboring a EZH2 Y646H mutation (ASH 57th Annual Meeting and Exposition, Dec 2015, Abstract # 473).",Actionable,6950,60060,non-Hodgkin lymphoma,DOID,1174,EZH2 Y646H,"[{'id': 5984, 'pubMedId': None, 'title': 'Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients', 'url': 'https://ash.confex.com/ash/2015/webprogram/Paper78128.html'}]",sensitive,2683,Tazemetostat,2146
40,Preclinical - Cell line xenograft,"In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C, in culture and in xenograft models, resulting in decreased cell survival and tumor growth (PMID: 26676756).",Actionable,8498,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4746,DZNep + Selumetinib,2146
41,Preclinical - Cell culture,"In a preclinical study, the addition of GSK343 did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8512,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4751,GSK343 + MK2206,2146
42,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8517,1793,pancreatic cancer,DOID,26341,KRAS G12C EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4746,DZNep + Selumetinib,2146
43,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8521,1793,pancreatic cancer,DOID,26341,KRAS G12C EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4747,DZNep + MK2206,2146
44,Preclinical - Cell culture,"In a preclinical study, the addition of Tazemetostat (EPZ-6438) increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8503,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4748,Selumetinib + Tazemetostat,2146
45,Preclinical - Cell culture,"In a preclinical study, the addition of GSK343 increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8502,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4750,GSK343 + Selumetinib,2146
46,Preclinical - Cell culture,"In a preclinical study, the addition of Tazemetostat (EPZ-6438) did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8513,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4749,MK2206 + Tazemetostat,2146
47,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C (PMID: 26676756).",Actionable,8510,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4747,DZNep + MK2206,2146
48,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8516,1793,pancreatic cancer,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4746,DZNep + Selumetinib,2146
49,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8520,1793,pancreatic cancer,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4747,DZNep + MK2206,2146
50,Preclinical - Cell culture,"In a preclinical study, the addition of GSK343 did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).",Actionable,8504,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4750,GSK343 + Selumetinib,2146
51,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8519,219,colon cancer,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4747,DZNep + MK2206,2146
52,Preclinical - Cell culture,"In a preclinical study, the addition of Tazemetostat (EPZ-6438) did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).",Actionable,8505,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4748,Selumetinib + Tazemetostat,2146
53,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).",Actionable,8500,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4746,DZNep + Selumetinib,2146
54,Preclinical - Cell culture,"In a preclinical study, the addition of GSK343 increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8507,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4751,GSK343 + MK2206,2146
55,Preclinical - Cell culture,"In a preclinical study, the addition of Tazemetostat (EPZ-6438) increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8508,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4749,MK2206 + Tazemetostat,2146
56,Preclinical - Cell line xenograft,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture and in xenograft models, resulting in decreased cell survival and tumor growth (PMID: 26676756).",Actionable,8506,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4747,DZNep + MK2206,2146
57,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8518,219,colon cancer,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4746,DZNep + Selumetinib,2146
58,Phase I,"In a Phase I trial, Tazemetostat (EPZ-6438) treatment resulted in a total response rate of 80% (4/5, 3 complete and partial response, 1 stable disease) in follicular lymphoma patients harboring wild-type EZH2 or a EZH2 Y646H mutation (ASH 57th Annual Meeting and Exposition, Dec 2015, Abstract # 473).",Actionable,6952,50873,follicular lymphoma,DOID,24158,EZH2 positive,"[{'id': 5984, 'pubMedId': None, 'title': 'Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients', 'url': 'https://ash.confex.com/ash/2015/webprogram/Paper78128.html'}]",sensitive,2683,Tazemetostat,2146
59,Phase I,"In a Phase I trial, Tazemetostat (EPZ-6438) treatment resulted in a total response rate (complete response and partial response) of 60% (9/15) in non-Hodgkin lymphoma patients harboring wild-type EZH2 or a EZH2 Y646H mutation (ASH 57th Annual Meeting and Exposition, Dec 2015, Abstract # 473).",Actionable,6949,60060,non-Hodgkin lymphoma,DOID,24158,EZH2 positive,"[{'id': 5984, 'pubMedId': None, 'title': 'Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients', 'url': 'https://ash.confex.com/ash/2015/webprogram/Paper78128.html'}]",sensitive,2683,Tazemetostat,2146
60,Phase I,"In a Phase I trial, Tazemetostat (EPZ-6438) treatment resulted in a total response rate (complete response and partial response) of 56% (5/9) in diffuse large B-cell lymphoma patients harboring wild-type EZH2 or a EZH2 Y646H mutation (ASH 57th Annual Meeting and Exposition, Dec 2015, Abstract # 473).",Actionable,6951,50745,diffuse large B-cell lymphoma,DOID,24158,EZH2 positive,"[{'id': 5984, 'pubMedId': None, 'title': 'Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients', 'url': 'https://ash.confex.com/ash/2015/webprogram/Paper78128.html'}]",sensitive,2683,Tazemetostat,2146
61,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12V (PMID: 26676756).",Actionable,8501,3910,lung adenocarcinoma,DOID,26342,KRAS G12V EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4746,DZNep + Selumetinib,2146
62,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12V (PMID: 26676756).",Actionable,8509,3910,lung adenocarcinoma,DOID,26342,KRAS G12V EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4747,DZNep + MK2206,2146
63,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12S in culture (PMID: 26676756).",Actionable,8499,3910,lung adenocarcinoma,DOID,26343,KRAS G12S EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4746,DZNep + Selumetinib,2146
64,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12S in culture (PMID: 26676756)",Actionable,8511,3910,lung adenocarcinoma,DOID,26343,KRAS G12S EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4747,DZNep + MK2206,2146
65,Preclinical,"In a preclinical study, treatment with EPZ-6438 inhibited proliferation and promoted cell death in lymphoma cells expressing EZH2 Y646F (PMID: 24563539). ",Actionable,2187,60058,lymphoma,DOID,1173,EZH2 Y646F,"[{'id': 2725, 'pubMedId': 24563539, 'title': 'Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24563539'}]",sensitive,2683,Tazemetostat,2146
66,Preclinical - Cell culture,"In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y646F demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture (PMID: 28135235). ",Actionable,11143,50745,diffuse large B-cell lymphoma,DOID,1173,EZH2 Y646F,"[{'id': 9115, 'pubMedId': 28135235, 'title': 'An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28135235'}]",sensitive,5886,EED226,2146
0,Preclinical,"In a preclinical study, homozygous deletion of FBXW7 is conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).",Actionable,719,5602,T-cell adult acute lymphocytic leukemia,DOID,1039,FBXW7 del,"[{'id': 379, 'pubMedId': 17646409, 'title': 'FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17646409'}]",resistant,1084,MRK-003,55294
1,Preclinical,"In a preclinical study, FBXW7 R465C conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).",Actionable,722,5602,T-cell adult acute lymphocytic leukemia,DOID,813,FBXW7 R465C,"[{'id': 379, 'pubMedId': 17646409, 'title': 'FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17646409'}]",resistant,1084,MRK-003,55294
2,Clinical Study,"In a clinical case report, a patient with lung adenocarcinoma harboring FBXW7 R465H demonstrated tumor shrinkage when treated with Torisel (temsirolimus) (PMID: 24360397).",Actionable,2504,3910,lung adenocarcinoma,DOID,1038,FBXW7 R465H,"[{'id': 3191, 'pubMedId': 24360397, 'title': 'Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24360397'}]",sensitive,936,Temsirolimus,55294
3,Preclinical,"In a preclinical study, FBXW7 R465H conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).",Actionable,718,5602,T-cell adult acute lymphocytic leukemia,DOID,1038,FBXW7 R465H,"[{'id': 379, 'pubMedId': 17646409, 'title': 'FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17646409'}]",resistant,1084,MRK-003,55294
4,Preclinical,"In a preclinical study, FBXW7 R479Q conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).",Actionable,721,5602,T-cell adult acute lymphocytic leukemia,DOID,1041,FBXW7 R479Q,"[{'id': 379, 'pubMedId': 17646409, 'title': 'FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17646409'}]",resistant,1084,MRK-003,55294
5,Preclinical - Cell culture,"In a preclinical study, colorectal cell lines with FBXW7 R505C demonstrated acquired resistance in regorafenib (PMID: 27399335).",Actionable,11965,9256,colorectal cancer,DOID,1040,FBXW7 R505C,"[{'id': 9938, 'pubMedId': 27399335, 'title': 'FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27399335'}]",resistant,890,Regorafenib,55294
6,Preclinical,"In a preclinical study, FBXW7 R505C conferred resistance to gamma secretase inhibitor, MRK-300, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).",Actionable,720,5602,T-cell adult acute lymphocytic leukemia,DOID,1040,FBXW7 R505C,"[{'id': 379, 'pubMedId': 17646409, 'title': 'FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17646409'}]",resistant,1084,MRK-003,55294
7,Preclinical,"In a preclinical study, Zolinza (vorinostat) inhibited growth of a head and neck squamous cell carcinoma cell line harboring FBXW7 R505C in culture (PMID: 23274910). ",Actionable,3375,5520,head and neck squamous cell carcinoma,DOID,1040,FBXW7 R505C,"[{'id': 570, 'pubMedId': 23274910, 'title': 'Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23274910'}]",sensitive,1077,Vorinostat,55294
8,Preclinical,"In a preclinical study, Rapamune (sirolimus) inhibited epithelial-mesenchymal transition, motility, and invasiveness in colon cancer cells lacking FBXW7 in culture (PMID: 23558291)",Actionable,1304,219,colon cancer,DOID,2397,FBXW7 loss,"[{'id': 572, 'pubMedId': 23558291, 'title': 'Rapamycin inhibits FBXW7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558291'}]",sensitive,917,Sirolimus,55294
9,Preclinical - Cell line xenograft,"In a preclinical study, breast cancer cells harboring a FBXW7 mutation demonstrated sensitivity to Rapamune (sirolimus) in culture and in cell line xenograft models (PMID: 18787170).",Actionable,2073,1612,breast cancer,DOID,5029,FBXW7 inact mut,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}]",sensitive,917,Sirolimus,55294
10,Preclinical,"In a preclinical study, Beleodaq (belinostat) inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).",Actionable,3388,10000003,Advanced Solid Tumor,JAX,5029,FBXW7 inact mut,"[{'id': 570, 'pubMedId': 23274910, 'title': 'Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23274910'}]",sensitive,1078,Belinostat,55294
11,Preclinical,"In a preclinical study, AR-42 inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).",Actionable,3391,2531,hematologic cancer,DOID,5029,FBXW7 inact mut,"[{'id': 570, 'pubMedId': 23274910, 'title': 'Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23274910'}]",sensitive,987,AR-42,55294
12,Preclinical,"In a preclinical study, human cancer cell lines harboring FBXW7 inactivating mutations were resistant to docetaxel in culture (PMID: 23274910). 
",Actionable,3387,10000003,Advanced Solid Tumor,JAX,5029,FBXW7 inact mut,"[{'id': 570, 'pubMedId': 23274910, 'title': 'Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23274910'}]",resistant,720,Docetaxel,55294
13,Preclinical,"In a preclinical study, entinostat (MS-275) inhibited cancer cells from advanced solid tumors and hematological cells harboring FBXW7 inactivating mutations in culture (PMID: 23274910).",Actionable,3754,2531,hematologic cancer,DOID,5029,FBXW7 inact mut,"[{'id': 570, 'pubMedId': 23274910, 'title': 'Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23274910'}]",sensitive,1541,Entinostat,55294
14,Preclinical,"In a preclinical study, Beleodaq (belinostat) inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).",Actionable,3389,2531,hematologic cancer,DOID,5029,FBXW7 inact mut,"[{'id': 570, 'pubMedId': 23274910, 'title': 'Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23274910'}]",sensitive,1078,Belinostat,55294
15,Phase I,"In a Phase I study, Rapamune (sirolimus) resulted in prolonged stable disease in a patient with hepatocellular fibrolamellar carcinoma harboring a FBXW7 mutation (PMID: 24586741).",Actionable,2072,5015,fibrolamellar carcinoma,DOID,5029,FBXW7 inact mut,"[{'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",sensitive,917,Sirolimus,55294
16,Preclinical,"In a preclinical study, entinostat (MS-275) inhibited cancer cells from advanced solid tumors and hematological cells harboring FBXW7 inactivating mutations in culture (PMID: 23274910).",Actionable,3386,10000003,Advanced Solid Tumor,JAX,5029,FBXW7 inact mut,"[{'id': 570, 'pubMedId': 23274910, 'title': 'Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23274910'}]",sensitive,1541,Entinostat,55294
17,Preclinical,"In a preclinical study, AR-42 inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).",Actionable,3390,10000003,Advanced Solid Tumor,JAX,5029,FBXW7 inact mut,"[{'id': 570, 'pubMedId': 23274910, 'title': 'Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23274910'}]",sensitive,987,AR-42,55294
18,Preclinical,"In a preclinical study, FBXW7 R505L may conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).",Actionable,723,5602,T-cell adult acute lymphocytic leukemia,DOID,839,FBXW7 R505L,"[{'id': 379, 'pubMedId': 17646409, 'title': 'FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17646409'}]",resistant,1084,MRK-003,55294
0,Preclinical - Cell line xenograft,"In a preclinical study, a variety of cancer cell lines harboring mutations in FGFR1, FGFR2, and/or FGFR3 demonstrated sensitivity to INCB054828 in culture and in cell line xenograft models, resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 771).",Actionable,7177,10000003,Advanced Solid Tumor,JAX,1221,FGFR1 mutant,"[{'id': 6136, 'pubMedId': None, 'title': 'Abstract 771: Preclinical characterization of the selective FGFR inhibitor INCB054828', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/771.short'}]",sensitive,4173,INCB054828,2260
1,Preclinical - Cell culture,"In a preclinical study, an estrogen-receptor positive breast cancer cell line harboring an FGFR1 amplification demonstrated resistance to Alpelisib (BYL719) in culture (PMID: 27126994). ",Actionable,9707,60075,estrogen-receptor positive breast cancer,DOID,812,FGFR1 amp,"[{'id': 7484, 'pubMedId': 27126994, 'title': 'A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27126994'}]",resistant,691,BYL719,2260
2,Preclinical,"In a preclinical study, Ofev (nintedanib) inhibited the growth of ER-positive breast cancer cells harboring FGFR1 amplification in culture (PMID: 22238366).
",Actionable,3531,60075,estrogen-receptor positive breast cancer,DOID,812,FGFR1 amp,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,831,Nintedanib,2260
3,Preclinical - Cell line xenograft,"In a preclinical study, JNJ-42756493 (erdafitinib) inhibited FGFR downstream signaling and proliferation of several lung cancer cell lines with FGFR1 amplification in culture, and inhibited tumor growth in an FGFR1-amplified lung cancer cell line xenograft model (PMID: 28341788).",Actionable,11179,1324,lung cancer,DOID,812,FGFR1 amp,"[{'id': 9140, 'pubMedId': 28341788, 'title': 'Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28341788'}]",predicted – sensitive,1028,JNJ-42756493,2260
4,Preclinical - Cell line xenograft,"In a preclinical study, GSK3052230 (FP-1039) treatment inhibited growth of FGFR1 amplified lung small cell carcinoma cell lines in culture and in cell line xenograft models (PMID: 23536011).",Actionable,11477,5409,lung small cell carcinoma,DOID,812,FGFR1 amp,"[{'id': 9409, 'pubMedId': 23536011, 'title': 'Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23536011'}]",sensitive,2899,GSK3052230,2260
5,Preclinical - Cell line xenograft,"In a preclinical study, addition of GSK3052230 (FP-1039) to Platinol (cisplatin) and Vepesid (etoposide) resulted in improved tumor growth inhibition in cell line xenograft models of FGFR1 amplified lung small cell carcinoma (PMID: 23536011).",Actionable,11479,5409,lung small cell carcinoma,DOID,812,FGFR1 amp,"[{'id': 9409, 'pubMedId': 23536011, 'title': 'Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23536011'}]",sensitive,6002,Cisplatin + Etoposide + GSK3052230,2260
6,Preclinical,"In a preclinical study, AZD4547 inhibited proliferation of a small cell lung cancer cell line harboring FGFR1 amplification in culture (PMID: 23082000).",Actionable,6866,5409,lung small cell carcinoma,DOID,812,FGFR1 amp,"[{'id': 5821, 'pubMedId': 23082000, 'title': 'Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23082000'}]",sensitive,654,AZD4547,2260
7,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in estrogen receptor (ER)-positive breast cancer cells harboring FGFR1 amplification in culture (PMID: 22238366).
",Actionable,3529,60075,estrogen-receptor positive breast cancer,DOID,812,FGFR1 amp,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,721,Dovitinib,2260
8,Preclinical - Cell culture,"In a preclinical study, BGJ398 inhibited survival of FGFR1 amplified synovial sarcoma cells in culture (PMID: 27535980).",Actionable,8025,5485,synovial sarcoma,DOID,812,FGFR1 amp,"[{'id': 6537, 'pubMedId': 27535980, 'title': 'Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535980'}]",sensitive,674,BGJ398,2260
9,Preclinical,"In a preclinical study, Cediranib (AZD-2171) inhibited growth of estrogen receptor (ER)-positive breast cancer cells with FGFR1 amplification in culture (PMID: 22238366).
",Actionable,3530,60075,estrogen-receptor positive breast cancer,DOID,812,FGFR1 amp,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,1001,Cediranib,2260
10,Preclinical - Pdx,"In a preclinical study, PRN1371 treatment resulted in tumor growth inhibition in patient-derived xenograft models of FGFR1-amplified non-small cell lung cancer (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8409,3908,non-small cell lung carcinoma,DOID,812,FGFR1 amp,"[{'id': 6640, 'pubMedId': None, 'title': 'PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1249'}]",sensitive,3583,PRN1371,2260
11,Preclinical - Cell line xenograft,"In a preclinical study, GSK3052230 (FP-1039) treatment resulted in greater tumor growth inhibition (56% vs 22%) in cell line xenograft models of FGFR1 amplified lung cancer compared to FGFR1 non-amplified models (PMID: 23536011).",Actionable,11476,1324,lung cancer,DOID,812,FGFR1 amp,"[{'id': 9409, 'pubMedId': 23536011, 'title': 'Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23536011'}]",sensitive,2899,GSK3052230,2260
12,Preclinical - Cell culture,"In a preclinical study, PD173074 inhibited survival of FGFR1 amplified synovial sarcoma cells in culture (PMID: 27535980).",Actionable,8023,5485,synovial sarcoma,DOID,812,FGFR1 amp,"[{'id': 6537, 'pubMedId': 27535980, 'title': 'Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535980'}]",sensitive,2948,PD173074,2260
13,Preclinical - Cell culture,"In a preclinical study, FGFR1 amplified non-small cell lung carcinoma cells were not sensitive to RO5126766 in culture (PMID: 26438159).",Actionable,8469,3908,non-small cell lung carcinoma,DOID,812,FGFR1 amp,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,2011,RO5126766,2260
14,Preclinical - Cell culture,"In a preclinical study, a small cell lung cancer cell line harboring FGFR1 amplification demonstrated sensitivity to E7090, resulting in decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969). ",Actionable,9140,5409,lung small cell carcinoma,DOID,812,FGFR1 amp,"[{'id': 6928, 'pubMedId': 27535969, 'title': 'E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535969'}]",sensitive,4911,E7090,2260
15,Preclinical - Cell culture,"In a preclinical study, an estrogen-receptor positive breast cancer cell line harboring FGFR1 amplification (PMID: 7506125) demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability (PMID: 27535969). ",Actionable,9127,60075,estrogen-receptor positive breast cancer,DOID,812,FGFR1 amp,"[{'id': 6928, 'pubMedId': 27535969, 'title': 'E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535969'}, {'id': 6929, 'pubMedId': 7506125, 'title': 'MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/7506125'}]",sensitive,4911,E7090,2260
16,Preclinical,"In a preclinical study, AZD4547 inhibited proliferation of a large cell lung cancer cell line harboring FGFR1 amplification in culture and induced tumor regression in xenograft models (PMID: 23082000).",Actionable,6865,4556,lung large cell carcinoma,DOID,812,FGFR1 amp,"[{'id': 5821, 'pubMedId': 23082000, 'title': 'Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23082000'}]",sensitive,654,AZD4547,2260
17,Preclinical - Cell culture,"In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) induced apoptosis in a squamous cell lung cancer cell line with amplification of FGFR1 in culture (PMID: 28108151).",Actionable,11212,3907,lung squamous cell carcinoma,DOID,812,FGFR1 amp,"[{'id': 9154, 'pubMedId': 28108151, 'title': 'A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28108151'}]",sensitive,5898,AZD4547 + BKM120,2260
18,Preclinical - Cell culture,"In a preclinical study, FGFR1 amplified non-small cell lung carcinoma cells were not sensitive to RO4987655 in culture (PMID: 26438159).",Actionable,8451,3908,non-small cell lung carcinoma,DOID,812,FGFR1 amp,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,903,RO4987655,2260
19,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in ER-positive breast cancer cells harboring FGFR1 amplification in culture (PMID: 22238366).
",Actionable,3528,1612,breast cancer,DOID,812,FGFR1 amp,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,877,Ponatinib,2260
20,Preclinical - Cell culture,"In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to RO5126766 in culture (PMID: 26438159).",Actionable,8467,5409,lung small cell carcinoma,DOID,812,FGFR1 amp,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,2011,RO5126766,2260
21,Preclinical - Cell line xenograft,"In a preclinical study, a non-small cell lung cancer cell line, harboring FGFR1 amplification, treated with E7090 demonstrated decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969). ",Actionable,9130,3908,non-small cell lung carcinoma,DOID,812,FGFR1 amp,"[{'id': 6928, 'pubMedId': 27535969, 'title': 'E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535969'}]",sensitive,4911,E7090,2260
22,Preclinical,"In a preclinical study, Debio 1347 inhibited proliferation of non-small cell lung cancer cell lines harboring FGFR1 amplification in culture (PMID: 25169980).",Actionable,4067,3908,non-small cell lung carcinoma,DOID,812,FGFR1 amp,"[{'id': 4388, 'pubMedId': 25169980, 'title': 'The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25169980'}]",sensitive,1014,FF-284,2260
23,Preclinical - Cell line xenograft,"In a preclinical study, GSK3052230 (FP-1039) treatment inhibited growth of FGFR1 amplified non-small cell lung carcinoma cell lines in culture and in cell line xenograft models (PMID: 23536011).",Actionable,11478,3908,non-small cell lung carcinoma,DOID,812,FGFR1 amp,"[{'id': 9409, 'pubMedId': 23536011, 'title': 'Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23536011'}]",sensitive,2899,GSK3052230,2260
24,Preclinical - Cell culture,"In a preclinical study, NGI-1 inhibited FGFR1 phosphorylation and proliferation of a FGFR1-amplified cell line dependent on FGFR1 signaling in culture, however, did not inhibit proliferation of an FGFR1-amplified cell line not dependent on FGFR1 signaling (PMID: 27694802).",Actionable,9229,3908,non-small cell lung carcinoma,DOID,812,FGFR1 amp,"[{'id': 7042, 'pubMedId': 27694802, 'title': 'Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27694802'}]",predicted – sensitive,4957,NGI-1,2260
25,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited growth of squamous cell lung cancer cell lines harboring FGFR1 amplification (PMID: 22238366).",Actionable,648,3907,lung squamous cell carcinoma,DOID,812,FGFR1 amp,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,877,Ponatinib,2260
26,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited survival of FGFR1 amplified synovial sarcoma cells in culture (PMID: 27535980).",Actionable,8024,5485,synovial sarcoma,DOID,812,FGFR1 amp,"[{'id': 6537, 'pubMedId': 27535980, 'title': 'Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535980'}]",sensitive,654,AZD4547,2260
27,Phase I,"In a Phase I trial, patients with lung squamous cell carcinoma harboring an FGFR1 amplification demonstrated a disease control rate of 50% (18/36) when treated with BGJ398, resulting in 14 patients with stable disease and 4 patients with a partial response (PMID: 27870574). ",Actionable,9731,3907,lung squamous cell carcinoma,DOID,812,FGFR1 amp,"[{'id': 7516, 'pubMedId': 27870574, 'title': 'Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27870574'}]",sensitive,674,BGJ398,2260
28,Preclinical - Cell culture,"In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to RO4987655 in culture (PMID: 26438159).",Actionable,8449,5409,lung small cell carcinoma,DOID,812,FGFR1 amp,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,903,RO4987655,2260
29,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of lung cancer cells with FGFR1 amplification in culture (PMID: 22238366).",Actionable,3541,1324,lung cancer,DOID,812,FGFR1 amp,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",no benefit,996,Brivanib,2260
30,Phase II,"In a Phase II clinical trial, treatment with AZD4547 resulted in a response rate of 12.5% (1/8) in patients with FGFR1-amplified breast cancer, and did not meet the predetermined criteria for efficacy (PMID: 27179038).",Actionable,7571,1612,breast cancer,DOID,812,FGFR1 amp,"[{'id': 6434, 'pubMedId': 27179038, 'title': 'High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27179038'}]",no benefit,654,AZD4547,2260
31,Phase I,"In a Phase I trial, Dovitinib (TKI258) promoted 6-month stable disease in Erbb2 (Her2)-positive breast cancer patients with FGFR1 amplification (PMID: 23658459).",Actionable,1043,60079,Her2-receptor positive breast cancer,DOID,812,FGFR1 amp,"[{'id': 754, 'pubMedId': 23658459, 'title': 'Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23658459'}]",sensitive,721,Dovitinib,2260
32,Preclinical - Cell culture,"In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) worked synergistically to induce apoptosis and inhibit growth of a urothelial cell carcinoma cell line with FGFR1 amplification in culture, with increased efficacy over either agent alone (PMID: 28108151).",Actionable,11213,2671,transitional cell carcinoma,DOID,812,FGFR1 amp,"[{'id': 9154, 'pubMedId': 28108151, 'title': 'A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28108151'}]",sensitive,5898,AZD4547 + BKM120,2260
33,Preclinical,"In a preclinical study, AZD4547 inhibited proliferation of lung cancer cell lines harboring FGFR1 amplification in culture and induced tumor regression in xenograft models (PMID: 23082000).",Actionable,6791,1324,lung cancer,DOID,812,FGFR1 amp,"[{'id': 5821, 'pubMedId': 23082000, 'title': 'Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23082000'}]",sensitive,654,AZD4547,2260
34,Preclinical - Cell culture,"In a preclinical study, FGFR1 amplified lung squamous cell carcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,8482,3907,lung squamous cell carcinoma,DOID,812,FGFR1 amp,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,913,Selumetinib,2260
35,Phase II,"In a Phase II clinical trial, dovitinib treatment resulted in a objective response rate of 11.5% (3/26, all partial responses) and disease control rate of 50% (13/26), and a median progression-free survival of 2.9 months in lung squamous cell carcinoma patients with FGFR1 amplification, and FGFR1 amplification was not determined to be a predictive biomarker for sensitivity (PMID: 27315356).",Actionable,7244,3907,lung squamous cell carcinoma,DOID,812,FGFR1 amp,"[{'id': 6256, 'pubMedId': 27315356, 'title': 'Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27315356'}]",no benefit,721,Dovitinib,2260
36,Preclinical - Cell culture,"In a preclinical study, FGFR1 amplified lung squamous cell carcinoma cells were not sensitive to RO4987655 in culture (PMID: 26438159).",Actionable,8450,3907,lung squamous cell carcinoma,DOID,812,FGFR1 amp,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,903,RO4987655,2260
37,Preclinical - Cell culture,"In a preclinical study, an estrogen-receptor positive breast cancer cell line harboring FGFR1 amplification demonstrated sensitivity to treatment with Lucitanib (E-3810) in culture (PMID: 27126994). ",Actionable,9708,60075,estrogen-receptor positive breast cancer,DOID,812,FGFR1 amp,"[{'id': 7484, 'pubMedId': 27126994, 'title': 'A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27126994'}]",sensitive,1029,Lucitanib,2260
38,Phase I,"In a Phase I trial, 28% (9/32) of breast cancer patients harboring FGFR1 amplification demonstrated stable disease when treated with BGJ398 (PMID: 27870574). ",Actionable,9735,1612,breast cancer,DOID,812,FGFR1 amp,"[{'id': 7516, 'pubMedId': 27870574, 'title': 'Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27870574'}]",sensitive,674,BGJ398,2260
39,Preclinical - Cell culture,"In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,8481,5409,lung small cell carcinoma,DOID,812,FGFR1 amp,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,913,Selumetinib,2260
40,Phase I,"In a Phase Ib trial, AZD4547 demonstrated limited efficacy in patients with squamous cell lung cancer with FGFR1 amplification, resulting in an overall response rate of 8% (1/15) and a median overall survival of 4.9 months (PMID: 28615371; NCT00979134).",Actionable,12086,3907,lung squamous cell carcinoma,DOID,812,FGFR1 amp,"[{'id': 10024, 'pubMedId': 28615371, 'title': 'A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615371'}]",no benefit,654,AZD4547,2260
41,Preclinical - Pdx,"In a preclinical study, AZD4547 inhibited FGFR1 signaling and resulted in tumor regression in patient-derived xenograft models of non-small cell lung carcinoma harboring FGFR1 amplification, wild-type for EGFR, K-Ras and negative for EML4-ALK fusion (PMID: 23082000).",Actionable,6868,3908,non-small cell lung carcinoma,DOID,812,FGFR1 amp,"[{'id': 5821, 'pubMedId': 23082000, 'title': 'Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23082000'}]",sensitive,654,AZD4547,2260
42,Preclinical - Cell culture,"In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) induced apoptosis in a small cell lung cancer cell line with amplification of FGFR1 in culture (PMID: 28108151).",Actionable,11211,5409,lung small cell carcinoma,DOID,812,FGFR1 amp,"[{'id': 9154, 'pubMedId': 28108151, 'title': 'A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28108151'}]",sensitive,5898,AZD4547 + BKM120,2260
43,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of estrogen receptor (ER)-positive breast cancer cells with FGFR2 amplification in culture (PMID: 22238366).",Actionable,3532,60075,estrogen-receptor positive breast cancer,DOID,812,FGFR1 amp,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",no benefit,996,Brivanib,2260
44,Preclinical - Cell culture,"In a preclinical study, FGFR1 amplified lung squamous cell carcinoma cells were not sensitive to RO5126766 in culture (PMID: 26438159).",Actionable,8468,3907,lung squamous cell carcinoma,DOID,812,FGFR1 amp,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,2011,RO5126766,2260
45,Phase I,"In a Phase I trial, ARQ 087 treatment resulted stable disease for greater than 22 months in an adrenocortical carcinoma patient harboring FGFR1 amplification (J Clin Oncol 33, 2015 (suppl; abstr 2545)).",Actionable,3992,3948,adrenocortical carcinoma,DOID,812,FGFR1 amp,"[{'id': 4359, 'pubMedId': None, 'title': 'Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/149025-156'}]",sensitive,2900,ARQ 087,2260
46,Preclinical - Cell culture,"In a preclinical study, FGFR1 amplified non-small cell lung carcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,8483,3908,non-small cell lung carcinoma,DOID,812,FGFR1 amp,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,913,Selumetinib,2260
47,Preclinical,"In a preclinical study, Debio 1347 inhibited proliferation of small cell lung cancer cell lines harboring FGFR1 amplification in culture (PMID: 25169980).",Actionable,4069,5409,lung small cell carcinoma,DOID,812,FGFR1 amp,"[{'id': 4388, 'pubMedId': 25169980, 'title': 'The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25169980'}]",sensitive,1014,FF-284,2260
48,Preclinical - Cell culture,"In a preclinical study, a lung cancer cell line with co-amplification of FGFR1 and EGFR and harboring KRAS G13C demonstrated insensitivity to JNJ-42756493 (erdafitinib) in culture (PMID: 28341788).",Actionable,11185,1324,lung cancer,DOID,27923,EGFR amp FGFR1 amp KRAS G13C,"[{'id': 9140, 'pubMedId': 28341788, 'title': 'Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28341788'}]",resistant,1028,JNJ-42756493,2260
49,Preclinical - Cell culture,"In a preclinical study, lung cancer cell lines with co-amplification of FGFR1 and EGFR demonstrated insensitivity to JNJ-42756493 (erdafitinib) in culture (PMID: 28341788).",Actionable,11184,1324,lung cancer,DOID,27922,EGFR amp FGFR1 amp,"[{'id': 9140, 'pubMedId': 28341788, 'title': 'Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28341788'}]",resistant,1028,JNJ-42756493,2260
50,Preclinical - Cell culture,"In a preclinical study, a lung cancer cell line harboring FGFR1 amplification and KRAS G13C demonstrated insensitivity to JNJ-42756493 (erdafitinib) in culture (PMID: 28341788).",Actionable,11186,1324,lung cancer,DOID,27924,FGFR1 amp KRAS G12V,"[{'id': 9140, 'pubMedId': 28341788, 'title': 'Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28341788'}]",resistant,1028,JNJ-42756493,2260
51,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer cell line, harboring FGFR1 amplification and FGFR2 amplification, treated with E7090 demonstrated decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969). ",Actionable,9126,1612,breast cancer,DOID,26745,FGFR1 amp FGFR2 amp,"[{'id': 6928, 'pubMedId': 27535969, 'title': 'E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535969'}]",sensitive,4911,E7090,2260
52,Preclinical - Cell culture,"In a preclinical study, a lung cancer cell line with co-amplification of FGFR1 and KRAS demonstrated insensitivity to JNJ-42756493 (erdafitinib) in culture (PMID: 28341788).",Actionable,11187,1324,lung cancer,DOID,27925,FGFR1 amp KRAS amp,"[{'id': 9140, 'pubMedId': 28341788, 'title': 'Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28341788'}]",resistant,1028,JNJ-42756493,2260
53,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR1 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a synergistic effect (PMID: 26936917). ",Actionable,7833,5520,head and neck squamous cell carcinoma,DOID,26058,EGFR over exp FGFR1 amp,"[{'id': 6507, 'pubMedId': 26936917, 'title': 'FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26936917'}]",sensitive,4585,AZD4547 + Gefitinib,2260
54,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells with EGFR over expression and FGFR1 amplification demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917). ",Actionable,7830,5520,head and neck squamous cell carcinoma,DOID,26058,EGFR over exp FGFR1 amp,"[{'id': 6507, 'pubMedId': 26936917, 'title': 'FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26936917'}]",resistant,654,AZD4547,2260
55,Preclinical,"In a preclinical study, transformed cells expressing constitutively active FGFR1 demonstrated reduced sensitivity to Ofev (Nintedanib) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).",Actionable,3488,10000003,Advanced Solid Tumor,JAX,1218,FGFR1 act mut,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",decreased response,831,Nintedanib,2260
56,Preclinical,"In a preclinical study, FIIN-01 inhibited Fgfr1 activation-induced proliferation and transformation of human breast epithelial cell lines in culture (PMID: 20338520).",Actionable,4021,1612,breast cancer,DOID,1218,FGFR1 act mut,"[{'id': 2410, 'pubMedId': 20338520, 'title': 'A structure-guided approach to creating covalent FGFR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20338520'}]",sensitive,2507,FIIN-01,2260
57,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).",Actionable,3493,10000003,Advanced Solid Tumor,JAX,1218,FGFR1 act mut,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",no benefit,996,Brivanib,2260
58,Phase I,"In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR1 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).",Actionable,1248,10000003,Advanced Solid Tumor,JAX,1218,FGFR1 act mut,"[{'id': 3622, 'pubMedId': None, 'title': 'Preliminary clinical pharmacokinetics and pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor.', 'url': 'http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2540'}]",sensitive,1014,FF-284,2260
59,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).
",Actionable,3472,10000003,Advanced Solid Tumor,JAX,1218,FGFR1 act mut,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,721,Dovitinib,2260
60,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted in stable disease in 70% (16/23) and partial response in 22% (5/23) of patients with advanced solid tumors harboring FGFR 1-4 activating mutations (including amplifications, mutations and translocations), while no antitumor activity was observed in patients with unknown or no known changes in FGFR (PMID: 26324363).",Actionable,3998,10000003,Advanced Solid Tumor,JAX,1218,FGFR1 act mut,"[{'id': 4363, 'pubMedId': 26324363, 'title': 'Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26324363'}]",sensitive,1028,JNJ-42756493,2260
61,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).
",Actionable,3469,10000003,Advanced Solid Tumor,JAX,1218,FGFR1 act mut,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,877,Ponatinib,2260
62,Preclinical,"In a preclinical study, transformed cells expressing constitutively active FGFR1 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Cediranib (AZD-2171) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).
",Actionable,3476,10000003,Advanced Solid Tumor,JAX,1218,FGFR1 act mut,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",decreased response,1001,Cediranib,2260
63,Preclinical - Cell culture,"In a preclinical study, PHA-665752 treatment did not result in decreased colony formation or reduced phosphorylation levels of FGFR1 and FGFR2 in hepatocellular carcinoma cells in culture (PMID: 26351320).",Actionable,9053,684,hepatocellular carcinoma,DOID,26701,FGFR1 pos FGFR2 pos,"[{'id': 6889, 'pubMedId': 26351320, 'title': 'Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26351320'}]",no benefit,2162,PHA-665752,2260
64,Preclinical - Cell culture,"In a preclinical study, hepatocellular carcinoma cell lines treated with AZD4547 demonstrated decreased phosphorylation of FGFR1 and FGFR2, reduced colony formation, and evidence of apoptotic activity in culture (PMID: 26351320). ",Actionable,9051,684,hepatocellular carcinoma,DOID,26701,FGFR1 pos FGFR2 pos,"[{'id': 6889, 'pubMedId': 26351320, 'title': 'Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26351320'}]",sensitive,654,AZD4547,2260
65,Preclinical - Cell culture,"In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980).",Actionable,8031,5485,synovial sarcoma,DOID,26138,FGFR1 positive,"[{'id': 6537, 'pubMedId': 27535980, 'title': 'Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535980'}]",decreased response,2948,PD173074,2260
66,Preclinical - Cell culture,"In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980).",Actionable,8032,1967,leiomyosarcoma,DOID,26138,FGFR1 positive,"[{'id': 6537, 'pubMedId': 27535980, 'title': 'Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535980'}]",decreased response,654,AZD4547,2260
67,Preclinical - Cell culture,"In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to BGJ398 in culture (PMID: 27535980).",Actionable,8037,5485,synovial sarcoma,DOID,26138,FGFR1 positive,"[{'id': 6537, 'pubMedId': 27535980, 'title': 'Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535980'}]",decreased response,674,BGJ398,2260
68,Phase I,"In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease with resolution of edema in a patient with FGFR1-positive hemangioendothelioma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).",Actionable,12005,255,hemangioma,DOID,26138,FGFR1 positive,"[{'id': 9963, 'pubMedId': None, 'title': 'A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study', 'url': 'http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts'}]",predicted – sensitive,2030,Rogaratinib,2260
69,Preclinical - Cell culture,"In a preclinical study, AZD4547 and Rapamune (sirolimus) synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture (PMID: 26359452).",Actionable,9349,3910,lung adenocarcinoma,DOID,26138,FGFR1 positive,"[{'id': 7121, 'pubMedId': 26359452, 'title': 'Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26359452'}]",sensitive,4985,AZD4547 + Sirolimus,2260
70,Preclinical - Cell culture,"In a preclinical study, AZD4547 and AZD8055 synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture (PMID: 26359452).",Actionable,9345,4556,lung large cell carcinoma,DOID,26138,FGFR1 positive,"[{'id': 7121, 'pubMedId': 26359452, 'title': 'Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26359452'}]",sensitive,4983,AZD4547 + AZD8055,2260
71,Preclinical - Cell culture,"In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent head and neck squamous cell carcinoma cells in culture (PMID: 26359452).",Actionable,9348,5520,head and neck squamous cell carcinoma,DOID,26138,FGFR1 positive,"[{'id': 7121, 'pubMedId': 26359452, 'title': 'Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26359452'}]",sensitive,4984,AZD4547 + Vistusertib,2260
72,Preclinical - Cell culture,"In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980).",Actionable,8034,5485,synovial sarcoma,DOID,26138,FGFR1 positive,"[{'id': 6537, 'pubMedId': 27535980, 'title': 'Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535980'}]",decreased response,654,AZD4547,2260
73,Preclinical - Cell culture,"In a preclinical study, AZD4547 and Rapamune (sirolimus) synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture (PMID: 26359452).",Actionable,9351,4556,lung large cell carcinoma,DOID,26138,FGFR1 positive,"[{'id': 7121, 'pubMedId': 26359452, 'title': 'Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26359452'}]",sensitive,4985,AZD4547 + Sirolimus,2260
74,Preclinical - Cell culture,"In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980).",Actionable,8030,5289,uterus leiomyosarcoma,DOID,26138,FGFR1 positive,"[{'id': 6537, 'pubMedId': 27535980, 'title': 'Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535980'}]",decreased response,2948,PD173074,2260
75,Preclinical - Cell culture,"In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to BGJ398 in culture (PMID: 27535980).",Actionable,8035,1967,leiomyosarcoma,DOID,26138,FGFR1 positive,"[{'id': 6537, 'pubMedId': 27535980, 'title': 'Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535980'}]",decreased response,674,BGJ398,2260
76,Preclinical - Cell culture,"In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to BGJ398 in culture (PMID: 27535980).",Actionable,8036,5289,uterus leiomyosarcoma,DOID,26138,FGFR1 positive,"[{'id': 6537, 'pubMedId': 27535980, 'title': 'Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535980'}]",decreased response,674,BGJ398,2260
77,Preclinical - Cell line xenograft,"In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture and in cell line xenograft models (PMID: 26359452).",Actionable,9347,3910,lung adenocarcinoma,DOID,26138,FGFR1 positive,"[{'id': 7121, 'pubMedId': 26359452, 'title': 'Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26359452'}]",sensitive,4984,AZD4547 + Vistusertib,2260
78,Preclinical - Cell culture,"In a preclinical study, AZD4547 and AZD8055 synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture (PMID: 26359452).",Actionable,9344,3910,lung adenocarcinoma,DOID,26138,FGFR1 positive,"[{'id': 7121, 'pubMedId': 26359452, 'title': 'Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26359452'}]",sensitive,4983,AZD4547 + AZD8055,2260
79,Preclinical - Cell culture,"In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980).",Actionable,8029,1967,leiomyosarcoma,DOID,26138,FGFR1 positive,"[{'id': 6537, 'pubMedId': 27535980, 'title': 'Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535980'}]",decreased response,2948,PD173074,2260
80,Preclinical - Cell line xenograft,"In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture and in cell line xenograft models (PMID: 26359452).",Actionable,9346,4556,lung large cell carcinoma,DOID,26138,FGFR1 positive,"[{'id': 7121, 'pubMedId': 26359452, 'title': 'Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26359452'}]",sensitive,4984,AZD4547 + Vistusertib,2260
81,Phase I,"In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including a partial remission in a patient with FGFR1-positive adenoid cystic carcinoma of the tongue (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).",Actionable,12000,4866,salivary gland adenoid cystic carcinoma,DOID,26138,FGFR1 positive,"[{'id': 9963, 'pubMedId': None, 'title': 'A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study', 'url': 'http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts'}]",predicted – sensitive,2030,Rogaratinib,2260
82,Preclinical - Cell culture,"In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980).",Actionable,8033,5289,uterus leiomyosarcoma,DOID,26138,FGFR1 positive,"[{'id': 6537, 'pubMedId': 27535980, 'title': 'Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535980'}]",decreased response,654,AZD4547,2260
83,Preclinical,"In a preclinical study, FIIN-01 inhibited Fgfr1 autophosphorylation in a human transformed embryonic kidney cell line harboring FGFR1 V561M mutation in culture (PMID: 20338520).",Actionable,4026,10000003,Advanced Solid Tumor,JAX,17133,FGFR1 V561M,"[{'id': 2410, 'pubMedId': 20338520, 'title': 'A structure-guided approach to creating covalent FGFR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20338520'}]",sensitive,2507,FIIN-01,2260
84,Preclinical,"In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS wild-type lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture  (PMID: 27338794).",Actionable,7364,1324,lung cancer,DOID,25310,FGFR1 dec exp KRAS wild-type,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",no benefit,2,Trametinib,2260
85,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition of KRAS mutant pancreatic cancer cells with decreased Fgfr1 expression through shRNA knockdown in culture (PMID: 27338794).",Actionable,7365,1793,pancreatic cancer,DOID,25304,FGFR1 dec exp KRAS mut,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",sensitive,2,Trametinib,2260
86,Preclinical - Cell line xenograft,"In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition in KRAS mutant lung cancer cells with decreased Fgfr1 expression through shRNA knockdown in culture, and tumor regression in xenograft models (PMID: 27338794).",Actionable,7360,1324,lung cancer,DOID,25304,FGFR1 dec exp KRAS mut,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",sensitive,2,Trametinib,2260
87,Preclinical - Cell culture,"In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS mutant colorectal cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).",Actionable,7366,9256,colorectal cancer,DOID,25304,FGFR1 dec exp KRAS mut,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",no benefit,2,Trametinib,2260
88,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring mutant EGFR and wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).",Actionable,3542,3908,non-small cell lung carcinoma,DOID,13351,EGFR mutant FGFR1 wild-type,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",resistant,877,Ponatinib,2260
89,Preclinical,"In a preclinical study, ER-positive breast cancer cells with wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).

",Actionable,3537,1612,breast cancer,DOID,542,FGFR1 wild-type,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",resistant,877,Ponatinib,2260
90,Preclinical,"In a preclinical study, FGFR1 non-amplified lung cancer cell lines demonstrated reduced sensitivity to AZD4547 induced growth inhibition in culture and in xenograft models (PMID: 23082000).",Actionable,6867,1324,lung cancer,DOID,542,FGFR1 wild-type,"[{'id': 5821, 'pubMedId': 23082000, 'title': 'Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23082000'}]",decreased response,654,AZD4547,2260
91,Preclinical,"In a preclinical study, primary cells from 8p11 myeloproliferative syndrome patients harboring FGFR1 rearrangement were sensitive to Dovitinib (TKI258)-induced growth inhibition in culture (PMID: 17698633).",Actionable,4039,2226,myeloproliferative neoplasm,DOID,1276,FGFR1 rearrange,"[{'id': 4384, 'pubMedId': 17698633, 'title': 'Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17698633'}]",sensitive,721,Dovitinib,2260
92,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited survival of small cell lung cancer cells harboring FGFR1 translocation in culture (PMID: 27550940).",Actionable,9121,5409,lung small cell carcinoma,DOID,1276,FGFR1 rearrange,"[{'id': 6925, 'pubMedId': 27550940, 'title': 'Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550940'}]",sensitive,654,AZD4547,2260
93,Preclinical - Cell line xenograft,"In a preclinical study, AZD4547 inhibited survival of leukemia cells harboring FGFR1 translocation in culture and in cell line xenograft models (PMID: 27550940).",Actionable,9120,1240,leukemia,DOID,1276,FGFR1 rearrange,"[{'id': 6925, 'pubMedId': 27550940, 'title': 'Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550940'}]",sensitive,654,AZD4547,2260
94,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited Erk, Stat5 signaling and survival of transformed cell lines overexpressing FGFR1 fusion proteins (ZMYM2-FGFR1 or BCR-FGFR1) in culture (PMID: 17698633).",Actionable,4037,10000003,Advanced Solid Tumor,JAX,14910,FGFR1 fusion,"[{'id': 4384, 'pubMedId': 17698633, 'title': 'Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17698633'}]",sensitive,721,Dovitinib,2260
95,Preclinical,"In a preclinical study, Dovitinib (TKI258) increased apoptosis and inhibited survival of acute myelogenous leukemia cell lines harboring FGFR1OP2-FGFR1 fusion in culture (PMID: 17698633).",Actionable,4038,9119,acute myeloid leukemia,DOID,14910,FGFR1 fusion,"[{'id': 4384, 'pubMedId': 17698633, 'title': 'Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17698633'}]",sensitive,721,Dovitinib,2260
96,Clinical Study,"In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",Actionable,11543,3498,pancreatic ductal adenocarcinoma,DOID,28131,EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*,"[{'id': 9613, 'pubMedId': 28476735, 'title': 'Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28476735'}]",resistant,706,Crizotinib,2260
97,Clinical Study,"In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",Actionable,11544,3498,pancreatic ductal adenocarcinoma,DOID,28131,EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*,"[{'id': 9613, 'pubMedId': 28476735, 'title': 'Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28476735'}]",predicted – sensitive,698,Alectinib,2260
98,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited Fgfr1 kinase activity and cell growth in transformed cells expressing the FGFR1-TACC1 fusion in culture (PMID: 22837387).",Actionable,2707,3070,malignant glioma,DOID,10477,FGFR1-TACC1,"[{'id': 3426, 'pubMedId': 22837387, 'title': 'Transforming fusions of FGFR and TACC genes in human glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22837387'}]",sensitive,654,AZD4547,2260
99,Preclinical - Cell culture,"In a preclinical study, BJG398 inhibited Fgfr1 kinase activity and cell growth in transformed cells expressing the FGFR1-TACC1 fusion in culture (PMID: 22837387).",Actionable,2708,3070,malignant glioma,DOID,10477,FGFR1-TACC1,"[{'id': 3426, 'pubMedId': 22837387, 'title': 'Transforming fusions of FGFR and TACC genes in human glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22837387'}]",sensitive,674,BGJ398,2260
100,Preclinical - Cell culture,"In a preclinical study, PD173074 inhibited Fgfr1 kinase activity and cell growth in transformed cells expressing the FGFR1-TACC1 fusion in culture (PMID: 22837387).",Actionable,2705,3070,malignant glioma,DOID,10477,FGFR1-TACC1,"[{'id': 3426, 'pubMedId': 22837387, 'title': 'Transforming fusions of FGFR and TACC genes in human glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22837387'}]",sensitive,2948,PD173074,2260
101,Preclinical - Cell culture,"In a preclinical study, an estrogen-receptor positive breast cancer cell line over expressing FGFR1 and expressing a PIK3CA mutation demonstrated sensitivity to the combination of Alpelisib (BYL719) and Lucitanib (E-3810) in culture (PMID: 27126994). ",Actionable,9709,60075,estrogen-receptor positive breast cancer,DOID,26996,FGFR1 over exp PIK3CA mut,"[{'id': 7484, 'pubMedId': 27126994, 'title': 'A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27126994'}]",sensitive,5164,Alpelisib + Lucitanib,2260
102,Phase II,"In a clinical analysis of a Phase II trial, high Fgfr1 expression level was associated with decreased progression free survival in renal cell carcinoma patients treated with Nexavar (sorafenib) (PMID: 25900027).",Emerging,7206,4450,renal cell carcinoma,DOID,4208,FGFR1 over exp,"[{'id': 6202, 'pubMedId': 25900027, 'title': 'The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25900027'}]",not applicable,920,Sorafenib,2260
103,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited survival of FGFR1 over expressing uterus leiomyosarcoma cells in culture (PMID: 27535980).",Actionable,8027,5289,uterus leiomyosarcoma,DOID,4208,FGFR1 over exp,"[{'id': 6537, 'pubMedId': 27535980, 'title': 'Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535980'}]",sensitive,654,AZD4547,2260
104,Preclinical,"In a preclinical study, BGJ398 inhibited cell growth and induced apoptosis in HNSCC cells over expressing Fgfr1 in culture and in xenograft models (PMID: 26015511). ",Actionable,3249,5520,head and neck squamous cell carcinoma,DOID,4208,FGFR1 over exp,"[{'id': 3696, 'pubMedId': 26015511, 'title': 'FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26015511'}]",sensitive,674,BGJ398,2260
105,Preclinical,"In a preclinical study, Lenvima (lenvatinib) inhibited FGFR1 phosphorylation and signaling in thyroid cancer cells overexpressing FGFR1 (PMID: 25295214).",Actionable,1893,1781,thyroid cancer,DOID,4208,FGFR1 over exp,"[{'id': 2207, 'pubMedId': 25295214, 'title': 'Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25295214'}]",sensitive,792,Lenvatinib,2260
106,Preclinical - Cell culture,"In a preclinical study, PD173074 inhibited survival of FGFR1 over expressing uterus leiomyosarcoma cells in culture (PMID: 27535980).",Actionable,8026,5289,uterus leiomyosarcoma,DOID,4208,FGFR1 over exp,"[{'id': 6537, 'pubMedId': 27535980, 'title': 'Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535980'}]",sensitive,2948,PD173074,2260
107,Preclinical - Cell culture,"In a preclinical study, PD173074 inhibited survival of FGFR1 over expressing uterus leiomyosarcoma cells in culture (PMID: 27535980).",Actionable,8028,5289,uterus leiomyosarcoma,DOID,4208,FGFR1 over exp,"[{'id': 6537, 'pubMedId': 27535980, 'title': 'Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535980'}]",sensitive,674,BGJ398,2260
108,Preclinical,"In a preclinical study, Iclusig (ponatinib) blocked proliferation of Ewing’s sarcoma cells over expressing Fgfr1 (PMID: 26179511).",Actionable,2566,4232,extraosseous Ewing's sarcoma,DOID,4208,FGFR1 over exp,"[{'id': 3316, 'pubMedId': 26179511, 'title': 'Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26179511'}, {'id': 3317, 'pubMedId': 26175911, 'title': ""Let's be pragmatic about clinical data."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26175911'}]",sensitive,877,Ponatinib,2260
109,Preclinical - Cell culture,"In a preclinical study, AZD4547 treatment of head and neck squamous cell carcinoma cells over expressing FGFR1 and negative for EGFR resulted in decreased cell growth and reduced downstream signaling of Erk1/2 (PMID: 26936917).",Actionable,7828,5520,head and neck squamous cell carcinoma,DOID,26061,EGFR neg FGFR1 over exp,"[{'id': 6507, 'pubMedId': 26936917, 'title': 'FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26936917'}]",sensitive,654,AZD4547,2260
0,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 V565I were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2587,10000003,Advanced Solid Tumor,JAX,9491,FGFR2 V565I,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",resistant,721,Dovitinib,2263
1,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 V565I were resistant to treatment with PD173074 (PMID: 23908597).",Actionable,3281,10000003,Advanced Solid Tumor,JAX,9491,FGFR2 V565I,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",resistant,2948,PD173074,2263
2,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 V565I were resistant to treatment with Iclusig (ponatinib) (PMID: 23908597).",Actionable,2601,10000003,Advanced Solid Tumor,JAX,9491,FGFR2 V565I,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",resistant,877,Ponatinib,2263
3,Clinical Study,"In a clinical study, FGFR2 mutations E565A, K659M, N549H, N549K and V564F were identified in the cell-free DNA of a cholangiocarcinoma patient harboring FGFR2-ZMYM4 fusion after the patient progressed while on BGJ398 treatment (PMID: 28034880).  ",Actionable,10147,4947,cholangiocarcinoma,DOID,27311,FGFR2 E565A FGFR2 K659M FGFR2 N549H FGFR2 N549K FGFR2 V564F FGFR2-ZMYM4,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",predicted – resistant,674,BGJ398,2263
4,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited downstream phosphorylation of Akt and Erk1/2 in cells expressing Fgfr2 S267_D273dup (PMID: 26048680).",Actionable,2677,10000003,Advanced Solid Tumor,JAX,9977,FGFR2 S267_D273dup,"[{'id': 3380, 'pubMedId': 26048680, 'title': 'Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26048680'}]",sensitive,877,Ponatinib,2263
5,Preclinical,"In a preclinical study, BGJ398 prevented oncogenic transformation of cells expressing FGFR2 S267_D273dup (PMID: 26048680).",Actionable,2674,10000003,Advanced Solid Tumor,JAX,9977,FGFR2 S267_D273dup,"[{'id': 3380, 'pubMedId': 26048680, 'title': 'Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26048680'}]",sensitive,674,BGJ398,2263
6,Preclinical - Cell culture,"In a preclinical study, hepatocellular carcinoma cell lines treated with AZD4547 demonstrated decreased phosphorylation of FGFR1 and FGFR2, reduced colony formation, and evidence of apoptotic activity in culture (PMID: 26351320). ",Actionable,9051,684,hepatocellular carcinoma,DOID,26701,FGFR1 pos FGFR2 pos,"[{'id': 6889, 'pubMedId': 26351320, 'title': 'Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26351320'}]",sensitive,654,AZD4547,2263
7,Preclinical - Cell culture,"In a preclinical study, PHA-665752 treatment did not result in decreased colony formation or reduced phosphorylation levels of FGFR1 and FGFR2 in hepatocellular carcinoma cells in culture (PMID: 26351320).",Actionable,9053,684,hepatocellular carcinoma,DOID,26701,FGFR1 pos FGFR2 pos,"[{'id': 6889, 'pubMedId': 26351320, 'title': 'Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26351320'}]",no benefit,2162,PHA-665752,2263
8,Phase I,"In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR2-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).",Actionable,12002,1612,breast cancer,DOID,9798,FGFR2 positive,"[{'id': 9963, 'pubMedId': None, 'title': 'A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study', 'url': 'http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts'}]",predicted – sensitive,2030,Rogaratinib,2263
9,Preclinical - Pdx & cell culture,"In a preclinical study, BAY1187982 inhibited survival of gastric cancer cell lines with elevated Fgfr2 expression level in culture, and suppressed tumor growth in cell line or patient-derived xenograft models (PMID: 27543601).",Actionable,9094,10534,stomach cancer,DOID,9798,FGFR2 positive,"[{'id': 6911, 'pubMedId': 27543601, 'title': 'Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27543601'}]",sensitive,2931,BAY1187982,2263
10,Preclinical - Pdx & cell culture,"In a preclinical study, BAY1187982 inhibited survival of Fgfr2 positive breast cancer cell lines in culture, and suppressed tumor growth in both cell line and patient-derived xenograft models (PMID: 27543601).",Actionable,9097,1612,breast cancer,DOID,9798,FGFR2 positive,"[{'id': 6911, 'pubMedId': 27543601, 'title': 'Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27543601'}]",sensitive,2931,BAY1187982,2263
11,Preclinical - Pdx & cell culture,"In a preclinical study, sensitivity to BAY1187982 positively correlated with Fgfr2 expression level in a variety of cancer cell lines in culture, and in cell line or patient-derived xenograft models (PMID: 27543601).",Actionable,9093,10000003,Advanced Solid Tumor,JAX,9798,FGFR2 positive,"[{'id': 6911, 'pubMedId': 27543601, 'title': 'Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27543601'}]",sensitive,2931,BAY1187982,2263
12,Preclinical,"In a preclinical study, a mouse breast carcinoma cell line xenograft model demonstrated inhibition of tumor growth when treated with E7090, a result of decreased FGFR2 and FGFR3 activity (PMID: 27535969). ",Actionable,9142,3459,breast carcinoma,DOID,26749,FGFR2 pos FGFR3 pos,"[{'id': 6928, 'pubMedId': 27535969, 'title': 'E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535969'}]",sensitive,4911,E7090,2263
13,Preclinical - Cell culture,"In a preclinical study, PRN1371 inhibited Fgfr2 activity in transformed cells over expressing FGFR2 K660N in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8400,10000003,Advanced Solid Tumor,JAX,26311,FGFR2 K660N,"[{'id': 6640, 'pubMedId': None, 'title': 'PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1249'}]",sensitive,3583,PRN1371,2263
14,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 I548V (PMID: 23908597).",Actionable,2605,10000003,Advanced Solid Tumor,JAX,9490,FGFR2 I548V,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",sensitive,877,Ponatinib,2263
15,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 I548V demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2591,10000003,Advanced Solid Tumor,JAX,9490,FGFR2 I548V,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",decreased response,721,Dovitinib,2263
16,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 I548V demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).",Actionable,2598,10000003,Advanced Solid Tumor,JAX,9490,FGFR2 I548V,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",decreased response,2948,PD173074,2263
17,Preclinical - Cell culture,"In a preclinical study, Debio 1347 did not inhibit Fgfr2 phosphorylation in transformed cells over expressing FGFR2 V564L in culture (PMID: 25169980).",Actionable,10190,10000003,Advanced Solid Tumor,JAX,27307,FGFR2 V564L,"[{'id': 4388, 'pubMedId': 25169980, 'title': 'The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25169980'}]",resistant,1014,FF-284,2263
18,Preclinical - Cell line xenograft,"In a preclinical study, S-49076 inhibited Met activation, resulting in growth inhibition of gastric carcinoma cells harboring FGFR2 activating mutations in culture and in cell line xenograft models (PMID: 23804704).",Actionable,1771,5517,stomach carcinoma,DOID,1219,FGFR2 act mut,"[{'id': 2007, 'pubMedId': 23804704, 'title': 'S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23804704'}]",sensitive,2158,S-49076,2263
19,Preclinical,"In a preclinical study, transformed cells expressing constitutively active FGFR2 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Brivanib (BMS-540215) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).",Actionable,3492,10000003,Advanced Solid Tumor,JAX,1219,FGFR2 act mut,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",decreased response,996,Brivanib,2263
20,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR2 in culture (PMID: 22238366).
",Actionable,3473,10000003,Advanced Solid Tumor,JAX,1219,FGFR2 act mut,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,721,Dovitinib,2263
21,Preclinical,"In a preclinical study, transformed cells expressing constitutively active FGFR2 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Cediranib (AZD-2171) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).",Actionable,3477,10000003,Advanced Solid Tumor,JAX,1219,FGFR2 act mut,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",decreased response,1001,Cediranib,2263
22,Phase I,"In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR2 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).
",Actionable,347,10000003,Advanced Solid Tumor,JAX,1219,FGFR2 act mut,"[{'id': 3622, 'pubMedId': None, 'title': 'Preliminary clinical pharmacokinetics and pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor.', 'url': 'http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2540'}]",sensitive,1014,FF-284,2263
23,Preclinical,"In a preclinical study, transformed cells expressing constitutively active FGFR2 demonstrated reduced sensitivity to Ofev (Nintedanib) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).",Actionable,3489,10000003,Advanced Solid Tumor,JAX,1219,FGFR2 act mut,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",decreased response,831,Nintedanib,2263
24,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR2 in culture (PMID: 22238366).
",Actionable,3470,10000003,Advanced Solid Tumor,JAX,1219,FGFR2 act mut,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,877,Ponatinib,2263
25,Preclinical - Cell line xenograft,"In a preclinical study, both cell lines and cell line xenograft models of endometrial cancer with FGFR2 activating mutations showed greater sensitivity to Dovitinib (TKI258) as compared to FGFR2 wild-type (PMID: 23443805). ",Actionable,328,1380,endometrial cancer,DOID,1219,FGFR2 act mut,"[{'id': 77, 'pubMedId': 23443805, 'title': 'Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23443805'}]",sensitive,721,Dovitinib,2263
26,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted in stable disease in 70% (16/23) and partial response in 22% (5/23) of patients with advanced solid tumors harboring FGFR 1-4 activating mutations (including amplifications, mutations and translocations), while no antitumor activity was observed in patients with unknown or no known changes in FGFR (PMID: 26324363).",Actionable,3999,10000003,Advanced Solid Tumor,JAX,1219,FGFR2 act mut,"[{'id': 4363, 'pubMedId': 26324363, 'title': 'Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26324363'}]",sensitive,1028,JNJ-42756493,2263
27,Preclinical - Patient cell culture,"In a preclincal study, BGJ398 demonstrated enhanced inhibition of the survival in patient-derived ovarian cancer cells harboring FGFR2 - FAM76A in culture (PMID: 24563622).",Actionable,7543,2394,ovarian cancer,DOID,25826,FGFR2-FAM76A,"[{'id': 6413, 'pubMedId': 24563622, 'title': 'Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24563622'}]",sensitive,674,BGJ398,2263
28,Preclinical - Pdx,"In a preclinical study, PRN1371 treatment resulted in tumor regression in patient-derived xenograft models of liver cancer harboring FGFR2-CCDC6 fusion (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8413,3571,liver cancer,DOID,17514,FGFR2-CCDC6,"[{'id': 6640, 'pubMedId': None, 'title': 'PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1249'}]",sensitive,3583,PRN1371,2263
29,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited downstream phosphorylation of Akt and Erk1/2 in cells expressing Fgfr2 W290_I291delinsC (PMID: 26048680).",Actionable,2678,10000003,Advanced Solid Tumor,JAX,9978,FGFR2 W290_I291delinsC,"[{'id': 3380, 'pubMedId': 26048680, 'title': 'Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26048680'}]",sensitive,877,Ponatinib,2263
30,Preclinical,"In a preclinical study, BGJ398 prevented oncogenic transformation of cells expressing FGFR2 W290_I291delinsC (PMID: 26048680).",Actionable,2675,10000003,Advanced Solid Tumor,JAX,9978,FGFR2 W290_I291delinsC,"[{'id': 3380, 'pubMedId': 26048680, 'title': 'Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26048680'}]",sensitive,674,BGJ398,2263
31,Preclinical - Pdx & cell culture,"In a preclinical study, AZD4547 inhibited proliferation of endometrial cells and delayed tumor growth in cell-line derived xenografts harboring the Fgfr2 double mutant, K310R, N550K (PMID: 26294741).",Actionable,8851,1380,endometrial cancer,DOID,26470,FGFR2 K310R FGFR2 N550K,"[{'id': 6769, 'pubMedId': 26294741, 'title': 'Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26294741'}]",sensitive,654,AZD4547,2263
32,Preclinical - Cell culture,"In a preclinical study, the combination of BGJ398 and Buparlisib (BKM120) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489). ",Actionable,10778,1380,endometrial cancer,DOID,27771,FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23,"[{'id': 8811, 'pubMedId': 28119489, 'title': 'PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2(mutant) Endometrial Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28119489'}]",sensitive,5612,BGJ398 + BKM120,2263
33,Preclinical - Cell culture,"In a preclinical study, the combination of BGJ398 and Alpelisib (BYL719) resulted in a synergistic effect, demonstrating inhibition of cell proliferation and induced cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489). ",Actionable,10780,1380,endometrial cancer,DOID,27771,FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23,"[{'id': 8811, 'pubMedId': 28119489, 'title': 'PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2(mutant) Endometrial Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28119489'}]",sensitive,1293,BGJ398 + BYL719,2263
34,Preclinical - Cell culture,"In a preclinical study, the combination of BGJ398 and Pictilisib (GDC-0941) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489). ",Actionable,10777,1380,endometrial cancer,DOID,27771,FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23,"[{'id': 8811, 'pubMedId': 28119489, 'title': 'PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2(mutant) Endometrial Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28119489'}]",sensitive,5613,BGJ398 + GDC-0941,2263
35,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 N550K were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2584,10000003,Advanced Solid Tumor,JAX,3428,FGFR2 N550K,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",resistant,721,Dovitinib,2263
36,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 N550K (PMID: 23908597).",Actionable,2607,10000003,Advanced Solid Tumor,JAX,3428,FGFR2 N550K,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",sensitive,877,Ponatinib,2263
37,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 N550K were resistant to PD173074 (PMID: 23908597). ",Actionable,3280,10000003,Advanced Solid Tumor,JAX,3428,FGFR2 N550K,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",resistant,2948,PD173074,2263
38,Preclinical - Cell culture,"In a preclinical study, endometrial cells harboring Fgfr2 N550K were less sensitive to the anti-proliferative effects of AZD4547 than the Fgfr2 double mutant, K310R, N550K (PMID: 26294741).",Actionable,8852,1380,endometrial cancer,DOID,3428,FGFR2 N550K,"[{'id': 6769, 'pubMedId': 26294741, 'title': 'Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26294741'}]",decreased response,654,AZD4547,2263
39,Preclinical - Cell culture,"In a preclinical study, PRN1371 inhibited Fgfr2 activity in transformed cells over expressing FGFR2 N550K in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8401,10000003,Advanced Solid Tumor,JAX,3428,FGFR2 N550K,"[{'id': 6640, 'pubMedId': None, 'title': 'PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1249'}]",sensitive,3583,PRN1371,2263
40,Preclinical,"In a preclinical study, an endometrial cancer cell line harboring FGFR2 C383R and expressing FGFR2 N550K demonstrated resistance when treated with PD173074 (PMID: 23908597). ",Actionable,3288,1380,endometrial cancer,DOID,13108,FGFR2 C383R FGFR2 N550K,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",resistant,2948,PD173074,2263
41,Phase I,"In a Phase I trial, a patient with cholangiocarcinoma harboring an FGFR2 mutation demonstrated a decreased tumor burden when treated with BGJ398 (PMID: 27870574). ",Actionable,9738,4947,cholangiocarcinoma,DOID,1185,FGFR2 mutant,"[{'id': 7516, 'pubMedId': 27870574, 'title': 'Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27870574'}]",sensitive,674,BGJ398,2263
42,Preclinical - Cell culture,"In a preclinical study, PRN1371 inhibited proliferation of endometrial cancer cells harboring FGFR2 mutations in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8406,1380,endometrial cancer,DOID,1185,FGFR2 mutant,"[{'id': 6640, 'pubMedId': None, 'title': 'PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1249'}]",sensitive,3583,PRN1371,2263
43,Preclinical,"In a preclinical study, BGJ398 inhibited the growth of FGFR2-mutated endometrial cancer cells in vitro and in xenograft models (PMID: 23443805).",Actionable,1274,1380,endometrial cancer,DOID,1185,FGFR2 mutant,"[{'id': 77, 'pubMedId': 23443805, 'title': 'Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23443805'}]",sensitive,674,BGJ398,2263
44,Preclinical - Cell culture,"In a preclinical study, a variety of cancer cell lines harboring mutations in FGFR1, FGFR2, and/or FGFR3 demonstrated sensitivity to INCB054828 in culture and in cell line xenograft models, resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 771).",Actionable,8390,10000003,Advanced Solid Tumor,JAX,1185,FGFR2 mutant,"[{'id': 6136, 'pubMedId': None, 'title': 'Abstract 771: Preclinical characterization of the selective FGFR inhibitor INCB054828', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/771.short'}]",sensitive,4173,INCB054828,2263
45,Preclinical,"In a preclinical study, treatment with PD173074 prevented transformation of cells expressing FGFR2-BICC1 in culture (PMID: 24122810).",Actionable,4216,10000003,Advanced Solid Tumor,JAX,17509,FGFR2-BICC1,"[{'id': 4202, 'pubMedId': 24122810, 'title': 'Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24122810'}]",sensitive,2948,PD173074,2263
46,Preclinical,"In a preclinical study, treatment with BGJ398 prevented transformation of cells expressing FGFR2-BICC1 in culture (PMID: 24122810).",Actionable,4215,10000003,Advanced Solid Tumor,JAX,17509,FGFR2-BICC1,"[{'id': 4202, 'pubMedId': 24122810, 'title': 'Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24122810'}]",sensitive,674,BGJ398,2263
47,Clinical Study,"In a clinical study, FGFR2 V564F was identified in the cell-free DNA of a cholangiocarcinoma patient harboring FGFR2-BICC1 fusion after the patient progressed while on BGJ398 treatment (PMID: 28034880).  ",Actionable,10149,4947,cholangiocarcinoma,DOID,27313,FGFR2 V564F FGFR2-BICC1,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",predicted – resistant,674,BGJ398,2263
48,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited downstream phosphorylation of Akt and Erk1/2 in cells expressing the fusion, FGFR2 - TACC3 (PMID: 26048680).",Actionable,2679,10000003,Advanced Solid Tumor,JAX,9979,FGFR2 - TACC3,"[{'id': 3380, 'pubMedId': 26048680, 'title': 'Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26048680'}]",sensitive,877,Ponatinib,2263
49,Preclinical,"In a preclinical study, BGJ398 prevented oncogenic transformation of cells expressing FGFR2 - TACC3 (PMID: 26048680).",Actionable,2676,10000003,Advanced Solid Tumor,JAX,9979,FGFR2 - TACC3,"[{'id': 3380, 'pubMedId': 26048680, 'title': 'Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26048680'}]",sensitive,674,BGJ398,2263
50,Clinical Study,"In a clinical study, FGFR2 mutations E565A, K641R, L617V, N549H and V564F were identified in the cell-free DNA of a cholangiocarcinoma patient harboring FGFR2-OPTN fusion after the patient progressed while on BGJ398 treatment (PMID: 28034880).  ",Actionable,10148,4947,cholangiocarcinoma,DOID,27312,FGR2 E565A FGFR2 K641R FGFR2 L617V FGFR2 N549H FGFR2 V564F FGFR2-OPTN,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",predicted – resistant,674,BGJ398,2263
51,Phase I,"In a Phase I trial, Dovitinib (TKI258) displayed safety and preliminary efficacy resulting in tumor regression of 28.2% and 18.5% in two patients with FGFR2 amplified Erbb2 (Her2)-receptor positive breast cancer (PMID: 23658459).",Actionable,1748,60079,Her2-receptor positive breast cancer,DOID,3147,FGFR2 amp,"[{'id': 754, 'pubMedId': 23658459, 'title': 'Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23658459'}]",sensitive,721,Dovitinib,2263
52,Preclinical - Cell culture,"In a preclinical study, FGFR2 amplified colorectal adenocarcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,8484,50861,colorectal adenocarcinoma,DOID,3147,FGFR2 amp,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,913,Selumetinib,2263
53,Preclinical - Cell line xenograft,"In a preclinical study, PRN1371 inhibited proliferation of FGFR2 amplified gastric cancer cells in culture and tumor growth in cell line xenograft models (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8404,10534,stomach cancer,DOID,3147,FGFR2 amp,"[{'id': 6640, 'pubMedId': None, 'title': 'PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1249'}]",sensitive,3583,PRN1371,2263
54,Preclinical - Cell line xenograft,"In a preclinical study, Debio 1347 inhibited proliferation of FGFR-amplified gastric cancer cells in culture and inhibited tumor growth in cell line xenograft models of gastric cancer harboring FGFR2 amplification (PMID: 25169980).",Actionable,4053,10534,stomach cancer,DOID,3147,FGFR2 amp,"[{'id': 4388, 'pubMedId': 25169980, 'title': 'The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25169980'}]",sensitive,1014,FF-284,2263
55,Preclinical - Cell culture,"In a preclinical study, FGFR2 amplified gastric carcinoma cell lines were not sensitive to RO4987655 in culture (PMID: 26438159).",Actionable,8453,5517,stomach carcinoma,DOID,3147,FGFR2 amp,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,903,RO4987655,2263
56,Preclinical - Cell culture,"In a preclinical study, FGFR2 amplified gastric carcinoma cell lines were not sensitive to RO5126766 in culture (PMID: 26438159).",Actionable,8471,5517,stomach carcinoma,DOID,3147,FGFR2 amp,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,2011,RO5126766,2263
57,Preclinical - Cell culture,"In a preclinical study, FGFR2 amplified colorectal adenocarcinoma cells demonstrated decreased response to RO4987655 in culture (PMID: 26438159).",Actionable,8452,50861,colorectal adenocarcinoma,DOID,3147,FGFR2 amp,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",decreased response,903,RO4987655,2263
58,Preclinical - Cell line xenograft,"In a preclinical study, JNJ-42756493 (erdafitinib) inhibited tumor growth in an FGFR2-amplified colorectal cancer cell line xenograft model (PMID: 28341788).",Actionable,11182,9256,colorectal cancer,DOID,3147,FGFR2 amp,"[{'id': 9140, 'pubMedId': 28341788, 'title': 'Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28341788'}]",sensitive,1028,JNJ-42756493,2263
59,Preclinical - Cell culture,"In a preclinical study, treatment with M-COPA resulted in decreased Fgfr2 cell surface expression and phosphorylation and reduced growth of an FGFR2-amplified signet cell gastric cancer cell line in culture (PMID: 27197184).",Actionable,7605,8025,gastric signet ring cell adenocarcinoma,DOID,3147,FGFR2 amp,"[{'id': 6440, 'pubMedId': 27197184, 'title': 'M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27197184'}]",sensitive,4522,M-COPA,2263
60,Preclinical - Cell line xenograft,"In a preclinical study, Debio 1347 inhibited tumor growth in cell line xenograft models of FGFR2 amplified gastric carcinoma (PMID: 26438159).",Actionable,8496,5517,stomach carcinoma,DOID,3147,FGFR2 amp,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",sensitive,1014,FF-284,2263
61,Preclinical,"In a preclinical study, Dovitinib (TKI258) increased apoptosis, inhibited cell proliferation and migration of myxoid liposarcoma cell lines harbors FGFR2 amplification in culture (PMID: 26036639).",Actionable,4036,5363,myxoid liposarcoma,DOID,3147,FGFR2 amp,"[{'id': 4383, 'pubMedId': 26036639, 'title': 'FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26036639'}]",sensitive,721,Dovitinib,2263
62,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in gastric cancer cell lines harboring FGFR2 amplification in culture (PMID: 22238366).
",Actionable,3522,10534,stomach cancer,DOID,3147,FGFR2 amp,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,721,Dovitinib,2263
63,Preclinical,"In a preclinical study, Debio 1347 inhibited proliferation of colorectal cancer cell lines harboring FGFR2 amplification in culture (PMID: 25169980).",Actionable,4071,9256,colorectal cancer,DOID,3147,FGFR2 amp,"[{'id': 4388, 'pubMedId': 25169980, 'title': 'The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25169980'}]",sensitive,1014,FF-284,2263
64,Preclinical - Cell line xenograft,"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of FGFR2-amplified gastric cancer cells in culture, and inhibited tumor growth in FGFR2-amplified gastric cancer cell line xenograft models (PMID: 22238366).",Actionable,3521,10534,stomach cancer,DOID,3147,FGFR2 amp,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,877,Ponatinib,2263
65,Preclinical,"In a preclinical study, Ofev (nintedanib) inhibited growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",Actionable,3546,219,colon cancer,DOID,3147,FGFR2 amp,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,831,Nintedanib,2263
66,Preclinical,"In a preclinical study, BGJ398 and Yondelis (trabectedin) worked synergistically to increase apoptosis, inhibit cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification in culture (PMID: 26036639).",Actionable,4047,5363,myxoid liposarcoma,DOID,3147,FGFR2 amp,"[{'id': 4383, 'pubMedId': 26036639, 'title': 'FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26036639'}]",sensitive,3423,BGJ398 + Trabectedin,2263
67,Preclinical - Pdx & cell culture,"In a preclinical study, Dovitinib (TKI258) inhibited cell growth of an FGFR2 amplified breast cancer cell line in culture and prevented tumor growth and induced tumor regression in FGFR2 amplified breast cancer patient derived xenograft (PDX) models (PMID: 23658459).",Actionable,1747,1612,breast cancer,DOID,3147,FGFR2 amp,"[{'id': 754, 'pubMedId': 23658459, 'title': 'Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23658459'}]",sensitive,721,Dovitinib,2263
68,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",Actionable,3547,219,colon cancer,DOID,3147,FGFR2 amp,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",no benefit,996,Brivanib,2263
69,Preclinical - Cell line xenograft,"In a preclinical study, JNJ-42756493 (erdafitinib) inhibited proliferation of a gastric cancer cell line with FGFR2 amplification in culture, and inhibited tumor growth in xenograft models (PMID: 28341788).",Actionable,11178,10534,stomach cancer,DOID,3147,FGFR2 amp,"[{'id': 9140, 'pubMedId': 28341788, 'title': 'Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28341788'}]",sensitive,1028,JNJ-42756493,2263
70,Preclinical - Pdx,"In a preclinical study, BAY1187982 inhibited tumor growth in patient-derived xenograft models of FGFR2 amplified ovarian cancer (PMID: 27543601).",Actionable,9095,2394,ovarian cancer,DOID,3147,FGFR2 amp,"[{'id': 6911, 'pubMedId': 27543601, 'title': 'Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27543601'}]",sensitive,2931,BAY1187982,2263
71,Preclinical - Pdx,"In a preclinical study, PRN1371 treatment resulted in tumor growth inhibition in patient-derived xenograft models of FGFR2-amplified non-small cell lung cancer (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8410,3908,non-small cell lung carcinoma,DOID,3147,FGFR2 amp,"[{'id': 6640, 'pubMedId': None, 'title': 'PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1249'}]",sensitive,3583,PRN1371,2263
72,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",Actionable,3544,219,colon cancer,DOID,3147,FGFR2 amp,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,721,Dovitinib,2263
73,Phase I,"In a Phase I trial, a breast cancer patient harboring an FGFR2 amplification demonstrated stable disease when treated with BGJ398 (PMID: 27870574). ",Actionable,9736,1612,breast cancer,DOID,3147,FGFR2 amp,"[{'id': 7516, 'pubMedId': 27870574, 'title': 'Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27870574'}]",sensitive,674,BGJ398,2263
74,Preclinical,"In a preclinical study, FIIN-01 inhibited Fgfr2-dependent cell proliferation of gastric cancer cell lines harboring FGFR2 amplification (PMID: 20338520).",Actionable,4022,10534,stomach cancer,DOID,3147,FGFR2 amp,"[{'id': 2410, 'pubMedId': 20338520, 'title': 'A structure-guided approach to creating covalent FGFR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20338520'}]",sensitive,2507,FIIN-01,2263
75,Phase II,"In a Phase II clinical trial, treatment with AZD4547 resulted in a 33% (3/9) response rate in patients with FGFR2-amplified gastroesophageal cancer, and high-level amplification was associated with clinical response (PMID: 27179038).",Actionable,7569,10534,stomach cancer,DOID,3147,FGFR2 amp,"[{'id': 6434, 'pubMedId': 27179038, 'title': 'High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27179038'}]",sensitive,654,AZD4547,2263
76,Preclinical,"In a preclinical study, AZD4547 inhibited FGFR signaling, and decreased proliferation and induced cell-cycle arrest in gastric cancer cells with amplification and over expression of FGFR2 in culture (PMID: 22869148).",Actionable,2580,10534,stomach cancer,DOID,3147,FGFR2 amp,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",sensitive,654,AZD4547,2263
77,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).
",Actionable,3543,219,colon cancer,DOID,3147,FGFR2 amp,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,877,Ponatinib,2263
78,Preclinical,"In a preclinical study, Debio 1347 inhibited proliferation of breast cancer cell lines harboring FGFR2 amplification in culture (PMID: 25169980).",Actionable,4070,1612,breast cancer,DOID,3147,FGFR2 amp,"[{'id': 4388, 'pubMedId': 25169980, 'title': 'The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25169980'}]",sensitive,1014,FF-284,2263
79,Preclinical - Cell line xenograft,"In a preclinical study, a gastric cancer cell line harboring FGFR2 amplification demonstrated decreased cell viability in culture and antitumor activity in xenograft models when treated with E7090 (PMID: 27535969). ",Actionable,9132,10534,stomach cancer,DOID,3147,FGFR2 amp,"[{'id': 6928, 'pubMedId': 27535969, 'title': 'E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535969'}]",sensitive,4911,E7090,2263
80,Preclinical,"In a preclinical study, BGJ398 increased apoptosis, and inhibited cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification  in culture (PMID: 26036639).",Actionable,4042,5363,myxoid liposarcoma,DOID,3147,FGFR2 amp,"[{'id': 4383, 'pubMedId': 26036639, 'title': 'FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26036639'}]",sensitive,674,BGJ398,2263
81,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in ER-negative breast cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).
",Actionable,3533,1612,breast cancer,DOID,3147,FGFR2 amp,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,877,Ponatinib,2263
82,Preclinical,"In a preclinical study, Selumetinib (AZD-6244) did not inhibit growth of gastric cancer cells with FGFR2 amplification in culture (PMID: 19755509).",Actionable,4032,10534,stomach cancer,DOID,3147,FGFR2 amp,"[{'id': 3510, 'pubMedId': 19755509, 'title': 'Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19755509'}]",resistant,913,Selumetinib,2263
83,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",Actionable,3525,10534,stomach cancer,DOID,3147,FGFR2 amp,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",no benefit,996,Brivanib,2263
84,Preclinical - Cell line xenograft,"In a preclinical study, PRN1109 treatment resulted in tumor regression in gastric cancer cell line xenograft models harboring FGFR2 amplification (Eu J Cancer 2014 Vol 50, Suppl 6:157).",Actionable,4627,10534,stomach cancer,DOID,3147,FGFR2 amp,"[{'id': 4638, 'pubMedId': None, 'title': 'Irreversible Covalent Pan-FGFR Inhibitors are Highly Efficacious Against FGFR-dependent Cancers', 'url': 'http://www.ejcancer.com/article/S0959-8049%2814%2970609-4/pdf'}]",predicted – sensitive,4645,PRN1109,2263
85,Preclinical,"In a preclinical study, Cediranib (AZD-2171) inhibited growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",Actionable,3545,219,colon cancer,DOID,3147,FGFR2 amp,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,1001,Cediranib,2263
86,Preclinical - Cell culture,"In a preclinical study, BGJ398 reduced Myc expression, induced cell-cycle arrest, and inhibited growth of a colon cancer cell line with FGFR2 amplification in culture (PMID: 27401245).",Actionable,10025,219,colon cancer,DOID,3147,FGFR2 amp,"[{'id': 7899, 'pubMedId': 27401245, 'title': 'c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27401245'}]",sensitive,674,BGJ398,2263
87,Preclinical,"In a preclinical study, PD173074 increased apoptosis, inhibited cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification  in culture (PMID: 26036639).",Actionable,4041,5363,myxoid liposarcoma,DOID,3147,FGFR2 amp,"[{'id': 4383, 'pubMedId': 26036639, 'title': 'FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26036639'}]",sensitive,2948,PD173074,2263
88,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of estrogen receptor (ER)-negative breast cancer cells with FGFR2 amplification in culture (PMID: 22238366).",Actionable,3535,60076,estrogen-receptor negative breast cancer,DOID,3147,FGFR2 amp,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",no benefit,996,Brivanib,2263
89,Preclinical,"In a preclinical study, BGJ398 inhibited proliferation of gastric cancer cell lines harboring FGFR2 amplification in culture (PMID: 26036639).",Actionable,4045,10534,stomach cancer,DOID,3147,FGFR2 amp,"[{'id': 4383, 'pubMedId': 26036639, 'title': 'FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26036639'}]",sensitive,674,BGJ398,2263
90,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited survival of FGFR2 amplified colon cancer cells in culture (PMID: 27550940).",Actionable,9115,219,colon cancer,DOID,3147,FGFR2 amp,"[{'id': 6925, 'pubMedId': 27550940, 'title': 'Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550940'}]",sensitive,654,AZD4547,2263
91,Preclinical - Cell culture,"In a preclinical study, RO5126766 inhibited proliferation of FGFR2 amplified colorectal adenocarcinoma cells in culture (PMID: 26438159).",Actionable,8470,50861,colorectal adenocarcinoma,DOID,3147,FGFR2 amp,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",predicted – sensitive,2011,RO5126766,2263
92,Preclinical,"In a preclinical study, Cediranib (AZD-2171) inhibited growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).
",Actionable,3523,10534,stomach cancer,DOID,3147,FGFR2 amp,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,1001,Cediranib,2263
93,Preclinical,"In a preclinical study, Dovitinib (TKI258) and Yondelis (trabectedin) worked synergistically to increase apoptosis, inhibit cell proliferation and migration of myxoid liposarcoma cell lines harbors FGFR2 amplification in culture (PMID: 26036639).",Actionable,4040,5363,myxoid liposarcoma,DOID,3147,FGFR2 amp,"[{'id': 4383, 'pubMedId': 26036639, 'title': 'FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26036639'}]",sensitive,3421,Dovitinib + Trabectedin,2263
94,Preclinical,"In a preclinical study, PD173034 and Yondelis (trabectedin) worked synergistically to increase apoptosis, inhibit cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification in culture (PMID: 26036639).",Actionable,4046,5363,myxoid liposarcoma,DOID,3147,FGFR2 amp,"[{'id': 4383, 'pubMedId': 26036639, 'title': 'FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26036639'}]",sensitive,3422,PD173074 + Trabectedin,2263
95,Phase I,"In a Phase I trial, TAS-120 treatment resulted in clinical response in a gastric cancer patient harboring FGFR2 amplification (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD).",Actionable,11984,10534,stomach cancer,DOID,3147,FGFR2 amp,"[{'id': 9948, 'pubMedId': None, 'title': 'First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]",predicted – sensitive,1053,TAS-120,2263
96,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited survival of FGFR2 amplified breast cancer cells in culture (PMID: 27550940).",Actionable,9116,1612,breast cancer,DOID,3147,FGFR2 amp,"[{'id': 6925, 'pubMedId': 27550940, 'title': 'Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550940'}]",sensitive,654,AZD4547,2263
97,Preclinical - Cell culture,"In a preclinical study, FGFR2-amplified gastric cancer cell lines demonstrated sensitivity to PD173074 in culture, with cell lines with high-level FGFR2 amplification displaying higher sensitivity compared to cell lines with low-level amplification (PMID: 27179038).",Actionable,7570,10534,stomach cancer,DOID,3147,FGFR2 amp,"[{'id': 6434, 'pubMedId': 27179038, 'title': 'High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27179038'}]",sensitive,2948,PD173074,2263
98,Preclinical - Cell culture,"In a preclinical study, PD173074 inhibited proliferation of a gastric cancer cell line harboring FGFR2 amplification in culture (PMID: 26036639).",Actionable,4043,10534,stomach cancer,DOID,3147,FGFR2 amp,"[{'id': 4383, 'pubMedId': 26036639, 'title': 'FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26036639'}]",sensitive,2948,PD173074,2263
99,Preclinical - Cell line xenograft,"In a preclinical study, AZD4547 inhibited survival of FGFR2 amplified endometrial cancer cells in cell line xenograft models (PMID: 27550940).",Actionable,9119,1380,endometrial cancer,DOID,3147,FGFR2 amp,"[{'id': 6925, 'pubMedId': 27550940, 'title': 'Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550940'}]",sensitive,654,AZD4547,2263
100,Preclinical - Pdx,"In a preclinical study, PRN1371 treatment resulted in tumor growth inhibition in patient-derived xenograft models of FGFR2-amplified breast cancer harboring FGFR2-GAB2 fusion (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8414,1612,breast cancer,DOID,26313,FGFR2 amp FGFR2 fusion,"[{'id': 6640, 'pubMedId': None, 'title': 'PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1249'}]",sensitive,3583,PRN1371,2263
101,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917). ",Actionable,7832,5520,head and neck squamous cell carcinoma,DOID,26059,EGFR over exp FGFR2 amp,"[{'id': 6507, 'pubMedId': 26936917, 'title': 'FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26936917'}]",resistant,654,AZD4547,2263
102,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a moderate synergistic effect (PMID: 26936917). ",Actionable,7835,5520,head and neck squamous cell carcinoma,DOID,26059,EGFR over exp FGFR2 amp,"[{'id': 6507, 'pubMedId': 26936917, 'title': 'FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26936917'}]",sensitive,4585,AZD4547 + Gefitinib,2263
103,Preclinical - Cell culture,"In a preclinical study, the combination of AZD-4547 and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and FGFR2 amplification in culture (PMID: 27595477).",Actionable,11556,4914,esophagus adenocarcinoma,DOID,28144,ERBB2 amp FGFR2 amp,"[{'id': 9641, 'pubMedId': 27595477, 'title': 'Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27595477'}]",sensitive,6062,AZD4547 + Lapatinib,2263
104,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer cell line, harboring FGFR1 amplification and FGFR2 amplification, treated with E7090 demonstrated decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969). ",Actionable,9126,1612,breast cancer,DOID,26745,FGFR1 amp FGFR2 amp,"[{'id': 6928, 'pubMedId': 27535969, 'title': 'E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535969'}]",sensitive,4911,E7090,2263
105,Preclinical - Pdx,"In a preclinical study, AZD4547 decreased Myc expression and inhibited tumor growth in patient-derived xenograft (PDX) models of gastric cancer with FGFR2 amplification and over expression (PMID: 27401245).",Actionable,10029,10534,stomach cancer,DOID,27227,FGFR2 amp FGFR2 over exp,"[{'id': 7899, 'pubMedId': 27401245, 'title': 'c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27401245'}]",sensitive,654,AZD4547,2263
106,Preclinical - Pdx,"In a preclinical study, BGJ398 decreased Myc expression and inhibited tumor growth in patient-derived xenograft (PDX) models of gastric cancer with FGFR2 amplification and over expression (PMID: 27401245).",Actionable,10028,10534,stomach cancer,DOID,27227,FGFR2 amp FGFR2 over exp,"[{'id': 7899, 'pubMedId': 27401245, 'title': 'c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27401245'}]",sensitive,674,BGJ398,2263
107,Clinical Study,"In a clinical study, FGFR2 V564F was identified in the cell-free DNA of 3 cholangiocarcinoma patients harboring FGFR2 fusion after the patients progressed while on BGJ398 treatment (PMID: 28034880).  ",Actionable,10150,4947,cholangiocarcinoma,DOID,27314,FGFR2 fusion FGFR2 V564F,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",predicted – resistant,674,BGJ398,2263
108,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted tumor shrinkage and no disease progression for 10 months in an adrenal carcinoma patient harboring FGFR3 - TACC3 and FGFR2 - CCDC6 fusions (PMID: 26324363).",Actionable,4007,3950,adrenal carcinoma,DOID,17093,FGFR2 fusion FGFR3 - TACC3,"[{'id': 4363, 'pubMedId': 26324363, 'title': 'Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26324363'}]",sensitive,1028,JNJ-42756493,2263
109,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted in partial response in an endometrial cancer patient harboring FGFR2 - BICC1 and FGFR2 - OFD1 fusions (PMID: 26324363).",Actionable,4006,1380,endometrial cancer,DOID,2969,FGFR2 fusion,"[{'id': 4363, 'pubMedId': 26324363, 'title': 'Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26324363'}]",sensitive,1028,JNJ-42756493,2263
110,Phase I,"In a Phase I clinical trial, ARQ 087 treatment resulted in stable disease for greater than 24 weeks and 26% tumor reduction in one, and a partial response in a second, of two intrahepatic cholangiocarcinoma patients harboring FGFR2 fusions (J Clin Oncol 33, 2015 (suppl; abstr 2545)).",Actionable,3993,4928,intrahepatic cholangiocarcinoma,DOID,2969,FGFR2 fusion,"[{'id': 4359, 'pubMedId': None, 'title': 'Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/149025-156'}]",sensitive,2900,ARQ 087,2263
111,Phase I,"In a Phase I trial, two patients with cholangiocarcinoma harboring FGFR2 fusions demonstrated a decreased tumor burden when treated with BGJ398 (PMID: 27870574). ",Actionable,9737,4947,cholangiocarcinoma,DOID,2969,FGFR2 fusion,"[{'id': 7516, 'pubMedId': 27870574, 'title': 'Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27870574'}]",sensitive,674,BGJ398,2263
112,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted in partial response for more than 12 months in a urothelial cancer patient harboring FGFR2 - BICC1 and FGFR2 - CASP7 fusions (PMID: 26324363).",Actionable,4003,3996,urinary system cancer,DOID,2969,FGFR2 fusion,"[{'id': 4363, 'pubMedId': 26324363, 'title': 'Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26324363'}]",sensitive,1028,JNJ-42756493,2263
113,Phase I,"In a Phase I trial, TAS-120 treatment resulted in stable disease over 24 weeks in two biliary tract cancer patients harboring FGFR2 fusions (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD).",Actionable,11986,4607,biliary tract cancer,DOID,2969,FGFR2 fusion,"[{'id': 9948, 'pubMedId': None, 'title': 'First-in-human (FIH) study of TAS-120, a highly selective covalent oral fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]",predicted – sensitive,1053,TAS-120,2263
114,Preclinical,"In a preclinical study, treatment with BGJ398 prevented transformation of cells expressing FGFR2-AHCYL1 in culture (PMID: 24122810).",Actionable,4213,10000003,Advanced Solid Tumor,JAX,17510,FGFR2-AHCYL1,"[{'id': 4202, 'pubMedId': 24122810, 'title': 'Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24122810'}]",sensitive,674,BGJ398,2263
115,Preclinical,"In a preclinical study, treatment with PD173074 prevented transformation of cells expressing FGFR2-AHCYL1 in culture (PMID: 24122810).",Actionable,4214,10000003,Advanced Solid Tumor,JAX,17510,FGFR2-AHCYL1,"[{'id': 4202, 'pubMedId': 24122810, 'title': 'Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24122810'}]",sensitive,2948,PD173074,2263
116,Preclinical,"In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring FGFR2 N549K mutation in culture (PMID: 25169980).",Actionable,4054,1380,endometrial cancer,DOID,547,FGFR2 N549K,"[{'id': 4388, 'pubMedId': 25169980, 'title': 'The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25169980'}]",sensitive,1014,FF-284,2263
117,Preclinical,"In a preclinical study, Dovitinib (TKI258) did not potently inhibit proliferation of endometrial cancer cell lines harboring FGFR2 N549K in cell culture (PMID: 22238366).",Actionable,3497,1380,endometrial cancer,DOID,547,FGFR2 N549K,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",decreased response,721,Dovitinib,2263
118,Preclinical,"In a preclinical study, Cediranib (AZD-2171) inhibited growth of endometrial cancer cells harboring FGFR2 N549K in cell culture (PMID: 22238366).",Actionable,3498,1380,endometrial cancer,DOID,547,FGFR2 N549K,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,1001,Cediranib,2263
119,Preclinical - Cell culture,"In a preclinical study, endometrial carcinoma cells harboring FGFR2 N549K were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,8486,2871,endometrial carcinoma,DOID,547,FGFR2 N549K,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,913,Selumetinib,2263
120,Preclinical - Cell line xenograft,"In a preclinical study, Iclusig (ponatinib) inhibited growth of endometrial cancer cells harboring FGFR2 N549K in culture and in cell line xenograft models (PMID: 22238366).",Actionable,3496,1380,endometrial cancer,DOID,547,FGFR2 N549K,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,877,Ponatinib,2263
121,Preclinical - Cell culture,"In a preclinical study, endometrial carcinoma cells harboring FGFR2 N549K were not sensitive to RO4987655 in culture (PMID: 26438159).",Actionable,8456,2871,endometrial carcinoma,DOID,547,FGFR2 N549K,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,903,RO4987655,2263
122,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of endometrial cancer cells harboring FGFR2 N549K in cell culture (PMID: 22238366).",Actionable,3500,1380,endometrial cancer,DOID,547,FGFR2 N549K,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",no benefit,996,Brivanib,2263
123,Preclinical,"In a preclinical study, FIIN-01 inhibited proliferation of endometrial carcinoma cell lines harboring FGFR2 N549K mutation in culture (PMID: 20338520).",Actionable,4023,2871,endometrial carcinoma,DOID,547,FGFR2 N549K,"[{'id': 2410, 'pubMedId': 20338520, 'title': 'A structure-guided approach to creating covalent FGFR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20338520'}]",sensitive,2507,FIIN-01,2263
124,Preclinical - Cell culture,"In a preclinical study, endometrial carcinoma cells harboring FGFR2 N549K were not sensitive to RO5126766 in culture (PMID: 26438159).",Actionable,8472,2871,endometrial carcinoma,DOID,547,FGFR2 N549K,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,2011,RO5126766,2263
125,Preclinical,"In a preclinical study, Ofev (Nintedanib) did not inhibit growth of endometrial cancer cells harboring FGFR2 N549K in cell culture (PMID: 22238366).
",Actionable,3499,1380,endometrial cancer,DOID,547,FGFR2 N549K,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",resistant,831,Nintedanib,2263
126,Preclinical - Cell culture,"In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO4987655 in culture (PMID: 26438159).",Actionable,8457,2871,endometrial carcinoma,DOID,17132,FGFR2 K310R FGFR2 N549K,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,903,RO4987655,2263
127,Preclinical,"In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring FGFR2 K310R and FGFR2 N549K mutations in culture (PMID: 25169980).",Actionable,4057,1380,endometrial cancer,DOID,17132,FGFR2 K310R FGFR2 N549K,"[{'id': 4388, 'pubMedId': 25169980, 'title': 'The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25169980'}]",sensitive,1014,FF-284,2263
128,Preclinical - Cell culture,"In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,8487,2871,endometrial carcinoma,DOID,17132,FGFR2 K310R FGFR2 N549K,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,913,Selumetinib,2263
129,Preclinical - Cell culture,"In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO5126766 in culture (PMID: 26438159).",Actionable,8473,2871,endometrial carcinoma,DOID,17132,FGFR2 K310R FGFR2 N549K,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,2011,RO5126766,2263
130,Preclinical,"In a preclinical study, FIIN-01 inhibited proliferation of endometrial carcinoma cell lines harboring FGFR2 N549K and FGFR2 K310R mutations in culture (PMID: 20338520).",Actionable,4024,2871,endometrial carcinoma,DOID,17132,FGFR2 K310R FGFR2 N549K,"[{'id': 2410, 'pubMedId': 20338520, 'title': 'A structure-guided approach to creating covalent FGFR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20338520'}]",sensitive,2507,FIIN-01,2263
131,Preclinical - Cell line xenograft,"In a preclinical study, BAY1187982 inhibited survival of colorectal cancer cells with over expressing Fgfr2 in culture, and suppressed tumor growth in cell line xenograft models (PMID: 27543601).",Actionable,9096,9256,colorectal cancer,DOID,8808,FGFR2 over exp,"[{'id': 6911, 'pubMedId': 27543601, 'title': 'Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27543601'}]",sensitive,2931,BAY1187982,2263
132,Preclinical - Cell culture,"In a preclinical study, endometrial cells with Fgfr2 overexpression were resistant to the anti-proliferative effects of AZD4547 (PMID: 26294741).",Actionable,8854,1380,endometrial cancer,DOID,8808,FGFR2 over exp,"[{'id': 6769, 'pubMedId': 26294741, 'title': 'Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26294741'}]",resistant,654,AZD4547,2263
133,Preclinical,"In a preclinical study, AZD4547 inhibited downstream Erk phosphorylation and proliferation of breast cancer cells over expressing FGFR2 in culture (PMID: 22869148).",Actionable,2579,1612,breast cancer,DOID,8808,FGFR2 over exp,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",sensitive,654,AZD4547,2263
134,Preclinical,"In a preclinical study, AZ8010 inhibited downstream Erk phosphorylation and proliferation of breast cancer cells over expressing FGFR2 in culture (PMID: 22869148).",Actionable,2577,1612,breast cancer,DOID,8808,FGFR2 over exp,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",sensitive,2955,AZ8010,2263
135,Preclinical,"In a preclinical study, PD173074 inhibited proliferation of breast cancer cells over expressing FGFR2 in culture (PMID: 22869148).",Actionable,3279,1612,breast cancer,DOID,8808,FGFR2 over exp,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",sensitive,2948,PD173074,2263
136,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 N550H demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2586,10000003,Advanced Solid Tumor,JAX,3427,FGFR2 N550H,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",decreased response,721,Dovitinib,2263
137,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 N550H were resistant to treatment with PD173074 (PMID: 23908597).",Actionable,2594,10000003,Advanced Solid Tumor,JAX,3427,FGFR2 N550H,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",resistant,2948,PD173074,2263
138,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 N550H (PMID: 23908597).",Actionable,2606,10000003,Advanced Solid Tumor,JAX,3427,FGFR2 N550H,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",sensitive,877,Ponatinib,2263
139,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 K660E demonstrated a decreased response when treated with PD173074 (PMID: 23908597).",Actionable,3283,10000003,Advanced Solid Tumor,JAX,3413,FGFR2 K660E,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",decreased response,2948,PD173074,2263
140,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 K660E were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2590,10000003,Advanced Solid Tumor,JAX,3413,FGFR2 K660E,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",resistant,721,Dovitinib,2263
141,Preclinical - Cell culture,"In a preclinical study, PRN1371 inhibited Fgfr2 activity in transformed cells over expressing FGFR K660E in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8399,10000003,Advanced Solid Tumor,JAX,3413,FGFR2 K660E,"[{'id': 6640, 'pubMedId': None, 'title': 'PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1249'}]",sensitive,3583,PRN1371,2263
142,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 K660E demonstrated a decreased response to treatment with Iclusig (ponatinib) (PMID: 23908597).",Actionable,2603,10000003,Advanced Solid Tumor,JAX,3413,FGFR2 K660E,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",decreased response,877,Ponatinib,2263
143,Preclinical - Cell culture,"In a preclinical study, endometrial carcinoma cells harboring FGFR2 S252W demonstrated decreased response to RO4987655 in culture (PMID: 26438159).",Actionable,8455,2871,endometrial carcinoma,DOID,3430,FGFR2 S252W,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",decreased response,903,RO4987655,2263
144,Preclinical,"In a preclinical study, Ofev (Nintedanib) inhibited cell proliferation in endometrial cancer cells harboring FGFR2 S252W mutation in culture (PMID: 22238366).",Actionable,3505,1380,endometrial cancer,DOID,3430,FGFR2 S252W,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,831,Nintedanib,2263
145,Preclinical,"In a preclinical study, Brivanib (BMS-540215) inhibited growth of endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 22238366).",Actionable,3504,1380,endometrial cancer,DOID,3430,FGFR2 S252W,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,996,Brivanib,2263
146,Preclinical,"In a preclinical study, Cediranib (AZD-2171) inhibited growth of endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 22238366).
",Actionable,3503,1380,endometrial cancer,DOID,3430,FGFR2 S252W,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,1001,Cediranib,2263
147,Preclinical - Cell culture,"In a preclinical study, RO5126766 inhibited proliferation of endometrial carcinoma cells harboring FGFR2 S252W in culture (PMID: 26438159).",Actionable,8497,2871,endometrial carcinoma,DOID,3430,FGFR2 S252W,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",sensitive,2011,RO5126766,2263
148,Preclinical,"In a preclinical study, Dovitinib (TKI258) did not potently inhibit cell proliferation in endometrial cancer cells harboring FGFR2 S252W mutation in culture (PMID: 22238366).",Actionable,3755,1380,endometrial cancer,DOID,3430,FGFR2 S252W,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",decreased response,721,Dovitinib,2263
149,Preclinical - Cell culture,"In a preclinical study, endometrial carcinoma cells harboring FGFR2 S252W demonstrated decreased sensitivity to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,8485,2871,endometrial carcinoma,DOID,3430,FGFR2 S252W,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",decreased response,913,Selumetinib,2263
150,Preclinical - Cell line xenograft,"In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring an FGFR2 S252W mutation in culture and inhibited tumor growth in FGFR2 S252W-positive endometrial cancer cell line xenograft models (PMID: 25169980).",Actionable,4059,1380,endometrial cancer,DOID,3430,FGFR2 S252W,"[{'id': 4388, 'pubMedId': 25169980, 'title': 'The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25169980'}]",sensitive,1014,FF-284,2263
151,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 S252W were sensitive to Dovitinib (TKI258) (PMID: 23908597). ",Actionable,3275,10000003,Advanced Solid Tumor,JAX,3430,FGFR2 S252W,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",sensitive,721,Dovitinib,2263
152,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and cell proliferation in endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 22238366).",Actionable,3501,1380,endometrial cancer,DOID,3430,FGFR2 S252W,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,877,Ponatinib,2263
153,Preclinical - Cell culture,"In a preclinical study, an endometrial cancer cell line harboring FGFR2 S252W (PMID: 18552176) demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability (PMID: 27535969). ",Actionable,9137,1380,endometrial cancer,DOID,3430,FGFR2 S252W,"[{'id': 252, 'pubMedId': 18552176, 'title': 'Drug-sensitive FGFR2 mutations in endometrial carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18552176'}, {'id': 6928, 'pubMedId': 27535969, 'title': 'E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535969'}]",sensitive,4911,E7090,2263
154,Preclinical - Cell line xenograft,"In a preclinical study, GSK3052230 (FP-1039) treatment resulted in greater tumor growth inhibition (95% vs 30%) in cell line xenograft models of endometrial carcinoma harboring FGFR2 S252W compared to FGFR2 wild-type models (PMID: 23536011).",Actionable,11475,2871,endometrial carcinoma,DOID,3430,FGFR2 S252W,"[{'id': 9409, 'pubMedId': 23536011, 'title': 'Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23536011'}]",sensitive,2899,GSK3052230,2263
155,Preclinical - Cell culture,"In a preclinical study, endometrial cells harboring Fgfr2 S252W were less sensitive to the anti-proliferative effects of AZD4547 than the Fgfr2 double mutant, K310R, N550K (PMID: 26294741).",Actionable,8853,1380,endometrial cancer,DOID,3430,FGFR2 S252W,"[{'id': 6769, 'pubMedId': 26294741, 'title': 'Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26294741'}]",decreased response,654,AZD4547,2263
156,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 M538I demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2592,10000003,Advanced Solid Tumor,JAX,9489,FGFR2 M538I,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",decreased response,721,Dovitinib,2263
157,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 M538I demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).",Actionable,2597,10000003,Advanced Solid Tumor,JAX,9489,FGFR2 M538I,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",decreased response,2948,PD173074,2263
158,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 M538I demonstrated a decreased response to treatment with Iclusig (ponatinib) (PMID: 23908597).",Actionable,2602,10000003,Advanced Solid Tumor,JAX,9489,FGFR2 M538I,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",decreased response,877,Ponatinib,2263
159,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 M536I (PMID: 23908597).",Actionable,2604,10000003,Advanced Solid Tumor,JAX,9488,FGFR2 M536I,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",sensitive,877,Ponatinib,2263
160,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 M536I demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2593,10000003,Advanced Solid Tumor,JAX,9488,FGFR2 M536I,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",decreased response,721,Dovitinib,2263
161,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 M536I demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).",Actionable,2596,10000003,Advanced Solid Tumor,JAX,9488,FGFR2 M536I,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",decreased response,2948,PD173074,2263
162,Clinical Study,"In clinical case study, a patient with olfactory neuroblastoma harboring EGFR R521K, FGFR2 M186T, KDR Q472H, KDR V297I, and RET M1009T demonstrated sensitivity to the combination of Sutent (sunitinib) and Erbitux (cetuximab), resulting in a complete response (PMID: 27149458).",Actionable,7758,369,olfactory neuroblastoma,DOID,26023,EGFR R521K FGFR2 M186T KDR Q472H KDR V297I RET M1009T,"[{'id': 6481, 'pubMedId': 27149458, 'title': 'Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27149458'}]",sensitive,4568,Cetuximab + Sunitinib,2263
163,Preclinical,"In a preclinical study, AZ12576089 (AZ6089) inhibited FGF2-induced ERK1/2 phosphorylation and cell proliferation in transformed fibroblasts in culture (PMID: 22869148).",Actionable,3995,10000003,Advanced Solid Tumor,JAX,543,FGFR2 wild-type,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",predicted – sensitive,2956,AZ6089,2263
164,Preclinical,"In a preclinical study, an endometrial carcinoma cell line harboring wild-type FGFR2 was resistant to FIIN-01-induced growth inhibition in culture (PMID: 20338520).",Actionable,4025,2871,endometrial carcinoma,DOID,543,FGFR2 wild-type,"[{'id': 2410, 'pubMedId': 20338520, 'title': 'A structure-guided approach to creating covalent FGFR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20338520'}]",resistant,2507,FIIN-01,2263
165,Preclinical,"In a preclinical study, ER-negative breast cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).",Actionable,3536,1612,breast cancer,DOID,543,FGFR2 wild-type,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",resistant,877,Ponatinib,2263
166,Preclinical,"In a preclinical study, colon cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).
",Actionable,3548,219,colon cancer,DOID,543,FGFR2 wild-type,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",resistant,877,Ponatinib,2263
167,Preclinical,"In a preclinical study, endometrial cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).
",Actionable,3506,1380,endometrial cancer,DOID,543,FGFR2 wild-type,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",resistant,877,Ponatinib,2263
168,Preclinical,"In a preclinical study, gastric cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).
",Actionable,3520,10534,stomach cancer,DOID,543,FGFR2 wild-type,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",resistant,877,Ponatinib,2263
169,Preclinical - Cell culture,"In a preclinical study, endometrial cells with Fgfr2 wild-type were resistant to the anti-proliferative effects of AZD4547 (PMID: 26294741).",Actionable,8855,1380,endometrial cancer,DOID,543,FGFR2 wild-type,"[{'id': 6769, 'pubMedId': 26294741, 'title': 'Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26294741'}]",resistant,654,AZD4547,2263
170,Preclinical - Cell culture,"In a preclinical study, PRN1371 inhibited Fgfr2 activity in transformed cells over expressing wild-type Fgfr2 in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8398,10000003,Advanced Solid Tumor,JAX,543,FGFR2 wild-type,"[{'id': 6640, 'pubMedId': None, 'title': 'PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1249'}]",sensitive,3583,PRN1371,2263
171,Preclinical,"In a preclinical study, gastric cancer cells with wild-type FGFR2  and ERBB2 (HER2) amplification were resistant to treatment with AZD4547 in culture (PMID: 22869148).",Actionable,2581,10534,stomach cancer,DOID,9482,FGFR2 wild-type ERBB2 amp,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",resistant,654,AZD4547,2263
172,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 N550S demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2585,10000003,Advanced Solid Tumor,JAX,9483,FGFR2 N550S,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",decreased response,721,Dovitinib,2263
173,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 N550S (PMID: 23908597).",Actionable,2608,10000003,Advanced Solid Tumor,JAX,9483,FGFR2 N550S,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",sensitive,877,Ponatinib,2263
174,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 N550S demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).",Actionable,2599,10000003,Advanced Solid Tumor,JAX,9483,FGFR2 N550S,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",decreased response,2948,PD173074,2263
175,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells over expressing FGFR2 V564F were resistant to AZD4547 in culture and in cell line xenograft models (PMID: 25169980).",Actionable,10185,10000003,Advanced Solid Tumor,JAX,27305,FGFR2 V564F,"[{'id': 4388, 'pubMedId': 25169980, 'title': 'The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25169980'}]",resistant,654,AZD4547,2263
176,Preclinical - Cell line xenograft,"In a preclinical study, Debio 1347 inhibited proliferation of transformed cells over expressing FGFR2 V564F in culture and inhibited tumor growth in cell line xenograft models (PMID: 25169980).",Actionable,10184,10000003,Advanced Solid Tumor,JAX,27305,FGFR2 V564F,"[{'id': 4388, 'pubMedId': 25169980, 'title': 'The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25169980'}]",sensitive,1014,FF-284,2263
177,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR2 V564F were resistant to BGJ398 in culture (PMID: 28034880).",Actionable,10183,10000003,Advanced Solid Tumor,JAX,27305,FGFR2 V564F,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",resistant,674,BGJ398,2263
178,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 L618M demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2589,10000003,Advanced Solid Tumor,JAX,9492,FGFR2 L618M,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",decreased response,721,Dovitinib,2263
179,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 L618M demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).",Actionable,2600,10000003,Advanced Solid Tumor,JAX,9492,FGFR2 L618M,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",decreased response,2948,PD173074,2263
180,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 L618M were sensitive to treatment with Iclusig (ponatinib) (PMID: 23908597).",Actionable,3282,10000003,Advanced Solid Tumor,JAX,9492,FGFR2 L618M,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",sensitive,877,Ponatinib,2263
181,Preclinical - Cell culture,"In a preclinical study, Debio 1347 did not inhibit Fgfr2 phosphorylation in transformed cells over expressing FGFR2 V564I in culture (PMID: 25169980).",Actionable,10188,10000003,Advanced Solid Tumor,JAX,27306,FGFR2 V564I,"[{'id': 4388, 'pubMedId': 25169980, 'title': 'The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25169980'}]",resistant,1014,FF-284,2263
182,Preclinical,"In a preclinical study, knocking down of Fgfr2 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).",Actionable,7362,1324,lung cancer,DOID,25308,FGFR2 dec exp KRAS mut,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",no benefit,2,Trametinib,2263
183,Preclinical - Cell culture,"In a preclinical study, BAY1187982 did not inhibit growth of breast cancer cells with very low Fgfr2 expression level in culture (PMID: 27543601).",Actionable,9098,1612,breast cancer,DOID,25307,FGFR2 dec exp,"[{'id': 6911, 'pubMedId': 27543601, 'title': 'Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27543601'}]",resistant,2931,BAY1187982,2263
184,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 E566G (PMID: 23908597).",Actionable,2609,10000003,Advanced Solid Tumor,JAX,9485,FGFR2 E566G,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",sensitive,877,Ponatinib,2263
185,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 E566G were resistant to treatment with PD173074 (PMID: 23908597).",Actionable,2595,10000003,Advanced Solid Tumor,JAX,9485,FGFR2 E566G,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",resistant,2948,PD173074,2263
186,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 E566G were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2588,10000003,Advanced Solid Tumor,JAX,9485,FGFR2 E566G,"[{'id': 2138, 'pubMedId': 23908597, 'title': 'The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23908597'}]",resistant,721,Dovitinib,2263
0,Preclinical,"In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to PD173074 in culture (PMID: 22869148).",Actionable,3278,2671,transitional cell carcinoma,DOID,13021,FGFR3 wild-type FGFR3 dec exp HRAS G12V,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",resistant,2948,PD173074,2261
1,Preclinical,"In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZD4547 in culture (PMID: 22869148).",Actionable,2576,2671,transitional cell carcinoma,DOID,13021,FGFR3 wild-type FGFR3 dec exp HRAS G12V,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",resistant,654,AZD4547,2261
2,Preclinical,"In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZ8010 in culture (PMID: 22869148).",Actionable,2575,2671,transitional cell carcinoma,DOID,13021,FGFR3 wild-type FGFR3 dec exp HRAS G12V,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",decreased response,2955,AZ8010,2261
3,Preclinical,"In a preclinical study, knocking down of Fgfr3 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture  (PMID: 27338794).",Actionable,7363,1324,lung cancer,DOID,25309,FGFR3 dec exp KRAS mut,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",no benefit,2,Trametinib,2261
4,Phase II,"In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response for 6 months in 33% (1/3) of non-muscle invasive bladder cancer patients harboring both FGFR3 mutations and FGFR3 over expression (J Clin Oncol 34, 2016 (suppl; abstr 4526)).",Actionable,6980,11054,urinary bladder cancer,DOID,24169,FGFR3 mut FGFR3 over exp,"[{'id': 5997, 'pubMedId': None, 'title': 'Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression: Hoosier Cancer Research Network GU12-157.', 'url': 'http://meetinglibrary.asco.org/content/167294-176'}]",sensitive,721,Dovitinib,2261
5,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited survival of bladder cancer cells harboring FGFR3 mutation in culture (PMID: 27550940).",Actionable,9123,11054,urinary bladder cancer,DOID,1222,FGFR3 mutant,"[{'id': 6925, 'pubMedId': 27550940, 'title': 'Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550940'}]",sensitive,654,AZD4547,2261
6,Preclinical - Cell line xenograft,"In a preclinical study, a variety of cancer cell lines harboring mutations in FGFR1, FGFR2, and/or FGFR3 demonstrated sensitivity to INCB054828 in culture and in cell line xenograft models, resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 771).",Actionable,8391,10000003,Advanced Solid Tumor,JAX,1222,FGFR3 mutant,"[{'id': 6136, 'pubMedId': None, 'title': 'Abstract 771: Preclinical characterization of the selective FGFR inhibitor INCB054828', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/771.short'}]",sensitive,4173,INCB054828,2261
7,Preclinical,"In a preclinical study, tumor cell lines with FGFR3 mutations demonstrated sensitivity to BGJ398 in culture (PMID: 23002168).",Actionable,1118,10000003,Advanced Solid Tumor,JAX,1222,FGFR3 mutant,"[{'id': 872, 'pubMedId': 23002168, 'title': 'FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23002168'}]",sensitive,674,BGJ398,2261
8,Phase II,"In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response in 33% (1/3) of patients with BCG-unresponsive, non–muscle-invasive, urothelial carcinoma of the bladder harboring FGFR3 mutations (PMID: 27932416).",Actionable,11227,4006,bladder urothelial carcinoma,DOID,1222,FGFR3 mutant,"[{'id': 9176, 'pubMedId': 27932416, 'title': 'A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27932416'}]",sensitive,721,Dovitinib,2261
9,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted in 25% tumor shrinkage at week 8 in an urothelial cancer patient harboring FGFR3 mutations (PMID: 26324363).",Actionable,4008,3996,urinary system cancer,DOID,1222,FGFR3 mutant,"[{'id': 4363, 'pubMedId': 26324363, 'title': 'Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26324363'}]",sensitive,1028,JNJ-42756493,2261
10,Phase I,"In a Phase I trial, patients with urinary bladder urothelial carcinoma demonstrated a disease control rate of 75% (6/8) when treated with BGJ398, resulting in 3 patients with a partial response and 3 with stable disease (PMID: 27870574). ",Actionable,9734,4006,bladder urothelial carcinoma,DOID,1222,FGFR3 mutant,"[{'id': 7516, 'pubMedId': 27870574, 'title': 'Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27870574'}]",sensitive,674,BGJ398,2261
11,Phase I,"In a Phase I trial, BGJ398 treatment resulted in complete response in 4% (1/25) and partial response in 32% (8/25) of urothelial carcinoma patients harboring FGFR3 mutations or fusions (J Clin Oncol 34, 2016 (suppl; abstr 4517)).",Actionable,6976,2671,transitional cell carcinoma,DOID,1222,FGFR3 mutant,"[{'id': 5994, 'pubMedId': None, 'title': 'Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations.', 'url': 'http://meetinglibrary.asco.org/content/164341-176'}]",sensitive,674,BGJ398,2261
12,Preclinical - Cell line xenograft,"In a preclinical study, R3Mab decreased wild-type FGFR3 activation, thereby inhibited cell proliferation of FGFR3 wild-type human bladder cancer cells in culture and in cell line xenograft models (PMID: 19381019).",Actionable,1035,4007,bladder carcinoma,DOID,544,FGFR3 wild-type,"[{'id': 742, 'pubMedId': 19381019, 'title': 'Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19381019'}]",sensitive,1465,R3Mab,2261
13,Preclinical - Cell culture,"In a preclinical study, SU5402 inhibited proliferation of myeloma cells expressing wild-type FGFR3 in culture (PMID: 23597562).",Actionable,7843,70004,myeloid neoplasm,DOID,544,FGFR3 wild-type,"[{'id': 2414, 'pubMedId': 23597562, 'title': 'Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23597562'}]",sensitive,3305,SU5402,2261
14,Preclinical,"In a preclinical study, SSR128129E inhibited proliferation of myeloma cells expressing wild-type FGFR3 in culture (PMID: 23597562).",Actionable,4015,70004,myeloid neoplasm,DOID,544,FGFR3 wild-type,"[{'id': 2414, 'pubMedId': 23597562, 'title': 'Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23597562'}]",sensitive,2508,SSR128129E,2261
15,Preclinical,"In a preclinical study, bladder cancer cells with wild-type FGFR3 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).",Actionable,3518,11054,urinary bladder cancer,DOID,544,FGFR3 wild-type,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",resistant,877,Ponatinib,2261
16,Preclinical - Cell culture,"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880).",Actionable,10160,10000003,Advanced Solid Tumor,JAX,25236,FGFR3 V555M,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",sensitive,877,Ponatinib,2261
17,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 V555M were resistant to AZD4547 in culture (PMID: 28034880).",Actionable,10169,10000003,Advanced Solid Tumor,JAX,25236,FGFR3 V555M,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",resistant,654,AZD4547,2261
18,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 V555M were resistant to BGJ398 in culture (PMID: 28034880).",Actionable,10155,10000003,Advanced Solid Tumor,JAX,25236,FGFR3 V555M,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",resistant,674,BGJ398,2261
19,Preclinical - Cell culture,"In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880).",Actionable,10166,10000003,Advanced Solid Tumor,JAX,25236,FGFR3 V555M,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",sensitive,721,Dovitinib,2261
20,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 V555M demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880).",Actionable,10171,10000003,Advanced Solid Tumor,JAX,25236,FGFR3 V555M,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",decreased response,1014,FF-284,2261
21,Preclinical - Cell culture,"In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880).",Actionable,10180,10000003,Advanced Solid Tumor,JAX,25236,FGFR3 V555M,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",sensitive,2032,LY2874455,2261
22,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 V555M demonstrated reduced sensitivity to FIIN-2 in culture (PMID: 28034880).",Actionable,10177,10000003,Advanced Solid Tumor,JAX,25236,FGFR3 V555M,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",decreased response,5421,FIIN-2,2261
23,Phase I,"In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR3 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).",Actionable,1249,10000003,Advanced Solid Tumor,JAX,1217,FGFR3 act mut,"[{'id': 3622, 'pubMedId': None, 'title': 'Preliminary clinical pharmacokinetics and pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor.', 'url': 'http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2540'}]",sensitive,1014,FF-284,2261
24,Preclinical,"In a preclinical study, transformed cells expressing constitutively active FGFR3 demonstrated reduced sensitivity to Ofev (Nintedanib) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).",Actionable,3490,10000003,Advanced Solid Tumor,JAX,1217,FGFR3 act mut,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",decreased response,831,Nintedanib,2261
25,Preclinical,"In a preclinical study, S-49076 inhibited autophosphorylation of FGFR3 and downstream signaling in bladder cancer cells over expressing constitutively active FGFR3 in culture (PMID: 23804704).",Actionable,4014,11054,urinary bladder cancer,DOID,1217,FGFR3 act mut,"[{'id': 2007, 'pubMedId': 23804704, 'title': 'S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23804704'}]",predicted – sensitive,2158,S-49076,2261
26,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR3 in culture (PMID: 22238366).",Actionable,3494,10000003,Advanced Solid Tumor,JAX,1217,FGFR3 act mut,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",no benefit,996,Brivanib,2261
27,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR3 in culture (PMID: 22238366).
",Actionable,3474,10000003,Advanced Solid Tumor,JAX,1217,FGFR3 act mut,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,721,Dovitinib,2261
28,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted in stable disease in 70% (16/23) and partial response in 22% (5/23) of patients with advanced solid tumors harboring FGFR 1-4 activating mutations (including amplifications, mutations and translocations), while no antitumor activity was observed in patients with unknown or no known changes in FGFR (PMID: 26324363).",Actionable,4000,10000003,Advanced Solid Tumor,JAX,1217,FGFR3 act mut,"[{'id': 4363, 'pubMedId': 26324363, 'title': 'Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26324363'}]",sensitive,1028,JNJ-42756493,2261
29,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR3 in culture (PMID: 22238366).
",Actionable,3471,10000003,Advanced Solid Tumor,JAX,1217,FGFR3 act mut,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,877,Ponatinib,2261
30,Preclinical,"In a preclinical study, transformed cells expressing constitutively active FGFR3 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Cediranib (AZD-2171) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).",Actionable,3478,10000003,Advanced Solid Tumor,JAX,1217,FGFR3 act mut,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",decreased response,1001,Cediranib,2261
31,Preclinical - Cell culture,"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 N540K in culture (PMID: 28034880).",Actionable,10161,10000003,Advanced Solid Tumor,JAX,25257,FGFR3 N540K,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",sensitive,877,Ponatinib,2261
32,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to LY2874455 in culture (PMID: 28034880).",Actionable,10182,10000003,Advanced Solid Tumor,JAX,25257,FGFR3 N540K,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",decreased response,2032,LY2874455,2261
33,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 N540K were reistant to growth inhibition by AZD4547 in culture (PMID: 26992226).",Actionable,7575,10000003,Advanced Solid Tumor,JAX,25257,FGFR3 N540K,"[{'id': 6316, 'pubMedId': 26992226, 'title': 'Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26992226'}]",resistant,654,AZD4547,2261
34,Preclinical - Cell culture,"In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 N540K in culture (PMID: 28034880).",Actionable,10165,10000003,Advanced Solid Tumor,JAX,25257,FGFR3 N540K,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",sensitive,721,Dovitinib,2261
35,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to FIIN-2 in culture (PMID: 28034880).",Actionable,10178,10000003,Advanced Solid Tumor,JAX,25257,FGFR3 N540K,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",decreased response,5421,FIIN-2,2261
36,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880).",Actionable,10172,10000003,Advanced Solid Tumor,JAX,25257,FGFR3 N540K,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",decreased response,1014,FF-284,2261
37,Preclinical - Cell culture,"In a preclinicl study, JNJ-42756493 inhibited proliferation of transformed cells over expressing FGFR3 K560E in culture (PMID: 26992226). ",Actionable,7577,10000003,Advanced Solid Tumor,JAX,25257,FGFR3 N540K,"[{'id': 6316, 'pubMedId': 26992226, 'title': 'Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26992226'}]",sensitive,1028,JNJ-42756493,2261
38,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 N540K were resistant to BGJ398 in culture (PMID: 28034880).",Actionable,10153,10000003,Advanced Solid Tumor,JAX,25257,FGFR3 N540K,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",resistant,674,BGJ398,2261
39,Preclinical - Cell culture,"In a preclinical study, Debio 1347 inhibited proliferation of a bladder cancer cell line harboring an FGFR3-BAIAP2L1 fusion in culture (PMID: 25169980).",Actionable,4061,11054,urinary bladder cancer,DOID,15037,FGFR3-BAIAP2L1,"[{'id': 4388, 'pubMedId': 25169980, 'title': 'The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25169980'}]",sensitive,1014,FF-284,2261
40,Preclinical - Cell line xenograft,"In a preclinical study, Debio 1347 decreased phosphorylation of ERK and FRS and inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture, and inhibited tumor growth in bladder cancer cell line xenograft models with FGFR3-BAIAP2L1 (PMID: 25589496)",Actionable,8348,11054,urinary bladder cancer,DOID,15037,FGFR3-BAIAP2L1,"[{'id': 6627, 'pubMedId': 25589496, 'title': 'Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25589496'}]",sensitive,1014,FF-284,2261
41,Preclinical - Cell culture,"In a preclinical study, BGJ398 inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).",Actionable,8351,11054,urinary bladder cancer,DOID,15037,FGFR3-BAIAP2L1,"[{'id': 6627, 'pubMedId': 25589496, 'title': 'Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25589496'}]",sensitive,674,BGJ398,2261
42,Preclinical - Cell culture,"In a preclinical study, Cediranib (AZD-2171) inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).",Actionable,8352,11054,urinary bladder cancer,DOID,15037,FGFR3-BAIAP2L1,"[{'id': 6627, 'pubMedId': 25589496, 'title': 'Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25589496'}]",sensitive,1001,Cediranib,2261
43,Preclinical - Cell culture,"In a preclinical study, PD173074 inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).",Actionable,8349,11054,urinary bladder cancer,DOID,15037,FGFR3-BAIAP2L1,"[{'id': 6627, 'pubMedId': 25589496, 'title': 'Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25589496'}]",sensitive,2948,PD173074,2261
44,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).",Actionable,8350,11054,urinary bladder cancer,DOID,15037,FGFR3-BAIAP2L1,"[{'id': 6627, 'pubMedId': 25589496, 'title': 'Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25589496'}]",sensitive,654,AZD4547,2261
45,Preclinical - Cell culture,"In a preclinical study, ASP5878 treatment inhibited proliferation of a bladder cancer cell line harboring an FGFR3-BAIAP2L1 fusion in culture (Mol Cancer Ther December 2015 14; A170).",Actionable,4635,11054,urinary bladder cancer,DOID,15037,FGFR3-BAIAP2L1,"[{'id': 4639, 'pubMedId': None, 'title': 'Preclinical antitumor activity of ASP5878, a novel inhibitor of FGFR1, 2, 3 and 4, in bladder cancer harboring FGFR3-fusion or -mutation', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/A170.short'}]",sensitive,3584,ASP5878,2261
46,Preclinical - Cell culture,"In a preclinical study, Dovitinib (TKI258) inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).",Actionable,8353,11054,urinary bladder cancer,DOID,15037,FGFR3-BAIAP2L1,"[{'id': 6627, 'pubMedId': 25589496, 'title': 'Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25589496'}]",sensitive,721,Dovitinib,2261
47,Preclinical,"In a preclinical study, a mouse breast carcinoma cell line xenograft model demonstrated inhibition of tumor growth when treated with E7090, a result of decreased FGFR2 and FGFR3 activity (PMID: 27535969). ",Actionable,9142,3459,breast carcinoma,DOID,26749,FGFR2 pos FGFR3 pos,"[{'id': 6928, 'pubMedId': 27535969, 'title': 'E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535969'}]",sensitive,4911,E7090,2261
48,Phase I,"In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including a partial remission in a patient with FGFR3-positive head and neck squamous cell carcinoma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).",Actionable,11999,5520,head and neck squamous cell carcinoma,DOID,9322,FGFR3 positive,"[{'id': 9963, 'pubMedId': None, 'title': 'A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study', 'url': 'http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts'}]",predicted – sensitive,2030,Rogaratinib,2261
49,Phase I,"In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR3-positive lung squamous cell carcinoma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).",Actionable,12006,3907,lung squamous cell carcinoma,DOID,9322,FGFR3 positive,"[{'id': 9963, 'pubMedId': None, 'title': 'A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study', 'url': 'http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts'}]",predicted – sensitive,2030,Rogaratinib,2261
50,Phase I,"In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR3-positive gastric cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).",Actionable,12004,10534,stomach cancer,DOID,9322,FGFR3 positive,"[{'id': 9963, 'pubMedId': None, 'title': 'A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study', 'url': 'http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts'}]",predicted – sensitive,2030,Rogaratinib,2261
51,Phase I,"In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR3-positive lung adenocarcinoma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).",Actionable,12001,3910,lung adenocarcinoma,DOID,9322,FGFR3 positive,"[{'id': 9963, 'pubMedId': None, 'title': 'A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study', 'url': 'http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts'}]",predicted – sensitive,2030,Rogaratinib,2261
52,Preclinical - Cell culture,"In a preclinical study, a head and neck squamous cell carcinoma cell line expressing FGFR3 S131L demonstrated decreased sensitivity to BGJ398 compared to cells expressing wild-type FGFR3 in culture (PMID: 27053219).",Actionable,9034,5520,head and neck squamous cell carcinoma,DOID,26695,FGFR3 S131L,"[{'id': 6884, 'pubMedId': 27053219, 'title': 'Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27053219'}]",decreased response,674,BGJ398,2261
53,Preclinical - Cell culture,"In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).",Actionable,10181,10000003,Advanced Solid Tumor,JAX,2183,FGFR3 K650E,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",sensitive,2032,LY2874455,2261
54,Preclinical - Cell culture,"In a preclinical study, SU5402 inhibited proliferation of myeloma cells expressing FGFR3 K650E in culture (PMID: 23597562).",Actionable,7844,70004,myeloid neoplasm,DOID,2183,FGFR3 K650E,"[{'id': 2414, 'pubMedId': 23597562, 'title': 'Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23597562'}]",sensitive,3305,SU5402,2261
55,Preclinical,"In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 K650E in culture (PMID: 25169980).",Actionable,4064,70004,myeloid neoplasm,DOID,2183,FGFR3 K650E,"[{'id': 4388, 'pubMedId': 25169980, 'title': 'The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25169980'}]",sensitive,1014,FF-284,2261
56,Preclinical - Cell culture,"In a preclinical study, FIIN-2 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).",Actionable,10176,10000003,Advanced Solid Tumor,JAX,2183,FGFR3 K650E,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",sensitive,5421,FIIN-2,2261
57,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 K650E demonstrated reduced sensitivity to growth inhibition by AZD4547 in culture (PMID: 26992226).",Actionable,7574,10000003,Advanced Solid Tumor,JAX,2183,FGFR3 K650E,"[{'id': 6316, 'pubMedId': 26992226, 'title': 'Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26992226'}]",decreased response,654,AZD4547,2261
58,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 K650E demonstrated reduced sensitivity to BGJ398 in culture (PMID: 28034880).",Actionable,10152,10000003,Advanced Solid Tumor,JAX,2183,FGFR3 K650E,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",decreased response,674,BGJ398,2261
59,Preclinical,"In a preclinical study, SSR128129E did not inhibit proliferation of myeloma cells expressing FGFR3 K650E in culture (PMID: 23597562).",Actionable,4016,70004,myeloid neoplasm,DOID,2183,FGFR3 K650E,"[{'id': 2414, 'pubMedId': 23597562, 'title': 'Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23597562'}]",no benefit,2508,SSR128129E,2261
60,Preclinical - Cell culture,"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).",Actionable,10163,10000003,Advanced Solid Tumor,JAX,2183,FGFR3 K650E,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",sensitive,877,Ponatinib,2261
61,Preclinical,"In a preclinical study, PD98059 inhibited FGFR3 K650E-induced transformation of cells in culture (PMID: 14534538).",Actionable,3997,10000003,Advanced Solid Tumor,JAX,2183,FGFR3 K650E,"[{'id': 4362, 'pubMedId': 14534538, 'title': 'The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/14534538'}]",sensitive,2617,PD98059,2261
62,Preclinical - Cell culture,"In a preclinical study, Debio 1347 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).",Actionable,10173,10000003,Advanced Solid Tumor,JAX,2183,FGFR3 K650E,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",sensitive,1014,FF-284,2261
63,Preclinical - Cell culture,"In a preclinicl study, JNJ-42756493 inhibited proliferation of transformed cells over expressing FGFR3 K560E in culture (PMID: 26992226). ",Actionable,7576,10000003,Advanced Solid Tumor,JAX,2183,FGFR3 K650E,"[{'id': 6316, 'pubMedId': 26992226, 'title': 'Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26992226'}]",sensitive,1028,JNJ-42756493,2261
64,Preclinical - Cell culture,"In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).",Actionable,10164,10000003,Advanced Solid Tumor,JAX,2183,FGFR3 K650E,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",sensitive,721,Dovitinib,2261
65,Preclinical,"In a preclinical study, PD173074 inhibited Fgfr3 signaling, induced cell-cycle arrest, and decreased proliferation of multiple myeloma cells harboring HRAS H117E and over expression of FGFR3 K650E in culture (PMID: 22869148).",Actionable,2578,9538,multiple myeloma,DOID,13017,FGFR3 K650E FGFR3 over exp HRAS K117E,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",sensitive,2948,PD173074,2261
66,Preclinical,"In a preclinical study, AZ8010 inhibited Fgfr3 signaling and decreased proliferation of myeloma cells with HRAS K117E and overexpression of FGFR3 K650E in culture (PMID: 22869148).",Actionable,2571,70004,myeloid neoplasm,DOID,13017,FGFR3 K650E FGFR3 over exp HRAS K117E,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",sensitive,2955,AZ8010,2261
67,Preclinical,"In a preclinical study, R3Mab prevented constitutive cell proliferation induced by FGFR3 R248C in cultured cells (PMID: 19381019).",Actionable,1030,10000003,Advanced Solid Tumor,JAX,1737,FGFR3 R248C,"[{'id': 742, 'pubMedId': 19381019, 'title': 'Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19381019'}]",sensitive,1465,R3Mab,2261
68,Preclinical - Cell culture,"In a preclinical study, FIIN-2 inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).",Actionable,10175,10000003,Advanced Solid Tumor,JAX,27303,FGFR3 L608V,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",sensitive,5421,FIIN-2,2261
69,Preclinical - Cell culture,"In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).",Actionable,10167,10000003,Advanced Solid Tumor,JAX,27303,FGFR3 L608V,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",sensitive,721,Dovitinib,2261
70,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880).",Actionable,10170,10000003,Advanced Solid Tumor,JAX,27303,FGFR3 L608V,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",decreased response,1014,FF-284,2261
71,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to AZD4547 in culture (PMID: 28034880).",Actionable,10168,10000003,Advanced Solid Tumor,JAX,27303,FGFR3 L608V,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",decreased response,654,AZD4547,2261
72,Preclinical - Cell culture,"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).",Actionable,10159,10000003,Advanced Solid Tumor,JAX,27303,FGFR3 L608V,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",sensitive,877,Ponatinib,2261
73,Preclinical - Cell culture,"In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).",Actionable,10179,10000003,Advanced Solid Tumor,JAX,27303,FGFR3 L608V,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",sensitive,2032,LY2874455,2261
74,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to BGJ398 in culture (PMID: 28034880).",Actionable,10151,10000003,Advanced Solid Tumor,JAX,27303,FGFR3 L608V,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",decreased response,674,BGJ398,2261
75,Preclinical - Cell culture,"In a preclinical study, BGJ398 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 amplification in culture (PMID: 27401245).",Actionable,10026,3996,urinary system cancer,DOID,3329,FGFR3 amp,"[{'id': 7899, 'pubMedId': 27401245, 'title': 'c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27401245'}]",sensitive,674,BGJ398,2261
76,Phase I,"In a Phase I trial, BGJ398 demonstrated safety and preliminary efficacy in patients with select solid tumors harboring FGFR alterations (Cancer Res October 1, 2014 74:CT326).",Actionable,2482,10000003,Advanced Solid Tumor,JAX,3329,FGFR3 amp,"[{'id': 2252, 'pubMedId': None, 'title': 'Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/CT326.short'}]",predicted – sensitive,674,BGJ398,2261
77,Preclinical - Cell culture,"In a preclinical study, AZD4547 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 amplification in culture (PMID: 27401245).",Actionable,10012,3996,urinary system cancer,DOID,3329,FGFR3 amp,"[{'id': 7899, 'pubMedId': 27401245, 'title': 'c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27401245'}]",sensitive,654,AZD4547,2261
78,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited growth of several tumor cell lines with FGFR alterations in culture (Cancer Res April 15, 2011 71:3560).",Actionable,2480,10000003,Advanced Solid Tumor,JAX,3329,FGFR3 amp,"[{'id': 3158, 'pubMedId': None, 'title': 'Abstract 3560: Ponatinib (AP24534), a potent pan-FGFR inhibitor with activity in multiple FGFR-driven cancer models', 'url': 'http://cancerres.aacrjournals.org/content/71/8_Supplement/3560.short'}]",predicted – sensitive,877,Ponatinib,2261
79,Phase I,"In a Phase I trial, ARQ 087 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including tumors with FGFR pathway alterations (J Clin Oncol 33, 2015 (suppl; abstr 2545)).",Actionable,7760,10000003,Advanced Solid Tumor,JAX,3329,FGFR3 amp,"[{'id': 4359, 'pubMedId': None, 'title': 'Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/149025-156'}]",predicted – sensitive,2900,ARQ 087,2261
80,Preclinical - Pdx,"In a preclinical study, PRN1371 treatment had no effect on tumor growth in patient-derived xenograft models of FGFR3-amplified non-small cell lung cancer (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8411,3908,non-small cell lung carcinoma,DOID,3329,FGFR3 amp,"[{'id': 6640, 'pubMedId': None, 'title': 'PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1249'}]",no benefit,3583,PRN1371,2261
81,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted in partial response in a glioblastoma patient harboring FGFR3 - TACC3 fusion (PMID: 26324363).",Actionable,4004,3068,glioblastoma multiforme,DOID,10071,FGFR3-TACC3,"[{'id': 4363, 'pubMedId': 26324363, 'title': 'Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26324363'}]",sensitive,1028,JNJ-42756493,2261
82,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted in tumor reduction and stable disease in 2 glioblastoma multiforme patients harboring FGFR3 - TACC3 fusion (PMID: 25609060).",Actionable,4005,3068,glioblastoma multiforme,DOID,10071,FGFR3-TACC3,"[{'id': 4364, 'pubMedId': 25609060, 'title': 'Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25609060'}]",sensitive,1028,JNJ-42756493,2261
83,Phase I,"In a Phase Ib trial, BGJ398 and Alpelisib (BYL719) combination treatment resulted in partial response and a complete shrinkage of target lesions lasting 4 months in one urothelial carcinoma patient harboring a FGFR3-TACC3 fusion (J Clin Oncol 34, 2016 (suppl; abstr 2500)).",Actionable,6546,2671,transitional cell carcinoma,DOID,10071,FGFR3-TACC3,"[{'id': 5692, 'pubMedId': None, 'title': 'Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.', 'url': 'http://abstracts.asco.org/176/AbstView_176_164336.html'}]",predicted – sensitive,1293,BGJ398 + BYL719,2261
84,Preclinical,"In a preclinical study, SU5402 induced cell-cycle arrest and inhibited proliferation of bladder cancer cells that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 21119661, PMID: 23175443).",Actionable,4068,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,"[{'id': 4048, 'pubMedId': 23175443, 'title': 'Oncogenic FGFR3 gene fusions in bladder cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23175443'}, {'id': 4133, 'pubMedId': 21119661, 'title': 'Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21119661'}]",sensitive,3305,SU5402,2261
85,Preclinical - Cell culture,"In a preclinicl study, AZD4547 inhibited proliferation of transformed cells over expressing FGFR3-TACC3 in culture (PMID: 26992226). ",Actionable,7579,10000003,Advanced Solid Tumor,JAX,10071,FGFR3-TACC3,"[{'id': 6316, 'pubMedId': 26992226, 'title': 'Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26992226'}]",sensitive,654,AZD4547,2261
86,Preclinical,"In a preclinical study, S-49076 inhibited autophosphorylation of FGFR3 and downstream signaling in bladder cancer cells that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 23804704, PMID: 23175443).",Actionable,4056,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,"[{'id': 2007, 'pubMedId': 23804704, 'title': 'S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23804704'}, {'id': 4048, 'pubMedId': 23175443, 'title': 'Oncogenic FGFR3 gene fusions in bladder cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23175443'}]",predicted – sensitive,2158,S-49076,2261
87,Preclinical - Cell line xenograft,"In a preclinical study, urinary bladder cancer cells harboring FGFR3-TACC3 demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability, and antitumor activity in xenograft models (PMID: 27535969). ",Actionable,9138,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,"[{'id': 4048, 'pubMedId': 23175443, 'title': 'Oncogenic FGFR3 gene fusions in bladder cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23175443'}, {'id': 6928, 'pubMedId': 27535969, 'title': 'E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535969'}]",sensitive,4911,E7090,2261
88,Preclinical - Cell line xenograft,"In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) worked synergistically to induce apoptosis and inhibit growth of a urothelial cell carcinoma cell line harboring FGFR3-TACC3 in culture, and inhibited tumor growth in xenograft models, with increased efficacy over either agent alone (PMID: 28108151).",Actionable,11210,2671,transitional cell carcinoma,DOID,10071,FGFR3-TACC3,"[{'id': 9154, 'pubMedId': 28108151, 'title': 'A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28108151'}]",sensitive,5898,AZD4547 + BKM120,2261
89,Preclinical,"In a preclinical study, Iclusig (ponatanib) inhibited growth and FGFR3 phosphorylation in cells expressing FGFR3-TACC3 fusion in culture (PMID: 25294908).",Actionable,2702,3910,lung adenocarcinoma,DOID,10071,FGFR3-TACC3,"[{'id': 3392, 'pubMedId': 25294908, 'title': 'Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25294908'}]",sensitive,877,Ponatinib,2261
90,Preclinical - Cell culture,"In a preclinical study, BJG398 inhibited Fgfr3 kinase activity in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture (PMID: 22837387).",Actionable,2709,3070,malignant glioma,DOID,10071,FGFR3-TACC3,"[{'id': 3426, 'pubMedId': 22837387, 'title': 'Transforming fusions of FGFR and TACC genes in human glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22837387'}]",sensitive,674,BGJ398,2261
91,Preclinical - Cell line xenograft,"In a preclinical study, Debio 1347 inhibited proliferation of bladder cancer cell lines harboring an FGFR3-TACC3 fusion in culture and inhibited tumor growth in FGFR3-TACC3-positive bladder cancer cell line xenograft models (PMID: 25169980).",Actionable,4060,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,"[{'id': 4388, 'pubMedId': 25169980, 'title': 'The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25169980'}]",sensitive,1014,FF-284,2261
92,Preclinical,"In a preclinical study, bladder cancer cells harboring FGFR3-TACC were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,4034,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,913,Selumetinib,2261
93,Preclinical,"In a preclinical study, JNJ-42756493 inhibited proliferation of glioma cells harboring FGFR3 - TACC3 fusion in culture and xenograft tumor growth in animal models (PMID: 25609060).",Actionable,4009,3070,malignant glioma,DOID,10071,FGFR3-TACC3,"[{'id': 4364, 'pubMedId': 25609060, 'title': 'Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25609060'}]",sensitive,1028,JNJ-42756493,2261
94,Preclinical - Pdx,"In a preclinical study, JNJ-42756493 (erdafitinib) inhibited pERK signaling and tumor growth in a patient-derived xenograft (PDX) model of non-small cell lung cancer harboring FGFR3-TACC3 (PMID: 28341788).",Actionable,11177,3908,non-small cell lung carcinoma,DOID,10071,FGFR3-TACC3,"[{'id': 9140, 'pubMedId': 28341788, 'title': 'Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28341788'}]",sensitive,1028,JNJ-42756493,2261
95,Preclinical,"In a preclinical study, U0126 inhibited downstream signaling and growth of glioblastoma cells expressing the FGFR3-TACC3 fusion in culture (PMID: 23298836).",Actionable,2712,3068,glioblastoma multiforme,DOID,10071,FGFR3-TACC3,"[{'id': 3393, 'pubMedId': 23298836, 'title': 'The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23298836'}]",sensitive,2427,U0126,2261
96,Phase I,"In a Phase I clinical trial, JNJ-42756493 treatment resulted in partial response in 2 urothelial cancer patients harboring FGFR3-TACC3 (PMID: 26324363).",Actionable,4002,3996,urinary system cancer,DOID,10071,FGFR3-TACC3,"[{'id': 4363, 'pubMedId': 26324363, 'title': 'Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26324363'}]",sensitive,1028,JNJ-42756493,2261
97,Preclinical - Cell culture,"In a preclinical study, bladder transitional cell papilloma cells harboring FGFR3-TACC3 were not sensitive to RO5126766 in culture (PMID: 26438159).",Actionable,8476,6933,bladder transitional cell papilloma,DOID,10071,FGFR3-TACC3,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,2011,RO5126766,2261
98,Preclinical - Cell line xenograft,"In a preclinical study, R3Mab inhibited FGFR3 signaling and tumor growth in bladder cancer cell line xenograft models harboring FGFR3-TACC3 (PMID: 25326231).",Actionable,4010,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,"[{'id': 4365, 'pubMedId': 25326231, 'title': 'MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25326231'}]",sensitive,1465,R3Mab,2261
99,Preclinical,"In a preclinical study, AZ12908010 (AZ8010) induced cell cycle arrest and inhibited proliferation of urothelial cancer cell lines that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 22869148, PMID: 23175443).",Actionable,4075,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}, {'id': 4048, 'pubMedId': 23175443, 'title': 'Oncogenic FGFR3 gene fusions in bladder cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23175443'}]",sensitive,2955,AZ8010,2261
100,Preclinical,"In a preclinical study, bladder cancer cells harboring FGFR3-TACC3 demonstrated sensitivity to Votrient (pazopanib) in culture (PMID: 23558953).",Actionable,4050,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,"[{'id': 4387, 'pubMedId': 23558953, 'title': 'Identification of targetable FGFR gene fusions in diverse cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558953'}]",sensitive,848,Pazopanib,2261
101,Preclinical - Pdx,"In a preclinical study, PRN1371 treatment resulted in tumor regression in patient-derived xenograft models of anaplastic oligodendroglioma harboring FGFR3-TACC3 fusion (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8412,3181,oligodendroglioma,DOID,10071,FGFR3-TACC3,"[{'id': 6640, 'pubMedId': None, 'title': 'PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1249'}]",sensitive,3583,PRN1371,2261
102,Preclinical - Cell line xenograft,"In a preclinical study, PD173074 inhibited Fgfr3 kinase activity and growth in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture and in cell line xenograft models (PMID: 22837387).",Actionable,2704,3070,malignant glioma,DOID,10071,FGFR3-TACC3,"[{'id': 3426, 'pubMedId': 22837387, 'title': 'Transforming fusions of FGFR and TACC genes in human glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22837387'}]",sensitive,2948,PD173074,2261
103,Preclinical - Cell line xenograft,"In a preclinical study, PRN1109 treatment resulted in tumor regression in bladder cancer cell line xenograft models harboring FGFR3-TACC3 fusion (Eu J Cancer 2014 Vol 50, Suppl 6:157).",Actionable,4626,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,"[{'id': 4638, 'pubMedId': None, 'title': 'Irreversible Covalent Pan-FGFR Inhibitors are Highly Efficacious Against FGFR-dependent Cancers', 'url': 'http://www.ejcancer.com/article/S0959-8049%2814%2970609-4/pdf'}]",sensitive,4645,PRN1109,2261
104,Preclinical - Cell line xenograft,"In a preclinical study, ASP5878 treatment inhibited proliferation of bladder cancer cell lines harboring a FGFR3-TACC3 fusion in culture, and resulted in tumor regression in a FGFR3-TACC3 positive bladder cancer cell line xenograft model (Mol Cancer Ther December 2015 14; A170).",Actionable,4634,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,"[{'id': 4639, 'pubMedId': None, 'title': 'Preclinical antitumor activity of ASP5878, a novel inhibitor of FGFR1, 2, 3 and 4, in bladder cancer harboring FGFR3-fusion or -mutation', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/A170.short'}]",sensitive,3584,ASP5878,2261
105,Preclinical,"In a preclinical study, BGJ398 inhibited growth and FGFR3 phosphorylation in cells expressing FGFR3-TACC3 fusion in culture (PMID: 25294908).",Actionable,2703,3910,lung adenocarcinoma,DOID,10071,FGFR3-TACC3,"[{'id': 3392, 'pubMedId': 25294908, 'title': 'Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25294908'}]",sensitive,674,BGJ398,2261
106,Preclinical,"In a preclinical study, FIIN-1 inhibited growth of the RT4 bladder cancer cell line, which has been demonstrated to harbor an FGFR3-TACC3 fusion, in culture (PMID: 20338520, PMID: 23175443).",Actionable,4078,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,"[{'id': 2410, 'pubMedId': 20338520, 'title': 'A structure-guided approach to creating covalent FGFR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20338520'}, {'id': 4048, 'pubMedId': 23175443, 'title': 'Oncogenic FGFR3 gene fusions in bladder cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23175443'}]",sensitive,2507,FIIN-01,2261
107,Preclinical - Cell culture,"In a preclinicl study, JNJ-42756493 inhibited proliferation of transformed cells over expressing FGFR3-TACC3 in culture (PMID: 26992226). ",Actionable,7578,10000003,Advanced Solid Tumor,JAX,10071,FGFR3-TACC3,"[{'id': 6316, 'pubMedId': 26992226, 'title': 'Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26992226'}]",sensitive,1028,JNJ-42756493,2261
108,Preclinical - Cell line xenograft,"In a preclinical study, PRN1371 inhibited proliferation of bladder transitional cell carcinoma cell lines harboring FGFR3-TACC3 fusion in culture and tumor growth in cell line xenograft models (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8405,4006,bladder urothelial carcinoma,DOID,10071,FGFR3-TACC3,"[{'id': 6640, 'pubMedId': None, 'title': 'PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1249'}]",sensitive,3583,PRN1371,2261
109,Preclinical - Cell culture,"In a preclinical study, bladder transitional cell papilloma cells harboring FGFR3-TACC3 were not sensitive to RO4987655 in culture (PMID: 26438159).",Actionable,8477,6933,bladder transitional cell papilloma,DOID,10071,FGFR3-TACC3,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,903,RO4987655,2261
110,Preclinical,"In a preclinical study, LY2874455 induced tumor regression in bladder cancer xenograft models that have been demonstrated to harbor an FGFR3-TACC3 fusion (PMID: 21900693, PMID: 23175443). ",Actionable,4052,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,"[{'id': 1842, 'pubMedId': 21900693, 'title': 'A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21900693'}, {'id': 4048, 'pubMedId': 23175443, 'title': 'Oncogenic FGFR3 gene fusions in bladder cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23175443'}]",sensitive,2032,LY2874455,2261
111,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited Fgfr3 kinase activity in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture (PMID: 22837387).",Actionable,2706,3070,malignant glioma,DOID,10071,FGFR3-TACC3,"[{'id': 3426, 'pubMedId': 22837387, 'title': 'Transforming fusions of FGFR and TACC genes in human glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22837387'}]",sensitive,654,AZD4547,2261
112,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited growth of bladder cancer cell lines that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 24325461, PMID: 23175443).",Actionable,4076,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,"[{'id': 4048, 'pubMedId': 23175443, 'title': 'Oncogenic FGFR3 gene fusions in bladder cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23175443'}, {'id': 4392, 'pubMedId': 24325461, 'title': 'Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24325461'}]",sensitive,721,Dovitinib,2261
113,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted tumor shrinkage and no disease progression for 10 months in an adrenal carcinoma patient harboring FGFR3 - TACC3 and FGFR2 - CCDC6 fusions (PMID: 26324363).",Actionable,4007,3950,adrenal carcinoma,DOID,17093,FGFR2 fusion FGFR3 - TACC3,"[{'id': 4363, 'pubMedId': 26324363, 'title': 'Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26324363'}]",sensitive,1028,JNJ-42756493,2261
114,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 V555L demonstrated reduced sensitivity to BGJ398 in culture (PMID: 28034880).",Actionable,10154,10000003,Advanced Solid Tumor,JAX,27304,FGFR3 V555L,"[{'id': 8146, 'pubMedId': 28034880, 'title': 'Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28034880'}]",decreased response,674,BGJ398,2261
115,Preclinical,"In a preclinical study, Cediranib (AZD-2171) inhibited growth of bladder cancer cells harboring FGFR3 S249C mutation in culture (PMID: 22238366).
",Actionable,3514,11054,urinary bladder cancer,DOID,1736,FGFR3 S249C,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,1001,Cediranib,2261
116,Preclinical - Cell culture,"In a preclinical study, renal pelvis transitional cell carcinoma cells harboring FGFR3 S249C were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,8489,5974,renal pelvis transitional cell carcinoma,DOID,1736,FGFR3 S249C,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,913,Selumetinib,2261
117,Preclinical - Cell line xenograft,"In a preclinical study, Iclusig (ponatinib) inhibited growth of bladder cancer cells harboring FGFR3 S249C in culture and in cell line xenograft models (PMID: 22238366).
",Actionable,3512,11054,urinary bladder cancer,DOID,1736,FGFR3 S249C,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,877,Ponatinib,2261
118,Preclinical - Cell line xenograft,"In a preclinical study, AZD4547 decreased Myc expression and inhibited growth of a urinary tract cancer cell line harboring FGFR3 S249C in culture and in xenograft models (PMID: 27401245).",Actionable,10011,3996,urinary system cancer,DOID,1736,FGFR3 S249C,"[{'id': 7899, 'pubMedId': 27401245, 'title': 'c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27401245'}]",sensitive,654,AZD4547,2261
119,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of bladder cancer cells harboring FGFR3 S249C in culture (PMID: 22238366).",Actionable,3517,11054,urinary bladder cancer,DOID,1736,FGFR3 S249C,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",no benefit,996,Brivanib,2261
120,Phase II,"In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response in a patient with BCG-unresponsive, non–muscle-invasive, urothelial carcinoma of the bladder harboring FGFR3 S249C (PMID: 27932416).",Actionable,11228,4006,bladder urothelial carcinoma,DOID,1736,FGFR3 S249C,"[{'id': 9176, 'pubMedId': 27932416, 'title': 'A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27932416'}]",sensitive,721,Dovitinib,2261
121,Preclinical,"In a preclinical study, bladder cancer cells harboring FGFR3 S249C were resistant to Ofev (Nintedanib) induced inhibition of cell proliferation in culture (PMID: 22238366).",Actionable,3516,11054,urinary bladder cancer,DOID,1736,FGFR3 S249C,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",resistant,831,Nintedanib,2261
122,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in bladder cancer cells harboring FGFR3 S249C mutation in culture (PMID: 22238366).
",Actionable,3513,11054,urinary bladder cancer,DOID,1736,FGFR3 S249C,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,721,Dovitinib,2261
123,Preclinical - Cell culture,"In a preclinical study, renal pelvis transitional cell carcinoma cells harboring FGFR3 S249C were not sensitive to RO5126766 in culture (PMID: 26438159).",Actionable,8475,5974,renal pelvis transitional cell carcinoma,DOID,1736,FGFR3 S249C,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,2011,RO5126766,2261
124,Preclinical - Cell culture,"In a preclinical study, BGJ398 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 S249C in culture (PMID: 27401245).",Actionable,10027,3996,urinary system cancer,DOID,1736,FGFR3 S249C,"[{'id': 7899, 'pubMedId': 27401245, 'title': 'c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27401245'}]",sensitive,674,BGJ398,2261
125,Preclinical - Cell line xenograft,"In a preclinical study, R3Mab decreased activation of FGFR3 S249C, thereby inhibited cell proliferation of human bladder cancer cells in culture and in cell line xenograft models (PMID: 19381019).",Actionable,1036,4007,bladder carcinoma,DOID,1736,FGFR3 S249C,"[{'id': 742, 'pubMedId': 19381019, 'title': 'Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19381019'}]",sensitive,1465,R3Mab,2261
126,Preclinical - Cell culture,"In a preclinical study, R3Mab inhibited proliferation of transformed cells over expressing FGFR3 S249C in culture (PMID: 19381019).",Actionable,1031,10000003,Advanced Solid Tumor,JAX,1736,FGFR3 S249C,"[{'id': 742, 'pubMedId': 19381019, 'title': 'Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19381019'}]",sensitive,1465,R3Mab,2261
127,Preclinical - Cell line xenograft,"In a preclinical study, Debio 1347 inhibited proliferation of bladder cancer cells harboring FGFR3 S249C in culture and inhibited tumor growth in FGFR3 S249C-positive bladder cancer cell line xenograft models (PMID: 25169980).",Actionable,4062,11054,urinary bladder cancer,DOID,1736,FGFR3 S249C,"[{'id': 4388, 'pubMedId': 25169980, 'title': 'The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25169980'}]",sensitive,1014,FF-284,2261
128,Preclinical - Cell culture,"In a preclinical study, renal pelvis transitional cell carcinoma cells harboring FGFR3 S249C were not sensitive to RO4987655 in culture (PMID: 26438159).",Actionable,8460,5974,renal pelvis transitional cell carcinoma,DOID,1736,FGFR3 S249C,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,903,RO4987655,2261
129,Preclinical - Cell line xenograft,"In a preclinical study, ASP5878 treatment inhibited proliferation of a bladder cancer cell line harboring FGFR3 S249C in culture, and resulted in tumor regression in xenograft models (Mol Cancer Ther December 2015 14; A170).",Actionable,4633,11054,urinary bladder cancer,DOID,1736,FGFR3 S249C,"[{'id': 4639, 'pubMedId': None, 'title': 'Preclinical antitumor activity of ASP5878, a novel inhibitor of FGFR1, 2, 3 and 4, in bladder cancer harboring FGFR3-fusion or -mutation', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/A170.short'}]",sensitive,3584,ASP5878,2261
130,Preclinical,"In a preclinical study, PD173074 inhibited growth of urothelial carcinoma (UC) cells expressing high levels of FGFR3 S249C, but had reduced efficacy against UC cells with low levels of FGFR3 S249C expression (PMID: 22869148).",Actionable,2583,2671,transitional cell carcinoma,DOID,13018,FGFR3 S249C FGFR3 over exp,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",sensitive,2948,PD173074,2261
131,Preclinical - Cell culture,"In a preclinical study, BGJ398 inhibited proliferation of a head and neck squamous cell carcinoma cell line expressing FGFR3 D788N in culture, however, cells expressing FGFR3 D788N did not demonstrate increased sensitivity to BGJ398 compared to cells expressing wild-type FGFR3 (PMID: 27053219).",Actionable,9032,5520,head and neck squamous cell carcinoma,DOID,26694,FGFR3 D788N,"[{'id': 6884, 'pubMedId': 27053219, 'title': 'Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27053219'}]",no benefit,674,BGJ398,2261
132,Preclinical,"In a preclinical study, R3Mab prevented ligand-dependent cell proliferation induced by FGFR3 G372C in cultured cells (PMID: 19381019).",Actionable,1032,10000003,Advanced Solid Tumor,JAX,1738,FGFR3 G372C,"[{'id': 742, 'pubMedId': 19381019, 'title': 'Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19381019'}]",sensitive,1465,R3Mab,2261
133,Preclinical,"In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 F386L in culture (PMID: 25169980).",Actionable,4066,70004,myeloid neoplasm,DOID,5005,FGFR3 F386L,"[{'id': 4388, 'pubMedId': 25169980, 'title': 'The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25169980'}]",sensitive,1014,FF-284,2261
134,Preclinical,"In a preclinical study, R3Mab prevented ligand-dependent cell proliferation induced by FGFR3 K652E in cultured cells (PMID: 19381019).",Actionable,1034,10000003,Advanced Solid Tumor,JAX,817,FGFR3 K652E,"[{'id': 742, 'pubMedId': 19381019, 'title': 'Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19381019'}]",sensitive,1465,R3Mab,2261
135,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in bladder cancer cells harboring FGFR3 Y375C in culture (PMID: 22238366).
",Actionable,3507,11054,urinary bladder cancer,DOID,1735,FGFR3 Y375C,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,877,Ponatinib,2261
136,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in bladder cancer cells harboring FGFR3 Y375C in culture (PMID: 22238366).",Actionable,3508,11054,urinary bladder cancer,DOID,1735,FGFR3 Y375C,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",sensitive,721,Dovitinib,2261
137,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of bladder cancer cells harboring FGFR3 Y375C in culture (PMID: 22238366).",Actionable,3511,11054,urinary bladder cancer,DOID,1735,FGFR3 Y375C,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",no benefit,996,Brivanib,2261
138,Preclinical,"In a preclinical study, bladder cancer cells harboring FGFR3 Y375C were resistant to growth inhibition by Ofev (Nintedanib) in culture (PMID: 22238366).",Actionable,3510,11054,urinary bladder cancer,DOID,1735,FGFR3 Y375C,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",resistant,831,Nintedanib,2261
139,Preclinical,"In a preclinical study, bladder cancer cells harboring an FGFR3 Y375C mutation were resistant to growth inhibition by Cediranib (AZD-2171) in culture (PMID: 22238366).
",Actionable,3509,11054,urinary bladder cancer,DOID,1735,FGFR3 Y375C,"[{'id': 311, 'pubMedId': 22238366, 'title': 'Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22238366'}]",resistant,1001,Cediranib,2261
140,Preclinical,"In a preclinical study, R3Mab prevented ligand-dependent cell proliferation induced by FGFR3 Y375C in cultured cells (PMID: 19381019).",Actionable,1033,10000003,Advanced Solid Tumor,JAX,1735,FGFR3 Y375C,"[{'id': 742, 'pubMedId': 19381019, 'title': 'Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19381019'}]",sensitive,1465,R3Mab,2261
141,Preclinical,"In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to PD173074 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148).",Actionable,3274,9538,multiple myeloma,DOID,13019,FGFR3 G384D FGFR3 over exp,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",decreased response,2948,PD173074,2261
142,Preclinical,"In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to AZD4547 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148).",Actionable,3276,9538,multiple myeloma,DOID,13019,FGFR3 G384D FGFR3 over exp,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",decreased response,654,AZD4547,2261
143,Preclinical,"In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to AZ8010 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148).",Actionable,3277,9538,multiple myeloma,DOID,13019,FGFR3 G384D FGFR3 over exp,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",decreased response,2955,AZ8010,2261
144,Preclinical,"In a preclinical study, PD173074 inhibited Fgfr3 signaling and decreased proliferation and survival of multiple myeloma cells over expressing FGFR3 Y373C in culture (PMID: 22869148).",Actionable,2582,9538,multiple myeloma,DOID,13015,FGFR3 Y373C FGFR3 over exp,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",sensitive,2948,PD173074,2261
145,Preclinical,"In a preclinical study, AZ8010 inhibited Fgfr3 signaling, induced cell-cycle arrest, and decreased proliferation of multiple myeloma cells over expressing FGFR3 Y373C in culture (PMID: 22869148).",Actionable,2570,9538,multiple myeloma,DOID,13015,FGFR3 Y373C FGFR3 over exp,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",sensitive,2955,AZ8010,2261
146,Preclinical - Cell culture,"In a preclinical study, myeloma cells harboring FGFR3 Y373C were not sensitive to RO4987655 in culture (PMID: 26438159).",Actionable,8458,70004,myeloid neoplasm,DOID,3514,FGFR3 Y373C,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,903,RO4987655,2261
147,Preclinical,"In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 Y373C in culture (PMID: 25169980).",Actionable,4063,70004,myeloid neoplasm,DOID,3514,FGFR3 Y373C,"[{'id': 4388, 'pubMedId': 25169980, 'title': 'The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25169980'}]",sensitive,1014,FF-284,2261
148,Preclinical - Cell culture,"In a preclinical study, myeloma cells harboring FGFR3 Y373C were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,8488,70004,myeloid neoplasm,DOID,3514,FGFR3 Y373C,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,913,Selumetinib,2261
149,Preclinical - Cell culture,"In a preclinical study, myeloma cells harboring FGFR3 Y373C were not sensitive to RO5126766 in culture (PMID: 26438159).",Actionable,8474,70004,myeloid neoplasm,DOID,3514,FGFR3 Y373C,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,2011,RO5126766,2261
150,Preclinical - Cell culture,"In a preclinical study, a multiple myeloma cell line harboring FGFR3 Y373C (PMID: 19901323) demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability (PMID: 27535969). ",Actionable,9136,9538,multiple myeloma,DOID,3514,FGFR3 Y373C,"[{'id': 6928, 'pubMedId': 27535969, 'title': 'E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535969'}, {'id': 6930, 'pubMedId': 19901323, 'title': 'Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19901323'}]",sensitive,4911,E7090,2261
151,Preclinical,"In a preclinical study, the combined therapy of AZD5363 and AZD4547 resulted in tumor regression in urinary bladder cancer xenograft models simultaneously harboring the mutations, AKT1 E17K and FGFR3 Y373C (PMID: 26351323). ",Actionable,3811,11054,urinary bladder cancer,DOID,14066,AKT1 E17K FGFR3 Y373C,"[{'id': 3912, 'pubMedId': 26351323, 'title': 'Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26351323'}]",sensitive,3346,AZD5363 + AZD4547,2261
152,Preclinical - Cell culture,"In a preclinical study, BGJ398 inhibited proliferation of a head and neck squamous cell carcinoma cell line expressing FGFR3 D764N in culture, however, cells expressing FGFR3 D764N did not demonstrate increased sensitivity to BGJ398 compared to cells expressing wild-type FGFR3 (PMID: 27053219).",Actionable,9033,5520,head and neck squamous cell carcinoma,DOID,26696,FGFR3 D764N,"[{'id': 6884, 'pubMedId': 27053219, 'title': 'Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27053219'}]",no benefit,674,BGJ398,2261
153,Preclinical - Pdx,"In a preclinical study, treatment with BGJ398 led to improved progression-free survival in a patient-derived xenograft (PDX) model of  bladder cancer with FGFR3 over expression (PMID: 26270481).",Actionable,7433,11054,urinary bladder cancer,DOID,8807,FGFR3 over exp,"[{'id': 6363, 'pubMedId': 26270481, 'title': 'Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26270481'}]",sensitive,674,BGJ398,2261
154,Preclinical,"In a preclinical study, LY2874455 induced tumor regression in FGFR3-over expressing bladder and multiple myeloma xenograft models (PMID: 21900693). ",Actionable,3996,10000003,Advanced Solid Tumor,JAX,8807,FGFR3 over exp,"[{'id': 1842, 'pubMedId': 21900693, 'title': 'A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21900693'}]",sensitive,2032,LY2874455,2261
155,Preclinical,"In a preclinical study, Rogaratinib (BAY 1163877) inhibited tumor growth in a head and neck squamous cell carcinoma xenograft model with FGFR3 overexpression (Cancer Res August 1, 2015 75:772).",Actionable,4077,5520,head and neck squamous cell carcinoma,DOID,8807,FGFR3 over exp,"[{'id': 4393, 'pubMedId': None, 'title': 'Abstract 772: Anti-tumor efficacy of the selective pan-FGFR Inhibitor BAY 1163877 in preclinical squamous cell carcinoma models of different origin', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/772.short'}]",sensitive,2030,Rogaratinib,2261
156,Preclinical - Cell culture,"In a preclinical study, PRN1371 inhibited Fgfr3 activity in transformed cells over expressing wild-type FGFR3 in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8402,10000003,Advanced Solid Tumor,JAX,8807,FGFR3 over exp,"[{'id': 6640, 'pubMedId': None, 'title': 'PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1249'}]",sensitive,3583,PRN1371,2261
157,Preclinical,"In a preclinical study, AZD4547 inhibited proliferation of urothelial cancer cells with over expression of FGFR3 in culture (PMID: 22869148).",Actionable,3272,2671,transitional cell carcinoma,DOID,8807,FGFR3 over exp,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",sensitive,654,AZD4547,2261
158,Preclinical - Pdx,"In a preclinical study, the combination of BEZ235 and Nexavar (sorafenib) resulted in improved progression-free survival in an FGFR3-over expressing patient-derived xenograft (PDX) model of bladder cancer with secondary resistance to BGJ398 due to reactivation of downstream signaling, as evidenced by increased activation of Akt and Erk (PMID: 26270481).",Actionable,7445,11054,urinary bladder cancer,DOID,8807,FGFR3 over exp,"[{'id': 6363, 'pubMedId': 26270481, 'title': 'Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26270481'}]",sensitive,1067,Sorafenib + BEZ235,2261
159,Preclinical,"In a preclinical study, AZ8010 inhibited proliferation of urothelial cancer cells with over expression of FGFR3 in culture (PMID: 22869148).",Actionable,3273,2671,transitional cell carcinoma,DOID,8807,FGFR3 over exp,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",sensitive,2955,AZ8010,2261
160,Phase II,"In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response for 6 months in 8% (1/13) of non-muscle invasive bladder cancer patients over expressing FGFR3 (J Clin Oncol 34, 2016 (suppl; abstr 4526)).",Actionable,6982,11054,urinary bladder cancer,DOID,8807,FGFR3 over exp,"[{'id': 5997, 'pubMedId': None, 'title': 'Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression: Hoosier Cancer Research Network GU12-157.', 'url': 'http://meetinglibrary.asco.org/content/167294-176'}]",sensitive,721,Dovitinib,2261
161,Preclinical,"In a preclinical study, U0126 inhibited downstream signaling and growth of glioblastoma cells over-expressing Fgfr3 in culture (PMID: 23298836).",Actionable,2713,3068,glioblastoma multiforme,DOID,8807,FGFR3 over exp,"[{'id': 3393, 'pubMedId': 23298836, 'title': 'The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23298836'}]",sensitive,2427,U0126,2261
162,Preclinical,"In a preclinical study, SU5402 inhibited growth of bladder cancer cells over expressing wild-type FGFR3 in culture (PMID: 21119661).",Actionable,4018,11054,urinary bladder cancer,DOID,8807,FGFR3 over exp,"[{'id': 4133, 'pubMedId': 21119661, 'title': 'Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21119661'}]",sensitive,3305,SU5402,2261
163,Phase I,"In a Phase I trial, MFGR1877S demonstrated safety and resulted in stable disease in 42% (6/14) of multiple myeloma patients overexpressing FGFR3 (Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 4029).",Actionable,2550,9538,multiple myeloma,DOID,8807,FGFR3 over exp,"[{'id': 3280, 'pubMedId': None, 'title': 'A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive', 'url': 'http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/4029'}]",sensitive,2936,MFGR1877S,2261
164,Preclinical - Cell culture,"In a preclinical study, PRN1371 inhibited Fgfr3 activity in transformed cells over expressing FGFR3 K650M in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8403,10000003,Advanced Solid Tumor,JAX,2184,FGFR3 K650M,"[{'id': 6640, 'pubMedId': None, 'title': 'PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1249'}]",sensitive,3583,PRN1371,2261
165,Phase I,"In a Phase I trial, BGJ398 treatment resulted in complete response in 4% (1/25) and partial response in 32% (8/25) of urothelial carcinoma patients harboring FGFR3 mutations or fusions (J Clin Oncol 34, 2016 (suppl; abstr 4517)).",Actionable,6977,2671,transitional cell carcinoma,DOID,14903,FGFR3 fusion,"[{'id': 5994, 'pubMedId': None, 'title': 'Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations.', 'url': 'http://meetinglibrary.asco.org/content/164341-176'}]",sensitive,674,BGJ398,2261
166,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited survival of bladder cancer cells harboring FGFR3 fusion in culture (PMID: 27550940).",Actionable,9124,11054,urinary bladder cancer,DOID,14903,FGFR3 fusion,"[{'id': 6925, 'pubMedId': 27550940, 'title': 'Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550940'}]",sensitive,654,AZD4547,2261
167,Preclinical - Cell line xenograft,"In a preclinical study, TAS-120 demonstrated growth inhibition and reduced FGFR phosphorylation in human cancer cell lines and xenograft models harboring FGFR mutations (Mol Cancer Ther 2013;12(11 Suppl):A270).
",Actionable,4020,10000003,Advanced Solid Tumor,JAX,14903,FGFR3 fusion,"[{'id': 2257, 'pubMedId': None, 'title': 'TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities', 'url': 'http://mct.aacrjournals.org/content/12/11_Supplement/A270.short'}]",predicted – sensitive,1053,TAS-120,2261
168,Preclinical - Cell line xenograft,"In a preclinical study, AZD4547 inhibited survival of myeloma cells harboring FGFR3 translocation in culture and in cell line xenograft models (PMID: 27550940).",Actionable,9122,70004,myeloid neoplasm,DOID,1318,FGFR3 rearrange,"[{'id': 6925, 'pubMedId': 27550940, 'title': 'Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550940'}]",sensitive,654,AZD4547,2261
169,Preclinical - Cell culture,"In a preclinical study, PRN1371 inhibited proliferation of myeloma cells harboring FGFR3 rearrangements in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8408,70004,myeloid neoplasm,DOID,1318,FGFR3 rearrange,"[{'id': 6640, 'pubMedId': None, 'title': 'PRN1371, an irreversible, covalent inhibitor of FGFR1, 2, 3 and 4 is highly efficacious in preclinical tumor models', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1249'}]",sensitive,3583,PRN1371,2261
0,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D839A were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4831,10000003,Advanced Solid Tumor,JAX,19296,FLT3 exon 14 ins FLT3 D839A,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
1,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835A mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4830,10000003,Advanced Solid Tumor,JAX,19297,FLT3 exon 14 ins FLT3 F691L FLT3 D839A,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
2,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835N mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4828,10000003,Advanced Solid Tumor,JAX,19282,FLT3 exon 14 ins FLT3 F691L FLT3 D835N,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
3,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD  along with FLT3 D835N were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4827,10000003,Advanced Solid Tumor,JAX,19281,FLT3 exon 14 ins FLT3 D835N,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
4,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/N676S mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4804,10000003,Advanced Solid Tumor,JAX,19314,FLT3 exon 14 ins FLT3 N676S FLT3 F691L,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
5,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 N676S were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4803,10000003,Advanced Solid Tumor,JAX,19313,FLT3 exon 14 ins FLT3 N676S,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
6,Preclinical,"In a preclinical study, FLT3 Y842C conferred resistance to PLX3397 when expressed in a compound mutation with FLT3-ITD in cell culture (PMID: 25847190).",Actionable,2403,10000003,Advanced Solid Tumor,JAX,19136,FLT3 exon 14 ins FLT3 Y842C,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
7,Preclinical - Cell culture,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and Y842C in culture (PMID: 27158668).",Actionable,9437,10000003,Advanced Solid Tumor,JAX,19136,FLT3 exon 14 ins FLT3 Y842C,"[{'id': 7187, 'pubMedId': 27158668, 'title': 'The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27158668'}]",sensitive,5016,MRX-2843,2322
8,Preclinical,"In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 Y842C in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).",Actionable,6463,1240,leukemia,DOID,19136,FLT3 exon 14 ins FLT3 Y842C,"[{'id': 5604, 'pubMedId': 26822154, 'title': 'The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26822154'}]",sensitive,1011,E6201,2322
9,Preclinical,"In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 N676D and Y842C in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).",Actionable,6464,1240,leukemia,DOID,23516,FLT3 ITD FLT3 N676D FLT3 Y842C,"[{'id': 5604, 'pubMedId': 26822154, 'title': 'The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26822154'}]",sensitive,1011,E6201,2322
10,Preclinical,"In a preclinical study, primary AML blasts expressing FLT3 Y842C were resistant to Gleevec (imatinib) as demonstrated by constitutively phosphorylated FLT3 and STAT-5 (PMID: 15345593).
",Actionable,2324,9119,acute myeloid leukemia,DOID,6801,FLT3 Y842C,"[{'id': 2895, 'pubMedId': 15345593, 'title': 'Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15345593'}]",resistant,770,Imatinib,2322
11,Preclinical - Cell culture,"In a preclinical study, Rydapt (midostaurin) induced cell death and inhibited FLT3 activation and downstream STAT5 activation in primary acute myeloid leukemic blasts harboring FLT3 Y842C in culture (PMID: 15345593).",Actionable,2323,9119,acute myeloid leukemia,DOID,6801,FLT3 Y842C,"[{'id': 2895, 'pubMedId': 15345593, 'title': 'Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15345593'}]",sensitive,810,Midostaurin,2322
12,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/Y842C mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4838,10000003,Advanced Solid Tumor,JAX,19286,FLT3 exon 14 ins FLT3 F691L FLT3 Y842C,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
13,Clinical Study,"In a clinical study, a patient with FLT3-ITD positive leukemia initially responded to PLX3397 therapy, but experienced relapse after emergence of FLT3 D835Y on the same allele as the FLT3-ITD mutation (PMID: 25847190).",Actionable,4846,1240,leukemia,DOID,19130,FLT3 exon 14 ins FLT3 D835Y,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
14,Preclinical,"In a preclinical study, FLT3 D835Y conferred resistance to PLX3397 when expressed in a compound mutation with FLT3-ITD in cell culture (PMID: 25847190).",Actionable,4793,10000003,Advanced Solid Tumor,JAX,19130,FLT3 exon 14 ins FLT3 D835Y,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
15,Preclinical - Cell culture,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and D835Y in culture (PMID: 27158668).",Actionable,9433,10000003,Advanced Solid Tumor,JAX,19130,FLT3 exon 14 ins FLT3 D835Y,"[{'id': 7187, 'pubMedId': 27158668, 'title': 'The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27158668'}]",sensitive,5016,MRX-2843,2322
16,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing FLT3 ITD and D835Y in culture (PMID: 27780853).",Actionable,9232,10000003,Advanced Solid Tumor,JAX,19130,FLT3 exon 14 ins FLT3 D835Y,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,2322
17,Preclinical - Cell line xenograft,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant acute myeloid leukemia cells harboring FLT3 internal tandem duplication (ITD) and D835Y in culture, and prolonged survival in cell line xenograft models (PMID: 27158668).",Actionable,9430,9119,acute myeloid leukemia,DOID,19130,FLT3 exon 14 ins FLT3 D835Y,"[{'id': 7187, 'pubMedId': 27158668, 'title': 'The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27158668'}]",sensitive,5016,MRX-2843,2322
18,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835Y mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4829,10000003,Advanced Solid Tumor,JAX,19343,FLT3 exon 14 ins FLT3 F691L FLT3 D835Y,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
19,Preclinical - Cell culture,"In a preclinical study, treatment with Rydapt (midostaurin) inhibited FLT3 phosphorylation and resulted in decreased proliferation and viability of transformed cells expressing FLT3 D835Y in culture (PMID: 12124173).",Actionable,1752,10000003,Advanced Solid Tumor,JAX,3153,FLT3 D835Y,"[{'id': 985, 'pubMedId': 12124173, 'title': 'Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12124173'}]",sensitive,810,Midostaurin,2322
20,Preclinical,"In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines over expressing FLT3 D835Y in culture (PMID: 26822154).",Actionable,6460,1240,leukemia,DOID,3153,FLT3 D835Y,"[{'id': 5604, 'pubMedId': 26822154, 'title': 'The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26822154'}]",sensitive,1011,E6201,2322
21,Preclinical - Cell culture,"In a preclinical study, E6201 induced apoptosis in blast samples derived from acute myeloid leukemia patients harboring FLT3 D835Y in culture (PMID: 26822154).",Actionable,7426,9119,acute myeloid leukemia,DOID,3153,FLT3 D835Y,"[{'id': 5604, 'pubMedId': 26822154, 'title': 'The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26822154'}]",sensitive,1011,E6201,2322
22,Clinical Study,"In a clinical case study, a patient with acute promyelocytic leukemia harboring FLT3 D835Y demonstrated a complete molecular remission after treatment with Trisenox (arsenic trioxide) and Vesanoid (tretinoin) combined with Cytosar-U (cytarabine) and Methotrexate (PMID: 27626069).",Actionable,11375,60318,acute promyelocytic leukemia,DOID,3153,FLT3 D835Y,"[{'id': 9268, 'pubMedId': 27626069, 'title': 'Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27626069'}]",sensitive,5965,Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin,2322
23,Preclinical,"In a preclinical study, transformed cells expressing FLT3 D835Y were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,5035,10000003,Advanced Solid Tumor,JAX,3153,FLT3 D835Y,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
24,Clinical Study,"In a clinical case study, a patient with acute promyelocytic leukemia developed meningeal relapse after maintenance therapy with Vesanoid (tretinoid), which was found to be due to a FLT3 D835Y variant (PMID: 27626069). ",Actionable,11376,60318,acute promyelocytic leukemia,DOID,3153,FLT3 D835Y,"[{'id': 9268, 'pubMedId': 27626069, 'title': 'Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27626069'}]",resistant,1877,Tretinoin  ,2322
25,Preclinical - Cell culture,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing FLT3 D835Y in culture (PMID: 27158668).",Actionable,9434,10000003,Advanced Solid Tumor,JAX,3153,FLT3 D835Y,"[{'id': 7187, 'pubMedId': 27158668, 'title': 'The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27158668'}]",sensitive,5016,MRX-2843,2322
26,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835E were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4809,10000003,Advanced Solid Tumor,JAX,19277,FLT3 exon 14 ins FLT3 D835E,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
27,Preclinical,"In a preclinical study, transformed cells expressing FLT3 ITD with R834Q and F691L were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4810,10000003,Advanced Solid Tumor,JAX,19278,FLT3 exon 14 ins FLT3 F691L FLT3 D835E,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
28,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691Q/G846R mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4845,10000003,Advanced Solid Tumor,JAX,19306,FLT3 exon 14 ins FLT3 F691L FLT3 G846R,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
29,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD /F691L/D839G mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4832,10000003,Advanced Solid Tumor,JAX,19283,FLT3 exon 14 ins FLT3 F691L FLT3 D839G,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
30,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/Y842H mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4839,10000003,Advanced Solid Tumor,JAX,19287,FLT3 exon 14 ins FLT3 F691L FLT3 Y842H,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
31,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D698N mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4806,10000003,Advanced Solid Tumor,JAX,19294,FLT3 exon 14 ins FLT3 F691L FLT3 D698N,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
32,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835G mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4812,10000003,Advanced Solid Tumor,JAX,19292,FLT3 exon 14 ins FLT3 F691L FLT3 D835G,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
33,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/Y842S mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4841,10000003,Advanced Solid Tumor,JAX,19324,FLT3 exon 14 ins FLT3 F691L FLT3 Y842S,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
34,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and F691L were resistant to Quizartinib (AC220) in culture (PMID: 23392356).",Actionable,9286,10000003,Advanced Solid Tumor,JAX,19129,FLT3 exon 14 ins FLT3 F691L,"[{'id': 7054, 'pubMedId': 23392356, 'title': 'The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23392356'}]",resistant,882,Quizartinib,2322
35,Preclinical,"In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 F691L in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).",Actionable,6462,1240,leukemia,DOID,19129,FLT3 exon 14 ins FLT3 F691L,"[{'id': 5604, 'pubMedId': 26822154, 'title': 'The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26822154'}]",sensitive,1011,E6201,2322
36,Preclinical - Cell culture,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and F691L in culture (PMID: 27158668).",Actionable,9432,10000003,Advanced Solid Tumor,JAX,19129,FLT3 exon 14 ins FLT3 F691L,"[{'id': 7187, 'pubMedId': 27158668, 'title': 'The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27158668'}]",sensitive,5016,MRX-2843,2322
37,Preclinical - Cell line xenograft,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant acute myeloid leukemia cells harboring FLT3 internal tandem duplication (ITD) and F691L in culture, and prolonged survival in cell line xenograft models (PMID: 27158668).",Actionable,9431,9119,acute myeloid leukemia,DOID,19129,FLT3 exon 14 ins FLT3 F691L,"[{'id': 7187, 'pubMedId': 27158668, 'title': 'The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27158668'}]",sensitive,5016,MRX-2843,2322
38,Preclinical,"In a preclinical study, PLX3397 inhibited growth of transformed cells expressing a compound FLT3 F691L/FLT3-ITD mutation in culture (PMID: 25847190).",Actionable,4789,10000003,Advanced Solid Tumor,JAX,19129,FLT3 exon 14 ins FLT3 F691L,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",sensitive,874,PLX3397,2322
39,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing FLT3 ITD and F691L in culture (PMID: 27780853).",Actionable,9251,10000003,Advanced Solid Tumor,JAX,19129,FLT3 exon 14 ins FLT3 F691L,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,2322
40,Preclinical,"In a preclinical study, PLX3397 inhibited proliferation of human leukemia cells harboring both FLT3-ITD and FLT3 F691L in culture (PMID: 25847190).",Actionable,4790,1240,leukemia,DOID,19129,FLT3 exon 14 ins FLT3 F691L,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",sensitive,874,PLX3397,2322
41,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and F691L were resistant to Nexavar (sorafenib) in culture (PMID: 23392356).",Actionable,9279,10000003,Advanced Solid Tumor,JAX,19129,FLT3 exon 14 ins FLT3 F691L,"[{'id': 7054, 'pubMedId': 23392356, 'title': 'The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23392356'}]",resistant,920,Sorafenib,2322
42,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691Q/R834Q mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4808,10000003,Advanced Solid Tumor,JAX,19276,FLT3 exon 14 ins FLT3 F691L FLT3 R834Q,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
43,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835H mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4825,10000003,Advanced Solid Tumor,JAX,19280,FLT3 exon 14 ins FLT3 F691L FLT3 D835H,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
44,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/M664I mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4802,10000003,Advanced Solid Tumor,JAX,19311,FLT3 exon 14 ins FLT3 M664I FLT3 F691L,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
45,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/N841K mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4837,10000003,Advanced Solid Tumor,JAX,19317,FLT3 exon 14 ins FLT3 F691L FLT3 N841K,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
46,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/R845G mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4843,10000003,Advanced Solid Tumor,JAX,19320,FLT3 exon 14 ins FLT3 F691L FLT3 R845G,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
47,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D839N were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4835,10000003,Advanced Solid Tumor,JAX,19302,FLT3 exon 14 ins FLT3 F691L FLT3 D839N,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
48,Clinical Study,"In a clinical case report, Nexavar (sorafenib) treatment targeting FLT3 amplification in a rectal adenocarcinoma patient who had progressed on all standard therapies resulted in rapid clinical improvement (PMID: 25848357).",Actionable,6018,9256,colorectal cancer,DOID,5008,FLT3 amp,"[{'id': 5236, 'pubMedId': 25848357, 'title': 'Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25848357'}]",sensitive,920,Sorafenib,2322
49,Preclinical - Cell culture,"In a preclinical study, Tandutinib (CT53518) inhibited phosphorylation of FLT3 and activation of ERK and STAT5, and reduced growth of transformed cells expressing FLT3 I836del in culture (PMID: 15256420).",Actionable,12171,162,cancer,DOID,6640,FLT3 I836del,"[{'id': 2706, 'pubMedId': 15256420, 'title': 'Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15256420'}]",sensitive,933,Tandutinib,2322
50,Preclinical - Cell culture,"In a preclinical study, Rydapt (midostaurin) inhibited phosphorylation of FLT3, ERK, and STAT5, and growth of transformed cells expressing FLT3 I836del in culture (PMID: 17827387).",Actionable,12172,162,cancer,DOID,6640,FLT3 I836del,"[{'id': 10126, 'pubMedId': 17827387, 'title': 'Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17827387'}]",sensitive,810,Midostaurin,2322
51,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 Y842S were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4840,10000003,Advanced Solid Tumor,JAX,19323,FLT3 exon 14 ins FLT3 Y842S,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
52,Preclinical,"In a preclinical study, FLT3 D835H conferred resistance to PLX3397 in transformed cells when expressed as a compound mutation with FLT3-ITD in culture (PMID: 25847190).",Actionable,4826,10000003,Advanced Solid Tumor,JAX,19279,FLT3 exon 14 ins FLT3 D835H,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
53,Clinical Study,"In a clinical study, a patient with FLT3-ITD positive leukemia initially responded to PLX3397, but experienced relapse after emergence of a FLT3 D835H mutation on the same allele as the FLT3-ITD mutation (PMID: 25847190).",Actionable,4850,1240,leukemia,DOID,19279,FLT3 exon 14 ins FLT3 D835H,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
54,Preclinical,"In a preclinical study, Crenolanib (CP-868596) inhibited Flt3 phosphorylation and induced apoptosis in leukemia cells expressing FLT3 D835H (PMID: 24623852).",Actionable,2295,9119,acute myeloid leukemia,DOID,3155,FLT3 D835H,"[{'id': 2972, 'pubMedId': 24623852, 'title': 'Crenolanib is a selective type I pan-FLT3 inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24623852'}]",sensitive,705,Crenolanib,2322
55,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 N841K were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4836,10000003,Advanced Solid Tumor,JAX,19316,FLT3 exon 14 ins FLT3 N841K,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
56,Clinical Study,"In multiple clinical studies, the combination of an NPM1 mutation and FLT3 wild-type in acute myeloid leukemia (AML) patients was associated with a favorable prognosis compared to AML patients harboring an NPM1 mutation and FLT3 internal tandem duplication (PMID: 19047294, PMID: 24573385, PMID: 25713434). ",Prognostic,6501,9119,acute myeloid leukemia,DOID,23600,NPM1 mutant FLT3 wild-type,"[{'id': 5668, 'pubMedId': 19047294, 'title': 'Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19047294'}, {'id': 5669, 'pubMedId': 24573385, 'title': 'The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24573385'}, {'id': 5670, 'pubMedId': 25713434, 'title': 'Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25713434'}]",not applicable,1776,N/A,2322
57,Phase Ib/II,"In a Phase Ib clinical trial, Rydapt (midostaurin) treatment after Daunorubicin and Cytosar-U (cytarabine) induction resulted in  complete remission in 74% (20 of 27) of acute myeloid leukemia patients carrying wild-type FLT3 (PMID: 22627678).",Actionable,3409,9119,acute myeloid leukemia,DOID,545,FLT3 wild-type,"[{'id': 3770, 'pubMedId': 22627678, 'title': 'Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22627678'}]",sensitive,3137,Cytarabine + Daunorubicin + Midostaurin,2322
58,Preclinical,"In a preclinical study, Ibrance (palbociclib) following TCS-359 treatment enhanced growth inhibition of FLT3 wild-type acute myeloid leukemia cell lines in culture (PMID: 27099147).",Actionable,6580,9119,acute myeloid leukemia,DOID,545,FLT3 wild-type,"[{'id': 5701, 'pubMedId': 27099147, 'title': 'Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27099147'}]",sensitive,4160,Palbociclib + TCS 359,2322
59,Preclinical - Cell culture,"In a preclinical study, Rydapt (midostaurin) inhibited FLT3 phosphorylation in transformed cells expressing wild-type FLT3 in culture (PMID: 12124173).",Actionable,3271,10000003,Advanced Solid Tumor,JAX,545,FLT3 wild-type,"[{'id': 985, 'pubMedId': 12124173, 'title': 'Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12124173'}]",sensitive,810,Midostaurin,2322
60,Preclinical,"In a preclinical study, TCS-359 inhibited growth of FLT3 wild-type acute myeloid leukemia cell lines in culture (PMID: 27099147).",Actionable,6582,9119,acute myeloid leukemia,DOID,545,FLT3 wild-type,"[{'id': 5701, 'pubMedId': 27099147, 'title': 'Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27099147'}]",sensitive,2615,TCS 359,2322
61,Preclinical,"In a preclinical study, Ibrance (palbociclib) inhibited growth of human FLT3 wild-type human leukemia cells in culture (PMID: 27099147).",Actionable,6578,9119,acute myeloid leukemia,DOID,545,FLT3 wild-type,"[{'id': 5701, 'pubMedId': 27099147, 'title': 'Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27099147'}]",sensitive,850,Palbociclib,2322
62,Preclinical - Cell culture,"In a preclinical study, Rydapt (midostaurin) inhibited FLT3-induced phosphorylation of ERK1/2 and reduced growth of transformed cells expressing FLT3 V592G in culture (PMID: 18068628).",Actionable,2284,10000003,Advanced Solid Tumor,JAX,6924,FLT3 V592G,"[{'id': 2803, 'pubMedId': 18068628, 'title': 'Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18068628'}]",sensitive,810,Midostaurin,2322
63,Preclinical - Cell line xenograft,"In a preclinical study, VS-5584 inhibited PI3K/mTOR signaling and cell proliferation in a FLT3-ITD positive human acute myeloid leukemia cell line in culture, and inhibited tumor growth in xenograft models (PMID: 23270925).",Actionable,8849,9119,acute myeloid leukemia,DOID,2774,FLT3 act mut,"[{'id': 351, 'pubMedId': 23270925, 'title': 'VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23270925'}]",sensitive,960,VS-5584,2322
64,Preclinical,"In a preclinical study, TCS-359 inhibited growth of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).",Actionable,6581,9119,acute myeloid leukemia,DOID,2774,FLT3 act mut,"[{'id': 5701, 'pubMedId': 27099147, 'title': 'Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27099147'}]",sensitive,2615,TCS 359,2322
65,Preclinical,"In a preclinical study, Ibrance (palbociclib) following TCS-359 treatment enhanced growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).",Actionable,6579,9119,acute myeloid leukemia,DOID,2774,FLT3 act mut,"[{'id': 5701, 'pubMedId': 27099147, 'title': 'Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27099147'}]",sensitive,4160,Palbociclib + TCS 359,2322
66,Preclinical,"In a preclinical study, Ibrance (palbociclib) blocked growth, induced apoptosis, and inhibited STAT activation in human FLT3-ITD positive human acute myeloid leukemia cells in culture (PMID: 27099147).",Actionable,6576,9119,acute myeloid leukemia,DOID,2774,FLT3 act mut,"[{'id': 5701, 'pubMedId': 27099147, 'title': 'Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27099147'}]",sensitive,850,Palbociclib,2322
67,Preclinical,"In a preclinical study, Ibrance (palbociclib) and tandutinib (MLN518) were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).",Actionable,6584,9119,acute myeloid leukemia,DOID,2774,FLT3 act mut,"[{'id': 5701, 'pubMedId': 27099147, 'title': 'Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27099147'}]",sensitive,4162,Palbociclib + Tandutinib,2322
68,Phase Ib/II,"In a Phase Ib/II trial, 59% (13/22) of acute myeloid leukemia patients harboring FLT3 activating mutations achieved complete remission following treatment with Sutent (sunitinib) in combination with Cytarabine and Daunorubicin (PMID: 25818407).",Actionable,2531,9119,acute myeloid leukemia,DOID,2774,FLT3 act mut,"[{'id': 3256, 'pubMedId': 25818407, 'title': 'A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25818407'}]",sensitive,2923,Sunitinib + Cytarabine + Daunorubicin,2322
69,Phase II,"In a Phase II trial, relapsed or refractory acute myeloid leukemia patients harboring FLT3 activating mutations without a history of FLT3 therapy demonstrated a significantly greater overall survival and event free survival compared to those that had prior FLT3 therapy when treated with Crenolanib (ASH meeting, Dec 2014, abstract #389).",Actionable,3584,9119,acute myeloid leukemia,DOID,2774,FLT3 act mut,"[{'id': 3856, 'pubMedId': None, 'title': 'Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations', 'url': 'https://ash.confex.com/ash/2014/webprogram/Paper74499.html'}]",sensitive,705,Crenolanib,2322
70,Preclinical,"In a preclinical study, Ibrance (palbociclib) and SGI-1776 were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).",Actionable,6585,9119,acute myeloid leukemia,DOID,2774,FLT3 act mut,"[{'id': 5701, 'pubMedId': 27099147, 'title': 'Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27099147'}]",sensitive,4184,Palbociclib + SGI-1776,2322
71,Preclinical,"In a preclinical study, Ibrance (palbociclib) and Quizartinib (AC220) were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).",Actionable,6583,9119,acute myeloid leukemia,DOID,2774,FLT3 act mut,"[{'id': 5701, 'pubMedId': 27099147, 'title': 'Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27099147'}]",sensitive,4161,Palbociclib + Quizartinib,2322
72,Preclinical - Cell line xenograft,"In a preclinical study, PLX3397 inhibited FLT3 autophosphorylation in leukemia cells overexpressing FLT3 or harboring FLT3 activating mutations, and inhibited growth of leukemia cells harboring FLT3-ITD mutations in culture and in cell line xenograft models (ASH Annual Meeting Abstracts 2011 118: 3632).",Actionable,2532,1240,leukemia,DOID,2774,FLT3 act mut,"[{'id': 3257, 'pubMedId': None, 'title': 'The Novel Inhibitor PLX3397 Effectively Inhibits FLT3-Mutant AML', 'url': 'http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/3632?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=PLX3397&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT'}]",sensitive,874,PLX3397,2322
73,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 G846R were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4844,10000003,Advanced Solid Tumor,JAX,19304,FLT3 exon 14 ins FLT3 G846R,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
74,Clinical Study,"In a clinical study, a leukemia patient with FLT3-ITD positive leukemia initially responded to PLX3397, but experienced relapse after emergence of a compound FLT3 M837G/S838R/D839H mutation on the FLT3-ITD allele (PMID: 25847190).",Actionable,4847,1240,leukemia,DOID,19288,FLT3 exon 14 ins FLT3 M837G FLT3 S838R FLT3 D839H,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
75,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD  along with FLT3 D839N were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4834,10000003,Advanced Solid Tumor,JAX,19301,FLT3 exon 14 ins FLT3 D839N,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
76,Preclinical,"In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 E612_F613insGYVDFREYEYDLKWEFRPRENLEF in culture (PMID: 12124172).",Actionable,1038,9119,acute myeloid leukemia,DOID,1758,FLT3 E612_F613insGYVDFREYEYDLKWEFRPRENLEF,"[{'id': 749, 'pubMedId': 12124172, 'title': 'CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12124172'}]",sensitive,933,Tandutinib,2322
77,Preclinical,"In a preclinical study, FLT3 D835G conferred resistance to PLX3397 when expressed in a compound mutation with FLT3-ITD in cell culture (PMID: 25847190).",Actionable,5034,10000003,Advanced Solid Tumor,JAX,19284,FLT3 exon 14 ins FLT3 D839G,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
78,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 R845G were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4842,10000003,Advanced Solid Tumor,JAX,19319,FLT3 exon 14 ins FLT3 R845G,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
79,Preclinical - Cell culture,"In a preclinical study, E6201 induced apoptosis in blast samples derived from acute myeloid leukemia patients harboring FLT3 D835G in culture (PMID: 26822154).",Actionable,7427,9119,acute myeloid leukemia,DOID,19290,FLT3 D835G,"[{'id': 5604, 'pubMedId': 26822154, 'title': 'The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26822154'}]",sensitive,1011,E6201,2322
80,Preclinical,"In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines over expressing FLT3 D835G in culture (PMID: 26822154).",Actionable,6458,1240,leukemia,DOID,19290,FLT3 D835G,"[{'id': 5604, 'pubMedId': 26822154, 'title': 'The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26822154'}]",sensitive,1011,E6201,2322
81,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835G were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4811,10000003,Advanced Solid Tumor,JAX,19291,FLT3 exon 14 ins FLT3 D835G,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
82,Preclinical,"In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 L611_E612insCSSDNEYFYVDFREYEYDLKWEFPRENL in culture (PMID: 12124172).",Actionable,1040,9119,acute myeloid leukemia,DOID,1757,FLT3 L611_E612insCSSDNEYFYVDFREYEYDLKWEFPRENL,"[{'id': 749, 'pubMedId': 12124172, 'title': 'CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12124172'}]",sensitive,933,Tandutinib,2322
83,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 M664I displayed reduced sensitivity to PLX3397 relative to cells expressing FLT3-ITD in culture (PMID: 25847190).",Actionable,4801,10000003,Advanced Solid Tumor,JAX,19310,FLT3 exon 14 ins FLT3 M664I,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",decreased response,874,PLX3397,2322
84,Phase I,"In a Phase I trial, two acute myeloid leukemia patients co-harboring a FLT3-ITD mutation and NPM1 mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088). ",Actionable,8008,9119,acute myeloid leukemia,DOID,26135,FLT3 exon 14 ins NPM1 mutant,"[{'id': 6531, 'pubMedId': 27406088, 'title': 'A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27406088'}]",sensitive,727,ENMD-2076,2322
85,Preclinical,"In a preclinical study, MI-503 inhibited growth of murine leukemia cells expressing an NPM1 mutation and FLT3 internal tandem duplication in culture, and improved survival in mouse models (PMID: 27535106).",Actionable,11489,1240,leukemia,DOID,26135,FLT3 exon 14 ins NPM1 mutant,"[{'id': 9547, 'pubMedId': 27535106, 'title': 'Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535106'}]",predicted – sensitive,6006,MI-503,2322
86,Preclinical,"In a preclinical study, EPZ004777 inhibited growth and induced differentiation of murine leukemia cells expressing an NPM1 mutation and FLT3 internal tandem duplication in culture, and improved survival in mouse models (PMID: 27535106).",Actionable,11490,1240,leukemia,DOID,26135,FLT3 exon 14 ins NPM1 mutant,"[{'id': 9547, 'pubMedId': 27535106, 'title': 'Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535106'}]",predicted – sensitive,1744,EPZ004777,2322
87,Clinical Study,"In a clinical study, a patient with FLT3-ITD positive leukemia initially responded to PLX3397, but experienced relapse after emergence of a FLT3 S652G mutation on the same allele as FLT3-ITD (PMID: 25847190).",Actionable,4849,1240,leukemia,DOID,19366,FLT3 exon 14 ins FLT3 S652G,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
88,Preclinical - Cell culture,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and D835F in culture (PMID: 27158668).",Actionable,9438,10000003,Advanced Solid Tumor,JAX,19133,FLT3 exon 14 ins FLT3 D835F,"[{'id': 7187, 'pubMedId': 27158668, 'title': 'The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27158668'}]",sensitive,5016,MRX-2843,2322
89,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835F were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4795,10000003,Advanced Solid Tumor,JAX,19133,FLT3 exon 14 ins FLT3 D835F,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
90,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and N676D were resistant to Rydapt (midostaurin) in culture (PMID: 23392356).",Actionable,9274,10000003,Advanced Solid Tumor,JAX,26809,FLT3 exon 14 ins FLT3 N676D,"[{'id': 7054, 'pubMedId': 23392356, 'title': 'The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23392356'}]",resistant,810,Midostaurin,2322
91,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and N676D demonstrated reduced sensitivity to Quizartinib (AC220) in culture (PMID: 23392356).",Actionable,9282,10000003,Advanced Solid Tumor,JAX,26809,FLT3 exon 14 ins FLT3 N676D,"[{'id': 7054, 'pubMedId': 23392356, 'title': 'The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23392356'}]",decreased response,882,Quizartinib,2322
92,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and Y842H demonstrated reduced sensitivity to Nexavar (sorafenib) in culture (PMID: 23392356).",Actionable,9281,10000003,Advanced Solid Tumor,JAX,19135,FLT3 exon 14 ins FLT3 Y842H,"[{'id': 7054, 'pubMedId': 23392356, 'title': 'The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23392356'}]",decreased response,920,Sorafenib,2322
93,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and Y842H demonstrated reduced sensitivity to Quizartinib (AC220) in culture (PMID: 23392356).",Actionable,9283,10000003,Advanced Solid Tumor,JAX,19135,FLT3 exon 14 ins FLT3 Y842H,"[{'id': 7054, 'pubMedId': 23392356, 'title': 'The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23392356'}]",decreased response,882,Quizartinib,2322
94,Preclinical - Cell culture,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and Y842H in culture (PMID: 27158668).",Actionable,9436,10000003,Advanced Solid Tumor,JAX,19135,FLT3 exon 14 ins FLT3 Y842H,"[{'id': 7187, 'pubMedId': 27158668, 'title': 'The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27158668'}]",sensitive,5016,MRX-2843,2322
95,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 Y842H were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4796,10000003,Advanced Solid Tumor,JAX,19135,FLT3 exon 14 ins FLT3 Y842H,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
96,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 R834Q were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4807,10000003,Advanced Solid Tumor,JAX,19275,FLT3 exon 14 ins FLT3 R834Q,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
97,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and A848P demonstrated reduced sensitivity to Quizartinib (AC220) in culture (PMID: 23392356).",Actionable,9284,10000003,Advanced Solid Tumor,JAX,26811,FLT3 exon 14 ins FLT3 A848P,"[{'id': 7054, 'pubMedId': 23392356, 'title': 'The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23392356'}]",decreased response,882,Quizartinib,2322
98,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and A848P demonstrated reduced sensitivity to Nexavar (sorafenib) in culture (PMID: 23392356).",Actionable,9280,10000003,Advanced Solid Tumor,JAX,26811,FLT3 exon 14 ins FLT3 A848P,"[{'id': 7054, 'pubMedId': 23392356, 'title': 'The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23392356'}]",decreased response,920,Sorafenib,2322
99,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and A848P were resistant to Sutent (sunitinib) in culture (PMID: 23392356).",Actionable,9277,10000003,Advanced Solid Tumor,JAX,26811,FLT3 exon 14 ins FLT3 A848P,"[{'id': 7054, 'pubMedId': 23392356, 'title': 'The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23392356'}]",resistant,930,Sunitinib,2322
100,Preclinical - Cell culture,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and D835V in culture (PMID: 27158668).",Actionable,9439,10000003,Advanced Solid Tumor,JAX,19131,FLT3 exon 14 ins FLT3 D835V,"[{'id': 7187, 'pubMedId': 27158668, 'title': 'The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27158668'}]",sensitive,5016,MRX-2843,2322
101,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835V were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4794,10000003,Advanced Solid Tumor,JAX,19131,FLT3 exon 14 ins FLT3 D835V,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
102,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and F691I were resistant to Quizartinib (AC220) in culture (PMID: 23392356).",Actionable,9285,10000003,Advanced Solid Tumor,JAX,26802,FLT3 exon 14 ins FLT3 F691I,"[{'id': 7054, 'pubMedId': 23392356, 'title': 'The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23392356'}]",resistant,882,Quizartinib,2322
103,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and F691I demonstrated reduced response to Sutent (sunitinib) in culture (PMID: 23392356).",Actionable,9276,10000003,Advanced Solid Tumor,JAX,26802,FLT3 exon 14 ins FLT3 F691I,"[{'id': 7054, 'pubMedId': 23392356, 'title': 'The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23392356'}]",decreased response,930,Sunitinib,2322
104,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing FLT3 ITD and F691I demonstrated reduced sensitivity to Brigatinib (AP26113) in culture (PMID: 27780853).",Actionable,9252,10000003,Advanced Solid Tumor,JAX,26802,FLT3 exon 14 ins FLT3 F691I,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",decreased response,634,AP26113,2322
105,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and F691I were resistant to Rydapt (midostaurin) in culture (PMID: 23392356).",Actionable,9275,10000003,Advanced Solid Tumor,JAX,26802,FLT3 exon 14 ins FLT3 F691I,"[{'id': 7054, 'pubMedId': 23392356, 'title': 'The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23392356'}]",resistant,810,Midostaurin,2322
106,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and F691I were resistant to Nexavar (sorafenib) in culture (PMID: 23392356).",Actionable,9278,10000003,Advanced Solid Tumor,JAX,26802,FLT3 exon 14 ins FLT3 F691I,"[{'id': 7054, 'pubMedId': 23392356, 'title': 'The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23392356'}]",resistant,920,Sorafenib,2322
107,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing FLT3 ITD in culture (PMID: 27780853).",Actionable,9231,10000003,Advanced Solid Tumor,JAX,19128,FLT3 exon 14 ins,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,2322
108,Preclinical - Pdx,"In a preclinical study, treatment with SHP099 resulted in reduction of CD45-positive leukemic cells and decreased splenomegaly in a human primary tumor-derived xenograft model of acute myeloid leukemia harboring a FLT3-ITD mutation (PMID: 27362227). ",Actionable,7519,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,"[{'id': 6394, 'pubMedId': 27362227, 'title': 'Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27362227'}]",predicted – sensitive,4504,SHP099,2322
109,Preclinical - Cell culture,"In a preclinical study, Altiratinib (DCC-0701) inhibited proliferation of an acute myeloid leukemia cell harboring a FLT3-ITD mutation in culture (PMID: 26285778).",Actionable,10068,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,"[{'id': 7263, 'pubMedId': 26285778, 'title': 'Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26285778'}]",sensitive,1656,Altiratinib,2322
110,Phase Ib/II,"In a Phase I/II trial, treatment with Gilteritinib (ASP2215) at a dose of 80mg/day or higher resulted in an overall response rate of 55% (77/141) in patients with relapsed or refractory acute myeloid leukemia harboring FLT3 internal tandem duplication mutations (PMID: 28645776; NCT02014558).",Actionable,11484,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,"[{'id': 9544, 'pubMedId': 28645776, 'title': 'Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28645776'}]",sensitive,2865,Gilteritinib,2322
111,Preclinical,"In a preclinical study, PLX3397 inhibited proliferation of transformed cells expressing FLT3-ITD in culture (PMID: 25847190).",Actionable,4788,10000003,Advanced Solid Tumor,JAX,19128,FLT3 exon 14 ins,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",sensitive,874,PLX3397,2322
112,Phase I,"In a Phase I trial, acute myeloid leukemia patients harboring a FLT3 internal tandem duplication did not benefit from treatment with Rebastinib (DCC-2036) (PMID: 27927766). ",Actionable,10755,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,"[{'id': 8807, 'pubMedId': 27927766, 'title': 'Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27927766'}]",no benefit,1045,rebastinib,2322
113,Preclinical - Cell line xenograft,"In a preclinical study, MRX-2843 inhibited Flt3 activation, resulted in growth inhibition in acute myeloid leukemia cell lines harboring FLT3 internal tandem duplication (ITD) in culture and in cell line xenograft models, and prolonged survival in patient-derived xenograft models (PMID: 27158668).",Actionable,9429,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,"[{'id': 7187, 'pubMedId': 27158668, 'title': 'The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27158668'}]",sensitive,5016,MRX-2843,2322
114,Phase I,"In a Phase I trial, acute myeloid leukemia (AML) pediatric patients harboring a FLT3-ITD mutation demonstrated a greater sensitivity to treatment with Quizartinib (AC220) when compared to AML patients with wild-type FLT3, resulting in three complete responses, four with stable disease, and a lower bone marrow blast cell count (PMID: 26920889).",Actionable,7770,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,"[{'id': 6489, 'pubMedId': 26920889, 'title': 'A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26920889'}]",sensitive,882,Quizartinib,2322
115,Phase I,"In a Phase I trial, an acute myeloid leukemia patient with a FLT3-ITD mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088). ",Actionable,8007,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,"[{'id': 6531, 'pubMedId': 27406088, 'title': 'A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27406088'}]",sensitive,727,ENMD-2076,2322
116,Phase III,"In a Phase III trial that supported FDA approval, treatment with Rydapt (midostaurin), combined with Cytosar-U (cytarabine) and Daunorubicin, improved overall survival (74.7 mo vs 25.6 mo) in patients with FLT3-mutant or FLT3-ITD acute myeloid leukemia compared to Cytosar-U (cytarabine) and Daunorubicin with placebo (PMID: 28644114). ",Actionable,11372,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,"[{'id': 9261, 'pubMedId': 28644114, 'title': 'Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28644114'}]",sensitive,3137,Cytarabine + Daunorubicin + Midostaurin,2322
117,Preclinical - Patient cell culture,"In a preclinical study, Iclusig (ponatinib) inhibited viability of patient derived acute myeloid leukemia cells harboring FLT3 ITD mutations in culture, and inhibited growth of tumors in cell line xenograft models (PMID: 21482694).",Actionable,2530,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,"[{'id': 3255, 'pubMedId': 21482694, 'title': 'Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21482694'}]",sensitive,877,Ponatinib,2322
118,Phase I,"In a Phase I trial, Iclusig (ponatinib) resulted in a 25% (3/12) overall response rate, indicated as partial remission or better, in acute myeloid leukemia patients harboring FLT3-ITD (PMID: 23691988).",Actionable,12174,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,"[{'id': 3851, 'pubMedId': 23691988, 'title': 'Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23691988'}]",sensitive,877,Ponatinib,2322
119,Preclinical - Cell culture,"In a preclinical study, E6201 induced apoptosis in blast samples derived from acute myeloid leukemia patients harboring FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).",Actionable,7429,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,"[{'id': 5604, 'pubMedId': 26822154, 'title': 'The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26822154'}]",sensitive,1011,E6201,2322
120,Preclinical - Cell line xenograft,"In a preclinical study, PLX3397 inhibited proliferation of human leukemia cells harboring FLT3-ITD in culture and in cell line xenograft models (PMID: 25847190).",Actionable,4791,1240,leukemia,DOID,19128,FLT3 exon 14 ins,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",sensitive,874,PLX3397,2322
121,Preclinical - Cell line xenograft,"In a preclinical study, E6201 induced growth inhibition and apoptosis in leukemia cell lines harboring FLT3 internal tandem duplications (ITD) and reduced tumor burden in xenograft models (PMID: 26822154).",Actionable,6457,1240,leukemia,DOID,19128,FLT3 exon 14 ins,"[{'id': 5604, 'pubMedId': 26822154, 'title': 'The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26822154'}]",sensitive,1011,E6201,2322
122,Phase I,"In a Phase I trial, Crenolanib treatment resulted in an overall survival (OS) of 238 days in AML patients harboring FLT3 exon 14 insertions (ITD) that received no prior therapy, and an OS of 158 days in those progressed on TKIs (J Clin Oncol 34, 2016 (suppl; abstr 7008)).",Actionable,6885,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,"[{'id': 5948, 'pubMedId': None, 'title': 'Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.', 'url': 'http://meetinglibrary.asco.org/content/170782-176'}]",sensitive,705,Crenolanib,2322
123,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing a FLT3-ITD mutation were sensitive to Cometriq (cabozantinib) in culture (PMID: 21926191).",Actionable,3574,10000003,Advanced Solid Tumor,JAX,19128,FLT3 exon 14 ins,"[{'id': 587, 'pubMedId': 21926191, 'title': 'Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21926191'}]",predicted – sensitive,998,cabozantinib,2322
124,Preclinical - Cell culture,"In a preclinical study, Rydapt (midostaurin) demonstrated efficacy in inhibiting proliferation and viability of transformed cells expressing a FLT3-ITD mutation in culture (PMID: 12124173).",Actionable,3270,10000003,Advanced Solid Tumor,JAX,19128,FLT3 exon 14 ins,"[{'id': 985, 'pubMedId': 12124173, 'title': 'Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12124173'}]",sensitive,810,Midostaurin,2322
125,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D839H were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4833,10000003,Advanced Solid Tumor,JAX,19285,FLT3 exon 14 ins FLT3 D839H,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
126,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D698N were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4805,10000003,Advanced Solid Tumor,JAX,19293,FLT3 exon 14 ins FLT3 D698N,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
127,Phase I,"In a Phase I trial, Crenolanib treatment resulted in an overall survival (OS) of 128 days in AML patients harboring both FLT3 D835X and exon 14 insertion (ITD) that received no prior therapy, and an OS of 63 days in those progressed on TKIs (J Clin Oncol 34, 2016 (suppl; abstr 7008)).",Actionable,6886,9119,acute myeloid leukemia,DOID,23954,FLT3 D835X FLT3 exon 14 ins,"[{'id': 5948, 'pubMedId': None, 'title': 'Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.', 'url': 'http://meetinglibrary.asco.org/content/170782-176'}]",sensitive,705,Crenolanib,2322
128,Preclinical,"In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE in culture (PMID: 12124172).",Actionable,1037,9119,acute myeloid leukemia,DOID,1755,FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE,"[{'id': 749, 'pubMedId': 12124172, 'title': 'CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12124172'}]",sensitive,933,Tandutinib,2322
129,Clinical Study,"In a retrospective analysis, of patients with acute myeloid leukemia, the combination of DNMT3A, FLT3, and NPM1 mutations was highly associated with decreased event free survival and overall survival, suggesting that this combination profile may serve as a future prognostic biomarker (PMID: 25281355).  ",Emerging,3573,9119,acute myeloid leukemia,DOID,13674,DNMT3A R882H FLT3 Y599_D600insSTDNEYFYVDFREYEY NPM1 W288fs,"[{'id': 3849, 'pubMedId': 25281355, 'title': 'Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25281355'}]",not applicable,1776,N/A,2322
130,Preclinical,"In a preclinical study, acute myeloid leukemia cells harboring a FLT3-ITD secondary resistance mutation demonstrated sensitivity to FLX925 (Cancer Res, August 1, 2015 75; 787).
",Actionable,3590,9119,acute myeloid leukemia,DOID,13493,FLT3 Y599_D600insSTDNEYFYVDFREYEY,"[{'id': 3864, 'pubMedId': None, 'title': 'Abstract 787: FLX925 (AMG 925) is a rationally designed FLT3, CDK4/6 inhibitor that retains potency against clinically relevant secondary resistance mutations in FLT3', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/787.short'}]",predicted – sensitive,2529,FLX925  ,2322
131,Phase I,"In a Phase I clinical trial, patients with refractory or relapsed acute myeloid leukemia positive for FLT3-ITD demonstrated a 53% (9/17) response rate compared to a 14% (5/37) response rate in those patients negative for FLT3-ITD when treated with Quizartinib (AC220) (PMID: 24002496). ",Actionable,3596,9119,acute myeloid leukemia,DOID,13493,FLT3 Y599_D600insSTDNEYFYVDFREYEY,"[{'id': 3874, 'pubMedId': 24002496, 'title': 'Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24002496'}]",predicted – sensitive,882,Quizartinib,2322
132,Preclinical - Cell line xenograft,"In a preclinical study, acute myeloid leukemia cells harboring a FLT3-ITD mutation treated with Pacritinib resulted in apoptosis and inhibition of cell proliferation in culture and in cell line xenograft models demonstrated tumor growth inhibition and tumor regression (PMID: 22829080). ",Actionable,3594,9119,acute myeloid leukemia,DOID,13493,FLT3 Y599_D600insSTDNEYFYVDFREYEY,"[{'id': 1802, 'pubMedId': 22829080, 'title': 'Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22829080'}]",predicted – sensitive,2006,Pacritinib,2322
133,Preclinical - Cell line xenograft,"In a preclinical study, E6201 induced cell death, inhibited cell growth, and decreased tumor burden in acute myeloid leukemia cells harboring FLT3-ITD mutations in culture and in cell line xenograft models (Blood Nov 2013, 122 (21) 2683). ",Actionable,3588,9119,acute myeloid leukemia,DOID,13493,FLT3 Y599_D600insSTDNEYFYVDFREYEY,"[{'id': 3838, 'pubMedId': None, 'title': 'Study Of Activity Of E6201, a Dual FLT3 and MEK Inhibitor, In Acute Myelogenous Leukemia With FLT3 Or RAS Mutation', 'url': 'http://www.bloodjournal.org/content/122/21/2683?sso-checked=true'}]",predicted – sensitive,1011,E6201,2322
134,Phase II,"In a Phase II trial, 93% (40/43) of acute myeloid leukemia patients harbored a FLT3-ITD and of the 37 patients that were evaluable, the combination therapy, Nexavar (sorafenib) and Vidaza (azacitidine), resulted in a 46% (17/37) response rate, which included 10 CRi, 6 CR, and 1 PR (PMID: 23613521).  ",Actionable,3578,9119,acute myeloid leukemia,DOID,13493,FLT3 Y599_D600insSTDNEYFYVDFREYEY,"[{'id': 3852, 'pubMedId': 23613521, 'title': 'Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23613521'}]",predicted – sensitive,1633,Sorafenib + Azacitidine,2322
135,Preclinical,"In a preclinical study, the combination of Enasidenib (AG-221) and Quizartinib (AC220) stimulated leukemic cell differentiation and reduced leukemic cell self-renewal in an acute myeloid leukemia mouse model simultaneously expressing IDH2 R140Q and a FLT3-ITD mutation (Blood Dec 2014, 124 (21) 437). ",Actionable,3593,9119,acute myeloid leukemia,DOID,13759,IDH2 R140W FLT3 Y599_D600insSTDNEYFYVDFREYEY,"[{'id': 3871, 'pubMedId': None, 'title': 'AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo', 'url': 'http://www.bloodjournal.org/content/124/21/437?sso-checked=true'}]",predicted – sensitive,3172,Enasidenib + Quizartinib,2322
136,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing FLT3 S451F demonstrated decreased sensitivity to inhibition of FLT3 phosphorylation and growth by Rydapt (midostaurin) in culture, when compared to cells expressing other FLT3 activating mutations (PMID: 18068628).",Actionable,2283,10000003,Advanced Solid Tumor,JAX,6896,FLT3 S451F,"[{'id': 2803, 'pubMedId': 18068628, 'title': 'Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18068628'}]",decreased response,810,Midostaurin,2322
137,Preclinical,"In a preclinical study, PD98059 inhibited ERK1/2 phosphorylation and reduced cell growth in transformed cells expressing FLT3 R834Q (PMID: 18068628).",Actionable,2286,10000003,Advanced Solid Tumor,JAX,6799,FLT3 R834Q,"[{'id': 2803, 'pubMedId': 18068628, 'title': 'Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18068628'}]",sensitive,2617,PD98059,2322
138,Preclinical - Cell culture,"In a preclinical study, Rydapt (midostaurin) inhibited FLT3-induced phosphorylation of ERK1/2 and reduced growth of transformed cells expressing FLT3 R834Q in culture (PMID: 18068628).",Actionable,2285,10000003,Advanced Solid Tumor,JAX,6799,FLT3 R834Q,"[{'id': 2803, 'pubMedId': 18068628, 'title': 'Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18068628'}]",sensitive,810,Midostaurin,2322
139,Preclinical - Cell culture,"In a preclinical study, Rydapt (midostaurin) inhibited FLT3 phosphorylation of ERK1/2 and reduced cell growth in transformed cells expressing FLT3 Y572C in culture (PMID: 18068628).",Actionable,2282,10000003,Advanced Solid Tumor,JAX,6805,FLT3 Y572C,"[{'id': 2803, 'pubMedId': 18068628, 'title': 'Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18068628'}]",sensitive,810,Midostaurin,2322
140,Preclinical,"In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 Y599_D600insGLYVDFREYEY in culture (PMID: 12124172).",Actionable,1041,9119,acute myeloid leukemia,DOID,1739,FLT3 Y599_D600insGLYVDFREYEY,"[{'id': 749, 'pubMedId': 12124172, 'title': 'CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12124172'}]",sensitive,933,Tandutinib,2322
141,Phase I,"In a Phase I trial, Crenolanib treatment resulted in an overall survival (OS) of 185 days in AML patients harboring FLT3 D835X that received no prior therapy (J Clin Oncol 34, 2016 (suppl; abstr 7008)).",Actionable,6884,9119,acute myeloid leukemia,DOID,5329,FLT3 D835X,"[{'id': 5948, 'pubMedId': None, 'title': 'Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.', 'url': 'http://meetinglibrary.asco.org/content/170782-176'}]",sensitive,705,Crenolanib,2322
142,Preclinical,"In a preclinical study, tandutinib (CT53518) inhibited cell proliferation in cell culture and in mouse models carrying FLT3 L601_K602insREYEYDL (PMID: 12124172).",Actionable,1039,9119,acute myeloid leukemia,DOID,1756,FLT3 L601_K602insREYEYDL,"[{'id': 749, 'pubMedId': 12124172, 'title': 'CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12124172'}]",sensitive,933,Tandutinib,2322
143,Preclinical,"In a preclinical study, UNC2025 inhibited FLT3 activation and growth of acute myeloid leukemia cells harboring a FLT3-ITD mutation in culture (PMID: 25068800).",Actionable,3751,9119,acute myeloid leukemia,DOID,1227,FLT3 mutant,"[{'id': 4104, 'pubMedId': 25068800, 'title': 'UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25068800'}]",sensitive,3291,UNC2025,2322
144,Phase Ib/II,"In a Phase Ib/II trial, acute myeloid leukemia patients harboring a FLT3 mutation demonstrated an improved remission duration when treated with the combination therapy, Rydapt (midostaurin) and Vidaza (azacitidine) (PMID: 25530214).",Actionable,3591,9119,acute myeloid leukemia,DOID,1227,FLT3 mutant,"[{'id': 3869, 'pubMedId': 25530214, 'title': 'Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25530214'}]",sensitive,2471,Azacitidine + Midostaurin,2322
145,Preclinical,"In a preclinical study, acute myeloid leukemia cell lines harboring FLT3 mutations demonstrated increased sensitivity to E6201 induced growth inhibition and apoptosis in culture compared to FLT3 wild-type cells (PMID: 26822154).",Actionable,6455,9119,acute myeloid leukemia,DOID,1227,FLT3 mutant,"[{'id': 5604, 'pubMedId': 26822154, 'title': 'The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26822154'}]",sensitive,1011,E6201,2322
146,Phase Ib/II,"In a Phase I/II trial, treatment with Gilteritinib (ASP2215) resulted in an overall response rate of 49% (93/191) in patients with relapsed or refractory acute myeloid leukemia harboring FLT3 mutations, compared to 12% (7/58) in patients with wild-type FLT3 (PMID: 28645776; NCT02014558).",Actionable,3583,9119,acute myeloid leukemia,DOID,1227,FLT3 mutant,"[{'id': 3855, 'pubMedId': None, 'title': 'Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML)', 'url': 'http://meetinglibrary.asco.org/content/146239-156'}, {'id': 9544, 'pubMedId': 28645776, 'title': 'Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28645776'}]",predicted – sensitive,2865,Gilteritinib,2322
147,Preclinical - Cell line xenograft,"In a preclinical study, TG02 inhibited growth of FLT3-mutated acute myeloid leukemia cells in culture, resulted in complete tumor regression in cell line xenograft animal models (PMID: 21860433).",Actionable,11216,9119,acute myeloid leukemia,DOID,1227,FLT3 mutant,"[{'id': 9049, 'pubMedId': 21860433, 'title': 'TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21860433'}]",sensitive,5836,TG02,2322
148,Phase Ib/II,"In a Phase Ib clinical trial, Rydapt (midostaurin) treatment after Daunorubicin and Cytosar-U (cytarabine) induction resulted in complete remission in 92% (12/13) of acute myeloid leukemia patients carrying FLT3 mutations, although overall survival rate was similar to patients with wild-type FLT3 (PMID: 22627678).",Actionable,3408,9119,acute myeloid leukemia,DOID,1227,FLT3 mutant,"[{'id': 3770, 'pubMedId': 22627678, 'title': 'Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22627678'}]",sensitive,3137,Cytarabine + Daunorubicin + Midostaurin,2322
149,FDA approved,"In a Phase III trial that supported FDA approval, treatment with Rydapt (midostaurin), combined with Cytosar-U (cytarabine) and Daunorubicin, improved overall survival (74.7 mo vs 25.6 mo) in patients with FLT3-mutant or FLT3-ITD acute myeloid leukemia compared to Cytosar-U (cytarabine) and Daunorubicin with placebo (PMID: 28644114). ",Actionable,10716,9119,acute myeloid leukemia,DOID,1227,FLT3 mutant,"[{'id': 8777, 'pubMedId': None, 'title': 'The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Mye', 'url': 'http://www.bloodjournal.org/content/126/23/6'}, {'id': 9261, 'pubMedId': 28644114, 'title': 'Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28644114'}]",sensitive,3137,Cytarabine + Daunorubicin + Midostaurin,2322
150,Phase I,"In a Phase I trial, Crenolanib treatment resulted in complete response (CR) in 39% (7/18), partial response (PR) in 11% (2/18), and an overall survival (OS) of 234 days in AML patients harboring FLT3 mutations (D835X, ITD, or both) that received no prior therapy, and CR in 17% (6/36), PR in 14% (5/36), and OS of 94 days in those progressed on TKIs (J Clin Oncol 34, 2016 (suppl; abstr 7008)).",Actionable,6883,9119,acute myeloid leukemia,DOID,1227,FLT3 mutant,"[{'id': 5948, 'pubMedId': None, 'title': 'Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.', 'url': 'http://meetinglibrary.asco.org/content/170782-176'}]",sensitive,705,Crenolanib,2322
151,Preclinical - Cell culture,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing FLT3 D835V in culture (PMID: 27158668).",Actionable,9435,10000003,Advanced Solid Tumor,JAX,3154,FLT3 D835V,"[{'id': 7187, 'pubMedId': 27158668, 'title': 'The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27158668'}]",sensitive,5016,MRX-2843,2322
152,Preclinical,"In a preclinical study, transformed cells expressing FLT3 D835V were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4792,10000003,Advanced Solid Tumor,JAX,3154,FLT3 D835V,"[{'id': 3027, 'pubMedId': 25847190, 'title': 'Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25847190'}]",resistant,874,PLX3397,2322
0,Preclinical,"FOXL2 C134W mutations are used in the diagnosis of adult granulosa cell tumors of the ovary (PMID: 26791928, PMID: 22240241).",Diagnostic,5775,2999,granulosa cell tumor,DOID,3836,FOXL2 C134W,"[{'id': 5151, 'pubMedId': 26791928, 'title': 'Impact of FOXL2 mutations on signaling in ovarian granulosa cell tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26791928'}, {'id': 5208, 'pubMedId': 22240241, 'title': 'Molecular pathogenesis of granulosa cell tumors of the ovary.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22240241'}]",not applicable,1776,N/A,668
0,Clinical Study,"GATA1 mutations are used in the diagnosis of Down Syndrome related acute megakaryoblastic leukemia (PMID: 25266042, PMID: 14636651, PMID: 12586620). ",Diagnostic,6078,8761,megakaryocytic leukemia,DOID,22437,GATA1 mutant,"[{'id': 5284, 'pubMedId': 25266042, 'title': 'Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25266042'}, {'id': 5285, 'pubMedId': 14636651, 'title': 'Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/14636651'}, {'id': 5286, 'pubMedId': 12586620, 'title': 'GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12586620'}]",not applicable,1776,N/A,2623
1,Preclinical - Cell culture,"In a preclinical study, high expression of GATA1 was associated with decreased sensitivity to Cytosar-U (cytarabine) in an non-Down Syndrome megakaryocytic leukemia cell line in culture (PMID: 23874683).",Actionable,1428,8761,megakaryocytic leukemia,DOID,2519,GATA1 over exp,"[{'id': 1278, 'pubMedId': 23874683, 'title': 'Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23874683'}]",decreased response,712,Cytarabine,2623
2,Preclinical - Cell culture,"In a preclinical study, high expression of GATA1 was associated with decreased sensitivity to Cerubidine (daunorubicin) in a non-Down Syndrome megakaryocytic leukemia cell line in culture (PMID: 23874683).",Actionable,1429,8761,megakaryocytic leukemia,DOID,2519,GATA1 over exp,"[{'id': 1278, 'pubMedId': 23874683, 'title': 'Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23874683'}]",decreased response,1006,Daunorubicin,2623
0,Clinical Study,"In clinical analyses, mutations in GATA2 were associated with better overall survival in patients with cytogenetically normal acute myeloid leukemia (CN-AML) harboring biallelic CEBPA gene mutations (PMID: 22814295, PMID: 23521373, PMID: 25241285).",Prognostic,3612,9119,acute myeloid leukemia,DOID,22783,CEBPA mutant GATA2 mutant,"[{'id': 3883, 'pubMedId': 22814295, 'title': 'GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22814295'}, {'id': 5352, 'pubMedId': 23521373, 'title': 'CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23521373'}, {'id': 5353, 'pubMedId': 25241285, 'title': 'GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25241285'}]",not applicable,1776,N/A,2624
1,Clinical Study,"In multiple clinical studies, GATA2 germline mutations were shown to be a risk factor for the development of acute myeloid leukemia following myelodysplastic syndrome (PMID: 21892162, PMID: 22271902, PMID: 22147895, PMID: 22533337). ",Prognostic,6221,9119,acute myeloid leukemia,DOID,11068,GATA2 mutant,"[{'id': 3111, 'pubMedId': 21892162, 'title': 'Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21892162'}, {'id': 5472, 'pubMedId': 22271902, 'title': 'Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22271902'}, {'id': 5473, 'pubMedId': 22147895, 'title': 'Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22147895'}, {'id': 5474, 'pubMedId': 22533337, 'title': 'Marked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22533337'}]",not applicable,1776,N/A,2624
2,Preclinical,"In a preclinical study, the combination of bortezomib and fasudil blocked GATA2 downstream signals in KRAS activated NSCLC cells, resulting in reduced tumor burden, size and number in treated mice (PMID: 22541434).  ",Actionable,1462,3908,non-small cell lung carcinoma,DOID,2563,KRAS mut + GATA2 wild-type,"[{'id': 1329, 'pubMedId': 22541434, 'title': 'The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22541434'}]",sensitive,1778,bortezomib + fasudil,2624
0,Preclinical - Pdx & cell culture,"In a preclinical study, treatment with the combination of Sotrastaurin (AEB071) and Afinitor (everolimus) inhibited tumor growth in patient-derived xenograft (PDX) models of uveal melanoma harboring GNA11 mutations, including tumor regression, and inhibited growth of GNA11-mutant uveal melanoma cell lines in culture (PMID: 27507190).",Actionable,10694,6039,uveal melanoma,DOID,24999,GNA11 mutant,"[{'id': 8749, 'pubMedId': 27507190, 'title': 'Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27507190'}]",predicted – sensitive,1951,AEB071 + Everolimus,2767
1,Preclinical - Pdx & cell culture,"In a preclinical study, treatment with the combination of Sotrastaurin (AEB071) and CGM097 resulted in tumor regression or stasis in patient-derived xenograft (PDX) models of uveal melanoma harboring GNA11 mutations, and induced apoptosis and inhibited growth of GNA11-mutant uveal melanoma cell lines in culture (PMID: 27507190).",Actionable,10692,6039,uveal melanoma,DOID,24999,GNA11 mutant,"[{'id': 8749, 'pubMedId': 27507190, 'title': 'Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27507190'}]",predicted – sensitive,5587,AEB071 + CGM097,2767
2,Preclinical - Pdx & cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Sotrastaurin (AEB071) inhibited tumor growth in patient-derived xenograft (PDX) models of uveal melanoma harboring GNA11 mutations, and inhibited growth of GNA11-mutant uveal melanoma cell lines in culture (PMID: 27507190).",Actionable,10696,6039,uveal melanoma,DOID,24999,GNA11 mutant,"[{'id': 8749, 'pubMedId': 27507190, 'title': 'Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27507190'}]",predicted – sensitive,1114,MEK162 + AEB071,2767
3,Preclinical - Cell culture,"In a preclinical study, uveal melanoma cell lines harboring GNA11 Q209L demonstrated increased sensitivity to growth inhibition by Mekinist (trametinib) in culture, compared to cells with wild-type GNA11 (PMID: 22733540).",Actionable,10641,6039,uveal melanoma,DOID,550,GNA11 Q209L,"[{'id': 8697, 'pubMedId': 22733540, 'title': 'Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22733540'}]",sensitive,2,Trametinib,2767
4,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Binimetinib (MEK162) and Sotrastaurin (AEB071) synergized to inhibit growth in a human uveal melanoma cancer cell line harboring a GNA11 Q209L mutation in culture and in xenograft models, and demonstrated improved efficacy over either agent alone (PMID: 24141786).",Actionable,1045,6039,uveal melanoma,DOID,550,GNA11 Q209L,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}]",sensitive,1114,MEK162 + AEB071,2767
5,Preclinical - Cell culture,"In a preclinical study, TAK-733 inhibited growth of uveal melanoma cell lines harboring GNA11 Q209L in culture (PMID: 22515704).",Actionable,10624,6039,uveal melanoma,DOID,550,GNA11 Q209L,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}]",sensitive,932,TAK-733,2767
0,Preclinical - Pdx & cell culture,"In a preclinical study, treatment with the combination of Sotrastaurin (AEB071) and Afinitor (everolimus) inhibited tumor growth in patient-derived xenograft (PDX) models of uveal melanoma harboring GNAQ mutations, including tumor regression or stasis, and inhibited growth of GNAQ-mutant uveal melanoma cell lines in culture (PMID: 27507190).",Actionable,10693,6039,uveal melanoma,DOID,25000,GNAQ mutant,"[{'id': 8749, 'pubMedId': 27507190, 'title': 'Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27507190'}]",predicted – sensitive,1951,AEB071 + Everolimus,2776
1,Preclinical - Pdx & cell culture,"In a preclinical study, treatment with the combination of Sotrastaurin (AEB071) and CGM097 resulted in tumor regression or stasis in patient-derived xenograft (PDX) models of uveal melanoma harboring GNAQ mutations, and induced apoptosis and inhibited growth of GNAQ-mutant uveal melanoma cell lines in culture (PMID: 27507190).",Actionable,10691,6039,uveal melanoma,DOID,25000,GNAQ mutant,"[{'id': 8749, 'pubMedId': 27507190, 'title': 'Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27507190'}]",predicted – sensitive,5587,AEB071 + CGM097,2776
2,Preclinical - Pdx & cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Sotrastaurin (AEB071) inhibited tumor growth in patient-derived xenograft (PDX) models of uveal melanoma harboring GNAQ mutations, and inhibited growth of GNAQ-mutant uveal melanoma cell lines in culture (PMID: 27507190).",Actionable,10695,6039,uveal melanoma,DOID,25000,GNAQ mutant,"[{'id': 8749, 'pubMedId': 27507190, 'title': 'Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27507190'}]",predicted – sensitive,1114,MEK162 + AEB071,2776
3,Phase I,"In a Phase I clinical trial, Refametinib (BAY 86-9766) demonstrated preliminary clinical activity in patients with several tumor types, including prolonged stable disease in an ocular melanoma patient harboring GNAQ Q209L and PTEN R173S (PMID: 23434733).",Actionable,10644,1752,ocular melanoma,DOID,27655,GNAQ Q209L PTEN R173S,"[{'id': 1066, 'pubMedId': 23434733, 'title': 'Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23434733'}]",predicted – sensitive,888,Refametinib,2776
4,Preclinical - Cell culture,"In a preclinical study, uveal melanoma cell lines harboring GNAQ Q209L demonstrated increased sensitivity to growth inhibition by Mekinist (trametinib) in culture, compared to cells with wild-type GNAQ (PMID: 22733540).",Actionable,10640,6039,uveal melanoma,DOID,561,GNAQ Q209L,"[{'id': 8697, 'pubMedId': 22733540, 'title': 'Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22733540'}]",sensitive,2,Trametinib,2776
5,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) induced cell-cycle arrest and decreased viability of uveal melanoma cells harboring GNAQ Q209L in culture (PMID: 22550165).",Actionable,10645,6039,uveal melanoma,DOID,561,GNAQ Q209L,"[{'id': 8677, 'pubMedId': 22550165, 'title': 'Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22550165'}]",sensitive,913,Selumetinib,2776
6,Preclinical - Cell culture,"In a preclinical study, Sotrastaurin (AEB071), in combination with PD-0325901, worked synergisitically to inhibit MAPK pathway activation and proliferation of a uveal melanoma cell line harboring GNAQ Q209L (PMID: 24141786).",Actionable,1783,6039,uveal melanoma,DOID,561,GNAQ Q209L,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}]",sensitive,2275,AEB071 + PD-0325901,2776
7,Preclinical - Cell culture,"In a preclinical study, treatment with U0126 resulted in reduced cell numbers in uveal melanoma cell lines harboring GNAQ Q209L in culture (PMID: 19078957).",Actionable,10647,6039,uveal melanoma,DOID,561,GNAQ Q209L,"[{'id': 8702, 'pubMedId': 19078957, 'title': 'Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19078957'}]",sensitive,2427,U0126,2776
8,Preclinical - Cell line xenograft,"In a preclinical study, human uveal melanoma cell lines harboring GNAQ Q209L demonstrated sensitivity to Sotrastaurin (AEB071) in culture, and Sotrastaurin (AEB071) decreased tumor growth in uveal melanoma cell line xenograft models harboring GNAQ Q209L (PMID: 24141786).",Actionable,10583,6039,uveal melanoma,DOID,561,GNAQ Q209L,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}]",sensitive,621,AEB071,2776
9,Preclinical - Cell culture,"In a preclinical study, TAK-733 inhibited growth of a uveal melanoma cell line harboring GNAQ Q209L in culture (PMID: 22515704).",Actionable,10622,6039,uveal melanoma,DOID,561,GNAQ Q209L,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}]",sensitive,932,TAK-733,2776
10,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of Mekinist (trametinib) and GSK2126458 induced apoptosis in uveal melanoma cell lines harboring GNAQ Q209L in culture (PMID: 22733540).",Actionable,10642,6039,uveal melanoma,DOID,561,GNAQ Q209L,"[{'id': 8697, 'pubMedId': 22733540, 'title': 'Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22733540'}]",sensitive,3027,GSK2126458 + Trametinib,2776
11,Preclinical - Cell line xenograft,"In a preclinical study, NAV-2729 inhibited signaling downstream of GNAQ Q209L in melanoma cells in culture, and inhibited initiation and growth of tumors in a uveal melanoma cell line xenograft model harboring GNAQ Q209L (PMID: 27265506).",Actionable,10591,6039,uveal melanoma,DOID,561,GNAQ Q209L,"[{'id': 8662, 'pubMedId': 27265506, 'title': 'ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27265506'}]",sensitive,5564,NAV-2729,2776
12,Preclinical - Cell line xenograft,"In a preclinical study, Visudyne (verteporfin) inhibited tumor formation in a uveal melanoma cell line xenograft model harboring GNAQ Q209L (PMID: 27308390).",Actionable,10632,6039,uveal melanoma,DOID,561,GNAQ Q209L,"[{'id': 8675, 'pubMedId': 27308390, 'title': 'YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27308390'}]",sensitive,3319,Verteporfin,2776
13,Preclinical - Cell culture,"In a preclinical study, Enzastaurin (LY317615) increased cell-cycle arrest and apoptosis and decreased viability of uveal melanoma cell lines harboring GNAQ Q209L in culture (PMID: 22253748).",Actionable,1266,6039,uveal melanoma,DOID,561,GNAQ Q209L,"[{'id': 982, 'pubMedId': 22253748, 'title': 'The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22253748'}]",sensitive,1682,Enzastaurin,2776
14,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) induced cell-cycle arrest and decreased viability of uveal melanoma cells harboring GNAQ Q209P in culture (PMID: 22550165).",Actionable,10646,6039,uveal melanoma,DOID,560,GNAQ Q209P,"[{'id': 8677, 'pubMedId': 22550165, 'title': 'Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22550165'}]",sensitive,913,Selumetinib,2776
15,Preclinical - Cell culture,"In a preclinical study, Sotrastaurin (AEB071) induced cell-cycle arrest and apoptosis, and decreased viability of a uveal melanoma cell line harboring GNAQ Q209P in culture (PMID: 22653968).",Actionable,10595,6039,uveal melanoma,DOID,560,GNAQ Q209P,"[{'id': 8663, 'pubMedId': 22653968, 'title': 'Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22653968'}]",sensitive,621,AEB071,2776
16,Preclinical - Cell culture,"In a preclinical study, TAK-733 inhibited growth of uveal melanoma cell lines harboring GNAQ Q209P in culture (PMID: 22515704). ",Actionable,10623,6039,uveal melanoma,DOID,560,GNAQ Q209P,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}]",sensitive,932,TAK-733,2776
17,Preclinical - Cell culture,"In a preclinical study, Enzastaurin (LY317615) increased cell-cycle arrest and apoptosis and decreased viability of a uveal melanoma cell line harboring GNAQ Q209P in culture (PMID: 22253748).",Actionable,10603,6039,uveal melanoma,DOID,560,GNAQ Q209P,"[{'id': 982, 'pubMedId': 22253748, 'title': 'The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22253748'}]",sensitive,1682,Enzastaurin,2776
0,Clinical Study,"Inactivating mutations in HNF1A (TCF1) are used in the diagnosis of the HCA-H subtype of hepatocellular adenoma (PMID: 25076298, PMID: 26961851, PMID: 25434466).",Diagnostic,3989,50868,hepatocellular adenoma,DOID,16436,HNF1A inact mut,"[{'id': 4196, 'pubMedId': 25076298, 'title': 'Update on the new classification of hepatic adenomas: clinical, molecular, and pathologic characteristics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25076298'}, {'id': 5209, 'pubMedId': 26961851, 'title': 'Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26961851'}, {'id': 5210, 'pubMedId': 25434466, 'title': 'Hepatocellular adenoma management: call for shared guidelines and multidisciplinary approach.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25434466'}]",not applicable,1776,N/A,6927
0,Preclinical,"In a preclinical study, BEZ235 inhibited growth of thyroid cancer cells harboring an HRAS pathway activating mutation in cell culture (PMID: 21831957).",Actionable,1700,1781,thyroid cancer,DOID,2870,HRAS inact mut,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",sensitive,672,BEZ235,3265
1,Preclinical - Cell culture,"In a preclinical study, human solid tumor cell lines harboring HRAS mutations demonstrated increased sensitivity to growth inhibition by  Selumetinib (AZD6244) in culture compared to cell lines with wild-type HRAS (PMID: 26544513).",Actionable,9456,10000003,Advanced Solid Tumor,JAX,1208,HRAS mutant,"[{'id': 7197, 'pubMedId': 26544513, 'title': 'Mutant HRAS as novel target for MEK and mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26544513'}]",predicted – sensitive,913,Selumetinib,3265
2,Phase Ib/II,"In a Phase Ib study,  Alpelisib (BYL719) in combination with Binimetinib (MEK162) demonstrated preliminary safety and efficacy in patients with RAS-mutant advanced solid tumors, including patients with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 9051).",Actionable,1689,2394,ovarian cancer,DOID,1208,HRAS mutant,"[{'id': 1765, 'pubMedId': None, 'title': 'A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/129278-144'}]",predicted – sensitive,1311,BYL719 + MEK162,3265
3,Preclinical,"In a preclinical study, mouse models of bladder cancer harboring an HRAS mutation were sensitive to Glucophage (metformin), resulting in tumor growth reduction and prevention of hyperplasia regression (PMID: 26921394).",Actionable,5174,11054,urinary bladder cancer,DOID,1208,HRAS mutant,"[{'id': 4848, 'pubMedId': 26951660, 'title': 'Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26951660'}, {'id': 4943, 'pubMedId': 26921394, 'title': 'High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26921394'}]",sensitive,1031,Metformin,3265
4,Preclinical,"In a preclinical study, human urinary transitional cell carcinoma cells harboring mutant HRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6737,2671,transitional cell carcinoma,DOID,1208,HRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,2,Trametinib,3265
5,Preclinical - Cell culture,"In a preclinical study, Binimetinib (MEK162) inhibited growth and induced apoptosis in human solid tumor cell lines harboring HRAS mutations in culture (PMID: 26544513).",Actionable,9457,10000003,Advanced Solid Tumor,JAX,1208,HRAS mutant,"[{'id': 7197, 'pubMedId': 26544513, 'title': 'Mutant HRAS as novel target for MEK and mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26544513'}]",predicted – sensitive,807,Binimetinib,3265
6,Phase III,"In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (47 vs 8 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RAS mutations (PMID: 27525386).",Actionable,10387,3973,thyroid medullary carcinoma,DOID,1208,HRAS mutant,"[{'id': 8408, 'pubMedId': 27525386, 'title': 'Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27525386'}]",sensitive,998,cabozantinib,3265
7,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of human endometrial cancer cells harboring mutant HRAS in culture (PMID: 26343583).",Actionable,6692,1380,endometrial cancer,DOID,1208,HRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,2,Trametinib,3265
8,Preclinical - Cell culture,"In a preclinical study, human solid tumor cell lines harboring HRAS mutations demonstrated increased sensitivity to growth inhibition by Afinitor (everolimus) in culture compared to cell lines with wild-type HRAS (PMID: 26544513).",Actionable,9466,10000003,Advanced Solid Tumor,JAX,1208,HRAS mutant,"[{'id': 7197, 'pubMedId': 26544513, 'title': 'Mutant HRAS as novel target for MEK and mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26544513'}]",predicted – sensitive,735,Everolimus,3265
9,Preclinical - Cell line xenograft,"In a preclinical study, Mekinist (trametinib) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M in culture and in cell line xenograft models (PMID: 27222538).",Actionable,7855,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,2,Trametinib,3265
10,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).",Actionable,7870,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,4601,Dasatinib + SCH772984,3265
11,Preclinical - Cell line xenograft,"In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture, and resulted in sustained tumor suppression and prolonged survival in cell line xenograft models (PMID: 27222538).",Actionable,7867,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,4599,Dasatinib + Trametinib,3265
12,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).",Actionable,7860,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,913,Selumetinib,3265
13,Preclinical - Cell line xenograft,"In a preclinical study, thyroid cancer cell lines harboring HRAS G13R and KRAS G12R with an acquired SRC T341M mutation demonstrated resistance to Sprycel (dasatinib) in culture and in cell line xenograft models (PMID: 27222538).",Actionable,7839,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",resistant,717,Dasatinib,3265
14,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).",Actionable,7868,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,4600,Dasatinib + Selumetinib,3265
15,Preclinical - Cell culture,"In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including an anaplastic thyroid cancer cell line harboring HRAS G13R (PMID: 21289267).",Actionable,8217,1781,thyroid cancer,DOID,3556,HRAS G13R,"[{'id': 6573, 'pubMedId': 21289267, 'title': 'The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21289267'}]",sensitive,816,MK2206,3265
16,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of a melanoma cell line harboring BRAF G466E and HRAS Q61K in culture (PMID: 28783719).",Actionable,11656,1909,melanoma,DOID,28179,BRAF G466E HRAS Q61K,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",sensitive,2,Trametinib,3265
17,Preclinical - Cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) worked synergistically to inhibit growth of transformed cells expressing HRAS Q61L in culture (PMID: 26544513).",Actionable,9481,10000003,Advanced Solid Tumor,JAX,3563,HRAS Q61L,"[{'id': 7197, 'pubMedId': 26544513, 'title': 'Mutant HRAS as novel target for MEK and mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26544513'}]",sensitive,5022,Binimetinib + Everolimus,3265
18,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) inhibited growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture, and inhibited tumor growth in xenograft models (PMID: 26544513).",Actionable,9458,3907,lung squamous cell carcinoma,DOID,3563,HRAS Q61L,"[{'id': 7197, 'pubMedId': 26544513, 'title': 'Mutant HRAS as novel target for MEK and mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26544513'}]",sensitive,913,Selumetinib,3265
19,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Selumetinib (AZD6244) and Afinitor (everolimus) inhibited growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture, and inhibited tumor growth in xenograft models, with increased efficacy compared to either agent alone (PMID: 26544513).",Actionable,9462,3907,lung squamous cell carcinoma,DOID,3563,HRAS Q61L,"[{'id': 7197, 'pubMedId': 26544513, 'title': 'Mutant HRAS as novel target for MEK and mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26544513'}]",sensitive,4901,Everolimus + Selumetinib,3265
20,Preclinical - Cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and AZD8055 reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture (PMID: 26544513).",Actionable,9467,3907,lung squamous cell carcinoma,DOID,3563,HRAS Q61L,"[{'id': 7197, 'pubMedId': 26544513, 'title': 'Mutant HRAS as novel target for MEK and mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26544513'}]",sensitive,5023,AZD8055 + Binimetinib,3265
21,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing HRAS Q61L demonstrated sensitivity to growth inhibition by Afinitor (everolimus) in culture (PMID: 26544513).",Actionable,9474,10000003,Advanced Solid Tumor,JAX,3563,HRAS Q61L,"[{'id': 7197, 'pubMedId': 26544513, 'title': 'Mutant HRAS as novel target for MEK and mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26544513'}]",sensitive,735,Everolimus,3265
22,Preclinical - Cell line xenograft,"In a preclinical study, PLX7904 did not stimulate growth of Zelboraf (vemurafenib)-induced cutaneous squamous cell carcinoma cells harboring HRAS Q61L in culture or in cell line xenograft models (PMID: 26466569).",Actionable,7902,3151,skin squamous cell carcinoma,DOID,3563,HRAS Q61L,"[{'id': 6521, 'pubMedId': 26466569, 'title': 'RAF inhibitors that evade paradoxical MAPK pathway activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26466569'}]",no benefit,4606,PLX7904,3265
23,Preclinical - Cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture (PMID: 26544513).",Actionable,9463,3907,lung squamous cell carcinoma,DOID,3563,HRAS Q61L,"[{'id': 7197, 'pubMedId': 26544513, 'title': 'Mutant HRAS as novel target for MEK and mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26544513'}]",sensitive,5022,Binimetinib + Everolimus,3265
24,Preclinical - Cell culture,"In a preclinical study, BKM120 did not inhibit growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture (PMID: 26544513)",Actionable,9459,3907,lung squamous cell carcinoma,DOID,3563,HRAS Q61L,"[{'id': 7197, 'pubMedId': 26544513, 'title': 'Mutant HRAS as novel target for MEK and mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26544513'}]",no benefit,680,BKM120,3265
25,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing HRAS Q61L demonstrated sensitivity to growth inhibition by Binimetinib (MEK162) in culture (PMID: 26544513). ",Actionable,9478,10000003,Advanced Solid Tumor,JAX,3563,HRAS Q61L,"[{'id': 7197, 'pubMedId': 26544513, 'title': 'Mutant HRAS as novel target for MEK and mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26544513'}]",sensitive,807,Binimetinib,3265
26,Preclinical - Cell culture,"In a preclinical study, bladder carcinoma cells expressing HRAS Q61L demonstrated sensitivity to NS1, resulting in inhibition of Mapk signaling and cell proliferation in culture (PMID: 27820802). ",Actionable,9780,4007,bladder carcinoma,DOID,3563,HRAS Q61L,"[{'id': 7600, 'pubMedId': 27820802, 'title': 'Inhibition of RAS function through targeting an allosteric regulatory site.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27820802'}]",sensitive,5228,NS1,3265
27,Preclinical - Cell line xenograft,"In a preclinical study, Rapamune (sirolimus) worked synergistically with Mekinist (trametinib) to inhibit proliferation of head and neck squamous carcinoma cell lines harboring HRAS Q61L in culture and to reduce tumor growth in cell line xenograft models (PMID: 26882569).",Actionable,4687,5520,head and neck squamous cell carcinoma,DOID,3563,HRAS Q61L,"[{'id': 4668, 'pubMedId': 26882569, 'title': 'A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26882569'}]",sensitive,3596,Sirolimus + Trametinib,3265
28,Preclinical - Cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) worked synergistically to inhibit growth of transformed cells expressing HRAS G12V in culture (PMID: 26544513).",Actionable,9480,10000003,Advanced Solid Tumor,JAX,2794,HRAS G12V,"[{'id': 7197, 'pubMedId': 26544513, 'title': 'Mutant HRAS as novel target for MEK and mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26544513'}]",sensitive,5022,Binimetinib + Everolimus,3265
29,Preclinical,"In a preclinical study, tumor cells expressing HRAS G12V demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 22797062).",Actionable,1692,10000003,Advanced Solid Tumor,JAX,2794,HRAS G12V,"[{'id': 1793, 'pubMedId': 22797062, 'title': 'Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22797062'}]",resistant,694,Cetuximab,3265
30,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing HRAS G12V demonstrated sensitivity to growth inhibition by Afinitor (everolimus) in culture (PMID: 26544513).",Actionable,9476,10000003,Advanced Solid Tumor,JAX,2794,HRAS G12V,"[{'id': 7197, 'pubMedId': 26544513, 'title': 'Mutant HRAS as novel target for MEK and mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26544513'}]",sensitive,735,Everolimus,3265
31,Preclinical - Cell line xenograft,"In a preclinical study, SF1126 inhibited Akt activation, proliferation, and migration of transgenic mouse glioma cells expressing HRAS G12V in culture, and suppressed tumor growth in xenograft models (PMID: 25425962).",Actionable,5211,3070,malignant glioma,DOID,2794,HRAS G12V,"[{'id': 4921, 'pubMedId': 25425962, 'title': 'Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12)\u2009V-Ha-Ras transgenic mouse glioma model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25425962'}]",sensitive,915,SF1126,3265
32,Preclinical - Cell culture,"In a preclinical study, Estybon (rigosertib) inhibited oncogenic transformation in fibroblast cells over-expressing HRAS G12V in culture (PMID: 27104980).",Actionable,8554,10000003,Advanced Solid Tumor,JAX,2794,HRAS G12V,"[{'id': 6686, 'pubMedId': 27104980, 'title': 'A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27104980'}]",sensitive,1046,rigosertib,3265
33,Preclinical - Cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a bladder cell line harboring HRAS G12V in culture (PMID: 26544513).",Actionable,9464,11054,urinary bladder cancer,DOID,2794,HRAS G12V,"[{'id': 7197, 'pubMedId': 26544513, 'title': 'Mutant HRAS as novel target for MEK and mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26544513'}]",sensitive,5022,Binimetinib + Everolimus,3265
34,Preclinical,"In a preclinical study, tumor cells expressing HRAS G12V demonstrated resistance to treatment with Vectibix (panitumumab) (PMID: 22797062).",Actionable,1693,10000003,Advanced Solid Tumor,JAX,2794,HRAS G12V,"[{'id': 1793, 'pubMedId': 22797062, 'title': 'Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22797062'}]",resistant,845,Panitumumab,3265
35,Preclinical - Cell culture,"In a preclinical study, the combination of Selumetinib (AZD6244) and Afinitor (everolimus) reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a bladder cancer cell line harboring HRAS G12V in culture (PMID: 26544513).",Actionable,9465,11054,urinary bladder cancer,DOID,2794,HRAS G12V,"[{'id': 7197, 'pubMedId': 26544513, 'title': 'Mutant HRAS as novel target for MEK and mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26544513'}]",sensitive,4901,Everolimus + Selumetinib,3265
36,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing HRAS G12V demonstrated sensitivity to growth inhibition by Binimetinib (MEK162) in culture (PMID: 26544513).",Actionable,9479,10000003,Advanced Solid Tumor,JAX,2794,HRAS G12V,"[{'id': 7197, 'pubMedId': 26544513, 'title': 'Mutant HRAS as novel target for MEK and mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26544513'}]",sensitive,807,Binimetinib,3265
37,Preclinical,In a preclinical study CI-1040 (PD-184352) inhibited melanoma progression in a transgenic zebrafish model of melanoma expressing HRAS G12V (PMID: 26267534).,Actionable,5784,1909,melanoma,DOID,2794,HRAS G12V,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",sensitive,699,CI-1040,3265
38,Preclinical - Cell line xenograft,"In a preclinical study, Pz-1 reduced tumor growth in xenograft models of transformed cells over expressing HRAS G12V in a dose-dependent manner (PMID: 26126987).",Actionable,6193,10000003,Advanced Solid Tumor,JAX,2794,HRAS G12V,"[{'id': 5385, 'pubMedId': 26126987, 'title': 'Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26126987'}]",sensitive,4089,Pz-1,3265
39,Preclinical,"In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to PD173074 in culture (PMID: 22869148).",Actionable,3278,2671,transitional cell carcinoma,DOID,13021,FGFR3 wild-type FGFR3 dec exp HRAS G12V,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",resistant,2948,PD173074,3265
40,Preclinical,"In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZD4547 in culture (PMID: 22869148).",Actionable,2576,2671,transitional cell carcinoma,DOID,13021,FGFR3 wild-type FGFR3 dec exp HRAS G12V,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",resistant,654,AZD4547,3265
41,Preclinical,"In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZ8010 in culture (PMID: 22869148).",Actionable,2575,2671,transitional cell carcinoma,DOID,13021,FGFR3 wild-type FGFR3 dec exp HRAS G12V,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",decreased response,2955,AZ8010,3265
42,Preclinical,"In a preclinical study, the farnesyltransferase inhibitor FTI-277 sensitized Hras transformed rat fibroblasts to radiation therapy (PMID: 8620483).",Actionable,1299,162,cancer,DOID,575,HRAS wild-type,"[{'id': 1008, 'pubMedId': 8620483, 'title': 'The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/8620483'}]",predicted – sensitive,1683,FTI-277,3265
43,Preclinical,"In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with wild-type HRAS (PMID: 23039341).",Actionable,5626,1909,melanoma,DOID,575,HRAS wild-type,"[{'id': 1840, 'pubMedId': 23039341, 'title': 'Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23039341'}]",sensitive,1011,E6201,3265
44,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",Actionable,7865,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,4600,Dasatinib + Selumetinib,3265
45,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",Actionable,7858,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,913,Selumetinib,3265
46,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",Actionable,7864,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,4599,Dasatinib + Trametinib,3265
47,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",Actionable,7866,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,4601,Dasatinib + SCH772984,3265
48,Preclinical - Cell line xenograft,"In a preclinical study, Mekinist (trametinib) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture and in cell line xenograft models (PMID: 27222538).",Actionable,7854,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,2,Trametinib,3265
49,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing HRAS Q61R demonstrated sensitivity to growth inhibition by Binimetinib (MEK162) in culture (PMID: 26544513). ",Actionable,9477,10000003,Advanced Solid Tumor,JAX,3564,HRAS Q61R,"[{'id': 7197, 'pubMedId': 26544513, 'title': 'Mutant HRAS as novel target for MEK and mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26544513'}]",sensitive,807,Binimetinib,3265
50,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing HRAS Q61R demonstrated sensitivity to growth inhibition by Afinitor (everolimus) in culture (PMID: 26544513).",Actionable,9475,10000003,Advanced Solid Tumor,JAX,3564,HRAS Q61R,"[{'id': 7197, 'pubMedId': 26544513, 'title': 'Mutant HRAS as novel target for MEK and mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26544513'}]",sensitive,735,Everolimus,3265
51,Preclinical,"In a preclinical study, PD173074 inhibited Fgfr3 signaling, induced cell-cycle arrest, and decreased proliferation of multiple myeloma cells harboring HRAS H117E and over expression of FGFR3 K650E in culture (PMID: 22869148).",Actionable,2578,9538,multiple myeloma,DOID,13017,FGFR3 K650E FGFR3 over exp HRAS K117E,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",sensitive,2948,PD173074,3265
52,Preclinical,"In a preclinical study, AZ8010 inhibited Fgfr3 signaling and decreased proliferation of myeloma cells with HRAS K117E and overexpression of FGFR3 K650E in culture (PMID: 22869148).",Actionable,2571,70004,myeloid neoplasm,DOID,13017,FGFR3 K650E FGFR3 over exp HRAS K117E,"[{'id': 3319, 'pubMedId': 22869148, 'title': 'Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869148'}]",sensitive,2955,AZ8010,3265
0,Preclinical,"In a preclinical study, BAY 1436032 inhibited growth of transformed cell lines over expressing IDH1 R132X in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2645).",Actionable,5927,10000003,Advanced Solid Tumor,JAX,10006,IDH1 R132X,"[{'id': 5199, 'pubMedId': None, 'title': 'BAY 1436032: A highly selective, potent and orally available inhibitor of mutant forms of IDH1', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=407e597a-33c8-4936-87f4-08ee4b23e8b9&cKey=7b015533-ade6-4611-8ab3-68f274bd3bac&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]",sensitive,3987,BAY 1436032,3417
1,Phase I,"In a Phase I trial, IDH305 treatment resulted in objective response in 33% (7/21) of acute myeloid leukemia patients harboring IDH1 R132 mutations, including complete remission in 3 (14%) and partial remission in 4 (19%) patients (Blood 2016 128 (22):1073).",Actionable,10000,9119,acute myeloid leukemia,DOID,10006,IDH1 R132X,"[{'id': 7891, 'pubMedId': None, 'title': 'A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations', 'url': 'http://www.bloodjournal.org/content/128/22/1073?sso-checked=true'}]",sensitive,2981,IDH305,3417
2,Phase I,"In a Phase I trial, IDH305 demonstrated safety and preliminary efficacy in patients with advanced solid tumors harboring IDH1 R132 mutations (Blood 2016 128 (22):1073).",Actionable,4403,10000003,Advanced Solid Tumor,JAX,10006,IDH1 R132X,"[{'id': 7891, 'pubMedId': None, 'title': 'A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations', 'url': 'http://www.bloodjournal.org/content/128/22/1073?sso-checked=true'}]",predicted – sensitive,2981,IDH305,3417
3,Phase I,"In a Phase I trial, IDH305 demonstrated safety and preliminary efficacy in patients with glioms harboring IDH1 R132 mutations (Blood 2016 128 (22):1073).",Actionable,9999,3070,malignant glioma,DOID,10006,IDH1 R132X,"[{'id': 7891, 'pubMedId': None, 'title': 'A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1R132 Mutations', 'url': 'http://www.bloodjournal.org/content/128/22/1073?sso-checked=true'}]",predicted – sensitive,2981,IDH305,3417
4,Preclinical,"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition compared to IDH1 wild-type cells in culture (PMID: 27231123).",Actionable,7348,4928,intrahepatic cholangiocarcinoma,DOID,5018,IDH1 R132S,"[{'id': 6322, 'pubMedId': 27231123, 'title': 'Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27231123'}]",sensitive,912,Saracatinib,3417
5,Preclinical - Patient cell culture,"In a preclinical study, BAY1436032 decreased (R)-2-hydroxyglutarate (R-2HG) levels, and inhibited growth and increased differentiation of patient-derived acute myeloid leukemia cells harboring IDH1 R132S in culture (PMID: 28232670).",Actionable,10940,9119,acute myeloid leukemia,DOID,5018,IDH1 R132S,"[{'id': 8943, 'pubMedId': 28232670, 'title': 'Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28232670'}]",sensitive,5698,BAY1436032,3417
6,Preclinical,"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S demonstrated increased sensitivity to Sprycel (dasatinib) induced growth inhibition compared to IDH1 wild-type cells in culture (PMID: 27231123).",Actionable,7347,4928,intrahepatic cholangiocarcinoma,DOID,5018,IDH1 R132S,"[{'id': 6322, 'pubMedId': 27231123, 'title': 'Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27231123'}]",sensitive,717,Dasatinib,3417
7,Preclinical,"In a preclinical study, colorectal cancer cells expressing IDH1 R132H were resistant to radiotherapy when treated with AGI-5198 (PMID: 26363012).",Actionable,5556,9256,colorectal cancer,DOID,1253,IDH1 R132H,"[{'id': 4901, 'pubMedId': 26363012, 'title': 'Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26363012'}]",resistant,3895,AGI-5198 + Radiotherapy,3417
8,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Zejula (niraparib)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9946,10000003,Advanced Solid Tumor,JAX,1253,IDH1 R132H,"[{'id': 7797, 'pubMedId': 28148839, 'title': '2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28148839'}]",sensitive,832,Niraparib,3417
9,Phase II,"In a Phase II trial, Caprelsa (vandetinib), in combination with Temodar (temozolomide) and radiation therapy, demonstrated a significant increase in PFS and OS in glioblastoma patients harboring IDH1 R132H compared to glioblastoma patients without IDH1 R132H (PMID: 25910950). ",Actionable,3237,3068,glioblastoma multiforme,DOID,1253,IDH1 R132H,"[{'id': 3688, 'pubMedId': 25910950, 'title': 'A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25910950'}]",sensitive,3094,Vandetanib + Temozolomide,3417
10,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Rubraca (rucaparib)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9948,10000003,Advanced Solid Tumor,JAX,1253,IDH1 R132H,"[{'id': 7797, 'pubMedId': 28148839, 'title': '2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28148839'}]",sensitive,906,Rucaparib,3417
11,Preclinical - Cell line xenograft,"In a preclinical study, AGI-5198 inhibited growth of a glioma cell line harboring IDH1 R132H in culture and in xenograft models (PMID: 23558169).",Actionable,2071,3070,malignant glioma,DOID,1253,IDH1 R132H,"[{'id': 2552, 'pubMedId': 23558169, 'title': 'An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558169'}]",sensitive,2569,AGI-5198,3417
12,Preclinical,"In a preclinical study, colorectal carcinoma cells expressing IDH1 R132H were sensitive to Glucophage (metformin), resulting in decreased cell proliferation in culture (PMID: 26363012). ",Actionable,5180,9256,colorectal cancer,DOID,1253,IDH1 R132H,"[{'id': 4901, 'pubMedId': 26363012, 'title': 'Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26363012'}]",sensitive,1031,Metformin,3417
13,Preclinical,"In a preclinical study, long-term treatment with Vidaza (azacitidine) resulted in increased cellular differentiation, decreased proliferation, and tumor regression in a patient-derived xenograft (PDX) model of anaplastic astrocytoma harboring IDH1 R132H (PMID: 24077805).",Actionable,849,3078,grade III astrocytoma,DOID,1253,IDH1 R132H,"[{'id': 493, 'pubMedId': 24077805, 'title': '5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24077805'}]",sensitive,651,Azacitidine,3417
14,Preclinical - Patient cell culture,"In a preclinical study, patient-derived glioma cells harboring IDH1 R132H demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9939,3070,malignant glioma,DOID,1253,IDH1 R132H,"[{'id': 7797, 'pubMedId': 28148839, 'title': '2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28148839'}]",sensitive,682,Talazoparib,3417
15,Preclinical,"In a preclinical study, colorectal cancer cells harboring IDH1 R132H demonstrated increased cell proliferation when treated with a combination of Glucophage (metformin) and AGI-5198 (PMID: 26363012). ",Actionable,5230,9256,colorectal cancer,DOID,1253,IDH1 R132H,"[{'id': 4901, 'pubMedId': 26363012, 'title': 'Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26363012'}]",resistant,3784,Metformin + AGI-5198,3417
16,Preclinical - Pdx & cell culture,"In a preclinical study, Dacogen (decitabine) decreased colony formation and tumor growth in patient derived xenograft (PDX) models of patient derived oligodendroglioma cells with IDH1 R132H mutations and co-deletion of 1p and 19q (PMID: 24077826).",Actionable,846,3181,oligodendroglioma,DOID,1253,IDH1 R132H,"[{'id': 490, 'pubMedId': 24077826, 'title': 'Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24077826'}]",sensitive,650,Decitabine,3417
17,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Lynparza (olaparib)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9943,10000003,Advanced Solid Tumor,JAX,1253,IDH1 R132H,"[{'id': 7797, 'pubMedId': 28148839, 'title': '2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28148839'}]",sensitive,837,Olaparib,3417
18,Preclinical - Cell culture,"In a preclinical study, colon carcinoma cells over expressing IDH1 R132H demonstrated increased sensitivity to Lynparza (olaparib)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9942,1520,colon carcinoma,DOID,1253,IDH1 R132H,"[{'id': 7797, 'pubMedId': 28148839, 'title': '2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28148839'}]",sensitive,837,Olaparib,3417
19,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to VX-970-induced growth inhibition in culture (PMID: 28148839).",Actionable,9941,10000003,Advanced Solid Tumor,JAX,1253,IDH1 R132H,"[{'id': 7797, 'pubMedId': 28148839, 'title': '2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28148839'}]",sensitive,2879,VX-970,3417
20,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9938,10000003,Advanced Solid Tumor,JAX,1253,IDH1 R132H,"[{'id': 7797, 'pubMedId': 28148839, 'title': '2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28148839'}]",sensitive,682,Talazoparib,3417
21,Preclinical - Cell culture,"In a preclinical study, Talazoparib (BMN-673) and Cisplatin synergistically inhibited growth of transformed cells over expressing IDH1 R132H in culture (PMID: 28148839).",Actionable,9949,10000003,Advanced Solid Tumor,JAX,1253,IDH1 R132H,"[{'id': 7797, 'pubMedId': 28148839, 'title': '2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28148839'}]",sensitive,5324,Cisplatin + Talazoparib,3417
22,Preclinical - Cell culture,"In a preclinical study, colon carcinoma cells over expressing IDH1 R132H demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9937,1520,colon carcinoma,DOID,1253,IDH1 R132H,"[{'id': 7797, 'pubMedId': 28148839, 'title': '2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28148839'}]",sensitive,682,Talazoparib,3417
23,Preclinical - Patient cell culture,"In a preclinical study, BAY1436032 decreased (R)-2-hydroxyglutarate (R-2HG) levels, and inhibited growth and increased differentiation of patient-derived acute myeloid leukemia cells harboring IDH1 R132H in culture (PMID: 28232670).",Actionable,10936,9119,acute myeloid leukemia,DOID,1253,IDH1 R132H,"[{'id': 8943, 'pubMedId': 28232670, 'title': 'Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28232670'}]",sensitive,5698,BAY1436032,3417
24,Preclinical - Cell culture,"In a preclinical study, AGI-5198 reverted the sensitivity of transformed cells over expressing IDH1 R132H to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9950,10000003,Advanced Solid Tumor,JAX,1253,IDH1 R132H,"[{'id': 7797, 'pubMedId': 28148839, 'title': '2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28148839'}]",decreased response,5325,AGI-5198 + Talazoparib,3417
25,Preclinical - Cell culture,"In a preclinical study, a glioma cell line expressing IDH1 R132H demonstrated increased sensitivity to growth inhibition by BPTES compared to a cell line expressing wild-type IDH1 in culture (PMID: 21045145).",Actionable,9755,3070,malignant glioma,DOID,1253,IDH1 R132H,"[{'id': 7525, 'pubMedId': 21045145, 'title': 'Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21045145'}]",sensitive,5194,BPTES,3417
26,Preclinical - Patient cell culture,"In a preclinical study, BAY1436032 decreased (R)-2-hydroxyglutarate (R-2HG) levels, and inhibited growth and increased differentiation of patient-derived acute myeloid leukemia cells harboring IDH1 R132L in culture (PMID: 28232670).",Actionable,10937,9119,acute myeloid leukemia,DOID,5017,IDH1 R132L,"[{'id': 8943, 'pubMedId': 28232670, 'title': 'Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28232670'}]",sensitive,5698,BAY1436032,3417
27,Preclinical - Pdx & cell culture,"In a preclinical study, BAY1436032 decreased R-2HG levels and inhibited growth of primary acute myeloid leukemia (AML) cells harboring IDH1 R132C in culture, and decreased blast number and increased survival of two AML patient-derived xenograft (PDX) models, one which harbored additional alterations in FLT3, NPM1, and NRAS and one which harbored a KMT2A (MLL) alteration (PMID: 28232670).",Actionable,10939,9119,acute myeloid leukemia,DOID,1252,IDH1 R132C,"[{'id': 8943, 'pubMedId': 28232670, 'title': 'Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28232670'}]",sensitive,5698,BAY1436032,3417
28,Preclinical - Cell line xenograft,"In a preclinical study, Lynparza (olaparib) treatment delayed tumor growth in cell line xenograft models of sarcoma harboring IDH1 R132C (PMID: 28148839).",Actionable,9945,1115,sarcoma,DOID,1252,IDH1 R132C,"[{'id': 7797, 'pubMedId': 28148839, 'title': '2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28148839'}]",sensitive,837,Olaparib,3417
29,Preclinical,"In a preclinical study, Sprycel (dasatinib)  inhibited growth of intrahepatic cholangiocarcinoma cells harboring IDH1 R132C in culture, and suppressed tumor growth in PDX models (PMID: 27231123).",Actionable,7350,4928,intrahepatic cholangiocarcinoma,DOID,1252,IDH1 R132C,"[{'id': 6322, 'pubMedId': 27231123, 'title': 'Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27231123'}]",sensitive,717,Dasatinib,3417
30,Preclinical,"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132C demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition compared to IDH1 wild-type cells in culture (PMID: 27231123).",Actionable,7349,4928,intrahepatic cholangiocarcinoma,DOID,1252,IDH1 R132C,"[{'id': 6322, 'pubMedId': 27231123, 'title': 'Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27231123'}]",sensitive,912,Saracatinib,3417
31,Preclinical - Cell culture,"In a preclinical study, AGI-5198 reverted the sensitivity of sarcoma cells harboring IDH1 R132C to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9951,1115,sarcoma,DOID,1252,IDH1 R132C,"[{'id': 7797, 'pubMedId': 28148839, 'title': '2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28148839'}]",decreased response,5325,AGI-5198 + Talazoparib,3417
32,Preclinical - Cell culture,"In a preclinical study, AGI-5198 reverted the sensitivity of sarcoma cells harboring IDH1 R132C to Lynparza (olaparib)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9952,1115,sarcoma,DOID,1252,IDH1 R132C,"[{'id': 7797, 'pubMedId': 28148839, 'title': '2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28148839'}]",decreased response,5326,AGI-5198 + Olaparib,3417
33,Preclinical - Patient cell culture,"In a preclinical study, patient-derived glioma cells harboring IDH1 R132C demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9940,3070,malignant glioma,DOID,1252,IDH1 R132C,"[{'id': 7797, 'pubMedId': 28148839, 'title': '2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28148839'}]",sensitive,682,Talazoparib,3417
34,Preclinical,"In a preclinical study, AGI-5198 inhibited growth and promoted differentiation in glioma cells expressing IDH1 R132C (PMID: 23558169).",Actionable,2070,3070,malignant glioma,DOID,1252,IDH1 R132C,"[{'id': 2552, 'pubMedId': 23558169, 'title': 'An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558169'}]",sensitive,2569,AGI-5198,3417
35,Preclinical,"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S acquired resistance to Sprycel (dasatinib) after over expressing SRC T341I in culture (PMID: 27231123).",Actionable,7355,4928,intrahepatic cholangiocarcinoma,DOID,25297,IDH1 R132C SRC T341I,"[{'id': 6322, 'pubMedId': 27231123, 'title': 'Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27231123'}]",resistant,717,Dasatinib,3417
36,Preclinical - Patient cell culture,"In a preclinical study, BAY1436032 decreased (R)-2-hydroxyglutarate (R-2HG) levels and increased differentiation of patient-derived acute myeloid leukemia cells harboring IDH1 R132G in culture (PMID: 28232670).",Actionable,10944,9119,acute myeloid leukemia,DOID,1256,IDH1 R132G,"[{'id': 8943, 'pubMedId': 28232670, 'title': 'Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28232670'}]",sensitive,5698,BAY1436032,3417
37,Phase I,"In a Phase I trial, Gemzar (gemcitabine) plus radiation therapy resulted in median overall survival of 73.5 months in 7 high-grade glioma patients with IDH mutated, non-codeleted tumors with ATRX loss (PMID: 26853339).",Actionable,6205,3070,malignant glioma,DOID,22833,ATRX loss IDH1 mutant,"[{'id': 5446, 'pubMedId': 26853339, 'title': 'Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26853339'}]",predicted – sensitive,4093,Gemcitabine + Radiotherapy,3417
38,Clinical Study,"In two meta-analyses, IDH1 mutations were associated with a worse overall survival in patients with acute myeloid leukemia (PMID: 22616558, PMID: 23226625).",Prognostic,6076,9119,acute myeloid leukemia,DOID,1781,IDH1 mutant,"[{'id': 5276, 'pubMedId': 22616558, 'title': 'Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22616558'}, {'id': 5277, 'pubMedId': 23226625, 'title': 'Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23226625'}]",not applicable,1776,N/A,3417
39,Preclinical,"In a preclinical study, BAY 1436032 inhibited growth of transformed cell lines over expressing mutant IDH1 in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2645).",Actionable,5926,10000003,Advanced Solid Tumor,JAX,1781,IDH1 mutant,"[{'id': 5199, 'pubMedId': None, 'title': 'BAY 1436032: A highly selective, potent and orally available inhibitor of mutant forms of IDH1', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=407e597a-33c8-4936-87f4-08ee4b23e8b9&cKey=7b015533-ade6-4611-8ab3-68f274bd3bac&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]",sensitive,3987,BAY 1436032,3417
40,Phase I,"In a Phase I clinical trial, treatment with AG-120 reduced R-2-hydroxy-glutarate (2-HG) levels and resulted in partial responses in 41% (7/17) and complete remission in 23% (4/17) of patients with acute myeloid leukemia with IDH1 mutations (PMID: 25583779).",Actionable,2228,9119,acute myeloid leukemia,DOID,1781,IDH1 mutant,"[{'id': 2800, 'pubMedId': 25583779, 'title': 'IDH1 inhibitor shows promising early results.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25583779'}]",sensitive,1491,AG-120,3417
41,Phase I,"In a Phase I trial, AG-120 demonstrated safety and preliminary efficacy in IDH1 mutant glioma patients ( Neuro Oncol (2016) 18 (suppl 6): vi12.).",Actionable,9361,3070,malignant glioma,DOID,1781,IDH1 mutant,"[{'id': 7126, 'pubMedId': None, 'title': 'AG120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: RESULTS FROM THE PHASE 1 GLIOMA EXPANSION COHORTS', 'url': 'http://neuro-oncology.oxfordjournals.org/content/18/suppl_6/vi12.1.abstract?sid=36b4e22f-cb42-46ee-b8dd-4ea89b6a04fe'}]",sensitive,1491,AG-120,3417
42,Phase II,"In a retrospective analysis of a Phase II trial, IDH1 mutation correlated with favorable overall survival in recurrent glioblastoma patients treated with a combination of  Avastin (bevacizumab) and Lomustine (PMID: 26762204).",Actionable,4332,3068,glioblastoma multiforme,DOID,1781,IDH1 mutant,"[{'id': 4498, 'pubMedId': 26762204, 'title': 'Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26762204'}]",predicted – sensitive,2118,Bevacizumab + Lomustine,3417
43,Phase I,"AG-881 is currently in clinical trials in patients with IDH1 mutations and advanced solid tumors (clinicaltrials.gov, Aug 2017). ",Actionable,9225,10000003,Advanced Solid Tumor,JAX,1781,IDH1 mutant,"[{'id': 303, 'pubMedId': None, 'title': '', 'url': 'https://clinicaltrials.gov/'}]",not applicable,2995,AG-881,3417
44,Preclinical,"In a preclinical study, lung adenocarcinoma cells harboring IDH1 mutations were resistant to Sprycel (dasatinib) in culture (PMID: 27231123).",Actionable,7352,3910,lung adenocarcinoma,DOID,1781,IDH1 mutant,"[{'id': 6322, 'pubMedId': 27231123, 'title': 'Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27231123'}]",resistant,717,Dasatinib,3417
45,Clinical Study,"In multiple clinical studies, including two meta-analyses, IDH1 mutations were associated with a greater overall survival and progression free survival in patients with glioblastoma (PMID: 23904262, PMID: 26945349, PMID: 20560678). ",Prognostic,6031,3068,glioblastoma multiforme,DOID,1781,IDH1 mutant,"[{'id': 5242, 'pubMedId': 23904262, 'title': 'IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23904262'}, {'id': 5243, 'pubMedId': 26945349, 'title': 'Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26945349'}, {'id': 5244, 'pubMedId': 20560678, 'title': 'Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20560678'}]",not applicable,1776,N/A,3417
46,Preclinical,"In a preclinical study, chondrosarcoma cells harboring IDH1 mutations were resistant to Sprycel (dasatinib) in culture (PMID: 27231123).",Actionable,7351,3371,chondrosarcoma,DOID,1781,IDH1 mutant,"[{'id': 6322, 'pubMedId': 27231123, 'title': 'Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27231123'}]",resistant,717,Dasatinib,3417
47,Phase II,"In a Phase II trial, 33% (4/12) of acute myeloid leukemia patients harboring either IDH1 or IDH2 mutations responded to treatment with Venclexta (venetoclax), demonstrating a complete response or complete response with incomplete blood count recovery (PMID: 27520294).",Actionable,8019,9119,acute myeloid leukemia,DOID,1781,IDH1 mutant,"[{'id': 6536, 'pubMedId': 27520294, 'title': 'Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27520294'}]",predicted – sensitive,1562,Venetoclax,3417
48,Clinical Study,"In multiple clinical studies, including two meta-analyses, IDH1 mutations were associated with improved overall survival and progression free survival in patients with gliomas (PMID: 23817809, PMID: 26220714, PMID: 23894344). ",Prognostic,6030,3070,malignant glioma,DOID,1781,IDH1 mutant,"[{'id': 5239, 'pubMedId': 23817809, 'title': 'A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23817809'}, {'id': 5240, 'pubMedId': 26220714, 'title': 'Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26220714'}, {'id': 5241, 'pubMedId': 23894344, 'title': 'IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23894344'}]",not applicable,1776,N/A,3417
49,Clinical Study,"IDH1 mutations are used in the diagnosis of various subtypes of gliomas (PMID: 23041832, PMID: 19755387, PMID: 19915484). ",Diagnostic,6033,3070,malignant glioma,DOID,1781,IDH1 mutant,"[{'id': 5246, 'pubMedId': 23041832, 'title': 'Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23041832'}, {'id': 5247, 'pubMedId': 19755387, 'title': 'IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19755387'}, {'id': 5248, 'pubMedId': 19915484, 'title': 'Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19915484'}]",not applicable,1776,N/A,3417
50,Phase I,"The Phase I trial of AG-881 in patients with IDH1 mutations and hematological cancers is active and no longer recruiting patients and there are no other trials for AG-881 (clinicaltrials.gov, Aug 2017). ",Actionable,9226,2531,hematologic cancer,DOID,1781,IDH1 mutant,"[{'id': 303, 'pubMedId': None, 'title': '', 'url': 'https://clinicaltrials.gov/'}]",not applicable,2995,AG-881,3417
0,Preclinical,"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH2 R172K and KRAS G12D demonstrated increased sensitivity to Sprycel (dasatinib) induced growth inhibition in culture and in xenograft models (PMID: 27231123).",Actionable,7353,4928,intrahepatic cholangiocarcinoma,DOID,25295,IDH2 R172K KRAS G12D,"[{'id': 6322, 'pubMedId': 27231123, 'title': 'Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27231123'}]",sensitive,717,Dasatinib,3418
1,Preclinical,"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH2 R172K and KRAS G12D demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition in culture (PMID: 27231123).",Actionable,7354,4928,intrahepatic cholangiocarcinoma,DOID,25295,IDH2 R172K KRAS G12D,"[{'id': 6322, 'pubMedId': 27231123, 'title': 'Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27231123'}]",sensitive,912,Saracatinib,3418
2,Preclinical - Cell culture,"In a preclinical study, Enasidenib (AG-221) decreased 2-hydroxyglutarate (2HG) levels in a glioblastoma cell line expressing IDH2 R172K in culture (PMID: 28193778).",Actionable,10741,3068,glioblastoma multiforme,DOID,1255,IDH2 R172K,"[{'id': 8791, 'pubMedId': 28193778, 'title': 'AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28193778'}]",predicted – sensitive,2982,Enasidenib,3418
3,Preclinical - Patient cell culture,"In a preclinical study, Enasidenib (AG-221) decreased 2-hydroxyglutarate (2HG) levels and induced differentiation of leukemic blasts from acute myeloid leukemia (AML) patients harboring IDH2 R172K in culture (PMID: 28193778).",Actionable,10739,9119,acute myeloid leukemia,DOID,1255,IDH2 R172K,"[{'id': 8791, 'pubMedId': 28193778, 'title': 'AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28193778'}]",sensitive,2982,Enasidenib,3418
4,Preclinical - Cell culture,"In a preclinical study, Enasidenib (AG-221) decreased 2-hydroxyglutarate (2HG) levels in a colorectal carcinoma cell line expressing IDH2 R172K in culture (PMID: 28193778).",Actionable,10742,9256,colorectal cancer,DOID,1255,IDH2 R172K,"[{'id': 8791, 'pubMedId': 28193778, 'title': 'AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28193778'}]",predicted – sensitive,2982,Enasidenib,3418
5,Phase II,"In a Phase II trial, an acute myeloid leukemia patient harboring IDH2 D76fs demonstrated sensitivity to treatment with Venclexta (venetoclax), achieving a complete response with incomplete blood count recovery after 24 weeks (PMID: 27520294). ",Actionable,8021,9119,acute myeloid leukemia,DOID,26136,IDH2 D76fs,"[{'id': 6536, 'pubMedId': 27520294, 'title': 'Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27520294'}]",sensitive,1562,Venetoclax,3418
6,Preclinical - Cell line xenograft,"In a preclinical study, Enasidenib (AG-221) decreased 2-hydroxyglutarate (2HG) levels in a glioblastoma cell line expressing IDH2 R140Q in culture and in xenograft models (PMID: 28193778).",Actionable,10740,3068,glioblastoma multiforme,DOID,1254,IDH2 R140Q,"[{'id': 8791, 'pubMedId': 28193778, 'title': 'AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28193778'}]",predicted – sensitive,2982,Enasidenib,3418
7,Preclinical - Pdx & cell culture,"In a preclinical study, Enasidenib (AG-221) treatment reduced 2-hydroxyglutarate (2HG) levels and induced differentiation of leukemic blasts from acute myeloid leukemia (AML) patients harboring IDH2 R140Q in culture, and decreased 2HG levels and blast percentage and improved survival relative to Cytosar-U (cytarabine) treatment in IDH2 R140Q-mutant primary AML xenograft models (PMID: 28193778).",Actionable,10738,9119,acute myeloid leukemia,DOID,1254,IDH2 R140Q,"[{'id': 8791, 'pubMedId': 28193778, 'title': 'AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28193778'}]",sensitive,2982,Enasidenib,3418
8,Preclinical,"In a preclinical study, treatment with AGI-6780 resulted in the differentiation of erythroleukemia and AML cell lines expressing IDH2 R140Q (PMID: 23558173).",Actionable,1138,9119,acute myeloid leukemia,DOID,1254,IDH2 R140Q,"[{'id': 881, 'pubMedId': 23558173, 'title': 'Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558173'}]",sensitive,1585,AGI-6780,3418
9,Phase I,"In a Phase I study, Enasidenib (AG-221) demonstrated safety and efficacy in patients with hematological cancer harboring IDH2 mutations and included 8 CR, 1 CRp, 3 CRi, and 8 PR (ASH Meeting, Dec 2014, abstract #115).",Actionable,3581,2531,hematologic cancer,DOID,5912,IDH2 mutant,"[{'id': 3854, 'pubMedId': None, 'title': 'AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies', 'url': 'https://ash.confex.com/ash/2014/webprogram/Paper70721.html'}]",sensitive,2982,Enasidenib,3418
10,Phase I,"The Phase I trial of AG-881 in patients with IDH2 mutations and hematological cancers is active and no longer recruiting patients and there are no other trials for AG-881 (clinicaltrials.gov, Aug 2017). ",Actionable,4400,2531,hematologic cancer,DOID,5912,IDH2 mutant,"[{'id': 303, 'pubMedId': None, 'title': '', 'url': 'https://clinicaltrials.gov/'}]",not applicable,2995,AG-881,3418
11,Phase II,"In a Phase II trial, 33% (4/12) of acute myeloid leukemia patients harboring either IDH1 or IDH2 mutations responded to treatment with Venclexta (venetoclax), demonstrating a complete response or complete response with incomplete blood count recovery (PMID: 27520294).",Actionable,8020,9119,acute myeloid leukemia,DOID,5912,IDH2 mutant,"[{'id': 6536, 'pubMedId': 27520294, 'title': 'Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27520294'}]",predicted – sensitive,1562,Venetoclax,3418
12,FDA approved,"In a Phase I/II trial that supported FDA approval, Idhifa (enasidenib) treatment resulted in an overall response rate of 40.3% (71/176), with a complete remission rate of 19.3% (34/176), and stable disease in 48.3% (85/176) of acute myeloid leukemia patients harboring IDH2 mutations (PMID: 28588020; NCT01915498).",Actionable,11292,9119,acute myeloid leukemia,DOID,5912,IDH2 mutant,"[{'id': 9651, 'pubMedId': 28588020, 'title': 'Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28588020'}]",sensitive,2982,Enasidenib,3418
13,Phase I,"AG-881 is currently in clinical trials in patients with IDH2 mutations and advanced solid tumors (clinicaltrials.gov, Aug 2017). ",Actionable,4402,10000003,Advanced Solid Tumor,JAX,5912,IDH2 mutant,"[{'id': 303, 'pubMedId': None, 'title': '', 'url': 'https://clinicaltrials.gov/'}]",not applicable,2995,AG-881,3418
14,Preclinical,"In a preclinical study, the combination of Enasidenib (AG-221) and Quizartinib (AC220) stimulated leukemic cell differentiation and reduced leukemic cell self-renewal in an acute myeloid leukemia mouse model simultaneously expressing IDH2 R140Q and a FLT3-ITD mutation (Blood Dec 2014, 124 (21) 437). ",Actionable,3593,9119,acute myeloid leukemia,DOID,13759,IDH2 R140W FLT3 Y599_D600insSTDNEYFYVDFREYEY,"[{'id': 3871, 'pubMedId': None, 'title': 'AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo', 'url': 'http://www.bloodjournal.org/content/124/21/437?sso-checked=true'}]",predicted – sensitive,3172,Enasidenib + Quizartinib,3418
0,Clinical Study,"In multiple clinical studies, including a meta-analysis, IKZF1 deletion was associated with a worse event-free survival and overall survival in patients with acute lymphocytic leukemia (PMID: 25335741, PMID: 26194343, PMID: 27067989).",Prognostic,6168,9952,acute lymphocytic leukemia,DOID,22784,IKZF1 del,"[{'id': 5360, 'pubMedId': 25335741, 'title': 'The impact of IKZF1 deletion on the prognosis of acute lymphoblastic leukemia: an updated meta-analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25335741'}, {'id': 5361, 'pubMedId': 26194343, 'title': 'Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26194343'}, {'id': 5362, 'pubMedId': 27067989, 'title': 'Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27067989'}]",not applicable,1776,N/A,10320
1,Preclinical,"In a preclinical study, Revlimid (lenalidomide) treatment resulted in IKZF1 degradation and decreased proliferation of multiple myeloma cells in culture (PMID: 24292625). ",Actionable,1492,9538,multiple myeloma,DOID,2606,IKZF1 wild-type,"[{'id': 1409, 'pubMedId': 24292625, 'title': 'Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24292625'}]",sensitive,1164,lenalidomide,10320
0,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the Y918H mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5582,2531,hematologic cancer,DOID,21295,ETV6 - JAK2 JAK2 Y918H,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,3717
1,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the P1057S mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5580,2531,hematologic cancer,DOID,21293,ETV6 - JAK2 JAK2 P1057S,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,3717
2,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the G831R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5576,2531,hematologic cancer,DOID,21289,ETV6 - JAK2 JAK2 G831R,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,3717
3,Clinical Study,"In a clinical study, a melanoma patient treated with Keytruda (pembrolizumab) initially demonstrated a partial response, however, post 734 days developed disease progression due to a splice site mutation in JAK2, which resulted in an intron inclusion and an early stop codon (PMID: 27433843). ",Actionable,7476,1909,melanoma,DOID,25521,JAK2 inact mut,"[{'id': 6365, 'pubMedId': 27433843, 'title': 'Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27433843'}]",predicted – resistant,1447,Pembrolizumab,3717
4,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 22271575).",Actionable,2409,2531,hematologic cancer,DOID,7466,JAK2 V617F JAK2 G935R,"[{'id': 3030, 'pubMedId': 22271575, 'title': 'Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22271575'}]",resistant,907,Ruxolitinib,3717
5,Preclinical - Cell culture,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).",Actionable,2411,2531,hematologic cancer,DOID,7466,JAK2 V617F JAK2 G935R,"[{'id': 3030, 'pubMedId': 22271575, 'title': 'Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22271575'}]",resistant,2785,NVP-BSK805,3717
6,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).",Actionable,2412,2531,hematologic cancer,DOID,7466,JAK2 V617F JAK2 G935R,"[{'id': 3030, 'pubMedId': 22271575, 'title': 'Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22271575'}]",resistant,2834,NVP-BVB808,3717
7,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) worked synergistically with SGI-1776 to inhibit proliferation of myeloproliferative cancer cell lines harboring JAK2 V617F in culture (PMID: 26472029).",Actionable,4583,4960,bone marrow cancer,DOID,591,JAK2 V617F,"[{'id': 4621, 'pubMedId': 26472029, 'title': 'The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26472029'}]",sensitive,3549,Ruxolitinib + SGI-1776,3717
8,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) worked synergistically with AZD1208 to inhibit proliferation of myeloproliferative cancer cell lines harboring JAK2 V617F  in culture (PMID: 26472029).",Actionable,4584,4960,bone marrow cancer,DOID,591,JAK2 V617F,"[{'id': 4621, 'pubMedId': 26472029, 'title': 'The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26472029'}]",sensitive,3550,AZD1208 + Ruxolitinib,3717
9,Preclinical,"In a preclinical study, acute myeloid leukemia cells harboring JAK2 V617F demonstrated sensitivity to A-1155463 in culture (PMID: 25787766).",Actionable,2087,9119,acute myeloid leukemia,DOID,591,JAK2 V617F,"[{'id': 2473, 'pubMedId': 25787766, 'title': 'Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25787766'}]",sensitive,2576,A-1155463,3717
10,Preclinical,"In a preclinical study, myeloproliferative cancer cell lines harboring JAK2 V617F demonstrated reduced sensitivity to SGI-1776 induced growth inhibition in culture (PMID: 26472029).",Actionable,4581,4960,bone marrow cancer,DOID,591,JAK2 V617F,"[{'id': 4621, 'pubMedId': 26472029, 'title': 'The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26472029'}]",decreased response,3533,SGI-1776,3717
11,Preclinical,"In a preclinical study, RP6530 worked synergistically with Jakafi (ruxolitinib) to inhibit proliferation of Jakafi (ruxolitinib)-resistant erythroleukemia cell lines carrying JAK2 V617F mutation ( Cancer Res August 1, 2015 75; 2704 ).",Actionable,5167,9119,acute myeloid leukemia,DOID,591,JAK2 V617F,"[{'id': 4892, 'pubMedId': None, 'title': 'RP6530, a dual PI3K ?/? inhibitor, potentiates ruxolitinib activity in the JAK2-V617F mutant erythroleukemia cell lines', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/2704.short'}]",sensitive,3765,RP6530 + Ruxolitinib,3717
12,Preclinical - Cell culture,"In a preclinical study, transformed mouse myeloid cells over expressing JAK2 V617F were resistant to Gleevec (imatinib) in culture (PMID: 21224473).",Actionable,7413,8692,myeloid leukemia,DOID,591,JAK2 V617F,"[{'id': 418, 'pubMedId': 21224473, 'title': 'Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21224473'}]",resistant,770,Imatinib,3717
13,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5797,10000003,Advanced Solid Tumor,JAX,591,JAK2 V617F,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3927,GDC-0941 + Ruxolitinib,3717
14,Preclinical - Cell culture,"In a preclinical study, SHP099 inhibited proliferation of a hematopoietic cancer cell line harboring JAK2 V617F in culture (PMID: 27362227).",Actionable,7516,2531,hematologic cancer,DOID,591,JAK2 V617F,"[{'id': 6394, 'pubMedId': 27362227, 'title': 'Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27362227'}]",sensitive,4504,SHP099,3717
15,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5803,10000003,Advanced Solid Tumor,JAX,591,JAK2 V617F,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3928,BEZ235 + Ruxolitinib,3717
16,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5790,10000003,Advanced Solid Tumor,JAX,591,JAK2 V617F,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3926,Ruxolitinib + ZSTK474,3717
17,Preclinical,"In a preclinical study, myeloproliferative cancer cell lines harboring JAK2 V617F demonstrated reduced sensitivity to AZD1208 induced growth inhibition in culture (PMID: 26472029).",Actionable,4582,4960,bone marrow cancer,DOID,591,JAK2 V617F,"[{'id': 4621, 'pubMedId': 26472029, 'title': 'The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26472029'}]",decreased response,3224,AZD1208,3717
18,Preclinical,"In a preclinical study, CHZ868 inhibited proliferation of myeloproliferative neoplasm cells harboring JAK2 V617F , including cells with decreased response to Type I JAK inhibitors following chronic exposure, and decreased mutant allele burden in a mouse polycythemia vera model expressing JAK2 V617F (PMID: 26175413).",Actionable,6061,4960,bone marrow cancer,DOID,591,JAK2 V617F,"[{'id': 5260, 'pubMedId': 26175413, 'title': 'CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26175413'}]",sensitive,4016,CHZ868,3717
19,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5808,10000003,Advanced Solid Tumor,JAX,591,JAK2 V617F,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3929,Ruxolitinib + TGX-221,3717
20,Preclinical,"In a preclinical study, Go 6976 inhibited proliferation of cultured acute myeloid leukemia cells expressing the JAK2 V617F mutation (PMID: 16956345).",Actionable,1810,9119,acute myeloid leukemia,DOID,591,JAK2 V617F,"[{'id': 2148, 'pubMedId': 16956345, 'title': 'Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16956345'}]",sensitive,2343,Go 6976,3717
21,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5788,10000003,Advanced Solid Tumor,JAX,21621,JAK2 V617F MPL wild-type,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3926,Ruxolitinib + ZSTK474,3717
22,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5794,10000003,Advanced Solid Tumor,JAX,21621,JAK2 V617F MPL wild-type,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3927,GDC-0941 + Ruxolitinib,3717
23,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5800,10000003,Advanced Solid Tumor,JAX,21621,JAK2 V617F MPL wild-type,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3928,BEZ235 + Ruxolitinib,3717
24,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5806,10000003,Advanced Solid Tumor,JAX,21621,JAK2 V617F MPL wild-type,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3929,Ruxolitinib + TGX-221,3717
25,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 E985K double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964).",Actionable,2408,2531,hematologic cancer,DOID,7465,JAK2 V617F JAK2 E985K,"[{'id': 3038, 'pubMedId': 21926964, 'title': 'Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21926964'}]",resistant,907,Ruxolitinib,3717
26,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 M929I double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964).",Actionable,2426,2531,hematologic cancer,DOID,7535,JAK2 V617F JAK2 M929I,"[{'id': 3038, 'pubMedId': 21926964, 'title': 'Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21926964'}]",resistant,907,Ruxolitinib,3717
27,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964).",Actionable,2427,2531,hematologic cancer,DOID,7555,JAK2 V617F JAK2 R938L,"[{'id': 3038, 'pubMedId': 21926964, 'title': 'Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21926964'}]",resistant,907,Ruxolitinib,3717
28,Preclinical - Cell culture,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to fedratinib (SAR302503) in culture (PMID: 21926964).",Actionable,2430,2531,hematologic cancer,DOID,7555,JAK2 V617F JAK2 R938L,"[{'id': 3038, 'pubMedId': 21926964, 'title': 'Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21926964'}]",resistant,911,SAR302503,3717
29,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to AZD1480 in culture (PMID: 21926964).",Actionable,2431,2531,hematologic cancer,DOID,7555,JAK2 V617F JAK2 R938L,"[{'id': 3038, 'pubMedId': 21926964, 'title': 'Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21926964'}]",resistant,652,AZD1480,3717
30,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to Momelotinib (CYT387) in culture (PMID: 21926964).",Actionable,2428,2531,hematologic cancer,DOID,7555,JAK2 V617F JAK2 R938L,"[{'id': 3038, 'pubMedId': 21926964, 'title': 'Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21926964'}]",resistant,823,Momelotinib,3717
31,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to lestauranib in culture (PMID: 21926964).",Actionable,2429,2531,hematologic cancer,DOID,7555,JAK2 V617F JAK2 R938L,"[{'id': 3038, 'pubMedId': 21926964, 'title': 'Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21926964'}]",resistant,793,Lestaurtinib,3717
32,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to AZD1480 in culture (PMID: 21926964).",Actionable,2418,2531,hematologic cancer,DOID,7470,JAK2 V617F JAK2 I960V,"[{'id': 3038, 'pubMedId': 21926964, 'title': 'Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21926964'}]",resistant,652,AZD1480,3717
33,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Lestauranib in culture (PMID: 21926964).",Actionable,2416,2531,hematologic cancer,DOID,7470,JAK2 V617F JAK2 I960V,"[{'id': 3038, 'pubMedId': 21926964, 'title': 'Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21926964'}]",resistant,793,Lestaurtinib,3717
34,Preclinical - Cell culture,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Fedratinib (SAR302503) in culture (PMID: 21926964).",Actionable,2417,2531,hematologic cancer,DOID,7470,JAK2 V617F JAK2 I960V,"[{'id': 3038, 'pubMedId': 21926964, 'title': 'Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21926964'}]",resistant,911,SAR302503,3717
35,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Momelotinib in culture (PMID: 21926964).",Actionable,2419,2531,hematologic cancer,DOID,7470,JAK2 V617F JAK2 I960V,"[{'id': 3038, 'pubMedId': 21926964, 'title': 'Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21926964'}]",resistant,823,Momelotinib,3717
36,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964).",Actionable,2415,2531,hematologic cancer,DOID,7470,JAK2 V617F JAK2 I960V,"[{'id': 3038, 'pubMedId': 21926964, 'title': 'Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21926964'}]",resistant,907,Ruxolitinib,3717
37,Preclinical - Cell culture,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 E864K double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).",Actionable,2404,2531,hematologic cancer,DOID,7462,JAK2 V617F JAK2 E864K,"[{'id': 3030, 'pubMedId': 22271575, 'title': 'Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22271575'}]",resistant,2785,NVP-BSK805,3717
38,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 E864K double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).",Actionable,2405,2531,hematologic cancer,DOID,7462,JAK2 V617F JAK2 E864K,"[{'id': 3030, 'pubMedId': 22271575, 'title': 'Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22271575'}]",resistant,2834,NVP-BVB808,3717
39,Preclinical,"In a preclinical study, cells harboring the JAK2 V617F/Y931C double mutation displayed resistance to ATP-competetive JAK inhibitors, such as  Jakafi (Ruxolitinib) (PMID: 21393331).",Actionable,1162,162,cancer,DOID,2065,JAK2 V617F JAK2 Y931C,"[{'id': 908, 'pubMedId': 21393331, 'title': 'Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21393331'}]",resistant,907,Ruxolitinib,3717
40,Preclinical,"In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 22271575).",Actionable,2410,162,cancer,DOID,7468,JAK2 R683G JAK2 G935R,"[{'id': 3030, 'pubMedId': 22271575, 'title': 'Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22271575'}]",resistant,907,Ruxolitinib,3717
41,Preclinical,"In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).",Actionable,2414,162,cancer,DOID,7468,JAK2 R683G JAK2 G935R,"[{'id': 3030, 'pubMedId': 22271575, 'title': 'Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22271575'}]",resistant,2834,NVP-BVB808,3717
42,Preclinical - Cell culture,"In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).",Actionable,2413,162,cancer,DOID,7468,JAK2 R683G JAK2 G935R,"[{'id': 3030, 'pubMedId': 22271575, 'title': 'Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22271575'}]",resistant,2785,NVP-BSK805,3717
43,Preclinical,"In a preclinical study, cells expressing the JAK2 R683G/E864K double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).",Actionable,2407,162,cancer,DOID,7464,JAK2 R683G JAK2 E864K,"[{'id': 3030, 'pubMedId': 22271575, 'title': 'Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22271575'}]",resistant,2834,NVP-BVB808,3717
44,Preclinical - Cell culture,"In a preclinical study, cells expressing the JAK2 R683G/E864K double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).",Actionable,2406,162,cancer,DOID,7464,JAK2 R683G JAK2 E864K,"[{'id': 3030, 'pubMedId': 22271575, 'title': 'Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22271575'}]",resistant,2785,NVP-BSK805,3717
45,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the R975G mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,2447,2531,hematologic cancer,DOID,7562,ETV6-JAK2 JAK2 R975G,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,3717
46,Preclinical,"In a preclinical study, cells harboring JAK2 Y931C displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",Actionable,1161,162,cancer,DOID,2064,JAK2 Y931C,"[{'id': 908, 'pubMedId': 21393331, 'title': 'Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21393331'}]",resistant,907,Ruxolitinib,3717
47,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the V881A mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,2448,2531,hematologic cancer,DOID,7564,ETV6-JAK2 JAK2 V881A,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,3717
48,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the G935R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5577,2531,hematologic cancer,DOID,21291,ETV6 - JAK2 JAK2 G935R,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,3717
49,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the E864K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5575,2531,hematologic cancer,DOID,21290,ETV6 - JAK2 JAK2 E864K,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,3717
50,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the N909K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,2449,2531,hematologic cancer,DOID,7560,ETV6-JAK2 JAK2 N909K,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,3717
51,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the M929I mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5579,2531,hematologic cancer,DOID,21292,ETV6 - JAK2 JAK2 M929I,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,3717
52,Preclinical,"In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to AZ960 in culture (PMID: 24398328).",Actionable,5587,2531,hematologic cancer,DOID,13666,JAK2 R867Q,"[{'id': 3844, 'pubMedId': 24398328, 'title': 'Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24398328'}]",decreased response,2786,AZ960,3717
53,Preclinical - Cell culture,"In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Fedratinib (SAR302503) in culture (PMID: 24398328).",Actionable,5585,2531,hematologic cancer,DOID,13666,JAK2 R867Q,"[{'id': 3844, 'pubMedId': 24398328, 'title': 'Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24398328'}]",decreased response,911,SAR302503,3717
54,Preclinical,"In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Momelotinib (CYT387) in culture (PMID: 24398328).",Actionable,5588,2531,hematologic cancer,DOID,13666,JAK2 R867Q,"[{'id': 3844, 'pubMedId': 24398328, 'title': 'Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24398328'}]",decreased response,823,Momelotinib,3717
55,Preclinical,"In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Jakafi (ruxolitinib) in culture (PMID: 24398328).",Actionable,5586,2531,hematologic cancer,DOID,13666,JAK2 R867Q,"[{'id': 3844, 'pubMedId': 24398328, 'title': 'Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24398328'}]",decreased response,907,Ruxolitinib,3717
56,Preclinical,"In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to AUY922 in culture (PMID: 24398328).",Actionable,5589,2531,hematologic cancer,DOID,13666,JAK2 R867Q,"[{'id': 3844, 'pubMedId': 24398328, 'title': 'Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24398328'}]",decreased response,647,AUY922,3717
57,Preclinical - Pdx,"In a preclinical study, NVP-BSK805 with Abraxane (paclitaxel) inhibited tumor growth in triple-negative breast cancer patient-derived xenograft models with JAK2 amplification (PMID: 27075627).",Actionable,5947,60081,triple-receptor negative breast cancer,DOID,22035,JAK2 amp,"[{'id': 5204, 'pubMedId': 27075627, 'title': 'Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27075627'}]",sensitive,3991,NVP-BSK805 + paclitaxel,3717
58,Preclinical - Pdx,"In a preclinical study, NVP-BSK805 inhibited tumor growth in triple-negative breast cancer patient-derived xenograft models harboring JAK2 amplification (PMID: 27075627).",Actionable,5948,60081,triple-receptor negative breast cancer,DOID,22035,JAK2 amp,"[{'id': 5204, 'pubMedId': 27075627, 'title': 'Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27075627'}]",sensitive,2785,NVP-BSK805,3717
59,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).",Actionable,5787,10000003,Advanced Solid Tumor,JAX,21624,JAK2 over exp MPL over exp,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3926,Ruxolitinib + ZSTK474,3717
60,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).",Actionable,5799,10000003,Advanced Solid Tumor,JAX,21624,JAK2 over exp MPL over exp,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3928,BEZ235 + Ruxolitinib,3717
61,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).",Actionable,5805,10000003,Advanced Solid Tumor,JAX,21624,JAK2 over exp MPL over exp,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3929,Ruxolitinib + TGX-221,3717
62,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).",Actionable,5793,10000003,Advanced Solid Tumor,JAX,21624,JAK2 over exp MPL over exp,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3927,GDC-0941 + Ruxolitinib,3717
63,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790).",Actionable,5802,10000003,Advanced Solid Tumor,JAX,21622,JAK2 over exp,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3928,BEZ235 + Ruxolitinib,3717
64,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790).",Actionable,5791,10000003,Advanced Solid Tumor,JAX,21622,JAK2 over exp,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3926,Ruxolitinib + ZSTK474,3717
65,Preclinical - Pdx,"In a preclinical study, NVP-BSK805 with Abraxane (paclitaxel) inhibited tumor growth in patient-derived xenograft models of triple-negative breast cancer with JAK2 overexpression (PMID: 27075627).",Actionable,5946,60081,triple-receptor negative breast cancer,DOID,21622,JAK2 over exp,"[{'id': 5204, 'pubMedId': 27075627, 'title': 'Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27075627'}]",sensitive,3991,NVP-BSK805 + paclitaxel,3717
66,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790).",Actionable,5796,10000003,Advanced Solid Tumor,JAX,21622,JAK2 over exp,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3927,GDC-0941 + Ruxolitinib,3717
67,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790).",Actionable,5809,10000003,Advanced Solid Tumor,JAX,21622,JAK2 over exp,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3929,Ruxolitinib + TGX-221,3717
68,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the R1127K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5581,2531,hematologic cancer,DOID,21294,ETV6 - JAK2 JAK2 R1127K,"[{'id': 3031, 'pubMedId': 22916261, 'title': 'Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22916261'}]",resistant,2797,Pyridone 6,3717
0,Preclinical - Cell culture,"In a preclinical study, JANEX-1 (WHI-P131) inhibited proliferation of transformed cells expressing JAK3 I87T in culture (PMID: 18397343).",Actionable,11807,10000003,Advanced Solid Tumor,JAX,2192,JAK3 I87T,"[{'id': 932, 'pubMedId': 18397343, 'title': 'Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18397343'}]",sensitive,2808,JANEX-1,3718
1,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing JAK3 E183G in culture demonstrated decreased cell survival, increased G1 arrest, elevated apoptotic activity, and reduced phosphorylation of Stat5a when treated with Xeljanz (tofacitinib) (PMID: 21821710).",Actionable,10921,10000003,Advanced Solid Tumor,JAX,27858,JAK3 E183G,"[{'id': 8930, 'pubMedId': 21821710, 'title': 'FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821710'}]",sensitive,941,Tofacitinib,3718
2,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing JAK3 V674A demonstrated reduced sensitivity to NIBR3049 in culture (PMID: 26446793).",Actionable,7406,10000003,Advanced Solid Tumor,JAX,7054,JAK3 V674A,"[{'id': 6343, 'pubMedId': 26446793, 'title': 'Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26446793'}]",decreased response,2809,NIBR3049,3718
3,Preclinical - Cell culture,"In a preclinical study, Jakafi (ruxolitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 V674A in culture (PMID: 26446793).",Actionable,7401,10000003,Advanced Solid Tumor,JAX,7054,JAK3 V674A,"[{'id': 6343, 'pubMedId': 26446793, 'title': 'Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26446793'}]",sensitive,907,Ruxolitinib,3718
4,Preclinical - Cell culture,"In a preclinical study, Xeljanz (tofacitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 V674A in culture (PMID: 26446793).",Actionable,7407,10000003,Advanced Solid Tumor,JAX,7054,JAK3 V674A,"[{'id': 6343, 'pubMedId': 26446793, 'title': 'Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26446793'}]",sensitive,941,Tofacitinib,3718
5,Preclinical,"In a preclinical study, Xeljanz (tofacitinib) treatment converted cells expressing JAK3 V221I from factor-independent to factor-dependent growth in cell culture (PMID: 25146434).",Actionable,1638,10000003,Advanced Solid Tumor,JAX,2791,JAK3 V722I,"[{'id': 1754, 'pubMedId': 25146434, 'title': 'Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25146434'}]",sensitive,941,Tofacitinib,3718
6,Preclinical - Cell culture,"In a preclinical study, NIBR3049 inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing both JAK3 L857P and Y100A in culture (PMID: 26446793). ",Actionable,7405,10000003,Advanced Solid Tumor,JAX,25374,JAK3 L857P JAK3 Y100A,"[{'id': 6343, 'pubMedId': 26446793, 'title': 'Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26446793'}]",sensitive,2809,NIBR3049,3718
7,Preclinical - Cell culture,"In a preclinical study, Xeljanz (tofacitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing both JAK3 L857P and Y100A in culture (PMID: 26446793).",Actionable,7409,10000003,Advanced Solid Tumor,JAX,25374,JAK3 L857P JAK3 Y100A,"[{'id': 6343, 'pubMedId': 26446793, 'title': 'Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26446793'}]",sensitive,941,Tofacitinib,3718
8,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing both JAK3 L857P and JAK3 Y100A demonstrated reduced sensitivity to Jakafi (ruxolitinib) in culture (PMID: 26446793).",Actionable,7403,10000003,Advanced Solid Tumor,JAX,25374,JAK3 L857P JAK3 Y100A,"[{'id': 6343, 'pubMedId': 26446793, 'title': 'Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26446793'}]",decreased response,907,Ruxolitinib,3718
9,Preclinical,"In a preclinical study, Xeljanz (tofacitinib), a pan-JAK inhibitor, reduced cell viability and increased apoptosis in a JAK3 A572V mutant natural killer/T-cell lymphoma cell line (PMID: 22705984). 
",Actionable,1087,50743,mature T-cell and NK-cell lymphoma,DOID,2168,JAK3 A572V,"[{'id': 821, 'pubMedId': 22705984, 'title': 'Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22705984'}]",sensitive,941,Tofacitinib,3718
10,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing JAK3 A572V in culture demonstrated decreased cell survival, increased G1 arrest, elevated apoptotic activity, and reduced phosphorylation of Stat5a when treated with Xeljanz (tofacitinib) (PMID: 21821710).",Actionable,10922,10000003,Advanced Solid Tumor,JAX,2168,JAK3 A572V,"[{'id': 8930, 'pubMedId': 21821710, 'title': 'FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821710'}]",sensitive,941,Tofacitinib,3718
11,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing JAK3 R172Q in culture demonstrated decreased cell survival, reduced phosphorylation of Stat5a, and G1 arrest when treated with Xeljanz (tofacitinib) (PMID: 21821710). ",Actionable,10919,10000003,Advanced Solid Tumor,JAX,27856,JAK3 R172Q,"[{'id': 8930, 'pubMedId': 21821710, 'title': 'FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821710'}]",sensitive,941,Tofacitinib,3718
12,Preclinical - Cell culture,"In a preclinical study, Xeljanz (tofacitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 L857P in culture (PMID: 26446793). ",Actionable,7408,10000003,Advanced Solid Tumor,JAX,25367,JAK3 L857P,"[{'id': 6343, 'pubMedId': 26446793, 'title': 'Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26446793'}]",sensitive,941,Tofacitinib,3718
13,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing JAK3 L857P demonstrated reduced sensitivity to Jakafi (ruxolitinib) in culture (PMID: 26446793).",Actionable,7402,10000003,Advanced Solid Tumor,JAX,25367,JAK3 L857P,"[{'id': 6343, 'pubMedId': 26446793, 'title': 'Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26446793'}]",decreased response,907,Ruxolitinib,3718
14,Preclinical - Cell culture,"In a preclinical study, NIBR3049 inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 L857P in culture (PMID: 26446793).",Actionable,7404,10000003,Advanced Solid Tumor,JAX,25367,JAK3 L857P,"[{'id': 6343, 'pubMedId': 26446793, 'title': 'Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26446793'}]",sensitive,2809,NIBR3049,3718
15,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing JAK3 L156P in culture demonstrated decreased cell survival, increased G1 arrest, and reduced phosphorylation of Stat5a when treated with Xeljanz (tofacitinib) (PMID: 21821710).",Actionable,10920,10000003,Advanced Solid Tumor,JAX,27857,JAK3 L156P,"[{'id': 8930, 'pubMedId': 21821710, 'title': 'FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821710'}]",sensitive,941,Tofacitinib,3718
0,Preclinical - Cell line xenograft,"In a preclinical study, GSK343 inhibited proliferation of KDM6A null urothelial bladder carcinoma cell lines in culture and delayed tumor onset, improved survival in cell line xenograft models (PMID: 28228601).",Actionable,10232,4006,bladder urothelial carcinoma,DOID,27321,KDM6A loss,"[{'id': 8173, 'pubMedId': 28228601, 'title': 'Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28228601'}]",sensitive,2701,GSK343,7403
0,Clinical Study,"In clinical case study, a patient with olfactory neuroblastoma harboring EGFR R521K, FGFR2 M186T, KDR Q472H, KDR V297I, and RET M1009T demonstrated sensitivity to the combination of Sutent (sunitinib) and Erbitux (cetuximab), resulting in a complete response (PMID: 27149458).",Actionable,7758,369,olfactory neuroblastoma,DOID,26023,EGFR R521K FGFR2 M186T KDR Q472H KDR V297I RET M1009T,"[{'id': 6481, 'pubMedId': 27149458, 'title': 'Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27149458'}]",sensitive,4568,Cetuximab + Sunitinib,3791
1,Preclinical,"In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes increased survival of melanoma mouse models (PMID: 23633494).",Actionable,1314,1909,melanoma,DOID,366,KDR wild-type,"[{'id': 1027, 'pubMedId': 23633494, 'title': 'Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23633494'}]",predicted – sensitive,984,Anti-VEGFR2 CAR CD8 lymphocytes,3791
2,Phase I,"In a Phase I trial, VEGFR2-169, in combination with Gemzar (gemcitabine), achieved a disease control rate of 67% (12/18) and an improved overall survival time to 8.7 months in pancreatic cancer patients expressing the HLA-A*2402 version of the KDR (VEGFR2) wild-type allele (PMID: 19930156).",Actionable,2555,1793,pancreatic cancer,DOID,366,KDR wild-type,"[{'id': 3285, 'pubMedId': 19930156, 'title': 'Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19930156'}]",sensitive,2938,VEGFR2-169 + Gemcitabine,3791
3,Preclinical,"In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes, displayed efficacy in inhibiting cell and tumor growth in a variety of solid tumor cell lines and mouse tumor models (PMID: 20978347).",Actionable,1007,10000003,Advanced Solid Tumor,JAX,366,KDR wild-type,"[{'id': 719, 'pubMedId': 20978347, 'title': 'Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20978347'}]",predicted – sensitive,984,Anti-VEGFR2 CAR CD8 lymphocytes,3791
4,Preclinical,"In a preclinical study, Pz-1 inhibited Kdr2 phosphorylation in transformed cells expressing KDR wild-type (PMID: 26126987).",Actionable,6192,10000003,Advanced Solid Tumor,JAX,366,KDR wild-type,"[{'id': 5385, 'pubMedId': 26126987, 'title': 'Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26126987'}]",predicted – sensitive,4089,Pz-1,3791
5,Phase I,"In a Phase I trial, Cyramza (ramucirumab), an inhibitor of KDR (VEGFR2), demonstrated safety and efficacy (partial response or stable disease) in patients with advanced solid tumors (PMID: 20048182).",Actionable,1283,10000003,Advanced Solid Tumor,JAX,366,KDR wild-type,"[{'id': 577, 'pubMedId': 20048182, 'title': 'Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20048182'}]",predicted – sensitive,886,Ramucirumab,3791
6,Preclinical,"In a preclinical study, upregulation of Kdr (Vegfr2) was identified in tumors acquired resistance to Sutent (sunitinib) in allograft models of breast cancer (PMID: 28011623). ",Actionable,10041,1612,breast cancer,DOID,20512,KDR over exp,"[{'id': 7922, 'pubMedId': 28011623, 'title': 'Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28011623'}]",predicted – resistant,930,Sunitinib,3791
7,Preclinical,"In a preclinical study, cells expressing KDR A1065T were sensitive to Sutent (sunitinib) in culture (PMID: 19723655).",Actionable,1572,10000003,Advanced Solid Tumor,JAX,14289,KDR A1065T,"[{'id': 217, 'pubMedId': 19723655, 'title': 'KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19723655'}]",sensitive,930,Sunitinib,3791
8,Preclinical - Cell culture,"In a preclinical study, cells expressing KDR D717V were sensitive to Sutent (sunitinib) in culture (PMID: 19723655).",Actionable,1573,10000003,Advanced Solid Tumor,JAX,2698,KDR D717V,"[{'id': 217, 'pubMedId': 19723655, 'title': 'KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19723655'}]",sensitive,930,Sunitinib,3791
9,Clinical Study,"In a clinical case study, Stivarga (regorafenib) treatment resulted in durable partial response in a colorectal cancer patient harboring KDR R961W and mutations in APC and KRAS (PMID: 27004155).",Actionable,5559,9256,colorectal cancer,DOID,21268,APC mutant KRAS mutant KDR R961W,"[{'id': 5105, 'pubMedId': 27004155, 'title': 'KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27004155'}]",sensitive,890,Regorafenib,3791
10,Phase I,"In a Phase I trial, Lucitanib (E-3810) demonstrated safety and efficacy in patients with FGF-aberrant or angiogenesis-sensitive advanced solid tumors (PMID: 25193991). ",Actionable,1023,10000003,Advanced Solid Tumor,JAX,635,KDR act mut,"[{'id': 739, 'pubMedId': 25193991, 'title': 'Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25193991'}]",predicted – sensitive,1029,Lucitanib,3791
11,Preclinical,"In a preclinical study, Nexavar (sorafenib) demonstrated efficacy in cells expressing KDR activating mutations (PMID: 19723655). ",Actionable,1434,10000003,Advanced Solid Tumor,JAX,635,KDR act mut,"[{'id': 217, 'pubMedId': 19723655, 'title': 'KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19723655'}]",sensitive,920,Sorafenib,3791
12,Phase II,"In a Phase II clinical trial of patients with metastatic urothelial cancer, Sutent (sunitinib) demonstrated limited antitumor activity, warranting further investigation of VEGF pathways as a therapeutic target (PMID: 20142593).
",Actionable,974,4006,bladder urothelial carcinoma,DOID,635,KDR act mut,"[{'id': 635, 'pubMedId': 20142593, 'title': 'Phase II study of sunitinib in patients with metastatic urothelial cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20142593'}]",predicted – sensitive,930,Sunitinib,3791
13,Preclinical,"In a preclinical study, cells expressing KDR activating mutations were sensitive to Sutent (sunitinib) in cell culture (PMID: 19723655).",Actionable,1571,10000003,Advanced Solid Tumor,JAX,635,KDR act mut,"[{'id': 217, 'pubMedId': 19723655, 'title': 'KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19723655'}]",sensitive,930,Sunitinib,3791
14,Preclinical,"In a preclinical study, pancreatic islet endothelial cells were sensitive to TAS-115, resulting in decreased phosphorylation of Vegfr2, and inhibition of cell growth and angiogenesis in culture and mouse models (PMID: 24140932). ",Actionable,5899,1793,pancreatic cancer,DOID,21996,KDR positive,"[{'id': 5188, 'pubMedId': 24140932, 'title': 'The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24140932'}]",sensitive,3976,TAS-115,3791
15,Preclinical - Cell line xenograft,"In a preclinical study, Motesanib (AMG 706) inhibited KDR (VEGFR2) phosphorylation, but had minimal activity against RET in a medullary thyroid carcinoma (MTC) cell line harboring RET C634W in culture, however, inhibited both RET and KDR (VEGFR2) phosphorylation and decreased tumor angiogenesis and growth in MTC cell line xenograft models with RET C634W (PMID: 21422803).",Actionable,8334,3973,thyroid medullary carcinoma,DOID,26230,KDR pos RET C634W,"[{'id': 996, 'pubMedId': 21422803, 'title': 'Anti-tumor activity of motesanib in a medullary thyroid cancer model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21422803'}]",predicted – sensitive,824,Motesanib,3791
16,Phase III,"In a retrospective analysis of a Phase III trial, treatment with Caprelsa (vandetanib) did not correlate with an improved PFS, OS, or objective response rate in non-small cell lung carcinoma patients harboring a KDR amplification nor did it inhibit cell proliferation of the KDR amplified archived tumor cells in culture (PMID: 26578684). ",Actionable,6035,3908,non-small cell lung carcinoma,DOID,3601,KDR amp,"[{'id': 5251, 'pubMedId': 26578684, 'title': 'KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26578684'}]",no benefit,953,Vandetanib,3791
17,Preclinical,"In a preclinical study, human melanoma cells harboring KDR (VEGFR2) Q472H demonstrated increased sensitivity to treatment with a VEGFR2 (KDR) function-blocking antibody compared to cells with wild-type KDR (VEGFR), resulting in decreased proliferation and invasion in culture (PMID: 26631613).",Actionable,5324,1909,melanoma,DOID,641,KDR Q472H,"[{'id': 4818, 'pubMedId': 26631613, 'title': 'Identification of a Novel Pathogenic Germline KDR Variant in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26631613'}]",sensitive,3842,unspecified VEGFR2 antibody,3791
0,Phase III,"In a Phase III trial, gastrointestinal stromal tumor patients harboring KIT exon 11 deletions or indels demonstrated improved improved recurrence-free survival (RFS) with 3-year adjuvant Gleevec (imatinib) treatment (5-year RFS, 70%), compared to patients receiving 1-year treatment (5-year RFS, 41.3%) (PMID: 28334365).",Actionable,10902,9253,gastrointestinal stromal tumor,DOID,27851,KIT exon 11 del,"[{'id': 8917, 'pubMedId': 28334365, 'title': 'Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28334365'}]",predicted – sensitive,770,Imatinib,3815
1,Preclinical - Pdx & cell culture,"In a preclinical study, a patient derived GIST cell line harboring KIT V560_L576del demonstrated sensitivity to Iclusig (ponatinib) in both culture and PDX models, resulting in phosphorylation inhibition of Akt, Kit, and Erk (PMID: 25239608). ",Actionable,6796,9253,gastrointestinal stromal tumor,DOID,3291,KIT V560_L576del,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
2,Preclinical - Pdx & cell culture,"In a preclinical study, a patient derived GIST cell line harboring KIT V560_L576del demonstrated sensitivity to Gleevec (imatinib) in both culture and PDX models, resulting in phosphorylation inhibition of Akt, Kit, and Erk (PMID: 25239608). ",Actionable,6797,9253,gastrointestinal stromal tumor,DOID,3291,KIT V560_L576del,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,770,Imatinib,3815
3,Preclinical,"In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_L576del and KIT V654A demonstrated sensitivity to treatment with Sutent (sunitinib) (PMID: 25239608). ",Actionable,6800,9253,gastrointestinal stromal tumor,DOID,23691,KIT V560_L576del KIT V654A,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,930,Sunitinib,3815
4,Phase II,"In a Phase II clinical trial, Sprycel (dasatinib) demonstrated preliminary activity in patients with Gleevec (imatinib)-resistant gastrointestinal stromal tumor (GIST), including patients harboring KIT exon 11 mutations, with a partial response rate of 32% (15/47),  median progression-free survival of 2.0 months, and overall survival of 19 months (J Clin Oncol 29: 2011 (suppl; abstr 10006)).",Actionable,8611,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,"[{'id': 6698, 'pubMedId': None, 'title': 'A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).', 'url': 'http://meetinglibrary.asco.org/content/79120-102'}]",predicted – sensitive,717,Dasatinib,3815
5,Clinical Study,"In a clinical case report, Gleevec (imatinib mesylate) treatment resulted in partial response in a patient with metastasized anal melanoma harboring a 21 base-pair duplication in exon 11 of KIT, reduced pulmonary metastasis by 60% (PMID: 20372153). ",Actionable,8613,1909,melanoma,DOID,19852,KIT exon 11,"[{'id': 6700, 'pubMedId': 20372153, 'title': 'Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20372153'}]",predicted – sensitive,770,Imatinib,3815
6,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Gleevec (imatinib) and MK2206 increased growth inhibition and decreased viability of gastrointestinal stromal tumor (GIST) cell lines harboring KIT exon 11 mutations in culture, and improved survival and inhibited tumor growth in a KIT exon 11-mutant GIST cell line xenograft model, with increased efficacy compared to either agent alone (PMID: 27370604).",Actionable,9688,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,"[{'id': 7483, 'pubMedId': 27370604, 'title': 'Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27370604'}]",sensitive,5163,Imatinib + MK2206,3815
7,Phase III,"In a Phase III trial, a 24 month progression free survival was observed in 69.6% of advanced GIST patients harboring KIT exon 11 mutations when treated with Tasigna (nilotinib) (J Clin Oncol May 2013 vol. 31 no. 15_suppl 10501).

",Actionable,8612,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,"[{'id': 6699, 'pubMedId': None, 'title': 'Phase III trial of nilotinib versus imatinib as first-line targeted therapy of advanced gastrointestinal stromal tumors (GIST)', 'url': 'http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/10501'}]",sensitive,829,Nilotinib,3815
8,Phase II,"In a Phase II clinical trial, treatment with Stivarga (regorafenib) resulted in a clinical benefit rate of 76% (25/33), a median progression-free survival (PFS) of 13.2 months, and a median overall survival of 25 months in patients with gastrointestinal stromal tumors, with patients with KIT exon 11 mutations demonstrating the longest PFS of 13.4 months (PMID: 27371698).",Actionable,8574,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,"[{'id': 6691, 'pubMedId': 27371698, 'title': 'Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27371698'}]",sensitive,890,Regorafenib,3815
9,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of XAV939 and Gleevec (imatinib) resulted in decreased viability of gastrointestinal stromal tumor (GIST) cell lines harboring KIT exon 11 mutations compared to Gleevec (imatinib) alone, in culture (PMID: 28611108).",Actionable,11960,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,"[{'id': 9934, 'pubMedId': 28611108, 'title': 'Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28611108'}]",sensitive,6214,Imatinib + XAV939,3815
10,Phase III,"In a Phase III trial, Gleevec (imatinib) treatment resulted in longer overall survival (OS) (66 vs 40 months) in gastrointestinal stromal tumor (GIST) patients harboring KIT exon 11 mutations compared to KIT and PDGFRA wild-type patients, while subtypes of KIT exon  11 mutations (deletion, insertation/duplication, point mutation) did not affect OS outcome (PMID: 28196207; NCT00009906).",Actionable,11705,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,"[{'id': 9713, 'pubMedId': 28196207, 'title': 'Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28196207'}]",sensitive,770,Imatinib,3815
11,Phase III,"In a Phase III trial, a long-term analysis of gastrointestinal stromal tumor (GIST) patients treated with Gleevec (imatinib) demonstrated patients harboring KIT exon 11 mutations had a median progression-free survival of 39.4 months, and median overall survival was not reached, with 69.1% of patients with KIT exon 11 mutations alive at 5 years (PMID: 26687836; NCT00367861).",Actionable,8571,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,"[{'id': 6690, 'pubMedId': 26687836, 'title': 'Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26687836'}]",sensitive,770,Imatinib,3815
12,Phase II,"In a Phase II trial, Iclusig (ponatinib) treatment resulted in partial response in 7% (2/27), stable disease in 59% (16/27), a median progression free survival of 4.3 months and a median overall survival of 15.0 months in gastrointestinal stromal tumor patients harboring KIT exon 11 mutations after prior tyrosine kinase inhibitor treatment failure (J Clin Oncol 33, 2015 (suppl; abstr 10535)).",Actionable,8608,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,"[{'id': 6695, 'pubMedId': None, 'title': 'Ponatinib efficacy and safety in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure: Results from a phase 2 study.', 'url': 'http://meetinglibrary.asco.org/content/148063-156'}]",predicted – sensitive,877,Ponatinib,3815
13,Clinical Study,"In a retrospective analysis, GIST patients with KIT exon 11 mutations showed decreased benefit compared to patients with exon 9 mutations, with median PFS of 7.0 months with exon 11 mutations vs. 12.3 months with exon 9 mutations, and an ORR of 6% (9/143) vs. 19% (8/42) following treatment with Sutent (sunitinib) (PMID: 26772734).",Actionable,5010,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,"[{'id': 4833, 'pubMedId': 26772734, 'title': 'Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26772734'}]",decreased response,930,Sunitinib,3815
14,Phase II,"In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41), which included a partial response of 38.5% (10/26) and a progression free survival of 5.4 months in melanoma patients harboring KIT exon 11 mutations (PMID: 28327988). ",Actionable,11229,1909,melanoma,DOID,19852,KIT exon 11,"[{'id': 9177, 'pubMedId': 28327988, 'title': 'Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28327988'}]",sensitive,829,Nilotinib,3815
15,Phase II,"In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 5% (1/19) and partial response in 21% (4/19) of melanoma patients harboring KIT exon 11 or exon 13 mutations (PMID: 28843487; NCT01168050).",Actionable,11854,1909,melanoma,DOID,19852,KIT exon 11,"[{'id': 9871, 'pubMedId': 28843487, 'title': 'STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28843487'}]",sensitive,829,Nilotinib,3815
16,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of PKF118-310 and Gleevec (imatinib) resulted in decreased viability of gastrointestinal stromal tumor (GIST) cell lines harboring KIT exon 11 mutations compared to Gleevec (imatinib) alone, in culture (PMID: 28611108).",Actionable,11959,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,"[{'id': 9934, 'pubMedId': 28611108, 'title': 'Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28611108'}]",sensitive,6216,Imatinib + PKF118-310,3815
17,Preclinical - Cell line xenograft,"In a preclinical study, DCC-2618 inhibited Kit phosphorylation and tumor growth in a gastrointestinal stromal tumor cell line xenograft model harboring a KIT exon 11 deletion mutation (Cancer Res 2015;75(15 Suppl):Abstract nr 2690).",Actionable,8602,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,"[{'id': 6694, 'pubMedId': None, 'title': 'Abstract 2690: DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/2690'}]",predicted – sensitive,4316,DCC-2618,3815
18,Preclinical - Cell culture,"In a preclinical study, the combination of Gleevec (imatinib) and MK2206 demonstrated synergy in inhibiting growth of a Gleevec (imatinib)-resistant gastrointestinal stromal tumor cell line harboring a KIT exon 11 deletion mutation and KIT V654A in culture (PMID: 27370604).",Actionable,9690,9253,gastrointestinal stromal tumor,DOID,26979,KIT exon 11 KIT V654A,"[{'id': 7483, 'pubMedId': 27370604, 'title': 'Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27370604'}]",sensitive,5163,Imatinib + MK2206,3815
19,Preclinical - Cell culture,"In a preclinical study, the combination of Gleevec (imatinib) and MK2206 demonstrated synergy in inhibiting growth of a Gleevec (imatinib)-resistant gastrointestinal stromal tumor cell line harboring a KIT exon 11 mutation and KIT A829P in culture (PMID: 27370604).",Actionable,9689,9253,gastrointestinal stromal tumor,DOID,26978,KIT exon 11 KIT A829P,"[{'id': 7483, 'pubMedId': 27370604, 'title': 'Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27370604'}]",sensitive,5163,Imatinib + MK2206,3815
20,Phase I,"In a Phase I trial, BLU-285 demonstrated preliminary antitumor activity in gastrointestinal stromal tumor patients harboring KIT mutations, with reduced tumor burden in 38% (5/13) of patients, including 1 partial response and 4 stable diseases, and 3 of the 5 responding patients harbored KIT exon 17 mutations (EORTC-NCI-AACR 2016, Abs 6LBA). ",Actionable,9776,9253,gastrointestinal stromal tumor,DOID,27079,KIT exon 17,"[{'id': 7597, 'pubMedId': None, 'title': 'Preliminary safety and activity in a first-in-human phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT and PDGFRa activation loop mutants in advanced gastrointestinal stromal tumor (GIST)', 'url': 'http://www.ecco-org.eu/Events/ENA2016/Searchable-Programme#anchorScpr'}]",sensitive,2941,BLU-285,3815
21,Preclinical - Pdx,"In a preclinical study, Cometriq (Cabometyx, cabozantinib) slowed tumor growth and decreased mitotic activity in a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT mutations, P577del, W557Lfs*5, and D820G (PMID: 27777285).  ",Actionable,9596,9253,gastrointestinal stromal tumor,DOID,26916,KIT P577del KIT W557Lfs*5 KIT D820G,"[{'id': 7300, 'pubMedId': 27777285, 'title': 'Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27777285'}]",sensitive,998,cabozantinib,3815
22,Preclinical - Pdx,"In a preclinical study, a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT mutations, P577del, W557Lfs*5, and D820G, demonstrated resistance to treatment with Gleevec (imatinib) (PMID: 27777285). ",Actionable,9593,9253,gastrointestinal stromal tumor,DOID,26916,KIT P577del KIT W557Lfs*5 KIT D820G,"[{'id': 7300, 'pubMedId': 27777285, 'title': 'Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27777285'}]",resistant,770,Imatinib,3815
23,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6908,10000003,Advanced Solid Tumor,JAX,24008,KIT W557_K558del KIT D820G,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,770,Imatinib,3815
24,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6913,10000003,Advanced Solid Tumor,JAX,24008,KIT W557_K558del KIT D820G,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,890,Regorafenib,3815
25,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6898,10000003,Advanced Solid Tumor,JAX,24008,KIT W557_K558del KIT D820G,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
26,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6903,10000003,Advanced Solid Tumor,JAX,24008,KIT W557_K558del KIT D820G,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,930,Sunitinib,3815
27,Preclinical - Pdx,"In a preclinical study, a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT A502_Y503dup demonstrated resistance to treatment with Gleevec (imatinib), resulting in increased tumor volume (PMID: 27777285). ",Actionable,9592,9253,gastrointestinal stromal tumor,DOID,10919,KIT A502_Y503dup,"[{'id': 7300, 'pubMedId': 27777285, 'title': 'Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27777285'}]",resistant,770,Imatinib,3815
28,Preclinical - Pdx,"In a preclinical study, Cometriq (Cabometyx, cabozantinib) resulted in decreased tumor volume and reduced mitotic activity in a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT A502_Y503dup (PMID: 27777285).  ",Actionable,9595,9253,gastrointestinal stromal tumor,DOID,10919,KIT A502_Y503dup,"[{'id': 7300, 'pubMedId': 27777285, 'title': 'Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27777285'}]",sensitive,998,cabozantinib,3815
29,Preclinical,"In a preclinical study, a gastrointestinal stromal tumor cell line harboring KIT V560D and KIT D820A demonstrated resistance to Sutent (sunitinib) in culture (PMID: 18955458).",Actionable,2681,9253,gastrointestinal stromal tumor,DOID,10025,KIT D820A KIT V560D,"[{'id': 3383, 'pubMedId': 18955458, 'title': 'Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18955458'}]",resistant,930,Sunitinib,3815
30,Preclinical,"In a preclinical study, a gastrointestinal stromal tumor cell line harboring KIT V560D and KIT D820A demonstrated resistance to Gleevec (imatinib) in culture (PMID: 16954519).",Actionable,2680,9253,gastrointestinal stromal tumor,DOID,10025,KIT D820A KIT V560D,"[{'id': 713, 'pubMedId': 16954519, 'title': 'Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16954519'}]",resistant,770,Imatinib,3815
31,Preclinical - Cell culture,"In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing KIT V560D in culture (PMID: 20633291).",Actionable,11824,10000003,Advanced Solid Tumor,JAX,1698,KIT V560D,"[{'id': 9827, 'pubMedId': 20633291, 'title': 'Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20633291'}]",sensitive,824,Motesanib,3815
32,Preclinical,"In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6759,10000003,Advanced Solid Tumor,JAX,1698,KIT V560D,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,930,Sunitinib,3815
33,Preclinical,"In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6758,10000003,Advanced Solid Tumor,JAX,1698,KIT V560D,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
34,Phase II,"In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT V560D demonstrating a partial response and progression free survival of 8.6 months and overall survival of 23.5 months (PMID: 28327988). ",Actionable,11236,1909,melanoma,DOID,1698,KIT V560D,"[{'id': 9177, 'pubMedId': 28327988, 'title': 'Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28327988'}]",sensitive,829,Nilotinib,3815
35,Preclinical,"In a preclinical study, transformed cells expressing KIT V560D were sensitive to Nexavar (sorafenib) in culture (PMID: 22665524).",Actionable,2535,10000003,Advanced Solid Tumor,JAX,1698,KIT V560D,"[{'id': 3258, 'pubMedId': 22665524, 'title': 'Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22665524'}]",sensitive,920,Sorafenib,3815
36,Preclinical,"In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Stivarga (regorafineb) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6761,10000003,Advanced Solid Tumor,JAX,1698,KIT V560D,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,890,Regorafenib,3815
37,Preclinical,"In a preclinical study, transformed cells expressing KIT V560D were sensitive to Sprycel (dasatinib) in culture (PMID: 16397263).",Actionable,2538,10000003,Advanced Solid Tumor,JAX,1698,KIT V560D,"[{'id': 657, 'pubMedId': 16397263, 'title': 'Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16397263'}]",sensitive,717,Dasatinib,3815
38,Preclinical,"In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6760,10000003,Advanced Solid Tumor,JAX,1698,KIT V560D,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,770,Imatinib,3815
39,Preclinical - Cell culture,"In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing a KIT V560D/V654A double mutation in culture (PMID: 20633291).",Actionable,11833,10000003,Advanced Solid Tumor,JAX,28309,KIT V560D KIT V654A,"[{'id': 9827, 'pubMedId': 20633291, 'title': 'Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20633291'}]",sensitive,824,Motesanib,3815
40,Preclinical - Cell culture,"In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing a KIT V560D/T670I double mutation in culture (PMID: 20633291).",Actionable,11834,10000003,Advanced Solid Tumor,JAX,28308,KIT T670I KIT V560D,"[{'id': 9827, 'pubMedId': 20633291, 'title': 'Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20633291'}]",sensitive,824,Motesanib,3815
41,Clinical Study,"In a clinical case study, a GIST patient harboring KIT S476I and MET R988C demonstrated sensitivity to the combination treatment, Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for 6 months (PMID: 25363205). ",Actionable,7766,9253,gastrointestinal stromal tumor,DOID,26035,KIT S476I MET R988C,"[{'id': 6478, 'pubMedId': 25363205, 'title': 'Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25363205'}]",sensitive,4517,Bevacizumab + Sorafenib,3815
42,Preclinical - Patient cell culture,"In a preclinical study, treatment with Tasigna (nilotinib) decreased proliferation of patient-derived neoplastic mast cells harboring KIT S476I in culture (PMID: 25209843).",Actionable,11811,9254,mast-cell leukemia,DOID,1637,KIT S476I,"[{'id': 9857, 'pubMedId': 25209843, 'title': 'Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25209843'}]",predicted – sensitive,829,Nilotinib,3815
43,Preclinical - Patient cell culture,"In a preclinical study, treatment with Rydapt (midostaurin) decreased proliferation of patient-derived neoplastic mast cells harboring KIT S476I in culture (PMID: 25209843).",Actionable,11810,9254,mast-cell leukemia,DOID,1637,KIT S476I,"[{'id': 9857, 'pubMedId': 25209843, 'title': 'Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25209843'}]",predicted – sensitive,810,Midostaurin,3815
44,Clinical Study,"In a clinical study, a GIST patient harboring KIT M552_K558del, resistant to multiple tyrosine kinase inhibitors, demonstrated resistance to Iclusig (ponatinib) treatment as indicated by disease progression after 4 weeks of treatment (PMID: 25239608). ",Actionable,6810,9253,gastrointestinal stromal tumor,DOID,23707,KIT M552_K558del,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,877,Ponatinib,3815
45,Phase II,"In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT W557R demonstrating a partial response and progression free survival of 35.4 months and overall survival of 35.4 months (PMID: 28327988). ",Actionable,11238,1909,melanoma,DOID,995,KIT W557R,"[{'id': 9177, 'pubMedId': 28327988, 'title': 'Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28327988'}]",sensitive,829,Nilotinib,3815
46,Phase II,"In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient co-harboring KIT L576P and KIT W557R demonstrating a partial response and a progression free survival of 5.3 months and overall survival of 14.7 months when treated with Tasigna (nilotinib) (PMID: 28327988). ",Actionable,11232,1909,melanoma,DOID,27931,KIT L576P KIT W557R,"[{'id': 9177, 'pubMedId': 28327988, 'title': 'Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28327988'}]",sensitive,829,Nilotinib,3815
47,Preclinical - Cell culture,"In a preclinical study, an acute myeloid leukemia cell line harboring KIT wild-type was sensitive to BPR1J373 in culture, demonstrating apoptotic induction and inhibition of cell proliferation (PMID: 27512117). ",Actionable,8706,9119,acute myeloid leukemia,DOID,582,KIT wild-type,"[{'id': 6711, 'pubMedId': 27512117, 'title': 'BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27512117'}]",sensitive,4798,BPR1J373,3815
48,Preclinical,"In a preclinical study, cells expressing KIT V560G demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).  ",Actionable,6752,10000003,Advanced Solid Tumor,JAX,1675,KIT V560G,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
49,Preclinical,"In a preclinical study, transformed cells expressing KIT V560G demonstrated inhibition of cell proliferation and tumor regression both in culture and in vivo when treated with Tasigna (nilotinib) (PMID: 20442311). ",Actionable,2540,10000003,Advanced Solid Tumor,JAX,1675,KIT V560G,"[{'id': 3260, 'pubMedId': 20442311, 'title': 'Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20442311'}]",sensitive,829,Nilotinib,3815
50,Preclinical,"In a preclinical study, KIT D816V conferred resistance to Quizartinib in a mast cell line harboring both KIT V560G and KIT D816V in culture (PMID: 23497317).",Actionable,3600,3664,mast cell neoplasm,DOID,13758,KIT D816V KIT V560G,"[{'id': 3862, 'pubMedId': 23497317, 'title': 'Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23497317'}]",resistant,882,Quizartinib,3815
51,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited growth of a human mast cell line harboring both KIT V560G and KIT D816V in culture (PMID: 24552773).",Actionable,3592,9254,mast-cell leukemia,DOID,13758,KIT D816V KIT V560G,"[{'id': 3870, 'pubMedId': 24552773, 'title': 'Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24552773'}]",sensitive,877,Ponatinib,3815
52,Preclinical - Cell culture,"In a preclinical study, a mast-cell leukemia cell line simultaneously harboring KIT D816V and KIT V560G was sensitive to BPR1J373 in culture, demonstrating inhibition of Kit phosphorylation and apoptotic activity (PMID: 27512117). ",Actionable,8709,9254,mast-cell leukemia,DOID,13758,KIT D816V KIT V560G,"[{'id': 6711, 'pubMedId': 27512117, 'title': 'BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27512117'}]",sensitive,4798,BPR1J373,3815
53,Preclinical,"In a preclinical study, Sprycel (dasatinib) inhibited growth and induced apoptosis in a mast-cell leukemia cell line harboring both KIT V560G and KIT D816V in culture (PMID: 18024392).",Actionable,3562,9254,mast-cell leukemia,DOID,13758,KIT D816V KIT V560G,"[{'id': 3822, 'pubMedId': 18024392, 'title': 'Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18024392'}]",sensitive,717,Dasatinib,3815
54,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820A were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6902,10000003,Advanced Solid Tumor,JAX,24007,KIT W557_K558del KIT D820A,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,930,Sunitinib,3815
55,Preclinical,"In a preclinical study, transformed cells co-expressing W557_K558del and KIT D820A were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6907,10000003,Advanced Solid Tumor,JAX,24007,KIT W557_K558del KIT D820A,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,770,Imatinib,3815
56,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820A were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6897,10000003,Advanced Solid Tumor,JAX,24007,KIT W557_K558del KIT D820A,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
57,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820A were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6912,10000003,Advanced Solid Tumor,JAX,24007,KIT W557_K558del KIT D820A,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,890,Regorafenib,3815
58,Clinical Study,"In a clinical case report, Gleevec (imatinib) in conjunction with third-line chemotherapy resulted in a complete response in a patient with stage IV chemoresistant pure seminoma with KIT over expression (PMID: 18751412).",Actionable,673,4440,seminoma,DOID,852,KIT over exp,"[{'id': 391, 'pubMedId': 18751412, 'title': 'Complete response after imatinib mesylate administration in a patient with chemoresistant stage IV seminoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18751412'}]",sensitive,770,Imatinib,3815
59,Clinical Study,"In a clinical case report, a patient with metastatic thymic carcinoma harboring KIT V560del with KIT over expression initially demonstrated stable disease and reduction in metastatic lesions following treatment with Gleevec (imatinib), but progressed after 6 months (PMID: 15201427).",Actionable,6748,3284,thymic carcinoma,DOID,23682,KIT V560del KIT over exp,"[{'id': 5814, 'pubMedId': 15201427, 'title': 'Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15201427'}]",sensitive,770,Imatinib,3815
60,Phase I,"In a Phase I trial, DCC-2618 demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including a partial response in a glioblastoma multiforme patient harboring KIT and PDGFRA amplification (EORTC-NCI-AACR 2016, Abs 7LBA).",Actionable,9778,3068,glioblastoma multiforme,DOID,27080,KIT amp PDGFRA amp,"[{'id': 7598, 'pubMedId': None, 'title': 'DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study', 'url': 'http://www.ecco-org.eu/Events/ENA2016/Searchable-Programme#anchorScpr'}]",sensitive,4316,DCC-2618,3815
61,Preclinical - Cell culture,"In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing KIT Y823D in culture (PMID: 20633291).",Actionable,11829,10000003,Advanced Solid Tumor,JAX,1652,KIT Y823D,"[{'id': 9827, 'pubMedId': 20633291, 'title': 'Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20633291'}]",sensitive,824,Motesanib,3815
62,Preclinical - Pdx,"In a preclinical study, DCC-2618 induced tumor regression in a patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT W557_K558del and KIT Y823D (Cancer Res 2015;75(15 Suppl):Abstract nr 2690).",Actionable,8605,9253,gastrointestinal stromal tumor,DOID,23695,KIT W557_K558del KIT Y823D,"[{'id': 6694, 'pubMedId': None, 'title': 'Abstract 2690: DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/2690'}]",sensitive,4316,DCC-2618,3815
63,Preclinical - Pdx & cell culture,"In a preclinical study, a patient derived GIST cell line co-harboring KIT W557_K558del and KIT Y823D demonstrated sensitivity to Iclusig (ponatinib) in a PDX model, resulting in complete tumor regression (PMID: 25239608). ",Actionable,6807,9253,gastrointestinal stromal tumor,DOID,23695,KIT W557_K558del KIT Y823D,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
64,Preclinical,"In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT A829P demonstrated a decreased response to treatment with Sutent (sunitinib) (PMID: 25239608). ",Actionable,6804,9253,gastrointestinal stromal tumor,DOID,23694,KIT V560_Y578del KIT A829P,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",decreased response,930,Sunitinib,3815
65,Preclinical,"In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT D816E demonstrated a decreased response to treatment with Sutent (sunitinib) (PMID: 25239608). ",Actionable,6803,9253,gastrointestinal stromal tumor,DOID,23693,KIT V560_Y578del KIT D816E,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",decreased response,930,Sunitinib,3815
66,Preclinical - Cell culture,"In a preclinical study, BGJ398 and Gleevec (imatinib mesylate) combination treatment demonstrated enhanced antiproliferative activity in gastrointestinal stromal tumor cells harboring KIT V560_Y578del in culture (PMID: 25673643).",Actionable,7786,9253,gastrointestinal stromal tumor,DOID,23687,KIT V560_Y578del,"[{'id': 6494, 'pubMedId': 25673643, 'title': 'FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25673643'}]",sensitive,2284,BGJ398 + Imatinib,3815
67,Preclinical,"In a preclinical study, a patient derived GIST cell line harboring KIT V560_Y578del demonstrated sensitivity to Gleevec (imatinib) in culture (PMID: 25239608). ",Actionable,6799,9253,gastrointestinal stromal tumor,DOID,23687,KIT V560_Y578del,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,770,Imatinib,3815
68,Preclinical - Patient cell culture,"In a preclinical study, a patient-derived gastrointestinal stromal tumor (GIST) cell line harboring KIT V560_Y578del demonstrated sensitivity to Iclusig (ponatinib) in culture (PMID: 25239608). ",Actionable,6798,9253,gastrointestinal stromal tumor,DOID,23687,KIT V560_Y578del,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
69,Preclinical,"In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT T670I demonstrated sensitivity to treatment with Iclusig (ponatinib) (PMID: 25239608). ",Actionable,6801,9253,gastrointestinal stromal tumor,DOID,23692,KIT V560_Y578del KIT T670I,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
70,Preclinical,"In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT T670I demonstrated sensitivity to treatment with Sutent (sunitinib) (PMID: 25239608). ",Actionable,6802,9253,gastrointestinal stromal tumor,DOID,23692,KIT V560_Y578del KIT T670I,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,930,Sunitinib,3815
71,Preclinical,"In a preclinical study, cells expressing KIT V654A demonstrated some sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).  ",Actionable,6757,10000003,Advanced Solid Tumor,JAX,1659,KIT V654A,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
72,Preclinical,"In a preclinical study, cells expressing KIT V654A demonstrated resistance to Gleevec (imatinib) in culture (PMID: 16751810). ",Actionable,6742,10000003,Advanced Solid Tumor,JAX,1659,KIT V654A,"[{'id': 5804, 'pubMedId': 16751810, 'title': 'Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16751810'}]",resistant,770,Imatinib,3815
73,Preclinical - Cell culture,"In a preclinical study, Tasigna (nilotinib) inhibited proliferation of transformed cells expressing a KIT V560del/V654A double mutation in culture (PMID: 17699867).",Actionable,11842,10000003,Advanced Solid Tumor,JAX,28310,KIT V560del KIT V654A,"[{'id': 676, 'pubMedId': 17699867, 'title': 'Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17699867'}]",sensitive,829,Nilotinib,3815
74,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT V654A demonstrated sensitivity to treatment with Sutent (sunitinib) in both culture and cell line xenograft models, resulting in reduced cell viability, decreased tumor volume, and tumor regression (PMID: 25239608). ",Actionable,6784,10000003,Advanced Solid Tumor,JAX,23688,KIT W557_K558del KIT V654A,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,930,Sunitinib,3815
75,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT V654A demonstrated no response to treatment with Gleevec (imatinib) in both culture and xenograft models (PMID: 25239608). ",Actionable,6785,10000003,Advanced Solid Tumor,JAX,23688,KIT W557_K558del KIT V654A,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",no benefit,770,Imatinib,3815
76,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT V654A demonstrated sensitivity to treatment with Iclusig (ponatinib) in both culture and cell line xenograft models, resulting in reduced cell viability and decreased tumor volume (PMID: 25239608). ",Actionable,6783,10000003,Advanced Solid Tumor,JAX,23688,KIT W557_K558del KIT V654A,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
77,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT V654A demonstrated resistance to treatment with Stivarga (regorafenib) in culture (PMID: 25239608). ",Actionable,6786,10000003,Advanced Solid Tumor,JAX,23688,KIT W557_K558del KIT V654A,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,890,Regorafenib,3815
78,Phase I,"In Phase I trials, KIT M541L has been associated with response to Gleevec (imatinib) in chronic eosinophilic leukemia, NOS (PMID: 25015329) and mastocytosis (PMID: 18795925).
",Actionable,1074,1036,chronic leukemia,DOID,1113,KIT M541L,"[{'id': 460, 'pubMedId': 18795925, 'title': 'Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18795925'}, {'id': 462, 'pubMedId': 25015329, 'title': 'Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25015329'}]",sensitive,770,Imatinib,3815
79,Clinical Study,"In a clinical case report, a patient with advanced thymic carcinoma harboring KIT P577_D579del demonstrated response to treatment with Nexavar (sorafenib), with a decrease in tumor size (PMID: 20970876).",Actionable,6749,3284,thymic carcinoma,DOID,23683,KIT P577_D579del,"[{'id': 5815, 'pubMedId': 20970876, 'title': 'Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20970876'}]",sensitive,920,Sorafenib,3815
80,Clinical Study,"In a clinical case report, a patient with thymic carcinoma harboring KIT D579del achieved disease stabilization following treatment with Gleevec (imatinib) (PMID: 24419427).",Actionable,6746,3284,thymic carcinoma,DOID,1700,KIT D579del,"[{'id': 5812, 'pubMedId': 24419427, 'title': 'Stabilization of disease after targeted therapy in a thymic carcinoma with KIT mutation detected by clinical next-generation sequencing.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419427'}]",sensitive,770,Imatinib,3815
81,Preclinical,"In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation efficiently in transformed human cells over expressing KIT W557G in culture (PMID: 23567324).",Actionable,6878,10000003,Advanced Solid Tumor,JAX,1639,KIT W557G,"[{'id': 647, 'pubMedId': 23567324, 'title': 'Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23567324'}]",sensitive,770,Imatinib,3815
82,Preclinical - Cell culture,"In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing KIT M552_V559del in culture (PMID: 20633291).",Actionable,11827,10000003,Advanced Solid Tumor,JAX,28307,KIT M552_V559del,"[{'id': 9827, 'pubMedId': 20633291, 'title': 'Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20633291'}]",sensitive,824,Motesanib,3815
83,Preclinical,"In a preclinical study, Gleevec (imatinib) inhibited growth of transformed cell lines over expressing KIT V560del in culture (PMID: 19861435).",Actionable,4366,10000003,Advanced Solid Tumor,JAX,3289,KIT V560del,"[{'id': 670, 'pubMedId': 19861435, 'title': 'Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19861435'}]",sensitive,770,Imatinib,3815
84,Preclinical,"In a preclinical study, Sutent (sunitinib) inhibited growth of transformed cell lines over expressing KIT V560del in culture (PMID: 19861435).",Actionable,4367,10000003,Advanced Solid Tumor,JAX,3289,KIT V560del,"[{'id': 670, 'pubMedId': 19861435, 'title': 'Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19861435'}]",sensitive,930,Sunitinib,3815
85,Clinical Study,"In a clinical case study, Gleevec (imatinib) treatment in a patient with metastatic melanoma resulted in regression of the lung metastasis, which harbored KIT V559A, however, neither the primary tumor or lymph node metastasis responded, which had wild-type KIT (PMID: 19812602).",Actionable,11823,1909,melanoma,DOID,1640,KIT V559A,"[{'id': 9862, 'pubMedId': 19812602, 'title': 'Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19812602'}]",predicted – sensitive,770,Imatinib,3815
86,Phase II,"In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT V559A demonstrating a partial response and progression free survival of 19.4 months and overall survival of 32.9 months (PMID: 28327988). ",Actionable,11235,1909,melanoma,DOID,1640,KIT V559A,"[{'id': 9177, 'pubMedId': 28327988, 'title': 'Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28327988'}]",sensitive,829,Nilotinib,3815
87,Guideline,Gleevec (imatinib) is an active regimen for melanoma patients with wild-type BRAF and a c-KIT positive mutation (Guidelines). ,Actionable,1938,1909,melanoma,DOID,4361,BRAF wild-type KIT positive,"[{'id': 1442, 'pubMedId': None, 'title': 'NCCN Guidelines Melanoma version 3.2015', 'url': 'http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf'}]",sensitive,770,Imatinib,3815
88,FDA approved,"In a Phase II trial that supported FDA approval, treatment with Gleevec (imatinib) resulted in a 38% overall response rate in patients with c-KIT positive GIST (PMID: 12374669). ",Actionable,716,9253,gastrointestinal stromal tumor,DOID,851,KIT positive,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 2369, 'pubMedId': 12374669, 'title': 'Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12374669'}]",sensitive,770,Imatinib,3815
89,Preclinical,"In a preclinical study, a prostate neuroendocrine tumor mouse model expressing Kit did not respond to Gleevec (imatinib), a result of impaired signaling of the Kit pathway (PMID: 27980106). ",Actionable,9913,2992,prostate neuroendocrine neoplasm,DOID,851,KIT positive,"[{'id': 7757, 'pubMedId': 27980106, 'title': 'Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial-Stromal Tumors by Targeting PDGFR-β.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27980106'}]",no benefit,770,Imatinib,3815
90,Phase II,"In a small Phase II study, 18 patients with KIT-positive refractory germ cell tumors treated with Gleevec (imatinib) experienced no significant antitumor activity (PMID: 16462496).",Actionable,672,2994,germ cell cancer,DOID,851,KIT positive,"[{'id': 390, 'pubMedId': 16462496, 'title': 'Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16462496'}]",resistant,770,Imatinib,3815
91,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) inhibited growth and induced apoptosis of transformed cells expressing KIT N822I in culture (PMID: 21689725).",Actionable,11819,10000003,Advanced Solid Tumor,JAX,1651,KIT N822I,"[{'id': 662, 'pubMedId': 21689725, 'title': 'Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21689725'}]",sensitive,717,Dasatinib,3815
92,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing KIT N822I demonstrated resistance to Gleevec (imatinib) in culture (PMID: 21689725).",Actionable,11818,10000003,Advanced Solid Tumor,JAX,1651,KIT N822I,"[{'id': 662, 'pubMedId': 21689725, 'title': 'Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21689725'}]",resistant,770,Imatinib,3815
93,Clinical Study,"In a clinical study, a GIST patient harboring KIT K558_V560del and KIT W557C, resistant to Gleevec (imatinib), Sutent (sunitinib), and Stivarga (regorafenib), demonstrated sensitivity when treated with Iclusig (ponatinib), which resulted in a radiologic response and stabilization for six months (PMID: 25239608). ",Actionable,6808,9253,gastrointestinal stromal tumor,DOID,23705,KIT K558_V560del KIT W557C,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
94,Preclinical,"In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation efficiently in transformed human cells over expressing both KIT W557C and KIT Y578C in culture (PMID: 23567324).",Actionable,6880,10000003,Advanced Solid Tumor,JAX,23934,KIT W557C KIT Y578C,"[{'id': 647, 'pubMedId': 23567324, 'title': 'Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23567324'}]",sensitive,770,Imatinib,3815
95,Preclinical - Pdx,"In a preclinical study, Nexavar (sorafenib) inhibited Erk signaling, induced apoptosis, resulted in tumor growth inhibition in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT P551_V555delinsTL (PMID: 19139124).",Actionable,8618,9253,gastrointestinal stromal tumor,DOID,26378,KIT P551_V555delinsTL,"[{'id': 6701, 'pubMedId': 19139124, 'title': 'Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19139124'}]",sensitive,920,Sorafenib,3815
96,Clinical Study,"In a retrospective analysis, GIST patients with KIT exon 9 mutations showed improved progression-free survival (PFS), overall survival, and objective response rate (ORR) compared to patients with exon 11 mutations, with a median PFS of 12.3 months vs. 7.0 months, and an ORR of 19% (8/42) vs. 6% (9/143) following treatment with Sutent (sunitinib) (PMID: 26772734).",Actionable,5009,9253,gastrointestinal stromal tumor,DOID,19853,KIT exon 9,"[{'id': 4833, 'pubMedId': 26772734, 'title': 'Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26772734'}]",predicted – sensitive,930,Sunitinib,3815
97,Preclinical,"In a preclinical study, transformed cells expressing a KIT exon 9 mutation demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6762,10000003,Advanced Solid Tumor,JAX,19853,KIT exon 9,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
98,Preclinical,"In a preclinical study, Gleevec (imatinib) had no effect on transformed cells expressing a KIT exon 9 mutation in culture (PMID: 25239608). ",Actionable,6764,10000003,Advanced Solid Tumor,JAX,19853,KIT exon 9,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,770,Imatinib,3815
99,Preclinical,"In a preclinical study, Stivarga (regorafineb) had no effect on transformed cells expressing a KIT exon 9 mutation in culture (PMID: 25239608). ",Actionable,6765,10000003,Advanced Solid Tumor,JAX,19853,KIT exon 9,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,890,Regorafenib,3815
100,Preclinical,"In a preclinical study, transformed cells expressing a KIT exon 9 mutation demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6763,10000003,Advanced Solid Tumor,JAX,19853,KIT exon 9,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,930,Sunitinib,3815
101,Preclinical,"In a preclinical study, Sutent (sunitinib) inhibited growth of transformed cell lines overexpressing KIT H697Y in culture (PMID: 19861435).",Actionable,4364,10000003,Advanced Solid Tumor,JAX,1656,KIT H697Y,"[{'id': 670, 'pubMedId': 19861435, 'title': 'Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19861435'}]",sensitive,930,Sunitinib,3815
102,Preclinical,"In a preclinical study, transformed cell lines overexpressing KIT H697Y demonstrated reduced sensitivity to Gleevec (imatinib mesylate)-induced growth inhibition in culture (PMID: 19861435).",Actionable,4365,10000003,Advanced Solid Tumor,JAX,1656,KIT H697Y,"[{'id': 670, 'pubMedId': 19861435, 'title': 'Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19861435'}]",decreased response,770,Imatinib,3815
103,Clinical Study,"In a clinical study, a GIST patient harboring KIT P551_W557delinsL, resistant to Gleevec (imatinib), Sutent (sunitinib), and Stivarga (regorafenib), demonstrated sensitivity to Iclusig (ponatinib) treatment, which resulted in tumor regression and stable disease (PMID: 25239608). ",Actionable,6809,9253,gastrointestinal stromal tumor,DOID,23708,KIT P551_W557delinsL,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
104,Preclinical - Cell culture,"In a preclinical study, DCC-2618 inhibited proliferation of a mouse mastocytosis cell line expressing KIT K816Y in culture (Cancer Res 2015;75(15 Suppl):Abstract nr 2690).",Actionable,8604,3664,mast cell neoplasm,DOID,1649,KIT D816Y,"[{'id': 6694, 'pubMedId': None, 'title': 'Abstract 2690: DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/2690'}]",sensitive,4316,DCC-2618,3815
105,Preclinical,"In a preclinical study, melanoma cells expressing KIT A829P demonstrated resistance to treatment with Gleevec (imatinib mesylate) (PMID: 23582185, PMID: 25594040).",Actionable,1811,1909,melanoma,DOID,1653,KIT A829P,"[{'id': 2193, 'pubMedId': 23582185, 'title': 'Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23582185'}, {'id': 2194, 'pubMedId': 25594040, 'title': 'Resistance to c-Kit inhibitors in melanoma: insights for future therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25594040'}]",resistant,770,Imatinib,3815
106,Preclinical,"In a preclinical study, cells expressing KIT A829P demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).  ",Actionable,6756,10000003,Advanced Solid Tumor,JAX,1653,KIT A829P,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
107,Preclinical,"In a preclinical study, melanoma cells expressing KIT A829P demonstrated resistance to treatment with Sutent (sunitinib) (PMID: 23582185, PMID: 25594040).",Actionable,1812,1909,melanoma,DOID,1653,KIT A829P,"[{'id': 2193, 'pubMedId': 23582185, 'title': 'Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23582185'}, {'id': 2194, 'pubMedId': 25594040, 'title': 'Resistance to c-Kit inhibitors in melanoma: insights for future therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25594040'}]",resistant,930,Sunitinib,3815
108,Preclinical,"In a preclinical study, Sprycel (dasatinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT A829P (PMID: 23582185, PMID: 25594040). ",Actionable,1814,1909,melanoma,DOID,1653,KIT A829P,"[{'id': 2193, 'pubMedId': 23582185, 'title': 'Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23582185'}, {'id': 2194, 'pubMedId': 25594040, 'title': 'Resistance to c-Kit inhibitors in melanoma: insights for future therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25594040'}]",sensitive,717,Dasatinib,3815
109,Preclinical,"In a preclinical study, Tasigna (nilotinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT A829P (PMID: 23582185, PMID: 25594040).",Actionable,1813,1909,melanoma,DOID,1653,KIT A829P,"[{'id': 2193, 'pubMedId': 23582185, 'title': 'Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23582185'}, {'id': 2194, 'pubMedId': 25594040, 'title': 'Resistance to c-Kit inhibitors in melanoma: insights for future therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25594040'}]",sensitive,829,Nilotinib,3815
110,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Sutent (sunitinb) in an in vitro kinase assay (PMID: 25239608).",Actionable,6905,10000003,Advanced Solid Tumor,JAX,24011,KIT W557_K558del KIT A829P,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,930,Sunitinib,3815
111,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6915,10000003,Advanced Solid Tumor,JAX,24011,KIT W557_K558del KIT A829P,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,890,Regorafenib,3815
112,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6910,10000003,Advanced Solid Tumor,JAX,24011,KIT W557_K558del KIT A829P,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,770,Imatinib,3815
113,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6900,10000003,Advanced Solid Tumor,JAX,24011,KIT W557_K558del KIT A829P,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
114,Preclinical,"In a preclinical study, transformed cells expressing K558delinsNP demonstrated sensitivity to treatment with Stivarga (regorafenib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6782,10000003,Advanced Solid Tumor,JAX,23686,KIT K558delinsNP,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,890,Regorafenib,3815
115,Preclinical,"In a preclinical study, transformed cells expressing KIT K558delinsNP demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6781,10000003,Advanced Solid Tumor,JAX,23686,KIT K558delinsNP,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,770,Imatinib,3815
116,Preclinical,"In a preclinical study, transformed cells expressing K558delinsNP demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6780,10000003,Advanced Solid Tumor,JAX,23686,KIT K558delinsNP,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,930,Sunitinib,3815
117,Preclinical,"In a preclinical study, transformed cells expressing KIT K558delinsNP demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6779,10000003,Advanced Solid Tumor,JAX,23686,KIT K558delinsNP,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
118,Clinical Study,"In a clinical case report, Nexavar (sorafenib) treatment resulted in stable disease in a patient with anal melanoma and pulmonary metastases harboring KIT D820Y (PMID: 20372153). ",Actionable,8616,1909,melanoma,DOID,1650,KIT D820Y,"[{'id': 6700, 'pubMedId': 20372153, 'title': 'Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20372153'}]",predicted – sensitive,920,Sorafenib,3815
119,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) inhibited proliferation of transformed cells expressing a KIT V559D/D820Y double mutation in culture (PMID: 17699867).",Actionable,11845,10000003,Advanced Solid Tumor,JAX,28311,KIT D820Y KIT V559D,"[{'id': 676, 'pubMedId': 17699867, 'title': 'Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17699867'}]",sensitive,717,Dasatinib,3815
120,Preclinical - Cell culture,"In a preclinical study, Nexavar (sorafenib) inhibited proliferation of transformed cells expressing a KIT V559D/D820Y double mutation in culture (PMID: 17699867).",Actionable,11846,10000003,Advanced Solid Tumor,JAX,28311,KIT D820Y KIT V559D,"[{'id': 676, 'pubMedId': 17699867, 'title': 'Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17699867'}]",sensitive,920,Sorafenib,3815
121,Preclinical - Cell culture,"In a preclinical study, Tasigna (nilotinib) inhibited proliferation of transformed cells expressing a KIT V559D/D820Y double mutation in culture, with increased potency compared to Sprycel (dasatinib) or Nexavar (sorafenib) (PMID: 17699867).",Actionable,11843,10000003,Advanced Solid Tumor,JAX,28311,KIT D820Y KIT V559D,"[{'id': 676, 'pubMedId': 17699867, 'title': 'Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17699867'}]",sensitive,829,Nilotinib,3815
122,Preclinical - Cell line xenograft,"In a preclinical study, an acute myeloid leukemia cell line harboring KIT N822K demonstrated sensitivity to treatment with BPR1J373, showing inhibition of Kit phosphorylation and apoptotic induction in culture, and tumor regression in xenograft models (PMID: 27512117).",Actionable,8696,9119,acute myeloid leukemia,DOID,3607,KIT N822K,"[{'id': 6711, 'pubMedId': 27512117, 'title': 'BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27512117'}]",sensitive,4798,BPR1J373,3815
123,Clinical Study,"In a clinical case study, KIT N822K was identified in the tumor of a gastrointestinal stromal tumor patient that was resistant to Gleevec (imatinib mesylate) treatment. (PMID: 26316776).",Actionable,6806,9253,gastrointestinal stromal tumor,DOID,3607,KIT N822K,"[{'id': 5823, 'pubMedId': 26316776, 'title': 'Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26316776'}]",resistant,770,Imatinib,3815
124,Preclinical - Cell culture,"In a preclinical study, Iclusig (ponatinib) inhibited Kit signaling and viability in leukemia cells harboring KIT N822K in culture (PMID: 21482694).",Actionable,8003,1240,leukemia,DOID,3607,KIT N822K,"[{'id': 3255, 'pubMedId': 21482694, 'title': 'Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21482694'}]",sensitive,877,Ponatinib,3815
125,Preclinical - Pdx,"In a preclinical study, DCC-2618 induced tumor regression in a patient-derived xenograft (PDX) model of acute myeloid leukemia harboring KIT N822K (Cancer Res 2015;75(15 Suppl):Abstract nr 2690).",Actionable,8606,9119,acute myeloid leukemia,DOID,3607,KIT N822K,"[{'id': 6694, 'pubMedId': None, 'title': 'Abstract 2690: DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/2690'}]",sensitive,4316,DCC-2618,3815
126,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6914,10000003,Advanced Solid Tumor,JAX,24010,KIT W557_K558del KIT N822K,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,890,Regorafenib,3815
127,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were resistant to Sutent (sunitinb) in an in vitro kinase assay (PMID: 25239608).",Actionable,6904,10000003,Advanced Solid Tumor,JAX,24010,KIT W557_K558del KIT N822K,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,930,Sunitinib,3815
128,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6909,10000003,Advanced Solid Tumor,JAX,24010,KIT W557_K558del KIT N822K,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,770,Imatinib,3815
129,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6899,10000003,Advanced Solid Tumor,JAX,24010,KIT W557_K558del KIT N822K,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
130,Preclinical,"In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation efficiently in transformed human cells over expressing KIT Y578C in culture (PMID: 23567324).",Actionable,6879,10000003,Advanced Solid Tumor,JAX,1661,KIT Y578C,"[{'id': 647, 'pubMedId': 23567324, 'title': 'Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23567324'}]",sensitive,770,Imatinib,3815
131,Preclinical - Cell culture,"In a preclinical study, the combination of Gleevec (imatinib) and MK2206 demonstrated synergy in inhibiting growth of a gastrointestinal stromal tumor cell line harboring a KIT exon 13 mutation in culture (PMID: 27370604).",Actionable,9691,9253,gastrointestinal stromal tumor,DOID,26977,KIT exon 13,"[{'id': 7483, 'pubMedId': 27370604, 'title': 'Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27370604'}]",sensitive,5163,Imatinib + MK2206,3815
132,Phase II,"In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41), which included a partial response in 7.7% (1/13) of melanoma patients harboring KIT exon 13 mutations (PMID: 28327988). ",Actionable,11230,1909,melanoma,DOID,26977,KIT exon 13,"[{'id': 9177, 'pubMedId': 28327988, 'title': 'Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28327988'}]",sensitive,829,Nilotinib,3815
133,Phase II,"In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 5% (1/19) and partial response in 21% (4/19) of melanoma patients harboring KIT exon 11 or exon 13 mutations (PMID: 28843487; NCT01168050).",Actionable,11855,1909,melanoma,DOID,26977,KIT exon 13,"[{'id': 9871, 'pubMedId': 28843487, 'title': 'STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28843487'}]",sensitive,829,Nilotinib,3815
134,Preclinical,"In a preclinical study, melanoma cells expressing KIT T670I demonstrated resistance to treatment with Gleevec (imatinib mesylate) (PMID: 23582185, PMID: 25594040). ",Actionable,1815,1909,melanoma,DOID,1657,KIT T670I,"[{'id': 2193, 'pubMedId': 23582185, 'title': 'Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23582185'}, {'id': 2194, 'pubMedId': 25594040, 'title': 'Resistance to c-Kit inhibitors in melanoma: insights for future therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25594040'}]",resistant,770,Imatinib,3815
135,Preclinical,"In a preclinical study, cells expressing KIT T670I demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).  ",Actionable,6753,10000003,Advanced Solid Tumor,JAX,1657,KIT T670I,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
136,Preclinical,"In a preclinical study, Sutent (sunitinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT T670I (PMID: 23582185, PMID: 25594040). ",Actionable,1818,1909,melanoma,DOID,1657,KIT T670I,"[{'id': 2193, 'pubMedId': 23582185, 'title': 'Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23582185'}, {'id': 2194, 'pubMedId': 25594040, 'title': 'Resistance to c-Kit inhibitors in melanoma: insights for future therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25594040'}]",sensitive,930,Sunitinib,3815
137,Preclinical,"In a preclinical study, melanoma cells expressing KIT T670I demonstrated resistance to treatment with Sprycel (dasatinib) (PMID: 23582185, PMID: 25594040). ",Actionable,1817,1909,melanoma,DOID,1657,KIT T670I,"[{'id': 2193, 'pubMedId': 23582185, 'title': 'Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23582185'}, {'id': 2194, 'pubMedId': 25594040, 'title': 'Resistance to c-Kit inhibitors in melanoma: insights for future therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25594040'}]",resistant,717,Dasatinib,3815
138,Clinical Study,"In a clinical case report, a patient with a gastrointestinal stromal tumor developed disease progression while being treated with Gleevec (imatinib), demonstrating a KIT T670I mutation in the progressive lesion (PMID: 15236194).",Actionable,6739,9253,gastrointestinal stromal tumor,DOID,1657,KIT T670I,"[{'id': 675, 'pubMedId': 15236194, 'title': 'A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15236194'}]",resistant,770,Imatinib,3815
139,Preclinical,"In a preclinical study, melanoma cells expressing KIT T670I demonstrated resistance to treatment with Tasigna (nilotinib) (PMID: 23582185, PMID: 25594040). ",Actionable,1816,1909,melanoma,DOID,1657,KIT T670I,"[{'id': 2193, 'pubMedId': 23582185, 'title': 'Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23582185'}, {'id': 2194, 'pubMedId': 25594040, 'title': 'Resistance to c-Kit inhibitors in melanoma: insights for future therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25594040'}]",resistant,829,Nilotinib,3815
140,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT T670I demonstrated resistance to treatment with Stivarga (regorafenib) in culture (PMID: 25239608). ",Actionable,6790,10000003,Advanced Solid Tumor,JAX,23689,KIT W557_K558del KIT T670I,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,890,Regorafenib,3815
141,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT T670I demonstrated no response to treatment with Gleevec (imatinib) in both culture and xenograft models (PMID: 25239608). ",Actionable,6789,10000003,Advanced Solid Tumor,JAX,23689,KIT W557_K558del KIT T670I,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",no benefit,770,Imatinib,3815
142,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT T670I demonstrated sensitivity to treatment with Iclusig (ponatinib) in both culture and cell line xenograft models, resulting in reduced cell viability and decreased tumor volume (PMID: 25239608). ",Actionable,6787,10000003,Advanced Solid Tumor,JAX,23689,KIT W557_K558del KIT T670I,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
143,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT T670I demonstrated sensitivity to treatment with Sutent (sunitinib) in both culture and cell line xenograft models, resulting in reduced cell viability, decreased tumor volume, and tumor regression (PMID: 25239608). ",Actionable,6788,10000003,Advanced Solid Tumor,JAX,23689,KIT W557_K558del KIT T670I,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,930,Sunitinib,3815
144,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing a KIT W557_K558del/T670I double mutation demonstrated resistance to Sprycel (dasatinib) in culture (PMID: 17699867).",Actionable,11839,10000003,Advanced Solid Tumor,JAX,23689,KIT W557_K558del KIT T670I,"[{'id': 676, 'pubMedId': 17699867, 'title': 'Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17699867'}]",resistant,717,Dasatinib,3815
145,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing a KIT W557_K558del/T670I double mutation demonstrated resistance to Tasigna (nilotinib) in culture (PMID: 17699867).",Actionable,11840,10000003,Advanced Solid Tumor,JAX,23689,KIT W557_K558del KIT T670I,"[{'id': 676, 'pubMedId': 17699867, 'title': 'Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17699867'}]",resistant,829,Nilotinib,3815
146,Preclinical - Cell culture,"In a preclinical study, Nexavar (sorafenib) inhibited proliferation and induced apoptosis of transformed cells expressing a KIT W557_K558del/T670I double mutation in culture (PMID: 17699867).",Actionable,11841,10000003,Advanced Solid Tumor,JAX,23689,KIT W557_K558del KIT T670I,"[{'id': 676, 'pubMedId': 17699867, 'title': 'Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17699867'}]",sensitive,920,Sorafenib,3815
147,Clinical Study,"In a case report study, a patient with mucosal melanoma harboring KIT C443S demonstrated a substantial response to Gleevec (imatinib) in the first two weeks and then developed progression at 15 weeks (PMID: 25003536). ",Actionable,6518,50929,mucosal melanoma,DOID,5733,KIT C443S,"[{'id': 5680, 'pubMedId': 25003536, 'title': 'Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25003536'}]",sensitive,770,Imatinib,3815
148,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) decreased KIT signaling, and inhibited growth and induced apoptosis of transformed cells expressing KIT V559D in culture (PMID: 21689725).",Actionable,11820,10000003,Advanced Solid Tumor,JAX,1641,KIT V559D,"[{'id': 662, 'pubMedId': 21689725, 'title': 'Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21689725'}]",sensitive,717,Dasatinib,3815
149,Preclinical,"In a preclinical study, cells expressing KIT V559D demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).  ",Actionable,6751,10000003,Advanced Solid Tumor,JAX,1641,KIT V559D,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
150,Preclinical - Cell culture,"In a preclinical study, Gleevec (imatinib) decreased KIT signaling, and inhibited growth and induced apoptosis of transformed cells expressing KIT V559D in culture (PMID: 21689725).",Actionable,11821,10000003,Advanced Solid Tumor,JAX,1641,KIT V559D,"[{'id': 662, 'pubMedId': 21689725, 'title': 'Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21689725'}]",sensitive,770,Imatinib,3815
151,Phase II,"In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT V559D demonstrating a partial response and progression free survival of 28.3 months and overall survival of 28.3 months (PMID: 28327988). ",Actionable,11234,1909,melanoma,DOID,1641,KIT V559D,"[{'id': 9177, 'pubMedId': 28327988, 'title': 'Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28327988'}]",sensitive,829,Nilotinib,3815
152,Clinical Study,"In a clinical case report, a patient with metastatic thymic carcinoma harboring KIT Y553N demonstrated improved clinical performance and reduction in metastatic lesions following treatment with Gleevec (imatinib) (PMID: 21969494).",Actionable,6747,3284,thymic carcinoma,DOID,3216,KIT Y553N,"[{'id': 5813, 'pubMedId': 21969494, 'title': 'Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21969494'}]",sensitive,770,Imatinib,3815
153,Preclinical,"In a preclinical study, Cometriq (cabozantinib) decreased cell viability in imatinib-sensitive and resistant gastrointestinal stromal tumor (GIST) cell lines harboring KIT activating mutations in culture, and induced tumor regression in KIT-mutant GIST mouse models (PMID: 25836719).",Actionable,2537,9253,gastrointestinal stromal tumor,DOID,1668,KIT act mut,"[{'id': 3259, 'pubMedId': 25836719, 'title': 'Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25836719'}]",sensitive,998,cabozantinib,3815
154,Preclinical - Cell line xenograft,"In a preclinical study, PLX3397 inhibited growth of gastrointestinal stromal tumor cell lines harboring KIT activating mutations in culture and in cell line xenograft models (PMID: 24583793).
",Actionable,2543,9253,gastrointestinal stromal tumor,DOID,1668,KIT act mut,"[{'id': 3262, 'pubMedId': 24583793, 'title': 'Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24583793'}]",sensitive,874,PLX3397,3815
155,Preclinical,"In a preclinical study, PLX9486 inhibited KIT mutations, including exon 17 mutations, and demonstrated in vivo and in vitro activity against tumors harboring KIT exon 17 mutations (Cancer Res February 1, 2016 76; IA32).",Actionable,6392,10000003,Advanced Solid Tumor,JAX,1668,KIT act mut,"[{'id': 5540, 'pubMedId': None, 'title': 'Optimizing kinase inhibitors to treat cancer', 'url': 'http://cancerres.aacrjournals.org/content/76/3_Supplement/IA32.short'}]",sensitive,2602,PLX9486,3815
156,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) inhibited growth and induced apoptosis of transformed cells expressing KIT W557_K558del in culture (PMID: 17699867).",Actionable,11838,10000003,Advanced Solid Tumor,JAX,1706,KIT W557_K558del,"[{'id': 676, 'pubMedId': 17699867, 'title': 'Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17699867'}]",sensitive,717,Dasatinib,3815
157,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells expressing KIT W557_K558del demonstrated sensitivity to treatment with Iclusig (ponatinib) in both culture and cell line xenograft models, resulting in reduced cell viability and near complete tumor regression (PMID: 25239608). ",Actionable,6766,10000003,Advanced Solid Tumor,JAX,1706,KIT W557_K558del,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
158,Preclinical - Cell culture,"In a preclinical study, Tasigna (nilotinib) inhibited growth of transformed cells expressing KIT W557_K558del in culture (PMID: 17699867).",Actionable,11837,10000003,Advanced Solid Tumor,JAX,1706,KIT W557_K558del,"[{'id': 676, 'pubMedId': 17699867, 'title': 'Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17699867'}]",sensitive,829,Nilotinib,3815
159,Preclinical,"In a preclinical study, transformed cells expressing KIT W557_K558del demonstrated sensitivity to treatment with Stivarga (regorafineb) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6769,10000003,Advanced Solid Tumor,JAX,1706,KIT W557_K558del,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,890,Regorafenib,3815
160,Preclinical,"In a preclinical study, transformed cells expressing KIT W557_K558del demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6768,10000003,Advanced Solid Tumor,JAX,1706,KIT W557_K558del,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,770,Imatinib,3815
161,Preclinical - Cell culture,"In a preclinical study, PD-0325901 treatment inhibited Erk phosphorylation and decreased expression of ETV1 and CXCR4 in gastrointestinal stromal tumor cells harboring KIT W557_K558del (PMID: 26936919). ",Actionable,7522,9253,gastrointestinal stromal tumor,DOID,1706,KIT W557_K558del,"[{'id': 6397, 'pubMedId': 26936919, 'title': 'KIT Exon 11 Codons 557-558 Deletion Mutation Promotes Liver Metastasis Through the CXCL12/CXCR4 Axis in Gastrointestinal Stromal Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26936919'}]",sensitive,849,PD-0325901,3815
162,Preclinical,"In a preclinical study, transformed cells expressing W557_K558del demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6767,10000003,Advanced Solid Tumor,JAX,1706,KIT W557_K558del,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,930,Sunitinib,3815
163,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6901,10000003,Advanced Solid Tumor,JAX,24005,KIT W557_K558del KIT D816G,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,930,Sunitinib,3815
164,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6896,10000003,Advanced Solid Tumor,JAX,24005,KIT W557_K558del KIT D816G,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,877,Ponatinib,3815
165,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6911,10000003,Advanced Solid Tumor,JAX,24005,KIT W557_K558del KIT D816G,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,890,Regorafenib,3815
166,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6906,10000003,Advanced Solid Tumor,JAX,24005,KIT W557_K558del KIT D816G,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,770,Imatinib,3815
167,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816H demonstrated a decreased response to treatment with Gleevec (imatinib) in both culture and xenograft models, resulting in only a slight decrease in tumor volume (PMID: 25239608). ",Actionable,6794,10000003,Advanced Solid Tumor,JAX,23690,KIT W557_K558del KIT D816H,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",decreased response,770,Imatinib,3815
168,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816H demonstrated sensitivity to treatment with Iclusig (ponatinib) in both culture and cell line xenograft models, resulting in reduced cell viability and tumor regression (PMID: 25239608). ",Actionable,6792,10000003,Advanced Solid Tumor,JAX,23690,KIT W557_K558del KIT D816H,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
169,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816H demonstrated a decreased response to treatment with Stivarga (regorafenib) in culture (PMID: 25239608). ",Actionable,6795,10000003,Advanced Solid Tumor,JAX,23690,KIT W557_K558del KIT D816H,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",decreased response,890,Regorafenib,3815
170,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816H demonstrated a decreased response to treatment with Sutent (sunitinib) in both culture and cell line xenograft models, resulting in only a slight decrease in tumor volume (PMID: 25239608). ",Actionable,6793,10000003,Advanced Solid Tumor,JAX,23690,KIT W557_K558del KIT D816H,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",decreased response,930,Sunitinib,3815
171,Preclinical,"In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6770,10000003,Advanced Solid Tumor,JAX,23684,KIT K550_W557del,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
172,Preclinical,"In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6771,10000003,Advanced Solid Tumor,JAX,23684,KIT K550_W557del,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,930,Sunitinib,3815
173,Preclinical,"In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Stivarga (regorafenib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6773,10000003,Advanced Solid Tumor,JAX,23684,KIT K550_W557del,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,890,Regorafenib,3815
174,Preclinical,"In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6772,10000003,Advanced Solid Tumor,JAX,23684,KIT K550_W557del,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,770,Imatinib,3815
175,Preclinical - Pdx,"In a preclinical study, Gleevec (imatinib) treatment resulted in tumor regression and decreased mitotic activity in gastrointestinal stromal tumor patient derived xenograft (PDX) models harboring KIT K558_G565delinsR (PMID: 27777285). ",Actionable,9591,9253,gastrointestinal stromal tumor,DOID,26913,KIT K558_G565delinsR,"[{'id': 7300, 'pubMedId': 27777285, 'title': 'Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27777285'}]",sensitive,770,Imatinib,3815
176,Preclinical - Pdx,"In a preclinical study, Cometriq (Cabometyx, cabozantinib) resulted in tumor regression, decreased mitotic activity, and increased apoptotic activity in a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT K558_G565delins (PMID: 27777285).  ",Actionable,9594,9253,gastrointestinal stromal tumor,DOID,26913,KIT K558_G565delinsR,"[{'id': 7300, 'pubMedId': 27777285, 'title': 'Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27777285'}]",sensitive,998,cabozantinib,3815
177,Clinical Study,"In a clinical case report, Gleevec (imatinib mesylate) treatment resulted in partial response in a patient with recurrent vulval melanoma harboring KIT K642E, reduced tumor mass by 35% (PMID: 20372153). ",Actionable,8614,2093,vulvar melanoma,DOID,1660,KIT K642E,"[{'id': 6700, 'pubMedId': 20372153, 'title': 'Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20372153'}]",predicted – sensitive,770,Imatinib,3815
178,Phase II,"In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT K642E demonstrating a partial response and a progression free survival of 5.8 months and overall survival of 18.6 months (PMID: 28327988). ",Actionable,11233,1909,melanoma,DOID,1660,KIT K642E,"[{'id': 9177, 'pubMedId': 28327988, 'title': 'Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28327988'}]",sensitive,829,Nilotinib,3815
179,Preclinical - Cell culture,"In a preclinical study, Stivarga (regorafenib) inhibited proliferation of gastrointestinal stromal tumor cells harboring KIT K642E in culture (PMID: 21170960).",Actionable,538,9253,gastrointestinal stromal tumor,DOID,1660,KIT K642E,"[{'id': 318, 'pubMedId': 21170960, 'title': 'Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21170960'}]",sensitive,890,Regorafenib,3815
180,Preclinical,"In a preclinical study, a patient derived GIST cell line harboring KIT K642E demonstrated sensitivity to Iclusig (ponatinib) in culture (PMID: 25239608). ",Actionable,6805,9253,gastrointestinal stromal tumor,DOID,1660,KIT K642E,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
181,Preclinical - Cell culture,"In a preclinical study, BGJ398 and Gleevec (imatinib mesylate) combination treatment demonstrated enhanced antiproliferative activity in gastrointestinal stromal tumor cells harboring KIT K642E in culture (PMID: 25673643).",Actionable,7785,9253,gastrointestinal stromal tumor,DOID,1660,KIT K642E,"[{'id': 6494, 'pubMedId': 25673643, 'title': 'FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25673643'}]",sensitive,2284,BGJ398 + Imatinib,3815
182,Preclinical,"In a preclinical study, KIT N505I induced phosphorylation of KIT, ERK, and AKT, and was inhibited by Nexavar (sorafenib) in cell culture of melanocytes, demonstrating sensitivity of N505I to sorafenib (PMID: 24317392).",Actionable,990,1909,melanoma,DOID,1642,KIT N505I,"[{'id': 651, 'pubMedId': 24317392, 'title': 'A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24317392'}]",sensitive,920,Sorafenib,3815
183,Preclinical,"In a preclinical study, Gleevec (imatinib) decreased phosphorylation of KIT, AKT, and ERK in melanocytes expressing KIT N505I in culture (PMID: 24317392).",Actionable,991,1909,melanoma,DOID,1642,KIT N505I,"[{'id': 651, 'pubMedId': 24317392, 'title': 'A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24317392'}]",predicted – sensitive,770,Imatinib,3815
184,Clinical Study,"In clinical analyses, coincident KIT mutations were associated with higher relapse rate and decreased overall survival in acute myeloid leukemia patients with RUNX1-RUNX1T1 fusions (PMID: 18648004, PMID: 16384925, PMID: 25111512).",Prognostic,6080,9119,acute myeloid leukemia,DOID,22438,RUNX1-RUNX1T1 KIT mut,"[{'id': 1127, 'pubMedId': 18648004, 'title': 'Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18648004'}, {'id': 5289, 'pubMedId': 25111512, 'title': 'Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25111512'}, {'id': 5290, 'pubMedId': 16384925, 'title': 'Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16384925'}]",not applicable,1776,N/A,3815
185,Phase I,"In a Phase I trial, DCC-2618 demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including KIT-mutant gastrointestinal stromal tumor (GIST), with 1 patient harboring KIT exon 11 and 17 mutations demonstrating a partial response, and 7/7 KIT-mutant GIST patients demonstrating a partial metabolic response (EORTC-NCI-AACR 2016, Abs 7LBA).",Actionable,9777,9253,gastrointestinal stromal tumor,DOID,1214,KIT mutant,"[{'id': 7598, 'pubMedId': None, 'title': 'DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study', 'url': 'http://www.ecco-org.eu/Events/ENA2016/Searchable-Programme#anchorScpr'}]",predicted – sensitive,4316,DCC-2618,3815
186,Phase II,"In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 4% (1/25), durable partial response in 16% (4/25), and stable disease in 56% (14/25) of melanoma patients harboring KIT mutations (PMID: 28843487; NCT01168050).",Actionable,11853,1909,melanoma,DOID,1214,KIT mutant,"[{'id': 9871, 'pubMedId': 28843487, 'title': 'STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28843487'}]",sensitive,829,Nilotinib,3815
187,Phase II,"In a Phase II trial, Tasigna (nilotinib) treatment in patients with melanoma harboring KIT mutations resulted in an overall response rate of 26.2% (11/42), which included 11 patients with a partial response, a median duration of response of 7.1 months, and an overall survival of 18 months (PMID: 28327988; NCT01028222). ",Actionable,3305,1909,melanoma,DOID,1214,KIT mutant,"[{'id': 9177, 'pubMedId': 28327988, 'title': 'Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28327988'}]",sensitive,829,Nilotinib,3815
188,Preclinical - Pdx,"In a preclinical study, BGJ398 and Gleevec (imatinib mesylate) combination treatment demonstrated enhanced antitumor activity in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT mutations (PMID: 25673643).",Actionable,7788,9253,gastrointestinal stromal tumor,DOID,1214,KIT mutant,"[{'id': 6494, 'pubMedId': 25673643, 'title': 'FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25673643'}]",sensitive,2284,BGJ398 + Imatinib,3815
189,Clinical Study,"KIT mutations are used in the diagnosis of gastrointestinal stromal tumors (PMID: 25193432, PMID: 26276366, PMID: 25729899).",Diagnostic,3968,9253,gastrointestinal stromal tumor,DOID,1214,KIT mutant,"[{'id': 4316, 'pubMedId': 25729899, 'title': 'Template for Reporting Results of Biomarker Testing of Specimens From Patients With Gastrointestinal Stromal Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25729899'}, {'id': 5211, 'pubMedId': 25193432, 'title': 'GEIS 2013 guidelines for gastrointestinal sarcomas (GIST).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25193432'}, {'id': 5212, 'pubMedId': 26276366, 'title': 'The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26276366'}]",not applicable,1776,N/A,3815
190,Clinical Study,"In a clinical study, a melanoma patient harboring KIT D816V and NRAS Q61R demonstrated progressive disease when treated with a combination of Mekinist (trametinib) and Keytruda (pembrolizumab) (PMID: 28514312). ",Actionable,11050,1909,melanoma,DOID,27900,KIT D816V NRAS Q61R,"[{'id': 9046, 'pubMedId': 28514312, 'title': 'Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28514312'}]",no benefit,1450,Pembrolizumab + Trametinib,3815
191,Preclinical,"In a preclinical study, Iclusig (ponatinib) did not inhibit growth of transformed cells expressing KIT D816V in culture (PMID: 22301675).",Actionable,3560,10000003,Advanced Solid Tumor,JAX,1643,KIT D816V,"[{'id': 3820, 'pubMedId': 22301675, 'title': 'Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22301675'}]",resistant,877,Ponatinib,3815
192,Preclinical,"In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Quizartinib in culture (PMID: 23497317).",Actionable,3601,10000003,Advanced Solid Tumor,JAX,1643,KIT D816V,"[{'id': 3862, 'pubMedId': 23497317, 'title': 'Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23497317'}]",resistant,882,Quizartinib,3815
193,Preclinical,"In a preclinical study, a mouse myeloid cell line expressing KIT D816V demonstrated resistance to Gleevec (imatinib) in culture (PMID: 12481435).",Actionable,3580,2531,hematologic cancer,DOID,1643,KIT D816V,"[{'id': 3853, 'pubMedId': 12481435, 'title': 'Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12481435'}]",resistant,770,Imatinib,3815
194,Preclinical,"In a preclinical study, transformed hematopoietic cells expressing KIT D816V demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 17229632).",Actionable,3561,2531,hematologic cancer,DOID,1643,KIT D816V,"[{'id': 3821, 'pubMedId': 17229632, 'title': 'The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17229632'}]",resistant,920,Sorafenib,3815
195,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing KIT D816V were sensitive to BPR1J373, demonstrating inhibition of Kit phosphorylation (PMID: 27512117).",Actionable,8707,10000003,Advanced Solid Tumor,JAX,1643,KIT D816V,"[{'id': 6711, 'pubMedId': 27512117, 'title': 'BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27512117'}]",predicted – sensitive,4798,BPR1J373,3815
196,Preclinical,"In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Gleevec (imatinib mesylate) in culture (PMID: 15790786).",Actionable,3579,10000003,Advanced Solid Tumor,JAX,1643,KIT D816V,"[{'id': 425, 'pubMedId': 15790786, 'title': 'Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15790786'}]",resistant,770,Imatinib,3815
197,Preclinical,"In a preclinical study, Tasigna (nilotinib) decreased viability of cells expressing KIT D816V in culture, but did not inhibit KIT phosphorylation or growth of KIT D816V-expressing tumors in mouse models (PMID: 20442311).",Actionable,3577,10000003,Advanced Solid Tumor,JAX,1643,KIT D816V,"[{'id': 3260, 'pubMedId': 20442311, 'title': 'Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20442311'}]",decreased response,829,Nilotinib,3815
198,Preclinical,"In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Cometriq (cabozantinib) in culture (PMID: 24205792).",Actionable,3585,10000003,Advanced Solid Tumor,JAX,1643,KIT D816V,"[{'id': 663, 'pubMedId': 24205792, 'title': 'Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24205792'}]",resistant,998,cabozantinib,3815
199,Clinical Study,"In a clinical case study, a patient with acute myeloid leukemia harboring KIT D816V achieved long-term remission and loss of KIT D816V following treatment with the combination of Sprycel (dasatinib) and Cytosar-U (cytarabine) (PMID: 18986703).",Actionable,3613,9119,acute myeloid leukemia,DOID,1643,KIT D816V,"[{'id': 3887, 'pubMedId': 18986703, 'title': 'Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18986703'}]",sensitive,3174,Dasatinib + Cytarabine,3815
200,FDA approved,Gleevec (imatinib) is not indicated for patients with aggressive systemic mastocytosis harboring KIT D816V (FDA.gov).,Actionable,1979,10000005,Indication other than cancer,JAX,1643,KIT D816V,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",resistant,770,Imatinib,3815
201,Preclinical,"In a preclinical study, KIT D816V mutations demonstrated resistance to Sutent (sunitinib) in a biochemical assay (PMID: 19164557).",Actionable,3575,10000003,Advanced Solid Tumor,JAX,1643,KIT D816V,"[{'id': 655, 'pubMedId': 19164557, 'title': 'KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19164557'}]",resistant,930,Sunitinib,3815
202,Preclinical,"In a preclinical study, cells expressing KIT D820E demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).  ",Actionable,6755,10000003,Advanced Solid Tumor,JAX,4900,KIT D820E,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
203,Clinical Study,"In a clinical case report, a patient with metastatic thymic carcinoma harboring KIT D820E demonstrated a partial response to treatment with Nexavar (sorafenib) (PMID: 19461405).",Actionable,6750,3284,thymic carcinoma,DOID,4900,KIT D820E,"[{'id': 5817, 'pubMedId': 19461405, 'title': 'Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19461405'}]",sensitive,920,Sorafenib,3815
204,Preclinical,"In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation in transformed cells over expressing KIT T417_D419delinsI in culture (PMID: 16015387). ",Actionable,6775,10000003,Advanced Solid Tumor,JAX,23697,KIT T417_D419delinsI,"[{'id': 5820, 'pubMedId': 16015387, 'title': 'Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16015387'}]",sensitive,770,Imatinib,3815
205,Preclinical - Pdx,"In a preclinical study, Nexavar (sorafenib) inhibited Erk signaling, induced apoptosis, resulted in tumor growth inhibition in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT P551_V555del (PMID: 19139124).",Actionable,8617,9253,gastrointestinal stromal tumor,DOID,1702,KIT P551_V555del,"[{'id': 6701, 'pubMedId': 19139124, 'title': 'Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19139124'}]",sensitive,920,Sorafenib,3815
206,Clinical Study,"In two clinical case studies, patients with Gleevec (imatinib)-melanoma that harboring KIT L576P demonstrated initial clinical benefit following treatment with Sprycel (dasatinib), however progressed after 3-4 months of treatment (PMID: 19671763).",Actionable,8609,1909,melanoma,DOID,1670,KIT L576P,"[{'id': 6696, 'pubMedId': 19671763, 'title': 'Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19671763'}]",sensitive,717,Dasatinib,3815
207,Phase II,"In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including three melanoma patients harboring KIT L576P demonstrating a partial response (PMID: 28327988). ",Actionable,11231,1909,melanoma,DOID,1670,KIT L576P,"[{'id': 9177, 'pubMedId': 28327988, 'title': 'Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28327988'}]",sensitive,829,Nilotinib,3815
208,Clinical Study,"In a clinical case report, Gleevec (imatinib mesylate) treatment resulted in initial tumor reduction followed by disease progression in a patient with metastasized labial melanoma harboring KIT L576P (PMID: 20372153). ",Actionable,8615,1909,melanoma,DOID,1670,KIT L576P,"[{'id': 6700, 'pubMedId': 20372153, 'title': 'Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20372153'}]",no benefit,770,Imatinib,3815
209,Clinical Study,"In a clinical case study, a melanoma patient harboring KIT L576P demonstrated sensitivity to the combination treatment of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in a partial response for 8 months (PMID: 25363205). ",Actionable,7765,1909,melanoma,DOID,1670,KIT L576P,"[{'id': 6478, 'pubMedId': 25363205, 'title': 'Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25363205'}]",sensitive,4517,Bevacizumab + Sorafenib,3815
210,Preclinical,"In a preclinical study, the combination of G007-LK and Gleevec (imatinib) demonstrated increased anti-tumor activity compared to either agent alone in a mouse model of gastrointestinal stromal tumor expressing Kit V558del (corresponding to human V559del) (PMID: 28611108).",Actionable,11962,9253,gastrointestinal stromal tumor,DOID,1699,KIT V559del,"[{'id': 9934, 'pubMedId': 28611108, 'title': 'Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28611108'}]",sensitive,6215,G007-LK + Imatinib,3815
211,Preclinical,"In a preclinical study, KIT D816H demonstrated resistance to Stivarga (regorafenib) in an in vitro assay, and conferred secondary resistance to Stivarga (regorafenib) in transformed cells expressing other KIT mutations (PMID: 25239608).",Actionable,3589,10000003,Advanced Solid Tumor,JAX,1646,KIT D816H,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",resistant,890,Regorafenib,3815
212,Preclinical,"In a preclinical study, cells expressing KIT D816H demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).  ",Actionable,6754,10000003,Advanced Solid Tumor,JAX,1646,KIT D816H,"[{'id': 3860, 'pubMedId': 25239608, 'title': 'Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25239608'}]",sensitive,877,Ponatinib,3815
0,Preclinical,"In a preclinical study, transformed cells expressing the fusion, KMT2A-MLLT10, demonstrated sensitivity to EPZ004777 in culture and in mouse models, resulting in cell cycle arrest, increased apoptotic activity, and inhibition of cell proliferation (PMID: 23138183). ",Actionable,6224,1240,leukemia,DOID,22961,KMT2A-MLLT10,"[{'id': 5485, 'pubMedId': 23138183, 'title': 'Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23138183'}]",sensitive,1744,EPZ004777,4297
1,Preclinical - Patient cell culture,"In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-MLLT10 in culture (PMID: 27294782).",Actionable,11381,9119,acute myeloid leukemia,DOID,22961,KMT2A-MLLT10,"[{'id': 9271, 'pubMedId': 27294782, 'title': 'Functional interdependence of BRD4 and DOT1L in MLL leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27294782'}]",sensitive,5966,I-BET151 + SGC0946,4297
2,Preclinical,"In a preclinical study, AZD0156 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).",Actionable,12168,9119,acute myeloid leukemia,DOID,20552,KMT2A-MLLT1 NRAS G12D,"[{'id': 10122, 'pubMedId': 27625305, 'title': 'Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27625305'}]",predicted – sensitive,3557,AZD0156,4297
3,Preclinical,"In a preclinical study, AZ20 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).",Actionable,12169,9119,acute myeloid leukemia,DOID,20552,KMT2A-MLLT1 NRAS G12D,"[{'id': 10122, 'pubMedId': 27625305, 'title': 'Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27625305'}]",predicted – sensitive,2880,AZ20,4297
4,Preclinical,"In a preclinical study, acute myeloid leukemia cells co-harboring KMT2A-MLLT1 and NRAS G12D demonstrated a decrease in tumor burden, reduced colony formation, and an increase in cell death when treated with Dinaciclib in both culture and mouse models (PMID: 26627013).",Actionable,5311,9119,acute myeloid leukemia,DOID,20552,KMT2A-MLLT1 NRAS G12D,"[{'id': 5010, 'pubMedId': 26627013, 'title': 'The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627013'}]",sensitive,719,Dinaciclib,4297
5,Preclinical - Cell culture,"In a preclinical study, MI-503 inhibited growth of an acute myeloid leukemia cell line harboring KMT2A-MLLT1 (MLL-ENL) in culture (PMID: 25817203).",Actionable,11493,9119,acute myeloid leukemia,DOID,20541,KMT2A-MLLT1,"[{'id': 9548, 'pubMedId': 25817203, 'title': 'Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25817203'}]",sensitive,6006,MI-503,4297
6,Preclinical - Patient cell culture,"In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A fusions in culture (PMID: 27294782).",Actionable,11382,9119,acute myeloid leukemia,DOID,27975,KMT2A fusion,"[{'id': 9271, 'pubMedId': 27294782, 'title': 'Functional interdependence of BRD4 and DOT1L in MLL leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27294782'}]",sensitive,5966,I-BET151 + SGC0946,4297
7,Preclinical - Cell culture,"In a preclinical study, MI-503 inhibited growth of several acute myeloid leukemia (AML) cell lines and primary AML samples harboring KMT2A (MLL) fusions in culture (PMID: 25817203).",Actionable,11496,9119,acute myeloid leukemia,DOID,27975,KMT2A fusion,"[{'id': 9548, 'pubMedId': 25817203, 'title': 'Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25817203'}]",predicted – sensitive,6006,MI-503,4297
8,Preclinical,"In a preclinical study, a transgenic leukemic mouse model harboring KMT2A-MLLT3 demonstrated sensitivity to IRAK1/4, resulting in delayed progression and improved survival (PMID: 28065413). ",Actionable,9763,1240,leukemia,DOID,20485,KMT2A-MLLT3,"[{'id': 7540, 'pubMedId': 28065413, 'title': 'Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28065413'}]",sensitive,5196,IRAK1/4,4297
9,Preclinical - Patient cell culture,"In a preclinical study, MI-503 inhibited growth of an acute myeloid leukemia (AML) cell line and primary AML samples harboring KMT2A-MLLT3 (MLL-AF9) in culture (PMID: 25817203).",Actionable,11491,9119,acute myeloid leukemia,DOID,20485,KMT2A-MLLT3,"[{'id': 9548, 'pubMedId': 25817203, 'title': 'Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25817203'}]",sensitive,6006,MI-503,4297
10,Preclinical,"In a preclinical study, treatment with Dinaciclib resulted in induced cell death of acute myeloid leukemia cells harboring KMT2A-MLLT3 in culture (PMID: 26627013).",Actionable,5312,9119,acute myeloid leukemia,DOID,20485,KMT2A-MLLT3,"[{'id': 5010, 'pubMedId': 26627013, 'title': 'The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627013'}]",sensitive,719,Dinaciclib,4297
11,Preclinical,"In a preclinical study, MI-503 reduced progression and improved survival of a mouse leukemia model expressing KMT2A-MLLT3 (MLL-AF9) (PMID: 25817203).",Actionable,11497,1240,leukemia,DOID,20485,KMT2A-MLLT3,"[{'id': 9548, 'pubMedId': 25817203, 'title': 'Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25817203'}]",sensitive,6006,MI-503,4297
12,Preclinical - Patient cell culture,"In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-MLLT3 in culture, and prolonged survival in animal models of mouse KMT2A-MLLT3-positive leukemia (PMID: 27294782).",Actionable,11378,9119,acute myeloid leukemia,DOID,20485,KMT2A-MLLT3,"[{'id': 9271, 'pubMedId': 27294782, 'title': 'Functional interdependence of BRD4 and DOT1L in MLL leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27294782'}]",sensitive,5966,I-BET151 + SGC0946,4297
13,Preclinical - Cell line xenograft,"In a preclinical study, AZD5153 inhibited proliferation of acute myeloid leukemia cells harboring KMT2A-AFF1 (MLL-AF4) in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27573426).",Actionable,9134,9119,acute myeloid leukemia,DOID,20536,KMT2A-AFF1,"[{'id': 6927, 'pubMedId': 27573426, 'title': 'AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27573426'}]",predicted – sensitive,4910,AZD5153,4297
14,Preclinical - Cell culture,"In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of leukemia cells harboring KMT2A-AFF1 in culture (PMID: 27294782).",Actionable,11377,1240,leukemia,DOID,20536,KMT2A-AFF1,"[{'id': 9271, 'pubMedId': 27294782, 'title': 'Functional interdependence of BRD4 and DOT1L in MLL leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27294782'}]",sensitive,5966,I-BET151 + SGC0946,4297
15,Preclinical - Cell culture,"In a preclinical study, leukemia cells harboring KMT2A-AFF1 demonstrated sensitivity to IRAK1/4 in culture, resulting in decreased cell proliferation (PMID: 28065413). ",Actionable,9762,1240,leukemia,DOID,20536,KMT2A-AFF1,"[{'id': 7540, 'pubMedId': 28065413, 'title': 'Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28065413'}]",sensitive,5196,IRAK1/4,4297
16,Preclinical - Cell line xenograft,"In a preclinical study, AZD5153 inhibited proliferation of acute lymphocytic leukemia cells harboring KMT2A-AFF1 (MLL-AF4) in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27573426).",Actionable,9128,9952,acute lymphocytic leukemia,DOID,20536,KMT2A-AFF1,"[{'id': 6927, 'pubMedId': 27573426, 'title': 'AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27573426'}]",predicted – sensitive,4910,AZD5153,4297
17,Preclinical - Cell line xenograft,"In a preclinical study, MI-503 reduced expression of KMT2A (MLL) fusion target genes, inhibited growth of an acute myeloid leukemia (AML) cell lines harboring KMT2A-AFF1 (MLL-AF4) in culture, and inhibited tumor growth and progression in an AML cell line xenograft model harboring KMT2A-AFF1 (MLL-AF4) (PMID: 25817203).",Actionable,11492,9119,acute myeloid leukemia,DOID,20536,KMT2A-AFF1,"[{'id': 9548, 'pubMedId': 25817203, 'title': 'Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25817203'}]",sensitive,6006,MI-503,4297
18,Preclinical,"In a preclinical study, treatment with Dinaciclib resulted in induced cell death of acute myeloid leukemia cells harboring KMT2A-AFF1 in culture (PMID: 26627013).",Actionable,5313,9119,acute myeloid leukemia,DOID,20536,KMT2A-AFF1,"[{'id': 5010, 'pubMedId': 26627013, 'title': 'The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627013'}]",sensitive,719,Dinaciclib,4297
19,Preclinical - Patient cell culture,"In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-SEPT6 in culture (PMID: 27294782).",Actionable,11379,9119,acute myeloid leukemia,DOID,27973,KMT2A-SEPT6,"[{'id': 9271, 'pubMedId': 27294782, 'title': 'Functional interdependence of BRD4 and DOT1L in MLL leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27294782'}]",sensitive,5966,I-BET151 + SGC0946,4297
20,Preclinical - Cell line xenograft,"In a preclinical study, Istodax (romidepsin) enhanced the effects of Cytosar-U (cytarabine) in acute lymphocytic leukemia cell lines harboring a KMT2A rearrangement in culture, and in cell line xenograft models, demonstrating decreased leukemic cells by 73% (PMID: 27443263). ",Actionable,9495,9952,acute lymphocytic leukemia,DOID,14079,KMT2A rearrange,"[{'id': 7225, 'pubMedId': 27443263, 'title': 'Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27443263'}]",sensitive,5035,Cytarabine + Romidepsin,4297
21,Preclinical,"In a preclinical study, I-CBP112 sensitized leukemia cells harboring KMT2A fusions to JQ1, resulting in decreased cell growth in culture (PMID: 26552700).",Actionable,3776,1240,leukemia,DOID,14079,KMT2A rearrange,"[{'id': 4120, 'pubMedId': 26552700, 'title': 'Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26552700'}]",predicted – sensitive,3298,I-CBP112 + JQ1,4297
22,Preclinical - Cell culture,"In a preclinical study, Mocetinostat (MGCD0103) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cell lines harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263). ",Actionable,9492,9952,acute lymphocytic leukemia,DOID,14079,KMT2A rearrange,"[{'id': 7225, 'pubMedId': 27443263, 'title': 'Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27443263'}]",sensitive,5037,Cytarabine + Mocetinostat,4297
23,Preclinical - Cell line xenograft,"In a preclinical study, Istodax (romidepsin) resulted in minimal activity in acute lymphocytic leukemia cell lines harboring a KMT2A rearrangement in culture, and in cell line xenograft models, demonstrating decreased leukemic cells by 16% (PMID: 27443263). ",Actionable,9497,9952,acute lymphocytic leukemia,DOID,14079,KMT2A rearrange,"[{'id': 7225, 'pubMedId': 27443263, 'title': 'Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27443263'}]",decreased response,1075,romidepsin,4297
24,Clinical Study,"In multiple clinical studies, KMT2A rearrangements, specifically partial tandem duplications, were associated with a poor overall survival in acute myeloid leukemia patients (PMID: 24487413, PMID: 22915647, PMID: 22417203, PMID: 21881046). ",Prognostic,6222,9119,acute myeloid leukemia,DOID,14079,KMT2A rearrange,"[{'id': 5338, 'pubMedId': 22915647, 'title': 'A novel hierarchical prognostic model of AML solely based on molecular mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22915647'}, {'id': 5346, 'pubMedId': 21881046, 'title': 'Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21881046'}, {'id': 5477, 'pubMedId': 24487413, 'title': 'Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24487413'}, {'id': 5478, 'pubMedId': 22417203, 'title': 'Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22417203'}]",not applicable,1776,N/A,4297
25,Preclinical - Cell culture,"In a preclinical study, Dacinostat (LAQ824) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cell lines harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263). ",Actionable,9493,9952,acute lymphocytic leukemia,DOID,14079,KMT2A rearrange,"[{'id': 7225, 'pubMedId': 27443263, 'title': 'Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27443263'}]",sensitive,5038,Cytarabine + Dacinostat,4297
26,Preclinical,"In a preclinical study, I-CBP112 sensitized leukemia cells harboring KMT2A fusions to Doxorubicin, leading to decreased cell growth in culture (PMID: 26552700).",Actionable,3775,1240,leukemia,DOID,14079,KMT2A rearrange,"[{'id': 4120, 'pubMedId': 26552700, 'title': 'Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26552700'}]",predicted – sensitive,3299,I-CBP112 + Doxorubicin,4297
27,Preclinical - Cell line xenograft,"In a preclinical study, Cytosar-U (cytarabine) decreased leukemic cells by 66% in acute lymphocytic leukemia cell line xenograft models harboring a KMT2A rearrangement (PMID: 27443263). ",Actionable,9498,9952,acute lymphocytic leukemia,DOID,14079,KMT2A rearrange,"[{'id': 7225, 'pubMedId': 27443263, 'title': 'Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27443263'}]",sensitive,712,Cytarabine,4297
28,Preclinical - Cell culture,"In a preclinical study, Farydak (panobinostat) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cells harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263). ",Actionable,9491,9952,acute lymphocytic leukemia,DOID,14079,KMT2A rearrange,"[{'id': 7225, 'pubMedId': 27443263, 'title': 'Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27443263'}]",sensitive,5036,Cytarabine + Panobinostat,4297
29,Preclinical - Patient cell culture,"In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-ELL in culture (PMID: 27294782).",Actionable,11380,9119,acute myeloid leukemia,DOID,27964,KMT2A-ELL,"[{'id': 9271, 'pubMedId': 27294782, 'title': 'Functional interdependence of BRD4 and DOT1L in MLL leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27294782'}]",sensitive,5966,I-BET151 + SGC0946,4297
30,Preclinical - Cell line xenograft,"In a preclinical study, treatment with AMI-408 decreased growth of leukemia cells expressing KMT2A-GAS7 (MLL-GAS7) in culture, and increased survival in xenograft models (PMID:26766589).",Actionable,10326,1240,leukemia,DOID,27356,KMT2A-GAS7,"[{'id': 8304, 'pubMedId': 26766589, 'title': 'Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26766589'}]",sensitive,5463,AMI-408,4297
31,Preclinical - Patient cell culture,"In a preclinical study, MI-503 inhibited growth of a primary acute myeloid sample harboring KMT2A-EP300 in culture (PMID: 25817203).",Actionable,11494,9119,acute myeloid leukemia,DOID,25868,KMT2A - EP300,"[{'id': 9548, 'pubMedId': 25817203, 'title': 'Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25817203'}]",sensitive,6006,MI-503,4297
0,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12S in culture (PMID: 26676756).",Actionable,8499,3910,lung adenocarcinoma,DOID,26343,KRAS G12S EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4746,DZNep + Selumetinib,3845
1,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12S in culture (PMID: 26676756)",Actionable,8511,3910,lung adenocarcinoma,DOID,26343,KRAS G12S EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4747,DZNep + MK2206,3845
2,Preclinical - Cell culture,"In a preclinical study, the combination of APS-2-49 and Binimetinib (MEK162) worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948).",Actionable,8015,1324,lung cancer,DOID,1128,KRAS G12S,"[{'id': 6534, 'pubMedId': 27556948, 'title': 'Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27556948'}]",sensitive,4621,APS-2-79 + Binimetinib,3845
3,Preclinical,"In a preclinical study, a colorectal cancer cell line harboring the KRAS G12S mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).",Actionable,817,9256,colorectal cancer,DOID,1128,KRAS G12S,"[{'id': 26, 'pubMedId': 23455880, 'title': 'KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23455880'}]",resistant,930,Sunitinib,3845
4,Preclinical,"In a preclinical study, a lung adenocarcinoma cell line harboring KRAS G12S demonstrated a decreased response when treated with Mekinist (trametinib) in culture (PMID: 26582713). ",Actionable,6450,1324,lung cancer,DOID,1128,KRAS G12S,"[{'id': 5602, 'pubMedId': 26582713, 'title': 'Identification of an ""Exceptional Responder"" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26582713'}]",decreased response,2,Trametinib,3845
5,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring KRAS G12S in culture (PMID: 21325073, PMID: 23012248).",Actionable,3133,3908,non-small cell lung carcinoma,DOID,1128,KRAS G12S,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3640, 'pubMedId': 23012248, 'title': 'Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23012248'}]",sensitive,1040,PF-05212384,3845
6,Preclinical - Cell culture,"In a preclinical study, the combination of APS-2-49 and Selumetinib (AZD6244) worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948).",Actionable,8017,1324,lung cancer,DOID,1128,KRAS G12S,"[{'id': 6534, 'pubMedId': 27556948, 'title': 'Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27556948'}]",sensitive,4622,APS-2-79 + Selumetinib,3845
7,Preclinical,"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring KRAS G12S mutation in culture (PMID: 26090892).",Actionable,3935,3908,non-small cell lung carcinoma,DOID,1128,KRAS G12S,"[{'id': 4301, 'pubMedId': 26090892, 'title': 'TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26090892'}]",sensitive,2086,TAE226,3845
8,Preclinical,"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 25665005).",Actionable,4535,3908,non-small cell lung carcinoma,DOID,1128,KRAS G12S,"[{'id': 4582, 'pubMedId': 25665005, 'title': 'The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25665005'}]",sensitive,1386,Trametinib + Navitoclax,3845
9,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 23629727).",Actionable,8179,3908,non-small cell lung carcinoma,DOID,1128,KRAS G12S,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,1659,Pimasertib + Sorafenib,3845
10,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 23629727).",Actionable,8184,3908,non-small cell lung carcinoma,DOID,1128,KRAS G12S,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4657,Pimasertib + Regorafenib,3845
11,Preclinical,"In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 25665005).",Actionable,4537,3908,non-small cell lung carcinoma,DOID,1128,KRAS G12S,"[{'id': 4582, 'pubMedId': 25665005, 'title': 'The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25665005'}]",sensitive,3532,Trametinib + TW-37,3845
12,Preclinical,"In a preclinical study, a lung cancer cell line harboring KRAS G12S demonstrated a decreased response when treated with PD-0325901 in culture (PMID: 26582713). ",Actionable,6452,1324,lung cancer,DOID,1128,KRAS G12S,"[{'id': 5602, 'pubMedId': 26582713, 'title': 'Identification of an ""Exceptional Responder"" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26582713'}]",decreased response,849,PD-0325901,3845
13,Preclinical - Cell culture,"In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of lung carcinoma cells harboring KRAS G12S (PMID: 28615361).",Actionable,11320,3905,lung carcinoma,DOID,1128,KRAS G12S,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",sensitive,5914,AZD4785,3845
14,Preclinical - Cell line xenograft,"In a preclinical study, Estybon (rigosertib) inhibited Mek/Erk signaling and tumor growth in cell line xenograft models of lung cancer harboring KRAS G12S (PMID: 27104980).",Actionable,8561,1324,lung cancer,DOID,1128,KRAS G12S,"[{'id': 6686, 'pubMedId': 27104980, 'title': 'A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27104980'}]",sensitive,1046,rigosertib,3845
15,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 23629727).",Actionable,8175,3908,non-small cell lung carcinoma,DOID,1128,KRAS G12S,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4656,Everolimus + Pimasertib,3845
16,Preclinical - Cell culture,"In a preclinical study, the combination of APS-2-49 and PD-0325901 worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948).",Actionable,8016,1324,lung cancer,DOID,1128,KRAS G12S,"[{'id': 6534, 'pubMedId': 27556948, 'title': 'Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27556948'}]",sensitive,4623,APS-2-79 + PD-0325901,3845
17,Preclinical - Cell culture,"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12S mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8987,3910,lung adenocarcinoma,DOID,1128,KRAS G12S,"[{'id': 6848, 'pubMedId': 27422710, 'title': 'Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27422710'}]",decreased response,807,Binimetinib,3845
18,Preclinical - Cell culture,"In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948).",Actionable,8012,1324,lung cancer,DOID,1128,KRAS G12S,"[{'id': 6534, 'pubMedId': 27556948, 'title': 'Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27556948'}]",sensitive,4620,APS-2-79 + Trametinib,3845
19,Preclinical,"In a preclinical study, pancreatic cell lines with KRAS codon 12 mutations had increased sensitivity to Binimetinib (MEK162) (PMID: 25167228).",Actionable,1445,1793,pancreatic cancer,DOID,1128,KRAS G12S,"[{'id': 1294, 'pubMedId': 25167228, 'title': 'KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25167228'}]",sensitive,807,Binimetinib,3845
20,Preclinical,"In a preclinical study, a lung adenocarcinoma cell line harboring KRAS G12S demonstrated a decreased response when treated with Refametinib (BAY86-9766) in culture (PMID: 26582713). ",Actionable,6451,1324,lung cancer,DOID,1128,KRAS G12S,"[{'id': 5602, 'pubMedId': 26582713, 'title': 'Identification of an ""Exceptional Responder"" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26582713'}]",decreased response,888,Refametinib,3845
21,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12S mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8995,3910,lung adenocarcinoma,DOID,1128,KRAS G12S,"[{'id': 6848, 'pubMedId': 27422710, 'title': 'Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27422710'}]",decreased response,913,Selumetinib,3845
22,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a human non-small cell lung cancer cell line harboring KRAS G12S and an STK11(LKB) inactivating mutation (PMID: 25637314).",Actionable,6336,3908,non-small cell lung carcinoma,DOID,23102,KRAS G12S STK11 inact mut,"[{'id': 5522, 'pubMedId': 25637314, 'title': 'The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25637314'}]",sensitive,1050,XL147,3845
23,Preclinical,"In a preclinical study, expression of KRAS G12S in lung adenocarcinoma cells harboring EGFR exon 19 deletion resulted in resistance to Tagrisso (osimertinib) in culture, consistent with KRAS G12S identified in tumor samples of a lung adenocarcinoma patient harboring EGFR exon 19 deletion who developed resistance to Tagrisso (osimertinib) (PMID: 27252416).",Actionable,8803,3910,lung adenocarcinoma,DOID,26445,EGFR exon 19 del KRAS G12S,"[{'id': 6756, 'pubMedId': 27252416, 'title': 'Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27252416'}]",resistant,660,Osimertinib,3845
24,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 in culture (PMID: 27312529).",Actionable,7686,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4544,Dabrafenib + SCH772984,3845
25,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment in culture, likely due to the acquired KRAS amplification (PMID: 27312529).",Actionable,7625,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4525,Cetuximab + Dabrafenib,3845
26,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7684,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1711,Vemurafenib + Cetuximab,3845
27,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",Actionable,7683,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1916,Cetuximab + Encorafenib,3845
28,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",Actionable,7685,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,2618,SCH772984,3845
29,Preclinical - Cell culture,"In a preclinical study, a lung cancer cell line with co-amplification of FGFR1 and KRAS demonstrated insensitivity to JNJ-42756493 (erdafitinib) in culture (PMID: 28341788).",Actionable,11187,1324,lung cancer,DOID,27925,FGFR1 amp KRAS amp,"[{'id': 9140, 'pubMedId': 28341788, 'title': 'Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28341788'}]",resistant,1028,JNJ-42756493,3845
30,Preclinical,"In a preclinical study, the combination of Tagrisso (osimertinib) and Selumetinib increased Parp cleavage, and highly suppressed phosphorylated Erk in human non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and a gain in KRAS in culture (PMID: 25870145).",Actionable,4500,3908,non-small cell lung carcinoma,DOID,18232,EGFR exon 19 del EGFR T790M KRAS amp,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",sensitive,2225,Osimertinib + Selumetinib,3845
31,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M and amplified KRAS were resistant to Tagrisso (osimertinib) treatment in culture (PMID: 25870145).",Actionable,4475,3908,non-small cell lung carcinoma,DOID,18232,EGFR exon 19 del EGFR T790M KRAS amp,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,660,Osimertinib,3845
32,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of EGFR T790M and amplified KRAS in culture (PMID: 25870145).",Actionable,4474,3908,non-small cell lung carcinoma,DOID,18232,EGFR exon 19 del EGFR T790M KRAS amp,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,751,Gefitinib,3845
33,Preclinical,"In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells with amplification of PIK3CA and KRAS in culture (PMID: 22662154).",Actionable,2142,1380,endometrial cancer,DOID,5417,PIK3CA amp KRAS amp,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",sensitive,2619,BEZ235 + PD98509,3845
34,Phase III,"In retrospective study of a Phase III trial, melanoma patients harboring KRAS amplification treated with a combination of Paraplatin (carboplatin), Taxol (paclitaxel), and Nexavar (sorafenib) demonstrated a greater overall survival when compared to Paraplatin (carboplatin) and Taxol (paclitaxel) without Nexavar (sorafenib) (PMID: 26307133).",Actionable,4086,1909,melanoma,DOID,1413,KRAS amp,"[{'id': 4403, 'pubMedId': 26307133, 'title': 'Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26307133'}]",sensitive,3428,Sorafenib + Carboplatin + Paclitaxel,3845
35,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified KRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4481,3908,non-small cell lung carcinoma,DOID,18233,EGFR exon 19 del KRAS amp,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,660,Osimertinib,3845
36,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified KRAS in culture (PMID: 25870145).",Actionable,4480,3908,non-small cell lung carcinoma,DOID,18233,EGFR exon 19 del KRAS amp,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,623,Afatinib,3845
37,Preclinical - Pdx,"In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12F and PIK3CA H1047R (PMID: 26855149).",Actionable,10884,3910,lung adenocarcinoma,DOID,27820,KRAS G12F PIK3CA H1047R,"[{'id': 8887, 'pubMedId': 26855149, 'title': 'Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26855149'}]",sensitive,5671,Dasatinib + Demcizumab,3845
38,Clinical Study,"In a retrospective study, Erbitux (cetuximab) treatment, alone or in combination, resulted in disease regression or stable disease in 88% (7/8) KRAS/BRAF-wild type colorectal carcinoma patients harboring a PIK3CA mutation (PMID: 25714871).",Actionable,3671,9256,colorectal cancer,DOID,14283,BRAF wild-type KRAS wild-type PIK3CA mutant,"[{'id': 3888, 'pubMedId': 25714871, 'title': 'AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25714871'}]",sensitive,694,Cetuximab,3845
39,Phase II,"In a Phase II clinical trial, 30% (8/27) of patients with ERBB2 (HER2)-positive KRAS wild-type colorectal cancer achieved an objective response and 44% (12/27) of patients had stable disease when treated with the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 27108243).",Actionable,6482,9256,colorectal cancer,DOID,23355,ERBB2 positive KRAS wild-type,"[{'id': 5566, 'pubMedId': 27108243, 'title': 'Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27108243'}]",sensitive,1414,Trastuzumab + Lapatinib,3845
40,Phase III,"In a Phase III trial, Avastin (bevacizumab) and Xeloda (capecitabine) maintenance treatment resulted in better time to first progression (HR = 0.27), time to second progression (HR = 0.42) and overall survival (HR = 0.64) in KRAS wild-type colorectal cancer patients compared to patients harboring KRAS mutations (HR = 0.40, 0.75, 1.07 respectively) (J Clin Oncol 34, 2016 (suppl; abstr 3525)).",Actionable,6954,9256,colorectal cancer,DOID,496,KRAS wild-type,"[{'id': 5985, 'pubMedId': None, 'title': 'Predictive value of KRAS mutation status in metastatic colorectal cancer (mCRC) patients treated with capecitabine and bevacizumab (CAP-B) maintenance treatment vs observation in the phase III CAIRO3 study.', 'url': 'http://meetinglibrary.asco.org/content/162510-176'}]",predicted – sensitive,2097,Bevacizumab + Capecitabine,3845
41,Phase Ib/II,"In a Phase Ib/II clinical trial, BBI608 and Vectibix (panitumumab) combination therapy resulted in PR in 22.2% (2/9), SD in 22.2% (2/9), and median PFS of 9 weeks in colorectal cancer patients carrying wild-type Kras naive for anti-EGFR therapy; compared to SD in 53.3% (8/15), and median PFS of 16.4 weeks in patients failed anti-EGFR treatment (J Clin Oncol 33, 2015 (suppl; abstr 3617)). ",Actionable,5442,9256,colorectal cancer,DOID,496,KRAS wild-type,"[{'id': 5055, 'pubMedId': None, 'title': 'A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy.', 'url': 'http://meetinglibrary.asco.org/content/153568-156'}]",predicted – sensitive,2092,BBI608 + Panitumumab,3845
42,Preclinical,"In a preclinical study, treatment with GA201 induced antibody-dependent cell-mediated cytotoxicity against KRAS wild-type gastric adenocarcinoma in culture, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3872,3717,gastric adenocarcinoma,DOID,496,KRAS wild-type,"[{'id': 3814, 'pubMedId': 23209031, 'title': 'GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209031'}]",sensitive,3154,GA201,3845
43,Phase III,"In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with RAS wild-type colorectal cancer compared to FOLFIRI treatment alone (PMID: 26341920).",Actionable,3268,9256,colorectal cancer,DOID,496,KRAS wild-type,"[{'id': 3703, 'pubMedId': 26341920, 'title': 'Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26341920'}]",sensitive,3102,Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan,3845
44,Phase III,"In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with KRAS exon 2 wild-type colorectal cancer compared to FOLFIRI treatment alone, with an overall response rate of 35% (105/297) with the combination versus 10% (28/285) with FOLFIRI alone (PMID: 26341920).",Actionable,3264,9256,colorectal cancer,DOID,496,KRAS wild-type,"[{'id': 3703, 'pubMedId': 26341920, 'title': 'Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26341920'}]",sensitive,3102,Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan,3845
45,Guideline,Vectibix (panitumumab) has demonstrated clinical efficacy only in colorectal cancer patients with wild-type KRAS (PMID: 18316791).  ,Actionable,578,10000003,Advanced Solid Tumor,JAX,496,KRAS wild-type,"[{'id': 340, 'pubMedId': 18316791, 'title': 'Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18316791'}]",sensitive,845,Panitumumab,3845
46,Preclinical - Cell line xenograft,"In a preclinical study, Glucophage (metformin) did not induce growth inhibition or apoptosis in a KRAS wild-type squamous cell carcinoma cell line in culture and did not inhibit tumor growth in xenograft models (PMID: 23877793).",Actionable,3222,1749,squamous cell carcinoma,DOID,496,KRAS wild-type,"[{'id': 342, 'pubMedId': 23877793, 'title': 'K‑ras gene mutation as a predictor of cancer cell responsiveness to metformin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23877793'}]",no benefit,1031,Metformin,3845
47,Phase III,"In a Phase III trial, Nexavar (sorafenib) treatment in KRAS wild-type non-small cell lung carcinoma patients did not meet its primary endpoint when compared to placebo, resulting in a similar overall survival, however, did meet its secondary endpoint, showing a longer progression free survival (PMID: 26743856).",Actionable,7711,3908,non-small cell lung carcinoma,DOID,496,KRAS wild-type,"[{'id': 6454, 'pubMedId': 26743856, 'title': 'Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26743856'}]",no benefit,920,Sorafenib,3845
48,Phase II,"In a Phase II clinical trial, the combination of Portrazza (necitumumab) and FOLFOX in colorectal cancer patients resulted in an objective response rate (ORR) of 63.6% (28/44) in the overall intent-to-treat population, with KRAS wild-type patients achieving an ORR of 87.5% (14/16), including complete response in 25% (4/16), and partial response in 62.5% (10/16) of patients (PMID: 26766738). ",Actionable,4368,9256,colorectal cancer,DOID,496,KRAS wild-type,"[{'id': 4508, 'pubMedId': 26766738, 'title': 'Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26766738'}]",predicted – sensitive,3498,Necitumumab + FOLFOX,3845
49,Phase I,"In a Phase I trial, Erbitux (cetuximab) and Revlimid (lenalidomide) combination therapy resulted in partial response in 5% (1/19) and stable disease in 32% (6/19) of KRAS wild-type colorectal cancer patients, and induced Revlimid (lenalidomide) dose-dependent increase of antibody-dependent cellular cytotoxicity (PMID: 27458141).",Actionable,8150,9256,colorectal cancer,DOID,496,KRAS wild-type,"[{'id': 6559, 'pubMedId': 27458141, 'title': 'A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27458141'}]",predicted – sensitive,4647,Cetuximab + lenalidomide,3845
50,Phase III,"In a post-hoc analysis of a Phase III trial, colorectal cancer patients with KRAS wild-type demonstrated a greater overall survival (8.1 mo) upon treatment with Vectibix (panitumumab) compared to overall survival (4.4 mo) of patients with KRAS mutations randomized to best supportive care only (PMID: 23625191).",Actionable,5505,9256,colorectal cancer,DOID,496,KRAS wild-type,"[{'id': 5071, 'pubMedId': 23625191, 'title': 'An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23625191'}]",sensitive,845,Panitumumab,3845
51,Phase III,"In a Phase III trial, Vectibix (panitumumab) treatment resulted in better overall survival (HR = 0.65) compared to Erbitux (cetuximab) in colorectal cancer patients harboring KRAS with wild-type exon 2 who received prior Avastin (bevacizumab) treatment (J Clin Oncol 34, 2016 (suppl; abstr 3538)).",Actionable,6955,9256,colorectal cancer,DOID,496,KRAS wild-type,"[{'id': 5986, 'pubMedId': None, 'title': 'Efficacy of panitumumab vs cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT.', 'url': 'http://meetinglibrary.asco.org/content/165575-176'}]",sensitive,845,Panitumumab,3845
52,FDA approved,Vectibix (panitumumab) has demonstrated clinical efficacy only in colorectal cancer patients with wild-type KRAS (PMID: 18316791).  ,Actionable,582,9256,colorectal cancer,DOID,496,KRAS wild-type,"[{'id': 340, 'pubMedId': 18316791, 'title': 'Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18316791'}]",sensitive,845,Panitumumab,3845
53,Phase III,"In a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI demonstrated a significant clinical benefit in OS, PFS, and objective response compared to FOLFIRI alone in colorectal cancer patients with RAS wild-type status (PMID: 25605843). ",Actionable,3356,9256,colorectal cancer,DOID,496,KRAS wild-type,"[{'id': 3760, 'pubMedId': 25605843, 'title': 'Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605843'}]",predicted – sensitive,2180,Cetuximab + FOLFIRI,3845
54,Phase III,"In a Phase III trial, addition of Erbitux (cetuximab) or Avastin (bevacizumab) to chemotherapy (FOLFIRI or mFOLFOX6) resulted in similar median overall survival (30.0 vs 29.0 months, HR=0.88, p=0.08) and median progression-free survival (10.5 vs 10.6 months, HR=0.95, p?=?0.45) in KRAS wild-type colorectal cancer patients (PMID: 28632865).",Actionable,11285,9256,colorectal cancer,DOID,496,KRAS wild-type,"[{'id': 9206, 'pubMedId': 28632865, 'title': 'Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28632865'}]",predicted – sensitive,694,Cetuximab,3845
55,Phase Ib/II,"In a Phase Ib/II trial, the combination of Erbitux (cetuximab), Sprycel (dasatinib), and FOLFOX demonstrated minimal clinical benefit in patients with metastatic colorectal adenocarcinoma, with an overall response rate of 20% (6/30) in the Phase Ib portion, and 13% (3/24) in KRAS codon 12/13 wild-type patients in the Phase II portion (PMID: 28280091; NCT00501410).",Actionable,11609,50861,colorectal adenocarcinoma,DOID,496,KRAS wild-type,"[{'id': 9667, 'pubMedId': 28280091, 'title': 'Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28280091'}]",no benefit,6074,Cetuximab + Dasatinib + FOLFOX,3845
56,Phase Ib/II,"In a Phase Ib trial, Cometriq (cabozantinib) and Vectibix (panitumumab) combination treatment resulted in a median progression free survival of 3.7 months, median overall survival of 7.5 months, and partial response in 14% (2/14) of KRAS wild-type colorectal patients (J Clin Oncol 34, 2016 (suppl; abstr 3548)). ",Actionable,6964,9256,colorectal cancer,DOID,496,KRAS wild-type,"[{'id': 5988, 'pubMedId': None, 'title': 'Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).', 'url': 'http://meetinglibrary.asco.org/content/166423-176'}]",sensitive,1985,Panitumumab + cabozantinib,3845
57,Phase Ib/II,"In a Phase Ib/II trial, the combination of HGF inhibitor, rilotumumab, with Vectibix (panitumumab) demonstrated efficacy in previously treated patients with wild-type KRAS metastatic colorectal cancer (PMID: 24919569).",Actionable,1454,9256,colorectal cancer,DOID,496,KRAS wild-type,"[{'id': 1308, 'pubMedId': 24919569, 'title': 'Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24919569'}]",sensitive,1775,Rilotumumab + Panitumumab,3845
58,Phase I,"In a Phase I trial, Tarceva (erlotinib) treatment resulted in a greater survival benefit in non-small cell lung cancer patients with wild-type KRAS compared to treatment in those patients harboring KRAS mutations (PMID: 18626007).
",Actionable,7859,3908,non-small cell lung carcinoma,DOID,496,KRAS wild-type,"[{'id': 6515, 'pubMedId': 18626007, 'title': 'Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18626007'}]",sensitive,4,Erlotinib,3845
59,Phase I,"In a Phase I trial, GDC-0632 treatment resulted in stable disease for more than 5 months in 13% (6/45) of patients with advanced solid tumors and 1 partial response in a squamous cell vaginal carcinoma patient carrying wild-type KRAS (Mol Cancer Ther 2013;12(11 Suppl):B75).",Actionable,4013,138,vaginal squamous tumor,DOID,496,KRAS wild-type,"[{'id': 4367, 'pubMedId': None, 'title': 'A first in-human phase I study to evaluate the MEK1/2 inhibitor GDC-0623 in patients with advanced solid tumors.', 'url': 'http://mct.aacrjournals.org/content/12/11_Supplement/B75.short'}]",sensitive,748,GDC-0623,3845
60,Phase Ib/II,"In a Phase I/II trial, Refametinib (BAY86-9766) and Gemzar (gemcitabine) combination treatment resulted in improved overall response rate, disease control rate, progression-free survival, and overall survival (48% vs. 28%, 81% vs. 69%, 8.8 vs. 5.3 months,18.2 vs. 6.6 months, respectively) in pancreatic cancer patients without detectable KRAS mutations in circulating tumor DNA (PMID: 27975152).",Actionable,10503,1793,pancreatic cancer,DOID,496,KRAS wild-type,"[{'id': 8575, 'pubMedId': 27975152, 'title': 'Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27975152'}]",predicted – sensitive,5545,Gemcitabine + Refametinib,3845
61,Preclinical - Cell culture,"In a preclinical study, KRAS wild-type lung carcinoma cell lines demonstrated decreased respond to AZD4785 compared to KRAS mutant cell lines in culture (PMID: 28615361).",Actionable,11329,3905,lung carcinoma,DOID,496,KRAS wild-type,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",decreased response,5914,AZD4785,3845
62,Clinical Study,"In a systematic review of 2,266 colorectal cancer patients, treatment with Avastin (bevacizumab) increased progression-free survival in patients harboring wild-type KRAS but not in patients with mutant KRAS (PMID: 23828442).",Actionable,1282,9256,colorectal cancer,DOID,496,KRAS wild-type,"[{'id': 454, 'pubMedId': 23828442, 'title': 'KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23828442'}]",sensitive,667,Bevacizumab,3845
63,Phase III,"In a Phase III trial, addition of Erbitux (cetuximab) or Avastin (bevacizumab) to chemotherapy (FOLFIRI or mFOLFOX6) resulted in similar median overall survival (30.0 vs 29.0 months, HR=0.88, p=0.08) and median progression-free survival (10.5 vs 10.6 months, HR=0.95, p?=?0.45) in KRAS wild-type colorectal cancer patients (PMID: 28632865).",Actionable,11286,9256,colorectal cancer,DOID,496,KRAS wild-type,"[{'id': 9206, 'pubMedId': 28632865, 'title': 'Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28632865'}]",sensitive,667,Bevacizumab,3845
64,Preclinical - Pdx,"In a preclinical study, AZD4785 inhibited Kras expression in tumors, but had no effect on tumor growth in patient-derived xenograft models of KRAS wild-type non-small cell lung carcinoma (PMID: 28615361).",Actionable,11333,3908,non-small cell lung carcinoma,DOID,496,KRAS wild-type,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",decreased response,5914,AZD4785,3845
65,Preclinical,"In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) combination treatment was less efficient at inhibiting proliferation of KRAS wild-type lung cancer cells in culture (PMID: 27338794). ",Actionable,7369,1324,lung cancer,DOID,496,KRAS wild-type,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",decreased response,4477,Ponatinib + Trametinib,3845
66,Phase II,"In a Phase II clinical trial, a PFS difference was not observed between KRAS wild-type biliary tract cancer patients when treated with a combination of Vectibix (panitumumab), Gemzar (gemcitabine), and Eloxatin (oxaliplatin) versus Gemzar (gemcitabine) and Eloxatin (oxaliplatin) only (PMID: 26540314). ",Actionable,3686,4607,biliary tract cancer,DOID,496,KRAS wild-type,"[{'id': 3992, 'pubMedId': 26540314, 'title': 'Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26540314'}]",predicted – sensitive,3226,Panitumumab + Gemcitabine + Oxaliplatin,3845
67,Preclinical - Cell culture,"In a preclinical study, KRAS wild-type pancreatic cancer cells were less sensitive to Aphanin induced growth inhibition and apoptosis in culture (PMID: 27333990).",Actionable,9100,1793,pancreatic cancer,DOID,496,KRAS wild-type,"[{'id': 6915, 'pubMedId': 27333990, 'title': 'Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27333990'}]",decreased response,4900,Aphanin,3845
68,Phase I,"In a Phase I trial, Erbitux (cetuximab) and Revlimid (lenalidomide) combination therapy resulted in stable disease in 67% (2/3) of KRAS wild-type head and neck squamous cell cancer patients, and induced Revlimid (lenalidomide) dose-dependent increase of antibody-dependent cellular cytotoxicity (PMID: 27458141).",Actionable,8151,5520,head and neck squamous cell carcinoma,DOID,496,KRAS wild-type,"[{'id': 6559, 'pubMedId': 27458141, 'title': 'A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27458141'}]",predicted – sensitive,4647,Cetuximab + lenalidomide,3845
69,Preclinical - Cell culture,"In a preclinical study, KRAS wild-type colorectal cancer cell lines demonstrated decreased respond to AZD4785 compared to KRAS mutant cell lines in culture (PMID: 28615361).",Actionable,11331,9256,colorectal cancer,DOID,496,KRAS wild-type,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",decreased response,5914,AZD4785,3845
70,FDA approved,Clinical efficacy of Erbitux (cetuximab) has only been demonstrated in patients with wild-type KRAS (PMID: 19064407).  ,Actionable,577,10000003,Advanced Solid Tumor,JAX,496,KRAS wild-type,"[{'id': 130, 'pubMedId': 19064407, 'title': 'Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19064407'}]",sensitive,694,Cetuximab,3845
71,Phase I,"In a Phase I trial, GDC-0632 treatment resulted in stable disease for more than 5 months in 13% (6/45) of patients with advanced solid tumors and 1 partial response in a squamous cell vaginal carcinoma patient carrying wild-type KRAS (Mol Cancer Ther 2013;12(11 Suppl):B75).",Actionable,4012,10000003,Advanced Solid Tumor,JAX,496,KRAS wild-type,"[{'id': 4367, 'pubMedId': None, 'title': 'A first in-human phase I study to evaluate the MEK1/2 inhibitor GDC-0623 in patients with advanced solid tumors.', 'url': 'http://mct.aacrjournals.org/content/12/11_Supplement/B75.short'}]",sensitive,748,GDC-0623,3845
72,Preclinical - Cell line xenograft,"In a preclinical study, treatment with the combination of GA201 and Camptosar (irinotecan) resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to either as a single agent (PMID: 23209031).",Actionable,3873,9256,colorectal cancer,DOID,16552,EGFR dec exp KRAS wild-type,"[{'id': 3814, 'pubMedId': 23209031, 'title': 'GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209031'}]",sensitive,3373,GA201 + Irinotecan,3845
73,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3871,9256,colorectal cancer,DOID,16552,EGFR dec exp KRAS wild-type,"[{'id': 3814, 'pubMedId': 23209031, 'title': 'GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209031'}]",sensitive,3154,GA201,3845
74,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment did not result in enhanced antitumor activity compared to Ibrance (palbociclib) alone in PDX models of KRAS wild-type colorectal cancer harboring BRAF V600E (PMID: 26369631).",Actionable,5623,9256,colorectal cancer,DOID,21304,BRAF V600E KRAS wild-type,"[{'id': 5128, 'pubMedId': 26369631, 'title': 'Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26369631'}]",no benefit,1368,Palbociclib + Trametinib,3845
75,Clinical Study,"In a retrospective study, 100% (2/2) colorectal carcinoma patients harboring an AKT1 E17K mutation and wild-type KRAS/BRAF demonstrated resistance to Erbitux (cetuximab) in combination with Camptosar (irinotecan) (PMID: 25714871).
",Actionable,3614,9256,colorectal cancer,DOID,13841,AKT1 E17K KRAS wild-type BRAF wild-type,"[{'id': 3888, 'pubMedId': 25714871, 'title': 'AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25714871'}]",resistant,1874,Cetuximab + Irinotecan,3845
76,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment did not result in enhanced antitumor activity compared to Ibrance (palbociclib) alone in PDX models of KRAS wild-type colorectal cancer harboring PIK3CA H1047R (PMID: 26369631).",Actionable,5622,9256,colorectal cancer,DOID,21303,KRAS wild-type PIK3CA H1047R,"[{'id': 5128, 'pubMedId': 26369631, 'title': 'Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26369631'}]",no benefit,1368,Palbociclib + Trametinib,3845
77,Phase I,"In a Phase I trial, a squamous non-small cell lung carcinoma patient with KRAS wild-type and loss of CDKN2A demonstrated a partial response when treated with Abemaciclib (LY2835219) (PMID: 27217383). ",Actionable,7431,3908,non-small cell lung carcinoma,DOID,25455,CDKN2A loss KRAS wild-type,"[{'id': 6356, 'pubMedId': 27217383, 'title': 'Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27217383'}]",sensitive,802,Abemaciclib,3845
78,Preclinical - Pdx,"In a preclinical study, LSN3074753 demonstrated limited efficacy in BRAF and KRAS wild-type patient-derived xenograft models of colorectal cancer, resulted in a disease control rate of 3.8% (1/26) (PMID: 28611205).",Actionable,12189,9256,colorectal cancer,DOID,28546,BRAF wild-type KRAS wild-type,"[{'id': 10143, 'pubMedId': 28611205, 'title': 'Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28611205'}]",decreased response,6337,LSN3074753,3845
79,Preclinical,"In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS wild-type lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture  (PMID: 27338794).",Actionable,7364,1324,lung cancer,DOID,25310,FGFR1 dec exp KRAS wild-type,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",no benefit,2,Trametinib,3845
80,Preclinical,"In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells wild-type for BRAF, KRAS, NRAS and PIK3CA in culture (PMID: 25838391).",Actionable,4934,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",sensitive,694,Cetuximab,3845
81,Preclinical,"In a preclinical study, colorectal cancer cell lines with wild-type BRAF, KRAS, NRAS and PIK3CA were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4944,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",resistant,890,Regorafenib,3845
82,Phase II,"In a Phase II trial, Erbitux (cetuximab) in combination with FOLFOX resulted in improved median progression-free survival (6.9 months) comparing to FOLFOX alone (5.3 months) in BRAF, KRAS, NRAS, and PIK3CA wild-type colorectal cancer patients (hazard ratio =0.56) (PMID: 27002107).",Actionable,5563,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,"[{'id': 5108, 'pubMedId': 27002107, 'title': 'Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27002107'}]",predicted – sensitive,2182,Cetuximab + FOLFOX,3845
83,Preclinical - Cell culture,"In a preclinical study, the combination of Gilotrif (afatinib) and Mekinist (trametinib) worked synergistically to inhibit growth of a pancreatic adenocarcinoma cell line with wild-type KRAS that demonstrated high EGFR expression and activation in culture (PMID: 28957417).",Actionable,12145,4074,pancreatic adenocarcinoma,DOID,28493,EGFR over exp KRAS wild-type,"[{'id': 10109, 'pubMedId': 28957417, 'title': 'Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28957417'}]",sensitive,4482,Afatinib + Trametinib,3845
84,Preclinical - Cell culture,"In a preclinical study, the combination of Triciribine (API-2) and Mekinist (trametinib) worked synergistically to inhibit growth of a pancreatic adenocarcinoma cell line with wild-type KRAS that demonstrated high EGFR expression and activation in culture (PMID: 28957417).",Actionable,12146,4074,pancreatic adenocarcinoma,DOID,28493,EGFR over exp KRAS wild-type,"[{'id': 10109, 'pubMedId': 28957417, 'title': 'Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28957417'}]",sensitive,6312,Trametinib + Triciribine,3845
85,Preclinical - Cell culture,"In a preclinical study, lung cancer cell lines harboring activating KRAS mutations demonstrated increased sensitivity to Dinaciclib (SCH 727965) in culture (PMID: 27550941).",Actionable,9139,1324,lung cancer,DOID,16855,KRAS act mut,"[{'id': 6931, 'pubMedId': 27550941, 'title': 'Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550941'}]",predicted – sensitive,719,Dinaciclib,3845
86,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) and AZ628 synergistically inhibited Mapk signaling and cell proliferation in colorectal cancer cell lines harboring KRAS activating mutations in culture (PMID: 26351322).",Actionable,8679,9256,colorectal cancer,DOID,16855,KRAS act mut,"[{'id': 6708, 'pubMedId': 26351322, 'title': 'Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26351322'}]",sensitive,4791,AZ628 + Selumetinib,3845
87,Preclinical - Cell culture,"In a preclinical study, inhibition of Erk signaling by VX-11e did not sensitize colorectal cancer cell lines harboring KRAS or BRAF activating mutations to Venclexta (venetoclax) in culture (PMID: 27974663).",Actionable,10076,9256,colorectal cancer,DOID,16855,KRAS act mut,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",no benefit,5375,Venetoclax + VX-11e,3845
88,Preclinical - Cell culture,"In a preclinical study, inhibition of Erk signaling by VX-11e sensitized colorectal cancer cell lines harboring KRAS or BRAF activating mutations to WEHI-539 in culture (PMID: 27974663).",Actionable,10074,9256,colorectal cancer,DOID,16855,KRAS act mut,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",predicted – sensitive,5374,VX-11e + WEHI-539,3845
89,Preclinical,"In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells harboring PIK3CA G1049R, KRAS G12D, and amplification of PIK3CA in culture (PMID: 22662154).",Actionable,2143,1380,endometrial cancer,DOID,5398,PIK3CA G1049R KRAS G12D PIK3CA amp,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",sensitive,2619,BEZ235 + PD98509,3845
90,Preclinical - Cell line xenograft,"In a preclinical study, Glucophage (metformin) inhibited cell proliferation and induced apoptosis in a PTEN-expressing human endometrial cancer cell line harboring KRAS G12D in culture and decreased tumor growth in xenograft models (PMID: 24077915).",Actionable,590,1380,endometrial cancer,DOID,26548,PTEN pos KRAS G12D,"[{'id': 986, 'pubMedId': 24077915, 'title': 'Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24077915'}]",sensitive,1031,Metformin,3845
91,Preclinical,"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH2 R172K and KRAS G12D demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition in culture (PMID: 27231123).",Actionable,7354,4928,intrahepatic cholangiocarcinoma,DOID,25295,IDH2 R172K KRAS G12D,"[{'id': 6322, 'pubMedId': 27231123, 'title': 'Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27231123'}]",sensitive,912,Saracatinib,3845
92,Preclinical,"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH2 R172K and KRAS G12D demonstrated increased sensitivity to Sprycel (dasatinib) induced growth inhibition in culture and in xenograft models (PMID: 27231123).",Actionable,7353,4928,intrahepatic cholangiocarcinoma,DOID,25295,IDH2 R172K KRAS G12D,"[{'id': 6322, 'pubMedId': 27231123, 'title': 'Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27231123'}]",sensitive,717,Dasatinib,3845
93,Preclinical,"In a preclinical study, KRAS G12D was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).",Actionable,6654,3910,lung adenocarcinoma,DOID,23661,EGFR L858R KRAS G12D,"[{'id': 5721, 'pubMedId': 26341921, 'title': 'Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26341921'}]",resistant,4190,Afatinib + Cetuximab,3845
94,Preclinical,"In a preclinical study, AZD5363 inhibited proliferation of the AGS gastric cancer cell line, which has been reported to harbor KRAS G12D and PIK3CA E453K mutations (PMID: 24088382, PMID: 19755509).",Actionable,2860,10534,stomach cancer,DOID,10717,KRAS G12D PIK3CA E453K,"[{'id': 1081, 'pubMedId': 24088382, 'title': 'The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24088382'}, {'id': 3510, 'pubMedId': 19755509, 'title': 'Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19755509'}]",sensitive,655,AZD5363,3845
95,Preclinical,"In a preclinical study, a human gastric cancer cell line with high levels of MET expression and expressing KRAS G12D was resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26432108).",Actionable,4082,10534,stomach cancer,DOID,17217,KRAS G12D MET over exp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",resistant,706,Crizotinib,3845
96,Clinical Study,"In a clinical case study, a patient with colorectal cancer harboring KRAS G12D and PIK3CA Q546R demonstrated sensitivity to treatment with the combination of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for more than 6 months (PMID: 25363205). ",Actionable,7768,9256,colorectal cancer,DOID,27864,KRAS G12D PIK3CA Q546R,"[{'id': 6478, 'pubMedId': 25363205, 'title': 'Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25363205'}]",sensitive,4517,Bevacizumab + Sorafenib,3845
97,Preclinical,"In a preclinical study, SRA737 (CCT245737) resulted in some decreased tumor volume in a pancreatic ductal adenocarcinoma transgenic mouse model harboring KRAS G12D and TP53 R175H when compared to control (PMID: 27167172). ",Actionable,9550,3498,pancreatic ductal adenocarcinoma,DOID,18195,KRAS G12D TP53 R175H,"[{'id': 7267, 'pubMedId': 27167172, 'title': 'Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27167172'}]",sensitive,5069,SRA737,3845
98,Preclinical,"In a preclinical study, the combination of pimasertib and Gemzar (gemcitabine) inhibited tumor growth in a syngeneic mouse model of pancreatic cancer expressing KRAS G12D and TP53 R175H (PMID: 26228206).",Actionable,4467,1793,pancreatic cancer,DOID,18195,KRAS G12D TP53 R175H,"[{'id': 4571, 'pubMedId': 26228206, 'title': 'The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26228206'}]",sensitive,3526,Pimasertib + Gemcitabine,3845
99,Preclinical,"In a preclinical study, Rapamune (sirolimus) treatment in transgenic animal models of pancreatic ductal adenocarcinoma harboring KRAS G12D and TP53 R175H resulted in proliferation of tumor cells in interior, hypovascularized tumor regions, but inhibited proliferation in outer, vascularized tumor regions, despite inhibition of mTORC signaling in both regions (PMID: 26144316).",Actionable,8856,3498,pancreatic ductal adenocarcinoma,DOID,18195,KRAS G12D TP53 R175H,"[{'id': 6770, 'pubMedId': 26144316, 'title': 'The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144316'}]",conflicting,917,Sirolimus,3845
100,Preclinical,"In a preclinical study, PI-3065 treatment prolonged survival and decreased metastasis in allograft animal models of pancreatic ductal adenocarcinoma harboring KRAS G12D and TP53 R175H through upregulation of host anti-tumor immune response(PMID: 24919154).",Actionable,5164,3498,pancreatic ductal adenocarcinoma,DOID,18195,KRAS G12D TP53 R175H,"[{'id': 3350, 'pubMedId': 24919154, 'title': 'Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24919154'}]",not applicable,2965,PI-3065,3845
101,Preclinical,"In a preclinical study, Gemzar (gemcitabine) resulted in enhanced antitumor efficacy, including decreased tumor volume, when combined with SRA737 (CCT245737) in a pancreatic ductal adenocarcinoma transgenic mouse model harboring KRAS G12D and TP53 R175H (PMID: 27167172). ",Actionable,9549,3498,pancreatic ductal adenocarcinoma,DOID,18195,KRAS G12D TP53 R175H,"[{'id': 7267, 'pubMedId': 27167172, 'title': 'Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27167172'}]",sensitive,5070,Gemcitabine + SRA737,3845
102,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of colorectal cancer cells harboring KRAS G12D and PIK3CA Q546L (PMID: 26369631).",Actionable,5619,9256,colorectal cancer,DOID,21301,KRAS G12D PIK3CA Q546L,"[{'id': 5128, 'pubMedId': 26369631, 'title': 'Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26369631'}]",sensitive,1368,Palbociclib + Trametinib,3845
103,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",Actionable,8702,9256,colorectal cancer,DOID,26376,KRAS G12D PIK3CA H1047R TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",decreased response,913,Selumetinib,3845
104,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",Actionable,8601,9256,colorectal cancer,DOID,26376,KRAS G12D PIK3CA H1047R TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,1420,Selumetinib + BEZ235,3845
105,Preclinical - Pdx,"In a preclinical study, BEZ235 inhibited tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",Actionable,8703,9256,colorectal cancer,DOID,26376,KRAS G12D PIK3CA H1047R TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",predicted – sensitive,672,BEZ235,3845
106,Preclinical,"In a preclinical study, Sapanisertib (MLN0128) inhibited lung tumor growth in mouse models with KRAS G12D and inactivation of STK11 (LKB1), and demonstrated limited efficacy in tumors with KRAS G12D and wild-type STK11 (PMID: 26574479).",Actionable,5409,1324,lung cancer,DOID,20862,KRAS G12D STK11 inact mut,"[{'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",sensitive,1282,Sapanisertib,3845
107,Preclinical,"In a preclinical study, BEZ235 did not induce tumor shrinkage in mouse lung cancer models carrying KRAS G12D (PMID: 19029981).",Actionable,1290,1324,lung cancer,DOID,746,KRAS G12D,"[{'id': 216, 'pubMedId': 19029981, 'title': 'Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19029981'}]",no benefit,672,BEZ235,3845
108,Preclinical - Cell line xenograft,"In a preclinical study, Pictilisib (GDC-0941) demonstrated limited efficacy as a single agent in a pancreatic cell line xenograft model harboring KRAS G12D (PMID: 22952903).",Actionable,2764,1793,pancreatic cancer,DOID,746,KRAS G12D,"[{'id': 3462, 'pubMedId': 22952903, 'title': 'K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22952903'}]",decreased response,749,GDC-0941,3845
109,Preclinical,"In a preclinical study, the treatment of KRAS G12D mutant mouse lung cancer with PX-866, a PI3K inhibitor, resulted in inhibition of tumor growth (PMID: 18493606). ",Actionable,980,3910,lung adenocarcinoma,DOID,746,KRAS G12D,"[{'id': 641, 'pubMedId': 18493606, 'title': 'Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18493606'}]",sensitive,881,PX-866,3845
110,Preclinical,"In a preclinical study, the combination of Buparlisib (BKM120) and Tyrphostin B42 (AG-490) worked synergistically to inhibit proliferation and induce apoptosis in gastric cancer cell lines harboring KRAS G12D in culture (PMID: 22159814).",Actionable,2739,10534,stomach cancer,DOID,746,KRAS G12D,"[{'id': 3447, 'pubMedId': 22159814, 'title': 'NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22159814'}]",sensitive,3019,BKM120 + AG490,3845
111,Preclinical,"In a preclinical study, UC-857993 did not inhibit growth of pancreatic cancer cells harboring KRAS G12D in culture (PMID: 25825487).",Actionable,2464,1793,pancreatic cancer,DOID,746,KRAS G12D,"[{'id': 3114, 'pubMedId': 25825487, 'title': 'Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25825487'}]",resistant,2861,UC-857993,3845
112,Preclinical,"In a preclinical study, a colorectal cancer cell line harboring the KRAS G12D mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).",Actionable,803,9256,colorectal cancer,DOID,746,KRAS G12D,"[{'id': 26, 'pubMedId': 23455880, 'title': 'KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23455880'}]",resistant,930,Sunitinib,3845
113,Preclinical,"In a preclinical study, the treatment of a mouse model lung adenocarcinoma harboring the KRAS G12D mutant with selumetinib, a MEK inhibitor, resulted in modest tumor regression (PMID: 19029981).",Actionable,978,3910,lung adenocarcinoma,DOID,746,KRAS G12D,"[{'id': 216, 'pubMedId': 19029981, 'title': 'Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19029981'}]",decreased response,913,Selumetinib,3845
114,Clinical Study,"In a clinical case study, a patient with metastatic colorectal cancer harboring KRAS G12D demonstrated regression of metastatic lung lesions and a partial response for 9 months following infusion of autologous tumor-infiltrating lymphocytes containing cytotoxic T-cells that specifically recognize KRAS G12D (PMID: 27959684).",Actionable,9636,9256,colorectal cancer,DOID,746,KRAS G12D,"[{'id': 7358, 'pubMedId': 27959684, 'title': 'T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27959684'}]",sensitive,5112,KRAS mutant-specific TIL,3845
115,Preclinical,"In a preclinical study, PD-0325901 inhibited growth of lung adenocarcinomas in mouse models expressing Kras G12D (PMID: 22684718).",Actionable,2733,3910,lung adenocarcinoma,DOID,746,KRAS G12D,"[{'id': 3443, 'pubMedId': 22684718, 'title': 'Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22684718'}]",sensitive,849,PD-0325901,3845
116,Preclinical,"In a preclinical study, LY294002 reduced phosphorylation of Akt in pancreatic epithelial cells expressing Kras G12D (PMID: 22871572). ",Actionable,2730,10000003,Advanced Solid Tumor,JAX,746,KRAS G12D,"[{'id': 3442, 'pubMedId': 22871572, 'title': 'KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22871572'}]",sensitive,1062,LY294002,3845
117,Preclinical - Cell culture,"In a preclinical study, AUY922 inhibited growth of a colon cancer cell line harboring KRAS G12D in culture (PMID: 26832792).",Actionable,9211,219,colon cancer,DOID,746,KRAS G12D,"[{'id': 5083, 'pubMedId': 26832792, 'title': 'Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26832792'}]",sensitive,647,AUY922,3845
118,Preclinical - Cell culture,"In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of pancreatic cancer cells harboring KRAS G12D (PMID: 28615361).",Actionable,11327,1793,pancreatic cancer,DOID,746,KRAS G12D,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",sensitive,5914,AZD4785,3845
119,Preclinical,"In a preclinical study, BEZ235 in combination with Selumetinib (AZD6244) induced tumor shrinkage in mouse lung cancer models carrying KRAS G12D (PMID: 19029981).",Actionable,1291,1324,lung cancer,DOID,746,KRAS G12D,"[{'id': 216, 'pubMedId': 19029981, 'title': 'Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19029981'}]",sensitive,1420,Selumetinib + BEZ235,3845
120,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Pictilisib (GDC-0941) and Selumetinib (AZD6244) worked synergistically to induce tumor regression in a pancreatic cancer cell line xenograft model harboring KRAS G12D (PMID: 22952903).",Actionable,2763,1793,pancreatic cancer,DOID,746,KRAS G12D,"[{'id': 3462, 'pubMedId': 22952903, 'title': 'K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22952903'}]",sensitive,3024,GDC-0941 + Selumetinib,3845
121,Preclinical - Pdx,"In a preclinical study, LSN3074753 resulted in tumor regression in a patient-derived xenograft model of colorectal cancer harboring KRAS G12D, but relapse upon discontinuation of treatment (PMID: 28611205).",Actionable,12193,9256,colorectal cancer,DOID,746,KRAS G12D,"[{'id': 10143, 'pubMedId': 28611205, 'title': 'Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28611205'}]",predicted – sensitive,6337,LSN3074753,3845
122,Preclinical,"In a preclinical study, SH-1242 inhibited lung tumor growth in a KRAS G12D-expressing transgenic mouse model that forms spontaneous lung tumors (PMID: 26645561).",Actionable,4618,1324,lung cancer,DOID,746,KRAS G12D,"[{'id': 4627, 'pubMedId': 26645561, 'title': 'Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26645561'}]",sensitive,3552,SH-1242,3845
123,Preclinical,"In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment resulted in continued tumor growth in xenograft models of patient derived colorectal cancer cells harboring KRAS G12D (PMID: 26243863).",Actionable,7129,9256,colorectal cancer,DOID,746,KRAS G12D,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",resistant,4359,Neratinib + Trastuzumab,3845
124,Preclinical,"In a preclinical study, Pictilisib (GDC-0941) demonstrated efficacy in a mouse model of chronic myelomonocytic leukemia expressing KRAS G12D (ASH Annual Meeting Abstracts 2012 120: 2862).",Actionable,2759,4972,myelodysplastic/myeloproliferative neoplasm,DOID,746,KRAS G12D,"[{'id': 3460, 'pubMedId': None, 'title': 'The PI3K Inhibitor GDC-0941 Attenuates Disease in a KrasG12D Mouse Model of CMML and JMML.', 'url': 'http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/2862?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=GDC-0941&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT'}]",sensitive,749,GDC-0941,3845
125,Preclinical,"In a preclinical study, the combination of Mekinist (trametinib) and Iclusig (ponatinib) induced cell death in tumors and prolonged survival in an animal model of pancreatic cancer harboring KRAS G12D (PMID: 27338794).",Actionable,7377,1793,pancreatic cancer,DOID,746,KRAS G12D,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",sensitive,4477,Ponatinib + Trametinib,3845
126,Preclinical,"In a preclinical study, Estybon (rigosertib) inhibited tumorigenesis in transgenic animal model of pancreatic cancer driven by KRAS G12D (PMID: 27104980).",Actionable,8562,1793,pancreatic cancer,DOID,746,KRAS G12D,"[{'id': 6686, 'pubMedId': 27104980, 'title': 'A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27104980'}]",sensitive,1046,rigosertib,3845
127,Preclinical,"In a preclinical study, AZD8055 worked synergistically with MK-1775 to inhibit proliferation and promote apoptosis in transformed cells expressing KRAS G12D in culture (PMID: 24791855).",Actionable,2711,10000003,Advanced Solid Tumor,JAX,746,KRAS G12D,"[{'id': 422, 'pubMedId': 24791855, 'title': 'Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24791855'}]",sensitive,3017,AZD8055 + MK-1775,3845
128,Preclinical - Cell culture,"In a preclinical study, Aphanin inhibited proliferation and induced apoptosis in pancreatic cancer cells harboring KRAS G12D in culture (PMID: 27333990).",Actionable,9099,1793,pancreatic cancer,DOID,746,KRAS G12D,"[{'id': 6915, 'pubMedId': 27333990, 'title': 'Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27333990'}]",predicted – sensitive,4900,Aphanin,3845
129,Guideline,"Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).

",Actionable,1527,9256,colorectal cancer,DOID,746,KRAS G12D,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}, {'id': 1450, 'pubMedId': None, 'title': 'Vectibix label', 'url': 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125147s194lbl.pdf'}]",resistant,845,Panitumumab,3845
130,FDA approved,Patients with metastatic colorectal cancer harboring KRAS mutations in codons 12 or 13 showed resistance to Vectibix (panitumumab) (PMID: 18316791).,Actionable,583,9256,colorectal cancer,DOID,746,KRAS G12D,"[{'id': 340, 'pubMedId': 18316791, 'title': 'Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18316791'}]",resistant,845,Panitumumab,3845
131,Preclinical - Pdx,"In a preclinical study, LSN3074753 and Erbitux (cetuximab) worked synergistically, resulting in tumor regression in patient-derived xenograft models of colorectal cancer harboring KRAS G12D (PMID: 28611205).",Actionable,12196,9256,colorectal cancer,DOID,746,KRAS G12D,"[{'id': 10143, 'pubMedId': 28611205, 'title': 'Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28611205'}]",sensitive,6338,Cetuximab + LSN3074753,3845
132,Clinical Study,"In a clinical case report, treatment with Reolysin (pelareorep) in combination with Gemzar (gemcitabine) resulted in stable disease in a patient with pancreatic cancer harboring KRAS G12D (PMID: 26156229).",Actionable,2747,1793,pancreatic cancer,DOID,746,KRAS G12D,"[{'id': 3451, 'pubMedId': 26156229, 'title': 'The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26156229'}]",sensitive,3020,Reolysin + Gemcitabine,3845
133,Preclinical,"In a preclinical study, a mouse lung adenocarcinoma model harboring the KRAS G12D mutation treated with a combination of the MEK inhibitor selumetinib (AZD6244) and the PI3K inhibitor BEZ235 resulted in significant tumor regression (PMID: 19029981).",Actionable,979,3910,lung adenocarcinoma,DOID,746,KRAS G12D,"[{'id': 216, 'pubMedId': 19029981, 'title': 'Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19029981'}]",sensitive,1420,Selumetinib + BEZ235,3845
134,Preclinical - Pdx,"In a preclinical study, TAK-733 induce tumor regression in patient derived xenografts of cholangiocarcinoma with Kras G12D mutations (AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2523).",Actionable,2771,4947,cholangiocarcinoma,DOID,746,KRAS G12D,"[{'id': 3467, 'pubMedId': None, 'title': 'BRAF is not the only predictor of sensitivity in vitro and in vivo for TAK-733, a selective potent inhibitor of MEK1/2', 'url': 'http://cancerres.aacrjournals.org/content/70/8_Supplement/2523.short'}]",sensitive,932,TAK-733,3845
135,Preclinical,"In a preclinical study, UC-773587 did not inhibit growth of pancreatic cancer cells harboring KRAS G12D in culture (PMID: 25825487).",Actionable,2463,1793,pancreatic cancer,DOID,746,KRAS G12D,"[{'id': 3114, 'pubMedId': 25825487, 'title': 'Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25825487'}]",resistant,2860,UC-773587,3845
136,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).,Actionable,1524,9256,colorectal cancer,DOID,746,KRAS G12D,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,694,Cetuximab,3845
137,Clinical Study,"In a clinical study, KRAS mutations in codon 12 or 13 were associated with resistance to Erbitux (cetuximab) in colorectal cancer patients (PMID: 18202412).",Actionable,575,9256,colorectal cancer,DOID,746,KRAS G12D,"[{'id': 339, 'pubMedId': 18202412, 'title': 'KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18202412'}]",resistant,694,Cetuximab,3845
138,FDA approved,Colorectal cancer patients with KRAS mutations in exon 12 or 13 are resistant to Vectibix (panitumumab) (PMID: 18316791).,Actionable,579,10000003,Advanced Solid Tumor,JAX,746,KRAS G12D,"[{'id': 340, 'pubMedId': 18316791, 'title': 'Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18316791'}]",predicted – resistant,845,Panitumumab,3845
139,Preclinical,"In a preclinical study, Nerlynx (neratinib) treatment resulted in continued tumor growth in xenograft models of patient derived colorectal cancer cells harboring KRAS G12D (PMID: 26243863).",Actionable,7128,9256,colorectal cancer,DOID,746,KRAS G12D,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",resistant,828,Neratinib,3845
140,Preclinical,"In a preclinical study, Aliqopa (copanlisib) and Refametinib (BAY86-9766) worked synergistically to inhibit proliferation and increase apoptosis of biliary tract cancer cells harboring KRAS G12D in culture (Cancer Res April 15, 2012 72:869).",Actionable,2721,4607,biliary tract cancer,DOID,746,KRAS G12D,"[{'id': 3436, 'pubMedId': None, 'title': 'Abstract 869: Potent in vitro and in vivo anti-tumor activity of PI3K inhibitor BAY 80-6946 and MEK inhibitor BAY 86-9766 in preclinical biliary tract cancer models', 'url': 'http://cancerres.aacrjournals.org/content/72/8_Supplement/869.short'}]",sensitive,3018,Copanlisib + Refametinib,3845
141,Preclinical,"In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) increased survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",Actionable,9201,9256,colorectal cancer,DOID,26772,APC inact mut KRAS G12D PTEN inact mut,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",sensitive,4932,BEZ235 + Binimetinib,3845
142,Preclinical,"In a preclinical study, Binimetinib (MEK162) increased both apoptosis and proliferation in tumors, resulted in no improvement in survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",Actionable,9194,9256,colorectal cancer,DOID,26772,APC inact mut KRAS G12D PTEN inact mut,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",no benefit,807,Binimetinib,3845
143,Preclinical,"In a preclinical study, BEZ235 inhibited mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation, and KRAS G12D (PMID: 26206338).",Actionable,9191,9256,colorectal cancer,DOID,26772,APC inact mut KRAS G12D PTEN inact mut,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",sensitive,672,BEZ235,3845
144,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment resulted in tumor growth stabilization in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D, PIK3CA E545K and H1047L (PMID: 26272063).",Actionable,8581,9256,colorectal cancer,DOID,26369,KRAS G12D PIK3CA E545K PIK3CA H1047L TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,3845
145,Preclinical,"In a preclinical study, a KRAS G12D driven lung adenocarcinoma mouse model with homozygous deletion of ATM was sensitive to VX-970, demonstrating decreased tumor volume and greater overall survival compared to control treated models (PMID: 28363999). ",Actionable,11388,3910,lung adenocarcinoma,DOID,27978,ATM del KRAS G12D,"[{'id': 9282, 'pubMedId': 28363999, 'title': 'ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363999'}]",sensitive,2879,VX-970,3845
146,Preclinical,"In a preclinical study, a KRAS G12D driven lung adenocarcinoma mouse model with homozygous deletion of ATM was sensitive to Lynparza (olaparib), demonstrating reduced tumor volume and greater overall survival when compared to models treated with control (PMID: 28363999).",Actionable,11387,3910,lung adenocarcinoma,DOID,27978,ATM del KRAS G12D,"[{'id': 9282, 'pubMedId': 28363999, 'title': 'ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363999'}]",sensitive,837,Olaparib,3845
147,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of endometrial cancer cells harboring PIK3CA G1049R and KRAS G12D mutations in culture (PMID: 21558396).",Actionable,2954,1380,endometrial cancer,DOID,10740,KRAS G12D PIK3CA G1049R,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,3845
148,Preclinical - Pdx,"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).",Actionable,8695,9256,colorectal cancer,DOID,26372,KRAS G12D PIK3CA H1047R TP53 R248W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",resistant,913,Selumetinib,3845
149,Preclinical - Pdx,"In a preclinical study, BEZ235 stabilized tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).",Actionable,8697,9256,colorectal cancer,DOID,26372,KRAS G12D PIK3CA H1047R TP53 R248W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",predicted – sensitive,672,BEZ235,3845
150,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R and TP53 R248W (PMID: 26272063).",Actionable,8596,9256,colorectal cancer,DOID,26372,KRAS G12D PIK3CA H1047R TP53 R248W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,1420,Selumetinib + BEZ235,3845
151,Clinical Study,"In a clinical case study, a patient with a MET amplified esophageal carcinoma that initially responded to AMG 337, developed resistance upon emergence of KRAS G12D (PMID: 26432108). ",Actionable,4081,1107,esophageal carcinoma,DOID,17216,KRAS G12D MET amp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",resistant,1064,AMG 337,3845
152,Phase I,"In a Phase I study, a patient with pancreatic adenocarcinoma harboring PTEN loss and KRAS G12D was treated with MK-2206 and demonstrated a 23% reduction in tumor size (PMID: 22025163).",Actionable,2147,4074,pancreatic adenocarcinoma,DOID,5589,PTEN loss KRAS G12D,"[{'id': 175, 'pubMedId': 22025163, 'title': 'First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22025163'}]",sensitive,816,MK2206,3845
153,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, decreased PTEN expression, and TP53 R306* (PMID: 26272063).",Actionable,8576,9256,colorectal cancer,DOID,26365,KRAS G12D PTEN dec exp TP53 R306*,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,4771,MLN0128 + PD-0325901,3845
154,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8516,1793,pancreatic cancer,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4746,DZNep + Selumetinib,3845
155,Preclinical - Cell line xenograft,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture and in xenograft models, resulting in decreased cell survival and tumor growth (PMID: 26676756).",Actionable,8506,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4747,DZNep + MK2206,3845
156,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8519,219,colon cancer,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4747,DZNep + MK2206,3845
157,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8520,1793,pancreatic cancer,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4747,DZNep + MK2206,3845
158,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8518,219,colon cancer,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4746,DZNep + Selumetinib,3845
159,Preclinical - Cell culture,"In a preclinical study, the addition of Tazemetostat (EPZ-6438) increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8508,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4749,MK2206 + Tazemetostat,3845
160,Preclinical - Cell culture,"In a preclinical study, the addition of GSK343 increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8507,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4751,GSK343 + MK2206,3845
161,Preclinical - Cell culture,"In a preclinical study, the addition of GSK343 did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).",Actionable,8504,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4750,GSK343 + Selumetinib,3845
162,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).",Actionable,8500,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4746,DZNep + Selumetinib,3845
163,Preclinical - Cell culture,"In a preclinical study, the addition of Tazemetostat (EPZ-6438) did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).",Actionable,8505,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4748,Selumetinib + Tazemetostat,3845
164,Preclinical - Cell line xenograft,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type pancreatic cancer cells harboring KRAS G12D in cell line xenograft models (PMID: 19276360).",Actionable,7887,1793,pancreatic cancer,DOID,26084,BRAF wild-type KRAS G12D,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",resistant,1095,GDC0879,3845
165,Preclinical,"In a preclinical study,  MK-1775 and Platinol (cisplatin) combination treatment resulted in improved survival in transgenic animal models of non-small cell lung carcinoma harboring KRAS G12D and STK11 loss compared to Platinol (cisplatin) alone (PMID: 28652249).",Actionable,11860,3908,non-small cell lung carcinoma,DOID,28318,KRAS G12D STK11 loss,"[{'id': 9874, 'pubMedId': 28652249, 'title': 'WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28652249'}]",predicted – sensitive,1725,MK-1775 + Cisplatin,3845
166,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PTEN loss, and TP53 V216M (PMID: 26272063).",Actionable,8575,9256,colorectal cancer,DOID,26364,KRAS G12D PTEN loss TP53 V216M,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,4771,MLN0128 + PD-0325901,3845
167,Preclinical - Pdx,"In a preclinical study, treatment with Selumetinib (AZD6244) slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).",Actionable,9374,1380,endometrial cancer,DOID,26839,KRAS G12D PIK3CA H1047R PTEN R130G,"[{'id': 7135, 'pubMedId': 26232337, 'title': 'Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26232337'}]",sensitive,913,Selumetinib,3845
168,Preclinical - Pdx,"In a preclinical study, treatment with BEZ235 slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).",Actionable,9375,1380,endometrial cancer,DOID,26839,KRAS G12D PIK3CA H1047R PTEN R130G,"[{'id': 7135, 'pubMedId': 26232337, 'title': 'Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26232337'}]",sensitive,672,BEZ235,3845
169,Preclinical - Pdx,"In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and BEZ235 resulted in stable disease in patient-derived xenograft (PDX) models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, and PTEN R130G, and demonstrated improved efficacy over either agent alone (PMID: 26232337).",Actionable,9373,1380,endometrial cancer,DOID,26839,KRAS G12D PIK3CA H1047R PTEN R130G,"[{'id': 7135, 'pubMedId': 26232337, 'title': 'Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26232337'}]",sensitive,1420,Selumetinib + BEZ235,3845
170,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7690,9256,colorectal cancer,DOID,25922,BRAF V600E KRAS G12D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4541,Cetuximab + Dabrafenib + Trametinib,3845
171,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7691,9256,colorectal cancer,DOID,25922,BRAF V600E KRAS G12D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4543,Cetuximab + SCH772984,3845
172,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).",Actionable,7689,9256,colorectal cancer,DOID,25922,BRAF V600E KRAS G12D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1917,LGX818 + Cetuximab + BYL719,3845
173,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquisition of KRAS G12D (PMID: 27312529).",Actionable,7626,9256,colorectal cancer,DOID,25922,BRAF V600E KRAS G12D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1711,Vemurafenib + Cetuximab,3845
174,Preclinical,"In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) resulted in reduced tumor growth and additive effect on survival compared to single agent in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",Actionable,9200,9256,colorectal cancer,DOID,26771,APC inact mut KRAS G12D,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",sensitive,4932,BEZ235 + Binimetinib,3845
175,Preclinical,"In a preclinical study, BEZ235 inhibited  PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",Actionable,9190,9256,colorectal cancer,DOID,26771,APC inact mut KRAS G12D,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",sensitive,672,BEZ235,3845
176,Preclinical,"In a preclinical study, Binimetinib (MEK162) increased apoptosis in tumors and improved survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",Actionable,9193,9256,colorectal cancer,DOID,26771,APC inact mut KRAS G12D,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",sensitive,807,Binimetinib,3845
177,Preclinical - Pdx,"In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12D and TP53 S127Y (PMID: 26855149).",Actionable,10885,3910,lung adenocarcinoma,DOID,27819,KRAS G12D TP53 S127Y,"[{'id': 8887, 'pubMedId': 26855149, 'title': 'Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26855149'}]",sensitive,5671,Dasatinib + Demcizumab,3845
178,Clinical Study,"In a clinical study, a colorectal cancer patient harboring a PIK3CA mutation and KRAS mutations at codons 12 and 13 demonstrated stable disease when treated with a combination of Torisel (temsirolimus) and Avastin (bevacizumab) (PMID: 21216929). ",Actionable,3378,9256,colorectal cancer,DOID,13305,PIK3CA mutant KRAS G12X KRAS G13X,"[{'id': 3726, 'pubMedId': 21216929, 'title': 'PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21216929'}]",sensitive,3133,Temsirolimus + Bevacizumab,3845
179,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).,Actionable,1560,9256,colorectal cancer,DOID,1193,KRAS G13X,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,694,Cetuximab,3845
180,Phase III,"In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in patients with KRAS exon 2 mutant colorectal cancer (PMID: 26341920).",Actionable,3266,9256,colorectal cancer,DOID,1193,KRAS G13X,"[{'id': 3703, 'pubMedId': 26341920, 'title': 'Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26341920'}]",no benefit,3102,Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan,3845
181,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).,Actionable,1558,9256,colorectal cancer,DOID,1193,KRAS G13X,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,845,Panitumumab,3845
182,FDA approved,"In clinical studies, lung adenocarcinoma patients with KRAS codon 12 or 13 mutations lack sensitivity to Iressa (gefitinib) (PMID: 15696205).",Actionable,1301,3910,lung adenocarcinoma,DOID,1193,KRAS G13X,"[{'id': 211, 'pubMedId': 15696205, 'title': 'KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15696205'}]",resistant,751,Gefitinib,3845
183,Preclinical,"In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colorectal tumor cell lines carrying KRAS codon 12 or 13 mutations (PMID: 23209813). ",Actionable,1440,9256,colorectal cancer,DOID,1193,KRAS G13X,"[{'id': 1282, 'pubMedId': 23209813, 'title': 'KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209813'}]",sensitive,1104,Oxaliplatin,3845
184,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12R mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8997,3910,lung adenocarcinoma,DOID,1732,KRAS G12R,"[{'id': 6848, 'pubMedId': 27422710, 'title': 'Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27422710'}]",decreased response,913,Selumetinib,3845
185,Preclinical,"In a preclinical study,  colorectal cancer cells harboring a KRAS G12R mutation demonstrated resistance to Sutent (sunitinib) treatment (PMID: 23455880).",Actionable,1017,9256,colorectal cancer,DOID,1732,KRAS G12R,"[{'id': 26, 'pubMedId': 23455880, 'title': 'KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23455880'}]",resistant,930,Sunitinib,3845
186,Preclinical - Cell line xenograft,"In a preclinical study, combination of Mekinist (trametinib) and Votrient (pazopanib) significantly delayed tumor progression in cell line xenograft models of thyroid cancer harboring KRAS G12R (PMID: 26324075).",Actionable,9960,1781,thyroid cancer,DOID,1732,KRAS G12R,"[{'id': 7820, 'pubMedId': 26324075, 'title': 'Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26324075'}]",sensitive,1310,Pazopanib + Trametinib,3845
187,Preclinical - Cell line xenograft,"In a preclinical study, Mekinist (trametinib) inhibited Erk activation and growth of thyroid cancer cells harboring KRAS G12R in culture, and reduced tumor size in cell line xenograft models (PMID: 26324075).",Actionable,9958,1781,thyroid cancer,DOID,1732,KRAS G12R,"[{'id': 7820, 'pubMedId': 26324075, 'title': 'Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26324075'}]",sensitive,2,Trametinib,3845
188,Preclinical - Cell culture,"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12R mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8989,3910,lung adenocarcinoma,DOID,1732,KRAS G12R,"[{'id': 6848, 'pubMedId': 27422710, 'title': 'Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27422710'}]",decreased response,807,Binimetinib,3845
189,Preclinical - Cell line xenograft,"In a preclinical study, Votrient (pazopanib) inhibited Erk activation and growth of thyroid cancer cells harboring KRAS G12R in culture, and reduced tumor size in cell line xenograft models (PMID: 26324075).",Actionable,9959,1781,thyroid cancer,DOID,1732,KRAS G12R,"[{'id': 7820, 'pubMedId': 26324075, 'title': 'Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26324075'}]",sensitive,848,Pazopanib,3845
190,Preclinical - Pdx,"In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12R and TP53 R248L (PMID: 26855149).",Actionable,10886,3910,lung adenocarcinoma,DOID,27821,KRAS G12R TP53 R248L,"[{'id': 8887, 'pubMedId': 26855149, 'title': 'Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26855149'}]",sensitive,5671,Dasatinib + Demcizumab,3845
191,Preclinical - Cell line xenograft,"In a preclinical study, thyroid cancer cell lines harboring HRAS G13R and KRAS G12R with an acquired SRC T341M mutation demonstrated resistance to Sprycel (dasatinib) in culture and in cell line xenograft models (PMID: 27222538).",Actionable,7839,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",resistant,717,Dasatinib,3845
192,Preclinical - Cell line xenograft,"In a preclinical study, Mekinist (trametinib) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M in culture and in cell line xenograft models (PMID: 27222538).",Actionable,7855,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,2,Trametinib,3845
193,Preclinical - Cell line xenograft,"In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture, and resulted in sustained tumor suppression and prolonged survival in cell line xenograft models (PMID: 27222538).",Actionable,7867,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,4599,Dasatinib + Trametinib,3845
194,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).",Actionable,7870,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,4601,Dasatinib + SCH772984,3845
195,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).",Actionable,7868,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,4600,Dasatinib + Selumetinib,3845
196,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).",Actionable,7860,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,913,Selumetinib,3845
197,Preclinical,"In a preclinical study, KRAS G12R was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).",Actionable,6655,3910,lung adenocarcinoma,DOID,23662,EGFR L858R KRAS G12R,"[{'id': 5721, 'pubMedId': 26341921, 'title': 'Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26341921'}]",resistant,4190,Afatinib + Cetuximab,3845
198,Preclinical,"In a preclinical study, human colorectal cancer cell lines harboring KRAS G13D, PIK3CA E545K and PIK3CA D549N were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4943,9256,colorectal cancer,DOID,11790,KRAS G13D PIK3CA E545K PIK3CA D549N,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",resistant,890,Regorafenib,3845
199,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G13D, PIK3CA E545K, and PIK3CA D549N in culture and reduced tumor growth in cell line xenograft models (PMID: 25838391).",Actionable,4946,9256,colorectal cancer,DOID,11790,KRAS G13D PIK3CA E545K PIK3CA D549N,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",sensitive,1305,Regorafenib + Cetuximab,3845
200,Preclinical,"In a preclinical study, human colon cancer cells harboring KRAS G13D, PIK3CA E545K, and PIK3CA D549N had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073, PMID: 24042735).
",Actionable,3132,219,colon cancer,DOID,11790,KRAS G13D PIK3CA E545K PIK3CA D549N,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3639, 'pubMedId': 24042735, 'title': 'Epigenetic and genetic features of 24 colon cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24042735'}]",decreased response,1040,PF-05212384,3845
201,Preclinical - Cell line xenograft,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R in culture and in cell line xenograft models (PMID: 26272063).",Actionable,8567,9256,colorectal cancer,DOID,26360,KRAS G13D PIK3CA H1047R TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,3845
202,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7673,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1711,Vemurafenib + Cetuximab,3845
203,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Selumetinib (AZD6244) in culture (PMID: 27312529).",Actionable,7675,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4536,Cetuximab + Selumetinib,3845
204,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture, likely due to the acquisition of KRAS G13D (PMID: 27312529).",Actionable,7622,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1916,Cetuximab + Encorafenib,3845
205,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7677,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4541,Cetuximab + Dabrafenib + Trametinib,3845
206,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7676,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1066,Trametinib + Dabrafenib,3845
207,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",Actionable,7678,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,2618,SCH772984,3845
208,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and SCH772984 in culture (PMID: 27312529).",Actionable,7679,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4543,Cetuximab + SCH772984,3845
209,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) in culture (PMID: 27312529).",Actionable,7668,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4525,Cetuximab + Dabrafenib,3845
210,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).",Actionable,7674,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1917,LGX818 + Cetuximab + BYL719,3845
211,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8207,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4657,Pimasertib + Regorafenib,3845
212,Preclinical - Cell line xenograft,"In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in colorectal cancer cell line xenograft models harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K (PMID: 23629727).",Actionable,8208,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,1660,Pimasertib + BEZ235,3845
213,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8197,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4656,Everolimus + Pimasertib,3845
214,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring KRAS G13D, PIK3CA D549N and PIK3CA E545K demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).",Actionable,8192,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",decreased response,871,Pimasertib,3845
215,Preclinical - Cell line xenograft,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited Mapk and Akt signaling, resulted in growth inhibition of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture and in cell line xenograft models (PMID: 23629727).",Actionable,8201,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,1659,Pimasertib + Sorafenib,3845
216,Preclinical,"In a preclinical study, AT-7867 inhibited proliferation of cultured HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations (PMID: 20423992, PMID: 24978597).",Actionable,2859,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 962, 'pubMedId': 24978597, 'title': 'Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24978597'}, {'id': 2290, 'pubMedId': 20423992, 'title': 'AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20423992'}]",sensitive,2447,AT-7867,3845
217,Preclinical - Cell line xenograft,"In a preclinical study, Gedatolisib (PKI-587) and Camptostar (irinotecan) synergistically suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R (PMID: 24042735) in xenograft models (PMID: 21325073).",Actionable,3901,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3639, 'pubMedId': 24042735, 'title': 'Epigenetic and genetic features of 24 colon cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24042735'}]",sensitive,3396,Gedatolisib + Irinotecan,3845
218,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) and Camptothecin in combination synergistictically enhanced Parp cleavage in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073, PMID: 24042735). ",Actionable,3903,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 3639, 'pubMedId': 24042735, 'title': 'Epigenetic and genetic features of 24 colon cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24042735'}, {'id': 4265, 'pubMedId': 25688157, 'title': 'Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25688157'}]",sensitive,3398,Gedatolisib + Camptothecin,3845
219,Preclinical,"In a preclinical study, CC-223 inhibited proliferation of HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations, in culture (PMID: 25855786, PMID: 24978597).",Actionable,2876,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 962, 'pubMedId': 24978597, 'title': 'Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24978597'}, {'id': 3513, 'pubMedId': 25855786, 'title': 'CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25855786'}]",sensitive,693,CC-223,3845
220,Preclinical,"In a preclinical study, Camptostar (irinotecan) suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in xenograft models (PMID: 21325073, PMID: 16707468).",Actionable,3902,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 4272, 'pubMedId': 16707468, 'title': 'KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16707468'}]",sensitive,1074,Irinotecan,3845
221,Preclinical,"In a preclinical study, human colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4942,9256,colorectal cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",resistant,890,Regorafenib,3845
222,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) decreased viability of a colorectal cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 27602501).",Actionable,12024,9256,colorectal cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",sensitive,691,BYL719,3845
223,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited tumor growth in xenograft models of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R mutations (PMID: 21558396).",Actionable,2836,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,3845
224,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Gedatolisib (PF-05212384) and PD-0325901 inhibited tumor growth in colon cancer cell line xenograft models harboring KRAS G13D and PIK3CA H1047R (PMID: 21325073).",Actionable,2856,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}]",sensitive,3025,PD-0325901 + Gedatolisib,3845
225,Preclinical,"In a preclinical study, CUDC-907 induced caspase activation in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 20570890, PMID: 22693356). 
",Actionable,3010,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 843, 'pubMedId': 20570890, 'title': 'Genomic and biological characterization of exon 4 KRAS mutations in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20570890'}, {'id': 1018, 'pubMedId': 22693356, 'title': 'Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693356'}]",sensitive,709,CUDC-907,3845
226,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human colon cancer cells harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073, PMID: 24042735).",Actionable,3131,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3639, 'pubMedId': 24042735, 'title': 'Epigenetic and genetic features of 24 colon cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24042735'}]",sensitive,1040,PF-05212384,3845
227,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G13D and PIK3CA H1047R in culture, and reduced tumor growth in cell line xenograft models (PMID: 25838391).",Actionable,4947,9256,colorectal cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",sensitive,1305,Regorafenib + Cetuximab,3845
228,Preclinical,"In a preclinical study, human colorectal cancer cells harboring KRAS G13D were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4938,9256,colorectal cancer,DOID,811,KRAS G13D,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",resistant,890,Regorafenib,3845
229,Preclinical,"In a preclinical studu, BKM120 alone failed to induce tumor regression in mouse xenograft models of Kras G13D mutant colorectal cancer (PMID: 24576621).",Actionable,684,219,colon cancer,DOID,811,KRAS G13D,"[{'id': 362, 'pubMedId': 24576621, 'title': 'Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24576621'}]",no benefit,680,BKM120,3845
230,Preclinical - Cell line xenograft,"In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of non-small cell lung carcinoma cells harboring KRAS G13D, and anti-tumor activity in cell line xenograft models (PMID: 28615361).",Actionable,11326,3908,non-small cell lung carcinoma,DOID,811,KRAS G13D,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",sensitive,5914,AZD4785,3845
231,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 23629727).",Actionable,8205,9256,colorectal cancer,DOID,811,KRAS G13D,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4657,Pimasertib + Regorafenib,3845
232,Preclinical,"In a preclinical study, LY3009120 inhibited growth of, and blocked MAPK signaling in human colorectal cancer cells harboring KRAS G13D in culture (PMID: 26343583).",Actionable,6590,9256,colorectal cancer,DOID,811,KRAS G13D,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,3268,LY3009120,3845
233,Preclinical,"In a preclinical study, a colorectal cancer cell line harboring the KRAS G13D mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).",Actionable,805,9256,colorectal cancer,DOID,811,KRAS G13D,"[{'id': 26, 'pubMedId': 23455880, 'title': 'KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23455880'}]",resistant,930,Sunitinib,3845
234,Preclinical,"In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis in human colorectal cancer cell lines harboring KRAS G13D in culture (PMID: 25838391).",Actionable,4952,9256,colorectal cancer,DOID,811,KRAS G13D,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",sensitive,1305,Regorafenib + Cetuximab,3845
235,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring KRAS G13D demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).",Actionable,8190,9256,colorectal cancer,DOID,811,KRAS G13D,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",decreased response,871,Pimasertib,3845
236,Preclinical,"In a preclinical study, colorectal cancer cells harboring KRAS G13D were less sensitive to Nerlynx (neratinib) induced growth inhibition in culture (PMID: 26243863).",Actionable,7116,9256,colorectal cancer,DOID,811,KRAS G13D,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",decreased response,828,Neratinib,3845
237,Preclinical - Cell line xenograft,"In a preclinical study, Estybon (rigosertib) inhibited Mek/Erk signaling and tumor growth in cell line xenograft models of colorectal cancer harboring KRAS G13D (PMID: 27104980).",Actionable,8560,9256,colorectal cancer,DOID,811,KRAS G13D,"[{'id': 6686, 'pubMedId': 27104980, 'title': 'A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27104980'}]",sensitive,1046,rigosertib,3845
238,Preclinical - Cell line xenograft,"In a preclinical study, GDC-0623 demonstrated efficacy against both KRAS-mutant and BRAF-mutant cancer models in cell based assays and cell line xenografts (PMID: 23934108).",Actionable,565,10000003,Advanced Solid Tumor,JAX,811,KRAS G13D,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",sensitive,748,GDC-0623,3845
239,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD-6244) inhibited proliferation of colorectal adenocarcinoma cells harboring KRAS G13D in culture (PMID: 26438159).",Actionable,8493,50861,colorectal adenocarcinoma,DOID,811,KRAS G13D,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",predicted – sensitive,913,Selumetinib,3845
240,Preclinical - Cell culture,"In a preclinical study, RO4987655 inhibited proliferation of colorectal adenocarcinoma cells harboring KRAS G13D in culture (PMID: 26438159).",Actionable,8463,50861,colorectal adenocarcinoma,DOID,811,KRAS G13D,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",sensitive,903,RO4987655,3845
241,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 23629727).",Actionable,8195,9256,colorectal cancer,DOID,811,KRAS G13D,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4656,Everolimus + Pimasertib,3845
242,Preclinical - Cell line xenograft,"In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of human colorectal cancer cell lines harboring KRAS G13D (PMID: 23934108).
",Actionable,1342,9256,colorectal cancer,DOID,811,KRAS G13D,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",sensitive,1004,Cobimetinib,3845
243,Preclinical - Cell line xenograft,"In a preclinical study, 3144 inhibited growth of a breast cancer cell line harboring KRAS G13D in culture and reduced tumor growth in xenograft models (PMID: 28235199).",Actionable,10840,1612,breast cancer,DOID,811,KRAS G13D,"[{'id': 8866, 'pubMedId': 28235199, 'title': 'Multivalent Small-Molecule Pan-RAS Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28235199'}]",sensitive,5658,3144,3845
244,Preclinical - Pdx & cell culture,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib) synergistically inhibited growth of colorectal cancer cells harboring KRAS G13D in culture and resulted in partial tumor regression in patient-derived xenograft models (PMID: 26369631). ",Actionable,5615,9256,colorectal cancer,DOID,811,KRAS G13D,"[{'id': 5128, 'pubMedId': 26369631, 'title': 'Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26369631'}]",sensitive,1368,Palbociclib + Trametinib,3845
245,Guideline,Colorectal cancer patients with KRAS mutations in exon 2 or 3 are resistant to Vectibix (panitumumab) (PMID: 18316791).,Actionable,581,10000003,Advanced Solid Tumor,JAX,811,KRAS G13D,"[{'id': 340, 'pubMedId': 18316791, 'title': 'Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18316791'}]",resistant,845,Panitumumab,3845
246,Preclinical,"In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colon tumor cell lines carrying KRAS G13D (PMID: 23209813). ",Actionable,1437,9256,colorectal cancer,DOID,811,KRAS G13D,"[{'id': 1282, 'pubMedId': 23209813, 'title': 'KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209813'}]",sensitive,1104,Oxaliplatin,3845
247,Guideline,"Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).
",Actionable,1525,9256,colorectal cancer,DOID,811,KRAS G13D,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,694,Cetuximab,3845
248,Clinical Study,"In a clinical study, KRAS mutations in codon 12 or 13 were associated with resistance to Erbitux (cetuximab) in colorectal cancer patients (PMID: 18202412).",Actionable,574,9256,colorectal cancer,DOID,811,KRAS G13D,"[{'id': 339, 'pubMedId': 18202412, 'title': 'KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18202412'}]",resistant,694,Cetuximab,3845
249,Preclinical - Cell culture,"In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of a colon cancer cell line harboring KRAS G13D in culture (PMID: 27556948).",Actionable,8014,219,colon cancer,DOID,811,KRAS G13D,"[{'id': 6534, 'pubMedId': 27556948, 'title': 'Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27556948'}]",sensitive,4620,APS-2-79 + Trametinib,3845
250,Guideline,"Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).
",Actionable,1528,9256,colorectal cancer,DOID,811,KRAS G13D,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}, {'id': 1450, 'pubMedId': None, 'title': 'Vectibix label', 'url': 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125147s194lbl.pdf'}]",resistant,845,Panitumumab,3845
251,FDA approved,Patients with metastatic colorectal cancer harboring KRAS mutations in codons 12 or 13 showed resistance to Vectibix (panitumumab) (PMID: 18316791).,Actionable,585,9256,colorectal cancer,DOID,811,KRAS G13D,"[{'id': 340, 'pubMedId': 18316791, 'title': 'Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18316791'}]",resistant,845,Panitumumab,3845
252,Preclinical - Cell culture,"In a preclinical study, RO5126766 inhibited proliferation of colorectal adenocarcinoma cells harboring KRAS G13D in culture (PMID: 26438159).",Actionable,8480,50861,colorectal adenocarcinoma,DOID,811,KRAS G13D,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",sensitive,2011,RO5126766,3845
253,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 23629727).",Actionable,8200,9256,colorectal cancer,DOID,811,KRAS G13D,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,1659,Pimasertib + Sorafenib,3845
254,Preclinical - Cell line xenograft,"In a preclinical study, a colon cancer cell line harboring KRAS G13D demonstrated increased sensitivity to AUY922 compared to cell lines with wild-type KRAS, resulting in decreased viability and increased apoptosis in culture and reduced tumor growth in xenograft models (PMID: 26832792). ",Actionable,5519,219,colon cancer,DOID,811,KRAS G13D,"[{'id': 5083, 'pubMedId': 26832792, 'title': 'Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26832792'}]",sensitive,647,AUY922,3845
255,Preclinical - Cell line xenograft,"In a preclinical study, Stivarga (regorafenib) inhibited proliferation of breast cancer cells harboring BRAF G464V and KRAS G13D in culture and inhibited angiogenesis and tumor growth in cell line xenograft models (PMID: 21170960).",Actionable,1075,1612,breast cancer,DOID,10754,BRAF G464V KRAS G13D,"[{'id': 318, 'pubMedId': 21170960, 'title': 'Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21170960'}]",sensitive,890,Regorafenib,3845
256,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring BRAF G464V and KRAS G13D in culture (PMID: 21325073, PMID: 17314276).",Actionable,3129,1612,breast cancer,DOID,10754,BRAF G464V KRAS G13D,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3636, 'pubMedId': 17314276, 'title': 'Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17314276'}]",sensitive,1040,PF-05212384,3845
257,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 demonstrated decreased response to tumor growth inhibition in xenograft models of human breast cancer cell lines harboring KRAS G13D and BRAF G464V (PMID: 21558396).",Actionable,2973,1612,breast cancer,DOID,10754,BRAF G464V KRAS G13D,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",decreased response,2152,CH5132799,3845
258,Preclinical - Cell line xenograft,"In a preclinical study, DHM25 increased cell death and decreased migration of a triple-negative breast cancer cell line harboring KRAS G13D and BRAF G464V in culture, and reduced tumor growth and lung metastasis in xenograft models (PMID: 26237138).",Actionable,10363,60081,triple-receptor negative breast cancer,DOID,10754,BRAF G464V KRAS G13D,"[{'id': 8367, 'pubMedId': 26237138, 'title': 'A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26237138'}]",sensitive,5494,DHM25,3845
259,Preclinical - Cell line xenograft,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type colon cancer cells harboring KRAS G13D in culture ann in cell line xenograft models (PMID: 19276360).",Actionable,7883,219,colon cancer,DOID,26083,BRAF wild-type KRAS G13D,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",resistant,1095,GDC0879,3845
260,Preclinical - Cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS G13D, PIK3CA E545K, and TP53 S241F in culture (PMID: 26272063).",Actionable,8564,9256,colorectal cancer,DOID,26357,KRAS G13D PIK3CA E545k TP53 S241F,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,3845
261,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Pictilisib (GDC-0941) and Cobimetinib (GDC-0973) inhibited tumor growth in a colorectal adenocarcinoma xenograft model harboring KRAS G13D and PIK3CA E545K mutations, and demonstrated improved efficacy over either agent alone (PMID: 22084396).",Actionable,2854,50861,colorectal adenocarcinoma,DOID,10712,KRAS G13D PIK3CA E545K,"[{'id': 353, 'pubMedId': 22084396, 'title': 'Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22084396'}]",sensitive,1702,GDC-0941 + cobimetinib,3845
262,Preclinical - Cell line xenograft,"In a preclinical study, expression of KRAS G13D in an endometrial cancer cell line harboring PIK3CA E545K conferred resistance to Afinitor (everolimus) in xenograft models (PMID: 20664172). ",Actionable,9329,1380,endometrial cancer,DOID,10712,KRAS G13D PIK3CA E545K,"[{'id': 1067, 'pubMedId': 20664172, 'title': 'Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20664172'}]",resistant,735,Everolimus,3845
263,Preclinical - Cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS Q61L, PIK3CA E542K, and TP53 T118Qfs*5 in culture (PMID: 26272063).",Actionable,8566,9256,colorectal cancer,DOID,26412,KRAS Q61L PIK3CA E542K TP53 T118Qfs*5,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,3845
264,Phase I,"In a Phase I trial, the combination of Erbitux (cetuximab) and Selumetinib (AZD6244) demonstrated safety, but minimal efficacy, in patients with metastatic colorectal cancer harboring KRAS exon 2 mutations, with no responses and 36% (5/14) of patients achieving stable disease (PMID: 26666244).",Actionable,10476,9256,colorectal cancer,DOID,27386,KRAS exon 2,"[{'id': 8531, 'pubMedId': 26666244, 'title': 'A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26666244'}]",no benefit,4536,Cetuximab + Selumetinib,3845
265,Phase II,"In a Phase II study, Selumetinib (AZD6244), in combination with Camptosar (irinotecan), resulted in a partial response in 9.7% (3/31) and stable disease in 51.6% (16/31) of colorectal cancer patients with KRAS exon 2 mutations (PMID: 25322874).",Actionable,2432,9256,colorectal cancer,DOID,27386,KRAS exon 2,"[{'id': 3049, 'pubMedId': 25322874, 'title': 'Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25322874'}]",predicted – sensitive,2835,Irinotecan + Selumetinib,3845
266,Preclinical - Cell culture,"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61K mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8991,3910,lung adenocarcinoma,DOID,1864,KRAS Q61K,"[{'id': 6848, 'pubMedId': 27422710, 'title': 'Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27422710'}]",decreased response,807,Binimetinib,3845
267,Preclinical - Cell line xenograft,"In a preclinical study, the combination of XL147 and Paraplatin (carboplatin) inhibited tumor growth and angiogenesis in xenograft models of a human non-small cell lung cancer cell line harboring KRAS Q61K, with increased efficacy compared to either agent alone (PMID: 25637314).",Actionable,6337,3908,non-small cell lung carcinoma,DOID,1864,KRAS Q61K,"[{'id': 5522, 'pubMedId': 25637314, 'title': 'The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25637314'}]",sensitive,4116,XL147 + Carboplatin,3845
268,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited tumor growth and vascularization in xenograft models of a human non-small cell lung cancer cell line harboring KRAS Q61K (PMID: 25637314).",Actionable,6330,3908,non-small cell lung carcinoma,DOID,1864,KRAS Q61K,"[{'id': 5522, 'pubMedId': 25637314, 'title': 'The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25637314'}]",sensitive,1050,XL147,3845
269,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61K mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8999,3910,lung adenocarcinoma,DOID,1864,KRAS Q61K,"[{'id': 6848, 'pubMedId': 27422710, 'title': 'Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27422710'}]",decreased response,913,Selumetinib,3845
270,Preclinical - Cell line xenograft,"In a preclinical study, BI-847325 inhibited MEK phosphorylation and proliferation and disrupted cell cycle progression in a non-small cell lung cancer cell line harboring KRAS Q61K in culture, and induced tumor stasis or regression in KRAS Q61K mutant non-small cell lung cancer cell line xenograft models (PMID: 27496137).",Actionable,8788,3908,non-small cell lung carcinoma,DOID,1864,KRAS Q61K,"[{'id': 6751, 'pubMedId': 27496137, 'title': 'Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27496137'}]",sensitive,1059,BI-847325,3845
271,Preclinical - Cell line xenograft,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS Q61K in culture and in cell line xenograft models (PMID: 19276360).",Actionable,7884,3908,non-small cell lung carcinoma,DOID,26085,BRAF wild-type KRAS Q61K,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",resistant,1095,GDC0879,3845
272,Clinical Study,"In a clinical case study, a patient with a carcinoma of unknown primary harboring MET amplification and KRAS G12V demonstrated a durable response following treatment with Xalkori (crizotinib) (PMID: 25232318).",Actionable,7753,305,carcinoma,DOID,25979,KRAS G12V MET amp,"[{'id': 6473, 'pubMedId': 25232318, 'title': 'Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25232318'}]",predicted – sensitive,706,Crizotinib,3845
273,Preclinical - Pdx,"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).",Actionable,8698,9256,colorectal cancer,DOID,26374,KRAS G12V PIK3CA E545K TP53 R273*,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",resistant,913,Selumetinib,3845
274,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K and TP53 R273* (PMID: 26272063).",Actionable,8597,9256,colorectal cancer,DOID,26374,KRAS G12V PIK3CA E545K TP53 R273*,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,1420,Selumetinib + BEZ235,3845
275,Preclinical - Pdx,"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to BEZ235 treatment (PMID: 26272063).",Actionable,8699,9256,colorectal cancer,DOID,26374,KRAS G12V PIK3CA E545K TP53 R273*,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",resistant,672,BEZ235,3845
276,Preclinical - Pdx,"In a preclinical study, BEZ235 delayed tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).",Actionable,8701,9256,colorectal cancer,DOID,26375,KRAS G12V PIK3CA Q546K TP53 R282W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",decreased response,672,BEZ235,3845
277,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) inhibited tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).",Actionable,8700,9256,colorectal cancer,DOID,26375,KRAS G12V PIK3CA Q546K TP53 R282W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",predicted – sensitive,913,Selumetinib,3845
278,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K and TP53 R282W (PMID: 26272063).",Actionable,8600,9256,colorectal cancer,DOID,26375,KRAS G12V PIK3CA Q546K TP53 R282W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,1420,Selumetinib + BEZ235,3845
279,Preclinical - Cell culture,"In a preclinical study, BRAF mutant melanoma cells over-expressing KRAS G12V were resistant to Selumetinib (AZD6244) and AZ628 combination treatment in culture (PMID: 26351322).",Actionable,8682,1909,melanoma,DOID,26406,BRAF mut KRAS G12V,"[{'id': 6708, 'pubMedId': 26351322, 'title': 'Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26351322'}]",resistant,4791,AZ628 + Selumetinib,3845
280,Preclinical,"In a preclinical study, KRAS G12V was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).",Actionable,6656,3910,lung adenocarcinoma,DOID,23663,EGFR L858R KRAS G12V,"[{'id': 5721, 'pubMedId': 26341921, 'title': 'Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26341921'}]",resistant,4190,Afatinib + Cetuximab,3845
281,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12V (PMID: 26676756).",Actionable,8501,3910,lung adenocarcinoma,DOID,26342,KRAS G12V EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4746,DZNep + Selumetinib,3845
282,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12V (PMID: 26676756).",Actionable,8509,3910,lung adenocarcinoma,DOID,26342,KRAS G12V EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4747,DZNep + MK2206,3845
283,Preclinical - Pdx,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS G12V in patient-derived xenograft models (PMID: 19276360).",Actionable,7895,3908,non-small cell lung carcinoma,DOID,26087,BRAF wild-type KRAS G12V,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",resistant,1095,GDC0879,3845
284,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring KRAS G12V and PTEN K6fs*4 in culture (PMID: 27699769).",Actionable,8821,10283,prostate cancer,DOID,26456,KRAS G12V PTEN K6fs*4,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",sensitive,994,BAY1125976,3845
285,Preclinical,"In a preclinical study, 7RH treatment had no effect on tumor cell apoptosis in KRAS G12V-driven animal models of lung cancer with TP53 knockout background (PMID: 26855149).",Actionable,10882,1324,lung cancer,DOID,27818,KRAS G12V TP53 del,"[{'id': 8887, 'pubMedId': 26855149, 'title': 'Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26855149'}]",resistant,5669,7RH,3845
286,Preclinical,"In a preclinical study, 7RH and LY411575 combination treatment induced apoptosis in KRAS G12V-driven animal models of lung cancer with TP53 knockout background (PMID: 26855149).",Actionable,10883,1324,lung cancer,DOID,27818,KRAS G12V TP53 del,"[{'id': 8887, 'pubMedId': 26855149, 'title': 'Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26855149'}]",sensitive,5670,7RH + LY411575,3845
287,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",Actionable,8603,9256,colorectal cancer,DOID,26377,KRAS G12V PIK3CA E545K TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,1420,Selumetinib + BEZ235,3845
288,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",Actionable,8705,9256,colorectal cancer,DOID,26377,KRAS G12V PIK3CA E545K TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",decreased response,913,Selumetinib,3845
289,Preclinical - Pdx,"In a preclinical study, BEZ235 delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",Actionable,8704,9256,colorectal cancer,DOID,26377,KRAS G12V PIK3CA E545K TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",decreased response,672,BEZ235,3845
290,Preclinical,"In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to BEZ235 compared with cells without KRAS mutations in culture (PMID: 22662154).",Actionable,2141,1380,endometrial cancer,DOID,5418,PIK3CA R88Q PTEN mut KRAS G12V,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",decreased response,672,BEZ235,3845
291,Preclinical,"In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to Afinitor (everolimus) compared with cells without KRAS mutations in culture (PMID: 22662154).",Actionable,2140,1380,endometrial cancer,DOID,5418,PIK3CA R88Q PTEN mut KRAS G12V,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",decreased response,735,Everolimus,3845
292,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R335fs (PMID: 26272063).",Actionable,8578,9256,colorectal cancer,DOID,26368,KRAS G12V PIK3CA E545K TP53 R335fs,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,4771,MLN0128 + PD-0325901,3845
293,Preclinical - Cell culture,"In a preclinical study, Aurora Kinase Inhibitor II (AI II) decreased viability of transformed lung cells expressing KRAS G12V  in culture (PMID: 26842935).",Actionable,9791,1324,lung cancer,DOID,1127,KRAS G12V,"[{'id': 7603, 'pubMedId': 26842935, 'title': 'Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26842935'}]",sensitive,5230,Aurora Kinase Inhibitor II,3845
294,Preclinical,"In a preclinical study, 7RH and LY411575 combination treatment resulted in additive effect on apoptosis in KRAS G12V-driven animal models of lung cancer (PMID: 26855149).",Actionable,10881,1324,lung cancer,DOID,1127,KRAS G12V,"[{'id': 8887, 'pubMedId': 26855149, 'title': 'Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26855149'}]",sensitive,5670,7RH + LY411575,3845
295,Preclinical,"In a preclinical study, a colorectal cancer cell line harboring the KRAS G12V mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).",Actionable,818,9256,colorectal cancer,DOID,1127,KRAS G12V,"[{'id': 26, 'pubMedId': 23455880, 'title': 'KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23455880'}]",resistant,930,Sunitinib,3845
296,Preclinical,"In a preclinical study, human colorectal cancer cells harboring KRAS G12V were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4939,9256,colorectal cancer,DOID,1127,KRAS G12V,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",resistant,890,Regorafenib,3845
297,Preclinical,"In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colorectal tumor cell lines carrying KRAS G12V (PMID: 23209813). ",Actionable,1438,9256,colorectal cancer,DOID,1127,KRAS G12V,"[{'id': 1282, 'pubMedId': 23209813, 'title': 'KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209813'}]",sensitive,1104,Oxaliplatin,3845
298,Preclinical - Cell culture,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of transformed cells over expressing KRAS G12V in culture, while single agent inhibition had no effect (PMID: 26140595).",Actionable,10249,10000003,Advanced Solid Tumor,JAX,1127,KRAS G12V,"[{'id': 8232, 'pubMedId': 26140595, 'title': 'A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26140595'}]",predicted – sensitive,5443,PF3644022 + PF-477736,3845
299,Phase I,"In a Phase I study, NSCLC patients harboring KRAS G12C or G12V mutations demonstrated a trend towards better overall survival, progression free survival, and objective response rate compared to NSCLC patients with other KRAS mutations when treated with the combination therapy, Selumetinib (AZD6244) and Taxotere (docetaxel) (PMID: 26125448). ",Actionable,2619,3908,non-small cell lung carcinoma,DOID,1127,KRAS G12V,"[{'id': 3343, 'pubMedId': 26125448, 'title': 'Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26125448'}]",predicted – sensitive,1117,Selumetinib + Docetaxel,3845
300,Preclinical - Cell culture,"In a preclinical study, 3144 inhibited growth of a colorectal cancer cell line harboring KRAS G12V in culture (PMID: 28235199).",Actionable,10841,9256,colorectal cancer,DOID,1127,KRAS G12V,"[{'id': 8866, 'pubMedId': 28235199, 'title': 'Multivalent Small-Molecule Pan-RAS Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28235199'}]",sensitive,5658,3144,3845
301,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12V mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8994,3910,lung adenocarcinoma,DOID,1127,KRAS G12V,"[{'id': 6848, 'pubMedId': 27422710, 'title': 'Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27422710'}]",decreased response,913,Selumetinib,3845
302,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12V in culture (PMID: 23629727).",Actionable,8148,3908,non-small cell lung carcinoma,DOID,1127,KRAS G12V,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,871,Pimasertib,3845
303,Clinical Study,"In a clinical case study, treatment with Selumetinib (AZD6244)  resulted in lack of tumor progression for greater than 7 years in patient with low grade serous ovarian carcinoma harboring KRAS G12V (PMID: 27231576). ",Actionable,7751,50933,ovarian serous carcinoma,DOID,1127,KRAS G12V,"[{'id': 6470, 'pubMedId': 27231576, 'title': 'A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27231576'}]",sensitive,913,Selumetinib,3845
304,Preclinical,"In a preclinical study, human colorectal cancer cells harboring KRAS G12V were resistant to Erbitux (cetuximab) in culture (PMID: 25838391).",Actionable,4937,9256,colorectal cancer,DOID,1127,KRAS G12V,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",resistant,694,Cetuximab,3845
305,Preclinical - Cell culture,"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12V mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8986,3910,lung adenocarcinoma,DOID,1127,KRAS G12V,"[{'id': 6848, 'pubMedId': 27422710, 'title': 'Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27422710'}]",decreased response,807,Binimetinib,3845
306,Preclinical - Cell culture,"In a preclinical study, AUY922 inhibited growth of colon cancer cell lines harboring KRAS G12V in culture (PMID: 26832792).",Actionable,9210,219,colon cancer,DOID,1127,KRAS G12V,"[{'id': 5083, 'pubMedId': 26832792, 'title': 'Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26832792'}]",sensitive,647,AUY922,3845
307,Preclinical,"In a preclinical study, colorectal cancer cells harboring KRAS G12V were less sensitive to Nerlynx (neratinib) induced growth inhibition in culture (PMID: 26243863).",Actionable,7115,9256,colorectal cancer,DOID,1127,KRAS G12V,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",decreased response,828,Neratinib,3845
308,Preclinical - Cell line xenograft,"In a preclinical study, Rapamune (sirolimus) worked synergistically with Mekinist (trametinib) to inhibit proliferation of head and neck squamous carcinoma cell lines overexpressing KRAS G12V in culture and to reduce tumor growth in cell line xenograft models (PMID: 26882569).",Actionable,4689,5520,head and neck squamous cell carcinoma,DOID,1127,KRAS G12V,"[{'id': 4668, 'pubMedId': 26882569, 'title': 'A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26882569'}]",sensitive,3596,Sirolimus + Trametinib,3845
309,Preclinical - Cell culture,"In a preclinical study, a colon cancer cell line harboring KRAS G12V demonstrated sensitivity to AZ-TAK1 in culture, resulting in inhibition of cell growth (PMID: 27655129). ",Actionable,10060,219,colon cancer,DOID,1127,KRAS G12V,"[{'id': 7992, 'pubMedId': 27655129, 'title': 'MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27655129'}]",sensitive,5359,AZ-TAK1,3845
310,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) decreased viability of a colorectal cancer cell line harboring KRAS G12V in culture (PMID: 27602501).",Actionable,12023,9256,colorectal cancer,DOID,1127,KRAS G12V,"[{'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",sensitive,691,BYL719,3845
311,Preclinical - Cell culture,"In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of colorectal cancer cell lines harboring KRAS G12V (PMID: 28615361).",Actionable,11325,9256,colorectal cancer,DOID,1127,KRAS G12V,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",sensitive,5914,AZD4785,3845
312,Preclinical,"In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G12V in culture (PMID: 25838391).",Actionable,4951,9256,colorectal cancer,DOID,1127,KRAS G12V,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",sensitive,1305,Regorafenib + Cetuximab,3845
313,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of PIK3CA wild-type colorectal cancer cells harboring KRAS G12V (PMID: 26369631).",Actionable,5618,9256,colorectal cancer,DOID,21300,KRAS G12V PIK3CA wild-type,"[{'id': 5128, 'pubMedId': 26369631, 'title': 'Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26369631'}]",sensitive,1368,Palbociclib + Trametinib,3845
314,Preclinical - Cell culture,"In a preclinical study, a lung cancer cell line harboring FGFR1 amplification and KRAS G13C demonstrated insensitivity to JNJ-42756493 (erdafitinib) in culture (PMID: 28341788).",Actionable,11186,1324,lung cancer,DOID,27924,FGFR1 amp KRAS G12V,"[{'id': 9140, 'pubMedId': 28341788, 'title': 'Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28341788'}]",resistant,1028,JNJ-42756493,3845
315,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 4 mutations (Guidelines).,Actionable,3836,9256,colorectal cancer,DOID,1870,KRAS A146P,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,694,Cetuximab,3845
316,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 4 mutations (Guidelines).,Actionable,3841,9256,colorectal cancer,DOID,1870,KRAS A146P,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,845,Panitumumab,3845
317,Preclinical - Cell culture,"In a preclinical study,  non-small cell lung carcinoma cells harboring KRAS mutation, STK11 and TP53 loss demonstrated increased sensitivity to MK-1775 and Platinol (cisplatin) combination treatment in culture compared to isogenic cell lines expressing wild-type Tp53 or Stk11 (PMID: 28652249).",Actionable,11859,3908,non-small cell lung carcinoma,DOID,28317,KRAS mut STK11 loss TP53 loss,"[{'id': 9874, 'pubMedId': 28652249, 'title': 'WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28652249'}]",predicted – sensitive,1725,MK-1775 + Cisplatin,3845
318,Preclinical,"In a preclinical study, human triple negative breast cancer cells harboring mutant BRAF, KRAS, and CDKN2A were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6690,60081,triple-receptor negative breast cancer,DOID,23670,BRAF mut KRAS mut CDKN2A mut,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,2,Trametinib,3845
319,Preclinical,"In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",Actionable,4571,219,colon cancer,DOID,18592,KRAS mutant PIK3CA H1047R,"[{'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",sensitive,680,BKM120,3845
320,Preclinical,"In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",Actionable,4573,219,colon cancer,DOID,18592,KRAS mutant PIK3CA H1047R,"[{'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",sensitive,3548,BKM120 + Cetuximab,3845
321,Preclinical,"In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",Actionable,4572,219,colon cancer,DOID,18592,KRAS mutant PIK3CA H1047R,"[{'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",no benefit,694,Cetuximab,3845
322,Preclinical,"In a preclinical study, knocking down of Fgfr3 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture  (PMID: 27338794).",Actionable,7363,1324,lung cancer,DOID,25309,FGFR3 dec exp KRAS mut,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",no benefit,2,Trametinib,3845
323,Preclinical - Cell culture,"In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to a KRAS mutation in culture (PMID: 25873592).",Actionable,7831,1909,melanoma,DOID,26062,BRAF mut KRAS mut,"[{'id': 6506, 'pubMedId': 25873592, 'title': 'The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25873592'}]",predicted – sensitive,1059,BI-847325,3845
324,Preclinical,"In a preclinical study, CUDC-907 inhibited growth and induced apoptosis in a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 22693356).",Actionable,2840,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 1018, 'pubMedId': 22693356, 'title': 'Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693356'}]",sensitive,709,CUDC-907,3845
325,Preclinical - Cell line xenograft,"In a preclinical study, treatment with Aliqopa (copanlisib) inhibited tumor growth in xenograft models of a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 24170767).",Actionable,2722,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 245, 'pubMedId': 24170767, 'title': 'BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24170767'}]",sensitive,995,Copanlisib,3845
326,Preclinical - Cell line xenograft,"In a preclincal study, GDC-0980 delayed tumor growth in colon cancer cell line xenograft models harboring KRAS and PIKC3A mutations (PMID: 21998291).",Actionable,2855,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 3508, 'pubMedId': 21998291, 'title': 'GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21998291'}]",sensitive,750,GDC-0980,3845
327,Preclinical,"In a preclinical study, Selumetinib (AZD6244) mildly inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with KRAS and PIK3CA mutations (PMID: 24939055).",Actionable,983,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 642, 'pubMedId': 24939055, 'title': 'Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24939055'}]",decreased response,913,Selumetinib,3845
328,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically prevented proliferation of an Iressa (gefitinib)-resistant NSCLC cell line harboring KRAS and PIK3CA mutations in culture and in cell line xenograft models (PMID: 24939055).",Actionable,989,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 642, 'pubMedId': 24939055, 'title': 'Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24939055'}]",sensitive,1420,Selumetinib + BEZ235,3845
329,Phase I,"In a Phase I trial, a colorectal cancer patient co-harboring a PIK3CA mutation and KRAS mutation progressed on treatment with Taselisib (GDC-0032) (PMID: 28331003). ",Actionable,11446,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 9393, 'pubMedId': 28331003, 'title': 'Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28331003'}]",no benefit,1016,GDC-0032,3845
330,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line co-harboring a KRAS mutation and PIK3CA mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture (PMID: 24634413). ",Actionable,10707,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 8768, 'pubMedId': 24634413, 'title': 'Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24634413'}]",sensitive,1051,SAR245409,3845
331,Phase II,"In a Phase II trial, one patient with Kras and Pikc3a mutant non-squamous NSCLC had a partial response to Buparlisib (BKM120) however, stage 2 of the study was not initiated due to failure of meeting overall stage 1 response endpoints (PMID: 26098748).",Actionable,9817,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 7642, 'pubMedId': 26098748, 'title': 'Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26098748'}]",sensitive,680,BKM120,3845
332,Preclinical - Cell line xenograft,"In a preclinical study, PF-04691502 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring both PIK3CA and KRAS mutations (PMID: 21750219).",Actionable,8388,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 226, 'pubMedId': 21750219, 'title': 'PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21750219'}]",sensitive,865,PF-04691502,3845
333,Preclinical,"In a preclinical study, human solid tumor cell lines harboring coincident PIK3CA and KRAS mutations demonstrated sensitivity to CH5132799 in culture (PMID: 21558396).",Actionable,2835,10000003,Advanced Solid Tumor,JAX,1630,KRAS mut PIK3CA mut,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,3845
334,Preclinical,"In a preclinical study, human cancer cells with PIK3CA mutations demonstrated sensitivity to Afinitor (everolimus), but a coincident KRAS mutation led to Afinitor (everolimus) resistance  (PMID: 20664172).",Actionable,145,10000003,Advanced Solid Tumor,JAX,1630,KRAS mut PIK3CA mut,"[{'id': 219, 'pubMedId': 20664174, 'title': ""PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20664174'}, {'id': 1067, 'pubMedId': 20664172, 'title': 'Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20664172'}]",resistant,735,Everolimus,3845
335,Phase I,"In a Phase I trial, Taselisib (GDC-0032) demonstrated activity in patients with PIK3CA-mutant advanced solid tumors, but preliminary data analysis suggested the presence of a KRAS mutation was associated with lack of response (Cancer Res October 1, 2014 74:915).",Actionable,2851,10000003,Advanced Solid Tumor,JAX,1630,KRAS mut PIK3CA mut,"[{'id': 3507, 'pubMedId': None, 'title': 'Abstract 915: Expanded biomarker results from a phase I dose escalation study of GDC-0032, a beta isoform-sparing PI3K inhibitor', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/915.short'}]",decreased response,1016,GDC-0032,3845
336,Preclinical,"In a preclinical study, BEZ235 inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with KRAS and PIK3CA mutations (PMID: 24939055).",Actionable,984,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 642, 'pubMedId': 24939055, 'title': 'Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24939055'}]",sensitive,672,BEZ235,3845
337,Preclinical - Cell line xenograft,"In a preclinical study, Navitoclax (ABT-263) improved the therapeutic effects of the combination of CGM097 and Mekinist (trametinib) in colorectal cancer cells, resulting in greater apoptotic activity and growth inhibition in culture, and tumor regression in xenograft models (PMID: 27659046). ",Actionable,9931,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 7782, 'pubMedId': 27659046, 'title': 'High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27659046'}]",sensitive,5315,ABT-263 + CGM097 + Trametinib,3845
338,Preclinical,"In a preclinical study, Deguelin inhibited growth of the AGS gastric cancer cell line, which has been reported to harbor PIK3CA and KRAS mutations, in culture (PMID: 20811676, PMID: 24978597).",Actionable,2844,10534,stomach cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 962, 'pubMedId': 24978597, 'title': 'Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24978597'}, {'id': 3500, 'pubMedId': 20811676, 'title': 'Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20811676'}]",predicted – sensitive,1867,Deguelin,3845
339,Preclinical,"In a preclinical study, a colon cancer cell line harboring PIK3CA and KRAS mutations demonstrated sensitivity to AT13148 in culture (PMID: 22781553).",Actionable,2779,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 204, 'pubMedId': 22781553, 'title': 'AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22781553'}]",sensitive,3653,AT13148,3845
340,Preclinical,"In a preclinical study, Alpelisib (BYL719) inhibited growth in multiple tumor cell lines expressing PIK3CA mutations, and concurrent KRAS mutations was not associated with resistance (PMID: 24608574).",Actionable,2874,10000003,Advanced Solid Tumor,JAX,1630,KRAS mut PIK3CA mut,"[{'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",sensitive,691,BYL719,3845
341,Preclinical - Cell line xenograft,"In a preclinical study, the combination of CGM097 and Mekinist (trametinib) treatment compared to treatment with either agent alone in a colorectal cancer cell line resulted in a greater decrease in colony formation in culture, and improved stable disease in xenograft models (PMID: 27659046). ",Actionable,9930,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 7782, 'pubMedId': 27659046, 'title': 'High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27659046'}]",sensitive,5314,CGM097 + Trametinib,3845
342,Preclinical,"In a preclinical study, the combination of AZD8055 and Selumetinib (AZD6244) inhibited tumor growth in a colorectal cancer xenograft model harboring PIK3CA and KRAS mutations and had increased efficacy compared to either agent alone (PMID: 22271687).",Actionable,2795,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 3482, 'pubMedId': 22271687, 'title': 'Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22271687'}]",sensitive,2561,AZD8055 + Selumetinib,3845
343,Preclinical,"In a preclinical study, colon cancer cells harboring KRAS and PIK3CA mutations demonstrated resistance to BEZ235 in culture and xenograft models (PMID: 23475782).",Actionable,2724,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 3437, 'pubMedId': 23475782, 'title': 'Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23475782'}]",resistant,672,BEZ235,3845
344,Preclinical,"In a preclinical study, A-443654 inhibited proliferation of colon cancer cell lines that have been reported to harbor KRAS and PIK3CA mutations in culture (PMID: 24569089, PMID: 24978597).
",Actionable,2864,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 962, 'pubMedId': 24978597, 'title': 'Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24978597'}, {'id': 3512, 'pubMedId': 24569089, 'title': 'Context-dependent antagonism between Akt inhibitors and topoisomerase poisons.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24569089'}]",sensitive,2448,A-443654,3845
345,Preclinical,"In a preclinical study, BKM120 suppressed growth of a gastric cancer cell line harboring PIK3CA and KRAS mutations in culture (PMID: 22159814).",Actionable,2799,10534,stomach cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 3447, 'pubMedId': 22159814, 'title': 'NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22159814'}]",sensitive,680,BKM120,3845
346,Preclinical - Cell line xenograft,"In a preclinical study, a non-small cell lung carcinoma cell line harboring a KRAS mutation and STK11 inactivating mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413). ",Actionable,10705,3908,non-small cell lung carcinoma,DOID,20861,KRAS mut STK11 inact mut,"[{'id': 8768, 'pubMedId': 24634413, 'title': 'Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24634413'}]",sensitive,1051,SAR245409,3845
347,Preclinical - Cell culture,"In a preclinical study, MK-1775 combined with radiation therapy demonstrated enhanced growth inhibition in non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations compared to cells expressing wild-type STK11 in culture (PMID: 28652249).",Actionable,11858,3908,non-small cell lung carcinoma,DOID,20861,KRAS mut STK11 inact mut,"[{'id': 9874, 'pubMedId': 28652249, 'title': 'WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28652249'}]",predicted – sensitive,4186,MK-1775 + Radiotherapy,3845
348,Preclinical - Cell culture,"In a preclinical study, MK-1775 and Platinol (cisplatin) combination treatment demonstrated enhanced growth inhibition in non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations compared to cells expressing wild-type STK11 in culture (PMID: 28652249).",Actionable,11857,3908,non-small cell lung carcinoma,DOID,20861,KRAS mut STK11 inact mut,"[{'id': 9874, 'pubMedId': 28652249, 'title': 'WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28652249'}]",predicted – sensitive,1725,MK-1775 + Cisplatin,3845
349,Preclinical,"In a preclinical study, Sapanisertib (MLN0128) in combination with phenformin induced apoptosis and energetic stress in human lung adenocarcinoma cell lines with concurrent KRAS and STK11 (LKB1) mutations in culture, with higher levels than either therapy as a single agent (PMID: 26574479).",Actionable,5408,3910,lung adenocarcinoma,DOID,20861,KRAS mut STK11 inact mut,"[{'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",sensitive,3861,MLN0128 + Phenformin,3845
350,Preclinical - Cell culture,"In a preclinical study, non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations demonstrated increased sensitivity to MK-1775 compared to cells expressing wild-type STK11 in culture (PMID: 28652249).",Actionable,11856,3908,non-small cell lung carcinoma,DOID,20861,KRAS mut STK11 inact mut,"[{'id': 9874, 'pubMedId': 28652249, 'title': 'WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28652249'}]",predicted – sensitive,822,MK-1775,3845
351,Preclinical,"In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and tumor growth in xenograft models (PMID: 26715098).",Actionable,4570,219,colon cancer,DOID,18590,KRAS mutant PIK3CA wild-type,"[{'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",sensitive,3548,BKM120 + Cetuximab,3845
352,Preclinical,"In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and reduced tumor growth in xenograft models (PMID: 26715098).",Actionable,4568,219,colon cancer,DOID,18590,KRAS mutant PIK3CA wild-type,"[{'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",sensitive,680,BKM120,3845
353,Preclinical - Pdx & cell culture,"In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture, and colorectal cancer patient-derived xenograft (PDX) models with KRAS or BRAF mutations and wild-type PIK3CA demonstrated a trend toward greater tumor growth inhibition (PMID: 26439693).",Actionable,10766,9256,colorectal cancer,DOID,18590,KRAS mutant PIK3CA wild-type,"[{'id': 8454, 'pubMedId': 26439693, 'title': 'Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26439693'}]",predicted – sensitive,932,TAK-733,3845
354,Preclinical,"In a preclinical study, knocking down of Fgfr2 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).",Actionable,7362,1324,lung cancer,DOID,25308,FGFR2 dec exp KRAS mut,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",no benefit,2,Trametinib,3845
355,Preclinical - Cell line xenograft,"In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition in KRAS mutant lung cancer cells with decreased Fgfr1 expression through shRNA knockdown in culture, and tumor regression in xenograft models (PMID: 27338794).",Actionable,7360,1324,lung cancer,DOID,25304,FGFR1 dec exp KRAS mut,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",sensitive,2,Trametinib,3845
356,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition of KRAS mutant pancreatic cancer cells with decreased Fgfr1 expression through shRNA knockdown in culture (PMID: 27338794).",Actionable,7365,1793,pancreatic cancer,DOID,25304,FGFR1 dec exp KRAS mut,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",sensitive,2,Trametinib,3845
357,Preclinical - Cell culture,"In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS mutant colorectal cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).",Actionable,7366,9256,colorectal cancer,DOID,25304,FGFR1 dec exp KRAS mut,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",no benefit,2,Trametinib,3845
358,Phase I,"In a clinical study, a retrospective analysis of a Phase I trial demonstrated four non-small cell lung carcinoma (NSCLC) patients co-harboring  a TP53 mutation and KRAS mutation had greater progression free survival compared to NSCLC patients harboring a single TP53 mutation or single KRAS mutation when treated with Keytruda (pembrolizumab) (PMID: 28039262). ",Actionable,11296,3908,non-small cell lung carcinoma,DOID,25456,KRAS mutant TP53 mutant,"[{'id': 9220, 'pubMedId': 28039262, 'title': 'Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28039262'}]",predicted – sensitive,1447,Pembrolizumab,3845
359,Preclinical - Cell culture,"In a preclinical study, the combination of Navitoclax (ABT-263), Mekinist (trametinib), Alpelisib (BYL719), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a KRAS mutation and TP53 mutation compared to the double or triple combinations of the therapies (PMID: 27659046). ",Actionable,9932,9256,colorectal cancer,DOID,25456,KRAS mutant TP53 mutant,"[{'id': 7782, 'pubMedId': 27659046, 'title': 'High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27659046'}]",sensitive,5316,ABT-263 + Alpelisib + Erlotinib + Trametinib,3845
360,Phase I,"In a Phase I trial, a colorectal cancer patient co-harboring a KRAS mutation and TP53 mutation demonstrated sensitivity when treated with Abemaciclib (LY2835219), which resulted in stable disease (PMID: 27217383). ",Actionable,7460,9256,colorectal cancer,DOID,25456,KRAS mutant TP53 mutant,"[{'id': 6356, 'pubMedId': 27217383, 'title': 'Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27217383'}]",sensitive,802,Abemaciclib,3845
361,Preclinical - Cell culture,"In a preclinical study, DEL-22379 inhibited growth of KRAS-mutant melanoma cells over expressing BRAF V600E in culture (PMID: 26267534).",Actionable,5815,9256,colorectal cancer,DOID,21629,BRAF V600E KRAS mutant,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",sensitive,3769,DEL-22379,3845
362,Preclinical,"In a preclinical study, over expression of BRAF V600E in KRAS-mutant colorectal cancer cells resulted in resistance to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",Actionable,5813,9256,colorectal cancer,DOID,21629,BRAF V600E KRAS mutant,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",resistant,849,PD-0325901,3845
363,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 induced antibody-dependent cell-mediated cytotoxicity against KRAS-mutant lung adenocarcinoma with low EGFR expression in culture and improved overall survival in low EGFR expressing, KRAS-mutant lung adenocarcinoma cell line xenograft models, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3866,3910,lung adenocarcinoma,DOID,16550,EGFR dec exp KRAS mut,"[{'id': 3814, 'pubMedId': 23209031, 'title': 'GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209031'}]",sensitive,3154,GA201,3845
364,Preclinical,"In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3867,9256,colorectal cancer,DOID,16550,EGFR dec exp KRAS mut,"[{'id': 3814, 'pubMedId': 23209031, 'title': 'GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209031'}]",sensitive,3154,GA201,3845
365,Preclinical - Cell line xenograft,"In a preclinical study, the combination of ER2 and Platinol (cisplatin) demonstrated synergy in inhibiting tumor growth in a non-small cell lung cancer cell line xenograft model with low expression of wild-type EGFR, that also harbors a KRAS mutation (PMID: 27040853).",Actionable,8042,3908,non-small cell lung carcinoma,DOID,16550,EGFR dec exp KRAS mut,"[{'id': 5133, 'pubMedId': 27040853, 'title': 'ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27040853'}]",sensitive,4625,ER2 + Cisplatin,3845
366,Preclinical,"In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant non-small cell lung cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3865,3908,non-small cell lung carcinoma,DOID,16550,EGFR dec exp KRAS mut,"[{'id': 3814, 'pubMedId': 23209031, 'title': 'GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209031'}]",sensitive,3154,GA201,3845
367,Clinical Study,"In a clinical case study, Stivarga (regorafenib) treatment resulted in durable partial response in a colorectal cancer patient harboring KDR R961W and mutations in APC and KRAS (PMID: 27004155).",Actionable,5559,9256,colorectal cancer,DOID,21268,APC mutant KRAS mutant KDR R961W,"[{'id': 5105, 'pubMedId': 27004155, 'title': 'KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27004155'}]",sensitive,890,Regorafenib,3845
368,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9394,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,4601,Dasatinib + SCH772984,3845
369,Preclinical - Pdx & cell culture,"In a preclinical study, AZD8186 and SCH772984 synergistically inhibited growth of both established and patient-derived, SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9369,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,4986,AZD8186 + SCH772984,3845
370,Preclinical - Cell culture,"In a preclinical study, Rydapt (midostaurin) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9393,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,5008,Midostaurin + SCH772984,3845
371,Phase Ib/II,"In a Phase Ib/II trial, the combination of Sprycel (dasatinib) and FOLFOX demonstrated minimal clinical benefit in patients with metastatic colorectal adenocarcinoma harboring KRAS codon 12/13 mutations, with no responses and a median time to treatment failure of 2.0 months (PMID: 28280091; NCT00501410).",Actionable,11610,50861,colorectal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 9667, 'pubMedId': 28280091, 'title': 'Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28280091'}]",no benefit,6075,Dasatinib + FOLFOX,3845
372,Preclinical,"In a preclinical study, BI-847325 promoted tumor regression in mutant KRAS pancreatic adenocarcinoma models (Cancer Res 2012;72(8 Suppl):Abstract nr 1919).",Actionable,1287,4074,pancreatic adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 999, 'pubMedId': None, 'title': 'Abstract 1919: Pharmacological characterization of BI 847325, a dual inhibitor of MEK and Aurora kinases', 'url': 'http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/8_MeetingAbstracts/1919'}]",sensitive,1059,BI-847325,3845
373,Preclinical - Cell culture,"In a preclinical study, the addition of combination PD-0325901 to treatment with Gedatolisib (PF-05212384) and PD-0325901 inhibited Gedatolisib (PF-05212384)-enhanced ERK activation, and the combination resulted in decreased proliferation of pancreatic ductal adenocarcinoma cell lines harboring KRAS mutations in culture (PMID: 25673820).",Actionable,2765,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 3463, 'pubMedId': 25673820, 'title': 'Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25673820'}]",sensitive,3025,PD-0325901 + Gedatolisib,3845
374,Preclinical,"In a preclinical study, the addition of PD-0325901 to treatment with GDC-0980 and inhibited GDC-0980-enhanced ERK activation, and the combination resulted in decreased proliferation of pancreatic cancer cells harboring KRAS mutations in culture (PMID: 25673820).",Actionable,2766,1793,pancreatic cancer,DOID,448,KRAS mutant,"[{'id': 3463, 'pubMedId': 25673820, 'title': 'Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25673820'}]",sensitive,3026,GDC-0980 + PD-0325901,3845
375,Preclinical - Cell culture,"In a preclinical study, Navitoclax (ABT-263)  and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9384,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,4998,Navitoclax + SCH772984,3845
376,Phase I,"In a Phase I trial, of eight patients with colorectal cancer, three patients harbored a KRAS mutation and demonstrated stable disease when treated with Mekinist (trametinib) (PMID: 22805291). ",Actionable,1435,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",sensitive,2,Trametinib,3845
377,Preclinical - Cell culture,"In a preclinical study, AZD8055 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9380,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,4994,AZD8055 + SCH772984,3845
378,Phase I,"In a Phase I trial, Binimetinib (MEK162) treatment resulted in an estimated progression free survival (PFS) of 1.5 months and overall survival (OS) of 4.7 months when dosed at 45mg, and PFS of 3.5 months and OS of 9.1 months when dosed at 60mg, in colorectal cancer patients harboring KRAS mutations (PMID: 28152546).",Actionable,10458,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 8465, 'pubMedId': 28152546, 'title': 'A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28152546'}]",predicted – sensitive,807,Binimetinib,3845
379,Clinical Study,"In a clinical study, KRAS mutations were associated with resistance to Afinitor (everolimus) in patients with advanced solid tumors (PMID: 20664172).",Actionable,1436,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,"[{'id': 1067, 'pubMedId': 20664172, 'title': 'Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20664172'}]",resistant,735,Everolimus,3845
380,Preclinical - Cell culture,"In a preclinical study, Ipatasertib (GDC-0068) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9379,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,5004,GDC-0941 + SCH772984,3845
381,Phase I,"In a Phase I trial, BI-847325 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including patients harboring KRAS mutations (Mol Cancer Ther 2013;12(11 Suppl):B281).",Actionable,2725,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,"[{'id': 998, 'pubMedId': None, 'title': 'Abstract B281: Phase I study of two dosing schedules of BI 847325, an orally administered dual inhibitor of MEK and aurora kinase B, in patients with advanced solid tumors.', 'url': 'http://mct.aacrjournals.org/content/12/11_Supplement/B281.meeting_abstract'}]",sensitive,1059,BI-847325,3845
382,Phase I,"In a Phase I trial, a patient with colon cancer harboring a KRAS mutation demonstrated stable disease when treated with OPB-111077 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118).",Actionable,10963,219,colon cancer,DOID,448,KRAS mutant,"[{'id': 8960, 'pubMedId': None, 'title': 'Abstract B118: A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/B118.short'}]",predicted – sensitive,5739,OPB-111077,3845
383,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant pancreatic cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11968,1793,pancreatic cancer,DOID,448,KRAS mutant,"[{'id': 9707, 'pubMedId': None, 'title': 'KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short'}]",predicted – sensitive,5747,KO-947,3845
384,Preclinical,"In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) synergistically inhibited proliferation of KRAS mutant pancreatic cancer cells in culture (PMID: 27338794).",Actionable,7368,1793,pancreatic cancer,DOID,448,KRAS mutant,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",sensitive,4477,Ponatinib + Trametinib,3845
385,Phase Ib/II,"In a Phase Ib/II clinical trial, treatment with Mekinist (trametinib) resulted in an overall response rate of 28% in RAS-mutant leukemia patients, with 12% (7/57) of patients achieving complete remission (ASH 2015 Annual Meeting, Abst 677).",Actionable,3563,1240,leukemia,DOID,448,KRAS mutant,"[{'id': 3823, 'pubMedId': None, 'title': '677 Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease', 'url': 'https://ash.confex.com/ash/2012/webprogram/Paper51144.html'}]",predicted – sensitive,2,Trametinib,3845
386,Phase I,"In a Phase I trial, two non-small cell lung carcinoma patients harboring a KRAS mutation demonstrated a partial response when treated with Mekinist (trametinib) (PMID: 22805291). ",Actionable,11974,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",sensitive,2,Trametinib,3845
387,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of non-small cell cancer cell lines harboring mutant KRAS in culture (PMID: 26343583).",Actionable,6700,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,2,Trametinib,3845
388,Preclinical - Cell culture,"In a preclinical study, the combination of Mekinist (trametinib) and AZD4547 synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",Actionable,7372,1324,lung cancer,DOID,448,KRAS mutant,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",sensitive,4478,AZD4547 + Trametinib,3845
389,Preclinical - Cell culture,"In a preclinical study, Linsitinib (OSI-906) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9388,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,5002,Linsitinib + SCH772984,3845
390,Preclinical,"In a preclinical study, human multiple myeloma cells harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6688,9538,multiple myeloma,DOID,448,KRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,2,Trametinib,3845
391,Phase I,"In a Phase I trial, BGB-283 demonstrated safety and preliminary efficacy, resulted in partial response in 14% (4/29), and prolonged stable disease in 48% (14/29) of advanced solid tumor patients harboring mutations in KRAS, NRAS, and/or BRAF (AACR Annual Meeting, Apr 2016, abstract # CT005).",Actionable,7226,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,"[{'id': 6230, 'pubMedId': None, 'title': 'Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=46a0776a-1444-49d6-b533-4f68e298c39d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]",predicted – sensitive,4025,BGB-283,3845
392,Preclinical - Cell culture,"In a preclinical study, BMS-754807 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9392,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,5007,BMS-754807 + SCH772984,3845
393,Preclinical - Cell culture,"In a preclinical study, the combination of Tarceva (erlotinib) and IRX4204 inhibited proliferation of non-small cell lung cancer cell lines in culture, including cell lines harboring KRAS mutations, and resulted in increased inhibition of proliferation and Src, p-AKT, and ribosomal S6 compared to either agent alone (J Clin Oncol 35, 2017 (suppl; abstr e14095)).",Actionable,11171,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 9131, 'pubMedId': None, 'title': 'IRX4204 in combination with erlotinib to target distinct pathways in lung cancer cells.', 'url': 'http://abstracts.asco.org/199/AbstView_199_192863.html'}]",predicted – sensitive,5135,Erlotinib + IRX4204,3845
394,Preclinical - Cell culture,"In a preclinical study, MK2206 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9383,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,4997,MK2206 + SCH772984,3845
395,Phase II,"In a Phase II study, Estybon (rigosertib) in combination with, gemcitabine, did not demonstrate increased efficacy over gemcitabine alone and there was no correlation of reponse with Kras mutational status in pancreatic patients (PMID: 26091808).",Actionable,2748,1793,pancreatic cancer,DOID,448,KRAS mutant,"[{'id': 3452, 'pubMedId': 26091808, 'title': 'A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26091808'}]",no benefit,3021,Rigosertib + Gemcitabine,3845
396,Preclinical - Pdx,"In a preclinical study, the combination of Dinaciclib (SCH 727965) and MK-2206 inhibited tumor growth and metastasis in KRAS-mutant patient-derived xenograft models of pancreatic ductal adenocarcinoma, with some models achieving complete response (PMID: 25931518).",Actionable,8377,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 3366, 'pubMedId': 25931518, 'title': 'Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25931518'}]",sensitive,2193,Dinaciclib + MK2206,3845
397,Preclinical,"In a preclinical study, the combination of Buparlisib (BKM120) and Tyrphostin B42 (AG-490) worked synergistically to inhibit proliferation and induce apoptosis in gastric cancer cell lines harboring KRAS mutations in culture (PMID: 22159814).",Actionable,2738,10534,stomach cancer,DOID,448,KRAS mutant,"[{'id': 3447, 'pubMedId': 22159814, 'title': 'NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22159814'}]",sensitive,3019,BKM120 + AG490,3845
398,Preclinical,"In a preclinical study, tumor cell lines harboring KRAS mutations were resistant to AZD8835 induced growth inhibition in culture (PMID: 26839307).",Actionable,5098,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,"[{'id': 4877, 'pubMedId': 26839307, 'title': 'Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26839307'}]",resistant,2013,AZD8835,3845
399,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant gastric carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11971,5517,stomach carcinoma,DOID,448,KRAS mutant,"[{'id': 9707, 'pubMedId': None, 'title': 'KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short'}]",predicted – sensitive,5747,KO-947,3845
400,Phase I,"In a Phase I/Ib trial, treatment with the combination of Mekinist (trametinib) and Taxotere (docetaxel) resulted in an overall response rate (ORR) of 24% (6/25, all partial responses), and stable disease in 36% (9/25) in the subset of patients with KRAS-mutant non-small cell lung cancer, compared to an ORR of 18% (4/22) in patients with wild-type or unknown KRAS status (PMID: 27876675).",Actionable,10762,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 8810, 'pubMedId': 27876675, 'title': 'A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced\xa0Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27876675'}]",predicted – sensitive,1264,Docetaxel + Trametinib,3845
401,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of squamous cell lung carcinoma cells harboring mutant KRAS in culture (PMID: 26343583).",Actionable,6701,3907,lung squamous cell carcinoma,DOID,448,KRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,2,Trametinib,3845
402,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of a majority (12/17) lung adenocarcinoma cell lines harboring mutant KRAS in culture (PMID: 26343583).",Actionable,6698,3910,lung adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,2,Trametinib,3845
403,Phase II,"In a Phase II trial, Tarceva (erlotinib) and MK2206 combination treatment resulted in comparable 8-week disease control rate in KRAS wild-type (57%, 16/28) and KRAS mutated (25%, 2/8) patients with advanced non-small cell lung carcinoma (PMID: 27480147).",Actionable,7740,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 6464, 'pubMedId': 27480147, 'title': 'The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27480147'}]",no benefit,1097,Erlotinib + MK2206,3845
404,Preclinical,"In a preclinical study, human endometrial cancer cells harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6693,1380,endometrial cancer,DOID,448,KRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,2,Trametinib,3845
405,Phase I,"In a Phase Ib trial, Tecentriq (atezolizumab) and Cotellic (cobimetinib) combination treatment resulted in partial response in 17% (4/23) and stable disease in 22% (5/23) of colorectal cancer patients harboring KRAS mutations (Ann Oncol (2016) 27 (suppl 2): ii140).",Actionable,7233,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 6232, 'pubMedId': None, 'title': 'Safety and efficacy of cobimetinib (cobi) and atezolizumab (atezo) in a Phase 1b study of metastatic colorectal cancer (mCRC)', 'url': 'http://annonc.oxfordjournals.org/content/27/suppl_2/ii140.1.full'}]",predicted – sensitive,1343,Atezolizumab + Cobimetinib,3845
406,Phase I,"In a Phase I clinical trial, GI-4000 was well-tolerated and led to some RAS-directed immune response in patients with RAS-mutant pancreatic cancer (PMID: 25585100).",Actionable,358,1793,pancreatic cancer,DOID,448,KRAS mutant,"[{'id': 193, 'pubMedId': 24372276, 'title': 'GI-4000 in KRAS mutant cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24372276'}, {'id': 5729, 'pubMedId': 25585100, 'title': 'Pancreatic cancer, treatment options, and GI-4000.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25585100'}]",predicted – sensitive,1018,GI-4000,3845
407,Phase I,"In a clinical study, a retrospective analysis of a Phase I trial demonstrated non-small cell lung carcinoma (NSCLC) patients harboring either a TP53 mutation (n=15) or KRAS mutation (n=8) had greater progression free survival compared to NSCLC patients harboring wild-type TP53 or KRAS (n=15) (14.5mo vs 14.7mo vs 3.5mo, respectively) when treated with Keytruda (pembrolizumab) (PMID: 28039262). ",Actionable,11295,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 9220, 'pubMedId': 28039262, 'title': 'Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28039262'}]",predicted – sensitive,1447,Pembrolizumab,3845
408,Preclinical,"In a preclinical study, MLN1117 (INK1117) did not inhibit tumor growth in xenograft models harboring mutations in KRAS (American Association for Cancer Research; 2011:Abstract nr 4501).",Actionable,1685,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,"[{'id': 1789, 'pubMedId': None, 'title': 'Abstract 4501: INK1117: A potent and orally efficacious PI3K?-selective inhibitor for the treatment of cancer', 'url': 'http://cancerres.aacrjournals.org/content/71/8_Supplement/4501.short'}]",no benefit,1033,MLN1117,3845
409,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS mutations due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,9001,3910,lung adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 6848, 'pubMedId': 27422710, 'title': 'Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27422710'}]",decreased response,913,Selumetinib,3845
410,Preclinical - Cell line xenograft,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant lung cancer (PMID: 26140595).",Actionable,10255,1324,lung cancer,DOID,448,KRAS mutant,"[{'id': 8232, 'pubMedId': 26140595, 'title': 'A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26140595'}]",predicted – sensitive,5443,PF3644022 + PF-477736,3845
411,Clinical Study,"In a clinical study, KRAS mutations were associated with resistance to Tarceva (erlotinib) in patients with lung adenocarcinoma (PMID: 15696205).",Actionable,141,3910,lung adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 211, 'pubMedId': 15696205, 'title': 'KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15696205'}]",resistant,4,Erlotinib,3845
412,Phase III,"In a Phase III trial supporting FDA approval, Stivarga (regorafenib) treatment resulted in a median progression free survival (PFS) of 2.3 months in metastatic colorectal cancer patients harboring KRAS mutations, and a median PFS of 2.1 months in KRAS wild-type patients (J Clin Oncol 34, 2016 (suppl 4S; abstr 735)).",Actionable,6004,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 5221, 'pubMedId': None, 'title': 'Regorafenib for previously treated metastatic colorectal cancer (mCRC): A subgroup analysis of 364 patients in the USA treated in the international, open-label phase IIIb CONSIGN study.', 'url': 'http://meetinglibrary.asco.org/content/160044-173'}]",predicted – sensitive,890,Regorafenib,3845
413,Preclinical - Pdx,"In a preclinical study, XMT-1536 induced tumor regression in patient-derived-xenograft models of of non-small cell lung cancer harboring KRAS mutations (Proceedings of AACR, Vol 57, Apr 2016, Abstract # 1194).",Actionable,6211,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 5466, 'pubMedId': None, 'title': 'Discovery and preclinical development of a highly potent NaPi2b-targeted antibody-drug conjugate (ADC) with significant activity in patient-derived non-small cell lung cancer (NSCLC) xenograft models', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=43ef76fe-c845-4b4b-8531-601f2b1c2c32&cKey=132d0ba9-cd0a-4831-b61a-3bba3ae06518&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]",predicted – sensitive,4094,XMT-1536,3845
414,Preclinical,"In a preclinical study, gastric cancer xenograft models harboring KRAS mutations demonstrated decreased sensitivity to BAY1082439 in culture (AACR; 2015. Abstract nr 2674).",Actionable,2719,10534,stomach cancer,DOID,448,KRAS mutant,"[{'id': 3435, 'pubMedId': None, 'title': 'Activity of BAY1082439, a balanced PI3Kalpha/beta inhibitor, in gastric cancer', 'url': 'http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=14323955-7e99-4856-aec7-b2f95e96b99b&cKey=5384c5ef-c9a4-49da-a50c-67bf77ceef19&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424'}]",decreased response,666,BAY1082439,3845
415,Preclinical,"In a preclinical study, AT13148 inhibited tumor growth in a human lung adenocarcinoma cell line xenograft model harboring mutant KRAS (PMID: 22781553).",Actionable,4787,3910,lung adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 204, 'pubMedId': 22781553, 'title': 'AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22781553'}]",sensitive,3653,AT13148,3845
416,Phase I,"In a Phase I trial, none of 30 colorectal cancer patients with KRAS mutations achieved favorable response after treatment with RO4987655 (PMID: 24947927).",Actionable,2751,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 3454, 'pubMedId': 24947927, 'title': 'Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24947927'}]",no benefit,903,RO4987655,3845
417,Preclinical,"In a preclinical study, Mekinist (trametinib) and Iressa (gefitinib) did not demonstrate synergy at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",Actionable,7375,1324,lung cancer,DOID,448,KRAS mutant,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",no benefit,4481,Gefitinib + Trametinib,3845
418,Preclinical - Cell line xenograft,"In a preclinical study, CI-1040 inhibited growth of a human ovarian cancer cell line harboring a KRAS mutation in culture, and inhibited tumor growth in xenograft models (PMID: 19018267).",Actionable,2741,2394,ovarian cancer,DOID,448,KRAS mutant,"[{'id': 3448, 'pubMedId': 19018267, 'title': 'KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19018267'}]",sensitive,699,CI-1040,3845
419,Preclinical - Cell culture,"In a preclinical study, the combination of AZ-TAK1 and Selumetinib (AZD6244) resulted in an additive effect in colon cancer cells harboring KRAS mutant in culture, demonstrating a 90% growth reduction (PMID: 27655129). ",Actionable,10059,219,colon cancer,DOID,448,KRAS mutant,"[{'id': 7992, 'pubMedId': 27655129, 'title': 'MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27655129'}]",sensitive,5360,AZ-TAK1 + Selumetinib,3845
420,Preclinical,"In a preclinical study, Mekinist (trametinib) and Xalkori (crizotinib) did not demonstrate synergy at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",Actionable,7374,1324,lung cancer,DOID,448,KRAS mutant,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",no benefit,4480,Crizotinib + Trametinib,3845
421,Preclinical - Cell culture,"In a preclinical study, Ralimetinib (LY2228820) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9386,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,5000,Ralimetinib + SCH772984,3845
422,Preclinical - Patient cell culture,"In a preclinical study, AZD8186 and BVD-523 synergistically inhibited growth of both established and patient-derived, SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 26725216).",Actionable,9370,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,4987,AZD8186 + BVD-523,3845
423,Preclinical - Cell line xenograft,"In a preclinical study, OSI-027 inhibited tumor growth in ovarian cancer cell line xenograft models harboring KRAS mutations (PMID: 21673091).",Actionable,8732,2394,ovarian cancer,DOID,448,KRAS mutant,"[{'id': 3483, 'pubMedId': 21673091, 'title': 'Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21673091'}]",sensitive,841,OSI-027,3845
424,Phase I,"In a Phase I trial, the combination of Ipatasertib (GDC-0068) and Cobimetinib (GDC-0973) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including patients harboring KRAS mutations (Cancer Res, October 1, 2014 74; CT328).",Actionable,2746,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,"[{'id': 1084, 'pubMedId': None, 'title': 'Abstract CT328: Clinical results of a phase Ib dose-escalation study of the Mek inhibitor cobimetinib (GDC-0973) and the Akt inhibitor ipatasertib (GDC-0068) in patients (pts) with solid tumors', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/CT328.short'}]",predicted – sensitive,1160,Cobimetinib + GDC-0068,3845
425,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in objective response in PDX models of colorectal cancer cells  harboring KRAS mutations (PMID: 26369631).",Actionable,5621,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 5128, 'pubMedId': 26369631, 'title': 'Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26369631'}]",sensitive,1368,Palbociclib + Trametinib,3845
426,Preclinical - Cell culture,"In a preclinical study, Danusertib (PHA-739358) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9385,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,4999,Danusertib + SCH772984,3845
427,Preclinical - Cell line xenograft,"In a preclinical study, Panulisib (P7170) demonstrated inhibition of tumor growth in cell line xenograft models of non-small cell lung cancer harboring KRAS mutations (Cancer Res 2012, 72(8 Suppl), Abstract  #3759).",Actionable,2732,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 1087, 'pubMedId': None, 'title': 'Abstract 3759: P7170, a novel inhibitor of phosphoinositide 3-kinase (PI3K)-mammalian target of Rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) as a new therapeutic option for Kras mutated non small cell lung cancer (NSCLC)', 'url': 'http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/8_MeetingAbstracts/3759'}]",sensitive,857,P7170,3845
428,Preclinical - Cell culture,"In a preclinical study, Gedatolisib (PF-05212384) inhibited growth of several human solid tumor cell lines in culture, including cell lines harboring KRAS mutations (PMID: 21325073).",Actionable,9539,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}]",predicted – sensitive,1040,PF-05212384,3845
429,Phase III,"In a post-hoc analysis of a Phase III trial, KRAS mutations in colon adenocarcinoma patients with microsatellite stable tumors were associated with a shorter disease-free survival and overall survival compared to those patients with microsatellite instability tumors, suggesting that KRAS mutations may serve as a future prognostic biomarker in this patient population (PMID: 26768652). ",Emerging,6440,234,colon adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 5600, 'pubMedId': 26768652, 'title': 'Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26768652'}]",not applicable,1776,N/A,3845
430,Preclinical - Pdx,"In a preclinical study, SCH772984 inhibited tumor growth in both cell line and patient-derived xenograft models of KRAS mutant pancreatic ductal adenocarcinoma through down-regulation of Myc protein level (PMID: 26725216).",Actionable,9371,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,2618,SCH772984,3845
431,Preclinical,"In a preclinical study, treatment with the combination of MK2206 and Istodax (romidepsin) resulted in greater cell death in tumor cell lines harboring Kras mutations compared to cell lines with wild-type Kras (Cancer Res April 15, 2012 72:4708)",Actionable,2491,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,"[{'id': 3165, 'pubMedId': None, 'title': 'Abstract 4708: Short-term romidepsin treatment combined with mitogen-activated protein kinase and phosphatidylinositol 3-kinase inhibition causes increased Bim expression and cell death in KRAS mutant cell lines', 'url': 'http://cancerres.aacrjournals.org/content/72/8_Supplement/4708.short'}]",sensitive,2875,MK2206 + Romidepsin,3845
432,Phase II,"In a Phase II clinical trial, the combination of Portrazza (necitumumab) and FOLFOX in colorectal cancer patients resulted in an objective response rate (ORR) of 63.6% (28/44) in the overall intent-to-treat population, with an ORR of 56.5% (5/9; all partial responses), and stable disease in 44.4% (4/9) of KRAS-mutant patients (PMID: 26766738). ",Actionable,4369,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 4508, 'pubMedId': 26766738, 'title': 'Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26766738'}]",predicted – sensitive,3498,Necitumumab + FOLFOX,3845
433,Phase II,"In a Phase II trial, Refametinib (BAY86-9766), in combination with Nexavar (sorafenib), demonstrated more clinical benefit in hepatocellular carcinoma patients with mutant Kras than in patients with wild-type Kras (PMID: 25294897).",Actionable,2436,684,hepatocellular carcinoma,DOID,448,KRAS mutant,"[{'id': 3050, 'pubMedId': 25294897, 'title': 'A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25294897'}]",sensitive,2221,Refametinib + Sorafenib,3845
434,Phase III,"In a retrospective analysis of a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI did not demonstrate an improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with RAS mutations (PMID: 25605843). ",Actionable,3354,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 3760, 'pubMedId': 25605843, 'title': 'Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605843'}]",no benefit,2180,Cetuximab + FOLFIRI,3845
435,Preclinical,"In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) combination treatment was less efficient at inhibiting proliferation of KRAS mutant colon cancer cells in culture (PMID: 27338794).",Actionable,7370,219,colon cancer,DOID,448,KRAS mutant,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",decreased response,4477,Ponatinib + Trametinib,3845
436,Preclinical - Cell culture,"In a preclinical study, PF-04691502 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9390,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,5005,PF-04691502 + SCH772984,3845
437,Phase II,"In a retrospective study of a Phase II trial, mutation status of KRAS was not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with Torisel (temsirolimus) (PMID: 27016228).",Actionable,6405,1380,endometrial cancer,DOID,448,KRAS mutant,"[{'id': 5557, 'pubMedId': 27016228, 'title': 'Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27016228'}]",no benefit,936,Temsirolimus,3845
438,Preclinical - Cell culture,"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS mutations due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8993,3910,lung adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 6848, 'pubMedId': 27422710, 'title': 'Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27422710'}]",decreased response,807,Binimetinib,3845
439,Phase III,"In a Phase II trial, Selumetinib (AZD6244) in combination with Taxotere (docetaxel) did not significantly improve median progression-free survival (3.9 vs 2.8 months), median overall survival (8.7 vs 7.9 months), and overall response rate (20.1% vs 13.7%) compared to placebo in KRAS-mutant non-small cell lung cancer patients (PMID: 28492898).",Actionable,9320,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 8947, 'pubMedId': 28492898, 'title': 'Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28492898'}]",no benefit,1117,Selumetinib + Docetaxel,3845
440,Phase II,"In a Phase II trial, Selumetinib (AZD6244) in combination with Taxotere (docetaxel) improved progression-free survival in KRAS-mutant non-small cell lung cancer patients (PMID: 23200175).",Actionable,150,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",no benefit,1117,Selumetinib + Docetaxel,3845
441,FDA approved,Vectibix (panitumumab) has demonstrated clinical efficacy only in colorectal cancer patients with wild-type KRAS (PMID: 19064407).,Actionable,148,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 130, 'pubMedId': 19064407, 'title': 'Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19064407'}]",resistant,845,Panitumumab,3845
442,Guideline,"Vectibix (panitumumab) is not indicated for use in patients with KRAS-mutant colorectal cancer (Guidelines).
",Actionable,1529,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}, {'id': 1450, 'pubMedId': None, 'title': 'Vectibix label', 'url': 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125147s194lbl.pdf'}]",resistant,845,Panitumumab,3845
443,Guideline,"Ertibux (cetuximab) is not indicated for use in patients with KRAS-mutant colorectal cancer (Guidelines).
",Actionable,1526,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}, {'id': 1449, 'pubMedId': None, 'title': 'Erbitux label', 'url': 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125084s242lbl.pdf'}]",resistant,694,Cetuximab,3845
444,Clinical Study,"In a clinical case report, an acquired KRAS mutation was associated with resistance to Erbitux (cetuximab) in a patient with metastatic colorectal cancer (PMID: 24304820).",Actionable,6670,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 247, 'pubMedId': 24304820, 'title': 'Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24304820'}]",resistant,694,Cetuximab,3845
445,Clinical Study,"In a clinical study, KRAS mutations were associated with resistance to Erbitux (cetuximab) in patients with colorectal cancer (PMID: 18202412).",Actionable,707,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 339, 'pubMedId': 18202412, 'title': 'KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18202412'}]",resistant,694,Cetuximab,3845
446,Preclinical - Cell culture,"In a preclinical study, Ridaforolimus (MK-8669) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9377,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,4991,Ridaforolimus + SCH772984,3845
447,Preclinical - Cell line xenograft,"In a preclinical study, Pictilisib (GDC-0941) demonstrated limited efficacy as a single agent in pancreatic cell line xenograft models harboring KRAS mutations (PMID: 22952903).",Actionable,2761,1793,pancreatic cancer,DOID,448,KRAS mutant,"[{'id': 3462, 'pubMedId': 22952903, 'title': 'K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22952903'}]",decreased response,749,GDC-0941,3845
448,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Pictilisib (GDC-0941) and Selumetinib (AZD6244) worked synergistically to induce tumor regression in pancreatic cancer cell line xenograft models harboring KRAS mutations (PMID: 22952903).",Actionable,2762,1793,pancreatic cancer,DOID,448,KRAS mutant,"[{'id': 3462, 'pubMedId': 22952903, 'title': 'K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22952903'}]",sensitive,3024,GDC-0941 + Selumetinib,3845
449,Preclinical - Pdx,"In a preclinical study, KO-947 resulted in tumor regression in patient derived xenograft (PDX) models harboring either a BRAF mutation, NRAS mutation, or KRAS mutation (EJC Dec 2016, 69:1; S126).",Actionable,10967,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,"[{'id': 8965, 'pubMedId': None, 'title': 'KO-947, a potent and selective ERK inhibitor with slow dissociation kinetics', 'url': 'http://www.ejcancer.com/article/S0959-8049(16)32974-4/abstract'}]",predicted – sensitive,5747,KO-947,3845
450,Phase I,"In a Phase I trial, BGB-283 resulted in partial response in 1 endometrial cancer patient harboring harboring KRAS mutation, who remained on treatment for over 456 days (AACR Annual Meeting, Apr 2016, abstract # CT005).",Actionable,7230,1380,endometrial cancer,DOID,448,KRAS mutant,"[{'id': 6230, 'pubMedId': None, 'title': 'Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=46a0776a-1444-49d6-b533-4f68e298c39d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]",predicted – sensitive,4025,BGB-283,3845
451,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring a KRAS mutation demonstrated growth inhibition, cell membrane dysruption, induction of apoptosis, and G2/M arrest in culture when treated with Reolysin (pelareorep) (PMID: 24798549). ",Actionable,10892,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 8908, 'pubMedId': 24798549, 'title': 'Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24798549'}]",sensitive,893,Reolysin,3845
452,Phase II,"In a Phase II trial, Nexavar (sorafenib) treatment resulted in comparable 8-week disease control rate in KRAS wild-type (47%, 20/43) and KRAS mutated (44%, 8/18) patients with advanced non-small cell lung carcinoma (PMID: 27480147).",Actionable,7742,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 6464, 'pubMedId': 27480147, 'title': 'The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27480147'}]",sensitive,920,Sorafenib,3845
453,Phase III,"In a Phase III trial, treatment with Nexavar (sorafenib) resulted in a longer progression free survival in patients with KRAS-mutant non-small cell lung cancer when compared to placebo, however, overall survival was similar between the two arms (PMID: 26743856).",Actionable,7714,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 6454, 'pubMedId': 26743856, 'title': 'Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26743856'}]",sensitive,920,Sorafenib,3845
454,Phase II,"In a Phase II trial, treatment with Nexavar (sorafenib) resulted in partial response in 8.8% (5/57) and stable disease in 43.8% (25/57) of patients with KRAS-mutant non-small cell lung cancer (PMID: 23224737).",Actionable,2489,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 3164, 'pubMedId': 23224737, 'title': 'A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23224737'}]",sensitive,920,Sorafenib,3845
455,Preclinical,"In a preclinical study, MLN2480 inhibited growth of RAS mutant melanoma and colorectal cancer cell lines in culture (Mol Cancer Ther November 2013 12; C146).",Actionable,1577,1909,melanoma,DOID,448,KRAS mutant,"[{'id': 421, 'pubMedId': None, 'title': 'Abstract C146: Combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 inhibits the growth of BRAF mutant and RAS mutant preclinical models of melanoma and CRC.', 'url': ''}]",predicted – sensitive,1034,MLN2480,3845
456,Preclinical - Cell culture,"In a preclinical study, Nerlynx (neratinib) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9398,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,5011,Neratinib + Selumetinib,3845
457,Preclinical - Cell line xenograft,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant pancreatic cancer (PMID: 26140595).",Actionable,10257,1793,pancreatic cancer,DOID,448,KRAS mutant,"[{'id': 8232, 'pubMedId': 26140595, 'title': 'A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26140595'}]",predicted – sensitive,5443,PF3644022 + PF-477736,3845
458,Preclinical,"In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture and induced tumor regression in xenograft models (PMID: 27338794).",Actionable,7367,1324,lung cancer,DOID,448,KRAS mutant,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",sensitive,4477,Ponatinib + Trametinib,3845
459,Preclinical - Cell culture,"In a preclinical study, AZD8186 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9378,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,4992,Everolimus + SCH772984,3845
460,Preclinical - Pdx & cell culture,"In a preclinical study, the small-molecule activators of PP2A (SMAP) DT-061 inhibited Mapk signaling, resulted in growth inhibition and apoptosis in KRAS mutant lung cancer cell lines in culture, and in both cell line and patient-derived xenograft models (PMID: 28504649).",Actionable,11389,1324,lung cancer,DOID,448,KRAS mutant,"[{'id': 9273, 'pubMedId': 28504649, 'title': 'Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28504649'}]",predicted – sensitive,5969,DT-061,3845
461,Preclinical - Cell culture,"In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of several KRAS mutant cancer cell lines in culture (PMID: 27556948).",Actionable,8018,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,"[{'id': 6534, 'pubMedId': 27556948, 'title': 'Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27556948'}]",predicted – sensitive,4620,APS-2-79 + Trametinib,3845
462,Phase I,"In a Phase I trial, a pancreatic cancer patient harboring a KRAS mutation demonstrated a partial response when treated with Mekinist (trametinib) (PMID: 22805291). ",Actionable,11970,1793,pancreatic cancer,DOID,448,KRAS mutant,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",predicted – sensitive,2,Trametinib,3845
463,Phase Ib/II,"In a Phase Ib trial, XL765 (SAR245409) in combination with, Pimasertib (MSC1936369B), demonstrated safety and preliminary efficacy in Kras mutant colorectal patients (Cancer Res 2013;73(8 Suppl):Abstract nr LB-147).",Actionable,2755,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 3459, 'pubMedId': None, 'title': 'Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.', 'url': 'http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-147.short'}]",sensitive,3023,SAR245409 + Pimasertib,3845
464,Preclinical - Pdx,"In a preclinical study, LSN3074753 resulted in a disease control rate of 11.4% (5/44) in KRAS mutant patient-derived xenograft models of colorectal cancer (PMID: 28611205).",Actionable,12190,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 10143, 'pubMedId': 28611205, 'title': 'Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28611205'}]",predicted – sensitive,6337,LSN3074753,3845
465,Phase I,"In a Phase I/Ib trial, treatment with the combination of Mekinist (trametinib) and Alimta (pemetrexed) resulted in an overall response rate (ORR) of 17% (4/23, all partial responses), and stable disease in 48% (11/23) in the subset of patients with KRAS-mutant non-small cell lung cancer, compared to an ORR of 11% (2/19) in patients with wild-type or unknown KRAS status (PMID: 27876675).",Actionable,10765,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 8810, 'pubMedId': 27876675, 'title': 'A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced\xa0Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27876675'}]",predicted – sensitive,1266,Pemetrexed + GSK1120212,3845
466,Preclinical - Patient cell culture,"In a preclinical study, primary tumor cells isolated from lung adenocarcinoma patients harboring KRAS mutations demonstrated increased sensitivity to Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 combination treatment in culture compared to cells lacking KRAS or BRAF mutations (PMID: 26140595).",Actionable,10262,3910,lung adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 8232, 'pubMedId': 26140595, 'title': 'A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26140595'}]",predicted – sensitive,5443,PF3644022 + PF-477736,3845
467,Preclinical - Cell culture,"In a preclinical study, Saracatinib (AZD0530) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9391,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,5006,Saracatinib + SCH772984,3845
468,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells harboring a KRAS mutation were more sensitive to BI2536 than cells wild-type for KRAS (PMID: 26597303). ",Actionable,6129,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 5317, 'pubMedId': 26597303, 'title': 'Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26597303'}]",sensitive,676,BI2536,3845
469,Phase I,"In a Phase I trial, TVB-2640 treatment resulted in stable disease for more than 17 weeks in 100% (3/3) of patients with non-small cell lung carcinoma harboring KRAS mutations (J Clin Oncol 34, 2016 (suppl; abstr 2512)).",Actionable,6550,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 5694, 'pubMedId': None, 'title': 'Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.', 'url': 'http://abstracts.asco.org/176/AbstView_176_166391.html'}]",predicted – sensitive,3611,TVB-2640,3845
470,Preclinical - Cell line xenograft,"In a preclinical study, colon cancer cell lines with KRAS codon 12 or 13 mutations demonstrated increased sensitivity to treatment with AUY922 in culture and in xenograft models (PMID: 26832792).",Actionable,9209,219,colon cancer,DOID,448,KRAS mutant,"[{'id': 5083, 'pubMedId': 26832792, 'title': 'Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26832792'}]",predicted – sensitive,647,AUY922,3845
471,Preclinical,"In a preclinical study, colorectal cancer cell lines harboring KRAS mutations demonstrated resistance to SHP099 in culture (PMID: 27362227). ",Actionable,7520,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 6394, 'pubMedId': 27362227, 'title': 'Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27362227'}]",predicted – resistant,4504,SHP099,3845
472,Phase I,"In a Phase I trial, Ixabepilone and Sutent (sunitinib) combination therapy resulted in an overall clinical benefit rate (complete response, partial response, or stable disease) of 53% (9/17) in colorectal cancer patients,  most of whom harbored KRAS mutations (PMID: 26864210).",Actionable,7528,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 6399, 'pubMedId': 26864210, 'title': 'A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26864210'}]",predicted – sensitive,4505,Ixabepilone + Sunitinib,3845
473,Preclinical - Cell culture,"In a preclinical study, Aurora Kinase Inhibitor II (AI II) induced apoptosis and inhibited growth of KRAS-mutant non-small cell lung cancer cell lines in culture (PMID: 26842935).",Actionable,9783,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 7603, 'pubMedId': 26842935, 'title': 'Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26842935'}]",sensitive,5230,Aurora Kinase Inhibitor II,3845
474,Preclinical - Cell line xenograft,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of various cancer cell lines harboring KRAS mutations in culture and in cell line xenograft models (PMID: 26140595).",Actionable,10253,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,"[{'id': 8232, 'pubMedId': 26140595, 'title': 'A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26140595'}]",predicted – sensitive,5443,PF3644022 + PF-477736,3845
475,Preclinical,"In a preclinical study, a human gastric cancer cell line harboring a KRAS mutation demonstrated resistance to Poziotinib (PMID: 21306821). ",Actionable,2839,10534,stomach cancer,DOID,448,KRAS mutant,"[{'id': 2314, 'pubMedId': 21306821, 'title': 'Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21306821'}]",resistant,1042,poziotinib,3845
476,Phase I,"In a Phase I trial, Mekinist (trametinib) reduced tumor formation in 36% (8/22) of solid tumor patients harboring KRAS mutations (PMID: 22805291).",Actionable,1627,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",sensitive,2,Trametinib,3845
477,Preclinical - Cell line xenograft,"In a preclinical study, GDC-0623 demonstrated efficacy in several human tumor cell line xenograft models harboring KRAS mutations (PMID: 23934108).",Actionable,2757,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",sensitive,748,GDC-0623,3845
478,Phase I,"In a Phase Ia trial, CC-90003 treatment did not result in any objective responses and demonstrated toxicity in advanced solid tumor patients harboring KRAS, NRAS, or BRAF mutations (J Clin Oncol 35, 2017 (suppl; abstr 2577)).",Actionable,11065,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,"[{'id': 9060, 'pubMedId': None, 'title': 'A phase Ia study of CC-90003, a selective extracellular signal-regulated kinase (ERK) inhibitor, in patients with relapsed or refractory BRAF or RAS-mutant tumors.', 'url': 'http://abstracts.asco.org/199/AbstView_199_186986.html'}]",no benefit,2874,CC-90003,3845
479,Preclinical - Cell line xenograft,"In a preclinical study, PF-04691502 resulted in tumor regression in KRAS-mutant non-small cell lung cancer cell line xenograft models (PMID: 21750219).",Actionable,8389,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 226, 'pubMedId': 21750219, 'title': 'PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21750219'}]",predicted – sensitive,865,PF-04691502,3845
480,Preclinical - Cell culture,"In a preclinical study, colon cancer cells harboring KRAS mutations were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).",Actionable,7877,219,colon cancer,DOID,448,KRAS mutant,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",resistant,1095,GDC0879,3845
481,Preclinical,"In a preclinical study, human tumor cell lines harboring KRAS mutations did not demonstrate sensitivity to CH5132799 in culture (PMID: 22159814).",Actionable,2740,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,"[{'id': 3447, 'pubMedId': 22159814, 'title': 'NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22159814'}]",no benefit,2152,CH5132799,3845
482,Preclinical - Cell culture,"In a preclinical study, Vistusertib (AZD2014) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9382,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,4996,SCH772984 + Vistusertib,3845
483,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing a KRAS mutation demonstrated sensitivity to NS1 in culture, resulting in decreased Mapk and Akt signaling and inhibition of cell transformation (PMID: 27820802). ",Actionable,9784,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,"[{'id': 7600, 'pubMedId': 27820802, 'title': 'Inhibition of RAS function through targeting an allosteric regulatory site.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27820802'}]",sensitive,5228,NS1,3845
484,Phase I,"In a Phase I trial, treatment with Abemaciclib (LY2835219) in non-small cell lung carcinoma patients harboring a KRAS mutation resulted in a disease control rate of 55% (16/29) and a median PFS of 2.8 months (LY2835219) (PMID: 27217383). ",Actionable,7430,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 6356, 'pubMedId': 27217383, 'title': 'Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27217383'}]",sensitive,802,Abemaciclib,3845
485,Phase II,"In a Phase II clinical trial, salirasib showed no benefit in KRAS-mutant lung adenocarcinoma patients (PMID: 21847063).",Actionable,149,3910,lung adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 227, 'pubMedId': 21847063, 'title': 'A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21847063'}]",no benefit,909,Salirasib,3845
486,Preclinical - Cell culture,"In a preclinical study, the addition of PD-0325901 to treatment with BEZ235 inhibited BEZ235-enhanced ERK activation, and the combination resulted in increased inhibition of cell proliferation in KRAS-mutant pancreatic ductal adenocarcinoma cell lines in culture compared to either agent alone (PMID: 25673820).",Actionable,9687,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 3463, 'pubMedId': 25673820, 'title': 'Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25673820'}]",predicted – sensitive,5162,BEZ235 + PD-0325901,3845
487,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of a majority (4/5) of human pancreatic adenocarcinoma cell lines harboring mutant KRAS in culture (PMID: 26343583).",Actionable,6732,4074,pancreatic adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,2,Trametinib,3845
488,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant colorectal cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11969,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 9707, 'pubMedId': None, 'title': 'KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short'}]",predicted – sensitive,5747,KO-947,3845
489,Preclinical,"In a preclinical study, colorectal cancer cells harboring KRAS mutations demonstrated sensitivity to CI-1040 in culture (PMID: 19372556).",Actionable,2743,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 3449, 'pubMedId': 19372556, 'title': 'KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19372556'}]",sensitive,699,CI-1040,3845
490,Phase III,"In a Phase III trial, Cyramza (ramucirumab) followed by FOLFIRI was equally efficacious in metastatic colorectal carcinoma patients with Kras exon 2 mutations as patients with wild-type Kras (PMID: 25877855).",Actionable,2446,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 2667, 'pubMedId': 25877855, 'title': 'Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877855'}]",sensitive,2633,Ramucirumab + FOLFIRI,3845
491,Phase II,"In a Phase II trial, Tarceva (erlotinib) treatment resulted in comparable 8-week disease control rate in KRAS wild-type (36%, 5/14) and KRAS mutated (20%, 1/5) patients with advanced non-small cell lung carcinoma (PMID: 27480147).",Actionable,7739,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 6464, 'pubMedId': 27480147, 'title': 'The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27480147'}]",no benefit,4,Erlotinib,3845
492,Preclinical - Cell culture,"In a preclinical study, Torisel (temsirolimus) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9376,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,4988,SCH772984 + Temsirolimus,3845
493,Preclinical - Cell line xenograft,"In a preclinical study, Glucophage (metformin) inhibited tumor growth in a variety of KRAS-mutant cancer cell line xenograft models (PMID: 23877793).",Actionable,589,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,"[{'id': 342, 'pubMedId': 23877793, 'title': 'K‑ras gene mutation as a predictor of cancer cell responsiveness to metformin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23877793'}]",sensitive,1031,Metformin,3845
494,Preclinical,"In a preclinical study, SH-1242 inhibited growth of non-small cell lung cancer cells expressing mutant KRAS in culture (PMID: 26645561).",Actionable,4617,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 4627, 'pubMedId': 26645561, 'title': 'Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26645561'}]",sensitive,3552,SH-1242,3845
495,Preclinical - Cell line xenograft,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant colon cancer (PMID: 26140595).",Actionable,10258,219,colon cancer,DOID,448,KRAS mutant,"[{'id': 8232, 'pubMedId': 26140595, 'title': 'A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26140595'}]",predicted – sensitive,5443,PF3644022 + PF-477736,3845
496,Phase III,"In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (47 vs 8 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RAS mutations (PMID: 27525386).",Actionable,10388,3973,thyroid medullary carcinoma,DOID,448,KRAS mutant,"[{'id': 8408, 'pubMedId': 27525386, 'title': 'Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27525386'}]",sensitive,998,cabozantinib,3845
497,Preclinical - Cell line xenograft,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant bladder cancer (PMID: 26140595).",Actionable,10256,11054,urinary bladder cancer,DOID,448,KRAS mutant,"[{'id': 8232, 'pubMedId': 26140595, 'title': 'A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26140595'}]",predicted – sensitive,5443,PF3644022 + PF-477736,3845
498,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant melanoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11967,1909,melanoma,DOID,448,KRAS mutant,"[{'id': 9707, 'pubMedId': None, 'title': 'KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short'}]",predicted – sensitive,5747,KO-947,3845
499,Preclinical,"In a preclinical study, human pancreatic ductal carcinoma cell lines harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6733,3587,pancreatic ductal carcinoma,DOID,448,KRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,2,Trametinib,3845
500,Preclinical,"In a preclinical study, gastric cancer cell lines with Kras mutations were sensitive to Selumetinib (AZD6244) (PMID: 24935174).",Actionable,2768,3717,gastric adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 3465, 'pubMedId': 24935174, 'title': 'Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24935174'}]",sensitive,913,Selumetinib,3845
501,Preclinical,"In a preclinical study, Mekinist (trametinib) and Gilotrif (afatinib) did not demonstrate synergy at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",Actionable,7376,1324,lung cancer,DOID,448,KRAS mutant,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",no benefit,4482,Afatinib + Trametinib,3845
502,Preclinical - Cell line xenograft,"In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of lung carcinoma cell lines harboring KRAS mutations, and anti-tumor activity in cell line xenograft models (PMID: 28615361).",Actionable,11328,3905,lung carcinoma,DOID,448,KRAS mutant,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",sensitive,5914,AZD4785,3845
503,Phase I,"In a Phase I trial, 11% (2/11) of NSCLC patients with Kras mutations achieved partial response after treatment with RO4987655 (PMID: 24947927).",Actionable,2750,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 3454, 'pubMedId': 24947927, 'title': 'Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24947927'}]",sensitive,903,RO4987655,3845
504,Phase III,"In a Phase III trial, the combination therapy of Tarceva (erlotinib), Paraplatin (carboplatin), and Taxol (paclitaxel) resulted in a worse overall response rate (8%) compared to Paraplatin (carboplatin) and Taxol (paclitaxel) without Tarceva (erlotinib) (23%) in non-small cell lung cancer patients harboring KRAS mutations (PMID: 16043828).
",Actionable,7857,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 6514, 'pubMedId': 16043828, 'title': 'Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16043828'}]",no benefit,4581,Carboplatin + Erlotinib + Paclitaxel,3845
505,Preclinical,"In a preclinical study, BEZ235 inhibited growth of colorectal cancer cells harboring KRAS mutations in culture and in xenograft models (PMID: 23475782).",Actionable,2723,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 3437, 'pubMedId': 23475782, 'title': 'Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23475782'}]",sensitive,672,BEZ235,3845
506,Preclinical - Pdx,"In a preclinical study, LSN3074753 and Erbitux (cetuximab) synergistically inhibited tumor growth in patient-derived xenograft models of colorectal cancer harboring KRAS mutations, resulted in a disease control rate of 41.7% (5/12) (PMID: 28611205).",Actionable,12195,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 10143, 'pubMedId': 28611205, 'title': 'Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28611205'}]",sensitive,6338,Cetuximab + LSN3074753,3845
507,Phase I,"In a Phase I clinical trial, Alpelisib (BYL719), in combination with Binimetinib (MEK162), demonstrated safety and preliminary efficacy in patients with KRAS-mutant advanced solid tumors, including patients with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 9051).",Actionable,1655,2394,ovarian cancer,DOID,448,KRAS mutant,"[{'id': 1765, 'pubMedId': None, 'title': 'A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/129278-144'}]",sensitive,1311,BYL719 + MEK162,3845
508,Preclinical - Cell culture,"In a preclinical study, OSI-027 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9381,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,4995,OSI-027 + SCH772984,3845
509,Preclinical - Cell line xenograft,"In a preclinical study, CUDC-907 induced apoptosis and cell cycle arrest in several human solid tumor and hematological cancer cell lines in culture and inhibited tumor growth in tumor cell line xenograft models, including those harboring KRAS mutations (PMID: 22693356).",Actionable,1690,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,"[{'id': 1018, 'pubMedId': 22693356, 'title': 'Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693356'}]",sensitive,709,CUDC-907,3845
510,Preclinical - Cell culture,"In a preclinical study, Farydak (panobinostat) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9387,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,5001,Panobinostat + SCH772984,3845
511,Phase I,"In a Phase I trial, BGB-283 resulted in partial response in 1 non-small cell lung carcinoma patient harboring KRAS mutation, who remained on treatment for over 572 days (AACR Annual Meeting, Apr 2016, abstract # CT005).",Actionable,7232,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 6230, 'pubMedId': None, 'title': 'Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=46a0776a-1444-49d6-b533-4f68e298c39d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]",predicted – sensitive,4025,BGB-283,3845
512,Phase II,"In a Phase II clinical trial, GI-4000 was well-tolerated and resulted in some immune response to KRAS in lung adenocarcinoma patients carrying KRAS mutations (PMID: 25044103).",Actionable,359,3910,lung adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 193, 'pubMedId': 24372276, 'title': 'GI-4000 in KRAS mutant cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24372276'}, {'id': 5728, 'pubMedId': 25044103, 'title': 'Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25044103'}]",sensitive,1018,GI-4000,3845
513,Preclinical - Cell culture,"In a preclinical study, Saracatinib (AZD0530) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9397,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,5010,Saracatinib + Selumetinib,3845
514,Clinical Study,"In a systematic review of 2,266 colorectal cancer patients, treatment with Avastin (bevacizumab) increased progression-free survival in patients harboring wild-type KRAS but not in patients with mutant KRAS (PMID: 23828442).",Actionable,800,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 454, 'pubMedId': 23828442, 'title': 'KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23828442'}]",decreased response,667,Bevacizumab,3845
515,Phase III,"In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with KRAS mutations (PMID: 26341920).",Actionable,3267,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 3703, 'pubMedId': 26341920, 'title': 'Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26341920'}]",no benefit,3102,Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan,3845
516,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant non-small cell lung cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11696,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 9707, 'pubMedId': None, 'title': 'KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short'}]",predicted – sensitive,5747,KO-947,3845
517,Preclinical - Cell culture,"In a preclinical study, Tasigna (nilotinib) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9389,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,5003,Nilotinib + SCH772984,3845
518,Preclinical,"In a preclinical study, DEL-22379 induced tumor regression in colorectal cancer xenograft models harboring mutant KRAS (PMID: 26267534).",Actionable,5781,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",sensitive,3769,DEL-22379,3845
519,Preclinical - Cell culture,"In a preclinical study, Pictilisib (GDC-0941) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9396,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,3024,GDC-0941 + Selumetinib,3845
520,Preclinical - Cell culture,"In a preclinical study, the combination of Reolysin (pelareorep) and Camptosar (irinotecan) resulted in a synergistic effect, demonstrating increased apoptotic activity and growth inhibition in colorectal cancer cells harboring a KRAS mutation in culture compared to either agent alone (PMID: 24798549). ",Actionable,10893,9256,colorectal cancer,DOID,448,KRAS mutant,"[{'id': 8908, 'pubMedId': 24798549, 'title': 'Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24798549'}]",sensitive,5674,Irinotecan + Reolysin,3845
521,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant cervical carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11973,2893,cervix carcinoma,DOID,448,KRAS mutant,"[{'id': 9707, 'pubMedId': None, 'title': 'KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short'}]",predicted – sensitive,5747,KO-947,3845
522,Preclinical,"In a preclinical study, the effect of Mekinist (trametinib) on human gastric adenocarcinoma cell lines harboring mutant KRAS is conflicting as cell lines were both sensitive and insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6735,3717,gastric adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",conflicting,2,Trametinib,3845
523,Preclinical - Cell culture,"In a preclinical study, Ipatasertib (GDC-0068) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9395,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 7128, 'pubMedId': 26725216, 'title': 'Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26725216'}]",sensitive,5009,Ipatasertib + Selumetinib,3845
524,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring KRAS mutations were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).",Actionable,7878,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",resistant,1095,GDC0879,3845
525,Preclinical - Cell culture,"In a preclinical study, KPT-185 resulted in greater apoptotic activity and decreased cell viability in non-small cell lung cancer (NSCLC) cell lines harboring KRAS mutations compared to NSCLC cell lines with wild-type KRAS, suggesting a synthetic lethal effect via XPO1 inhibition (PMID: 27680702).",Actionable,8804,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 6758, 'pubMedId': 27680702, 'title': 'XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27680702'}]",sensitive,4814,KPT-185,3845
526,Preclinical - Patient cell culture,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 combination treatment resulted in significant apoptosis in primary tumor cells isolated from pancreas adenocarcinoma patients harboring KRAS mutations in culture (PMID: 26140595).",Actionable,10263,4074,pancreatic adenocarcinoma,DOID,448,KRAS mutant,"[{'id': 8232, 'pubMedId': 26140595, 'title': 'A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26140595'}]",predicted – sensitive,5443,PF3644022 + PF-477736,3845
527,Phase Ib/II,"In a Phase Ib study, Alpelisib (BYL719) in combination with Binimetinib (MEK162) demonstrated preliminary safety and efficacy in patients with KRAS-mutant advanced solid tumors, including patients with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 9051).",Actionable,1695,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,"[{'id': 1765, 'pubMedId': None, 'title': 'A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/129278-144'}]",sensitive,1311,BYL719 + MEK162,3845
528,Phase I,"In a Phase I trial, TVB-2640 and Taxol (paclitaxel) combination treatment resulted in partial response in 33% (1/3) and stable disease for more than 21 weeks in 67% (2/3) of patients with non-small cell lung carcinoma harboring KRAS mutations (J Clin Oncol 34, 2016 (suppl; abstr 2512)).",Actionable,6549,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 5694, 'pubMedId': None, 'title': 'Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.', 'url': 'http://abstracts.asco.org/176/AbstView_176_166391.html'}]",predicted – sensitive,3743,Paclitaxel + TVB-2640,3845
529,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells harboring a KRAS mutation were more sensitive to volasertib than cells wild-type for KRAS (PMID: 26597303). ",Actionable,6132,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 5317, 'pubMedId': 26597303, 'title': 'Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26597303'}]",sensitive,957,Volasertib,3845
530,Preclinical - Cell culture,"In a preclinical study, the combination of Mekinist (trametinib) and BGJ398 synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",Actionable,7373,1324,lung cancer,DOID,448,KRAS mutant,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",sensitive,4479,BGJ398 + Trametinib,3845
531,Phase II,"In a Phase II trial, Selumetinib (AZD6244) and MK2206 combination treatment resulted in comparable 8-week disease control rate in KRAS wild-type (49%, 24/49) and KRAS mutated (62%, 13/21) patients with advanced non-small cell lung carcinoma (PMID: 27480147).",Actionable,7741,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,"[{'id': 6464, 'pubMedId': 27480147, 'title': 'The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27480147'}]",no benefit,1098,MK2206 + Selumetinib,3845
532,Preclinical - Cell culture,"In a preclinical study, a colon cancer cell line harboring a KRAS mutation demonstrated sensitivity to AZ-TAK1 in culture, resulting in a 50% cell growth reduction (PMID: 27655129). ",Actionable,10058,219,colon cancer,DOID,448,KRAS mutant,"[{'id': 7992, 'pubMedId': 27655129, 'title': 'MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27655129'}]",sensitive,5359,AZ-TAK1,3845
533,Preclinical - Cell line xenograft,"In a preclinical study, PKI-402 inhibited growth of a non-small cell lung cancer cell line harboring both KRAS and STK11 mutations in culture and in cell line xenograft models (PMID: 20371716).",Actionable,5398,3908,non-small cell lung carcinoma,DOID,20858,KRAS mut STK11 mut,"[{'id': 5041, 'pubMedId': 20371716, 'title': 'Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20371716'}]",sensitive,3857,PKI-402,3845
534,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 resulted in improved overall survival in EGFR-positive pancreatic cancer cell line xenograft models harboring KRAS mutations, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).
",Actionable,3869,1793,pancreatic cancer,DOID,16548,EGFR pos KRAS mut,"[{'id': 3814, 'pubMedId': 23209031, 'title': 'GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209031'}]",sensitive,3154,GA201,3845
535,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 resulted in increased tumor growth inhibition in EGFR-positive triple-negative breast cancer cell line xenograft models harboring KRAS mutations when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).
",Actionable,3870,60081,triple-receptor negative breast cancer,DOID,16548,EGFR pos KRAS mut,"[{'id': 3814, 'pubMedId': 23209031, 'title': 'GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209031'}]",sensitive,3154,GA201,3845
536,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 resulted in improved overall survival in EGFR-positive renal cell carcinoma cell line xenograft models harboring KRAS mutations, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3868,4450,renal cell carcinoma,DOID,16548,EGFR pos KRAS mut,"[{'id': 3814, 'pubMedId': 23209031, 'title': 'GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209031'}]",sensitive,3154,GA201,3845
537,Preclinical - Cell culture,"In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Mekinist (trametinib), and CGM097 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a KRAS mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046). ",Actionable,9935,9256,colorectal cancer,DOID,2521,KRAS mut + TP53 wild-type,"[{'id': 7782, 'pubMedId': 27659046, 'title': 'High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27659046'}]",sensitive,5319,ABT-263 + Alpelisib + CGM097 + Trametinib,3845
538,Preclinical,"In a preclinical study, Eloxatin (oxaliplatin), in combination with ABT-737, was only effective in tumor cell lines carrying KRAS mutants and wild-type TP53 (PMID: 21468686).",Actionable,1443,10000003,Advanced Solid Tumor,JAX,2521,KRAS mut + TP53 wild-type,"[{'id': 1293, 'pubMedId': 21468686, 'title': 'Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21468686'}]",sensitive,1773,Oxaliplatin + ABT-737,3845
539,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 induced activation of Tp53 target genes and inhibited growth of a colorectal cancer (CRC) cell line with wild-type TP53, that also harbored a KRAS mutation, in culture and inhibited tumor growth in a TP53 wild-type KRAS-mutant CRC cell line xenograft model (PMID: 25567130).",Actionable,8094,9256,colorectal cancer,DOID,2521,KRAS mut + TP53 wild-type,"[{'id': 2082, 'pubMedId': 25567130, 'title': 'The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25567130'}]",sensitive,1452,AMG 232,3845
540,Preclinical - Cell line xenograft,"In a preclinical study, the combination of AMG 232 and Camptosaur (irinotecan) inhibited tumor growth in a TP53 wild-type colorectal cancer cell line xenograft model, which also harbors a KRAS mutation, with increased efficacy over either agent alone (PMID: 25567130).",Actionable,8140,9256,colorectal cancer,DOID,2521,KRAS mut + TP53 wild-type,"[{'id': 2082, 'pubMedId': 25567130, 'title': 'The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25567130'}]",sensitive,4639,AMG 232 + Irinotecan,3845
541,Preclinical,"In a preclinical study, the combination of bortezomib and fasudil blocked GATA2 downstream signals in KRAS activated NSCLC cells, resulting in reduced tumor burden, size and number in treated mice (PMID: 22541434).  ",Actionable,1462,3908,non-small cell lung carcinoma,DOID,2563,KRAS mut + GATA2 wild-type,"[{'id': 1329, 'pubMedId': 22541434, 'title': 'The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22541434'}]",sensitive,1778,bortezomib + fasudil,3845
542,Phase II,"In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 G105C, V157fs and mutations in Kras (PMID: 27998224). ",Actionable,11778,2394,ovarian cancer,DOID,28237,KRAS mut TP53 G105C TP53 V157fs,"[{'id': 9762, 'pubMedId': 27998224, 'title': 'Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27998224'}]",predicted – sensitive,1194,MK-1775 + Carboplatin ,3845
543,Preclinical,"In a preclinical study, colon cancer cell lines harboring mutant KRAS and PIK3CA E545K demonstrated reduced sensitivity to Buparlisib (BKM120) induced growth inhibition in culture (PMID: 26715098).",Actionable,4574,219,colon cancer,DOID,18591,KRAS mutant PIK3CA E545K,"[{'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",decreased response,680,BKM120,3845
544,Preclinical,"In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098).",Actionable,4575,219,colon cancer,DOID,18591,KRAS mutant PIK3CA E545K,"[{'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",no benefit,694,Cetuximab,3845
545,Preclinical,"In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098).",Actionable,4576,219,colon cancer,DOID,18591,KRAS mutant PIK3CA E545K,"[{'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",sensitive,3548,BKM120 + Cetuximab,3845
546,Clinical Study,"In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in a patient with ovarian carcinoma harboring both a PIK3CA mutation and a KRAS Q61 mutation (PMID: 21216929).",Actionable,3383,4001,ovarian carcinoma,DOID,13307,PIK3CA mutant KRAS Q61X,"[{'id': 3726, 'pubMedId': 21216929, 'title': 'PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21216929'}]",sensitive,1121,Bevacizumab + Temsirolimus + Doxil,3845
547,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 3 mutations (Guidelines).,Actionable,3843,9256,colorectal cancer,DOID,1194,KRAS Q61X,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,845,Panitumumab,3845
548,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 3 mutations (Guidelines).,Actionable,3834,9256,colorectal cancer,DOID,1194,KRAS Q61X,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,694,Cetuximab,3845
549,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",Actionable,7865,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,4600,Dasatinib + Selumetinib,3845
550,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",Actionable,7858,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,913,Selumetinib,3845
551,Preclinical - Cell line xenograft,"In a preclinical study, Mekinist (trametinib) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture and in cell line xenograft models (PMID: 27222538).",Actionable,7854,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,2,Trametinib,3845
552,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",Actionable,7866,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,4601,Dasatinib + SCH772984,3845
553,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",Actionable,7864,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,4599,Dasatinib + Trametinib,3845
554,Preclinical - Cell culture,"In a preclinical study, a lung cancer cell line with co-amplification of FGFR1 and EGFR and harboring KRAS G13C demonstrated insensitivity to JNJ-42756493 (erdafitinib) in culture (PMID: 28341788).",Actionable,11185,1324,lung cancer,DOID,27923,EGFR amp FGFR1 amp KRAS G13C,"[{'id': 9140, 'pubMedId': 28341788, 'title': 'Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28341788'}]",resistant,1028,JNJ-42756493,3845
555,Preclinical - Cell line xenograft,"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring KRAS G13C, PIK3CA H1047Y, PTEN G143fs*4, and PTEN K267fs*9 was sensitive to treatment with DS-7423, demonstrating inhibition of cell proliferation in culture and tumor growth inhibition in xenograft models (PMID: 24504419). ",Actionable,10541,5304,ovarian clear cell adenocarcinoma,DOID,27593,KRAS G13C PIK3CA H1047Y PTEN G143fs*4 PTEN K267fs*9,"[{'id': 4912, 'pubMedId': 24504419, 'title': 'Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24504419'}]",sensitive,722,DS-7423,3845
556,Preclinical - Cell culture,"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G13C mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8990,3910,lung adenocarcinoma,DOID,1438,KRAS G13C,"[{'id': 6848, 'pubMedId': 27422710, 'title': 'Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27422710'}]",decreased response,807,Binimetinib,3845
557,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G13C mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8998,3910,lung adenocarcinoma,DOID,1438,KRAS G13C,"[{'id': 6848, 'pubMedId': 27422710, 'title': 'Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27422710'}]",decreased response,913,Selumetinib,3845
558,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 3 mutations (Guidelines).,Actionable,3833,9256,colorectal cancer,DOID,3416,KRAS A59G,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,694,Cetuximab,3845
559,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 3 mutations (Guidelines).,Actionable,3844,9256,colorectal cancer,DOID,3416,KRAS A59G,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,845,Panitumumab,3845
560,Preclinical - Cell culture,"In a preclinical study, the addition of Tazemetostat (EPZ-6438) increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8503,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4748,Selumetinib + Tazemetostat,3845
561,Preclinical - Cell culture,"In a preclinical study, the addition of GSK343 increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8502,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4750,GSK343 + Selumetinib,3845
562,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8517,1793,pancreatic cancer,DOID,26341,KRAS G12C EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4746,DZNep + Selumetinib,3845
563,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C (PMID: 26676756).",Actionable,8510,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4747,DZNep + MK2206,3845
564,Preclinical - Cell culture,"In a preclinical study, the addition of Tazemetostat (EPZ-6438) did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8513,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4749,MK2206 + Tazemetostat,3845
565,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8521,1793,pancreatic cancer,DOID,26341,KRAS G12C EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4747,DZNep + MK2206,3845
566,Preclinical - Cell line xenograft,"In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C, in culture and in xenograft models, resulting in decreased cell survival and tumor growth (PMID: 26676756).",Actionable,8498,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",sensitive,4746,DZNep + Selumetinib,3845
567,Preclinical - Cell culture,"In a preclinical study, the addition of GSK343 did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8512,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,"[{'id': 6667, 'pubMedId': 26676756, 'title': 'Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676756'}]",no benefit,4751,GSK343 + MK2206,3845
568,Preclinical - Pdx,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS G12C in patient-derived xenograft models (PMID: 19276360).",Actionable,7893,3908,non-small cell lung carcinoma,DOID,26088,BRAF wild-type KRAS G12C,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",resistant,1095,GDC0879,3845
569,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12C, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).",Actionable,8577,9256,colorectal cancer,DOID,26366,KRAS G12C PIK3CA H1047R TP53 R248W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,4771,MLN0128 + PD-0325901,3845
570,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12C mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8996,3910,lung adenocarcinoma,DOID,1042,KRAS G12C,"[{'id': 6848, 'pubMedId': 27422710, 'title': 'Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27422710'}]",decreased response,913,Selumetinib,3845
571,Preclinical,"In a preclinical study, Mekinist (trametinib) and SCH772984 combination treatment demonstrated enhanced growth inhibition and sustained inhibition of Erk signaling in lung cancer cells harboring KRAS G12C in culture (PMID: 27338794).",Actionable,7356,1324,lung cancer,DOID,1042,KRAS G12C,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",sensitive,4476,SCH772984 + Trametinib,3845
572,Preclinical,"In a preclinical study, SML-10-70-1 inhibited proliferation and Erk/Akt signaling in cells expressing KRAS G12C (PMID: 24259466).",Actionable,2770,10000003,Advanced Solid Tumor,JAX,1042,KRAS G12C,"[{'id': 2046, 'pubMedId': 24259466, 'title': 'Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24259466'}]",sensitive,2227,SML-10-70-1 ,3845
573,Preclinical - Cell line xenograft,"In a preclinical study, GDC-0623 induced tumor regression in pancreatic cancer cell line xenograft models harboring KRAS G12C (PMID: 23934108).",Actionable,2758,1793,pancreatic cancer,DOID,1042,KRAS G12C,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",sensitive,748,GDC-0623,3845
574,Preclinical - Cell culture,"In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12C demonstrated sensitivity to growth inhibition by MEK inhibitors, including Refametinib (BAY86-9766), in culture (PMID: 28957417).",Actionable,12138,4074,pancreatic adenocarcinoma,DOID,1042,KRAS G12C,"[{'id': 10109, 'pubMedId': 28957417, 'title': 'Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28957417'}]",sensitive,888,Refametinib,3845
575,Preclinical - Cell line xenograft,"In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human non-small cell lung cancer cell line harboring KRAS G12C (PMID: 23934108).",Actionable,1446,3908,non-small cell lung carcinoma,DOID,1042,KRAS G12C,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",sensitive,1004,Cobimetinib,3845
576,Preclinical - Pdx,"In a preclinical study, AZD4785 inhibited Kras expression and downstream signaling, resulted in tumor growth inhibition in patient-derived xenograft models of lung cancer harboring KRAS G12C (PMID: 28615361).",Actionable,11332,1324,lung cancer,DOID,1042,KRAS G12C,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",sensitive,5914,AZD4785,3845
577,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human pancreatic cancer cell lines harboring KRAS G12C in culture (PMID: 21325073, PMID: 12068308).

",Actionable,3137,1793,pancreatic cancer,DOID,1042,KRAS G12C,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 637, 'pubMedId': 12068308, 'title': 'Mutations of the BRAF gene in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12068308'}]",sensitive,1040,PF-05212384,3845
578,Preclinical,"In a preclinical study, CID1067700 inhibited growth and increased apoptosis of non-small cell lung cancer cells that harbor KRAS G12C in culture (PMID: 26247207, PMID: 19477428).
",Actionable,3568,3908,non-small cell lung carcinoma,DOID,1042,KRAS G12C,"[{'id': 3837, 'pubMedId': 26247207, 'title': 'A Pan-GTPase Inhibitor as a Molecular Probe.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26247207'}, {'id': 4103, 'pubMedId': 19477428, 'title': 'A gene expression signature associated with ""K-Ras addiction"" reveals regulators of EMT and tumor cell survival.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19477428'}]",sensitive,3158,CID1067700,3845
579,Preclinical - Cell culture,"In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12C demonstrated sensitivity to growth inhibition by MEK inhibitors, including Mekinist (trametinib), in culture (PMID: 28957417).",Actionable,12143,4074,pancreatic adenocarcinoma,DOID,1042,KRAS G12C,"[{'id': 10109, 'pubMedId': 28957417, 'title': 'Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28957417'}]",sensitive,2,Trametinib,3845
580,Preclinical,"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring KRAS G12C in culture (PMID: 25665005).",Actionable,4536,3908,non-small cell lung carcinoma,DOID,1042,KRAS G12C,"[{'id': 4582, 'pubMedId': 25665005, 'title': 'The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25665005'}]",sensitive,1386,Trametinib + Navitoclax,3845
581,Preclinical - Cell culture,"In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12C demonstrated sensitivity to growth inhibition by MEK inhibitors, including PD-0325901, in culture (PMID: 28957417).",Actionable,12136,4074,pancreatic adenocarcinoma,DOID,1042,KRAS G12C,"[{'id': 10109, 'pubMedId': 28957417, 'title': 'Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28957417'}]",sensitive,849,PD-0325901,3845
582,Phase II,"In a Phase II trial, treatment with Nexavar (sorafenib) resulted in partial response (PR) in 8.8% (5/57) and stable disease (SD) in 43.8% (25/57) of patients with KRAS-mutant non-small cell lung cancer, including SD in 12 patients and PR in 3 patients with KRAS G12C (PMID: 23224737).",Actionable,2490,3908,non-small cell lung carcinoma,DOID,1042,KRAS G12C,"[{'id': 3164, 'pubMedId': 23224737, 'title': 'A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23224737'}]",sensitive,920,Sorafenib,3845
583,Preclinical,"In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human lung cells harboring KRAS G12C in culture (PMID: 25665005).",Actionable,4538,3908,non-small cell lung carcinoma,DOID,1042,KRAS G12C,"[{'id': 4582, 'pubMedId': 25665005, 'title': 'The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25665005'}]",sensitive,3532,Trametinib + TW-37,3845
584,Phase I,"In a Phase I/Ib trial, the subgroup of non-small cell lung cancer patients harboring KRAS G12C demonstrated a disease control rate (DCR) of 80% (8/10; 4 partial responses, 4 stable disease) following treatment with the combination of Mekinist (trametinib) and Taxotere (docetaxel), compared to a DCR of 60% (15/25) in the overall KRAS-mutant population (PMID: 27876675).",Actionable,10763,3908,non-small cell lung carcinoma,DOID,1042,KRAS G12C,"[{'id': 8810, 'pubMedId': 27876675, 'title': 'A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced\xa0Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27876675'}]",predicted – sensitive,1264,Docetaxel + Trametinib,3845
585,Preclinical - Cell culture,"In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring KRAS G12C in culture (PMID: 28179366).",Actionable,10313,9256,colorectal cancer,DOID,1042,KRAS G12C,"[{'id': 8298, 'pubMedId': 28179366, 'title': 'Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179366'}]",sensitive,3505,Cetuximab + Trametinib,3845
586,Preclinical - Cell line xenograft,"In a preclinical study, BI-847325 induced sustained tumor regression in pancreatic adenocarcinoma cell line xenograft models harboring KRAS G12C (PMID: 27496137).",Actionable,8789,4074,pancreatic adenocarcinoma,DOID,1042,KRAS G12C,"[{'id': 6751, 'pubMedId': 27496137, 'title': 'Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27496137'}]",sensitive,1059,BI-847325,3845
587,Phase I,"In a Phase I study, NSCLC patients harboring KRAS G12C or G12V mutations demonstrated a trend towards better overall survival, progression free survival, and objective response rate compared to NSCLC patients with other KRAS mutations when treated with the combination therapy, Selumetinib (AZD6244) and Taxotere (docetaxel) (PMID: 26125448). ",Actionable,2618,3908,non-small cell lung carcinoma,DOID,1042,KRAS G12C,"[{'id': 3343, 'pubMedId': 26125448, 'title': 'Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26125448'}]",predicted – sensitive,1117,Selumetinib + Docetaxel,3845
588,Preclinical - Cell culture,"In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12C demonstrated sensitivity to growth inhibition by Selumetinib (AZD6244) in culture (PMID: 28957417).",Actionable,12135,4074,pancreatic adenocarcinoma,DOID,1042,KRAS G12C,"[{'id': 10109, 'pubMedId': 28957417, 'title': 'Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28957417'}]",sensitive,913,Selumetinib,3845
589,Preclinical - Cell line xenograft,"In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human pancreatic cancer cell line harboring KRAS G12C (PMID: 23934108).",Actionable,1447,1793,pancreatic cancer,DOID,1042,KRAS G12C,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",sensitive,1004,Cobimetinib,3845
590,Preclinical - Cell line xenograft,"In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of non-small cell lung carcinoma cell lines harboring KRAS G12C, and anti-tumor activity in cell line xenograft models (PMID: 28615361).",Actionable,11323,3908,non-small cell lung carcinoma,DOID,1042,KRAS G12C,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",sensitive,5914,AZD4785,3845
591,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).,Actionable,1531,9256,colorectal cancer,DOID,1042,KRAS G12C,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}, {'id': 1450, 'pubMedId': None, 'title': 'Vectibix label', 'url': 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125147s194lbl.pdf'}]",resistant,845,Panitumumab,3845
592,Preclinical - Cell culture,"In a preclinical study, ARS-853 treatment in culture resulted in decreased cell proliferation and apoptotic induction in non-small cell lung carcinoma cells harboring KRAS G12C (PMID: 26841430).",Actionable,7869,3908,non-small cell lung carcinoma,DOID,1042,KRAS G12C,"[{'id': 5919, 'pubMedId': 26841430, 'title': 'Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26841430'}]",sensitive,3553,ARS-853,3845
593,Preclinical - Cell culture,"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12C mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8988,3910,lung adenocarcinoma,DOID,1042,KRAS G12C,"[{'id': 6848, 'pubMedId': 27422710, 'title': 'Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27422710'}]",decreased response,807,Binimetinib,3845
594,Clinical Study,"In a clinical study, KRAS mutations in codon 12 or 13 were associated with resistance to Erbitux (cetuximab) in colorectal cancer patients (PMID: 18202412).",Actionable,742,9256,colorectal cancer,DOID,1042,KRAS G12C,"[{'id': 339, 'pubMedId': 18202412, 'title': 'KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18202412'}]",resistant,694,Cetuximab,3845
595,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).,Actionable,1530,9256,colorectal cancer,DOID,1042,KRAS G12C,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,694,Cetuximab,3845
596,Preclinical,"In a preclinical study, a colorectal cancer cell line harboring the KRAS G12C mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).",Actionable,802,9256,colorectal cancer,DOID,1042,KRAS G12C,"[{'id': 26, 'pubMedId': 23455880, 'title': 'KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23455880'}]",resistant,930,Sunitinib,3845
597,Preclinical,"In a preclinical study, ARS-853 inhibited growth of several human tumor cell lines harboring KRAS G12C in 3-dimensional culture conditions (PMID: 26739882).",Actionable,4619,10000003,Advanced Solid Tumor,JAX,1042,KRAS G12C,"[{'id': 4628, 'pubMedId': 26739882, 'title': 'Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26739882'}]",sensitive,3553,ARS-853,3845
598,Preclinical,"In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition and sustained inhibition of Erk signaling in lung cancer cells harboring KRAS G12C with decreased Braf expression through shRNA knockdown in culture (PMID: 27338794).",Actionable,7359,1324,lung cancer,DOID,25302,BRAF dec exp KRAS G12C,"[{'id': 6325, 'pubMedId': 27338794, 'title': 'A combinatorial strategy for treating KRAS-mutant lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27338794'}]",sensitive,2,Trametinib,3845
599,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 4 mutations (Guidelines).,Actionable,3842,9256,colorectal cancer,DOID,1868,KRAS K117N,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,845,Panitumumab,3845
600,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 4 mutations (Guidelines).,Actionable,3835,9256,colorectal cancer,DOID,1868,KRAS K117N,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,694,Cetuximab,3845
601,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of colorectal cancer cells harboring KRAS Q61H and PIK3CA E542K (PMID: 26369631).",Actionable,5620,9256,colorectal cancer,DOID,21302,KRAS Q61H PIK3CA E542K,"[{'id': 5128, 'pubMedId': 26369631, 'title': 'Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26369631'}]",sensitive,1368,Palbociclib + Trametinib,3845
602,Clinical Study,"In a clinical case study, a patient with ovarian carcinoma harboring KRAS Q61H demonstrated sensitivity to treatment with the combination of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in 62% tumor regression (PMID: 25363205). ",Actionable,7767,4001,ovarian carcinoma,DOID,1862,KRAS Q61H,"[{'id': 6478, 'pubMedId': 25363205, 'title': 'Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25363205'}]",sensitive,4517,Bevacizumab + Sorafenib,3845
603,Preclinical,"In a preclinical study, CUDC-907 inhibited growth and repressed RAF-MEK-MAPK signaling as indicated by reduced phosphorylation of Craf, Mek, and Mapk in a human non-small cell lung cancer cell line harboring KRAS Q61H in culture (PMID: 19165201, PMID: 22693356).",Actionable,3013,3908,non-small cell lung carcinoma,DOID,1862,KRAS Q61H,"[{'id': 1018, 'pubMedId': 22693356, 'title': 'Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693356'}, {'id': 3568, 'pubMedId': 19165201, 'title': 'LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19165201'}]",sensitive,709,CUDC-907,3845
604,Preclinical - Cell culture,"In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of non-small cell lung carcinoma cell lines harboring KRAS Q61H (PMID: 28615361).",Actionable,11324,3908,non-small cell lung carcinoma,DOID,1862,KRAS Q61H,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",sensitive,5914,AZD4785,3845
605,Preclinical - Cell culture,"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61H mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8992,3910,lung adenocarcinoma,DOID,1862,KRAS Q61H,"[{'id': 6848, 'pubMedId': 27422710, 'title': 'Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27422710'}]",decreased response,807,Binimetinib,3845
606,Preclinical,"In a preclinical study, a human non-small cell lung cancer cell line harboring KRAS Q61H (PMID: 19165201) were insensitive to pictilisib (GDC-0941) growth inhibition in culture (PMID: 22693356).",Actionable,3008,3908,non-small cell lung carcinoma,DOID,1862,KRAS Q61H,"[{'id': 1018, 'pubMedId': 22693356, 'title': 'Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693356'}, {'id': 3568, 'pubMedId': 19165201, 'title': 'LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19165201'}]",resistant,749,GDC-0941,3845
607,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61H mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,9000,3910,lung adenocarcinoma,DOID,1862,KRAS Q61H,"[{'id': 6848, 'pubMedId': 27422710, 'title': 'Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27422710'}]",decreased response,913,Selumetinib,3845
608,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8185,3908,non-small cell lung carcinoma,DOID,26184,KRAS Q61H PIK3CA E545K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4657,Pimasertib + Regorafenib,3845
609,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8180,3908,non-small cell lung carcinoma,DOID,26184,KRAS Q61H PIK3CA E545K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,1659,Pimasertib + Sorafenib,3845
610,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).",Actionable,8171,3908,non-small cell lung carcinoma,DOID,26184,KRAS Q61H PIK3CA E545K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",decreased response,871,Pimasertib,3845
611,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8176,3908,non-small cell lung carcinoma,DOID,26184,KRAS Q61H PIK3CA E545K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4656,Everolimus + Pimasertib,3845
612,Preclinical,"In a preclinical study, treatment with Refametanib (BAY86-9766) had no effect on a lung adenocarcinoma cell line co-harboring MAP2K1 Y134C and KRAS Q61H in culture (PMID: 26582713). ",Actionable,6449,3910,lung adenocarcinoma,DOID,23451,MAP2K1 Y134C KRAS Q61H,"[{'id': 5602, 'pubMedId': 26582713, 'title': 'Identification of an ""Exceptional Responder"" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26582713'}]",no benefit,888,Refametinib,3845
613,Preclinical,"In a preclinical study, treatment with Mekinist (trametinib) had no effect on a lung adenocarcinoma cell line co-harboring MAP2K1 Y134C and KRAS Q61H in culture (PMID: 26582713). ",Actionable,6448,3910,lung adenocarcinoma,DOID,23451,MAP2K1 Y134C KRAS Q61H,"[{'id': 5602, 'pubMedId': 26582713, 'title': 'Identification of an ""Exceptional Responder"" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26582713'}]",no benefit,2,Trametinib,3845
614,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 4 mutations (Guidelines).,Actionable,3839,9256,colorectal cancer,DOID,1869,KRAS A146V,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,845,Panitumumab,3845
615,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 4 mutations (Guidelines).,Actionable,3838,9256,colorectal cancer,DOID,1869,KRAS A146V,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,694,Cetuximab,3845
616,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",Actionable,7695,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1916,Cetuximab + Encorafenib,3845
617,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7698,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1711,Vemurafenib + Cetuximab,3845
618,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) in culture (PMID: 27312529).",Actionable,7697,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4525,Cetuximab + Dabrafenib,3845
619,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Selumetinib (AZD6244) in culture (PMID: 27312529).",Actionable,7699,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4536,Cetuximab + Selumetinib,3845
620,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to combination treatment consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture, likely due to the acquisition of KRAS A146V and A146T secondary resistance mutations (PMID: 27312529).",Actionable,7628,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1917,LGX818 + Cetuximab + BYL719,3845
621,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7680,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1711,Vemurafenib + Cetuximab,3845
622,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).",Actionable,7687,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1917,LGX818 + Cetuximab + BYL719,3845
623,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment in culture, likely due to the acquired secondary resistance mutation KRAS A146T (PMID: 27312529).",Actionable,7624,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4525,Cetuximab + Dabrafenib,3845
624,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture (PMID: 27312529).",Actionable,7682,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4541,Cetuximab + Dabrafenib + Trametinib,3845
625,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture, likely due to the acquired secondary resistance mutation KRAS A146T (PMID: 27312529).",Actionable,7623,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1916,Cetuximab + Encorafenib,3845
626,Preclinical - Cell line xenograft,"In a preclinical study, PD-0325901 inhibited growth of colorectal cancer cell lines harboring KRAS A146T in culture and in cell line xenograft models (PMID: 20570890).",Actionable,1708,9256,colorectal cancer,DOID,1441,KRAS A146T,"[{'id': 843, 'pubMedId': 20570890, 'title': 'Genomic and biological characterization of exon 4 KRAS mutations in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20570890'}]",sensitive,849,PD-0325901,3845
627,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 4 mutations (Guidelines).,Actionable,3837,9256,colorectal cancer,DOID,1441,KRAS A146T,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,694,Cetuximab,3845
628,Preclinical - Cell line xenograft,"In preclinical studies, Erbitux (cetuximab) decreased pERK and cyclin D1 expression, induced p27, and inhibited cell growth in several human colorectal cancer cell line harboring KRAS A146T in culture; it decreased pERK and cyclin D1 expression, induced p27, and inhbited tumor growth in one colorectal cancer cell line harboring KRAS A146T in xenograft models (PMID: 24141978).",Actionable,1709,9256,colorectal cancer,DOID,1441,KRAS A146T,"[{'id': 843, 'pubMedId': 20570890, 'title': 'Genomic and biological characterization of exon 4 KRAS mutations in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20570890'}]",resistant,694,Cetuximab,3845
629,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 4 mutations (Guidelines).,Actionable,3840,9256,colorectal cancer,DOID,1441,KRAS A146T,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,845,Panitumumab,3845
630,Clinical Study,"In a clinical case study, a colon cancer patient harboring KRAS A59T demonstrated sensitivity to the combination treatment of Vectibix (panitumumab) and FOLFIRI, which resulted in an objective response of a 36% decrease according to RECIST (PMID: 28404754). ",Actionable,10670,219,colon cancer,DOID,862,KRAS A59T,"[{'id': 8729, 'pubMedId': 28404754, 'title': 'Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28404754'}]",sensitive,5573,Panitumumab + FOLFIRI,3845
631,Clinical Study,"In a clinical study, the combination of XL147 plus Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in progressive disease in a patient with colorectal cancer harboring a PIK3CA H1047 mutation and KRAS G12 mutation (PMID: 21216929). ",Actionable,3385,9256,colorectal cancer,DOID,13308,PIK3CA H1047X KRAS G12X,"[{'id': 3726, 'pubMedId': 21216929, 'title': 'PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21216929'}]",resistant,3135,XL147 + Carboplatin + Paclitaxel,3845
632,FDA approved,Lung adenocarcinoma patients with KRAS codon 12 or 13 mutations lack sensitivity to Iressa (gefitinib) (PMID: 15696205).,Actionable,146,3910,lung adenocarcinoma,DOID,1192,KRAS G12X,"[{'id': 211, 'pubMedId': 15696205, 'title': 'KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15696205'}]",resistant,751,Gefitinib,3845
633,Phase III,"In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in patients with KRAS exon 2 mutant colorectal cancer (PMID: 26341920).",Actionable,3265,9256,colorectal cancer,DOID,1192,KRAS G12X,"[{'id': 3703, 'pubMedId': 26341920, 'title': 'Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26341920'}]",no benefit,3102,Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan,3845
634,Preclinical,"In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colorectal tumor cell lines carrying KRAS codon 12 or 13 mutations (PMID: 23209813). ",Actionable,1439,50861,colorectal adenocarcinoma,DOID,1192,KRAS G12X,"[{'id': 1282, 'pubMedId': 23209813, 'title': 'KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23209813'}]",sensitive,1104,Oxaliplatin,3845
635,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).,Actionable,1559,9256,colorectal cancer,DOID,1192,KRAS G12X,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,694,Cetuximab,3845
636,Preclinical - Cell line xenograft,"In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human non-small cell lung cancer cell line harboring a KRAS codon 12 mutation (PMID: 23934108).
",Actionable,1449,3908,non-small cell lung carcinoma,DOID,1192,KRAS G12X,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",sensitive,1004,Cobimetinib,3845
637,Preclinical,"In a preclinical study, pancreatic cell lines with KRAS codon 12 mutations had increased sensitivity to Binimetinib (MEK162) (PMID: 25167228).",Actionable,1444,1793,pancreatic cancer,DOID,1192,KRAS G12X,"[{'id': 1294, 'pubMedId': 25167228, 'title': 'KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25167228'}]",sensitive,807,Binimetinib,3845
638,Preclinical,"In a preclinical study, a pancreatic cancer cell line harboring a KRAS codon 12 mutation demonstrated resistance to PHT-427, resulting in increased Akt activity (PMID: 20197390, PMID: 20418756).",Actionable,4824,1793,pancreatic cancer,DOID,1192,KRAS G12X,"[{'id': 3643, 'pubMedId': 20418756, 'title': 'Phenotype and genotype of pancreatic cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20418756'}, {'id': 4754, 'pubMedId': 20197390, 'title': 'Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20197390'}]",resistant,3148,PHT-427,3845
639,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).,Actionable,1557,9256,colorectal cancer,DOID,1192,KRAS G12X,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,845,Panitumumab,3845
640,Preclinical - Cell line xenograft,"In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human pancreatic cancer cell line harboring a KRAS codon 12 mutation (PMID: 23934108).",Actionable,1448,1793,pancreatic cancer,DOID,1192,KRAS G12X,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",sensitive,1004,Cobimetinib,3845
641,Preclinical,"In a preclinical study, transformed cell lines with various KRAS codon 12 mutations displayed differential inhibition by PD-0325901 (PMID: 26037647).",Actionable,2442,10000003,Advanced Solid Tumor,JAX,1192,KRAS G12X,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 3052, 'pubMedId': 26037647, 'title': 'Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26037647'}]",sensitive,849,PD-0325901,3845
642,Clinical Study,"In a clinical study, two colorectal cancer patients harboring both a PIK3CA E545 and KRAS G12 mutation demonstrated stable disease when treated with Torisel (temsirolimus) (PMID: 21216929). ",Actionable,3312,9256,colorectal cancer,DOID,13163,PIK3CA E545X KRAS G12X,"[{'id': 3726, 'pubMedId': 21216929, 'title': 'PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21216929'}]",sensitive,936,Temsirolimus,3845
643,Preclinical,"In a preclinical study, CUDC-907 induced caspase activation and apoptosis in a human multiple myeloma cell line harboring KRAS G12A in culture (PMID: 19490892, PMID: 22693356).",Actionable,3011,9538,multiple myeloma,DOID,2381,KRAS G12A,"[{'id': 1018, 'pubMedId': 22693356, 'title': 'Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693356'}, {'id': 2128, 'pubMedId': 19490892, 'title': 'Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19490892'}]",sensitive,709,CUDC-907,3845
644,Preclinical,"In a preclinical study, Farydak (panobinostat) induced caspase activation and apoptosis in a human multiple myeloma cell line harboring KRAS G12A in culture (PMD: 19490892, PMID: 22693356).",Actionable,3012,9538,multiple myeloma,DOID,2381,KRAS G12A,"[{'id': 1018, 'pubMedId': 22693356, 'title': 'Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693356'}, {'id': 2128, 'pubMedId': 19490892, 'title': 'Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19490892'}]",sensitive,1080,Panobinostat,3845
645,Preclinical,"In a preclinical study, colorectal cancer cells harboring KRAS G12A were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4941,9256,colorectal cancer,DOID,2381,KRAS G12A,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",resistant,890,Regorafenib,3845
646,Preclinical,"In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells harboring KRAS G12A in culture (PMID: 25838391).",Actionable,4935,9256,colorectal cancer,DOID,2381,KRAS G12A,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",sensitive,694,Cetuximab,3845
647,Preclinical - Cell culture,"In a preclinical study, a MET-amplified lung cancer cell line harboring KRAS G12A was not sensitive to growth inhibition by AMG 337 in culture (PMID: 27196782).",Actionable,9029,1324,lung cancer,DOID,25935,KRAS G12A MET amp,"[{'id': 6878, 'pubMedId': 27196782, 'title': 'In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196782'}]",resistant,1064,AMG 337,3845
648,Preclinical - Cell culture,"In a preclinical study, MET amplified lung cancer cells harboring KRAS G12A were insensitive to SAR125844-mediated growth inhibition in culture (PMID: 25504634).",Actionable,7733,1324,lung cancer,DOID,25935,KRAS G12A MET amp,"[{'id': 2009, 'pubMedId': 25504634, 'title': 'The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25504634'}]",resistant,2159,SAR125844,3845
0,Clinical Study,"In a clinical case study, a patient with colorectal cancer developed liver metastases harboring MAP2K1 K57T that were insensitive to Erbitux (cetuximab) treatment and the mutation was confirmed to cause resistance in human colorectal cancer cell lines in culture (PMID: 26644315).",Actionable,4421,9256,colorectal cancer,DOID,3890,MAP2K1 K57T,"[{'id': 4531, 'pubMedId': 26644315, 'title': 'Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26644315'}]",resistant,694,Cetuximab,5604
1,Preclinical,"In a preclinical study, a colorectal cancer cell line expressing MAP2K1 K57T was resistant to Vectibix (panitumumab) in culture (PMID: 26644315).",Actionable,4422,9256,colorectal cancer,DOID,3890,MAP2K1 K57T,"[{'id': 4531, 'pubMedId': 26644315, 'title': 'Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26644315'}]",resistant,845,Panitumumab,5604
2,Preclinical,"In a preclinical study, Erbitux (cetuximab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57T in culture (PMID: 26644315).",Actionable,4425,9256,colorectal cancer,DOID,3890,MAP2K1 K57T,"[{'id': 4531, 'pubMedId': 26644315, 'title': 'Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26644315'}]",sensitive,3505,Cetuximab + Trametinib,5604
3,Clinical Study,"In a clinical case study, a combination of Vectibix (panitumumab) and Mekinist (trametinib) caused tumor regression in a patient’s colorectal cancer metastases harboring MAP2K1 K57T after being identified pre-clinically as a combination likely to inhibit MAP2K1 K57T expressing colorectal cancer (PMID: 26644315).",Actionable,4428,9256,colorectal cancer,DOID,3890,MAP2K1 K57T,"[{'id': 4531, 'pubMedId': 26644315, 'title': 'Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26644315'}]",sensitive,1991,Panitumumab + Trametinib,5604
4,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7702,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1066,Trametinib + Dabrafenib,5604
5,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",Actionable,7700,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1916,Cetuximab + Encorafenib,5604
6,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by CI-1040 in cell culture (PMID: 19915144).",Actionable,5820,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 134, 'pubMedId': 19915144, 'title': 'MEK1 mutations confer resistance to MEK and B-RAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19915144'}]",resistant,699,CI-1040,5604
7,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12152,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",resistant,2,Trametinib,5604
8,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment in culture, likely due to the acquired secondary resistant mutation of MAP2K1 V211D (PMID: 27312529).",Actionable,7629,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4536,Cetuximab + Selumetinib,5604
9,Preclinical - Cell culture,"In a preclinical study, BVD-523 (Ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712). ",Actionable,12158,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",sensitive,997,BVD-523,5604
10,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7703,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,4541,Cetuximab + Dabrafenib + Trametinib,5604
11,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).",Actionable,12155,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",sensitive,342,Vemurafenib,5604
12,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by Selumetinib (AZD6244) in cell culture (PMID: 19915144).",Actionable,5821,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 134, 'pubMedId': 19915144, 'title': 'MEK1 mutations confer resistance to MEK and B-RAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19915144'}]",resistant,913,Selumetinib,5604
13,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",Actionable,7704,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,2618,SCH772984,5604
14,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",Actionable,7002,1909,melanoma,DOID,24281,BRAF V600E MAP2K1 V60E,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",sensitive,4351,VRT11E,5604
15,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",Actionable,7056,1909,melanoma,DOID,24281,BRAF V600E MAP2K1 V60E,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,3,Dabrafenib,5604
16,Preclinical,"In a preclinical study, a melanoma cell line expressing MAP2K1 V60E demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 24265153).",Actionable,6825,1909,melanoma,DOID,23745,MAP2K1 V60E,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,3,Dabrafenib,5604
17,Preclinical,"In a preclinical study, a melanoma cell line expressing MAP2K1 V60E demonstrated resistance to Mekinist (trametinib) in culture (PMID: 24265153).",Actionable,6824,1909,melanoma,DOID,23745,MAP2K1 V60E,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,2,Trametinib,5604
18,Clinical Study,"In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153).",Actionable,7068,1909,melanoma,DOID,24385,BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,342,Vemurafenib,5604
19,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12149,1909,melanoma,DOID,28495,BRAF V600E MAP2K1 I111N,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",resistant,2,Trametinib,5604
20,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N  in culture (PMID: 28655712).",Actionable,12153,1909,melanoma,DOID,28495,BRAF V600E MAP2K1 I111N,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",sensitive,342,Vemurafenib,5604
21,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).",Actionable,5983,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,4004,Dabrafenib + GSK2126458,5604
22,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).",Actionable,5964,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,2,Trametinib,5604
23,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E harboring MAP2K1 K59del in culture (PMID: 22389471).",Actionable,5980,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,1066,Trametinib + Dabrafenib,5604
24,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5957,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,342,Vemurafenib,5604
25,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).",Actionable,5984,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,3027,GSK2126458 + Trametinib,5604
26,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5969,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,763,GSK2126458,5604
27,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5953,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,3,Dabrafenib,5604
28,Preclinical,"In a preclinical study, treatment with Mekinist (trametinib) had no effect on a lung adenocarcinoma cell line co-harboring MAP2K1 Y134C and KRAS Q61H in culture (PMID: 26582713). ",Actionable,6448,3910,lung adenocarcinoma,DOID,23451,MAP2K1 Y134C KRAS Q61H,"[{'id': 5602, 'pubMedId': 26582713, 'title': 'Identification of an ""Exceptional Responder"" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26582713'}]",no benefit,2,Trametinib,5604
29,Preclinical,"In a preclinical study, treatment with Refametanib (BAY86-9766) had no effect on a lung adenocarcinoma cell line co-harboring MAP2K1 Y134C and KRAS Q61H in culture (PMID: 26582713). ",Actionable,6449,3910,lung adenocarcinoma,DOID,23451,MAP2K1 Y134C KRAS Q61H,"[{'id': 5602, 'pubMedId': 26582713, 'title': 'Identification of an ""Exceptional Responder"" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26582713'}]",no benefit,888,Refametinib,5604
30,Preclinical,"In a preclinical study, MAP2K1 (MEK1) K57E mutations restored extracellular signal–regulated kinase (ERK) activation in the presence of Tafinlar (dabrafenib) in cultured melanoma cell lines (PMID:24463458).",Actionable,666,1909,melanoma,DOID,846,MAP2K1 K57E,"[{'id': 384, 'pubMedId': 24463458, 'title': 'BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24463458'}]",resistant,3,Dabrafenib,5604
31,Preclinical - Cell culture,"In a preclinical study, expression of MAP2K1 K57E in a melanoma cell line harboring BRAF V600E conferred resistance to Tafinlar (dabrafenib) in culture (PMID: 25370473).",Actionable,7592,1909,melanoma,DOID,25914,BRAF V600E MAP2K1 K57E,"[{'id': 6439, 'pubMedId': 25370473, 'title': 'Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25370473'}]",resistant,3,Dabrafenib,5604
32,Preclinical - Cell culture,"In a preclinical study, CI-1040 (PD184352) did not inhibit kinase activity of Map2k1 L115P expressed in transformed human kidney cells (PMID: 12370306).",Actionable,10420,10000003,Advanced Solid Tumor,JAX,21626,MAP2K1 L115P,"[{'id': 5157, 'pubMedId': 12370306, 'title': 'Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12370306'}]",resistant,699,CI-1040,5604
33,Preclinical - Cell culture,"In a preclinical study, CI-1040 (PD184352) did not inhibit proliferation of melanoma cells expressing Map2k1 L115P (PMID: 19915144).",Actionable,10421,1909,melanoma,DOID,21626,MAP2K1 L115P,"[{'id': 134, 'pubMedId': 19915144, 'title': 'MEK1 mutations confer resistance to MEK and B-RAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19915144'}]",resistant,699,CI-1040,5604
34,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) did not inhibit proliferation of melanoma cells expressing Map2k1 L115P (PMID: 19915144).",Actionable,10422,1909,melanoma,DOID,21626,MAP2K1 L115P,"[{'id': 134, 'pubMedId': 19915144, 'title': 'MEK1 mutations confer resistance to MEK and B-RAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19915144'}]",resistant,913,Selumetinib,5604
35,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7654,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,1916,Cetuximab + Encorafenib,5604
36,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 28655712).",Actionable,12154,1909,melanoma,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",sensitive,342,Vemurafenib,5604
37,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7655,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4525,Cetuximab + Dabrafenib,5604
38,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7660,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4543,Cetuximab + SCH772984,5604
39,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7658,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4541,Cetuximab + Dabrafenib + Trametinib,5604
40,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7656,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,1711,Vemurafenib + Cetuximab,5604
41,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7661,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4544,Dabrafenib + SCH772984,5604
42,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7657,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,1917,LGX818 + Cetuximab + BYL719,5604
43,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture, likely due to the acquired secondary resistance mutation MAP2K1 L115P (PMID: 27312529).",Actionable,7620,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",resistant,1066,Trametinib + Dabrafenib,5604
44,Preclinical - Cell culture,"In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 26267534).",Actionable,5817,1909,melanoma,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",sensitive,3769,DEL-22379,5604
45,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7662,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,4542,Cetuximab + Dabrafenib + SCH772984,5604
46,Preclinical,"In a preclinical study, over expression of MAPK21 L115P in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",Actionable,5812,1909,melanoma,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",resistant,849,PD-0325901,5604
47,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12151,1909,melanoma,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",resistant,2,Trametinib,5604
48,Preclinical - Cell culture,"In a preclinical study, SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7659,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,"[{'id': 6445, 'pubMedId': 27312529, 'title': 'Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27312529'}]",sensitive,2618,SCH772984,5604
49,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).",Actionable,12161,1909,melanoma,DOID,28497,BRAF V600E MAP2K1 E203K,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",resistant,342,Vemurafenib,5604
50,Preclinical - Cell culture,"In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K in culture (PMID: 28655712). ",Actionable,12166,1909,melanoma,DOID,28497,BRAF V600E MAP2K1 E203K,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",sensitive,997,BVD-523,5604
51,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12160,1909,melanoma,DOID,28497,BRAF V600E MAP2K1 E203K,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",resistant,2,Trametinib,5604
52,Preclinical,"In a preclinical study, Vectibix (panitumumab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57N in culture (PMID: 26644315).",Actionable,4427,9256,colorectal cancer,DOID,504,MAP2K1 K57N,"[{'id': 4531, 'pubMedId': 26644315, 'title': 'Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26644315'}]",sensitive,1991,Panitumumab + Trametinib,5604
53,Clinical Study,"In a clinical study, a patient with refractory Erdheim–Chester disease harboring a MAP2K1 K57N mutation had a sustained clinical response to Mekinist (trametinib) for over 6 months (PMID: 26566875).",Actionable,6025,60073,lymphatic system cancer,DOID,504,MAP2K1 K57N,"[{'id': 5227, 'pubMedId': 26566875, 'title': 'Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26566875'}]",sensitive,2,Trametinib,5604
54,Preclinical,"In a preclinical study, Erbitux (cetuximab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57N in culture (PMID: 26644315).",Actionable,4426,9256,colorectal cancer,DOID,504,MAP2K1 K57N,"[{'id': 4531, 'pubMedId': 26644315, 'title': 'Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26644315'}]",sensitive,3505,Cetuximab + Trametinib,5604
55,Preclinical,"In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Vectibix (panitumumab) in culture (PMID: 26644315).",Actionable,4424,9256,colorectal cancer,DOID,504,MAP2K1 K57N,"[{'id': 4531, 'pubMedId': 26644315, 'title': 'Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26644315'}]",resistant,845,Panitumumab,5604
56,Preclinical,"In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Erbitux (cetuximab) in culture (PMID: 26644315).",Actionable,4423,9256,colorectal cancer,DOID,504,MAP2K1 K57N,"[{'id': 4531, 'pubMedId': 26644315, 'title': 'Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26644315'}]",resistant,694,Cetuximab,5604
57,Preclinical,"In a preclinical study, selumetinib (AZD6244) inhibited phosphorylation of ERK in cells expressing MAP2K1 K57N and inhibited MAP2K1 K57N-dependent growth in cell culture (PMID: 18632602).",Actionable,182,3910,lung adenocarcinoma,DOID,504,MAP2K1 K57N,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}]",sensitive,913,Selumetinib,5604
58,Preclinical - Patient cell culture,"In a preclinical study, NSCLC patient derived cells harboring an ALK rearrangement demonstrated resistance to Zykadia (ceritinib) due to the acquired mutation MAP2K1 K57N, however, sensitivity was restored to Zykadia (ceritinib) with the addition of AZD6244, resulting in decreased cell survival in culture and reduced tumor volume in xenograft models (PMID: 25394791).",Actionable,8661,3908,non-small cell lung carcinoma,DOID,26393,ALK rearrange MAP2K1 K57N,"[{'id': 1693, 'pubMedId': 25394791, 'title': 'Patient-derived models of acquired resistance can identify effective drug combinations for cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25394791'}]",sensitive,4786,Ceritinib + Selumetinib,5604
59,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Mekinist (trametinib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",Actionable,7059,1909,melanoma,DOID,24283,BRAF V600E MAP2K1 G128V,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,2,Trametinib,5604
60,Preclinical,"In a preclinical study, MAP2K1 G128V conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).",Actionable,7033,1909,melanoma,DOID,24283,BRAF V600E MAP2K1 G128V,"[{'id': 6036, 'pubMedId': 24265154, 'title': 'MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265154'}]",resistant,1066,Trametinib + Dabrafenib,5604
61,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",Actionable,7005,1909,melanoma,DOID,24283,BRAF V600E MAP2K1 G128V,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",sensitive,4351,VRT11E,5604
62,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",Actionable,7058,1909,melanoma,DOID,24283,BRAF V600E MAP2K1 G128V,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,3,Dabrafenib,5604
63,Preclinical - Cell culture,"In a preclinical study, CI-1040 (PD184352) did not inhibit proliferation of melanoma cells expressing Map2k1 I103N (PMID: 19915144). ",Actionable,10427,1909,melanoma,DOID,21625,MAP2K1 I103N,"[{'id': 134, 'pubMedId': 19915144, 'title': 'MEK1 mutations confer resistance to MEK and B-RAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19915144'}]",resistant,699,CI-1040,5604
64,Preclinical - Cell culture,"In a preclinical study, CI-1040 (PD184352) partially inhibited kinase activity of Map2k1 I103N expressed in transformed human kidney cells (PMID: 12370306).",Actionable,10425,10000003,Advanced Solid Tumor,JAX,21625,MAP2K1 I103N,"[{'id': 5157, 'pubMedId': 12370306, 'title': 'Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12370306'}]",decreased response,699,CI-1040,5604
65,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) did not inhibit proliferation of melanoma cells expressing Map2k1 I103N (PMID: 19915144). ",Actionable,10426,1909,melanoma,DOID,21625,MAP2K1 I103N,"[{'id': 134, 'pubMedId': 19915144, 'title': 'MEK1 mutations confer resistance to MEK and B-RAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19915144'}]",resistant,913,Selumetinib,5604
66,Preclinical - Cell culture,"In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N in culture (PMID: 26267534).",Actionable,5816,1909,melanoma,DOID,21628,BRAF V600E MAP2K1 I103N,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",sensitive,3769,DEL-22379,5604
67,Preclinical,"In a preclinical study, over expression of MAPK21 I103N in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",Actionable,5811,1909,melanoma,DOID,21628,BRAF V600E MAP2K1 I103N,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",resistant,849,PD-0325901,5604
68,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5954,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,3,Dabrafenib,5604
69,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5958,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,342,Vemurafenib,5604
70,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5968,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,763,GSK2126458,5604
71,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).",Actionable,5963,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,2,Trametinib,5604
72,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",Actionable,5994,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,3027,GSK2126458 + Trametinib,5604
73,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5966,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,763,GSK2126458,5604
74,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) did not improve the response to human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture (PMID: 22389471).",Actionable,5989,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",no benefit,4004,Dabrafenib + GSK2126458,5604
75,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E and also had reduced sensitivity in comparison to cell lines harboring BRAF V600E and NRAS A146T in culture (PMID: 22389471).",Actionable,5960,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,2,Trametinib,5604
76,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5950,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,3,Dabrafenib,5604
77,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",Actionable,5992,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,3027,GSK2126458 + Trametinib,5604
78,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5956,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,342,Vemurafenib,5604
79,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5962,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,2,Trametinib,5604
80,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 22389471).",Actionable,5961,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,342,Vemurafenib,5604
81,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",Actionable,5993,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,3027,GSK2126458 + Trametinib,5604
82,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5952,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,3,Dabrafenib,5604
83,Preclinical,"In a preclinical study, the response of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S to Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) was conflicting as one cell line with this mutation profile responded to the combination and another cell line with the mutation profile did not (PMID: 22389471).",Actionable,5990,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",conflicting,4004,Dabrafenib + GSK2126458,5604
84,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5967,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,763,GSK2126458,5604
85,Clinical Study,"In a clinical case study, a patient harboring BRAF V600E demonstrated an initial response to treatment with Zelboraf (vemurafenib), but progressed following emergence of a MAP2K1 C121S mutation (PMID: 21383288).",Actionable,7037,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,"[{'id': 4378, 'pubMedId': 21383288, 'title': 'Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21383288'}]",decreased response,342,Vemurafenib,5604
86,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E mutation and overexpressing MAP2K1 C121S were less sensitive than those overexpressing wild-type MAP2K1 to Zelboraf (vemurafenib)-induced inhibition of Mapk pathway activation and cell proliferation in culture (PMID: 24448821).",Actionable,4030,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,"[{'id': 4380, 'pubMedId': 24448821, 'title': 'Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24448821'}]",decreased response,342,Vemurafenib,5604
87,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12159,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",resistant,2,Trametinib,5604
88,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E mutation and overexpressing MAP2K1 C121S were less sensitive than those overexpressing wild-type MAP2K1 to Selumetinib (AZD6244)-induced inhibition of Mapk pathway activation and cell proliferation in culture (PMID: 24448821).",Actionable,4031,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,"[{'id': 4380, 'pubMedId': 24448821, 'title': 'Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24448821'}]",decreased response,913,Selumetinib,5604
89,Preclinical,"In a preclinical study, expression of MAP2K1 C121S conferred resistance to PLX4720 in melanoma cells harboring BRAF V600E in culture (PMID: 21383288).",Actionable,7038,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,"[{'id': 4378, 'pubMedId': 21383288, 'title': 'Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21383288'}]",resistant,1060,PLX4720,5604
90,Preclinical,"In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell line harboring BRAF V600E mutation and overexpressing MAP2K1 C121S in culture (PMID: 24448821).",Actionable,4029,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,"[{'id': 4380, 'pubMedId': 24448821, 'title': 'Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24448821'}]",sensitive,1011,E6201,5604
91,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",Actionable,7003,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",sensitive,4351,VRT11E,5604
92,Preclinical,"In a preclinical study, MAP2K1 C121S conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).",Actionable,7032,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,"[{'id': 6036, 'pubMedId': 24265154, 'title': 'MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265154'}]",resistant,1066,Trametinib + Dabrafenib,5604
93,Preclinical - Cell culture,"In a preclinical study, expression of MAP2K1 C121S conferred resistance to Erbitux (cetuximab) in colorectal cancer cells in culture (PMID: 28179366).",Actionable,10310,9256,colorectal cancer,DOID,17134,MAP2K1 C121S,"[{'id': 8298, 'pubMedId': 28179366, 'title': 'Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179366'}]",resistant,694,Cetuximab,5604
94,Preclinical - Cell culture,"In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring MAP2K1 C121S in culture (PMID: 28179366).",Actionable,10312,9256,colorectal cancer,DOID,17134,MAP2K1 C121S,"[{'id': 8298, 'pubMedId': 28179366, 'title': 'Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179366'}]",sensitive,3505,Cetuximab + Trametinib,5604
95,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 24265153).",Actionable,7061,1909,melanoma,DOID,24282,BRAF V600E MAP2K1 P124S,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,2,Trametinib,5604
96,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and MAP2K1 P124S demonstrated decreased sensitivity to Selumetinib (AZD6244) compared to cells harboring BRAF V600E alone in culture (PMID: 22197931).",Actionable,7035,1909,melanoma,DOID,24282,BRAF V600E MAP2K1 P124S,"[{'id': 429, 'pubMedId': 22197931, 'title': 'Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22197931'}]",decreased response,913,Selumetinib,5604
97,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",Actionable,7004,1909,melanoma,DOID,24282,BRAF V600E MAP2K1 P124S,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",sensitive,4351,VRT11E,5604
98,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture (PMID: 24265153).",Actionable,7057,1909,melanoma,DOID,24282,BRAF V600E MAP2K1 P124S,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,3,Dabrafenib,5604
99,Preclinical,"In a preclinical study, a colorectal cancer cell line harboring MAP2K1 F53L demonstrated sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713). ",Actionable,6453,9256,colorectal cancer,DOID,21379,MAP2K1 F53L,"[{'id': 5602, 'pubMedId': 26582713, 'title': 'Identification of an ""Exceptional Responder"" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26582713'}]",sensitive,2,Trametinib,5604
100,Preclinical - Cell culture,"In a preclinical study, expression of MAP2K1 F53L conferred resistance to Erbitux (cetuximab) in colorectal cancer cells in culture (PMID: 28179366).",Actionable,10309,9256,colorectal cancer,DOID,21379,MAP2K1 F53L,"[{'id': 8298, 'pubMedId': 28179366, 'title': 'Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179366'}]",resistant,694,Cetuximab,5604
101,Preclinical - Cell culture,"In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring MAP2K1 F53L in culture (PMID: 28179366).",Actionable,10311,9256,colorectal cancer,DOID,21379,MAP2K1 F53L,"[{'id': 8298, 'pubMedId': 28179366, 'title': 'Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179366'}]",sensitive,3505,Cetuximab + Trametinib,5604
102,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E treated with Selumetinib (AZD6244) in culture demonstrated resistance, which was a result of the resistance mutation, MAP2K1 H119P (PMID: 19915144).",Actionable,6895,1909,melanoma,DOID,23996,BRAF V600E MAP2K1 H119P,"[{'id': 134, 'pubMedId': 19915144, 'title': 'MEK1 mutations confer resistance to MEK and B-RAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19915144'}]",resistant,913,Selumetinib,5604
103,Preclinical - Cell culture,"In a preclinical study, CI-1040 (PD184352) partially inhibited kinase activity of Map2k1 L115A expressed in transformed human kidney cells (PMID: 12370306).",Actionable,10423,10000003,Advanced Solid Tumor,JAX,27458,MAP2K1 L115A,"[{'id': 5157, 'pubMedId': 12370306, 'title': 'Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12370306'}]",decreased response,699,CI-1040,5604
104,Preclinical - Cell culture,"In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).",Actionable,7601,1909,melanoma,DOID,25913,BRAF V600K MAP2K1 P124Q,"[{'id': 6439, 'pubMedId': 25370473, 'title': 'Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25370473'}]",sensitive,2804,VX-11e,5604
105,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).",Actionable,7602,1909,melanoma,DOID,25913,BRAF V600K MAP2K1 P124Q,"[{'id': 6439, 'pubMedId': 25370473, 'title': 'Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25370473'}]",sensitive,2,Trametinib,5604
106,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).",Actionable,7598,1909,melanoma,DOID,25913,BRAF V600K MAP2K1 P124Q,"[{'id': 6439, 'pubMedId': 25370473, 'title': 'Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25370473'}]",decreased response,3,Dabrafenib,5604
107,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in cell culture (PMID: 25370473).",Actionable,7593,1909,melanoma,DOID,25915,BRAF V600E MAP2K1 P124Q,"[{'id': 6439, 'pubMedId': 25370473, 'title': 'Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25370473'}]",decreased response,3,Dabrafenib,5604
108,Preclinical,"In a preclinical study, a colorectal cancer cell line harboring MAP2K1 mutations Q56P, H119Y, and D351G and an EGFR G719S mutation demonstrated some sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713). ",Actionable,6493,9256,colorectal cancer,DOID,23597,MAP2K1 Q56P MAP2K1 H119Y MAP2K1 D351G EGFR G719S,"[{'id': 5602, 'pubMedId': 26582713, 'title': 'Identification of an ""Exceptional Responder"" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26582713'}]",sensitive,2,Trametinib,5604
109,Preclinical,"In a preclinical study, selumetinib (AZD6244) inhibited growth of a gastric cancer cell line that requires MAP2K1 Q56P and inhibited phosphorylation of ERK in these cells (PMID: 22327936).",Actionable,502,10534,stomach cancer,DOID,584,MAP2K1 Q56P,"[{'id': 135, 'pubMedId': 22327936, 'title': 'Oncogenic MAP2K1 mutations in human epithelial tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22327936'}]",sensitive,913,Selumetinib,5604
110,Preclinical,"In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Mekinist (trametinib), resulting in decreased cell viability (PMID: 26582713). ",Actionable,6444,3910,lung adenocarcinoma,DOID,584,MAP2K1 Q56P,"[{'id': 5602, 'pubMedId': 26582713, 'title': 'Identification of an ""Exceptional Responder"" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26582713'}]",sensitive,2,Trametinib,5604
111,Preclinical,"In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Selumetinib (AZD6244), resulting in decreased cell viability (PMID: 26582713). ",Actionable,6445,3910,lung adenocarcinoma,DOID,584,MAP2K1 Q56P,"[{'id': 5602, 'pubMedId': 26582713, 'title': 'Identification of an ""Exceptional Responder"" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26582713'}]",sensitive,913,Selumetinib,5604
112,Preclinical,"In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Refametinib (BAY86-9766), resulting in decreased cell viability (PMID: 26582713). ",Actionable,6446,3910,lung adenocarcinoma,DOID,584,MAP2K1 Q56P,"[{'id': 5602, 'pubMedId': 26582713, 'title': 'Identification of an ""Exceptional Responder"" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26582713'}]",sensitive,888,Refametinib,5604
113,Clinical Study,"In a clinical study, a patient with refractory Erdheim–Chester disease harboring a MAP2K1 Q56P mutation had a reduction of lymphatic infiltrates to background within a month of receiving Cotellic (cobimetinib) therapy (PMID: 26566875).",Actionable,6026,60073,lymphatic system cancer,DOID,584,MAP2K1 Q56P,"[{'id': 5227, 'pubMedId': 26566875, 'title': 'Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26566875'}]",sensitive,1004,Cobimetinib,5604
114,Preclinical,"In a preclinical study, a gastric cancer cell line harboring MAP2K1 Q56P demonstrated sensitivity to Mekinist (trametinib), resulting in decreased cell viability (PMID: 26582713). ",Actionable,6492,10534,stomach cancer,DOID,584,MAP2K1 Q56P,"[{'id': 5602, 'pubMedId': 26582713, 'title': 'Identification of an ""Exceptional Responder"" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26582713'}]",sensitive,2,Trametinib,5604
115,Preclinical,"In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to PD-0325901, resulting in decreased cell viability (PMID: 26582713). ",Actionable,6447,3910,lung adenocarcinoma,DOID,584,MAP2K1 Q56P,"[{'id': 5602, 'pubMedId': 26582713, 'title': 'Identification of an ""Exceptional Responder"" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26582713'}]",sensitive,849,PD-0325901,5604
116,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P displayed reduced sensitivity to Mekinist (trametinib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).",Actionable,5976,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,2,Trametinib,5604
117,Preclinical,"In a preclinical study, the combination of Talfinlar (dabrafenib)    and Mekinist (trametinib) resulted in improved growth inhibition in melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 22389471).",Actionable,5982,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,1066,Trametinib + Dabrafenib,5604
118,Preclinical - Cell culture,"In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 28655712). ",Actionable,12165,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",sensitive,997,BVD-523,5604
119,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling in culture (PMID: 22389471).",Actionable,5975,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,3,Dabrafenib,5604
120,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712). ",Actionable,12164,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",resistant,342,Vemurafenib,5604
121,Preclinical,"In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the B-RAF inhibitor PLX4720 in culture (PMID: 19915144).",Actionable,505,1909,melanoma,DOID,520,MAP2K1 Q56P BRAF V600E,"[{'id': 134, 'pubMedId': 19915144, 'title': 'MEK1 mutations confer resistance to MEK and B-RAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19915144'}]",resistant,1060,PLX4720,5604
122,Preclinical,"In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the MEK inhibitor selumetinib (AZD6244) cell culture.",Actionable,183,1909,melanoma,DOID,520,MAP2K1 Q56P BRAF V600E,"[{'id': 134, 'pubMedId': 19915144, 'title': 'MEK1 mutations confer resistance to MEK and B-RAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19915144'}]",resistant,913,Selumetinib,5604
123,Preclinical,"In a preclinical study, combined treatment with selumetinib and PLX4720 strongly suppressed the emergence of resistant MAP2K1 mutations in BRAF V600E cells in culture (PMID: 19915144).",Actionable,506,1909,melanoma,DOID,520,MAP2K1 Q56P BRAF V600E,"[{'id': 134, 'pubMedId': 19915144, 'title': 'MEK1 mutations confer resistance to MEK and B-RAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19915144'}]",sensitive,1061,Selumetinib + PLX4720,5604
124,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).",Actionable,7603,1909,melanoma,DOID,25916,BRAF V600K MAP2K1 P124L,"[{'id': 6439, 'pubMedId': 25370473, 'title': 'Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25370473'}]",sensitive,2,Trametinib,5604
125,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124L demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).",Actionable,7599,1909,melanoma,DOID,25916,BRAF V600K MAP2K1 P124L,"[{'id': 6439, 'pubMedId': 25370473, 'title': 'Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25370473'}]",decreased response,3,Dabrafenib,5604
126,Preclinical,"In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).",Actionable,7600,1909,melanoma,DOID,25916,BRAF V600K MAP2K1 P124L,"[{'id': 6439, 'pubMedId': 25370473, 'title': 'Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25370473'}]",sensitive,2804,VX-11e,5604
127,Preclinical,"In a preclinical study, transformed human melanoma cells expressing MAP2K1 P124L demonstrated resistance to the MEK inhibitor, Selumetinib (AZD6244) (PMID: 19915144).",Actionable,1859,1909,melanoma,DOID,3892,MAP2K1 P124L,"[{'id': 134, 'pubMedId': 19915144, 'title': 'MEK1 mutations confer resistance to MEK and B-RAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19915144'}]",resistant,913,Selumetinib,5604
128,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).",Actionable,12163,1909,melanoma,DOID,28498,BRAF V600E MAP2K1 P124L,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",decreased response,342,Vemurafenib,5604
129,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Mekinist (trametinib) in culture (PMID: 28655712). ",Actionable,12162,1909,melanoma,DOID,28498,BRAF V600E MAP2K1 P124L,"[{'id': 10118, 'pubMedId': 28655712, 'title': 'BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28655712'}]",decreased response,2,Trametinib,5604
130,Preclinical - Cell line xenograft,"In a preclinical study, a colorectal cancer cell line harboring MAP2K1 F129L demonstrated sensitivity to treatment with RO4927350 in culture and in cell line xenograft models, demonstrating inhibition of tumor growth (PMID: 21705440).",Actionable,7719,9256,colorectal cancer,DOID,21391,MAP2K1 F129L,"[{'id': 6458, 'pubMedId': 21705440, 'title': 'Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21705440'}]",sensitive,4552,RO4927350,5604
131,Preclinical - Cell culture,"In a preclinical study, CI-1040 (PD184352) inhibited kinase activity of Map2k1 F53S expressed in transformed human kidney cells (PMID: 12370306).",Actionable,10424,10000003,Advanced Solid Tumor,JAX,23728,MAP2K1 F53S,"[{'id': 5157, 'pubMedId': 12370306, 'title': 'Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12370306'}]",sensitive,699,CI-1040,5604
132,Phase I,"LXH 254 is currently in clinical trials in patients with MAPK pathway alterations and advanced solid tumors (clinicaltrials.gov, Sep 2017). ",Actionable,9587,10000003,Advanced Solid Tumor,JAX,1238,MAP2K1 mutant,"[{'id': 303, 'pubMedId': None, 'title': '', 'url': 'https://clinicaltrials.gov/'}]",not applicable,4442,LXH 254,5604
0,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing MET D1228V were sensitive to Glesatinib (MGCD265) in culture, resulting in suppression of Met phosphorylation (PMID: 27694386).",Actionable,9519,10000003,Advanced Solid Tumor,JAX,26872,MET D1228V,"[{'id': 7247, 'pubMedId': 27694386, 'title': 'Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27694386'}]",sensitive,809,MGCD265,4233
1,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing MET D1228V were sensitive to Cometriq (Cabometyx, cabozantinib) in culture, resulting in suppression of Met phosphorylation (PMID: 27694386).",Actionable,9518,10000003,Advanced Solid Tumor,JAX,26872,MET D1228V,"[{'id': 7247, 'pubMedId': 27694386, 'title': 'Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27694386'}]",sensitive,998,cabozantinib,4233
2,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing MET D1228V demonstrated resistance to treatment with Savolitinib (AZD6094) in culture, resulting in sustained Met phosphorylation (PMID: 27694386).",Actionable,9515,10000003,Advanced Solid Tumor,JAX,26872,MET D1228V,"[{'id': 7247, 'pubMedId': 27694386, 'title': 'Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27694386'}]",resistant,2161,Savolitinib,4233
3,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing MET D1228V were sensitive to Merestinib (LY2801653) in culture, resulting in suppression of Met phosphorylation (PMID: 27694386).",Actionable,9520,10000003,Advanced Solid Tumor,JAX,26872,MET D1228V,"[{'id': 7247, 'pubMedId': 27694386, 'title': 'Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27694386'}]",sensitive,1030,LY2801653,4233
4,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing MET D1228V demonstrated resistance to treatment with Capmatinib (INC280) in culture, resulting in sustained Met phosphorylation (PMID: 27694386). ",Actionable,9517,10000003,Advanced Solid Tumor,JAX,26872,MET D1228V,"[{'id': 7247, 'pubMedId': 27694386, 'title': 'Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27694386'}]",resistant,1065,Capmatinib,4233
5,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing MET D1228V demonstrated resistance to treatment with Xalkori (crizotinib) in culture, resulting in sustained Met phosphorylation (PMID: 27694386).",Actionable,9516,10000003,Advanced Solid Tumor,JAX,26872,MET D1228V,"[{'id': 7247, 'pubMedId': 27694386, 'title': 'Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27694386'}]",resistant,706,Crizotinib,4233
6,Clinical Study,"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion, MET amplification, and MET D1228V demonstrated a strong response to the combination of Tarceva (erlotinib) and Cometriq (Cabometyx, cabozantinib), resulting in reduced tumor size (PMID: 27694386).",Actionable,9534,3910,lung adenocarcinoma,DOID,26887,EGFR exon 19 del MET amp MET D1228V,"[{'id': 7247, 'pubMedId': 27694386, 'title': 'Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27694386'}]",sensitive,1255,Cabozantinib + Erlotinib,4233
7,Preclinical,"In a preclinical study, SU11274 induced apoptosis of cells expressing MET E168D, which demonstrated increased sensitivity compared to cells expressing wild-type MET (PMID: 19723643).",Actionable,4759,10000003,Advanced Solid Tumor,JAX,3122,MET E168D,"[{'id': 2020, 'pubMedId': 19723643, 'title': 'Ethnic differences and functional analysis of MET mutations in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19723643'}]",sensitive,1089,SU11274,4233
8,Preclinical - Cell culture,"In a preclinical study, Altiratinib (DCC-2701) inhibited MET activity, including MET activating mutations, and inhibited proliferation of MET-driven tumor cell lines in culture (PMID: 26285778).",Actionable,9535,10000003,Advanced Solid Tumor,JAX,2096,MET act mut,"[{'id': 7263, 'pubMedId': 26285778, 'title': 'Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26285778'}]",sensitive,1656,Altiratinib,4233
9,Phase I,"In a Phase I clinical trial, Xalkori (crizotinib) was generally well-tolerated and demonstrated preliminary efficacy in patients with non-small cell lung cancer harboring MET exon 14 alterations, with anti-tumor activity demonstrated in 10/15 evaluable patients (J Clin Oncol 34, 2016 (suppl; abstr 108)).",Actionable,6822,3908,non-small cell lung carcinoma,DOID,2096,MET act mut,"[{'id': 5837, 'pubMedId': None, 'title': 'Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC).', 'url': 'http://abstracts.asco.org/176/AbstView_176_167889.html'}]",predicted – sensitive,706,Crizotinib,4233
10,Preclinical,"In a preclinical study, Emibetuzumab (LY2875358) treatment inhibited MET activation and proliferation of tumor cells with constitutive MET activation in culture, and inhibited tumor growth in xenograft models (PMID: 25231402).",Actionable,1696,10000003,Advanced Solid Tumor,JAX,2096,MET act mut,"[{'id': 1762, 'pubMedId': 25231402, 'title': 'LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231402'}]",sensitive,803,Emibetuzumab,4233
11,Preclinical - Cell line xenograft,"In a preclinical study, Merestinib (LY2801653) demonstrated anti-tumor activity in cell line xenograft models of glioma with autocrine activation of Met signaling (PMID: 23275061).",Actionable,9980,3070,malignant glioma,DOID,2096,MET act mut,"[{'id': 331, 'pubMedId': 23275061, 'title': 'LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23275061'}]",sensitive,1030,LY2801653,4233
12,Preclinical,"In a preclinical study, Tepotinib (MSC2156119J) inhibited tumor growth in hepatocellular cancer (HCC) mouse xenograft models with MET overexpression or activation (Cancer Res April 15, 2013; 73(8 Supplement): 925)",Actionable,3792,684,hepatocellular carcinoma,DOID,2096,MET act mut,"[{'id': 529, 'pubMedId': None, 'title': 'Abstract 925: The c-Met inhibitor MSC2156119J effectively inhibits growth of liver cancer models.', 'url': ''}]",sensitive,1398,MSC2156119J,4233
13,Preclinical,"In a preclinical study, BMS-777607 (ASLAN002) demonstrated efficacy in blocking Met phosphorylation and inhibiting cell proliferation and metastasis in cultured cells and murine models with activating Met mutations (PMID: 22286523).",Actionable,1757,1115,sarcoma,DOID,2096,MET act mut,"[{'id': 2026, 'pubMedId': 22286523, 'title': 'Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22286523'}]",sensitive,687,BMS-777607,4233
14,Preclinical,"In a preclinical study, cells harboring MET activating mutations demonstrated sensitivity to treatment with Glesatinib (MGCD265) in cell-based assays (AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3609).",Actionable,9538,10000003,Advanced Solid Tumor,JAX,2096,MET act mut,"[{'id': 7264, 'pubMedId': None, 'title': 'Abstract 3609: MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor in Phase II clinical development, potently inhibits clinically relevant Met mutants', 'url': 'http://cancerres.aacrjournals.org/content/70/8_Supplement/3609.short'}]",sensitive,809,MGCD265,4233
15,Phase II,"In a Phase II trial, treatment with Savolitinib (AZD6094) resulted in an overall response rate (ORR) of 18% (8/44, all partial responses) in the subgroup of patients with MET-driven papillary renal cell carcinoma (PRCC), which included patients with MET kinase domain mutations, compared to an ORR of 0% (0/46) in patients with MET-independent PRCC (PMID: 28644771; NCT02127710).",Actionable,11440,4465,papillary renal cell carcinoma,DOID,2096,MET act mut,"[{'id': 9389, 'pubMedId': 28644771, 'title': 'Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28644771'}]",predicted – sensitive,2161,Savolitinib,4233
16,Preclinical - Cell line xenograft,"In a preclinical study, S-49076 inhibited Met activation, resulting in growth inhibition of gastric carcinoma cells harboring MET activating mutations in culture and in cell line xenograft models (PMID: 23804704).",Actionable,1770,5517,stomach carcinoma,DOID,2096,MET act mut,"[{'id': 2007, 'pubMedId': 23804704, 'title': 'S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23804704'}]",sensitive,2158,S-49076,4233
17,Preclinical - Cell line xenograft,"In a preclinical study, acquired MET Y1230C and MET Y1230H mutations were associated with secondary resistance to Xalkori (crizotinib) in a MET-over expressing gastric cancer cell line xenograft model, and cells derived from this model demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 21266357).",Actionable,10119,10534,stomach cancer,DOID,27263,MET over exp MET Y1230C MET Y1230H,"[{'id': 8043, 'pubMedId': 21266357, 'title': 'Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21266357'}]",resistant,706,Crizotinib,4233
18,Preclinical - Cell line xenograft,"In a preclinical study, MET Y1230H was associated with resistance to PHA-665752 in a gastric cancer cell line with MET over expression in culture (PMID: 21266357).",Actionable,10117,10534,stomach cancer,DOID,27261,MET over exp MET Y1230H,"[{'id': 8043, 'pubMedId': 21266357, 'title': 'Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21266357'}]",resistant,2162,PHA-665752,4233
19,Preclinical - Cell culture,"In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) co-harboring MET Y1230H and MET F1200L was sensitive to treatment with Glesatinib (MGCD265), demonstrating cell growth inhibition in culture (PMID: 28765324). ",Actionable,11771,10534,stomach cancer,DOID,28234,MET F1200L MET Y1230H,"[{'id': 9757, 'pubMedId': 28765324, 'title': 'Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28765324'}, {'id': 9765, 'pubMedId': 15494073, 'title': 'Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15494073'}]",sensitive,809,MGCD265,4233
20,Preclinical - Cell culture,"In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) treated with Xalkori (crizotinib) in culture for several months developed resistance and was found to co-harbor MET Y1230H and MET F1200L(PMID: 28765324). ",Actionable,11768,10534,stomach cancer,DOID,28234,MET F1200L MET Y1230H,"[{'id': 9757, 'pubMedId': 28765324, 'title': 'Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28765324'}, {'id': 9765, 'pubMedId': 15494073, 'title': 'Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15494073'}]",resistant,706,Crizotinib,4233
21,Preclinical - Cell culture,"In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) co-harboring MET Y1230H and MET F1200L demonstrated resistance when treated with Capmatinib (INC280) in culture (PMID: 28765324). ",Actionable,11769,10534,stomach cancer,DOID,28234,MET F1200L MET Y1230H,"[{'id': 9757, 'pubMedId': 28765324, 'title': 'Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28765324'}, {'id': 9765, 'pubMedId': 15494073, 'title': 'Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15494073'}]",resistant,1065,Capmatinib,4233
22,Clinical Study,"In a clinical case study, a patient with lung adenocarcinoma harboring MET del exon14 responded to Xalkori (crizotinib), demonstrating a near complete response at 3 months, however, after 9 months progression ensued and a re-biospy identified MET del exon14, MET amplification, MET D1228N, MET Y1230H, MET Y1230S, and MET G1163R (PMID: 28522754). ",Actionable,11740,3910,lung adenocarcinoma,DOID,28219,MET amp MET del exon14 MET D1228N MET G1163R MET Y1230H MET Y1230S,"[{'id': 9758, 'pubMedId': 28522754, 'title': 'MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28522754'}]",resistant,706,Crizotinib,4233
23,Clinical Study,"In a clinical case study, a lung adenocarcinoma patient harboring MET del exon14 and MET amplification demonstrated resistance to Xalkori (crizotinib), and the patient was found to have acquired MET Y1230H, MET D1228N, MET Y1230S, and MET G1163R (PMID: 28765324). ",Actionable,11788,3910,lung adenocarcinoma,DOID,28219,MET amp MET del exon14 MET D1228N MET G1163R MET Y1230H MET Y1230S,"[{'id': 9757, 'pubMedId': 28765324, 'title': 'Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28765324'}]",resistant,706,Crizotinib,4233
24,Preclinical,"In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET Y1230H in an in vitro kinase assay (PMID: 26285778).",Actionable,10073,10000003,Advanced Solid Tumor,JAX,26643,MET Y1230H,"[{'id': 7263, 'pubMedId': 26285778, 'title': 'Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26285778'}]",predicted – sensitive,1656,Altiratinib,4233
25,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to MET Y1230H in humans) were resistant to treatment with Savolitinib (AZD6094), demonstrating sustained cell growth in culture (PMID: 28396313). ",Actionable,11732,10000003,Advanced Solid Tumor,JAX,26643,MET Y1230H,"[{'id': 9744, 'pubMedId': 28396313, 'title': 'Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28396313'}]",predicted – resistant,2161,Savolitinib,4233
26,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to Y1230H in humans) were sensitive to treatment with BMS-777607 (ASLAN002), demonstrating inhibition of cell growth in culture (PMID: 28396313). ",Actionable,11734,10000003,Advanced Solid Tumor,JAX,26643,MET Y1230H,"[{'id': 9744, 'pubMedId': 28396313, 'title': 'Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28396313'}]",predicted – sensitive,687,BMS-777607,4233
27,Preclinical,"In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to MET Y1230H in humans) were sensitive to treatment with Cometriq (Cabometyx, cabozantinib), demonstrating inhibition of cell growth in culture and tumor growth inhibition in mouse models (PMID: 28396313). ",Actionable,11728,10000003,Advanced Solid Tumor,JAX,26643,MET Y1230H,"[{'id': 9744, 'pubMedId': 28396313, 'title': 'Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28396313'}]",predicted – sensitive,998,cabozantinib,4233
28,Preclinical,"In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to MET Y1230H in humans) were resistant to treatment with Capmatinib (INC280), demonstrating sustained cell growth in culture and minimal tumor growth inhibition in mouse models (PMID: 28396313). ",Actionable,11726,10000003,Advanced Solid Tumor,JAX,26643,MET Y1230H,"[{'id': 9744, 'pubMedId': 28396313, 'title': 'Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28396313'}]",predicted – resistant,1065,Capmatinib,4233
29,Preclinical,"In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to MET Y1230H in humans) were resistant to treatment with Xalkori (crizotinib) demonstrating sustained cell growth in culture and minimal tumor growth inhibition in mouse models (PMID: 28396313). ",Actionable,11727,10000003,Advanced Solid Tumor,JAX,26643,MET Y1230H,"[{'id': 9744, 'pubMedId': 28396313, 'title': 'Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28396313'}]",predicted – resistant,706,Crizotinib,4233
30,Phase III,"In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).",Actionable,8747,4944,gastroesophageal junction adenocarcinoma,DOID,26426,ERBB2 neg MET pos,"[{'id': 6730, 'pubMedId': None, 'title': 'METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).', 'url': 'http://meetinglibrary.asco.org/content/147779-156'}]",no benefit,838,Onartuzumab,4233
31,Phase III,"In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).",Actionable,8744,4944,gastroesophageal junction adenocarcinoma,DOID,26426,ERBB2 neg MET pos,"[{'id': 6729, 'pubMedId': None, 'title': 'Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal juncti', 'url': 'http://meetinglibrary.asco.org/content/147255-156'}]",no benefit,629,AMG102,4233
32,Phase III,"In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).",Actionable,10904,3717,gastric adenocarcinoma,DOID,26426,ERBB2 neg MET pos,"[{'id': 8918, 'pubMedId': 27918764, 'title': 'Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27918764'}]",no benefit,5676,Onartuzumab + mFOLFOX6,4233
33,Phase III,"In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).",Actionable,10905,4914,esophagus adenocarcinoma,DOID,26426,ERBB2 neg MET pos,"[{'id': 8918, 'pubMedId': 27918764, 'title': 'Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27918764'}]",no benefit,5676,Onartuzumab + mFOLFOX6,4233
34,Phase III,"In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).",Actionable,8746,3717,gastric adenocarcinoma,DOID,26426,ERBB2 neg MET pos,"[{'id': 6730, 'pubMedId': None, 'title': 'METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).', 'url': 'http://meetinglibrary.asco.org/content/147779-156'}]",no benefit,838,Onartuzumab,4233
35,Phase III,"In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).",Actionable,8745,3717,gastric adenocarcinoma,DOID,26426,ERBB2 neg MET pos,"[{'id': 6729, 'pubMedId': None, 'title': 'Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal juncti', 'url': 'http://meetinglibrary.asco.org/content/147255-156'}]",no benefit,629,AMG102,4233
36,Preclinical - Cell line xenograft,"In a preclinical study, Cometriq (cabozantinib) inhibited Met activity, cell growth, and invasive cellular characteristics in a human MET positive TNBC cell line in culture, and reduced tumor volume in xenograft models (PMID: 26432786).",Actionable,6225,60081,triple-receptor negative breast cancer,DOID,1240,MET positive,"[{'id': 5492, 'pubMedId': 26432786, 'title': 'Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432786'}]",sensitive,998,cabozantinib,4233
37,Phase I,"In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 19% (5/26) of MET-positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).

",Actionable,7063,3908,non-small cell lung carcinoma,DOID,1240,MET positive,"[{'id': 6064, 'pubMedId': None, 'title': 'Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).', 'url': 'http://meetinglibrary.asco.org/content/165406-176'}]",sensitive,1065,Capmatinib,4233
38,Phase I,"In a Phase I trial, Emibetuzumab (LY2875358) and Tarceva (erlotinib) combination treatment resulted in durable partial response in 15% (2/13) of Met-positive patients with non-small cell lung carcinoma (J Clin Oncol 31, 2013 (suppl; abstr 8093)).",Actionable,9972,3908,non-small cell lung carcinoma,DOID,1240,MET positive,"[{'id': 7831, 'pubMedId': None, 'title': 'First-in-human dose escalation study of LY2875358 (LY), a bivalent MET antibody, as monotherapy and in combination with erlotinib (E) in patients with advanced cancer.', 'url': 'http://meetinglibrary.asco.org/content/115545-132'}]",sensitive,1179,Emibetuzumab + Erlotinib,4233
39,Phase I,"In a Phase I trial, Emibetuzumab (LY2875358) and Tarceva (erlotinib) combination treatment resulted in durable partial response in 14.3% (2/14) of patients with non-small cell lung carcinoma, with both responders being Met positive (PMID: 27803065).",Actionable,10639,3908,non-small cell lung carcinoma,DOID,1240,MET positive,"[{'id': 8681, 'pubMedId': 27803065, 'title': 'A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27803065'}]",sensitive,1179,Emibetuzumab + Erlotinib,4233
40,Phase I,"In a Phase I trial, INCB028060 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, as indicated by decreased whole blood Met phosphorylation level (J Clin Oncol 29: 2011 (suppl; abstr 3091)).",Actionable,9984,10000003,Advanced Solid Tumor,JAX,1240,MET positive,"[{'id': 7835, 'pubMedId': None, 'title': 'A phase I dose-escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/82236-102'}]",sensitive,776,INCB028060,4233
41,Phase I,"In a Phase I trial, Emibetuzumab (LY2875358) treatment resulted in durable partial response in 4% (1/23) of Met-positive patients with advanced solid tumors (J Clin Oncol 31, 2013 (suppl; abstr 8093)).",Actionable,9971,10000003,Advanced Solid Tumor,JAX,1240,MET positive,"[{'id': 7831, 'pubMedId': None, 'title': 'First-in-human dose escalation study of LY2875358 (LY), a bivalent MET antibody, as monotherapy and in combination with erlotinib (E) in patients with advanced cancer.', 'url': 'http://meetinglibrary.asco.org/content/115545-132'}]",sensitive,803,Emibetuzumab,4233
42,Phase III,"In a Phase II clinical trial, Onartuzumab (RO5490258), in combination with Tarceva (erlotinib) demonstrated efficacy in patients with Met-positive NSCLC (PMID: 24101053). However, a subsequent Phase III clinical trial has been unable to confirm this efficacy (J Clin Oncol 32:5s, 2014 (suppl; abstr 8000)).",Actionable,1769,3908,non-small cell lung carcinoma,DOID,1240,MET positive,"[{'id': 2030, 'pubMedId': 24101053, 'title': 'Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24101053'}, {'id': 2031, 'pubMedId': None, 'title': 'Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial.', 'url': 'http://meetinglibrary.asco.org/content/128045-144'}]",conflicting,1280,Onartuzumab + Erlotinib,4233
43,Preclinical - Cell line xenograft,"In a preclinical study, Altiratinib (DCC-2701) inhibited MET activation, decreased viability and migration of c-MET positive ovarian cancer cells in culture, and reduced tumor growth in ovarian cancer cell line xenograft models (PMID: 24362531).",Actionable,1644,2394,ovarian cancer,DOID,1240,MET positive,"[{'id': 1757, 'pubMedId': 24362531, 'title': 'Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24362531'}]",predicted – sensitive,1656,Altiratinib,4233
44,Phase I,"In a Phase I clinical trial, ABBV-399 was well-tolerated and demonstrated preliminary efficacy in patients with MET-positive non-small cell lung cancer, with 30% (3/10) of patients demonstrating a partial response (J Clin Oncol 34, 2016 (suppl; abstr 2510)).",Actionable,9983,3908,non-small cell lung carcinoma,DOID,1240,MET positive,"[{'id': 7834, 'pubMedId': None, 'title': 'Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/164513-176'}]",sensitive,1363,ABBV-399,4233
45,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Altiratinib (DCC-2701) and Avastin (bevacizumab) inhibited tumor growth and invasiveness, decreased blood vessel formation, and prolonged survival in cell line xenograft models of MET-expressing glioblastoma (PMID: 26965451).",Actionable,7040,3068,glioblastoma multiforme,DOID,1240,MET positive,"[{'id': 6048, 'pubMedId': 26965451, 'title': 'Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26965451'}]",sensitive,4353,Altiratinib + Bevacizumab,4233
46,Phase I,"In a Phase I trial, Ficlatuzumab treatment resulted in stable disease in 57% (12/21) of patients with advanced solid tumors and a decrease in phosphorylated Met in one patient with multiple myeloma (PMID: 24901237).",Actionable,9975,9538,multiple myeloma,DOID,1240,MET positive,"[{'id': 7832, 'pubMedId': 24901237, 'title': 'Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24901237'}]",predicted – sensitive,740,Ficlatuzumab,4233
47,Phase II,"In a Phase II trial, higher baseline soluble Met level correlated with longer overall survival in cholangiocarcinoma patients treated with Cometriq (cabozantinib) (PMID: 28192597).
",Emerging,10414,4947,cholangiocarcinoma,DOID,1240,MET positive,"[{'id': 8428, 'pubMedId': 28192597, 'title': 'A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28192597'}]",predicted – sensitive,998,cabozantinib,4233
48,Preclinical - Cell line xenograft,"In a preclinical study, Altiratinib (DCC-2701) inhibited viability of several MET-expressing glioblastoma cell lines in culture and inhibited tumor growth in cell line xenograft models (PMID: 26965451).",Actionable,7041,3068,glioblastoma multiforme,DOID,1240,MET positive,"[{'id': 6048, 'pubMedId': 26965451, 'title': 'Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26965451'}]",predicted – sensitive,1656,Altiratinib,4233
49,Phase I,"In a Phase I trial, ARGX-111 demonstrated safety and resulted in some efficacy in patients with advanced solid tumors expressing MET, including a decrease in circulating tumor cells positive for MET (Journal of Clinical Oncology 33, no. 15_suppl, May 2015, 2580-2580).",Actionable,9969,10000003,Advanced Solid Tumor,JAX,1240,MET positive,"[{'id': 7830, 'pubMedId': None, 'title': 'A phase I, first-in-human study of argx-111, a monoclonal antibody targeting c-met in patients with solid tumors', 'url': 'http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.2580'}]",sensitive,2157,ARGX-111,4233
50,Preclinical,"In a preclinical study, a cell line expressing MET M1268T demonstrated sensitivity to SU11274 treatment (PMID: 15064724).",Actionable,809,162,cancer,DOID,965,MET M1268T,"[{'id': 452, 'pubMedId': 15064724, 'title': 'The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15064724'}]",sensitive,1089,SU11274,4233
51,Preclinical,"In preclinical studies, cell lines transformed by MET M1268T were sensitive to K252a treatment in both culture and mouse model experiments (PMID: 12118367).",Actionable,808,162,cancer,DOID,965,MET M1268T,"[{'id': 451, 'pubMedId': 12118367, 'title': 'K252a inhibits the oncogenic properties of Met, the HGF receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12118367'}]",sensitive,1088,K252a,4233
52,Preclinical,"In a preclinical study, a cell line expressing MET H1112L demonstrated sensitivity to SU11274 treatment (PMID: 19783361).",Actionable,816,162,cancer,DOID,1126,MET H1112L,"[{'id': 455, 'pubMedId': 19783361, 'title': 'Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19783361'}]",sensitive,1089,SU11274,4233
53,Preclinical,"In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET Y1230D in an in vitro kinase assay (PMID: 26285778).",Actionable,10078,10000003,Advanced Solid Tumor,JAX,27241,MET Y1230D,"[{'id': 7263, 'pubMedId': 26285778, 'title': 'Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26285778'}]",predicted – sensitive,1656,Altiratinib,4233
54,Preclinical,"In a preclinical study, decreasing Brca2 expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells with Met over expression to Rubraca (rucaparib) in culture (PMID: 26779812).",Actionable,6151,60081,triple-receptor negative breast cancer,DOID,22730,BRCA2 dec exp MET over exp,"[{'id': 5319, 'pubMedId': 26779812, 'title': 'Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26779812'}]",no benefit,906,Rucaparib,4233
55,Preclinical - Cell culture,"In a preclinical study, shRNA knock-down of Tp53 in Met over-expressing gastric carcinoma cells enhanced sensitivity to the combination of EMD 1214063 and radiation in culture (PMID: 26358474).",Actionable,9470,5517,stomach carcinoma,DOID,26857,MET over exp TP53 dec exp,"[{'id': 7198, 'pubMedId': 26358474, 'title': 'Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26358474'}]",sensitive,5024,EMD 1214063 + Radiotherapy,4233
56,Preclinical - Cell line xenograft,"In a preclinical study, an acquired MET Y1230C mutation was associated with resistance to PHA-665752 in a MET-over expressing gastric cancer cell line xenograft model, and cells derived from this xenograft model demonstrated sustained MET activation following treatment with PHA-665752 in culture (PMID: 21266357).",Actionable,10118,10534,stomach cancer,DOID,27262,MET over exp MET Y1230C,"[{'id': 8043, 'pubMedId': 21266357, 'title': 'Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21266357'}]",resistant,2162,PHA-665752,4233
57,Preclinical - Pdx,"In a preclinical study, the combination of Mekinist (trametinib) and Capmatinib (INC280) induced tumor regression in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",Actionable,11662,4464,collecting duct carcinoma,DOID,28180,BRAF D594N BRAF G466A EGFR over exp MET over exp,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",sensitive,6103,INC280 + Trametinib,4233
58,Preclinical - Pdx,"In a preclinical study, treatment with Mekinist (trametinib) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",Actionable,11661,4464,collecting duct carcinoma,DOID,28180,BRAF D594N BRAF G466A EGFR over exp MET over exp,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",sensitive,2,Trametinib,4233
59,Preclinical - Pdx,"In a preclinical study, treatment with Capmatinib (INC280) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",Actionable,11660,4464,collecting duct carcinoma,DOID,28180,BRAF D594N BRAF G466A EGFR over exp MET over exp,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",sensitive,1065,Capmatinib,4233
60,Preclinical,"In a preclinical study, a human gastric cancer cell line with high levels of MET expression and expressing KRAS G12D was resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26432108).",Actionable,4082,10534,stomach cancer,DOID,17217,KRAS G12D MET over exp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",resistant,706,Crizotinib,4233
61,Phase I,"In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 29% (5/17) of EGFR wild-type, MET over-expressing non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).",Actionable,7065,3908,non-small cell lung carcinoma,DOID,24382,EGFR wild-type MET over exp,"[{'id': 6064, 'pubMedId': None, 'title': 'Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).', 'url': 'http://meetinglibrary.asco.org/content/165406-176'}]",sensitive,1065,Capmatinib,4233
62,Preclinical,"In a preclinical study, decreasing Brca1 expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells with Met over expression to Rubraca (rucaparib) in culture (PMID: 26779812).",Actionable,6150,60081,triple-receptor negative breast cancer,DOID,22729,BRCA1 dec exp MET over exp,"[{'id': 5319, 'pubMedId': 26779812, 'title': 'Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26779812'}]",no benefit,906,Rucaparib,4233
63,Preclinical - Cell culture,"In a preclinical study, the addition of JNJ-38877605 to Erbitux (cetuximab) treatment overcame Erbitux (cetuximab) resistance in colorectal cancer cell lines over expressing MET in culture (PMID: 23729478).",Actionable,11352,9256,colorectal cancer,DOID,5392,MET over exp,"[{'id': 9245, 'pubMedId': 23729478, 'title': 'Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23729478'}]",sensitive,5951,Cetuximab + JNJ 38877605,4233
64,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of a human gastric cancer cell line with high levels of MET expression in culture (PMID: 26432108).",Actionable,4083,10534,stomach cancer,DOID,5392,MET over exp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",sensitive,706,Crizotinib,4233
65,Phase II,"In a Phase II trial, a cholangiocarcinoma patient with high Met expression in tumor stayed on Cometriq (cabozantinib) treatment for 278 days (PMID: 28192597).
",Actionable,10413,4947,cholangiocarcinoma,DOID,5392,MET over exp,"[{'id': 8428, 'pubMedId': 28192597, 'title': 'A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28192597'}]",predicted – sensitive,998,cabozantinib,4233
66,Preclinical - Cell line xenograft,"In a preclinical study, LY2801653 blocked tumor growth in a gastric cancer cell line xenograft model over expressing Met (PMID: 23275061).  ",Actionable,9536,10534,stomach cancer,DOID,5392,MET over exp,"[{'id': 331, 'pubMedId': 23275061, 'title': 'LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23275061'}]",sensitive,1030,LY2801653,4233
67,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Xalkori (crizotinib) and Rubraca (rucaparib) synergized to inhibit growth of Met-over expressing human triple-receptor negative breast cancer cell lines in culture, and reduced tumor growth in xenograft models (PMID: 26779812).",Actionable,6146,60081,triple-receptor negative breast cancer,DOID,5392,MET over exp,"[{'id': 5319, 'pubMedId': 26779812, 'title': 'Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26779812'}]",sensitive,4070,Crizotinib + Rucaparib,4233
68,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Xalkori (crizotinib) and Rubraca (rucaparib) synergized to inhibit growth of a Met-over expressing human lung cancer cell line in culture, and reduced tumor growth in xenograft models (PMID: 26779812).",Actionable,6160,1324,lung cancer,DOID,5392,MET over exp,"[{'id': 5319, 'pubMedId': 26779812, 'title': 'Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26779812'}]",sensitive,4070,Crizotinib + Rucaparib,4233
69,Preclinical,"In a preclinical study, Foretinib (GSK1363089) and Rubraca (rucaparib) combination treatment resulted in enhanced growth inhibition in Met-over expressing triple-receptor negative breast cancer cells in culture (PMID: 26779812).",Actionable,6147,60081,triple-receptor negative breast cancer,DOID,5392,MET over exp,"[{'id': 5319, 'pubMedId': 26779812, 'title': 'Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26779812'}]",sensitive,4071,Foretinib + Rucaparib,4233
70,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Xalkori (crizotinib) and Rubraca (rucaparib) synergized to inhibit growth of a Met-over expressing human breast cancer cell line in culture, and reduced tumor growth in xenograft models (PMID: 26779812).",Actionable,6159,1612,breast cancer,DOID,5392,MET over exp,"[{'id': 5319, 'pubMedId': 26779812, 'title': 'Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26779812'}]",sensitive,4070,Crizotinib + Rucaparib,4233
71,Preclinical - Cell culture,"In a preclinical study, EMD 1214063 inhibited Met phosphorylation and cell viability of Met over-expressing gasric carcinoma cell lines in culture, regardless of their TP53 status (PMID: 26358474).",Actionable,9468,5517,stomach carcinoma,DOID,5392,MET over exp,"[{'id': 7198, 'pubMedId': 26358474, 'title': 'Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26358474'}]",sensitive,726,EMD 1214063,4233
72,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines over-expressing MET (PMID: 25122427).",Actionable,2987,5409,lung small cell carcinoma,DOID,5392,MET over exp,"[{'id': 3555, 'pubMedId': 25122427, 'title': 'RET mutation and expression in small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25122427'}]",sensitive,877,Ponatinib,4233
73,Preclinical - Cell line xenograft,"In a preclinical study, Altiratinib (DCC-2701) inhibited Met phosphorylation and viability of several Met over expressing glioblastoma cell lines in culture and inhibited tumor growth in cell line xenograft models (PMID: 26965451).",Actionable,7039,3068,glioblastoma multiforme,DOID,5392,MET over exp,"[{'id': 6048, 'pubMedId': 26965451, 'title': 'Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26965451'}]",predicted – sensitive,1656,Altiratinib,4233
74,Preclinical - Cell culture,"In a preclinical study, treatment with ABBV-399 resulted in complete response in a MET-over expressing papillary lung adenocarcinoma cell line xenograft model (PMID: 27573171).",Actionable,9978,5588,lung papillary adenocarcinoma,DOID,5392,MET over exp,"[{'id': 7833, 'pubMedId': 27573171, 'title': 'ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27573171'}]",sensitive,1363,ABBV-399,4233
75,Preclinical - Cell culture,"In a preclinical study, EMD 1214063 inhibited Met phosphorylation and cell viability of Met over-expressing lung squamous cell carcinoma cells in culture (PMID: 26358474).",Actionable,9469,3907,lung squamous cell carcinoma,DOID,5392,MET over exp,"[{'id': 7198, 'pubMedId': 26358474, 'title': 'Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26358474'}]",sensitive,726,EMD 1214063,4233
76,Phase I,"In a Phase I trial, the combination of ABBV-399 and Tarceva (erlotinib) resulted in a partial response in 31% (4/13) of non-small cell lung carcinoma patients and disease control at 12 weeks in 61.5% (8/13) of patients (J Clin Oncol 35, 2017 (suppl; abstr 2509)). ",Actionable,11070,3908,non-small cell lung carcinoma,DOID,5392,MET over exp,"[{'id': 9062, 'pubMedId': None, 'title': 'Phase I study of ABBV-399, a c-Met antibody-drug conjugate (ADC), as monotherapy and in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC)', 'url': 'http://abstracts.asco.org/199/AbstView_199_183940.html'}]",sensitive,1364,ABBV-399 + Erlotinib,4233
77,Preclinical - Cell culture,"In a preclinical study, the addition of JNJ-38877605 to Vectibix (panitumumab) treatment overcame Vectibix (panitumumab) resistance in colorectal cancer cell lines over expressing MET in culture (PMID: 23729478).",Actionable,11353,9256,colorectal cancer,DOID,5392,MET over exp,"[{'id': 9245, 'pubMedId': 23729478, 'title': 'Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23729478'}]",sensitive,5952,JNJ 38877605 + Panitumumab,4233
78,Preclinical - Pdx,"In a preclinical study, Tepotinib (MSC2156119J) treatment resulted in tumor regression in patient-derived xenograft models of hepatocellular cancer with high Met expression level (PMID: 25256830).",Actionable,869,684,hepatocellular carcinoma,DOID,5392,MET over exp,"[{'id': 7829, 'pubMedId': 25256830, 'title': 'The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25256830'}]",sensitive,1398,MSC2156119J,4233
79,Preclinical - Cell line xenograft,"In a preclinical study, Merestinib (LY2801653) demonstrated anti-tumor activity in cell line xenograft models of lung adenocarcinoma with Met over expression (PMID: 23275061).",Actionable,9981,3910,lung adenocarcinoma,DOID,5392,MET over exp,"[{'id': 331, 'pubMedId': 23275061, 'title': 'LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23275061'}]",sensitive,1030,LY2801653,4233
80,Preclinical - Cell culture,"In a preclinical study, over expression of MET conferred resistance to Erbitux (cetuximab) in colorectal cancer cell lines in culture (PMID: 23729478).",Actionable,11347,9256,colorectal cancer,DOID,5392,MET over exp,"[{'id': 9245, 'pubMedId': 23729478, 'title': 'Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23729478'}]",resistant,694,Cetuximab,4233
81,Preclinical - Pdx,"In a preclinical study, ABBV-399 demonstrated efficacy in MET-expressing lung adenocarcinoma patient-derived xenograft (PDX) models, with the PDX model with higher MET expression levels showing improved tumor growth delay (PMID: 27573171).",Actionable,9982,3910,lung adenocarcinoma,DOID,5392,MET over exp,"[{'id': 7833, 'pubMedId': 27573171, 'title': 'ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27573171'}]",predicted – sensitive,1363,ABBV-399,4233
82,Preclinical,"In a preclinical study, XL147 inhibited migration and growth of mouse melanoma cells with MET over expression in culture (PMID: 25637314).",Actionable,6303,1909,melanoma,DOID,5392,MET over exp,"[{'id': 5522, 'pubMedId': 25637314, 'title': 'The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25637314'}]",sensitive,1050,XL147,4233
83,Preclinical,"In a preclinical study, KRC-00509 induced cell-cycle arrest and inhibited growth of Met-over expressing gastric cancer cell lines in culture, and did not inhibit growth of cell lines with low Met expression (PMID: 26801760).",Actionable,5500,10534,stomach cancer,DOID,5392,MET over exp,"[{'id': 5073, 'pubMedId': 26801760, 'title': 'Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26801760'}]",sensitive,3872,KRC-00509,4233
84,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cell lines over expressing Met demonstrated decreased sensitivity to Rubraca (rucaparib) induced growth and colony formation inhibition in culture (PMID: 26779812).",Actionable,6145,60081,triple-receptor negative breast cancer,DOID,5392,MET over exp,"[{'id': 5319, 'pubMedId': 26779812, 'title': 'Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26779812'}]",decreased response,906,Rucaparib,4233
85,Preclinical - Cell line xenograft,"In a preclinical study, Foretinib (GSK1363089) and Veliparib (ABT-888) worked synergistically to inhibit growth of Met-over expressing triple-receptor negative breast cancer cells in culture, and reduced tumor growth in xenograft models (PMID: 26779812).",Actionable,6158,60081,triple-receptor negative breast cancer,DOID,5392,MET over exp,"[{'id': 5319, 'pubMedId': 26779812, 'title': 'Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26779812'}]",sensitive,4072,Foretinib + Veliparib,4233
86,Preclinical - Cell culture,"In a preclinical study, ABBV-399 inhibited growth of MET over expressing non-small cell lung cancer cell lines in culture (PMID: 27573171).",Actionable,10001,3908,non-small cell lung carcinoma,DOID,5392,MET over exp,"[{'id': 7833, 'pubMedId': 27573171, 'title': 'ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27573171'}]",sensitive,1363,ABBV-399,4233
87,Phase I,"In a Phase I trial, ABBV-399 resulted in a partial response in 19% (3/16) of patients with non-small cell lung carcinoma while 37.5% (6/16) of patients experienced disease control at 12 weeks (J Clin Oncol 35, 2017 (suppl; abstr 2509)). ",Actionable,11069,3908,non-small cell lung carcinoma,DOID,5392,MET over exp,"[{'id': 9062, 'pubMedId': None, 'title': 'Phase I study of ABBV-399, a c-Met antibody-drug conjugate (ADC), as monotherapy and in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC)', 'url': 'http://abstracts.asco.org/199/AbstView_199_183940.html'}]",sensitive,1363,ABBV-399,4233
88,Preclinical,"In a preclinical study, KRC-00715 induced cell-cycle arrest and inhibited growth of Met-over expressing gastric cancer cell lines in culture and in xenograft models, and did not inhibit growth of cell lines with low Met expression (PMID: 26801760).",Actionable,5498,10534,stomach cancer,DOID,5392,MET over exp,"[{'id': 5073, 'pubMedId': 26801760, 'title': 'Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26801760'}]",sensitive,3871,KRC-00715,4233
89,Preclinical - Cell culture,"In a preclinical study, over expression of MET conferred resistance to Vectibix (panitumumab) in colorectal cancer cell lines in culture (PMID: 23729478).",Actionable,11348,9256,colorectal cancer,DOID,5392,MET over exp,"[{'id': 9245, 'pubMedId': 23729478, 'title': 'Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23729478'}]",resistant,845,Panitumumab,4233
90,Preclinical - Cell culture,"In a preclinical study, Altiratinib (DCC-2701) inhibited Met phosphorylation and proliferation of a non-small cell lung cancer cell line with MET amplification and overexpression in culture (PMID: 26285778).",Actionable,10063,3908,non-small cell lung carcinoma,DOID,1066,MET amp over exp,"[{'id': 7263, 'pubMedId': 26285778, 'title': 'Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26285778'}]",sensitive,1656,Altiratinib,4233
91,Preclinical - Cell line xenograft,"In a preclinical study, Altiratinib (DCC-0701) inhibited Met phosphorylation and proliferation of a gastric cancer cell line with MET amplification and over expression in culture, and inhibited tumor growth and induced tumor regression in xenograft models (PMID: 26285778).",Actionable,10067,10534,stomach cancer,DOID,1066,MET amp over exp,"[{'id': 7263, 'pubMedId': 26285778, 'title': 'Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26285778'}]",sensitive,1656,Altiratinib,4233
92,Preclinical,"In preclinical studies, a MET amplified, gastric carcinoma cell over expressing Met was sensitive to K252a treatment in both culture and mouse model experiments (PMID: 12118367).",Actionable,799,5517,stomach carcinoma,DOID,1066,MET amp over exp,"[{'id': 451, 'pubMedId': 12118367, 'title': 'K252a inhibits the oncogenic properties of Met, the HGF receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12118367'}]",sensitive,1088,K252a,4233
93,Preclinical,"In a preclinical study, a cell line expressing MET H1112Y demonstrated sensitivity to SU11274 treatment (PMID: 19783361).",Actionable,810,162,cancer,DOID,1120,MET H1112Y,"[{'id': 452, 'pubMedId': 15064724, 'title': 'The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15064724'}]",sensitive,1089,SU11274,4233
94,Preclinical,"In a preclinical study, a cell line expressing MET Y1248H showed resistance to SU11274 treatment (PMID: 15064724).",Actionable,812,162,cancer,DOID,1122,MET Y1248H,"[{'id': 452, 'pubMedId': 15064724, 'title': 'The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15064724'}]",resistant,1089,SU11274,4233
95,Preclinical,"In a preclinical study, a cell line expressing MET L1213V showed resistance to SU11274 treatment (PMID: 15064724).",Actionable,811,162,cancer,DOID,1121,MET L1213V,"[{'id': 452, 'pubMedId': 15064724, 'title': 'The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15064724'}]",resistant,1089,SU11274,4233
96,Preclinical,"In a preclinical study, MET T1010I showed sensitivity to Xalkori (crizotinib) in cell culture (PMID: 17483355).",Actionable,878,10000003,Advanced Solid Tumor,JAX,1408,MET T1010I,"[{'id': 333, 'pubMedId': 17483355, 'title': 'An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17483355'}]",sensitive,706,Crizotinib,4233
97,Preclinical,"In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET D1228H in an in vitro kinase assay (PMID: 26285778).",Actionable,10071,10000003,Advanced Solid Tumor,JAX,26646,MET D1228H,"[{'id': 7263, 'pubMedId': 26285778, 'title': 'Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26285778'}]",predicted – sensitive,1656,Altiratinib,4233
98,Preclinical,"In a preclinical study, a cell line expressing MET V1238I demonstrated sensitivity to SU11274 treatment (PMID: 19783361).",Actionable,814,162,cancer,DOID,1124,MET V1238I,"[{'id': 455, 'pubMedId': 19783361, 'title': 'Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19783361'}]",sensitive,1089,SU11274,4233
99,Preclinical,"In a preclinical study, Cometriq (cabozantinib) treatment had no effect on the cellular outgrowth or tumor volume of a TNBC cell line negative for MET expression in culture (PMID: 26432786). ",Actionable,6226,60081,triple-receptor negative breast cancer,DOID,22988,MET negative,"[{'id': 5492, 'pubMedId': 26432786, 'title': 'Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432786'}]",no benefit,998,cabozantinib,4233
100,Clinical Study,"In a clinical case study, a patient with ovarian cancer harboring MET N375S demonstrated sensitivity to the combination treatment, Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for greater than six months (PMID: 25363205). ",Actionable,7769,4001,ovarian carcinoma,DOID,3165,MET N375S,"[{'id': 6478, 'pubMedId': 25363205, 'title': 'Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25363205'}]",sensitive,4517,Bevacizumab + Sorafenib,4233
101,Clinical Study,"In a clinical study, a patient with oral cavity cancer harboring MET N375S demonstrated progressive disease and overall survival of five weeks when treated with Xalkori (crizotinib) (PMID: 28514312). ",Actionable,11049,8618,oral cavity cancer,DOID,3165,MET N375S,"[{'id': 9046, 'pubMedId': 28514312, 'title': 'Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28514312'}]",no benefit,706,Crizotinib,4233
102,Preclinical,"In a preclinical study, cells expressing MET N375S had decreased sensitivity to SU11274 in culture compared to cells expressing wild-type MET (PMID: 19723643).",Actionable,2622,10000003,Advanced Solid Tumor,JAX,3165,MET N375S,"[{'id': 2020, 'pubMedId': 19723643, 'title': 'Ethnic differences and functional analysis of MET mutations in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19723643'}]",decreased response,1089,SU11274,4233
103,Phase I,"In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 100% (2/2) of non-small cell lung carcinoma patients harboring MET exon 14 mutations (J Clin Oncol 34, 2016 (suppl; abstr 9067)).
",Actionable,7064,3908,non-small cell lung carcinoma,DOID,24383,MET exon 14,"[{'id': 6064, 'pubMedId': None, 'title': 'Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).', 'url': 'http://meetinglibrary.asco.org/content/165406-176'}]",sensitive,1065,Capmatinib,4233
104,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells expressing MET del exon14 and MET Y1230C were sensitive to Glesatinib (MGCD265) treatment, demonstrating cell growth inhibition in culture and 52% tumor regression in xenograft models (PMID: 28765324).",Actionable,11781,10000003,Advanced Solid Tumor,JAX,28240,MET del exon14 MET Y1230C,"[{'id': 9757, 'pubMedId': 28765324, 'title': 'Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28765324'}]",sensitive,809,MGCD265,4233
105,Preclinical - Cell culture,"In a preclinical study, a Capmatinib (INC280)-resistant gastric cancer cell line (PMID: 15494073) harboring MET Y1230C also demonstrated resistance when treated with Xalkori (crizotinib) (PMID: 28765324). ",Actionable,11761,10534,stomach cancer,DOID,26644,MET Y1230C,"[{'id': 9757, 'pubMedId': 28765324, 'title': 'Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28765324'}, {'id': 9765, 'pubMedId': 15494073, 'title': 'Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15494073'}]",resistant,706,Crizotinib,4233
106,Preclinical - Cell line xenograft,"In a preclinical study, a transformed cell line expressing MET Y1230C was sensitive to Glesatinib (MGCD265), demonstrating inhibition of cell growth in culture and 88% tumor regression in xenograft models (PMID: 28765324). ",Actionable,11785,10000003,Advanced Solid Tumor,JAX,26644,MET Y1230C,"[{'id': 9757, 'pubMedId': 28765324, 'title': 'Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28765324'}]",sensitive,809,MGCD265,4233
107,Preclinical,"In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET Y1230C in an in vitro kinase assay (PMID: 26285778).",Actionable,10080,10000003,Advanced Solid Tumor,JAX,26644,MET Y1230C,"[{'id': 7263, 'pubMedId': 26285778, 'title': 'Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26285778'}]",predicted – sensitive,1656,Altiratinib,4233
108,Preclinical - Cell culture,"In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) treated with Capmatinib (INC280) in culture for several months developed resistance and was found to harbor MET Y1230C (PMID: 28765324). ",Actionable,11760,10534,stomach cancer,DOID,26644,MET Y1230C,"[{'id': 9757, 'pubMedId': 28765324, 'title': 'Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28765324'}, {'id': 9765, 'pubMedId': 15494073, 'title': 'Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15494073'}]",resistant,1065,Capmatinib,4233
109,Preclinical - Cell culture,"In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells over expressing MET Y1230C in culture (PMID: 23275061).",Actionable,9976,10000003,Advanced Solid Tumor,JAX,26644,MET Y1230C,"[{'id': 331, 'pubMedId': 23275061, 'title': 'LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23275061'}]",sensitive,1030,LY2801653,4233
110,Preclinical - Cell culture,"In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) harboring MET Y1230C was sensitive to treatment with Glesatinib (MGCD265), demonstrating cell growth inhibition in culture (PMID: 28765324). ",Actionable,11770,10534,stomach cancer,DOID,26644,MET Y1230C,"[{'id': 9757, 'pubMedId': 28765324, 'title': 'Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28765324'}, {'id': 9765, 'pubMedId': 15494073, 'title': 'Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15494073'}]",sensitive,809,MGCD265,4233
111,Clinical Study,"In a clinical case study, a patient with a MET amplified esophageal carcinoma that initially responded to AMG 337, developed resistance upon emergence of KRAS G12D (PMID: 26432108). ",Actionable,4081,1107,esophageal carcinoma,DOID,17216,KRAS G12D MET amp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",resistant,1064,AMG 337,4233
112,Preclinical - Pdx,"In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in a patient-derived xenograft model of non-small cell lung cancer harboring EGFR L858R and MET amplification, resulting in tumor growth inhibition (PMID: 27283993).",Actionable,9249,3908,non-small cell lung carcinoma,DOID,26799,EGFR L858R MET amp,"[{'id': 7047, 'pubMedId': 27283993, 'title': 'Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27283993'}]",sensitive,4962,CO1686 + Crizotinib,4233
113,Preclinical,"In a preclinical study, Xalkori (crizotinib) treatment resulted in complete tumor regression in transplant models of TP53-null-luminal breast cancer harboring MET amplification (PMID: 27149990).",Actionable,11535,1612,breast cancer,DOID,28118,MET amp TP53 del,"[{'id': 9604, 'pubMedId': 27149990, 'title': 'Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27149990'}]",sensitive,706,Crizotinib,4233
114,Preclinical - Cell line xenograft,"In a preclinical study, JNJ-61186372 inhibited tumor growth in Tarceva (erlotinib)-resistant non-small cell lung cancer cell line xenograft models harboring an EGFR exon 19 deletion and MET amplification (PMID: 27216193).",Actionable,7503,3908,non-small cell lung carcinoma,DOID,25627,EGFR exon 19 del MET amp,"[{'id': 6352, 'pubMedId': 27216193, 'title': 'A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27216193'}]",sensitive,4491,JNJ-61186372,4233
115,Clinical Study,"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification demonstrated a near complete response when treated with the combination of Savolitinib (AZD6094) and Tagrisso (osimertinib), however, after 36 weeks presented with progression (PMID: 27694386).",Actionable,9533,3910,lung adenocarcinoma,DOID,25627,EGFR exon 19 del MET amp,"[{'id': 7247, 'pubMedId': 27694386, 'title': 'Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27694386'}]",sensitive,2224,Osimertinib + Savolitinib,4233
116,Clinical Study,"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Gilotrif (afatinib) (PMID: 27694386). ",Actionable,9531,3910,lung adenocarcinoma,DOID,25627,EGFR exon 19 del MET amp,"[{'id': 7247, 'pubMedId': 27694386, 'title': 'Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27694386'}]",sensitive,623,Afatinib,4233
117,Clinical Study,"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Tarceva (erlotinib) (PMID: 27694386). ",Actionable,9532,3910,lung adenocarcinoma,DOID,25627,EGFR exon 19 del MET amp,"[{'id': 7247, 'pubMedId': 27694386, 'title': 'Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27694386'}]",resistant,4,Erlotinib,4233
118,Preclinical - Pdx,"In a preclinical study, Xalkori (crizotinib) inhibited tumor grow in patient-derived xenograft models of MET amplified liver cancer (PMID: 26483207).",Actionable,9179,3571,liver cancer,DOID,1629,MET amp,"[{'id': 6982, 'pubMedId': 26483207, 'title': 'c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26483207'}]",sensitive,706,Crizotinib,4233
119,Preclinical,"In a preclinical study, Emibetuzumab (LY2875358) treatment inhibited MET activation and proliferation of tumor cells with MET amplification in culture, and inhibited growth in MET-amplified tumor xenograft models (PMID: 25231402). ",Actionable,1650,10000003,Advanced Solid Tumor,JAX,1629,MET amp,"[{'id': 1762, 'pubMedId': 25231402, 'title': 'LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231402'}]",sensitive,803,Emibetuzumab,4233
120,Preclinical - Pdx,"In a preclinical study, Xalkori (crizotinib) inhibited tumor grow in patient-derived xenograft models of MET amplified non-small cell lung cancer (PMID: 26483207).",Actionable,9178,3908,non-small cell lung carcinoma,DOID,1629,MET amp,"[{'id': 6982, 'pubMedId': 26483207, 'title': 'c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26483207'}]",sensitive,706,Crizotinib,4233
121,Preclinical - Pdx & cell culture,"In a preclinical study, AMG 337 inhibited Met phosphorylation and growth of hepatocellular carcinoma (HCC) cell lines with MET amplification in culture, and inhibited tumor growth in MET-amplified HCC patient-derived xenograft models (PMID: 27196749).",Actionable,6929,684,hepatocellular carcinoma,DOID,1629,MET amp,"[{'id': 5957, 'pubMedId': 27196749, 'title': 'Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196749'}]",sensitive,1064,AMG 337,4233
122,Preclinical,"In a preclinical study, Selumetinib (AZD6244) suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with MET amplification (PMID: 24939055).",Actionable,981,3908,non-small cell lung carcinoma,DOID,1629,MET amp,"[{'id': 642, 'pubMedId': 24939055, 'title': 'Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24939055'}]",sensitive,913,Selumetinib,4233
123,Preclinical - Cell line xenograft,"In a preclinical study, AMG 337 inhibited growth of gastric cancer cell lines in culture, and inhibited growth and induced regression of tumors in MET-amplified gastric cancer cell line xenograft models (PMID: 27196782).",Actionable,9027,10534,stomach cancer,DOID,1629,MET amp,"[{'id': 6878, 'pubMedId': 27196782, 'title': 'In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196782'}]",sensitive,1064,AMG 337,4233
124,Preclinical - Cell culture,"In a preclinical study, SGX523 inhibited survival of MET-amplified non-small cell lung cancer cells in culture (PMID: 26483207).",Actionable,9172,3908,non-small cell lung carcinoma,DOID,1629,MET amp,"[{'id': 6982, 'pubMedId': 26483207, 'title': 'c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26483207'}]",sensitive,916,SGX523,4233
125,Preclinical - Cell line xenograft,"In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of lung cancer cells in culture and tumor regression in cell line xenograft models (PMID: 19832844).",Actionable,10757,1324,lung cancer,DOID,1629,MET amp,"[{'id': 41, 'pubMedId': 19832844, 'title': 'E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19832844'}]",sensitive,1019,Golvatinib,4233
126,Clinical Study,"In a clinical case study, a patient with MET amplified esophageal adenocarcinoma had a partial response to AMG 337 therapy after 2 months of treatment (PMID: 26432108).",Actionable,4100,4914,esophagus adenocarcinoma,DOID,1629,MET amp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",sensitive,1064,AMG 337,4233
127,Clinical Study,"In a retrospective study, advanced solid tumor patients harboring MET amplification only achieved stable disease in 29% (2/7) of the population, while MET-nonamplified patients achieved partial response in 10% (14/134) and stable disease in 36% (48/134) of the population, when treated with Met inhibitors including AMG 337 and EMD 1204831 (PMID: 25326232).",Actionable,5557,10000003,Advanced Solid Tumor,JAX,1629,MET amp,"[{'id': 5104, 'pubMedId': 25326232, 'title': 'Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25326232'}]",decreased response,1064,AMG 337,4233
128,Preclinical - Cell line xenograft,"In a preclinical study, M-COPA reduced Met cell surface expression and downstream signaling and decreased growth of MET-amplified gastric cancer cell lines in culture, and demonstrated antitumor activity in MET-amplified gastric cancer cell line xenograft models (PMID: 27197184).",Actionable,7604,10534,stomach cancer,DOID,1629,MET amp,"[{'id': 6440, 'pubMedId': 27197184, 'title': 'M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27197184'}]",sensitive,4522,M-COPA,4233
129,Phase I,"In a Phase I trial, a gastric cancer patient harboring MET amplification was sensitive to treatment with ARGX-111, demonstrating stable disease, a metabolic response, and a decrease in circulating tumor cells (Journal of Clinical Oncology 33, no. 15_suppl (May 2015) 2580-2580).",Actionable,9970,10534,stomach cancer,DOID,1629,MET amp,"[{'id': 7830, 'pubMedId': None, 'title': 'A phase I, first-in-human study of argx-111, a monoclonal antibody targeting c-met in patients with solid tumors', 'url': 'http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.2580'}]",sensitive,2157,ARGX-111,4233
130,Preclinical,"In a preclinical study, BEZ235 suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with MET amplification (PMID: 24939055).",Actionable,985,3908,non-small cell lung carcinoma,DOID,1629,MET amp,"[{'id': 642, 'pubMedId': 24939055, 'title': 'Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24939055'}]",sensitive,672,BEZ235,4233
131,Clinical Study,"In clinical case studies, patients with MET amplified esophageal cancer responded to AMG 337 therapy (PMID: 26432108).",Actionable,4080,5041,esophageal cancer,DOID,1629,MET amp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",sensitive,1064,AMG 337,4233
132,Phase I,"In a Phase I study, Tepotinib (MSC2156119J) demonstrated safety and preliminary efficacy in advanced solid tumor patients with MET amplification (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2591).",Actionable,3178,10000003,Advanced Solid Tumor,JAX,1629,MET amp,"[{'id': 3666, 'pubMedId': None, 'title': 'Efficacy, safety, biomarkers, and phase II dose modeling in a phase I trial of the oral selective c-Met inhibitor tepotinib (MSC2156119J).', 'url': 'http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2591'}]",sensitive,1398,MSC2156119J,4233
133,Clinical Study,"In a retrospective study, advanced solid tumor patients harboring MET amplification demonstrated worse overall survival (7.23 months) comparing to patients without MET amplification (8.62 months) (PMID: 25326232), suggesting that this may serve as a future prognostic biomarker.",Emerging,5555,10000003,Advanced Solid Tumor,JAX,1629,MET amp,"[{'id': 5104, 'pubMedId': 25326232, 'title': 'Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25326232'}]",not applicable,1776,N/A,4233
134,Preclinical - Cell line xenograft,"In a preclinical study, EMD 1214063 induced tumor regression in mouse cell line xenograft models of gastric carcinoma harboring MET amplification (PMID: 23553846).",Actionable,7727,5517,stomach carcinoma,DOID,1629,MET amp,"[{'id': 336, 'pubMedId': 23553846, 'title': 'EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23553846'}]",sensitive,726,EMD 1214063,4233
135,Preclinical - Cell line xenograft,"In a preclinical study, disruption of multiple kinases with Hsp90 inhibitor Alvespimycin inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture and in cell line xenograft models (PMID: 26483207).",Actionable,9176,3908,non-small cell lung carcinoma,DOID,1629,MET amp,"[{'id': 6982, 'pubMedId': 26483207, 'title': 'c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26483207'}]",predicted – sensitive,627,Alvespimycin,4233
136,Preclinical - Cell line xenograft,"In a preclinical study, SGX523 inhibited Met signaling and proliferation of MET amplified gastric cancer cells in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 19934279).",Actionable,9171,10534,stomach cancer,DOID,1629,MET amp,"[{'id': 6981, 'pubMedId': 19934279, 'title': 'SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19934279'}]",sensitive,916,SGX523,4233
137,Preclinical - Cell line xenograft,"In a preclinical study, ABBV-399 inhibited growth of MET-amplified gastric cancer cell in culture, and induced tumor regression in a MET-amplified gastric cancer cell line xenograft model (PMID: 27573171).",Actionable,9979,10534,stomach cancer,DOID,1629,MET amp,"[{'id': 7833, 'pubMedId': 27573171, 'title': 'ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27573171'}]",sensitive,1363,ABBV-399,4233
138,Preclinical - Cell line xenograft,"In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of gastric cancer cell lines in culture and in cell line xenograft models (PMID: 19832844).",Actionable,10756,10534,stomach cancer,DOID,1629,MET amp,"[{'id': 41, 'pubMedId': 19832844, 'title': 'E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19832844'}]",sensitive,1019,Golvatinib,4233
139,Preclinical - Cell culture,"In a preclinical study, KTN0073-IgG2 inhibited MET phosphorylation and induced MET degradation, and inhibited proliferation of a MET-amplified non-small cell lung cancer cell line in culture (PMID: 27550450).",Actionable,8712,3908,non-small cell lung carcinoma,DOID,1629,MET amp,"[{'id': 6713, 'pubMedId': 27550450, 'title': 'Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550450'}]",sensitive,4799,KTN0073-IgG2,4233
140,Preclinical - Cell culture,"In a preclinical study, the multitarget kinase inhibitor Sprycel (dasatinib) inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207).",Actionable,9173,3908,non-small cell lung carcinoma,DOID,1629,MET amp,"[{'id': 6982, 'pubMedId': 26483207, 'title': 'c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26483207'}]",predicted – sensitive,717,Dasatinib,4233
141,Preclinical - Cell culture,"In a preclinical study, the multitarget kinase inhibitor PP-121 inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207).",Actionable,9174,3908,non-small cell lung carcinoma,DOID,1629,MET amp,"[{'id': 6982, 'pubMedId': 26483207, 'title': 'c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26483207'}]",predicted – sensitive,2251,PP-121,4233
142,Clinical Study,"In a clinical study, MET amplification was associated with resistance to Erbitux (cetuximab) in 2 colorectal cancer patients, and in patient-derived xenograft (PDX) models (PMID: 23729478).",Actionable,11344,9256,colorectal cancer,DOID,1629,MET amp,"[{'id': 9245, 'pubMedId': 23729478, 'title': 'Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23729478'}]",resistant,694,Cetuximab,4233
143,Preclinical - Cell line xenograft,"In a preclinical study, Debio 1347 did not inhibit tumor growth in cell line xenograft models of MET amplified gastric cancer (PMID: 26438159).",Actionable,8495,10534,stomach cancer,DOID,1629,MET amp,"[{'id': 4382, 'pubMedId': 26438159, 'title': 'ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438159'}]",no benefit,1014,FF-284,4233
144,Preclinical - Cell culture,"In a preclinical study, SAR125844 inhibited Met signaling, leading to growth inhibition of MET amplified lung cancer cells in culture (PMID: 25504634).",Actionable,7731,1324,lung cancer,DOID,1629,MET amp,"[{'id': 2009, 'pubMedId': 25504634, 'title': 'The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25504634'}]",sensitive,2159,SAR125844,4233
145,Phase I,"In a Phase I clinical trial, SAR125844 demonstrated safety and preliminary evidence of efficacy in patients with advanced solid tumors, including one patient with Met amplified lung adenocarcinoma (J Clin Oncol 32:5s, 2014 (suppl; abstr 2506)).",Actionable,1774,10000003,Advanced Solid Tumor,JAX,1629,MET amp,"[{'id': 2035, 'pubMedId': None, 'title': 'A first-in-human (FIH) phase I study of SAR125844, a novel selective MET kinase inhibitor, in patients (pts) with advanced solid tumors: Dose escalation results.', 'url': 'http://meetinglibrary.asco.org/content/126762-144'}]",predicted – sensitive,2159,SAR125844,4233
146,Preclinical - Cell line xenograft,"In a preclinical study, KTN0073-IgG2 inhibited MET phosphorylation and induced MET degradation, and inhibited growth of a MET-amplified gastric cancer cell line in culture and in xenograft models (PMID: 27550450).",Actionable,8708,10534,stomach cancer,DOID,1629,MET amp,"[{'id': 6713, 'pubMedId': 27550450, 'title': 'Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550450'}]",sensitive,4799,KTN0073-IgG2,4233
147,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically inhibited proliferation of an Iressa (gefitinib)-resistant NSCLC cell line harboring MET amplification in culture and in cell line xenograft models (PMID: 24939055).",Actionable,988,3908,non-small cell lung carcinoma,DOID,1629,MET amp,"[{'id': 642, 'pubMedId': 24939055, 'title': 'Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24939055'}]",sensitive,1420,Selumetinib + BEZ235,4233
148,Preclinical,"In a preclinical study, TAE226 treatment inhibited proliferation of gastric cancer cell lines harboring MET amplification in culture (PMID: 26090892).",Actionable,3937,10534,stomach cancer,DOID,1629,MET amp,"[{'id': 4301, 'pubMedId': 26090892, 'title': 'TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26090892'}]",sensitive,2086,TAE226,4233
149,Preclinical,"In a preclinical study, MET amplified gastric cancer cell lines were sensitive to TAS-115, resulting in suppression of cell proliferation in culture (PMID: 24140932). ",Actionable,5898,10534,stomach cancer,DOID,1629,MET amp,"[{'id': 5188, 'pubMedId': 24140932, 'title': 'The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24140932'}]",sensitive,3976,TAS-115,4233
150,Preclinical - Cell line xenograft,"In a preclinical study, SAR125844 inhibited Met signaling leading to growth inhibition of MET amplified gastric cancer cell lines  in culture and in xenograft models (PMID: 25504634).",Actionable,1773,10534,stomach cancer,DOID,1629,MET amp,"[{'id': 2009, 'pubMedId': 25504634, 'title': 'The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25504634'}]",sensitive,2159,SAR125844,4233
151,Phase I,"In a Phase I trial, INC280 displayed safety and preliminary efficacy in patients with MET dependent solid tumors (J Clin Oncol 32:5s, 2014 (suppl; abstr 2520)).",Actionable,1634,10000003,Advanced Solid Tumor,JAX,1629,MET amp,"[{'id': 4034, 'pubMedId': None, 'title': 'Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/128427-144'}]",predicted – sensitive,1065,Capmatinib,4233
152,Preclinical - Cell culture,"In a preclinical study, AMG 337 inhibited growth of MET-amplified lung cancer cell lines in culture (PMID: 27196782).",Actionable,9028,1324,lung cancer,DOID,1629,MET amp,"[{'id': 6878, 'pubMedId': 27196782, 'title': 'In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196782'}]",sensitive,1064,AMG 337,4233
153,Clinical Study,"In a retrospective study, advanced solid tumor patients harboring MET amplification only achieved stable disease in 29% (2/7) of the population, while MET-nonamplified patients achieved partial response in 10% (14/134) and stable disease in 36% (48/134) of the population, when treated with Met inhibitors including AMG 337 and EMD 1204831 (PMID: 25326232).",Actionable,5558,10000003,Advanced Solid Tumor,JAX,1629,MET amp,"[{'id': 5104, 'pubMedId': 25326232, 'title': 'Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25326232'}]",decreased response,725,EMD 1204831,4233
154,Phase I,"In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 63% (5/8) of MET amplified non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).",Actionable,7066,3908,non-small cell lung carcinoma,DOID,1629,MET amp,"[{'id': 6064, 'pubMedId': None, 'title': 'Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).', 'url': 'http://meetinglibrary.asco.org/content/165406-176'}]",sensitive,1065,Capmatinib,4233
155,Preclinical - Pdx,"In a preclinical study, JNJ-38877605 inhibited tumor growth in colorectal cancer patient-derived xenograft models with MET amplification (PMID: 23729478).",Actionable,11345,9256,colorectal cancer,DOID,1629,MET amp,"[{'id': 9245, 'pubMedId': 23729478, 'title': 'Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23729478'}]",sensitive,783,JNJ 38877605,4233
156,Phase II,"In a Phase II trial, treatment with Savolitinib (AZD6094) resulted in an overall response rate (ORR) of 18% (8/44, all partial responses) in the subgroup of patients with MET-driven papillary renal cell carcinoma (PRCC), which included patients with MET amplification, compared to an ORR of 0% (0/46) in patients with MET-independent PRCC (PMID: 28644771; NCT02127710).",Actionable,11441,4465,papillary renal cell carcinoma,DOID,1629,MET amp,"[{'id': 9389, 'pubMedId': 28644771, 'title': 'Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28644771'}]",sensitive,2161,Savolitinib,4233
157,Preclinical - Pdx,"In a preclinical study, Savolitinib (AZD6094) demonstrated antitumor activity in patient-derived papillary renal cell carcinoma xenograft models harboring MET amplification (PMID: 25779944). ",Actionable,2460,4465,papillary renal cell carcinoma,DOID,1629,MET amp,"[{'id': 3106, 'pubMedId': 25779944, 'title': 'The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25779944'}]",sensitive,2161,Savolitinib,4233
158,Phase I,"In a Phase I trial, ABT-700 demonstrated safety and preliminary efficacy in patients with MET-amplified advanced solid tumors, including a patient with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 2507)).",Actionable,1698,10000003,Advanced Solid Tumor,JAX,1629,MET amp,"[{'id': 1811, 'pubMedId': None, 'title': 'Phase 1, open-label, dose-escalation, and expansion study of ABT-700, an anti-C-met antibody, in patients (pts) with advanced solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/134301-144'}]",sensitive,1063,ABT-700,4233
159,Preclinical - Cell culture,"In a preclinical study, disruption of multiple kinases with Hsp90 inhibitor Ganetespib inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207).",Actionable,9175,3908,non-small cell lung carcinoma,DOID,1629,MET amp,"[{'id': 6982, 'pubMedId': 26483207, 'title': 'c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26483207'}]",predicted – sensitive,745,Ganetespib,4233
160,Preclinical - Cell line xenograft,"In a preclinical study, EMD 1214063 induced tumor regression in mouse cell line xenograft models of non-small cell lung carcinoma harboring MET amplification (PMID: 23553846).",Actionable,7728,3908,non-small cell lung carcinoma,DOID,1629,MET amp,"[{'id': 336, 'pubMedId': 23553846, 'title': 'EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23553846'}]",sensitive,726,EMD 1214063,4233
161,Preclinical - Pdx & cell culture,"In a preclinical study, Sym015 inhibited growth of cancer cell lines with MET amplification in culture, and inhibited tumor growth in MET-amplified patient-derived xenograft (PDX) models (Cancer Res July 15 2016 (76) (14 Supplement) 1219).",Actionable,9967,10000003,Advanced Solid Tumor,JAX,1629,MET amp,"[{'id': 7828, 'pubMedId': None, 'title': 'Abstract 1219: Sym015, a novel antibody mixture targeting non-overlapping epitopes of MET, effectively inhibits growth of MET dependent tumors and overcomes resistance to a single monoclonal antibody', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1219'}]",sensitive,4322,SYM015,4233
162,Preclinical,"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring MET amplification in culture (PMID: 26090892).",Actionable,3936,3908,non-small cell lung carcinoma,DOID,1629,MET amp,"[{'id': 4301, 'pubMedId': 26090892, 'title': 'TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26090892'}]",sensitive,2086,TAE226,4233
163,Preclinical - Pdx,"In a preclinical study, treatment with Gilotrif (afatinib) did not demonstrate benefit in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification, with all treated mice demonstrating progression (PMID: 28961841).",Actionable,12157,3910,lung adenocarcinoma,DOID,26798,EGFR E746_A750del MET amp,"[{'id': 10116, 'pubMedId': 28961841, 'title': 'Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28961841'}]",no benefit,623,Afatinib,4233
164,Preclinical - Cell line xenograft,"In a preclinical study, the addition of NPS-1034 to treatment with Iressa (gefitinib) overcame Iressa (gefitinib) resistance in a cell line xenograft model of non-small cell lung cancer reported to harbor EGFR E746_A750del (PMID: 23542356), which has acquired resistance to Iressa (gefitinib) due to MET amplification and over expression, resulting in tumor growth inhibition (PMID: 24165158).",Actionable,9655,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,"[{'id': 7367, 'pubMedId': 24165158, 'title': 'MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24165158'}, {'id': 7368, 'pubMedId': 23542356, 'title': 'Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23542356'}]",sensitive,5116,Gefitinib + NPS-1034,4233
165,Preclinical - Pdx,"In a preclinical study, treatment with Capmatinib (INC280) resulted in improved survival in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification (PMID: 28961841).",Actionable,12148,3910,lung adenocarcinoma,DOID,26798,EGFR E746_A750del MET amp,"[{'id': 10116, 'pubMedId': 28961841, 'title': 'Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28961841'}]",sensitive,1065,Capmatinib,4233
166,Clinical Study,"In a clinical case study, a patient with metastatic lung adenocarcinoma harboring EGFR E746_A750del (referred to as K745_A750delinsK) and T790M demonstrated an initial response, but subsequent progression, of the brain metastasis following Tagrisso (osimertinib) treatment, and analysis of the brain metastasis showed loss of EGFR T790M as well as acquisition of high-level MET amplification, and resistance to Tagrisso (osimertinib) was recapitulated in a patient-derived xenograft (PDX) model (PMID: 28961841)",Actionable,12147,3910,lung adenocarcinoma,DOID,26798,EGFR E746_A750del MET amp,"[{'id': 10116, 'pubMedId': 28961841, 'title': 'Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28961841'}]",resistant,660,Osimertinib,4233
167,Preclinical - Pdx,"In a preclinical study, treatment with Capmatinib (INC280) plus Gilotrif (afatinib) resulted in improved survival with no evidence of tumor 300 days post-transplantation in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification (PMID: 28961841).",Actionable,12150,3910,lung adenocarcinoma,DOID,26798,EGFR E746_A750del MET amp,"[{'id': 10116, 'pubMedId': 28961841, 'title': 'Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28961841'}]",sensitive,6313,Afatinib + Capmatinib,4233
168,Preclinical - Cell culture,"In a preclinical study, acquired amplification of MET conferred resistance to Iressa (gefitinib) in a non-small cell lung cancer cell line harboring EGFR E746_A750del in culture (PMID: 27612490).",Actionable,9557,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,"[{'id': 7271, 'pubMedId': 27612490, 'title': 'Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27612490'}]",resistant,751,Gefitinib,4233
169,Preclinical - Cell line xenograft,"In a preclinical study, emergence of MET amplification was associated with resistance to Rociletinib (CO1686) in non-small cell lung cancer cell line xenograft models harboring EGFR E746_A750del (PMID: 27283993).",Actionable,9247,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,"[{'id': 7047, 'pubMedId': 27283993, 'title': 'Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27283993'}]",resistant,1003,CO1686,4233
170,Preclinical - Cell culture,"In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in non-small cell lung cancer cell line harboring EGFR E746_A750del and MET amplification in culture (PMID: 27283993).",Actionable,9248,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,"[{'id': 7047, 'pubMedId': 27283993, 'title': 'Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27283993'}]",sensitive,4962,CO1686 + Crizotinib,4233
171,Preclinical - Cell line xenograft,"In a preclinical study, the combination of PHA-665752 and Iressa (gefitinib) overcame Iressa (gefitinib) resistance in a cell line xenograft model of non-small cell lung cancer reported to harbor EGFR E746_A750del (PMID: 23542356), which has acquired resistance to Iressa (gefitinib) due to MET amplification and over expression, resulting in tumor growth inhibition (PMID: 24165158).",Actionable,9656,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,"[{'id': 7367, 'pubMedId': 24165158, 'title': 'MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24165158'}, {'id': 7368, 'pubMedId': 23542356, 'title': 'Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23542356'}]",sensitive,5094,Gefitinib + PHA-665752,4233
172,Preclinical - Cell culture,"In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with EGFR and MET copy number gain in culture (PMID: 27595477).",Actionable,11557,4914,esophagus adenocarcinoma,DOID,17304,EGFR amp MET amp,"[{'id': 9641, 'pubMedId': 27595477, 'title': 'Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27595477'}]",sensitive,3440,Crizotinib + Lapatinib,4233
173,Preclinical,"In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was sensitive to inhibition by Tykerb (lapatinib) and Xalkori (crizotinib) in culture (PMID: 26432108).",Actionable,4092,1107,esophageal carcinoma,DOID,17215,ERBB2 amp MET amp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",sensitive,3440,Crizotinib + Lapatinib,4233
174,Preclinical - Cell culture,"In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and MET amplification in culture (PMID: 27595477).",Actionable,11555,4914,esophagus adenocarcinoma,DOID,17215,ERBB2 amp MET amp,"[{'id': 9641, 'pubMedId': 27595477, 'title': 'Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27595477'}]",sensitive,3440,Crizotinib + Lapatinib,4233
175,Clinical Study,"In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma had near complete regression of the disease after 2 months of treatment with Herceptin (trastuzumab), Xalkori (crizotinib) and weekly Taxol (paclitaxel) (PMID: 26432108).",Actionable,4094,3717,gastric adenocarcinoma,DOID,17215,ERBB2 amp MET amp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",sensitive,3442,Crizotinib + Trastuzumab + Paclitaxel,4233
176,Preclinical,"In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 and MET was resistant to Tykerb (lapatinib) in culture (PMID: 26432108).",Actionable,4090,1107,esophageal carcinoma,DOID,17215,ERBB2 amp MET amp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",resistant,787,Lapatinib,4233
177,Clinical Study,"In a clinical case study, a patient with ERBB2 (HER2) and MET amplified gastric adenocarcinoma was insensitive to treatment with Herceptin (trastuzumab) and FOLFOX (PMID: 26432108).",Actionable,4091,3717,gastric adenocarcinoma,DOID,17215,ERBB2 amp MET amp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",resistant,3439,Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin,4233
178,Clinical Study,"In a clinical case study, a patient with ERBB2 (HER2) and MET amplified gastric adenocarcinoma was insensitive to AMG 337 therapy (PMID: 26432108).",Actionable,4084,3717,gastric adenocarcinoma,DOID,17215,ERBB2 amp MET amp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",resistant,1064,AMG 337,4233
179,Preclinical,"In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 and MET was resistant to Xalkori (crizotinib) in culture (PMID: 26432108).",Actionable,4089,1107,esophageal carcinoma,DOID,17215,ERBB2 amp MET amp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",resistant,706,Crizotinib,4233
180,Clinical Study,"In a clinical case study, a patient with ERBB2 (HER2) amplified gastric adenocarcinoma progressed rapidly when treated with Herceptin (trastuzumab) with Xeloda (capecitabine), Eloxatin (oxaliplatin), and Avastin (bevacizumab), and reprofiling of the tumor revealed co-amplification of MET (PMID: 26432108).",Actionable,4093,3717,gastric adenocarcinoma,DOID,17215,ERBB2 amp MET amp,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",resistant,3441,Bevacizumab + Capecitabine + Oxaliplatin + Trastuzumab,4233
181,Clinical Study,"In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M and resistance to Tagrisso (osimertinib) following acquired MET amplification, demonstrated some improvement in symptoms with treatment with Xalkori (crizotinib) (PMID: 27393507).",Actionable,9238,3910,lung adenocarcinoma,DOID,18241,EGFR exon 19 del EGFR T790M MET amp,"[{'id': 7045, 'pubMedId': 27393507, 'title': 'High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27393507'}]",predicted – sensitive,706,Crizotinib,4233
182,Clinical Study,"In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M developed resistance to Tagrisso (osimertinib), and was found to have acquired high level amplification of MET (PMID: 27393507).",Actionable,9236,3910,lung adenocarcinoma,DOID,18241,EGFR exon 19 del EGFR T790M MET amp,"[{'id': 7045, 'pubMedId': 27393507, 'title': 'High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27393507'}]",resistant,660,Osimertinib,4233
183,Preclinical,"In a preclinical study, amplification of MET conferred resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring an EGFR exon 19 deletion mutation in culture (PMID: 17463250).",Actionable,2471,3908,non-small cell lung carcinoma,DOID,8120,EGFR del exon19 MET amp,"[{'id': 3145, 'pubMedId': 17463250, 'title': 'MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17463250'}]",resistant,751,Gefitinib,4233
184,Clinical Study,"In a clinical case study, a patient with a carcinoma of unknown primary harboring MET amplification and KRAS G12V demonstrated a durable response following treatment with Xalkori (crizotinib) (PMID: 25232318).",Actionable,7753,305,carcinoma,DOID,25979,KRAS G12V MET amp,"[{'id': 6473, 'pubMedId': 25232318, 'title': 'Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25232318'}]",predicted – sensitive,706,Crizotinib,4233
185,Preclinical,"In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Rociletinib (CO-1686) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416).",Actionable,8801,3910,lung adenocarcinoma,DOID,26437,EGFR T790M MET amp,"[{'id': 6756, 'pubMedId': 27252416, 'title': 'Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27252416'}]",resistant,1003,CO1686,4233
186,Preclinical,"In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Tagrisso (osimertinib) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416).",Actionable,8802,3910,lung adenocarcinoma,DOID,26437,EGFR T790M MET amp,"[{'id': 6756, 'pubMedId': 27252416, 'title': 'Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27252416'}]",resistant,660,Osimertinib,4233
187,Clinical Study,"In an analysis of EGFR T790M-positive non-small cell lung cancer patients, emergence of MET amplification was identified in 26% (28/43) of patients with acquired resistance to Rociletinib (CO1686), and patients with MET amplification prior to Rociletinib (CO1686) treatment demonstrated a decreased response compared to patients without MET amplification (PMID: 27283993).",Actionable,9246,3908,non-small cell lung carcinoma,DOID,26437,EGFR T790M MET amp,"[{'id': 7047, 'pubMedId': 27283993, 'title': 'Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27283993'}]",resistant,1003,CO1686,4233
188,Clinical Study,"In a clinical case study, a lung adenocarcinoma patient previously harboring MET amp, MET del exon14, MET D1228N, MET Y1230H, MET Y1230S, and MET G1163R demonstrated a decrease in lesion size when treated with Glesatinib (MGCD265), however, progression ensued and plasma testing indicated the patient lost Y1230H and Y1230S, but acquired MET L1195V (PMID: 28765324). ",Actionable,11787,3910,lung adenocarcinoma,DOID,28246,MET amp MET del exon14 MET D1228N MET G1163R MET L1195V,"[{'id': 9757, 'pubMedId': 28765324, 'title': 'Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28765324'}]",resistant,809,MGCD265,4233
189,Preclinical - Pdx,"In a preclinical study, a lung cancer patient-derived xenograft (PDX) model harboring MET amplification and MET del exon14 demonstrated tumor regression when treated with Glesatinib (MGCD265) (PMID: 28765324). ",Actionable,11767,1324,lung cancer,DOID,28229,MET amp MET del exon14,"[{'id': 9757, 'pubMedId': 28765324, 'title': 'Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28765324'}]",sensitive,809,MGCD265,4233
190,Clinical Study,"In a clinical case study, a lung adenocarcinoma patient co-harboring MET del exon14 and MET amp was sensitive to Xalkori (crizotinib), demonstrating a partial response for 8 months (PMID: 28765324). ",Actionable,11786,3910,lung adenocarcinoma,DOID,28229,MET amp MET del exon14,"[{'id': 9757, 'pubMedId': 28765324, 'title': 'Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28765324'}]",sensitive,706,Crizotinib,4233
191,Preclinical - Cell culture,"In a preclinical study, a MET-amplified lung cancer cell line harboring KRAS G12A was not sensitive to growth inhibition by AMG 337 in culture (PMID: 27196782).",Actionable,9029,1324,lung cancer,DOID,25935,KRAS G12A MET amp,"[{'id': 6878, 'pubMedId': 27196782, 'title': 'In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196782'}]",resistant,1064,AMG 337,4233
192,Preclinical - Cell culture,"In a preclinical study, MET amplified lung cancer cells harboring KRAS G12A were insensitive to SAR125844-mediated growth inhibition in culture (PMID: 25504634).",Actionable,7733,1324,lung cancer,DOID,25935,KRAS G12A MET amp,"[{'id': 2009, 'pubMedId': 25504634, 'title': 'The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25504634'}]",resistant,2159,SAR125844,4233
193,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells expressing MET del exon14 and MET D1228N were sensitive to Glesatinib (MGCD265) treatment, demonstrating cell growth inhibition in culture and 21% tumor regression in xenograft models (PMID: 28765324).",Actionable,11775,10000003,Advanced Solid Tumor,JAX,27264,MET del exon14 MET D1228N,"[{'id': 9757, 'pubMedId': 28765324, 'title': 'Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28765324'}]",sensitive,809,MGCD265,4233
194,Clinical Study,"In a clinical case study, a patient with squamous cell lung cancer harboring a MET exon 14 skipping mutation was determined to have acquired MET D1228N after progression on Xalkori (crizotinib) therapy (PMID: 27343442).",Actionable,10126,3907,lung squamous cell carcinoma,DOID,27264,MET del exon14 MET D1228N,"[{'id': 8066, 'pubMedId': 27343442, 'title': 'Acquired Resistance to Crizotinib in NSCLC with MET\xa0Exon 14 Skipping.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27343442'}]",predicted – resistant,706,Crizotinib,4233
195,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing MET del exon14 were sensitive to Capmatinib (INC280) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324). ",Actionable,11773,10000003,Advanced Solid Tumor,JAX,26413,MET del exon14,"[{'id': 9757, 'pubMedId': 28765324, 'title': 'Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28765324'}]",sensitive,1065,Capmatinib,4233
196,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing MET del exon14 were sensitive to Xalkori (crizotinib) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324). ",Actionable,11774,10000003,Advanced Solid Tumor,JAX,26413,MET del exon14,"[{'id': 9757, 'pubMedId': 28765324, 'title': 'Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28765324'}]",sensitive,706,Crizotinib,4233
197,Clinical Study,"In a clinical study, three patients with lung adenocarcinoma harboring MET del exon14 demonstrated partial responses when treated with Xalkori (crizotinib) (PMID: 25971939).
",Actionable,9565,3910,lung adenocarcinoma,DOID,26413,MET del exon14,"[{'id': 7281, 'pubMedId': 25971939, 'title': 'Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25971939'}]",sensitive,706,Crizotinib,4233
198,Clinical Study,"In a clinical study, a patient with lung adenocarcinoma harboring MET del exon14 demonstrated a 66% reduction in target lesion size and maintained a partial response for 7 months when treated with Glesatinib (MGCD265) (PMID: 28765324). ",Actionable,11759,3910,lung adenocarcinoma,DOID,26413,MET del exon14,"[{'id': 9757, 'pubMedId': 28765324, 'title': 'Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28765324'}]",sensitive,809,MGCD265,4233
199,Preclinical - Pdx & cell culture,"In a preclinical study, Sym015 inhibited growth of cancer cell lines harboring MET exon 14 deletion in culture, and inhibited tumor growth in patient-derived xenograft (PDX) models with MET exon 14 deletion (Cancer Res July 15 2016 (76) (14 Supplement) 1219).",Actionable,9968,10000003,Advanced Solid Tumor,JAX,26413,MET del exon14,"[{'id': 7828, 'pubMedId': None, 'title': 'Abstract 1219: Sym015, a novel antibody mixture targeting non-overlapping epitopes of MET, effectively inhibits growth of MET dependent tumors and overcomes resistance to a single monoclonal antibody', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1219'}]",sensitive,4322,SYM015,4233
200,Preclinical - Cell culture,"In a preclinical study, KTN0073-IgG1 inhibited growth of a non-small cell lung cancer cell line harboring deletion of MET exon 14 in culture (PMID: 27550450).",Actionable,8737,3908,non-small cell lung carcinoma,DOID,26413,MET del exon14,"[{'id': 6713, 'pubMedId': 27550450, 'title': 'Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550450'}]",sensitive,4802,KTN0073-IgG1,4233
201,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing MET del exon14 were sensitive to Glesatinib (MGCD265) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324). ",Actionable,11772,10000003,Advanced Solid Tumor,JAX,26413,MET del exon14,"[{'id': 9757, 'pubMedId': 28765324, 'title': 'Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28765324'}]",sensitive,809,MGCD265,4233
202,Clinical Study,"In a clinical case study, Capmatinib (INC280) treatment resulted in a decreased tumor volume of 61% in a patient with lung squamous cell carcinoma harboring MET del exon14 (PMID: 25971938).",Actionable,9563,3907,lung squamous cell carcinoma,DOID,26413,MET del exon14,"[{'id': 6712, 'pubMedId': 25971938, 'title': 'Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25971938'}]",sensitive,1065,Capmatinib,4233
203,Clinical Study,"In a clinical study, a patient with lung adenocarcinoma harboring MET del exon14 demonstrated a complete response via PERCIST criteria when treated with Cometriq (Cabometyx, cabozantinib) (PMID: 25971939).",Actionable,9564,3910,lung adenocarcinoma,DOID,26413,MET del exon14,"[{'id': 7281, 'pubMedId': 25971939, 'title': 'Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25971939'}]",sensitive,998,cabozantinib,4233
204,Preclinical - Cell line xenograft,"In a preclinical study, Onartuzumab inhibited tumor growth and decreased MET expression in a non-small cell lung cancer xenograft model harboring MET exon 14 deletion (PMID: 23882082).",Actionable,9973,3908,non-small cell lung carcinoma,DOID,26413,MET del exon14,"[{'id': 2006, 'pubMedId': 23882082, 'title': 'Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23882082'}]",sensitive,838,Onartuzumab,4233
205,Clinical Study,"In a clinical case study, Capmatinib (INC280) treatment resulted in decreased tumor volume by 53% in a patient with large cell lung carcinoma harboring MET del exon14 and TP53 N30fs*14 (PMID: 25971938).",Actionable,9562,4556,lung large cell carcinoma,DOID,26905,MET del exon14 TP53 N30fs*14,"[{'id': 6712, 'pubMedId': 25971938, 'title': 'Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25971938'}]",sensitive,1065,Capmatinib,4233
206,Clinical Study,"In a clinical case study, Xalkori (crizotinib) treatment resulted in a decrease in tumor volume by more than 60% in a patient with histiocytic sarcoma harboring MET del exon14 and TP53 R175H (PMID: 25971938).",Actionable,9561,5621,histiocytic and dendritic cell cancer,DOID,26903,MET del exon14 TP53 R175H,"[{'id': 6712, 'pubMedId': 25971938, 'title': 'Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25971938'}]",sensitive,706,Crizotinib,4233
207,Clinical Study,"In a clinical study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312).",Actionable,11053,1909,melanoma,DOID,27904,CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H,"[{'id': 9046, 'pubMedId': 28514312, 'title': 'Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28514312'}]",sensitive,5833,Imatinib + Carboplatin + Paclitaxel,4233
208,Preclinical,"In a preclinical study, decreasing Brca2 expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells with low expression of Met to Rubraca (rucaparib) in culture (PMID: 26779812).",Actionable,6149,60081,triple-receptor negative breast cancer,DOID,22728,BRCA2 dec exp MET dec exp,"[{'id': 5319, 'pubMedId': 26779812, 'title': 'Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26779812'}]",sensitive,906,Rucaparib,4233
209,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cell lines with decreased Met expression via shRNA knockdown demonstrated increased sensitivity to Veliparib (ABT-888) induced growth and colony formation inhibition in culture (PMID: 26779812).",Actionable,6143,60081,triple-receptor negative breast cancer,DOID,22706,MET dec exp,"[{'id': 5319, 'pubMedId': 26779812, 'title': 'Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26779812'}]",sensitive,954,Veliparib,4233
210,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cell lines with decreased Met expression via shRNA knockdown demonstrated increased sensitivity to Lynparza (olaparib) induced growth and colony formation inhibition in culture (PMID: 26779812).",Actionable,6142,60081,triple-receptor negative breast cancer,DOID,22706,MET dec exp,"[{'id': 5319, 'pubMedId': 26779812, 'title': 'Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26779812'}]",sensitive,837,Olaparib,4233
211,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cell lines with decreased Met expression via shRNA knockdown demonstrated increased sensitivity to Rubraca (rucaparib) induced growth and colony formation inhibition in culture (PMID: 26779812).",Actionable,6144,60081,triple-receptor negative breast cancer,DOID,22706,MET dec exp,"[{'id': 5319, 'pubMedId': 26779812, 'title': 'Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26779812'}]",sensitive,906,Rucaparib,4233
212,Preclinical,"In a preclinical study, decreasing Brca1 expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells with low expression of Met to Rubraca (rucaparib) in culture (PMID: 26779812).",Actionable,6148,60081,triple-receptor negative breast cancer,DOID,22726,BRCA1 dec exp MET dec exp,"[{'id': 5319, 'pubMedId': 26779812, 'title': 'Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26779812'}]",sensitive,906,Rucaparib,4233
213,Preclinical,"In a preclinical study, Amuvatinib (MP470) demonstrated efficacy in reducing Met phosphorylation and inducing apoptosis in cultured myeloma cells (PMID: 24326130).",Actionable,1756,70004,myeloid neoplasm,DOID,587,MET wild-type,"[{'id': 2025, 'pubMedId': 24326130, 'title': 'Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24326130'}]",sensitive,632,Amuvatinib,4233
214,Preclinical,"In a preclinical study, BMS-777607 (ASLAN002) demonstrated efficacy in inhibiting migration and invasion of cultured prostate cancer cells expressing wild-type Met (PMID: 20515943).",Actionable,1758,10283,prostate cancer,DOID,587,MET wild-type,"[{'id': 2000, 'pubMedId': 20515943, 'title': 'BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20515943'}]",sensitive,687,BMS-777607,4233
215,Preclinical - Pdx & cell culture,"In a preclinical study, LY2801653 inhibited phosphorylation of Met, resulting in inhibition of cholangiocarcinoma proliferation in cell culture and growth of tumors in Pdx models (PMID: 26757360).",Actionable,9581,4947,cholangiocarcinoma,DOID,587,MET wild-type,"[{'id': 7287, 'pubMedId': 26757360, 'title': 'Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26757360'}]",sensitive,1030,LY2801653,4233
216,Preclinical,"In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET M1250T in an in vitro kinase assay (PMID: 26285778).",Actionable,10079,10000003,Advanced Solid Tumor,JAX,24002,MET M1250T,"[{'id': 7263, 'pubMedId': 26285778, 'title': 'Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26285778'}]",predicted – sensitive,1656,Altiratinib,4233
217,Preclinical,"In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET D1228N in an in vitro kinase assay (PMID: 26285778).",Actionable,10072,10000003,Advanced Solid Tumor,JAX,26645,MET D1228N,"[{'id': 7263, 'pubMedId': 26285778, 'title': 'Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26285778'}]",predicted – sensitive,1656,Altiratinib,4233
218,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were resistant to treatment with Savolitinib (AZD6094), demonstrating sustained cell growth in culture (PMID: 28396313). ",Actionable,11733,10000003,Advanced Solid Tumor,JAX,26645,MET D1228N,"[{'id': 9744, 'pubMedId': 28396313, 'title': 'Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28396313'}]",predicted – resistant,2161,Savolitinib,4233
219,Preclinical - Cell culture,"In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells over expressing MET D1228N in culture (PMID: 23275061).",Actionable,9977,10000003,Advanced Solid Tumor,JAX,26645,MET D1228N,"[{'id': 331, 'pubMedId': 23275061, 'title': 'LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23275061'}]",sensitive,1030,LY2801653,4233
220,Preclinical,"In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were resistant to treatment with Capmatinib (INC280), demonstrating sustained cell growth in culture and minimal tumor growth inhibition in mouse models (PMID: 28396313). ",Actionable,11730,10000003,Advanced Solid Tumor,JAX,26645,MET D1228N,"[{'id': 9744, 'pubMedId': 28396313, 'title': 'Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28396313'}]",predicted – resistant,1065,Capmatinib,4233
221,Preclinical,"In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were resistant to treatment with Xalkori (crizotinib), demonstrating sustained cell growth in culture and minimal tumor growth inhibition in mouse models (PMID: 28396313). ",Actionable,11731,10000003,Advanced Solid Tumor,JAX,26645,MET D1228N,"[{'id': 9744, 'pubMedId': 28396313, 'title': 'Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28396313'}]",predicted – resistant,706,Crizotinib,4233
222,Preclinical,"In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were sensitive to treatment with Cometriq (Cabometyx, cabozantinib), demonstrating inhibition of cell growth in culture and tumor growth inhibition in mouse models (PMID: 28396313). ",Actionable,11729,10000003,Advanced Solid Tumor,JAX,26645,MET D1228N,"[{'id': 9744, 'pubMedId': 28396313, 'title': 'Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28396313'}]",predicted – sensitive,998,cabozantinib,4233
223,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to D1228N in humans) were sensitive to treatment with BMS-777607 (ASLAN002), demonstrating inhibition of cell growth in culture (PMID: 28396313). ",Actionable,11735,10000003,Advanced Solid Tumor,JAX,26645,MET D1228N,"[{'id': 9744, 'pubMedId': 28396313, 'title': 'Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28396313'}]",predicted – sensitive,687,BMS-777607,4233
224,Clinical Study,"In a clinical case study, a GIST patient harboring KIT S476I and MET R988C demonstrated sensitivity to the combination treatment, Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for 6 months (PMID: 25363205). ",Actionable,7766,9253,gastrointestinal stromal tumor,DOID,26035,KIT S476I MET R988C,"[{'id': 6478, 'pubMedId': 25363205, 'title': 'Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25363205'}]",sensitive,4517,Bevacizumab + Sorafenib,4233
225,Preclinical,"In a preclinical study, cultured cells with MET R998C mutations demonstrated sensitivity to Xalkori (crizotinib, PF-2341066) (PMID: 17483355).",Actionable,559,10000003,Advanced Solid Tumor,JAX,810,MET R988C,"[{'id': 333, 'pubMedId': 17483355, 'title': 'An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17483355'}]",sensitive,706,Crizotinib,4233
226,Preclinical,"In a preclinical study, a cell line expressing MET V1110I demonstrated sensitivity to SU11274 treatment (PMID: 19783361).",Actionable,813,162,cancer,DOID,1123,MET V1110I,"[{'id': 455, 'pubMedId': 19783361, 'title': 'Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19783361'}]",sensitive,1089,SU11274,4233
227,Preclinical,"In a preclinical study, a cell line expressing MET V1206I demonstrated sensitivity to SU11274 treatment (PMID: 19783361).",Actionable,815,162,cancer,DOID,1125,MET V1206L,"[{'id': 455, 'pubMedId': 19783361, 'title': 'Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19783361'}]",sensitive,1089,SU11274,4233
0,Preclinical - Cell culture,"In a preclinical study, MLH1 deficient colon cancer cell lines were sensitive to KU60648 in culture, demonstrating decreased cell viability and reduced colony formation (PMID: 28224663). ",Actionable,11383,219,colon cancer,DOID,25004,MLH1 loss,"[{'id': 9237, 'pubMedId': 28224663, 'title': 'Loss of MLH1 sensitizes colon cancer cells to DNA-PKcs inhibitor KU60648.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28224663'}]",sensitive,5967,KU60648,4292
1,Preclinical,"In a preclinical study, MLH1 inactivation through hypermethylation was associated with high microsatellite instability (MSI-H) colorectal carcinoma by whole genome sequencing of tumor samples (PMID: 22810696), suggesting it may be a potential biomarker.",Emerging,5782,9256,colorectal cancer,DOID,16867,MLH1 inact mut,"[{'id': 5152, 'pubMedId': 22810696, 'title': 'Comprehensive molecular characterization of human colon and rectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22810696'}]",not applicable,1776,N/A,4292
2,Phase I,"Clinical trials are currently enrolling patients with mutations in MLH1 (clinicaltrials.gov, Oct 2017).",Actionable,5783,10000003,Advanced Solid Tumor,JAX,17286,MLH1 mutant,"[{'id': 303, 'pubMedId': None, 'title': '', 'url': 'https://clinicaltrials.gov/'}]",not applicable,1776,N/A,4292
0,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5794,10000003,Advanced Solid Tumor,JAX,21621,JAK2 V617F MPL wild-type,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3927,GDC-0941 + Ruxolitinib,4352
1,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5800,10000003,Advanced Solid Tumor,JAX,21621,JAK2 V617F MPL wild-type,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3928,BEZ235 + Ruxolitinib,4352
2,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5806,10000003,Advanced Solid Tumor,JAX,21621,JAK2 V617F MPL wild-type,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3929,Ruxolitinib + TGX-221,4352
3,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5788,10000003,Advanced Solid Tumor,JAX,21621,JAK2 V617F MPL wild-type,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3926,Ruxolitinib + ZSTK474,4352
4,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).",Actionable,5801,10000003,Advanced Solid Tumor,JAX,589,MPL W515L,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3928,BEZ235 + Ruxolitinib,4352
5,Phase II,"In a phase II study of patients with myelofibrosis, 2/2 patients with MPL W515L/K had tumor response to everolimus, with one patient displaying clinical benefit (PMID: 21725052).",Actionable,1099,4971,myelofibrosis,DOID,589,MPL W515L,"[{'id': 838, 'pubMedId': 21725052, 'title': 'Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21725052'}]",sensitive,735,Everolimus,4352
6,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).",Actionable,5789,10000003,Advanced Solid Tumor,JAX,589,MPL W515L,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3926,Ruxolitinib + ZSTK474,4352
7,Preclinical,"In a preclinical study, MK2206 treatment reduced disease burden in MPL W515L transduced mouse models of myelofibrosis (PMID: 23748344).",Actionable,5814,4971,myelofibrosis,DOID,589,MPL W515L,"[{'id': 839, 'pubMedId': 23748344, 'title': 'AKT is a therapeutic target in myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23748344'}]",sensitive,816,MK2206,4352
8,Preclinical,"In a preclinical study, CHZ868 demonstrated efficacy in a mouse model of MPL W515L induced myelofibrosis (PMID: 26175413). ",Actionable,6062,4971,myelofibrosis,DOID,589,MPL W515L,"[{'id': 5260, 'pubMedId': 26175413, 'title': 'CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26175413'}]",sensitive,4016,CHZ868,4352
9,Preclinical,"In a preclinical study, CHZ868 inhibited proliferation of bone marrow cell lines expressing MPL W515L in culture, including cells with decreased response to Type I JAK inhibitors due to chronic exposure (PMID: 26175413).",Actionable,6063,2531,hematologic cancer,DOID,589,MPL W515L,"[{'id': 5260, 'pubMedId': 26175413, 'title': 'CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26175413'}]",sensitive,4016,CHZ868,4352
10,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).",Actionable,5807,10000003,Advanced Solid Tumor,JAX,589,MPL W515L,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3929,Ruxolitinib + TGX-221,4352
11,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).",Actionable,5795,10000003,Advanced Solid Tumor,JAX,589,MPL W515L,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3927,GDC-0941 + Ruxolitinib,4352
12,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).",Actionable,5799,10000003,Advanced Solid Tumor,JAX,21624,JAK2 over exp MPL over exp,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3928,BEZ235 + Ruxolitinib,4352
13,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).",Actionable,5793,10000003,Advanced Solid Tumor,JAX,21624,JAK2 over exp MPL over exp,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3927,GDC-0941 + Ruxolitinib,4352
14,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).",Actionable,5805,10000003,Advanced Solid Tumor,JAX,21624,JAK2 over exp MPL over exp,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3929,Ruxolitinib + TGX-221,4352
15,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).",Actionable,5787,10000003,Advanced Solid Tumor,JAX,21624,JAK2 over exp MPL over exp,"[{'id': 5156, 'pubMedId': 24251790, 'title': 'Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24251790'}]",sensitive,3926,Ruxolitinib + ZSTK474,4352
16,Phase II,"In a phase II study of patients with myelofibrosis, 2/2 patients with MPL W515L/K had tumor response to everolimus, with one patient displaying clinical benefit (PMID: 21725052).",Actionable,1100,4971,myelofibrosis,DOID,590,MPL W515K,"[{'id': 838, 'pubMedId': 21725052, 'title': 'Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21725052'}]",sensitive,735,Everolimus,4352
0,Preclinical,"In a preclinical study, glioblastoma cells harboring a MSH6 T1219I mutation were resistant to Temodar (temozolomide) in cell culture (PMID: 19584161).",Actionable,1545,3068,glioblastoma multiforme,DOID,2665,MSH6 T1219I,"[{'id': 1465, 'pubMedId': 19584161, 'title': 'MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19584161'}]",resistant,1141,Temozolomide,2956
1,Preclinical - Cell culture,"In a preclinical study, MSH6 deficient colon cancer cells did not respond to treatment with KU60648 in culture (PMID: 28224663). ",Actionable,11384,219,colon cancer,DOID,7744,MSH6 loss,"[{'id': 9237, 'pubMedId': 28224663, 'title': 'Loss of MLH1 sensitizes colon cancer cells to DNA-PKcs inhibitor KU60648.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28224663'}]",no benefit,5967,KU60648,2956
2,Preclinical,"Preclinical shRNA mediated-inhibition of PTEN-induced putative kinase 1 (PINK1) in colon carcinoma cells with MSH6 loss resulted in synthetic lethality, suggesting PINK1 may be a promising therapeutic target for MSH6 deficient cancer cells (PMID: 21242281). ",Emerging,2456,1520,colon carcinoma,DOID,7744,MSH6 loss,"[{'id': 3097, 'pubMedId': 21242281, 'title': 'Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21242281'}]",not applicable,1776,N/A,2956
3,Clinical Study,"Germline mutations in MSH6 are associated with microsatellite instability in colorectal cancer (CRC), and are diagnostic for Lynch syndrome (hereditary nonpolyposis colorectal cancer) in colorectal cancer patients (PMID: 26582061; PMID: 19125127).",Actionable,6034,9256,colorectal cancer,DOID,17288,MSH6 mutant,"[{'id': 5249, 'pubMedId': 26582061, 'title': 'Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26582061'}, {'id': 5250, 'pubMedId': 19125127, 'title': 'EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19125127'}]",not applicable,1776,N/A,2956
4,Phase I,"Clinical trials are currently enrolling patients with mutations in MSH6 (clinicaltrials.gov, Oct 2017).",Actionable,5458,10000003,Advanced Solid Tumor,JAX,17288,MSH6 mutant,"[{'id': 303, 'pubMedId': None, 'title': '', 'url': 'https://clinicaltrials.gov/'}]",not applicable,1776,N/A,2956
0,Preclinical,"In a preclinical study, STS2825 demonstrated effective inhibition of MYD88 homodimerization and signalling in cultured cells and is currently being evaluated in preclinical studies of B cell lymphoma  (Blood Lymph Canc 2013; 3: 53-61). ",Actionable,1115,50745,diffuse large B-cell lymphoma,DOID,593,MYD88 wild-type,"[{'id': 861, 'pubMedId': None, 'title': 'Emerging targets in human lymphoma: targeting the MYD88 mutation', 'url': ''}]",predicted – sensitive,1563,ST2825,4615
1,Clinical Study,"MYD88 mutations are used in the diagnosis of lymphoplasmacytic lymphoma (Guidelines, PMID: 22944768).",Diagnostic,3967,50747,lymphoplasmacytic lymphoma,DOID,1917,MYD88 mutant,"[{'id': 4315, 'pubMedId': 26230596, 'title': 'Significance of MYD88 L265P Mutation Status in the Subclassification of Low-Grade B-Cell Lymphoma/Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26230596'}, {'id': 5214, 'pubMedId': 22944768, 'title': 'IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22944768'}, {'id': 5215, 'pubMedId': None, 'title': ""NCCN Guidelines Version 2.2016 Non-Hodgkin's Lymphomas"", 'url': ''}]",not applicable,1776,N/A,4615
2,Preclinical - Cell culture,"In a preclinical study, a diffuse large B-cell lymphoma cell line harboring MYD88 L256P demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased apoptosis (PMID: 27733371).",Actionable,10340,50745,diffuse large B-cell lymphoma,DOID,6507,MYD88 L265P,"[{'id': 8322, 'pubMedId': 27733371, 'title': 'TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27733371'}]",sensitive,1077,Vorinostat,4615
3,Phase I,"In a Phase I trial, two patients with primary central nervous system lymphoma each harboring MYD88 L265P demonstrated a complete response when treated with Imbruvica (ibrutinib) (PMID: 28619981). ",Actionable,12106,3234,central nervous system lymphoma,DOID,6507,MYD88 L265P,"[{'id': 10035, 'pubMedId': 28619981, 'title': 'Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28619981'}]",sensitive,768,Ibrutinib,4615
4,Preclinical - Cell line xenograft,"In a preclinical study, treatment with IMO-8400 resulted in decreased survival of B-cell lymphoma cell lines harboring MYD88 L265P in culture, and decreased tumor growth in a MYD88 L265P-positive B-cell lymphoma cell line xenograft models (Cancer Res October 1, 2014 74:2570).",Actionable,2469,707,B-cell lymphoma,DOID,6507,MYD88 L265P,"[{'id': 3125, 'pubMedId': None, 'title': 'Abstract 2570: IMO-8400, a selective antagonist of TLRs 7, 8 and 9, inhibits MYD88 L265P mutation-driven signaling and cell survival: A potential novel approach for treatment of B-cell lymphomas harboring MYD88 L265P mutation', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/2570.short'}]",sensitive,2866,IMO-8400,4615
5,Clinical Study,"In multiple clinical studies, MYD88 L265P was associated with a worse overall survival in patients with diffuse large B-cell lymphoma when compared to MYD88 wild-type (PMID: 24903481, PMID: 25055137, PMID: 26792260). ",Prognostic,6344,50745,diffuse large B-cell lymphoma,DOID,6507,MYD88 L265P,"[{'id': 5531, 'pubMedId': 24903481, 'title': 'MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24903481'}, {'id': 5532, 'pubMedId': 25055137, 'title': 'High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25055137'}, {'id': 5533, 'pubMedId': 26792260, 'title': 'MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26792260'}]",not applicable,1776,N/A,4615
6,Preclinical - Pdx,"In a preclinical study, a non-Hodgkin lymphoma (NHL) patient derived xenograft (PDX) model harboring both CD79B Y197N and MYD88 L265P demonstrated sensitivity to Ibruvica (ibrutinib) while an NHL patient derived xenograft (PDX) model harboring only MYD88 L265P did not respond to Ibruvica (ibrutinib) (ASH 57th Annual Meeting, 2015, abstract #2759). ",Actionable,3704,60060,non-Hodgkin lymphoma,DOID,6507,MYD88 L265P,"[{'id': 4013, 'pubMedId': None, 'title': 'Biomarker Predictive Ibrutinib Response Using Profiled ABC-DLBCL Patient Derived Xenografts', 'url': 'https://ash.confex.com/ash/2015/webprogram/Paper81154.html'}]",no benefit,768,Ibrutinib,4615
7,Preclinical - Cell line xenograft,"In a preclinical study, eFT508 demonstrated anti-tumor activity in two diffuse large B-cell lymphoma cell line xenograft models, both harboring MYD88 activating mutations (Blood Dec 2015, 126 (23) 1554).",Actionable,6009,50745,diffuse large B-cell lymphoma,DOID,22222,MYD88 act mut,"[{'id': 5231, 'pubMedId': None, 'title': 'eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)', 'url': 'http://www.bloodjournal.org/content/126/23/1554'}]",predicted – sensitive,4005,eFT508,4615
0,Preclinical - Pdx,"In a preclinical study, xenograft models of patient-derived acute lymphocytic leukemia cells harboring NOTCH1 activating muatations demonstrated better response to Brontictuzumab (OMP-52M51) compared to NOTCH1 wild-type models (PMID: 23774673).",Actionable,7156,9952,acute lymphocytic leukemia,DOID,2334,NOTCH1 act mut,"[{'id': 2506, 'pubMedId': 23774673, 'title': 'Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23774673'}]",sensitive,839,Brontictuzumab,4851
1,Preclinical - Pdx,"In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) resulted in reduced leukemia burden and a greater survival benefit in a NOTCH1 activated T-cell acute lymphoblastic leukemia patient derived xenograft (PDX) model when compared to control or either agent alone (PMID: 28151717). ",Actionable,10054,5602,T-cell adult acute lymphocytic leukemia,DOID,2334,NOTCH1 act mut,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",predicted – sensitive,5355,Ribociclib + Dexamethasone,4851
2,Preclinical - Pdx,"In a preclinical study, Brontictuzumab (OMP-52M51) inhibited tumor growth and reduced cancer stem cells in xenograft models of tumor derived from a breast cancer patient harboring activating NOTCH1 mutations (Cancer Res 2013;73(8 Suppl):Abstract nr 3728).",Actionable,7154,1612,breast cancer,DOID,2334,NOTCH1 act mut,"[{'id': 6111, 'pubMedId': None, 'title': 'Anti-Notch1 antibody (OMP-52M51) impedes tumor growth and cancer stem cell frequency (CSC) in a chemo-refractory breast cancer xenograft model with an activating Notch1 mutation and screening for activated Notch1 across multiple solid tumor types.', 'url': 'http://cancerres.aacrjournals.org/content/73/8_Supplement/3728.short'}]",sensitive,839,Brontictuzumab,4851
3,Preclinical - Cell culture,"In a preclinical study, the gamma secretase inhibitor PF-03084014 reduced Notch1 cleavage, decreased activation of Notch targets, and increased apoptosis in colorectal cancer cell lines exhibiting increased Notch activation (PMID: 23868008).",Actionable,1263,9256,colorectal cancer,DOID,2334,NOTCH1 act mut,"[{'id': 978, 'pubMedId': 23868008, 'title': 'Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23868008'}]",sensitive,859,PF-03084014,4851
4,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1707T in culture (PMID: 25104330).",Actionable,4328,3347,osteosarcoma,DOID,6144,NOTCH1 A1707T,"[{'id': 3550, 'pubMedId': 25104330, 'title': 'Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25104330'}]",sensitive,1084,MRK-003,4851
5,Preclinical,"In a preclinical study, transformed cells expressing NOTCH1 A1707T demonstrated sensitivity to MRK-003 in culture (PMID: 25104330).",Actionable,2984,10000003,Advanced Solid Tumor,JAX,6144,NOTCH1 A1707T,"[{'id': 3550, 'pubMedId': 25104330, 'title': 'Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25104330'}]",sensitive,1084,MRK-003,4851
6,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 I1680S in culture (PMID: 25104330).",Actionable,4321,3347,osteosarcoma,DOID,17691,NOTCH1 I1680S,"[{'id': 3550, 'pubMedId': 25104330, 'title': 'Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25104330'}]",sensitive,1084,MRK-003,4851
7,Preclinical,"In a preclinical study, LGK974 inhibited growth of head and neck squamous cell carcinoma cells harboring NOTCH1 C478F in culture and xenograft models (PMID: 24277854).",Actionable,2689,5520,head and neck squamous cell carcinoma,DOID,10166,NOTCH1 C478F,"[{'id': 3402, 'pubMedId': 24277854, 'title': 'Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24277854'}]",sensitive,1937,LGK974,4851
8,Preclinical - Cell culture,"In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 demonstrated sensitivity to treatment with Kisqali (ribociclib) in culture, resulting in inhibition of cell growth (PMID: 28151717). ",Actionable,10032,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,790,Ribociclib,4851
9,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10051,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,5357,Ribociclib + JQ1,4851
10,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and NOTCH1 resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, however, survival did not differ between xenograft models treated with the combination or Kisqali (ribociclib) alone (PMID: 28151717). ",Actionable,10044,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",conflicting,5355,Ribociclib + Dexamethasone,4851
11,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10034,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",decreased response,5352,Ribociclib + Methotrexate,4851
12,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10036,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",decreased response,5353,Ribociclib + Mercaptopurine,4851
13,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture, and prolonged survival in cell-line xenograft models (PMID: 28151717). ",Actionable,10049,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,5073,Ribociclib + Everolimus,4851
14,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10047,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,5356,Ribociclib + Prednisolone,4851
15,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10042,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",decreased response,5354,Ribociclib + Asparaginase,4851
16,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10053,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,5358,Ribociclib + Bortezomib,4851
17,Preclinical - Cell culture,"In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type NOTCH1 and loss of RB1 demonstrated resistance to Kisqali (ribociclib) in culture, resulting in limited inhibition of cell growth (PMID: 28151717). ",Actionable,10045,5602,T-cell adult acute lymphocytic leukemia,DOID,27230,NOTCH1 wild-type RB1 loss,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",resistant,790,Ribociclib,4851
18,Preclinical,"In a preclinical study, triple receptor-negative breast cancer xenograft models harboring wild-type NOTCH1 demonstrated reduced sensitivity to MRK-003 induced tumor growth inhibition (PMID: 25104330).",Actionable,4317,60081,triple-receptor negative breast cancer,DOID,597,NOTCH1 wild-type,"[{'id': 3550, 'pubMedId': 25104330, 'title': 'Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25104330'}]",decreased response,1084,MRK-003,4851
19,Preclinical,"In a preclinical study, the combination of MRK-003 and Taxol (paclitaxel) did not potentiate the anti-tumor effects compared to single agent therapy in triple receptor-negative breast cancer xenograft models harboring wild-type NOTCH1 (PMID: 25104330).",Actionable,4319,60081,triple-receptor negative breast cancer,DOID,597,NOTCH1 wild-type,"[{'id': 3550, 'pubMedId': 25104330, 'title': 'Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25104330'}]",no benefit,3491,MRK-003 + Paclitaxel,4851
20,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1552G in culture (PMID: 25104330).",Actionable,4323,3347,osteosarcoma,DOID,17693,NOTCH1 A1552G,"[{'id': 3550, 'pubMedId': 25104330, 'title': 'Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25104330'}]",sensitive,1084,MRK-003,4851
21,Preclinical,"In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of lung cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).",Actionable,7134,1324,lung cancer,DOID,5943,NOTCH1 positive,"[{'id': 3325, 'pubMedId': None, 'title': 'Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.', 'url': 'http://cancerres.aacrjournals.org/content/73/8_Supplement/1131.short'}]",sensitive,2958,LY3039478,4851
22,Phase I,"In a Phase I trial, addition of RO4929097 to Temodar (temozolomide) and radiation therapy inhibited Notch signaling and cell proliferation in patient tumor samples, resulted in a median overall survival of 21 months and a median progression free survival of 13 months in glioblastoma patients (PMID: 27154916).",Actionable,8728,3068,glioblastoma multiforme,DOID,5943,NOTCH1 positive,"[{'id': 6719, 'pubMedId': 27154916, 'title': 'Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27154916'}]",sensitive,4803,Radiotherapy + RO4929097 + Temozolomide,4851
23,Preclinical,"In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of colon cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).",Actionable,7133,219,colon cancer,DOID,5943,NOTCH1 positive,"[{'id': 3325, 'pubMedId': None, 'title': 'Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.', 'url': 'http://cancerres.aacrjournals.org/content/73/8_Supplement/1131.short'}]",sensitive,2958,LY3039478,4851
24,Preclinical - Cell line xenograft,"In a preclinical study, PF-03084014 and Taxotere (docetaxel) in combination inhibited growth of Notch1-expressing Taxotere (docetaxel)-resistant prostate cancer cell lines in culture, and inhibited both soft tissue and bony tumor growth in Taxotere (docetaxel)-resistant prostate cancer cell line xenograft models, with increased efficacy over either agent alone (PMID: 26202948).",Actionable,9081,10283,prostate cancer,DOID,5943,NOTCH1 positive,"[{'id': 6897, 'pubMedId': 26202948, 'title': 'Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26202948'}]",predicted – sensitive,1115,PF-03084014 + Docetaxel,4851
25,Preclinical,"In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of ovarian cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).",Actionable,7135,2394,ovarian cancer,DOID,5943,NOTCH1 positive,"[{'id': 3325, 'pubMedId': None, 'title': 'Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.', 'url': 'http://cancerres.aacrjournals.org/content/73/8_Supplement/1131.short'}]",sensitive,2958,LY3039478,4851
26,Preclinical,"In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of glioblastoma (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).",Actionable,7138,3068,glioblastoma multiforme,DOID,5943,NOTCH1 positive,"[{'id': 3325, 'pubMedId': None, 'title': 'Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.', 'url': 'http://cancerres.aacrjournals.org/content/73/8_Supplement/1131.short'}]",sensitive,2958,LY3039478,4851
27,Preclinical,"In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of breast cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).",Actionable,7137,1612,breast cancer,DOID,5943,NOTCH1 positive,"[{'id': 3325, 'pubMedId': None, 'title': 'Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.', 'url': 'http://cancerres.aacrjournals.org/content/73/8_Supplement/1131.short'}]",sensitive,2958,LY3039478,4851
28,Preclinical,"In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of gastric cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).",Actionable,7136,10534,stomach cancer,DOID,5943,NOTCH1 positive,"[{'id': 3325, 'pubMedId': None, 'title': 'Abstract 1131: Novel inhibitor of Notch signaling for the treatment of cancer.', 'url': 'http://cancerres.aacrjournals.org/content/73/8_Supplement/1131.short'}]",sensitive,2958,LY3039478,4851
29,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 E1567K in culture (PMID: 25104330).",Actionable,4322,3347,osteosarcoma,DOID,17692,NOTCH1 E1567K,"[{'id': 3550, 'pubMedId': 25104330, 'title': 'Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25104330'}]",sensitive,1084,MRK-003,4851
30,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 V1575A in culture (PMID: 25104330).",Actionable,4326,3347,osteosarcoma,DOID,17697,NOTCH1 V1575A,"[{'id': 3550, 'pubMedId': 25104330, 'title': 'Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25104330'}]",sensitive,1084,MRK-003,4851
31,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 R1683W in culture (PMID: 25104330).",Actionable,4329,3347,osteosarcoma,DOID,17699,NOTCH1 R1683W,"[{'id': 3550, 'pubMedId': 25104330, 'title': 'Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25104330'}]",sensitive,1084,MRK-003,4851
32,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 V1599M in culture (PMID: 25104330).",Actionable,4327,3347,osteosarcoma,DOID,17698,NOTCH1 V1599M,"[{'id': 3550, 'pubMedId': 25104330, 'title': 'Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25104330'}]",sensitive,1084,MRK-003,4851
33,Preclinical,"In a preclinical study, MRK-003 inhibited growth of triple receptor-negative breast cancer cells harboring NOTCH1 rearrangement in culture and reduced tumor growth in xenograft models (PMID: 25104330).",Actionable,4289,60081,triple-receptor negative breast cancer,DOID,17701,NOTCH1 rearrange,"[{'id': 3550, 'pubMedId': 25104330, 'title': 'Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25104330'}]",sensitive,1084,MRK-003,4851
34,Preclinical,"In a preclinical study, SCH772984 did not potentiate the growth inhibition effect of MRK-003 in triple receptor-negative breast cancer cells harboring NOTCH1 rearrangement in culture (PMID: 25104330).",Actionable,4315,60081,triple-receptor negative breast cancer,DOID,17701,NOTCH1 rearrange,"[{'id': 3550, 'pubMedId': 25104330, 'title': 'Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25104330'}]",no benefit,3492,MRK-003 + SCH772984,4851
35,Preclinical,"In a preclinical study, MRK-003 and Taxol (paclitaxel) worked synergistically to inhibit tumor growth in triple receptor-negative breast cancer xenograft models harboring NOTCH1 rearrangement, resulting in tumor regression (PMID: 25104330).",Actionable,4318,60081,triple-receptor negative breast cancer,DOID,17701,NOTCH1 rearrange,"[{'id': 3550, 'pubMedId': 25104330, 'title': 'Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25104330'}]",sensitive,3491,MRK-003 + Paclitaxel,4851
36,Phase I,"In a Phase I trial, Brontictuzumab (OMP-52M51) treatment resulted in stable disease in 43% (3/7) of advanced solid tumor patients with elevated levels of Notch1 intracellular domain (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C42).",Actionable,7155,10000003,Advanced Solid Tumor,JAX,4730,NOTCH1 over exp,"[{'id': 6112, 'pubMedId': None, 'title': 'Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/C42.short'}]",sensitive,839,Brontictuzumab,4851
37,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1570G in culture (PMID: 25104330).",Actionable,4325,3347,osteosarcoma,DOID,17695,NOTCH1 A1570G,"[{'id': 3550, 'pubMedId': 25104330, 'title': 'Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25104330'}]",sensitive,1084,MRK-003,4851
38,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 V1676I in culture (PMID: 25104330).",Actionable,4330,3347,osteosarcoma,DOID,879,NOTCH1 V1676I,"[{'id': 3550, 'pubMedId': 25104330, 'title': 'Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25104330'}]",sensitive,1084,MRK-003,4851
39,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1552V in culture (PMID: 25104330).",Actionable,4324,3347,osteosarcoma,DOID,17694,NOTCH1 A1552V,"[{'id': 3550, 'pubMedId': 25104330, 'title': 'Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25104330'}]",sensitive,1084,MRK-003,4851
40,Preclinical - Pdx,"In a preclinical study, PF-03084014 treatment resulted in tumor regression in patient derived xenograft animal models of triple receptor negative breast cancer harboring NOTCH1 S2449fs (PMID: 25564152).
",Actionable,3666,60081,triple-receptor negative breast cancer,DOID,15929,NOTCH1 S2449fs,"[{'id': 3942, 'pubMedId': 25564152, 'title': 'PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25564152'}]",sensitive,859,PF-03084014,4851
41,Preclinical - Cell culture,"In a preclinical study, a T-cell acute lymphoblastic leukemia cell line co-harboring wild-type RB1 and a NOTCH1 mutation demonstrated sensitivity to treatment with Kisqali (ribociclib) in culture, resulting in inhibition of cell growth (PMID: 28151717). ",Actionable,10031,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,790,Ribociclib,4851
42,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10033,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",decreased response,5352,Ribociclib + Methotrexate,4851
43,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture (PMID: 28151717). ",Actionable,10048,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,5073,Ribociclib + Everolimus,4851
44,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10052,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,5358,Ribociclib + Bortezomib,4851
45,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10046,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,5356,Ribociclib + Prednisolone,4851
46,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10037,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",decreased response,5354,Ribociclib + Asparaginase,4851
47,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10035,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",decreased response,5353,Ribociclib + Mercaptopurine,4851
48,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10050,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,5357,Ribociclib + JQ1,4851
49,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, and a greater survival benefit in xenograft models when compared to Kisqali (ribociclib) alone (PMID: 28151717). ",Actionable,10043,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,5355,Ribociclib + Dexamethasone,4851
50,Preclinical - Pdx,"In a preclinical study, PF-03084014 treatment resulted in tumor regression in patient-derived xenograft models of triple receptor negative breast cancer harboring NOTCH1 mutations (PMID: 25564152).
",Actionable,3668,60081,triple-receptor negative breast cancer,DOID,14278,NOTCH1 mutant,"[{'id': 3942, 'pubMedId': 25564152, 'title': 'PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25564152'}]",sensitive,859,PF-03084014,4851
0,Preclinical,"In a preclinical study, MI-503 inhibited growth of murine leukemia cells expressing an NPM1 mutation and FLT3 internal tandem duplication in culture, and improved survival in mouse models (PMID: 27535106).",Actionable,11489,1240,leukemia,DOID,26135,FLT3 exon 14 ins NPM1 mutant,"[{'id': 9547, 'pubMedId': 27535106, 'title': 'Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535106'}]",predicted – sensitive,6006,MI-503,4869
1,Phase I,"In a Phase I trial, two acute myeloid leukemia patients co-harboring a FLT3-ITD mutation and NPM1 mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088). ",Actionable,8008,9119,acute myeloid leukemia,DOID,26135,FLT3 exon 14 ins NPM1 mutant,"[{'id': 6531, 'pubMedId': 27406088, 'title': 'A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27406088'}]",sensitive,727,ENMD-2076,4869
2,Preclinical,"In a preclinical study, EPZ004777 inhibited growth and induced differentiation of murine leukemia cells expressing an NPM1 mutation and FLT3 internal tandem duplication in culture, and improved survival in mouse models (PMID: 27535106).",Actionable,11490,1240,leukemia,DOID,26135,FLT3 exon 14 ins NPM1 mutant,"[{'id': 9547, 'pubMedId': 27535106, 'title': 'Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535106'}]",predicted – sensitive,1744,EPZ004777,4869
3,Clinical Study,"In multiple clinical studies, the combination of an NPM1 mutation and FLT3 wild-type in acute myeloid leukemia (AML) patients was associated with a favorable prognosis compared to AML patients harboring an NPM1 mutation and FLT3 internal tandem duplication (PMID: 19047294, PMID: 24573385, PMID: 25713434). ",Prognostic,6501,9119,acute myeloid leukemia,DOID,23600,NPM1 mutant FLT3 wild-type,"[{'id': 5668, 'pubMedId': 19047294, 'title': 'Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19047294'}, {'id': 5669, 'pubMedId': 24573385, 'title': 'The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24573385'}, {'id': 5670, 'pubMedId': 25713434, 'title': 'Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25713434'}]",not applicable,1776,N/A,4869
4,Preclinical - Patient cell culture,"In a preclinical study, EPZ004777 decreased HOX gene expression, and reduced proliferation and increased differentiation of a human acute myeloid leukemia (AML) cell line and primary AML samples harboring NPM1 mutations in culture (PMID: 27535106).",Actionable,11486,9119,acute myeloid leukemia,DOID,8907,NPM1 mutant,"[{'id': 9547, 'pubMedId': 27535106, 'title': 'Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535106'}]",predicted – sensitive,1744,EPZ004777,4869
5,Preclinical,"In a preclinical study, acute myeloid leukemia cells harboring a NPM1 mutation were sensitive to NSC348884 as demonstrated by induced apoptosis (PMID: 21719597). ",Actionable,2521,9119,acute myeloid leukemia,DOID,8907,NPM1 mutant,"[{'id': 3230, 'pubMedId': 21719597, 'title': 'Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21719597'}]",sensitive,2905,NSC348884,4869
6,Clinical Study,"In clinical analyses, mutations in NPM1 were associated with favorable prognosis in acute myeloid leukemia patients with normal karyotype in the absence of a FLT3 ITD mutation (PMID: 26239249, PMID: 26586702, PMID: 26676635, PMID: 16109776). ",Prognostic,5660,9119,acute myeloid leukemia,DOID,8907,NPM1 mutant,"[{'id': 5139, 'pubMedId': 16109776, 'title': 'Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16109776'}, {'id': 5357, 'pubMedId': 26676635, 'title': 'The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676635'}, {'id': 5358, 'pubMedId': 26586702, 'title': 'Bioinformatics Analysis to Determine Prognostic Mutations of 72 de novo Acute Myeloid Leukemia Cases from the Cancer Genome Atlas (TCGA) with 23 Most Common Mutations and no Abnormal Cytogenetics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26586702'}, {'id': 5359, 'pubMedId': 26239249, 'title': 'Molecular Genetic Markers in Acute Myeloid Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26239249'}]",not applicable,1776,N/A,4869
7,Preclinical,"In  preclinical study, treatment with EPZ004777 resulted in reduced proliferation and increased differentiation of murine leukemia cells expressing an NPM1 mutation, and improved survival in NPM1-mutant murine leukemia models (PMID: 27535106).",Actionable,11487,1240,leukemia,DOID,8907,NPM1 mutant,"[{'id': 9547, 'pubMedId': 27535106, 'title': 'Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535106'}]",predicted – sensitive,1744,EPZ004777,4869
8,Phase I,"In a Phase I trial, three acute myeloid leukemia patient harboring an NPM1 mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088). ",Actionable,8009,9119,acute myeloid leukemia,DOID,8907,NPM1 mutant,"[{'id': 6531, 'pubMedId': 27406088, 'title': 'A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27406088'}]",sensitive,727,ENMD-2076,4869
9,Preclinical - Cell line xenograft,"In a preclinical study, MI-503 inhibited growth of an acute myeloid leukemia cell line and primary AML samples harboring NPM1 mutations in culture, and reduced tumor burden and improved survival in an NPM1-mutant AML cell line xenograft model (PMID: 27535106).",Actionable,11488,9119,acute myeloid leukemia,DOID,8907,NPM1 mutant,"[{'id': 9547, 'pubMedId': 27535106, 'title': 'Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27535106'}]",predicted – sensitive,6006,MI-503,4869
10,Clinical Study,"In a retrospective analysis, of patients with acute myeloid leukemia, the combination of DNMT3A, FLT3, and NPM1 mutations was highly associated with decreased event free survival and overall survival, suggesting that this combination profile may serve as a future prognostic biomarker (PMID: 25281355).  ",Emerging,3573,9119,acute myeloid leukemia,DOID,13674,DNMT3A R882H FLT3 Y599_D600insSTDNEYFYVDFREYEY NPM1 W288fs,"[{'id': 3849, 'pubMedId': 25281355, 'title': 'Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25281355'}]",not applicable,1776,N/A,4869
11,Preclinical - Cell culture,"In a preclinical study, Ixazomib (MLN9708) and Zolinza (vorinostat) synergistically induced apoptosis in NPMc+ (due to NPM1 exon 12 mutations) acute myeloid leukemia cells in culture (PMID: 26634271).",Actionable,10911,9119,acute myeloid leukemia,DOID,2682,NPM1 exon12,"[{'id': 8925, 'pubMedId': 26634271, 'title': 'Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26634271'}]",sensitive,1360,Ixazomib + Vorinostat,4869
12,Preclinical,"In preclinical studies, deguelin treatment of an AML cell line harboring NPM1 exon12 mutation resulted in reduced levels of mutant Npm1 protein and induced differentiation of the cells (PMID: 25242579, PMID: 25348016).",Actionable,1561,9119,acute myeloid leukemia,DOID,2682,NPM1 exon12,"[{'id': 1526, 'pubMedId': 25242579, 'title': 'Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25242579'}, {'id': 1527, 'pubMedId': 25348016, 'title': 'Nontoxic-dose of deguelin induce NPMc+ AML cell differentiation by selectively targeting Mt NPM1/SIRT1 instead of HDAC1/3.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25348016'}]",sensitive,1867,Deguelin,4869
13,Clinical Study,"In a clinical study, Ixazomib (MLN9708) treatment resulted in significantly reduced peripheral blast cells in a NPMc+ (due to NPM1 exon 12 mutations) acute myeloid leukemia (AML) patient, and demonstrated selective toxicity towards NPMc+ AML cell lines in culture (PMID: 26634271).",Actionable,10910,9119,acute myeloid leukemia,DOID,2682,NPM1 exon12,"[{'id': 8925, 'pubMedId': 26634271, 'title': 'Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26634271'}]",predicted – sensitive,1359,Ixazomib,4869
14,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK demonstrated a decreased response compared to parental cell lines harboring NPM1-ALK when treated with Alecensa (alectinib) in culture (PMID: 25421750).",Actionable,3427,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,698,Alectinib,4869
15,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3431,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,643,ASP3026,4869
16,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).",Actionable,3425,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,706,Crizotinib,4869
17,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Brigatinib (AP26113) in culture (PMID: 25421750).",Actionable,3432,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,4869
18,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).",Actionable,3426,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,789,Ceritinib,4869
19,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK F1174L in culture (PMID: 27009859).",Actionable,5344,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,634,AP26113,4869
20,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).",Actionable,5352,50744,anaplastic large cell lymphoma,DOID,20659,NPM1-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,4869
21,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5341,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,698,Alectinib,4869
22,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5346,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,643,ASP3026,4869
23,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5347,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,1586,AZD3463,4869
24,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5339,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,4869
25,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5337,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,706,Crizotinib,4869
26,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK E1210K were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5415,50744,anaplastic large cell lymphoma,DOID,20888,NPM1-ALK ALK E1210K,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,4869
27,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with E1210K were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5490,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,789,Ceritinib,4869
28,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5439,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,698,Alectinib,4869
29,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5431,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,634,AP26113,4869
30,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5501,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,869,PF-06463922,4869
31,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK E1210K in culture (PMID: 25749034).",Actionable,5483,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,706,Crizotinib,4869
32,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5422,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,4869
33,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3444,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,4869
34,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1198F in culture (PMID: 25421750).",Actionable,3457,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,706,Crizotinib,4869
35,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).",Actionable,3481,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,789,Ceritinib,4869
36,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3462,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,698,Alectinib,4869
37,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3555,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,643,ASP3026,4869
38,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5436,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,698,Alectinib,4869
39,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5495,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,869,PF-06463922,4869
40,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5427,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,634,AP26113,4869
41,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5421,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,4869
42,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK C1156F in culture (PMID: 25749034).",Actionable,5480,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,706,Crizotinib,4869
43,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5486,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,789,Ceritinib,4869
44,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156F were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5416,50744,anaplastic large cell lymphoma,DOID,20881,NPM1-ALK ALK C1156F,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,4869
45,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK F1174I were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5392,50744,anaplastic large cell lymphoma,DOID,20772,NPM1-ALK ALK F1174I,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,4869
46,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5435,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,634,AP26113,4869
47,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5484,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,789,Ceritinib,4869
48,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5481,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,706,Crizotinib,4869
49,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5493,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,869,PF-06463922,4869
50,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5433,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,698,Alectinib,4869
51,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174I were resistant to ASP3026 relative to wild type NPM1-ALK in culture (PMID: 25749034).",Actionable,5424,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,4869
52,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3465,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,698,Alectinib,4869
53,Preclinical,"In a preclinical trial, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).",Actionable,3484,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,789,Ceritinib,4869
54,Preclinical,"In a preclinical trial, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3557,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,643,ASP3026,4869
55,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).",Actionable,3456,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,706,Crizotinib,4869
56,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).",Actionable,3443,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,634,AP26113,4869
57,Preclinical,"In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).",Actionable,3549,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,643,ASP3026,4869
58,Preclinical,"In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).",Actionable,3464,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,698,Alectinib,4869
59,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).",Actionable,3455,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,706,Crizotinib,4869
60,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK P1139S in culture (PMID: 25421750).",Actionable,3446,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,634,AP26113,4869
61,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3486,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,789,Ceritinib,4869
62,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3454,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,706,Crizotinib,4869
63,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750).",Actionable,3437,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,634,AP26113,4869
64,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with  ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3554,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,643,ASP3026,4869
65,Preclinical,"In a preclinical trial, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750).",Actionable,3485,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,789,Ceritinib,4869
66,Preclinical,"In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3466,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,698,Alectinib,4869
67,Preclinical,"In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3450,10000003,Advanced Solid Tumor,JAX,11406,NPM1-ALK,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,643,ASP3026,4869
68,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of an anaplastic large cell lymphoma cell line harboring NPM1-ALK in culture (PMID: 25421750).",Actionable,3428,50744,anaplastic large cell lymphoma,DOID,11406,NPM1-ALK,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,698,Alectinib,4869
69,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3445,10000003,Advanced Solid Tumor,JAX,11406,NPM1-ALK,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,634,AP26113,4869
70,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3447,10000003,Advanced Solid Tumor,JAX,11406,NPM1-ALK,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,706,Crizotinib,4869
71,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3449,10000003,Advanced Solid Tumor,JAX,11406,NPM1-ALK,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,789,Ceritinib,4869
72,Preclinical,"In a preclinical study, TAE684 inhibited proliferation of transformed cells expressing NPM1-ALK in culture (PMID: 20207848). ",Actionable,3112,10000003,Advanced Solid Tumor,JAX,11406,NPM1-ALK,"[{'id': 3632, 'pubMedId': 20207848, 'title': 'ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20207848'}]",sensitive,2386,TAE684,4869
73,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cells harboring NPM1-ALK were sensitive to Entrectinib (RXDX-101) in culture and in mouse models, resulting in inhibition of NPM1-ALK autophosphorylation and near complete tumor regression (PMID: 26939704).",Actionable,5635,50744,anaplastic large cell lymphoma,DOID,11406,NPM1-ALK,"[{'id': 5130, 'pubMedId': 26939704, 'title': 'Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26939704'}]",sensitive,1455,Entrectinib,4869
74,Preclinical,"In a preclinical study, ASP3026 inhibited growth of an anaplastic large cell lymphoma cell line harboring NPM1-ALK in culture (PMID: 25421750).",Actionable,3429,50744,anaplastic large cell lymphoma,DOID,11406,NPM1-ALK,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,643,ASP3026,4869
75,Preclinical - Cell line xenograft,"In a preclinical study, Xalkori (crizotinib) inhibited cell growth, Alk phosphorylation, downstream signaling and induced apoptosis in human anaplastic large cell lymphoma cell lines harboring a NPM1-ALK fusion in culture and in xenograft models (PMID: 18089725).",Actionable,3110,50744,anaplastic large cell lymphoma,DOID,11406,NPM1-ALK,"[{'id': 3631, 'pubMedId': 18089725, 'title': 'Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18089725'}]",sensitive,706,Crizotinib,4869
76,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of an anaplastic large cell lymphoma cell line harboring NPM1-ALK in culture (PMID: 25421750).",Actionable,3430,50744,anaplastic large cell lymphoma,DOID,11406,NPM1-ALK,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,789,Ceritinib,4869
77,Preclinical - Cell line xenograft,"In a preclinical study, Brigatinib (AP26113) inhibited Alk phosphorylation and growth in anaplastic large cell lymphoma cell lines harboring NPM1-ALK in culture, and induced near complete tumor regression in cell line xenograft models (PMID: 27780853).",Actionable,3433,50744,anaplastic large cell lymphoma,DOID,11406,NPM1-ALK,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,4869
78,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25749034).",Actionable,5492,10000003,Advanced Solid Tumor,JAX,11406,NPM1-ALK,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,869,PF-06463922,4869
79,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3448,10000003,Advanced Solid Tumor,JAX,11406,NPM1-ALK,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,698,Alectinib,4869
80,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156Y were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5410,50744,anaplastic large cell lymphoma,DOID,20770,NPM1-ALK ALK C1156Y,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,4869
81,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).",Actionable,5381,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,634,AP26113,4869
82,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5378,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,706,Crizotinib,4869
83,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).",Actionable,5383,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,1586,AZD3463,4869
84,Preclinical,"In a preclinical study, ASP3026 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).",Actionable,5382,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,643,ASP3026,4869
85,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).",Actionable,5351,50744,anaplastic large cell lymphoma,DOID,20662,NPM1-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,706,Crizotinib,4869
86,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5380,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,698,Alectinib,4869
87,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5379,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,4869
88,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Brigatinib (AP26113) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5369,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,634,AP26113,4869
89,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5368,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,698,Alectinib,4869
90,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5371,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,1586,AZD3463,4869
91,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).",Actionable,5353,50744,anaplastic large cell lymphoma,DOID,20657,NPM1-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,4869
92,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5366,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,706,Crizotinib,4869
93,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5367,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,4869
94,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5370,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,643,ASP3026,4869
95,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3483,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,789,Ceritinib,4869
96,Preclinical,"In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3467,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,698,Alectinib,4869
97,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3442,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,4869
98,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).",Actionable,3452,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,706,Crizotinib,4869
99,Preclinical,"In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N in culture (PMID: 25421750).",Actionable,3550,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,643,ASP3026,4869
100,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3459,10000003,Advanced Solid Tumor,JAX,13326,NPM1-ALK ALK L1122V,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,698,Alectinib,4869
101,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3441,10000003,Advanced Solid Tumor,JAX,13326,NPM1-ALK ALK L1122V,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,4869
102,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3551,10000003,Advanced Solid Tumor,JAX,13326,NPM1-ALK ALK L1122V,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,643,ASP3026,4869
103,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).",Actionable,3480,10000003,Advanced Solid Tumor,JAX,13326,NPM1-ALK ALK L1122V,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,789,Ceritinib,4869
104,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5430,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,634,AP26113,4869
105,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5425,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",decreased response,643,ASP3026,4869
106,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK N1178H were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5417,50744,anaplastic large cell lymphoma,DOID,20899,NPM1-ALK ALK N1178H,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,4869
107,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034).",Actionable,5482,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,706,Crizotinib,4869
108,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5499,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,869,PF-06463922,4869
109,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5489,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,789,Ceritinib,4869
110,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034).",Actionable,5434,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,698,Alectinib,4869
111,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5441,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,698,Alectinib,4869
112,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK G1128S in culture (PMID: 25749034).",Actionable,5426,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,634,AP26113,4869
113,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5485,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,789,Ceritinib,4869
114,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1128S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5413,50744,anaplastic large cell lymphoma,DOID,20894,NPM1-ALK ALK G1128S,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,4869
115,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).",Actionable,5476,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,706,Crizotinib,4869
116,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5420,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,4869
117,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5494,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,869,PF-06463922,4869
118,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Brigatinib (AP26113) in culture (PMID: 25421750).",Actionable,3435,50744,anaplastic large cell lymphoma,DOID,13328,NPM1-ALK ALK L1122V ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,4869
119,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3460,10000003,Advanced Solid Tumor,JAX,13328,NPM1-ALK ALK L1122V ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,698,Alectinib,4869
120,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).",Actionable,3451,10000003,Advanced Solid Tumor,JAX,13328,NPM1-ALK ALK L1122V ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,706,Crizotinib,4869
121,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3552,10000003,Advanced Solid Tumor,JAX,13328,NPM1-ALK ALK L1122V ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,643,ASP3026,4869
122,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3440,10000003,Advanced Solid Tumor,JAX,13328,NPM1-ALK ALK L1122V ALK L1196M,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,4869
123,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK ALK S1206C were resistant to brigatinib (AP26113) in culture (PMID: 25421750).",Actionable,3436,50744,anaplastic large cell lymphoma,DOID,13332,NPM1-ALK ALK S1206C,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,4869
124,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3439,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,4869
125,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3487,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,789,Ceritinib,4869
126,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3463,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,698,Alectinib,4869
127,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3453,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",decreased response,706,Crizotinib,4869
128,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK and ALK S1206C were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3556,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,643,ASP3026,4869
129,Preclinical,"In a preclinical study, ASP3026 inhibited growth of human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing the crizotinib-resistant mutation ALK L1196Q in culture (PMID: 25749034).",Actionable,5503,50744,anaplastic large cell lymphoma,DOID,20952,NPM1-ALK ALK L1196Q,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",sensitive,643,ASP3026,4869
130,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing ALK L1196Q were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).",Actionable,5504,50744,anaplastic large cell lymphoma,DOID,20952,NPM1-ALK ALK L1196Q,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,706,Crizotinib,4869
131,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5428,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,634,AP26113,4869
132,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5487,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,789,Ceritinib,4869
133,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5412,50744,anaplastic large cell lymphoma,DOID,20769,NPM1-ALK ALK I1171N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,4869
134,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).",Actionable,5477,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,706,Crizotinib,4869
135,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5418,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,4869
136,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5437,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,698,Alectinib,4869
137,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5496,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,869,PF-06463922,4869
138,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5357,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,634,AP26113,4869
139,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK R1192P were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).",Actionable,5350,50744,anaplastic large cell lymphoma,DOID,20661,NPM1-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,706,Crizotinib,4869
140,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5355,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,4869
141,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P had a reduced response to AZD3463 mediated growth inhibition in culture relative to NPM1-ALK (PMID: 27009859).",Actionable,5359,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",decreased response,1586,AZD3463,4869
142,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Xalkori (Crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5354,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,706,Crizotinib,4869
143,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5356,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,698,Alectinib,4869
144,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5358,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,643,ASP3026,4869
145,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859).",Actionable,5332,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,634,AP26113,4869
146,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5334,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,643,ASP3026,4869
147,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5327,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,789,Ceritinib,4869
148,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5329,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,698,Alectinib,4869
149,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5326,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,706,Crizotinib,4869
150,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859).",Actionable,5335,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",sensitive,1586,AZD3463,4869
151,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1161S were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).",Actionable,5349,50744,anaplastic large cell lymphoma,DOID,20654,NPM1-ALK ALK I1171S,"[{'id': 5026, 'pubMedId': 27009859, 'title': 'TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27009859'}]",resistant,706,Crizotinib,4869
152,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171T were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5411,50744,anaplastic large cell lymphoma,DOID,5337,NPM1-ALK ALK I1171T,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,4869
153,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).",Actionable,5478,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,706,Crizotinib,4869
154,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5488,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,789,Ceritinib,4869
155,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5429,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,634,AP26113,4869
156,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5419,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,4869
157,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5497,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,869,PF-06463922,4869
158,Preclinical,"In a preclinical study, an anaplastic large-cell lymphoma cell line expressing NPM-ALK I1171T demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 24509625).",Actionable,2057,50744,anaplastic large cell lymphoma,DOID,5337,NPM1-ALK ALK I1171T,"[{'id': 1898, 'pubMedId': 24509625, 'title': 'Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24509625'}]",resistant,706,Crizotinib,4869
159,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5438,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,698,Alectinib,4869
160,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with C1156F and D1203N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5491,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,789,Ceritinib,4869
161,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5502,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,869,PF-06463922,4869
162,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5423,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,4869
163,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).",Actionable,5479,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,706,Crizotinib,4869
164,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5432,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,634,AP26113,4869
165,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK C1156F and D1203N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5414,50744,anaplastic large cell lymphoma,DOID,20896,NPM1-ALK ALK C1156F ALK D1203N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,643,ASP3026,4869
166,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5440,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,"[{'id': 5029, 'pubMedId': 25749034, 'title': 'NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749034'}]",resistant,698,Alectinib,4869
167,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Brigatinib (AP26113) in culture (PMID: 25421750).",Actionable,3434,50744,anaplastic large cell lymphoma,DOID,13333,NPM1-ALK ALK F1174V ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,4869
168,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK1198F were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3438,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,634,AP26113,4869
169,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3461,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,698,Alectinib,4869
170,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3553,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,643,ASP3026,4869
171,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F in culture (PMID: 25421750).",Actionable,3458,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",sensitive,706,Crizotinib,4869
172,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).",Actionable,3482,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,"[{'id': 3791, 'pubMedId': 25421750, 'title': 'Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25421750'}]",resistant,789,Ceritinib,4869
0,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",Actionable,5994,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,3027,GSK2126458 + Trametinib,4893
1,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5958,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,342,Vemurafenib,4893
2,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5954,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,3,Dabrafenib,4893
3,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5968,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,763,GSK2126458,4893
4,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).",Actionable,5963,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,2,Trametinib,4893
5,Preclinical,"In a preclinical study, human melanoma cells harboring BRAF G469R and NRAS G61K were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).",Actionable,6612,1909,melanoma,DOID,23638,BRAF G469R NRAS Q61K,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,342,Vemurafenib,4893
6,Preclinical,"In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).",Actionable,6603,1909,melanoma,DOID,23638,BRAF G469R NRAS Q61K,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",decreased response,913,Selumetinib,4893
7,Preclinical,"In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).",Actionable,6592,1909,melanoma,DOID,23638,BRAF G469R NRAS Q61K,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,3268,LY3009120,4893
8,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Ibrance (palbociclib) and Mekinist (trametinib) induced tumor regression in a mouse melanoma model expressing NRAS Q61K and harboring CDKN2A loss (PMID: 22983396).",Actionable,2923,1909,melanoma,DOID,10733,NRAS Q61K CDKN2A loss,"[{'id': 3528, 'pubMedId': 22983396, 'title': 'Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22983396'}]",sensitive,1368,Palbociclib + Trametinib,4893
9,Preclinical,"In a preclinical study, SBI-0640726 delayed tumor growth of melanomas in mice with a genetic background of NRAS Q61K and CDKN2A loss (PMID: 26603897).",Actionable,3791,1909,melanoma,DOID,10733,NRAS Q61K CDKN2A loss,"[{'id': 4137, 'pubMedId': 26603897, 'title': 'SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26603897'}]",sensitive,3306,SBI-0640756,4893
10,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4495,3908,non-small cell lung carcinoma,DOID,18261,EGFR L858R EGFR T790M NRAS Q61K,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,660,Osimertinib,4893
11,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to WZ4002 after the emergence of NRAS Q61K in culture (PMID: 25870145).",Actionable,4487,3908,non-small cell lung carcinoma,DOID,18236,EGFR exon 19 del NRAS Q61K,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,3075,WZ4002,4893
12,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4485,3908,non-small cell lung carcinoma,DOID,18236,EGFR exon 19 del NRAS Q61K,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,660,Osimertinib,4893
13,Preclinical,"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K in culture (PMID: 25870145).",Actionable,4486,3908,non-small cell lung carcinoma,DOID,18236,EGFR exon 19 del NRAS Q61K,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",sensitive,913,Selumetinib,4893
14,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5971,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,3,Dabrafenib,4893
15,Preclinical,"In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471).",Actionable,5974,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,763,GSK2126458,4893
16,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were 3-7 fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600K in culture (PMID: 22389471).",Actionable,5972,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,2,Trametinib,4893
17,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).",Actionable,5981,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,1066,Trametinib + Dabrafenib,4893
18,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).",Actionable,5995,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,3027,GSK2126458 + Trametinib,4893
19,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).",Actionable,5996,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,4004,Dabrafenib + GSK2126458,4893
20,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",Actionable,7956,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",decreased response,342,Vemurafenib,4893
21,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909).",Actionable,7939,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,3300,TAK-632,4893
22,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909).",Actionable,7909,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,1093,AZ628,4893
23,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61L demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).",Actionable,7949,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",decreased response,4606,PLX7904,4893
24,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).",Actionable,7964,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",decreased response,3,Dabrafenib,4893
25,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4494,3908,non-small cell lung carcinoma,DOID,18240,EGFR exon 19 del EGFR T790M NRAS Q61K,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,660,Osimertinib,4893
26,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5962,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,2,Trametinib,4893
27,Preclinical,"In a preclinical study, the response of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S to Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) was conflicting as one cell line with this mutation profile responded to the combination and another cell line with the mutation profile did not (PMID: 22389471).",Actionable,5990,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",conflicting,4004,Dabrafenib + GSK2126458,4893
28,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 22389471).",Actionable,5961,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,342,Vemurafenib,4893
29,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",Actionable,5993,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,3027,GSK2126458 + Trametinib,4893
30,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5952,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,3,Dabrafenib,4893
31,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5967,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,763,GSK2126458,4893
32,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cells harboring BRAF V600E and NRAS A146T and NRAS Q61K in culture (PMID: 22389471).",Actionable,5979,1909,melanoma,DOID,22097,BRAF V600E NRAS Q61K NRAS A146T,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,1066,Trametinib + Dabrafenib,4893
33,Clinical Study,"In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, BRAF amplification and NRAS Q61K, during treatment with Zelboraf (vemurafenib) (PMID: 24265153).",Actionable,7070,1909,melanoma,DOID,24387,BRAF amp BRAF V600X NRAS Q61K,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,342,Vemurafenib,4893
34,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) growth of a non-small cell lung cancer cell line harboring BRAF G466V and expressing NRAS Q61K in culture (PMID: 28783719).",Actionable,11667,3908,non-small cell lung carcinoma,DOID,28181,BRAF G466V NRAS Q61K,"[{'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}]",sensitive,2,Trametinib,4893
35,Preclinical,"In a preclinical study, human melanoma cell lines harboring NRAS Q61K were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).",Actionable,6609,1909,melanoma,DOID,646,NRAS Q61K,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,342,Vemurafenib,4893
36,Phase II,"In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587).",Actionable,10897,1909,melanoma,DOID,646,NRAS Q61K,"[{'id': 180, 'pubMedId': 23414587, 'title': 'MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23414587'}]",sensitive,807,Binimetinib,4893
37,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727).",Actionable,8174,3908,non-small cell lung carcinoma,DOID,646,NRAS Q61K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4656,Everolimus + Pimasertib,4893
38,Preclinical,"In a preclinical study, Selumetinib (AZD6244) inhibited proliferation of human melanoma cell lines harboring NRAS Q61K in culture (PMID: 26343583).",Actionable,6601,1909,melanoma,DOID,646,NRAS Q61K,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,913,Selumetinib,4893
39,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727).",Actionable,8183,3908,non-small cell lung carcinoma,DOID,646,NRAS Q61K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4657,Pimasertib + Regorafenib,4893
40,Preclinical,"In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring NRAS Q61K in culture (PMID: 26343583).",Actionable,6591,1909,melanoma,DOID,646,NRAS Q61K,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,3268,LY3009120,4893
41,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727).",Actionable,8147,3908,non-small cell lung carcinoma,DOID,646,NRAS Q61K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,871,Pimasertib,4893
42,Preclinical,"In a preclinical study, human non-small cell lung cancer cells harboring NRAS Q61K had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073, PMID: 12068308).",Actionable,3136,3908,non-small cell lung carcinoma,DOID,646,NRAS Q61K,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 637, 'pubMedId': 12068308, 'title': 'Mutations of the BRAF gene in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12068308'}]",decreased response,1040,PF-05212384,4893
43,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727).",Actionable,8178,3908,non-small cell lung carcinoma,DOID,646,NRAS Q61K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,1659,Pimasertib + Sorafenib,4893
44,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).",Actionable,5978,1909,melanoma,DOID,6906,BRAF V600E NRAS Q61K,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,1066,Trametinib + Dabrafenib,4893
45,Preclinical,"In a preclinical study, treatment with XL888 resulted in increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant melanoma cells harboring BRAF V600E along with NRAS Q61K in cell culture (PMID: 22351686).",Actionable,2275,1909,melanoma,DOID,6906,BRAF V600E NRAS Q61K,"[{'id': 2956, 'pubMedId': 22351686, 'title': 'The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22351686'}]",sensitive,970,XL888,4893
46,Preclinical,"In a preclinical study, a NRAS Q61K mutation conferred resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323).",Actionable,2279,1909,melanoma,DOID,6906,BRAF V600E NRAS Q61K,"[{'id': 2959, 'pubMedId': 21107323, 'title': 'Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21107323'}]",resistant,342,Vemurafenib,4893
47,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing NRAS Q61K were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).",Actionable,5949,1909,melanoma,DOID,6906,BRAF V600E NRAS Q61K,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,3,Dabrafenib,4893
48,Preclinical - Pdx,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type melanoma cells harboring NRAS Q61K in patient-derived xenograft models (PMID: 19276360).",Actionable,7889,1909,melanoma,DOID,26086,BRAF wild-type NRAS Q61K,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",resistant,1095,GDC0879,4893
49,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring NRAS G12V demonstrated resistance to Erbitux (cetuximab) in culture (PMID: 28179366).",Actionable,10315,9256,colorectal cancer,DOID,3354,NRAS G12V,"[{'id': 8298, 'pubMedId': 28179366, 'title': 'Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179366'}]",resistant,694,Cetuximab,4893
50,Preclinical - Cell culture,"In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring NRAS G12V in culture (PMID: 28179366).",Actionable,10314,9256,colorectal cancer,DOID,3354,NRAS G12V,"[{'id': 8298, 'pubMedId': 28179366, 'title': 'Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28179366'}]",sensitive,3505,Cetuximab + Trametinib,4893
51,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12V were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4490,3908,non-small cell lung carcinoma,DOID,18238,EGFR exon 19 del NRAS G12V,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,660,Osimertinib,4893
52,Preclinical,"In a preclinical study, expression of NRAS G12V in melanoma cells harboring BRAF V600E conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 26267534).",Actionable,5785,1909,melanoma,DOID,21619,BRAF V600E NRAS G12V,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",resistant,342,Vemurafenib,4893
53,Preclinical - Cell culture,"In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and over expressing NRAS G12V in culture (PMID: 26267534).",Actionable,5786,1909,melanoma,DOID,21619,BRAF V600E NRAS G12V,"[{'id': 4897, 'pubMedId': 26267534, 'title': 'Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26267534'}]",sensitive,3769,DEL-22379,4893
54,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with NRAS exon 2 mutations (Guidelines).,Actionable,3851,9256,colorectal cancer,DOID,1197,NRAS G13X,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,845,Panitumumab,4893
55,Guideline,Erbitux (cetuximab) is not indicated for use in colorectal cancer patients with NRAS exon 2 mutations (Guidelines).,Actionable,3846,9256,colorectal cancer,DOID,1197,NRAS G13X,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,694,Cetuximab,4893
56,Preclinical - Cell line xenograft,"In a preclinical study, PLX4720 did not inhibit growth of melanoma cells harboring NRAS Q61L in culture or in cell line xenograft models (PMID: 25500121, PMID: 23431193).",Actionable,3317,1909,melanoma,DOID,3375,NRAS Q61L,"[{'id': 3714, 'pubMedId': 25500121, 'title': 'Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25500121'}, {'id': 3728, 'pubMedId': 23431193, 'title': 'Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23431193'}]",resistant,1060,PLX4720,4893
57,Preclinical - Cell line xenograft,"In a preclinical study, CCT241161 inhibited MEK and ERK activation and growth of a melanoma cell line harboring NRAS Q61L in culture, and inhibited tumor growth in a NRAS Q61L-mutant melanoma cell line xenograft model (PMID: 25500121, PMID: 23431193).",Actionable,3315,1909,melanoma,DOID,3375,NRAS Q61L,"[{'id': 3714, 'pubMedId': 25500121, 'title': 'Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25500121'}, {'id': 3728, 'pubMedId': 23431193, 'title': 'Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23431193'}]",sensitive,3106,CCT241161,4893
58,Preclinical,"In a preclinical study, human melanoma cells harboring NRAS Q61L were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).",Actionable,6611,1909,melanoma,DOID,3375,NRAS Q61L,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,342,Vemurafenib,4893
59,Preclinical - Cell line xenograft,"In a preclinical study, CCT196969 inhibited MEK and ERK activation and growth of a melanoma cell line harboring NRAS Q61L in culture, and inhibited tumor growth in a NRAS Q61L-mutant melanoma cell line xenograft model (PMID: 25500121, PMID: 23431193).",Actionable,3316,1909,melanoma,DOID,3375,NRAS Q61L,"[{'id': 3714, 'pubMedId': 25500121, 'title': 'Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25500121'}, {'id': 3728, 'pubMedId': 23431193, 'title': 'Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23431193'}]",sensitive,3105,CCT196969,4893
60,Phase II,"In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587).",Actionable,10896,1909,melanoma,DOID,3375,NRAS Q61L,"[{'id': 180, 'pubMedId': 23414587, 'title': 'MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23414587'}]",sensitive,807,Binimetinib,4893
61,Preclinical,"In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring NRAS Q61L in culture (PMID: 26343583).",Actionable,6604,1909,melanoma,DOID,3375,NRAS Q61L,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",decreased response,913,Selumetinib,4893
62,Preclinical,"In a preclinical study, LY3009120 modestly inhibited soft agar growth of human melanoma cancer cells harboring NRAS Q61L in culture (PMID: 26343583).",Actionable,6594,1909,melanoma,DOID,3375,NRAS Q61L,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",decreased response,3268,LY3009120,4893
63,Preclinical,"In a preclinical study, human acute lymphoblastic leukemia cells harboring NRAS and CDKN2A mutations were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6683,9952,acute lymphocytic leukemia,DOID,23669,NRAS mut CDKN2A mut,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,2,Trametinib,4893
64,Preclinical - Pdx,"In a preclinical study, LSN3074753 and Erbitux (cetuximab) worked synergistically, resulting in tumor regression in a patient-derived xenograft model of colorectal cancer harboring BRAF G596V and NRAS G13R (PMID: 28611205).",Actionable,12197,9256,colorectal cancer,DOID,28547,BRAF G596V NRAS G13R,"[{'id': 10143, 'pubMedId': 28611205, 'title': 'Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28611205'}]",sensitive,6338,Cetuximab + LSN3074753,4893
65,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",Actionable,7957,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",decreased response,342,Vemurafenib,4893
66,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).",Actionable,7965,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",decreased response,3,Dabrafenib,4893
67,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).",Actionable,7911,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,1093,AZ628,4893
68,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).",Actionable,7951,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",decreased response,4606,PLX7904,4893
69,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).",Actionable,7941,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,3300,TAK-632,4893
70,Preclinical,"In a preclinical study, Binimetinib (MEK162) inhibited growth of acute myeloid leukemia cells that have been demonstrated to harbor NRAS G12D in culture and decreased disease burden in xenograft models with NRAS G12D (PMID: 24569456, PMID: 11238126).
",Actionable,3595,9119,acute myeloid leukemia,DOID,2899,NRAS G12D,"[{'id': 3872, 'pubMedId': 24569456, 'title': 'Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24569456'}, {'id': 3873, 'pubMedId': 11238126, 'title': 'Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11238126'}]",sensitive,807,Binimetinib,4893
71,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Binimetinib (MEK162) and Alpelisib (BYL719) inhibited proliferation in a human acute myeloid leukemia (AML) cell line harboring NRAS G12D in culture, and decreased disease burden in xenograft models (PMID: 24569456).",Actionable,3597,9119,acute myeloid leukemia,DOID,2899,NRAS G12D,"[{'id': 3872, 'pubMedId': 24569456, 'title': 'Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24569456'}]",sensitive,1311,BYL719 + MEK162,4893
72,Preclinical - Cell culture,"In a preclinical study, N-Arachidonoyl Dopamine (NADA) disrupted NRAS protein membrane localization and decreased NRAS downstream signaling, and inhibited proliferation and induced cell death in transformed cells expressing NRAS G12D in culture (PMID: 27760835).",Actionable,9740,10000003,Advanced Solid Tumor,JAX,2899,NRAS G12D,"[{'id': 7517, 'pubMedId': 27760835, 'title': 'N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane Translocation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27760835'}]",sensitive,5185,N-Arachidonoyl Dopamine ,4893
73,Preclinical,"In a preclinical study, AZD0156 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).",Actionable,12168,9119,acute myeloid leukemia,DOID,20552,KMT2A-MLLT1 NRAS G12D,"[{'id': 10122, 'pubMedId': 27625305, 'title': 'Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27625305'}]",predicted – sensitive,3557,AZD0156,4893
74,Preclinical,"In a preclinical study, AZ20 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).",Actionable,12169,9119,acute myeloid leukemia,DOID,20552,KMT2A-MLLT1 NRAS G12D,"[{'id': 10122, 'pubMedId': 27625305, 'title': 'Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27625305'}]",predicted – sensitive,2880,AZ20,4893
75,Preclinical,"In a preclinical study, acute myeloid leukemia cells co-harboring KMT2A-MLLT1 and NRAS G12D demonstrated a decrease in tumor burden, reduced colony formation, and an increase in cell death when treated with Dinaciclib in both culture and mouse models (PMID: 26627013).",Actionable,5311,9119,acute myeloid leukemia,DOID,20552,KMT2A-MLLT1 NRAS G12D,"[{'id': 5010, 'pubMedId': 26627013, 'title': 'The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627013'}]",sensitive,719,Dinaciclib,4893
76,Preclinical - Cell line xenograft,"In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring AKT E17K and NRAS G12D in culture, and demonstrated antitumor activity in xenograft models (PMID: 27699769).",Actionable,8810,10283,prostate cancer,DOID,26446,AKT1 E17K NRAS G12D,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",sensitive,994,BAY1125976,4893
77,Preclinical,"In a preclinical study, LY3009120 modestly inhibited soft agar growth of human melanoma cancer cells harboring NRAS R167L, BRAF K601E, and BRAF A665V in culture (PMID: 26343583).",Actionable,6597,1909,melanoma,DOID,23641,NRAS R167L BRAF K601E BRAF A665V,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",decreased response,3268,LY3009120,4893
78,Preclinical,"In a preclinical study, human melanoma cells harboring BRAF K601E, BRAF A665V, and NRAS R167L were insensitive to Selumetinib (AZD6244) in culture (PMID: 26343583).",Actionable,6605,1909,melanoma,DOID,23641,NRAS R167L BRAF K601E BRAF A665V,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,913,Selumetinib,4893
79,Preclinical,"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R in culture (PMID: 25870145).",Actionable,4492,3908,non-small cell lung carcinoma,DOID,18239,EGFR exon 19 del NRAS G12R,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",sensitive,913,Selumetinib,4893
80,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4491,3908,non-small cell lung carcinoma,DOID,18239,EGFR exon 19 del NRAS G12R,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,660,Osimertinib,4893
81,Preclinical - Pdx & cell culture,"In a preclinical study, 3144 inhibited growth of patient-derived T-cell acute lymphocytic leukemia cells harboring NRAS G13V in culture, and reduced tumor burden in xenograft models (PMID: 28235199).",Actionable,10842,50523,adult T-cell leukemia,DOID,3366,NRAS G13V,"[{'id': 8866, 'pubMedId': 28235199, 'title': 'Multivalent Small-Molecule Pan-RAS Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28235199'}]",sensitive,5658,3144,4893
82,Preclinical,"In a preclinical study, human melanoma cells harboring NRAS G13D were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).",Actionable,6610,1909,melanoma,DOID,3361,NRAS G13D,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,342,Vemurafenib,4893
83,Preclinical,"In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring NRAS G13D in culture (PMID: 26343583).",Actionable,6593,1909,melanoma,DOID,3361,NRAS G13D,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,3268,LY3009120,4893
84,Preclinical - Cell culture,"In a preclinical study, 3144 inhibited growth of patient-derived T-cell acute lymphocytic leukemia cells harboring NRAS G13D in culture (PMID: 28235199).",Actionable,10843,50523,adult T-cell leukemia,DOID,3361,NRAS G13D,"[{'id': 8866, 'pubMedId': 28235199, 'title': 'Multivalent Small-Molecule Pan-RAS Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28235199'}]",sensitive,5658,3144,4893
85,Preclinical,"In a preclinical study, Selumetinib (AZD6244) inhibited proliferation of human melanoma cells harboring NRAS G13D in culture (PMID: 26343583).",Actionable,6602,1909,melanoma,DOID,3361,NRAS G13D,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,913,Selumetinib,4893
86,Preclinical,"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K in culture (PMID: 25870145).",Actionable,4476,3908,non-small cell lung carcinoma,DOID,18231,EGFR exon 19 del NRAS E63K,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",sensitive,913,Selumetinib,4893
87,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K were resistant to Tagrisso (osimertinib) AZD9291 treatment in culture (PMID: 25870145).",Actionable,4478,3908,non-small cell lung carcinoma,DOID,18231,EGFR exon 19 del NRAS E63K,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,660,Osimertinib,4893
88,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of NRAS E63K in culture (PMID: 25870145).",Actionable,4477,3908,non-small cell lung carcinoma,DOID,18231,EGFR exon 19 del NRAS E63K,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,751,Gefitinib,4893
89,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5966,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,763,GSK2126458,4893
90,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5950,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,3,Dabrafenib,4893
91,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E and also had reduced sensitivity in comparison to cell lines harboring BRAF V600E and NRAS A146T in culture (PMID: 22389471).",Actionable,5960,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,2,Trametinib,4893
92,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5956,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,342,Vemurafenib,4893
93,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",Actionable,5992,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,3027,GSK2126458 + Trametinib,4893
94,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) did not improve the response to human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture (PMID: 22389471).",Actionable,5989,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",no benefit,4004,Dabrafenib + GSK2126458,4893
95,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5965,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,763,GSK2126458,4893
96,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5955,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,342,Vemurafenib,4893
97,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5951,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",resistant,3,Dabrafenib,4893
98,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",Actionable,5977,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,1066,Trametinib + Dabrafenib,4893
99,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",Actionable,5991,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,3027,GSK2126458 + Trametinib,4893
100,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were >10-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5959,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",decreased response,2,Trametinib,4893
101,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",Actionable,5988,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,"[{'id': 2092, 'pubMedId': 22389471, 'title': 'Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389471'}]",sensitive,4004,Dabrafenib + GSK2126458,4893
102,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with NRAS exon 4 mutations (Guidelines).,Actionable,3849,9256,colorectal cancer,DOID,3351,NRAS A146T,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,845,Panitumumab,4893
103,Guideline,Erbitux (cetuximab) is not indicated for use in colorectal cancer patients with NRAS exon 4 mutations (Guidelines).,Actionable,3848,9256,colorectal cancer,DOID,3351,NRAS A146T,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,694,Cetuximab,4893
104,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited Akt activation and downstream signaling in bladder cancer cell lines carrying both Akt1 E17K and Nras Q61R mutations (AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3685).",Actionable,3830,4007,bladder carcinoma,DOID,16525,AKT1 E17K NRAS Q61R,"[{'id': 2275, 'pubMedId': None, 'title': 'Abstract 3685: BAY 1125976, is a selective allosteric AKT1/2 inhibitor with high efficacy in AKT1-mutated cancers', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/3685'}]",sensitive,994,BAY1125976,4893
105,Phase II,"In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587).",Actionable,10898,1909,melanoma,DOID,3043,NRAS Q61R,"[{'id': 180, 'pubMedId': 23414587, 'title': 'MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23414587'}]",sensitive,807,Binimetinib,4893
106,Preclinical - Cell culture,"In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including an anaplastic thyroid cancer cell line harboring NRAS Q61R (PMID: 21289267).",Actionable,8218,1781,thyroid cancer,DOID,3043,NRAS Q61R,"[{'id': 6573, 'pubMedId': 21289267, 'title': 'The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21289267'}]",sensitive,816,MK2206,4893
107,Clinical Study,"In a clinical study, a melanoma patient harboring KIT D816V and NRAS Q61R demonstrated progressive disease when treated with a combination of Mekinist (trametinib) and Keytruda (pembrolizumab) (PMID: 28514312). ",Actionable,11050,1909,melanoma,DOID,27900,KIT D816V NRAS Q61R,"[{'id': 9046, 'pubMedId': 28514312, 'title': 'Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28514312'}]",no benefit,1450,Pembrolizumab + Trametinib,4893
108,Clinical Study,"In a clinical study, a melanoma patient harboring an ATM mutation and NRAS Q61R demonstrated a partial response and 16 month progression free survival when treated with Binimetinib (MEK162) (PMID: 28514312). ",Actionable,11054,1909,melanoma,DOID,27905,ATM mut NRAS Q61R,"[{'id': 9046, 'pubMedId': 28514312, 'title': 'Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28514312'}]",sensitive,807,Binimetinib,4893
109,Clinical Study,"In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153).",Actionable,7068,1909,melanoma,DOID,24385,BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,342,Vemurafenib,4893
110,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified NRAS in culture (PMID: 25870145).",Actionable,4484,3908,non-small cell lung carcinoma,DOID,18234,EGFR exon 19 del NRAS amp,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,623,Afatinib,4893
111,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4483,3908,non-small cell lung carcinoma,DOID,18234,EGFR exon 19 del NRAS amp,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",resistant,660,Osimertinib,4893
112,Preclinical,"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS in culture (PMID: 25870145).  ",Actionable,4482,3908,non-small cell lung carcinoma,DOID,18234,EGFR exon 19 del NRAS amp,"[{'id': 4580, 'pubMedId': 25870145, 'title': 'Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870145'}]",sensitive,913,Selumetinib,4893
113,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with NRAS exon 2 mutations (Guidelines).,Actionable,3852,9256,colorectal cancer,DOID,1196,NRAS G12X,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,845,Panitumumab,4893
114,Guideline,Erbitux (cetuximab) is not indicated for use in colorectal cancer patients with NRAS exon 2 mutations (Guidelines).,Actionable,3845,9256,colorectal cancer,DOID,1196,NRAS G12X,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,694,Cetuximab,4893
115,Guideline,Erbitux (cetuximab) is not indicated for use in colorectal cancer patients with NRAS exon 3 mutations (Guidelines).,Actionable,3847,9256,colorectal cancer,DOID,1198,NRAS Q61X,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,694,Cetuximab,4893
116,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with NRAS exon 3 mutations (Guidelines).,Actionable,3850,9256,colorectal cancer,DOID,1198,NRAS Q61X,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,845,Panitumumab,4893
117,Phase I,"In a Phase I trial, Abemaciclib (LY2835219) resulted in a partial response in a melanoma patient with CDKN2A loss and NRAS mutation (PMID: 27217383).",Actionable,2266,1909,melanoma,DOID,6894,CDKN2A loss NRAS mutant,"[{'id': 2947, 'pubMedId': None, 'title': 'A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer', 'url': 'http://meetinglibrary.asco.org/content/111069-132'}, {'id': 6356, 'pubMedId': 27217383, 'title': 'Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27217383'}]",sensitive,802,Abemaciclib,4893
118,Preclinical,"In a preclinical study, human liver cancer cells harboring mutant NRAS and mutant CTNNB1 were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6696,3571,liver cancer,DOID,23671,CTNNB1 mut NRAS mut,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,2,Trametinib,4893
119,Preclinical - Cell culture,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in NRAS mutated melanoma cell lines resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).",Actionable,7794,1909,melanoma,DOID,26045,NRAS mut STAG2 dec exp,"[{'id': 6497, 'pubMedId': 27500726, 'title': 'Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27500726'}]",decreased response,2,Trametinib,4893
120,Preclinical - Cell culture,"In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to an NRAS mutation in culture (PMID: 25873592).",Actionable,7829,1909,melanoma,DOID,14782,BRAF mut NRAS mut,"[{'id': 6506, 'pubMedId': 25873592, 'title': 'The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25873592'}]",predicted – sensitive,1059,BI-847325,4893
121,Phase I,"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 50% (1/2) of melanoma patients harboring both BRAF and NRAS mutations (PMID: 26169970).",Actionable,3688,1909,melanoma,DOID,14782,BRAF mut NRAS mut,"[{'id': 3994, 'pubMedId': 26169970, 'title': 'Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26169970'}]",sensitive,792,Lenvatinib,4893
122,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS and with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture (PMID: 26439693).",Actionable,10774,9256,colorectal cancer,DOID,27788,NRAS mut PIK3CA wild-type,"[{'id': 8454, 'pubMedId': 26439693, 'title': 'Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26439693'}]",predicted – sensitive,932,TAK-733,4893
123,Phase I,"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 83% (5/6) of melanoma patients harboring NRAS mutations and wild-type BRAF (PMID: 26169970).",Actionable,3797,1909,melanoma,DOID,1299,BRAF wild-type NRAS mutant,"[{'id': 3994, 'pubMedId': 26169970, 'title': 'Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26169970'}]",sensitive,792,Lenvatinib,4893
124,Preclinical - Cell line xenograft,"In a preclinical study, the combination treatment of PD-0325901 and Ibrance (palbociclib) resulted in tumor regression in 33% (2/6) of melanoma xenograft models harboring an NRAS mutation (PMID: 27488531). ",Actionable,8553,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",sensitive,1823,PD-0325901 + Palbociclib,4893
125,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of liver cancer cell lines harboring mutant NRAS in culture (PMID: 26343583).",Actionable,6695,3571,liver cancer,DOID,3,NRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,2,Trametinib,4893
126,Preclinical,"In a preclinical study, human melanoma cell lines harboring a mutation in NRAS were resistant to Zelboraf (vemurafenib) mediated growth inhibition in culture (PMID: 26343583).",Actionable,6615,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,342,Vemurafenib,4893
127,Preclinical,"In a preclinical study, human non-Hodgkin lymphoma cells harboring mutant NRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6689,60060,non-Hodgkin lymphoma,DOID,3,NRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,2,Trametinib,4893
128,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of human acute myeloid leukemia cell lines harboring mutant NRAS in culture (PMID: 26343583).",Actionable,6684,9119,acute myeloid leukemia,DOID,3,NRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,2,Trametinib,4893
129,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of human multiple myeloma cells harboring mutant NRAS in culture (PMID: 26343583).",Actionable,6686,9538,multiple myeloma,DOID,3,NRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,2,Trametinib,4893
130,Preclinical,"In a preclinical study, Tubastatin A inhibited proliferation of NRAS mutant melanoma cell lines in culture (PMID: 25957812).",Actionable,4763,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 4713, 'pubMedId': 25957812, 'title': 'Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25957812'}]",sensitive,3635,Tubastatin A,4893
131,Preclinical,"In a preclinical study, obatoclax decreased proliferation in human tumor cell lines with NRAS mutation in culture (PMID: 22460902).",Actionable,1824,10000003,Advanced Solid Tumor,JAX,3,NRAS mutant,"[{'id': 2158, 'pubMedId': 22460902, 'title': 'Systematic identification of genomic markers of drug sensitivity in cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22460902'}]",sensitive,834,Obatoclax,4893
132,Preclinical,"In a preclinical study, CCT241161 inhibited growth of melanoma cells harboring NRAS mutations in culture (PMID: 25500121).",Actionable,3319,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 3714, 'pubMedId': 25500121, 'title': 'Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25500121'}]",sensitive,3106,CCT241161,4893
133,Phase II,"In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587). ",Actionable,709,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 180, 'pubMedId': 23414587, 'title': 'MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23414587'}]",conflicting,807,Binimetinib,4893
134,Phase III,"In a Phase III clinical trial, treatment with Binimetinib (MEK162) improved median progression-free survival compared to treatment with Deticene (dacarbazine) (2.8 mo. vs. 1.5 mo.), but did not improve overall survival in patients with NRAS-mutant melanoma (PMID: 28284557).",Actionable,10334,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 8316, 'pubMedId': 28284557, 'title': 'Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28284557'}]",conflicting,807,Binimetinib,4893
135,Phase I,"In a Phase I trial, Mekinist (trametinib) treatment resulted in stable disease in 29% (2/7) of patients with NRAS mutated melanoma (PMID: 22805292).",Actionable,10895,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 233, 'pubMedId': 22805292, 'title': 'Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805292'}]",predicted – sensitive,2,Trametinib,4893
136,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant colorectal cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11700,9256,colorectal cancer,DOID,3,NRAS mutant,"[{'id': 9707, 'pubMedId': None, 'title': 'KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short'}]",predicted – sensitive,5747,KO-947,4893
137,Preclinical,"In a preclinical study, BI-69A11 inhibited proliferation and transformation of human melanoma cell lines harboring NRAS mutation in culture (PMID: 26603897).",Actionable,3786,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 4137, 'pubMedId': 26603897, 'title': 'SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26603897'}]",sensitive,3308,BI-69A11,4893
138,Phase I,"In a Phase I trial, Binimetinib (MEK162) treatment resulted in partial response in a biliary tract cancer patient harboring NRAS mutation (PMID: 28152546)",Actionable,10460,4607,biliary tract cancer,DOID,3,NRAS mutant,"[{'id': 8465, 'pubMedId': 28152546, 'title': 'A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28152546'}]",predicted – sensitive,807,Binimetinib,4893
139,Phase I,"In a Phase I study, selumetinib demonstrated an increase in iodine uptake and retention in a subgroup of patients with thyroid cancer that was refractory to radioiodine; including patients with BRAF and NRAS mutations disease (PMID: 23406027).",Actionable,1280,1781,thyroid cancer,DOID,3,NRAS mutant,"[{'id': 744, 'pubMedId': 23406027, 'title': 'Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23406027'}]",sensitive,913,Selumetinib,4893
140,Guideline,Vectibix (panitumumab) is not indicated for use in patients with NRAS-mutant colorectal cancer (Guidelines). ,Actionable,1961,9256,colorectal cancer,DOID,3,NRAS mutant,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,845,Panitumumab,4893
141,Preclinical - Cell line xenograft,"In a preclinical study, AZD5153 inhibited proliferation of acute myeloid leukemia cells harboring NRAS mutation in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27573426).",Actionable,9133,9119,acute myeloid leukemia,DOID,3,NRAS mutant,"[{'id': 6927, 'pubMedId': 27573426, 'title': 'AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27573426'}]",predicted – sensitive,4910,AZD5153,4893
142,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant gastric carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11702,5517,stomach carcinoma,DOID,3,NRAS mutant,"[{'id': 9707, 'pubMedId': None, 'title': 'KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short'}]",predicted – sensitive,5747,KO-947,4893
143,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of human autonomic ganglia cancer cells harboring mutant NRAS in culture (PMID: 26343583).",Actionable,6682,2621,autonomic nervous system neoplasm,DOID,3,NRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,2,Trametinib,4893
144,Phase Ib/II,"In a Phase Ib/II clinical trial, treatment with Mekinist (trametinib) resulted in an overall response rate of 28% in RAS-mutant leukemia patients, with 12% (7/57) of patients achieving complete remission (ASH 2015 Annual Meeting, Abst 677).",Actionable,3586,1240,leukemia,DOID,3,NRAS mutant,"[{'id': 3823, 'pubMedId': None, 'title': '677 Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease', 'url': 'https://ash.confex.com/ash/2012/webprogram/Paper51144.html'}]",predicted – sensitive,2,Trametinib,4893
145,Preclinical,"In a preclinical study, human urinary tract transitional cell carcinoma cells harboring mutant NRAS were moderately sensitive to Mekinist (trametinib) growth inhibition in culture (PMID: 26343583).",Actionable,6736,2671,transitional cell carcinoma,DOID,3,NRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",decreased response,2,Trametinib,4893
146,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant pancreatic cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11698,1793,pancreatic cancer,DOID,3,NRAS mutant,"[{'id': 9707, 'pubMedId': None, 'title': 'KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short'}]",predicted – sensitive,5747,KO-947,4893
147,Phase III,"In a Phase III trial, Binimetinib (MEK162) treatment resulted in improved progression free survival (2.8 months), objective response rate (15%, 40/269) and disease control rate (58%, 156/269) compared to Deticene (dacarbazine) (1.5 months, 7%, 25%, respectively) in NRAS-mutant cutaneous melanoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9500)).",Actionable,6819,8923,skin melanoma,DOID,3,NRAS mutant,"[{'id': 5835, 'pubMedId': None, 'title': 'Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma.', 'url': 'http://meetinglibrary.asco.org/content/166136-176'}]",sensitive,807,Binimetinib,4893
148,Preclinical - Cell line xenograft,"In a preclinical study, Ibrance (palbociclib) treatment resulted in stable tumor growth in melanoma cell line xenograft models harboring an NRAS mutation, however, growth later ensued and thus, demonstrated a lack of benefit (PMID: 27488531). ",Actionable,8552,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",no benefit,850,Palbociclib,4893
149,Phase III,"In a retrospective analysis of a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI did not demonstrate an improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with RAS mutations (PMID: 25605843). ",Actionable,3355,9256,colorectal cancer,DOID,3,NRAS mutant,"[{'id': 3760, 'pubMedId': 25605843, 'title': 'Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605843'}]",no benefit,2180,Cetuximab + FOLFIRI,4893
150,Preclinical,"In a preclinical study, hematopoietic cancer cell lines harboring NRAS mutations demonstrated resistance to SHP099 in cell culture (PMID: 27362227).",Actionable,7529,2531,hematologic cancer,DOID,3,NRAS mutant,"[{'id': 6394, 'pubMedId': 27362227, 'title': 'Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27362227'}]",predicted – resistant,4504,SHP099,4893
151,Preclinical - Pdx,"In a preclinical study, KO-947 resulted in tumor regression in patient derived xenograft (PDX) models harboring either a BRAF mutation, NRAS mutation, or KRAS mutation (EJC Dec 2016, 69:1; S126).",Actionable,10966,10000003,Advanced Solid Tumor,JAX,3,NRAS mutant,"[{'id': 8965, 'pubMedId': None, 'title': 'KO-947, a potent and selective ERK inhibitor with slow dissociation kinetics', 'url': 'http://www.ejcancer.com/article/S0959-8049(16)32974-4/abstract'}]",predicted – sensitive,5747,KO-947,4893
152,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant cervical carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11704,2893,cervix carcinoma,DOID,3,NRAS mutant,"[{'id': 9707, 'pubMedId': None, 'title': 'KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short'}]",predicted – sensitive,5747,KO-947,4893
153,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant non-small cell lung cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11966,3908,non-small cell lung carcinoma,DOID,3,NRAS mutant,"[{'id': 9707, 'pubMedId': None, 'title': 'KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short'}]",predicted – sensitive,5747,KO-947,4893
154,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant melanoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11694,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 9707, 'pubMedId': None, 'title': 'KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors', 'url': 'http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short'}]",predicted – sensitive,5747,KO-947,4893
155,Preclinical - Cell line xenograft,"In a preclinical study, Buparlisib (BKM120) treatment in human melanoma cell line xenograft models with brain metastases and harboring an NRAS mutation resulted in inhibition of brain tumor growth and an improved survival benefit (PMID: 27307593). ",Actionable,10125,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",sensitive,680,BKM120,4893
156,Guideline,Erbitux (cetuximab) is not indicated for use in patients with NRAS-mutant colorectal cancer (Guidelines). ,Actionable,1960,9256,colorectal cancer,DOID,3,NRAS mutant,"[{'id': 1448, 'pubMedId': None, 'title': 'NCCN Guidelines Version 1.2017 Colon Cancer', 'url': 'https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf'}]",resistant,694,Cetuximab,4893
157,Preclinical,"In a preclinical study, CCT196969 inhibited growth of melanoma cells harboring NRAS mutations in culture (PMID: 25500121).",Actionable,3318,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 3714, 'pubMedId': 25500121, 'title': 'Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25500121'}]",sensitive,3105,CCT196969,4893
158,Preclinical - Cell culture,"In a preclinical study, combination of S63845 and Mekinist (trametinib) resulted in potent cytotoxic effects in NRAS-mutated melanoma cells in culture compared to the cytostatic effect of Mekinist (trametinib) alone (PMID: 27760111).",Actionable,9040,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 6851, 'pubMedId': 27760111, 'title': 'The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27760111'}]",sensitive,4864,S63845 + Trametinib,4893
159,Preclinical,"In a preclinical study, LY3009120 inhibited growth of NRAS mutant human melanoma cell lines in culture (PMID: 26343583).",Actionable,6616,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,3268,LY3009120,4893
160,Phase I,"In a Phase I trial, BGB-283 demonstrated safety and preliminary efficacy, resulted in partial response in 14% (4/29), and prolonged stable disease in 48% (14/29) of advanced solid tumor patients harboring mutations in KRAS, NRAS, and/or BRAF (AACR Annual Meeting, Apr 2016, abstract # CT005).",Actionable,7227,10000003,Advanced Solid Tumor,JAX,3,NRAS mutant,"[{'id': 6230, 'pubMedId': None, 'title': 'Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=46a0776a-1444-49d6-b533-4f68e298c39d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]",predicted – sensitive,4025,BGB-283,4893
161,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of human central nervous system cancer cells harboring mutant NRAS in culture (PMID: 26343583).",Actionable,6691,3620,central nervous system cancer,DOID,3,NRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,2,Trametinib,4893
162,Preclinical,"In a preclinical study, SBI-0640756 inhibited proliferation and transformation of human melanoma cell lines harboring NRAS mutation in culture (PMID: 26603897).",Actionable,3787,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 4137, 'pubMedId': 26603897, 'title': 'SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26603897'}]",sensitive,3306,SBI-0640756,4893
163,Preclinical,"In a preclinical study, human sarcoma cells harboring mutant NRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6734,1115,sarcoma,DOID,3,NRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,2,Trametinib,4893
164,Preclinical,"In a preclinical study, human lung adenocarcinoma cell lines harboring mutant NRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6699,3910,lung adenocarcinoma,DOID,3,NRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",resistant,2,Trametinib,4893
165,Phase Ib/II,"In a Phase Ib trial, the combination of Binimetinib (MEK162) and Kisqali (ribociclib) resulted in a median progression-free survival of 6.7 months, a partial response in 25% (4/16), and stable disease in 44% (7/16) of NRAS mutant melanoma patients (J Clin Oncol 35, 2017 (suppl; abstr 9519)). ",Actionable,11414,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 9296, 'pubMedId': None, 'title': 'Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).', 'url': 'http://meetinglibrary.asco.org/record/147511/abstract'}]",sensitive,5,Binimetinib + Ribociclib,4893
166,Phase Ib/II,"In a Phase Ib/II trial, the combination of Binimetinib (MEK162) and Kisqali (ribociclib) resulted in a partial response in 43% (6/14) and stable disease in 43% (6/14) of NRAS mutant melanoma patients (J Clin Oncol 32:5s, 2014 (Suppl;abstr 9009)). ",Actionable,2265,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 2946, 'pubMedId': None, 'title': 'A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity', 'url': 'http://meetinglibrary.asco.org/content/130034-144'}]",sensitive,5,Binimetinib + Ribociclib,4893
167,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of human lymphoma cells harboring mutant NRAS in culture (PMID: 26343583).",Actionable,6685,60058,lymphoma,DOID,3,NRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,2,Trametinib,4893
168,Phase I,"In a Phase Ia trial, CC-90003 treatment did not result in any objective responses and demonstrated toxicity in advanced solid tumor patients harboring KRAS, NRAS, or BRAF mutations (J Clin Oncol 35, 2017 (suppl; abstr 2577)).",Actionable,11067,10000003,Advanced Solid Tumor,JAX,3,NRAS mutant,"[{'id': 9060, 'pubMedId': None, 'title': 'A phase Ia study of CC-90003, a selective extracellular signal-regulated kinase (ERK) inhibitor, in patients with relapsed or refractory BRAF or RAS-mutant tumors.', 'url': 'http://abstracts.asco.org/199/AbstView_199_186986.html'}]",no benefit,2874,CC-90003,4893
169,Preclinical,"In a preclinical study, LY3009120 inhibited proliferation of human NRAS mutant acute myeloid leukemia cell lines in culture (PMID: 26343583).",Actionable,6600,9119,acute myeloid leukemia,DOID,3,NRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,3268,LY3009120,4893
170,Preclinical - Cell culture,"In a preclinical study, colon cancer cells harboring NRAS mutations were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).",Actionable,7880,219,colon cancer,DOID,3,NRAS mutant,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",resistant,1095,GDC0879,4893
171,Preclinical,"In a preclinical study, MK-1775 showed efficacy in NRAS mutant melanoma and in mutant KRAS colorectal, pancreatic, and lung cancers (PMID:24791855).",Actionable,689,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 422, 'pubMedId': 24791855, 'title': 'Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24791855'}]",sensitive,822,MK-1775,4893
172,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing an NRAS mutation did not respond to treatment with NS1 in culture, resulting in sustained downstream signaling and cell transformation (PMID: 27820802). ",Actionable,9785,10000003,Advanced Solid Tumor,JAX,3,NRAS mutant,"[{'id': 7600, 'pubMedId': 27820802, 'title': 'Inhibition of RAS function through targeting an allosteric regulatory site.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27820802'}]",no benefit,5228,NS1,4893
173,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of ovarian cancer cells harboring mutant NRAS in culture (PMID: 26343583).",Actionable,6702,2394,ovarian cancer,DOID,3,NRAS mutant,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,2,Trametinib,4893
174,Preclinical - Cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring an NRAS mutation (PMID: 27307593). ",Actionable,10121,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",sensitive,5400,Binimetinib + BKM120,4893
175,Preclinical,"In a preclinical study, SBI-0640726 inhibited proliferation and transformation of human melanoma cell lines harboring NRAS mutation in culture (PMID: 26603897).",Actionable,3788,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 4137, 'pubMedId': 26603897, 'title': 'SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26603897'}]",sensitive,3307,SBI-0640726,4893
176,Preclinical - Cell line xenograft,"In a preclinical study, PD-0325901 treatment resulted in stable tumor growth in melanoma cell line xenograft models harboring an NRAS mutation, however, growth later ensued and thus, demonstrates a lack of benefit (PMID: 27488531). ",Actionable,8551,1909,melanoma,DOID,3,NRAS mutant,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",no benefit,849,PD-0325901,4893
177,Preclinical - Cell culture,"In a preclinical study, an NRAS wild-type melanoma cell line demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531). ",Actionable,8545,1909,melanoma,DOID,481,NRAS wild-type,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",decreased response,1368,Palbociclib + Trametinib,4893
178,Phase III,"In a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI demonstrated a significant clinical benefit in OS, PFS, and objective response compared to FOLFIRI alone in colorectal cancer patients with RAS wild-type status (PMID: 25605843). ",Actionable,3357,9256,colorectal cancer,DOID,481,NRAS wild-type,"[{'id': 3760, 'pubMedId': 25605843, 'title': 'Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25605843'}]",predicted – sensitive,2180,Cetuximab + FOLFIRI,4893
179,Phase III,"In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with RAS wild-type colorectal cancer compared to FOLFIRI treatment alone (PMID: 26341920).",Actionable,3269,9256,colorectal cancer,DOID,481,NRAS wild-type,"[{'id': 3703, 'pubMedId': 26341920, 'title': 'Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26341920'}]",predicted – sensitive,845,Panitumumab,4893
180,Preclinical,"In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with wild-type NRAS (PMID: 23039341).",Actionable,5625,1909,melanoma,DOID,481,NRAS wild-type,"[{'id': 1840, 'pubMedId': 23039341, 'title': 'Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23039341'}]",sensitive,1011,E6201,4893
181,Preclinical - Cell culture,"In a preclinical study, NRAS wild-type melanoma cells demonstrated decreased cell viability when treated with Ibrance (palbociclib) in culture (PMID: 27488531). ",Actionable,8535,1909,melanoma,DOID,481,NRAS wild-type,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",sensitive,850,Palbociclib,4893
182,Preclinical - Cell culture,"In a preclinical study, an NRAS wild-type melanoma cell line demonstrated inhibition of cell growth when treated with Mekinist (trametinib) in culture (PMID: 27488531). ",Actionable,8538,1909,melanoma,DOID,481,NRAS wild-type,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",sensitive,2,Trametinib,4893
183,Phase I,"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 44% (4/9) and partial response in 22% (2/9) of melanoma patients carrying wild-type BRAF and NRAS (PMID: 26169970).",Actionable,3798,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,"[{'id': 3994, 'pubMedId': 26169970, 'title': 'Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26169970'}]",sensitive,792,Lenvatinib,4893
184,Preclinical - Cell culture,"In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to Zelboraf (vemurafenib) in culture (PMID: 27523909).",Actionable,7960,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",resistant,342,Vemurafenib,4893
185,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).",Actionable,7945,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,3300,TAK-632,4893
186,Preclinical - Cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line with wild-type BRAF and wild-type NRAS in culture (PMID: 27307593). ",Actionable,10122,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,"[{'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",sensitive,5400,Binimetinib + BKM120,4893
187,Preclinical - Cell culture,"In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to PLX7904 in culture (PMID: 27523909).",Actionable,7952,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",resistant,4606,PLX7904,4893
188,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).",Actionable,7935,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,"[{'id': 6522, 'pubMedId': 27523909, 'title': 'An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27523909'}]",sensitive,1093,AZ628,4893
189,Phase I,"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 100% (5/5) of melanoma patients harboring BRAF mutations and wild-type NRAS (PMID: 26169970).",Actionable,3796,1909,melanoma,DOID,15931,BRAF mut NRAS wild-type,"[{'id': 3994, 'pubMedId': 26169970, 'title': 'Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26169970'}]",sensitive,792,Lenvatinib,4893
190,Preclinical,"In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells wild-type for BRAF, KRAS, NRAS and PIK3CA in culture (PMID: 25838391).",Actionable,4934,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",sensitive,694,Cetuximab,4893
191,Phase II,"In a Phase II trial, Erbitux (cetuximab) in combination with FOLFOX resulted in improved median progression-free survival (6.9 months) comparing to FOLFOX alone (5.3 months) in BRAF, KRAS, NRAS, and PIK3CA wild-type colorectal cancer patients (hazard ratio =0.56) (PMID: 27002107).",Actionable,5563,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,"[{'id': 5108, 'pubMedId': 27002107, 'title': 'Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27002107'}]",predicted – sensitive,2182,Cetuximab + FOLFOX,4893
192,Preclinical,"In a preclinical study, colorectal cancer cell lines with wild-type BRAF, KRAS, NRAS and PIK3CA were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4944,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",resistant,890,Regorafenib,4893
0,Preclinical,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA G853D in culture (PMID: 24132921).",Actionable,1826,10000003,Advanced Solid Tumor,JAX,3615,PDGFRA G853D,"[{'id': 2242, 'pubMedId': 24132921, 'title': 'Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24132921'}]",sensitive,770,Imatinib,5156
1,Preclinical,"In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA G853D in culture (PMID: 24132921).",Actionable,1827,10000003,Advanced Solid Tumor,JAX,3615,PDGFRA G853D,"[{'id': 2242, 'pubMedId': 24132921, 'title': 'Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24132921'}]",sensitive,705,Crenolanib,5156
2,Preclinical - Cell culture,"In a preclinical study, Gleevec (imatinib) inhibited growth of transformed mouse myeloid cells over expressing PDGFRA Y849S in culture (PMID: 21224473).",Actionable,7417,8692,myeloid leukemia,DOID,24650,PDGFRA Y849S,"[{'id': 418, 'pubMedId': 21224473, 'title': 'Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21224473'}]",sensitive,770,Imatinib,5156
3,Preclinical - Cell culture,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and cell proliferation in transformed cells over expressing PDGFRA Y849S in culture (PMID: 21224473).",Actionable,7420,10000003,Advanced Solid Tumor,JAX,24650,PDGFRA Y849S,"[{'id': 418, 'pubMedId': 21224473, 'title': 'Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21224473'}]",sensitive,770,Imatinib,5156
4,Phase I,"In a Phase I trial, Vistusertib (AZD2014) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a patient with pancreatic cancer harboring a PDGFRA activating mutation (PMID: 25805799). ",Actionable,2368,1793,pancreatic cancer,DOID,2881,PDGFRA act mut,"[{'id': 3000, 'pubMedId': 25805799, 'title': 'First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25805799'}]",predicted – sensitive,991,Vistusertib,5156
5,Preclinical,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in cells expressing PDGFRA H845Y in culture (PMID: 24132921).",Actionable,1848,10000003,Advanced Solid Tumor,JAX,3745,PDGFRA H845Y,"[{'id': 2242, 'pubMedId': 24132921, 'title': 'Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24132921'}]",sensitive,770,Imatinib,5156
6,Preclinical,"In a preclinical study, crenolanib inhibited Pdgfra phosphorylation in cells expressing PDGFRA H845Y in culture (PMID: 24132921).",Actionable,1847,10000003,Advanced Solid Tumor,JAX,3745,PDGFRA H845Y,"[{'id': 2242, 'pubMedId': 24132921, 'title': 'Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24132921'}]",sensitive,705,Crenolanib,5156
7,Preclinical - Cell line xenograft,"In a preclinical study, Gleevec (imatinib) inhibited growth of transformed mouse myeloid cells over expressing PDGFRA R748G in culture and prolonged survival in xenograft models (PMID: 21224473).",Actionable,7418,8692,myeloid leukemia,DOID,24649,PDGFRA R748G,"[{'id': 418, 'pubMedId': 21224473, 'title': 'Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21224473'}]",sensitive,770,Imatinib,5156
8,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing PDGFRA D842_I843delinsIM were resistant to inhibition of Pdgfra phosphorylation by Gleevec (imatinib) in culture (PMID: 21224473).",Actionable,7422,10000003,Advanced Solid Tumor,JAX,24640,PDGFRA D842_I843delinsIM,"[{'id': 418, 'pubMedId': 21224473, 'title': 'Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21224473'}]",resistant,770,Imatinib,5156
9,Preclinical - Cell culture,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in transformed cells over expressing PDGFRA S566_E571delinsR in culture (PMID: 21224473).",Actionable,7425,10000003,Advanced Solid Tumor,JAX,24637,PDGFRA S566_E571delinsR,"[{'id': 418, 'pubMedId': 21224473, 'title': 'Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21224473'}]",sensitive,770,Imatinib,5156
10,Preclinical,"In a preclinical study, cells expressing PDGFRA V561D demonstrated sensitivity to Gleevec (imatinib) in cell culture (PMID: 15928335).",Actionable,191,10000003,Advanced Solid Tumor,JAX,603,PDGFRA V561D,"[{'id': 272, 'pubMedId': 15928335, 'title': 'PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15928335'}]",sensitive,770,Imatinib,5156
11,Preclinical - Cell culture,"In a preclinical study, PDGFRA D842V conferred resistance to inhibition of PDGFRA phosphorylation by Sutent (sunitinib) in cells expressing PDGFRA V561D in culture (PMID: 18955458).",Actionable,8936,10000003,Advanced Solid Tumor,JAX,26542,PDGFRA D842V PDGFRA V561D,"[{'id': 3383, 'pubMedId': 18955458, 'title': 'Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18955458'}]",resistant,930,Sunitinib,5156
12,Preclinical,"In a preclinical study, crenolanib decreased Pdgfra phosphorylation in cells expressing PDGFRA N659K in culture (PMID: 22745105).",Actionable,1831,10000003,Advanced Solid Tumor,JAX,3648,PDGFRA N659K,"[{'id': 2167, 'pubMedId': 22745105, 'title': 'Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22745105'}]",sensitive,705,Crenolanib,5156
13,Preclinical,"In a preclinical study, Gleevec (imatinib) decreased Pdgfra phosphorylation in cells expressing PDGFRA N659K in culture (PMID: 22745105).",Actionable,1830,10000003,Advanced Solid Tumor,JAX,3648,PDGFRA N659K,"[{'id': 2167, 'pubMedId': 22745105, 'title': 'Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22745105'}]",sensitive,770,Imatinib,5156
14,Preclinical,"In a preclinical study, Gleevec (imatinib) decreased phosphorylation of Pdgfra in cell lines expressing PDGFRA I843del mutation in culture (PMID: 14645423).",Actionable,1829,10000003,Advanced Solid Tumor,JAX,3643,PDGFRA I843del,"[{'id': 2255, 'pubMedId': 14645423, 'title': 'Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/14645423'}]",sensitive,770,Imatinib,5156
15,Preclinical,"In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA V658A in culture (PMID: 24132921).

",Actionable,1843,10000003,Advanced Solid Tumor,JAX,3699,PDGFRA V658A,"[{'id': 2242, 'pubMedId': 24132921, 'title': 'Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24132921'}]",sensitive,705,Crenolanib,5156
16,Preclinical,"In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA V658A in culture (PMID: 24132921).",Actionable,7190,10000003,Advanced Solid Tumor,JAX,3699,PDGFRA V658A,"[{'id': 2242, 'pubMedId': 24132921, 'title': 'Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24132921'}]",sensitive,770,Imatinib,5156
17,Preclinical,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA D842Y in culture (PMID: 24132921).",Actionable,7188,10000003,Advanced Solid Tumor,JAX,3676,PDGFRA D842Y,"[{'id': 2242, 'pubMedId': 24132921, 'title': 'Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24132921'}]",sensitive,770,Imatinib,5156
18,Preclinical,"In a preclinical study, Crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA D842Y in culture (PMID: 24132921).",Actionable,7189,10000003,Advanced Solid Tumor,JAX,3676,PDGFRA D842Y,"[{'id': 2242, 'pubMedId': 24132921, 'title': 'Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24132921'}]",sensitive,705,Crenolanib,5156
19,Preclinical,"In a preclinical study, mice injected with transformed cells harboring PDGFRA H650Q developed leukemia-like disease that is sensitive to Gleevec (imatinib) (PMID: 21224473).",Actionable,727,1240,leukemia,DOID,980,PDGFRA H650Q,"[{'id': 418, 'pubMedId': 21224473, 'title': 'Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21224473'}]",sensitive,770,Imatinib,5156
20,Preclinical - Cell culture,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in transformed cells over expressing PDGFRA V561_I562insER in culture (PMID: 21224473).",Actionable,7424,10000003,Advanced Solid Tumor,JAX,24633,PDGFRA V561_I562insER,"[{'id': 418, 'pubMedId': 21224473, 'title': 'Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21224473'}]",sensitive,770,Imatinib,5156
21,Phase I,"In a Phase I trial, BLU-285 demonstrated preliminary antitumor activity in gastrointestinal stromal tumor patients harboring PDGFRA D842 mutations, with partial responses in 50% (6/12) and stable disease in 50% (6/12) of patients (EORTC-NCI-AACR 2016, Abs 6LBA).",Actionable,9775,9253,gastrointestinal stromal tumor,DOID,27078,PDGFRA D842X,"[{'id': 7597, 'pubMedId': None, 'title': 'Preliminary safety and activity in a first-in-human phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT and PDGFRa activation loop mutants in advanced gastrointestinal stromal tumor (GIST)', 'url': 'http://www.ecco-org.eu/Events/ENA2016/Searchable-Programme#anchorScpr'}]",sensitive,2941,BLU-285,5156
22,Preclinical,"In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA P577S in culture (PMID: 24132921).",Actionable,1833,10000003,Advanced Solid Tumor,JAX,3650,PDGFRA P577S,"[{'id': 2242, 'pubMedId': 24132921, 'title': 'Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24132921'}]",sensitive,705,Crenolanib,5156
23,Preclinical,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA P577S in culture (PMID: 24132921).",Actionable,1832,10000003,Advanced Solid Tumor,JAX,3650,PDGFRA P577S,"[{'id': 2242, 'pubMedId': 24132921, 'title': 'Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24132921'}]",sensitive,770,Imatinib,5156
24,Phase I,"In a Phase I retrospective study, treatment with Gleevec (imatinib) demonstrated a prolonged response in a patient with a gastrointestinal stromal tumor harboring a PDGFRA L221F mutation (PMID: 22718859).",Actionable,676,9253,gastrointestinal stromal tumor,DOID,863,PDGFRA L221F,"[{'id': 396, 'pubMedId': 22718859, 'title': 'Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22718859'}]",sensitive,770,Imatinib,5156
25,Clinical Study,"In a clinical study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312).",Actionable,11053,1909,melanoma,DOID,27904,CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H,"[{'id': 9046, 'pubMedId': 28514312, 'title': 'Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28514312'}]",sensitive,5833,Imatinib + Carboplatin + Paclitaxel,5156
26,Clinical Study,"PDGFRA mutations are used in the diagnosis of gastrointestinal stromal tumors (PMID: 26276366, PMID: 25729899).",Diagnostic,3969,9253,gastrointestinal stromal tumor,DOID,1215,PDGFRA mutant,"[{'id': 4316, 'pubMedId': 25729899, 'title': 'Template for Reporting Results of Biomarker Testing of Specimens From Patients With Gastrointestinal Stromal Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25729899'}, {'id': 5212, 'pubMedId': 26276366, 'title': 'The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26276366'}]",not applicable,1776,N/A,5156
27,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing PDGFRA R841_D842delinsKI were resistant to inhibition of Pdgfra phosphorylation by Gleevec (imatinib) in culture (PMID: 21224473).",Actionable,7423,10000003,Advanced Solid Tumor,JAX,24639,PDGFRA R841_D842delinsKI,"[{'id': 418, 'pubMedId': 21224473, 'title': 'Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21224473'}]",resistant,770,Imatinib,5156
28,Preclinical - Cell culture,"In a preclinical study, transformed mouse myeloid cells over expressing PDGFRA N659S demonstrated reduced sensitivity to Gleevec (imatinib) in culture (PMID: 21224473).",Actionable,7415,8692,myeloid leukemia,DOID,24648,PDGFRA N659S,"[{'id': 418, 'pubMedId': 21224473, 'title': 'Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21224473'}]",decreased response,770,Imatinib,5156
29,FDA approved,Gleevec (imatinib) is FDA approved for myelodysplastic/myeloproliferative cancers that are associated with PDGFR rearrangements (FDA.gov). ,Actionable,1974,4972,myelodysplastic/myeloproliferative neoplasm,DOID,1320,PDGFRA rearrange,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",sensitive,770,Imatinib,5156
30,Preclinical - Cell culture,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and cell proliferation in transformed cells over expressing PDGFRA D846Y in culture (PMID: 21224473).",Actionable,7421,10000003,Advanced Solid Tumor,JAX,3677,PDGFRA D846Y,"[{'id': 418, 'pubMedId': 21224473, 'title': 'Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21224473'}]",sensitive,770,Imatinib,5156
31,Preclinical,"In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA R841K in culture (PMID: 24132921).

",Actionable,1842,10000003,Advanced Solid Tumor,JAX,3696,PDGFRA R841K,"[{'id': 2242, 'pubMedId': 24132921, 'title': 'Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24132921'}]",sensitive,705,Crenolanib,5156
32,Preclinical,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA R841K in culture (PMID: 24132921).",Actionable,1841,10000003,Advanced Solid Tumor,JAX,3696,PDGFRA R841K,"[{'id': 2242, 'pubMedId': 24132921, 'title': 'Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24132921'}]",sensitive,770,Imatinib,5156
33,Phase I,"In a Phase I trial, DCC-2618 demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including a partial response in a glioblastoma multiforme patient harboring KIT and PDGFRA amplification (EORTC-NCI-AACR 2016, Abs 7LBA).",Actionable,9778,3068,glioblastoma multiforme,DOID,27080,KIT amp PDGFRA amp,"[{'id': 7598, 'pubMedId': None, 'title': 'DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study', 'url': 'http://www.ecco-org.eu/Events/ENA2016/Searchable-Programme#anchorScpr'}]",sensitive,4316,DCC-2618,5156
34,Preclinical,"In a preclinical study, Gleevec (imatinib) and Iressa (gefitinib) acted synergistically to decrease downstream signaling activity and inhibit cell growth of glioblastoma cell lines with EGFR and PDGFRA coamplification (PMID: 22323597). ",Actionable,1860,3068,glioblastoma multiforme,DOID,4004,PDGFRA amp EGFR amp,"[{'id': 2352, 'pubMedId': 22323597, 'title': 'Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22323597'}]",sensitive,2483,Gefitinib + Imatinib,5156
35,Preclinical,"In a preclinical study, Gleevec (imatinib) inhibited growth of lung squamous cell cancer cells with PDGFRA amplification in culture (PMID: 22328973).",Actionable,5090,3907,lung squamous cell carcinoma,DOID,1417,PDGFRA amp,"[{'id': 141, 'pubMedId': 22328973, 'title': 'Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22328973'}]",sensitive,770,Imatinib,5156
36,Preclinical,"In a preclinical study, a malignant peripheral nerve sheath tumor cell line harboring a PDGFRA amplification demonstrated cell growth inhibition when treated with Gleevec (imatinib) (PMID: 16357008). ",Actionable,1897,5940,malignant peripheral nerve sheath tumor,DOID,1417,PDGFRA amp,"[{'id': 2384, 'pubMedId': 16357008, 'title': 'Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16357008'}]",sensitive,770,Imatinib,5156
37,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited growth of lung squamous cell cancer cells with PDGFRA amplification in culture (PMID: 22328973).
",Actionable,5094,5409,lung small cell carcinoma,DOID,1417,PDGFRA amp,"[{'id': 141, 'pubMedId': 22328973, 'title': 'Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22328973'}]",sensitive,877,Ponatinib,5156
38,Preclinical,"In a preclinical study, Sutent (sunitinib) decreased cell proliferation and inhibited downstream signaling in a NSCLC cell line harboring a PDGFRA amplification (PMID: 19366796). ",Actionable,1898,3908,non-small cell lung carcinoma,DOID,1417,PDGFRA amp,"[{'id': 2385, 'pubMedId': 19366796, 'title': 'Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19366796'}]",sensitive,930,Sunitinib,5156
39,Preclinical - Cell line xenograft,"In a preclinical study, Sprycel (dasatinib) inhibited growth of a lung squamous cell cancer (SCC) cell line with amplification of PDGFRA in culture, and inhibited tumor growth in PDGFRA-amplified lung SCC xenograft models (PMID: 22328973).",Actionable,5082,3907,lung squamous cell carcinoma,DOID,1417,PDGFRA amp,"[{'id': 141, 'pubMedId': 22328973, 'title': 'Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22328973'}]",sensitive,717,Dasatinib,5156
40,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing PDGFRA D842V demonstrated resistance to growth inhibition by Tasigna (nilotinib) in culture (PMID: 18794084).",Actionable,8848,10000003,Advanced Solid Tumor,JAX,604,PDGFRA D842V,"[{'id': 6767, 'pubMedId': 18794084, 'title': 'Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18794084'}]",resistant,829,Nilotinib,5156
41,Clinical Study,"In a clinical study, Stivarga (regorafenib) treatment resulted in partial response in 11% (2/18) of patients and stable disease in 39% (7/18) of gastrointestinal stromal tumor patients, including prolonged stable disease for 12 months in a patient harboring PDGFRA D842V (PMID: 25905001).",Actionable,8923,9253,gastrointestinal stromal tumor,DOID,604,PDGFRA D842V,"[{'id': 6788, 'pubMedId': 25905001, 'title': 'Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25905001'}]",predicted – sensitive,890,Regorafenib,5156
42,Phase Ib/II,"In a Phase I/II trial, treatment with Crenolanib (CP-868596) resulted in a clinical benefit rate of 31% (5/16) in gastronintestinal stromal tumor patients harboring PDGFRA D842V, with partial response in 2/16 and stable disease in 3/16 patients (J Clin Oncol 34, 2016 (suppl; abstr 11010)).",Actionable,8922,9253,gastrointestinal stromal tumor,DOID,604,PDGFRA D842V,"[{'id': 6787, 'pubMedId': None, 'title': 'Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations.', 'url': 'http://meetinglibrary.asco.org/content/170566-176'}]",sensitive,705,Crenolanib,5156
43,Preclinical,"In a preclinical study, expression of PDGFRA D842V conferred resistance to Gleevec (imatinib) in cell culture (PMID: 15928335).",Actionable,834,10000003,Advanced Solid Tumor,JAX,604,PDGFRA D842V,"[{'id': 272, 'pubMedId': 15928335, 'title': 'PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15928335'}]",resistant,770,Imatinib,5156
44,Preclinical - Cell culture,"In a preclinical study, Crenolanib inhibited Pdgfra phosphorylation and proliferation of transformed cells expressing PDGFRA D842V in culture (PMID: 22745105).",Actionable,8847,10000003,Advanced Solid Tumor,JAX,604,PDGFRA D842V,"[{'id': 2167, 'pubMedId': 22745105, 'title': 'Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22745105'}]",sensitive,705,Crenolanib,5156
45,Preclinical - Cell culture,"In a preclinical study, cells expressing PDGFRA D842V demonstrated resistance to inhibition of PDGFRA phosphorylation by Sutent (sunitinib) in culture (PMID: 18955458).",Actionable,8935,10000003,Advanced Solid Tumor,JAX,604,PDGFRA D842V,"[{'id': 3383, 'pubMedId': 18955458, 'title': 'Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18955458'}]",resistant,930,Sunitinib,5156
46,Preclinical - Cell culture,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in transformed cells over expressing PDGFRA H845_N848delinsP in culture (PMID: 21224473).",Actionable,7419,10000003,Advanced Solid Tumor,JAX,24642,PDGFRA H845_N848delinsP,"[{'id': 418, 'pubMedId': 21224473, 'title': 'Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21224473'}]",sensitive,770,Imatinib,5156
0,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment resulted in tumor growth stabilization in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D, PIK3CA E545K and H1047L (PMID: 26272063).",Actionable,8581,9256,colorectal cancer,DOID,26369,KRAS G12D PIK3CA E545K PIK3CA H1047L TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,5290
1,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).",Actionable,4243,1612,breast cancer,DOID,3636,PIK3CA H1047L,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,787,Lapatinib,5290
2,Preclinical,"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).",Actionable,4236,1612,breast cancer,DOID,3636,PIK3CA H1047L,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,816,MK2206,5290
3,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).",Actionable,4229,1612,breast cancer,DOID,3636,PIK3CA H1047L,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,691,BYL719,5290
4,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).",Actionable,4250,1612,breast cancer,DOID,3636,PIK3CA H1047L,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,828,Neratinib,5290
5,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).",Actionable,4257,1612,breast cancer,DOID,3636,PIK3CA H1047L,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,2,Trametinib,5290
6,Preclinical,"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).",Actionable,4222,1612,breast cancer,DOID,3636,PIK3CA H1047L,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,672,BEZ235,5290
7,Clinical Study,"In a clinical study, the PIK3CA R425L mutation was identified as a potential resistance mechanism in a non-small cell lung carcinoma patient harboring ERBB2 (HER2) A775_G776insYVMA, that progressed during Herceptin (trastuzumab) treatment (PMID: 28167203). ",Actionable,10134,3908,non-small cell lung carcinoma,DOID,27298,ERBB2 A775_G776insYVMA PIK3CA R425L,"[{'id': 8141, 'pubMedId': 28167203, 'title': 'ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28167203'}]",predicted – resistant,947,Trastuzumab,5290
8,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells harboring both BRAF G596R and PIK3CA E545K in culture (PMID: 26243863).",Actionable,7117,9256,colorectal cancer,DOID,24419,BRAF G596R PIK3CA E545K,"[{'id': 6069, 'pubMedId': 26243863, 'title': 'HER2 activating mutations are targets for colorectal cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26243863'}]",sensitive,828,Neratinib,5290
9,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).",Actionable,8171,3908,non-small cell lung carcinoma,DOID,26184,KRAS Q61H PIK3CA E545K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",decreased response,871,Pimasertib,5290
10,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8180,3908,non-small cell lung carcinoma,DOID,26184,KRAS Q61H PIK3CA E545K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,1659,Pimasertib + Sorafenib,5290
11,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8176,3908,non-small cell lung carcinoma,DOID,26184,KRAS Q61H PIK3CA E545K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4656,Everolimus + Pimasertib,5290
12,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8185,3908,non-small cell lung carcinoma,DOID,26184,KRAS Q61H PIK3CA E545K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4657,Pimasertib + Regorafenib,5290
13,Preclinical - Cell line xenograft,"In a preclinical study, Gedatolisib (PKI-587) inhibited PI3K signaling, cell growth and induced apoptosis in human breast cancer cells harboring ERBB2 (HER2) amplification, PIK3CA E545K, and PIK3CA K567R in culture and in cell line xenografts (PMID: 21325073, PMID: 17314276).",Actionable,3124,60079,Her2-receptor positive breast cancer,DOID,11788,ERBB2 amp PIK3CA E545K PIK3CA K567R,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3636, 'pubMedId': 17314276, 'title': 'Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17314276'}]",sensitive,1040,PF-05212384,5290
14,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K and TP53 R273* (PMID: 26272063).",Actionable,8597,9256,colorectal cancer,DOID,26374,KRAS G12V PIK3CA E545K TP53 R273*,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,1420,Selumetinib + BEZ235,5290
15,Preclinical - Pdx,"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to BEZ235 treatment (PMID: 26272063).",Actionable,8699,9256,colorectal cancer,DOID,26374,KRAS G12V PIK3CA E545K TP53 R273*,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",resistant,672,BEZ235,5290
16,Preclinical - Pdx,"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).",Actionable,8698,9256,colorectal cancer,DOID,26374,KRAS G12V PIK3CA E545K TP53 R273*,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",resistant,913,Selumetinib,5290
17,Preclinical - Cell culture,"In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA E545K resulted in resistance to Pictilisib (GDC-0941) in culture (PMID: 27604488).",Actionable,8896,1612,breast cancer,DOID,26498,AKT1 over exp PIK3CA E545K,"[{'id': 6782, 'pubMedId': 27604488, 'title': 'Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27604488'}]",resistant,749,GDC-0941,5290
18,Preclinical - Cell culture,"In a preclinical study, treatment with ARQ092 resulted in growth inhibition in hormone receptor positive breast cancer cells harboring PIK3CA E545K in culture (PMID: 26469692).",Actionable,10269,1612,breast cancer,DOID,2421,PIK3CA E545K,"[{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",sensitive,635,ARQ092,5290
19,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).",Actionable,4241,1612,breast cancer,DOID,2421,PIK3CA E545K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,787,Lapatinib,5290
20,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited PI3K signaling and proliferation of a human breast carcinoma cell line harboring PIK3CA E545K in culture and inhibited tumor growth in xenograft models (PMID: 25637314).",Actionable,6309,3459,breast carcinoma,DOID,2421,PIK3CA E545K,"[{'id': 5522, 'pubMedId': 25637314, 'title': 'The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25637314'}]",sensitive,1050,XL147,5290
21,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of breast cancer cells expressing PIK3CA E545K (PMID: 21558396).",Actionable,2949,1612,breast cancer,DOID,2421,PIK3CA E545K,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
22,Preclinical - Pdx,"In a preclinical study, Aliqopa (copanlisib), in combination with Taxol (paclitaxel), induced tumor regression in PIK3CA E545K-mutant patient-derived non-small cell lung cancer xenografts (PMID: 24170767).",Actionable,1375,3908,non-small cell lung carcinoma,DOID,2421,PIK3CA E545K,"[{'id': 245, 'pubMedId': 24170767, 'title': 'BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24170767'}]",sensitive,1276,Copanlisib + Paclitaxel,5290
23,Preclinical,"In a preclinical study, WYE-125132 inhibited proliferation of breast cancer cells with a PIK3CA E545K mutation (PMID: 20068177).",Actionable,2899,1612,breast cancer,DOID,2421,PIK3CA E545K,"[{'id': 2065, 'pubMedId': 20068177, 'title': 'Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20068177'}]",sensitive,2242,WYE-125132,5290
24,Preclinical,"In a preclinical study, LY294002 inhibited cell proliferation of esophagus squamous cell carcinoma cells expressing PIK3CA E545K (PMID: 18262558). ",Actionable,2780,3748,esophagus squamous cell carcinoma,DOID,2421,PIK3CA E545K,"[{'id': 3478, 'pubMedId': 18262558, 'title': 'PIK3CA mutation status in Japanese esophageal squamous cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18262558'}]",sensitive,1062,LY294002,5290
25,Phase II,"In a Phase II trial, treatment with Torisel (temsirolimus) resulted in disease stabilization in 57.6% (19/33) and tumor shrinkage in 39.4% (13/33) of patients with head and neck squamous cell carcinoma (PMID: 25527417).",Actionable,2481,5520,head and neck squamous cell carcinoma,DOID,2421,PIK3CA E545K,"[{'id': 3159, 'pubMedId': 25527417, 'title': 'TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25527417'}]",sensitive,936,Temsirolimus,5290
26,Preclinical,"In a preclinical study, breast cancer cell lines harboring a PIK3CA E545K mutation had increased sensitivity to Afinitor (everolimus) in culture (PMID: 20664172).",Actionable,1390,1612,breast cancer,DOID,2421,PIK3CA E545K,"[{'id': 1067, 'pubMedId': 20664172, 'title': 'Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20664172'}]",sensitive,735,Everolimus,5290
27,Preclinical - Cell culture,"In a preclinical study, DHM25 increased cell death in a breast cancer cell line harboring PIK3CA E545K in culture (PMID: 26237138).",Actionable,10357,1612,breast cancer,DOID,2421,PIK3CA E545K,"[{'id': 8367, 'pubMedId': 26237138, 'title': 'A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26237138'}]",sensitive,5494,DHM25,5290
28,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of ovarian cancer cells harboring PIK3CA E545K in culture (PMID: 21558396).",Actionable,2950,2394,ovarian cancer,DOID,2421,PIK3CA E545K,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
29,Preclinical,"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).",Actionable,4234,1612,breast cancer,DOID,2421,PIK3CA E545K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,816,MK2206,5290
30,Preclinical - Cell culture,"In a preclinical study, Estybon (rigosertib) inhibited oncogenic transformation in fibroblast cells over-expressing PIK3CA E545K in culture (PMID: 27104980).",Actionable,8555,10000003,Advanced Solid Tumor,JAX,2421,PIK3CA E545K,"[{'id': 6686, 'pubMedId': 27104980, 'title': 'A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27104980'}]",sensitive,1046,rigosertib,5290
31,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).",Actionable,4248,1612,breast cancer,DOID,2421,PIK3CA E545K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,828,Neratinib,5290
32,Clinical Study,"In a retrospective study, treatment with the combination of Erbitux (cetuximab) and Camptosar (irinotecan) resulted in stable disease in 50% (1/2) and 14 months without evidence of disease in 50% (1/2) of colorectal carcinoma patients harboring a PIK3CA E545K mutation (PMID: 25714871).",Actionable,3759,9256,colorectal cancer,DOID,2421,PIK3CA E545K,"[{'id': 3888, 'pubMedId': 25714871, 'title': 'AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25714871'}]",sensitive,1874,Cetuximab + Irinotecan,5290
33,Preclinical - Cell culture,"In a preclinical study, a breast cancer cell line harboring PIK3CA E545K was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692). ",Actionable,10274,1612,breast cancer,DOID,2421,PIK3CA E545K,"[{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",sensitive,4331,ARQ 751,5290
34,Phase II,"In a Phase II trial, a patient with head and neck squamous cell carcinoma harboring PIK3CA E545K demonstrated a partial response when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834). ",Actionable,12182,5520,head and neck squamous cell carcinoma,DOID,2421,PIK3CA E545K,"[{'id': 10139, 'pubMedId': 28961834, 'title': 'A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28961834'}]",predicted – sensitive,6333,Carboplatin + Paclitaxel + Temsirolimus,5290
35,Preclinical,"In a preclinical study, PW12 inhibited proliferation of cervical cancer cells with a PIK3CA E545K mutation (PMID: 22391131).",Actionable,2828,4362,cervical cancer,DOID,2421,PIK3CA E545K,"[{'id': 3492, 'pubMedId': 22391131, 'title': 'High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22391131'}]",sensitive,2961,PW12,5290
36,Phase I,"In a Phase I trial, Apitolisib (GDC-0980) resulted in a partial response in two patients, one with head and neck squamous cell carcinoma and another with ovarian cancer, both harboring PIK3CA E545K (PMID: 26787751). ",Actionable,6086,10000003,Advanced Solid Tumor,JAX,2421,PIK3CA E545K,"[{'id': 4915, 'pubMedId': 26787751, 'title': 'Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26787751'}]",sensitive,750,GDC-0980,5290
37,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring PIK3CA E545K in culture (PMID: 21325073, PMID: 17314276).",Actionable,3128,1612,breast cancer,DOID,2421,PIK3CA E545K,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3636, 'pubMedId': 17314276, 'title': 'Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17314276'}]",sensitive,1040,PF-05212384,5290
38,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA E545K to Venclexta (venetoclax) in culture (PMID: 27974663).",Actionable,10083,1612,breast cancer,DOID,2421,PIK3CA E545K,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",no benefit,5376,BEZ235 + Venetoclax,5290
39,Preclinical,"In a preclinical study, BEZ235 decreased cell proliferation in colorectal cancer cells harboring a PIK3CA E545K mutation in cell culture (PMID: 21966435).",Actionable,1393,9256,colorectal cancer,DOID,2421,PIK3CA E545K,"[{'id': 1143, 'pubMedId': 21966435, 'title': 'The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21966435'}]",sensitive,672,BEZ235,5290
40,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA E545K in culture (PMID: 26013318).",Actionable,7974,3907,lung squamous cell carcinoma,DOID,2421,PIK3CA E545K,"[{'id': 6528, 'pubMedId': 26013318, 'title': 'Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26013318'}]",sensitive,691,BYL719,5290
41,Preclinical,"In a preclinical study, gastric cancer cells harboring PI3KCA E545K mutations were sensitive to the AKT inhibitor AZD5363 (PMID: 24088382).",Actionable,1388,3119,gastrointestinal system cancer,DOID,2421,PIK3CA E545K,"[{'id': 1081, 'pubMedId': 24088382, 'title': 'The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24088382'}]",sensitive,655,AZD5363,5290
42,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).",Actionable,4227,1612,breast cancer,DOID,2421,PIK3CA E545K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,691,BYL719,5290
43,Preclinical,"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).",Actionable,4220,1612,breast cancer,DOID,2421,PIK3CA E545K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,672,BEZ235,5290
44,Preclinical - Cell line xenograft,"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K in culture, and inhibited AKT signaling and tumor growth in xenograft models (PMID: 27699769).",Actionable,8815,1612,breast cancer,DOID,2421,PIK3CA E545K,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",sensitive,994,BAY1125976,5290
45,Preclinical - Cell culture,"In a preclinical study, expression of PIK3CA E545K in a thyroid cancer cell line resulted in increased sensitivity to MK2206 in culture (PMID: 21289267).",Actionable,8221,1781,thyroid cancer,DOID,2421,PIK3CA E545K,"[{'id': 6573, 'pubMedId': 21289267, 'title': 'The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21289267'}]",sensitive,816,MK2206,5290
46,Preclinical - Cell culture,"In a preclinical study, Buparlisib (BKM120) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA E545K in culture (PMID: 26013318).",Actionable,7968,3907,lung squamous cell carcinoma,DOID,2421,PIK3CA E545K,"[{'id': 6528, 'pubMedId': 26013318, 'title': 'Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26013318'}]",sensitive,680,BKM120,5290
47,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).",Actionable,4255,1612,breast cancer,DOID,2421,PIK3CA E545K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,2,Trametinib,5290
48,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).",Actionable,4265,10000003,Advanced Solid Tumor,JAX,2421,PIK3CA E545K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,2,Trametinib,5290
49,Preclinical,"In a preclinical study, cancer cell lines harboring PIK3CA E545K did not demonstrate sensitivity to A66 in culture, in contrast with cells harboring PIK3CA H1047R (PMID: 21668414).",Actionable,2775,10000003,Advanced Solid Tumor,JAX,2421,PIK3CA E545K,"[{'id': 223, 'pubMedId': 21668414, 'title': 'A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21668414'}]",resistant,617,A66,5290
50,Preclinical,"In a preclinical study, LY3023414 inhibited tumor growth in a transgenic animal model of leukemia driven by PIK3CA E545K (PMID: 27439478).",Actionable,8942,1240,leukemia,DOID,2421,PIK3CA E545K,"[{'id': 6792, 'pubMedId': 27439478, 'title': 'Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27439478'}]",sensitive,1069,LY3023414,5290
51,Preclinical - Pdx,"In a preclinical study, Alpelisib (BYL719) inhibited PIK3CA E545K and showed anti-tumor activity in patient-derived xenograft models harboring a PIK3CA E545K mutation (PMID: 24608574).",Actionable,1395,10000003,Advanced Solid Tumor,JAX,2421,PIK3CA E545K,"[{'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",sensitive,691,BYL719,5290
52,Preclinical,"In a preclinical study, AZD8835 inhibited proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA E545K in culture and suppressed tumor growth in xenograft models (PMID: 26839307).",Actionable,5109,60075,estrogen-receptor positive breast cancer,DOID,2421,PIK3CA E545K,"[{'id': 4877, 'pubMedId': 26839307, 'title': 'Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26839307'}]",sensitive,2013,AZD8835,5290
53,Phase I,"In a Phase I trial, a colon cancer patient harboring PIK3CA E545K was sensitive to LY2780301, demonstrating stable disease for approximately 125 days (PMID: 25902900).",Actionable,10298,219,colon cancer,DOID,2421,PIK3CA E545K,"[{'id': 3473, 'pubMedId': 25902900, 'title': 'A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25902900'}]",sensitive,800,LY2780301,5290
54,Preclinical,"In a preclinical study, Rapamune (sirolimus) demonstrated efficacy in inhibiting transformation of cultured cells containing PIK3CA E545K mutations (PMID: 15647370).",Actionable,1387,10000003,Advanced Solid Tumor,JAX,2421,PIK3CA E545K,"[{'id': 1077, 'pubMedId': 15647370, 'title': 'Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15647370'}]",sensitive,917,Sirolimus,5290
55,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer cell line harboring PIK3CA E545K was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation and colony formation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413).",Actionable,10702,1612,breast cancer,DOID,2421,PIK3CA E545K,"[{'id': 8768, 'pubMedId': 24634413, 'title': 'Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24634413'}]",sensitive,1051,SAR245409,5290
56,Preclinical - Cell line xenograft,"In a preclinical study, treatment with PKI-402 resulted in decreased Akt phosphorylation and tumor regression in ERBB2 (HER2)-positive breast cancer cell line xenograft models harboring PIK3CA E545K (PMID: 20371716).",Actionable,5399,1612,breast cancer,DOID,2421,PIK3CA E545K,"[{'id': 5041, 'pubMedId': 20371716, 'title': 'Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20371716'}]",sensitive,3857,PKI-402,5290
57,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA E545K to WEHI-539 in culture (PMID: 27974663).",Actionable,10086,1612,breast cancer,DOID,2421,PIK3CA E545K,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",predicted – sensitive,5377,BEZ235 + WEHI-539,5290
58,Preclinical - Pdx,"In a preclinical study, head and neck squamous cell carcinoma patient-derived xenograft models harboring a PIK3CA E545K mutation demonstrated increased sensitivity to Estybon (rigosertib) (PMID: 23873848).",Actionable,1407,5520,head and neck squamous cell carcinoma,DOID,2421,PIK3CA E545K,"[{'id': 1151, 'pubMedId': 23873848, 'title': 'The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23873848'}]",sensitive,1046,rigosertib,5290
59,Preclinical - Cell culture,"In a preclinical study, BEZ235 induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA E545K in culture (PMID: 26013318).",Actionable,7971,3907,lung squamous cell carcinoma,DOID,2421,PIK3CA E545K,"[{'id': 6528, 'pubMedId': 26013318, 'title': 'Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26013318'}]",sensitive,672,BEZ235,5290
60,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells over expressing PIK3CA E545K were resistant to Erbitux (cetuximab) and Fluorouracil combination treatment in culture (PMID: 28424201).",Actionable,11722,9256,colorectal cancer,DOID,2421,PIK3CA E545K,"[{'id': 9728, 'pubMedId': 28424201, 'title': 'PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28424201'}]",resistant,2000,Fluorouracil + Cetuximab,5290
61,Preclinical - Cell line xenograft,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA E545K in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).",Actionable,7749,60079,Her2-receptor positive breast cancer,DOID,20859,ERBB2 pos PIK3CA E545K,"[{'id': 6466, 'pubMedId': 26920887, 'title': 'Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26920887'}]",sensitive,1402,trastuzumab emtansine,5290
62,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R335fs (PMID: 26272063).",Actionable,8578,9256,colorectal cancer,DOID,26368,KRAS G12V PIK3CA E545K TP53 R335fs,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,4771,MLN0128 + PD-0325901,5290
63,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K and ERBB2 (HER2) amplification in culture (PMID: 21558396).",Actionable,3003,1612,breast cancer,DOID,11011,ERBB2 amp PIK3CA E545K,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
64,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer cell line xenograft model co-harboring ERBB2 (HER2) amplification and PIK3CA E545K demonstrated tumor regression within the mammary fat pad when treated with Buparlisib (BKM120) (PMID: 28539475). ",Actionable,11514,1612,breast cancer,DOID,11011,ERBB2 amp PIK3CA E545K,"[{'id': 9597, 'pubMedId': 28539475, 'title': 'The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28539475'}]",sensitive,680,BKM120,5290
65,Preclinical - Cell line xenograft,"In a preclinical study, expression of KRAS G13D in an endometrial cancer cell line harboring PIK3CA E545K conferred resistance to Afinitor (everolimus) in xenograft models (PMID: 20664172). ",Actionable,9329,1380,endometrial cancer,DOID,10712,KRAS G13D PIK3CA E545K,"[{'id': 1067, 'pubMedId': 20664172, 'title': 'Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20664172'}]",resistant,735,Everolimus,5290
66,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Pictilisib (GDC-0941) and Cobimetinib (GDC-0973) inhibited tumor growth in a colorectal adenocarcinoma xenograft model harboring KRAS G13D and PIK3CA E545K mutations, and demonstrated improved efficacy over either agent alone (PMID: 22084396).",Actionable,2854,50861,colorectal adenocarcinoma,DOID,10712,KRAS G13D PIK3CA E545K,"[{'id': 353, 'pubMedId': 22084396, 'title': 'Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22084396'}]",sensitive,1702,GDC-0941 + cobimetinib,5290
67,Preclinical - Cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS G13D, PIK3CA E545K, and TP53 S241F in culture (PMID: 26272063).",Actionable,8564,9256,colorectal cancer,DOID,26357,KRAS G13D PIK3CA E545k TP53 S241F,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,5290
68,Preclinical,"In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098).",Actionable,4575,219,colon cancer,DOID,18591,KRAS mutant PIK3CA E545K,"[{'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",no benefit,694,Cetuximab,5290
69,Preclinical,"In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098).",Actionable,4576,219,colon cancer,DOID,18591,KRAS mutant PIK3CA E545K,"[{'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",sensitive,3548,BKM120 + Cetuximab,5290
70,Preclinical,"In a preclinical study, colon cancer cell lines harboring mutant KRAS and PIK3CA E545K demonstrated reduced sensitivity to Buparlisib (BKM120) induced growth inhibition in culture (PMID: 26715098).",Actionable,4574,219,colon cancer,DOID,18591,KRAS mutant PIK3CA E545K,"[{'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",decreased response,680,BKM120,5290
71,Preclinical - Cell line xenograft,"In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in colorectal cancer cell line xenograft models harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K (PMID: 23629727).",Actionable,8208,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,1660,Pimasertib + BEZ235,5290
72,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8197,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4656,Everolimus + Pimasertib,5290
73,Preclinical - Cell line xenograft,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited Mapk and Akt signaling, resulted in growth inhibition of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture and in cell line xenograft models (PMID: 23629727).",Actionable,8201,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,1659,Pimasertib + Sorafenib,5290
74,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring KRAS G13D, PIK3CA D549N and PIK3CA E545K demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).",Actionable,8192,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",decreased response,871,Pimasertib,5290
75,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8207,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4657,Pimasertib + Regorafenib,5290
76,Preclinical - Pdx,"In a preclinical study, BEZ235 delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",Actionable,8704,9256,colorectal cancer,DOID,26377,KRAS G12V PIK3CA E545K TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",decreased response,672,BEZ235,5290
77,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",Actionable,8603,9256,colorectal cancer,DOID,26377,KRAS G12V PIK3CA E545K TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,1420,Selumetinib + BEZ235,5290
78,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",Actionable,8705,9256,colorectal cancer,DOID,26377,KRAS G12V PIK3CA E545K TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",decreased response,913,Selumetinib,5290
79,Preclinical,"In a preclinical study, human colon cancer cells harboring KRAS G13D, PIK3CA E545K, and PIK3CA D549N had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073, PMID: 24042735).
",Actionable,3132,219,colon cancer,DOID,11790,KRAS G13D PIK3CA E545K PIK3CA D549N,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3639, 'pubMedId': 24042735, 'title': 'Epigenetic and genetic features of 24 colon cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24042735'}]",decreased response,1040,PF-05212384,5290
80,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G13D, PIK3CA E545K, and PIK3CA D549N in culture and reduced tumor growth in cell line xenograft models (PMID: 25838391).",Actionable,4946,9256,colorectal cancer,DOID,11790,KRAS G13D PIK3CA E545K PIK3CA D549N,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",sensitive,1305,Regorafenib + Cetuximab,5290
81,Preclinical,"In a preclinical study, human colorectal cancer cell lines harboring KRAS G13D, PIK3CA E545K and PIK3CA D549N were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4943,9256,colorectal cancer,DOID,11790,KRAS G13D PIK3CA E545K PIK3CA D549N,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",resistant,890,Regorafenib,5290
82,Phase I,"In a Phase I clinical trial, an endometrial carcinoma patient harboring PIK3CA T1052K, R88L, and E453del, as well as a PTEN mutation and loss of PTEN protein expression demonstrated a complete response to treatment with Aliqopa (copanlisib) (PMID: 27672108). ",Actionable,9350,2871,endometrial carcinoma,DOID,26828, PIK3CA E453del PIK3CA T1025K PIK3CA R88L PTEN mut PTEN loss,"[{'id': 7122, 'pubMedId': 27672108, 'title': ""First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27672108'}]",sensitive,995,Copanlisib,5290
83,Preclinical - Cell culture,"In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA T1025A in culture (PMID: 24240111).",Actionable,8282,5409,lung small cell carcinoma,DOID,3719,PIK3CA T1025A,"[{'id': 4924, 'pubMedId': 24240111, 'title': 'Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24240111'}]",sensitive,867,PF-4989216,5290
84,Preclinical - Cell culture,"In a preclinical study, small cell lung carcinoma cells harboring PIK3CA D1029Y and PTEN inactivating mutation were resistant to PF-4989216 induced growth inhibition in culture (PMID: 24240111).",Actionable,5214,5409,lung small cell carcinoma,DOID,26219,PIK3CA D1029Y PTEN inact mut,"[{'id': 4924, 'pubMedId': 24240111, 'title': 'Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24240111'}]",resistant,867,PF-4989216,5290
85,Preclinical - Cell line xenograft,"In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA H1047R, PIK3CA K111R, and wild-type PTEN in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111).",Actionable,5218,5409,lung small cell carcinoma,DOID,20308,PIK3CA H1047R PIK3CA K111R PTEN wild-type,"[{'id': 4924, 'pubMedId': 24240111, 'title': 'Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24240111'}]",sensitive,867,PF-4989216,5290
86,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited cell growth in a human endometrial cancer cell line harboring a PIK3CA H1047Y mutation, and inhibited tumor growth in xenograft models (PMID: 21558396).
",Actionable,2947,1380,endometrial cancer,DOID,3652,PIK3CA H1047Y,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
87,Preclinical,"In a preclinical study, glioblastoma cell lines harboring PIK3CA H1047Y demonstrated increased sensitivity to YM-204 induced growth inhibition (PMID: 24718026).",Actionable,5181,3068,glioblastoma multiforme,DOID,3652,PIK3CA H1047Y,"[{'id': 4902, 'pubMedId': 24718026, 'title': 'Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24718026'}]",sensitive,2967,YM-024,5290
88,Preclinical - Cell line xenograft,"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring KRAS G13C, PIK3CA H1047Y, PTEN G143fs*4, and PTEN K267fs*9 was sensitive to treatment with DS-7423, demonstrating inhibition of cell proliferation in culture and tumor growth inhibition in xenograft models (PMID: 24504419). ",Actionable,10541,5304,ovarian clear cell adenocarcinoma,DOID,27593,KRAS G13C PIK3CA H1047Y PTEN G143fs*4 PTEN K267fs*9,"[{'id': 4912, 'pubMedId': 24504419, 'title': 'Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24504419'}]",sensitive,722,DS-7423,5290
89,Preclinical - Cell line xenograft,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).",Actionable,7745,60079,Her2-receptor positive breast cancer,DOID,25948,ERBB2 pos PIK3CA K111N,"[{'id': 6466, 'pubMedId': 26920887, 'title': 'Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26920887'}]",sensitive,1402,trastuzumab emtansine,5290
90,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA K111N and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).",Actionable,2969,1612,breast cancer,DOID,10753,ERBB2 amp PIK3CA K111N,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
91,Preclinical - Cell culture,"In a preclinical study, hormone receptor positive breast cancer cells harboring PIK3CA K111N were sensitive to ARQ092 in culture, demonstrating inhibition of cell growth (PMID: 26469692). ",Actionable,10270,1612,breast cancer,DOID,3658,PIK3CA K111N,"[{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",sensitive,635,ARQ092,5290
92,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 27699769).",Actionable,8813,1612,breast cancer,DOID,3658,PIK3CA K111N,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",sensitive,994,BAY1125976,5290
93,Preclinical,"In a preclinical study, AZD8835 inhibited proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA K111N in culture and induced tumor regression in xenograft models (PMID: 26839307).",Actionable,5110,60075,estrogen-receptor positive breast cancer,DOID,3658,PIK3CA K111N,"[{'id': 4877, 'pubMedId': 26839307, 'title': 'Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26839307'}]",sensitive,2013,AZD8835,5290
94,Preclinical - Cell culture,"In a preclinical study, a breast cancer cell line harboring PIK3CA K111N was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692). ",Actionable,10275,1612,breast cancer,DOID,3658,PIK3CA K111N,"[{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",sensitive,4331,ARQ 751,5290
95,Preclinical - Cell culture,"In a preclinical study, DHM25 increased cell death in a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 26237138).",Actionable,10362,1612,breast cancer,DOID,3658,PIK3CA K111N,"[{'id': 8367, 'pubMedId': 26237138, 'title': 'A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26237138'}]",sensitive,5494,DHM25,5290
96,Preclinical - Cell culture,"In a preclinical study, PF-04691502 inhibited Akt phosphorylation and proliferation of breast cancer cells harboring both PIK3CA P539R and H1047R in culture (PMID: 21750219).",Actionable,2621,1612,breast cancer,DOID,9797,PIK3CA P539R PIK3CA H1047R,"[{'id': 226, 'pubMedId': 21750219, 'title': 'PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21750219'}]",sensitive,865,PF-04691502,5290
97,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PIK3CA P539R and H1047R were sensitive to ARQ092 in culture, demonstrating inhibition of cell growth (PMID: 26469692). ",Actionable,10273,1612,breast cancer,DOID,9797,PIK3CA P539R PIK3CA H1047R,"[{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",sensitive,635,ARQ092,5290
98,Preclinical - Cell culture,"In a preclinical study, a breast cancer cell line harboring PIK3CA P539R and PH1047R was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692). ",Actionable,10276,1612,breast cancer,DOID,9797,PIK3CA P539R PIK3CA H1047R,"[{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",sensitive,4331,ARQ 751,5290
99,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA P539R in culture (PMID: 27699769).",Actionable,8820,1612,breast cancer,DOID,2913,PIK3CA P539R,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",sensitive,994,BAY1125976,5290
100,Preclinical - Cell culture,"In a preclinical study, the combination of BGJ398 and Buparlisib (BKM120) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489). ",Actionable,10778,1380,endometrial cancer,DOID,27771,FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23,"[{'id': 8811, 'pubMedId': 28119489, 'title': 'PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2(mutant) Endometrial Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28119489'}]",sensitive,5612,BGJ398 + BKM120,5290
101,Preclinical - Cell culture,"In a preclinical study, the combination of BGJ398 and Alpelisib (BYL719) resulted in a synergistic effect, demonstrating inhibition of cell proliferation and induced cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489). ",Actionable,10780,1380,endometrial cancer,DOID,27771,FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23,"[{'id': 8811, 'pubMedId': 28119489, 'title': 'PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2(mutant) Endometrial Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28119489'}]",sensitive,1293,BGJ398 + BYL719,5290
102,Preclinical - Cell culture,"In a preclinical study, the combination of BGJ398 and Pictilisib (GDC-0941) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489). ",Actionable,10777,1380,endometrial cancer,DOID,27771,FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23,"[{'id': 8811, 'pubMedId': 28119489, 'title': 'PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2(mutant) Endometrial Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28119489'}]",sensitive,5613,BGJ398 + GDC-0941,5290
103,Clinical Study,"In a clinical study, PIK3CA K944N was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in colorectal cancer patients, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA K944N (PMID: 28424201).",Actionable,11717,9256,colorectal cancer,DOID,28196,PIK3CA K944N,"[{'id': 9728, 'pubMedId': 28424201, 'title': 'PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28424201'}]",resistant,2000,Fluorouracil + Cetuximab,5290
104,Preclinical,"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA E365K and PTEN mutations in culture (PMID: 22662154).",Actionable,2139,7519,endocervical carcinoma,DOID,5401,PIK3CA E365K PTEN mut,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",sensitive,672,BEZ235,5290
105,Preclinical,"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA E365K and PTEN mutations in culture (PMID: 22662154).",Actionable,2113,1380,endometrial cancer,DOID,5401,PIK3CA E365K PTEN mut,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",sensitive,672,BEZ235,5290
106,Clinical Study,"In a clinical study, PIK3CA F930S was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in colorectal cancer patients, which is consistent with cell culture studies demonstrating moderate resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA F930S (PMID: 28424201).",Actionable,11724,9256,colorectal cancer,DOID,28200,PIK3CA F930S,"[{'id': 9728, 'pubMedId': 28424201, 'title': 'PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28424201'}]",resistant,2000,Fluorouracil + Cetuximab,5290
107,Phase II,"In a Phase II study, MK2206 increased stable disease to 12 months in a nasopharyngeal carcinoma patient with Pik3ca amplification (PMID: 26084990).",Actionable,2478,9261,nasopharynx carcinoma,DOID,1191,PIK3CA amp,"[{'id': 3155, 'pubMedId': 26084990, 'title': 'Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26084990'}]",sensitive,816,MK2206,5290
108,Preclinical - Cell line xenograft,"In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis in HNSCC cell lines and cell line xenograft models with PIK3CA amplification (PMID: 26589432).",Actionable,3914,5520,head and neck squamous cell carcinoma,DOID,1191,PIK3CA amp,"[{'id': 4291, 'pubMedId': 26589432, 'title': 'Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26589432'}]",sensitive,3967,GDC-0032 + Radiotherapy,5290
109,Preclinical,"In a preclinical study, Panulisib (P7170) downregulated mTOR pathway signaling in ovarian cancer cells with amplified PIK3CA (PMID: 25700704).",Actionable,2819,2394,ovarian cancer,DOID,1191,PIK3CA amp,"[{'id': 3487, 'pubMedId': 25700704, 'title': 'P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25700704'}]",sensitive,857,P7170,5290
110,Preclinical - Cell culture,"In a preclinical study, Linsitinib (OSI-906) enhanced sensitivity of PIK3CA amplified triple-receptor negative breast cancer cells to Pictilisib (GDC-0941) in culture (PMID: 27196766).",Actionable,8345,60081,triple-receptor negative breast cancer,DOID,1191,PIK3CA amp,"[{'id': 6624, 'pubMedId': 27196766, 'title': 'Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196766'}]",sensitive,4713,GDC-0941 + Linsitinib,5290
111,Preclinical - Cell culture,"In a preclinical study, small cell lung carcinoma cells harboring amplification of wild-type PIK3CA were resistant to PF-4989216 induced growth inhibition in culture (PMID: 24240111).",Actionable,8287,5409,lung small cell carcinoma,DOID,1191,PIK3CA amp,"[{'id': 4924, 'pubMedId': 24240111, 'title': 'Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24240111'}]",resistant,867,PF-4989216,5290
112,Preclinical - Cell culture,"In a preclinical study, BEZ235 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PIK3CA amplification in culture (PMID: 28446642). ",Actionable,11510,5520,head and neck squamous cell carcinoma,DOID,1191,PIK3CA amp,"[{'id': 9596, 'pubMedId': 28446642, 'title': 'Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28446642'}]",sensitive,672,BEZ235,5290
113,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited PI3K signaling and proliferation of a PIK3CA amplified human ovarian cancer cell line in culture, and inhibited tumor growth in xenograft models (PMID: 25637314).",Actionable,6312,2394,ovarian cancer,DOID,1191,PIK3CA amp,"[{'id': 5522, 'pubMedId': 25637314, 'title': 'The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25637314'}]",sensitive,1050,XL147,5290
114,Preclinical - Cell culture,"In a preclinical study, NVP-AEW541 enhanced sensitivity of PIK3CA amplified triple-receptor negative breast cancer cells to Pictilisib (GDC-0941) in culture (PMID: 27196766).",Actionable,8346,60081,triple-receptor negative breast cancer,DOID,1191,PIK3CA amp,"[{'id': 6624, 'pubMedId': 27196766, 'title': 'Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196766'}]",sensitive,4046,GDC-0941 + NVP-AEW541,5290
115,Preclinical - Cell line xenograft,"In a preclinical study, an ovarian cancer cell line harboring PIK3CA E545K was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413).",Actionable,10703,2394,ovarian cancer,DOID,1191,PIK3CA amp,"[{'id': 8768, 'pubMedId': 24634413, 'title': 'Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24634413'}]",sensitive,1051,SAR245409,5290
116,Preclinical - Cell culture,"In a preclinical study, treatment with AZD8055 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PIK3CA amplification in culture (PMID: 28446642). ",Actionable,11508,5520,head and neck squamous cell carcinoma,DOID,1191,PIK3CA amp,"[{'id': 9596, 'pubMedId': 28446642, 'title': 'Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28446642'}]",predicted – sensitive,1519,AZD8055,5290
117,Preclinical,"In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells harboring PIK3CA G1049R, KRAS G12D, and amplification of PIK3CA in culture (PMID: 22662154).",Actionable,2143,1380,endometrial cancer,DOID,5398,PIK3CA G1049R KRAS G12D PIK3CA amp,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",sensitive,2619,BEZ235 + PD98509,5290
118,Preclinical,"In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells with amplification of PIK3CA and KRAS in culture (PMID: 22662154).",Actionable,2142,1380,endometrial cancer,DOID,5417,PIK3CA amp KRAS amp,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",sensitive,2619,BEZ235 + PD98509,5290
119,Preclinical,"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",Actionable,4238,1612,breast cancer,DOID,3668,PIK3CA N345K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,816,MK2206,5290
120,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",Actionable,4231,1612,breast cancer,DOID,3668,PIK3CA N345K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,691,BYL719,5290
121,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",Actionable,4252,1612,breast cancer,DOID,3668,PIK3CA N345K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,828,Neratinib,5290
122,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",Actionable,4245,1612,breast cancer,DOID,3668,PIK3CA N345K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,787,Lapatinib,5290
123,Preclinical,"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",Actionable,4224,1612,breast cancer,DOID,3668,PIK3CA N345K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,672,BEZ235,5290
124,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",Actionable,4262,10000003,Advanced Solid Tumor,JAX,3668,PIK3CA N345K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,2,Trametinib,5290
125,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",Actionable,4259,1612,breast cancer,DOID,3668,PIK3CA N345K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,2,Trametinib,5290
126,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA N345K and ERBB2 (HER2) amplification in culture (PMID: 21558396).",Actionable,2952,1612,breast cancer,DOID,10739,ERBB2 amp PIK3CA N345K,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
127,Preclinical,"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154).",Actionable,2109,1380,endometrial cancer,DOID,5393,PIK3CA R88Q PTEN mut,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",sensitive,672,BEZ235,5290
128,Preclinical,"In a preclinical study, Afinitor (everolimus) inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154).",Actionable,2110,1380,endometrial cancer,DOID,5393,PIK3CA R88Q PTEN mut,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",sensitive,735,Everolimus,5290
129,Preclinical,"In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to BEZ235 compared with cells without KRAS mutations in culture (PMID: 22662154).",Actionable,2141,1380,endometrial cancer,DOID,5418,PIK3CA R88Q PTEN mut KRAS G12V,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",decreased response,672,BEZ235,5290
130,Preclinical,"In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to Afinitor (everolimus) compared with cells without KRAS mutations in culture (PMID: 22662154).",Actionable,2140,1380,endometrial cancer,DOID,5418,PIK3CA R88Q PTEN mut KRAS G12V,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",decreased response,735,Everolimus,5290
131,Phase I,"In a Phase I trial, treatment with Apitolisib (GDC-0980) resulted in a partial response in a patient with malignant pleural mesothelioma harboring PIK3CA R88Q (PMID: 26787751). ",Actionable,6084,7474,malignant pleural mesothelioma,DOID,3041,PIK3CA R88Q,"[{'id': 4915, 'pubMedId': 26787751, 'title': 'Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26787751'}]",sensitive,750,GDC-0980,5290
132,Clinical Study,"In a retrospective study, treatment with the combination of Erbitux (cetuximab), Adrucil (fluorouracil), Camptosar (irinotecan), and Floxuridine resulted in at least 24 months without evidence of disease in a colorectal carcinoma patient harboring a PIK3CA R88Q mutation (PMID: 25714871).
",Actionable,3756,9256,colorectal cancer,DOID,3041,PIK3CA R88Q,"[{'id': 3888, 'pubMedId': 25714871, 'title': 'AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25714871'}]",sensitive,3292,Cetuximab + Fluorouracil + Irinotecan + Floxuridine,5290
133,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).",Actionable,4246,1612,breast cancer,DOID,2914,PIK3CA Q546K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,787,Lapatinib,5290
134,Preclinical,"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).",Actionable,4239,1612,breast cancer,DOID,2914,PIK3CA Q546K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,816,MK2206,5290
135,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).",Actionable,4253,1612,breast cancer,DOID,2914,PIK3CA Q546K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,828,Neratinib,5290
136,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).",Actionable,4260,1612,breast cancer,DOID,2914,PIK3CA Q546K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,2,Trametinib,5290
137,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).",Actionable,4232,1612,breast cancer,DOID,2914,PIK3CA Q546K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,691,BYL719,5290
138,Preclinical,"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).",Actionable,4225,1612,breast cancer,DOID,2914,PIK3CA Q546K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,672,BEZ235,5290
139,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).",Actionable,4261,10000003,Advanced Solid Tumor,JAX,2914,PIK3CA Q546K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,2,Trametinib,5290
140,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) inhibited tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).",Actionable,8700,9256,colorectal cancer,DOID,26375,KRAS G12V PIK3CA Q546K TP53 R282W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",predicted – sensitive,913,Selumetinib,5290
141,Preclinical - Pdx,"In a preclinical study, BEZ235 delayed tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).",Actionable,8701,9256,colorectal cancer,DOID,26375,KRAS G12V PIK3CA Q546K TP53 R282W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",decreased response,672,BEZ235,5290
142,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K and TP53 R282W (PMID: 26272063).",Actionable,8600,9256,colorectal cancer,DOID,26375,KRAS G12V PIK3CA Q546K TP53 R282W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,1420,Selumetinib + BEZ235,5290
143,Phase Ib/II,"In a Phase Ib trial, an estrogen-receptor positive breast cancer patient harboring PIK3CA mutations, E78K, D939G, and E726K, demonstrated progressive disease when treated with a combination of Femara (letrozole) and Alpelisib (BYL719) (PMID: 27126994). ",Actionable,9703,60075,estrogen-receptor positive breast cancer,DOID,26992,PIK3CA E78K PIK3CA D939G PIK3CA E726K,"[{'id': 7484, 'pubMedId': 27126994, 'title': 'A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27126994'}]",no benefit,1553,Letrozole + BYL719,5290
144,Preclinical,"In a preclinical study, YM-024 did not inhibit proliferation of glioblastoma cell lines harboring PIK3CA V344G in culture (PMID: 24718026).",Actionable,5183,3068,glioblastoma multiforme,DOID,3729,PIK3CA V344G,"[{'id': 4902, 'pubMedId': 24718026, 'title': 'Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24718026'}]",no benefit,2967,YM-024,5290
145,Preclinical,"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R108H and PTEN mutations in culture (PMID: 22662154).",Actionable,2111,1380,endometrial cancer,DOID,5394,PIK3CA R108H PTEN mut,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",sensitive,672,BEZ235,5290
146,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of endometrial cancer cells harboring PIK3CA G1049R and KRAS G12D mutations in culture (PMID: 21558396).",Actionable,2954,1380,endometrial cancer,DOID,10740,KRAS G12D PIK3CA G1049R,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
147,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).",Actionable,4256,1612,breast cancer,DOID,3629,PIK3CA G1049R,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,2,Trametinib,5290
148,Preclinical,"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).",Actionable,4221,1612,breast cancer,DOID,3629,PIK3CA G1049R,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,672,BEZ235,5290
149,Preclinical,"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).",Actionable,4235,1612,breast cancer,DOID,3629,PIK3CA G1049R,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,816,MK2206,5290
150,Preclinical,"In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).",Actionable,4228,1612,breast cancer,DOID,3629,PIK3CA G1049R,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,691,BYL719,5290
151,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).",Actionable,4242,1612,breast cancer,DOID,3629,PIK3CA G1049R,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,787,Lapatinib,5290
152,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).",Actionable,4264,10000003,Advanced Solid Tumor,JAX,3629,PIK3CA G1049R,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,2,Trametinib,5290
153,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).",Actionable,4249,1612,breast cancer,DOID,3629,PIK3CA G1049R,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,828,Neratinib,5290
154,Preclinical,"In a preclinical study, AZD5363 inhibited proliferation of the AGS gastric cancer cell line, which has been reported to harbor KRAS G12D and PIK3CA E453K mutations (PMID: 24088382, PMID: 19755509).",Actionable,2860,10534,stomach cancer,DOID,10717,KRAS G12D PIK3CA E453K,"[{'id': 1081, 'pubMedId': 24088382, 'title': 'The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24088382'}, {'id': 3510, 'pubMedId': 19755509, 'title': 'Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19755509'}]",sensitive,655,AZD5363,5290
155,Preclinical,"In a preclinical study, Rapamune (sirolimus) inhibited proliferation in cultured cells expressing PIK3CA M1043V (PMID: 17376864). ",Actionable,2362,10000003,Advanced Solid Tumor,JAX,3663,PIK3CA M1043V,"[{'id': 101, 'pubMedId': 17376864, 'title': 'Rare cancer-specific mutations in PIK3CA show gain of function.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17376864'}]",sensitive,917,Sirolimus,5290
156,Clinical Study,"In a clinical study, PIK3CA V955G was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in colorectal cancer patients, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA V955G (PMID: 28424201).",Actionable,11718,9256,colorectal cancer,DOID,28197,PIK3CA V955G,"[{'id': 9728, 'pubMedId': 28424201, 'title': 'PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28424201'}]",resistant,2000,Fluorouracil + Cetuximab,5290
157,Preclinical - Cell line xenograft,"In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN R55fs*1 were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111).",Actionable,8286,5409,lung small cell carcinoma,DOID,26222,PIK3CA wild-type PTEN R55fs*1,"[{'id': 4924, 'pubMedId': 24240111, 'title': 'Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24240111'}]",resistant,867,PF-4989216,5290
158,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and U0126 (PMID: 21358673). ",Actionable,10370,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,"[{'id': 3638, 'pubMedId': 21358673, 'title': 'PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21358673'}]",no benefit,5499,Everolimus + U0126,5290
159,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of Torkinib (PP242) and Selumetinib (AZD6244) in culture (PMID: 21358673). ",Actionable,10373,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,"[{'id': 3638, 'pubMedId': 21358673, 'title': 'PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21358673'}]",sensitive,5501,Selumetinib + Torkinib,5290
160,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and Selumetinib (AZD6244) (PMID: 21358673).",Actionable,10371,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,"[{'id': 3638, 'pubMedId': 21358673, 'title': 'PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21358673'}]",no benefit,4901,Everolimus + Selumetinib,5290
161,Preclinical,"In a preclinical study, human breast cancer cells with wild-type PIK3CA and loss of PTEN were resistant to growth inhibition by AZD8835 in culture (PMID: 26839307).",Actionable,5112,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,"[{'id': 4877, 'pubMedId': 26839307, 'title': 'Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26839307'}]",resistant,2013,AZD8835,5290
162,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of Torkinib (PP242) and U0126 in culture (PMID: 21358673). ",Actionable,10372,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,"[{'id': 3638, 'pubMedId': 21358673, 'title': 'PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21358673'}]",sensitive,5500,Torkinib + U0126,5290
163,Preclinical - Cell line xenograft,"In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN inactivating mutations were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111).",Actionable,5215,5409,lung small cell carcinoma,DOID,26218,PIK3CA wild-type PTEN inact mut,"[{'id': 4924, 'pubMedId': 24240111, 'title': 'Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24240111'}]",decreased response,867,PF-4989216,5290
164,Preclinical,"In a preclinical study, colorectal cancer cell lines with wild-type BRAF, KRAS, NRAS and PIK3CA were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4944,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",resistant,890,Regorafenib,5290
165,Phase II,"In a Phase II trial, Erbitux (cetuximab) in combination with FOLFOX resulted in improved median progression-free survival (6.9 months) comparing to FOLFOX alone (5.3 months) in BRAF, KRAS, NRAS, and PIK3CA wild-type colorectal cancer patients (hazard ratio =0.56) (PMID: 27002107).",Actionable,5563,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,"[{'id': 5108, 'pubMedId': 27002107, 'title': 'Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27002107'}]",predicted – sensitive,2182,Cetuximab + FOLFOX,5290
166,Preclinical,"In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells wild-type for BRAF, KRAS, NRAS and PIK3CA in culture (PMID: 25838391).",Actionable,4934,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",sensitive,694,Cetuximab,5290
167,Preclinical - Pdx & cell culture,"In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture, and colorectal cancer patient-derived xenograft (PDX) models with KRAS or BRAF mutations and wild-type PIK3CA demonstrated a trend toward greater tumor growth inhibition (PMID: 26439693).",Actionable,10766,9256,colorectal cancer,DOID,18590,KRAS mutant PIK3CA wild-type,"[{'id': 8454, 'pubMedId': 26439693, 'title': 'Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26439693'}]",predicted – sensitive,932,TAK-733,5290
168,Preclinical,"In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and reduced tumor growth in xenograft models (PMID: 26715098).",Actionable,4568,219,colon cancer,DOID,18590,KRAS mutant PIK3CA wild-type,"[{'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",sensitive,680,BKM120,5290
169,Preclinical,"In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and tumor growth in xenograft models (PMID: 26715098).",Actionable,4570,219,colon cancer,DOID,18590,KRAS mutant PIK3CA wild-type,"[{'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",sensitive,3548,BKM120 + Cetuximab,5290
170,Preclinical - Cell line xenograft,"In a preclinical study, Taselisib (GDC-0032) did not result in delay of cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, however, did result in tumor growth inhibition in xenograft models (PMID: 26333383). ",Actionable,9063,5750,uterine corpus serous adenocarcinoma,DOID,26704,ERBB2 amp PIK3CA wild-type,"[{'id': 6891, 'pubMedId': 26333383, 'title': 'Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26333383'}]",sensitive,1016,GDC-0032,5290
171,Preclinical - Cell culture,"In a preclinical study, the combination of Taselisib (GDC-0032) and Nerlynx (neratinib) delayed cell cycle activity in a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture (PMID: 26333383). ",Actionable,9065,5750,uterine corpus serous adenocarcinoma,DOID,26704,ERBB2 amp PIK3CA wild-type,"[{'id': 6891, 'pubMedId': 26333383, 'title': 'Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26333383'}]",sensitive,4871,GDC-0032 + Neratinib,5290
172,Preclinical - Cell line xenograft,"In a preclinical study, Nerlynx (neratinib) delayed cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, and inhibited tumor growth in xenograft models (PMID: 26333383). ",Actionable,9064,5750,uterine corpus serous adenocarcinoma,DOID,26704,ERBB2 amp PIK3CA wild-type,"[{'id': 6891, 'pubMedId': 26333383, 'title': 'Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26333383'}]",sensitive,828,Neratinib,5290
173,Preclinical - Pdx & cell culture,"In a preclinical study, mutations in BRAF, KRAS, or NRAS were associated with sensitivity to TAK-733 in colorectal cancer cell lines in culture, and patient-derived xenograft models harboring KRAS or BRAF mutations with wild-type PIK3CA demonstrated a trend toward higher tumor growth inhibition following TAK-733 treatment (PMID: 26439693).",Actionable,10776,9256,colorectal cancer,DOID,27794,BRAF mut PIK3CA wild-type,"[{'id': 8454, 'pubMedId': 26439693, 'title': 'Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26439693'}]",predicted – sensitive,932,TAK-733,5290
174,Preclinical,"In a preclinical study, Selumetinib (AZD6244) and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5184,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,"[{'id': 4903, 'pubMedId': 26137449, 'title': 'Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26137449'}]",sensitive,3773,Selumetinib + Vemurafenib,5290
175,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) and ZSTK474 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergistically inhibited tumor growth in cell line xenograft models (PMID: 26137449).",Actionable,5187,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,"[{'id': 4903, 'pubMedId': 26137449, 'title': 'Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26137449'}]",sensitive,3771,Selumetinib + ZSTK474,5290
176,Preclinical,"In a preclinical study, ZSTK474 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5186,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,"[{'id': 4903, 'pubMedId': 26137449, 'title': 'Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26137449'}]",sensitive,3772,Vemurafenib + ZSTK474,5290
177,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergitically inhibited tumor growth in cell line xenograft models (PMID: 26137449).",Actionable,5188,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,"[{'id': 4903, 'pubMedId': 26137449, 'title': 'Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26137449'}]",sensitive,1420,Selumetinib + BEZ235,5290
178,Preclinical,"In a preclinical study, Zydelig (idelalisib) did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5192,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,"[{'id': 4903, 'pubMedId': 26137449, 'title': 'Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26137449'}]",no benefit,1023,Idelalisib,5290
179,Preclinical,"In a preclinical study, BEZ235 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5185,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,"[{'id': 4903, 'pubMedId': 26137449, 'title': 'Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26137449'}]",sensitive,3774,BEZ235 + Vemurafenib,5290
180,Preclinical,"In a preclinical study, A66 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5190,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,"[{'id': 4903, 'pubMedId': 26137449, 'title': 'Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26137449'}]",no benefit,617,A66,5290
181,Preclinical,"In a preclinical study, TGX-221 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5191,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,"[{'id': 4903, 'pubMedId': 26137449, 'title': 'Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26137449'}]",no benefit,2514,TGX-221,5290
182,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS and with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture (PMID: 26439693).",Actionable,10774,9256,colorectal cancer,DOID,27788,NRAS mut PIK3CA wild-type,"[{'id': 8454, 'pubMedId': 26439693, 'title': 'Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26439693'}]",predicted – sensitive,932,TAK-733,5290
183,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize PIK3CA wild-type breast cancer cell lines to WEHI-539 in culture (PMID: 27974663).",Actionable,10088,1612,breast cancer,DOID,430,PIK3CA wild-type,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",no benefit,5377,BEZ235 + WEHI-539,5290
184,Preclinical,"In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in PIK3CA wild-type, triple-receptor negative breast cancer cell lines in culture (PMID: 27020857).",Actionable,5861,60081,triple-receptor negative breast cancer,DOID,430,PIK3CA wild-type,"[{'id': 5181, 'pubMedId': 27020857, 'title': 'Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27020857'}]",no benefit,3956,Palbociclib + GDC-0941,5290
185,Phase I,"In a Phase I study, PX-866 demonstrated efficacy and was well tolerated in patients with advanced solid tumor with both PIK3CA wild-type and mutant status (PMID: 22693357).
",Actionable,108,10000003,Advanced Solid Tumor,JAX,430,PIK3CA wild-type,"[{'id': 231, 'pubMedId': 22693357, 'title': 'A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693357'}]",sensitive,881,PX-866,5290
186,Phase II,"In a Phase II trial, the combination of Taxol (paclitaxel) plus Herceptin (trastuzumab) and Tykerb (lapatinib) resulted in a higher pathologic complete remission rate in ERBB2 (HER2)-receptor positive breast cancer patients with PIK3CA wild-type compared to those harboring a PIK3CA mutation (PMID: 26245675).",Actionable,3359,60079,Her2-receptor positive breast cancer,DOID,430,PIK3CA wild-type,"[{'id': 3761, 'pubMedId': 26245675, 'title': 'Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26245675'}]",sensitive,3130,Paclitaxel + Lapatinib + Trastuzumab,5290
187,Preclinical - Cell culture,"In a preclinical study, combination of WEHI-539 and A-1210477 resulted in enhanced apoptosis in PIK3CA wild-type breast cancer cell lines in culture (PMID: 27974663).",Actionable,10110,1612,breast cancer,DOID,430,PIK3CA wild-type,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",predicted – sensitive,5392,A-1210477 + WEHI-539,5290
188,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of PIK3CA wild-type colorectal cancer cells harboring KRAS G12V (PMID: 26369631).",Actionable,5618,9256,colorectal cancer,DOID,21300,KRAS G12V PIK3CA wild-type,"[{'id': 5128, 'pubMedId': 26369631, 'title': 'Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26369631'}]",sensitive,1368,Palbociclib + Trametinib,5290
189,Preclinical - Cell line xenograft,"In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN Y27fs*1 were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111).",Actionable,8285,5409,lung small cell carcinoma,DOID,26223,PIK3CA wild-type PTEN Y27fs*1,"[{'id': 4924, 'pubMedId': 24240111, 'title': 'Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24240111'}]",resistant,867,PF-4989216,5290
190,Clinical Study,"In a retrospective study, Erbitux (cetuximab) treatment resulted in stable disease in a colorectal carcinoma patient harboring a PIK3CA E542V mutation (PMID: 25714871).
",Actionable,3758,9256,colorectal cancer,DOID,3617,PIK3CA E542V,"[{'id': 3888, 'pubMedId': 25714871, 'title': 'AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25714871'}]",sensitive,694,Cetuximab,5290
191,Clinical Study,"In a clinical study, two colorectal cancer patients harboring both a PIK3CA E545 and KRAS G12 mutation demonstrated stable disease when treated with Torisel (temsirolimus) (PMID: 21216929). ",Actionable,3312,9256,colorectal cancer,DOID,13163,PIK3CA E545X KRAS G12X,"[{'id': 3726, 'pubMedId': 21216929, 'title': 'PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21216929'}]",sensitive,936,Temsirolimus,5290
192,Preclinical - Cell culture,"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA E545V was sensitive to DS-7423 in culture, demonstrating inhibition of cell proliferation (PMID: 24504419). ",Actionable,10544,5304,ovarian clear cell adenocarcinoma,DOID,3622,PIK3CA E545V,"[{'id': 4912, 'pubMedId': 24504419, 'title': 'Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24504419'}]",sensitive,722,DS-7423,5290
193,Preclinical - Cell culture,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture (PMID: 26920887).",Actionable,7746,60079,Her2-receptor positive breast cancer,DOID,25949,ERBB2 pos PIK3CA I391M,"[{'id': 6466, 'pubMedId': 26920887, 'title': 'Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26920887'}]",sensitive,1402,trastuzumab emtansine,5290
194,Clinical Study,"In a clinical study, a uterine cancer patient harboring PIK3CA I391M demonstrated stable disease when treated with Rapamune (sirolimus) (PMID: 28514312). ",Actionable,11051,363,uterine cancer,DOID,2891,PIK3CA I391M,"[{'id': 9046, 'pubMedId': 28514312, 'title': 'Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28514312'}]",sensitive,917,Sirolimus,5290
195,Preclinical - Cell culture,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA C420R in culture (PMID: 26920887).",Actionable,7747,60079,Her2-receptor positive breast cancer,DOID,25950,ERBB2 pos PIK3CA C420R,"[{'id': 6466, 'pubMedId': 26920887, 'title': 'Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26920887'}]",sensitive,1402,trastuzumab emtansine,5290
196,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA C420R and ERBB2 (HER2) amplification (PMID: 21558396).",Actionable,2951,1612,breast cancer,DOID,10738,ERBB2 amp PIK3CA C420R,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
197,Preclinical,"In a preclinical study, cells expressing PIK3CA C420R were sensitive to Rapamune (sirolimus) in culture (PMID: 17376864).",Actionable,1665,10000003,Advanced Solid Tumor,JAX,2790,PIK3CA C420R,"[{'id': 101, 'pubMedId': 17376864, 'title': 'Rare cancer-specific mutations in PIK3CA show gain of function.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17376864'}]",sensitive,917,Sirolimus,5290
198,Preclinical - Cell culture,"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA C420R was sensitive to DS-7423 in culture, demonstrating inhibition of cell proliferation (PMID: 24504419). ",Actionable,10542,5304,ovarian clear cell adenocarcinoma,DOID,2790,PIK3CA C420R,"[{'id': 4912, 'pubMedId': 24504419, 'title': 'Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24504419'}]",sensitive,722,DS-7423,5290
199,Preclinical - Cell line xenograft,"In a preclinical study, LY3023414 inhibited proliferation of non-small cell lung cancer cells harboring PIK3CA G118D in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27439478).",Actionable,8940,3908,non-small cell lung carcinoma,DOID,3633,PIK3CA G118D,"[{'id': 6792, 'pubMedId': 27439478, 'title': 'Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27439478'}]",sensitive,1069,LY3023414,5290
200,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).",Actionable,8177,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4656,Everolimus + Pimasertib,5290
201,Preclinical - Cell line xenograft,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited Mapk and Akt signaling, resulted in growth inhibition of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture and in cell line xenograft models (PMID: 23629727).",Actionable,8181,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,1659,Pimasertib + Sorafenib,5290
202,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, T790M, and PIK3CA G118D demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).",Actionable,8172,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",decreased response,871,Pimasertib,5290
203,Preclinical - Cell line xenograft,"In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).",Actionable,8187,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,1660,Pimasertib + BEZ235,5290
204,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).",Actionable,8186,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4657,Pimasertib + Regorafenib,5290
205,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12C, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).",Actionable,8577,9256,colorectal cancer,DOID,26366,KRAS G12C PIK3CA H1047R TP53 R248W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,4771,MLN0128 + PD-0325901,5290
206,Preclinical,"In a preclinical study, the combination of Herceptin (trastuzumab) and Buparlisib (BKM120) inhibited tumor growth in mouse ERBB2 (HER2)-over expressing breast cancer models expressing PIK3CA H1047R, with moderate efficacy over Buparlisib (BKM120) alone (PMID: 23940356).",Actionable,968,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,"[{'id': 240, 'pubMedId': 23940356, 'title': 'Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23940356'}]",sensitive,1417,BKM120 + Trastuzumab,5290
207,Preclinical,"In a preclinical study, treatment with Buparlisib (BKM120) resulted in decreased tumor growth, but not tumor regression, in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R (PMID: 23940356).",Actionable,967,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,"[{'id': 240, 'pubMedId': 23940356, 'title': 'Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23940356'}]",sensitive,1178,BKM120 + Bevacizumab,5290
208,Preclinical,"In a preclinical study, a mouse breast cancer model with ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Heceptin (trastuzumab) and Perjeta (pertuzumab) (PMID: 23940356).",Actionable,970,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,"[{'id': 240, 'pubMedId': 23940356, 'title': 'Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23940356'}]",resistant,1389,Trastuzumab + Pertuzumab,5290
209,Preclinical,"In a preclinical study, mouse breast cancer models over expressing ERBB2 (HER2) and expressing PIK3CA H1047R were resistant to Herceptin (trastuzumab) (PMID: 23940356).",Actionable,966,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,"[{'id': 240, 'pubMedId': 23940356, 'title': 'Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23940356'}]",resistant,947,Trastuzumab,5290
210,Preclinical,"In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Tykerb (lapatinib) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, but efficacy was not significantly improved over Buparlisib (BKM120) alone (PMID: 23940356). ",Actionable,972,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,"[{'id': 240, 'pubMedId': 23940356, 'title': 'Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23940356'}]",no benefit,1419,BKM120 + Trastuzumab + Lapatinib,5290
211,Preclinical,"In a preclinical study, a mouse breast cancer model with mammary ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23940356).",Actionable,969,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,"[{'id': 240, 'pubMedId': 23940356, 'title': 'Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23940356'}]",resistant,1414,Trastuzumab + Lapatinib,5290
212,Preclinical,"In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Perjeta (pertuzumab) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, with improved efficacy over Buparlisib (BKM120) alone (PMID: 23940356).",Actionable,971,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,"[{'id': 240, 'pubMedId': 23940356, 'title': 'Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23940356'}]",sensitive,1418,BKM120 + Trastuzumab + Pertuzumab,5290
213,Preclinical - Pdx,"In a preclinical study, BEZ235 stabilized tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).",Actionable,8697,9256,colorectal cancer,DOID,26372,KRAS G12D PIK3CA H1047R TP53 R248W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",predicted – sensitive,672,BEZ235,5290
214,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R and TP53 R248W (PMID: 26272063).",Actionable,8596,9256,colorectal cancer,DOID,26372,KRAS G12D PIK3CA H1047R TP53 R248W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,1420,Selumetinib + BEZ235,5290
215,Preclinical - Pdx,"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).",Actionable,8695,9256,colorectal cancer,DOID,26372,KRAS G12D PIK3CA H1047R TP53 R248W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",resistant,913,Selumetinib,5290
216,Preclinical - Cell line xenograft,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R in culture and in cell line xenograft models (PMID: 26272063).",Actionable,8567,9256,colorectal cancer,DOID,26360,KRAS G13D PIK3CA H1047R TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,5290
217,Preclinical,"In a preclinical study, Sirolimus (rapamycin) failed to inhibit tumor growth in a mouse lung adenocarcinoma model expressing the PIK3CA H1047R mutation (PMID: 19029981).",Actionable,1016,3910,lung adenocarcinoma,DOID,1731,PIK3CA H1047R,"[{'id': 216, 'pubMedId': 19029981, 'title': 'Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19029981'}]",no benefit,917,Sirolimus,5290
218,Preclinical,"In a preclinical study, A66 delayed tumor growth in human tumor xenograft models harboring PIK3CA H1047R mutations (PMID: 21668414).",Actionable,2776,10000003,Advanced Solid Tumor,JAX,1731,PIK3CA H1047R,"[{'id': 223, 'pubMedId': 21668414, 'title': 'A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21668414'}]",sensitive,617,A66,5290
219,Preclinical - Cell culture,"In a preclinical study, a breast cancer cell line harboring PIK3CA H1047R demonstrated sensitivity to treatment with ARQ092 in culture, resulting in inhibition of cell proliferation (PMID: 26469692). ",Actionable,10267,1612,breast cancer,DOID,1731,PIK3CA H1047R,"[{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",sensitive,635,ARQ092,5290
220,Phase I,"In a Phase I trial, four patients with breast cancer harboring PIK3CA H1047R demonstrated a confirmed partial response when treated with Taselisib (GDC-0032) (PMID: 28331003).",Actionable,11445,1612,breast cancer,DOID,1731,PIK3CA H1047R,"[{'id': 9393, 'pubMedId': 28331003, 'title': 'Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28331003'}]",sensitive,1016,GDC-0032,5290
221,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer cell line xenograft model harboring PIK3CA H1047R demonstrated tumor regression within the mammary fat pad when treated with Buparlisib (BKM120) (PMID: 28539475). ",Actionable,11515,1612,breast cancer,DOID,1731,PIK3CA H1047R,"[{'id': 9597, 'pubMedId': 28539475, 'title': 'The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28539475'}]",sensitive,680,BKM120,5290
222,Preclinical - Pdx,"In a preclinical study, BEZ235 inhibited tumor growth in a patient-derived xenograft (PDX) model of bladder cancer harboring PIK3CA H1047R (PMID: 26270481).",Actionable,7452,11054,urinary bladder cancer,DOID,1731,PIK3CA H1047R,"[{'id': 6363, 'pubMedId': 26270481, 'title': 'Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26270481'}]",sensitive,672,BEZ235,5290
223,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring PIK3CA H1047R in culture (PMID: 21325073, PMID: 17314276).",Actionable,3127,1612,breast cancer,DOID,1731,PIK3CA H1047R,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3636, 'pubMedId': 17314276, 'title': 'Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17314276'}]",sensitive,1040,PF-05212384,5290
224,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells over expressing PIK3CA H1047R were resistant to Erbitux (cetuximab) and Fluorouracil combination treatment in culture (PMID: 28424201).",Actionable,11723,9256,colorectal cancer,DOID,1731,PIK3CA H1047R,"[{'id': 9728, 'pubMedId': 28424201, 'title': 'PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28424201'}]",resistant,2000,Fluorouracil + Cetuximab,5290
225,Preclinical,"In a preclinical study, transformed cells expressing PIK3CA H1047R were sensitive to Rapamune (sirolimus), resulting in inhibition of transformation in culture (PMID: 15647370). ",Actionable,6003,10000003,Advanced Solid Tumor,JAX,1731,PIK3CA H1047R,"[{'id': 1077, 'pubMedId': 15647370, 'title': 'Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15647370'}]",sensitive,917,Sirolimus,5290
226,Preclinical - Cell line xenograft,"In a preclinical study, PF-04691502 inhibited Pi3k signaling, resulted in growth inhibition of ovarian cancer cells harboring PIK3CA H1047R in culture and in cell line xenograft models (PMID: 21750219).",Actionable,1801,2394,ovarian cancer,DOID,1731,PIK3CA H1047R,"[{'id': 226, 'pubMedId': 21750219, 'title': 'PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21750219'}]",sensitive,865,PF-04691502,5290
227,Preclinical,"In a preclinical study, Sirolimus (rapamycin) did not induce tumor shrinkage in mouse lung cancer models carrying PIK3CA H1047R (PMID: 19029981).",Actionable,1289,1324,lung cancer,DOID,1731,PIK3CA H1047R,"[{'id': 216, 'pubMedId': 19029981, 'title': 'Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19029981'}]",no benefit,917,Sirolimus,5290
228,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",Actionable,4251,1612,breast cancer,DOID,1731,PIK3CA H1047R,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,828,Neratinib,5290
229,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of breast cancer cells harboring PIK3CA H1047R in culture (PMID: 21558396).",Actionable,2946,1612,breast cancer,DOID,1731,PIK3CA H1047R,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
230,Phase I,"In a Phase I trial, CH5132799 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a partial response in a patient with ovarian cancer harboring PIK3CA H1047R (PMID: 25231405).",Actionable,2837,2394,ovarian cancer,DOID,1731,PIK3CA H1047R,"[{'id': 3498, 'pubMedId': 25231405, 'title': 'First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231405'}]",sensitive,2152,CH5132799,5290
231,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",Actionable,4263,10000003,Advanced Solid Tumor,JAX,1731,PIK3CA H1047R,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,2,Trametinib,5290
232,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cell lines harboring PIK3CA H1047R demonstrated sensitivity to treatment with Gedatolisib (PF-05212384) in culture (PMID: 25977343). ",Actionable,8244,5520,head and neck squamous cell carcinoma,DOID,1731,PIK3CA H1047R,"[{'id': 6585, 'pubMedId': 25977343, 'title': 'MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25977343'}]",sensitive,1040,PF-05212384,5290
233,Preclinical - Cell culture,"In a preclinical study, a breast cancer cell line harboring PIK3CA H1047R demonstrated sensitivity to treatment with ARQ 751 in culture, resulting in inhibition of cell proliferation (PMID: 26469692). ",Actionable,10268,1612,breast cancer,DOID,1731,PIK3CA H1047R,"[{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",sensitive,4331,ARQ 751,5290
234,Preclinical - Cell culture,"In a preclinical study, Estybon (rigosertib) inhibited oncogenic transformation in fibroblast cells over-expressing PIK3CA H1047R in culture (PMID: 27104980).",Actionable,8556,10000003,Advanced Solid Tumor,JAX,1731,PIK3CA H1047R,"[{'id': 6686, 'pubMedId': 27104980, 'title': 'A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27104980'}]",sensitive,1046,rigosertib,5290
235,Preclinical - Cell line xenograft,"In a preclinical study, Glucophage (metformin) demonstrated efficacy in treating dietary restriction-resistant human colorectal cancer cell line xenograft tumors harboring PIK3CA H1047R (PMID: 23986086).",Actionable,9357,9256,colorectal cancer,DOID,1731,PIK3CA H1047R,"[{'id': 1086, 'pubMedId': 23986086, 'title': 'Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23986086'}]",sensitive,1031,Metformin,5290
236,Preclinical,"In a preclinical study, AZD8835 inhibited tumor growth in mouse xenografts of ovarian cancer with a Pik3ca H1047R mutation (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2830).",Actionable,3752,2394,ovarian cancer,DOID,1731,PIK3CA H1047R,"[{'id': 4105, 'pubMedId': None, 'title': 'Discovery of AZD8835, a potent and selective inhibitor of PI3K? and PI3K? for the treatment of PIK3CA-dependent cancers', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/2830.short'}]",sensitive,2013,AZD8835,5290
237,Preclinical - Cell culture,"In a preclinical study, BEZ235 induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA H1047R in culture (PMID: 26013318).",Actionable,7972,3907,lung squamous cell carcinoma,DOID,1731,PIK3CA H1047R,"[{'id': 6528, 'pubMedId': 26013318, 'title': 'Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26013318'}]",sensitive,672,BEZ235,5290
238,Preclinical - Cell culture,"In a preclinical study, DHM25 increased cell death in breast cancer cell lines harboring PIK3CA H1047R in culture (PMID: 26237138).",Actionable,10358,1612,breast cancer,DOID,1731,PIK3CA H1047R,"[{'id': 8367, 'pubMedId': 26237138, 'title': 'A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26237138'}]",sensitive,5494,DHM25,5290
239,Preclinical - Pdx,"In a preclinical study, AZD5363 inhibited growth in a patient-derived xenograft model of gastric cancer harboring a PIK3CA H1047R mutation (PMID: 24088382).",Actionable,2794,10534,stomach cancer,DOID,1731,PIK3CA H1047R,"[{'id': 1081, 'pubMedId': 24088382, 'title': 'The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24088382'}]",sensitive,655,AZD5363,5290
240,Preclinical,"In a preclinical study, BEZ235 reduced tumor size in mouse models of lung cancer carrying PIK3CA H1047R (PMID: 19029981).",Actionable,1288,1324,lung cancer,DOID,1731,PIK3CA H1047R,"[{'id': 216, 'pubMedId': 19029981, 'title': 'Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19029981'}]",sensitive,672,BEZ235,5290
241,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA H1047R in culture (PMID: 26013318).",Actionable,7973,3907,lung squamous cell carcinoma,DOID,1731,PIK3CA H1047R,"[{'id': 6528, 'pubMedId': 26013318, 'title': 'Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26013318'}]",sensitive,691,BYL719,5290
242,Preclinical - Cell line xenograft,"In a preclinical study, BAY1125976 inhibited proliferation of  breast cancer cell lines harboring PIK3CA H1047R in culture, and inhibited AKT signaling and tumor growth in a PIK3CA H1047R-mutant cell line xenograft model (PMID: 27699769).",Actionable,8814,1612,breast cancer,DOID,1731,PIK3CA H1047R,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",sensitive,994,BAY1125976,5290
243,Preclinical - Cell line xenograft,"In a preclinical study, Glucophage (metformin) inhibited cell proliferation of a dietary restriction-resistant PIK3CA H1047R-harboring human breast cancer cell line in culture, and inhibited tumor growth in xenograft models (PMID: 23986086).",Actionable,9356,1612,breast cancer,DOID,1731,PIK3CA H1047R,"[{'id': 1086, 'pubMedId': 23986086, 'title': 'Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23986086'}]",sensitive,1031,Metformin,5290
244,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer xenograft model harboring PIK3CA H1047R was sensitive to M2698 (MSC2363318A), demonstrating inhibition of tumor growth (PMID: 27186432).",Actionable,10289,1612,breast cancer,DOID,1731,PIK3CA H1047R,"[{'id': 7643, 'pubMedId': 27186432, 'title': 'M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27186432'}]",sensitive,1037,MSC2363318A,5290
245,Preclinical,"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",Actionable,4223,1612,breast cancer,DOID,1731,PIK3CA H1047R,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,672,BEZ235,5290
246,Preclinical,"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",Actionable,4237,1612,breast cancer,DOID,1731,PIK3CA H1047R,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,816,MK2206,5290
247,Preclinical - Cell culture,"In a preclinical study, Buparlisib (BKM120) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing wild-type Pik3ca in culture (PMID: 26013318).",Actionable,7969,3907,lung squamous cell carcinoma,DOID,1731,PIK3CA H1047R,"[{'id': 6528, 'pubMedId': 26013318, 'title': 'Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26013318'}]",sensitive,680,BKM120,5290
248,Preclinical,"In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",Actionable,4230,1612,breast cancer,DOID,1731,PIK3CA H1047R,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,691,BYL719,5290
249,Preclinical,"In a preclinical study, BEZ235 promoted tumor regression in a mouse lung adenocarcinoma model expressing PIK3CA H1047R (PMID: 19029981).",Actionable,1015,3910,lung adenocarcinoma,DOID,1731,PIK3CA H1047R,"[{'id': 216, 'pubMedId': 19029981, 'title': 'Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19029981'}]",sensitive,672,BEZ235,5290
250,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",Actionable,4244,1612,breast cancer,DOID,1731,PIK3CA H1047R,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,787,Lapatinib,5290
251,Preclinical - Cell culture,"In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including an anaplastic thyroid cancer cell line harboring PIK3CA H1047R (PMID: 21289267).",Actionable,8214,1781,thyroid cancer,DOID,1731,PIK3CA H1047R,"[{'id': 6573, 'pubMedId': 21289267, 'title': 'The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21289267'}]",sensitive,816,MK2206,5290
252,Clinical Study,"In a retrospective study, Erbitux (cetuximab) combined with radiation therapy resulted in stable disease for 6 months in a colorectal carcinoma patient harboring a PIK3CA H1047R mutation (PMID: 25714871).",Actionable,3760,9256,colorectal cancer,DOID,1731,PIK3CA H1047R,"[{'id': 3888, 'pubMedId': 25714871, 'title': 'AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25714871'}]",sensitive,694,Cetuximab,5290
253,Preclinical - Cell culture,"In a preclinical study, MK2206 and Torisel (temsirolimus) demonstrated synergy in inhibiting growth of an anaplastic thyroid cancer cell line harboring PIK3CA H1047R in culture (PMID: 21289267).",Actionable,8222,1781,thyroid cancer,DOID,1731,PIK3CA H1047R,"[{'id': 6573, 'pubMedId': 21289267, 'title': 'The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21289267'}]",sensitive,4664,MK2206 + Temsirolimus,5290
254,Preclinical,"In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis of head and neck squamous carcinoma cells harboring PIK3CA H1047R (PMID: 26589432). ",Actionable,5866,5520,head and neck squamous cell carcinoma,DOID,1731,PIK3CA H1047R,"[{'id': 4291, 'pubMedId': 26589432, 'title': 'Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26589432'}]",sensitive,3967,GDC-0032 + Radiotherapy,5290
255,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",Actionable,4258,1612,breast cancer,DOID,1731,PIK3CA H1047R,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,2,Trametinib,5290
256,Preclinical - Cell line xenograft,"In a preclinical study, A66 delayed tumor growth in an ovarian cancer cell line xenograft model harboring PIK3CA H1047R (PMID: 21668414).",Actionable,7533,2394,ovarian cancer,DOID,1731,PIK3CA H1047R,"[{'id': 223, 'pubMedId': 21668414, 'title': 'A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21668414'}]",sensitive,617,A66,5290
257,Preclinical - Cell line xenograft,"In a preclinical study, Rapamune (sirolimus) worked synergistically with Mekinist (trametinib) to inhibit proliferation of head and neck squamous carcinoma cell lines harboring PIK3CA H1047R in culture and to reduce tumor growth in cell line xenograft models (PMID: 26882569).",Actionable,4688,5520,head and neck squamous cell carcinoma,DOID,1731,PIK3CA H1047R,"[{'id': 4668, 'pubMedId': 26882569, 'title': 'A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26882569'}]",sensitive,3596,Sirolimus + Trametinib,5290
258,Clinical Study,"In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to treatment with Afinitor (everolimus) (PMID: 27797976). ",Actionable,10814,3963,thyroid carcinoma,DOID,26356,BRAF V600E PIK3CA H1047R,"[{'id': 8849, 'pubMedId': 27797976, 'title': 'Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27797976'}]",resistant,735,Everolimus,5290
259,Clinical Study,"In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to the combination therapy, Mekinist (trametinib) and Tafinlar (dabrafenib) (PMID: 27797976).",Actionable,10815,3963,thyroid carcinoma,DOID,26356,BRAF V600E PIK3CA H1047R,"[{'id': 8849, 'pubMedId': 27797976, 'title': 'Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27797976'}]",resistant,1066,Trametinib + Dabrafenib,5290
260,Clinical Study,"In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated tumor regression when treated with the triple combination, Tafinlar (dabrafenib), Mekinist (trametinib), and Afinitor (everolimus) (PMID: 27797976).",Actionable,10812,3963,thyroid carcinoma,DOID,26356,BRAF V600E PIK3CA H1047R,"[{'id': 8849, 'pubMedId': 27797976, 'title': 'Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27797976'}]",sensitive,5650,Dabrafenib + Everolimus + Trametinib,5290
261,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",Actionable,8702,9256,colorectal cancer,DOID,26376,KRAS G12D PIK3CA H1047R TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",decreased response,913,Selumetinib,5290
262,Preclinical - Pdx,"In a preclinical study, BEZ235 inhibited tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",Actionable,8703,9256,colorectal cancer,DOID,26376,KRAS G12D PIK3CA H1047R TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",predicted – sensitive,672,BEZ235,5290
263,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",Actionable,8601,9256,colorectal cancer,DOID,26376,KRAS G12D PIK3CA H1047R TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,1420,Selumetinib + BEZ235,5290
264,Preclinical - Cell line xenograft,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA H1047R in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).",Actionable,7748,60079,Her2-receptor positive breast cancer,DOID,25951,ERBB2 pos PIK3CA H1047R,"[{'id': 6466, 'pubMedId': 26920887, 'title': 'Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26920887'}]",sensitive,1402,trastuzumab emtansine,5290
265,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA H1047R and PTEN E307K in culture (PMID: 27699769).",Actionable,8819,1612,breast cancer,DOID,26449,PIK3CA H1047R PTEN E307K,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",sensitive,994,BAY1125976,5290
266,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to WEHI-539 in culture (PMID: 27974663).",Actionable,10085,1612,breast cancer,DOID,27242,PIK3CA H1047R PTEN loss,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",predicted – sensitive,5377,BEZ235 + WEHI-539,5290
267,Preclinical - Cell line xenograft,"In a preclinical study, ABT-737 and BEZ235 combination treatment resulted in tumor regression in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663).",Actionable,10091,60081,triple-receptor negative breast cancer,DOID,27242,PIK3CA H1047R PTEN loss,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",predicted – sensitive,5381,ABT-737 + BEZ235,5290
268,Preclinical - Cell line xenograft,"In a preclinical study, ABT-737 and Sapanisertib (MLN0128) combination treatment resulted in inhibition of tumor growth in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663).",Actionable,10097,60081,triple-receptor negative breast cancer,DOID,27242,PIK3CA H1047R PTEN loss,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",predicted – sensitive,5388,ABT-737 + MLN0128,5290
269,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to Venclexta (venetoclax) in culture (PMID: 27974663).",Actionable,10082,1612,breast cancer,DOID,27242,PIK3CA H1047R PTEN loss,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",no benefit,5376,BEZ235 + Venetoclax,5290
270,Preclinical - Cell culture,"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA H1047R and TP53 S90fs*33 demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419). ",Actionable,10545,5304,ovarian clear cell adenocarcinoma,DOID,27594,PIK3CA H1047R TP53 S90fs*33,"[{'id': 4912, 'pubMedId': 24504419, 'title': 'Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24504419'}]",decreased response,722,DS-7423,5290
271,Preclinical - Cell culture,"In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",Actionable,8881,1612,breast cancer,DOID,26496,AKT1 over exp PIK3CA H1047R,"[{'id': 6782, 'pubMedId': 27604488, 'title': 'Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27604488'}]",resistant,691,BYL719,5290
272,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring ERBB2 (HER2) amplification and PIK3CA H1047R in culture (PMID: 21325073, PMID: 17314276).",Actionable,3125,1612,breast cancer,DOID,10752,ERBB2 amp PIK3CA H1047R,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3636, 'pubMedId': 17314276, 'title': 'Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17314276'}]",sensitive,1040,PF-05212384,5290
273,Preclinical - Cell line xenograft,"In a preclinical study, the combination of CH5132799 and Herceptin (trastuzumab) inhibited tumor growth and overcame Herceptin (trastuzumab) insensitivity in xenograft models of a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification (PMID: 21558396).",Actionable,2975,1612,breast cancer,DOID,10752,ERBB2 amp PIK3CA H1047R,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,3039,CH5132799 + Trastuzumab,5290
274,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).",Actionable,2968,1612,breast cancer,DOID,10752,ERBB2 amp PIK3CA H1047R,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
275,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited cell growth in a human ovarian cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).
",Actionable,2970,2394,ovarian cancer,DOID,10752,ERBB2 amp PIK3CA H1047R,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
276,Preclinical - Pdx,"In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12F and PIK3CA H1047R (PMID: 26855149).",Actionable,10884,3910,lung adenocarcinoma,DOID,27820,KRAS G12F PIK3CA H1047R,"[{'id': 8887, 'pubMedId': 26855149, 'title': 'Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26855149'}]",sensitive,5671,Dasatinib + Demcizumab,5290
277,Preclinical - Pdx,"In a preclinical study, treatment with Iclusig (ponatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft model of bladder cancer with SRC over expression, which also over expressed ERBB2 (HER2) and harbored PIK3CA H1047R (PMID: 26270481).",Actionable,7457,11054,urinary bladder cancer,DOID,25513,ERBB2 over exp PIK3CA H1047R SRC over exp,"[{'id': 6363, 'pubMedId': 26270481, 'title': 'Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26270481'}]",no benefit,877,Ponatinib,5290
278,Preclinical - Pdx,"In a preclinical study, treatment with Tykerb (lapatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft model of bladder cancer with ERBB2 (HER2) over expression, which also over expressed SRC and harbored PIK3CA H1047R (PMID: 26270481).",Actionable,7456,11054,urinary bladder cancer,DOID,25513,ERBB2 over exp PIK3CA H1047R SRC over exp,"[{'id': 6363, 'pubMedId': 26270481, 'title': 'Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26270481'}]",no benefit,787,Lapatinib,5290
279,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment did not result in enhanced antitumor activity compared to Ibrance (palbociclib) alone in PDX models of KRAS wild-type colorectal cancer harboring PIK3CA H1047R (PMID: 26369631).",Actionable,5622,9256,colorectal cancer,DOID,21303,KRAS wild-type PIK3CA H1047R,"[{'id': 5128, 'pubMedId': 26369631, 'title': 'Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26369631'}]",no benefit,1368,Palbociclib + Trametinib,5290
280,Clinical Study,"In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153). ",Actionable,7082,1909,melanoma,DOID,24398,BRAF V600X PIK3CA H1047R PTEN Y86fs,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,342,Vemurafenib,5290
281,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited tumor growth in xenograft models of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R mutations (PMID: 21558396).",Actionable,2836,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
282,Preclinical,"In a preclinical study, AT-7867 inhibited proliferation of cultured HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations (PMID: 20423992, PMID: 24978597).",Actionable,2859,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 962, 'pubMedId': 24978597, 'title': 'Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24978597'}, {'id': 2290, 'pubMedId': 20423992, 'title': 'AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20423992'}]",sensitive,2447,AT-7867,5290
283,Preclinical - Cell line xenograft,"In a preclinical study, Gedatolisib (PKI-587) and Camptostar (irinotecan) synergistically suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R (PMID: 24042735) in xenograft models (PMID: 21325073).",Actionable,3901,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3639, 'pubMedId': 24042735, 'title': 'Epigenetic and genetic features of 24 colon cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24042735'}]",sensitive,3396,Gedatolisib + Irinotecan,5290
284,Preclinical,"In a preclinical study, CUDC-907 induced caspase activation in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 20570890, PMID: 22693356). 
",Actionable,3010,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 843, 'pubMedId': 20570890, 'title': 'Genomic and biological characterization of exon 4 KRAS mutations in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20570890'}, {'id': 1018, 'pubMedId': 22693356, 'title': 'Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693356'}]",sensitive,709,CUDC-907,5290
285,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Gedatolisib (PF-05212384) and PD-0325901 inhibited tumor growth in colon cancer cell line xenograft models harboring KRAS G13D and PIK3CA H1047R (PMID: 21325073).",Actionable,2856,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}]",sensitive,3025,PD-0325901 + Gedatolisib,5290
286,Preclinical,"In a preclinical study, CC-223 inhibited proliferation of HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations, in culture (PMID: 25855786, PMID: 24978597).",Actionable,2876,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 962, 'pubMedId': 24978597, 'title': 'Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24978597'}, {'id': 3513, 'pubMedId': 25855786, 'title': 'CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25855786'}]",sensitive,693,CC-223,5290
287,Preclinical,"In a preclinical study, human colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4942,9256,colorectal cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",resistant,890,Regorafenib,5290
288,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) and Camptothecin in combination synergistictically enhanced Parp cleavage in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073, PMID: 24042735). ",Actionable,3903,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 3639, 'pubMedId': 24042735, 'title': 'Epigenetic and genetic features of 24 colon cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24042735'}, {'id': 4265, 'pubMedId': 25688157, 'title': 'Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25688157'}]",sensitive,3398,Gedatolisib + Camptothecin,5290
289,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human colon cancer cells harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073, PMID: 24042735).",Actionable,3131,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3639, 'pubMedId': 24042735, 'title': 'Epigenetic and genetic features of 24 colon cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24042735'}]",sensitive,1040,PF-05212384,5290
290,Preclinical,"In a preclinical study, Camptostar (irinotecan) suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in xenograft models (PMID: 21325073, PMID: 16707468).",Actionable,3902,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 4272, 'pubMedId': 16707468, 'title': 'KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16707468'}]",sensitive,1074,Irinotecan,5290
291,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) decreased viability of a colorectal cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 27602501).",Actionable,12024,9256,colorectal cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",sensitive,691,BYL719,5290
292,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G13D and PIK3CA H1047R in culture, and reduced tumor growth in cell line xenograft models (PMID: 25838391).",Actionable,4947,9256,colorectal cancer,DOID,10711,KRAS G13D PIK3CA H1047R,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",sensitive,1305,Regorafenib + Cetuximab,5290
293,Preclinical - Cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063).",Actionable,8568,9256,colorectal cancer,DOID,26361,BRAF V600E PIK3CA H1047R TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,5290
294,Preclinical,"In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",Actionable,4571,219,colon cancer,DOID,18592,KRAS mutant PIK3CA H1047R,"[{'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",sensitive,680,BKM120,5290
295,Preclinical,"In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",Actionable,4573,219,colon cancer,DOID,18592,KRAS mutant PIK3CA H1047R,"[{'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",sensitive,3548,BKM120 + Cetuximab,5290
296,Preclinical,"In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",Actionable,4572,219,colon cancer,DOID,18592,KRAS mutant PIK3CA H1047R,"[{'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",no benefit,694,Cetuximab,5290
297,Preclinical - Pdx,"In a preclinical study, treatment with BEZ235 slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).",Actionable,9375,1380,endometrial cancer,DOID,26839,KRAS G12D PIK3CA H1047R PTEN R130G,"[{'id': 7135, 'pubMedId': 26232337, 'title': 'Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26232337'}]",sensitive,672,BEZ235,5290
298,Preclinical - Pdx,"In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and BEZ235 resulted in stable disease in patient-derived xenograft (PDX) models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, and PTEN R130G, and demonstrated improved efficacy over either agent alone (PMID: 26232337).",Actionable,9373,1380,endometrial cancer,DOID,26839,KRAS G12D PIK3CA H1047R PTEN R130G,"[{'id': 7135, 'pubMedId': 26232337, 'title': 'Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26232337'}]",sensitive,1420,Selumetinib + BEZ235,5290
299,Preclinical - Pdx,"In a preclinical study, treatment with Selumetinib (AZD6244) slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).",Actionable,9374,1380,endometrial cancer,DOID,26839,KRAS G12D PIK3CA H1047R PTEN R130G,"[{'id': 7135, 'pubMedId': 26232337, 'title': 'Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26232337'}]",sensitive,913,Selumetinib,5290
300,Clinical Study,"In a clinical study, PIK3CA V955I was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in colorectal cancer patients, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA V955I (PMID: 28424201).",Actionable,11719,9256,colorectal cancer,DOID,28198,PIK3CA V955I,"[{'id': 9728, 'pubMedId': 28424201, 'title': 'PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28424201'}]",resistant,2000,Fluorouracil + Cetuximab,5290
301,Phase I,"In a Phase I trial, a non-small cell lung carcinoma patient harboring a mutation at PIK3CA H1047 demonstrated a confirmed partial response when treated with Taselisib (GDC-0032) (PMID: 28331003). ",Actionable,11447,3908,non-small cell lung carcinoma,DOID,13164,PIK3CA H1047X,"[{'id': 9393, 'pubMedId': 28331003, 'title': 'Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28331003'}]",sensitive,1016,GDC-0032,5290
302,Clinical Study,"In a clinical study, a colorectal cancer patient harboring a mutation at PIK3CA H1047 demonstrated progressive disease when treated with Torisel (temsirolimus) and Avastin (bevacizumab) (PMID: 21216929). ",Actionable,3379,9256,colorectal cancer,DOID,13164,PIK3CA H1047X,"[{'id': 3726, 'pubMedId': 21216929, 'title': 'PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21216929'}]",resistant,3133,Temsirolimus + Bevacizumab,5290
303,Clinical Study,"In a clinical study, the combination of Torisel (temsirolimus) plus Velcade (bortezomib) and Hycamtin (topotecan) resulted in progressive disease in a patient with small intestine adenocarcinoma harboring a PIK3CA H1047 mutation (PMID: 21216929). ",Actionable,3384,4906,small intestine adenocarcinoma,DOID,13164,PIK3CA H1047X,"[{'id': 3726, 'pubMedId': 21216929, 'title': 'PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21216929'}]",resistant,3134,Bortezomib + Temsirolimus + Topotecan,5290
304,Clinical Study,"In a clinical study, a patient with endometrial adenocarcinoma harboring a PIK3CA H1047 mutation demonstrated a partial response when treated with Torisel (temsirolimus) (PMID: 21216929). ",Actionable,3314,2870,endometrial adenocarcinoma,DOID,13164,PIK3CA H1047X,"[{'id': 3726, 'pubMedId': 21216929, 'title': 'PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21216929'}]",sensitive,936,Temsirolimus,5290
305,Clinical Study,"In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in a patient with ovarian clear cell carcinoma harboring PIK3CA H1047 and BRAF V600 mutations (PMID: 21216929).",Actionable,3381,4001,ovarian carcinoma,DOID,13306,PIK3CA H1047X BRAF V600X,"[{'id': 3726, 'pubMedId': 21216929, 'title': 'PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21216929'}]",sensitive,1121,Bevacizumab + Temsirolimus + Doxil,5290
306,Clinical Study,"In a clinical study, the combination of XL147 plus Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in progressive disease in a patient with colorectal cancer harboring a PIK3CA H1047 mutation and KRAS G12 mutation (PMID: 21216929). ",Actionable,3385,9256,colorectal cancer,DOID,13308,PIK3CA H1047X KRAS G12X,"[{'id': 3726, 'pubMedId': 21216929, 'title': 'PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21216929'}]",resistant,3135,XL147 + Carboplatin + Paclitaxel,5290
307,Preclinical,"In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Erbitux (cetuximab) in culture (PMID: 25838391).",Actionable,4936,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",resistant,694,Cetuximab,5290
308,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",Actionable,8199,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,1659,Pimasertib + Sorafenib,5290
309,Preclinical,"In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4940,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",resistant,890,Regorafenib,5290
310,Preclinical,"In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring BRAF V600E and PIK3CA P449T in culture (PMID: 25838391).",Actionable,4950,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,"[{'id': 4805, 'pubMedId': 25838391, 'title': 'Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25838391'}]",sensitive,1305,Regorafenib + Cetuximab,5290
311,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",Actionable,8204,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4657,Pimasertib + Regorafenib,5290
312,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",Actionable,8194,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,4656,Everolimus + Pimasertib,5290
313,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",Actionable,8189,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,"[{'id': 337, 'pubMedId': 23629727, 'title': 'Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23629727'}]",sensitive,871,Pimasertib,5290
314,Preclinical - Cell line xenograft,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and growth of colorectal cancer cells harboring BRAF V600E, PIK3CA P449T, and TP53 R273H in culture and in cell line xenograft models, but did not have synergistic effect on apoptosis (PMID: 26272063).",Actionable,8565,9256,colorectal cancer,DOID,26358,BRAF V600E PIK3CA P449T TP53 R273H,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,5290
315,Clinical Study,"In a clinical study, PIK3CA V952A was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in colorectal cancer patients, which is consistent with cell culture studies demonstrating moderate resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA V952A (PMID: 28424201).",Actionable,11725,9256,colorectal cancer,DOID,28201,PIK3CA V952A,"[{'id': 9728, 'pubMedId': 28424201, 'title': 'PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28424201'}]",resistant,2000,Fluorouracil + Cetuximab,5290
316,Preclinical - Cell line xenograft,"In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA G106_R108del and wild-type PTEN in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111).",Actionable,5217,5409,lung small cell carcinoma,DOID,20307,PIK3CA G106_R108del PTEN wild-type,"[{'id': 4924, 'pubMedId': 24240111, 'title': 'Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24240111'}]",sensitive,867,PF-4989216,5290
317,Clinical Study,"In a clinical study, PIK3CA K966E was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in colorectal cancer patients, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA K966E (PMID: 28424201).",Actionable,11720,9256,colorectal cancer,DOID,28199,PIK3CA K966E,"[{'id': 9728, 'pubMedId': 28424201, 'title': 'PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28424201'}]",resistant,2000,Fluorouracil + Cetuximab,5290
318,Preclinical - Pdx,"In a preclinical study, a patient-derived xenograft (PDX) model of endometrial cancer harboring PIK3CA D350G, PIK3CA R93W, and PTEN R130G was sensitive to ARQ092, demonstrating greater than 90% inhibition of tumor growth (PMID: 26469692). ",Actionable,10283,1380,endometrial cancer,DOID,27339,PIK3CA D350G PIK3CA R93W PTEN R130G,"[{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",sensitive,635,ARQ092,5290
319,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of prostate cancer cells harboring PIK3CA Q546R in culture (PMID: 21558396).",Actionable,2953,10283,prostate cancer,DOID,2658,PIK3CA Q546R,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
320,Clinical Study,"In a clinical case study, a patient with colorectal cancer harboring KRAS G12D and PIK3CA Q546R demonstrated sensitivity to treatment with the combination of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for more than 6 months (PMID: 25363205). ",Actionable,7768,9256,colorectal cancer,DOID,27864,KRAS G12D PIK3CA Q546R,"[{'id': 6478, 'pubMedId': 25363205, 'title': 'Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25363205'}]",sensitive,4517,Bevacizumab + Sorafenib,5290
321,Preclinical - Pdx,"In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring BRAF V600E and PIK3CA H1047K was sensitive to the combination treatment of ARQ092 and Mekinist (trametinib), demonstrating a greater inhibition of tumor growth when compared to either agent alone (PMID: 26469692). ",Actionable,10288,1909,melanoma,DOID,27343,BRAF V600E PIK3CA H1047K,"[{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",sensitive,5456,ARQ092 + Trametinib,5290
322,Preclinical - Cell culture,"In a preclinical study, a hormone breast cancer cell line harboring PIK3CA E542K was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692). ",Actionable,10277,1612,breast cancer,DOID,808,PIK3CA E542K,"[{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",sensitive,635,ARQ092,5290
323,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells over expressing PIK3CA E542K were resistant to Erbitux (cetuximab) and Fluorouracil combination treatment in culture (PMID: 28424201).",Actionable,11721,9256,colorectal cancer,DOID,808,PIK3CA E542K,"[{'id': 9728, 'pubMedId': 28424201, 'title': 'PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28424201'}]",resistant,2000,Fluorouracil + Cetuximab,5290
324,Preclinical,"In a preclinical study, Rapamune (sirolimus) demonstrated efficacy in inhibiting transformation of cultured cells containing PIK3CA E542K mutations (PMID: 15647370).",Actionable,1360,10000003,Advanced Solid Tumor,JAX,808,PIK3CA E542K,"[{'id': 1077, 'pubMedId': 15647370, 'title': 'Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15647370'}]",sensitive,917,Sirolimus,5290
325,Phase I,"In a Phase I trial, Apitolisib (GDC-0980) treatment resulted in a partial response in a patient with head and neck squamous cell carcinoma harboring a PIK3CA E542K mutation (PMID: 26787751).",Actionable,6085,5520,head and neck squamous cell carcinoma,DOID,808,PIK3CA E542K,"[{'id': 4915, 'pubMedId': 26787751, 'title': 'Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26787751'}]",sensitive,750,GDC-0980,5290
326,Preclinical - Cell line xenograft,"In preclinical studies, the combination of GDC-0941 and PD-0325901 (PI3K and MEK inhibitors, respectively) inhibited tumor growth in colorectal cancer cell line xenograft models (PMID: 24339963).",Actionable,1298,9256,colorectal cancer,DOID,808,PIK3CA E542K,"[{'id': 354, 'pubMedId': 24339963, 'title': 'The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24339963'}]",sensitive,1822,PD-0325901 + GDC-0941,5290
327,Phase I,"In a Phase I trial, an ovarian cancer patient harboring a PIK3CA E542 mutation demonstrated stable disease when treated with Torisel (temsirolimus) (PMID: 21216929). ",Actionable,3313,2394,ovarian cancer,DOID,808,PIK3CA E542K,"[{'id': 3726, 'pubMedId': 21216929, 'title': 'PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21216929'}]",predicted – sensitive,936,Temsirolimus,5290
328,Preclinical - Cell culture,"In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including a papillary thyroid cancer cell line harboring PIK3CA E542K (PMID: 21289267).",Actionable,8216,3969,papillary thyroid carcinoma,DOID,808,PIK3CA E542K,"[{'id': 6573, 'pubMedId': 21289267, 'title': 'The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21289267'}]",sensitive,816,MK2206,5290
329,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).",Actionable,4247,1612,breast cancer,DOID,808,PIK3CA E542K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,828,Neratinib,5290
330,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).",Actionable,4226,1612,breast cancer,DOID,808,PIK3CA E542K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,691,BYL719,5290
331,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).",Actionable,4240,1612,breast cancer,DOID,808,PIK3CA E542K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,787,Lapatinib,5290
332,Preclinical,"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).",Actionable,4219,1612,breast cancer,DOID,808,PIK3CA E542K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,672,BEZ235,5290
333,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).",Actionable,4254,1612,breast cancer,DOID,808,PIK3CA E542K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,2,Trametinib,5290
334,Preclinical,"In preclinical studies, VS-5584 demonstrated efficacy in a variety of cancer cell lines, particularly those harboring PIK3CA mutations (PMID: 23270925).",Actionable,640,234,colon adenocarcinoma,DOID,808,PIK3CA E542K,"[{'id': 351, 'pubMedId': 23270925, 'title': 'VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23270925'}]",sensitive,960,VS-5584,5290
335,Preclinical,"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).",Actionable,4233,1612,breast cancer,DOID,808,PIK3CA E542K,"[{'id': 4255, 'pubMedId': 26627007, 'title': 'Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26627007'}]",sensitive,816,MK2206,5290
336,Clinical Study,"In a retrospective study, treatment with the combination of Erbitux (cetuximab) and Camptosar (irinotecan) resulted in partial response in 50% (1/2) and stable disease in 50% (1/2) of colorectal carcinoma patients harboring a PIK3CA E542K mutation (PMID: 25714871).
",Actionable,3757,9256,colorectal cancer,DOID,808,PIK3CA E542K,"[{'id': 3888, 'pubMedId': 25714871, 'title': 'AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25714871'}]",sensitive,1874,Cetuximab + Irinotecan,5290
337,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA E542K in culture (PMID: 21558396).",Actionable,3002,1612,breast cancer,DOID,808,PIK3CA E542K,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
338,Preclinical - Cell culture,"In a preclinical study, MK2206 suppressed activation of AKT induced by Torisel (temsirolimus), and MK2206 and Torisel (temsirolimus) demonstrated synergy in inhibiting growth of a papillary thyroid cancer cell line harboring PIK3CA E542K in culture (PMID: 21289267).",Actionable,8223,3969,papillary thyroid carcinoma,DOID,808,PIK3CA E542K,"[{'id': 6573, 'pubMedId': 21289267, 'title': 'The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21289267'}]",sensitive,4664,MK2206 + Temsirolimus,5290
339,Phase Ib/II,"In a Phase Ib trial, a patient with cervical squamous cell carcinoma harboring PIK3CA E542K demonstrated a partial response when treated with a combination of LY2780301 and Gemzar (gemcitabine) (PMID: 28750271). ",Actionable,11830,3744,cervical squamous cell carcinoma,DOID,808,PIK3CA E542K,"[{'id': 9864, 'pubMedId': 28750271, 'title': 'Safety, tolerability\xa0and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28750271'}]",sensitive,6168,Gemcitabine + LY2780301,5290
340,Preclinical,"In a preclinical study, gastric cancer cells harboring PI3KCA E542K mutations were sensitive to the AKT inhibitor AZD5363 (PMID: 24088382).",Actionable,1362,3119,gastrointestinal system cancer,DOID,808,PIK3CA E542K,"[{'id': 1081, 'pubMedId': 24088382, 'title': 'The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24088382'}]",sensitive,655,AZD5363,5290
341,Preclinical - Cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS Q61L, PIK3CA E542K, and TP53 T118Qfs*5 in culture (PMID: 26272063).",Actionable,8566,9256,colorectal cancer,DOID,26412,KRAS Q61L PIK3CA E542K TP53 T118Qfs*5,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,5290
342,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA E542K and PTEN loss to WEHI-539 in culture (PMID: 27974663).",Actionable,10087,1612,breast cancer,DOID,27243,PIK3CA E542K PTEN loss,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",predicted – sensitive,5377,BEZ235 + WEHI-539,5290
343,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of colorectal cancer cells harboring KRAS Q61H and PIK3CA E542K (PMID: 26369631).",Actionable,5620,9256,colorectal cancer,DOID,21302,KRAS Q61H PIK3CA E542K,"[{'id': 5128, 'pubMedId': 26369631, 'title': 'Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26369631'}]",sensitive,1368,Palbociclib + Trametinib,5290
344,Clinical Study,"In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in a patient with ovarian carcinoma harboring both a PIK3CA mutation and a KRAS Q61 mutation (PMID: 21216929).",Actionable,3383,4001,ovarian carcinoma,DOID,13307,PIK3CA mutant KRAS Q61X,"[{'id': 3726, 'pubMedId': 21216929, 'title': 'PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21216929'}]",sensitive,1121,Bevacizumab + Temsirolimus + Doxil,5290
345,Preclinical,"In a preclinical study, CUDC-907 inhibited downstream signaling and growth of PIK3CA-mutant breast cancer cells with ERBB2 amplification in culture (PMID: 22693356).",Actionable,3016,1612,breast cancer,DOID,19124,ERBB2 amp PIK3CA mut,"[{'id': 1018, 'pubMedId': 22693356, 'title': 'Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693356'}]",sensitive,709,CUDC-907,5290
346,Preclinical - Cell line xenograft,"In a preclinical study, Aliqopa (copanlisib) promoted tumor regression in xenograft models of a human ERBB2 (HER2)-amplified breast cancer cell line harboring a PIK3CA activating mutation (PMID: 24170767).",Actionable,1374,60079,Her2-receptor positive breast cancer,DOID,19124,ERBB2 amp PIK3CA mut,"[{'id': 245, 'pubMedId': 24170767, 'title': 'BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24170767'}]",sensitive,995,Copanlisib,5290
347,Preclinical - Cell line xenograft,"In a preclinical study, ERBB2 (HER2)-receptor positive breast cancer cell line xenograft models harboring amplification of ERBB2 (HER2) and a PIK3CA mutation demonstrated sensitivity to treatment with Ipatasertib (GDC-0068), resulting in inhibition of tumor growth (PMID: 24141624). ",Actionable,8966,60079,Her2-receptor positive breast cancer,DOID,19124,ERBB2 amp PIK3CA mut,"[{'id': 191, 'pubMedId': 24141624, 'title': 'Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141624'}]",sensitive,747,Ipatasertib,5290
348,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Nerlynx (neratinib) and Taselisib (GDC-0032), compared to either agent alone, resulted in greater inhibition of cell cycle activity in a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification and a PIK3CA mutation in culture, and in xenograft models, showed increased tumor growth inhibition and tumor regression (PMID: 26333383). ",Actionable,9067,5750,uterine corpus serous adenocarcinoma,DOID,19124,ERBB2 amp PIK3CA mut,"[{'id': 6891, 'pubMedId': 26333383, 'title': 'Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26333383'}]",sensitive,4871,GDC-0032 + Neratinib,5290
349,Preclinical,"In a preclinical study, a breast cancer cell line harboring mutations in PIK3CA and CDKN2A demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369). ",Actionable,2105,1612,breast cancer,DOID,5388,PIK3CA mutant CDKN2A mutant,"[{'id': 2380, 'pubMedId': 25261369, 'title': 'Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25261369'}]",sensitive,1282,Sapanisertib,5290
350,Preclinical,"In a preclinical study, BEZ235 inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with KRAS and PIK3CA mutations (PMID: 24939055).",Actionable,984,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 642, 'pubMedId': 24939055, 'title': 'Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24939055'}]",sensitive,672,BEZ235,5290
351,Preclinical,"In a preclinical study, the combination of AZD8055 and Selumetinib (AZD6244) inhibited tumor growth in a colorectal cancer xenograft model harboring PIK3CA and KRAS mutations and had increased efficacy compared to either agent alone (PMID: 22271687).",Actionable,2795,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 3482, 'pubMedId': 22271687, 'title': 'Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22271687'}]",sensitive,2561,AZD8055 + Selumetinib,5290
352,Preclinical,"In a preclinical study, BKM120 suppressed growth of a gastric cancer cell line harboring PIK3CA and KRAS mutations in culture (PMID: 22159814).",Actionable,2799,10534,stomach cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 3447, 'pubMedId': 22159814, 'title': 'NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22159814'}]",sensitive,680,BKM120,5290
353,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically prevented proliferation of an Iressa (gefitinib)-resistant NSCLC cell line harboring KRAS and PIK3CA mutations in culture and in cell line xenograft models (PMID: 24939055).",Actionable,989,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 642, 'pubMedId': 24939055, 'title': 'Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24939055'}]",sensitive,1420,Selumetinib + BEZ235,5290
354,Preclinical - Cell line xenograft,"In a preclinical study, Navitoclax (ABT-263) improved the therapeutic effects of the combination of CGM097 and Mekinist (trametinib) in colorectal cancer cells, resulting in greater apoptotic activity and growth inhibition in culture, and tumor regression in xenograft models (PMID: 27659046). ",Actionable,9931,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 7782, 'pubMedId': 27659046, 'title': 'High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27659046'}]",sensitive,5315,ABT-263 + CGM097 + Trametinib,5290
355,Preclinical,"In a preclinical study, a colon cancer cell line harboring PIK3CA and KRAS mutations demonstrated sensitivity to AT13148 in culture (PMID: 22781553).",Actionable,2779,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 204, 'pubMedId': 22781553, 'title': 'AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22781553'}]",sensitive,3653,AT13148,5290
356,Preclinical - Cell line xenograft,"In a preclincal study, GDC-0980 delayed tumor growth in colon cancer cell line xenograft models harboring KRAS and PIKC3A mutations (PMID: 21998291).",Actionable,2855,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 3508, 'pubMedId': 21998291, 'title': 'GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21998291'}]",sensitive,750,GDC-0980,5290
357,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line co-harboring a KRAS mutation and PIK3CA mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture (PMID: 24634413). ",Actionable,10707,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 8768, 'pubMedId': 24634413, 'title': 'Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24634413'}]",sensitive,1051,SAR245409,5290
358,Preclinical,"In a preclinical study, Deguelin inhibited growth of the AGS gastric cancer cell line, which has been reported to harbor PIK3CA and KRAS mutations, in culture (PMID: 20811676, PMID: 24978597).",Actionable,2844,10534,stomach cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 962, 'pubMedId': 24978597, 'title': 'Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24978597'}, {'id': 3500, 'pubMedId': 20811676, 'title': 'Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20811676'}]",predicted – sensitive,1867,Deguelin,5290
359,Preclinical - Cell line xenograft,"In a preclinical study, treatment with Aliqopa (copanlisib) inhibited tumor growth in xenograft models of a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 24170767).",Actionable,2722,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 245, 'pubMedId': 24170767, 'title': 'BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24170767'}]",sensitive,995,Copanlisib,5290
360,Preclinical - Cell line xenograft,"In a preclinical study, the combination of CGM097 and Mekinist (trametinib) treatment compared to treatment with either agent alone in a colorectal cancer cell line resulted in a greater decrease in colony formation in culture, and improved stable disease in xenograft models (PMID: 27659046). ",Actionable,9930,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 7782, 'pubMedId': 27659046, 'title': 'High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27659046'}]",sensitive,5314,CGM097 + Trametinib,5290
361,Preclinical,"In a preclinical study, Selumetinib (AZD6244) mildly inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with KRAS and PIK3CA mutations (PMID: 24939055).",Actionable,983,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 642, 'pubMedId': 24939055, 'title': 'Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24939055'}]",decreased response,913,Selumetinib,5290
362,Preclinical,"In a preclinical study, human solid tumor cell lines harboring coincident PIK3CA and KRAS mutations demonstrated sensitivity to CH5132799 in culture (PMID: 21558396).",Actionable,2835,10000003,Advanced Solid Tumor,JAX,1630,KRAS mut PIK3CA mut,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
363,Preclinical - Cell line xenograft,"In a preclinical study, PF-04691502 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring both PIK3CA and KRAS mutations (PMID: 21750219).",Actionable,8388,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 226, 'pubMedId': 21750219, 'title': 'PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21750219'}]",sensitive,865,PF-04691502,5290
364,Phase I,"In a Phase I trial, Taselisib (GDC-0032) demonstrated activity in patients with PIK3CA-mutant advanced solid tumors, but preliminary data analysis suggested the presence of a KRAS mutation was associated with lack of response (Cancer Res October 1, 2014 74:915).",Actionable,2851,10000003,Advanced Solid Tumor,JAX,1630,KRAS mut PIK3CA mut,"[{'id': 3507, 'pubMedId': None, 'title': 'Abstract 915: Expanded biomarker results from a phase I dose escalation study of GDC-0032, a beta isoform-sparing PI3K inhibitor', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/915.short'}]",decreased response,1016,GDC-0032,5290
365,Preclinical,"In a preclinical study, CUDC-907 inhibited growth and induced apoptosis in a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 22693356).",Actionable,2840,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 1018, 'pubMedId': 22693356, 'title': 'Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693356'}]",sensitive,709,CUDC-907,5290
366,Preclinical,"In a preclinical study, Alpelisib (BYL719) inhibited growth in multiple tumor cell lines expressing PIK3CA mutations, and concurrent KRAS mutations was not associated with resistance (PMID: 24608574).",Actionable,2874,10000003,Advanced Solid Tumor,JAX,1630,KRAS mut PIK3CA mut,"[{'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",sensitive,691,BYL719,5290
367,Preclinical,"In a preclinical study, human cancer cells with PIK3CA mutations demonstrated sensitivity to Afinitor (everolimus), but a coincident KRAS mutation led to Afinitor (everolimus) resistance  (PMID: 20664172).",Actionable,145,10000003,Advanced Solid Tumor,JAX,1630,KRAS mut PIK3CA mut,"[{'id': 219, 'pubMedId': 20664174, 'title': ""PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20664174'}, {'id': 1067, 'pubMedId': 20664172, 'title': 'Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20664172'}]",resistant,735,Everolimus,5290
368,Phase I,"In a Phase I trial, a colorectal cancer patient co-harboring a PIK3CA mutation and KRAS mutation progressed on treatment with Taselisib (GDC-0032) (PMID: 28331003). ",Actionable,11446,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 9393, 'pubMedId': 28331003, 'title': 'Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28331003'}]",no benefit,1016,GDC-0032,5290
369,Preclinical,"In a preclinical study, colon cancer cells harboring KRAS and PIK3CA mutations demonstrated resistance to BEZ235 in culture and xenograft models (PMID: 23475782).",Actionable,2724,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 3437, 'pubMedId': 23475782, 'title': 'Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23475782'}]",resistant,672,BEZ235,5290
370,Preclinical,"In a preclinical study, A-443654 inhibited proliferation of colon cancer cell lines that have been reported to harbor KRAS and PIK3CA mutations in culture (PMID: 24569089, PMID: 24978597).
",Actionable,2864,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 962, 'pubMedId': 24978597, 'title': 'Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24978597'}, {'id': 3512, 'pubMedId': 24569089, 'title': 'Context-dependent antagonism between Akt inhibitors and topoisomerase poisons.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24569089'}]",sensitive,2448,A-443654,5290
371,Phase II,"In a Phase II trial, one patient with Kras and Pikc3a mutant non-squamous NSCLC had a partial response to Buparlisib (BKM120) however, stage 2 of the study was not initiated due to failure of meeting overall stage 1 response endpoints (PMID: 26098748).",Actionable,9817,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,"[{'id': 7642, 'pubMedId': 26098748, 'title': 'Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26098748'}]",sensitive,680,BKM120,5290
372,Clinical Study,"In a retrospective study, Erbitux (cetuximab) treatment, alone or in combination, resulted in disease regression or stable disease in 88% (7/8) KRAS/BRAF-wild type colorectal carcinoma patients harboring a PIK3CA mutation (PMID: 25714871).",Actionable,3671,9256,colorectal cancer,DOID,14283,BRAF wild-type KRAS wild-type PIK3CA mutant,"[{'id': 3888, 'pubMedId': 25714871, 'title': 'AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25714871'}]",sensitive,694,Cetuximab,5290
373,Preclinical,"In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369). ",Actionable,2135,9256,colorectal cancer,DOID,5415,APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut,"[{'id': 2380, 'pubMedId': 25261369, 'title': 'Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25261369'}]",sensitive,1282,Sapanisertib,5290
374,Clinical Study,"In a clinical study, a retrospective analysis of the combined treatment, Herceptin (trastuzumab) and Tykerb (lapatinib), in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302). ",Actionable,9165,60079,Her2-receptor positive breast cancer,DOID,1669,PIK3CA mutant ERBB2 pos,"[{'id': 6968, 'pubMedId': 27687302, 'title': 'Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27687302'}]",decreased response,1414,Trastuzumab + Lapatinib,5290
375,Phase II,"In a Phase II trial, ERBB2-positive breast cancer patients harboring PIK3CA mutations demonstrated lower pathologic complete remission rate (12.5%) compared to those with wild-type PIK3CA (48.4%) after Herceptin (trastuzumab) and Tykerb (lapatinib) combination therapy (PMID: 26245675).",Actionable,5246,60079,Her2-receptor positive breast cancer,DOID,1669,PIK3CA mutant ERBB2 pos,"[{'id': 3761, 'pubMedId': 26245675, 'title': 'Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26245675'}]",decreased response,1414,Trastuzumab + Lapatinib,5290
376,Clinical Study,"In a clinical study, a colorectal cancer patient harboring a PIK3CA mutation and KRAS mutations at codons 12 and 13 demonstrated stable disease when treated with a combination of Torisel (temsirolimus) and Avastin (bevacizumab) (PMID: 21216929). ",Actionable,3378,9256,colorectal cancer,DOID,13305,PIK3CA mutant KRAS G12X KRAS G13X,"[{'id': 3726, 'pubMedId': 21216929, 'title': 'PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21216929'}]",sensitive,3133,Temsirolimus + Bevacizumab,5290
377,Phase I,"In a Phase I trial, CC-223 demonstrated safety and preliminary efficacy in patients with solid tumors, including stable disease for greater than 110 days in 2 patients with PIK3CA mutation or PTEN deletion (PMID: 26177599).",Actionable,1396,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 364, 'pubMedId': None, 'title': 'Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid tumors.', 'url': ''}, {'id': 3493, 'pubMedId': 26177599, 'title': 'A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26177599'}]",sensitive,693,CC-223,5290
378,Preclinical,"In preclinical studies, VS-5584 demonstrated efficacy in a variety of cancer cell lines, particularly those harboring PIK3CA mutations (PMID: 23270925).",Actionable,1675,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 351, 'pubMedId': 23270925, 'title': 'VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23270925'}]",sensitive,960,VS-5584,5290
379,Phase I,"In a Phase I clinical trial, carboxyamidotriazole orotate treatment demonstrated some efficacy in patients with various solid tumors, including patients harboring PIK3CA mutations (J Clin Oncol 31, 2013 (suppl; abstr 2518)).",Actionable,1669,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 1082, 'pubMedId': None, 'title': 'A phase I study of carboxyamidotriazole orotate (CTO) in of advanced solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/115114-132'}]",sensitive,999,Carboxyamidotriazole Orotate,5290
380,Preclinical,"In a preclinical study, AZD8835 inhibited tumor growth in breast cancer xenograft models harboring PIK3CA mutations (AACR; 2015. Abstract nr 2665).",Actionable,2718,1612,breast cancer,DOID,429,PIK3CA mutant,"[{'id': 3434, 'pubMedId': None, 'title': 'High dose intermittent scheduling of AZD8835, a novel potent and selective inhibitor of PI3K-alpha and PI3K-delta, identifies potential treatment strategies for PIK3CA-dependent cancers', 'url': 'http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=14323955-7e99-4856-aec7-b2f95e96b99b&cKey=7627fe75-d2b2-4175-8cd6-98aaeb2524e2&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424'}]",sensitive,2013,AZD8835,5290
381,Preclinical,"In a preclinical study, PWT33597 decreased signaling of mTOR and PIK3 pathways in non-small cell lung cancer cells with Pik3ca mutations (Cancer Res 2011;71(8 Suppl):Abstract nr 4485).",Actionable,2744,3908,non-small cell lung carcinoma,DOID,429,PIK3CA mutant,"[{'id': 3450, 'pubMedId': None, 'title': 'Preclinical characterization of PWT33597, a dual inhibitor of PI3-kinase alpha and mTOR', 'url': 'http://cancerres.aacrjournals.org/content/71/8_Supplement/4485.short'}]",sensitive,880,PWT33597,5290
382,Phase I,"In a Phase I clinical trial, carboxyamidotriazole orotate treatment demonstrated some efficacy in patients with various solid tumors including squamous cell carcinomas (tonsil) with PI3KCA and NRAS mutations (J Clin Oncol 31, 2013 (suppl; abstr 2518)).",Actionable,1363,1749,squamous cell carcinoma,DOID,429,PIK3CA mutant,"[{'id': 1082, 'pubMedId': None, 'title': 'A phase I study of carboxyamidotriazole orotate (CTO) in of advanced solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/115114-132'}]",sensitive,999,Carboxyamidotriazole Orotate,5290
383,Preclinical - Cell line xenograft,"In a preclinical study, a ERBB3 (HER3) positive breast cancer cell line xenograft model harboring a PIK3CA mutation was demonstrated decreased tumor growth when treated with AT13148 (PMID: 22781553). ",Actionable,10801,1612,breast cancer,DOID,429,PIK3CA mutant,"[{'id': 204, 'pubMedId': 22781553, 'title': 'AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22781553'}]",sensitive,3653,AT13148,5290
384,Phase I,"In a Phase I clinical trial, GSK2141795 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, with 4 patients with PIK3CA mutations and/or PTEN loss achieving stable disease for greater than 6 months (J Clin Oncol 29: 2011 (suppl; abstr 3003)). ",Actionable,3875,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 4253, 'pubMedId': None, 'title': 'Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study.', 'url': 'http://meetinglibrary.asco.org/content/80659-102'}]",predicted – sensitive,764,GSK2141795,5290
385,Phase II,"In a Phase II trial, PIK3CA mutations were more frequent in  muscle-invasive urothelial bladder cancer patients that did not respond to Nexavar (sorafenib), Platinol (cisplatin) and Gemzar (gemcitabine) combination therapy than those who did respond (J Clin Oncol 35, 2017 (suppl 6S; abstract 345)).",Actionable,10324,6477,invasive bladder transitional cell carcinoma,DOID,429,PIK3CA mutant,"[{'id': 8305, 'pubMedId': None, 'title': 'Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): Final results and translational findings of an open-label, single-arm, phase II study.', 'url': 'http://meetinglibrary.asco.org/content/179076-197'}]",predicted – resistant,5462,Cisplatin + Gemcitabine + Sorafenib,5290
386,Phase I,"In a Phase I clinical trial AZD5363 demonstrated safety and efficacy in patients with advanced solid tumors, including one patient with a PIK3CA mutated ovarian cancer (American Association for Cancer Research; 06 Apr 2013-10 Apr 2013; Abstract LB-66). ",Actionable,1651,2394,ovarian cancer,DOID,429,PIK3CA mutant,"[{'id': 1761, 'pubMedId': None, 'title': 'Results of two Phase 1 multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors.', 'url': 'https://www.escholar.manchester.ac.uk/uk-ac-man-scw:194446'}]",sensitive,655,AZD5363,5290
387,Phase I,"In a Phase I clinical trial, SAR245409 (XL765) demonstrated equivalent safety and efficacy in patients with PIK3CA mutant or PIK3CA wild-type advanced solid tumors (PMID: 24583798).
",Actionable,1216,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 100, 'pubMedId': 24583798, 'title': 'Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24583798'}]",sensitive,1051,SAR245409,5290
388,Phase Ib/II,"In a Phase Ib trial, Taselisib (GDC-0032) and Femara (letrozole) combination therapy resulted in an overall response rate of 38% in breast cancer patients with PIK3CA mutations, compared to 9% in patients with wild-type PIK3CA (Cancer Res May 1, 2015 75; PD5-2).",Actionable,6343,1612,breast cancer,DOID,429,PIK3CA mutant,"[{'id': 5530, 'pubMedId': None, 'title': 'Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer', 'url': 'http://cancerres.aacrjournals.org/content/75/9_Supplement/PD5-2.short'}]",sensitive,4118,GDC-0032  + Letrozole,5290
389,Preclinical,"In a preclinical study, breast cancer cells with PIK3CA mutations, both with and without ERBB2 (HER2) amplification, demonstrated sensitivity to CH5132799 in culture (PMID: 21558396).",Actionable,2939,1612,breast cancer,DOID,429,PIK3CA mutant,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
390,Preclinical - Pdx & cell culture,"In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis in HNSCC cell lines, cell line xenograft models, and a patient derived xenograft (PDX) model, all with PIK3CA mutations (PMID: 26589432).",Actionable,3913,5520,head and neck squamous cell carcinoma,DOID,429,PIK3CA mutant,"[{'id': 4291, 'pubMedId': 26589432, 'title': 'Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26589432'}]",sensitive,3967,GDC-0032 + Radiotherapy,5290
391,Phase II,"In a Phase II trial, Apitolisib (GDC-0980) was poorly tolerated, but demonstrated efficacy in endometrial cancer patients harboring mutations in PIK3CA, PTEN, or AKT1 (J Clin Oncol 32:5s, 2014 (suppl; abstr 5513)).",Actionable,5203,1380,endometrial cancer,DOID,429,PIK3CA mutant,"[{'id': 4913, 'pubMedId': None, 'title': 'Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results.', 'url': 'http://meetinglibrary.asco.org/content/132500-144'}]",sensitive,750,GDC-0980,5290
392,Phase II,"In a Phase II trial, Torisel (temsirolimus) treatment resulted in stable disease in 9.7% (3/31) of breast cancer patients positive for ER, PR or ERBB2 (HER2), however there was no association between PIK3CA mutational status and clinical benefits (PMID: 22245973).
",Actionable,2379,1612,breast cancer,DOID,429,PIK3CA mutant,"[{'id': 3010, 'pubMedId': 22245973, 'title': 'Phase II trial of temsirolimus in patients with metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22245973'}]",no benefit,936,Temsirolimus,5290
393,Preclinical,"In a preclinical study, BAY1082439 inhibited growth of gastric cancer cells harboring PIK3CA mutations in culture and xenograft models (AACR; 2015. Abstract nr 2674).",Actionable,2720,10534,stomach cancer,DOID,429,PIK3CA mutant,"[{'id': 3435, 'pubMedId': None, 'title': 'Activity of BAY1082439, a balanced PI3Kalpha/beta inhibitor, in gastric cancer', 'url': 'http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=14323955-7e99-4856-aec7-b2f95e96b99b&cKey=5384c5ef-c9a4-49da-a50c-67bf77ceef19&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424'}]",sensitive,666,BAY1082439,5290
394,Phase II,"In a Phase II trial, the addition of AZD5363 to Taxol (paclitaxel) therapy did not improve progression-free survival compared to placebo (10.9 vs 10.8 months) in patients with PIK3CA-mutant, Esr1-positive, Erbb2 (Her2)-negative breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #241PD; NCT01625286).",Actionable,12064,60080,Her2-receptor negative breast cancer,DOID,429,PIK3CA mutant,"[{'id': 9995, 'pubMedId': None, 'title': 'BEECH: A randomised Phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]",no benefit,2192,AZD5363 + Paclitaxel,5290
395,Phase I,"In a Phase I clinical trial, Torisel (temsirolimus) demonstrated limited efficacy in ovarian cancer patients with PIK3CA mutations (PMID: 22271473).",Actionable,1642,2394,ovarian cancer,DOID,429,PIK3CA mutant,"[{'id': 1756, 'pubMedId': 22271473, 'title': 'PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22271473'}]",sensitive,936,Temsirolimus,5290
396,Preclinical,"In a preclinical study, Sapanisertib (MLN0128) demonstrated efficacy in PIK3CA mutant breast cancer xenograft models (PMID: 23085766).",Actionable,410,1612,breast cancer,DOID,429,PIK3CA mutant,"[{'id': 179, 'pubMedId': 23085766, 'title': 'Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23085766'}]",sensitive,1282,Sapanisertib,5290
397,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of ovarian cancer cells with PIK3CA mutations in culture (PMID: 21558396).",Actionable,2940,2394,ovarian cancer,DOID,429,PIK3CA mutant,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
398,Phase II,"In a Phase II trial, two patients with head and neck squamous cell carcinoma harboring a PIK3CA mutation who had stable disease demonstrated some tumor regression when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834). ",Actionable,12183,5520,head and neck squamous cell carcinoma,DOID,429,PIK3CA mutant,"[{'id': 10139, 'pubMedId': 28961834, 'title': 'A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28961834'}]",predicted – sensitive,6333,Carboplatin + Paclitaxel + Temsirolimus,5290
399,Clinical Study,"In a clinical study, the combination of Torisel (temisirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxirubicin) resulted in stable disease in patients with advanced solid tumors harboring PIK3CA mutations (PMID: 21216929).",Actionable,3380,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 3726, 'pubMedId': 21216929, 'title': 'PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21216929'}]",sensitive,1121,Bevacizumab + Temsirolimus + Doxil,5290
400,Clinical Study,"In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in patients with advanced solid tumors harboring PIK3CA mutations (PMID: 21216929).",Actionable,3382,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 3726, 'pubMedId': 21216929, 'title': 'PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21216929'}]",sensitive,1121,Bevacizumab + Temsirolimus + Doxil,5290
401,Preclinical,"In a preclinical study, AZD5363 inhibited growth in breast cancer cell lines and xenograft models expressing PIK3CA mutations (PMID: 22294718). ",Actionable,2363,1612,breast cancer,DOID,429,PIK3CA mutant,"[{'id': 693, 'pubMedId': 22294718, 'title': 'Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22294718'}]",sensitive,655,AZD5363,5290
402,Preclinical - Cell line xenograft,"In a preclinical study, OSI-027 inhibited tumor growth in ovarian cancer cell line xenograft models harboring PIK3CA mutations (PMID: 21673091).",Actionable,2796,2394,ovarian cancer,DOID,429,PIK3CA mutant,"[{'id': 3483, 'pubMedId': 21673091, 'title': 'Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21673091'}]",sensitive,841,OSI-027,5290
403,Preclinical,"In a preclinical study, PI-103 enhanced sensitivity to 5-FU in gastric cancer cells with mutant PIK3CA (PMID: 22336586).",Actionable,2820,3717,gastric adenocarcinoma,DOID,429,PIK3CA mutant,"[{'id': 3488, 'pubMedId': 22336586, 'title': 'Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22336586'}]",sensitive,3031,PI-103 + 5-FU,5290
404,Preclinical - Cell line xenograft,"In a preclinical study, CUDC-907 inhibited PIK3CA, blocked downstream AKT pathway activation, and induced apoptosis and cell cycle arrest in both PIK3CA wild-type and PIK3CA mutant human cancer cell lines and xenograft models of multiple solid and hematologic cancers (PMID: 22693356).
",Actionable,1311,2531,hematologic cancer,DOID,429,PIK3CA mutant,"[{'id': 1018, 'pubMedId': 22693356, 'title': 'Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693356'}]",sensitive,709,CUDC-907,5290
405,Phase II,"In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients harboring mutations in PIK3CA, AKT1, or PTEN (J Clin Oncol 35, 2017 (suppl; abstr 1009)).",Actionable,11168,60081,triple-receptor negative breast cancer,DOID,429,PIK3CA mutant,"[{'id': 9130, 'pubMedId': None, 'title': 'LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).', 'url': 'http://abstracts.asco.org/199/AbstView_199_183382.html'}]",predicted – sensitive,1588,Ipatasertib + Paclitaxel,5290
406,Preclinical - Cell line xenograft,"In a preclinical study, CUDC-907 inhibited PIK3CA, blocked downstream AKT pathway activation, and induced apoptosis and cell cycle arrest in both PIK3CA wild-type and PIK3CA mutant human cancer cell lines and xenograft models of multiple tumor types (PMID: 22693356).",Actionable,102,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 1018, 'pubMedId': 22693356, 'title': 'Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693356'}]",sensitive,709,CUDC-907,5290
407,Preclinical,"In a preclinical study, AZD8835 inhibited growth of a variety of advanced solid tumor models with Pik3ca mutations in culture (PMID: 26839307).",Actionable,3753,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 4877, 'pubMedId': 26839307, 'title': 'Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26839307'}]",sensitive,2013,AZD8835,5290
408,Preclinical - Cell line xenograft,"In a preclinical study, GSK2334470 resensitized Alpelisib (BYL719)-resistant breast cancer cell lines harboring PIK3CA mutations to Alpelisib (BYL719) in culture and in cell line xenograft models (PMID: 27451907).",Actionable,7568,1612,breast cancer,DOID,429,PIK3CA mutant,"[{'id': 6431, 'pubMedId': 27451907, 'title': 'PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27451907'}]",sensitive,4519,Alpelisib + GSK2334470,5290
409,Preclinical - Cell line xenograft,"In a preclinical study, OSI-027 induced tumor regression in breast cancer cell line xenograft models harboring PIK3CA mutations (PMID: 21673091).",Actionable,8734,1612,breast cancer,DOID,429,PIK3CA mutant,"[{'id': 3483, 'pubMedId': 21673091, 'title': 'Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21673091'}]",sensitive,841,OSI-027,5290
410,Preclinical,"In a preclinical study, GDC-0941 inhibited growth and induced apoptosis in breast cancer cells expressing PIK3CA mutations (PMID: 24601221). ",Actionable,2369,1612,breast cancer,DOID,429,PIK3CA mutant,"[{'id': 3001, 'pubMedId': 24601221, 'title': 'More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24601221'}]",sensitive,749,GDC-0941,5290
411,Preclinical,"In a preclinical study, MSC2363318A demonstrated anti-proliferative activity against many solid tumor cell lines with PI3K pathway genomic alterations, and inhibited tumor growth in several human cancer xenograft models of breast, pancreatic, glioblastoma and ovarian cancers (Mol Cancer Ther 2013;12(11 Suppl):A162).",Actionable,423,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 1013, 'pubMedId': None, 'title': 'Abstract A162: Identification of brain penetrant p70S6K/Akt inhibitor MSC2363318A.', 'url': 'http://mct.aacrjournals.org/content/12/11_Supplement/A162.short'}]",sensitive,1037,MSC2363318A,5290
412,Preclinical - Cell line xenograft,"In a preclinical study, Acalisib (GS-9820) resulted in tumor growth inhibition in xenograft models of breast adenocarcinoma harboring a PIK3CA mutation (Mol Cancer Ther 2009;8(12 Suppl):B136).",Actionable,363,3458,breast adenocarcinoma,DOID,429,PIK3CA mutant,"[{'id': 1019, 'pubMedId': None, 'title': 'Abstract B136: CAL?120, a novel dual p110beta/p110delta phosphatidylinositol?3?kinase (PI3K) inhibitor, attenuates PI3K signaling and demonstrates potent in vivo antitumor activity against solid tumors', 'url': 'http://mct.aacrjournals.org/content/8/12_Supplement/B136.short'}]",sensitive,1021,GS-9820,5290
413,Preclinical - Cell culture,"In a preclinical study, Pictilisib (GDC-0941) and MS417 in combination resulted in improved growth inhibition and increased cell death compared to either agent alone in colorectal cancer cell lines harboring PIK3CA mutations in culture (PMID: 26058079).",Actionable,8598,9256,colorectal cancer,DOID,429,PIK3CA mutant,"[{'id': 6693, 'pubMedId': 26058079, 'title': 'Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26058079'}]",predicted – sensitive,4774,GDC-0941 + MS417,5290
414,Phase I,"In a Phase I clinical trial, XL147 (SAR24508) was shown to be safe and potentially efficacious, with clinical activity seen irrespective of tumor PI3K pathway molecular alterations (PMID: 24166903).",Actionable,1182,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 89, 'pubMedId': 24166903, 'title': 'Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24166903'}]",sensitive,1050,XL147,5290
415,Preclinical,"In a preclinical study, tumor cell lines with PIK3CA mutations demonstrated sensitivity to XL147 in culture (PMID:     25637314).",Actionable,6300,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 5522, 'pubMedId': 25637314, 'title': 'The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25637314'}]",sensitive,1050,XL147,5290
416,Phase I,"In a Phase I trial, MLN1117 treatment resulted in partial response in 3 patients with breast cancer harboring PI3CA mutations (PMID: 28490463). ",Actionable,11831,1612,breast cancer,DOID,429,PIK3CA mutant,"[{'id': 9865, 'pubMedId': 28490463, 'title': 'A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28490463'}]",predicted – sensitive,1033,MLN1117,5290
417,Preclinical,"In a preclinical study, the combination of Buparlisib (BKM120) and Lynparza (olaparib) worked synergistically to induce apoptosis and inhibit growth of ovarian cancer cell lines harboring PIK3CA mutations, and induced apoptosis and decreased proliferation of PIK3CA-mutant ovarian cancer cells in xenograft models (PMID: 26909613).",Actionable,6930,2394,ovarian cancer,DOID,429,PIK3CA mutant,"[{'id': 5958, 'pubMedId': 26909613, 'title': 'Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26909613'}]",sensitive,2170,BKM120 + Olaparib,5290
418,Preclinical,"In a preclinical study, BAY1082439 induced regression in xenograft models of advanced solid tumors with PIK3CA mutations (Cancer Res April 15, 2012 72; 2799). ",Actionable,2365,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 2999, 'pubMedId': None, 'title': 'Abstract 2799: BAY 1082439, a highly selective and balanced PI3K?/? inhibitor demonstrated potent activity in tumors with activated PI3K? and loss-of-function of PTEN', 'url': 'http://cancerres.aacrjournals.org/content/72/8_Supplement/2799.short'}]",sensitive,666,BAY1082439,5290
419,Phase II,"In a Phase II trial, Falsodex (fulvestrant) treatment resulted in similar progression free survival in ER positive breast cancer patients harboring PIK3CA mutations and those who were PIK3CA wild-type (PMID: 27174596).",Actionable,7078,60075,estrogen-receptor positive breast cancer,DOID,429,PIK3CA mutant,"[{'id': 6177, 'pubMedId': 27174596, 'title': 'Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27174596'}]",no benefit,744,Fulvestrant,5290
420,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of endometrial cancer cells with PIK3CA mutations in culture (PMID: 21558396).",Actionable,2942,1380,endometrial cancer,DOID,429,PIK3CA mutant,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
421,Preclinical,"In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit the survival of triple-receptor negative breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",Actionable,5859,60081,triple-receptor negative breast cancer,DOID,429,PIK3CA mutant,"[{'id': 5181, 'pubMedId': 27020857, 'title': 'Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27020857'}]",sensitive,3956,Palbociclib + GDC-0941,5290
422,Clinical Study,"In a Phase I trial, MLN1117 treatment resulted in partial response in 3 patients with gastric cancer harboring PI3CA mutations (PMID: 28490463). ",Actionable,11832,10534,stomach cancer,DOID,429,PIK3CA mutant,"[{'id': 9865, 'pubMedId': 28490463, 'title': 'A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28490463'}]",predicted – sensitive,1033,MLN1117,5290
423,Preclinical,"In a preclinical study, CUDC-907 inhibited growth of human breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 22693356).",Actionable,3014,1612,breast cancer,DOID,429,PIK3CA mutant,"[{'id': 1018, 'pubMedId': 22693356, 'title': 'Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693356'}]",sensitive,709,CUDC-907,5290
424,Preclinical,"In a preclinical study, cells expressing mutant PIK3CA demonstrated increased sensitivity to A-443654 compared to cells expressing wild-type PIK3CA (PMID: 19208828).",Actionable,2774,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 2291, 'pubMedId': 19208828, 'title': 'Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19208828'}]",sensitive,2448,A-443654,5290
425,Phase I,"In a Phase I trial, GSK2126458 was well-tolerated and resulted in some efficacy in patients with breast cancer harboring a PIK3CA mutation including stable disease in 22% (2/9), however, objective response rate was not associated with PIK3CA mutations when compared to those without PIK3CA mutations (PMID: 26603258).",Actionable,5828,1612,breast cancer,DOID,429,PIK3CA mutant,"[{'id': 5171, 'pubMedId': 26603258, 'title': 'First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26603258'}]",no benefit,763,GSK2126458,5290
426,Preclinical,"In a preclinical study, PIK3CA mutant breast cancer cells showed increased sensitivity to VS-5584 compared to PIK3CA wild-type cells in culture (PMID: 23270925).",Actionable,93,1612,breast cancer,DOID,429,PIK3CA mutant,"[{'id': 351, 'pubMedId': 23270925, 'title': 'VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23270925'}]",sensitive,960,VS-5584,5290
427,Phase II,"In a Phase II trial, Falsodex (fulvestrant) and Pictilisib (GDC-0941) combination treatment resulted in similar progression free survival in ER positive breast cancer patients harboring PIK3CA mutations and those who were PIK3CA wild-type (PMID: 27174596).",Actionable,7077,60075,estrogen-receptor positive breast cancer,DOID,429,PIK3CA mutant,"[{'id': 6177, 'pubMedId': 27174596, 'title': 'Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27174596'}]",no benefit,4357,Fulvestrant + GDC-0941,5290
428,Phase I,"In a Phase I trial, PX-866 demonstrated efficacy and was well tolerated in patients with advanced solid tumor with both PIK3CA wild-type and mutant status (PMID: 22693357).
",Actionable,121,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 231, 'pubMedId': 22693357, 'title': 'A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693357'}]",sensitive,881,PX-866,5290
429,Preclinical,"In a preclinical study, AT-7867 inhibited proliferation in several human tumor cell lines harboring PIK3CA mutations in culture (PMID: 20423992).",Actionable,2792,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 2290, 'pubMedId': 20423992, 'title': 'AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20423992'}]",sensitive,2447,AT-7867,5290
430,Phase I,"In a Phase I trial, Apitolisib (GDC-0980) treatment resulted in partial response in 21% (3/14) and stable disease in 57% (8/14) of patients with advanced solid tumors harboring PIK3CA mutations (PMID: 26787751). ",Actionable,5207,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 4915, 'pubMedId': 26787751, 'title': 'Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26787751'}]",sensitive,750,GDC-0980,5290
431,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of prostate cancer cells with PIK3CA mutations in culture (PMID: 21558396).",Actionable,2941,10283,prostate cancer,DOID,429,PIK3CA mutant,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
432,Preclinical - Cell line xenograft,"In a preclinical study, CCT128930 induced growth arrest and inhibited tumor growth in a xenograft model of a ERBB2 (HER2)-positive human breast cancer cell line harboring a PIK3CA mutation (PMID: 21191045).",Actionable,998,60079,Her2-receptor positive breast cancer,DOID,429,PIK3CA mutant,"[{'id': 692, 'pubMedId': 21191045, 'title': 'Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21191045'}]",sensitive,1445,CCT128930,5290
433,Phase I,"In a Phase I trial, Taselisib (GDC-0032) demonstrated activity in patients with PIK3CA-mutant advanced solid tumors, in the absence of alterations in the MAPK or PTEN pathways (Cancer Res October 1, 2014 74:915).",Actionable,2853,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 3507, 'pubMedId': None, 'title': 'Abstract 915: Expanded biomarker results from a phase I dose escalation study of GDC-0032, a beta isoform-sparing PI3K inhibitor', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/915.short'}]",sensitive,1016,GDC-0032,5290
434,Preclinical,"In a preclinical study, AZD8835 inhibited proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA mutations in culture and suppressed tumor growth in xenograft models (PMID: 26839307).",Actionable,5111,60075,estrogen-receptor positive breast cancer,DOID,429,PIK3CA mutant,"[{'id': 4877, 'pubMedId': 26839307, 'title': 'Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26839307'}]",sensitive,2013,AZD8835,5290
435,Preclinical - Cell culture,"In a preclinical study, triple-receptor negative breast cancer cell lines harboring PIK3CA mutations demonstrated increased sensitivity to Pictilisib (GDC-0941) in culture (PMID: 27196766).",Actionable,8343,60081,triple-receptor negative breast cancer,DOID,429,PIK3CA mutant,"[{'id': 6624, 'pubMedId': 27196766, 'title': 'Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196766'}]",sensitive,749,GDC-0941,5290
436,Phase II,"In a Phase II clinical trial, Erbitux (cetuximab) treatment, in addition to radiochemotherapy, did not result in any complete responses (0/8) and demonstrated a worse disease free survival when compared to radiochemotherapy alone in cervical cancer patients harboring PIK3CA mutations (PMID: 25724520).",Actionable,3874,4362,cervical cancer,DOID,429,PIK3CA mutant,"[{'id': 4251, 'pubMedId': 25724520, 'title': 'PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25724520'}]",decreased response,694,Cetuximab,5290
437,Preclinical,"In a preclinical study, endometrioid endometrial cancer cell lines harboring PIK3CA mutations demonstrated increased sensitivity to GDC-0941 (Pictilisib) induced growth inhibition comparing to PIK3CA wild-type cells in culture (PMID: 23674493).",Actionable,4966,1380,endometrial cancer,DOID,429,PIK3CA mutant,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}]",sensitive,749,GDC-0941,5290
438,Preclinical - Cell line xenograft,"In a preclinical study, PF-04691502 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring PIK3CA mutations (PMID: 21750219).",Actionable,8387,3908,non-small cell lung carcinoma,DOID,429,PIK3CA mutant,"[{'id': 226, 'pubMedId': 21750219, 'title': 'PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21750219'}]",sensitive,865,PF-04691502,5290
439,Preclinical,"In a preclinical study, BEZ235 demonstrated efficacy in promoting apoptosis of gastric cancer cells harboring a PIK3CA mutation in culture (PMID: 22543857).",Actionable,4391,10534,stomach cancer,DOID,429,PIK3CA mutant,"[{'id': 361, 'pubMedId': 22543857, 'title': 'Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22543857'}]",sensitive,672,BEZ235,5290
440,Preclinical,"In a preclinical study, BEZ235 demonstrated efficacy in promoting apoptosis of colon cancer cells harboring a PIK3CA mutation in culture  (PMID: 22543857).",Actionable,628,219,colon cancer,DOID,429,PIK3CA mutant,"[{'id': 361, 'pubMedId': 22543857, 'title': 'Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22543857'}]",sensitive,672,BEZ235,5290
441,Phase I,"In a Phase I trial, MLN1117 demonstrated safety and preliminary efficacy in a variety of patients with advanced solid tumors carrying PIK3CA mutations (Journal of Clinical Oncology, 2015 ASCO Annual Meeting Vol 33, No 15_suppl., 2015: 2501).",Actionable,2793,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 3481, 'pubMedId': None, 'title': 'First-in-human, phase I, dose-escalation study of selective PI3K? isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies.', 'url': 'http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2501'}]",sensitive,1033,MLN1117,5290
442,Preclinical,"In a preclinical study, MLN1117 inhibited proliferation of tumor cells harboring oncogenic PIK3CA mutations in culture and inhibited tumor growth in PIK3CA mutant xenograft models (Cancer Ther 2011;10(11 Suppl):Abstract nr A171).",Actionable,1674,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 1779, 'pubMedId': None, 'title': 'Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://mct.aacrjournals.org/content/10/11_Supplement/A171.short'}]",sensitive,1033,MLN1117,5290
443,Phase II,"In a retrospective study of a Phase II trial, mutation status of PIK3CA was not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with Torisel (temsirolimus) (PMID: 27016228).",Actionable,6403,1380,endometrial cancer,DOID,429,PIK3CA mutant,"[{'id': 5557, 'pubMedId': 27016228, 'title': 'Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27016228'}]",no benefit,936,Temsirolimus,5290
444,Preclinical - Cell line xenograft,"In a preclinical study, PIK3CA mutations were associated with sensitivity to Alpelisib (BYL719) in human tumor cell lines in culture and in xenograft models (PMID: 24608574). ",Actionable,4493,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",sensitive,691,BYL719,5290
445,Phase I,"In a Phase I trial, Alpelisib (BYL719) demonstrated safety and preliminary efficacy in advanced solid tumor patients with PIK3CA genetic alterations (Cancer Res 2012;72(8 Suppl):Abstract nr CT-01. doi:1538-7445.AM2012-CT-01).",Actionable,1668,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 1778, 'pubMedId': None, 'title': 'Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study', 'url': 'http://cancerres.aacrjournals.org/content/72/8_Supplement/CT-01'}]",sensitive,691,BYL719,5290
446,Preclinical,"In a preclinical study, human cancer cell lines harboring PIK3CA mutations were sensitive to Sapanisertib (MLN0128) as demonstrated by significant growth inhibition (PMID: 25261369). ",Actionable,2066,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,"[{'id': 2380, 'pubMedId': 25261369, 'title': 'Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25261369'}]",sensitive,1282,Sapanisertib,5290
447,Preclinical,"In a preclinical study, PWT33597 decreased signaling of mTOR and PIK3 pathways in colon cancer cells with Pik3ca mutations (Cancer Res 2011;71(8 Suppl):Abstract nr 4485).",Actionable,2745,219,colon cancer,DOID,429,PIK3CA mutant,"[{'id': 3450, 'pubMedId': None, 'title': 'Preclinical characterization of PWT33597, a dual inhibitor of PI3-kinase alpha and mTOR', 'url': 'http://cancerres.aacrjournals.org/content/71/8_Supplement/4485.short'}]",sensitive,880,PWT33597,5290
448,Preclinical - Cell culture,"In a preclinical study, an estrogen-receptor positive breast cancer cell line over expressing FGFR1 and expressing a PIK3CA mutation demonstrated sensitivity to the combination of Alpelisib (BYL719) and Lucitanib (E-3810) in culture (PMID: 27126994). ",Actionable,9709,60075,estrogen-receptor positive breast cancer,DOID,26996,FGFR1 over exp PIK3CA mut,"[{'id': 7484, 'pubMedId': 27126994, 'title': 'A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27126994'}]",sensitive,5164,Alpelisib + Lucitanib,5290
449,Preclinical - Cell line xenograft,"In a preclinical study, AT13148 inhibited tumor growth in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model harboring mutant PIK3CA (PMID: 22781553).",Actionable,4784,60079,Her2-receptor positive breast cancer,DOID,25947,ERBB2 pos PIK3CA mut,"[{'id': 204, 'pubMedId': 22781553, 'title': 'AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22781553'}]",sensitive,3653,AT13148,5290
450,Clinical Study,"In a clinical study, a retrospective analysis of Tykerb (lapatinib) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302). ",Actionable,9163,60079,Her2-receptor positive breast cancer,DOID,25947,ERBB2 pos PIK3CA mut,"[{'id': 6968, 'pubMedId': 27687302, 'title': 'Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27687302'}]",decreased response,787,Lapatinib,5290
451,Clinical Study,"In a clinical study, a retrospective analysis of Herceptin (trastuzumab) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302). ",Actionable,9164,60079,Her2-receptor positive breast cancer,DOID,25947,ERBB2 pos PIK3CA mut,"[{'id': 6968, 'pubMedId': 27687302, 'title': 'Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27687302'}]",decreased response,947,Trastuzumab,5290
452,Phase III,"In a Phase III trial, Tykerb (lapatinib) and Xeloda (capecitabine) combination treatment resulted in decreased median progression free survival (4.3 vs. 6.4 months), median overall survival (17.3 vs. 27.8 months), and overall response rate(17.1% vs. 39.7%) in ERBB2 (HER2) positive breast cancer patients harboring PIK3CA mutations compared to PIK3CA wild type patients (PMID: 26920887). ",Actionable,7744,60079,Her2-receptor positive breast cancer,DOID,25947,ERBB2 pos PIK3CA mut,"[{'id': 6466, 'pubMedId': 26920887, 'title': 'Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26920887'}]",decreased response,1399,Lapatinib + Capecitabine,5290
453,Preclinical - Cell line xenograft,"In a preclinical study, a colorectal cancer cell line xenograft model co-harboring BRAF V600E and a PIK3CA mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).",Actionable,11042,9256,colorectal cancer,DOID,27895,BRAF V600E PIK3CA mut,"[{'id': 9035, 'pubMedId': None, 'title': 'Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/B100.short'}]",sensitive,5827,ASN003,5290
454,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of ARQ092 and Taxol (paclitaxel), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692). ",Actionable,10287,1612,breast cancer,DOID,26179,ERBB2 over exp PIK3CA mut,"[{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",sensitive,5455,ARQ092 + Paclitaxel,5290
455,Preclinical - Cell line xenograft,"In a preclinical study, PKI-179 inhibited growth of breast cancer cells harboring PIK3CA mutations and ERBB2 (HER2) over expression in culture and cell line xenograft models (PMID: 20797855).",Actionable,2737,60079,Her2-receptor positive breast cancer,DOID,26179,ERBB2 over exp PIK3CA mut,"[{'id': 1040, 'pubMedId': 20797855, 'title': 'PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20797855'}]",sensitive,872,PKI-179,5290
456,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of ARQ092 and Herceptin (trastuzumab), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692). ",Actionable,10286,1612,breast cancer,DOID,26179,ERBB2 over exp PIK3CA mut,"[{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",sensitive,5454,ARQ092 + Trastuzumab,5290
457,Preclinical - Pdx,"In a preclinical study, AZD6482 and Alpelisib (BYL719) combination treatment inhibited Akt signaling and growth in a breast cancer patient-derived xenograft (PDX) model harboring a PIK3CA mutation and PTEN loss (Cancer Res October 1, 2014 74; LB-327).",Actionable,4990,1612,breast cancer,DOID,19846,PIK3CA mutant PTEN loss,"[{'id': 4826, 'pubMedId': None, 'title': 'Loss of PTEN leads to clinical resistance to the PI3K? inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/LB-327.short'}]",sensitive,3714,AZD6482 + BYL719,5290
458,Preclinical - Cell culture,"In a preclinical study, PKI-179 inhibited growth of prostate cancer cells harboring PIK3CA mutations and PTEN loss in culture (PMID: 20797855).",Actionable,8146,10283,prostate cancer,DOID,19846,PIK3CA mutant PTEN loss,"[{'id': 1040, 'pubMedId': 20797855, 'title': 'PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20797855'}]",sensitive,872,PKI-179,5290
459,Clinical Study,"In a case study, a breast cancer patient harboring a PIK3CA mutation developed resistance to Alpelisib (BYL719) treatment and progressive disease after initial response, accompanied by a loss of PTEN (Cancer Res October 1, 2014 74; LB-327).",Actionable,4983,1612,breast cancer,DOID,19846,PIK3CA mutant PTEN loss,"[{'id': 4826, 'pubMedId': None, 'title': 'Loss of PTEN leads to clinical resistance to the PI3K? inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/LB-327.short'}]",resistant,691,BYL719,5290
460,Preclinical - Pdx,"In a preclinical study, a breast cancer patient-derived xenograft (PDX) model harboring a PIK3CA mutation and PTEN loss was resistant to Alpelisib (BYL719)-induced inhibition of Akt signaling and growth (Cancer Res October 1, 2014 74; LB-327).",Actionable,4988,1612,breast cancer,DOID,19846,PIK3CA mutant PTEN loss,"[{'id': 4826, 'pubMedId': None, 'title': 'Loss of PTEN leads to clinical resistance to the PI3K? inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/LB-327.short'}]",resistant,691,BYL719,5290
461,Preclinical - Pdx,"In a preclinical study, Buparlisib (BKM120) inhibited Akt signaling and growth in a PDX model of breast cancer cells harboring a PIK3CA mutation and PTEN loss ( Cancer Res October 1, 2014 74; LB-327 ).",Actionable,4989,1612,breast cancer,DOID,19846,PIK3CA mutant PTEN loss,"[{'id': 4826, 'pubMedId': None, 'title': 'Loss of PTEN leads to clinical resistance to the PI3K? inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/LB-327.short'}]",sensitive,680,BKM120,5290
462,Preclinical - Cell culture,"In a preclinical study, some head and neck squamous cell carcinoma cell lines over expressing PIK3CA demonstrated sensitivity to treatment with Gedatolisib (PF-05212384) (PMID: 25977343). ",Actionable,8241,5520,head and neck squamous cell carcinoma,DOID,20299,PIK3CA over exp,"[{'id': 6585, 'pubMedId': 25977343, 'title': 'MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25977343'}]",sensitive,1040,PF-05212384,5290
463,Preclinical - Cell line xenograft,"In a preclinical study, Alpelisib (BYL719) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing wild-type PIK3CA in culture, and inhibited tumor growth in cell line xenograft models (PMID: 26013318).",Actionable,7975,3907,lung squamous cell carcinoma,DOID,20299,PIK3CA over exp,"[{'id': 6528, 'pubMedId': 26013318, 'title': 'Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26013318'}]",sensitive,691,BYL719,5290
464,Preclinical - Cell culture,"In a preclinical study, BEZ235 induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing wild-type Pik3ca in culture (PMID: 26013318).",Actionable,7970,3907,lung squamous cell carcinoma,DOID,20299,PIK3CA over exp,"[{'id': 6528, 'pubMedId': 26013318, 'title': 'Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26013318'}]",sensitive,672,BEZ235,5290
465,Preclinical - Cell culture,"In a preclinical study, Buparlisib (BKM120) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing wild-type Pik3ca in culture (PMID: 26013318).",Actionable,7967,3907,lung squamous cell carcinoma,DOID,20299,PIK3CA over exp,"[{'id': 6528, 'pubMedId': 26013318, 'title': 'Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26013318'}]",sensitive,680,BKM120,5290
466,Preclinical,"In a preclinical study, YM-024 inhibited proliferation and anchorage-independent growth of glioblastoma cell lines with elevated Pik3ca protein level in culture (PMID: 24718026).",Actionable,5182,3068,glioblastoma multiforme,DOID,20299,PIK3CA over exp,"[{'id': 4902, 'pubMedId': 24718026, 'title': 'Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24718026'}]",sensitive,2967,YM-024,5290
467,Phase II,"In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Apitolisib (GDC-0980) had no difference in progression free survival when stratified by the presence (n=21) or absence (n=15) of PIK3CA activating mutation or loss of Pten expression (PMID: 26951309).",Actionable,5734,4450,renal cell carcinoma,DOID,21542,PIK3CA act mut PTEN dec exp,"[{'id': 4914, 'pubMedId': 26951309, 'title': 'Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26951309'}]",no benefit,750,GDC-0980,5290
468,Phase II,"In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Afinitor (everolimus) had no difference in progression free survival when stratified by the presence (n=21) or absence (n=17) of PIK3CA activating mutations (PMID: 26951309).",Actionable,5739,4450,renal cell carcinoma,DOID,21542,PIK3CA act mut PTEN dec exp,"[{'id': 4914, 'pubMedId': 26951309, 'title': 'Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26951309'}]",no benefit,735,Everolimus,5290
469,Preclinical - Cell culture,"In a preclinical study, 9/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Torkinib (PP242) in culture, resulting in decreased cell viability (PMID: 21358673). ",Actionable,10366,1612,breast cancer,DOID,27384,PIK3CA act mut PTEN wild-type,"[{'id': 3638, 'pubMedId': 21358673, 'title': 'PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21358673'}]",sensitive,2240,Torkinib,5290
470,Preclinical - Cell culture,"In a preclinical study, 8/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Afinitor (everolimus) in culture, resulting in decreased cell viability (PMID: 21358673). ",Actionable,10365,1612,breast cancer,DOID,27384,PIK3CA act mut PTEN wild-type,"[{'id': 3638, 'pubMedId': 21358673, 'title': 'PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21358673'}]",sensitive,735,Everolimus,5290
471,Preclinical,"In a preclinical study, Taselisib (GDC-0032) inhibited growth of HER2 positive uterine cancer cell lines with PIK3CA mutations (PMID: 25172762).",Actionable,2850,363,uterine cancer,DOID,1409,ERBB2 pos PIK3CA act mut,"[{'id': 3505, 'pubMedId': 25172762, 'title': 'Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25172762'}]",sensitive,1016,GDC-0032,5290
472,Phase I,"In a Phase I trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on trastuzumab-based therapy (PMID: 24470511).",Actionable,286,60079,Her2-receptor positive breast cancer,DOID,1409,ERBB2 pos PIK3CA act mut,"[{'id': 196, 'pubMedId': 24470511, 'title': 'Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24470511'}]",predicted – sensitive,1417,BKM120 + Trastuzumab,5290
473,Preclinical,"In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit survival of ERBB2 (HER2)-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",Actionable,5857,60079,Her2-receptor positive breast cancer,DOID,1409,ERBB2 pos PIK3CA act mut,"[{'id': 5181, 'pubMedId': 27020857, 'title': 'Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27020857'}]",sensitive,3956,Palbociclib + GDC-0941,5290
474,Clinical Study,"In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563).",Actionable,6664,60079,Her2-receptor positive breast cancer,DOID,1409,ERBB2 pos PIK3CA act mut,"[{'id': 213, 'pubMedId': 17936563, 'title': 'A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17936563'}]",decreased response,947,Trastuzumab,5290
475,Clinical Study,"In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation due to PTEN loss and/or PIK3CA activating mutation demonstrated a decreased median progression-free survival of 4.5 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217).",Actionable,875,60079,Her2-receptor positive breast cancer,DOID,1409,ERBB2 pos PIK3CA act mut,"[{'id': 224, 'pubMedId': 21676217, 'title': 'PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21676217'}]",decreased response,947,Trastuzumab,5290
476,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Navitoclax (ABT-263) and GDC-0941 resulted in increased tumor growth delay and apoptosis in a small cell lung cancer cell line xenograft model harboring a PIK3CA activating mutation compared to either drug alone (PMID: 27197306).",Actionable,7301,5409,lung small cell carcinoma,DOID,743,PIK3CA act mut,"[{'id': 6304, 'pubMedId': 27197306, 'title': 'Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27197306'}]",predicted – sensitive,4446,GDC-0941 + Navitoclax,5290
477,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).",Actionable,10084,1612,breast cancer,DOID,743,PIK3CA act mut,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",predicted – sensitive,5377,BEZ235 + WEHI-539,5290
478,Preclinical,"In a preclinical study, BAY1125976 demonstrated anti-tumor efficacy in multiple xenograft tumor models of different cancers with PIK3CA mutations or PTEN deletions and displayed synergy with other anti-cancer therapies (Cancer Res 2013;73(8 Suppl):Abstract nr 2050).",Actionable,1346,10000003,Advanced Solid Tumor,JAX,743,PIK3CA act mut,"[{'id': 1054, 'pubMedId': None, 'title': 'BAY 1125976, a highly selective and potent allosteric AKT1/2 inhibitor, for the treatment of cancers with aberrations in the PI3K-AKT-mTOR pathway', 'url': 'http://cancerres.aacrjournals.org/content/73/8_Supplement/2050'}]",sensitive,994,BAY1125976,5290
479,Preclinical - Cell culture,"In a preclinical study, the combination of AZD5363 and 4-hydroxytamoxifen (4-OHT) worked synergistically or additively to inhibit growth of several estrogen receptor-positive breast cancer cell lines in culture, including cell lines with PIK3CA activating mutations, and overcame tamoxifen resistance in a resistant cell line (PMID: 26116361).",Actionable,7397,60075,estrogen-receptor positive breast cancer,DOID,743,PIK3CA act mut,"[{'id': 6340, 'pubMedId': 26116361, 'title': 'AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26116361'}]",predicted – sensitive,4489,AZD5363 + Tamoxifen,5290
480,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA activating mutations to Venclexta (venetoclax) in culture (PMID: 27974663).",Actionable,10081,1612,breast cancer,DOID,743,PIK3CA act mut,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",no benefit,5376,BEZ235 + Venetoclax,5290
481,Phase I,"In a Phase I clinical trial, Ridaforolimus in combination with MK-2206 demonstrated clinical activity in breast cancer patients expressing a PI3K pathway dependent gene expression signature, with complete response in 14.3% (2/14), partial response in 12.5% (2/16), and 2 patients achieving stable disease (PMID: 26187616).",Actionable,4294,1612,breast cancer,DOID,743,PIK3CA act mut,"[{'id': 4136, 'pubMedId': 26187616, 'title': 'A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26187616'}]",predicted – sensitive,3478,Ridaforolimus + MK2206,5290
482,Preclinical - Pdx,"In a preclinical study, two head and neck squamous cell carcinoma patient-derived xenograft (PDX) models harboring a PIK3CA activating mutation demonstrated greater delayed tumor growth when treated with a combination of AZD8055 and Erbitux (cetuximab) compared to either agent alone (PMID: 28446642). ",Actionable,11512,5520,head and neck squamous cell carcinoma,DOID,743,PIK3CA act mut,"[{'id': 9596, 'pubMedId': 28446642, 'title': 'Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28446642'}]",predicted – sensitive,6008,AZD8055 + Cetuximab,5290
483,Preclinical - Cell line xenograft,"In preclinical studies, Taselisib (GDC-0032) effectively suppressed growth of multiple tumor types in a cell line xenograft models, with greater selectivity for PIK3CA activating mutants (PMID: 23662903).",Actionable,350,10000003,Advanced Solid Tumor,JAX,743,PIK3CA act mut,"[{'id': 206, 'pubMedId': 23662903, 'title': 'Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23662903'}]",sensitive,1016,GDC-0032,5290
484,Preclinical,"In a preclinical study, various tumor cell lines harboring PI3KCA activating mutations demonstrated increased sensitivity to Afuresertib (GSK2110183) in cultured cells (PMID: 24978597).",Actionable,1399,10000003,Advanced Solid Tumor,JAX,743,PIK3CA act mut,"[{'id': 962, 'pubMedId': 24978597, 'title': 'Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24978597'}]",sensitive,625,Afuresertib,5290
485,Preclinical - Cell line xenograft,"In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cell lines harboring activating PIK3CA mutations in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111).",Actionable,5213,5409,lung small cell carcinoma,DOID,743,PIK3CA act mut,"[{'id': 4924, 'pubMedId': 24240111, 'title': 'Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24240111'}]",sensitive,867,PF-4989216,5290
486,Preclinical - Cell culture,"In a preclinical study, the ATP–competitive mTORC1/2 inhibitor Sapanisertib (MLN0128) sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).",Actionable,10095,1612,breast cancer,DOID,743,PIK3CA act mut,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",predicted – sensitive,5386,MLN0128 + WEHI-539,5290
487,Preclinical - Cell line xenograft,"In preclinical studies, the PI3K inhibitor GDC-0941 demonstrated efficacy against NSCLC tumor cell lines in culture and in xenograft models harboring alterations in the PI3K pathway (PMID: 23136191).",Actionable,103,3908,non-small cell lung carcinoma,DOID,743,PIK3CA act mut,"[{'id': 234, 'pubMedId': 23136191, 'title': 'Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23136191'}]",sensitive,749,GDC-0941,5290
488,Preclinical - Cell culture,"In a preclinical study, the ATP–competitive mTORC1/2 inhibitor Vistusertib (AZD2014) sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).",Actionable,10096,1612,breast cancer,DOID,743,PIK3CA act mut,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",predicted – sensitive,5385,Vistusertib + WEHI-539,5290
489,Preclinical - Cell culture,"In a preclinical study, Buparlisib (BKM120) did not sensitize breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).",Actionable,10092,1612,breast cancer,DOID,743,PIK3CA act mut,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",no benefit,5382,BKM120 + WEHI-539,5290
490,Preclinical,"In a preclinical study, PF-05212384 decreased viability of head and neck squamous carcinoma cells harboring a PIK3CA activating mutation in cell culture (PMID: 24823695).",Actionable,1405,5520,head and neck squamous cell carcinoma,DOID,743,PIK3CA act mut,"[{'id': 1065, 'pubMedId': 24823695, 'title': 'The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24823695'}]",sensitive,1040,PF-05212384,5290
491,Phase I,"In a Phase I trial, triple-receptor negative breast cancer patients, including those with PIK3CA activating mutations, demonstrated an overall response rate of 21% (11/52) and clinical benefit rate of 40% (21/52) when treated with a combination of Avastin (bevacizumab), Adriamycin (doxorubicin), and either Afinitor (everolimus) or Torisel (temsirolimus) (PMID: 27893038). ",Actionable,10651,60081,triple-receptor negative breast cancer,DOID,743,PIK3CA act mut,"[{'id': 8709, 'pubMedId': 27893038, 'title': 'Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27893038'}]",predicted – sensitive,5569,Bevacizumab + Doxorubicin + Everolimus,5290
492,Phase I,"In a Phase I trial, triple-receptor negative breast cancer patients, including those with PIK3CA activating mutations, demonstrated an overall response rate of 21% (11/52) and clinical benefit rate of 40% (21/52) when treated with a combination of Avastin (bevacizumab), Adriamycin (doxorubicin), and either Afinitor (everolimus) or Torisel (temsirolimus) (PMID: 27893038). ",Actionable,10656,60081,triple-receptor negative breast cancer,DOID,743,PIK3CA act mut,"[{'id': 8709, 'pubMedId': 27893038, 'title': 'Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27893038'}]",predicted – sensitive,5570,Bevacizumab + Doxorubicin + Temsirolimus,5290
493,Preclinical,"In a preclinical study, solid tumor cell lines harboring PIK3CA activating mutations demonstrated increased sensitivity to GSK1059615 in culture (Clin Cancer Res October 1, 2008 14; B37).",Actionable,5209,10000003,Advanced Solid Tumor,JAX,743,PIK3CA act mut,"[{'id': 4916, 'pubMedId': None, 'title': 'In vitro sensitivity data suggests targeting several tumor types and molecular subtypes with the PI3K inhibitor GSK1059615 could maximize response rates in early clinical trials', 'url': 'http://clincancerres.aacrjournals.org/content/14/19_Supplement/B37.short'}]",sensitive,2248,GSK1059615,5290
494,Preclinical,"In a preclinical study, BEZ235 demonstrated efficacy in mouse xenograft models of ovarian clear cell adenocarcinoma with PIK3CA mutations (PMID: 24927217). ",Actionable,1653,5304,ovarian clear cell adenocarcinoma,DOID,743,PIK3CA act mut,"[{'id': 1763, 'pubMedId': 24927217, 'title': 'The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24927217'}]",sensitive,672,BEZ235,5290
495,Preclinical,"In a preclinical study, Glucophage (metformin) demonstrated efficacy in treating dietary restriction-resistant human xenograft tumors harboring a PIK3CA-activating mutation (PMID: 23986086).",Actionable,1371,10000003,Advanced Solid Tumor,JAX,743,PIK3CA act mut,"[{'id': 1086, 'pubMedId': 23986086, 'title': 'Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23986086'}]",sensitive,1031,Metformin,5290
496,Preclinical - Cell line xenograft,"In a preclinical study, Afinitor (everolimus) demonstrated efficacy in multiple cancer cell lines in culture and xenograft models with PIK3CA activating mutations (PMID: 20664172).",Actionable,1356,10000003,Advanced Solid Tumor,JAX,743,PIK3CA act mut,"[{'id': 1067, 'pubMedId': 20664172, 'title': 'Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20664172'}]",sensitive,735,Everolimus,5290
497,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) did not sensitize breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).",Actionable,10093,1612,breast cancer,DOID,743,PIK3CA act mut,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",no benefit,5383,Alpelisib + WEHI-539,5290
498,Preclinical,"In a preclinical study, breast cancer cell lines with a PIK3CA activating mutation and/or ERBB2 (HER2) over expression demonstrated increased sensitivity to inhibition of proliferation by Aliqopa (copanlisib) in culture, compared to ERBB2 (HER2)-negative and wild-type PIK3CA cell lines (PMID: 24170767).",Actionable,550,1612,breast cancer,DOID,743,PIK3CA act mut,"[{'id': 245, 'pubMedId': 24170767, 'title': 'BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24170767'}]",sensitive,995,Copanlisib,5290
499,Phase Ib/II,"In a Phase Ib trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) demonstrated safety and anti-tumor activity in patients with advanced solid tumors, including patients with PIK3CA activating mutations (Annals of Oncology (2014) 25 (suppl_4): iv146-iv164. 10.1093/annonc/mdu331).",Actionable,1398,10000003,Advanced Solid Tumor,JAX,743,PIK3CA act mut,"[{'id': 1146, 'pubMedId': None, 'title': '446PD - Phase Ib dose-escalation study of the Akt inhibitor ipatasertib (Ipat) with paclitaxel (P) in patients (pts) with advanced solid tumors', 'url': 'http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Developmental-Therapeutics/Phase-Ib-dose-escalation-study-of-the-Akt-inhibitor-ipatasertib-Ipat-with-paclitaxel-P-in-patients-pts-with-advanced-'}]",sensitive,1588,Ipatasertib + Paclitaxel,5290
500,Preclinical - Cell culture,"In a preclinical study, the ATP–competitive mTORC1/2 inhibitor Torin1 sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).",Actionable,10094,1612,breast cancer,DOID,743,PIK3CA act mut,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",predicted – sensitive,5384,Torin 1 + WEHI-539,5290
501,Preclinical,"In a preclinical study, breast cancer cell lines harboring activating mutations in PIK3CA had increased sensitivity to MK2206 in cell culture (PMID: 22932669).",Actionable,1403,1612,breast cancer,DOID,743,PIK3CA act mut,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}]",sensitive,816,MK2206,5290
502,Preclinical,"In a preclinical study, breast cancer cells with mutations in both ERBB2 (HER2) and PIK3CA were more sensitive to VS-5584 (PMID: 23270925). ",Actionable,2894,1612,breast cancer,DOID,10726,PIK3CA act mut ERBB2 act mut,"[{'id': 351, 'pubMedId': 23270925, 'title': 'VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23270925'}]",sensitive,960,VS-5584,5290
503,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of an endometrial cancer cell line harboring PIK3CA R38C and PTEN loss in culture (PMID: 21558396).",Actionable,2955,1380,endometrial cancer,DOID,10741,PIK3CA R38C  PTEN loss,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5290
504,Preclinical,"In a preclinical study, BEZ235 decreased growth of endometrial cancer cells harboring PIK3CA R38C and PTEN mutations in culture and in xenograft models (PMID: 22662154).",Actionable,2112,1380,endometrial cancer,DOID,5397,PIK3CA R38C PTEN mut,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",sensitive,672,BEZ235,5290
505,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of colorectal cancer cells harboring KRAS G12D and PIK3CA Q546L (PMID: 26369631).",Actionable,5619,9256,colorectal cancer,DOID,21301,KRAS G12D PIK3CA Q546L,"[{'id': 5128, 'pubMedId': 26369631, 'title': 'Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26369631'}]",sensitive,1368,Palbociclib + Trametinib,5290
0,Clinical Study,"In a clinical study, a melanoma patient harboring a BRAF V600 mutation and PTEN H93D treated with Zelboraf (vemurafenib) for 66 weeks demonstrated a partial response (PMID: 24265153).",Actionable,7083,1909,melanoma,DOID,24401,BRAF V600X PTEN H93D,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",sensitive,342,Vemurafenib,5728
1,Preclinical,"In a preclincal study, mucinous ovarian carcinoma cell lines over-expressing PTEN G129R were less sensitive to KX2-391 induced growth inhibition in culture and tumor suppression in xenograft models (PMID: 24100628).",Actionable,5908,6067,ovarian mucinous neoplasm,DOID,4015,PTEN G129R,"[{'id': 5193, 'pubMedId': 24100628, 'title': 'Targeting SRC and tubulin in mucinous ovarian carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24100628'}]",decreased response,786,KX2-391,5728
2,Preclinical - Cell culture,"In a preclinical study, expression of AKT1 Q79K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).",Actionable,8106,1909,melanoma,DOID,26173,AKT1 Q79K BRAF V600X PTEN pos,"[{'id': 6551, 'pubMedId': 24265152, 'title': 'A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265152'}]",resistant,342,Vemurafenib,5728
3,Preclinical - Cell culture,"In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited AKT activation and growth of PTEN-expressing BRAF V600-mutant melanoma cells expressing AKT1 Q79K in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8125,1909,melanoma,DOID,26173,AKT1 Q79K BRAF V600X PTEN pos,"[{'id': 6551, 'pubMedId': 24265152, 'title': 'A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265152'}]",sensitive,4635,MK2206 + Vemurafenib,5728
4,Preclinical - Cell culture,"In a preclinical study, expression of AKT1 E17K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).",Actionable,8103,1909,melanoma,DOID,26172,AKT1 E17K BRAF V600X PTEN pos,"[{'id': 6551, 'pubMedId': 24265152, 'title': 'A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265152'}]",resistant,342,Vemurafenib,5728
5,Preclinical - Cell line xenograft,"In a preclinical study, Glucophage (metformin) inhibited cell proliferation and induced apoptosis in a PTEN-expressing human endometrial cancer cell line harboring KRAS G12D in culture and decreased tumor growth in xenograft models (PMID: 24077915).",Actionable,590,1380,endometrial cancer,DOID,26548,PTEN pos KRAS G12D,"[{'id': 986, 'pubMedId': 24077915, 'title': 'Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24077915'}]",sensitive,1031,Metformin,5728
6,Clinical Study,"In a clinical study, melanoma patients with PTEN positive tumors demonstrated a decrease in tumor size when treated with Keytruda (pembrolizumab) (PMID: 26645196). ",Actionable,4451,1909,melanoma,DOID,18161,PTEN positive,"[{'id': 4556, 'pubMedId': 26645196, 'title': 'Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26645196'}]",sensitive,1447,Pembrolizumab,5728
7,Clinical Study,"In a clinical study, melanoma patients with PTEN positive tumors demonstrated a decrease in tumor size when treated with Opdivo (nivolumab) (PMID: 26645196). ",Actionable,4452,1909,melanoma,DOID,18161,PTEN positive,"[{'id': 4556, 'pubMedId': 26645196, 'title': 'Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26645196'}]",sensitive,1312,Nivolumab,5728
8,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring PTEN A72fs*5 in culture (PMID: 21325073, PMID: 17314276).",Actionable,3126,1612,breast cancer,DOID,11789,PTEN A72fs*5,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3636, 'pubMedId': 17314276, 'title': 'Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17314276'}]",sensitive,1040,PF-05212384,5728
9,Preclinical - Cell culture,"In a preclinical study, DHM25 increased cell death in a triple-negative breast cancer cell line harboring PTEN A72fs*5 in culture (PMID: 26237138).",Actionable,10360,60081,triple-receptor negative breast cancer,DOID,11789,PTEN A72fs*5,"[{'id': 8367, 'pubMedId': 26237138, 'title': 'A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26237138'}]",sensitive,5494,DHM25,5728
10,Preclinical - Cell culture,"In a preclinical study, lack of PTEN expression was associated with increased sensitivity to GSK2141795 in BRAF V600-mutant melanoma cell lines in culture (PMID: 24265152).",Actionable,8168,1909,melanoma,DOID,26183,BRAF V600X PTEN neg,"[{'id': 6551, 'pubMedId': 24265152, 'title': 'A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265152'}]",sensitive,764,GSK2141795,5728
11,Phase II,"In a Phase II trial, one patient with Pten negative squamous NSCLC had a partial response to Buparlisib (BKM120) however, stage 2 of the study was not initiated due to failure of meeting overall stage 1 response endpoints (PMID: 26098748).",Actionable,9816,3907,lung squamous cell carcinoma,DOID,2077,PTEN negative,"[{'id': 7642, 'pubMedId': 26098748, 'title': 'Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26098748'}]",sensitive,680,BKM120,5728
12,Phase II,"In a Phase II trial, Caprelsa (vandetinib), in combination with radiation therapy and Temodar (temozolomide), demonstrated no difference in PFS and OS when compared between glioblastoma patients negative for PTEN versus those positive for PTEN (PMID: 25910950). ",Actionable,3240,3068,glioblastoma multiforme,DOID,2077,PTEN negative,"[{'id': 3688, 'pubMedId': 25910950, 'title': 'A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25910950'}]",no benefit,3094,Vandetanib + Temozolomide,5728
13,Preclinical,"In a preclinical study, PTEN deficient cancer cell lines with DNA repair deficiency demonstrated high sensitivity to the PARP inhibitor, BMN673 (PMID: 23881923). ",Actionable,1180,10000003,Advanced Solid Tumor,JAX,2077,PTEN negative,"[{'id': 520, 'pubMedId': 23881923, 'title': 'BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23881923'}]",sensitive,682,Talazoparib,5728
14,Clinical Study,"In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153). ",Actionable,7082,1909,melanoma,DOID,24398,BRAF V600X PIK3CA H1047R PTEN Y86fs,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",resistant,342,Vemurafenib,5728
15,Phase II,"In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients with low Pten expression (J Clin Oncol 35, 2017 (suppl; abstr 1009)).",Actionable,11167,60081,triple-receptor negative breast cancer,DOID,13314,PTEN dec exp,"[{'id': 9130, 'pubMedId': None, 'title': 'LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).', 'url': 'http://abstracts.asco.org/199/AbstView_199_183382.html'}]",predicted – sensitive,1588,Ipatasertib + Paclitaxel,5728
16,Phase II,"In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Afinitor (everolimus) had no difference in progression free survival when stratified by high expression (n=17) and low expression (n=21) of Pten (PMID: 26951309).",Actionable,5738,4450,renal cell carcinoma,DOID,13314,PTEN dec exp,"[{'id': 4914, 'pubMedId': 26951309, 'title': 'Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26951309'}]",no benefit,735,Everolimus,5728
17,Phase Ib/II,"In a Phase I/II trial, GSK2636771 treatment inhibited Akt signaling, and resulted in partial response in 2% (1/53) and stable disease in 25% (13/53) of patients with PTEN-deficient advanced solid tumors (J Clin Oncol 32:5s, 2014 (suppl; abstr 2514)).",Actionable,4965,10000003,Advanced Solid Tumor,JAX,13314,PTEN dec exp,"[{'id': 4819, 'pubMedId': None, 'title': 'A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.', 'url': 'http://meetinglibrary.asco.org/content/131727-144'}]",sensitive,765,GSK2636771,5728
18,Preclinical - Cell line xenograft,"In a preclinical study, SAR260301 inhibited tumor growth in xenograft models of melanoma cell lines harboring PTEN deficiency (PMID: 24387221).",Actionable,4960,1909,melanoma,DOID,13314,PTEN dec exp,"[{'id': 4811, 'pubMedId': 24387221, 'title': 'Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387221'}]",sensitive,1052,SAR260301,5728
19,Phase I,"In a Phase I clinical trial, low Pten expression or lack of Pten expression was associated with better response to treatment with the combination of Alimta (pemetrexed) and Nexavar (sorafenib) in patients with advanced solid tumors (PMID: 27213589).",Actionable,7308,10000003,Advanced Solid Tumor,JAX,13314,PTEN dec exp,"[{'id': 6305, 'pubMedId': 27213589, 'title': 'Phase I study of pemetrexed with sorafenib in advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27213589'}]",predicted – sensitive,1482,Pemetrexed + Sorafenib,5728
20,Phase II,"In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Apitolisib (GDC-0980) had no difference in progression free survival when stratified by high expression (n=17) and low expression (n=19) of Pten (PMID: 26951309).",Actionable,5733,4450,renal cell carcinoma,DOID,13314,PTEN dec exp,"[{'id': 4914, 'pubMedId': 26951309, 'title': 'Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26951309'}]",no benefit,750,GDC-0980,5728
21,Preclinical,"In a preclinical study, knockdown of PTEN expression resulted in a decreased response to treatment with CDX-3379 (KTN3379) in ERBB2 (HER2)-amplified breast cancer cells in culture (PMID: 26880266).",Actionable,6465,60079,Her2-receptor positive breast cancer,DOID,23519,ERBB2 amp PTEN dec exp,"[{'id': 5601, 'pubMedId': 26880266, 'title': 'A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26880266'}]",decreased response,2054,CDX-3379,5728
22,Clinical Study,"In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563).",Actionable,6663,60079,Her2-receptor positive breast cancer,DOID,23664,ERBB2 pos PTEN dec exp,"[{'id': 213, 'pubMedId': 17936563, 'title': 'A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17936563'}]",decreased response,947,Trastuzumab,5728
23,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, decreased PTEN expression, and TP53 R306* (PMID: 26272063).",Actionable,8576,9256,colorectal cancer,DOID,26365,KRAS G12D PTEN dec exp TP53 R306*,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,4771,MLN0128 + PD-0325901,5728
24,Phase II,"In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Afinitor (everolimus) had no difference in progression free survival when stratified by the presence (n=21) or absence (n=17) of PIK3CA activating mutations (PMID: 26951309).",Actionable,5739,4450,renal cell carcinoma,DOID,21542,PIK3CA act mut PTEN dec exp,"[{'id': 4914, 'pubMedId': 26951309, 'title': 'Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26951309'}]",no benefit,735,Everolimus,5728
25,Phase II,"In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Apitolisib (GDC-0980) had no difference in progression free survival when stratified by the presence (n=21) or absence (n=15) of PIK3CA activating mutation or loss of Pten expression (PMID: 26951309).",Actionable,5734,4450,renal cell carcinoma,DOID,21542,PIK3CA act mut PTEN dec exp,"[{'id': 4914, 'pubMedId': 26951309, 'title': 'Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26951309'}]",no benefit,750,GDC-0980,5728
26,Preclinical - Cell culture,"In a preclinical study, DHM25 increased cell death and decreased migration of a triple-negative breast cancer cell line harboring PTEN V275* in culture (PMID: 26237138).",Actionable,10364,60081,triple-receptor negative breast cancer,DOID,27383,PTEN V275*,"[{'id': 8367, 'pubMedId': 26237138, 'title': 'A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26237138'}]",sensitive,5494,DHM25,5728
27,Preclinical,"In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Ibrance (palbociclib) induced growth inhibition in culture (PMID: 27020857).",Actionable,5865,60081,triple-receptor negative breast cancer,DOID,21971,PTEN loss RB1 loss,"[{'id': 5181, 'pubMedId': 27020857, 'title': 'Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27020857'}]",resistant,850,Palbociclib,5728
28,Preclinical,"In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Pictilisib (GDC-0941) induced growth inhibition in culture (PMID: 27020857).",Actionable,5864,60081,triple-receptor negative breast cancer,DOID,21971,PTEN loss RB1 loss,"[{'id': 5181, 'pubMedId': 27020857, 'title': 'Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27020857'}]",resistant,749,GDC-0941,5728
29,Preclinical,"In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in triple-receptor negative breast cancer cell lines harboring PTEN and RB1 loss in culture (PMID: 27020857).",Actionable,5863,60081,triple-receptor negative breast cancer,DOID,21971,PTEN loss RB1 loss,"[{'id': 5181, 'pubMedId': 27020857, 'title': 'Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27020857'}]",no benefit,3956,Palbociclib + GDC-0941,5728
30,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600D (PMID: 25637314).",Actionable,6320,1909,melanoma,DOID,23100,BRAF V600D PTEN loss,"[{'id': 5522, 'pubMedId': 25637314, 'title': 'The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25637314'}]",sensitive,1050,XL147,5728
31,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PTEN loss, and TP53 V216M (PMID: 26272063).",Actionable,8575,9256,colorectal cancer,DOID,26364,KRAS G12D PTEN loss TP53 V216M,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,4771,MLN0128 + PD-0325901,5728
32,Preclinical,"In a preclinical study, the PI3K inhibitor GDC-0941 reduced tumor growth rate in immunodeficient mice engrafted with endometrial tumors from PTEN/STK11 (LKB1) deficient mice (PMID: 24322983).",Actionable,601,1380,endometrial cancer,DOID,18395,PTEN loss STK11 loss,"[{'id': 350, 'pubMedId': 24322983, 'title': 'A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24322983'}]",sensitive,749,GDC-0941,5728
33,Preclinical - Cell line xenograft,"In a preclinical study, SAR260301 and Zelboraf (vemurafenib) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",Actionable,7773,1909,melanoma,DOID,18163,BRAF mut PTEN loss,"[{'id': 6491, 'pubMedId': 27196754, 'title': 'Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196754'}]",sensitive,1225,SAR260301 + Vemurafenib,5728
34,Preclinical - Cell line xenograft,"In a preclinical study, SAR260301 inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",Actionable,7771,1909,melanoma,DOID,18163,BRAF mut PTEN loss,"[{'id': 6491, 'pubMedId': 27196754, 'title': 'Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196754'}]",sensitive,1052,SAR260301,5728
35,Preclinical,"In a preclinical study, a melanoma mouse model harboring a BRAF mutation and PTEN loss was sensitive to the combination of GSK2636771 and Keytruda (pembrolizumab), demonstrating greater tumor growth inhibition and improved survival when compared to either therapy alone (PMID: 26645196). ",Actionable,4455,1909,melanoma,DOID,18163,BRAF mut PTEN loss,"[{'id': 4556, 'pubMedId': 26645196, 'title': 'Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26645196'}]",sensitive,3518,GSK2636771 + Pembrolizumab,5728
36,Preclinical,"In a preclinical study, GSK2636771 resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196). ",Actionable,4456,1909,melanoma,DOID,18163,BRAF mut PTEN loss,"[{'id': 4556, 'pubMedId': 26645196, 'title': 'Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26645196'}]",no benefit,765,GSK2636771,5728
37,Preclinical,"In a preclinical study, Keytruda (pembrolizumab) resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196). ",Actionable,4457,1909,melanoma,DOID,18163,BRAF mut PTEN loss,"[{'id': 4556, 'pubMedId': 26645196, 'title': 'Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26645196'}]",no benefit,1447,Pembrolizumab,5728
38,Preclinical - Cell line xenograft,"In a preclinical study, SAR260301 and Selumetinib (AZD6244) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",Actionable,7774,1909,melanoma,DOID,18163,BRAF mut PTEN loss,"[{'id': 6491, 'pubMedId': 27196754, 'title': 'Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196754'}]",sensitive,4573,SAR260301 + Selumetinib,5728
39,Phase I,"In a Phase I clinical trial, an endometrial carcinoma patient harboring PIK3CA T1052K, R88L, and E453del, as well as a PTEN mutation and loss of PTEN protein expression demonstrated a complete response to treatment with Aliqopa (copanlisib) (PMID: 27672108). ",Actionable,9350,2871,endometrial carcinoma,DOID,26828, PIK3CA E453del PIK3CA T1025K PIK3CA R88L PTEN mut PTEN loss,"[{'id': 7122, 'pubMedId': 27672108, 'title': ""First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27672108'}]",sensitive,995,Copanlisib,5728
40,Preclinical,"In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in ERBB2 (HER2)-positive breast cancer cell lines harboring PTEN loss in culture (PMID: 27020857).",Actionable,5862,60079,Her2-receptor positive breast cancer,DOID,1410,ERBB2 pos PTEN loss ,"[{'id': 5181, 'pubMedId': 27020857, 'title': 'Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27020857'}]",no benefit,3956,Palbociclib + GDC-0941,5728
41,Phase I,"In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PTEN loss demonstrated a decreased median progression-free survival of 6.0 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217).",Actionable,874,60079,Her2-receptor positive breast cancer,DOID,1410,ERBB2 pos PTEN loss ,"[{'id': 224, 'pubMedId': 21676217, 'title': 'PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21676217'}]",decreased response,947,Trastuzumab,5728
42,Preclinical,"In a preclinical study, treatment with the combination of GSK2636771 and a PD-1 antibody resulted in greater tumor infiltration of T-cells and tumor growth inhibition in mouse melanoma models expressing BRAF V600E with PTEN loss compared to either agent alone (PMID: 26645196).",Actionable,10891,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,"[{'id': 4556, 'pubMedId': 26645196, 'title': 'Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26645196'}]",sensitive,5673,GSK2636771 + unspecified PD-1 antibody,5728
43,Clinical Study,"In a clinical study, a melanoma patient harboring PTEN loss and BRAF V600E demonstrated resistance to Afinitor (everolimus) treatment, resulting in progressive disease (PMID: 20664172).",Actionable,1233,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,"[{'id': 219, 'pubMedId': 20664174, 'title': ""PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20664174'}, {'id': 1067, 'pubMedId': 20664172, 'title': 'Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20664172'}]",resistant,735,Everolimus,5728
44,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600E (PMID: 25637314).",Actionable,6318,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,"[{'id': 5522, 'pubMedId': 25637314, 'title': 'The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25637314'}]",sensitive,1050,XL147,5728
45,Preclinical,"In a preclinical study, a melanoma cell line harboring BRAF V600E and PTEN loss demonstrated sensitivity when treated with a combination of Pictilisib (GDC-0941) and PLX4720, resulting in decreased cell proliferation in culture (PMID: 24265153).",Actionable,7081,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,"[{'id': 5840, 'pubMedId': 24265153, 'title': 'The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265153'}]",sensitive,4358,GDC-0941 + PLX4720,5728
46,Preclinical - Cell culture,"In a preclinical study, GDC0879 and Pictilisib (GDC-0941) synergistically inhibited survival of melanoma cell lines harboring BFAF V600E and PTEN loss in cell culture (PMID: 19276360).",Actionable,7899,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,"[{'id': 6516, 'pubMedId': 19276360, 'title': 'Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19276360'}]",sensitive,4605,GDC0879 + GDC-0941,5728
47,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human glioma cells with PTEN loss in culture (PMID: 21325073).",Actionable,3155,60108,brain glioma,DOID,479,PTEN loss,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}]",sensitive,1040,PF-05212384,5728
48,Phase I,"In a Phase I trial in patients with advanced solid tumors, Estybon (rigosertib) treatment resulted in responses in 2 patients with head and neck squamous cell carcinoma (1 complete response and 1 partial response), 1 harboring PIK3CA amplification and the other harboring PTEN loss (Cancer Res April 15 2013 (73) (8 Supplement) LB-198).",Actionable,10890,5520,head and neck squamous cell carcinoma,DOID,479,PTEN loss,"[{'id': 8903, 'pubMedId': None, 'title': 'Abstract LB-198: Phase I and molecular correlates study of oral rigosertib in patients with refractory metastatic head and neck cancer and advanced solid tumors.', 'url': 'http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-198.short'}]",predicted – sensitive,1046,rigosertib,5728
49,Preclinical,"In a preclinical study, the combination of Talazoparib (BMN-673) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res, Feb 2016 14; B12).",Actionable,4995,60081,triple-receptor negative breast cancer,DOID,479,PTEN loss,"[{'id': 4828, 'pubMedId': None, 'title': 'Co-targeting PTEN-defined TNBC with p110beta-isoform specific inhibitor and PARP inhibitor BMN 673: A predictive context to sensitize PARP inhibitors in TNBC', 'url': 'http://mcr.aacrjournals.org/content/14/2_Supplement/B12.short'}]",sensitive,3717,AZD6482 + Talazoparib,5728
50,Preclinical - Cell line xenograft,"In preclinical studies, CCT128930 prevented tumor growth in a PTEN-null human glioblastoma cell line xenograft model (PMID: 21191045).",Actionable,997,3068,glioblastoma multiforme,DOID,479,PTEN loss,"[{'id': 692, 'pubMedId': 21191045, 'title': 'Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21191045'}]",sensitive,1445,CCT128930,5728
51,Preclinical - Cell culture,"In a preclinical study, BGT226 treatment in PTEN-deficient acute lymphoblastic leukemia cells resulted in inhibition of PI3K/Akt signaling and apoptotic activity in culture (PMID: 23705826).",Actionable,10531,9952,acute lymphocytic leukemia,DOID,479,PTEN loss,"[{'id': 8616, 'pubMedId': 23705826, 'title': 'Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23705826'}]",sensitive,675,BGT226,5728
52,Preclinical - Cell line xenograft,"In a preclinical study, OSI-027 inhibited tumor growth in PTEN-null ovarian cancer cell line xenograft models (PMID: 21673091).",Actionable,8733,2394,ovarian cancer,DOID,479,PTEN loss,"[{'id': 3483, 'pubMedId': 21673091, 'title': 'Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21673091'}]",sensitive,841,OSI-027,5728
53,Preclinical - Cell line xenograft,"In a preclinical study, a triple-receptor negative breast cancer xenograft model harboring PTEN loss was sensitive to M2698 (MSC2363318A), demonstrating inhibition of tumor growth and tumor regression (PMID: 27186432). ",Actionable,10290,60081,triple-receptor negative breast cancer,DOID,479,PTEN loss,"[{'id': 7643, 'pubMedId': 27186432, 'title': 'M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27186432'}]",sensitive,1037,MSC2363318A,5728
54,Preclinical,"In a preclinical study, human melanoma cells with PTEN loss were sensitive to GSK2636771, resulting in decreased activation of Akt and some inhibition of tumor growth (PMID: 26645196). ",Actionable,4453,1909,melanoma,DOID,479,PTEN loss,"[{'id': 4556, 'pubMedId': 26645196, 'title': 'Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26645196'}]",sensitive,765,GSK2636771,5728
55,Preclinical - Cell line xenograft,"In a preclinical study, two PTEN-deficient glioblastoma cell line xenograft models were sensitive to GDC-0084 treatment, resulting in decreased tumor volumes by 70% and 40%, and inhibition of PI3K pathway signaling (PMID: 27638506). ",Actionable,10643,3068,glioblastoma multiforme,DOID,479,PTEN loss,"[{'id': 8698, 'pubMedId': 27638506, 'title': 'Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27638506'}]",sensitive,2018,GDC-0084,5728
56,Preclinical - Cell line xenograft,"In a preclinical study, OSI-027 induced tumor regression in PTEN-null breast cancer cell line xenograft models (PMID: 21673091).",Actionable,8735,1612,breast cancer,DOID,479,PTEN loss,"[{'id': 3483, 'pubMedId': 21673091, 'title': 'Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21673091'}]",sensitive,841,OSI-027,5728
57,Preclinical,"In a preclinical study, YU238259 demonstrated increased cytotoxicity in PTEN-deficient sarcoma cell lines in culture (PMID: 26116172).",Actionable,5532,1115,sarcoma,DOID,479,PTEN loss,"[{'id': 5087, 'pubMedId': 26116172, 'title': 'YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26116172'}]",sensitive,3880,YU238259,5728
58,Preclinical - Cell line xenograft,"In a preclinical study, AT13148 inhibited tumor growth in a PTEN-deficient human uterine sarcoma cell line xenograft model (PMID: 22781553).",Actionable,4786,5165,uterine corpus sarcoma,DOID,479,PTEN loss,"[{'id': 204, 'pubMedId': 22781553, 'title': 'AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22781553'}]",sensitive,3653,AT13148,5728
59,Preclinical,"In a preclinical study, the combination of Lynparza (olaparib) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res Feb 2016 14; B12).",Actionable,4997,60081,triple-receptor negative breast cancer,DOID,479,PTEN loss,"[{'id': 4828, 'pubMedId': None, 'title': 'Co-targeting PTEN-defined TNBC with p110beta-isoform specific inhibitor and PARP inhibitor BMN 673: A predictive context to sensitize PARP inhibitors in TNBC', 'url': 'http://mcr.aacrjournals.org/content/14/2_Supplement/B12.short'}]",sensitive,3719,AZD6482 + Olaparib,5728
60,Preclinical,"In a preclinical study, human renal carcinoma cells with PTEN loss had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073).",Actionable,3156,4451,renal carcinoma,DOID,479,PTEN loss,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}]",decreased response,1040,PF-05212384,5728
61,Phase I,"In a Phase I clinical trial, 8 patients with metastatic, castration-resistant prostate cancer harboring a loss of PTEN did not respond to MK-2206 therapy, but prolonged stable disease was observed in 2 patients (PMID: 26187616).",Actionable,3782,10283,prostate cancer,DOID,479,PTEN loss,"[{'id': 4136, 'pubMedId': 26187616, 'title': 'A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26187616'}]",no benefit,816,MK2206,5728
62,Preclinical,"In a preclinical study, KU-55933 induced cell cycle arrest and caspase activation in PTEN deficient human colon cancer cells in culture (PMID: 25870146).",Actionable,4780,219,colon cancer,DOID,479,PTEN loss,"[{'id': 4736, 'pubMedId': 25870146, 'title': 'Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870146'}]",sensitive,3116,KU-55933,5728
63,Preclinical,"In a preclinical study, prostate cancer mouse models deficient for Pten demonstrated inhibition of the PI3K/Akt signaling pathway and a decrease in both tumor size and cell proliferation when treated with OP449 (PMID: 26563471).",Actionable,4755,10283,prostate cancer,DOID,479,PTEN loss,"[{'id': 4697, 'pubMedId': 26563471, 'title': 'Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26563471'}]",sensitive,3606,OP449,5728
64,Preclinical,"In a preclinical study, AZD6482 inhibited viability of breast cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493).",Actionable,4974,1612,breast cancer,DOID,479,PTEN loss,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}]",sensitive,659,AZD6482,5728
65,Clinical Study,"In a clinical study, melanoma patients with PTEN loss demonstrated decreased response to anti–PD-1 antibodies, including Opdivo (nivolumab), as compared to patients in which PTEN is present (PMID: 26645196). ",Actionable,4450,1909,melanoma,DOID,479,PTEN loss,"[{'id': 4556, 'pubMedId': 26645196, 'title': 'Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26645196'}]",decreased response,1312,Nivolumab,5728
66,Preclinical - Cell line xenograft,"In a preclinical study, Acalisib (GS-9820) resulted in tumor growth inhibition in xenograft models of prostate cancer with PTEN deficiency (Mol Cancer Ther 2009;8(12 Suppl):B136).",Actionable,8288,10283,prostate cancer,DOID,479,PTEN loss,"[{'id': 1019, 'pubMedId': None, 'title': 'Abstract B136: CAL?120, a novel dual p110beta/p110delta phosphatidylinositol?3?kinase (PI3K) inhibitor, attenuates PI3K signaling and demonstrates potent in vivo antitumor activity against solid tumors', 'url': 'http://mct.aacrjournals.org/content/8/12_Supplement/B136.short'}]",sensitive,1021,GS-9820,5728
67,Phase Ib/II,"In a Phase Ib trial, a breast adenocarcinoma patient harboring PTEN loss demonstrated a partial response when treated with a combination of LY2780301 and Gemzar (gemcitabine) (PMID: 28750271). ",Actionable,11828,3458,breast adenocarcinoma,DOID,479,PTEN loss,"[{'id': 9864, 'pubMedId': 28750271, 'title': 'Safety, tolerability\xa0and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28750271'}]",sensitive,6168,Gemcitabine + LY2780301,5728
68,Preclinical - Cell line xenograft,"In a preclinical study, a prostate cancer cell line with PTEN loss was sensitive to XL765 (SAR245409) treatment, demonstrating inhibition of the PI3K pathway and decreased colony formation in culture, and inhibition of tumor growth and reduced tumor vascularization in cell line xenograft models (PMID: 24634413).",Actionable,10701,10283,prostate cancer,DOID,479,PTEN loss,"[{'id': 8768, 'pubMedId': 24634413, 'title': 'Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24634413'}]",sensitive,1051,SAR245409,5728
69,Phase I,"In a Phase I trial, a patient with castration resistant prostate cancer harboring a loss of PTEN demonstrated an improved prostate specific antigen when treated with Ipatasertib (GDC-0068) (PMID: 27872130). ",Actionable,9712,10283,prostate cancer,DOID,479,PTEN loss,"[{'id': 7487, 'pubMedId': 27872130, 'title': 'A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27872130'}]",sensitive,747,Ipatasertib,5728
70,Preclinical - Cell culture,"In a preclinical study, breast cancer cell lines with PTEN loss demonstrated resistance to Torkinib (PP242) in culture (PMID: 21358673). ",Actionable,10369,1612,breast cancer,DOID,479,PTEN loss,"[{'id': 3638, 'pubMedId': 21358673, 'title': 'PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21358673'}]",resistant,2240,Torkinib,5728
71,Preclinical,"In a preclinical study, treatment with AZD5363 decreased AKT phosphorylation and downstream signaling and reduced tumor burden in mouse models of PTEN-deficient prostate cancer, including both castration-naive and castration resistant models (PMID: 26910118).",Actionable,10887,10283,prostate cancer,DOID,479,PTEN loss,"[{'id': 8893, 'pubMedId': 26910118, 'title': 'Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26910118'}]",sensitive,655,AZD5363,5728
72,Preclinical - Cell culture,"In a preclinical study, a breast adenocarcinoma cell line harboring PTEN loss was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture (PMID: 24634413). ",Actionable,10706,3458,breast adenocarcinoma,DOID,479,PTEN loss,"[{'id': 8768, 'pubMedId': 24634413, 'title': 'Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24634413'}]",sensitive,1051,SAR245409,5728
73,Preclinical - Cell line xenograft,"In preclinical studies, the PI3K inhibitor GDC-0941 demonstrated efficacy against NSCLC tumor cell lines in both culture and xenograft models harboring alterations in the PI3K pathway (PMID: 23136191).
",Actionable,130,3908,non-small cell lung carcinoma,DOID,479,PTEN loss,"[{'id': 234, 'pubMedId': 23136191, 'title': 'Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23136191'}]",sensitive,749,GDC-0941,5728
74,Preclinical - Cell line xenograft,"In a preclinical study, PF-04691502 inhibited Akt phosphorylation, resulted in growth inhibition of PTEN-null glioblastoma cells in culture and in cell line xenograft models (PMID: 21750219).",Actionable,2620,3068,glioblastoma multiforme,DOID,479,PTEN loss,"[{'id': 226, 'pubMedId': 21750219, 'title': 'PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21750219'}]",sensitive,865,PF-04691502,5728
75,Preclinical - Cell line xenograft,"In a preclinical study, A66 did not inhibit tumor growth in a PTEN-null cell line xenograft model of glioblastoma (PMID: 21668414).",Actionable,7534,3068,glioblastoma multiforme,DOID,479,PTEN loss,"[{'id': 223, 'pubMedId': 21668414, 'title': 'A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21668414'}]",resistant,617,A66,5728
76,Preclinical,"In a preclinical study, AZD6482 inhibited viability of prostate cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493).",Actionable,4973,10283,prostate cancer,DOID,479,PTEN loss,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}]",sensitive,659,AZD6482,5728
77,Preclinical,"In a preclinical study, AZD8186 inhibited tumor growth of PTEN deficient prostate xenografts models (PMID: 25514658).",Actionable,3766,10283,prostate cancer,DOID,479,PTEN loss,"[{'id': 4117, 'pubMedId': 25514658, 'title': 'Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25514658'}]",sensitive,992,AZD8186,5728
78,Preclinical - Cell culture,"In a preclinical study, treatment with AZD8055 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PTEN loss in culture (PMID: 28446642). ",Actionable,11509,5520,head and neck squamous cell carcinoma,DOID,479,PTEN loss,"[{'id': 9596, 'pubMedId': 28446642, 'title': 'Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28446642'}]",predicted – sensitive,1519,AZD8055,5728
79,Preclinical,"In a preclinical study, the combination of Veliparib (ABT-888) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res Feb 2016 14; B12).",Actionable,4999,60081,triple-receptor negative breast cancer,DOID,479,PTEN loss,"[{'id': 4828, 'pubMedId': None, 'title': 'Co-targeting PTEN-defined TNBC with p110beta-isoform specific inhibitor and PARP inhibitor BMN 673: A predictive context to sensitize PARP inhibitors in TNBC', 'url': 'http://mcr.aacrjournals.org/content/14/2_Supplement/B12.short'}]",sensitive,3720,AZD6482 + Veliparib,5728
80,Preclinical - Cell line xenograft,"In a preclinical study, DETD-35 treatment resulted in reduced tumor size in cell line xenograft models of Zelboraf (vemurafenib)-resistant melanoma harboring PTEN loss (PMID: 27048951).",Actionable,6675,1909,melanoma,DOID,479,PTEN loss,"[{'id': 5730, 'pubMedId': 27048951, 'title': 'A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27048951'}]",sensitive,4230,DETD-35,5728
81,Preclinical - Cell line xenograft,"In a preclinical study, AT13148 inhibited tumor growth in a PTEN-deficient human prostate cancer cell line xenograft model (PMID: 22781553).",Actionable,4785,10283,prostate cancer,DOID,479,PTEN loss,"[{'id': 204, 'pubMedId': 22781553, 'title': 'AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22781553'}]",sensitive,3653,AT13148,5728
82,Preclinical,"In a preclinical study, KU-60019 blocked tumor growth in PTEN-deficient human prostate cancer xenograft models (PMID: 25870146).",Actionable,4781,10283,prostate cancer,DOID,479,PTEN loss,"[{'id': 4736, 'pubMedId': 25870146, 'title': 'Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25870146'}]",sensitive,3652,KU-60019,5728
83,Preclinical - Cell culture,"In a preclinical study, the combination of Zejula (niraparib) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res Feb 2016 14; B12).",Actionable,4996,60081,triple-receptor negative breast cancer,DOID,479,PTEN loss,"[{'id': 4828, 'pubMedId': None, 'title': 'Co-targeting PTEN-defined TNBC with p110beta-isoform specific inhibitor and PARP inhibitor BMN 673: A predictive context to sensitize PARP inhibitors in TNBC', 'url': 'http://mcr.aacrjournals.org/content/14/2_Supplement/B12.short'}]",sensitive,3718,AZD6482 + Niraparib,5728
84,Preclinical,"In a preclinical study, BAY1125976 demonstrated anti-tumor efficacy in multiple xenograft tumor models of different cancers with PIK3CA mutations or PTEN deletions and displayed synergy with other anti-cancer therapies (Cancer Res 2013;73(8 Suppl):Abstract nr 2050).",Actionable,1347,10000003,Advanced Solid Tumor,JAX,479,PTEN loss,"[{'id': 1054, 'pubMedId': None, 'title': 'BAY 1125976, a highly selective and potent allosteric AKT1/2 inhibitor, for the treatment of cancers with aberrations in the PI3K-AKT-mTOR pathway', 'url': 'http://cancerres.aacrjournals.org/content/73/8_Supplement/2050'}]",sensitive,994,BAY1125976,5728
85,Phase II,"In a Phase II trial, Afinitor (everolimus) treatment in patients with advanced solid tumors harboring PTEN loss did not reach its primary endpoint, resulting in only stable disease or progressive disease (PMID: 28330462).",Actionable,10529,10000003,Advanced Solid Tumor,JAX,479,PTEN loss,"[{'id': 8613, 'pubMedId': 28330462, 'title': 'Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28330462'}]",no benefit,735,Everolimus,5728
86,Preclinical,"In a preclinical study, CX-6258 treatment resulted in decreased carcinoma in situ in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174).",Actionable,9330,10283,prostate cancer,DOID,479,PTEN loss,"[{'id': 7070, 'pubMedId': 27486174, 'title': 'The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27486174'}]",predicted – sensitive,3675,CX-6258,5728
87,Clinical Study,"In a clinical study, melanoma patients with PTEN loss demonstrated decreased response to anti–PD-1 antibodies, including Keytruda (pembrolizumab), compared to patients in which PTEN is present (PMID: 26645196). ",Actionable,4449,1909,melanoma,DOID,479,PTEN loss,"[{'id': 4556, 'pubMedId': 26645196, 'title': 'Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26645196'}]",decreased response,1447,Pembrolizumab,5728
88,Preclinical,"In a preclinical study, GSK2636771 inhibited viability of prostate cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493).",Actionable,4975,10283,prostate cancer,DOID,479,PTEN loss,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}]",sensitive,765,GSK2636771,5728
89,Preclinical,"In a preclinical study, the combination of Rubraca (rucaparib) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res Feb 2016 14; B12).",Actionable,4998,60081,triple-receptor negative breast cancer,DOID,479,PTEN loss,"[{'id': 4828, 'pubMedId': None, 'title': 'Co-targeting PTEN-defined TNBC with p110beta-isoform specific inhibitor and PARP inhibitor BMN 673: A predictive context to sensitize PARP inhibitors in TNBC', 'url': 'http://mcr.aacrjournals.org/content/14/2_Supplement/B12.short'}]",sensitive,3721,AZD6482 + Rucaparib,5728
90,Preclinical,"In a preclinical study, KX2-391 and Eloxatin (oxaliplatin) combination treatment did not show improved tumor suppression in xenograft models of ovarian mucinous carcinoma harboring PTEN loss when compared to single agent treatment (PMID: 24100628).",Actionable,5909,6067,ovarian mucinous neoplasm,DOID,479,PTEN loss,"[{'id': 5193, 'pubMedId': 24100628, 'title': 'Targeting SRC and tubulin in mucinous ovarian carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24100628'}]",no benefit,3979,KX2-391 + Oxaliplatin,5728
91,Preclinical - Cell line xenograft,"In a preclinical study, DETD-35 and Zelboraf (vemurafenib) combination treatment resulted in further reduction of tumor size in cell line xenograft models of Zelboraf (vemurafenib)-resistant melanoma harboring PTEN loss when compared to single agent treatment (PMID: 27048951).",Actionable,6676,1909,melanoma,DOID,479,PTEN loss,"[{'id': 5730, 'pubMedId': 27048951, 'title': 'A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27048951'}]",sensitive,4232,DETD-35 + Vemurafenib,5728
92,Preclinical - Pdx,"In a preclinical study, AZD5363 inhibited growth of renal cancer Pdx models with Pten loss (PMID: 22294718).",Actionable,9813,4451,renal carcinoma,DOID,479,PTEN loss,"[{'id': 693, 'pubMedId': 22294718, 'title': 'Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22294718'}]",sensitive,655,AZD5363,5728
93,Phase I,"In a Phase I trial, SAR260301 demonstrated acceptable safety but undesirable pharmacokinetics, and resulted in no response in patients with advanced solid tumors harboring PTEN loss (J Clin Oncol 33, 2015 (suppl; abstr 2564)).",Actionable,5067,10000003,Advanced Solid Tumor,JAX,479,PTEN loss,"[{'id': 4873, 'pubMedId': None, 'title': 'First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).', 'url': 'http://meetinglibrary.asco.org/content/146302-156'}]",no benefit,1052,SAR260301,5728
94,Preclinical,"In a preclinical study, GSK2636771 inhibited viability of breast cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493).",Actionable,4976,1612,breast cancer,DOID,479,PTEN loss,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}]",sensitive,765,GSK2636771,5728
95,Preclinical,"In a preclincal study, mucinous ovarian carcinoma cell lines harboring PTEN loss were less sensitive to KX2-391 induced growth inhibition in culture and tumor suppression in xenograft models (PMID: 24100628).",Actionable,5907,6067,ovarian mucinous neoplasm,DOID,479,PTEN loss,"[{'id': 5193, 'pubMedId': 24100628, 'title': 'Targeting SRC and tubulin in mucinous ovarian carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24100628'}]",decreased response,786,KX2-391,5728
96,Clinical Study,"In a clinical study, the combination of Ipatasertib (GDC-0068) and Zytiga (abiraterone) resulted in a better progression free survival in metastatic castration resistant prostate cancer patients with PTEN loss when compared to placebo combined with Zytiga (abiraterone) (Ann Oncol (2016) 27 (suppl_6): 718O).",Actionable,10246,10283,prostate cancer,DOID,479,PTEN loss,"[{'id': 8227, 'pubMedId': None, 'title': 'PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)', 'url': 'https://academic.oup.com/annonc/article/27/suppl_6/718O/2799456/PTEN-loss-as-a-predictive-biomarker-for-the-Akt'}]",sensitive,5438,Abiraterone + Ipatasertib,5728
97,Preclinical - Cell line xenograft,"In a precliinical study, PTEN deficient prostate carcinoma cells demonstrated reduced response to SAR260301 in cell culture and in cell line xenograft models (PMID: 27196754).",Actionable,7772,10286,prostate carcinoma,DOID,479,PTEN loss,"[{'id': 6491, 'pubMedId': 27196754, 'title': 'Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196754'}]",decreased response,1052,SAR260301,5728
98,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PTEN loss demonstrated resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",Actionable,8905,1612,breast cancer,DOID,479,PTEN loss,"[{'id': 6782, 'pubMedId': 27604488, 'title': 'Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27604488'}]",resistant,691,BYL719,5728
99,Preclinical - Cell line xenograft,"In a preclinical study, a glioblastoma cell line harboring PTEN loss (PMID: 24634413) was sensitive to SF1126, demonstrating a 76% decrease in tumor growth in cell line xenograft models (PMID: 18172313). ",Actionable,10710,10283,prostate cancer,DOID,479,PTEN loss,"[{'id': 8768, 'pubMedId': 24634413, 'title': 'Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24634413'}, {'id': 8775, 'pubMedId': 18172313, 'title': 'A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18172313'}]",sensitive,915,SF1126,5728
100,Preclinical - Cell culture,"In a preclinical study, AZD5363 inhibited growth of various solid tumor cell culture models with loss of Pten (PMID: 22294718).",Actionable,9815,10000003,Advanced Solid Tumor,JAX,479,PTEN loss,"[{'id': 693, 'pubMedId': 22294718, 'title': 'Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22294718'}]",sensitive,655,AZD5363,5728
101,Preclinical,"In a preclinical study, BLZ945 resulted in limited benefit in transgenic mouse models of glioblastoma harboring a loss of PTEN (PMID: 27199435). ",Actionable,8587,3068,glioblastoma multiforme,DOID,479,PTEN loss,"[{'id': 6692, 'pubMedId': 27199435, 'title': 'The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27199435'}]",no benefit,2844,BLZ945,5728
102,Preclinical - Cell culture,"In a preclinical study, GSK2334470 partially restored sensitivity to Zydelig (idelalisib) in diffuse large B-cell lymphoma cells harboring PTEN loss that acquired resistance to Zydelig (idelalisib), resulting in increased apoptosis in culture (PMID: 28178345).",Actionable,11890,50745,diffuse large B-cell lymphoma,DOID,479,PTEN loss,"[{'id': 9819, 'pubMedId': 28178345, 'title': 'PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28178345'}]",predicted – sensitive,6201,GSK2334470 + Idelalisib ,5728
103,Phase II,"In a Phase II trial, 57% (8/14) of transitional cell carcinoma patients that demonstrated uncontrolled disease after treatment with Afinitor (everolimus) harbored PTEN loss compared to 0% of patients with controlled disease demonstrating no evidence of PTEN loss (PMID: 22473592). ",Actionable,10355,2671,transitional cell carcinoma,DOID,479,PTEN loss,"[{'id': 8355, 'pubMedId': 22473592, 'title': 'Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22473592'}]",resistant,735,Everolimus,5728
104,Preclinical,"In a preclinical study, CX-6258 and CX-5461 combination treatment resulted in decreased tumor burden in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174).",Actionable,9331,10283,prostate cancer,DOID,479,PTEN loss,"[{'id': 7070, 'pubMedId': 27486174, 'title': 'The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27486174'}]",predicted – sensitive,4969,CX-5461 + CX-6258,5728
105,Preclinical - Cell culture,"In a preclinical study, MK2206 partially restored sensitivity to Zydelig (idelalisib) in diffuse large B-cell lymphoma cells harboring PTEN loss with acquired resistance to Zydelig (idelalisib), resulting in increased apoptosis in culture (PMID: 28178345).",Actionable,11887,50745,diffuse large B-cell lymphoma,DOID,479,PTEN loss,"[{'id': 9819, 'pubMedId': 28178345, 'title': 'PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28178345'}]",predicted – sensitive,6200,Idelalisib + MK2206,5728
106,Phase I,"In a Phase I trial, AZD8186 demonstrated preliminary efficacy in patients with tumor types with prevalent PTEN-deficiency, including squamous non-small cell lung cancer (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT329).",Actionable,3771,3907,lung squamous cell carcinoma,DOID,479,PTEN loss,"[{'id': 4118, 'pubMedId': None, 'title': 'Phase I study of the PI3K?/? inhibitor AZD8186 in patients with advanced castration resistant prostate cancer, triple negative breast cancer, squamous non-small cell lung cancer or PTEN deficient solid tumors: update from dose-finding', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/CT329.short'}]",predicted – sensitive,992,AZD8186,5728
107,Preclinical - Cell culture,"In a preclinical study, BEZ235 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PTEN loss in culture (PMID: 28446642). ",Actionable,11511,5520,head and neck squamous cell carcinoma,DOID,479,PTEN loss,"[{'id': 9596, 'pubMedId': 28446642, 'title': 'Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28446642'}]",predicted – sensitive,672,BEZ235,5728
108,Preclinical - Cell line xenograft,"In a preclinical study, Panulisib (P7170) inhibited tumor growth in PTEN null prostate cancer cell xenograft models (PMID: 25700704).",Actionable,3772,10283,prostate cancer,DOID,479,PTEN loss,"[{'id': 3487, 'pubMedId': 25700704, 'title': 'P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25700704'}]",sensitive,857,P7170,5728
109,Phase I,"In a Phase I trial, AZD8186 demonstrated preliminary efficacy in patients with tumor types with prevalent PTEN-deficiency, including triple negative breast cancer (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT329).",Actionable,3770,60081,triple-receptor negative breast cancer,DOID,479,PTEN loss,"[{'id': 4118, 'pubMedId': None, 'title': 'Phase I study of the PI3K?/? inhibitor AZD8186 in patients with advanced castration resistant prostate cancer, triple negative breast cancer, squamous non-small cell lung cancer or PTEN deficient solid tumors: update from dose-finding', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/CT329.short'}]",predicted – sensitive,992,AZD8186,5728
110,Preclinical,"In a preclinical study, CX-5461 treatment did not result in histological change in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174).",Actionable,9332,10283,prostate cancer,DOID,479,PTEN loss,"[{'id': 7070, 'pubMedId': 27486174, 'title': 'The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27486174'}]",no benefit,4963,CX-5461,5728
111,Phase I,"In a Phase I trial, the combination of AZD8186 and Vistusertib (AZD2014) resulted in a partial response in a patient with PTEN-deficient colorectal cancer (J Clin Oncol 35, 2017 (suppl; abstr 2570)).",Actionable,11126,9256,colorectal cancer,DOID,479,PTEN loss,"[{'id': 9097, 'pubMedId': None, 'title': 'A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate', 'url': 'http://abstracts.asco.org/199/AbstView_199_183406.html'}]",sensitive,5868,AZD8186 + Vistusertib,5728
112,Preclinical - Cell line xenograft,"In a preclinical study, PKI-402 inhibited tumor growth in PTEN-negative glioblastoma multiforme cell line xenograft models (PMID: 20371716).",Actionable,5402,3068,glioblastoma multiforme,DOID,479,PTEN loss,"[{'id': 5041, 'pubMedId': 20371716, 'title': 'Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20371716'}]",sensitive,3857,PKI-402,5728
113,Preclinical - Cell culture,"In a preclinical study, 10/12 breast cancer cell lines with PTEN loss demonstrated resistance to Afinitor (everolimus) in culture (PMID: 21358673). ",Actionable,10368,1612,breast cancer,DOID,479,PTEN loss,"[{'id': 3638, 'pubMedId': 21358673, 'title': 'PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21358673'}]",resistant,735,Everolimus,5728
114,Preclinical - Cell line xenograft,"In a preclinical study, LY3023414 inhibited Pi3k/mTor signaling and proliferation in PTEN deficient glioblastoma cells in culture, and resulted in tumor growth inhibition in cell line xenograft models (PMID: 27439478).",Actionable,8939,3068,glioblastoma multiforme,DOID,479,PTEN loss,"[{'id': 6792, 'pubMedId': 27439478, 'title': 'Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27439478'}]",sensitive,1069,LY3023414,5728
115,Preclinical - Cell culture,"In a preclinical study, PKI-179 inhibited growth of prostate cancer cells harboring PIK3CA mutations and PTEN loss in culture (PMID: 20797855).",Actionable,8146,10283,prostate cancer,DOID,19846,PIK3CA mutant PTEN loss,"[{'id': 1040, 'pubMedId': 20797855, 'title': 'PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20797855'}]",sensitive,872,PKI-179,5728
116,Preclinical - Pdx,"In a preclinical study, AZD6482 and Alpelisib (BYL719) combination treatment inhibited Akt signaling and growth in a breast cancer patient-derived xenograft (PDX) model harboring a PIK3CA mutation and PTEN loss (Cancer Res October 1, 2014 74; LB-327).",Actionable,4990,1612,breast cancer,DOID,19846,PIK3CA mutant PTEN loss,"[{'id': 4826, 'pubMedId': None, 'title': 'Loss of PTEN leads to clinical resistance to the PI3K? inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/LB-327.short'}]",sensitive,3714,AZD6482 + BYL719,5728
117,Clinical Study,"In a case study, a breast cancer patient harboring a PIK3CA mutation developed resistance to Alpelisib (BYL719) treatment and progressive disease after initial response, accompanied by a loss of PTEN (Cancer Res October 1, 2014 74; LB-327).",Actionable,4983,1612,breast cancer,DOID,19846,PIK3CA mutant PTEN loss,"[{'id': 4826, 'pubMedId': None, 'title': 'Loss of PTEN leads to clinical resistance to the PI3K? inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/LB-327.short'}]",resistant,691,BYL719,5728
118,Preclinical - Pdx,"In a preclinical study, a breast cancer patient-derived xenograft (PDX) model harboring a PIK3CA mutation and PTEN loss was resistant to Alpelisib (BYL719)-induced inhibition of Akt signaling and growth (Cancer Res October 1, 2014 74; LB-327).",Actionable,4988,1612,breast cancer,DOID,19846,PIK3CA mutant PTEN loss,"[{'id': 4826, 'pubMedId': None, 'title': 'Loss of PTEN leads to clinical resistance to the PI3K? inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/LB-327.short'}]",resistant,691,BYL719,5728
119,Preclinical - Pdx,"In a preclinical study, Buparlisib (BKM120) inhibited Akt signaling and growth in a PDX model of breast cancer cells harboring a PIK3CA mutation and PTEN loss ( Cancer Res October 1, 2014 74; LB-327 ).",Actionable,4989,1612,breast cancer,DOID,19846,PIK3CA mutant PTEN loss,"[{'id': 4826, 'pubMedId': None, 'title': 'Loss of PTEN leads to clinical resistance to the PI3K? inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/LB-327.short'}]",sensitive,680,BKM120,5728
120,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of an endometrial cancer cell line harboring PIK3CA R38C and PTEN loss in culture (PMID: 21558396).",Actionable,2955,1380,endometrial cancer,DOID,10741,PIK3CA R38C  PTEN loss,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5728
121,Preclinical,"In a preclinical study, human renal carcinoma cells with PTEN loss and VHL loss had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073).",Actionable,3157,4451,renal carcinoma,DOID,11820,PTEN loss VHL loss,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}]",decreased response,1040,PF-05212384,5728
122,Phase I,"In a Phase I study, a patient with pancreatic adenocarcinoma harboring PTEN loss and KRAS G12D was treated with MK-2206 and demonstrated a 23% reduction in tumor size (PMID: 22025163).",Actionable,2147,4074,pancreatic adenocarcinoma,DOID,5589,PTEN loss KRAS G12D,"[{'id': 175, 'pubMedId': 22025163, 'title': 'First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22025163'}]",sensitive,816,MK2206,5728
123,Preclinical,"In a preclinical study, treatment with AZD5363 improved overall survival and progression-free survival in mouse models of  prostate cancer with inactivated PTEN and TP53 (PMID: 26910118).",Actionable,10888,10283,prostate cancer,DOID,27832,PTEN loss TP53 loss,"[{'id': 8893, 'pubMedId': 26910118, 'title': 'Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26910118'}]",sensitive,655,AZD5363,5728
124,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA E542K and PTEN loss to WEHI-539 in culture (PMID: 27974663).",Actionable,10087,1612,breast cancer,DOID,27243,PIK3CA E542K PTEN loss,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",predicted – sensitive,5377,BEZ235 + WEHI-539,5728
125,Preclinical - Cell line xenograft,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PTEN loss in culture and in cell line xenograft models (PMID: 26272063).",Actionable,8569,9256,colorectal cancer,DOID,26362,BRAF V600E PTEN loss TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,5728
126,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and Selumetinib (AZD6244) (PMID: 21358673).",Actionable,10371,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,"[{'id': 3638, 'pubMedId': 21358673, 'title': 'PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21358673'}]",no benefit,4901,Everolimus + Selumetinib,5728
127,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and U0126 (PMID: 21358673). ",Actionable,10370,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,"[{'id': 3638, 'pubMedId': 21358673, 'title': 'PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21358673'}]",no benefit,5499,Everolimus + U0126,5728
128,Preclinical,"In a preclinical study, human breast cancer cells with wild-type PIK3CA and loss of PTEN were resistant to growth inhibition by AZD8835 in culture (PMID: 26839307).",Actionable,5112,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,"[{'id': 4877, 'pubMedId': 26839307, 'title': 'Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26839307'}]",resistant,2013,AZD8835,5728
129,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of Torkinib (PP242) and U0126 in culture (PMID: 21358673). ",Actionable,10372,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,"[{'id': 3638, 'pubMedId': 21358673, 'title': 'PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21358673'}]",sensitive,5500,Torkinib + U0126,5728
130,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of Torkinib (PP242) and Selumetinib (AZD6244) in culture (PMID: 21358673). ",Actionable,10373,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,"[{'id': 3638, 'pubMedId': 21358673, 'title': 'PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21358673'}]",sensitive,5501,Selumetinib + Torkinib,5728
131,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to WEHI-539 in culture (PMID: 27974663).",Actionable,10085,1612,breast cancer,DOID,27242,PIK3CA H1047R PTEN loss,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",predicted – sensitive,5377,BEZ235 + WEHI-539,5728
132,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to Venclexta (venetoclax) in culture (PMID: 27974663).",Actionable,10082,1612,breast cancer,DOID,27242,PIK3CA H1047R PTEN loss,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",no benefit,5376,BEZ235 + Venetoclax,5728
133,Preclinical - Cell line xenograft,"In a preclinical study, ABT-737 and BEZ235 combination treatment resulted in tumor regression in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663).",Actionable,10091,60081,triple-receptor negative breast cancer,DOID,27242,PIK3CA H1047R PTEN loss,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",predicted – sensitive,5381,ABT-737 + BEZ235,5728
134,Preclinical - Cell line xenograft,"In a preclinical study, ABT-737 and Sapanisertib (MLN0128) combination treatment resulted in inhibition of tumor growth in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663).",Actionable,10097,60081,triple-receptor negative breast cancer,DOID,27242,PIK3CA H1047R PTEN loss,"[{'id': 8002, 'pubMedId': 27974663, 'title': 'PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27974663'}]",predicted – sensitive,5388,ABT-737 + MLN0128,5728
135,Preclinical - Pdx & cell culture,"In a preclinical study, patient-derived EGFR amplified glioblastoma cells harboring PTEN loss demonstrated reduced sensitivity to Dacomitinib induced growth inhibition in culture and in xenograft models (PMID: 25939761).",Actionable,8045,3068,glioblastoma multiforme,DOID,26141,EGFR amp PTEN loss,"[{'id': 6540, 'pubMedId': 25939761, 'title': 'Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25939761'}]",decreased response,714,Dacomitinib,5728
136,Preclinical,"In a preclinical study, Alpelisib (BYL719) and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6106,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",no benefit,4047,BYL719 + NVP-AEW541,5728
137,Preclinical,"In a preclinical study, AZD6482 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6110,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4048,AZD6482 + LGX818,5728
138,Preclinical,"In a preclinical study, Alpelisib (BYL719) and Encorafenib (LGX818) combination treatment did not enhance growth inhibition in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6113,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",no benefit,4049,BYL719 + LGX818,5728
139,Preclinical - Cell culture,"In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6127,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4059,AZD6482 + Binimetinib + BYL719,5728
140,Preclinical,"In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6128,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4060,AZD6482 + Binimetinib + NVP-AEW541,5728
141,Preclinical,"In a preclinical study, Pictilisib (GDC-0941) and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6115,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4053,GDC-0941 + Binimetinib,5728
142,Preclinical,"In a preclinical study, AZD6482 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6117,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4054,AZD6482 + Binimetinib,5728
143,Preclinical,"In a preclinical study, Pictilisib (GDC-0941) and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6109,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4056,GDC-0941 + LGX818,5728
144,Preclinical - Cell line xenograft,"In a preclinical study, combination treatment consisting of GSK2636771, Encorafenib (LGX818), and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",Actionable,6138,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4069,GSK2636771 + LGX818 + unspecified IGF-1R antibody,5728
145,Preclinical,"In a preclinical study, AZD6482 and Alpelisib (BYL719) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6101,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,3714,AZD6482 + BYL719,5728
146,Preclinical - Cell line xenograft,"In a preclinical study, the combination of GSK2636771 and Alpelisib (BYL719) synergized to inhibit proliferation of human melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture, and inhibited tumor growth in xenograft models of one cell line harboring these mutations (PMID: 26577700).",Actionable,6102,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4042,BYL719 + GSK2636771,5728
147,Preclinical,"In a preclincal study, Pictilisib (GDC-0941) inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6099,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,749,GDC-0941,5728
148,Preclinical,"In a preclinical study, GSK2636771 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6118,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4052,GSK2636771 + Binimetinib,5728
149,Preclinical,"In a preclinical study, combination treatment consisting of AZD6482, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6125,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4062,AZD6482 + LGX818 + BYL719,5728
150,Preclinical,"In a preclinical study, Pictilisib (GDC-0941) and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6105,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4046,GDC-0941 + NVP-AEW541,5728
151,Preclinical - Cell line xenograft,"In a preclinical study, the combination of GSK2636771, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently inhibited tumor growth in xenograft models of a human melanoma cell line harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",Actionable,6133,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4065,BYL719 + GSK2636771 + LGX818,5728
152,Preclinical,"In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6130,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4064,AZD6482 + Binimetinib + LGX818 + NVP-AEW541,5728
153,Preclinical,"In a preclincal study, melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations were less sensitive to Alpelisib (BYL719)-induced growth inhibition in culture (PMID: 26577700).",Actionable,6100,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",decreased response,691,BYL719,5728
154,Preclinical,"In a preclinical study, GSK2636771 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6104,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4045,GSK2636771 + NVP-AEW541,5728
155,Preclinical,"In a preclinical study, GSK2636771 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6111,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4055,GSK2636771 + LGX818,5728
156,Preclinical,"In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6131,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4063,AZD6482 + Binimetinib + LGX818 + BYL719,5728
157,Preclinical,"In a preclincal study, AZD6482 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6097,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,659,AZD6482,5728
158,Preclinical,"In a preclinical study, combination treatment consists of AZD6482, Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6126,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4061,AZD6482 + LGX818 + NVP-AEW541,5728
159,Preclinical,"In a preclinical study, AZD6482 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6103,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4044,AZD6482 + NVP-AEW541,5728
160,Preclinical,"In a preclincal study, TGX-221 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6098,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,2514,TGX-221,5728
161,Preclinical - Cell line xenograft,"In a preclinical study, combination treatment consisting of GSK2636771 and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",Actionable,6136,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4067,GSK2636771 + unspecified IGF-1R antibody,5728
162,Preclinical,"In a preclinical study, Alpelisib (BYL719) and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6119,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",no benefit,1311,BYL719 + MEK162,5728
163,Preclinical,"In a preclinical study, combination treatment consists of Encorafenib (LGX818) and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",Actionable,6137,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",sensitive,4068,LGX818 + unspecified IGF-1R antibody,5728
164,Preclinical - Cell culture,"In a preclinical study, small cell lung carcinoma cells harboring PIK3CA D1029Y and PTEN inactivating mutation were resistant to PF-4989216 induced growth inhibition in culture (PMID: 24240111).",Actionable,5214,5409,lung small cell carcinoma,DOID,26219,PIK3CA D1029Y PTEN inact mut,"[{'id': 4924, 'pubMedId': 24240111, 'title': 'Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24240111'}]",resistant,867,PF-4989216,5728
165,Preclinical - Cell line xenograft,"In a preclinical study, a glioblastoma cell line harboring a PTEN inactivating mutation (PMID: 24634413) was sensitive to SF1126, demonstrating inhibition of tumor growth in cell line xenograft models (PMID: 18172313). ",Actionable,10709,3068,glioblastoma multiforme,DOID,2095,PTEN inact mut,"[{'id': 8768, 'pubMedId': 24634413, 'title': 'Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24634413'}, {'id': 8775, 'pubMedId': 18172313, 'title': 'A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18172313'}]",sensitive,915,SF1126,5728
166,Preclinical - Cell culture,"In a preclinical study, AZD5363 inhibited growth of various solid tumor cell culture models with inactivating Pten mutations (PMID: 22294718).",Actionable,9814,10000003,Advanced Solid Tumor,JAX,2095,PTEN inact mut,"[{'id': 693, 'pubMedId': 22294718, 'title': 'Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22294718'}]",sensitive,655,AZD5363,5728
167,Preclinical - Cell culture,"In a preclinical study, a PTEN deficient estrogen-receptor (ER) positive breast cancer cell line demonstrated increased sensitivity to treatment in culture when Pictilisib (GDC-0941) was given at a higher dose for a shorter duration, resulting in inhibition of cell growth (PMID: 26733612). ",Actionable,8366,60075,estrogen-receptor positive breast cancer,DOID,2095,PTEN inact mut,"[{'id': 6631, 'pubMedId': 26733612, 'title': 'Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26733612'}]",sensitive,749,GDC-0941,5728
168,Preclinical - Cell line xenograft,"In a preclinical study, a glioblastoma cell line harboring a PTEN inactivating mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413).",Actionable,10704,3068,glioblastoma multiforme,DOID,2095,PTEN inact mut,"[{'id': 8768, 'pubMedId': 24634413, 'title': 'Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24634413'}]",sensitive,1051,SAR245409,5728
169,Preclinical - Cell line xenograft,"In a preclinical study, LY3023414 inhibited proliferation of renal cancer cells harboring PTEN inactivating mutation in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27439478).",Actionable,8941,263,kidney cancer,DOID,2095,PTEN inact mut,"[{'id': 6792, 'pubMedId': 27439478, 'title': 'Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27439478'}]",sensitive,1069,LY3023414,5728
170,Preclinical - Cell line xenograft,"In a preclinical study, the combination of XL147 and Taxol (paclitaxel) inhibited tumor growth and angiogenesis in xenograft models of a human prostate adenocarcinoma cell line harboring an inactivating mutation in PTEN, with increased efficacy compared to either agent alone (PMID: 25637314).",Actionable,6338,2526,prostate adenocarcinoma,DOID,2095,PTEN inact mut,"[{'id': 5522, 'pubMedId': 25637314, 'title': 'The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25637314'}]",sensitive,4115,XL147 + Paclitaxel,5728
171,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited PI3K signaling, growth, and migration of a human prostate adenocarcinoma cell line harboring a PTEN inactivating mutation in culture, and inhibited tumor growth and vascularization in xenograft models (PMID: 25637314).",Actionable,6322,2526,prostate adenocarcinoma,DOID,2095,PTEN inact mut,"[{'id': 5522, 'pubMedId': 25637314, 'title': 'The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25637314'}]",sensitive,1050,XL147,5728
172,Preclinical - Cell culture,"In a preclinical study, the combination of Faslodex (fulvestrant) and PIctilisib (GDC-0941) resulted in decreased cell viability and increased apoptotic activity in PTEN deficient estrogen-receptor (ER) positive breast cancer cells in culture (PMID: 26733612).",Actionable,8367,60075,estrogen-receptor positive breast cancer,DOID,2095,PTEN inact mut,"[{'id': 6631, 'pubMedId': 26733612, 'title': 'Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26733612'}]",sensitive,4357,Fulvestrant + GDC-0941,5728
173,Preclinical,"In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) did not improve survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",Actionable,9199,9256,colorectal cancer,DOID,26770,APC inact mut PTEN inact mut,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",no benefit,4932,BEZ235 + Binimetinib,5728
174,Preclinical,"In a preclinical study, Binimetinib (MEK162) reduced proliferation in tumors acutely but did not improve survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",Actionable,9192,9256,colorectal cancer,DOID,26770,APC inact mut PTEN inact mut,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",no benefit,807,Binimetinib,5728
175,Preclinical,"In a preclinical study, BEZ235 inhibited  PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",Actionable,9189,9256,colorectal cancer,DOID,26770,APC inact mut PTEN inact mut,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",sensitive,672,BEZ235,5728
176,Preclinical,"In a preclinical study, Binimetinib (MEK162) increased both apoptosis and proliferation in tumors, resulted in no improvement in survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",Actionable,9194,9256,colorectal cancer,DOID,26772,APC inact mut KRAS G12D PTEN inact mut,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",no benefit,807,Binimetinib,5728
177,Preclinical,"In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) increased survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",Actionable,9201,9256,colorectal cancer,DOID,26772,APC inact mut KRAS G12D PTEN inact mut,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",sensitive,4932,BEZ235 + Binimetinib,5728
178,Preclinical,"In a preclinical study, BEZ235 inhibited mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation, and KRAS G12D (PMID: 26206338).",Actionable,9191,9256,colorectal cancer,DOID,26772,APC inact mut KRAS G12D PTEN inact mut,"[{'id': 7007, 'pubMedId': 26206338, 'title': 'Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206338'}]",sensitive,672,BEZ235,5728
179,Preclinical - Cell line xenograft,"In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN inactivating mutations were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111).",Actionable,5215,5409,lung small cell carcinoma,DOID,26218,PIK3CA wild-type PTEN inact mut,"[{'id': 4924, 'pubMedId': 24240111, 'title': 'Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24240111'}]",decreased response,867,PF-4989216,5728
180,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring KRAS G12V and PTEN K6fs*4 in culture (PMID: 27699769).",Actionable,8821,10283,prostate cancer,DOID,26456,KRAS G12V PTEN K6fs*4,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",sensitive,994,BAY1125976,5728
181,Preclinical,"In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to Afinitor (everolimus) compared with cells without KRAS mutations in culture (PMID: 22662154).",Actionable,2140,1380,endometrial cancer,DOID,5418,PIK3CA R88Q PTEN mut KRAS G12V,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",decreased response,735,Everolimus,5728
182,Preclinical,"In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to BEZ235 compared with cells without KRAS mutations in culture (PMID: 22662154).",Actionable,2141,1380,endometrial cancer,DOID,5418,PIK3CA R88Q PTEN mut KRAS G12V,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",decreased response,672,BEZ235,5728
183,Preclinical,"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154).",Actionable,2109,1380,endometrial cancer,DOID,5393,PIK3CA R88Q PTEN mut,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",sensitive,672,BEZ235,5728
184,Preclinical,"In a preclinical study, Afinitor (everolimus) inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154).",Actionable,2110,1380,endometrial cancer,DOID,5393,PIK3CA R88Q PTEN mut,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",sensitive,735,Everolimus,5728
185,Preclinical - Cell line xenograft,"In a preclinical study, Afinitor (everolimus) inhibited growth of endometrial cancer cells harboring a PTEN nonsense mutation in culture and in xenograft models (PMID: 22662154).",Actionable,2138,1380,endometrial cancer,DOID,1213,PTEN mutant,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",sensitive,735,Everolimus,5728
186,Preclinical,"In a preclinical study, A66 and AZD6482 combination treatment inhibited viability of endometrioid endometrial cancer cell lines harboring PTEN mutations in culture (PMID: 23674493).",Actionable,4977,1380,endometrial cancer,DOID,1213,PTEN mutant,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}]",sensitive,3707,A66 + AZD6482,5728
187,Preclinical - Cell line xenograft,"In a preclinical study, BI-69A11 resulted in antitumor activity in a melanoma cell line harboring a PTEN mutation, including induction of cell death in culture, and in xenograft models, tumor growth inhibition and tumor regression (PMID: 19175524). ",Actionable,10291,1909,melanoma,DOID,1213,PTEN mutant,"[{'id': 4138, 'pubMedId': 19175524, 'title': 'BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19175524'}]",sensitive,3308,BI-69A11,5728
188,Phase II,"In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients harboring mutations in PIK3CA, AKT1, or PTEN (J Clin Oncol 35, 2017 (suppl; abstr 1009)).",Actionable,11170,60081,triple-receptor negative breast cancer,DOID,1213,PTEN mutant,"[{'id': 9130, 'pubMedId': None, 'title': 'LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).', 'url': 'http://abstracts.asco.org/199/AbstView_199_183382.html'}]",predicted – sensitive,1588,Ipatasertib + Paclitaxel,5728
189,Preclinical,"In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to GSK2636771 induced growth inhibition in culture (PMID: 23674493).",Actionable,4969,1380,endometrial cancer,DOID,1213,PTEN mutant,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}]",resistant,765,GSK2636771,5728
190,Preclinical - Cell culture,"In a preclinical study, CUDC-907 inhibited growth of breast cancer cells lines harboring Pten mutations and/or deletions (PMID: 22693356).",Actionable,9818,1612,breast cancer,DOID,1213,PTEN mutant,"[{'id': 1018, 'pubMedId': 22693356, 'title': 'Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693356'}]",sensitive,709,CUDC-907,5728
191,Preclinical,"In a preclinical study, Sapanisertib (MLN0128) induced apoptosis and inhibited MTORC1 signaling in breast cancer cells harboring a PTEN mutation (PMID: 25261369).",Actionable,2077,1612,breast cancer,DOID,1213,PTEN mutant,"[{'id': 2380, 'pubMedId': 25261369, 'title': 'Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25261369'}]",sensitive,1282,Sapanisertib,5728
192,Preclinical,"In a preclinical study, uterine cancer cells harboring a PTEN mutation were more sensitive to the combination of GSK2256098 and Hycamtin (topotecan) than uterine cancer cells wild-type for PTEN, resulting in decreased tumor growth in culture and in mouse models (PMID: 25833835). ",Actionable,5566,363,uterine cancer,DOID,1213,PTEN mutant,"[{'id': 4669, 'pubMedId': 25833835, 'title': 'PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25833835'}]",sensitive,3897,GSK2256098 + Topotecan,5728
193,Preclinical,"In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to AZD6482 induced growth inhibition in culture (PMID: 23674493).",Actionable,4970,1380,endometrial cancer,DOID,1213,PTEN mutant,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}]",resistant,659,AZD6482,5728
194,Preclinical,"In a preclinical study, BEZ235 decreased growth of endometrial cancer cells harboring a PTEN nonsense mutation in culture and in xenograft models (PMID: 22662154).",Actionable,2137,1380,endometrial cancer,DOID,1213,PTEN mutant,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",sensitive,672,BEZ235,5728
195,Phase II,"In a Phase II trial, Apitolisib (GDC-0980) was poorly tolerated, but demonstrated efficacy in endometrial cancer patients harboring mutations in PIK3CA, PTEN, or AKT1 (J Clin Oncol 32:5s, 2014 (suppl; abstr 5513)).",Actionable,5204,1380,endometrial cancer,DOID,1213,PTEN mutant,"[{'id': 4913, 'pubMedId': None, 'title': 'Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results.', 'url': 'http://meetinglibrary.asco.org/content/132500-144'}]",sensitive,750,GDC-0980,5728
196,Phase II,"In a retrospective study of a Phase II trial, mutation status of PTEN was not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with Torisel (temsirolimus) (PMID: 27016228).",Actionable,4967,1380,endometrial cancer,DOID,1213,PTEN mutant,"[{'id': 5557, 'pubMedId': 27016228, 'title': 'Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27016228'}]",no benefit,936,Temsirolimus,5728
197,Preclinical,"In a preclinical study, uterine cancer cells harboring a PTEN mutation were more sensitive to the combination of GSK2256098 and Taxol (paclitaxel) than uterine cancer cells wild-type for PTEN, resulting in decreased tumor growth in culture and in mouse models (PMID: 25833835). ",Actionable,5565,363,uterine cancer,DOID,1213,PTEN mutant,"[{'id': 4669, 'pubMedId': 25833835, 'title': 'PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25833835'}]",sensitive,3896,GSK2256098 + Paclitaxel,5728
198,Preclinical,"In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to A66 induced growth inhibition in culture (PMID: 23674493).",Actionable,4972,1380,endometrial cancer,DOID,1213,PTEN mutant,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}]",resistant,617,A66,5728
199,Preclinical - Cell culture,"In a preclinical study, Pictilisib (GDC-0941) and MS417 in combination resulted in improved growth inhibition and increased cell death compared to either agent alone in a PTEN-mutant breast cancer cell line in culture (PMID: 26058079).",Actionable,8599,1612,breast cancer,DOID,1213,PTEN mutant,"[{'id': 6693, 'pubMedId': 26058079, 'title': 'Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26058079'}]",predicted – sensitive,4774,GDC-0941 + MS417,5728
200,Preclinical,"In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to TGX-221 induced growth inhibition in culture (PMID: 23674493).",Actionable,4971,1380,endometrial cancer,DOID,1213,PTEN mutant,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}]",resistant,2514,TGX-221,5728
201,Preclinical,"In a preclinical study, uterine cancer cells harboring a PTEN mutation demonstrated sensitivity to GSK2256098, resulting in inhibition of Ptk2 (Fak) phosphorylation, decreased tumor growth, and apoptosis both in culture and in mouse models (PMID: 25833835).",Actionable,4690,363,uterine cancer,DOID,1213,PTEN mutant,"[{'id': 4669, 'pubMedId': 25833835, 'title': 'PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25833835'}]",sensitive,3078,GSK2256098,5728
202,Preclinical,"In a preclinical study, A66 and GSK2636771 combination treatment inhibited viability of endometrioid endometrial cancer cell lines harboring PTEN mutations in culture (PMID: 23674493).",Actionable,4978,1380,endometrial cancer,DOID,1213,PTEN mutant,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}]",sensitive,3708,A66 + GSK2636771,5728
203,Preclinical - Cell line xenograft,"In a preclinical study, head and neck squamous cell carcinoma cell lines and cell line xenograft models with PTEN alterations were resistant to the apoptotic effects of Taselisib (GDC-0032) (PMID: 26589432).",Actionable,3915,5520,head and neck squamous cell carcinoma,DOID,1213,PTEN mutant,"[{'id': 4291, 'pubMedId': 26589432, 'title': 'Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26589432'}]",resistant,1016,GDC-0032,5728
204,Preclinical - Cell line xenograft,"In a preclinical study, a melanoma cell line xenograft model co-harboring BRAF V600E and a PTEN mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).",Actionable,11043,1909,melanoma,DOID,27896,BRAF V600E PTEN mut,"[{'id': 9035, 'pubMedId': None, 'title': 'Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/B100.short'}]",sensitive,5827,ASN003,5728
205,Preclinical - Cell line xenograft,"In a preclinical study, E6201 resulted in a cytostatic response in melanoma cell lines harboring both BRAF and PTEN mutations in culture and only inhibited tumor growth at very high doses in cell line xenograft models (PMID: 23039341).",Actionable,5628,1909,melanoma,DOID,21306,BRAF mut PTEN mut,"[{'id': 1840, 'pubMedId': 23039341, 'title': 'Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23039341'}]",decreased response,1011,E6201,5728
206,Preclinical,"In a preclinical study, BEZ235 decreased growth of endometrial cancer cells harboring PIK3CA R38C and PTEN mutations in culture and in xenograft models (PMID: 22662154).",Actionable,2112,1380,endometrial cancer,DOID,5397,PIK3CA R38C PTEN mut,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",sensitive,672,BEZ235,5728
207,Preclinical - Cell culture,"In a preclinical study, the combination of ONC201 (TIC10) and Navitoclax (ABT-263) increased apoptosis and worked synergistically to inhibit proliferation of a glioblastoma cell line harboring mutations in PTEN and TP53 in culture (PMID: 26474387).",Actionable,9825,3068,glioblastoma multiforme,DOID,5387,PTEN mutant TP53 mutant,"[{'id': 7647, 'pubMedId': 26474387, 'title': 'TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26474387'}]",sensitive,5245,Navitoclax + ONC201,5728
208,Preclinical,"In a preclinical study, a skin cancer cell line harboring mutations in PTEN and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369). ",Actionable,2104,4159,skin cancer,DOID,5387,PTEN mutant TP53 mutant,"[{'id': 2380, 'pubMedId': 25261369, 'title': 'Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25261369'}]",sensitive,1282,Sapanisertib,5728
209,Preclinical,"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA E365K and PTEN mutations in culture (PMID: 22662154).",Actionable,2113,1380,endometrial cancer,DOID,5401,PIK3CA E365K PTEN mut,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",sensitive,672,BEZ235,5728
210,Preclinical,"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA E365K and PTEN mutations in culture (PMID: 22662154).",Actionable,2139,7519,endocervical carcinoma,DOID,5401,PIK3CA E365K PTEN mut,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",sensitive,672,BEZ235,5728
211,Preclinical,"In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369). ",Actionable,2106,4159,skin cancer,DOID,5389,PTEN mut RB1 mut SMAD4 mut TP53 mut,"[{'id': 2380, 'pubMedId': 25261369, 'title': 'Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25261369'}]",sensitive,1282,Sapanisertib,5728
212,Preclinical,"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R108H and PTEN mutations in culture (PMID: 22662154).",Actionable,2111,1380,endometrial cancer,DOID,5394,PIK3CA R108H PTEN mut,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",sensitive,672,BEZ235,5728
213,Phase I,"In a Phase I clinical trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on Herceptin (trastuzumab)-based therapy (PMID: 24470511).",Actionable,4370,60079,Her2-receptor positive breast cancer,DOID,23651,ERBB2 pos PTEN mut,"[{'id': 196, 'pubMedId': 24470511, 'title': 'Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24470511'}]",predicted – sensitive,1417,BKM120 + Trastuzumab,5728
214,Preclinical - Cell line xenograft,"In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN R55fs*1 were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111).",Actionable,8286,5409,lung small cell carcinoma,DOID,26222,PIK3CA wild-type PTEN R55fs*1,"[{'id': 4924, 'pubMedId': 24240111, 'title': 'Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24240111'}]",resistant,867,PF-4989216,5728
215,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA H1047R and PTEN E307K in culture (PMID: 27699769).",Actionable,8819,1612,breast cancer,DOID,26449,PIK3CA H1047R PTEN E307K,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",sensitive,994,BAY1125976,5728
216,Preclinical - Cell culture,"In a preclinical study, the combination of BGJ398 and Buparlisib (BKM120) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489). ",Actionable,10778,1380,endometrial cancer,DOID,27771,FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23,"[{'id': 8811, 'pubMedId': 28119489, 'title': 'PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2(mutant) Endometrial Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28119489'}]",sensitive,5612,BGJ398 + BKM120,5728
217,Preclinical - Cell culture,"In a preclinical study, the combination of BGJ398 and Alpelisib (BYL719) resulted in a synergistic effect, demonstrating inhibition of cell proliferation and induced cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489). ",Actionable,10780,1380,endometrial cancer,DOID,27771,FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23,"[{'id': 8811, 'pubMedId': 28119489, 'title': 'PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2(mutant) Endometrial Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28119489'}]",sensitive,1293,BGJ398 + BYL719,5728
218,Preclinical - Cell culture,"In a preclinical study, the combination of BGJ398 and Pictilisib (GDC-0941) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489). ",Actionable,10777,1380,endometrial cancer,DOID,27771,FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23,"[{'id': 8811, 'pubMedId': 28119489, 'title': 'PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2(mutant) Endometrial Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28119489'}]",sensitive,5613,BGJ398 + GDC-0941,5728
219,Phase II,"In a Phase II trial, a patient with head and neck squamous cell carcinoma harboring PTEN R130Q demonstrated a partial response when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834). ",Actionable,12185,5520,head and neck squamous cell carcinoma,DOID,4174,PTEN R130Q,"[{'id': 10139, 'pubMedId': 28961834, 'title': 'A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28961834'}]",predicted – sensitive,6333,Carboplatin + Paclitaxel + Temsirolimus,5728
220,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PTEN C136Y demonstrated resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",Actionable,8904,1612,breast cancer,DOID,3852,PTEN C136Y,"[{'id': 6782, 'pubMedId': 27604488, 'title': 'Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27604488'}]",resistant,691,BYL719,5728
221,Preclinical - Cell line xenograft,"In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN Y27fs*1 were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111).",Actionable,8285,5409,lung small cell carcinoma,DOID,26223,PIK3CA wild-type PTEN Y27fs*1,"[{'id': 4924, 'pubMedId': 24240111, 'title': 'Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24240111'}]",resistant,867,PF-4989216,5728
222,Preclinical,"In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).",Actionable,6037,3068,glioblastoma multiforme,DOID,22287,EGFR amp EGFR act mut PTEN R308C,"[{'id': 5255, 'pubMedId': 26561558, 'title': 'InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26561558'}]",sensitive,4008,Gefitinib + Linsitinib,5728
223,Preclinical,"In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).",Actionable,6045,3068,glioblastoma multiforme,DOID,22287,EGFR amp EGFR act mut PTEN R308C,"[{'id': 5255, 'pubMedId': 26561558, 'title': 'InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26561558'}]",sensitive,4009,BMS-754807 + Dacomitinib,5728
224,Preclinical,"In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR (A289T, EGFRvIII) and PTEN (N69D, I253N) mutations in culture (PMID: 26561558).",Actionable,6046,3068,glioblastoma multiforme,DOID,22288,EGFR act mut EGFR A289T PTEN I253N PTEN N69D,"[{'id': 5255, 'pubMedId': 26561558, 'title': 'InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26561558'}]",sensitive,4009,BMS-754807 + Dacomitinib,5728
225,Preclinical,"In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring mutations in EGFR (EGFRvIII, A289T) and PTEN (I253N, N69D) in culture (PMID: 26561558).",Actionable,6038,3068,glioblastoma multiforme,DOID,22288,EGFR act mut EGFR A289T PTEN I253N PTEN N69D,"[{'id': 5255, 'pubMedId': 26561558, 'title': 'InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26561558'}]",sensitive,4008,Gefitinib + Linsitinib,5728
226,Preclinical - Cell line xenograft,"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring KRAS G13C, PIK3CA H1047Y, PTEN G143fs*4, and PTEN K267fs*9 was sensitive to treatment with DS-7423, demonstrating inhibition of cell proliferation in culture and tumor growth inhibition in xenograft models (PMID: 24504419). ",Actionable,10541,5304,ovarian clear cell adenocarcinoma,DOID,27593,KRAS G13C PIK3CA H1047Y PTEN G143fs*4 PTEN K267fs*9,"[{'id': 4912, 'pubMedId': 24504419, 'title': 'Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24504419'}]",sensitive,722,DS-7423,5728
227,Preclinical - Cell culture,"In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including an follicular thyroid cancer cell line harboring PTEN R130* and loss of one PTEN allele (PMID: 21289267).",Actionable,8215,3962,follicular thyroid carcinoma,DOID,4166,PTEN R130*,"[{'id': 6573, 'pubMedId': 21289267, 'title': 'The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21289267'}]",sensitive,816,MK2206,5728
228,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a human glioblastoma cell line harboring PTEN V54fs (PMID: 25637314).",Actionable,6317,3068,glioblastoma multiforme,DOID,23098,PTEN V54fs,"[{'id': 5522, 'pubMedId': 25637314, 'title': 'The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25637314'}]",sensitive,1050,XL147,5728
229,Preclinical - Pdx,"In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and BEZ235 resulted in stable disease in patient-derived xenograft (PDX) models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, and PTEN R130G, and demonstrated improved efficacy over either agent alone (PMID: 26232337).",Actionable,9373,1380,endometrial cancer,DOID,26839,KRAS G12D PIK3CA H1047R PTEN R130G,"[{'id': 7135, 'pubMedId': 26232337, 'title': 'Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26232337'}]",sensitive,1420,Selumetinib + BEZ235,5728
230,Preclinical - Pdx,"In a preclinical study, treatment with BEZ235 slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).",Actionable,9375,1380,endometrial cancer,DOID,26839,KRAS G12D PIK3CA H1047R PTEN R130G,"[{'id': 7135, 'pubMedId': 26232337, 'title': 'Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26232337'}]",sensitive,672,BEZ235,5728
231,Preclinical - Pdx,"In a preclinical study, treatment with Selumetinib (AZD6244) slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).",Actionable,9374,1380,endometrial cancer,DOID,26839,KRAS G12D PIK3CA H1047R PTEN R130G,"[{'id': 7135, 'pubMedId': 26232337, 'title': 'Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26232337'}]",sensitive,913,Selumetinib,5728
232,Preclinical - Pdx,"In a preclinical study, a patient-derived xenograft (PDX) model of endometrial cancer harboring PIK3CA D350G, PIK3CA R93W, and PTEN R130G was sensitive to ARQ092, demonstrating greater than 90% inhibition of tumor growth (PMID: 26469692). ",Actionable,10283,1380,endometrial cancer,DOID,27339,PIK3CA D350G PIK3CA R93W PTEN R130G,"[{'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",sensitive,635,ARQ092,5728
233,Preclinical,"In a preclinical study, GSK2636771 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6122,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",no benefit,4052,GSK2636771 + Binimetinib,5728
234,Preclinical,"In a preclinical study, AZD6482 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6107,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",no benefit,4044,AZD6482 + NVP-AEW541,5728
235,Preclinical,"In a preclinical study, GSK2636771 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6108,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",no benefit,4045,GSK2636771 + NVP-AEW541,5728
236,Preclinical,"In a preclinical study, GSK2636771 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6124,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",no benefit,4055,GSK2636771 + LGX818,5728
237,Preclinical,"In a preclinical study, AZD6482 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6123,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",no benefit,4048,AZD6482 + LGX818,5728
238,Preclinical,"In a preclinical study, AZD6482 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6121,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,"[{'id': 5314, 'pubMedId': 26577700, 'title': 'Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26577700'}]",no benefit,4054,AZD6482 + Binimetinib,5728
239,Preclinical - Cell line xenograft,"In a preclinical study, E6201 resulted in a cytocidal response in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture and inhibited tumor growth in cell line xenograft models (PMID: 23039341).",Actionable,5629,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,"[{'id': 1840, 'pubMedId': 23039341, 'title': 'Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23039341'}]",sensitive,1011,E6201,5728
240,Preclinical - Cell culture,"In a preclinical study, 8/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Afinitor (everolimus) in culture, resulting in decreased cell viability (PMID: 21358673). ",Actionable,10365,1612,breast cancer,DOID,27384,PIK3CA act mut PTEN wild-type,"[{'id': 3638, 'pubMedId': 21358673, 'title': 'PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21358673'}]",sensitive,735,Everolimus,5728
241,Preclinical - Cell culture,"In a preclinical study, 9/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Torkinib (PP242) in culture, resulting in decreased cell viability (PMID: 21358673). ",Actionable,10366,1612,breast cancer,DOID,27384,PIK3CA act mut PTEN wild-type,"[{'id': 3638, 'pubMedId': 21358673, 'title': 'PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21358673'}]",sensitive,2240,Torkinib,5728
242,Preclinical - Cell line xenograft,"In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA H1047R, PIK3CA K111R, and wild-type PTEN in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111).",Actionable,5218,5409,lung small cell carcinoma,DOID,20308,PIK3CA H1047R PIK3CA K111R PTEN wild-type,"[{'id': 4924, 'pubMedId': 24240111, 'title': 'Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24240111'}]",sensitive,867,PF-4989216,5728
243,Preclinical - Cell line xenograft,"In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA G106_R108del and wild-type PTEN in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111).",Actionable,5217,5409,lung small cell carcinoma,DOID,20307,PIK3CA G106_R108del PTEN wild-type,"[{'id': 4924, 'pubMedId': 24240111, 'title': 'Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24240111'}]",sensitive,867,PF-4989216,5728
244,Preclinical,"In a preclinical study, KX2-391 inhibited survival of PTEN wild-type mucinous ovarian carcinoma cell lines in culture, and reduced tumor growth in xenograft models (PMID: 24100628).",Actionable,5905,6067,ovarian mucinous neoplasm,DOID,683,PTEN wild-type,"[{'id': 5193, 'pubMedId': 24100628, 'title': 'Targeting SRC and tubulin in mucinous ovarian carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24100628'}]",sensitive,786,KX2-391,5728
245,Preclinical,"In a preclinical study, 2-Methoxyestradiol (2ME2) inhibited tumor-induced angiogenesis and reduced tumor growth in PTEN reconstituted GBM cell lines and mouse models (PMID: 24162827).",Actionable,848,3068,glioblastoma multiforme,DOID,683,PTEN wild-type,"[{'id': 492, 'pubMedId': 24162827, 'title': 'PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24162827'}]",sensitive,1341,2-Methoxyestradiol ,5728
246,Preclinical,"In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and sensitivity was associated with wild-type PTEN (PMID: 23039341).",Actionable,4079,1909,melanoma,DOID,683,PTEN wild-type,"[{'id': 1840, 'pubMedId': 23039341, 'title': 'Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23039341'}]",sensitive,1011,E6201,5728
247,Preclinical,"In a preclinical study, KX2-391 and Eloxatin (oxaliplatin) synergistically inhibited survival of PTEN wild-type mucinous ovarian carcinoma cell lines in culture, and reduced tumor growth in xenograft models (PMID: 24100628).",Actionable,5906,6067,ovarian mucinous neoplasm,DOID,683,PTEN wild-type,"[{'id': 5193, 'pubMedId': 24100628, 'title': 'Targeting SRC and tubulin in mucinous ovarian carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24100628'}]",sensitive,3979,KX2-391 + Oxaliplatin,5728
248,Preclinical,"In a preclinical study, GSK2256098 treatment resulted in a decreased response in uterine cancer cells with PTEN wild-type versus uterine cancer cells harboring a PTEN mutation (PMID: 25833835).",Actionable,4691,363,uterine cancer,DOID,683,PTEN wild-type,"[{'id': 4669, 'pubMedId': 25833835, 'title': 'PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25833835'}]",decreased response,3078,GSK2256098,5728
249,Preclinical,"In a preclinical study, AZD8186 and Alpelisib (BYL719) combination treatment resulted in minor inhibition of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).",Actionable,5091,10283,prostate cancer,DOID,2408,PTEN del,"[{'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",sensitive,3749,AZD8186 + BYL719,5728
250,Preclinical,"In a preclinical study, Rubraca (rucaparib) induced senescence and increased radiosensitivity in PTEN null prostate cancer cells in culture (PMID: 23565244).",Actionable,2700,10283,prostate cancer,DOID,2408,PTEN del,"[{'id': 3425, 'pubMedId': 23565244, 'title': 'PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23565244'}]",sensitive,906,Rucaparib,5728
251,Preclinical,"In a preclinical study, head and neck squamous cell carcinoma cells homozygous for PTEN deletion were resistant to Taselisib (GDC-0032) in culture (PMID: 26589432).",Actionable,5867,5520,head and neck squamous cell carcinoma,DOID,2408,PTEN del,"[{'id': 4291, 'pubMedId': 26589432, 'title': 'Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26589432'}]",resistant,1016,GDC-0032,5728
252,Preclinical - Cell culture,"In a preclinical study, CUDC-907 inhibited growth of breast cancer cells lines harboring Pten mutations and/or deletions (PMID: 22693356).",Actionable,9819,1612,breast cancer,DOID,2408,PTEN del,"[{'id': 1018, 'pubMedId': 22693356, 'title': 'Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693356'}]",sensitive,709,CUDC-907,5728
253,Phase I,"In a Phase I trial, AZD8186 demonstrated preliminary efficacy in patients with tumor types with prevalent PTEN-deficiency, including prostate cancer (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT329).",Actionable,3769,10283,prostate cancer,DOID,2408,PTEN del,"[{'id': 4118, 'pubMedId': None, 'title': 'Phase I study of the PI3K?/? inhibitor AZD8186 in patients with advanced castration resistant prostate cancer, triple negative breast cancer, squamous non-small cell lung cancer or PTEN deficient solid tumors: update from dose-finding', 'url': 'http://cancerres.aacrjournals.org/content/75/15_Supplement/CT329.short'}]",predicted – sensitive,992,AZD8186,5728
254,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 induced tumor regression in xenograft models of a human stomach cancer cell line with deletion of PTEN (PMID: 21558396).
",Actionable,2971,10534,stomach cancer,DOID,2408,PTEN del,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5728
255,Preclinical,"In a preclinical study, AZD8186 and XTANDI (enzalutamide) combination treatment resulted in suppression of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).",Actionable,5093,10283,prostate cancer,DOID,2408,PTEN del,"[{'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",sensitive,3752,AZD8186 + Enzalutamide,5728
256,Preclinical - Cell line xenograft,"In a preclinical study, VS-5584 inhibited PI3K/mTOR signaling and cell proliferation in a human prostate cancer cell line harboring a PTEN deletion in culture, and inhibited PI3K/MTOR signaling and tumor growth in xenograft models (PMID: 23270925).",Actionable,2509,10283,prostate cancer,DOID,2408,PTEN del,"[{'id': 351, 'pubMedId': 23270925, 'title': 'VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23270925'}]",not applicable,960,VS-5584,5728
257,Preclinical,"In a preclinical study, AZD8186, Alpelisib (BYL719), and Xtandi (enzalutamide) combination treatment resulted in near-complete suppression of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).",Actionable,5092,10283,prostate cancer,DOID,2408,PTEN del,"[{'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",sensitive,3750,AZD8186 + BYL719 + Enzalutamide,5728
258,Preclinical - Cell line xenograft,"In a preclinical study, prostate cancer cell line xenograft models with PTEN deletion demonstrated sensitivity to treatment with Ipatasertib (GDC-0068), resulting in inhibition of tumor growth (PMID: 24141624). ",Actionable,8965,10283,prostate cancer,DOID,2408,PTEN del,"[{'id': 191, 'pubMedId': 24141624, 'title': 'Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141624'}]",sensitive,747,Ipatasertib,5728
259,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human prostate cancer cells harboring PTEN deletion in culture (PMID: 21325073, PMID: 14737113).",Actionable,3138,10283,prostate cancer,DOID,2408,PTEN del,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3644, 'pubMedId': 14737113, 'title': 'PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/14737113'}]",sensitive,1040,PF-05212384,5728
260,Preclinical,"In a preclinical study, bladder cancer cells with PTEN deletion were sensitive to Glucophage (metformin) in culture, resulting in inhibition of cell growth (PMID: 26921394). ",Actionable,5176,11054,urinary bladder cancer,DOID,2408,PTEN del,"[{'id': 4943, 'pubMedId': 26921394, 'title': 'High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26921394'}]",sensitive,1031,Metformin,5728
261,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited tumor growth in xenograft models of a human prostate cancer cell line with deletion of PTEN (PMID: 21558396).",Actionable,2972,10283,prostate cancer,DOID,2408,PTEN del,"[{'id': 1985, 'pubMedId': 21558396, 'title': 'The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21558396'}]",sensitive,2152,CH5132799,5728
262,Preclinical,"In a preclinical study, GDC-0941 and Zolinza (vorinostat) acted synergistically to inhibit growth of a human prostate cancer cell line harboring a PTEN deletion in culture (PMID: 9661880, PMID: 22693356).",Actionable,3009,10283,prostate cancer,DOID,2408,PTEN del,"[{'id': 1018, 'pubMedId': 22693356, 'title': 'Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22693356'}, {'id': 3569, 'pubMedId': 9661880, 'title': 'Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/9661880'}]",sensitive,3070,GDC-0941 + vorinostat,5728
263,Phase I,"In a Phase I trial, CC-223 demonstrated safety and preliminary efficacy in patients with solid tumors, including stable disease for greater than 110 days in 2 patients with PIK3CA mutation or PTEN deletion (PMID: 26177599).",Actionable,4498,10000003,Advanced Solid Tumor,JAX,2408,PTEN del,"[{'id': 3493, 'pubMedId': 26177599, 'title': 'A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26177599'}]",sensitive,693,CC-223,5728
264,Preclinical - Cell line xenograft,"In a preclinical study, PF-04691502 inhibited tumor growth in PTEN-deleted non-small cell lung cancer cell line xenograft models (PMID: 21750219).
",Actionable,106,3908,non-small cell lung carcinoma,DOID,2408,PTEN del,"[{'id': 226, 'pubMedId': 21750219, 'title': 'PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21750219'}]",predicted – sensitive,865,PF-04691502,5728
265,Phase I,"In a Phase I trial, patients with advanced solid tumors deficient in PTEN lacked benefit from GSK2636771 (PMID: 26117819).",Actionable,3731,10000003,Advanced Solid Tumor,JAX,2408,PTEN del,"[{'id': 4036, 'pubMedId': 26117819, 'title': 'Drugging PI3K in cancer: refining targets and therapeutic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26117819'}]",no benefit,765,GSK2636771,5728
266,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PTEN L108R in culture (PMID: 27699769).",Actionable,8816,1612,breast cancer,DOID,4086,PTEN L108R,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",sensitive,994,BAY1125976,5728
267,Preclinical - Cell culture,"In a preclinical study, DHM25 increased cell death in a breast cancer cell line harboring PTEN L108R in culture (PMID: 26237138).",Actionable,10359,1612,breast cancer,DOID,4086,PTEN L108R,"[{'id': 8367, 'pubMedId': 26237138, 'title': 'A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26237138'}]",sensitive,5494,DHM25,5728
268,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PTEN T319fs*1 in culture (PMID: 27699769).",Actionable,8817,1612,breast cancer,DOID,4239,PTEN T319fs*1,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",sensitive,994,BAY1125976,5728
269,Phase I,"In a Phase I clinical trial, Refametinib (BAY 86-9766) demonstrated preliminary clinical activity in patients with several tumor types, including prolonged stable disease in an ocular melanoma patient harboring GNAQ Q209L and PTEN R173S (PMID: 23434733).",Actionable,10644,1752,ocular melanoma,DOID,27655,GNAQ Q209L PTEN R173S,"[{'id': 1066, 'pubMedId': 23434733, 'title': 'Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23434733'}]",predicted – sensitive,888,Refametinib,5728
270,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) inhibited Akt signaling and cell migration in prostate cancer cells expressing PTEN A126G in culture (PMID: 26504226).",Actionable,4906,10283,prostate cancer,DOID,19788,PTEN A126G,"[{'id': 4785, 'pubMedId': 26504226, 'title': 'Discovery and functional characterization of a neomorphic PTEN mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26504226'}]",sensitive,691,BYL719,5728
271,Preclinical,"In a preclinical study, AZD6482 inhibited Akt signaling and cell migration in prostate cancer cell lines overexpressing PTEN A126G (PMID: 26504226).",Actionable,4907,10283,prostate cancer,DOID,19788,PTEN A126G,"[{'id': 4785, 'pubMedId': 26504226, 'title': 'Discovery and functional characterization of a neomorphic PTEN mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26504226'}]",sensitive,659,AZD6482,5728
0,Preclinical - Cell culture,"In a preclinical study, knocking down of Ptpn11 expression via shRNA sensitized BRAF mutant colorectal cancer cell lines to PLX4720 in culture (PMID: 26351322).",Actionable,8668,9256,colorectal cancer,DOID,26402,BRAF mut PTPN11 dec exp,"[{'id': 6708, 'pubMedId': 26351322, 'title': 'Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26351322'}]",sensitive,1060,PLX4720,5781
1,Preclinical,"In a preclinical study, Rafemetinib (BAY86-9766) inhibited growth of NSCLC cells harboring activating PTPN11 mutations in culture (J Clin Oncol 33, 2015(Suppl; abstr 11077)). ",Actionable,2639,3908,non-small cell lung carcinoma,DOID,9820,PTPN11 act mut,"[{'id': 3363, 'pubMedId': None, 'title': 'Protein tyrosine phosphatase non receptor 11 (PTPN11/Shp2) as a driver oncogene and a novel therapeutic target in non-small cell lung cancer (NSCLC)', 'url': 'http://meetinglibrary.asco.org/content/147146-156'}]",sensitive,888,Refametinib,5781
2,Preclinical,"In a preclinical study, hematopoietic progenitor cells expressing PTPN11 E76K were sensitive to II-B08, resulting in decreased cell proliferation (PMID: 20170098).",Actionable,3984,2531,hematologic cancer,DOID,9830,PTPN11 E76K,"[{'id': 3348, 'pubMedId': 20170098, 'title': 'Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20170098'}]",sensitive,2963,II-B08,5781
3,Preclinical,"In a preclinical study, U0126 induced apoptotic activity of leukemia cells expressing PTPN11 E76K in culture (PMID: 17942397).",Actionable,2640,1240,leukemia,DOID,9830,PTPN11 E76K,"[{'id': 3365, 'pubMedId': 17942397, 'title': 'Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17942397'}]",sensitive,2427,U0126,5781
4,Preclinical,"In a preclinical study, myeloid cells harboring PTPN11 E76K were sensitive to cryptotanshinone in culture, resulting in decreased cell growth (PMID: 23957426).",Actionable,3983,50458,juvenile myelomonocytic leukemia,DOID,9830,PTPN11 E76K,"[{'id': 4300, 'pubMedId': 23957426, 'title': 'Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23957426'}]",sensitive,3415,cryptotanshinone,5781
5,Preclinical,"In a preclinical study, PD98059 induced apoptotic activity of leukemia cells expressing PTPN11 E76K in culture (PMID: 17942397).",Actionable,2641,1240,leukemia,DOID,9830,PTPN11 E76K,"[{'id': 3365, 'pubMedId': 17942397, 'title': 'Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17942397'}]",sensitive,2617,PD98059,5781
6,Clinical Study,"In two clinical studies, PTPN11 mutations were frequently identified in patients with juvenile myelomonocytic leukemia and were found to be associated with poor survival (PMID: 19047918, PMID: 21901340), suggesting that this may serve as a future prognostic biomarker.",Emerging,3817,50458,juvenile myelomonocytic leukemia,DOID,9821,PTPN11 mutant,"[{'id': 4191, 'pubMedId': 19047918, 'title': 'Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19047918'}, {'id': 5428, 'pubMedId': 21901340, 'title': 'Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21901340'}]",not applicable,1776,N/A,5781
0,Preclinical,"In a preclinical study, siRNA inhibition of RAD21 in breast cancer cells resulted in increased sensitivity to Toposaur (etoposide) in culture, suggesting RAD21 may be a potential therapeutic target for enhanced sensitivity to chemotherapeutics (PMID: 15767545). ",Emerging,6484,1612,breast cancer,DOID,23596,RAD21 wild-type,"[{'id': 5649, 'pubMedId': 15767545, 'title': 'Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15767545'}]",not applicable,1776,N/A,5885
0,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and NOTCH1 resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, however, survival did not differ between xenograft models treated with the combination or Kisqali (ribociclib) alone (PMID: 28151717). ",Actionable,10044,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",conflicting,5355,Ribociclib + Dexamethasone,5925
1,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10034,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",decreased response,5352,Ribociclib + Methotrexate,5925
2,Preclinical - Cell culture,"In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 demonstrated sensitivity to treatment with Kisqali (ribociclib) in culture, resulting in inhibition of cell growth (PMID: 28151717). ",Actionable,10032,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,790,Ribociclib,5925
3,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture, and prolonged survival in cell-line xenograft models (PMID: 28151717). ",Actionable,10049,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,5073,Ribociclib + Everolimus,5925
4,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10042,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",decreased response,5354,Ribociclib + Asparaginase,5925
5,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10047,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,5356,Ribociclib + Prednisolone,5925
6,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10053,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,5358,Ribociclib + Bortezomib,5925
7,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10051,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,5357,Ribociclib + JQ1,5925
8,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10036,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",decreased response,5353,Ribociclib + Mercaptopurine,5925
9,Preclinical,"In a preclinical study, R547 inhibited proliferation of osteosarcoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).",Actionable,4359,3347,osteosarcoma,DOID,17822,TP53 mutant RB1 wild-type,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,5925
10,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4352,3459,breast carcinoma,DOID,17822,TP53 mutant RB1 wild-type,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,5925
11,Preclinical,"In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).",Actionable,4355,1520,colon carcinoma,DOID,17822,TP53 mutant RB1 wild-type,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,5925
12,Preclinical,"In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).",Actionable,4361,50746,mantle cell lymphoma,DOID,17822,TP53 mutant RB1 wild-type,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,5925
13,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10035,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",decreased response,5353,Ribociclib + Mercaptopurine,5925
14,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, and a greater survival benefit in xenograft models when compared to Kisqali (ribociclib) alone (PMID: 28151717). ",Actionable,10043,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,5355,Ribociclib + Dexamethasone,5925
15,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10050,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,5357,Ribociclib + JQ1,5925
16,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10033,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",decreased response,5352,Ribociclib + Methotrexate,5925
17,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10046,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,5356,Ribociclib + Prednisolone,5925
18,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture (PMID: 28151717). ",Actionable,10048,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,5073,Ribociclib + Everolimus,5925
19,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10037,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",decreased response,5354,Ribociclib + Asparaginase,5925
20,Preclinical - Cell culture,"In a preclinical study, a T-cell acute lymphoblastic leukemia cell line co-harboring wild-type RB1 and a NOTCH1 mutation demonstrated sensitivity to treatment with Kisqali (ribociclib) in culture, resulting in inhibition of cell growth (PMID: 28151717). ",Actionable,10031,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,790,Ribociclib,5925
21,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10052,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",sensitive,5358,Ribociclib + Bortezomib,5925
22,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of melanoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4360,1909,melanoma,DOID,17823,TP53 wild-type RB1 wild-type,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,5925
23,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4354,1520,colon carcinoma,DOID,17823,TP53 wild-type RB1 wild-type,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,5925
24,Preclinical,"In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911).",Actionable,4353,3459,breast carcinoma,DOID,17823,TP53 wild-type RB1 wild-type,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,5925
25,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of lung carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4356,3905,lung carcinoma,DOID,17823,TP53 wild-type RB1 wild-type,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,5925
26,Preclinical,"In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911).",Actionable,4362,50746,mantle cell lymphoma,DOID,17823,TP53 wild-type RB1 wild-type,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,5925
27,Preclinical,"In a preclinical study, Sirolimus (rapamycin) decreased tumor occurrence, tumor hypoxia and  tumor vascularization in a retinoblastoma mouse model with functionally inactivated Rb protein (PMID: 21468343, PMID: 1689463).
",Actionable,1153,768,retinoblastoma,DOID,2007,RB1 loss,"[{'id': 904, 'pubMedId': 21468343, 'title': 'Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21468343'}, {'id': 905, 'pubMedId': 1689463, 'title': 'Retinoblastoma in transgenic mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/1689463'}]",sensitive,917,Sirolimus,5925
28,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Trilaciclib (G1T28) and Hycamtin (topotecan) inhibited tumor growth in RB1-deficient small cell lung cancer cell line xenograft models, with greater efficacy than Hycamtin (topotecan) alone (PMID: 26826116).",Actionable,6269,5409,lung small cell carcinoma,DOID,2007,RB1 loss,"[{'id': 5519, 'pubMedId': 26826116, 'title': 'Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26826116'}]",sensitive,4109,Trilaciclib + Topotecan,5925
29,Preclinical - Cell culture,"In a preclinical study, Trichostatin A (TSA) inhibited growth of retinoblastoma cell lines in culture (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719).",Actionable,10295,768,retinoblastoma,DOID,2007,RB1 loss,"[{'id': 8274, 'pubMedId': 18483379, 'title': 'Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18483379'}, {'id': 8275, 'pubMedId': 23498719, 'title': 'Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23498719'}]",sensitive,2867,Trichostatin A,5925
30,Preclinical,"In preclinical studies, the CDK4/6 inhibitor, Ibrance (palbociclib), was not effective in a variety of solid tumors with Rb1-deficiency (PMID: 26649278).",Actionable,3904,10000003,Advanced Solid Tumor,JAX,2007,RB1 loss,"[{'id': 4276, 'pubMedId': 26649278, 'title': 'CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26649278'}]",no benefit,850,Palbociclib,5925
31,Preclinical - Cell culture,"In a preclinical study, Zolinza (vorinostat) inhibited growth of retinoblastoma cell lines in culture (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719).",Actionable,10296,768,retinoblastoma,DOID,2007,RB1 loss,"[{'id': 8274, 'pubMedId': 18483379, 'title': 'Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18483379'}, {'id': 8275, 'pubMedId': 23498719, 'title': 'Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23498719'}]",sensitive,1077,Vorinostat,5925
32,Preclinical,"In a preclinical study, Sirolimus (rapamycin) slowed pituitary tumors and decreased the occurrence of thyroid tumors in Rb1+/- mice (PMID: 23454836).",Actionable,1152,169,neuroendocrine tumor,DOID,2007,RB1 loss,"[{'id': 903, 'pubMedId': 23454836, 'title': 'Rapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23454836'}]",sensitive,917,Sirolimus,5925
33,Preclinical - Cell line xenograft,"In a preclinical study, Entinostat (MS-275) inhibited growth of retinoblastoma cell lines in culture and inhibited tumor growth in a retinoblastoma cell line xenograft model (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719).",Actionable,10297,768,retinoblastoma,DOID,2007,RB1 loss,"[{'id': 8274, 'pubMedId': 18483379, 'title': 'Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18483379'}, {'id': 8275, 'pubMedId': 23498719, 'title': 'Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23498719'}]",sensitive,1541,Entinostat,5925
34,Preclinical - Cell line xenograft,"In a preclinical study, RB1-deficient small cell lung cancer cell lines were resistant to Trilaciclib (G1T28) in culture and in xenograft models (PMID: 26826116).",Actionable,6268,5409,lung small cell carcinoma,DOID,2007,RB1 loss,"[{'id': 5519, 'pubMedId': 26826116, 'title': 'Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26826116'}]",resistant,3074,Trilaciclib,5925
35,Preclinical - Cell culture,"In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type NOTCH1 and loss of RB1 demonstrated resistance to Kisqali (ribociclib) in culture, resulting in limited inhibition of cell growth (PMID: 28151717). ",Actionable,10045,5602,T-cell adult acute lymphocytic leukemia,DOID,27230,NOTCH1 wild-type RB1 loss,"[{'id': 7921, 'pubMedId': 28151717, 'title': 'Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28151717'}]",resistant,790,Ribociclib,5925
36,Preclinical,"In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Ibrance (palbociclib) induced growth inhibition in culture (PMID: 27020857).",Actionable,5865,60081,triple-receptor negative breast cancer,DOID,21971,PTEN loss RB1 loss,"[{'id': 5181, 'pubMedId': 27020857, 'title': 'Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27020857'}]",resistant,850,Palbociclib,5925
37,Preclinical,"In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Pictilisib (GDC-0941) induced growth inhibition in culture (PMID: 27020857).",Actionable,5864,60081,triple-receptor negative breast cancer,DOID,21971,PTEN loss RB1 loss,"[{'id': 5181, 'pubMedId': 27020857, 'title': 'Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27020857'}]",resistant,749,GDC-0941,5925
38,Preclinical,"In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in triple-receptor negative breast cancer cell lines harboring PTEN and RB1 loss in culture (PMID: 27020857).",Actionable,5863,60081,triple-receptor negative breast cancer,DOID,21971,PTEN loss RB1 loss,"[{'id': 5181, 'pubMedId': 27020857, 'title': 'Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27020857'}]",no benefit,3956,Palbociclib + GDC-0941,5925
39,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line with a BRAF mutation and loss of RB1 demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531). ",Actionable,8546,1909,melanoma,DOID,26352,BRAF mut RB1 loss,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",decreased response,1368,Palbociclib + Trametinib,5925
40,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring a BRAF mutation and RB1 loss demonstrated reduced sensitivity when treated with Mekinist (trametinib) in culture (PMID: 27488531). ",Actionable,8539,1909,melanoma,DOID,26352,BRAF mut RB1 loss,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",decreased response,2,Trametinib,5925
41,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring a BRAF mutation and loss of RB1 demonstrated a decreased response to Ibrance (palbociclib) treatment in culture when compared to treatment of melanoma cell lines wild-type for BRAF (PMID: 27488531). ",Actionable,8536,1909,melanoma,DOID,26352,BRAF mut RB1 loss,"[{'id': 6683, 'pubMedId': 27488531, 'title': 'An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27488531'}]",decreased response,850,Palbociclib,5925
42,Clinical Study,"In a clinical case study, RB1 C706F and loss of exons 1-11 in TP53 were identified in the pericardium infiltrating small cell lung cancer that developed while on Lorlatinib (PF-06463922) treatment in a patient with ALK-rearranged non-small cell lung carcinoma (PMID: 28285684).",Actionable,10437,5409,lung small cell carcinoma,DOID,27462,ALK rearrange RB1 C706F TP53 loss,"[{'id': 8449, 'pubMedId': 28285684, 'title': 'Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28285684'}]",predicted – resistant,869,PF-06463922,5925
43,Preclinical,"In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369). ",Actionable,2106,4159,skin cancer,DOID,5389,PTEN mut RB1 mut SMAD4 mut TP53 mut,"[{'id': 2380, 'pubMedId': 25261369, 'title': 'Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25261369'}]",sensitive,1282,Sapanisertib,5925
44,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of prostate carcinoma cell lines harboring Tp53 and Rb1 mutations in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4358,10286,prostate carcinoma,DOID,17821,RB1 mut TP53 mut,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,5925
45,Preclinical,"In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring TP53 and RB1 mutations in culture (PMID: 17121911).",Actionable,4351,3459,breast carcinoma,DOID,17821,RB1 mut TP53 mut,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,5925
46,Preclinical,"In a preclinical study, R547 inhibited proliferation of cervical carcinoma cell lines harboring Tp53 and Rb1 mutations (PMID: 17121911).",Actionable,4357,4362,cervical cancer,DOID,17821,RB1 mut TP53 mut,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,5925
47,Preclinical - Cell line xenograft,"In a preclinical study, VCN-01 decreased viability of a human RB1-mutant primary osteosarcoma cell line in culture, and inhibited tumor growth and decreased lung metastases in xenograft models (PMID: 26603261).",Actionable,6090,3347,osteosarcoma,DOID,22588,RB1 mutant,"[{'id': 5296, 'pubMedId': 26603261, 'title': 'The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26603261'}]",sensitive,4038,VCN-01,5925
48,Preclinical - Cell line xenograft,"In a preclinical study, Ibrance (palbociclib) inhibited proliferation of RB1-proficient glioblastoma cell lines in culture and inhibited tumor growth in intracranial cell line xenograft models (PMID: 20354191).",Actionable,9353,3068,glioblastoma multiforme,DOID,2395,RB1 positive,"[{'id': 4520, 'pubMedId': 20354191, 'title': 'Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20354191'}]",predicted – sensitive,850,Palbociclib,5925
49,Preclinical - Pdx,"In a preclinical study, Ibrance (palbociclib) inhibited Rb1 phosphorylation in tumor tissues and improved survival in patient-derived intracranial xenograft models of medulloblastoma (PMID: 27012813).",Actionable,6864,50902,medulloblastoma,DOID,2395,RB1 positive,"[{'id': 5910, 'pubMedId': 27012813, 'title': 'DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27012813'}]",sensitive,850,Palbociclib,5925
50,Phase I,"In a Phase I clinical trial, Kisqali (ribociclib) demonstrated safety and preliminary efficacy in patients with RB1-positive solid tumors and lymphomas, resulting in partial responses in 2.3% (3/132) of patients and stable disease in 32.6% (41/132) of patients, including 8 patients demonstrating stable disease for greater than 6 months (PMID: 27542767).",Actionable,1680,10000003,Advanced Solid Tumor,JAX,2395,RB1 positive,"[{'id': 1549, 'pubMedId': 24795392, 'title': 'Molecular pathways: CDK4 inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24795392'}, {'id': 1781, 'pubMedId': None, 'title': 'A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas.', 'url': 'http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2528'}, {'id': 7226, 'pubMedId': 27542767, 'title': 'A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27542767'}]",predicted – sensitive,790,Ribociclib,5925
51,Preclinical - Patient cell culture,"In a preclinical study, patient-derived glioblastoma cells harboring RB1 truncation mutation and expressing Cdkn2a were resistant to Ibrance (palbociclib) in culture (PMID: 22711607).",Actionable,9364,3068,glioblastoma multiforme,DOID,26833,CDKN2A pos RB1 inact mut,"[{'id': 3561, 'pubMedId': 22711607, 'title': 'p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22711607'}]",resistant,850,Palbociclib,5925
52,Preclinical,"In a preclinical study, a retinoblastoma cell line was sensitive to BAY 61-3606 in cell culture and in xenograft models, demonstrating increased apoptosis (PMID: 22237022). ",Actionable,2180,768,retinoblastoma,DOID,5891,RB1 inact mut,"[{'id': 2704, 'pubMedId': 22237022, 'title': 'A novel retinoblastoma therapy from genomic and epigenetic analyses.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22237022'}]",sensitive,2665,BAY 61-3606,5925
53,Preclinical,"In a preclinical study, retinoblastoma cell lines demonstrated sensitivity to Fostamatinib resulting in cell death (PMID: 22237022). ",Actionable,2179,768,retinoblastoma,DOID,5891,RB1 inact mut,"[{'id': 2704, 'pubMedId': 22237022, 'title': 'A novel retinoblastoma therapy from genomic and epigenetic analyses.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22237022'}]",sensitive,1528,Fostamatinib,5925
54,Preclinical - Cell line xenograft,"In a preclinical study, Ibrance (palbociclib) failed to inhibit growth of RB1-deficient glioblastoma cell lines in culture and in intracranial cell line xenograft models (PMID: 20354191).",Actionable,9354,3068,glioblastoma multiforme,DOID,5891,RB1 inact mut,"[{'id': 4520, 'pubMedId': 20354191, 'title': 'Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20354191'}]",resistant,850,Palbociclib,5925
55,Preclinical,"In a preclinical study, Nutlin-3a induced p53 pathway signaling in MDMX mouse models with retinoblastoma and 69% (70/102) of the eyes harvested from the mouse models demonstrated complete response or stable disease after 18 weeks of therapy (PMID: 21515735). ",Actionable,2181,768,retinoblastoma,DOID,5891,RB1 inact mut,"[{'id': 2705, 'pubMedId': 21515735, 'title': 'Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21515735'}]",sensitive,1405,Nutlin-3a,5925
0,Preclinical - Cell culture,"In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806F in culture demonstrated inhibition of Ret phosphorylation and activity in kinase assays when treated with Caprelsa (vandetanib) (PMID: 19029224).",Actionable,10663,10000003,Advanced Solid Tumor,JAX,27719,RET C634R RET Y806F,"[{'id': 8446, 'pubMedId': 19029224, 'title': 'Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19029224'}]",predicted – sensitive,953,Vandetanib,5979
1,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation in cells expressing RET S891A in culture (PMID: 17664273).
",Actionable,1761,10000003,Advanced Solid Tumor,JAX,3187,RET S891A,"[{'id': 589, 'pubMedId': 17664273, 'title': 'Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17664273'}]",sensitive,920,Sorafenib,5979
2,Preclinical,"In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET S891A in culture (PMID: 15184865).",Actionable,3418,10000003,Advanced Solid Tumor,JAX,3187,RET S891A,"[{'id': 3687, 'pubMedId': 15184865, 'title': 'Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15184865'}]",sensitive,953,Vandetanib,5979
3,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET S891A in culture (PMID: 23526464).",Actionable,3253,10000003,Advanced Solid Tumor,JAX,3187,RET S891A,"[{'id': 312, 'pubMedId': 23526464, 'title': 'Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23526464'}]",sensitive,877,Ponatinib,5979
4,Preclinical - Cell culture,"In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806E were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224). ",Actionable,10662,10000003,Advanced Solid Tumor,JAX,27718,RET C634R RET Y806E,"[{'id': 8446, 'pubMedId': 19029224, 'title': 'Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19029224'}]",resistant,953,Vandetanib,5979
5,Clinical Study,"In clinical case study, a patient with olfactory neuroblastoma harboring EGFR R521K, FGFR2 M186T, KDR Q472H, KDR V297I, and RET M1009T demonstrated sensitivity to the combination of Sutent (sunitinib) and Erbitux (cetuximab), resulting in a complete response (PMID: 27149458).",Actionable,7758,369,olfactory neuroblastoma,DOID,26023,EGFR R521K FGFR2 M186T KDR Q472H KDR V297I RET M1009T,"[{'id': 6481, 'pubMedId': 27149458, 'title': 'Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27149458'}]",sensitive,4568,Cetuximab + Sunitinib,5979
6,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited wild-type RET and RET mutations to prevent cell proliferation in cell culture (PMID: 17664273).",Actionable,905,162,cancer,DOID,1232,RET mutant,"[{'id': 589, 'pubMedId': 17664273, 'title': 'Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17664273'}]",sensitive,920,Sorafenib,5979
7,Preclinical - Cell line xenograft,"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of cancer cell lines harboring RET mutations in cultured and in cell line xenograft models (PMID: 23526464). ",Actionable,904,10000003,Advanced Solid Tumor,JAX,1232,RET mutant,"[{'id': 312, 'pubMedId': 23526464, 'title': 'Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23526464'}]",sensitive,877,Ponatinib,5979
8,Phase II,"In a Phase II clinical trial, Afinitor (everolimus) treatment resulted in stable disease in 71% (5/7) of medullary thyroid cancer patients, including patients harboring RET mutations, with median progression-free survival of 33 weeks (PMID: 26294908).",Actionable,3370,3973,thyroid medullary carcinoma,DOID,1232,RET mutant,"[{'id': 3764, 'pubMedId': 26294908, 'title': 'Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26294908'}]",sensitive,735,Everolimus,5979
9,Phase III,"In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (60 vs 20 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RET mutations (PMID: 27525386).",Actionable,10385,3973,thyroid medullary carcinoma,DOID,1232,RET mutant,"[{'id': 8408, 'pubMedId': 27525386, 'title': 'Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27525386'}]",sensitive,998,cabozantinib,5979
10,Preclinical,"In a preclinical study, Iclusig (ponatinib) demonstrated efficacy in RET mutant positive colorectal cancer cell lines (PMID: 23811235). ",Actionable,921,9256,colorectal cancer,DOID,1232,RET mutant,"[{'id': 602, 'pubMedId': 23811235, 'title': 'Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23811235'}]",sensitive,877,Ponatinib,5979
11,Preclinical,"In a preclinical study, transformed cell lines expressing Ret protein carrying both C634R and V804G mutations were more sensitive to Vandetanib induced inhibition of Ret activity than cells expressing Ret C634R alone in culture (PMID: 15184865).",Actionable,3468,10000003,Advanced Solid Tumor,JAX,13345,RET C634R RET V804G,"[{'id': 3687, 'pubMedId': 15184865, 'title': 'Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15184865'}]",sensitive,953,Vandetanib,5979
12,Preclinical,"In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET V804L (PMID: 26126987).",Actionable,6190,10000003,Advanced Solid Tumor,JAX,2411,RET V804L,"[{'id': 5385, 'pubMedId': 26126987, 'title': 'Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26126987'}]",predicted – sensitive,4089,Pz-1,5979
13,Preclinical,"In a preclinical study, transformed human cell lines expressing RET V804L demonstrated sensitivity to Iclusig (ponatinib) (PMID: 23811235).",Actionable,1851,10000003,Advanced Solid Tumor,JAX,2411,RET V804L,"[{'id': 602, 'pubMedId': 23811235, 'title': 'Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23811235'}]",sensitive,877,Ponatinib,5979
14,Preclinical,"In a preclinical study, transformed cells expressing RET V804L demonstrated resistance to growth inhibition by Caprelsa (vandetanib) in culture (PMID: 15184865).",Actionable,3421,10000003,Advanced Solid Tumor,JAX,2411,RET V804L,"[{'id': 3687, 'pubMedId': 15184865, 'title': 'Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15184865'}]",resistant,953,Vandetanib,5979
15,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET E884K in culture (PMID: 23526464).",Actionable,3252,10000003,Advanced Solid Tumor,JAX,12968,RET E884K,"[{'id': 312, 'pubMedId': 23526464, 'title': 'Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23526464'}]",sensitive,877,Ponatinib,5979
16,Preclinical,"In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET Y791F in culture (PMID: 15184865).",Actionable,3417,10000003,Advanced Solid Tumor,JAX,1000,RET Y791F,"[{'id': 3687, 'pubMedId': 15184865, 'title': 'Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15184865'}]",sensitive,953,Vandetanib,5979
17,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET Y971F in culture (PMID: 23526464).",Actionable,3232,10000003,Advanced Solid Tumor,JAX,1000,RET Y791F,"[{'id': 312, 'pubMedId': 23526464, 'title': 'Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23526464'}]",sensitive,877,Ponatinib,5979
18,Preclinical - Cell culture,"In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806C were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224). ",Actionable,10661,10000003,Advanced Solid Tumor,JAX,27717,RET C634R RET Y806C,"[{'id': 8446, 'pubMedId': 19029224, 'title': 'Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19029224'}]",resistant,953,Vandetanib,5979
19,Preclinical,"In a preclinical study, Caprelsa (vandetanib) inhibited RET phosphorylation and decreased growth of transformed cells expressing RET C634R in culture (PMID: 15184865).",Actionable,3423,10000003,Advanced Solid Tumor,JAX,2945,RET C634R,"[{'id': 3687, 'pubMedId': 15184865, 'title': 'Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15184865'}]",sensitive,953,Vandetanib,5979
20,Phase II,"In a Phase II trial, Nexavar (sorafenib) treatment resulted in partial response in 50% (1/2) and stable disease in 50% (1/2) of patients with medullary thyroid carcinoma harboring RET C634R (PMID: 20368568).",Actionable,10452,3973,thyroid medullary carcinoma,DOID,2945,RET C634R,"[{'id': 8463, 'pubMedId': 20368568, 'title': 'Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20368568'}]",predicted – sensitive,920,Sorafenib,5979
21,Preclinical - Cell line xenograft,"In a preclinical study, Pz-1 inhibited Ret signaling in transformed cells over expressing RET C634R and inhibited tumor growth in cell line xenografts models (PMID: 26126987).",Actionable,6188,10000003,Advanced Solid Tumor,JAX,2945,RET C634R,"[{'id': 5385, 'pubMedId': 26126987, 'title': 'Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26126987'}]",sensitive,4089,Pz-1,5979
22,Preclinical,"In a preclinical study, transformed human cell lines expressing RET C634R demonstrated sensitivity to Iclusig (ponatinib) (PMID: 23811235).",Actionable,1850,10000003,Advanced Solid Tumor,JAX,2945,RET C634R,"[{'id': 602, 'pubMedId': 23811235, 'title': 'Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23811235'}]",sensitive,877,Ponatinib,5979
23,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of cells expressing RET C634R in culture (PMID: 17664273).",Actionable,1765,10000003,Advanced Solid Tumor,JAX,2945,RET C634R,"[{'id': 589, 'pubMedId': 17664273, 'title': 'Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17664273'}]",sensitive,920,Sorafenib,5979
24,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited RET kinase activity and proliferation in transformed cells expressing RET C634R in culture (PMID: 16507829). ",Actionable,2190,10000003,Advanced Solid Tumor,JAX,2945,RET C634R,"[{'id': 2736, 'pubMedId': 16507829, 'title': 'BAY 43-9006 inhibition of oncogenic RET mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16507829'}]",sensitive,920,Sorafenib,5979
25,Preclinical - Cell culture,"In a preclinical study, transformed human cells co-expressing RET C634R and RET V804M were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224). ",Actionable,10660,10000003,Advanced Solid Tumor,JAX,27716,RET C634R RET V804M,"[{'id': 8446, 'pubMedId': 19029224, 'title': 'Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19029224'}]",resistant,953,Vandetanib,5979
26,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells harboring RET C634Y in culture (PMID: 23526464).",Actionable,3242,10000003,Advanced Solid Tumor,JAX,3731,RET C634Y,"[{'id': 312, 'pubMedId': 23526464, 'title': 'Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23526464'}]",sensitive,877,Ponatinib,5979
27,Phase II,"In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C634Y (PMID: 20368568).",Actionable,10453,3973,thyroid medullary carcinoma,DOID,3731,RET C634Y,"[{'id': 8463, 'pubMedId': 20368568, 'title': 'Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20368568'}]",predicted – sensitive,920,Sorafenib,5979
28,Preclinical,"In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350).",Actionable,5148,10000003,Advanced Solid Tumor,JAX,3731,RET C634Y,"[{'id': 4887, 'pubMedId': 26046350, 'title': 'Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26046350'}]",sensitive,3761,XMD15-44,5979
29,Preclinical,"In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350).",Actionable,5149,10000003,Advanced Solid Tumor,JAX,3731,RET C634Y,"[{'id': 4887, 'pubMedId': 26046350, 'title': 'Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26046350'}]",sensitive,3274,ALW-II-41-27,5979
30,Preclinical,"In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350).",Actionable,5147,10000003,Advanced Solid Tumor,JAX,3731,RET C634Y,"[{'id': 4887, 'pubMedId': 26046350, 'title': 'Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26046350'}]",sensitive,3762,HG-6-63-01,5979
31,Preclinical,"In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET E768D in culture (PMID: 15184865).",Actionable,3415,10000003,Advanced Solid Tumor,JAX,3746,RET E768D,"[{'id': 3687, 'pubMedId': 15184865, 'title': 'Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15184865'}]",sensitive,953,Vandetanib,5979
32,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET E768D in culture (PMID: 23526464).",Actionable,3233,10000003,Advanced Solid Tumor,JAX,3746,RET E768D,"[{'id': 312, 'pubMedId': 23526464, 'title': 'Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23526464'}]",sensitive,877,Ponatinib,5979
33,Clinical Study,"In a clinical case study, addition of Afinitor (everolimus)  to Caprelsa (vandetanib) treatment resulted in significant tumor reduction in a medullary thyroid carcinoma patient harboring ATM L804fs*4, ATM S978fs*12, and RET M918T, that achieved prolonged stable disease on Caprelsa (vandetanib) treatment alone (PMID: 27683183).",Actionable,10637,3973,thyroid medullary carcinoma,DOID,27653,ATM L804fs*4 ATM S978fs*12 RET M918T ,"[{'id': 8676, 'pubMedId': 27683183, 'title': 'RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27683183'}]",predicted – sensitive,1163,Vandetanib + Everolimus,5979
34,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of colorectal cancer cells harboring a RET M918T mutation in culture (PMID: 17664273).",Actionable,1762,9256,colorectal cancer,DOID,3055,RET M918T,"[{'id': 589, 'pubMedId': 17664273, 'title': 'Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17664273'}]",sensitive,920,Sorafenib,5979
35,Preclinical,"In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET M918T in culture (PMID: 26046350).
",Actionable,5150,10000003,Advanced Solid Tumor,JAX,3055,RET M918T,"[{'id': 4887, 'pubMedId': 26046350, 'title': 'Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26046350'}]",sensitive,3762,HG-6-63-01,5979
36,Preclinical,"In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thryoid carcinoma cells harboring RET M918T in culture (PMID: 26046350).",Actionable,5158,3973,thyroid medullary carcinoma,DOID,3055,RET M918T,"[{'id': 4887, 'pubMedId': 26046350, 'title': 'Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26046350'}]",sensitive,3274,ALW-II-41-27,5979
37,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited RET signaling and decreased proliferation of thyroid carcinoma cells harboring a RET M918T mutation in culture (PMID: 23526464). ",Actionable,1777,3963,thyroid carcinoma,DOID,3055,RET M918T,"[{'id': 312, 'pubMedId': 23526464, 'title': 'Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23526464'}]",sensitive,877,Ponatinib,5979
38,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines expressing RET M918T (PMID: 25122427).",Actionable,2988,5409,lung small cell carcinoma,DOID,3055,RET M918T,"[{'id': 3555, 'pubMedId': 25122427, 'title': 'RET mutation and expression in small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25122427'}]",sensitive,877,Ponatinib,5979
39,Preclinical,"In a preclinical study, Caprelsa (vandetanib) inhibited growth of small cell lung carcinoma lines expressing RET M918T (PMID: 25122427).",Actionable,2990,5409,lung small cell carcinoma,DOID,3055,RET M918T,"[{'id': 3555, 'pubMedId': 25122427, 'title': 'RET mutation and expression in small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25122427'}]",sensitive,953,Vandetanib,5979
40,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET M918T in culture (PMID: 23526464).",Actionable,3236,10000003,Advanced Solid Tumor,JAX,3055,RET M918T,"[{'id': 312, 'pubMedId': 23526464, 'title': 'Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23526464'}]",sensitive,877,Ponatinib,5979
41,Preclinical,"In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET M918T in culture (PMID: 26046350).",Actionable,5156,3973,thyroid medullary carcinoma,DOID,3055,RET M918T,"[{'id': 4887, 'pubMedId': 26046350, 'title': 'Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26046350'}]",sensitive,3762,HG-6-63-01,5979
42,Preclinical,"In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET M918T (PMID: 26126987).",Actionable,6189,10000003,Advanced Solid Tumor,JAX,3055,RET M918T,"[{'id': 5385, 'pubMedId': 26126987, 'title': 'Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26126987'}]",predicted – sensitive,4089,Pz-1,5979
43,Preclinical - Cell culture,"In a preclinical study, AZD1480 reduced phosphorylation of RET and downstream effectors, and inhibited growth and increased apoptosis of a medullary thyroid cancer cell line harboring RET M918T in culture (PMID: 23056499).",Actionable,8074,3973,thyroid medullary carcinoma,DOID,3055,RET M918T,"[{'id': 6545, 'pubMedId': 23056499, 'title': 'AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23056499'}]",sensitive,652,AZD1480,5979
44,Phase II,"In a Phase II trial, Nexavar (sorafenib) treatment resulted in partial response in 10% (1/10) and stable disease in 90% (9/10) of patients with medullary thyroid carcinoma harboring RET M918T (PMID: 20368568).",Actionable,10451,3973,thyroid medullary carcinoma,DOID,3055,RET M918T,"[{'id': 8463, 'pubMedId': 20368568, 'title': 'Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20368568'}]",predicted – sensitive,920,Sorafenib,5979
45,Phase III,"In a Phase III trial, Cometriq (cabozantinib) increased overall survival to 25.4 months in medullary thyroid carcinoma patients with RET M918T (J Clin Oncol 33, 2015, suppl; abstr 6012).",Actionable,2496,3973,thyroid medullary carcinoma,DOID,3055,RET M918T,"[{'id': 3168, 'pubMedId': None, 'title': 'Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline.', 'url': 'http://meetinglibrary.asco.org/content/147994-156'}]",sensitive,998,cabozantinib,5979
46,Phase III,"In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (61 vs 17 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RET M918T (PMID: 27525386).",Actionable,10386,3973,thyroid medullary carcinoma,DOID,3055,RET M918T,"[{'id': 8408, 'pubMedId': 27525386, 'title': 'Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27525386'}]",sensitive,998,cabozantinib,5979
47,Preclinical,"In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET M918T in culture (PMID: 26046350).",Actionable,5152,10000003,Advanced Solid Tumor,JAX,3055,RET M918T,"[{'id': 4887, 'pubMedId': 26046350, 'title': 'Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26046350'}]",sensitive,3274,ALW-II-41-27,5979
48,Preclinical,"In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation and transforming activity in cells expressing RET M918T in culture (PMID: 15184865).",Actionable,3419,10000003,Advanced Solid Tumor,JAX,3055,RET M918T,"[{'id': 3687, 'pubMedId': 15184865, 'title': 'Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15184865'}]",sensitive,953,Vandetanib,5979
49,Preclinical,"In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET M918T in culture (PMID: 26046350).",Actionable,5157,3973,thyroid medullary carcinoma,DOID,3055,RET M918T,"[{'id': 4887, 'pubMedId': 26046350, 'title': 'Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26046350'}]",sensitive,3761,XMD15-44,5979
50,Phase II,"In a Phase II clinical trial, Afinitor (everolimus) treatment resulted in stable disease in 71% (5/7)  of medullary thyroid cancer patients, and 4 of the 7 patients carried a RET M918T mutation (PMID: 26294908).",Actionable,3374,3973,thyroid medullary carcinoma,DOID,3055,RET M918T,"[{'id': 3764, 'pubMedId': 26294908, 'title': 'Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26294908'}]",sensitive,735,Everolimus,5979
51,Preclinical,"In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET M918T in culture (PMID: 26046350).",Actionable,5151,10000003,Advanced Solid Tumor,JAX,3055,RET M918T,"[{'id': 4887, 'pubMedId': 26046350, 'title': 'Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26046350'}]",sensitive,3761,XMD15-44,5979
52,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased proliferation of cells expressing RET M918T in culture (PMID: 17664273).",Actionable,1763,10000003,Advanced Solid Tumor,JAX,3055,RET M918T,"[{'id': 589, 'pubMedId': 17664273, 'title': 'Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17664273'}]",sensitive,920,Sorafenib,5979
53,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines expressing wild-type RET (PMID: 25122427).",Actionable,2989,5409,lung small cell carcinoma,DOID,686,RET wild-type,"[{'id': 3555, 'pubMedId': 25122427, 'title': 'RET mutation and expression in small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25122427'}]",sensitive,877,Ponatinib,5979
54,Preclinical,"In a preclinical study, Caprelsa (vandetanib) inhibited growth of small cell lung carcinoma lines expressing wild-type RET (PMID: 25122427).",Actionable,2986,5409,lung small cell carcinoma,DOID,686,RET wild-type,"[{'id': 3555, 'pubMedId': 25122427, 'title': 'RET mutation and expression in small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25122427'}]",sensitive,953,Vandetanib,5979
55,Phase II,"In a Phase II trial, Caprelsa (vandetanib) treatment resulted in partial remission in 17% (3/18) and stable disease in 44% (8/18) of non-small cell lung adenocarcinoma patients harboring RET fusions (J Clin Oncol 34, 2016 (suppl; abstr 9013)).",Actionable,6990,3908,non-small cell lung carcinoma,DOID,2903,RET fusion,"[{'id': 6002, 'pubMedId': None, 'title': 'A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.', 'url': 'http://meetinglibrary.asco.org/content/166941-176'}]",sensitive,953,Vandetanib,5979
56,Phase II,"In a Phase II trial, Caprelsa (vandetanib) treatment resulted in a disease control rate of 88% (15/17), median progression-free survival (PFS) of 4.7 months, and partial response in 53% (9/17) of non-small cell lung adenocarcinoma patients harboring RET fusions (J Clin Oncol 34, 2016 (suppl; abstr 9012)).",Actionable,6987,3908,non-small cell lung carcinoma,DOID,2903,RET fusion,"[{'id': 6000, 'pubMedId': None, 'title': 'A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study.', 'url': 'http://meetinglibrary.asco.org/content/163941-176'}]",sensitive,953,Vandetanib,5979
57,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET Y806C in culture (PMID: 23526464).",Actionable,3223,10000003,Advanced Solid Tumor,JAX,12957,RET Y806C,"[{'id': 312, 'pubMedId': 23526464, 'title': 'Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23526464'}]",sensitive,877,Ponatinib,5979
58,Phase II,"In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C634F (PMID: 20368568).",Actionable,10454,3973,thyroid medullary carcinoma,DOID,4919,RET C634F,"[{'id': 8463, 'pubMedId': 20368568, 'title': 'Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20368568'}]",predicted – sensitive,920,Sorafenib,5979
59,Preclinical - Cell line xenograft,"In a preclinical study, Motesanib (AMG 706) inhibited KDR (VEGFR2) phosphorylation, but had minimal activity against RET in a medullary thyroid carcinoma (MTC) cell line harboring RET C634W in culture, however, inhibited both RET and KDR (VEGFR2) phosphorylation and decreased tumor angiogenesis and growth in MTC cell line xenograft models with RET C634W (PMID: 21422803).",Actionable,8334,3973,thyroid medullary carcinoma,DOID,26230,KDR pos RET C634W,"[{'id': 996, 'pubMedId': 21422803, 'title': 'Anti-tumor activity of motesanib in a medullary thyroid cancer model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21422803'}]",predicted – sensitive,824,Motesanib,5979
60,Preclinical - Cell culture,"In a preclinical study, Stivarga (regorafenib) inhibited proliferation of thyroid cancer cells harboring RET C634W in culture (PMID: 21170960).",Actionable,7720,1781,thyroid cancer,DOID,3188,RET C634W,"[{'id': 318, 'pubMedId': 21170960, 'title': 'Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21170960'}]",sensitive,890,Regorafenib,5979
61,Preclinical,"In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET C634W in culture (PMID: 26046350).",Actionable,5154,3973,thyroid medullary carcinoma,DOID,3188,RET C634W,"[{'id': 4887, 'pubMedId': 26046350, 'title': 'Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26046350'}]",sensitive,3274,ALW-II-41-27,5979
62,Preclinical - Cell line xenograft,"In a preclinical study, Iclusig (ponatinib) inhibited RET signaling and decreased growth of thyroid carcinoma cells harboring a RET C634W mutation in culture and in cell line xenograft models (PMID: 23526464). ",Actionable,1776,3963,thyroid carcinoma,DOID,3188,RET C634W,"[{'id': 312, 'pubMedId': 23526464, 'title': 'Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23526464'}]",sensitive,877,Ponatinib,5979
63,Preclinical - Cell culture,"In a preclinical study, RXDX-105 (CEP-32496) reduced phosphorylation of RET and downstream signaling and inhibited proliferation of a medullary thyroid cancer cell line harboring RET C634W in culture (PMID: 28011461).",Actionable,11237,3973,thyroid medullary carcinoma,DOID,3188,RET C634W,"[{'id': 9178, 'pubMedId': 28011461, 'title': 'Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28011461'}]",sensitive,1002,CEP-32496,5979
64,Preclinical,"In a preclinical study, Lenvima (lenvatinib) inhibited RET phosphorylation and signaling in thyroid cancer cells expressing RET C634W (PMID: 25295214).
",Actionable,1894,1781,thyroid cancer,DOID,3188,RET C634W,"[{'id': 2207, 'pubMedId': 25295214, 'title': 'Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25295214'}]",sensitive,792,Lenvatinib,5979
65,Preclinical - Cell line xenograft,"In a preclinical study, Cometriq (cabozantinib) inhibited phosphorylation of RET C634W and decreased tumor growth in xenograft models of a human thyroid carcinoma cell line harboring RET C634W mutation (PMID: 23705946).",Actionable,1779,3963,thyroid carcinoma,DOID,3188,RET C634W,"[{'id': 2039, 'pubMedId': 23705946, 'title': 'In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23705946'}]",sensitive,998,cabozantinib,5979
66,Preclinical - Cell culture,"In a preclinical study, AZD1480 reduced phosphorylation of RET and downstream effectors, and inhibited growth and increased apoptosis of a thyroid cancer cell line harboring RET C634W in culture (PMID: 23056499).",Actionable,8075,1781,thyroid cancer,DOID,3188,RET C634W,"[{'id': 6545, 'pubMedId': 23056499, 'title': 'AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23056499'}]",sensitive,652,AZD1480,5979
67,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of thyroid carcinoma cells harboring a RET C634W mutation in culture (PMID: 17664273).
",Actionable,1766,3963,thyroid carcinoma,DOID,3188,RET C634W,"[{'id': 589, 'pubMedId': 17664273, 'title': 'Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17664273'}]",sensitive,920,Sorafenib,5979
68,Preclinical,"In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET C634W in culture (PMID: 26046350).",Actionable,5155,3973,thyroid medullary carcinoma,DOID,3188,RET C634W,"[{'id': 4887, 'pubMedId': 26046350, 'title': 'Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26046350'}]",sensitive,3762,HG-6-63-01,5979
69,Preclinical - Cell line xenograft,"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and inhibited tumor growth in cell line xenograft models of medullary thyroid carcinoma harboring RET C634W (PMID: 16507829).",Actionable,2192,3973,thyroid medullary carcinoma,DOID,3188,RET C634W,"[{'id': 2736, 'pubMedId': 16507829, 'title': 'BAY 43-9006 inhibition of oncogenic RET mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16507829'}]",sensitive,920,Sorafenib,5979
70,Preclinical,"In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET C634W in culture (PMID: 26046350).",Actionable,5153,3973,thyroid medullary carcinoma,DOID,3188,RET C634W,"[{'id': 4887, 'pubMedId': 26046350, 'title': 'Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26046350'}]",sensitive,3761,XMD15-44,5979
71,Preclinical,"In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET V804M (PMID: 26126987).",Actionable,6191,10000003,Advanced Solid Tumor,JAX,2412,RET V804M,"[{'id': 5385, 'pubMedId': 26126987, 'title': 'Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26126987'}]",predicted – sensitive,4089,Pz-1,5979
72,Preclinical,"In a preclinical study, transformed cells expressing RET V804M demonstrated resistance to growth inhibition by Caprelsa (vandetanib) in culture (PMID: 15184865).",Actionable,3422,10000003,Advanced Solid Tumor,JAX,2412,RET V804M,"[{'id': 3687, 'pubMedId': 15184865, 'title': 'Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15184865'}]",resistant,953,Vandetanib,5979
73,Preclinical,"In a preclinical study, transformed human cell lines expressing RET V804M demonstrated sensitivity to Iclusig (ponatinib) (PMID: 23811235).",Actionable,1852,10000003,Advanced Solid Tumor,JAX,2412,RET V804M,"[{'id': 602, 'pubMedId': 23811235, 'title': 'Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23811235'}]",sensitive,877,Ponatinib,5979
74,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of transformed cells expressing RET V804M in culture (PMID: 16507829).",Actionable,2191,10000003,Advanced Solid Tumor,JAX,2412,RET V804M,"[{'id': 2736, 'pubMedId': 16507829, 'title': 'BAY 43-9006 inhibition of oncogenic RET mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16507829'}]",sensitive,920,Sorafenib,5979
75,Phase II,"In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C618R (PMID: 20368568).",Actionable,10455,3973,thyroid medullary carcinoma,DOID,3725,RET C618R,"[{'id': 8463, 'pubMedId': 20368568, 'title': 'Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20368568'}]",predicted – sensitive,920,Sorafenib,5979
76,Preclinical - Cell line xenograft,"In a preclinical study, Y078-DM1 induced cytotoxicity in a human breast cancer cell line with high levels of RET expression in culture and inhibited tumor growth in xenograft models (PMID: 26240273).",Actionable,5643,1612,breast cancer,DOID,21323,RET over exp,"[{'id': 5131, 'pubMedId': 26240273, 'title': 'Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26240273'}]",sensitive,3912,Y078-DM1,5979
77,Preclinical,"In a preclinical study, Y078-DM4 induced cytotoxicity in a RET-expressing medullary thyroid cell line in culture (PMID: 26240273).",Actionable,5642,3973,thyroid medullary carcinoma,DOID,2882,RET positive,"[{'id': 5131, 'pubMedId': 26240273, 'title': 'Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26240273'}]",sensitive,3913,Y078-DM4,5979
78,Preclinical - Cell line xenograft,"In a preclinical study, Y078-DM4 induced cytotoxicity in RET-expressing human breast cancer cell lines in culture and inhibited tumor growth in xenograft models (PMID: 26240273).",Actionable,5641,1612,breast cancer,DOID,2882,RET positive,"[{'id': 5131, 'pubMedId': 26240273, 'title': 'Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26240273'}]",sensitive,3913,Y078-DM4,5979
79,Phase I,"In a Phase I clinical trial, two patients with germline RET G691S mutations demonstrated sensitivity to Dovitinib (TKI258) treatment (PMID: 25103625).",Actionable,1210,10000003,Advanced Solid Tumor,JAX,724,RET G691S,"[{'id': 941, 'pubMedId': 25103625, 'title': 'Selective activity over a constitutively active RET-variant of the oral multikinase inhibitor dovitinib: results of the CNIO-BR002 phase I-trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25103625'}]",sensitive,721,Dovitinib,5979
80,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET A883F in culture (PMID: 23526464).",Actionable,3224,10000003,Advanced Solid Tumor,JAX,12807,RET A883F,"[{'id': 312, 'pubMedId': 23526464, 'title': 'Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23526464'}]",sensitive,877,Ponatinib,5979
81,Preclinical,"In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET A883F in culture (PMID: 15184865).",Actionable,3420,10000003,Advanced Solid Tumor,JAX,12807,RET A883F,"[{'id': 3687, 'pubMedId': 15184865, 'title': 'Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15184865'}]",sensitive,953,Vandetanib,5979
82,Phase II,"In a Phase II clinical trial, treatment with Cometriq (cabozantinib) resulted in an overall response rate of 28% (7/25) in patients with RET-rearranged lung cancer (PMID: 27825636).",Actionable,9722,1324,lung cancer,DOID,1326,RET rearrange,"[{'id': 7513, 'pubMedId': 27825636, 'title': 'Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27825636'}]",sensitive,998,cabozantinib,5979
83,Preclinical - Pdx,"In a preclinical study, CEP-32496 (RXDX-105) induced tumor regression in patient-derived xenograft models of several advanced solid tumor type with RET rearrangements (2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Abstract A174).",Actionable,3689,10000003,Advanced Solid Tumor,JAX,1326,RET rearrange,"[{'id': 7240, 'pubMedId': None, 'title': '', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/A174'}]",sensitive,1002,CEP-32496,5979
84,Clinical Study,"In a clinical case study, a patient with non-small cell lung cancer harboring a RET rearrangement demonstrated a sustained partial response following treatment with RXDX-105 (CEP-32496) on a Phase Ib clinical trial (PMID: 28011461).",Actionable,11255,3908,non-small cell lung carcinoma,DOID,1326,RET rearrange,"[{'id': 9178, 'pubMedId': 28011461, 'title': 'Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28011461'}]",sensitive,1002,CEP-32496,5979
85,Clinical Study,"In a clinical study, analysis of patients with RET-rearranged non-small cell lung cancer treated with RET inhibitors demonstrated a response rate of 18% (2/9, all partial responses), and stable disease in 33% (3/9) of patients following Sutent (sunitinib) treatment (PMID: 28447912).",Actionable,10836,3908,non-small cell lung carcinoma,DOID,1326,RET rearrange,"[{'id': 8863, 'pubMedId': 28447912, 'title': 'Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28447912'}]",sensitive,930,Sunitinib,5979
86,Clinical Study,"In a clinical study, analysis of patients with RET-rearranged non-small cell lung cancer treated with RET inhibitors demonstrated a response rate of 18% (2/11, all partial responses) and stable disease in 27% (3/11) of patients following Caprelsa (vandetanib) treatment (PMID: 28447912).",Actionable,10835,3908,non-small cell lung carcinoma,DOID,1326,RET rearrange,"[{'id': 8863, 'pubMedId': 28447912, 'title': 'Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28447912'}]",sensitive,953,Vandetanib,5979
87,Preclinical,"In a preclinical study, Iclusig (ponatinib) decreased proliferation of papillary thyroid carcinoma cells harboring the RET/PTC1 rearrangement in culture (PMID: 23526464). ",Actionable,1778,3969,papillary thyroid carcinoma,DOID,1326,RET rearrange,"[{'id': 312, 'pubMedId': 23526464, 'title': 'Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23526464'}]",sensitive,877,Ponatinib,5979
88,Clinical Study,"In a clinical study, Alecensa (alectinib) treatment resulted in objective radiographic response in 50% (2/4) and stable disease in 25% (1/4) of non-small cell lung carcinoma patients harboring RET rearrangement (PMID: 27544060).",Actionable,10416,3908,non-small cell lung carcinoma,DOID,1326,RET rearrange,"[{'id': 8430, 'pubMedId': 27544060, 'title': 'Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27544060'}]",predicted – sensitive,698,Alectinib,5979
89,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and activation of downstream signaling, and decreased growth of papillary thyroid carcinoma cells harboring the RET/PTC1 oncogene in culture (PMID: 17664273).
",Actionable,1768,3969,papillary thyroid carcinoma,DOID,1326,RET rearrange,"[{'id': 589, 'pubMedId': 17664273, 'title': 'Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17664273'}]",sensitive,920,Sorafenib,5979
90,Clinical Study,"In a clinical study, analysis of patients with RET-rearranged non-small cell lung cancer treated with RET inhibitors demonstrated a response rate of 37% (7/19), with complete response in 5% (1/19) and partial response in 32% (6/19) of patients, and stable disease in 26% (5/19) of patients following Cometriq (cabozantinib) treatment (PMID: 28447912).",Actionable,10834,3908,non-small cell lung carcinoma,DOID,1326,RET rearrange,"[{'id': 8863, 'pubMedId': 28447912, 'title': 'Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28447912'}]",sensitive,998,cabozantinib,5979
91,Preclinical - Cell culture,"In a preclinical study, Iclusig (ponatinib) inhibited RET phosphorylation and reduced viability of non-small cell lung cancer cells with RET activating mutations (Cancer Res April 15, 2013 73; 2084). ",Actionable,1432,3908,non-small cell lung carcinoma,DOID,2294,RET act mut,"[{'id': 1280, 'pubMedId': None, 'title': 'Abstract 2084: Ponatinib is a highly potent inhibitor of activated variants of RET found in MTC and NSCLC .', 'url': 'http://cancerres.aacrjournals.org/content/73/8_Supplement/2084.short'}]",sensitive,877,Ponatinib,5979
92,Preclinical,"In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET L790F in culture (PMID: 15184865).",Actionable,3416,10000003,Advanced Solid Tumor,JAX,12809,RET L790F,"[{'id': 3687, 'pubMedId': 15184865, 'title': 'Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15184865'}]",sensitive,953,Vandetanib,5979
93,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET L790F in culture (PMID: 23526464).",Actionable,3234,10000003,Advanced Solid Tumor,JAX,12809,RET L790F,"[{'id': 312, 'pubMedId': 23526464, 'title': 'Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23526464'}]",sensitive,877,Ponatinib,5979
94,Phase II,"In a Phase II clinical trial, Afinitor (everolimus) treatment resulted in stable disease of 116 weeks in a MEN2A patient with medullary thyroid cancer carrying a RET C620R mutation (PMID: 26294908).",Actionable,3373,3973,thyroid medullary carcinoma,DOID,11125,RET C620R,"[{'id': 3764, 'pubMedId': 26294908, 'title': 'Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26294908'}]",sensitive,735,Everolimus,5979
95,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET D898V in culture (PMID: 23526464).",Actionable,3235,10000003,Advanced Solid Tumor,JAX,12808,RET D898V,"[{'id': 312, 'pubMedId': 23526464, 'title': 'Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23526464'}]",sensitive,877,Ponatinib,5979
0,Phase II,"In a Phase II trial, treatment with Zykadia (ceritinib) resulted in an overall response rate of 62% (20/32, including 1 complete response), a disease control rate of 81% (26/32), and a progression-free survival of 9.3 months in all patients and 19.3 months in Xalkori (crizotinib)-naive patients with non-small cell lung cancer harboring a ROS1 rearrangement (PMID: 28520527; NCT01964157).",Actionable,11444,3908,non-small cell lung carcinoma,DOID,11085,ROS1 rearrange,"[{'id': 9391, 'pubMedId': 28520527, 'title': 'Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28520527'}]",sensitive,789,Ceritinib,6098
1,FDA approved,"In a Phase I clinical trial that supported FDA approval, NSCLC patients with ROS1 rearrangements treated with Xalkori (crizotinib) demonstrated an objective response rate of 72% (36/50), with 3 complete responses and 33 partial responses, a median duration of response of 17.6 months, and a median progression-free survival of 19.2 months (PMID: 25264305).",Actionable,5011,3908,non-small cell lung carcinoma,DOID,11085,ROS1 rearrange,"[{'id': 4835, 'pubMedId': 25264305, 'title': 'Crizotinib in ROS1-rearranged non-small-cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25264305'}]",sensitive,706,Crizotinib,6098
2,Clinical Study,"In a clinical case study, a patient with ROS1-rearranged non-small cell lung cancer with acquired resistance to Xalkori (crizotinib) demonstrated partial response to treatment with Cometriq (cabozantinib) prior to progressing after approximately 10 weeks (PMID: 27370605).",Actionable,9718,3908,non-small cell lung carcinoma,DOID,11085,ROS1 rearrange,"[{'id': 7489, 'pubMedId': 27370605, 'title': 'Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27370605'}]",predicted – sensitive,998,cabozantinib,6098
3,Preclinical - Cell culture,"In a preclinical study, NPS-1034 inhibited ROS1 activity and proliferation of a non-small cell lung cancer cell line harboring a ROS1 rearrangement in culture (PMID: 24165158).",Actionable,9661,3908,non-small cell lung carcinoma,DOID,11085,ROS1 rearrange,"[{'id': 7367, 'pubMedId': 24165158, 'title': 'MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24165158'}]",sensitive,5115,NPS-1034,6098
4,Phase I,"In a clinical study analyzing combined results of 2 Phase I trials, Entrectinib (RXDX-101) treatment resulted in complete response in 2 and partial response in 10 patients with ROS-1 rearranged non-small cell lung carcinoma that were treatment-naive (PMID: 28183697).",Actionable,10492,3908,non-small cell lung carcinoma,DOID,11085,ROS1 rearrange,"[{'id': 8566, 'pubMedId': 28183697, 'title': 'Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28183697'}]",predicted – sensitive,1455,Entrectinib,6098
5,Phase I,"In a clinical study analyzing combined results of 2 Phase I trials, Entrectinib (RXDX-101) treatment resulted in an objective response rate of 86% (12/14) in patients with ROS-1 rearranged advanced solid tumors that were treatment-naive, but no response (0/6) in patients received prior Xalkori (crizotinib) (PMID: 28183697).",Actionable,10491,10000003,Advanced Solid Tumor,JAX,11085,ROS1 rearrange,"[{'id': 8566, 'pubMedId': 28183697, 'title': 'Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28183697'}]",sensitive,1455,Entrectinib,6098
6,Phase I,"In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in complete response in 13% (1/12) and objection response in 75% (6/8) of patients with advanced solid tumors harboring rearrangement in ROS1 gene (AACR Apr 2016, Abstract # CT007).",Actionable,6728,10000003,Advanced Solid Tumor,JAX,11085,ROS1 rearrange,"[{'id': 5790, 'pubMedId': None, 'title': 'Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=4abd89d1-63f0-4e65-b91c-486888d54e7a&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267'}]",sensitive,1455,Entrectinib,6098
7,Phase II,"In a Phase I trial, Xalkori (crizotinib) treatment resulted in an objective response rate of 69% (89/129), and a median duration of treatment of 7.8 months in ALK negative, ROS1 positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9022)).",Actionable,6993,3908,non-small cell lung carcinoma,DOID,24174,ALK neg ROS1 pos,"[{'id': 6003, 'pubMedId': None, 'title': 'Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).', 'url': 'http://meetinglibrary.asco.org/content/168126-176'}]",sensitive,706,Crizotinib,6098
8,Phase I,"In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in stable disease in a patient with ROS1-positive pancreatic cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 2502)).",Actionable,10351,1793,pancreatic cancer,DOID,1771,ROS1 positive,"[{'id': 8339, 'pubMedId': None, 'title': 'Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.', 'url': 'http://meetinglibrary.asco.org/content/131059-144'}]",predicted – sensitive,1455,Entrectinib,6098
9,Phase I,"In a retrospective analysis of Phase I clinical data, Xalkori (crizotinib) resulted in an objective response rate of 80% (24/30) and a median PFS of 9.1 months in patients with ROS1 fusion positive lung adenocarcinoma (PMID: 25667280).",Actionable,2767,3910,lung adenocarcinoma,DOID,1249,ROS1 fusion,"[{'id': 3397, 'pubMedId': 25667280, 'title': 'Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25667280'}]",sensitive,706,Crizotinib,6098
10,Phase I,"In a Phase I clinical trial, Lorlatinib (PF-06463922) demonstrated safety and resulted in a 50% (26/52) overall response rate in patients with ALK-positive or ROS1-positive non-small cell lung cancer, including intracranial responses in patients with CNS metastasis (J Clin Oncol 34, 2016 (suppl; abstr 9009)).",Actionable,6818,3908,non-small cell lung carcinoma,DOID,1249,ROS1 fusion,"[{'id': 5834, 'pubMedId': None, 'title': 'Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).', 'url': 'http://abstracts.asco.org/176/AbstView_176_161846.html'}]",sensitive,869,PF-06463922,6098
11,Phase I,"In a Phase I clinical trial, DS-6051b was well-tolerated and demonstrated some preliminary efficacy in patients with advanced solid tumors, including a partial response in a patient with non-small cell lung cancer liver metastases harboring a ROS1 fusion (Cancer Res July 15 2016 (76) (14 Supplement) CT024).",Actionable,9875,3908,non-small cell lung carcinoma,DOID,1249,ROS1 fusion,"[{'id': 7729, 'pubMedId': None, 'title': 'Abstract CT024: First-in-human phase 1 dose-escalation study of DS-6051b, an oral ROS1 and NTRK inhibitor, in subjects with advanced solid tumors', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/CT024.short'}]",predicted – sensitive,4343,DS6051b,6098
12,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ROS1 fusion proteins in culture (PMID: 27780853).",Actionable,9244,10000003,Advanced Solid Tumor,JAX,1249,ROS1 fusion,"[{'id': 7044, 'pubMedId': 27780853, 'title': 'The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27780853'}]",sensitive,634,AP26113,6098
0,Clinical Study,"In clinical analyses, RUNX1 mutations were associated with adverse clinical outcome in acute myeloid leukemia patients (PMID: 21343560, PMID: 22689681, PMID: 22753902, PMID: 25652455).",Prognostic,3570,9119,acute myeloid leukemia,DOID,22427,RUNX1 mutant,"[{'id': 3845, 'pubMedId': 21343560, 'title': 'RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21343560'}, {'id': 5363, 'pubMedId': 22689681, 'title': 'RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22689681'}, {'id': 5364, 'pubMedId': 22753902, 'title': 'RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22753902'}, {'id': 5365, 'pubMedId': 25652455, 'title': 'Integrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25652455'}]",not applicable,1776,N/A,861
1,Clinical Study,"In clinical analyses, RUNX1 mutations were associated with poor overall survival in patients with myelodysplastic syndrome (PMID: 21714648, PMID: 22869879).",Actionable,6077,50908,myelodysplastic syndrome,DOID,22427,RUNX1 mutant,"[{'id': 5254, 'pubMedId': 21714648, 'title': 'Clinical effect of point mutations in myelodysplastic syndromes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21714648'}, {'id': 5282, 'pubMedId': 22869879, 'title': 'Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22869879'}]",not applicable,1776,N/A,861
2,Preclinical,"In a preclinical study, the combination of I-CBP112 and Doxorubicin worked synergistically to inhibit growth of leukemia cells harboring a RUNX1-RUNX1T1 (AML1-ETO) fusion in culture (PMID: 26552700) ",Actionable,3778,1240,leukemia,DOID,15350,RUNX1-RUNX1T1,"[{'id': 4120, 'pubMedId': 26552700, 'title': 'Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26552700'}]",sensitive,3299,I-CBP112 + Doxorubicin,861
3,Clinical Study,"In clinical analyses, the t(8;21) cytogenetic abnormality, which leads to the RUNX1-RUNX1T1 fusion, is associated with core-binding factor acute myeloid leukemia and favorable prognosis (PMID: 22180162, PMID: 9746770, PMID: 25111512).",Prognostic,6079,9119,acute myeloid leukemia,DOID,15350,RUNX1-RUNX1T1,"[{'id': 5287, 'pubMedId': 22180162, 'title': 'Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22180162'}, {'id': 5288, 'pubMedId': 9746770, 'title': ""The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/9746770'}, {'id': 5289, 'pubMedId': 25111512, 'title': 'Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25111512'}]",not applicable,1776,N/A,861
4,Preclinical - Cell culture,"In a preclinical study, GSK690 inhibited growth of acute myeloid leukemia cell lines harboring RUNX1-RUNX1T1 in culture (PMID: 26837761).",Actionable,10464,9119,acute myeloid leukemia,DOID,15350,RUNX1-RUNX1T1,"[{'id': 8467, 'pubMedId': 26837761, 'title': 'Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26837761'}]",sensitive,5507,GSK690,861
5,Preclinical,"In a preclinical study, the combination of I-CBP112 and JQ1 worked synergistically to inhibit growth of leukemia cells harboring a RUNX1-RUNX1T1 (AML1-ETO) fusion in culture (PMID: 26552700) ",Actionable,3777,1240,leukemia,DOID,15350,RUNX1-RUNX1T1,"[{'id': 4120, 'pubMedId': 26552700, 'title': 'Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26552700'}]",sensitive,3298,I-CBP112 + JQ1,861
6,Preclinical - Cell line xenograft,"In a preclinical study, RN-1 inhibited growth of acute myeloid leukemia cell lines harboring RUNX1-RUNX1T1 in culture, and inhibited tumor growth in xenograft models (PMID: 26837761).",Actionable,10463,9119,acute myeloid leukemia,DOID,15350,RUNX1-RUNX1T1,"[{'id': 8467, 'pubMedId': 26837761, 'title': 'Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26837761'}]",sensitive,5506,RN-1,861
7,Preclinical,"In a preclinical study, I-CBP112 inhibited clonogenic growth in a leukemia cell line harboring a RUNX1-RUNX1T1 (AML1-ETO) fusion in culture (PMID: 26552700).",Actionable,3774,1240,leukemia,DOID,15350,RUNX1-RUNX1T1,"[{'id': 4120, 'pubMedId': 26552700, 'title': 'Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26552700'}]",sensitive,3297,I-CBP112,861
8,Clinical Study,"In clinical analyses, coincident KIT mutations were associated with higher relapse rate and decreased overall survival in acute myeloid leukemia patients with RUNX1-RUNX1T1 fusions (PMID: 18648004, PMID: 16384925, PMID: 25111512).",Prognostic,6080,9119,acute myeloid leukemia,DOID,22438,RUNX1-RUNX1T1 KIT mut,"[{'id': 1127, 'pubMedId': 18648004, 'title': 'Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18648004'}, {'id': 5289, 'pubMedId': 25111512, 'title': 'Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25111512'}, {'id': 5290, 'pubMedId': 16384925, 'title': 'Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16384925'}]",not applicable,1776,N/A,861
0,Preclinical,"In a preclinical study, SETPB1 missense mutations conferred a predicted gain-of-function, resulting in transformation of murine myeloid progenitors and increased Pp2ac phosphorylation compared to wild-type SETBP1 in culture, suggesting that Setbp1 may serve as a potential therapeutic target (PMID: 23832012). ",Emerging,1596,4972,myelodysplastic/myeloproliferative neoplasm,DOID,2731,SETBP1 mutant,"[{'id': 1599, 'pubMedId': 23832012, 'title': 'Somatic SETBP1 mutations in myeloid malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23832012'}]",not applicable,1776,N/A,26040
0,Preclinical - Cell culture,"In a preclinical study, mouse cells expressing SF3B1 K700E demonstrated sensitivity to E7107 in culture, resulting in decreased viability of cells (PMID: 27622333). ",Actionable,9170,2531,hematologic cancer,DOID,22989,SF3B1 K700E,"[{'id': 6980, 'pubMedId': 27622333, 'title': 'Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27622333'}]",sensitive,4927,E7107,23451
1,Preclinical,"In a preclinical study, Spliceostatin A inhibited survival of pancreatic cancer cells harboring SF3B1 K700E in culture (PMID: 25424858).",Actionable,6228,1793,pancreatic cancer,DOID,22989,SF3B1 K700E,"[{'id': 5494, 'pubMedId': 25424858, 'title': 'SF3B1 mutations constitute a novel therapeutic target in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25424858'}]",sensitive,4096,Spliceostatin A,23451
2,Preclinical,"In a preclinical study, Spliceostatin A inhibited survival of endometrial cancer cells harboring SF3B1 K666N in culture (PMID: 25424858).",Actionable,6227,1380,endometrial cancer,DOID,22964,SF3B1 K666N,"[{'id': 5494, 'pubMedId': 25424858, 'title': 'SF3B1 mutations constitute a novel therapeutic target in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25424858'}]",sensitive,4096,Spliceostatin A,23451
3,Guideline,"In multiple clinical studies, SF3B1 mutations were associated with better overall survival in patients with myelodysplastic syndrome (PMID: 21998214, PMID: 22096241, PMID: 24220272), but may not have independent prognostic significance (PMID: 22096241).",Prognostic,6164,50908,myelodysplastic syndrome,DOID,22743,SF3B1 mutant,"[{'id': 5253, 'pubMedId': 24220272, 'title': 'Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24220272'}, {'id': 5329, 'pubMedId': 22096241, 'title': 'SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22096241'}, {'id': 5330, 'pubMedId': 21998214, 'title': 'Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21998214'}]",not applicable,1776,N/A,23451
0,Clinical Study,"In clinical and meta-analyses, loss of Smad4 expression and SMAD4 inactivating mutations were associated with decreased survival in patients with pancreatic cancer (PMID: 26947875, PMID: 25760429, PMID: 22504380, PMID: 19584151).",Prognostic,4949,1793,pancreatic cancer,DOID,16537,SMAD4 dec exp,"[{'id': 4806, 'pubMedId': 26947875, 'title': 'Prognostic Value of SMAD4 in Pancreatic Cancer: A Meta-Analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26947875'}, {'id': 5369, 'pubMedId': 25760429, 'title': 'SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25760429'}, {'id': 5370, 'pubMedId': 22504380, 'title': 'SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22504380'}, {'id': 5371, 'pubMedId': 19584151, 'title': 'SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19584151'}]",not applicable,1776,N/A,4089
1,Clinical Study,"In clinical and meta-analyses, decreased expression of Smad4 was correlated with poor prognosis in colorectal cancer (PMID: 25749173, PMID: 19478385, PMID: 25681512, PMID: 26861460).",Prognostic,3859,9256,colorectal cancer,DOID,16537,SMAD4 dec exp,"[{'id': 4241, 'pubMedId': 25749173, 'title': 'A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25749173'}, {'id': 5366, 'pubMedId': 26861460, 'title': 'Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26861460'}, {'id': 5367, 'pubMedId': 25681512, 'title': 'Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25681512'}, {'id': 5368, 'pubMedId': 19478385, 'title': 'Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19478385'}]",not applicable,1776,N/A,4089
2,Preclinical,"In a preclinical study, pancreatic cancer cell lines harboring SMAD4 homozygous deletions were half as sensitive to gemcitabine in vitro as wild-type cells (PMID: 22753594).",Actionable,1173,1793,pancreatic cancer,DOID,20413,SMAD4 del,"[{'id': 917, 'pubMedId': 22753594, 'title': 'Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22753594'}]",decreased response,755,Gemcitabine,4089
3,Preclinical,"In a preclinical study, pancreatic cancer cell lines harboring inactivated SMAD4 (mutations or deletion) displayed 4.5-fold greater sensitivity to irinotecan in vitro than wild-type (PMID: 22753594).
",Actionable,1172,1793,pancreatic cancer,DOID,20413,SMAD4 del,"[{'id': 917, 'pubMedId': 22753594, 'title': 'Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22753594'}]",sensitive,1074,Irinotecan,4089
4,Preclinical,"In a preclinical study, pancreatic cancer cell lines harboring SMAD4 homozygous deletions were twice as sensitive to cisplatin in vitro as wild-type cells (PMID: 22753594).",Actionable,1171,1793,pancreatic cancer,DOID,20413,SMAD4 del,"[{'id': 917, 'pubMedId': 22753594, 'title': 'Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22753594'}]",sensitive,700,Cisplatin,4089
5,Preclinical,"In a preclinical study, SD-093 reduced the migration and invasiveness of pancreatic carcinoma cell lines lacking Smad4 (PMID: 15289325).",Actionable,2260,4905,pancreatic carcinoma,DOID,2068,SMAD4 loss,"[{'id': 2873, 'pubMedId': 15289325, 'title': 'Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15289325'}]",sensitive,2750,SD-093,4089
6,Preclinical,"In a preclinical study, pancreatic cancer cell lines harboring inactivated SMAD4 (mutations or deletion) displayed 4.5-fold greater sensitivity to irinotecan in vitro than wild-type (PMID: 22753594).",Actionable,5253,1793,pancreatic cancer,DOID,20414,SMAD4 inact mut,"[{'id': 917, 'pubMedId': 22753594, 'title': 'Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22753594'}]",sensitive,1074,Irinotecan,4089
7,Clinical Study,"In a clinical study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312).",Actionable,11053,1909,melanoma,DOID,27904,CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H,"[{'id': 9046, 'pubMedId': 28514312, 'title': 'Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28514312'}]",sensitive,5833,Imatinib + Carboplatin + Paclitaxel,4089
8,Clinical Study,"In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",Actionable,11543,3498,pancreatic ductal adenocarcinoma,DOID,28131,EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*,"[{'id': 9613, 'pubMedId': 28476735, 'title': 'Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28476735'}]",resistant,706,Crizotinib,4089
9,Clinical Study,"In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",Actionable,11544,3498,pancreatic ductal adenocarcinoma,DOID,28131,EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*,"[{'id': 9613, 'pubMedId': 28476735, 'title': 'Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28476735'}]",predicted – sensitive,698,Alectinib,4089
10,Preclinical,"In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369). ",Actionable,2106,4159,skin cancer,DOID,5389,PTEN mut RB1 mut SMAD4 mut TP53 mut,"[{'id': 2380, 'pubMedId': 25261369, 'title': 'Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25261369'}]",sensitive,1282,Sapanisertib,4089
11,Preclinical,"In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369). ",Actionable,2135,9256,colorectal cancer,DOID,5415,APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut,"[{'id': 2380, 'pubMedId': 25261369, 'title': 'Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25261369'}]",sensitive,1282,Sapanisertib,4089
0,Preclinical,"In a preclinical study, Ibrance (palbociclib) inhibited growth of  SMARCB1-negative malignant rhabdoid tumor cell lines in culture, and sensitivity was associated with low levels of p16 expression (PMID: 21871868).",Actionable,5768,3672,rhabdoid cancer,DOID,2085,SMARCB1 negative,"[{'id': 5148, 'pubMedId': 21871868, 'title': 'Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21871868'}]",sensitive,850,Palbociclib,6598
1,Preclinical,"In a preclinical study, the combination of Zolinza (vorinostat) and fenretinide induced apoptosis and inhibited growth of rhabdoid tumor cell lines in culture (PMID: 23764045).",Actionable,5764,3672,rhabdoid cancer,DOID,2085,SMARCB1 negative,"[{'id': 5146, 'pubMedId': 23764045, 'title': 'The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23764045'}]",sensitive,3923,Fenretinide + Vorinostat,6598
2,Preclinical,"In a preclinical study, Tazemetostat (EPZ-6438) inhibited growth of SMARCB1-deficient malignant rhabdoid tumore cell lines in culture (PMID: 23620515).",Actionable,5772,3672,rhabdoid cancer,DOID,2085,SMARCB1 negative,"[{'id': 2724, 'pubMedId': 23620515, 'title': 'Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23620515'}]",sensitive,2683,Tazemetostat,6598
3,Preclinical - Cell line xenograft,"In a preclinical study, Alvocidib (flavopiridol) induced cell-cycle arrest and inhibited growth of human rhabdoid tumor cell lines with SMARCB1 biallelic deficiency in culture and inhibted tumor growth in SMARCB1-deficient cell line xenograft models (PMID: 18223228).",Actionable,1181,3672,rhabdoid cancer,DOID,2085,SMARCB1 negative,"[{'id': 923, 'pubMedId': 18223228, 'title': 'Rhabdoid tumor growth is inhibited by flavopiridol.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223228'}]",sensitive,628,Alvocidib,6598
4,Preclinical,"In a preclinical study, DZNep induced apoptosis and cell-cycle arrest and inhibited growth of SMARCB1-negative atypical teratoid rhabdoid tumor cell lines in culture (PMID: 23190500).",Actionable,5765,2129,atypical teratoid rhabdoid tumor,DOID,2085,SMARCB1 negative,"[{'id': 5147, 'pubMedId': 23190500, 'title': 'Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23190500'}]",sensitive,2702,DZNeP,6598
5,Preclinical,"In a preclinical study, DZNep increased radiosensitivity in SMARCB1-negative atypical teratoid rhabdoid tumor cell lines in culture (PMID: 23190500).",Actionable,5766,2129,atypical teratoid rhabdoid tumor,DOID,2085,SMARCB1 negative,"[{'id': 5147, 'pubMedId': 23190500, 'title': 'Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23190500'}]",sensitive,3924,DZNeP + radiotherapy,6598
6,Preclinical,"In a preclinical study, CDKN2A (p16) over expression was associated with decreased sensitivity to Ibrance (palbociclib) in a SMARCB1-negative malignant rhabdoid tumor cell line in culture (PMID: 21871868).",Actionable,5767,3672,rhabdoid cancer,DOID,21572,CDKN2A over exp SMARCB1 negative,"[{'id': 5148, 'pubMedId': 21871868, 'title': 'Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21871868'}]",decreased response,850,Palbociclib,6598
7,Preclinical - Cell culture,"In a preclinical study, over expression of EZH2 Y111D in rhabdoid tumor cells harboring an SMARCB1 inactivating mutation resulted in resistance to Tazemetostat (EPZ-6438) treatment in culture (PMID: 26360609).",Actionable,7826,3672,rhabdoid cancer,DOID,26057,EZH2 Y111D SMARCB1 inact mut,"[{'id': 6504, 'pubMedId': 26360609, 'title': 'Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26360609'}]",resistant,2683,Tazemetostat,6598
8,Preclinical - Cell culture,"In a preclinical study, CFI-400945 inhibited proliferation and decreased survival and migration of SMARCB1-deficient atypical teratoid rhabdoid tumor cells in culture (PMID: 28398638).",Actionable,10779,2129,atypical teratoid rhabdoid tumor,DOID,13297,SMARCB1 loss,"[{'id': 8816, 'pubMedId': 28398638, 'title': 'A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28398638'}]",sensitive,4029,CFI-400945,6598
9,Preclinical - Cell line xenograft,"In a preclinical study, Tazemetostat (EPZ-6438) inhibited H3K27 trimethylation and induced tumor regression in SMARCB1-deleted human cell line xenograft models of  malignant rhabdoid tumors (PMID: 23620515).",Actionable,5774,3672,rhabdoid cancer,DOID,21573,SMARCB1 del,"[{'id': 2724, 'pubMedId': 23620515, 'title': 'Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23620515'}]",sensitive,2683,Tazemetostat,6598
0,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6291,10000003,Advanced Solid Tumor,JAX,23090,SMO T241M,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",decreased response,1428,Sonidegib,6608
1,Preclinical,"In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).",Actionable,6298,10000003,Advanced Solid Tumor,JAX,23090,SMO T241M,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",sensitive,1574,JQ1,6608
2,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6277,10000003,Advanced Solid Tumor,JAX,23090,SMO T241M,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",decreased response,1587,Taladegib,6608
3,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to Erivedge (vismodegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6275,10000003,Advanced Solid Tumor,JAX,23090,SMO T241M,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",decreased response,956,Vismodegib,6608
4,Clinical Study,"In a single patient study, the SMO D473H mutant conferred secondary resistance to the hedgehog pathway inhibitor Erivedge (vismodegib) in a medulloblastoma patient (PMID: 19726788).
",Actionable,1142,50902,medulloblastoma,DOID,1973,SMO D473H,"[{'id': 885, 'pubMedId': 19726788, 'title': 'Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19726788'}]",resistant,956,Vismodegib,6608
5,Phase I,"In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient harboring SMO D473H with resistance to Erivedge (vismodegib) (PMID: 26546616).",Actionable,4279,2513,basal cell carcinoma,DOID,1973,SMO D473H,"[{'id': 4477, 'pubMedId': 26546616, 'title': 'An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26546616'}]",resistant,1428,Sonidegib,6608
6,Preclinical,"In a preclinical study, TAK-441 inhibited Gli-reporter activation in cells transfected with SMO D473H in culture (PMID: 24291104).",Actionable,6074,10000003,Advanced Solid Tumor,JAX,1973,SMO D473H,"[{'id': 5273, 'pubMedId': 24291104, 'title': 'Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24291104'}]",predicted – sensitive,2425,TAK-441,6608
7,Preclinical,"In a preclinical study, LY2940680, inhibited the activity of SMO D473H, which is a mutant that confers resistance to the treatment of vismodegib (Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1, Abstract #2819).",Actionable,1141,10000003,Advanced Solid Tumor,JAX,1973,SMO D473H,"[{'id': 883, 'pubMedId': None, 'title': '', 'url': 'http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/71/8_MeetingAbstracts/2819?si'}]",sensitive,1587,Taladegib,6608
8,Preclinical,"In a preclinical study, transformed human cells expressing SMO L325F displayed reduced binding to MRT-92 (PMID: 25636740).",Actionable,5021,10000003,Advanced Solid Tumor,JAX,19860,SMO L325F,"[{'id': 2240, 'pubMedId': 25636740, 'title': 'MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25636740'}]",predicted – resistant,2418,MRT-92,6608
9,Preclinical,"In a preclinical study, transformed human cells expressing SMO D384A displayed reduced binding to MRT-92 (PMID: 25636740).",Actionable,5017,10000003,Advanced Solid Tumor,JAX,19856,SMO D384A,"[{'id': 2240, 'pubMedId': 25636740, 'title': 'MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25636740'}]",predicted – resistant,2418,MRT-92,6608
10,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6284,10000003,Advanced Solid Tumor,JAX,23088,SMO C469Y,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",decreased response,1587,Taladegib,6608
11,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6285,10000003,Advanced Solid Tumor,JAX,23088,SMO C469Y,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",decreased response,1428,Sonidegib,6608
12,Preclinical,"In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).",Actionable,6292,10000003,Advanced Solid Tumor,JAX,23088,SMO C469Y,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",sensitive,1574,JQ1,6608
13,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to Erivedge (vismodegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6271,10000003,Advanced Solid Tumor,JAX,23088,SMO C469Y,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",decreased response,956,Vismodegib,6608
14,Preclinical,"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO D477G (corresponding to human SMO D473G) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).",Actionable,6307,10000003,Advanced Solid Tumor,JAX,6248,SMO D473G,"[{'id': 5515, 'pubMedId': 26823493, 'title': 'Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26823493'}]",resistant,956,Vismodegib,6608
15,Preclinical,"In a preclinical study, a transformed cell line expressing SMO D473G was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020). ",Actionable,2197,2513,basal cell carcinoma,DOID,6248,SMO D473G,"[{'id': 2677, 'pubMedId': 25759020, 'title': 'Smoothened variants explain the majority of drug resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759020'}]",resistant,956,Vismodegib,6608
16,Preclinical,"In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO D477G (corresponding to human SMO D473G) in culture (PMID: 26823493).",Actionable,6325,10000003,Advanced Solid Tumor,JAX,6248,SMO D473G,"[{'id': 5515, 'pubMedId': 26823493, 'title': 'Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26823493'}]",sensitive,4108,Posaconazole,6608
17,Phase I,"In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient harboring SMO D473G with resistance to Erivedge (vismodegib) (PMID: 26546616).",Actionable,4280,2513,basal cell carcinoma,DOID,6248,SMO D473G,"[{'id': 4477, 'pubMedId': 26546616, 'title': 'An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26546616'}]",resistant,1428,Sonidegib,6608
18,Preclinical,"In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO D477G (corresponding to human SMO D473G) in culture (PMID: 26823493).",Actionable,6335,10000003,Advanced Solid Tumor,JAX,6248,SMO D473G,"[{'id': 5515, 'pubMedId': 26823493, 'title': 'Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26823493'}]",sensitive,4117,Arsenic trioxide + Posaconazole,6608
19,Preclinical,"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO S391N (corresponding to human SMO S387N) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).",Actionable,6310,10000003,Advanced Solid Tumor,JAX,23084,SMO S387N,"[{'id': 5515, 'pubMedId': 26823493, 'title': 'Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26823493'}]",resistant,956,Vismodegib,6608
20,Preclinical,"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO S391N (corresponding to human SMO S387N) were resistant to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).",Actionable,6311,10000003,Advanced Solid Tumor,JAX,23084,SMO S387N,"[{'id': 5515, 'pubMedId': 26823493, 'title': 'Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26823493'}]",resistant,1428,Sonidegib,6608
21,Preclinical,"In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO S391N (corresponding to human SMO S387N) in culture (PMID: 26823493).",Actionable,6327,10000003,Advanced Solid Tumor,JAX,23084,SMO S387N,"[{'id': 5515, 'pubMedId': 26823493, 'title': 'Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26823493'}]",sensitive,4108,Posaconazole,6608
22,Preclinical,"In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO S391N (corresponding to human SMO S387N) in culture (PMID: 26823493).",Actionable,6333,10000003,Advanced Solid Tumor,JAX,23084,SMO S387N,"[{'id': 5515, 'pubMedId': 26823493, 'title': 'Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26823493'}]",sensitive,4117,Arsenic trioxide + Posaconazole,6608
23,Preclinical,"In a preclinical study, mouse sarcoma cell lines over expressing SMO S387N demonstrated reduced response to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 25759019).",Actionable,6304,1115,sarcoma,DOID,23084,SMO S387N,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",decreased response,956,Vismodegib,6608
24,Preclinical,"In a preclinical study, Vismodegib (GDC-0449) inhibited Hedgehog pathway signaling, increased apoptosis, and decreased proliferation of a gastric cancer cell line in culture (PMID: 26676867).",Actionable,5026,10534,stomach cancer,DOID,691,SMO wild-type,"[{'id': 4842, 'pubMedId': 26676867, 'title': 'Reduced proliferation and increased apoptosis of the SGC‑7901 gastric cancer cell line on exposure to GDC‑0449.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26676867'}]",predicted – sensitive,956,Vismodegib,6608
25,Preclinical,"In a preclinical study, LY2940680 was demonstrated to bind to the Smo receptor and inhibit hedgehog signaling in a human medulloblastoma tumor cell line (Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1, Abstract #2819).",Actionable,1140,50902,medulloblastoma,DOID,691,SMO wild-type,"[{'id': 883, 'pubMedId': None, 'title': '', 'url': 'http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/71/8_MeetingAbstracts/2819?si'}]",sensitive,1587,Taladegib,6608
26,Preclinical,"In a preclinical study, amplification of SMO conferred acquired resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring EGFR E746_A750del in culture (PMID: 26124204).",Actionable,2547,3908,non-small cell lung carcinoma,DOID,9076,EGFR E746_A750del SMO amp,"[{'id': 3267, 'pubMedId': 26124204, 'title': 'SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26124204'}]",resistant,751,Gefitinib,6608
27,Preclinical,"In a preclinical study, Odomzo (sonidegib) did not decrease viability or migration of non-small cell lung cancer cells harboring EGFR E746_A750del and amplification of SMO in culture (PMID: 26124204).",Actionable,2656,3908,non-small cell lung carcinoma,DOID,9076,EGFR E746_A750del SMO amp,"[{'id': 3267, 'pubMedId': 26124204, 'title': 'SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26124204'}]",no benefit,1428,Sonidegib,6608
28,Preclinical,"In a preclinical study, the combination of Odomzo (sonidegib) and Iressa (gefitinib) decreased viability and migration of non-small cell lung cancer (NSCLC) cells harboring an EGFR E746_A750del mutation and SMO amplification in culture and inhibited tumor growth in NSCLC xenograft models with EGFR E746_A750del and SMO amplification (PMID: 26124204).",Actionable,2657,3908,non-small cell lung carcinoma,DOID,9076,EGFR E746_A750del SMO amp,"[{'id': 3267, 'pubMedId': 26124204, 'title': 'SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26124204'}]",sensitive,2986,Gefitinib + Sonidegib,6608
29,Preclinical,"In a preclinical study, the combination of Odomzo (sonidegib) and PHA-665752 decreased viability and migration of non-small cell lung cancer (NSCLC) cells harboring EGFR E746_A750del and SMO amplification in culture, and resulted in complete response in 100% (8/8) of NSCLC xenograft models with EGFR E746_A750del and SMO amplification (PMID: 26124204).",Actionable,2658,3908,non-small cell lung carcinoma,DOID,9076,EGFR E746_A750del SMO amp,"[{'id': 3267, 'pubMedId': 26124204, 'title': 'SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26124204'}]",sensitive,2987,PHA-665752 + Sonidegib,6608
30,Phase I,"In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in stable disease in a basal cell carcinoma patient harboring SMO W535L with resistance to Erivedge (vismodegib) (PMID: 26546616).",Actionable,4277,2513,basal cell carcinoma,DOID,3611,SMO W535L,"[{'id': 4477, 'pubMedId': 26546616, 'title': 'An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26546616'}]",predicted – sensitive,1428,Sonidegib,6608
31,Preclinical,"In a preclinical study, Posaconazole did not inhibit Hedghog signaling in mouse fibroblasts over expressing murine SMO W539L (corresponding to human SMO W535L) in culture (PMID: 26823493).",Actionable,6321,10000003,Advanced Solid Tumor,JAX,3611,SMO W535L,"[{'id': 5515, 'pubMedId': 26823493, 'title': 'Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26823493'}]",resistant,4108,Posaconazole,6608
32,Preclinical,"In a preclinical study, a transformed cell line expressing SMO W535L demonstrated resistance to Erivedge (vismodegib) (PMID: 25759020).",Actionable,2169,10000003,Advanced Solid Tumor,JAX,3611,SMO W535L,"[{'id': 2677, 'pubMedId': 25759020, 'title': 'Smoothened variants explain the majority of drug resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759020'}]",resistant,956,Vismodegib,6608
33,Preclinical,"In a preclinical study, treatment with arsenic trioxide resulted in improved survival in a transgenic mouse model of medulloblastoma expressing SMO W535L (PMID: 21183792).",Actionable,1466,50902,medulloblastoma,DOID,3611,SMO W535L,"[{'id': 1335, 'pubMedId': 21183792, 'title': 'Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21183792'}]",sensitive,640,Arsenic trioxide,6608
34,Preclinical,"In a preclinical study, a transformed cell line expressing SMO L412F demonstrated resistance to Erivedge (vismodegib) (PMID: 25759020). ",Actionable,2196,10000003,Advanced Solid Tumor,JAX,6247,SMO L412F,"[{'id': 2677, 'pubMedId': 25759020, 'title': 'Smoothened variants explain the majority of drug resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759020'}]",resistant,956,Vismodegib,6608
35,Preclinical,"In a preclinical study, a transformed cell line expressing SMO Q477E was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020). ",Actionable,2205,2513,basal cell carcinoma,DOID,6279,SMO Q477E,"[{'id': 2677, 'pubMedId': 25759020, 'title': 'Smoothened variants explain the majority of drug resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759020'}]",resistant,956,Vismodegib,6608
36,Phase I,"In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient harboring SMO Q477E with resistance to Erivedge (vismodegib) (PMID: 26546616).",Actionable,4278,2513,basal cell carcinoma,DOID,6279,SMO Q477E,"[{'id': 4477, 'pubMedId': 26546616, 'title': 'An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26546616'}]",no benefit,1428,Sonidegib,6608
37,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6279,10000003,Advanced Solid Tumor,JAX,6277,SMO W281C,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",decreased response,1587,Taladegib,6608
38,Preclinical,"In a preclinical study, a transformed cell line expressing SMO W281C was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020). ",Actionable,2203,2513,basal cell carcinoma,DOID,6277,SMO W281C,"[{'id': 2677, 'pubMedId': 25759020, 'title': 'Smoothened variants explain the majority of drug resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759020'}]",resistant,956,Vismodegib,6608
39,Preclinical,"In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).",Actionable,6297,10000003,Advanced Solid Tumor,JAX,6277,SMO W281C,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",sensitive,1574,JQ1,6608
40,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6290,10000003,Advanced Solid Tumor,JAX,6277,SMO W281C,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",decreased response,1428,Sonidegib,6608
41,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6280,10000003,Advanced Solid Tumor,JAX,5734,SMO V321M,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",decreased response,1587,Taladegib,6608
42,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6289,10000003,Advanced Solid Tumor,JAX,5734,SMO V321M,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",decreased response,1428,Sonidegib,6608
43,Preclinical,"In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO V321M on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).",Actionable,6296,10000003,Advanced Solid Tumor,JAX,5734,SMO V321M,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",sensitive,1574,JQ1,6608
44,Preclinical,"In a preclinical study, a transformed cell line expressing SMO V321M demonstrated resistance to Erivedge (vismodegib) (PMID: 25759020).",Actionable,2170,10000003,Advanced Solid Tumor,JAX,5734,SMO V321M,"[{'id': 2677, 'pubMedId': 25759020, 'title': 'Smoothened variants explain the majority of drug resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759020'}]",resistant,956,Vismodegib,6608
45,Preclinical,"In a preclincal, transformed human cells expressing SMO R400A displayed reduced binding to MRT-92 (PMID: 25636740).",Actionable,5019,10000003,Advanced Solid Tumor,JAX,19859,SMO R400A,"[{'id': 2240, 'pubMedId': 25636740, 'title': 'MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25636740'}]",predicted – sensitive,2418,MRT-92,6608
46,Preclinical,"In a preclinical study, transformed human cells expressing SMO T466F displayed reduced binding to MRT-92 (PMID: 25636740).",Actionable,5023,10000003,Advanced Solid Tumor,JAX,19865,SMO T466F,"[{'id': 2240, 'pubMedId': 25636740, 'title': 'MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25636740'}]",predicted – resistant,2418,MRT-92,6608
47,Preclinical,"In a preclinical study, transformed human cells expressing SMO V329F displayed reduced binding to MRT-92 (PMID: 25636740).",Actionable,5022,10000003,Advanced Solid Tumor,JAX,19862,SMO V329F,"[{'id': 2240, 'pubMedId': 25636740, 'title': 'MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25636740'}]",predicted – resistant,2418,MRT-92,6608
48,Preclinical,"In a preclinical study, transformed human cells expressing SMO M525G displayed reduced binding to MRT-92 (PMID: 25636740).",Actionable,5024,10000003,Advanced Solid Tumor,JAX,19867,SMO M525G,"[{'id': 2240, 'pubMedId': 25636740, 'title': 'MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25636740'}]",predicted – resistant,2418,MRT-92,6608
49,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6287,10000003,Advanced Solid Tumor,JAX,23091,SMO A459V,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",decreased response,1428,Sonidegib,6608
50,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6282,10000003,Advanced Solid Tumor,JAX,23091,SMO A459V,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",decreased response,1587,Taladegib,6608
51,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Erivedge (vismodegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6274,10000003,Advanced Solid Tumor,JAX,23091,SMO A459V,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",decreased response,956,Vismodegib,6608
52,Preclinical,"In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).",Actionable,6293,10000003,Advanced Solid Tumor,JAX,23091,SMO A459V,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",sensitive,1574,JQ1,6608
53,Preclinical,"In a preclinical study, SANT1 inhibited survival of osteosarcoma cell lines with reduced SMO mRNA level in culture (PMID: 26781311).",Actionable,7021,3347,osteosarcoma,DOID,24364,SMO dec exp,"[{'id': 6046, 'pubMedId': 26781311, 'title': 'Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26781311'}]",predicted – sensitive,3990,SANT1,6608
54,Preclinical,"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO N223D (corresponding to human SMO N219D) were resistant to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).",Actionable,6314,10000003,Advanced Solid Tumor,JAX,23086,SMO N219D,"[{'id': 5515, 'pubMedId': 26823493, 'title': 'Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26823493'}]",resistant,1428,Sonidegib,6608
55,Preclinical,"In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO N223D (corresponding to human SMO N219D) in culture (PMID: 26823493).",Actionable,6329,10000003,Advanced Solid Tumor,JAX,23086,SMO N219D,"[{'id': 5515, 'pubMedId': 26823493, 'title': 'Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26823493'}]",sensitive,4108,Posaconazole,6608
56,Preclinical,"In a preclinical study, mouse sarcoma cell lines over expressing SMO N219D demonstrated reduced response to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 25759019).",Actionable,6306,1115,sarcoma,DOID,23086,SMO N219D,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",decreased response,956,Vismodegib,6608
57,Preclinical,"In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO N223D (corresponding to human SMO N219D) in culture (PMID: 26823493).",Actionable,6331,10000003,Advanced Solid Tumor,JAX,23086,SMO N219D,"[{'id': 5515, 'pubMedId': 26823493, 'title': 'Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26823493'}]",sensitive,4117,Arsenic trioxide + Posaconazole,6608
58,Phase I,"In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient with resistance to Erivedge (vismodegib) harboring SMO D533N (PMID: 26546616).",Actionable,4454,2513,basal cell carcinoma,DOID,18162,SMO S533N,"[{'id': 4477, 'pubMedId': 26546616, 'title': 'An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26546616'}]",resistant,1428,Sonidegib,6608
59,Preclinical,"In a preclinical study, a transformed cell line expressing SMO H231R was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020). ",Actionable,2204,2513,basal cell carcinoma,DOID,6278,SMO H231R,"[{'id': 2677, 'pubMedId': 25759020, 'title': 'Smoothened variants explain the majority of drug resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759020'}]",resistant,956,Vismodegib,6608
60,Preclinical,"In a preclinical study, transformed human cells expressing SMO Y394A displayed reduced binding to MRT-92 (PMID: 25636740).",Actionable,5018,10000003,Advanced Solid Tumor,JAX,19858,SMO Y394A,"[{'id': 2240, 'pubMedId': 25636740, 'title': 'MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25636740'}]",predicted – resistant,2418,MRT-92,6608
61,Preclinical,"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO D388N (corresponding to human SMO D384N) were resistant to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).",Actionable,6313,10000003,Advanced Solid Tumor,JAX,23085,SMO D384N,"[{'id': 5515, 'pubMedId': 26823493, 'title': 'Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26823493'}]",resistant,1428,Sonidegib,6608
62,Preclinical,"In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO D388N (corresponding to human SMO D384N) in culture (PMID: 26823493).",Actionable,6328,10000003,Advanced Solid Tumor,JAX,23085,SMO D384N,"[{'id': 5515, 'pubMedId': 26823493, 'title': 'Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26823493'}]",sensitive,4108,Posaconazole,6608
63,Preclinical,"In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO D388N (corresponding to human SMO D384N) in culture (PMID: 26823493).",Actionable,6332,10000003,Advanced Solid Tumor,JAX,23085,SMO D384N,"[{'id': 5515, 'pubMedId': 26823493, 'title': 'Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26823493'}]",sensitive,4117,Arsenic trioxide + Posaconazole,6608
64,Preclinical,"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO D388N (corresponding to human SMO D384N) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).",Actionable,6315,10000003,Advanced Solid Tumor,JAX,23085,SMO D384N,"[{'id': 5515, 'pubMedId': 26823493, 'title': 'Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26823493'}]",resistant,956,Vismodegib,6608
65,Preclinical,"In a preclinical study, mouse sarcoma cell lines over expressing SMO D384N demonstrated reduced response to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 25759019).",Actionable,6305,1115,sarcoma,DOID,23085,SMO D384N,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",decreased response,956,Vismodegib,6608
66,Preclinical,"In a preclinical study, a transformed cell line expressing SMO F460L demonstrated resistance to Erivedge (vismodegib) as compared to wild-type (PMID: 25759020).",Actionable,2195,10000003,Advanced Solid Tumor,JAX,6246,SMO F460L,"[{'id': 2677, 'pubMedId': 25759020, 'title': 'Smoothened variants explain the majority of drug resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759020'}]",resistant,956,Vismodegib,6608
67,Preclinical,"In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO E522K (corresponding to human SMO E518K) in culture (PMID: 26823493).",Actionable,6326,10000003,Advanced Solid Tumor,JAX,19866,SMO E518K,"[{'id': 5515, 'pubMedId': 26823493, 'title': 'Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26823493'}]",sensitive,4108,Posaconazole,6608
68,Preclinical,"In a preclinical study, transformed human cells expressing SMO E518K displayed reduced binding to MRT-92 (PMID: 25636740).",Actionable,5020,10000003,Advanced Solid Tumor,JAX,19866,SMO E518K,"[{'id': 2240, 'pubMedId': 25636740, 'title': 'MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25636740'}]",predicted – resistant,2418,MRT-92,6608
69,Preclinical,"In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO E522K (corresponding to human SMO E518K) in culture (PMID: 26823493).",Actionable,6334,10000003,Advanced Solid Tumor,JAX,19866,SMO E518K,"[{'id': 5515, 'pubMedId': 26823493, 'title': 'Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26823493'}]",sensitive,4117,Arsenic trioxide + Posaconazole,6608
70,Preclinical,"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO E522K (corresponding to human SMO E518K) demonstrated decreased response to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).",Actionable,6316,10000003,Advanced Solid Tumor,JAX,19866,SMO E518K,"[{'id': 5515, 'pubMedId': 26823493, 'title': 'Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26823493'}]",decreased response,1428,Sonidegib,6608
71,Preclinical,"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO E522K (corresponding to human SMO E518K) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).",Actionable,6308,10000003,Advanced Solid Tumor,JAX,19866,SMO E518K,"[{'id': 5515, 'pubMedId': 26823493, 'title': 'Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26823493'}]",resistant,956,Vismodegib,6608
72,Preclinical,"In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).",Actionable,6295,10000003,Advanced Solid Tumor,JAX,23087,SMO I408V,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",sensitive,1574,JQ1,6608
73,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6281,10000003,Advanced Solid Tumor,JAX,23087,SMO I408V,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",decreased response,1587,Taladegib,6608
74,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6288,10000003,Advanced Solid Tumor,JAX,23087,SMO I408V,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",decreased response,1428,Sonidegib,6608
75,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Erivedge (vismodegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6272,10000003,Advanced Solid Tumor,JAX,23087,SMO I408V,"[{'id': 5520, 'pubMedId': 25759019, 'title': 'Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25759019'}]",decreased response,956,Vismodegib,6608
0,Preclinical,"In a preclinical study, BIRB-796 in combination with Sprycel (dasatinib) resulted in improved growth inhibition in both 2D and 3D cultures of triple-receptor negative breast cancer cell lines with elevated Src activity compared to single agent treatment (PMID: 27154914).",Actionable,6877,60081,triple-receptor negative breast cancer,DOID,4696,SRC act mut,"[{'id': 5940, 'pubMedId': 27154914, 'title': 'UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27154914'}]",sensitive,4289,BIRB-796 + Dasatinib,6714
1,Preclinical - Cell line xenograft,"In a preclinical study, UM-164 inhibited proliferation and induced apoptosis in human triple-receptor negative breast cancer cell lines with elevated Src activity in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27154914).",Actionable,6876,60081,triple-receptor negative breast cancer,DOID,4696,SRC act mut,"[{'id': 5940, 'pubMedId': 27154914, 'title': 'UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27154914'}]",predicted – sensitive,4287,UM-164,6714
2,Preclinical,"In a preclinical study, lung cancer cell lines harboring EML4-ALK and elevated Src activity were resistant to Xalkori (crizotinib) induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",Actionable,5835,1324,lung cancer,DOID,21947,EML4 - ALK SRC act mut,"[{'id': 5176, 'pubMedId': None, 'title': 'The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=055d4461-9793-4f83-b663-f356d9ae0fdb&cKey=ff6f8d25-f06a-4ae4-9dbf-7e390ef45123&mKey={1D10D749-4B6A-4AB3-BCD4-F80FB1922267}'}]",resistant,706,Crizotinib,6714
3,Preclinical,"In a preclinical study, lung cancer cell lines harboring EML4-ALK and elevated Src activity were resistant to Zykadia (ceritinib) induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",Actionable,5836,10000003,Advanced Solid Tumor,JAX,21947,EML4 - ALK SRC act mut,"[{'id': 5176, 'pubMedId': None, 'title': 'The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=055d4461-9793-4f83-b663-f356d9ae0fdb&cKey=ff6f8d25-f06a-4ae4-9dbf-7e390ef45123&mKey={1D10D749-4B6A-4AB3-BCD4-F80FB1922267}'}]",resistant,789,Ceritinib,6714
4,Preclinical,"In a preclinical study, TPX-0005 inhibited Alk and Src signaling, and cell proliferation in lung cancer cell lines harboring EML4-ALK and elevated Src activity in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",Actionable,5831,1324,lung cancer,DOID,21947,EML4 - ALK SRC act mut,"[{'id': 5176, 'pubMedId': None, 'title': 'The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors', 'url': 'http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=055d4461-9793-4f83-b663-f356d9ae0fdb&cKey=ff6f8d25-f06a-4ae4-9dbf-7e390ef45123&mKey={1D10D749-4B6A-4AB3-BCD4-F80FB1922267}'}]",sensitive,3950,TPX-0005,6714
5,Phase I,"In a Phase I trial, ARQ 087 treatment resulted in 24% tumor reduction and stable disease for 32 weeks in a squamous non-small cell lung carcinoma patient harboring SRC amplification (J Clin Oncol 33, 2015 (suppl; abstr 2545)).",Actionable,3991,3908,non-small cell lung carcinoma,DOID,17091,SRC amp,"[{'id': 4359, 'pubMedId': None, 'title': 'Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.', 'url': 'http://meetinglibrary.asco.org/content/149025-156'}]",sensitive,2900,ARQ 087,6714
6,Preclinical - Cell line xenograft,"In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture, and resulted in sustained tumor suppression and prolonged survival in cell line xenograft models (PMID: 27222538).",Actionable,7867,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,4599,Dasatinib + Trametinib,6714
7,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).",Actionable,7870,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,4601,Dasatinib + SCH772984,6714
8,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).",Actionable,7860,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,913,Selumetinib,6714
9,Preclinical - Cell line xenograft,"In a preclinical study, thyroid cancer cell lines harboring HRAS G13R and KRAS G12R with an acquired SRC T341M mutation demonstrated resistance to Sprycel (dasatinib) in culture and in cell line xenograft models (PMID: 27222538).",Actionable,7839,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",resistant,717,Dasatinib,6714
10,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).",Actionable,7868,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,4600,Dasatinib + Selumetinib,6714
11,Preclinical - Cell line xenograft,"In a preclinical study, Mekinist (trametinib) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M in culture and in cell line xenograft models (PMID: 27222538).",Actionable,7855,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,"[{'id': 6508, 'pubMedId': 27222538, 'title': 'The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27222538'}]",sensitive,2,Trametinib,6714
12,Preclinical - Pdx,"In a preclinical study, treatment with Tykerb (lapatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft model of bladder cancer with ERBB2 (HER2) over expression, which also over expressed SRC and harbored PIK3CA H1047R (PMID: 26270481).",Actionable,7456,11054,urinary bladder cancer,DOID,25513,ERBB2 over exp PIK3CA H1047R SRC over exp,"[{'id': 6363, 'pubMedId': 26270481, 'title': 'Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26270481'}]",no benefit,787,Lapatinib,6714
13,Preclinical - Pdx,"In a preclinical study, treatment with Iclusig (ponatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft model of bladder cancer with SRC over expression, which also over expressed ERBB2 (HER2) and harbored PIK3CA H1047R (PMID: 26270481).",Actionable,7457,11054,urinary bladder cancer,DOID,25513,ERBB2 over exp PIK3CA H1047R SRC over exp,"[{'id': 6363, 'pubMedId': 26270481, 'title': 'Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26270481'}]",no benefit,877,Ponatinib,6714
14,Phase II,"In a Phase II clinical trial, baseline expression of SRC was not predictive for response to Saracatinib (AZD0530) and Recentin (cediranib) relative to Recentin (cediranib) in patients with metastatic clear-cell renal cell carcinoma (PMID: 26802156).",Actionable,5936,4467,renal clear cell carcinoma,DOID,2760,SRC over exp,"[{'id': 5202, 'pubMedId': 26802156, 'title': 'A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26802156'}]",no benefit,3922,Cediranib + Saracatinib,6714
15,Preclinical - Patient cell culture,"In a preclinical study, the combination of Saracatinib (AZD0530) and (Zykadia) ceritinib demonstrated efficacy in non-small cell lung cancer patient derived cells harboring an ALK fusion and upregulation of SRC in culture (PMID: 25394791).",Actionable,1618,3908,non-small cell lung carcinoma,DOID,26396,ALK rearrange SRC pos,"[{'id': 1693, 'pubMedId': 25394791, 'title': 'Patient-derived models of acquired resistance can identify effective drug combinations for cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25394791'}]",sensitive,1939,Saracatinib + Ceritinib,6714
16,Preclinical - Cell line xenograft,"In a preclinical study, Si306 inhibited SRC phosphorylation and proliferation of SRC-expressing glioblastoma cell lines in culture, and inhibited tumor growth and increased survival in cell line xenograft models (PMID: 27196762).",Actionable,7272,3068,glioblastoma multiforme,DOID,1875,SRC positive,"[{'id': 6269, 'pubMedId': 27196762, 'title': 'Suppression of SRC Signaling Is Effective in Reducing Synergy between Glioblastoma and Stromal Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196762'}]",sensitive,4430,Si306,6714
17,Preclinical,"In a preclinical study, KX2-392 inhibited Src signaling and proliferation in triple-receptor negative breast cancer cell lines in culture, and suppressed tumor growth in xenograft models (PMID: 22784709).",Actionable,5903,60081,triple-receptor negative breast cancer,DOID,1875,SRC positive,"[{'id': 5190, 'pubMedId': 22784709, 'title': 'Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22784709'}]",sensitive,786,KX2-391,6714
18,Preclinical - Cell line xenograft,"In a preclinical study, Bosulif (bosutinib) inhibited Src signaling, resulted in cell cycle arrest and decreased invasion of billary tract cancer cell lines in culture, and delayed tumor growth in cell line xenograft models (PMID: 27196758).",Actionable,9453,4607,biliary tract cancer,DOID,1875,SRC positive,"[{'id': 7196, 'pubMedId': 27196758, 'title': 'Src as a Therapeutic Target in Biliary Tract Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196758'}]",sensitive,690,Bosutinib,6714
19,Preclinical,"In a preclinical study, KX2-392 and Taxol (paclitaxel) worked synergistically to inhibit Src signaling and proliferation of triple-receptor negative breast cancer cell lines in culture, induced tumor regression and suppressed metastasis in xenograft models (PMID: 22784709).",Actionable,5904,60081,triple-receptor negative breast cancer,DOID,1875,SRC positive,"[{'id': 5190, 'pubMedId': 22784709, 'title': 'Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22784709'}]",sensitive,3978,KX2-391 + Paclitaxel,6714
20,Preclinical - Cell line xenograft,"In a preclinical study, Bosulif (bosutinib) and Platinol (cisplatin) synergistically inhibited Src signaling, decreased proliferation and migration of billary tract cancer cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27196758).",Actionable,9455,4607,biliary tract cancer,DOID,1875,SRC positive,"[{'id': 7196, 'pubMedId': 27196758, 'title': 'Src as a Therapeutic Target in Biliary Tract Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196758'}]",sensitive,5021,Bosutinib + Cisplatin,6714
21,Preclinical - Cell line xenograft,"In a preclinical study, Si306 in combination with radiotherapy decreased growth of radiotherapy-sensitive SRC-positive glioblastoma cells in culture and decreased tumor growth in cell line xenograft models, with increased efficacy compared to Si306 or radiotherapy alone (PMID: 27196762).",Actionable,7273,3068,glioblastoma multiforme,DOID,1875,SRC positive,"[{'id': 6269, 'pubMedId': 27196762, 'title': 'Suppression of SRC Signaling Is Effective in Reducing Synergy between Glioblastoma and Stromal Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196762'}]",sensitive,4431,Si306 + Radiotherapy,6714
22,Preclinical - Cell line xenograft,"In a preclinical study, Bosulif (bosutinib) and Gemzar (gemcitabine) synergistically inhibited Src signaling, decreased proliferation and migration of billary tract cancer cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27196758).",Actionable,9454,4607,biliary tract cancer,DOID,1875,SRC positive,"[{'id': 7196, 'pubMedId': 27196758, 'title': 'Src as a Therapeutic Target in Biliary Tract Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196758'}]",sensitive,5020,Bosutinib + Gemcitabine,6714
23,Preclinical,"In a preclinical study, Sprycel (dasatinib) exhibits a strong antitumoral effect in GBM cell lines with high levels of SRC phosphorylation (PMID: 19098899).",Actionable,1103,3068,glioblastoma multiforme,DOID,1875,SRC positive,"[{'id': 845, 'pubMedId': 19098899, 'title': 'Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19098899'}]",sensitive,717,Dasatinib,6714
24,Preclinical,"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S acquired resistance to Sprycel (dasatinib) after over expressing SRC T341I in culture (PMID: 27231123).",Actionable,7355,4928,intrahepatic cholangiocarcinoma,DOID,25297,IDH1 R132C SRC T341I,"[{'id': 6322, 'pubMedId': 27231123, 'title': 'Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27231123'}]",resistant,717,Dasatinib,6714
0,Clinical Study,"In multiple clinical studies, SRSF2 mutations were associated with shortened survival in patients with myelodysplastic syndrome (PMID: 26769228, PMID: 26508027).",Prognostic,6212,50908,myelodysplastic syndrome,DOID,22843,SRSF2 mutant,"[{'id': 5327, 'pubMedId': 26769228, 'title': 'Myelodysplastic syndromes: Contemporary review and how we treat.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26769228'}, {'id': 5467, 'pubMedId': 26508027, 'title': 'Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26508027'}]",not applicable,1776,N/A,6427
0,Preclinical,"In a preclinical study, colorectal cancer cells with knockdown of STAG2 expression demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture (PMID: 24356817).",Actionable,6217,9256,colorectal cancer,DOID,22919,STAG2 dec exp,"[{'id': 5471, 'pubMedId': 24356817, 'title': 'Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24356817'}]",sensitive,837,Olaparib,10735
1,Preclinical - Cell culture,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in NRAS mutated melanoma cell lines resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).",Actionable,7794,1909,melanoma,DOID,26045,NRAS mut STAG2 dec exp,"[{'id': 6497, 'pubMedId': 27500726, 'title': 'Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27500726'}]",decreased response,2,Trametinib,10735
2,Preclinical - Cell culture,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment in culture (PMID: 27500726).",Actionable,7793,1909,melanoma,DOID,26042,BRAF mut STAG2 dec exp,"[{'id': 6497, 'pubMedId': 27500726, 'title': 'Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27500726'}]",decreased response,1066,Trametinib + Dabrafenib,10735
3,Preclinical - Cell culture,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Tafinlar (dabrafenib) in culture (PMID: 27500726).",Actionable,7790,1909,melanoma,DOID,26042,BRAF mut STAG2 dec exp,"[{'id': 6497, 'pubMedId': 27500726, 'title': 'Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27500726'}]",decreased response,3,Dabrafenib,10735
4,Preclinical - Cell line xenograft,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Zelboraf (vemurafenib) both in culture and in cell line xenograft models (PMID: 27500726).",Actionable,7791,1909,melanoma,DOID,26042,BRAF mut STAG2 dec exp,"[{'id': 6497, 'pubMedId': 27500726, 'title': 'Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27500726'}]",decreased response,342,Vemurafenib,10735
5,Preclinical - Cell culture,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).",Actionable,7792,1909,melanoma,DOID,26042,BRAF mut STAG2 dec exp,"[{'id': 6497, 'pubMedId': 27500726, 'title': 'Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27500726'}]",decreased response,2,Trametinib,10735
6,Preclinical,"In a preclinical study, glioblastoma cells harboring STAG2 S653* demonstrated increased sensitivity to the combination of Lynparza (olaparib) and camptothecin compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817, PMID: 21852505).",Actionable,6220,3068,glioblastoma multiforme,DOID,22907,STAG2 S653*,"[{'id': 5470, 'pubMedId': 21852505, 'title': 'Mutational inactivation of STAG2 causes aneuploidy in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21852505'}, {'id': 5471, 'pubMedId': 24356817, 'title': 'Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24356817'}]",sensitive,3397,Camptothecin,10735
7,Preclinical,"In a preclinical study, a glioblastoma cell line harboring STAG2 S653* demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817, PMID: 21852505).",Actionable,6216,3068,glioblastoma multiforme,DOID,22907,STAG2 S653*,"[{'id': 5470, 'pubMedId': 21852505, 'title': 'Mutational inactivation of STAG2 causes aneuploidy in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21852505'}, {'id': 5471, 'pubMedId': 24356817, 'title': 'Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24356817'}]",sensitive,837,Olaparib,10735
8,Preclinical - Cell culture,"In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to treatment with Veliparib (ABT-888) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817).",Actionable,6214,3068,glioblastoma multiforme,DOID,22904,STAG2 N357fs,"[{'id': 5470, 'pubMedId': 21852505, 'title': 'Mutational inactivation of STAG2 causes aneuploidy in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21852505'}, {'id': 5471, 'pubMedId': 24356817, 'title': 'Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24356817'}]",sensitive,954,Veliparib,10735
9,Preclinical,"In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505), demonstrated increased sensitivity to treatment with Rubraca (rucaparib) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817).",Actionable,6215,3068,glioblastoma multiforme,DOID,22904,STAG2 N357fs,"[{'id': 5470, 'pubMedId': 21852505, 'title': 'Mutational inactivation of STAG2 causes aneuploidy in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21852505'}, {'id': 5471, 'pubMedId': 24356817, 'title': 'Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24356817'}]",sensitive,906,Rucaparib,10735
10,Preclinical - Cell culture,"In a preclinical study, glioblastoma cells harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to the combination of Lynparza (olaparib) and camptothecin compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817).",Actionable,6219,3068,glioblastoma multiforme,DOID,22904,STAG2 N357fs,"[{'id': 5470, 'pubMedId': 21852505, 'title': 'Mutational inactivation of STAG2 causes aneuploidy in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21852505'}, {'id': 5471, 'pubMedId': 24356817, 'title': 'Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24356817'}]",sensitive,4095,Camptothecin + Olaparib,10735
11,Preclinical - Cell culture,"In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505)  demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture, resulting in decreased proliferation and colony formation, and increased DNA damage compared to isogenic cells with wild-type STAG2 (PMID: 24356817).",Actionable,6213,3068,glioblastoma multiforme,DOID,22904,STAG2 N357fs,"[{'id': 5471, 'pubMedId': 24356817, 'title': 'Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24356817'}]",sensitive,837,Olaparib,10735
12,Preclinical - Cell culture,"In a preclinical study, glioblastoma cells harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to the combination of Lynparza (olaparib) and Temodar (temozolomide) compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817).",Actionable,6218,3068,glioblastoma multiforme,DOID,22904,STAG2 N357fs,"[{'id': 5470, 'pubMedId': 21852505, 'title': 'Mutational inactivation of STAG2 causes aneuploidy in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21852505'}, {'id': 5471, 'pubMedId': 24356817, 'title': 'Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24356817'}]",sensitive,1438,Olaparib + Temozolomide,10735
0,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 E57fs, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).",Actionable,10532,3908,non-small cell lung carcinoma,DOID,27555,STK11 E57fs,"[{'id': 7607, 'pubMedId': 27821489, 'title': 'A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27821489'}]",sensitive,2,Trametinib,6794
1,Preclinical - Cell culture,"In a preclinical study, the presence an STK11 loss expression signature, which correlates with STK11 inactivating mutations, was associated with increased sensitivity to CI-1040 (PD184352) in human tumor cell lines in culture (PMID: 27821489).",Actionable,9800,10000003,Advanced Solid Tumor,JAX,8084,STK11 inact mut,"[{'id': 7607, 'pubMedId': 27821489, 'title': 'A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27821489'}]",sensitive,699,CI-1040,6794
2,Preclinical,"In a preclinical study, Rapamune (sirolimus) reduced S6K phosphorylation and inhibited tumor growth in mouse models of STK11 (LKB1)-deficient endometrial cancer, including models with advanced tumors (PMID: 20142330).",Actionable,5447,1380,endometrial cancer,DOID,8084,STK11 inact mut,"[{'id': 5060, 'pubMedId': 20142330, 'title': 'Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20142330'}]",sensitive,917,Sirolimus,6794
3,Preclinical - Cell culture,"In a preclinical study, the presence of an STK11 loss expression signature, which correlated to STK11 inactivating mutations, was associated with increased sensitivity to Mekinist (trametinib) in human tumor cell lines in culture (PMID: 27821489).",Actionable,9793,10000003,Advanced Solid Tumor,JAX,8084,STK11 inact mut,"[{'id': 7607, 'pubMedId': 27821489, 'title': 'A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27821489'}]",sensitive,2,Trametinib,6794
4,Preclinical - Cell culture,"In a preclinical study, the presence of an STK11 loss expression signature, which correlates with STK11 inactivating mutations, was associated with increased sensitivity to PD-0325901 in human tumor cell lines in culture (PMID: 27821489).",Actionable,9801,10000003,Advanced Solid Tumor,JAX,8084,STK11 inact mut,"[{'id': 7607, 'pubMedId': 27821489, 'title': 'A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27821489'}]",sensitive,849,PD-0325901,6794
5,Preclinical - Cell culture,"In a preclinical study, the presence of an STK11 loss expression signature, which correlates with STK11 inactivating mutations, was associated with increased sensitivity to RDEA119 in human tumor cell lines in culture (PMID: 27821489).",Actionable,9799,10000003,Advanced Solid Tumor,JAX,8084,STK11 inact mut,"[{'id': 7607, 'pubMedId': 27821489, 'title': 'A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27821489'}]",sensitive,887,RDEA119,6794
6,Clinical Study,"In a clinical case study, a patient with adenocorticotropic pituitary carcinoma harboring an STK11 inactivating mutation demonstrated clinical efficacy for greater than 6 months when treated with a combination of Afinitor (everolimus) and radiotherapy (PMID: 27615706).",Actionable,9512,4916,pituitary carcinoma,DOID,8084,STK11 inact mut,"[{'id': 7245, 'pubMedId': 27615706, 'title': 'Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27615706'}]",sensitive,5060,Everolimus + Radiotherapy,6794
7,Preclinical - Cell culture,"In a preclinical study, the presence of an STK11 inactivating mutation and STK11 loss expression signature was associated with increased sensitivity to Selumetinib (AZD6244) in human tumor cell lines in culture (PMID: 27821489).",Actionable,9792,10000003,Advanced Solid Tumor,JAX,8084,STK11 inact mut,"[{'id': 7607, 'pubMedId': 27821489, 'title': 'A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27821489'}]",sensitive,913,Selumetinib,6794
8,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).",Actionable,9794,3908,non-small cell lung carcinoma,DOID,8084,STK11 inact mut,"[{'id': 7607, 'pubMedId': 27821489, 'title': 'A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27821489'}]",sensitive,2,Trametinib,6794
9,Preclinical,"In a preclinical study, Sapanisertib (MLN0128) inhibited lung tumor growth in mouse models with KRAS G12D and inactivation of STK11 (LKB1), and demonstrated limited efficacy in tumors with KRAS G12D and wild-type STK11 (PMID: 26574479).",Actionable,5409,1324,lung cancer,DOID,20862,KRAS G12D STK11 inact mut,"[{'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",sensitive,1282,Sapanisertib,6794
10,Preclinical - Cell culture,"In a preclinical study, MK-1775 and Platinol (cisplatin) combination treatment demonstrated enhanced growth inhibition in non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations compared to cells expressing wild-type STK11 in culture (PMID: 28652249).",Actionable,11857,3908,non-small cell lung carcinoma,DOID,20861,KRAS mut STK11 inact mut,"[{'id': 9874, 'pubMedId': 28652249, 'title': 'WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28652249'}]",predicted – sensitive,1725,MK-1775 + Cisplatin,6794
11,Preclinical - Cell culture,"In a preclinical study, MK-1775 combined with radiation therapy demonstrated enhanced growth inhibition in non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations compared to cells expressing wild-type STK11 in culture (PMID: 28652249).",Actionable,11858,3908,non-small cell lung carcinoma,DOID,20861,KRAS mut STK11 inact mut,"[{'id': 9874, 'pubMedId': 28652249, 'title': 'WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28652249'}]",predicted – sensitive,4186,MK-1775 + Radiotherapy,6794
12,Preclinical,"In a preclinical study, Sapanisertib (MLN0128) in combination with phenformin induced apoptosis and energetic stress in human lung adenocarcinoma cell lines with concurrent KRAS and STK11 (LKB1) mutations in culture, with higher levels than either therapy as a single agent (PMID: 26574479).",Actionable,5408,3910,lung adenocarcinoma,DOID,20861,KRAS mut STK11 inact mut,"[{'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",sensitive,3861,MLN0128 + Phenformin,6794
13,Preclinical - Cell line xenograft,"In a preclinical study, a non-small cell lung carcinoma cell line harboring a KRAS mutation and STK11 inactivating mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413). ",Actionable,10705,3908,non-small cell lung carcinoma,DOID,20861,KRAS mut STK11 inact mut,"[{'id': 8768, 'pubMedId': 24634413, 'title': 'Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24634413'}]",sensitive,1051,SAR245409,6794
14,Preclinical - Cell culture,"In a preclinical study, non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations demonstrated increased sensitivity to MK-1775 compared to cells expressing wild-type STK11 in culture (PMID: 28652249).",Actionable,11856,3908,non-small cell lung carcinoma,DOID,20861,KRAS mut STK11 inact mut,"[{'id': 9874, 'pubMedId': 28652249, 'title': 'WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28652249'}]",predicted – sensitive,822,MK-1775,6794
15,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a human non-small cell lung cancer cell line harboring KRAS G12S and an STK11(LKB) inactivating mutation (PMID: 25637314).",Actionable,6336,3908,non-small cell lung carcinoma,DOID,23102,KRAS G12S STK11 inact mut,"[{'id': 5522, 'pubMedId': 25637314, 'title': 'The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25637314'}]",sensitive,1050,XL147,6794
16,Clinical Study,"In a clinical case study, a pancreatic cancer patient with Peutz-Jeghers syndrome harboring STK11 D194E and loss of heterozygosity of the other STK11 allele in the tumor achieved a partial response following treatment with Afinitor (everolimus), but progressed after 9 months (PMID: 21189378).",Actionable,5451,1793,pancreatic cancer,DOID,20914,STK11 D194E STK11 loss,"[{'id': 5063, 'pubMedId': 21189378, 'title': 'mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21189378'}]",sensitive,735,Everolimus,6794
17,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 E199*, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).",Actionable,9796,3908,non-small cell lung carcinoma,DOID,11914,STK11 E199*,"[{'id': 7607, 'pubMedId': 27821489, 'title': 'A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27821489'}]",sensitive,2,Trametinib,6794
18,Preclinical - Cell line xenograft,"In a preclinical study, PKI-402 inhibited growth of a non-small cell lung cancer cell line harboring both KRAS and STK11 mutations in culture and in cell line xenograft models (PMID: 20371716).",Actionable,5398,3908,non-small cell lung carcinoma,DOID,20858,KRAS mut STK11 mut,"[{'id': 5041, 'pubMedId': 20371716, 'title': 'Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20371716'}]",sensitive,3857,PKI-402,6794
19,Clinical Study,"In a clinical study, mutant STK11 correlated with a worse response to Opdivo (nivolumab) compared to wild-type STK11 in non-small cell lung carcinoma patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 1138PD).",Actionable,12098,3908,non-small cell lung carcinoma,DOID,1246,STK11 mutant,"[{'id': 10039, 'pubMedId': None, 'title': 'Immune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC)', 'url': 'http://www.esmo.org/content/download/117241/2057634/file/ESMO-2017-Abstract-Book.pdf'}]",decreased response,1312,Nivolumab,6794
20,Preclinical,"In a preclinical study, Gedatolisib (PF-05212384) inhibited growth of human non-small cell lung carcinoma cells harboring an STK11 mutation in culture (PMID: 21325073).",Actionable,3154,3908,non-small cell lung carcinoma,DOID,1246,STK11 mutant,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}]",sensitive,1040,PF-05212384,6794
21,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 K48fs, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).",Actionable,9802,3908,non-small cell lung carcinoma,DOID,27553,STK11 K48fs,"[{'id': 7607, 'pubMedId': 27821489, 'title': 'A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27821489'}]",sensitive,2,Trametinib,6794
22,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 W332*, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).",Actionable,9797,3908,non-small cell lung carcinoma,DOID,18157,STK11 W332*,"[{'id': 7607, 'pubMedId': 27821489, 'title': 'A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27821489'}]",sensitive,2,Trametinib,6794
23,Preclinical - Cell line xenograft,"In a preclinical study, knockdown of STK11 increased sensitivity to Mekinist (trametinib) in non-small cell lung cancer cell lines in culture and in xenograft models (PMID: 27821489).",Actionable,9798,3908,non-small cell lung carcinoma,DOID,27096,STK11 dec exp,"[{'id': 7607, 'pubMedId': 27821489, 'title': 'A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27821489'}]",sensitive,2,Trametinib,6794
24,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 Q37*, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).",Actionable,9795,3908,non-small cell lung carcinoma,DOID,12105,STK11 Q37*,"[{'id': 7607, 'pubMedId': 27821489, 'title': 'A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27821489'}]",sensitive,2,Trametinib,6794
25,Preclinical,"In a preclinical study, AZD8055 inhibited tumor growth in a mouse model of spontaneous breast cancer harboring an ERBB2 (HER2) activating mutation and loss of STK11 (LKB1), which was enhanced by the addition of 2-DG (2-deoxyglucose) (PMID: 25436981).",Actionable,5405,1612,breast cancer,DOID,20860,ERBB2 act mut STK11 loss,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}]",sensitive,1519,AZD8055,6794
26,Preclinical,"In a preclinical study,  MK-1775 and Platinol (cisplatin) combination treatment resulted in improved survival in transgenic animal models of non-small cell lung carcinoma harboring KRAS G12D and STK11 loss compared to Platinol (cisplatin) alone (PMID: 28652249).",Actionable,11860,3908,non-small cell lung carcinoma,DOID,28318,KRAS G12D STK11 loss,"[{'id': 9874, 'pubMedId': 28652249, 'title': 'WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28652249'}]",predicted – sensitive,1725,MK-1775 + Cisplatin,6794
27,Preclinical,"In a preclinical study, Glucophage (metformin) was unable to inhibit cancer cell growth in cancer cell lines with biallelic loss of STK11 (PMID: 17062558, 18006825).",Actionable,1111,10000003,Advanced Solid Tumor,JAX,1882,STK11 loss,"[{'id': 853, 'pubMedId': 18006825, 'title': 'Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18006825'}, {'id': 854, 'pubMedId': 17062558, 'title': 'Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17062558'}]",no benefit,1031,Metformin,6794
28,Preclinical,"In a preclinical study, PD-1 antibodies were ineffective in treating Stk11 (also known as Lkb1) deficient lung tumors in mice (PMID: 26833127).",Actionable,5597,1324,lung cancer,DOID,1882,STK11 loss,"[{'id': 5119, 'pubMedId': 26833127, 'title': 'STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26833127'}]",resistant,3890,unspecified PD-1 antibody,6794
29,Preclinical - Cell culture,"In a preclinical study,  non-small cell lung carcinoma cells harboring KRAS mutation, STK11 and TP53 loss demonstrated increased sensitivity to MK-1775 and Platinol (cisplatin) combination treatment in culture compared to isogenic cell lines expressing wild-type Tp53 or Stk11 (PMID: 28652249).",Actionable,11859,3908,non-small cell lung carcinoma,DOID,28317,KRAS mut STK11 loss TP53 loss,"[{'id': 9874, 'pubMedId': 28652249, 'title': 'WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28652249'}]",predicted – sensitive,1725,MK-1775 + Cisplatin,6794
30,Preclinical,"In a preclinical study, the PI3K inhibitor GDC-0941 reduced tumor growth rate in immunodeficient mice engrafted with endometrial tumors from PTEN/STK11 (LKB1) deficient mice (PMID: 24322983).",Actionable,601,1380,endometrial cancer,DOID,18395,PTEN loss STK11 loss,"[{'id': 350, 'pubMedId': 24322983, 'title': 'A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24322983'}]",sensitive,749,GDC-0941,6794
31,Preclinical,"In a preclinical studies, Glucophage (metformin) inhibited cancer cell growth by activating the AMP kinase pathway in a variety of cancer cell lines that retained one functional allele of STK11 (PMID: 17062558, 18006825).",Actionable,1109,10000003,Advanced Solid Tumor,JAX,693,STK11 wild-type,"[{'id': 853, 'pubMedId': 18006825, 'title': 'Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18006825'}, {'id': 854, 'pubMedId': 17062558, 'title': 'Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17062558'}]",sensitive,1031,Metformin,6794
0,Clinical Study,"In a clinical study, myelodysplastic syndrome patients carrying wild-type ASXL1 and TET2 mutations demonstrated increased response to the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) (PMID: 25224413).",Actionable,6169,4972,myelodysplastic/myeloproliferative neoplasm,DOID,22786,ASXL1 wild-type TET2 mutant,"[{'id': 3740, 'pubMedId': 25224413, 'title': 'TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25224413'}]",sensitive,651,Azacitidine,54790
1,Clinical Study,"In a clinical study, myelodysplastic syndrome patients carrying wild-type ASXL1 and TET2 mutations demonstrated increased response to the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) (PMID: 25224413).",Actionable,6170,4972,myelodysplastic/myeloproliferative neoplasm,DOID,22786,ASXL1 wild-type TET2 mutant,"[{'id': 3740, 'pubMedId': 25224413, 'title': 'TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25224413'}]",sensitive,650,Decitabine,54790
2,Clinical Study,"In multiple clinical studies, including a meta-analysis, TET2 mutations were associated with shorter overall survival in patients with acute myeloid leukemia (PMID: 24524305, PMID: 25412851, PMID: 24994606).",Prognostic,6223,9119,acute myeloid leukemia,DOID,13182,TET2 mutant,"[{'id': 5481, 'pubMedId': 24524305, 'title': 'Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24524305'}, {'id': 5482, 'pubMedId': 25412851, 'title': 'Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25412851'}, {'id': 5483, 'pubMedId': 24994606, 'title': 'Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24994606'}]",not applicable,1776,N/A,54790
3,Clinical Study,"In clinical analyses, TET2 mutations correlated with favorable prognosis and increased response to treatment in patients with myelodysplastic syndrome (PMID: 25224413, PMID: 26769228, PMID: 19666869, PMID: 23099237, PMID: 24507812).",Prognostic,3333,50908,myelodysplastic syndrome,DOID,13182,TET2 mutant,"[{'id': 3740, 'pubMedId': 25224413, 'title': 'TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25224413'}, {'id': 5327, 'pubMedId': 26769228, 'title': 'Myelodysplastic syndromes: Contemporary review and how we treat.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26769228'}, {'id': 5377, 'pubMedId': 24507812, 'title': 'Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24507812'}, {'id': 5378, 'pubMedId': 23099237, 'title': 'TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23099237'}, {'id': 5379, 'pubMedId': 19666869, 'title': 'TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19666869'}]",not applicable,1776,N/A,54790
4,Phase I,"In a retrospective analysis, presence of a TET2 mutation correlated with higher overall response rate (ORR) in patients with myelodysplastic syndrome and acute myeloid leukemia following treatment with Vidaza (azacitidine), with an ORR of 85% (11/3) in TET2-mutated patients, compared to 47% (34/47) in patients with wild-type TET2, but did not correlate with overall survival (PMID: 21494260).",Actionable,3330,9119,acute myeloid leukemia,DOID,13182,TET2 mutant,"[{'id': 3737, 'pubMedId': 21494260, 'title': 'Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21494260'}]",predicted – sensitive,651,Azacitidine,54790
0,Preclinical - Patient cell culture,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived fallopian tube cancer cells harboring TP53 C238F in culture (PMID: 27179933). ",Actionable,9806,1964,fallopian tube cancer,DOID,26954,TP53 C238F,"[{'id': 7621, 'pubMedId': 27179933, 'title': 'Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27179933'}]",sensitive,3443,APR-246 + Cisplatin,7157
1,Preclinical,"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 P177T in culture (PMID: 26438783).",Actionable,4738,769,neuroblastoma,DOID,18889,ALK	wild-type TP53 P177T,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,7157
2,Preclinical,"In a preclinical study, TP53 P177T resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).",Actionable,914,3347,osteosarcoma,DOID,1484,TP53 P177T,"[{'id': 585, 'pubMedId': 21643018, 'title': 'Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21643018'}]",resistant,1405,Nutlin-3a,7157
3,Preclinical - Pdx,"In a preclinical study, BEZ235 delayed tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).",Actionable,8701,9256,colorectal cancer,DOID,26375,KRAS G12V PIK3CA Q546K TP53 R282W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",decreased response,672,BEZ235,7157
4,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K and TP53 R282W (PMID: 26272063).",Actionable,8600,9256,colorectal cancer,DOID,26375,KRAS G12V PIK3CA Q546K TP53 R282W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,1420,Selumetinib + BEZ235,7157
5,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) inhibited tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).",Actionable,8700,9256,colorectal cancer,DOID,26375,KRAS G12V PIK3CA Q546K TP53 R282W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",predicted – sensitive,913,Selumetinib,7157
6,Preclinical - Patient cell culture,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 P151H in culture (PMID: 27179933). ",Actionable,9804,2394,ovarian cancer,DOID,5647,TP53 P151H,"[{'id': 7621, 'pubMedId': 27179933, 'title': 'Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27179933'}]",sensitive,3443,APR-246 + Cisplatin,7157
7,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R335fs (PMID: 26272063).",Actionable,8578,9256,colorectal cancer,DOID,26368,KRAS G12V PIK3CA E545K TP53 R335fs,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,4771,MLN0128 + PD-0325901,7157
8,Phase I,"In a Phase I clinical trial, a breast cancer patient carrying TP53 P72R and Y220C mutations demonstrated incomplete response to treatment with an Ellence (epirubicin)-Cytoxan (cyclophosphamide) combination regimen (PMID: 17388661).",Actionable,745,1612,breast cancer,DOID,1050,TP53 P72R TP53 Y220C,"[{'id': 446, 'pubMedId': 17388661, 'title': 'Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17388661'}]",no benefit,1087,Epirubicin + Cyclophosphamide,7157
9,Phase I,"In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804).",Actionable,329,1612,breast cancer,DOID,621,TP53 P72R,"[{'id': 13, 'pubMedId': 16243804, 'title': 'p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16243804'}]",predicted – sensitive,1008,Doxil,7157
10,Phase I,"In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations, who were also hormone receptor negative, demonstrated a favorable response to Ellence (epirubicin) in combination with other chemotherapeutic agents (PMID: 22903472).",Actionable,341,1612,breast cancer,DOID,621,TP53 P72R,"[{'id': 67, 'pubMedId': 22903472, 'title': 'Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22903472'}]",sensitive,1013,epirubicin,7157
11,Phase I,"In a Phase I clinical trial, sarcoma patients harboring TP53 P72R mutations had longer progression-free survival after treatment with Cyfos (ifosfamide) and Adriamycin (doxorubicin) (PMID: 23165797).",Actionable,845,1115,sarcoma,DOID,621,TP53 P72R,"[{'id': 485, 'pubMedId': 23165797, 'title': 'Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23165797'}]",sensitive,1472,Doxorubicin + Ifosfamide,7157
12,Phase I,"In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804).",Actionable,324,1612,breast cancer,DOID,621,TP53 P72R,"[{'id': 13, 'pubMedId': 16243804, 'title': 'p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16243804'}]",predicted – sensitive,1006,Daunorubicin,7157
13,Phase I,"In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804).",Actionable,325,1612,breast cancer,DOID,621,TP53 P72R,"[{'id': 13, 'pubMedId': 16243804, 'title': 'p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16243804'}]",predicted – sensitive,1007,Daunoxome,7157
14,Phase I,"In a Phase I clinical trial, breast cancer patients harboring TP53 P72R who were estrogen receptor negative had a more favorable response to Doxil (doxorubicin) in combination with Adrucil (fluorouracil) and Cytoxan (cyclophosphamide) (PMID: 16243804).",Actionable,330,60076,estrogen-receptor negative breast cancer,DOID,621,TP53 P72R,"[{'id': 13, 'pubMedId': 16243804, 'title': 'p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16243804'}]",sensitive,1706,Doxorubicin + Flourouracil + Cyclophosphamide,7157
15,Phase I,"In phase I clinical studies, NSCLC patients with TP53 P72R mutations had a longer progression-free survival than wild-type TP53 patients, after combined treatment with Camptosar (irinotecan) and  Platinol (cisplatin) (PMID: 18618574).",Actionable,925,3908,non-small cell lung carcinoma,DOID,621,TP53 P72R,"[{'id': 603, 'pubMedId': 18618574, 'title': 'Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18618574'}]",sensitive,1406,Camptosar + Cisplatin,7157
16,Phase II,"In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 E298* and mutations in BRCA1 (PMID: 27998224). ",Actionable,11779,2394,ovarian cancer,DOID,28241,BRCA1 mut TP53 E298*,"[{'id': 9762, 'pubMedId': 27998224, 'title': 'Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27998224'}]",predicted – sensitive,1194,MK-1775 + Carboplatin ,7157
17,Preclinical - Pdx,"In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12D and TP53 S127Y (PMID: 26855149).",Actionable,10885,3910,lung adenocarcinoma,DOID,27819,KRAS G12D TP53 S127Y,"[{'id': 8887, 'pubMedId': 26855149, 'title': 'Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26855149'}]",sensitive,5671,Dasatinib + Demcizumab,7157
18,Preclinical - Patient cell culture,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 P278R in culture (PMID: 27179933). ",Actionable,9809,2394,ovarian cancer,DOID,27100,TP53 P278R,"[{'id': 7621, 'pubMedId': 27179933, 'title': 'Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27179933'}]",sensitive,3443,APR-246 + Cisplatin,7157
19,Preclinical - Pdx,"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to BEZ235 treatment (PMID: 26272063).",Actionable,8699,9256,colorectal cancer,DOID,26374,KRAS G12V PIK3CA E545K TP53 R273*,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",resistant,672,BEZ235,7157
20,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K and TP53 R273* (PMID: 26272063).",Actionable,8597,9256,colorectal cancer,DOID,26374,KRAS G12V PIK3CA E545K TP53 R273*,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,1420,Selumetinib + BEZ235,7157
21,Preclinical - Pdx,"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).",Actionable,8698,9256,colorectal cancer,DOID,26374,KRAS G12V PIK3CA E545K TP53 R273*,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",resistant,913,Selumetinib,7157
22,Preclinical,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of small lung cancer cells harboring TP53 Y163C in culture (PMID: 26086967).
",Actionable,4098,5409,lung small cell carcinoma,DOID,5742,TP53 Y163C,"[{'id': 4407, 'pubMedId': 26086967, 'title': 'APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26086967'}]",sensitive,3443,APR-246 + Cisplatin,7157
23,Preclinical,"In a preclinical study, Ganetespib inhibited growth of human prostate cancer cells harboring TP53 P223L and V274F in culture (PMID: 26009011).",Actionable,5016,10283,prostate cancer,DOID,19855,TP53 P223L TP53 V274F,"[{'id': 4831, 'pubMedId': 26009011, 'title': 'Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26009011'}]",resistant,745,Ganetespib,7157
24,Phase II,"In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 G105C, V157fs and mutations in Kras (PMID: 27998224). ",Actionable,11778,2394,ovarian cancer,DOID,28237,KRAS mut TP53 G105C TP53 V157fs,"[{'id': 9762, 'pubMedId': 27998224, 'title': 'Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27998224'}]",predicted – sensitive,1194,MK-1775 + Carboplatin ,7157
25,Preclinical,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of non-small lung cancer cells harboring TP53 R248W in culture (PMID: 26086967).",Actionable,4096,3908,non-small cell lung carcinoma,DOID,3386,TP53 R248W,"[{'id': 4407, 'pubMedId': 26086967, 'title': 'APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26086967'}]",sensitive,3443,APR-246 + Cisplatin,7157
26,Preclinical - Cell culture,"In a preclinical study, TP53 R248W was associated with resistance to PT2399 in VHL-defective clear cell renal cell carcinoma cell lines in culture (PMID: 27595393).",Actionable,8269,4467,renal clear cell carcinoma,DOID,26217,TP53 R248W VHL inact mut,"[{'id': 6586, 'pubMedId': 27595393, 'title': 'On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27595393'}]",resistant,4670,PT2399,7157
27,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R and TP53 R248W (PMID: 26272063).",Actionable,8596,9256,colorectal cancer,DOID,26372,KRAS G12D PIK3CA H1047R TP53 R248W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,1420,Selumetinib + BEZ235,7157
28,Preclinical - Pdx,"In a preclinical study, BEZ235 stabilized tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).",Actionable,8697,9256,colorectal cancer,DOID,26372,KRAS G12D PIK3CA H1047R TP53 R248W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",predicted – sensitive,672,BEZ235,7157
29,Preclinical - Pdx,"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).",Actionable,8695,9256,colorectal cancer,DOID,26372,KRAS G12D PIK3CA H1047R TP53 R248W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",resistant,913,Selumetinib,7157
30,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12C, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).",Actionable,8577,9256,colorectal cancer,DOID,26366,KRAS G12C PIK3CA H1047R TP53 R248W,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,4771,MLN0128 + PD-0325901,7157
31,Preclinical,"In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in neuroblastoma cell lines harboring Alk amplification and functional TP53, resulting in growth inhibition in culture (PMID: 26438783).",Actionable,4740,769,neuroblastoma,DOID,18891,ALK amp Tp53 wild-type,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,7157
32,Preclinical - Cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063).",Actionable,8568,9256,colorectal cancer,DOID,26361,BRAF V600E PIK3CA H1047R TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,7157
33,Preclinical,"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and wild-type TP53 in culture (PMID: 26438783).",Actionable,4741,769,neuroblastoma,DOID,18892,ALK wild-type TP53 wild-type,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,7157
34,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",Actionable,8702,9256,colorectal cancer,DOID,26376,KRAS G12D PIK3CA H1047R TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",decreased response,913,Selumetinib,7157
35,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",Actionable,8601,9256,colorectal cancer,DOID,26376,KRAS G12D PIK3CA H1047R TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,1420,Selumetinib + BEZ235,7157
36,Preclinical - Pdx,"In a preclinical study, BEZ235 inhibited tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",Actionable,8703,9256,colorectal cancer,DOID,26376,KRAS G12D PIK3CA H1047R TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",predicted – sensitive,672,BEZ235,7157
37,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to sustain tumor regression in xenograft models of a crizotinib-resistant human neuroblastoma cell line harboring ALK F1174L and wild-type TP53 (PMID: 26438783).",Actionable,4731,769,neuroblastoma,DOID,18879,ALK	F1174L TP53	wild-type,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,7157
38,Preclinical,"In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in patient-derived neuroblastoma cell lines harboring Alk mutations and functional TP53, resulting in growth inhibition in culture and tumor regression in animal models (PMID: 26438783).",Actionable,4736,769,neuroblastoma,DOID,18888,ALK mutant TP53 wild-type,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,7157
39,Preclinical - Pdx,"In a preclinical study, BEZ235 delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",Actionable,8704,9256,colorectal cancer,DOID,26377,KRAS G12V PIK3CA E545K TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",decreased response,672,BEZ235,7157
40,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",Actionable,8603,9256,colorectal cancer,DOID,26377,KRAS G12V PIK3CA E545K TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,1420,Selumetinib + BEZ235,7157
41,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",Actionable,8705,9256,colorectal cancer,DOID,26377,KRAS G12V PIK3CA E545K TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",decreased response,913,Selumetinib,7157
42,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4354,1520,colon carcinoma,DOID,17823,TP53 wild-type RB1 wild-type,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,7157
43,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of melanoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4360,1909,melanoma,DOID,17823,TP53 wild-type RB1 wild-type,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,7157
44,Preclinical,"In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911).",Actionable,4362,50746,mantle cell lymphoma,DOID,17823,TP53 wild-type RB1 wild-type,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,7157
45,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of lung carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4356,3905,lung carcinoma,DOID,17823,TP53 wild-type RB1 wild-type,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,7157
46,Preclinical,"In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911).",Actionable,4353,3459,breast carcinoma,DOID,17823,TP53 wild-type RB1 wild-type,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,7157
47,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 inhibited growth of a melanoma cell line with wild-type TP53, that also harbored a BRAF mutation, in culture and inhibited tumor growth in a TP53 wild-type BRAF-mutant melanoma cell line xenograft model (PMID: 25567130).",Actionable,8097,1909,melanoma,DOID,3307,BRAF mut + TP53 wild-type,"[{'id': 2082, 'pubMedId': 25567130, 'title': 'The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25567130'}]",sensitive,1452,AMG 232,7157
48,Preclinical - Cell culture,"In a preclinical study, the combination of Navitoclax (ABT-263), CGM097, Tafinlar (dabrafenib), and PF04217903 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046). ",Actionable,9933,9256,colorectal cancer,DOID,3307,BRAF mut + TP53 wild-type,"[{'id': 7782, 'pubMedId': 27659046, 'title': 'High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27659046'}]",sensitive,5317,ABT-263 + CGM097 + Dabrafenib + PF-04217903,7157
49,Preclinical,"In a preclinical study, the combination of CGM097 and Encorafenib (LGX818) synergized to inhibit cell growth of a human melanoma cell line harboring mutant BRAF and wild-type TP53 in culture, and promoted tumor regression in xenograft models (Cancer Res October 1, 2014 74; 5466).",Actionable,1787,1909,melanoma,DOID,3307,BRAF mut + TP53 wild-type,"[{'id': 7241, 'pubMedId': None, 'title': '', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/5466'}]",sensitive,2285,CGM097 + LGX818,7157
50,Phase I,"In a Phase I trial, MK-8242 demonstrated safety and some preliminary clinical activity in patients with TP53 wild-type advanced solid tumors, particularly those with liposarcoma (LPS), with an overall response rate (ORR) of 6.4% (3/41; all partial responses), all in patients with LPS (ORR in LPS 11.1% (3/27)), and 75.6% (31/41) of patients achieving stable disease (PMID: 28240971).",Actionable,10721,10000003,Advanced Solid Tumor,JAX,642,TP53 wild-type,"[{'id': 8785, 'pubMedId': 28240971, 'title': 'Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28240971'}]",unknown,3153,MK-8242,7157
51,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type osteosarcoma cells in culture and in cell line xenograft models (PMID: 26162687).",Actionable,8260,3347,osteosarcoma,DOID,642,TP53 wild-type,"[{'id': 6588, 'pubMedId': 26162687, 'title': 'Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26162687'}]",sensitive,4671,AMG 232 + Radiotherapy,7157
52,Phase I,"In a Phase I trial, treatment with ALRN-6924 in patients with advanced solid tumors and lymphomas resulted in a disease control rate of 45% (25/55), with 2 patients experiencing a complete response, 2 patients achieving a partial response, and 21 patients demonstrating stable disease (J Clin Oncol 35, 2017 (suppl; abstr 2505)).",Actionable,11082,60058,lymphoma,DOID,642,TP53 wild-type,"[{'id': 9071, 'pubMedId': None, 'title': 'Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas', 'url': 'http://abstracts.asco.org/199/AbstView_199_187803.html'}]",predicted – sensitive,2273,ALRN-6924,7157
53,Preclinical - Cell line xenograft,"In a preclinical study, a TP53 wild-type dedifferentiated papillary thyroid carcinoma cell line treated with APG-115 demonstrated decreased cell viability and induction of cell cycle arrest and apoptosis in culture, and tumor growth suppression and tumor regression in xenograft models (PMID: 28498808).",Actionable,11033,3969,papillary thyroid carcinoma,DOID,642,TP53 wild-type,"[{'id': 9032, 'pubMedId': 28498808, 'title': 'Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28498808'}]",sensitive,5826,APG-115,7157
54,Preclinical - Cell culture,"In a preclinical study, Roscovotine (seliciclib) induced substantial apoptosis in non-small cell lung carcinoma cells overexpressing wild-type TP53 in culture (PMID: 22862161).",Actionable,11749,3908,non-small cell lung carcinoma,DOID,642,TP53 wild-type,"[{'id': 609, 'pubMedId': 22862161, 'title': 'Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22862161'}]",sensitive,1129,Seliciclib,7157
55,Preclinical - Cell line xenograft,"In a preclinical study, SAR405838 inhibited growth of TP53 wild-type prostate cancer cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).",Actionable,1790,10283,prostate cancer,DOID,642,TP53 wild-type,"[{'id': 1886, 'pubMedId': 25145672, 'title': 'SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25145672'}]",sensitive,2078,SAR405838,7157
56,Preclinical - Cell line xenograft,"In a preclinical study, RO6839921 demonstrated anti-tumor activity in TP53 wild-type disseminated acute myeloid leukemia cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).",Actionable,9316,9119,acute myeloid leukemia,DOID,642,TP53 wild-type,"[{'id': 7077, 'pubMedId': None, 'title': 'Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/A156.short'}]",sensitive,2155,RO6839921,7157
57,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 induced activation of Tp53 target genes and inhibited growth of a non-small cell lung cancer (NSCLC) cell line with wild-type TP53 in culture and inhibited tumor growth in a TP53 wild-type NSCLC cell line xenograft model (PMID: 25567130).",Actionable,8093,3908,non-small cell lung carcinoma,DOID,642,TP53 wild-type,"[{'id': 2082, 'pubMedId': 25567130, 'title': 'The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25567130'}]",sensitive,1452,AMG 232,7157
58,Preclinical,"In a preclinical study, CPUY201112 reduced viability and induced apoptosis in a colon cancer cell line with wild-type TP53 in culture, and had a limited effect on a colon cancer cell line lacking TP53 (PMID: 26743233).",Actionable,4644,219,colon cancer,DOID,642,TP53 wild-type,"[{'id': 4657, 'pubMedId': 26743233, 'title': 'CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26743233'}]",sensitive,3589,CPUY201112,7157
59,Preclinical,"In a preclinical study, GSK283071 and Adriamycin (doxorubicin) worked synergistically to inhibit proliferation of neuroblastoma cell lines carrying wild-type TP53 (PMID: 25658463).",Actionable,5285,769,neuroblastoma,DOID,642,TP53 wild-type,"[{'id': 4979, 'pubMedId': 25658463, 'title': 'WIP1 phosphatase as a potential therapeutic target in neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25658463'}]",predicted – sensitive,3815,Doxorubicin + GSK2830371,7157
60,Phase I,"In a Phase I trial, ALRN-6924 treatment in a patient with peripheral T-cell lymphoma resulted in a complete response (J Clin Oncol 35, 2017 (suppl; abstr 2505)). ",Actionable,11085,50749,peripheral T-cell lymphoma,DOID,642,TP53 wild-type,"[{'id': 9071, 'pubMedId': None, 'title': 'Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas', 'url': 'http://abstracts.asco.org/199/AbstView_199_187803.html'}]",sensitive,2273,ALRN-6924,7157
61,Phase I,"In Phase I and Phase II clinical trials, various forms of p53 gene therapy (such as adenoviral-p53) have been shown to be generally safe and have demonstrated clinical efficacy in patients with ovarian cancer (PMID: 12082455; PMID: 19621448; PMID: 21927947; PMID: 15297186; PMID: 12082456).",Actionable,232,2394,ovarian cancer,DOID,642,TP53 wild-type,"[{'id': 33, 'pubMedId': 12082455, 'title': 'A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12082455'}, {'id': 34, 'pubMedId': 12082456, 'title': 'Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12082456'}, {'id': 35, 'pubMedId': 15297186, 'title': 'A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15297186'}, {'id': 39, 'pubMedId': 19621448, 'title': 'Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19621448'}, {'id': 58, 'pubMedId': 21927947, 'title': 'A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21927947'}]",predicted – sensitive,978,Ad.p53-DC vaccine,7157
62,Preclinical - Cell culture,"In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type breast cancer cells in culture (PMID: 26162687).",Actionable,8250,1612,breast cancer,DOID,642,TP53 wild-type,"[{'id': 6588, 'pubMedId': 26162687, 'title': 'Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26162687'}]",sensitive,1452,AMG 232,7157
63,Preclinical - Cell culture,"In a preclinical study, treatment with Trifluridine (FTD) resulted in Tp53-dependent cell-cycle arrest and decreased expression of CyclinB1 and Cdk1 in a Tp53-proficient colon cancer cancer cell line in culture (PMID: 25700705).",Actionable,7840,219,colon cancer,DOID,642,TP53 wild-type,"[{'id': 6509, 'pubMedId': 25700705, 'title': 'Trifluridine Induces p53-Dependent Sustained G2 Phase Arrest with Its Massive Misincorporation into DNA and Few DNA Strand Breaks.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25700705'}]",sensitive,4586,Trifluridine,7157
64,Phase I,"In a Phase I trial, ALRN-6924 treatment resulted in a partial response in a patient with colorectal cancer (J Clin Oncol 35, 2017 (suppl; abstr 2505)).",Actionable,11088,9256,colorectal cancer,DOID,642,TP53 wild-type,"[{'id': 9071, 'pubMedId': None, 'title': 'Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas', 'url': 'http://abstracts.asco.org/199/AbstView_199_187803.html'}]",sensitive,2273,ALRN-6924,7157
65,Preclinical - Cell line xenograft,"In a preclinical study, RO6839921 and Cytosar-U (cytarabine) combination treatment demonstrated anti-tumor activity in TP53 wild-type disseminated acute myeloid leukemia cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).",Actionable,9317,9119,acute myeloid leukemia,DOID,642,TP53 wild-type,"[{'id': 7077, 'pubMedId': None, 'title': 'Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/A156.short'}]",sensitive,4968,Cytarabine + RO6839921,7157
66,Preclinical - Cell line xenograft,"In a preclinical study, APR-246 inhibited growth of TP53 wild-type melanoma cells in 3D culture and in cell line xenograft models (PMID: 21239882).",Actionable,10708,1909,melanoma,DOID,642,TP53 wild-type,"[{'id': 8774, 'pubMedId': 21239882, 'title': 'PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21239882'}]",sensitive,1946,APR-246,7157
67,Preclinical - Pdx & cell culture,"In a preclinical study, the combination of MK-1775 and Gemzar (gemcitabine) induced cell death in a variety of sarcoma cell lines and inhibited tumor growth in a patient-derived sarcoma xenograft model, independent of TP53 mutational status (PMID: 23520471).",Actionable,842,1115,sarcoma,DOID,642,TP53 wild-type,"[{'id': 484, 'pubMedId': 23520471, 'title': 'Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23520471'}]",sensitive,1279,MK-1775 + Gemcitabine,7157
68,Phase I,"In a Phase I trial, MK-8242 demonstrated safety and some preliminary clinical activity in patients with advanced solid tumors, particularly those with TP53 wild-type liposarcoma (LPS), with an overall response rate (ORR) of 6.4% (3/41; all partial responses), all in patients with LPS (ORR in LPS 11.1% (3/27)), and a median progression-free survival in LPS of 237 days (PMID: 28240971).",Actionable,10720,3382,liposarcoma,DOID,642,TP53 wild-type,"[{'id': 8785, 'pubMedId': 28240971, 'title': 'Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28240971'}]",predicted – sensitive,3153,MK-8242,7157
69,Preclinical - Pdx,"In a preclinical study, SAR405838 (MI-77301) induced p53 signaling and inhibited tumor growth in patient-derived xenograft models of endocrine therapy-resistant breast cancer  with wild-type TP53, and induced cell-cycle arrest and inhibited growth of patient-derived  endocrine therapy-resistant breast cancer cells in culture (PMID: 27765850).",Actionable,9542,1612,breast cancer,DOID,642,TP53 wild-type,"[{'id': 7266, 'pubMedId': 27765850, 'title': 'Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27765850'}]",predicted – sensitive,2078,SAR405838,7157
70,Phase I,"In a Phase I trial, treatment with ALRN-6924 in patients with advanced solid tumors and lymphomas resulted in a disease control rate of 45% (25/55), with 2 patients experiencing a complete response, 2 patients achieving a partial response, and 21 patients demonstrating stable disease (J Clin Oncol 35, 2017 (suppl; abstr 2505)).",Actionable,11081,10000003,Advanced Solid Tumor,JAX,642,TP53 wild-type,"[{'id': 9071, 'pubMedId': None, 'title': 'Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas', 'url': 'http://abstracts.asco.org/199/AbstView_199_187803.html'}]",predicted – sensitive,2273,ALRN-6924,7157
71,Preclinical - Cell culture,"In a preclinical study, AZD6738 treatment increased sensitivity to radiotherapy in a lung carcinoma cell line harboring wild-type TP53 in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 28062704). ",Actionable,10015,3905,lung carcinoma,DOID,642,TP53 wild-type,"[{'id': 7909, 'pubMedId': 28062704, 'title': 'Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28062704'}]",sensitive,5346,AZD6738 + Radiotherapy,7157
72,Preclinical - Cell line xenograft,"In a preclinical study, the combination of AMG 232 and Platinol (cisplatin) worked synergistically to inhibit tumor growth in a TP53 wild-type non-small cell lung cancer cell line xenograft model, with increased efficacy over either agent alone, resulting in tumor stasis (PMID: 25567130).",Actionable,8133,3908,non-small cell lung carcinoma,DOID,642,TP53 wild-type,"[{'id': 2082, 'pubMedId': 25567130, 'title': 'The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25567130'}]",sensitive,4637,AMG 232 + Cisplatin,7157
73,Preclinical - Pdx,"In a preclinical study, the combination of SAR405838 (MI-773) and Platinol (cisplatin) resulted in increased Tp53 and Mdm2 expression, and demonstrated improved efficacy over either agent alone in TP53 wild-type patient-derived xenograft (PDX) models of salivary gland adenoid cystic carcinoma, resulting in tumor regression without tumor rebound after cessation of therapy (PMID: 27550999).",Actionable,10030,4866,salivary gland adenoid cystic carcinoma,DOID,642,TP53 wild-type,"[{'id': 7920, 'pubMedId': 27550999, 'title': 'Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550999'}]",predicted – sensitive,2078,SAR405838,7157
74,Preclinical - Cell line xenograft,"In a preclinical study, RO6839921 and Doxil combination treatment demonstrated sustained survival benefit in TP53 wild-type fibrosarcoma cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).",Actionable,9315,3355,fibrosarcoma,DOID,642,TP53 wild-type,"[{'id': 7077, 'pubMedId': None, 'title': 'Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration', 'url': 'http://mct.aacrjournals.org/content/14/12_Supplement_2/A156.short'}]",sensitive,4967,Doxil + RO6839921,7157
75,Preclinical - Cell line xenograft,"In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment increased Tp53 and Cdkn1a protein levels, resulted in growth inhibition of TP53 wild-type endometrioid ovary carcinoma cells in culture and in cell line xenograft models (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221).",Actionable,10735,5828,endometrioid ovary carcinoma,DOID,642,TP53 wild-type,"[{'id': 8790, 'pubMedId': None, 'title': 'Kevetrin induces p53-dependent and independent cell cycle arrest and apoptosis in ovarian cancer cell lines representing heterogeneous histologies', 'url': 'http://www.abstractsonline.com/pp8/#!/4292/presentation/3876'}]",sensitive,2999,thioureidobutyronitrile,7157
76,Preclinical - Cell line xenograft,"In a preclinical study, HDM201 treatment resulted in tumor regression in various cell line xenograft models of Tp53 wild-type tumors (Cancer Res 2016;76(14 Suppl):Abstract nr 4855).",Actionable,9985,10000003,Advanced Solid Tumor,JAX,642,TP53 wild-type,"[{'id': 7836, 'pubMedId': None, 'title': 'Discovery of NVP-HDM201 - First disclosure of a Next-Generation Mdm2 inhibitor with superior characteristics', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/4855'}]",sensitive,2186,HDM201,7157
77,Preclinical,"In a preclinical study, CTX-1 improved survival time in mouse models of acute myeloid leukemia using TP53 wild-type primary human acute myeloid leukemia cells (PMID: 26883273).",Actionable,5578,9119,acute myeloid leukemia,DOID,642,TP53 wild-type,"[{'id': 5110, 'pubMedId': 26883273, 'title': 'Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26883273'}]",sensitive,3899,CTX-1,7157
78,Preclinical - Cell culture,"In a preclinical study, MK-8745 treatment resulted in apoptosis in Tp53 wild-type colorectal cancer cells in culture (PMID: 22293494).",Actionable,10681,9256,colorectal cancer,DOID,642,TP53 wild-type,"[{'id': 8741, 'pubMedId': 22293494, 'title': 'The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293494'}]",predicted – sensitive,2328,MK-8745,7157
79,Preclinical,"In a preclinical study, Prodigiosin inhibited self-renewal of Tp53 wild-type colorectal cancer cell lines in culture (PMID: 26759239).",Actionable,5769,9256,colorectal cancer,DOID,642,TP53 wild-type,"[{'id': 5150, 'pubMedId': 26759239, 'title': 'Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated ΔNp73 Inhibition and p73 Activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26759239'}]",sensitive,3925,Prodigiosin,7157
80,Phase I,"In a Phase I study, patients with advanced solid tumor harboring TP53 mutations had increased progression-free survival and overall survival than TP53 wild-type patients after treatment with Votrient (pazopanib) in combination with Zolinza (vorinostat) (J Clin Oncol 32:5s, 2014 (suppl; abstr 2576)).",Actionable,838,10000003,Advanced Solid Tumor,JAX,642,TP53 wild-type,"[{'id': 481, 'pubMedId': None, 'title': 'A phase I trial of pazopanib and vorinostat: The role of TP53 mutations.', 'url': 'http://meetinglibrary.asco.org/content/132490-144'}]",decreased response,1211,Pazopanib + Vorinostat,7157
81,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type colon cancer cells in culture and in cell line xenograft models (PMID: 26162687).",Actionable,8259,219,colon cancer,DOID,642,TP53 wild-type,"[{'id': 6588, 'pubMedId': 26162687, 'title': 'Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26162687'}]",sensitive,4671,AMG 232 + Radiotherapy,7157
82,Preclinical,"In a preclinical study, CPUY201112 reduced viability and induced apoptosis in an osteosarcoma cell line with wild-type TP53 in culture, and had a limited effect on an osteosarcoma cell line lacking TP53 (PMID: 26743233).
",Actionable,4646,3347,osteosarcoma,DOID,642,TP53 wild-type,"[{'id': 4657, 'pubMedId': 26743233, 'title': 'CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26743233'}]",sensitive,3589,CPUY201112,7157
83,Preclinical,"In a preclinical study, medulloblastoma cell lines with TP53 mutations had significantly less sensitivity to the BET inhibitor, JQ1, than cell lines carrying wild-type TP53 (PMID: 24231268).",Actionable,1134,50902,medulloblastoma,DOID,642,TP53 wild-type,"[{'id': 878, 'pubMedId': 24231268, 'title': 'BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24231268'}]",sensitive,1574,JQ1,7157
84,Preclinical,"In a preclinical study the TTK (MPS1) inhibitor, MPI-0479605, inhibited cell cycle progression of colon carcinoma cells deficient for Tp53 with equivalent efficacy to cells with wild-type Tp53 (PMID: 21980130).",Actionable,4206,1520,colon carcinoma,DOID,642,TP53 wild-type,"[{'id': 4435, 'pubMedId': 21980130, 'title': 'Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21980130'}]",sensitive,3458,MPI-0479605,7157
85,Preclinical - Cell line xenograft,"In a preclinical study, SAR405838 inhibited growth of TP53 wild-type colon cancer cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).
",Actionable,1791,219,colon cancer,DOID,642,TP53 wild-type,"[{'id': 1886, 'pubMedId': 25145672, 'title': 'SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25145672'}]",sensitive,2078,SAR405838,7157
86,Preclinical,"In a preclinical study, CTX-1 induced cell death in several solid tumor cell lines with wild-type TP53 in culture (PMID: 26883273).",Actionable,5570,10000003,Advanced Solid Tumor,JAX,642,TP53 wild-type,"[{'id': 5110, 'pubMedId': 26883273, 'title': 'Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26883273'}]",sensitive,3899,CTX-1,7157
87,Preclinical - Cell line xenograft,"In a preclinical study, the combination of AMG 232 and Paraplatin (carboplatin) worked synergistically to inhibit tumor growth in a TP53 wild-type non-small cell lung cancer cell line xenograft model, with increased efficacy over either agent alone (PMID: 25567130).",Actionable,8135,3908,non-small cell lung carcinoma,DOID,642,TP53 wild-type,"[{'id': 2082, 'pubMedId': 25567130, 'title': 'The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25567130'}]",sensitive,4638,AMG 232 + Carboplatin,7157
88,Preclinical,"In a preclinical study, MK-1775, in combination with the Chk1 inhibitor, PF-00477736, showed efficacy in various human cancer cell lines (breast, ovarian, colon, prostate), independently of p53 status (PMID: 22713237).",Actionable,1126,219,colon cancer,DOID,642,TP53 wild-type,"[{'id': 394, 'pubMedId': 22713237, 'title': 'Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22713237'}]",sensitive,1566,MK-1775 + PF-00477736,7157
89,Preclinical - Cell line xenograft,"In a preclinical study, SAR405838 inhibited growth of TP53 wild-type acute leukemia cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).
",Actionable,1789,12603,acute leukemia,DOID,642,TP53 wild-type,"[{'id': 1886, 'pubMedId': 25145672, 'title': 'SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25145672'}]",sensitive,2078,SAR405838,7157
90,Preclinical - Cell culture,"In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type osteosarcoma cells in culture (PMID: 26162687).",Actionable,8254,3347,osteosarcoma,DOID,642,TP53 wild-type,"[{'id': 6588, 'pubMedId': 26162687, 'title': 'Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26162687'}]",sensitive,1452,AMG 232,7157
91,Phase I,"In a Phase I trial, ALRN-6924 treatment resulted in a partial response in a patient with liposarcoma (J Clin Oncol 35, 2017 (suppl; abstr 2505)).",Actionable,11089,3382,liposarcoma,DOID,642,TP53 wild-type,"[{'id': 9071, 'pubMedId': None, 'title': 'Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas', 'url': 'http://abstracts.asco.org/199/AbstView_199_187803.html'}]",sensitive,2273,ALRN-6924,7157
92,Preclinical,"In a preclinical study, CTX-1 and Nutlin-3 worked cooperatively to induce cell death in several TP53 wild-type human tumor cell lines in culture (PMID: 26883273).",Actionable,5584,10000003,Advanced Solid Tumor,JAX,642,TP53 wild-type,"[{'id': 5110, 'pubMedId': 26883273, 'title': 'Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26883273'}]",sensitive,3900,CTX-1 + Nutlin-3,7157
93,Preclinical - Cell culture,"In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type colon cancer cells in culture (PMID: 26162687).",Actionable,8252,219,colon cancer,DOID,642,TP53 wild-type,"[{'id': 6588, 'pubMedId': 26162687, 'title': 'Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26162687'}]",sensitive,1452,AMG 232,7157
94,Preclinical - Cell line xenograft,"In a preclinical study, NSC319726 did not inhibit tumor growth in xenograft models of TP53 wild-type lung large cell carcinoma (PMID: 22624712).",Actionable,10714,4556,lung large cell carcinoma,DOID,642,TP53 wild-type,"[{'id': 4308, 'pubMedId': 22624712, 'title': 'Allele-specific p53 mutant reactivation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22624712'}]",resistant,3405,NSC319726,7157
95,Preclinical - Cell culture,"In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type lung cancer cell lines in culture (PMID: 26162687).",Actionable,8249,1324,lung cancer,DOID,642,TP53 wild-type,"[{'id': 6588, 'pubMedId': 26162687, 'title': 'Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26162687'}]",sensitive,1452,AMG 232,7157
96,Preclinical,"In a preclinical study, GSK283071 and Paraplatin (carboplatin) worked synergistically to inhibit proliferation of neuroblastoma cell lines carrying wild-type TP53 (PMID: 25658463).",Actionable,5284,769,neuroblastoma,DOID,642,TP53 wild-type,"[{'id': 4979, 'pubMedId': 25658463, 'title': 'WIP1 phosphatase as a potential therapeutic target in neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25658463'}]",predicted – sensitive,3814,Carboplatin + GSK2830371,7157
97,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 induced activation of Tp53 target genes and inhibited growth of several human tumor cell lines with wild-type TP53 in culture and in cell line xenograft models (PMID: 25567130).",Actionable,8091,10000003,Advanced Solid Tumor,JAX,642,TP53 wild-type,"[{'id': 2082, 'pubMedId': 25567130, 'title': 'The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25567130'}]",sensitive,1452,AMG 232,7157
98,Phase II,"In a Phase II trial, p53-SLP vaccine was demonstrated to be safe, well tolerated and to induce p53-specific T-cell responses in ovarian cancer patients; however clinical impact was lacking (PMID: 19621448, PMID: 21328579).",Actionable,433,2394,ovarian cancer,DOID,642,TP53 wild-type,"[{'id': 39, 'pubMedId': 19621448, 'title': 'Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19621448'}, {'id': 48, 'pubMedId': 21328579, 'title': 'Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21328579'}]",no benefit,1039,p53-SLP vaccine,7157
99,Preclinical,"In a preclinical study, the combination of CTX-1 and Nutlin-3 resulting in improved survival time in mouse models of acute myeloid leukemia using TP53 wild-type primary human acute myeloid leukemia cells (PMID: 26883273).",Actionable,5583,9119,acute myeloid leukemia,DOID,642,TP53 wild-type,"[{'id': 5110, 'pubMedId': 26883273, 'title': 'Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26883273'}]",sensitive,3900,CTX-1 + Nutlin-3,7157
100,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type breast cancer cells in culture (PMID: 26162687).",Actionable,8258,1612,breast cancer,DOID,642,TP53 wild-type,"[{'id': 6588, 'pubMedId': 26162687, 'title': 'Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26162687'}]",sensitive,4671,AMG 232 + Radiotherapy,7157
101,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type melanoma cells in culture and in cell line xenograft models (PMID: 26162687).",Actionable,8257,1909,melanoma,DOID,642,TP53 wild-type,"[{'id': 6588, 'pubMedId': 26162687, 'title': 'Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26162687'}]",sensitive,4671,AMG 232 + Radiotherapy,7157
102,Preclinical,"In a preclinical study, the combination of CEP-8983 and Platinol (cisplatin) worked synergistically to induce cell death in non-small cell lung cancer cell lines in culture, irrespective of TP53 status (PMID: 23428903).",Actionable,4555,3908,non-small cell lung carcinoma,DOID,642,TP53 wild-type,"[{'id': 4605, 'pubMedId': 23428903, 'title': 'Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23428903'}]",sensitive,3537,CEP-8983 + Cisplatin,7157
103,Preclinical - Cell culture,"In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type melanoma cells in culture (PMID: 26162687).",Actionable,8253,1909,melanoma,DOID,642,TP53 wild-type,"[{'id': 6588, 'pubMedId': 26162687, 'title': 'Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26162687'}]",sensitive,1452,AMG 232,7157
104,Preclinical - Pdx & cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically induced apoptosis in TP53 wild-type but not TP53 mutated colorectal cancer cell lines in culture, and demonstrated anti-tumor activity in TP53 wild-type but not TP53 mutated patient-derived xenograft models (PMID: 26272063).",Actionable,8570,9256,colorectal cancer,DOID,642,TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",predicted – sensitive,4771,MLN0128 + PD-0325901,7157
105,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type lung cancer cell lines in culture and in cell line xenograft models (PMID: 26162687).",Actionable,8256,1324,lung cancer,DOID,642,TP53 wild-type,"[{'id': 6588, 'pubMedId': 26162687, 'title': 'Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26162687'}]",sensitive,4671,AMG 232 + Radiotherapy,7157
106,Phase I,"In a Phase I trial, ALRN-6924 treatment in a patient with Merkel cell carcinoma resulted in a complete response (J Clin Oncol 35, 2017 (suppl; abstr 2505)). ",Actionable,11086,3965,Merkel cell carcinoma,DOID,642,TP53 wild-type,"[{'id': 9071, 'pubMedId': None, 'title': 'Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas', 'url': 'http://abstracts.asco.org/199/AbstView_199_187803.html'}]",sensitive,2273,ALRN-6924,7157
107,Preclinical,"In a preclinical study, GSK2830371 inhibited proliferation of neuroblastoma cell lines carrying wild-type TP53 in culture (PMID: 25658463).",Actionable,5282,769,neuroblastoma,DOID,642,TP53 wild-type,"[{'id': 4979, 'pubMedId': 25658463, 'title': 'WIP1 phosphatase as a potential therapeutic target in neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25658463'}]",predicted – sensitive,3735,GSK2830371,7157
108,Preclinical - Pdx,"In a preclinical study, Xalkori (crizotinib) worked synergistically with Topotecan and Cytoxan (cyclophosphamide), resulting in sustained tumor regression in crizotinib-resistant neuroblastoma PDX models harboring ALK F1245C and wild-type Tp53 (PMID: 26438783).",Actionable,4732,769,neuroblastoma,DOID,18883,ALK	F1245C TP53	wild-type,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,7157
109,Clinical Study,"In a clinical study, treatment with first-line tyrosine kinase inhibitors resulted in a median progression free survival of 4.2 months in non-small cell lung carcinoma patients harboring both TP53 exon 8 and EGFR mutations, compared to 16.8 months in patients harboring TP53 exon 8 wild-type and EGFR exon 19 deletion (J Clin Oncol 34, 2016 (suppl; abstr 9052)).",Actionable,7001,3908,non-small cell lung carcinoma,DOID,24186,EGFR exon 19 del TP53 wild-type,"[{'id': 6006, 'pubMedId': None, 'title': 'Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.', 'url': 'http://meetinglibrary.asco.org/content/165599-176'}]",sensitive,1776,N/A,7157
110,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to delay tumor growth in xenograft models of a human neuroblastoma cell line harboring constitutively phosphorylated wild-type Alk and wild-type TP53 (PMID: 26438783).",Actionable,4733,769,neuroblastoma,DOID,18886,ALK act mut TP53 wild-type,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",predicted – sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,7157
111,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment resulted in tumor growth stabilization in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D, PIK3CA E545K and H1047L (PMID: 26272063).",Actionable,8581,9256,colorectal cancer,DOID,26369,KRAS G12D PIK3CA E545K PIK3CA H1047L TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,7157
112,Preclinical - Cell line xenograft,"In a preclinical study, the combination of AMG 232 and Camptosaur (irinotecan) inhibited tumor growth in a TP53 wild-type colorectal cancer cell line xenograft model, which also harbors a KRAS mutation, with increased efficacy over either agent alone (PMID: 25567130).",Actionable,8140,9256,colorectal cancer,DOID,2521,KRAS mut + TP53 wild-type,"[{'id': 2082, 'pubMedId': 25567130, 'title': 'The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25567130'}]",sensitive,4639,AMG 232 + Irinotecan,7157
113,Preclinical,"In a preclinical study, Eloxatin (oxaliplatin), in combination with ABT-737, was only effective in tumor cell lines carrying KRAS mutants and wild-type TP53 (PMID: 21468686).",Actionable,1443,10000003,Advanced Solid Tumor,JAX,2521,KRAS mut + TP53 wild-type,"[{'id': 1293, 'pubMedId': 21468686, 'title': 'Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21468686'}]",sensitive,1773,Oxaliplatin + ABT-737,7157
114,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 induced activation of Tp53 target genes and inhibited growth of a colorectal cancer (CRC) cell line with wild-type TP53, that also harbored a KRAS mutation, in culture and inhibited tumor growth in a TP53 wild-type KRAS-mutant CRC cell line xenograft model (PMID: 25567130).",Actionable,8094,9256,colorectal cancer,DOID,2521,KRAS mut + TP53 wild-type,"[{'id': 2082, 'pubMedId': 25567130, 'title': 'The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25567130'}]",sensitive,1452,AMG 232,7157
115,Preclinical - Cell culture,"In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Mekinist (trametinib), and CGM097 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a KRAS mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046). ",Actionable,9935,9256,colorectal cancer,DOID,2521,KRAS mut + TP53 wild-type,"[{'id': 7782, 'pubMedId': 27659046, 'title': 'High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27659046'}]",sensitive,5319,ABT-263 + Alpelisib + CGM097 + Trametinib,7157
116,Preclinical - Cell line xenograft,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R in culture and in cell line xenograft models (PMID: 26272063).",Actionable,8567,9256,colorectal cancer,DOID,26360,KRAS G13D PIK3CA H1047R TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,7157
117,Preclinical - Cell line xenograft,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PTEN loss in culture and in cell line xenograft models (PMID: 26272063).",Actionable,8569,9256,colorectal cancer,DOID,26362,BRAF V600E PTEN loss TP53 wild-type,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,7157
118,Preclinical - Cell culture,"In a preclinical study, NSC319726 did not inhibit tumor growth in xenograft models of breast cancer harboring TP53 R273W (PMID: 22624712).",Actionable,10715,1612,breast cancer,DOID,27738,TP53 R273W,"[{'id': 4308, 'pubMedId': 22624712, 'title': 'Allele-specific p53 mutant reactivation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22624712'}]",resistant,3405,NSC319726,7157
119,Preclinical - Cell culture,"In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 A159V demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).",Actionable,11747,3908,non-small cell lung carcinoma,DOID,28222,TP53 A159V,"[{'id': 609, 'pubMedId': 22862161, 'title': 'Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22862161'}]",decreased response,1129,Seliciclib,7157
120,Clinical Study,"In a clinical case study, Capmatinib (INC280) treatment resulted in decreased tumor volume by 53% in a patient with large cell lung carcinoma harboring MET del exon14 and TP53 N30fs*14 (PMID: 25971938).",Actionable,9562,4556,lung large cell carcinoma,DOID,26905,MET del exon14 TP53 N30fs*14,"[{'id': 6712, 'pubMedId': 25971938, 'title': 'Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25971938'}]",sensitive,1065,Capmatinib,7157
121,Preclinical - Cell culture,"In a preclinical study, shRNA knock-down of Tp53 in Met over-expressing gastric carcinoma cells enhanced sensitivity to the combination of EMD 1214063 and radiation in culture (PMID: 26358474).",Actionable,9470,5517,stomach carcinoma,DOID,26857,MET over exp TP53 dec exp,"[{'id': 7198, 'pubMedId': 26358474, 'title': 'Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26358474'}]",sensitive,5024,EMD 1214063 + Radiotherapy,7157
122,Preclinical,"In a preclinical study, TP53 E258Q resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).",Actionable,913,3347,osteosarcoma,DOID,1552,TP53 E258Q,"[{'id': 585, 'pubMedId': 21643018, 'title': 'Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21643018'}]",resistant,1405,Nutlin-3a,7157
123,Phase II,"In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 Y163* (PMID: 27998224). ",Actionable,11782,2394,ovarian cancer,DOID,28224,TP53 Y163*,"[{'id': 9762, 'pubMedId': 27998224, 'title': 'Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27998224'}]",predicted – sensitive,1194,MK-1775 + Carboplatin ,7157
124,Preclinical - Cell culture,"In a preclinical study, the combination of Platinol (cisplatin) and NSC59984 worked synergistically to decrease viability of a colorectal cancer cell line harboring TP53 R273H and TP53 P309S in culture (PMID: 26294215).",Actionable,8270,9256,colorectal cancer,DOID,26216,TP53 R273H TP53 P309S,"[{'id': 4303, 'pubMedId': 26294215, 'title': 'Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26294215'}]",sensitive,4675,Cisplatin + NSC59984,7157
125,Preclinical - Cell culture,"In a preclinical study, treatment with NSC59984 induced Tp53 pathway signaling, degradation of mutant Tp53, and cell death in a colorectal cancer cell line harboring TP53 R273H and TP53 P309S in culture (PMID: 26294215).",Actionable,8267,9256,colorectal cancer,DOID,26216,TP53 R273H TP53 P309S,"[{'id': 4303, 'pubMedId': 26294215, 'title': 'Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26294215'}]",sensitive,3402,NSC59984,7157
126,Preclinical - Patient cell culture,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived peritoneum cancer cells harboring TP53 C135Y in culture (PMID: 27179933). ",Actionable,9805,1725,peritoneum cancer,DOID,13303,TP53 C135Y,"[{'id': 7621, 'pubMedId': 27179933, 'title': 'Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27179933'}]",sensitive,3443,APR-246 + Cisplatin,7157
127,Preclinical - Cell culture,"In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 S215G were resistant to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).",Actionable,11744,3908,non-small cell lung carcinoma,DOID,28223,TP53 S215G,"[{'id': 609, 'pubMedId': 22862161, 'title': 'Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22862161'}]",resistant,1129,Seliciclib,7157
128,Phase II,"In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in disease progression in an ovarian cancer patient harboring TP53 P98fs, R175C, and S215G (PMID: 27998224). ",Actionable,11784,2394,ovarian cancer,DOID,28235,TP53 P98fs TP53 R175C TP53 S215G,"[{'id': 9762, 'pubMedId': 27998224, 'title': 'Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27998224'}]",predicted – resistant,1194,MK-1775 + Carboplatin ,7157
129,Preclinical - Cell line xenograft,"In a preclinical study, Xalkori (crizotinib) did not improve the effect of Topotecan and Cytoxan (cyclophosphamide) on tumor growth suppression in xenograft models of a human neuroblastoma cell line harboring wild-type ALK and TP53 H168R (PMID: 26438783).",Actionable,4734,769,neuroblastoma,DOID,18884,ALK	wild-type TP53 H168R,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,7157
130,Preclinical,"In a preclinical study, Topotecan and Cytoxan (cyclophosphamide) combination treatment resulted in mild  tumor growth suppression in neuroblastoma xenograft models harboring wild-type Alk and TP53 H168R (PMID: 26438783).",Actionable,4742,769,neuroblastoma,DOID,18884,ALK	wild-type TP53 H168R,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",not applicable,2590,Cyclophosphamide + Topotecan,7157
131,Clinical Study,"In a clinical study, treatment with first-line tyrosine kinase inhibitors resulted in a disease control rate (DCR) of 67% (8/13) in EGFR mutated, non-small cell lung carcinoma patients harboring nondisruptive TP53 mutations, compared to a DCR of 87% (21/24) in patients harboring disruptive TP53 mutations (J Clin Oncol 34, 2016 (suppl; abstr 9052)).",Actionable,7000,3908,non-small cell lung carcinoma,DOID,24180,EGFR mut TP53 inact mut,"[{'id': 6006, 'pubMedId': None, 'title': 'Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.', 'url': 'http://meetinglibrary.asco.org/content/165599-176'}]",sensitive,1776,N/A,7157
132,Preclinical - Cell line xenograft,"In a preclinical study, APR-246 induced apoptosis in small-cell lung cancer (SCLC) cell lines and decreased tumor growth in SCLC cell line xenograft models harboring Tp53 inactivating mutations (PMID: 21415220).",Actionable,1986,5409,lung small cell carcinoma,DOID,489,TP53 inact mut,"[{'id': 2429, 'pubMedId': 21415220, 'title': 'PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21415220'}]",sensitive,1946,APR-246,7157
133,Preclinical,"In a preclinical study, ReACp53 induced cell death and decreased proliferation of ovarian carcinoma cells harboring TP53 mutations in culture, but did not effect viability of ovarian carcinoma cells with wild-type TP53 (PMID: 26748848).",Actionable,3982,4001,ovarian carcinoma,DOID,489,TP53 inact mut,"[{'id': 4309, 'pubMedId': 26748848, 'title': 'A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26748848'}]",sensitive,3406,ReACp53,7157
134,Preclinical,"In a preclinical study, LB100 treatment decreased PP2A activity and increased sensitivity to Platinol (cisplatin) in a cisplatin-resistant ovarian cancer cell line harboring a TP53 inactivating mutation in culture (PMID: 25376608).",Actionable,4446,2394,ovarian cancer,DOID,489,TP53 inact mut,"[{'id': 4553, 'pubMedId': 25376608, 'title': 'The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25376608'}]",sensitive,3515,LB-100 + Cisplatin,7157
135,Preclinical,"In a preclinical study, Nutlin-3 and cisplatin worked cooperatively to induce apoptosis in ovarian cancer cell lines with TP53 inactivating mutations in culture (PMID: 25964101).",Actionable,6068,2394,ovarian cancer,DOID,489,TP53 inact mut,"[{'id': 5272, 'pubMedId': 25964101, 'title': 'Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964101'}]",sensitive,4018,Nutlin-3 + Cisplatin,7157
136,Preclinical,"In a preclinical study, breast cancer cell lines with TP53 loss of function mutations had more pronounced apoptosis after treatment with AMG 900 in culture (PMID: 24091768).",Actionable,1009,1612,breast cancer,DOID,489,TP53 inact mut,"[{'id': 725, 'pubMedId': 24091768, 'title': 'AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24091768'}]",sensitive,983,AMG 900,7157
137,Preclinical,"In a preclinical study, MK-1775 increased the efficacy of radiation in breast cancer cells with defective TP53 in culture (PMID: 21799033).",Actionable,908,1612,breast cancer,DOID,489,TP53 inact mut,"[{'id': 594, 'pubMedId': 21799033, 'title': 'MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21799033'}]",sensitive,4186,MK-1775 + Radiotherapy,7157
138,Preclinical,"In a preclinical study, AZD6482 induced cell death in TP53-deficient chronic lymphocytic leukemia cells in culture and inhibited tumor growth in xenograft models (PMID: 26563132).",Actionable,5521,1040,chronic lymphocytic leukemia,DOID,489,TP53 inact mut,"[{'id': 5085, 'pubMedId': 26563132, 'title': 'ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26563132'}]",predicted – sensitive,659,AZD6482,7157
139,Preclinical,"In a preclinical study, AZD6738 sensitized TP53-deficient chronic lymphocytic leukemia cells to Imbruvica (Ibrutinib) treatment in culture (PMID: 26563132).",Actionable,5523,1040,chronic lymphocytic leukemia,DOID,489,TP53 inact mut,"[{'id': 5085, 'pubMedId': 26563132, 'title': 'ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26563132'}]",sensitive,3877,AZD6738 + Ibrutinib,7157
140,Phase I,"In a Phase I trial, ovarian patients with TP53 deficiency had a 78.6% response rate to MK-1775 in combination with carboplatin and paclitaxel (J Clin Oncol 31, 2013 (suppl; abstr 5518)).
",Actionable,174,2394,ovarian cancer,DOID,489,TP53 inact mut,"[{'id': 4963, 'pubMedId': None, 'title': 'Targeting p53 mutant ovarian cancer: Phase I results of the WEE1 inhibitor MK-1775 with carboplatin plus paclitaxel in patients (pts) with platinum-sensitive, p53-mutant ovarian cancer (OC).', 'url': 'http://meetinglibrary.asco.org/content/110824-132'}]",sensitive,3800,MK-1775 + Carboplatin + Paclitaxel,7157
141,Preclinical - Cell culture,"In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 Y234C demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).",Actionable,11748,3908,non-small cell lung carcinoma,DOID,16659,TP53 Y234C,"[{'id': 609, 'pubMedId': 22862161, 'title': 'Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22862161'}]",decreased response,1129,Seliciclib,7157
142,Preclinical,"In a preclinical study, ReACp53 induced cell death in human primary ovarian carcinoma cells harboring TP53 Y234C in culture (PMID: 26748848).",Actionable,3980,4001,ovarian carcinoma,DOID,16659,TP53 Y234C,"[{'id': 4309, 'pubMedId': 26748848, 'title': 'A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26748848'}]",sensitive,3406,ReACp53,7157
143,Preclinical - Cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS Q61L, PIK3CA E542K, and TP53 T118Qfs*5 in culture (PMID: 26272063).",Actionable,8566,9256,colorectal cancer,DOID,26412,KRAS Q61L PIK3CA E542K TP53 T118Qfs*5,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,7157
144,Preclinical - Pdx,"In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12R and TP53 R248L (PMID: 26855149).",Actionable,10886,3910,lung adenocarcinoma,DOID,27821,KRAS G12R TP53 R248L,"[{'id': 8887, 'pubMedId': 26855149, 'title': 'Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26855149'}]",sensitive,5671,Dasatinib + Demcizumab,7157
145,Phase I,"In a Phase I clinical trial, APR-246 demonstrated safety and preliminary clinical activity in patients with hematological cancers, including an acute myeloid leukemia patient harboring TP53 V173M that achieved a decrease in bone marrow blast percentage from 46% to 26% (PMID: 22965953).",Actionable,8039,9119,acute myeloid leukemia,DOID,26139,TP53 V173M,"[{'id': 6539, 'pubMedId': 22965953, 'title': 'Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22965953'}]",predicted – sensitive,1946,APR-246,7157
146,Preclinical,"In a preclinical study, ReACp53 induced cell death and decreased proliferation of human primary ovarian carcinoma cells harboring both TP53 I195* and TP53 R248Q in culture (PMID: 26748848).",Actionable,3979,4001,ovarian carcinoma,DOID,16640,TP53 I195* TP53 R248Q,"[{'id': 4309, 'pubMedId': 26748848, 'title': 'A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26748848'}]",sensitive,3406,ReACp53,7157
147,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring TP53 R138G in culture (PMID: 21325073, PMID: 23980093).",Actionable,3139,3908,non-small cell lung carcinoma,DOID,11799,TP53 R158G,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}, {'id': 3645, 'pubMedId': 23980093, 'title': 'Integrative radiogenomic profiling of squamous cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23980093'}]",sensitive,1040,PF-05212384,7157
148,Preclinical - Patient cell culture,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 Y163H in culture (PMID: 27179933). ",Actionable,9808,2394,ovarian cancer,DOID,27099,TP53 Y163H,"[{'id': 7621, 'pubMedId': 27179933, 'title': 'Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27179933'}]",sensitive,3443,APR-246 + Cisplatin,7157
149,Preclinical - Cell culture,"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA H1047R and TP53 S90fs*33 demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419). ",Actionable,10545,5304,ovarian clear cell adenocarcinoma,DOID,27594,PIK3CA H1047R TP53 S90fs*33,"[{'id': 4912, 'pubMedId': 24504419, 'title': 'Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24504419'}]",decreased response,722,DS-7423,7157
150,Preclinical - Cell culture,"In a preclinical study, treatment with NSC59984 resulted in increased degradation of mutant Tp53 and cell death in a colorectal cancer cell line harboring TP53 R175L in culture (PMID: 26294215).",Actionable,8264,9256,colorectal cancer,DOID,4502,TP53 R175L,"[{'id': 4303, 'pubMedId': 26294215, 'title': 'Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26294215'}]",sensitive,3402,NSC59984,7157
151,Preclinical - Cell culture,"In a preclinical study, lung large cell carcinoma cells harboring TP53 R175L demonstrated increased sensitivity to NSC319726 in culture (PMID: 22624712).",Actionable,10712,4556,lung large cell carcinoma,DOID,4502,TP53 R175L,"[{'id': 4308, 'pubMedId': 22624712, 'title': 'Allele-specific p53 mutant reactivation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22624712'}]",sensitive,3405,NSC319726,7157
152,Preclinical,"In a preclinical study, TP53 I232S resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).
",Actionable,912,3347,osteosarcoma,DOID,1554,TP53 I232S,"[{'id': 585, 'pubMedId': 21643018, 'title': 'Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21643018'}]",resistant,1405,Nutlin-3a,7157
153,Preclinical - Cell line xenograft,"In a preclinical study, APR-246 demonstrated efficacy in cell line xenograft models of small cell lung cancer harboring TP53 R273L (PMID: 21415220).",Actionable,8284,5409,lung small cell carcinoma,DOID,3604,TP53 R273L,"[{'id': 2429, 'pubMedId': 21415220, 'title': 'PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21415220'}]",sensitive,1946,APR-246,7157
154,Preclinical - Cell culture,"In a preclinical study, TP53-null non-small cell lung carcinoma cells demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).",Actionable,11742,3908,non-small cell lung carcinoma,DOID,1647,TP53 negative,"[{'id': 609, 'pubMedId': 22862161, 'title': 'Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22862161'}]",decreased response,1129,Seliciclib,7157
155,Phase I,"In a pilot trial, TP53-negative breast cancer patients demonstrated increased survival following treatment with Avastin (bevacizumab) in combination with chemotherapy agents, Adriamycin (doxorubicin) and Taxotere (docetaxel), compared to patients with TP53-positive tumors (PMID: 21399868).",Actionable,992,1612,breast cancer,DOID,1647,TP53 negative,"[{'id': 658, 'pubMedId': 21399868, 'title': 'p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21399868'}]",sensitive,1421,Avastin + Doxorubicin + Docetaxel,7157
156,Preclinical,"In a preclinical study, Gemzar (gemcitabine) resulted in enhanced antitumor efficacy, including decreased tumor volume, when combined with SRA737 (CCT245737) in a pancreatic ductal adenocarcinoma transgenic mouse model harboring KRAS G12D and TP53 R175H (PMID: 27167172). ",Actionable,9549,3498,pancreatic ductal adenocarcinoma,DOID,18195,KRAS G12D TP53 R175H,"[{'id': 7267, 'pubMedId': 27167172, 'title': 'Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27167172'}]",sensitive,5070,Gemcitabine + SRA737,7157
157,Preclinical,"In a preclinical study, SRA737 (CCT245737) resulted in some decreased tumor volume in a pancreatic ductal adenocarcinoma transgenic mouse model harboring KRAS G12D and TP53 R175H when compared to control (PMID: 27167172). ",Actionable,9550,3498,pancreatic ductal adenocarcinoma,DOID,18195,KRAS G12D TP53 R175H,"[{'id': 7267, 'pubMedId': 27167172, 'title': 'Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27167172'}]",sensitive,5069,SRA737,7157
158,Preclinical,"In a preclinical study, Rapamune (sirolimus) treatment in transgenic animal models of pancreatic ductal adenocarcinoma harboring KRAS G12D and TP53 R175H resulted in proliferation of tumor cells in interior, hypovascularized tumor regions, but inhibited proliferation in outer, vascularized tumor regions, despite inhibition of mTORC signaling in both regions (PMID: 26144316).",Actionable,8856,3498,pancreatic ductal adenocarcinoma,DOID,18195,KRAS G12D TP53 R175H,"[{'id': 6770, 'pubMedId': 26144316, 'title': 'The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26144316'}]",conflicting,917,Sirolimus,7157
159,Preclinical,"In a preclinical study, PI-3065 treatment prolonged survival and decreased metastasis in allograft animal models of pancreatic ductal adenocarcinoma harboring KRAS G12D and TP53 R175H through upregulation of host anti-tumor immune response(PMID: 24919154).",Actionable,5164,3498,pancreatic ductal adenocarcinoma,DOID,18195,KRAS G12D TP53 R175H,"[{'id': 3350, 'pubMedId': 24919154, 'title': 'Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24919154'}]",not applicable,2965,PI-3065,7157
160,Preclinical,"In a preclinical study, the combination of pimasertib and Gemzar (gemcitabine) inhibited tumor growth in a syngeneic mouse model of pancreatic cancer expressing KRAS G12D and TP53 R175H (PMID: 26228206).",Actionable,4467,1793,pancreatic cancer,DOID,18195,KRAS G12D TP53 R175H,"[{'id': 4571, 'pubMedId': 26228206, 'title': 'The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26228206'}]",sensitive,3526,Pimasertib + Gemcitabine,7157
161,Preclinical,"In a preclinical study, Alvespimycin (17-DMAG) and Zolinza (vorinostat) extended survival by 59% in mice with tumors expressing Tp53 R172H (which corresponds to R175H in the human Tp53 protein) (PMID: 26009011).",Actionable,5005,10000003,Advanced Solid Tumor,JAX,838,TP53 R175H,"[{'id': 4831, 'pubMedId': 26009011, 'title': 'Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26009011'}]",sensitive,3723,Alvespimycin + Vorinostat,7157
162,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring TP53 R175H demonstrated increased sensitivity to NSC319726 in culture (PMID: 22624712).",Actionable,10713,1612,breast cancer,DOID,838,TP53 R175H,"[{'id': 4308, 'pubMedId': 22624712, 'title': 'Allele-specific p53 mutant reactivation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22624712'}]",sensitive,3405,NSC319726,7157
163,Preclinical - Cell culture,"In a preclinical study, ovarian cancer cells harboring TP53 R175H demonstrated increased sensitivity to NSC319726-induced growth inhibition in culture and in cell line xenograft models (PMID: 22624712).",Actionable,10711,2394,ovarian cancer,DOID,838,TP53 R175H,"[{'id': 4308, 'pubMedId': 22624712, 'title': 'Allele-specific p53 mutant reactivation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22624712'}]",sensitive,3405,NSC319726,7157
164,Preclinical,"In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 R175H in culture (PIMD: 26009011).",Actionable,5014,1612,breast cancer,DOID,838,TP53 R175H,"[{'id': 4831, 'pubMedId': 26009011, 'title': 'Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26009011'}]",sensitive,745,Ganetespib,7157
165,Preclinical - Cell culture,"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring TP53 S241F demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419). ",Actionable,10548,5304,ovarian clear cell adenocarcinoma,DOID,838,TP53 R175H,"[{'id': 4912, 'pubMedId': 24504419, 'title': 'Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24504419'}]",decreased response,722,DS-7423,7157
166,Preclinical - Cell culture,"In a preclinical study, treatment with NSC59984 resulted in increased degradation of mutant Tp53 and cell death in a colorectal cancer cell line harboring TP53 R175H in culture (PMID: 26294215).",Actionable,8265,9256,colorectal cancer,DOID,838,TP53 R175H,"[{'id': 4303, 'pubMedId': 26294215, 'title': 'Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26294215'}]",sensitive,3402,NSC59984,7157
167,Preclinical,"In a preclinical study, ReACp53 induced cell death and decreased proliferation of head and neck carcinoma cells harboring TP53 R175H in culture (PMID: 26748848).",Actionable,3977,11934,head and neck cancer,DOID,838,TP53 R175H,"[{'id': 4309, 'pubMedId': 26748848, 'title': 'A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26748848'}]",sensitive,3406,ReACp53,7157
168,Preclinical - Cell culture,"In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 R175H were resistant to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).",Actionable,11743,3908,non-small cell lung carcinoma,DOID,838,TP53 R175H,"[{'id': 609, 'pubMedId': 22862161, 'title': 'Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22862161'}]",resistant,1129,Seliciclib,7157
169,Preclinical,"In a preclinical study, treatment with ReACp53 induced cell death in primary human uterine fibroblasts expressing TP53 R175H in culture (PMID: 26748848).",Actionable,3974,10000003,Advanced Solid Tumor,JAX,838,TP53 R175H,"[{'id': 4309, 'pubMedId': 26748848, 'title': 'A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26748848'}]",sensitive,3406,ReACp53,7157
170,Clinical Study,"In a clinical case study, Xalkori (crizotinib) treatment resulted in a decrease in tumor volume by more than 60% in a patient with histiocytic sarcoma harboring MET del exon14 and TP53 R175H (PMID: 25971938).",Actionable,9561,5621,histiocytic and dendritic cell cancer,DOID,26903,MET del exon14 TP53 R175H,"[{'id': 6712, 'pubMedId': 25971938, 'title': 'Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25971938'}]",sensitive,706,Crizotinib,7157
171,Preclinical,"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 C176F in culture (PMID: 26438783).",Actionable,4737,769,neuroblastoma,DOID,18880,ALK	wild-type TP53 C176F,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,7157
172,Preclinical - Cell line xenograft,"In a preclinical study, treatment with CP-31398 resulted in decreased proliferation, increased apoptosis, and cell-cycle arrest in a hepatocellular carcinoma cell line harboring TP53 R249S in culture, and inhibited tumor growth in xenograft models (PMID: 26250460).",Actionable,8985,684,hepatocellular carcinoma,DOID,3052,TP53 R249S,"[{'id': 6838, 'pubMedId': 26250460, 'title': 'CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26250460'}]",sensitive,3404,CP-31398,7157
173,Preclinical,"In a preclinical study, ReACp53 induced cell death in human primary ovarian carcinoma cells harboring TP53 Y327L in culture (PMID: 26748848).",Actionable,3981,4001,ovarian carcinoma,DOID,16642,TP53 Y327L,"[{'id': 4309, 'pubMedId': 26748848, 'title': 'A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26748848'}]",sensitive,3406,ReACp53,7157
174,Clinical Study,"In a clinical case study, RB1 C706F and loss of exons 1-11 in TP53 were identified in the pericardium infiltrating small cell lung cancer that developed while on Lorlatinib (PF-06463922) treatment in a patient with ALK-rearranged non-small cell lung carcinoma (PMID: 28285684).",Actionable,10437,5409,lung small cell carcinoma,DOID,27462,ALK rearrange RB1 C706F TP53 loss,"[{'id': 8449, 'pubMedId': 28285684, 'title': 'Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28285684'}]",predicted – resistant,869,PF-06463922,7157
175,Preclinical - Cell culture,"In a preclinical study,  non-small cell lung carcinoma cells harboring KRAS mutation, STK11 and TP53 loss demonstrated increased sensitivity to MK-1775 and Platinol (cisplatin) combination treatment in culture compared to isogenic cell lines expressing wild-type Tp53 or Stk11 (PMID: 28652249).",Actionable,11859,3908,non-small cell lung carcinoma,DOID,28317,KRAS mut STK11 loss TP53 loss,"[{'id': 9874, 'pubMedId': 28652249, 'title': 'WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28652249'}]",predicted – sensitive,1725,MK-1775 + Cisplatin,7157
176,Preclinical,"In a preclinical study, treatment with AZD5363 improved overall survival and progression-free survival in mouse models of  prostate cancer with inactivated PTEN and TP53 (PMID: 26910118).",Actionable,10888,10283,prostate cancer,DOID,27832,PTEN loss TP53 loss,"[{'id': 8893, 'pubMedId': 26910118, 'title': 'Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26910118'}]",sensitive,655,AZD5363,7157
177,Preclinical - Cell culture,"In a preclinical study, TP53-null lung cancer cells were resistant to AMG 232 induced growth inhibition in culture (PMID: 26162687).",Actionable,8255,1324,lung cancer,DOID,630,TP53 loss,"[{'id': 6588, 'pubMedId': 26162687, 'title': 'Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26162687'}]",resistant,1452,AMG 232,7157
178,Preclinical,"In a preclinical study, Ad5CMV-p53 gene therapy suppressed growth of allograft colorectal cancer in rat models (PMID: 15608394).",Actionable,233,9256,colorectal cancer,DOID,630,TP53 loss,"[{'id': 162, 'pubMedId': 15608394, 'title': 'In vivo recombinant adenovirus-mediated p53 gene therapy in a syngeneic rat model for colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/15608394'}]",predicted – sensitive,979,Ad5CMV-p53 gene,7157
179,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 did not enhance radiation-induced cytotoxicity in TP53-null lung cancer cells in culture and in cell line xenograft models (PMID: 26162687).",Actionable,8261,1324,lung cancer,DOID,630,TP53 loss,"[{'id': 6588, 'pubMedId': 26162687, 'title': 'Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26162687'}]",resistant,4671,AMG 232 + Radiotherapy,7157
180,Preclinical,"In a preclincial study, ReACp53 did not induce cell death in ovarian cancer cells with loss of TP53 in culture (PMID: 26748848).",Actionable,4273,2394,ovarian cancer,DOID,630,TP53 loss,"[{'id': 4309, 'pubMedId': 26748848, 'title': 'A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26748848'}]",no benefit,3406,ReACp53,7157
181,Preclinical,"In a preclinical study the TTK (MPS1) inhibitor, MPI-0479605, inhibited cell cycle progression of colon carcinoma cells deficient for Tp53 with equivalent efficacy to cells with wild-type Tp53 (PMID: 21980130).",Actionable,4205,1520,colon carcinoma,DOID,630,TP53 loss,"[{'id': 4435, 'pubMedId': 21980130, 'title': 'Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21980130'}]",sensitive,3458,MPI-0479605,7157
182,Preclinical,"In a preclinical study, colon cancer cells lacking TP53 had a decreased response to CPUY201112 in culture, when compared to colon cancer cells with wild-type TP53 (PMID: 26743233).",Actionable,4645,219,colon cancer,DOID,630,TP53 loss,"[{'id': 4657, 'pubMedId': 26743233, 'title': 'CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26743233'}]",decreased response,3589,CPUY201112,7157
183,Preclinical,"In a preclinical study, tumor cell lines carrying deficient TP53 were sensitized to DNA-damaging agents upon MK-1775 administration (PMID: 19887545).",Actionable,1123,10000003,Advanced Solid Tumor,JAX,630,TP53 loss,"[{'id': 874, 'pubMedId': 19887545, 'title': 'Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19887545'}]",sensitive,822,MK-1775,7157
184,Preclinical,"In a preclinical study, treatment with BLZ945 demonstrated some efficacy, specifically a 56% tumor reduction, in transgenic mouse models of glioblastoma with a loss of TP53 (PMID: 27199435). ",Actionable,8588,3068,glioblastoma multiforme,DOID,630,TP53 loss,"[{'id': 6692, 'pubMedId': 27199435, 'title': 'The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27199435'}]",sensitive,2844,BLZ945,7157
185,Preclinical - Pdx,"In a preclinical study, PHA-680632 synergized with radiotherapy to decrease tumor growth in Pdx models deficient in Tp53 (PMID: 18026198).",Actionable,10393,9256,colorectal cancer,DOID,630,TP53 loss,"[{'id': 8415, 'pubMedId': 18026198, 'title': 'Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18026198'}]",sensitive,5503,PHA-680632 + Radiotherapy,7157
186,Preclinical - Pdx,"In a preclinical study, the combination of MK-1775 and Gemzar (gemcitabine) inhibited Wee1 expression, Cdc2 phosphorylation, and tumor growth in several patient-derived xenograft models of pancreatic cancer harboring TP53 mutations (PMID: 21389100).
",Actionable,403,1793,pancreatic cancer,DOID,630,TP53 loss,"[{'id': 50, 'pubMedId': 21389100, 'title': 'MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21389100'}]",sensitive,1279,MK-1775 + Gemcitabine,7157
187,Preclinical,"In a preclinical study, an osteosarcoma cell line lacking TP53 demonstrated a decreased response to CPUY201112 in culture, when compared to osteosarcoma cells with wild-type TP53 (PMID: 26743233).",Actionable,4647,3347,osteosarcoma,DOID,630,TP53 loss,"[{'id': 4657, 'pubMedId': 26743233, 'title': 'CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26743233'}]",decreased response,3589,CPUY201112,7157
188,Preclinical,"In a preclinical study, CTX-1 induced cell death in TP53-deficient human tumor cell lines in culture, but had a greater effect on cell lines with wild-type TP53 compared to isogenic cell lines with TP53 loss (PMID: 26883273).",Actionable,5571,10000003,Advanced Solid Tumor,JAX,630,TP53 loss,"[{'id': 5110, 'pubMedId': 26883273, 'title': 'Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26883273'}]",decreased response,3899,CTX-1,7157
189,Preclinical,"In a preclinical study, LB100 treatment decreased PP2A activity and increased sensitivity to Platinol (cisplatin) in cisplatin-resistant ovarian cancer cells with TP53 loss in culture and in xenograft models (PMID: 25376608).",Actionable,4445,2394,ovarian cancer,DOID,630,TP53 loss,"[{'id': 4553, 'pubMedId': 25376608, 'title': 'The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25376608'}]",sensitive,3515,LB-100 + Cisplatin,7157
190,Preclinical - Cell line xenograft,"In a preclinical study, AZD6738 increased sensitivity to radiotherapy in colorectal cancer xenograft models harboring a loss of TP53, resulting in a greater delay of tumor growth compared to radiation alone and an improved survival compared to control or either agent alone (PMID: 28062704). ",Actionable,10018,9256,colorectal cancer,DOID,630,TP53 loss,"[{'id': 7909, 'pubMedId': 28062704, 'title': 'Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28062704'}]",sensitive,5346,AZD6738 + Radiotherapy,7157
191,Preclinical,"In a preclinical study, Prodigiosin inhibited self-renewal of colorectal cancer cell lines harboring TP53 loss in culture (PMID: 26759239).",Actionable,5771,9256,colorectal cancer,DOID,630,TP53 loss,"[{'id': 5150, 'pubMedId': 26759239, 'title': 'Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated ΔNp73 Inhibition and p73 Activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26759239'}]",sensitive,3925,Prodigiosin,7157
192,Preclinical,"In a preclinical study, SP600125 induced cell death in colon carcinoma cells deficient for p53 (PMID: 22438244).",Actionable,4085,1520,colon carcinoma,DOID,630,TP53 loss,"[{'id': 4399, 'pubMedId': 22438244, 'title': 'Selective killing of p53-deficient cancer cells by SP600125.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22438244'}]",sensitive,3366,SP600125,7157
193,Preclinical,"In a preclinical study, mouse breast cancer models harboring BRCA1 C61G with conditional loss of Tp53 had a decreased response to Lynparza (olaparib) compared to models with conditional loss of Brca1 and Tp53 (PMID: 22172724).",Actionable,2016,1612,breast cancer,DOID,4728,BRCA1 C61G TP53 loss,"[{'id': 2497, 'pubMedId': 22172724, 'title': 'BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22172724'}]",decreased response,837,Olaparib,7157
194,Preclinical,"In a preclinical study, a breast cancer model lacking BRCA1 and TP53 demonstrated sensitivity to treatment with AZD2461, which resulted in decreased tumor volume (PMID: 27550455). ",Actionable,8945,1612,breast cancer,DOID,26544,BRCA1 loss TP53 loss,"[{'id': 6793, 'pubMedId': 27550455, 'title': 'The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27550455'}]",sensitive,2542,AZD2461,7157
195,Preclinical - Cell line xenograft,"In a preclinical study, YW3-56 inhibited proliferation of a human triple-negative breast cancer (TNBC) cell line harboring TP53 R280K in culture and inhibited tumor growth in TP53 R280K-mutant TNBC cell line xenograft models (PMID: 25612620).",Actionable,6021,60081,triple-receptor negative breast cancer,DOID,17595,TP53 R280K,"[{'id': 5233, 'pubMedId': 25612620, 'title': 'ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25612620'}]",sensitive,4006,YW3-56,7157
196,Preclinical,"In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 R280K in culture (PMID: 26009011).",Actionable,5012,1612,breast cancer,DOID,17595,TP53 R280K,"[{'id': 4831, 'pubMedId': 26009011, 'title': 'Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26009011'}]",sensitive,745,Ganetespib,7157
197,Preclinical - Patient cell culture,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically in culture, resulting in reduced cell viability in patient derived ovarian cancer cells harboring TP53 R280K (PMID: 27179933). ",Actionable,9803,2394,ovarian cancer,DOID,17595,TP53 R280K,"[{'id': 7621, 'pubMedId': 27179933, 'title': 'Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27179933'}]",sensitive,3443,APR-246 + Cisplatin,7157
198,Phase I,"In a phase I study, Ankara (MVAp53) demonstrated safety and efficacy in patients with metastatic colon, gastric and pancreas cancer stained positive for p53 (J Clin Oncol 31, 2013 (suppl; abstr 3089)).",Actionable,424,10000003,Advanced Solid Tumor,JAX,2836,TP53 positive,"[{'id': 1014, 'pubMedId': None, 'title': 'A phase I study of an MVA vaccine targeting p53 in cancer.', 'url': 'meetinglibrary.asco.org/content/111188-132'}]",sensitive,1038,MVAp53,7157
199,Phase I,"In a Phase I trial, treatment with p28 was well-tolerated and demonstrated preliminary efficacy in patients with Tp53-positive advanced solid tumors, with complete response in 6% (1/15), partial response in 20% (3/15), and stable disease in 46% (7/15) of patients (PMID: 23449360).",Actionable,8309,10000003,Advanced Solid Tumor,JAX,2836,TP53 positive,"[{'id': 6598, 'pubMedId': 23449360, 'title': 'A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23449360'}]",predicted – sensitive,4694,p28,7157
200,Phase I,"In a Phase I trial, Serdemetan (JNJ-26854165) treatment increased Tp53 expression in tumor and surrogate tissue, resulted in partial response in 1.8% (1/57) and stable disease in 38.6% (22/57) of patients with advanced solid tumors (PMID: 21831953).",Actionable,10724,10000003,Advanced Solid Tumor,JAX,2836,TP53 positive,"[{'id': 8787, 'pubMedId': 21831953, 'title': 'A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831953'}]",sensitive,2309,Serdemetan,7157
201,Preclinical - Cell culture,"In a preclinical study, NU6027 enhanced the efficacy of Temodar (temozolomide) in ovarian cancer cells with mismatch repair activity and positive for TP53 in culture, demonstrating a 50% greater decrease in cell survival compared to Temodar (temozolomide) alone (PMID: 21730979). ",Actionable,11883,2394,ovarian cancer,DOID,2836,TP53 positive,"[{'id': 3171, 'pubMedId': 21730979, 'title': 'Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21730979'}]",predicted – sensitive,6196,NU6027 + Temozolomide,7157
202,Phase I,"In a Phase I trial, Serdemetan (JNJ-26854165) treatment induced a 102% increase of Tp53 expression in tumor tissue, resulted in partial response in a patient with breast cancer (PMID: 21831953).",Actionable,10725,1612,breast cancer,DOID,2836,TP53 positive,"[{'id': 8787, 'pubMedId': 21831953, 'title': 'A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831953'}]",sensitive,2309,Serdemetan,7157
203,Preclinical - Cell line xenograft,"In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment resulted in Tp53-independent increase of Cdkn1a expression and apoptosis of ovarian clear cell carcinoma cells harboring TP53 deletion in culture and in cell line xenograft models (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221).",Actionable,10737,50934,ovarian clear cell carcinoma,DOID,17613,TP53 del,"[{'id': 8790, 'pubMedId': None, 'title': 'Kevetrin induces p53-dependent and independent cell cycle arrest and apoptosis in ovarian cancer cell lines representing heterogeneous histologies', 'url': 'http://www.abstractsonline.com/pp8/#!/4292/presentation/3876'}]",predicted – sensitive,2999,thioureidobutyronitrile,7157
204,Preclinical - Cell culture,"In a preclinical study, MK-8745 treatment resulted in polyploidy in TP53-null colorectal cancer cells in culture (PMID: 22293494).",Actionable,10682,9256,colorectal cancer,DOID,17613,TP53 del,"[{'id': 8741, 'pubMedId': 22293494, 'title': 'The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293494'}]",predicted – sensitive,5579,TC-A2317,7157
205,Preclinical,"In a preclinical study, treatment with Nutlin-3 had little effect on growth of ovarian cancer cells with deletion of TP53 in culture (PMID: 25964101).",Actionable,6069,2394,ovarian cancer,DOID,17613,TP53 del,"[{'id': 5272, 'pubMedId': 25964101, 'title': 'Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964101'}]",no benefit,1405,Nutlin-3a,7157
206,Preclinical,"In a preclinical study, Nutlin-3 and etoposide worked cooperatively to induce apoptosis and decrease growth of ovarian cancer cells with TP53 deletion in culture (PMID: 25964101).",Actionable,6071,2394,ovarian cancer,DOID,17613,TP53 del,"[{'id': 5272, 'pubMedId': 25964101, 'title': 'Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964101'}]",sensitive,4017,Nutlin-3 + Etoposide,7157
207,Preclinical - Cell culture,"In a preclinical study, sequential administration of Roscovotine (seliciclib) followed by Adriamycin (doxorubicin) synergistically induced apoptosis in TP53-null colorectal cancer cells in culture (PMID: 26826118).",Actionable,10907,9256,colorectal cancer,DOID,17613,TP53 del,"[{'id': 8919, 'pubMedId': 26826118, 'title': 'Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26826118'}]",predicted – sensitive,5678,Doxorubicin + Seliciclib,7157
208,Preclinical,"In a preclinical study, Nutlin-3 and cisplatin worked cooperatively to induce apoptosis and decrease growth of ovarian cancer cells with TP53 deletion in culture (PMID: 25964101).",Actionable,6070,2394,ovarian cancer,DOID,17613,TP53 del,"[{'id': 5272, 'pubMedId': 25964101, 'title': 'Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964101'}]",sensitive,4018,Nutlin-3 + Cisplatin,7157
209,Preclinical,"In a preclinical study, Xalkori (crizotinib) treatment resulted in complete tumor regression in transplant models of TP53-null-luminal breast cancer harboring MET amplification (PMID: 27149990).",Actionable,11535,1612,breast cancer,DOID,28118,MET amp TP53 del,"[{'id': 9604, 'pubMedId': 27149990, 'title': 'Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27149990'}]",sensitive,706,Crizotinib,7157
210,Preclinical,"In a preclinical study, 7RH treatment had no effect on tumor cell apoptosis in KRAS G12V-driven animal models of lung cancer with TP53 knockout background (PMID: 26855149).",Actionable,10882,1324,lung cancer,DOID,27818,KRAS G12V TP53 del,"[{'id': 8887, 'pubMedId': 26855149, 'title': 'Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26855149'}]",resistant,5669,7RH,7157
211,Preclinical,"In a preclinical study, 7RH and LY411575 combination treatment induced apoptosis in KRAS G12V-driven animal models of lung cancer with TP53 knockout background (PMID: 26855149).",Actionable,10883,1324,lung cancer,DOID,27818,KRAS G12V TP53 del,"[{'id': 8887, 'pubMedId': 26855149, 'title': 'Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26855149'}]",sensitive,5670,7RH + LY411575,7157
212,Preclinical,"In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369). ",Actionable,2106,4159,skin cancer,DOID,5389,PTEN mut RB1 mut SMAD4 mut TP53 mut,"[{'id': 2380, 'pubMedId': 25261369, 'title': 'Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25261369'}]",sensitive,1282,Sapanisertib,7157
213,Preclinical,"In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).",Actionable,4361,50746,mantle cell lymphoma,DOID,17822,TP53 mutant RB1 wild-type,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,7157
214,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4352,3459,breast carcinoma,DOID,17822,TP53 mutant RB1 wild-type,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,7157
215,Preclinical,"In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).",Actionable,4355,1520,colon carcinoma,DOID,17822,TP53 mutant RB1 wild-type,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,7157
216,Preclinical,"In a preclinical study, R547 inhibited proliferation of osteosarcoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).",Actionable,4359,3347,osteosarcoma,DOID,17822,TP53 mutant RB1 wild-type,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,7157
217,Phase I,"In a clinical study, a retrospective analysis of a Phase I trial demonstrated four non-small cell lung carcinoma (NSCLC) patients co-harboring  a TP53 mutation and KRAS mutation had greater progression free survival compared to NSCLC patients harboring a single TP53 mutation or single KRAS mutation when treated with Keytruda (pembrolizumab) (PMID: 28039262). ",Actionable,11296,3908,non-small cell lung carcinoma,DOID,25456,KRAS mutant TP53 mutant,"[{'id': 9220, 'pubMedId': 28039262, 'title': 'Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28039262'}]",predicted – sensitive,1447,Pembrolizumab,7157
218,Phase I,"In a Phase I trial, a colorectal cancer patient co-harboring a KRAS mutation and TP53 mutation demonstrated sensitivity when treated with Abemaciclib (LY2835219), which resulted in stable disease (PMID: 27217383). ",Actionable,7460,9256,colorectal cancer,DOID,25456,KRAS mutant TP53 mutant,"[{'id': 6356, 'pubMedId': 27217383, 'title': 'Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27217383'}]",sensitive,802,Abemaciclib,7157
219,Preclinical - Cell culture,"In a preclinical study, the combination of Navitoclax (ABT-263), Mekinist (trametinib), Alpelisib (BYL719), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a KRAS mutation and TP53 mutation compared to the double or triple combinations of the therapies (PMID: 27659046). ",Actionable,9932,9256,colorectal cancer,DOID,25456,KRAS mutant TP53 mutant,"[{'id': 7782, 'pubMedId': 27659046, 'title': 'High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27659046'}]",sensitive,5316,ABT-263 + Alpelisib + Erlotinib + Trametinib,7157
220,Phase I,"In a retrospective analysis of a Phase I trial, MK-1775 combined with a chemotherapy resulted in a 21% (4/19) response rate in advanced solid tumor patients harboring a TP53 mutation and in those without a TP53 mutation, a 12% (4/33) response rate was observed (PMID: 27601554).",Actionable,9288,10000003,Advanced Solid Tumor,JAX,434,TP53 mutant,"[{'id': 7062, 'pubMedId': 27601554, 'title': 'Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27601554'}]",sensitive,822,MK-1775,7157
221,Preclinical - Cell culture,"In a preclinical study, AMG 232 did not inhibit growth of human tumor cell lines harboring TP53 mutations in culture (PMID: 25567130).",Actionable,8090,10000003,Advanced Solid Tumor,JAX,434,TP53 mutant,"[{'id': 2082, 'pubMedId': 25567130, 'title': 'The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25567130'}]",resistant,1452,AMG 232,7157
222,Preclinical - Cell line xenograft,"In a preclinical study, the combination of MK-1775 and radiation therapy synergized to inhibit tumor growth in a human glioblastoma multiforme cell line xenograft model harboring mutant TP53 (PMID: 21992793).",Actionable,1149,3068,glioblastoma multiforme,DOID,434,TP53 mutant,"[{'id': 898, 'pubMedId': 21992793, 'title': 'Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21992793'}]",sensitive,4186,MK-1775 + Radiotherapy,7157
223,Preclinical - Cell culture,"In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Erbb3 (Her3) antibody resulted in inhibition of survival in TP53 mutated hypopharyngeal carcinoma cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",Actionable,7782,8533,hypopharynx cancer,DOID,434,TP53 mutant,"[{'id': 6493, 'pubMedId': 27196767, 'title': 'Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196767'}]",predicted – sensitive,4579,unspecified EGFR antibody + unspecified ERBB3 antibody,7157
224,Phase I,"In a Phase I trial, the combination of Votrient (pazopanib) and Zolinza (vorinostat) resulted in improved progression-free survival and overall survival in metastatic sarcoma and colorectal cancer patients harboring TP53 hotspot mutations, and resulted in a stable disease rate of 83% (5/6), compared to a stable disease rate of 9% (1/11) in patients without detected TP53 mutations (PMID: 25669829).",Actionable,3424,9256,colorectal cancer,DOID,434,TP53 mutant,"[{'id': 3774, 'pubMedId': 25669829, 'title': 'Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25669829'}]",sensitive,1211,Pazopanib + Vorinostat,7157
225,Preclinical,"In a preclinical study, neuroblastoma cell lines harboring TP53 mutations were resistant to GSK2830371 induced growth inhibition in culture (PMID: 25658463).",Actionable,5283,769,neuroblastoma,DOID,434,TP53 mutant,"[{'id': 4979, 'pubMedId': 25658463, 'title': 'WIP1 phosphatase as a potential therapeutic target in neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25658463'}]",resistant,3735,GSK2830371,7157
226,Preclinical - Cell culture,"In a preclinical study, AZD6738 treatment increased sensitivity to radiotherapy in a tongue squamous cell carcinoma cell line harboring a TP53 mutation in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 28062704). ",Actionable,10016,50865,tongue squamous cell carcinoma,DOID,434,TP53 mutant,"[{'id': 7909, 'pubMedId': 28062704, 'title': 'Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28062704'}]",sensitive,5346,AZD6738 + Radiotherapy,7157
227,Preclinical,"In a preclinical study, neuroblastoma cell lines harboring TP53 mutant were resistant to MI-63 mediated growth inhibition (PMID: 21725357).",Actionable,2994,769,neuroblastoma,DOID,434,TP53 mutant,"[{'id': 3556, 'pubMedId': 21725357, 'title': 'MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21725357'}]",resistant,1582,MI-63,7157
228,Clinical Study,"In a retrospective study, advanced sarcoma patients with TP53 mutations displayed improved progression-free survival (208 days versus 136 days) relative to patients with wild-type TP53 when treated with Votrient (pazopanib) (PMID: 26646755).",Actionable,4932,1115,sarcoma,DOID,434,TP53 mutant,"[{'id': 4803, 'pubMedId': 26646755, 'title': 'TP53 mutational status is predictive of pazopanib response in advanced sarcomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26646755'}]",sensitive,848,Pazopanib,7157
229,Preclinical,"In a preclinical study, the combination of CEP-8983 and Platinol (cisplatin) worked synergistically to induce cell death in non-small cell lung cancer cell lines in culture, irrespective of TP53 status (PMID: 23428903).",Actionable,4556,3908,non-small cell lung carcinoma,DOID,434,TP53 mutant,"[{'id': 4605, 'pubMedId': 23428903, 'title': 'Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23428903'}]",sensitive,3537,CEP-8983 + Cisplatin,7157
230,Preclinical,"In a preclinical study, the treatment of a head and neck squamous cell carcinoma cell line with mutant TP53 (C176F and A161S) with AZD7762, a pan Chk1/2 inhibitor, sensitizes the cells to Platinol (cisplatin) (PMID: 23839309).",Actionable,1505,5520,head and neck squamous cell carcinoma,DOID,434,TP53 mutant,"[{'id': 1211, 'pubMedId': 23839309, 'title': 'Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23839309'}]",sensitive,1755,AZD7762 + Cisplatin,7157
231,Preclinical - Cell culture,"In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment decreased mutant Tp53 level, resulted in apoptosis of ovarian serous carcinoma cells harboring TP53 mutations in culture (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221).",Actionable,10736,50933,ovarian serous carcinoma,DOID,434,TP53 mutant,"[{'id': 8790, 'pubMedId': None, 'title': 'Kevetrin induces p53-dependent and independent cell cycle arrest and apoptosis in ovarian cancer cell lines representing heterogeneous histologies', 'url': 'http://www.abstractsonline.com/pp8/#!/4292/presentation/3876'}]",sensitive,2999,thioureidobutyronitrile,7157
232,Preclinical - Cell line xenograft,"In a preclinical study, NSC59984 treatment resulted in increased Tp53 signaling and cell death in colorectal cancer cell lines harboring TP53 mutations, and inhibited tumor growth in TP53-mutant cell line colorectal cancer xenograft models (PMID: 26294215).",Actionable,8263,9256,colorectal cancer,DOID,434,TP53 mutant,"[{'id': 4303, 'pubMedId': 26294215, 'title': 'Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26294215'}]",predicted – sensitive,3402,NSC59984,7157
233,Preclinical - Cell culture,"In a preclinical study, combination of two unspecified EGFR antibodies targeting nonoverlapping epitopes of Egfr did not inhibit proliferation of Tp53 mutated hypopharyngeal carcinoma cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",Actionable,7777,8533,hypopharynx cancer,DOID,434,TP53 mutant,"[{'id': 6493, 'pubMedId': 27196767, 'title': 'Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196767'}]",resistant,4575,unspecified EGFR antibody,7157
234,Phase I,"In a Phase I clinical trial, the majority of 19 leukemia patients with identified TP53 mutations did not demonstrate response to treatment with RG7112, with 2 acute myeloid leukemia patients harboring TP53 mutations showing clinical activity, but not improvement, and 1 sCLL/CLL patient achieving stable disease (PMID: 26459177).",Actionable,5068,1240,leukemia,DOID,434,TP53 mutant,"[{'id': 4871, 'pubMedId': 26459177, 'title': 'Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26459177'}]",decreased response,2076,RG7112,7157
235,Phase II,"In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in an overall response rate of 43% (9/21), a median progression-free survival of 5.3 months and a median overall survival of 12.6 months in ovarian cancer patients harboring TP53 mutations (PMID: 27998224).",Actionable,11765,2394,ovarian cancer,DOID,434,TP53 mutant,"[{'id': 9762, 'pubMedId': 27998224, 'title': 'Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27998224'}]",predicted – sensitive,1194,MK-1775 + Carboplatin ,7157
236,Preclinical,"In a preclinical study, neuroblastoma cell lines harboring TP53 mutant were resistant to nutlin-3 mediated growth inhibition (PMID: 21725357).",Actionable,2993,769,neuroblastoma,DOID,434,TP53 mutant,"[{'id': 3556, 'pubMedId': 21725357, 'title': 'MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21725357'}]",resistant,1405,Nutlin-3a,7157
237,Clinical Study,"In a retrospective study, Avastin (bevacizumab) treatment was associated with increased progression-free survival in cancer patients carrying TP53 mutations (PMID: 23670029).",Actionable,209,10000003,Advanced Solid Tumor,JAX,434,TP53 mutant,"[{'id': 79, 'pubMedId': 23670029, 'title': 'P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670029'}]",sensitive,667,Bevacizumab,7157
238,Clinical Study,"In a clinical study, 106 advanced solid tumor patients harboring a TP53 mutation demonstrated a greater sensitivity to VEGF/VEGFR inhibitors, such as Avastin (bevacizumab), when compared to 82 treated patients harboring TP53 wild-type, resulting in improved rates of SD, PR, and CR, better time-to-treatment failure, and overall survival (PMID: 27466356).",Actionable,7787,10000003,Advanced Solid Tumor,JAX,434,TP53 mutant,"[{'id': 6495, 'pubMedId': 27466356, 'title': 'TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27466356'}]",sensitive,667,Bevacizumab,7157
239,Phase I,"In a Phase I trial, Duvelisib (IPI-145) treatment inhibited Akt phosphorylation, resulted in complete response in 2% (1/49), partial response in 53% (26/49), and stable disease in 43% (21/49) of chronic lymphocytic leukemia patients, of which 49% (23/47) carried TP53 mutations (Blood 124 (21): 3334).  ",Actionable,5145,1040,chronic lymphocytic leukemia,DOID,434,TP53 mutant,"[{'id': 4888, 'pubMedId': None, 'title': 'Duvelisib (IPI-145), a PI3K-?,? Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia', 'url': 'http://www.bloodjournal.org/content/124/21/3334.abstract?sso-checked=true'}]",predicted – sensitive,1024,Duvelisib,7157
240,Phase I,"In a Phase I trial, the combination of Votrient (pazopanib) and Zolinza (vorinostat) improved progression-free survival and overall survival in advanced solid tumor patients harboring TP53 hotspot mutations, and resulted in an increased stable disease rate of 45% (5/11), compared to a stable disease rate of 16% (4/25) in patients without detected TP53 mutations (PMID: 25669829).",Actionable,3413,10000003,Advanced Solid Tumor,JAX,434,TP53 mutant,"[{'id': 3774, 'pubMedId': 25669829, 'title': 'Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25669829'}]",sensitive,1211,Pazopanib + Vorinostat,7157
241,Preclinical - Cell line xenograft,"In a preclinical study, Prodigiosin inhibited self-renewal of colorectal cancer cell lines harboring TP53 mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 26759239).",Actionable,5770,9256,colorectal cancer,DOID,434,TP53 mutant,"[{'id': 5150, 'pubMedId': 26759239, 'title': 'Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated ΔNp73 Inhibition and p73 Activation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26759239'}]",sensitive,3925,Prodigiosin,7157
242,Preclinical - Cell culture,"In a preclinical study, combination of an unspecified EGFR antibody, an unspecified Erbb3 (Her3) antibody, and an unspecified Igf-1r antibody resulted in potent inhibition of survival in TP53 mutated hypopharyngeal carcinoma cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",Actionable,7784,8533,hypopharynx cancer,DOID,434,TP53 mutant,"[{'id': 6493, 'pubMedId': 27196767, 'title': 'Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196767'}]",predicted – sensitive,4580,EGFR antibody + ERBB3 antibody + IGF-1R antibody,7157
243,Preclinical - Cell culture,"In a preclinical study, TP53-mutated breast cancer cell lines demonstrated increased sensitivity to PK11007 compared to TP53-wild type cells in culture, regardless of Esr1 and Erbb2 (Her2) status (J Clin Oncol 35, 2017 (suppl; abstr e14099)).",Actionable,11113,1612,breast cancer,DOID,434,TP53 mutant,"[{'id': 9085, 'pubMedId': None, 'title': 'Targeting mutant p53 with PK11007: A new approach for the treatment of patients with triple-negative breast cancer?', 'url': 'http://abstracts.asco.org/199/AbstView_199_189403.html'}]",sensitive,5862,PK11007,7157
244,Preclinical,"In a preclinical study, treatment with Nutlin-3 had little effect on growth of ovarian cancer cells with TP53 mutations in culture (PMID: 25964101).",Actionable,6065,2394,ovarian cancer,DOID,434,TP53 mutant,"[{'id': 5272, 'pubMedId': 25964101, 'title': 'Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964101'}]",no benefit,1405,Nutlin-3a,7157
245,Phase I,"In a clinical study, a retrospective analysis of a Phase I trial demonstrated non-small cell lung carcinoma (NSCLC) patients harboring either a TP53 mutation (n=15) or KRAS mutation (n=8) had greater progression free survival compared to NSCLC patients harboring wild-type TP53 or KRAS (n=15) (14.5mo vs 14.7mo vs 3.5mo, respectively) when treated with Keytruda (pembrolizumab) (PMID: 28039262). ",Actionable,11294,3908,non-small cell lung carcinoma,DOID,434,TP53 mutant,"[{'id': 9220, 'pubMedId': 28039262, 'title': 'Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28039262'}]",predicted – sensitive,1447,Pembrolizumab,7157
246,Preclinical,"In a preclinical study, CTX-1 induced increased Tp53 protein levels and cell death in human tumor cell lines with mutant Tp53 in culture (PMID: 26883273).",Actionable,5574,10000003,Advanced Solid Tumor,JAX,434,TP53 mutant,"[{'id': 5110, 'pubMedId': 26883273, 'title': 'Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26883273'}]",sensitive,3899,CTX-1,7157
247,Preclinical - Cell culture,"In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Igf-1r antibody resulted in inhibition of survival in TP53 mutated hypopharyngeal carcinoma cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",Actionable,7783,8533,hypopharynx cancer,DOID,434,TP53 mutant,"[{'id': 6493, 'pubMedId': 27196767, 'title': 'Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196767'}]",predicted – sensitive,4578,unspecified EGFR antibody + unspecified IGF-1R antibody,7157
248,Preclinical - Pdx,"In a preclinical study, treatment with MK-1775 decreased CDK1 phosphorylation and reduced tumor growth in patient-derived xenograft models of glioblastoma multiforme that harbor TP53 mutations (PMID: 27196784).",Actionable,7043,3068,glioblastoma multiforme,DOID,434,TP53 mutant,"[{'id': 6050, 'pubMedId': 27196784, 'title': 'Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27196784'}]",sensitive,822,MK-1775,7157
249,Phase I,"In a Phase I trial, treatment with GDC-0425 followed by Gemzar (gemcitabine) resulted in a partial response in a patient with triple-receptor negative breast cancer harboring a TP53 mutation (PMID: 27815358). ",Actionable,10956,60081,triple-receptor negative breast cancer,DOID,434,TP53 mutant,"[{'id': 8959, 'pubMedId': 27815358, 'title': 'Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27815358'}]",predicted – sensitive,5734,GDC-0425 + Gemcitabine,7157
250,Preclinical - Cell culture,"In a preclinical study, AZD6738 treatment increased sensitivity to radiotherapy in a pharynx squamous cell carcinoma cell line harboring a TP53 mutation in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 28062704). ",Actionable,10017,50921,pharynx squamous cell carcinoma,DOID,434,TP53 mutant,"[{'id': 7909, 'pubMedId': 28062704, 'title': 'Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28062704'}]",sensitive,5346,AZD6738 + Radiotherapy,7157
251,Preclinical,"In a preclinical study, medulloblastoma cell lines with TP53 mutations had significantly less sensitivity to the BET inhibitor, JQ1, than cell lines carrying wild-type TP53 (PMID: 24231268).",Actionable,1133,50902,medulloblastoma,DOID,434,TP53 mutant,"[{'id': 878, 'pubMedId': 24231268, 'title': 'BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24231268'}]",decreased response,1574,JQ1,7157
252,Preclinical,"In a preclinical study, ovarian clear cell adenocarcinoma cell lines harboring TP53 mutations demonstrated reduced sensitivity to DS-7423 induced apoptosis in culture compared to TP53 wild-type cells (PMID: 24504419).",Actionable,5200,5304,ovarian clear cell adenocarcinoma,DOID,434,TP53 mutant,"[{'id': 4912, 'pubMedId': 24504419, 'title': 'Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24504419'}]",decreased response,722,DS-7423,7157
253,Phase I,"In a Phase I trial, the combination of Votrient (pazopanib) and Zolinza (vorinostat) resulted in improved progression-free survival and overall survival in metastatic sarcoma and colorectal cancer patients harboring TP53 hotspot mutations, and resulted in a stable disease rate of 83% (5/6), compared to a stable disease rate of 9% (1/11) in patients without detected TP53 mutations (PMID: 25669829).",Actionable,3414,1115,sarcoma,DOID,434,TP53 mutant,"[{'id': 3774, 'pubMedId': 25669829, 'title': 'Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25669829'}]",sensitive,1211,Pazopanib + Vorinostat,7157
254,Preclinical,"In a preclinical study, Nutlin-3 and etoposide worked cooperatively to induce apoptosis in ovarian cancer cell lines with TP53 inactivating mutations in culture (PMID: 25964101).",Actionable,6067,2394,ovarian cancer,DOID,434,TP53 mutant,"[{'id': 5272, 'pubMedId': 25964101, 'title': 'Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25964101'}]",sensitive,4017,Nutlin-3 + Etoposide,7157
255,Preclinical - Cell culture,"In a preclinical study, Nutlin-3 and Paraplatin (carboplatin) synergistically inhibited growth in TP53 mutated triple-receptor negative breast cancer cell lines in culture and in cell line xenograft models (PMID: 26494859).",Actionable,9183,60081,triple-receptor negative breast cancer,DOID,434,TP53 mutant,"[{'id': 7000, 'pubMedId': 26494859, 'title': 'Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26494859'}]",predicted – sensitive,4928,Carboplatin + Nutlin-3,7157
256,Preclinical - Cell line xenograft,"In a preclinical study, sequential administration of Roscovotine (seliciclib) followed by Adriamycin (doxorubicin) synergistically induced apoptosis in TP53-mutant triple-receptor negative breast cancer cell lines in culture, and inhibited tumor growth, prolonged survival in cell line xenograft models (PMID: 26826118).",Actionable,10906,60081,triple-receptor negative breast cancer,DOID,434,TP53 mutant,"[{'id': 8919, 'pubMedId': 26826118, 'title': 'Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26826118'}]",predicted – sensitive,5678,Doxorubicin + Seliciclib,7157
257,Phase III,"In a Phase III trial, Avastin (bevacizumab), in combination with chemotherapy, provided a significant survival benefit in patients with colorectal cancers regardless of mutational status in KRAS, BRAF, and TP53 (PMID: 17145525).",Actionable,915,9256,colorectal cancer,DOID,434,TP53 mutant,"[{'id': 599, 'pubMedId': 17145525, 'title': 'Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17145525'}]",sensitive,667,Bevacizumab,7157
258,Preclinical,"In a preclinical study, PD0166285 sensitizes colorectal cancer cells with TP53 mutation to radiation induced cell death (PMID: 11719452).
",Actionable,138,9256,colorectal cancer,DOID,434,TP53 mutant,"[{'id': 209, 'pubMedId': 11719452, 'title': 'Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11719452'}]",sensitive,851,PD0166285,7157
259,Preclinical,"In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369). ",Actionable,2135,9256,colorectal cancer,DOID,5415,APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut,"[{'id': 2380, 'pubMedId': 25261369, 'title': 'Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25261369'}]",sensitive,1282,Sapanisertib,7157
260,Clinical Study,"In a clinical study, treatment with first-line tyrosine kinase inhibitors resulted in a disease control rate (DCR) of 70% (26/37) in non-small cell lung carcinoma patients harboring both EGFR and TP53 mutations, compared to a DCR of 88% (76/86) in TP53 wild-type, EGFR mutated patients (J Clin Oncol 34, 2016 (suppl; abstr 9052)).",Actionable,6998,3908,non-small cell lung carcinoma,DOID,24178,EGFR mut TP53 mut,"[{'id': 6006, 'pubMedId': None, 'title': 'Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.', 'url': 'http://meetinglibrary.asco.org/content/165599-176'}]",decreased response,1776,N/A,7157
261,Preclinical,"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 mutations in culture (PMID: 26438783).",Actionable,4739,769,neuroblastoma,DOID,18890,ALK	wild-type TP53 mutant,"[{'id': 4681, 'pubMedId': 26438783, 'title': 'Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26438783'}]",no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,7157
262,Preclinical - Cell culture,"In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Tafinlar (dabrafenib), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and TP53 mutation in culture compared to the double or triple combinations of the therapies (PMID: 27659046). ",Actionable,9934,9256,colorectal cancer,DOID,27213,BRAF mut TP53 mut,"[{'id': 7782, 'pubMedId': 27659046, 'title': 'High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27659046'}]",sensitive,5318,ABT-263 + Alpelisib + Dabrafenib + Erlotinib,7157
263,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of prostate carcinoma cell lines harboring Tp53 and Rb1 mutations in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4358,10286,prostate carcinoma,DOID,17821,RB1 mut TP53 mut,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,7157
264,Preclinical,"In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring TP53 and RB1 mutations in culture (PMID: 17121911).",Actionable,4351,3459,breast carcinoma,DOID,17821,RB1 mut TP53 mut,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,7157
265,Preclinical,"In a preclinical study, R547 inhibited proliferation of cervical carcinoma cell lines harboring Tp53 and Rb1 mutations (PMID: 17121911).",Actionable,4357,4362,cervical cancer,DOID,17821,RB1 mut TP53 mut,"[{'id': 4503, 'pubMedId': 17121911, 'title': 'In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17121911'}]",sensitive,3497,R547,7157
266,Preclinical - Cell culture,"In a preclinical study, the combination of ONC201 (TIC10) and Navitoclax (ABT-263) increased apoptosis and worked synergistically to inhibit proliferation of a glioblastoma cell line harboring mutations in PTEN and TP53 in culture (PMID: 26474387).",Actionable,9825,3068,glioblastoma multiforme,DOID,5387,PTEN mutant TP53 mutant,"[{'id': 7647, 'pubMedId': 26474387, 'title': 'TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26474387'}]",sensitive,5245,Navitoclax + ONC201,7157
267,Preclinical,"In a preclinical study, a skin cancer cell line harboring mutations in PTEN and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369). ",Actionable,2104,4159,skin cancer,DOID,5387,PTEN mutant TP53 mutant,"[{'id': 2380, 'pubMedId': 25261369, 'title': 'Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25261369'}]",sensitive,1282,Sapanisertib,7157
268,Clinical Study,"In a clinical case study, a patient with gastric adenocarcinoma containing amplification of ERBB2 (HER2) and a TP53 R158H mutation progressed and developed metastases while being treated with AMG 337 (PMID: 26432108).",Actionable,4099,3717,gastric adenocarcinoma,DOID,17302,ERBB2 amp TP53 R158H,"[{'id': 4397, 'pubMedId': 26432108, 'title': 'Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26432108'}]",predicted – resistant,1064,AMG 337,7157
269,Preclinical - Pdx & cell culture,"In a preclinical study, ReACp53 rescued p53 activity and decreased viability of ovarian cancer cells harboring TP53 R248Q in culture, and induced tumor regression in patient-derived ovarian cancer xenograft models harboring TP53 R248Q (PMID: 26748848).",Actionable,3978,2394,ovarian cancer,DOID,3457,TP53 R248Q,"[{'id': 4309, 'pubMedId': 26748848, 'title': 'A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26748848'}]",sensitive,3406,ReACp53,7157
270,Preclinical,"In a preclinical study, Ganetespib extended survival by 48% in mice with tumors expressing TP53 R248Q (PMID: 26009011).",Actionable,5004,10000003,Advanced Solid Tumor,JAX,3457,TP53 R248Q,"[{'id': 4831, 'pubMedId': 26009011, 'title': 'Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26009011'}]",sensitive,745,Ganetespib,7157
271,Preclinical,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of a Platinol (cisplatin)-resistant ovarian cancer cell line harboring TP53 R248Q in culture and inhibited tumor growth in TP53 R248Q-carrying ovarian cancer cell line xenograft models (PMID: 26086967).",Actionable,4095,2394,ovarian cancer,DOID,3457,TP53 R248Q,"[{'id': 4407, 'pubMedId': 26086967, 'title': 'APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26086967'}]",sensitive,3443,APR-246 + Cisplatin,7157
272,Clinical Study,"In a clinical study, treatment with first-line tyrosine kinase inhibitors resulted in a disease control rate (DCR) of 42% (5/12), median PFS and OS of 4.2 and 16.2 months in non-small cell lung carcinoma patients harboring both TP53 exon 8 and EGFR mutations, compared to 87% (97/111),  12.5 and 32.3 months in TP53 exon 8 wild-type patients (J Clin Oncol 34, 2016 (suppl; abstr 9052)).",Actionable,6999,3908,non-small cell lung carcinoma,DOID,24179,EGFR mut TP53 exon 8,"[{'id': 6006, 'pubMedId': None, 'title': 'Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.', 'url': 'http://meetinglibrary.asco.org/content/165599-176'}]",decreased response,1776,N/A,7157
273,Preclinical,"In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 L194F in culture (PIMD: 26009011).",Actionable,5013,1612,breast cancer,DOID,19851,TP53 L194F,"[{'id': 4831, 'pubMedId': 26009011, 'title': 'Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26009011'}]",sensitive,745,Ganetespib,7157
274,Preclinical - Cell line xenograft,"In a preclinical study, Tanespimycin (17-AAG) inhibited tumor growth in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011).",Actionable,5007,1612,breast cancer,DOID,19851,TP53 L194F,"[{'id': 4831, 'pubMedId': 26009011, 'title': 'Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26009011'}]",sensitive,934,Tanespimycin,7157
275,Preclinical - Cell line xenograft,"In a preclinical study, Tanespimycin (17-AAG) and Zolinza (vorinostat) were synergistic towards tumor growth inhibition in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011).",Actionable,5006,1612,breast cancer,DOID,19851,TP53 L194F,"[{'id': 4831, 'pubMedId': 26009011, 'title': 'Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26009011'}]",sensitive,4644,Tanespimycin + Vorinostat,7157
276,Preclinical - Cell line xenograft,"In a preclinical study, Zolinza (vorinostat) inhibited tumor growth in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011).",Actionable,5008,1612,breast cancer,DOID,19851,TP53 L194F,"[{'id': 4831, 'pubMedId': 26009011, 'title': 'Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26009011'}]",sensitive,1077,Vorinostat,7157
277,Clinical Study,"In a clinical study, a colon cancer patient harboring BRAF V600E and TP53 Q192K demonstrated a partial response when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 28514312). ",Actionable,11052,219,colon cancer,DOID,27902,BRAF V600E TP53 Q192K,"[{'id': 9046, 'pubMedId': 28514312, 'title': 'Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28514312'}]",sensitive,1717,Vemurafenib + Panitumumab,7157
278,Preclinical - Cell culture,"In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 P98A demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).",Actionable,11746,3908,non-small cell lung carcinoma,DOID,1477,TP53 P98A,"[{'id': 609, 'pubMedId': 22862161, 'title': 'Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22862161'}]",decreased response,1129,Seliciclib,7157
279,Preclinical - Cell line xenograft,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and growth of colorectal cancer cells harboring BRAF V600E, PIK3CA P449T, and TP53 R273H in culture and in cell line xenograft models, but did not have synergistic effect on apoptosis (PMID: 26272063).",Actionable,8565,9256,colorectal cancer,DOID,26358,BRAF V600E PIK3CA P449T TP53 R273H,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,7157
280,Preclinical,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of non-small lung cancer cells harboring TP53 R248W in culture (PMID: 26086967).",Actionable,4097,3908,non-small cell lung carcinoma,DOID,837,TP53 R273H,"[{'id': 4407, 'pubMedId': 26086967, 'title': 'APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26086967'}]",sensitive,3443,APR-246 + Cisplatin,7157
281,Phase I,"In a Phase I trial, VX-970 and Paraplatin (carboplatin) combination treatment resulted in partial response for 6 months in a PARP inhibitor-resistant ovarian cancer patient harboring a germline BRCA1 mutation and TP53 Y220C (J Clin Oncol 34, 2016 (suppl; abstr 2504)).",Actionable,6711,2394,ovarian cancer,DOID,23675,BRCA1 mut TP53 Y220C,"[{'id': 5761, 'pubMedId': None, 'title': 'Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies.', 'url': 'http://abstracts.asco.org/176/AbstView_176_165738.html'}]",sensitive,4253,Carboplatin + VX-970,7157
282,Preclinical - Cell culture,"In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 Y220C were resistant to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).",Actionable,11745,3908,non-small cell lung carcinoma,DOID,1043,TP53 Y220C,"[{'id': 609, 'pubMedId': 22862161, 'title': 'Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22862161'}]",resistant,1129,Seliciclib,7157
283,Preclinical - Cell culture,"In a preclinical study, treatment with CP-31398 resulted in decreased proliferation, increased apoptosis, and cell-cycle arrest in a hepatocellular carcinoma cell line harboring TP53 Y220C in culture (PMID: 26250460).",Actionable,8984,684,hepatocellular carcinoma,DOID,1043,TP53 Y220C,"[{'id': 6838, 'pubMedId': 26250460, 'title': 'CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26250460'}]",sensitive,3404,CP-31398,7157
284,Preclinical,"In a preclinical study, TP53 R280M resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).",Actionable,911,3347,osteosarcoma,DOID,1553,TP53 R280M,"[{'id': 585, 'pubMedId': 21643018, 'title': 'Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21643018'}]",resistant,1405,Nutlin-3a,7157
285,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PTEN loss, and TP53 V216M (PMID: 26272063).",Actionable,8575,9256,colorectal cancer,DOID,26364,KRAS G12D PTEN loss TP53 V216M,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,4771,MLN0128 + PD-0325901,7157
286,Preclinical,"In a preclinical study, LY3009120 modestly inhibited soft agar growth of human melanoma cancer cells harboring TP53 D259Y in culture (PMID: 26343583).",Actionable,6595,1909,melanoma,DOID,23639,TP53 D259Y,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,3268,LY3009120,7157
287,Preclinical,"In a preclinical study, Selumetinib (AZD6244) inhibited proliferation of human melanoma cells harboring TP53 D259Y in culture (PMID: 26343583).",Actionable,6607,1909,melanoma,DOID,23639,TP53 D259Y,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,913,Selumetinib,7157
288,Preclinical,"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of human melanoma cells TP53 D259Y in culture (PMID: 26343583).",Actionable,6608,1909,melanoma,DOID,23639,TP53 D259Y,"[{'id': 5709, 'pubMedId': 26343583, 'title': 'Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26343583'}]",sensitive,342,Vemurafenib,7157
289,Preclinical - Cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS G13D, PIK3CA E545K, and TP53 S241F in culture (PMID: 26272063).",Actionable,8564,9256,colorectal cancer,DOID,26357,KRAS G13D PIK3CA E545k TP53 S241F,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",sensitive,4771,MLN0128 + PD-0325901,7157
290,Preclinical - Cell line xenograft,"In a preclinical study, APR-246 demonstrated efficacy in xenograft models of small cell lung cancer harboring TP53 S241F (PMID: 21415220).",Actionable,8283,5409,lung small cell carcinoma,DOID,16831,TP53 S241F,"[{'id': 2429, 'pubMedId': 21415220, 'title': 'PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21415220'}]",sensitive,1946,APR-246,7157
291,Preclinical,"In a preclinical study, Ganetespib inhibited growth of human ovarian cancer cells harboring TP53 S241F in culture (PMID: 26009011).",Actionable,5015,2394,ovarian cancer,DOID,16831,TP53 S241F,"[{'id': 4831, 'pubMedId': 26009011, 'title': 'Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26009011'}]",sensitive,745,Ganetespib,7157
292,Preclinical - Cell culture,"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring TP53 S241F demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419). ",Actionable,10547,5304,ovarian clear cell adenocarcinoma,DOID,16831,TP53 S241F,"[{'id': 4912, 'pubMedId': 24504419, 'title': 'Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24504419'}]",decreased response,722,DS-7423,7157
293,Preclinical - Patient cell culture,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 L111Q in culture (PMID: 27179933). ",Actionable,9807,2394,ovarian cancer,DOID,27098,TP53 L111Q,"[{'id': 7621, 'pubMedId': 27179933, 'title': 'Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27179933'}]",sensitive,3443,APR-246 + Cisplatin,7157
294,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, decreased PTEN expression, and TP53 R306* (PMID: 26272063).",Actionable,8576,9256,colorectal cancer,DOID,26365,KRAS G12D PTEN dec exp TP53 R306*,"[{'id': 6689, 'pubMedId': 26272063, 'title': 'MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26272063'}]",no benefit,4771,MLN0128 + PD-0325901,7157
0,Clinical Study,"In multiple clinical studies, the presence of U2AF1 mutations was associated with a trend toward risk of progression to acute myeloid leukemia, however, the prognostic significance of U2AF1 mutations is still unclear (PMID: 25465125, PMID: 22158538, PMID: 22389253).",Emerging,6424,50908,myelodysplastic syndrome,DOID,23383,U2AF1 mutant,"[{'id': 5580, 'pubMedId': 25465125, 'title': 'The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25465125'}, {'id': 5581, 'pubMedId': 22158538, 'title': 'Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22158538'}, {'id': 5582, 'pubMedId': 22389253, 'title': 'Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22389253'}]",not applicable,1776,N/A,7307
0,Phase II,"In a Phase II clinical study, baseline expression of VHL was not predictive for response to Saracatinib (AZD0530) and Recentin (cediranib) relative to Recentin (cediranib) in patients with metastatic clear-cell renal cell carcinoma (PMID: 26802156).",Actionable,5935,4467,renal clear cell carcinoma,DOID,22001,VHL over exp,"[{'id': 5202, 'pubMedId': 26802156, 'title': 'A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26802156'}]",no benefit,3922,Cediranib + Saracatinib,7428
1,Preclinical - Cell line xenograft,"In a preclinical study, Stivarga (regorafenib) inhibited angiogenesis and tumor growth in cell line xenograft models of renal cell carcinoma harboring VHL gene deletion (PMID: 21170960).",Actionable,7721,4450,renal cell carcinoma,DOID,25932,VHL del,"[{'id': 318, 'pubMedId': 21170960, 'title': 'Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21170960'}]",predicted – sensitive,890,Regorafenib,7428
2,Preclinical - Pdx,"In a preclinical study, PT2399 had variable impact on tumor growth in clear cell renal cell carcinoma (ccRCC) cell line and patient-derived xenograft (PDX) models with defective VHL, with decreased tumor growth in a VHL-defective ccRCC PDX model and some VHL-defective ccRCC cell line xenograft models, and no tumor suppression in other cell line xenograft models (PMID: 27595393).",Actionable,8268,4467,renal clear cell carcinoma,DOID,6849,VHL inact mut,"[{'id': 6586, 'pubMedId': 27595393, 'title': 'On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27595393'}]",conflicting,4670,PT2399,7428
3,Clinical Study,"In a retrospective analysis, VHL alterations did not impact overall survival or objective response in renal cell carcinoma patients treated with a VEGF-targeted therapy,including Avastin (bevacizumab) and Alpha 2 Interferon combination therapy, but were associated with a prolonged time to progression (PMID: 16827904).",Actionable,9339,4450,renal cell carcinoma,DOID,6849,VHL inact mut,"[{'id': 7115, 'pubMedId': 16827904, 'title': 'Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16827904'}]",predicted – sensitive,2511,Bevacizumab + Alpha 2 Interferon,7428
4,Phase II,"In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Afinitor (everolimus) had a trend towards improved in progression free survival when stratified by the presence (median PFS=8.6 months, n=15) or absence (median PFS=5.5 months, n=16) of deleterious VHL mutations (PMID: 26951309).",Actionable,5740,4450,renal cell carcinoma,DOID,6849,VHL inact mut,"[{'id': 4914, 'pubMedId': 26951309, 'title': 'Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26951309'}]",predicted – sensitive,735,Everolimus,7428
5,Phase II,"In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Apitolisib (GDC-0980) had no difference in progression free survival when stratified by the presence (n=5) or absence (n=17) of deleterious VHL mutations (PMID: 26951309).",Actionable,5735,4450,renal cell carcinoma,DOID,6849,VHL inact mut,"[{'id': 4914, 'pubMedId': 26951309, 'title': 'Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26951309'}]",no benefit,750,GDC-0980,7428
6,Preclinical - Cell culture,"In a preclinical study, TP53 R248W was associated with resistance to PT2399 in VHL-defective clear cell renal cell carcinoma cell lines in culture (PMID: 27595393).",Actionable,8269,4467,renal clear cell carcinoma,DOID,26217,TP53 R248W VHL inact mut,"[{'id': 6586, 'pubMedId': 27595393, 'title': 'On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27595393'}]",resistant,4670,PT2399,7428
7,Phase I,"In a Phase I study, Afinitor (everolimus), as compared to Apitolisib (GDC-0980), resulted in a greater progression free survival and overall survival in patients with renal cell carcinoma harboring VHL mutations (J Clin Oncol 32:5s, 2014 (suppl; abstr 4525)). ",Actionable,2280,4450,renal cell carcinoma,DOID,4973,VHL mut,"[{'id': 2962, 'pubMedId': None, 'title': 'A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT)', 'url': 'http://meetinglibrary.asco.org/content/132562-144'}]",sensitive,735,Everolimus,7428
8,Phase I,"In a Phase I study, 33% (6/18) of renal cell carcinoma archived patient samples with VHL mutations demonstrated partial response when treated with Sutent (sunitinib) (PMID: 22105611).",Actionable,2271,4450,renal cell carcinoma,DOID,4973,VHL mut,"[{'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",sensitive,930,Sunitinib,7428
9,Preclinical - Pdx,"In a preclinical study, combination of Mekinist (trametinib) and Sutent (sunitinib) inhibited tumor growth in patient-derived xenograft models of renal cancer harboring VHL V155fs*4 (PMID: 26487278).",Actionable,9079,263,kidney cancer,DOID,26715,VHL V155fs,"[{'id': 6896, 'pubMedId': 26487278, 'title': 'Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26487278'}]",predicted – sensitive,4874,Sunitinib + Trametinib,7428
10,Preclinical,"In a preclinical study, STF-62247 induced selective cytotoxicity and inhibited tumor growth of renal cell carcinoma cells lacking VHL (PMID: 18769110, PMID: 18598947).",Actionable,1112,4450,renal cell carcinoma,DOID,1883,VHL negative,"[{'id': 856, 'pubMedId': 18769110, 'title': 'Targeted therapy for the loss of von Hippel-Lindau in renal cell carcinoma: a novel molecule that induces autophagic cell death.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18769110'}, {'id': 857, 'pubMedId': 18598947, 'title': 'A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18598947'}]",sensitive,1561,STF-62247,7428
11,Preclinical,"In a preclinical study, human renal carcinoma cells with PTEN loss and VHL loss had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073).",Actionable,3157,4451,renal carcinoma,DOID,11820,PTEN loss VHL loss,"[{'id': 220, 'pubMedId': 21325073, 'title': 'Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21325073'}]",decreased response,1040,PF-05212384,7428
12,Preclinical - Cell culture,"In a preclinical study, VHL-deficient renal cell carcinoma cells demonstrated growth inhibition in culture when treated with CB-839 (PMID: 28346230).",Actionable,10900,4450,renal cell carcinoma,DOID,6901,VHL loss,"[{'id': 8915, 'pubMedId': 28346230, 'title': 'Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28346230'}]",sensitive,1667,CB-839,7428
13,Preclinical - Cell line xenograft,"In a preclinical study, the combination of CB-839 and Lynparza (olaparib) resulted in a synergistic effect, demonstrating greater reduction in tumor volume compared to either agent alone in renal carcinoma cell xenograft models deficient for VHL (PMID: 28346230). ",Actionable,10901,4450,renal cell carcinoma,DOID,6901,VHL loss,"[{'id': 8915, 'pubMedId': 28346230, 'title': 'Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28346230'}]",sensitive,5675,CB-839 + Olaparib,7428
14,Preclinical - Cell culture,"In a preclinical study, VHL-deficient renal cell carcinoma cells demonstrated growth inhibition and suppression of DNA synthesis in culture when treated with BPTES (PMID: 28346230).",Actionable,10899,4450,renal cell carcinoma,DOID,6901,VHL loss,"[{'id': 8915, 'pubMedId': 28346230, 'title': 'Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28346230'}]",sensitive,5194,BPTES,7428
15,Preclinical,"In a preclinical study, clear cell renal cell carcinoma xenograft models with VHL loss demonstrated sensitivity to Avastin (bevacizumab) (PMID: 22931246).",Actionable,2272,4450,renal cell carcinoma,DOID,6901,VHL loss,"[{'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",sensitive,667,Bevacizumab,7428
16,Preclinical - Cell line xenograft,"In a preclinical study, renal cell carcinoma cells deficient for VHL were sensitive to ELR510444 both in culture and in cell line xenograft models (PMID: 22295124).",Actionable,2273,4450,renal cell carcinoma,DOID,6901,VHL loss,"[{'id': 2953, 'pubMedId': 22295124, 'title': 'ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22295124'}]",sensitive,2790,ELR510444,7428
17,Preclinical - Cell culture,"In a preclinical study, the combination of BPTES and Lynparza (olaparib) resulted in a synergistic effect, demonstrating growth inhbition of VHL-deficient renal cell carcinoma cells in culture (PMID: 28346230). ",Actionable,10903,4450,renal cell carcinoma,DOID,6901,VHL loss,"[{'id': 8915, 'pubMedId': 28346230, 'title': 'Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28346230'}]",sensitive,5677,BPTES + Olaparib,7428
